Entry	target_uniprot	Protein names	Gene names	Cross-reference (PDB)	Cross-reference (ChEMBL)	Cross-reference (BindingDB)	Cross-reference (DrugBank)	Pathway	Cross-reference (Pfam)	Cross-reference (InterPro)	Gene ontology (biological process)	Gene ontology (molecular function)	Gene ontology (cellular component)
P04229	2B11_HUMAN	HLA class II histocompatibility antigen, DRB1-1 beta chain (MHC class II antigen DRB1*1) (DR-1) (DR1)	HLA-DRB1	1AQD;1DLH;1FYT;1HXY;1JWM;1JWS;1JWU;1KG0;1KLG;1KLU;1LO5;1PYW;1R5I;1SEB;1SJE;1SJH;1T5W;1T5X;2FSE;2G9H;2IAM;2IAN;2ICW;2IPK;2OJE;2XN9;3L6F;3PDO;3PGC;3PGD;3QXA;3QXD;3S4S;3S5L;4AEN;4AH2;4C56;4E41;4FQX;4GBX;4I5B;4OV5;4X5W;4X5X;	CHEMBL1943;	P04229;	DB05259;		PF07654;PF00969;	IPR007110;IPR013783;IPR003006;IPR003597;IPR011162;IPR014745;IPR000353;	antigen processing and presentation of exogenous peptide antigen via MHC class II [GO:0019886]; detection of bacterium [GO:0016045]; humoral immune response mediated by circulating immunoglobulin [GO:0002455]; immune response [GO:0006955]; immunoglobulin production involved in immunoglobulin mediated immune response [GO:0002381]; inflammatory response to antigenic stimulus [GO:0002437]; interferon-gamma-mediated signaling pathway [GO:0060333]; negative regulation of interferon-gamma production [GO:0032689]; negative regulation of T cell proliferation [GO:0042130]; positive regulation of insulin secretion involved in cellular response to glucose stimulus [GO:0035774]; protein tetramerization [GO:0051262]; regulation of interleukin-10 secretion [GO:2001179]; regulation of interleukin-4 production [GO:0032673]; T cell costimulation [GO:0031295]; T cell receptor signaling pathway [GO:0050852]; T-helper 1 type immune response [GO:0042088]	MHC class II protein complex binding [GO:0023026]; peptide antigen binding [GO:0042605]; virus receptor activity [GO:0001618]	clathrin-coated endocytic vesicle membrane [GO:0030669]; endocytic vesicle membrane [GO:0030666]; ER to Golgi transport vesicle membrane [GO:0012507]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; Golgi membrane [GO:0000139]; integral component of lumenal side of endoplasmic reticulum membrane [GO:0071556]; late endosome membrane [GO:0031902]; lysosomal membrane [GO:0005765]; MHC class II protein complex [GO:0042613]; plasma membrane [GO:0005886]; trans-Golgi network membrane [GO:0032588]; transport vesicle membrane [GO:0030658]
P14060	3BHS1_HUMAN	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 (3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type I) (3-beta-HSD I) (Trophoblast antigen FDO161G) [Includes: 3-beta-hydroxy-Delta(5)-steroid dehydrogenase (EC 1.1.1.145) (3-beta-hydroxy-5-ene steroid dehydrogenase) (Progesterone reductase); Steroid Delta-isomerase (EC 5.3.3.1) (Delta-5-3-ketosteroid isomerase)]	HSD3B1 3BH HSDB3A		CHEMBL1958;	P14060;	DB01108;	PATHWAY: Lipid metabolism; steroid biosynthesis.	PF01073;	IPR002225;IPR016040;	androgen biosynthetic process [GO:0006702]; estrogen biosynthetic process [GO:0006703]; glucocorticoid biosynthetic process [GO:0006704]; mineralocorticoid biosynthetic process [GO:0006705]; steroid biosynthetic process [GO:0006694]	3-beta-hydroxy-delta5-steroid dehydrogenase activity [GO:0003854]; steroid delta-isomerase activity [GO:0004769]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrial intermembrane space [GO:0005758]; smooth endoplasmic reticulum membrane [GO:0030868]
P26439	3BHS2_HUMAN	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2 (3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type II) (3-beta-HSD II) (3-beta-HSD adrenal and gonadal type) [Includes: 3-beta-hydroxy-Delta(5)-steroid dehydrogenase (EC 1.1.1.145) (3-beta-hydroxy-5-ene steroid dehydrogenase) (Progesterone reductase); Steroid Delta-isomerase (EC 5.3.3.1) (Delta-5-3-ketosteroid isomerase)]	HSD3B2 HSDB3B		CHEMBL3670;	P26439;	DB01285;DB00603;DB01108;	PATHWAY: Lipid metabolism; steroid biosynthesis.	PF01073;	IPR002225;IPR016040;	androgen biosynthetic process [GO:0006702]; glucocorticoid biosynthetic process [GO:0006704]; mineralocorticoid biosynthetic process [GO:0006705]; steroid biosynthetic process [GO:0006694]	3-beta-hydroxy-delta5-steroid dehydrogenase activity [GO:0003854]; steroid delta-isomerase activity [GO:0004769]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrial intermembrane space [GO:0005758]; mitochondrial membrane [GO:0031966]; smooth endoplasmic reticulum membrane [GO:0030868]
P31937	3HIDH_HUMAN	3-hydroxyisobutyrate dehydrogenase, mitochondrial (HIBADH) (EC 1.1.1.31)	HIBADH	2GF2;2I9P;				PATHWAY: Amino-acid degradation; L-valine degradation. {ECO:0000269|PubMed:16466957}.	PF14833;PF03446;	IPR002204;IPR008927;IPR013328;IPR006115;IPR011548;IPR015815;IPR016040;IPR029154;	branched-chain amino acid catabolic process [GO:0009083]; valine catabolic process [GO:0006574]	3-hydroxyisobutyrate dehydrogenase activity [GO:0008442]; NAD binding [GO:0051287]; phosphogluconate dehydrogenase (decarboxylating) activity [GO:0004616]	mitochondrial matrix [GO:0005759]
P08908	5HT1A_HUMAN	5-hydroxytryptamine receptor 1A (5-HT-1A) (5-HT1A) (G-21) (Serotonin receptor 1A)	HTR1A ADRB2RL1 ADRBRL1		CHEMBL214;	P08908;	DB01614;DB00866;DB01616;DB00321;DB00543;DB00714;DB01238;DB06216;DB08807;DB09128;DB01200;DB00490;DB00248;DB06016;DB00477;DB08810;DB00363;DB01151;DB00988;DB01142;DB00216;DB01049;DB00696;DB04908;DB04946;DB00458;DB01221;DB00589;DB00408;DB08815;DB00247;DB06148;DB01618;DB00952;DB01149;DB00540;DB00334;DB00904;DB01267;DB01359;DB01186;DB00960;DB01621;DB00413;DB00571;DB01224;DB00734;DB00268;DB05271;DB00669;DB01622;DB00656;DB00726;DB06684;DB09068;DB01392;DB00246;DB00315;		PF00001;	IPR000610;IPR002231;IPR000276;IPR017452;	adenylate cyclase-inhibiting serotonin receptor signaling pathway [GO:0007198]; behavioral fear response [GO:0001662]; cell proliferation [GO:0008283]; chemical synaptic transmission [GO:0007268]; exploration behavior [GO:0035640]; G-protein coupled receptor signaling pathway [GO:0007186]; positive regulation of cell proliferation [GO:0008284]; regulation of behavior [GO:0050795]; regulation of dopamine metabolic process [GO:0042053]; regulation of hormone secretion [GO:0046883]; regulation of serotonin secretion [GO:0014062]; serotonin metabolic process [GO:0042428]; serotonin receptor signaling pathway [GO:0007210]; vasoconstriction [GO:0042310]	G-protein coupled serotonin receptor activity [GO:0004993]; neurotransmitter receptor activity [GO:0030594]; serotonin binding [GO:0051378]	dendrite [GO:0030425]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P28222	5HT1B_HUMAN	5-hydroxytryptamine receptor 1B (5-HT-1B) (5-HT1B) (S12) (Serotonin 1D beta receptor) (5-HT-1D-beta) (Serotonin receptor 1B)	HTR1B HTR1DB	2G1X;4IAQ;4IAR;	CHEMBL1898;	P28222;	DB00918;DB00321;DB00543;DB00714;DB01238;DB06216;DB08807;DB01200;DB00248;DB00363;DB00320;DB00216;DB01049;DB00696;DB00998;DB01221;DB00589;DB00408;DB00247;DB00952;DB00334;DB00904;DB01359;DB01186;DB00960;DB00413;DB00571;DB01224;DB00953;DB00268;DB00669;DB09068;DB01392;DB00246;DB00315;		PF00001;	IPR002147;IPR002231;IPR000276;IPR017452;	adenylate cyclase-inhibiting serotonin receptor signaling pathway [GO:0007198]; bone remodeling [GO:0046849]; cellular response to alkaloid [GO:0071312]; cellular response to drug [GO:0035690]; cellular response to temperature stimulus [GO:0071502]; chemical synaptic transmission [GO:0007268]; drinking behavior [GO:0042756]; G-protein coupled receptor internalization [GO:0002031]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; negative regulation of cAMP biosynthetic process [GO:0030818]; negative regulation of serotonin secretion [GO:0014063]; negative regulation of synaptic transmission, GABAergic [GO:0032229]; negative regulation of synaptic transmission, glutamatergic [GO:0051967]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; protein kinase C-activating G-protein coupled receptor signaling pathway [GO:0007205]; regulation of behavior [GO:0050795]; regulation of dopamine secretion [GO:0014059]; release of sequestered calcium ion into cytosol [GO:0051209]; response to cocaine [GO:0042220]; response to ethanol [GO:0045471]; response to mineralocorticoid [GO:0051385]; vasoconstriction [GO:0042310]	drug binding [GO:0008144]; G-protein coupled serotonin receptor activity [GO:0004993]; neurotransmitter receptor activity [GO:0030594]; serotonin binding [GO:0051378]	cytoplasm [GO:0005737]; dendrite [GO:0030425]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P28221	5HT1D_HUMAN	5-hydroxytryptamine receptor 1D (5-HT-1D) (5-HT1D) (Serotonin 1D alpha receptor) (5-HT-1D-alpha) (Serotonin receptor 1D)	HTR1D HTR1DA HTRL		CHEMBL1983;	P28221;	DB00918;DB00321;DB00714;DB01238;DB01200;DB00248;DB00363;DB00320;DB00216;DB01049;DB00696;DB00998;DB01221;DB00589;DB00408;DB00952;DB00334;DB01267;DB01186;DB00413;DB01224;DB00734;DB00953;DB00268;DB00669;DB00726;DB01392;DB00246;DB00315;		PF00001;	IPR000505;IPR002231;IPR000276;IPR017452;	adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway [GO:0007193]; chemical synaptic transmission [GO:0007268]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; intestine smooth muscle contraction [GO:0014827]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; regulation of behavior [GO:0050795]; regulation of locomotion [GO:0040012]; release of sequestered calcium ion into cytosol [GO:0051209]; response to drug [GO:0042493]; response to toxic substance [GO:0009636]; vasoconstriction [GO:0042310]	G-protein coupled serotonin receptor activity [GO:0004993]; neurotransmitter receptor activity [GO:0030594]; serotonin binding [GO:0051378]	dendrite [GO:0030425]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P28566	5HT1E_HUMAN	5-hydroxytryptamine receptor 1E (5-HT-1E) (5-HT1E) (S31) (Serotonin receptor 1E)	HTR1E		CHEMBL2182;	P28566;	DB01238;DB00363;DB00216;DB01049;DB01221;DB00408;DB00247;DB00334;DB01224;DB00246;		PF00001;	IPR027425;IPR002231;IPR000276;IPR017452;	adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway [GO:0007193]; chemical synaptic transmission [GO:0007268]; G-protein coupled receptor signaling pathway [GO:0007186]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; negative regulation of cAMP metabolic process [GO:0030815]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; release of sequestered calcium ion into cytosol [GO:0051209]; response to drug [GO:0042493]	G-protein coupled receptor activity [GO:0004930]; G-protein coupled serotonin receptor activity [GO:0004993]; neurotransmitter receptor activity [GO:0030594]; serotonin binding [GO:0051378]	dendrite [GO:0030425]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P30939	5HT1F_HUMAN	5-hydroxytryptamine receptor 1F (5-HT-1F) (5-HT1F) (Serotonin receptor 1F)	HTR1F HTR1EL		CHEMBL1805;	P30939;	DB00216;DB01049;DB00696;DB01221;DB00247;DB06148;DB00952;DB00953;DB00669;DB00315;		PF00001;	IPR000450;IPR002231;IPR000276;IPR017452;	adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway [GO:0007193]; chemical synaptic transmission [GO:0007268]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; release of sequestered calcium ion into cytosol [GO:0051209]; response to drug [GO:0042493]	G-protein coupled serotonin receptor activity [GO:0004993]; neurotransmitter receptor activity [GO:0030594]; serotonin binding [GO:0051378]	dendrite [GO:0030425]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P28223	5HT2A_HUMAN	5-hydroxytryptamine receptor 2A (5-HT-2) (5-HT-2A) (Serotonin receptor 2A)	HTR2A HTR2		CHEMBL224;	P28223;	DB01614;DB06288;DB00321;DB00543;DB00714;DB01238;DB06216;DB09128;DB01200;DB09016;DB00248;DB06016;DB00477;DB01239;DB08810;DB00604;DB01242;DB00363;DB00924;DB00434;DB01151;DB00843;DB01142;DB00751;DB01049;DB00696;DB04908;DB00875;DB04842;DB00502;DB04946;DB00458;DB01221;DB00589;DB00408;DB08815;DB00934;DB00933;DB01403;DB00247;DB06148;DB00805;DB00370;DB01618;DB01149;DB00540;DB00334;DB01267;DB00715;DB01186;DB01621;DB00413;DB00420;DB01069;DB00777;DB01224;DB00409;DB00734;DB00268;DB06144;DB01622;DB00679;DB01623;DB00656;DB00726;DB01392;DB00246;DB01624;		PF00001;	IPR000455;IPR002231;IPR000276;IPR017452;	activation of phospholipase C activity [GO:0007202]; adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway [GO:0007193]; aging [GO:0007568]; artery smooth muscle contraction [GO:0014824]; behavioral response to cocaine [GO:0048148]; cell death [GO:0008219]; cellular calcium ion homeostasis [GO:0006874]; chemical synaptic transmission [GO:0007268]; detection of mechanical stimulus involved in sensory perception of pain [GO:0050966]; detection of temperature stimulus involved in sensory perception of pain [GO:0050965]; memory [GO:0007613]; negative regulation of potassium ion transport [GO:0043267]; negative regulation of synaptic transmission, glutamatergic [GO:0051967]; phosphatidylinositol 3-kinase signaling [GO:0014065]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; phospholipase C-activating serotonin receptor signaling pathway [GO:0007208]; positive regulation of cell proliferation [GO:0008284]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of fat cell differentiation [GO:0045600]; positive regulation of glycolytic process [GO:0045821]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of phosphatidylinositol biosynthetic process [GO:0010513]; positive regulation of vasoconstriction [GO:0045907]; protein localization to cytoskeleton [GO:0044380]; regulation of behavior [GO:0050795]; regulation of dopamine secretion [GO:0014059]; regulation of hormone secretion [GO:0046883]; release of sequestered calcium ion into cytosol [GO:0051209]; response to drug [GO:0042493]; serotonin receptor signaling pathway [GO:0007210]; sleep [GO:0030431]; temperature homeostasis [GO:0001659]; urinary bladder smooth muscle contraction [GO:0014832]	1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding [GO:0071886]; drug binding [GO:0008144]; G-protein coupled serotonin receptor activity [GO:0004993]; neurotransmitter receptor activity [GO:0030594]; serotonin binding [GO:0051378]; virus receptor activity [GO:0001618]	axon [GO:0030424]; caveola [GO:0005901]; cell body fiber [GO:0070852]; cytoplasmic, membrane-bounded vesicle [GO:0016023]; cytosol [GO:0005829]; dendrite [GO:0030425]; dendritic shaft [GO:0043198]; integral component of plasma membrane [GO:0005887]; neuronal cell body [GO:0043025]; plasma membrane [GO:0005886]
P41595	5HT2B_HUMAN	5-hydroxytryptamine receptor 2B (5-HT-2B) (5-HT2B) (Serotonin receptor 2B)	HTR2B	4IB4;4NC3;	CHEMBL1833;	P41595;	DB00543;DB00714;DB06216;DB01200;DB00248;DB06016;DB00477;DB01239;DB01242;DB00320;DB01142;DB00216;DB01049;DB01221;DB00589;DB00247;DB06148;DB00805;DB00370;DB00334;DB01186;DB00413;DB00268;DB00508;DB01392;		PF00001;	IPR000482;IPR002231;IPR000276;IPR017452;	activation of phospholipase C activity [GO:0007202]; adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway [GO:0007193]; behavior [GO:0007610]; calcium-mediated signaling [GO:0019722]; cardiac muscle hypertrophy [GO:0003300]; cellular calcium ion homeostasis [GO:0006874]; cellular response to temperature stimulus [GO:0071502]; cGMP biosynthetic process [GO:0006182]; chemical synaptic transmission [GO:0007268]; embryonic morphogenesis [GO:0048598]; ERK1 and ERK2 cascade [GO:0070371]; G-protein coupled receptor internalization [GO:0002031]; G-protein coupled receptor signaling pathway [GO:0007186]; heart morphogenesis [GO:0003007]; intestine smooth muscle contraction [GO:0014827]; negative regulation of apoptotic process [GO:0043066]; negative regulation of autophagy [GO:0010507]; negative regulation of cell death [GO:0060548]; neural crest cell differentiation [GO:0014033]; neural crest cell migration [GO:0001755]; phosphatidylinositol 3-kinase signaling [GO:0014065]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; phosphorylation [GO:0016310]; positive regulation of cell division [GO:0051781]; positive regulation of cell proliferation [GO:0008284]; positive regulation of cytokine production [GO:0001819]; positive regulation of cytokine secretion [GO:0050715]; positive regulation of endothelial cell proliferation [GO:0001938]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of nitric-oxide synthase activity [GO:0051000]; positive regulation of phosphatidylinositol biosynthetic process [GO:0010513]; protein kinase C-activating G-protein coupled receptor signaling pathway [GO:0007205]; protein kinase C signaling [GO:0070528]; regulation of behavior [GO:0050795]; release of sequestered calcium ion into cytosol [GO:0051209]; response to drug [GO:0042493]; serotonin receptor signaling pathway [GO:0007210]; vasoconstriction [GO:0042310]	drug binding [GO:0008144]; G-protein alpha-subunit binding [GO:0001965]; G-protein coupled serotonin receptor activity [GO:0004993]; GTPase activator activity [GO:0005096]; neurotransmitter receptor activity [GO:0030594]; serotonin binding [GO:0051378]	cell junction [GO:0030054]; cytoplasm [GO:0005737]; dendrite [GO:0030425]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; synapse [GO:0045202]
P28335	5HT2C_HUMAN	5-hydroxytryptamine receptor 2C (5-HT-2C) (5-HT2C) (5-HTR2C) (5-hydroxytryptamine receptor 1C) (5-HT-1C) (5-HT1C) (Serotonin receptor 2C)	HTR2C HTR1C		CHEMBL225;	P28335;	DB06594;DB00321;DB00543;DB00714;DB01238;DB06216;DB01200;DB00248;DB09014;DB00477;DB01239;DB01242;DB00363;DB00434;DB01151;DB01191;DB01142;DB01049;DB00696;DB00458;DB01221;DB00589;DB04871;DB00408;DB00934;DB01403;DB00247;DB06148;DB00805;DB00370;DB01149;DB00540;DB00334;DB01267;DB01186;DB00413;DB00420;DB00777;DB01224;DB00734;DB00268;DB06144;DB00193;DB00656;DB00726;DB01392;DB00246;		PF00001;	IPR000377;IPR002231;IPR000276;IPR017452;	adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway [GO:0007193]; behavioral fear response [GO:0001662]; cellular calcium ion homeostasis [GO:0006874]; cGMP biosynthetic process [GO:0006182]; chemical synaptic transmission [GO:0007268]; feeding behavior [GO:0007631]; locomotory behavior [GO:0007626]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; phospholipase C-activating serotonin receptor signaling pathway [GO:0007208]; positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway [GO:0051482]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of fat cell differentiation [GO:0045600]; positive regulation of phosphatidylinositol biosynthetic process [GO:0010513]; regulation of appetite [GO:0032098]; regulation of corticotropin-releasing hormone secretion [GO:0043397]; regulation of neurological system process [GO:0031644]; release of sequestered calcium ion into cytosol [GO:0051209]; response to drug [GO:0042493]; serotonin receptor signaling pathway [GO:0007210]	1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding [GO:0071886]; drug binding [GO:0008144]; G-protein coupled serotonin receptor activity [GO:0004993]; Gq/11-coupled serotonin receptor activity [GO:0001587]; neurotransmitter receptor activity [GO:0030594]; serotonin binding [GO:0051378]	dendrite [GO:0030425]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P46098	5HT3R_HUMAN	5-hydroxytryptamine receptor 3A (5-HT3-A) (5-HT3A) (5-hydroxytryptamine receptor 3) (5-HT-3) (5-HT3R) (Serotonin receptor 3A) (Serotonin-gated ion channel receptor)	HTR3A 5HT3R HTR3		CHEMBL1899;	P46098;	DB00969;DB00543;DB01238;DB01161;DB00604;DB00363;DB00757;DB01049;DB00898;DB00889;DB00408;DB01043;DB00333;DB01233;DB00370;DB00334;DB00904;DB00377;DB00721;DB01224;DB00728;DB06204;DB00726;DB01199;DB09068;DB00246;		PF02931;PF02932;	IPR008132;IPR008133;IPR027361;IPR006202;IPR006201;IPR006029;IPR018000;	cellular response to growth factor stimulus [GO:0071363]; ion transmembrane transport [GO:0034220]; positive regulation of ion transmembrane transporter activity [GO:0032414]; response to cocaine [GO:0042220]; response to ethanol [GO:0045471]	serotonin-activated cation-selective channel activity [GO:0005232]; serotonin binding [GO:0051378]; serotonin-gated cation channel activity [GO:0022850]	axon [GO:0030424]; cell junction [GO:0030054]; cytoplasm [GO:0005737]; neuronal cell body [GO:0043025]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]; serotonin-activated cation-selective channel complex [GO:1904602]
Q13639	5HT4R_HUMAN	5-hydroxytryptamine receptor 4 (5-HT-4) (5-HT4) (Serotonin receptor 4)	HTR4		CHEMBL1875;	Q13639;	DB08810;DB00604;DB01049;DB01233;DB00904;DB06480;		PF00001;	IPR001520;IPR000276;IPR017452;	chemical synaptic transmission [GO:0007268]; gamma-aminobutyric acid signaling pathway [GO:0007214]; G-protein coupled receptor signaling pathway [GO:0007186]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; regulation of appetite [GO:0032098]	G-protein coupled serotonin receptor activity [GO:0004993]	cytoplasm [GO:0005737]; endosome [GO:0005768]; integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]
P50406	5HT6R_HUMAN	5-hydroxytryptamine receptor 6 (5-HT-6) (5-HT6) (Serotonin receptor 6)	HTR6		CHEMBL3371;	P50406;	DB00321;DB00543;DB01238;DB06216;DB00477;DB00363;DB01142;DB01049;DB04946;DB00458;DB00408;DB06148;DB00540;DB00334;DB01224;DB06144;DB00246;		PF00001;	IPR000276;IPR017452;	cerebral cortex cell migration [GO:0021795]; chemical synaptic transmission [GO:0007268]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; positive regulation of TOR signaling [GO:0032008]	G-protein coupled serotonin receptor activity [GO:0004993]; histamine receptor activity [GO:0004969]; neurotransmitter receptor activity [GO:0030594]	cilium [GO:0005929]; dendrite [GO:0030425]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P34969	5HT7R_HUMAN	5-hydroxytryptamine receptor 7 (5-HT-7) (5-HT7) (5-HT-X) (Serotonin receptor 7)	HTR7		CHEMBL3155;	P34969;	DB06288;DB00321;DB00543;DB01238;DB06216;DB01200;DB00248;DB00477;DB00363;DB00988;DB00216;DB00751;DB01049;DB04946;DB00458;DB00408;DB08815;DB00934;DB00247;DB06148;DB00370;DB00334;DB01224;DB09068;DB00246;		PF00001;	IPR001069;IPR000276;IPR017452;	adenylate cyclase-activating serotonin receptor signaling pathway [GO:0007192]; blood circulation [GO:0008015]; chemical synaptic transmission [GO:0007268]; circadian rhythm [GO:0007623]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; smooth muscle contraction [GO:0006939]; vasoconstriction [GO:0042310]	G-protein coupled serotonin receptor activity [GO:0004993]; neurotransmitter receptor activity [GO:0030594]	dendrite [GO:0030425]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P49902	5NTC_HUMAN	Cytosolic purine 5'-nucleotidase (EC 3.1.3.5) (Cytosolic 5'-nucleotidase II)	NT5C2 NT5B NT5CP PNT5	2J2C;2JC9;2JCM;2XCV;2XCW;2XCX;2XJB;2XJC;2XJD;2XJE;2XJF;4H4B;5CQZ;5CR7;5L4Z;5L50;			DB00171;DB00811;		PF05761;	IPR023214;IPR008380;IPR016695;	adenosine metabolic process [GO:0046085]; drug metabolic process [GO:0017144]; IMP metabolic process [GO:0046040]; purine nucleotide catabolic process [GO:0006195]	5'-nucleotidase activity [GO:0008253]; metal ion binding [GO:0046872]; nucleoside phosphotransferase activity [GO:0050146]; nucleotide binding [GO:0000166]	cytosol [GO:0005829]
P21589	5NTD_HUMAN	5'-nucleotidase (5'-NT) (EC 3.1.3.5) (Ecto-5'-nucleotidase) (CD antigen CD73)	NT5E NT5 NTE	4H1S;4H1Y;4H2B;4H2F;4H2G;4H2I;	CHEMBL5957;	P21589;	DB00987;DB00806;		PF02872;PF00149;	IPR008334;IPR006146;IPR006179;IPR004843;IPR029052;	adenosine biosynthetic process [GO:0046086]; AMP catabolic process [GO:0006196]; DNA metabolic process [GO:0006259]; leukocyte cell-cell adhesion [GO:0007159]; negative regulation of inflammatory response [GO:0050728]; purine nucleotide catabolic process [GO:0006195]; pyrimidine nucleoside catabolic process [GO:0046135]	5'-nucleotidase activity [GO:0008253]; metal ion binding [GO:0046872]; nucleotide binding [GO:0000166]	anchored component of membrane [GO:0031225]; cell surface [GO:0009986]; cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; plasma membrane [GO:0005886]
P02763	A1AG1_HUMAN	Alpha-1-acid glycoprotein 1 (AGP 1) (Orosomucoid-1) (OMD 1)	ORM1 AGP1	3KQ0;	CHEMBL4285;	P02763;	DB05812;DB01418;DB01426;DB00802;DB00321;DB00543;DB01429;DB01156;DB08907;DB00482;DB00477;DB01151;DB00280;DB00590;DB01142;DB00530;DB00472;DB00317;DB00619;DB00458;DB08820;DB00934;DB08893;DB00731;DB00540;DB00334;DB00497;DB01359;DB00454;DB00946;DB08860;DB00457;DB00571;DB00908;DB08931;DB01232;DB00864;DB00706;DB05521;DB01041;DB00656;DB08867;DB05294;DB08881;DB08828;DB00682;		PF00061;	IPR001500;IPR012674;IPR011038;IPR000566;	acute-phase response [GO:0006953]; inflammatory response [GO:0006954]; negative regulation of interleukin-6 production [GO:0032715]; negative regulation of tumor necrosis factor production [GO:0032720]; platelet degranulation [GO:0002576]; regulation of immune system process [GO:0002682]		blood microparticle [GO:0072562]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; platelet alpha granule lumen [GO:0031093]
P01009	A1AT_HUMAN	Alpha-1-antitrypsin (Alpha-1 protease inhibitor) (Alpha-1-antiproteinase) (Serpin A1) [Cleaved into: Short peptide from AAT (SPAAT)]	SERPINA1 AAT PI PRO0684 PRO2209	1ATU;1D5S;1EZX;1HP7;1IZ2;1KCT;1OO8;1OPH;1PSI;1QLP;1QMB;2D26;2QUG;3CWL;3CWM;3DRM;3DRU;3NDD;3NDF;3NE4;3T1P;4PYW;5IO1;7API;8API;9API;					PF00079;	IPR023795;IPR023796;IPR000215;	acute-phase response [GO:0006953]; blood coagulation [GO:0007596]; COPII vesicle coating [GO:0048208]; ER to Golgi vesicle-mediated transport [GO:0006888]; platelet degranulation [GO:0002576]	glycoprotein binding [GO:0001948]; identical protein binding [GO:0042802]; protease binding [GO:0002020]; serine-type endopeptidase inhibitor activity [GO:0004867]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum-Golgi intermediate compartment membrane [GO:0033116]; endoplasmic reticulum lumen [GO:0005788]; ER to Golgi transport vesicle [GO:0030134]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; Golgi apparatus [GO:0005794]; Golgi membrane [GO:0000139]; platelet alpha granule lumen [GO:0031093]; proteinaceous extracellular matrix [GO:0005578]
P01023	A2MG_HUMAN	Alpha-2-macroglobulin (Alpha-2-M) (C3 and PZP-like alpha-2-macroglobulin domain-containing protein 5)	A2M CPAMD5 FWP007	1BV8;2P9R;4ACQ;			DB00626;DB00102;DB08888;		PF00207;PF07678;PF01835;PF07703;PF07677;PF10569;	IPR009048;IPR011626;IPR002890;IPR011625;IPR014756;IPR001599;IPR019742;IPR019565;IPR008930;IPR010916;	blood coagulation, intrinsic pathway [GO:0007597]; extracellular matrix disassembly [GO:0022617]; negative regulation of complement activation, lectin pathway [GO:0001869]; platelet degranulation [GO:0002576]; regulation of small GTPase mediated signal transduction [GO:0051056]; stem cell differentiation [GO:0048863]	calcium-dependent protein binding [GO:0048306]; enzyme binding [GO:0019899]; growth factor binding [GO:0019838]; GTPase activator activity [GO:0005096]; interleukin-1 binding [GO:0019966]; interleukin-8 binding [GO:0019959]; protease binding [GO:0002020]; receptor binding [GO:0005102]; serine-type endopeptidase inhibitor activity [GO:0004867]; tumor necrosis factor binding [GO:0043120]	blood microparticle [GO:0072562]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; platelet alpha granule lumen [GO:0031093]
P30542	AA1R_HUMAN	Adenosine receptor A1	ADORA1		CHEMBL226;	P30542;	DB00640;DB01223;DB00201;DB04932;DB00651;DB00824;DB00996;DB01303;DB00806;DB01412;DB00277;		PF00001;	IPR001068;IPR001634;IPR000276;IPR017452;	activation of MAPKK activity [GO:0000186]; adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway [GO:0007193]; apoptotic signaling pathway [GO:0097190]; cell-cell signaling [GO:0007267]; cognition [GO:0050890]; detection of temperature stimulus involved in sensory perception of pain [GO:0050965]; excitatory postsynaptic potential [GO:0060079]; inflammatory response [GO:0006954]; lipid catabolic process [GO:0016042]; negative regulation of acute inflammatory response [GO:0002674]; negative regulation of apoptotic process [GO:0043066]; negative regulation of blood pressure [GO:0045776]; negative regulation of cardiac muscle contraction [GO:0055118]; negative regulation of cell proliferation [GO:0008285]; negative regulation of circadian sleep/wake cycle, non-REM sleep [GO:0042323]; negative regulation of glutamate secretion [GO:0014050]; negative regulation of hormone secretion [GO:0046888]; negative regulation of leukocyte migration [GO:0002686]; negative regulation of lipid catabolic process [GO:0050995]; negative regulation of long term synaptic depression [GO:1900453]; negative regulation of mucus secretion [GO:0070256]; negative regulation of neurotrophin production [GO:0032900]; negative regulation of renal sodium excretion [GO:0035814]; negative regulation of synaptic transmission, GABAergic [GO:0032229]; negative regulation of synaptic transmission, glutamatergic [GO:0051967]; negative regulation of vasodilation [GO:0045908]; nervous system development [GO:0007399]; phagocytosis [GO:0006909]; positive regulation of blood pressure [GO:0045777]; positive regulation of epidermal growth factor-activated receptor activity [GO:0045741]; positive regulation of nucleoside transport [GO:0032244]; positive regulation of peptide secretion [GO:0002793]; positive regulation of potassium ion transport [GO:0043268]; positive regulation of protein dephosphorylation [GO:0035307]; protein targeting to membrane [GO:0006612]; regulation of glomerular filtration [GO:0003093]; regulation of respiratory gaseous exchange by neurological system process [GO:0002087]; regulation of sensory perception of pain [GO:0051930]; relaxation of vascular smooth muscle [GO:0060087]; response to hypoxia [GO:0001666]; signal transduction [GO:0007165]; temperature homeostasis [GO:0001659]	G-protein coupled adenosine receptor activity [GO:0001609]; phospholipase C activity [GO:0004629]; purine nucleoside binding [GO:0001883]	asymmetric synapse [GO:0032279]; axolemma [GO:0030673]; basolateral plasma membrane [GO:0016323]; dendritic spine [GO:0043197]; endoplasmic reticulum [GO:0005783]; integral component of plasma membrane [GO:0005887]; neuronal cell body [GO:0043025]; plasma membrane [GO:0005886]; postsynaptic density [GO:0014069]; postsynaptic membrane [GO:0045211]; presynaptic active zone [GO:0048786]; presynaptic membrane [GO:0042734]; terminal bouton [GO:0043195]
P29274	AA2AR_HUMAN	Adenosine receptor A2a	ADORA2A ADORA2	1MMH;1UPE;2YDO;2YDV;3EML;3PWH;3QAK;3REY;3RFM;3UZA;3UZC;3VG9;3VGA;4EIY;4UG2;4UHR;5G53;5IU4;5IU7;5IU8;5IUA;5IUB;5K2A;5K2B;	CHEMBL251;	P29274;	DB00640;DB00201;DB04932;DB00651;DB00824;DB00358;DB01303;DB00806;DB06213;DB01412;DB00277;		PF00001;	IPR001513;IPR001634;IPR000276;IPR017452;	adenylate cyclase-modulating G-protein coupled receptor signaling pathway [GO:0007188]; apoptotic process [GO:0006915]; blood circulation [GO:0008015]; blood coagulation [GO:0007596]; cAMP biosynthetic process [GO:0006171]; cell-cell signaling [GO:0007267]; cellular defense response [GO:0006968]; cellular protein metabolic process [GO:0044267]; central nervous system development [GO:0007417]; inflammatory response [GO:0006954]; phagocytosis [GO:0006909]; positive regulation of adenylate cyclase activity involved in G-protein coupled receptor signaling pathway [GO:0010579]; sensory perception [GO:0007600]	enzyme binding [GO:0019899]; G-protein coupled adenosine receptor activity [GO:0001609]; identical protein binding [GO:0042802]	integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]
P29275	AA2BR_HUMAN	Adenosine receptor A2b	ADORA2B		CHEMBL255;	P29275;	DB00640;DB04932;DB00824;DB00277;		PF00001;	IPR001435;IPR001634;IPR000276;IPR017452;	activation of adenylate cyclase activity [GO:0007190]; activation of MAPK activity [GO:0000187]; adenylate cyclase-activating G-protein coupled receptor signaling pathway [GO:0007189]; cellular defense response [GO:0006968]; cellular protein metabolic process [GO:0044267]; cellular response to extracellular stimulus [GO:0031668]; excretion [GO:0007588]; G-protein coupled receptor signaling pathway [GO:0007186]; JNK cascade [GO:0007254]; positive regulation of chemokine production [GO:0032722]; positive regulation of chronic inflammatory response to non-antigenic stimulus [GO:0002882]; positive regulation of guanylate cyclase activity [GO:0031284]; positive regulation of interleukin-6 production [GO:0032755]; positive regulation of mast cell degranulation [GO:0043306]; positive regulation of vascular endothelial growth factor production [GO:0010575]; relaxation of vascular smooth muscle [GO:0060087]	G-protein coupled adenosine receptor activity [GO:0001609]	integral component of plasma membrane [GO:0005887]; intracellular [GO:0005622]; plasma membrane [GO:0005886]
P0DMS8	AA3R_HUMAN	Adenosine receptor A3	ADORA3	1OEA;1R7N;	CHEMBL256;	P0DMS8;	DB00640;DB01223;DB00824;		PF00001;	IPR000466;IPR001634;IPR000276;IPR017452;		G-protein coupled adenosine receptor activity [GO:0001609]	integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]
Q15758	AAAT_HUMAN	Neutral amino acid transporter B(0) (ATB(0)) (Baboon M7 virus receptor) (RD114/simian type D retrovirus receptor) (Sodium-dependent neutral amino acid transporter type 2) (Solute carrier family 1 member 5)	SLC1A5 ASCT2 M7V1 RDR RDRC				DB00174;DB00130;		PF00375;	IPR001991;IPR018107;	amino acid transport [GO:0006865]; extracellular amino acid transport [GO:0006860]; glutamine transport [GO:0006868]; neutral amino acid transport [GO:0015804]	amino acid transmembrane transporter activity [GO:0015171]; L-glutamine transmembrane transporter activity [GO:0015186]; L-serine transmembrane transporter activity [GO:0015194]; neutral amino acid transmembrane transporter activity [GO:0015175]; receptor activity [GO:0004872]; symporter activity [GO:0015293]; virus receptor activity [GO:0001618]	extracellular exosome [GO:0070062]; Golgi apparatus [GO:0005794]; integral component of plasma membrane [GO:0005887]; melanosome [GO:0042470]; membrane [GO:0016020]; plasma membrane [GO:0005886]
Q8N5Z0	AADAT_HUMAN	Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial (KAT/AadAT) (2-aminoadipate aminotransferase) (2-aminoadipate transaminase) (EC 2.6.1.39) (Alpha-aminoadipate aminotransferase) (AadAT) (Kynurenine aminotransferase II) (Kynurenine--oxoglutarate aminotransferase II) (Kynurenine--oxoglutarate transaminase 2) (EC 2.6.1.7) (Kynurenine--oxoglutarate transaminase II)	AADAT KAT2	2QLR;2R2N;2VGZ;2XH1;3DC1;3UE8;4GDY;4GE4;4GE7;4GE9;4GEB;5EFS;5EUN;	CHEMBL2046259;	Q8N5Z0;		PATHWAY: Amino-acid degradation; L-lysine degradation via saccharopine pathway; glutaryl-CoA from L-lysine: step 4/6.	PF00155;	IPR004839;IPR015424;IPR015421;IPR015422;	2-oxoglutarate metabolic process [GO:0006103]; biosynthetic process [GO:0009058]; glutamate metabolic process [GO:0006536]; kynurenine metabolic process [GO:0070189]; L-lysine catabolic process to acetyl-CoA via saccharopine [GO:0033512]; lysine catabolic process [GO:0006554]; tryptophan catabolic process [GO:0006569]; tryptophan catabolic process to kynurenine [GO:0019441]	2-aminoadipate transaminase activity [GO:0047536]; kynurenine-oxoglutarate transaminase activity [GO:0016212]; protein homodimerization activity [GO:0042803]; pyridoxal phosphate binding [GO:0030170]	mitochondrial matrix [GO:0005759]
Q9Y478	AAKB1_HUMAN	5'-AMP-activated protein kinase subunit beta-1 (AMPK subunit beta-1) (AMPKb)	PRKAB1 AMPK	4CFE;4CFF;4ZHX;5EZV;	CHEMBL3847;	Q9Y478;	DB00945;DB00131;DB00331;		PF16561;PF04739;	IPR032640;IPR030080;IPR006828;IPR014756;	cell cycle arrest [GO:0007050]; fatty acid biosynthetic process [GO:0006633]; macroautophagy [GO:0016236]; positive regulation of gene expression [GO:0010628]; protein heterooligomerization [GO:0051291]; protein phosphorylation [GO:0006468]; regulation of protein kinase activity [GO:0045859]; regulation of signal transduction by p53 class mediator [GO:1901796]; signal transduction [GO:0007165]	AMP-activated protein kinase activity [GO:0004679]; protein kinase activity [GO:0004672]	cytosol [GO:0005829]; nucleoplasm [GO:0005654]; nucleotide-activated protein kinase complex [GO:0031588]
O43741	AAKB2_HUMAN	5'-AMP-activated protein kinase subunit beta-2 (AMPK subunit beta-2)	PRKAB2	2F15;2V8Q;2V92;2V9J;2Y8L;2Y8Q;2YA3;4CFH;4EAI;4EAJ;4RER;4REW;	CHEMBL3038456;		DB00945;DB00131;		PF16561;PF04739;	IPR032640;IPR030081;IPR006828;IPR014756;	carnitine shuttle [GO:0006853]; cell cycle arrest [GO:0007050]; fatty acid biosynthetic process [GO:0006633]; macroautophagy [GO:0016236]; protein phosphorylation [GO:0006468]; regulation of fatty acid biosynthetic process [GO:0042304]; regulation of protein kinase activity [GO:0045859]; regulation of signal transduction by p53 class mediator [GO:1901796]; signal transduction [GO:0007165]		cytosol [GO:0005829]; nucleoplasm [GO:0005654]; nucleotide-activated protein kinase complex [GO:0031588]
Q13131	AAPK1_HUMAN	5'-AMP-activated protein kinase catalytic subunit alpha-1 (AMPK subunit alpha-1) (EC 2.7.11.1) (Acetyl-CoA carboxylase kinase) (ACACA kinase) (EC 2.7.11.27) (Hydroxymethylglutaryl-CoA reductase kinase) (HMGCR kinase) (EC 2.7.11.31) (Tau-protein kinase PRKAA1) (EC 2.7.11.26)	PRKAA1 AMPK1	4RED;4RER;4REW;5EZV;	CHEMBL4045;	Q13131;	DB00945;DB00131;DB00171;DB00914;		PF16579;PF00069;	IPR032270;IPR028375;IPR011009;IPR000719;IPR017441;IPR008271;	activation of MAPK activity [GO:0000187]; CAMKK-AMPK signaling cascade [GO:0061762]; cell cycle arrest [GO:0007050]; cellular response to ethanol [GO:0071361]; cellular response to glucose starvation [GO:0042149]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to hypoxia [GO:0071456]; cellular response to nutrient levels [GO:0031669]; cellular response to organonitrogen compound [GO:0071417]; cellular response to prostaglandin E stimulus [GO:0071380]; cholesterol biosynthetic process [GO:0006695]; cold acclimation [GO:0009631]; fatty acid biosynthetic process [GO:0006633]; fatty acid homeostasis [GO:0055089]; fatty acid oxidation [GO:0019395]; glucose homeostasis [GO:0042593]; glucose metabolic process [GO:0006006]; intracellular signal transduction [GO:0035556]; lipid biosynthetic process [GO:0008610]; macroautophagy [GO:0016236]; negative regulation of apoptotic process [GO:0043066]; negative regulation of glucose import in response to insulin stimulus [GO:2001274]; negative regulation of glucosylceramide biosynthetic process [GO:0046318]; negative regulation of lipid catabolic process [GO:0050995]; negative regulation of TOR signaling [GO:0032007]; positive regulation of autophagy [GO:0010508]; positive regulation of cell proliferation [GO:0008284]; positive regulation of cholesterol biosynthetic process [GO:0045542]; positive regulation of gene expression [GO:0010628]; positive regulation of glycolytic process [GO:0045821]; positive regulation of skeletal muscle tissue development [GO:0048643]; protein heterooligomerization [GO:0051291]; protein phosphorylation [GO:0006468]; regulation of circadian rhythm [GO:0042752]; regulation of energy homeostasis [GO:2000505]; regulation of peptidyl-serine phosphorylation [GO:0033135]; regulation of signal transduction by p53 class mediator [GO:1901796]; regulation of transcription, DNA-templated [GO:0006355]; regulation of vesicle-mediated transport [GO:0060627]; response to activity [GO:0014823]; response to caffeine [GO:0031000]; response to camptothecin [GO:1901563]; response to gamma radiation [GO:0010332]; response to hypoxia [GO:0001666]; response to UV [GO:0009411]; rhythmic process [GO:0048511]; signal transduction [GO:0007165]; transcription, DNA-templated [GO:0006351]; Wnt signaling pathway [GO:0016055]	[acetyl-CoA carboxylase] kinase activity [GO:0050405]; [hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity [GO:0047322]; AMP-activated protein kinase activity [GO:0004679]; ATP binding [GO:0005524]; cAMP-dependent protein kinase activity [GO:0004691]; chromatin binding [GO:0003682]; histone serine kinase activity [GO:0035174]; metal ion binding [GO:0046872]; protein kinase activity [GO:0004672]; tau-protein kinase activity [GO:0050321]	apical plasma membrane [GO:0016324]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; intracellular [GO:0005622]; nucleoplasm [GO:0005654]; nucleotide-activated protein kinase complex [GO:0031588]; nucleus [GO:0005634]
Q9UDR5	AASS_HUMAN	Alpha-aminoadipic semialdehyde synthase, mitochondrial (LKR/SDH) [Includes: Lysine ketoglutarate reductase (LKR) (LOR) (EC 1.5.1.8); Saccharopine dehydrogenase (SDH) (EC 1.5.1.9)]	AASS					PATHWAY: Amino-acid degradation; L-lysine degradation via saccharopine pathway; glutaryl-CoA from L-lysine: step 1/6.; PATHWAY: Amino-acid degradation; L-lysine degradation via saccharopine pathway; glutaryl-CoA from L-lysine: step 2/6.	PF05222;PF16653;PF03435;	IPR007886;IPR007698;IPR016040;IPR032095;IPR005097;	L-lysine catabolic process to acetyl-CoA via saccharopine [GO:0033512]; lysine catabolic process [GO:0006554]; protein tetramerization [GO:0051262]	saccharopine dehydrogenase (NAD+, L-glutamate-forming) activity [GO:0047131]; saccharopine dehydrogenase (NADP+, L-lysine-forming) activity [GO:0047130]	intracellular membrane-bounded organelle [GO:0043231]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
P17174	AATC_HUMAN	Aspartate aminotransferase, cytoplasmic (cAspAT) (EC 2.6.1.1) (EC 2.6.1.3) (Cysteine aminotransferase, cytoplasmic) (Cysteine transaminase, cytoplasmic) (cCAT) (Glutamate oxaloacetate transaminase 1) (Transaminase A)	GOT1	3II0;3WZF;	CHEMBL2189139;		DB00128;DB00151;		PF00155;	IPR004839;IPR000796;IPR004838;IPR015424;IPR015421;	2-oxoglutarate metabolic process [GO:0006103]; aspartate biosynthetic process [GO:0006532]; aspartate catabolic process [GO:0006533]; aspartate metabolic process [GO:0006531]; cellular amino acid biosynthetic process [GO:0008652]; cellular response to insulin stimulus [GO:0032869]; fatty acid homeostasis [GO:0055089]; gluconeogenesis [GO:0006094]; glutamate catabolic process to 2-oxoglutarate [GO:0019551]; glutamate catabolic process to aspartate [GO:0019550]; glutamate metabolic process [GO:0006536]; glycerol biosynthetic process [GO:0006114]; Notch signaling pathway [GO:0007219]; oxaloacetate metabolic process [GO:0006107]; response to glucocorticoid [GO:0051384]	carboxylic acid binding [GO:0031406]; identical protein binding [GO:0042802]; L-aspartate:2-oxoglutarate aminotransferase activity [GO:0004069]; L-cysteine:2-oxoglutarate aminotransferase activity [GO:0047801]; L-phenylalanine:2-oxoglutarate aminotransferase activity [GO:0080130]; phosphatidylserine decarboxylase activity [GO:0004609]; pyridoxal phosphate binding [GO:0030170]	axon terminus [GO:0043679]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; lysosome [GO:0005764]; nucleus [GO:0005634]
O95477	ABCA1_HUMAN	ATP-binding cassette sub-family A member 1 (ATP-binding cassette transporter 1) (ABC-1) (ATP-binding cassette 1) (Cholesterol efflux regulatory protein)	ABCA1 ABC1 CERP		CHEMBL2362986;		DB00171;DB01016;DB01599;		PF00005;	IPR003593;IPR026082;IPR003439;IPR017871;IPR030365;IPR027417;	cellular response to cholesterol [GO:0071397]; cellular response to lipopolysaccharide [GO:0071222]; cellular response to retinoic acid [GO:0071300]; cholesterol efflux [GO:0033344]; cholesterol homeostasis [GO:0042632]; cholesterol metabolic process [GO:0008203]; endosomal transport [GO:0016197]; G-protein coupled receptor signaling pathway [GO:0007186]; high-density lipoprotein particle assembly [GO:0034380]; interleukin-1 beta secretion [GO:0050702]; intracellular cholesterol transport [GO:0032367]; lipoprotein metabolic process [GO:0042157]; lysosome organization [GO:0007040]; negative regulation of cholesterol storage [GO:0010887]; negative regulation of macrophage derived foam cell differentiation [GO:0010745]; peptide secretion [GO:0002790]; phagocytosis, engulfment [GO:0006911]; phospholipid efflux [GO:0033700]; phospholipid homeostasis [GO:0055091]; phospholipid translocation [GO:0045332]; platelet dense granule organization [GO:0060155]; positive regulation of cAMP biosynthetic process [GO:0030819]; positive regulation of cholesterol efflux [GO:0010875]; protein lipidation [GO:0006497]; regulation of Cdc42 protein signal transduction [GO:0032489]; regulation of high-density lipoprotein particle assembly [GO:0090107]; response to drug [GO:0042493]; response to laminar fluid shear stress [GO:0034616]; response to low-density lipoprotein particle [GO:0055098]; response to nutrient [GO:0007584]; reverse cholesterol transport [GO:0043691]	anion transmembrane transporter activity [GO:0008509]; apolipoprotein A-I binding [GO:0034186]; apolipoprotein A-I receptor activity [GO:0034188]; apolipoprotein binding [GO:0034185]; ATPase activity [GO:0016887]; ATPase activity, coupled to transmembrane movement of substances [GO:0042626]; ATPase binding [GO:0051117]; ATP binding [GO:0005524]; cholesterol binding [GO:0015485]; cholesterol transporter activity [GO:0017127]; phosphatidylcholine-translocating ATPase activity [GO:0090554]; phosphatidylserine-translocating ATPase activity [GO:0090556]; phospholipid binding [GO:0005543]; phospholipid transporter activity [GO:0005548]; receptor binding [GO:0005102]; small GTPase binding [GO:0031267]; syntaxin binding [GO:0019905]	endocytic vesicle [GO:0030139]; endoplasmic reticulum membrane [GO:0005789]; external side of plasma membrane [GO:0009897]; Golgi apparatus [GO:0005794]; high-density lipoprotein particle [GO:0034364]; integral component of plasma membrane [GO:0005887]; membrane raft [GO:0045121]; perinuclear region of cytoplasm [GO:0048471]; phagocytic vesicle [GO:0045335]; plasma membrane [GO:0005886]
O95342	ABCBB_HUMAN	Bile salt export pump (ATP-binding cassette sub-family B member 11)	ABCB11 BSEP		CHEMBL6020;	O95342;	DB00171;DB00559;DB00477;DB02659;DB00501;DB00845;DB00091;DB00694;DB03619;DB01234;DB00390;DB00997;DB00977;DB00693;DB02703;DB01016;DB01026;DB01051;DB01229;DB01174;DB08901;DB00175;DB00396;DB00908;DB00206;DB01045;DB01098;DB00675;DB01586;DB00661;DB00570;DB00541;		PF00664;PF00005;	IPR003593;IPR011527;IPR003439;IPR017871;IPR030278;IPR027417;	bile acid and bile salt transport [GO:0015721]; bile acid biosynthetic process [GO:0006699]; canalicular bile acid transport [GO:0015722]; transport [GO:0006810]	ATP binding [GO:0005524]; bile acid-exporting ATPase activity [GO:0015432]; canalicular bile acid transmembrane transporter activity [GO:0015126]; sodium-exporting ATPase activity, phosphorylative mechanism [GO:0008554]; transporter activity [GO:0005215]	apical part of cell [GO:0045177]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; intercellular canaliculus [GO:0046581]; membrane [GO:0016020]; plasma membrane [GO:0005886]
Q09428	ABCC8_HUMAN	ATP-binding cassette sub-family C member 8 (Sulfonylurea receptor 1)	ABCC8 HRINS SUR SUR1		CHEMBL2071;	Q09428;	DB00171;DB00672;DB01120;DB00222;DB01067;DB01251;DB01016;DB01382;DB01252;DB00731;DB00912;DB01124;		PF00664;PF00005;	IPR003593;IPR011527;IPR003439;IPR017871;IPR000844;IPR027417;IPR000388;	cellular response to organic substance [GO:0071310]; negative regulation of insulin secretion [GO:0046676]; positive regulation of potassium ion transport [GO:0043268]; potassium ion transport [GO:0006813]; regulation of insulin secretion [GO:0050796]; response to drug [GO:0042493]; response to insulin [GO:0032868]; response to lipopolysaccharide [GO:0032496]; response to pH [GO:0009268]; response to zinc ion [GO:0010043]; transmembrane transport [GO:0055085]	ATP-activated inward rectifier potassium channel activity [GO:0015272]; ATPase-coupled anion transmembrane transporter activity [GO:0043225]; ATP binding [GO:0005524]; ion channel binding [GO:0044325]; potassium channel activity [GO:0005267]; sulfonylurea receptor activity [GO:0008281]	plasma membrane [GO:0005886]; sarcolemma [GO:0042383]; synaptic vesicle membrane [GO:0030672]; voltage-gated potassium channel complex [GO:0008076]
O60706	ABCC9_HUMAN	ATP-binding cassette sub-family C member 9 (Sulfonylurea receptor 2)	ABCC9 SUR2		CHEMBL1971;	O60706;	DB00171;DB01016;		PF00664;PF00005;	IPR003593;IPR011527;IPR003439;IPR017871;IPR001475;IPR027417;IPR000388;	defense response to virus [GO:0051607]; potassium ion import [GO:0010107]; potassium ion transport [GO:0006813]; regulation of cardiac conduction [GO:1903779]; transmembrane transport [GO:0055085]	ATPase-coupled anion transmembrane transporter activity [GO:0043225]; ATP binding [GO:0005524]; ion channel binding [GO:0044325]; potassium channel activity [GO:0005267]; potassium channel regulator activity [GO:0015459]; sulfonylurea receptor activity [GO:0008281]; transporter activity [GO:0005215]	ATP-sensitive potassium channel complex [GO:0008282]; plasma membrane [GO:0005886]; sarcolemma [GO:0042383]; sarcomere [GO:0030017]; voltage-gated potassium channel complex [GO:0008076]
P45844	ABCG1_HUMAN	ATP-binding cassette sub-family G member 1 (ATP-binding cassette transporter 8) (White protein homolog)	ABCG1 ABC8 WHT1				DB00171;		PF01061;PF00005;	IPR003593;IPR013525;IPR003439;IPR017871;IPR020064;IPR027417;IPR005284;	amyloid precursor protein catabolic process [GO:0042987]; cholesterol efflux [GO:0033344]; cholesterol homeostasis [GO:0042632]; cholesterol metabolic process [GO:0008203]; detection of hormone stimulus [GO:0009720]; glycoprotein transport [GO:0034436]; high-density lipoprotein particle remodeling [GO:0034375]; intracellular cholesterol transport [GO:0032367]; lipoprotein metabolic process [GO:0042157]; low-density lipoprotein particle remodeling [GO:0034374]; negative regulation of cholesterol storage [GO:0010887]; negative regulation of macrophage derived foam cell differentiation [GO:0010745]; phospholipid efflux [GO:0033700]; phospholipid homeostasis [GO:0055091]; positive regulation of cholesterol biosynthetic process [GO:0045542]; positive regulation of cholesterol efflux [GO:0010875]; regulation of cholesterol esterification [GO:0010872]; regulation of transcription, DNA-templated [GO:0006355]; response to high density lipoprotein particle [GO:0055099]; response to lipid [GO:0033993]; response to organic substance [GO:0010033]; reverse cholesterol transport [GO:0043691]; transmembrane transport [GO:0055085]	ADP binding [GO:0043531]; ATP binding [GO:0005524]; cholesterol binding [GO:0015485]; cholesterol transporter activity [GO:0017127]; glycoprotein transporter activity [GO:0034437]; phospholipid binding [GO:0005543]; phospholipid transporter activity [GO:0005548]; protein dimerization activity [GO:0046983]; protein heterodimerization activity [GO:0046982]; protein homodimerization activity [GO:0042803]; sterol-transporting ATPase activity [GO:0034041]; toxin transporter activity [GO:0019534]	endoplasmic reticulum membrane [GO:0005789]; endosome [GO:0005768]; external side of plasma membrane [GO:0009897]; Golgi apparatus [GO:0005794]; Golgi membrane [GO:0000139]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; intracellular membrane-bounded organelle [GO:0043231]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; plasma membrane [GO:0005886]; recycling endosome [GO:0055037]
Q9UNQ0	ABCG2_HUMAN	ATP-binding cassette sub-family G member 2 (Breast cancer resistance protein) (CDw338) (Mitoxantrone resistance-associated protein) (Placenta-specific ATP-binding cassette transporter) (Urate exporter) (CD antigen CD338)	ABCG2 ABCP BCRP BCRP1 MXR		CHEMBL5393;	Q9UNQ0;	DB08916;DB11363;DB06605;DB00921;DB06772;DB00958;DB00515;DB00242;DB00631;DB09065;DB05239;DB00286;DB00091;DB08912;DB09102;DB00970;DB01254;DB00694;DB01234;DB00255;DB01248;DB00997;DB00470;DB00530;DB00783;DB00655;DB00773;DB00973;DB00544;DB00158;DB00317;DB01016;DB01094;DB00741;DB09054;DB00619;DB00762;DB00602;DB00709;DB00448;DB01097;DB09078;DB00563;DB01204;DB00688;DB00220;DB04868;DB00698;DB01051;DB00338;DB09330;DB00526;DB01229;DB00213;DB06589;DB08860;DB08901;DB00175;DB00457;DB01129;DB08896;DB08864;DB00740;DB08931;DB00503;DB09291;DB01098;DB01232;DB08934;DB00398;DB00795;DB00669;DB01268;DB00675;DB00966;DB00444;DB08880;DB00624;DB01030;DB05294;DB08881;DB00285;DB00661;DB00541;DB08828;DB00549;DB00495;		PF01061;PF00005;	IPR003593;IPR013525;IPR003439;IPR027417;	cellular iron ion homeostasis [GO:0006879]; response to drug [GO:0042493]; transport [GO:0006810]; urate metabolic process [GO:0046415]	ATPase activity, coupled to transmembrane movement of substances [GO:0042626]; ATP binding [GO:0005524]; heme transporter activity [GO:0015232]; protein homodimerization activity [GO:0042803]; transporter activity [GO:0005215]; xenobiotic-transporting ATPase activity [GO:0008559]	integral component of membrane [GO:0016021]; mitochondrial membrane [GO:0031966]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
P00519	ABL1_HUMAN	Tyrosine-protein kinase ABL1 (EC 2.7.10.2) (Abelson murine leukemia viral oncogene homolog 1) (Abelson tyrosine-protein kinase 1) (Proto-oncogene c-Abl) (p150)	ABL1 ABL JTK7	1AB2;1ABL;1AWO;1BBZ;1JU5;1OPL;1ZZP;2ABL;2E2B;2F4J;2FO0;2G1T;2G2F;2G2H;2G2I;2GQG;2HIW;2HYY;2HZ0;2HZ4;2HZI;2O88;2V7A;3CS9;3EG0;3EG1;3EG2;3EG3;3EGU;3K2M;3PYY;3QRI;3QRJ;3QRK;3T04;3UE4;3UYO;4J9B;4J9C;4J9D;4J9E;4J9F;4J9G;4J9H;4J9I;4JJB;4JJC;4JJD;4TWP;4WA9;4XEY;4YC8;4ZOG;5DC0;5DC4;5DC9;5HU9;	CHEMBL1862;	P00519;	DB00171;DB06616;DB01254;DB00619;DB04868;DB08901;DB08896;		PF08919;PF07714;PF00017;PF00018;	IPR033221;IPR015015;IPR011009;IPR000719;IPR017441;IPR001245;IPR000980;IPR001452;IPR008266;IPR020635;	actin cytoskeleton organization [GO:0030036]; actin filament branching [GO:0090135]; actin filament polymerization [GO:0030041]; activated T cell proliferation [GO:0050798]; activation of protein kinase C activity [GO:1990051]; alpha-beta T cell differentiation [GO:0046632]; associative learning [GO:0008306]; autophagy [GO:0006914]; B-1 B cell homeostasis [GO:0001922]; B cell proliferation involved in immune response [GO:0002322]; B cell receptor signaling pathway [GO:0050853]; Bergmann glial cell differentiation [GO:0060020]; cell cycle arrest [GO:0007050]; cellular protein modification process [GO:0006464]; cellular response to DNA damage stimulus [GO:0006974]; cellular response to dopamine [GO:1903351]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to lipopolysaccharide [GO:0071222]; cellular response to oxidative stress [GO:0034599]; cellular response to transforming growth factor beta stimulus [GO:0071560]; cerebellum morphogenesis [GO:0021587]; collateral sprouting [GO:0048668]; DNA damage induced protein phosphorylation [GO:0006975]; epidermal growth factor receptor signaling pathway [GO:0007173]; establishment of protein localization [GO:0045184]; Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096]; glomerular visceral epithelial cell apoptotic process [GO:1903210]; innate immune response [GO:0045087]; intrinsic apoptotic signaling pathway in response to DNA damage [GO:0008630]; microspike assembly [GO:0030035]; mismatch repair [GO:0006298]; mitochondrial depolarization [GO:0051882]; mitotic nuclear division [GO:0007067]; negative regulation of BMP signaling pathway [GO:0030514]; negative regulation of cell-cell adhesion [GO:0022408]; negative regulation of cellular senescence [GO:2000773]; negative regulation of endothelial cell apoptotic process [GO:2000352]; negative regulation of ERK1 and ERK2 cascade [GO:0070373]; negative regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043124]; negative regulation of mitotic cell cycle [GO:0045930]; negative regulation of phospholipase C activity [GO:1900275]; negative regulation of protein serine/threonine kinase activity [GO:0071901]; negative regulation of ubiquitin-protein transferase activity [GO:0051444]; neuromuscular process controlling balance [GO:0050885]; peptidyl-tyrosine autophosphorylation [GO:0038083]; peptidyl-tyrosine phosphorylation [GO:0018108]; platelet-derived growth factor receptor-beta signaling pathway [GO:0035791]; positive regulation of actin filament binding [GO:1904531]; positive regulation of apoptotic process [GO:0043065]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of dendrite development [GO:1900006]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of extracellular matrix organization [GO:1903055]; positive regulation of fibroblast proliferation [GO:0048146]; positive regulation of hydrogen peroxide-mediated programmed cell death [GO:1901300]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of interferon-gamma secretion [GO:1902715]; positive regulation of interleukin-2 secretion [GO:1900042]; positive regulation of microtubule binding [GO:1904528]; positive regulation of mitotic cell cycle [GO:0045931]; positive regulation of muscle cell differentiation [GO:0051149]; positive regulation of neuron apoptotic process [GO:0043525]; positive regulation of osteoblast proliferation [GO:0033690]; positive regulation of oxidoreductase activity [GO:0051353]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of release of sequestered calcium ion into cytosol [GO:0051281]; positive regulation of vasoconstriction [GO:0045907]; positive regulation of Wnt signaling pathway, planar cell polarity pathway [GO:2000096]; protein autophosphorylation [GO:0046777]; regulation of actin cytoskeleton organization [GO:0032956]; regulation of actin cytoskeleton reorganization [GO:2000249]; regulation of autophagy [GO:0010506]; regulation of axon extension [GO:0030516]; regulation of cell adhesion [GO:0030155]; regulation of cell motility [GO:2000145]; regulation of cell proliferation [GO:0042127]; regulation of endocytosis [GO:0030100]; regulation of microtubule polymerization [GO:0031113]; regulation of response to DNA damage stimulus [GO:2001020]; regulation of transcription, DNA-templated [GO:0006355]; response to drug [GO:0042493]; response to endoplasmic reticulum stress [GO:0034976]; response to epinephrine [GO:0071871]; response to oxidative stress [GO:0006979]; signal transduction in response to DNA damage [GO:0042770]; spleen development [GO:0048536]; substrate adhesion-dependent cell spreading [GO:0034446]; thymus development [GO:0048538]; transitional one stage B cell differentiation [GO:0002333]	actin monomer binding [GO:0003785]; ATP binding [GO:0005524]; DNA binding [GO:0003677]; magnesium ion binding [GO:0000287]; manganese ion binding [GO:0030145]; mitogen-activated protein kinase binding [GO:0051019]; nicotinate-nucleotide adenylyltransferase activity [GO:0004515]; non-membrane spanning protein tyrosine kinase activity [GO:0004715]; proline-rich region binding [GO:0070064]; protein C-terminus binding [GO:0008022]; protein kinase activity [GO:0004672]; protein kinase C binding [GO:0005080]; protein tyrosine kinase activity [GO:0004713]; SH3 domain binding [GO:0017124]; syntaxin binding [GO:0019905]	actin cytoskeleton [GO:0015629]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; extrinsic component of cytoplasmic side of plasma membrane [GO:0031234]; growth cone [GO:0030426]; mitochondrion [GO:0005739]; neuronal cell body [GO:0043025]; nuclear membrane [GO:0031965]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; ruffle [GO:0001726]; synapse [GO:0045202]
P42684	ABL2_HUMAN	Abelson tyrosine-protein kinase 2 (EC 2.7.10.2) (Abelson murine leukemia viral oncogene homolog 2) (Abelson-related gene protein) (Tyrosine-protein kinase ARG)	ABL2 ABLL ARG	2ECD;2KK1;2XYN;3GVU;3HMI;3ULR;4EIH;	CHEMBL4014;	P42684;	DB00171;DB01254;		PF08919;PF07714;PF00017;PF00018;	IPR033217;IPR015015;IPR011009;IPR000719;IPR017441;IPR001245;IPR000980;IPR001452;IPR008266;IPR020635;	actin cytoskeleton organization [GO:0030036]; cell adhesion [GO:0007155]; cell migration [GO:0016477]; cellular protein modification process [GO:0006464]; cellular response to retinoic acid [GO:0071300]; innate immune response [GO:0045087]; peptidyl-tyrosine autophosphorylation [GO:0038083]; peptidyl-tyrosine phosphorylation [GO:0018108]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of neuron projection development [GO:0010976]; positive regulation of oxidoreductase activity [GO:0051353]; positive regulation of phospholipase C activity [GO:0010863]; regulation of actin cytoskeleton reorganization [GO:2000249]; regulation of autophagy [GO:0010506]; regulation of cell adhesion [GO:0030155]; regulation of cell motility [GO:2000145]; regulation of cell proliferation [GO:0042127]; regulation of endocytosis [GO:0030100]; signal transduction [GO:0007165]; transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169]	actin filament binding [GO:0051015]; actin monomer binding [GO:0003785]; ATP binding [GO:0005524]; magnesium ion binding [GO:0000287]; manganese ion binding [GO:0030145]; non-membrane spanning protein tyrosine kinase activity [GO:0004715]; protein kinase activity [GO:0004672]; protein tyrosine kinase activity [GO:0004713]	actin cytoskeleton [GO:0015629]; cytosol [GO:0005829]; extrinsic component of cytoplasmic side of plasma membrane [GO:0031234]
P19801	ABP1_HUMAN	Amiloride-sensitive amine oxidase [copper-containing] (DAO) (Diamine oxidase) (EC 1.4.3.22) (Amiloride-binding protein 1) (Amine oxidase copper domain-containing protein 1) (Histaminase) (Kidney amine oxidase) (KAO)	AOC1 ABP1 DAO1	3HI7;3HIG;3HII;3K5T;3MPH;	CHEMBL2118;	P19801;	DB00594;		PF01179;PF02727;PF02728;	IPR000269;IPR015798;IPR016182;IPR015800;IPR015802;	amine metabolic process [GO:0009308]; cellular response to azide [GO:0097185]; cellular response to copper ion [GO:0071280]; cellular response to copper ion starvation [GO:0035874]; cellular response to heparin [GO:0071504]; cellular response to histamine [GO:0071420]; oxidation-reduction process [GO:0055114]; response to antibiotic [GO:0046677]; response to drug [GO:0042493]; xenobiotic metabolic process [GO:0006805]	calcium ion binding [GO:0005509]; copper ion binding [GO:0005507]; diamine oxidase activity [GO:0052597]; drug binding [GO:0008144]; heparin binding [GO:0008201]; histamine oxidase activity [GO:0052598]; methylputrescine oxidase activity [GO:0052599]; primary amine oxidase activity [GO:0008131]; propane-1,3-diamine oxidase activity [GO:0052600]; protein complex binding [GO:0032403]; protein homodimerization activity [GO:0042803]; quinone binding [GO:0048038]; receptor activity [GO:0004872]; zinc ion binding [GO:0008270]	bicellular tight junction [GO:0005923]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; peroxisome [GO:0005777]; plasma membrane [GO:0005886]
Q9UKU7	ACAD8_HUMAN	Isobutyryl-CoA dehydrogenase, mitochondrial (EC 1.3.99.-) (Activator-recruited cofactor 42 kDa component) (ARC42) (Acyl-CoA dehydrogenase family member 8) (ACAD-8)	ACAD8 ARC42 IBD	1RX0;			DB03147;	PATHWAY: Amino-acid degradation; L-valine degradation.	PF00441;PF02770;PF02771;	IPR006089;IPR006091;IPR009075;IPR013786;IPR009100;	branched-chain amino acid catabolic process [GO:0009083]; fatty acid beta-oxidation using acyl-CoA dehydrogenase [GO:0033539]; lipid homeostasis [GO:0055088]; lipid metabolic process [GO:0006629]; regulation of transcription, DNA-templated [GO:0006355]; transcription, DNA-templated [GO:0006351]; valine catabolic process [GO:0006574]	acyl-CoA dehydrogenase activity [GO:0003995]; electron carrier activity [GO:0009055]; fatty-acyl-CoA binding [GO:0000062]; flavin adenine dinucleotide binding [GO:0050660]; oxidoreductase activity, acting on the CH-CH group of donors, with a flavin as acceptor [GO:0052890]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
P11310	ACADM_HUMAN	Medium-chain specific acyl-CoA dehydrogenase, mitochondrial (MCAD) (EC 1.3.8.7)	ACADM	1EGC;1EGD;1EGE;1T9G;2A1T;4P13;			DB03147;	PATHWAY: Lipid metabolism; mitochondrial fatty acid beta-oxidation.	PF00441;PF02770;PF02771;	IPR006089;IPR006091;IPR009075;IPR013786;IPR009100;	carnitine biosynthetic process [GO:0045329]; carnitine metabolic process, CoA-linked [GO:0019254]; fatty acid beta-oxidation [GO:0006635]; fatty acid beta-oxidation using acyl-CoA dehydrogenase [GO:0033539]; lipid homeostasis [GO:0055088]; medium-chain fatty acid catabolic process [GO:0051793]; medium-chain fatty acid metabolic process [GO:0051791]; oxidation-reduction process [GO:0055114]	acyl-CoA dehydrogenase activity [GO:0003995]; electron carrier activity [GO:0009055]; fatty-acyl-CoA binding [GO:0000062]; flavin adenine dinucleotide binding [GO:0050660]; identical protein binding [GO:0042802]; medium-chain-acyl-CoA dehydrogenase activity [GO:0070991]; oxidoreductase activity, acting on the CH-CH group of donors, with a flavin as acceptor [GO:0052890]	axon [GO:0030424]; extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]
P16219	ACADS_HUMAN	Short-chain specific acyl-CoA dehydrogenase, mitochondrial (SCAD) (EC 1.3.8.1) (Butyryl-CoA dehydrogenase)	ACADS	2VIG;			DB03147;	PATHWAY: Lipid metabolism; mitochondrial fatty acid beta-oxidation.	PF00441;PF02770;PF02771;	IPR006089;IPR006091;IPR009075;IPR013786;IPR009100;	butyrate catabolic process [GO:0046359]; fatty acid beta-oxidation [GO:0006635]; fatty acid beta-oxidation using acyl-CoA dehydrogenase [GO:0033539]; lipid homeostasis [GO:0055088]	acyl-CoA dehydrogenase activity [GO:0003995]; butyryl-CoA dehydrogenase activity [GO:0004085]; electron carrier activity [GO:0009055]; fatty-acyl-CoA binding [GO:0000062]; flavin adenine dinucleotide binding [GO:0050660]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]
Q16515	ACCN1_HUMAN	Acid-sensing ion channel 2 (ASIC2) (Amiloride-sensitive brain sodium channel) (Amiloride-sensitive cation channel 1, neuronal) (Amiloride-sensitive cation channel neuronal 1) (Brain sodium channel 1) (BNC1) (BNaC1) (Mammalian degenerin homolog)	ASIC2 ACCN ACCN1 BNAC1 MDEG		CHEMBL1628467;		DB00594;		PF00858;	IPR004724;IPR001873;IPR020903;	central nervous system development [GO:0007417]; chemical synaptic transmission [GO:0007268]; detection of mechanical stimulus involved in sensory perception [GO:0050974]; ion transmembrane transport [GO:0034220]; monovalent inorganic cation transport [GO:0015672]; negative regulation of apoptotic process [GO:0043066]; peripheral nervous system development [GO:0007422]; phototransduction [GO:0007602]; positive regulation of synapse assembly [GO:0051965]; protein localization to synapse [GO:0035418]; regulation of blood coagulation [GO:0030193]; regulation of gene expression [GO:0010468]; regulation of ion transmembrane transport [GO:0034765]; regulation of membrane potential [GO:0042391]; regulation of systemic arterial blood pressure by aortic arch baroreceptor feedback [GO:0003026]; regulation of vasoconstriction [GO:0019229]; response to acidic pH [GO:0010447]; sensory perception of sound [GO:0007605]; sensory perception of sour taste [GO:0050915]	acid-sensing ion channel activity [GO:0044736]; ion gated channel activity [GO:0022839]; ligand-gated sodium channel activity [GO:0015280]	dendritic spine [GO:0043197]; integral component of plasma membrane [GO:0005887]; neuronal cell body [GO:0043025]; plasma membrane [GO:0005886]
P78348	ACCN2_HUMAN	Acid-sensing ion channel 1 (ASIC1) (Amiloride-sensitive cation channel 2, neuronal) (Brain sodium channel 2) (BNaC2)	ASIC1 ACCN2 BNAC2		CHEMBL1628477;	P78348;	DB00594;DB00586;		PF00858;	IPR004724;IPR001873;IPR020903;	associative learning [GO:0008306]; calcium ion transmembrane transport [GO:0070588]; cellular response to pH [GO:0071467]; ion transmembrane transport [GO:0034220]; memory [GO:0007613]; negative regulation of neurotransmitter secretion [GO:0046929]; protein homotrimerization [GO:0070207]; regulation of membrane potential [GO:0042391]; response to acidic pH [GO:0010447]; response to pH [GO:0009268]; sensory perception of sour taste [GO:0050915]; signal transduction [GO:0007165]; sodium ion transmembrane transport [GO:0035725]; sodium ion transport [GO:0006814]; transport [GO:0006810]	acid-sensing ion channel activity [GO:0044736]; ion gated channel activity [GO:0022839]; ligand-gated sodium channel activity [GO:0015280]	cell surface [GO:0009986]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; synapse [GO:0045202]
P45954	ACDSB_HUMAN	Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial (SBCAD) (EC 1.3.8.5) (2-methyl branched chain acyl-CoA dehydrogenase) (2-MEBCAD) (2-methylbutyryl-coenzyme A dehydrogenase) (2-methylbutyryl-CoA dehydrogenase)	ACADSB	2JIF;			DB00167;DB00313;	PATHWAY: Lipid metabolism; mitochondrial fatty acid beta-oxidation.	PF00441;PF02770;PF02771;	IPR006089;IPR006091;IPR009075;IPR013786;IPR009100;	branched-chain amino acid catabolic process [GO:0009083]; fatty acid beta-oxidation using acyl-CoA dehydrogenase [GO:0033539]; fatty acid metabolic process [GO:0006631]; lipid homeostasis [GO:0055088]	acyl-CoA dehydrogenase activity [GO:0003995]; electron carrier activity [GO:0009055]; fatty-acyl-CoA binding [GO:0000062]; flavin adenine dinucleotide binding [GO:0050660]; oxidoreductase activity, acting on the CH-CH group of donors, with a flavin as acceptor [GO:0052890]	extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
Q9BYF1	ACE2_HUMAN	Angiotensin-converting enzyme 2 (EC 3.4.17.23) (ACE-related carboxypeptidase) (Angiotensin-converting enzyme homolog) (ACEH) (Metalloprotease MPROT15) [Cleaved into: Processed angiotensin-converting enzyme 2]	ACE2 UNQ868/PRO1885	1R42;1R4L;1XJP;2AJF;3D0G;3D0H;3D0I;3KBH;3SCI;3SCJ;3SCK;3SCL;	CHEMBL3736;	Q9BYF1;	DB00722;DB00691;		PF16959;PF01401;	IPR033591;IPR031588;IPR001548;	angiotensin catabolic process in blood [GO:0002005]; angiotensin maturation [GO:0002003]; angiotensin-mediated drinking behavior [GO:0003051]; positive regulation of cardiac muscle contraction [GO:0060452]; positive regulation of gap junction assembly [GO:1903598]; positive regulation of reactive oxygen species metabolic process [GO:2000379]; receptor biosynthetic process [GO:0032800]; receptor-mediated virion attachment to host cell [GO:0046813]; regulation of cardiac conduction [GO:1903779]; regulation of cell proliferation [GO:0042127]; regulation of cytokine production [GO:0001817]; regulation of inflammatory response [GO:0050727]; regulation of systemic arterial blood pressure by renin-angiotensin [GO:0003081]; regulation of vasoconstriction [GO:0019229]; regulation of vasodilation [GO:0042312]; tryptophan transport [GO:0015827]; viral entry into host cell [GO:0046718]	carboxypeptidase activity [GO:0004180]; endopeptidase activity [GO:0004175]; glycoprotein binding [GO:0001948]; metallocarboxypeptidase activity [GO:0004181]; virus receptor activity [GO:0001618]; zinc ion binding [GO:0008270]	cell surface [GO:0009986]; cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; integral component of membrane [GO:0016021]; membrane raft [GO:0045121]; plasma membrane [GO:0005886]
P22303	ACES_HUMAN	Acetylcholinesterase (AChE) (EC 3.1.1.7)	ACHE	1B41;1F8U;1PUV;1PUW;1VZJ;2CLJ;2X8B;3LII;4BDT;4EY4;4EY5;4EY6;4EY7;4EY8;4M0E;4M0F;4PQE;5FOQ;5FPQ;5HF5;5HF6;5HF8;5HF9;5HFA;	CHEMBL220;	P22303;	DB03128;DB01122;DB00122;DB01245;DB00944;DB08996;DB00449;DB00843;DB01010;DB01364;DB00674;DB00483;DB00677;DB00358;DB00805;DB01400;DB00981;DB00733;DB00545;DB00989;DB01199;		PF08674;PF00135;	IPR029058;IPR014788;IPR002018;IPR019826;IPR019819;IPR000997;	acetylcholine catabolic process [GO:0006581]; acetylcholine catabolic process in synaptic cleft [GO:0001507]; amyloid precursor protein metabolic process [GO:0042982]; cell adhesion [GO:0007155]; cell proliferation [GO:0008283]; DNA replication [GO:0006260]; muscle organ development [GO:0007517]; negative regulation of synaptic transmission, cholinergic [GO:0032223]; nervous system development [GO:0007399]; neurotransmitter biosynthetic process [GO:0042136]; neurotransmitter receptor biosynthetic process [GO:0045212]; osteoblast development [GO:0002076]; phosphatidylcholine biosynthetic process [GO:0006656]; positive regulation of protein secretion [GO:0050714]; protein tetramerization [GO:0051262]; receptor internalization [GO:0031623]; regulation of receptor recycling [GO:0001919]; response to wounding [GO:0009611]; retina development in camera-type eye [GO:0060041]; synapse assembly [GO:0007416]	acetylcholine binding [GO:0042166]; acetylcholinesterase activity [GO:0003990]; beta-amyloid binding [GO:0001540]; cholinesterase activity [GO:0004104]; collagen binding [GO:0005518]; hydrolase activity [GO:0016787]; laminin binding [GO:0043236]; protein homodimerization activity [GO:0042803]; serine hydrolase activity [GO:0017171]	anchored component of membrane [GO:0031225]; basal lamina [GO:0005605]; cell junction [GO:0030054]; cell surface [GO:0009986]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; Golgi apparatus [GO:0005794]; membrane [GO:0016020]; neuromuscular junction [GO:0031594]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; synapse [GO:0045202]; synaptic cleft [GO:0043083]
P12821	ACET_HUMAN,ACE_HUMAN	Angiotensin-converting enzyme (ACE) (EC 3.2.1.-) (EC 3.4.15.1) (Dipeptidyl carboxypeptidase I) (Kininase II) (CD antigen CD143) [Cleaved into: Angiotensin-converting enzyme, soluble form]	ACE DCP DCP1	1O86;1O8A;1UZE;1UZF;2C6F;2C6N;2IUL;2IUX;2OC2;2XY9;2XYD;2YDM;3BKK;3BKL;3L3N;3NXQ;4APH;4APJ;4BXK;4BZR;4BZS;4C2N;4C2O;4C2P;4C2Q;4C2R;4CA5;4CA6;4UFA;4UFB;5AM8;5AM9;5AMA;5AMB;5AMC;	CHEMBL1808;	P12821;	DB00542;DB00616;DB01197;DB01340;DB00584;DB00492;DB00722;DB00691;DB00790;DB00881;DB00178;DB01180;DB01348;DB00519;		PF01401;	IPR001548;	angiotensin catabolic process in blood [GO:0002005]; angiotensin maturation [GO:0002003]; antigen processing and presentation of peptide antigen via MHC class I [GO:0002474]; arachidonic acid secretion [GO:0050482]; beta-amyloid metabolic process [GO:0050435]; blood vessel remodeling [GO:0001974]; cell proliferation in bone marrow [GO:0071838]; heart contraction [GO:0060047]; hematopoietic stem cell differentiation [GO:0060218]; hormone catabolic process [GO:0042447]; kidney development [GO:0001822]; mononuclear cell proliferation [GO:0032943]; negative regulation of gap junction assembly [GO:1903597]; negative regulation of gene expression [GO:0010629]; negative regulation of protein binding [GO:0032091]; neutrophil mediated immunity [GO:0002446]; peptide catabolic process [GO:0043171]; positive regulation of peptidyl-cysteine S-nitrosylation [GO:2000170]; positive regulation of peptidyl-tyrosine autophosphorylation [GO:1900086]; positive regulation of protein binding [GO:0032092]; positive regulation of protein tyrosine kinase activity [GO:0061098]; positive regulation of systemic arterial blood pressure [GO:0003084]; posttranscriptional regulation of gene expression [GO:0010608]; regulation of angiotensin metabolic process [GO:0060177]; regulation of blood pressure [GO:0008217]; regulation of hematopoietic stem cell proliferation [GO:1902033]; regulation of renal output by angiotensin [GO:0002019]; regulation of smooth muscle cell migration [GO:0014910]; regulation of systemic arterial blood pressure by renin-angiotensin [GO:0003081]; regulation of vasoconstriction [GO:0019229]; regulation of vasodilation [GO:0042312]; spermatogenesis [GO:0007283]	actin binding [GO:0003779]; bradykinin receptor binding [GO:0031711]; carboxypeptidase activity [GO:0004180]; chloride ion binding [GO:0031404]; drug binding [GO:0008144]; endopeptidase activity [GO:0004175]; exopeptidase activity [GO:0008238]; metallodipeptidase activity [GO:0070573]; metallopeptidase activity [GO:0008237]; mitogen-activated protein kinase binding [GO:0051019]; mitogen-activated protein kinase kinase binding [GO:0031434]; peptidyl-dipeptidase activity [GO:0008241]; tripeptidyl-peptidase activity [GO:0008240]; zinc ion binding [GO:0008270]	endosome [GO:0005768]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; integral component of membrane [GO:0016021]; lysosome [GO:0005764]; plasma membrane [GO:0005886]
Q9GZZ6	ACH10_HUMAN	Neuronal acetylcholine receptor subunit alpha-10 (Nicotinic acetylcholine receptor subunit alpha-10) (NACHR alpha-10)	CHRNA10 NACHRA10		CHEMBL2109238;	Q9GZZ6;	DB01161;DB00898;DB00674;DB00333;DB00184;DB01090;DB00202;DB01116;		PF02931;PF02932;	IPR027361;IPR006202;IPR006201;IPR006029;IPR018000;IPR002394;	detection of mechanical stimulus involved in sensory perception of sound [GO:0050910]; inner ear morphogenesis [GO:0042472]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; regulation of cell proliferation [GO:0042127]; signal transduction [GO:0007165]; synaptic transmission, cholinergic [GO:0007271]	acetylcholine-activated cation-selective channel activity [GO:0004889]; acetylcholine binding [GO:0042166]; calcium channel activity [GO:0005262]; receptor binding [GO:0005102]	acetylcholine-gated channel complex [GO:0005892]; axon [GO:0030424]; cell junction [GO:0030054]; membrane [GO:0016020]; perikaryon [GO:0043204]; postsynaptic membrane [GO:0045211]
Q15822	ACHA2_HUMAN	Neuronal acetylcholine receptor subunit alpha-2	CHRNA2	5FJV;	CHEMBL2109236;	Q15822;	DB00732;DB00810;DB00411;DB00565;DB01245;DB00514;DB01135;DB00898;DB00674;DB00483;DB00657;DB01336;DB01226;DB00184;DB01337;DB01338;DB00721;DB00728;DB01199;DB01339;		PF02931;PF02932;	IPR027361;IPR006202;IPR006201;IPR006029;IPR018000;IPR002394;	ion transport [GO:0006811]; neuromuscular synaptic transmission [GO:0007274]; protein heterooligomerization [GO:0051291]; response to nicotine [GO:0035094]; signal transduction [GO:0007165]; synaptic transmission, cholinergic [GO:0007271]	acetylcholine-activated cation-selective channel activity [GO:0004889]; acetylcholine binding [GO:0042166]; acetylcholine receptor activity [GO:0015464]; drug binding [GO:0008144]; ligand-gated ion channel activity [GO:0015276]	acetylcholine-gated channel complex [GO:0005892]; cell junction [GO:0030054]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
P43681	ACHA4_HUMAN	Neuronal acetylcholine receptor subunit alpha-4	CHRNA4 NACRA4	2GVT;2LLY;	CHEMBL1882;	P43681;	DB01351;DB01352;DB00237;DB00241;DB01353;DB09028;DB00514;DB00898;DB00674;DB01354;DB01355;DB00849;DB00184;DB00312;DB01174;DB00794;DB00418;DB00306;DB00599;DB01273;		PF02931;PF02932;	IPR027361;IPR006202;IPR006201;IPR006029;IPR018000;IPR002394;	action potential [GO:0001508]; B cell activation [GO:0042113]; behavioral response to nicotine [GO:0035095]; calcium ion transport [GO:0006816]; chemical synaptic transmission [GO:0007268]; cognition [GO:0050890]; DNA repair [GO:0006281]; exploration behavior [GO:0035640]; inhibitory postsynaptic potential [GO:0060080]; ion transport [GO:0006811]; locomotory behavior [GO:0007626]; membrane depolarization [GO:0051899]; neurological system process [GO:0050877]; neuromuscular synaptic transmission [GO:0007274]; regulation of dopamine secretion [GO:0014059]; regulation of membrane potential [GO:0042391]; respiratory gaseous exchange [GO:0007585]; response to hypoxia [GO:0001666]; response to nicotine [GO:0035094]; response to oxidative stress [GO:0006979]; sensory perception of pain [GO:0019233]; signal transduction [GO:0007165]; synaptic transmission, cholinergic [GO:0007271]	acetylcholine-activated cation-selective channel activity [GO:0004889]; acetylcholine binding [GO:0042166]; acetylcholine receptor activity [GO:0015464]; ligand-gated ion channel activity [GO:0015276]	acetylcholine-gated channel complex [GO:0005892]; cell junction [GO:0030054]; dendrite [GO:0030425]; external side of plasma membrane [GO:0009897]; integral component of membrane [GO:0016021]; membrane [GO:0016020]; neuronal cell body [GO:0043025]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
P36544	ACHA7_HUMAN	Neuronal acetylcholine receptor subunit alpha-7	CHRNA7 NACHRA7	2MAW;5AFH;5AFJ;5AFK;5AFL;5AFM;5AFN;	CHEMBL2492;	P36544;	DB01351;DB01352;DB00237;DB00241;DB01353;DB09028;DB00514;DB00898;DB00674;DB01354;DB01355;DB00849;DB00184;DB00312;DB01174;DB00794;DB00418;DB00306;DB00599;DB01273;		PF02931;PF02932;	IPR027361;IPR006202;IPR006201;IPR006029;IPR018000;IPR002394;	activation of MAPK activity [GO:0000187]; associative learning [GO:0008306]; B cell activation [GO:0042113]; behavioral response to ethanol [GO:0048149]; behavioral response to nicotine [GO:0035095]; calcium ion transport [GO:0006816]; cellular calcium ion homeostasis [GO:0006874]; cognition [GO:0050890]; endocytosis [GO:0006897]; flagellated sperm motility [GO:0030317]; generation of ovulation cycle rhythm [GO:0060112]; ion transmembrane transport [GO:0034220]; ion transport [GO:0006811]; memory [GO:0007613]; negative regulation of inflammatory response [GO:0050728]; negative regulation of interleukin-1 beta production [GO:0032691]; negative regulation of interleukin-6 production [GO:0032715]; negative regulation of tumor necrosis factor production [GO:0032720]; positive regulation of angiogenesis [GO:0045766]; positive regulation of cell proliferation [GO:0008284]; positive regulation of heart rate involved in baroreceptor response to decreased systemic arterial blood pressure [GO:0001988]; regulation of membrane potential [GO:0042391]; regulation of norepinephrine secretion [GO:0014061]; regulation of synaptic transmission, dopaminergic [GO:0032225]; response to food [GO:0032094]; response to hypoxia [GO:0001666]; response to nicotine [GO:0035094]; signal transduction [GO:0007165]; synaptic transmission, cholinergic [GO:0007271]; T cell activation [GO:0042110]	acetylcholine-activated cation-selective channel activity [GO:0004889]; acetylcholine binding [GO:0042166]; acetylcholine-gated cation channel activity [GO:0022848]; acetylcholine receptor activity [GO:0015464]; beta-amyloid binding [GO:0001540]; chloride channel regulator activity [GO:0017081]; ligand-gated ion channel activity [GO:0015276]; protein homodimerization activity [GO:0042803]; toxic substance binding [GO:0015643]	acetylcholine-gated channel complex [GO:0005892]; apical plasma membrane [GO:0016324]; axolemma [GO:0030673]; cell junction [GO:0030054]; external side of plasma membrane [GO:0009897]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
Q9UGM1	ACHA9_HUMAN	Neuronal acetylcholine receptor subunit alpha-9 (Nicotinic acetylcholine receptor subunit alpha-9) (NACHR alpha-9)	CHRNA9 NACHRA9	4D01;4UXU;4UY2;	CHEMBL2184;	Q9UGM1;	DB00898;DB00674;DB00184;		PF02931;PF02932;	IPR027361;IPR006202;IPR006201;IPR006029;IPR018000;IPR002394;	detection of mechanical stimulus involved in sensory perception of sound [GO:0050910]; inner ear morphogenesis [GO:0042472]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; synaptic transmission, cholinergic [GO:0007271]	acetylcholine-activated cation-selective channel activity [GO:0004889]; acetylcholine binding [GO:0042166]; acetylcholine-gated cation channel activity [GO:0022848]; calcium channel activity [GO:0005262]; ligand-gated ion channel activity [GO:0015276]	acetylcholine-gated channel complex [GO:0005892]; cell junction [GO:0030054]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
P17787	ACHB2_HUMAN	Neuronal acetylcholine receptor subunit beta-2	CHRNB2	2GVT;2K58;2K59;2KSR;2LM2;	CHEMBL1883;	P17787;	DB00514;DB00898;DB00674;DB00184;		PF02931;PF02932;	IPR027361;IPR032932;IPR006202;IPR006201;IPR006029;IPR018000;IPR002394;	action potential [GO:0001508]; associative learning [GO:0008306]; B cell activation [GO:0042113]; behavioral response to nicotine [GO:0035095]; calcium ion transport [GO:0006816]; central nervous system projection neuron axonogenesis [GO:0021952]; cognition [GO:0050890]; conditioned taste aversion [GO:0001661]; ion transport [GO:0006811]; lateral geniculate nucleus development [GO:0021771]; learning [GO:0007612]; locomotory behavior [GO:0007626]; membrane depolarization [GO:0051899]; memory [GO:0007613]; negative regulation of action potential [GO:0045759]; neurological system process [GO:0050877]; neuromuscular synaptic transmission [GO:0007274]; optic nerve morphogenesis [GO:0021631]; positive regulation of B cell proliferation [GO:0030890]; positive regulation of dopamine secretion [GO:0033603]; positive regulation of synaptic transmission, dopaminergic [GO:0032226]; protein heterooligomerization [GO:0051291]; regulation of circadian sleep/wake cycle, non-REM sleep [GO:0045188]; regulation of circadian sleep/wake cycle, REM sleep [GO:0042320]; regulation of dendrite morphogenesis [GO:0048814]; regulation of dopamine metabolic process [GO:0042053]; regulation of dopamine secretion [GO:0014059]; regulation of synapse assembly [GO:0051963]; regulation of synaptic transmission, dopaminergic [GO:0032225]; response to cocaine [GO:0042220]; response to ethanol [GO:0045471]; response to hypoxia [GO:0001666]; response to nicotine [GO:0035094]; sensory perception of pain [GO:0019233]; sensory perception of sound [GO:0007605]; signal transduction [GO:0007165]; smooth muscle contraction [GO:0006939]; social behavior [GO:0035176]; synaptic transmission, cholinergic [GO:0007271]; synaptic transmission involved in micturition [GO:0060084]; vestibulocochlear nerve development [GO:0021562]; visual learning [GO:0008542]; visual perception [GO:0007601]	acetylcholine-activated cation-selective channel activity [GO:0004889]; acetylcholine binding [GO:0042166]; acetylcholine receptor activity [GO:0015464]; drug binding [GO:0008144]; ligand-gated ion channel activity [GO:0015276]	acetylcholine-gated channel complex [GO:0005892]; cell junction [GO:0030054]; external side of plasma membrane [GO:0009897]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
Q07912	ACK1_HUMAN	Activated CDC42 kinase 1 (ACK-1) (EC 2.7.10.2) (EC 2.7.11.1) (Tyrosine kinase non-receptor protein 2)	TNK2 ACK1	1CF4;1U46;1U4D;1U54;3EQP;3EQR;4EWH;4HZR;4HZS;4ID7;	CHEMBL4599;	Q07912;	DB00171;		PF09027;PF11555;PF07714;PF14604;	IPR015116;IPR011009;IPR021619;IPR000719;IPR017441;IPR001245;IPR001452;IPR008266;IPR020635;	cell differentiation [GO:0030154]; cell migration [GO:0016477]; cell surface receptor signaling pathway [GO:0007166]; endocytosis [GO:0006897]; innate immune response [GO:0045087]; peptidyl-tyrosine autophosphorylation [GO:0038083]; phosphorylation [GO:0016310]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; regulation of cell proliferation [GO:0042127]; regulation of clathrin-dependent endocytosis [GO:2000369]; small GTPase mediated signal transduction [GO:0007264]; transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169]	ATP binding [GO:0005524]; epidermal growth factor receptor binding [GO:0005154]; GTPase inhibitor activity [GO:0005095]; metal ion binding [GO:0046872]; non-membrane spanning protein tyrosine kinase activity [GO:0004715]; protein serine/threonine/tyrosine kinase activity [GO:0004712]; protein serine/threonine kinase activity [GO:0004674]; protein tyrosine kinase activity [GO:0004713]; WW domain binding [GO:0050699]	adherens junction [GO:0005912]; clathrin-coated pit [GO:0005905]; clathrin-coated vesicle [GO:0030136]; cytoplasm [GO:0005737]; cytoplasmic vesicle membrane [GO:0030659]; endosome [GO:0005768]; extrinsic component of cytoplasmic side of plasma membrane [GO:0031234]; Grb2-EGFR complex [GO:0070436]; membrane [GO:0016020]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
P11229	ACM1_HUMAN	Muscarinic acetylcholine receptor M1	CHRM1	5CXV;	CHEMBL216;	P11229;	DB08897;DB00321;DB00543;DB00517;DB01238;DB00572;DB00245;DB00810;DB00835;DB00354;DB00411;DB00185;DB00477;DB01239;DB00568;DB00215;DB00771;DB00363;DB00907;DB00785;DB00979;DB00942;DB00434;DB00496;DB01151;DB00804;DB01231;DB00280;DB01142;DB00366;DB01175;DB00392;DB06702;DB01148;DB00875;DB00986;DB00725;DB00424;DB00458;DB00332;DB01221;DB00408;DB00934;DB04843;DB00940;DB01403;DB00462;DB00340;DB01233;DB00805;DB01618;DB00622;DB00540;DB00334;DB01062;DB00383;DB00219;DB00715;DB00454;DB01085;DB00670;DB00387;DB00420;DB01069;DB00782;DB00777;DB01224;DB00747;DB01591;DB00202;DB01409;DB01036;DB00508;DB00376;DB00726;DB00809;DB00209;DB09076;DB00246;		PF00001;	IPR000276;IPR017452;IPR002228;IPR000995;	adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway [GO:0007197]; cell proliferation [GO:0008283]; cellular protein modification process [GO:0006464]; cognition [GO:0050890]; G-protein coupled acetylcholine receptor signaling pathway [GO:0007213]; G-protein coupled receptor signaling pathway [GO:0007186]; nervous system development [GO:0007399]; neuromuscular synaptic transmission [GO:0007274]; phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway [GO:0007207]; positive regulation of cell proliferation [GO:0008284]; positive regulation of intracellular protein transport [GO:0090316]; positive regulation of ion transport [GO:0043270]; protein kinase C-activating G-protein coupled receptor signaling pathway [GO:0007205]; regulation of locomotion [GO:0040012]; regulation of vascular smooth muscle contraction [GO:0003056]; saliva secretion [GO:0046541]; signal transduction [GO:0007165]; synaptic transmission, cholinergic [GO:0007271]	drug binding [GO:0008144]; G-protein coupled acetylcholine receptor activity [GO:0016907]; phosphatidylinositol phospholipase C activity [GO:0004435]	asymmetric synapse [GO:0032279]; axon terminus [GO:0043679]; cell junction [GO:0030054]; dendrite [GO:0030425]; integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]; postsynaptic density [GO:0014069]; postsynaptic membrane [GO:0045211]; synapse [GO:0045202]
P08172	ACM2_HUMAN	Muscarinic acetylcholine receptor M2	CHRM2	1LUB;3UON;4MQS;4MQT;	CHEMBL211;	P08172;	DB08897;DB00321;DB00543;DB00517;DB01238;DB00572;DB01019;DB00835;DB00411;DB01239;DB00568;DB00363;DB00907;DB00785;DB00434;DB00496;DB01151;DB00804;DB08801;DB01231;DB00280;DB01135;DB01142;DB00392;DB06702;DB01148;DB00483;DB00986;DB00725;DB00424;DB00458;DB00332;DB01221;DB00408;DB00934;DB01403;DB00462;DB00340;DB01336;DB01226;DB00622;DB00540;DB00334;DB01062;DB00383;DB01337;DB00715;DB00454;DB01085;DB01338;DB00387;DB00420;DB01069;DB00777;DB01224;DB00728;DB00747;DB01591;DB00202;DB01409;DB01036;DB00508;DB00376;DB00726;DB00809;DB09076;DB00246;		PF00001;	IPR000276;IPR017452;IPR001065;IPR000995;	adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway [GO:0007197]; adenylate cyclase-modulating G-protein coupled receptor signaling pathway [GO:0007188]; G-protein coupled acetylcholine receptor signaling pathway [GO:0007213]; G-protein coupled receptor signaling pathway [GO:0007186]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; nervous system development [GO:0007399]; phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway [GO:0007207]; regulation of heart contraction [GO:0008016]; regulation of smooth muscle contraction [GO:0006940]; response to virus [GO:0009615]; synaptic transmission, cholinergic [GO:0007271]	drug binding [GO:0008144]; G-protein coupled acetylcholine receptor activity [GO:0016907]	asymmetric synapse [GO:0032279]; axon terminus [GO:0043679]; cell junction [GO:0030054]; dendrite [GO:0030425]; integral component of plasma membrane [GO:0005887]; neuronal cell body [GO:0043025]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]; symmetric synapse [GO:0032280]; synapse [GO:0045202]
P20309	ACM3_HUMAN	Muscarinic acetylcholine receptor M3	CHRM3	2CSA;	CHEMBL245;	P20309;	DB08897;DB00321;DB00543;DB00517;DB01238;DB00572;DB00835;DB00185;DB00477;DB01239;DB00568;DB00363;DB00785;DB00434;DB00496;DB01151;DB00729;DB01231;DB00280;DB01142;DB06702;DB00986;DB00725;DB00424;DB00458;DB00332;DB01625;DB01221;DB00408;DB00934;DB04843;DB06709;DB01403;DB00462;DB00340;DB01226;DB00622;DB00540;DB00334;DB01062;DB00383;DB01337;DB00715;DB00454;DB01085;DB01338;DB00387;DB00420;DB01069;DB00777;DB01224;DB00747;DB01591;DB00202;DB01409;DB01036;DB00193;DB00376;DB00726;DB00809;DB09076;DB00246;		PF00001;	IPR000276;IPR017452;IPR001183;IPR000995;	adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway [GO:0007197]; cell proliferation [GO:0008283]; cellular protein modification process [GO:0006464]; G-protein coupled acetylcholine receptor signaling pathway [GO:0007213]; G-protein coupled receptor signaling pathway [GO:0007186]; nervous system development [GO:0007399]; phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway [GO:0007207]; positive regulation of smooth muscle contraction [GO:0045987]; regulation of vascular smooth muscle contraction [GO:0003056]; saliva secretion [GO:0046541]; signal transduction [GO:0007165]; smooth muscle contraction [GO:0006939]; synaptic transmission, cholinergic [GO:0007271]	acetylcholine binding [GO:0042166]; drug binding [GO:0008144]; G-protein coupled acetylcholine receptor activity [GO:0016907]; phosphatidylinositol phospholipase C activity [GO:0004435]; receptor activity [GO:0004872]	asymmetric synapse [GO:0032279]; axon terminus [GO:0043679]; basolateral plasma membrane [GO:0016323]; cell junction [GO:0030054]; dendrite [GO:0030425]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]; synapse [GO:0045202]
P08173	ACM4_HUMAN	Muscarinic acetylcholine receptor M4	CHRM4	5DSG;	CHEMBL1821;	P08173;	DB08897;DB00321;DB00543;DB01238;DB00572;DB00835;DB01239;DB00568;DB00363;DB00785;DB00496;DB01151;DB01142;DB06702;DB00725;DB00424;DB00458;DB01625;DB01221;DB00408;DB00934;DB01403;DB00340;DB00622;DB00540;DB00334;DB00715;DB00454;DB00387;DB00420;DB01069;DB00777;DB01224;DB00747;DB01591;DB01036;DB00376;DB00726;DB00809;DB09076;DB00246;		PF00001;	IPR000276;IPR017452;IPR001432;IPR000995;	adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway [GO:0007197]; cell proliferation [GO:0008283]; cell surface receptor signaling pathway [GO:0007166]; G-protein coupled acetylcholine receptor signaling pathway [GO:0007213]; phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway [GO:0007207]; regulation of locomotion [GO:0040012]; signal transduction [GO:0007165]; synaptic transmission, cholinergic [GO:0007271]	G-protein coupled acetylcholine receptor activity [GO:0016907]	cell junction [GO:0030054]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]; synapse [GO:0045202]
P08912	ACM5_HUMAN	Muscarinic acetylcholine receptor M5	CHRM5		CHEMBL2035;	P08912;	DB08897;DB00321;DB00543;DB01238;DB00572;DB00835;DB01239;DB00568;DB00363;DB00785;DB00496;DB01151;DB01142;DB06702;DB00725;DB00458;DB01221;DB00408;DB00934;DB01403;DB00340;DB00622;DB00540;DB00334;DB00715;DB00454;DB00420;DB01069;DB00777;DB01224;DB00747;DB01591;DB01036;DB00376;DB00726;DB09076;DB00246;		PF00001;	IPR000276;IPR017452;IPR000502;IPR000995;	adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway [GO:0007197]; cell proliferation [GO:0008283]; dopamine transport [GO:0015872]; gastric acid secretion [GO:0001696]; G-protein coupled acetylcholine receptor signaling pathway [GO:0007213]; phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway [GO:0007207]; regulation of phosphatidylinositol dephosphorylation [GO:0060304]; synaptic transmission, cholinergic [GO:0007271]; transmission of nerve impulse [GO:0019226]	G-protein coupled acetylcholine receptor activity [GO:0016907]; phosphatidylinositol phospholipase C activity [GO:0004435]	cell junction [GO:0030054]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]; synapse [GO:0045202]
O14561	ACPM_HUMAN	Acyl carrier protein, mitochondrial (ACP) (CI-SDAP) (NADH-ubiquinone oxidoreductase 9.6 kDa subunit)	NDUFAB1	2DNW;	CHEMBL2363065;				PF00550;	IPR003231;IPR009081;IPR006162;	fatty acid biosynthetic process [GO:0006633]; glyoxylate metabolic process [GO:0046487]; mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]; protein lipoylation [GO:0009249]	ACP phosphopantetheine attachment site binding involved in fatty acid biosynthetic process [GO:0000036]; calcium ion binding [GO:0005509]; fatty acid binding [GO:0005504]; NADH dehydrogenase (ubiquinone) activity [GO:0008137]	mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]; mitochondrial membrane [GO:0031966]; mitochondrial respiratory chain complex I [GO:0005747]
Q9NUB1	ACS2L_HUMAN	Acetyl-coenzyme A synthetase 2-like, mitochondrial (EC 6.2.1.1) (Acetate--CoA ligase 2) (Acetyl-CoA synthetase 2) (AceCS2) (Acyl-CoA synthetase short-chain family member 1)	ACSS1 ACAS2L KIAA1846	3GLR;3GLT;3GLU;4BVE;4BVF;4BVG;4C78;			DB00131;DB00171;		PF16177;PF00501;PF13193;	IPR011904;IPR032387;IPR025110;IPR020845;IPR000873;	acetate biosynthetic process [GO:0019413]; acetyl-CoA biosynthetic process [GO:0006085]; acetyl-CoA biosynthetic process from acetate [GO:0019427]; ethanol oxidation [GO:0006069]; propionate biosynthetic process [GO:0019542]	acetate-CoA ligase activity [GO:0003987]; AMP binding [GO:0016208]; ATP binding [GO:0005524]	mitochondrial matrix [GO:0005759]
Q9NR19	ACSA_HUMAN	Acetyl-coenzyme A synthetase, cytoplasmic (EC 6.2.1.1) (Acetate--CoA ligase) (Acetyl-CoA synthetase) (ACS) (AceCS) (Acyl-CoA synthetase short-chain family member 2) (Acyl-activating enzyme)	ACSS2 ACAS2				DB00131;DB00171;		PF16177;PF00501;PF13193;	IPR011904;IPR032387;IPR025110;IPR020845;IPR000873;	acetate biosynthetic process [GO:0019413]; acetyl-CoA biosynthetic process from acetate [GO:0019427]; ethanol oxidation [GO:0006069]; lipid biosynthetic process [GO:0008610]; propionate biosynthetic process [GO:0019542]	acetate-CoA ligase activity [GO:0003987]; AMP binding [GO:0016208]; ATP binding [GO:0005524]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; intracellular membrane-bounded organelle [GO:0043231]; nucleoplasm [GO:0005654]
P33121	ACSL1_HUMAN	Long-chain-fatty-acid--CoA ligase 1 (EC 6.2.1.3) (Acyl-CoA synthetase 1) (ACS1) (Long-chain acyl-CoA synthetase 1) (LACS 1) (Long-chain acyl-CoA synthetase 2) (LACS 2) (Long-chain fatty acid-CoA ligase 2) (Palmitoyl-CoA ligase 1) (Palmitoyl-CoA ligase 2)	ACSL1 FACL1 FACL2 LACS LACS1 LACS2				DB00131;DB00171;		PF00501;	IPR020845;IPR000873;	adiponectin-activated signaling pathway [GO:0033211]; alpha-linolenic acid metabolic process [GO:0036109]; fatty acid transport [GO:0015908]; linoleic acid metabolic process [GO:0043651]; lipid biosynthetic process [GO:0008610]; long-chain fatty acid import [GO:0044539]; long-chain fatty acid metabolic process [GO:0001676]; long-chain fatty-acyl-CoA biosynthetic process [GO:0035338]; positive regulation of protein serine/threonine kinase activity [GO:0071902]; response to drug [GO:0042493]; response to nutrient [GO:0007584]; response to oleic acid [GO:0034201]; response to organic cyclic compound [GO:0014070]; triglyceride metabolic process [GO:0006641]; xenobiotic catabolic process [GO:0042178]	ATP binding [GO:0005524]; decanoate--CoA ligase activity [GO:0102391]; long-chain fatty acid-CoA ligase activity [GO:0004467]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; membrane [GO:0016020]; mitochondrial outer membrane [GO:0005741]; mitochondrion [GO:0005739]; peroxisomal membrane [GO:0005778]; plasma membrane [GO:0005886]
O95573	ACSL3_HUMAN	Long-chain-fatty-acid--CoA ligase 3 (EC 6.2.1.3) (Long-chain acyl-CoA synthetase 3) (LACS 3)	ACSL3 ACS3 FACL3 LACS3				DB00159;		PF00501;	IPR020845;IPR000873;	brain development [GO:0007420]; fatty acid biosynthetic process [GO:0006633]; long-chain fatty acid import [GO:0044539]; long-chain fatty-acyl-CoA biosynthetic process [GO:0035338]; positive regulation of Golgi to plasma membrane protein transport [GO:0042998]; positive regulation of phosphatidylcholine biosynthetic process [GO:2001247]; positive regulation of secretion [GO:0051047]; response to nutrient [GO:0007584]; response to organic cyclic compound [GO:0014070]; very-low-density lipoprotein particle assembly [GO:0034379]	ATP binding [GO:0005524]; decanoate--CoA ligase activity [GO:0102391]; long-chain fatty acid-CoA ligase activity [GO:0004467]; protein domain specific binding [GO:0019904]; protein kinase binding [GO:0019901]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; Golgi apparatus [GO:0005794]; integral component of membrane [GO:0016021]; lipid particle [GO:0005811]; membrane [GO:0016020]; mitochondrial outer membrane [GO:0005741]; perinuclear region of cytoplasm [GO:0048471]; peroxisomal membrane [GO:0005778]
O60488	ACSL4_HUMAN	Long-chain-fatty-acid--CoA ligase 4 (EC 6.2.1.3) (Long-chain acyl-CoA synthetase 4) (LACS 4)	ACSL4 ACS4 FACL4 LACS4				DB00159;DB00412;		PF00501;	IPR020845;IPR000873;	dendritic spine development [GO:0060996]; embryonic process involved in female pregnancy [GO:0060136]; fatty acid transport [GO:0015908]; lipid biosynthetic process [GO:0008610]; lipid metabolic process [GO:0006629]; long-chain fatty-acyl-CoA biosynthetic process [GO:0035338]; negative regulation of prostaglandin secretion [GO:0032307]; positive regulation of cell growth [GO:0030307]; response to interleukin-15 [GO:0070672]; response to nutrient [GO:0007584]; triglyceride metabolic process [GO:0006641]	arachidonate-CoA ligase activity [GO:0047676]; ATP binding [GO:0005524]; decanoate--CoA ligase activity [GO:0102391]; long-chain fatty acid-CoA ligase activity [GO:0004467]; very long-chain fatty acid-CoA ligase activity [GO:0031957]	cytoplasm [GO:0005737]; endoplasmic reticulum membrane [GO:0005789]; ER-mitochondrion membrane contact site [GO:0044233]; extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; lipid particle [GO:0005811]; membrane [GO:0016020]; mitochondrial outer membrane [GO:0005741]; neuronal cell body [GO:0043025]; peroxisomal membrane [GO:0005778]
Q01718	ACTHR_HUMAN	Adrenocorticotropic hormone receptor (ACTH receptor) (ACTH-R) (Adrenocorticotropin receptor) (Melanocortin receptor 2) (MC2-R)	MC2R ACTHR		CHEMBL1965;	Q01718;	DB01285;DB01284;		PF00001;	IPR001168;IPR000276;IPR017452;IPR001671;	G-protein coupled receptor signaling pathway [GO:0007186]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; placenta development [GO:0001890]; positive regulation of cAMP biosynthetic process [GO:0030819]	corticotropin receptor activity [GO:0004978]; melanocortin receptor activity [GO:0004977]	cytoplasm [GO:0005737]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P36896	ACV1B_HUMAN	Activin receptor type-1B (EC 2.7.11.30) (Activin receptor type IB) (ACTR-IB) (Activin receptor-like kinase 4) (ALK-4) (Serine/threonine-protein kinase receptor R2) (SKR2)	ACVR1B ACVRLK4 ALK4		CHEMBL5310;	P36896;	DB00171;		PF01064;PF00069;PF08515;	IPR000472;IPR003605;IPR011009;IPR000719;IPR017441;IPR008271;IPR000333;	activin receptor signaling pathway [GO:0032924]; central nervous system development [GO:0007417]; development of primary female sexual characteristics [GO:0046545]; extrinsic apoptotic signaling pathway [GO:0097191]; G1/S transition of mitotic cell cycle [GO:0000082]; hair follicle development [GO:0001942]; in utero embryonic development [GO:0001701]; negative regulation of cell growth [GO:0030308]; negative regulation of gene expression [GO:0010629]; nodal signaling pathway [GO:0038092]; peptidyl-threonine phosphorylation [GO:0018107]; positive regulation of activin receptor signaling pathway [GO:0032927]; positive regulation of erythrocyte differentiation [GO:0045648]; positive regulation of pathway-restricted SMAD protein phosphorylation [GO:0010862]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of trophoblast cell migration [GO:1901165]; protein autophosphorylation [GO:0046777]; protein phosphorylation [GO:0006468]; regulation of transcription, DNA-templated [GO:0006355]; signal transduction [GO:0007165]; transmembrane receptor protein serine/threonine kinase signaling pathway [GO:0007178]	activin receptor activity, type I [GO:0016361]; ATP binding [GO:0005524]; inhibin binding [GO:0034711]; metal ion binding [GO:0046872]; protein serine/threonine kinase activity [GO:0004674]; receptor signaling protein serine/threonine kinase activity [GO:0004702]; SMAD binding [GO:0046332]; transmembrane receptor protein serine/threonine kinase activity [GO:0004675]; ubiquitin protein ligase binding [GO:0031625]	activin receptor complex [GO:0048179]; cell surface [GO:0009986]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]
P37023	ACVL1_HUMAN	Serine/threonine-protein kinase receptor R3 (SKR3) (EC 2.7.11.30) (Activin receptor-like kinase 1) (ALK-1) (TGF-B superfamily receptor type I) (TSR-I)	ACVRL1 ACVRLK1 ALK1	2LCR;3MY0;4FAO;	CHEMBL5311;	P37023;	DB00171;		PF07714;PF08515;	IPR003605;IPR011009;IPR000719;IPR017441;IPR001245;IPR008271;IPR000333;	angiogenesis [GO:0001525]; artery development [GO:0060840]; blood circulation [GO:0008015]; blood vessel endothelial cell proliferation involved in sprouting angiogenesis [GO:0002043]; blood vessel maturation [GO:0001955]; blood vessel remodeling [GO:0001974]; BMP signaling pathway [GO:0030509]; cellular response to BMP stimulus [GO:0071773]; cellular response to transforming growth factor beta stimulus [GO:0071560]; dorsal aorta morphogenesis [GO:0035912]; endocardial cushion morphogenesis [GO:0003203]; endothelial tube morphogenesis [GO:0061154]; in utero embryonic development [GO:0001701]; lymphangiogenesis [GO:0001946]; lymphatic endothelial cell differentiation [GO:0060836]; negative regulation of blood vessel endothelial cell migration [GO:0043537]; negative regulation of cell adhesion [GO:0007162]; negative regulation of cell growth [GO:0030308]; negative regulation of cell migration [GO:0030336]; negative regulation of cell proliferation [GO:0008285]; negative regulation of DNA biosynthetic process [GO:2000279]; negative regulation of endothelial cell differentiation [GO:0045602]; negative regulation of endothelial cell migration [GO:0010596]; negative regulation of endothelial cell proliferation [GO:0001937]; negative regulation of focal adhesion assembly [GO:0051895]; negative regulation of gene expression [GO:0010629]; positive regulation of angiogenesis [GO:0045766]; positive regulation of BMP signaling pathway [GO:0030513]; positive regulation of chondrocyte differentiation [GO:0032332]; positive regulation of endothelial cell differentiation [GO:0045603]; positive regulation of endothelial cell proliferation [GO:0001938]; positive regulation of pathway-restricted SMAD protein phosphorylation [GO:0010862]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; protein heterooligomerization [GO:0051291]; protein phosphorylation [GO:0006468]; regulation of blood pressure [GO:0008217]; regulation of blood vessel endothelial cell migration [GO:0043535]; regulation of DNA replication [GO:0006275]; regulation of endothelial cell proliferation [GO:0001936]; regulation of transcription, DNA-templated [GO:0006355]; response to hypoxia [GO:0001666]; retina vasculature development in camera-type eye [GO:0061298]; signal transduction [GO:0007165]; transforming growth factor beta receptor signaling pathway [GO:0007179]; venous blood vessel development [GO:0060841]; wound healing, spreading of epidermal cells [GO:0035313]	activin binding [GO:0048185]; activin receptor activity, type I [GO:0016361]; ATP binding [GO:0005524]; BMP receptor activity [GO:0098821]; metal ion binding [GO:0046872]; protein kinase binding [GO:0019901]; protein serine/threonine kinase activity [GO:0004674]; receptor signaling protein serine/threonine kinase activity [GO:0004702]; SMAD binding [GO:0046332]; transforming growth factor beta-activated receptor activity [GO:0005024]; transforming growth factor beta binding [GO:0050431]; transforming growth factor beta receptor activity, type I [GO:0005025]; transmembrane receptor protein serine/threonine kinase activity [GO:0004675]	cell surface [GO:0009986]; dendrite [GO:0030425]; integral component of plasma membrane [GO:0005887]; neuronal cell body [GO:0043025]; plasma membrane [GO:0005886]
Q04771	ACVR1_HUMAN	Activin receptor type-1 (EC 2.7.11.30) (Activin receptor type I) (ACTR-I) (Activin receptor-like kinase 2) (ALK-2) (Serine/threonine-protein kinase receptor R1) (SKR1) (TGF-B superfamily receptor type I) (TSR-I)	ACVR1 ACVRLK2	3H9R;3MTF;3OOM;3Q4U;4BGG;4C02;4DYM;	CHEMBL5903;	Q04771;	DB00171;		PF01064;PF00069;PF08515;	IPR000472;IPR003605;IPR011009;IPR000719;IPR017441;IPR008271;IPR000333;	activin receptor signaling pathway [GO:0032924]; acute inflammatory response [GO:0002526]; atrial septum primum morphogenesis [GO:0003289]; atrioventricular valve morphogenesis [GO:0003181]; BMP signaling pathway [GO:0030509]; BMP signaling pathway involved in heart development [GO:0061312]; cardiac muscle cell fate commitment [GO:0060923]; cellular response to BMP stimulus [GO:0071773]; determination of left/right symmetry [GO:0007368]; embryonic heart tube morphogenesis [GO:0003143]; endocardial cushion cell fate commitment [GO:0061445]; endocardial cushion fusion [GO:0003274]; endocardial cushion morphogenesis [GO:0003203]; G1/S transition of mitotic cell cycle [GO:0000082]; gastrulation with mouth forming second [GO:0001702]; germ cell development [GO:0007281]; in utero embryonic development [GO:0001701]; mesoderm formation [GO:0001707]; mitral valve morphogenesis [GO:0003183]; negative regulation of activin receptor signaling pathway [GO:0032926]; negative regulation of extrinsic apoptotic signaling pathway [GO:2001237]; negative regulation of signal transduction [GO:0009968]; neural crest cell migration [GO:0001755]; pathway-restricted SMAD protein phosphorylation [GO:0060389]; patterning of blood vessels [GO:0001569]; peptidyl-threonine phosphorylation [GO:0018107]; pharyngeal system development [GO:0060037]; positive regulation of bone mineralization [GO:0030501]; positive regulation of cell migration [GO:0030335]; positive regulation of determination of dorsal identity [GO:2000017]; positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation [GO:1905007]; positive regulation of osteoblast differentiation [GO:0045669]; positive regulation of pathway-restricted SMAD protein phosphorylation [GO:0010862]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; protein phosphorylation [GO:0006468]; regulation of ossification [GO:0030278]; smooth muscle cell differentiation [GO:0051145]; transforming growth factor beta receptor signaling pathway [GO:0007179]; ventricular septum morphogenesis [GO:0060412]	activin binding [GO:0048185]; activin receptor activity, type I [GO:0016361]; ATP binding [GO:0005524]; metal ion binding [GO:0046872]; peptide hormone binding [GO:0017046]; protein homodimerization activity [GO:0042803]; protein kinase activity [GO:0004672]; protein serine/threonine kinase activity [GO:0004674]; receptor signaling protein serine/threonine kinase activity [GO:0004702]; SMAD binding [GO:0046332]; transforming growth factor beta binding [GO:0050431]; transforming growth factor beta receptor activity, type I [GO:0005025]; transmembrane receptor protein serine/threonine kinase activity [GO:0004675]	activin receptor complex [GO:0048179]; apical part of cell [GO:0045177]; integral component of plasma membrane [GO:0005887]
Q03154	ACY1_HUMAN	Aminoacylase-1 (ACY-1) (EC 3.5.1.14) (N-acyl-L-amino-acid amidohydrolase)	ACY1	1Q7L;			DB06151;DB00128;		PF07687;PF01546;	IPR001261;IPR010159;IPR002933;IPR011650;	cellular amino acid metabolic process [GO:0006520]; peptide catabolic process [GO:0043171]; xenobiotic metabolic process [GO:0006805]	aminoacylase activity [GO:0004046]; metallodipeptidase activity [GO:0070573]; zinc ion binding [GO:0008270]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P45381	ACY2_HUMAN	Aspartoacylase (EC 3.5.1.15) (Aminoacylase-2) (ACY-2)	ASPA ACY2 ASP	2I3C;2O4H;2O53;2Q51;4MRI;4MXU;4NFR;4TNU;			DB00128;		PF04952;	IPR016708;IPR007036;	aspartate catabolic process [GO:0006533]; cellular amino acid biosynthetic process [GO:0008652]	aminoacylase activity [GO:0004046]; aspartoacylase activity [GO:0019807]; hydrolase activity, acting on ester bonds [GO:0016788]; metal ion binding [GO:0046872]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleus [GO:0005634]
Q96HD9	ACY3_HUMAN	N-acyl-aromatic-L-amino acid amidohydrolase (carboxylate-forming) (EC 3.5.1.114) (Acylase III) (Aminoacylase-3) (ACY-3) (Aspartoacylase-2) (Hepatitis C virus core-binding protein 1) (HCBP1) (HCV core-binding protein 1)	ACY3 ASPA2				DB00128;		PF04952;	IPR016708;IPR007036;	viral process [GO:0016032]; xenobiotic metabolic process [GO:0006805]	aminoacylase activity [GO:0004046]; hydrolase activity, acting on ester bonds [GO:0016788]; metal ion binding [GO:0046872]	apical plasma membrane [GO:0016324]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P35348	ADA1A_HUMAN	Alpha-1A adrenergic receptor (Alpha-1A adrenoreceptor) (Alpha-1A adrenoceptor) (Alpha-1C adrenergic receptor) (Alpha-adrenergic receptor 1c)	ADRA1A ADRA1C		CHEMBL229;	P35348;	DB01614;DB00346;DB00321;DB00543;DB00182;DB00964;DB01238;DB06216;DB00865;DB01295;DB01200;DB00248;DB01136;DB00477;DB00215;DB00575;DB00363;DB00298;DB01151;DB01576;DB00449;DB00590;DB01142;DB04855;DB00450;DB06262;DB01364;DB00751;DB00668;DB01049;DB01253;DB00696;DB01175;DB00800;DB00875;DB04946;DB00458;DB06706;DB00598;DB06707;DB00408;DB00934;DB01365;DB00610;DB01403;DB00723;DB06148;DB00211;DB00370;DB06711;DB01149;DB00622;DB00699;DB00368;DB00540;DB00334;DB00935;DB01267;DB01186;DB01579;DB00925;DB00692;DB00388;DB00397;DB00457;DB00420;DB01069;DB00777;DB00852;DB01224;DB00734;DB06144;DB06207;DB00706;DB01162;DB06764;DB01622;DB00679;DB00797;DB00656;DB00831;DB00726;DB06694;DB00246;DB01624;		PF00001;	IPR002233;IPR001004;IPR000276;IPR017452;	activation of phospholipase C activity [GO:0007202]; adenylate cyclase-activating adrenergic receptor signaling pathway [GO:0071880]; adult heart development [GO:0007512]; aging [GO:0007568]; apoptotic process [GO:0006915]; calcium ion transport into cytosol [GO:0060402]; cell-cell signaling [GO:0007267]; cell growth [GO:0016049]; G-protein coupled receptor signaling pathway [GO:0007186]; intracellular signal transduction [GO:0035556]; micturition [GO:0060073]; negative regulation of cell proliferation [GO:0008285]; negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressure [GO:0001985]; negative regulation of Rho protein signal transduction [GO:0035024]; norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure [GO:0001994]; organ growth [GO:0035265]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; pilomotor reflex [GO:0097195]; positive regulation of action potential [GO:0045760]; positive regulation of cardiac muscle contraction [GO:0060452]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of heart rate by epinephrine-norepinephrine [GO:0001996]; positive regulation of MAPK cascade [GO:0043410]; positive regulation of protein kinase C signaling [GO:0090037]; positive regulation of smooth muscle contraction [GO:0045987]; positive regulation of synaptic transmission, GABAergic [GO:0032230]; positive regulation of systemic arterial blood pressure [GO:0003084]; positive regulation of the force of heart contraction by epinephrine-norepinephrine [GO:0001997]; positive regulation of vasoconstriction [GO:0045907]; response to drug [GO:0042493]; response to hormone [GO:0009725]; signal transduction [GO:0007165]; smooth muscle contraction [GO:0006939]	alpha1-adrenergic receptor activity [GO:0004937]; protein heterodimerization activity [GO:0046982]	integral component of plasma membrane [GO:0005887]; nuclear membrane [GO:0031965]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; T-tubule [GO:0030315]; Z disc [GO:0030018]
P35368	ADA1B_HUMAN	Alpha-1B adrenergic receptor (Alpha-1B adrenoreceptor) (Alpha-1B adrenoceptor)	ADRA1B		CHEMBL232;	P35368;	DB01614;DB00346;DB00321;DB00543;DB00182;DB01238;DB09128;DB01200;DB00248;DB01136;DB00477;DB00575;DB00363;DB00298;DB01151;DB01576;DB00590;DB01142;DB04855;DB06262;DB00668;DB01049;DB00696;DB00800;DB00458;DB00598;DB01255;DB00408;DB00934;DB01365;DB01403;DB00723;DB06148;DB00211;DB00370;DB00745;DB01149;DB00622;DB00368;DB00540;DB00334;DB00935;DB01267;DB01186;DB01579;DB00925;DB00388;DB00457;DB00420;DB01608;DB00777;DB01224;DB00734;DB06144;DB06207;DB00706;DB01162;DB01622;DB00679;DB00726;DB06694;DB00246;		PF00001;	IPR002233;IPR001115;IPR000276;IPR017452;	adenylate cyclase-activating adrenergic receptor signaling pathway [GO:0071880]; adenylate cyclase-modulating G-protein coupled receptor signaling pathway [GO:0007188]; cell-cell signaling [GO:0007267]; cell proliferation [GO:0008283]; glucose homeostasis [GO:0042593]; G-protein coupled receptor signaling pathway [GO:0007186]; intracellular signal transduction [GO:0035556]; multicellular organism development [GO:0007275]; norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure [GO:0001994]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of MAPK cascade [GO:0043410]; positive regulation of smooth muscle contraction [GO:0045987]; positive regulation of vasoconstriction [GO:0045907]; regulation of cardiac muscle contraction [GO:0055117]	alpha1-adrenergic receptor activity [GO:0004937]; protein heterodimerization activity [GO:0046982]	integral component of plasma membrane [GO:0005887]; nuclear membrane [GO:0031965]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
P25100	ADA1D_HUMAN	Alpha-1D adrenergic receptor (Alpha-1A adrenergic receptor) (Alpha-1D adrenoreceptor) (Alpha-1D adrenoceptor) (Alpha-adrenergic receptor 1a)	ADRA1D ADRA1A		CHEMBL223;	P25100;	DB00346;DB00321;DB00543;DB00182;DB01200;DB00248;DB01136;DB00477;DB00575;DB00298;DB01151;DB00590;DB01142;DB04855;DB06262;DB00668;DB01049;DB00696;DB00800;DB00458;DB00598;DB00934;DB01365;DB01403;DB00723;DB06148;DB00211;DB00370;DB00622;DB00368;DB00540;DB00935;DB01186;DB00925;DB00388;DB00457;DB00420;DB00777;DB01224;DB06144;DB06207;DB00706;DB01162;DB06694;		PF00001;	IPR002233;IPR000363;IPR000276;IPR017452;	adenylate cyclase-activating adrenergic receptor signaling pathway [GO:0071880]; adenylate cyclase-modulating G-protein coupled receptor signaling pathway [GO:0007188]; cell-cell signaling [GO:0007267]; cell proliferation [GO:0008283]; DNA metabolic process [GO:0006259]; G-protein coupled receptor signaling pathway [GO:0007186]; multicellular organism development [GO:0007275]; norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure [GO:0001994]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; positive regulation of cell proliferation [GO:0008284]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of smooth muscle contraction [GO:0045987]; positive regulation of vasoconstriction [GO:0045907]	alpha1-adrenergic receptor activity [GO:0004937]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P08913	ADA2A_HUMAN	Alpha-2A adrenergic receptor (Alpha-2 adrenergic receptor subtype C10) (Alpha-2A adrenoreceptor) (Alpha-2A adrenoceptor) (Alpha-2AAR)	ADRA2A ADRA2R ADRAR	1HLL;1HO9;1HOD;1HOF;	CHEMBL1867;	P08913;	DB00321;DB00543;DB00182;DB00714;DB00964;DB01238;DB06216;DB00865;DB00217;DB00484;DB01200;DB00248;DB01136;DB00477;DB00575;DB00363;DB01151;DB00633;DB00320;DB00449;DB01142;DB04855;DB06262;DB01363;DB00751;DB00668;DB01049;DB00696;DB00800;DB06623;DB00629;DB01018;DB00589;DB04948;DB00408;DB08815;DB00934;DB01365;DB01577;DB01403;DB00968;DB06148;DB00370;DB06711;DB01149;DB00368;DB00540;DB00334;DB00935;DB01267;DB01186;DB00925;DB00692;DB00397;DB00413;DB00457;DB01608;DB00852;DB01224;DB00734;DB00268;DB00697;DB00797;DB00656;DB00726;DB06694;DB01392;DB00246;DB01624;		PF00001;	IPR002233;IPR001946;IPR000276;IPR017452;	actin cytoskeleton organization [GO:0030036]; activation of MAPK activity by adrenergic receptor signaling pathway [GO:0071883]; activation of protein kinase activity [GO:0032147]; activation of protein kinase B activity [GO:0032148]; adenylate cyclase-activating adrenergic receptor signaling pathway [GO:0071880]; adenylate cyclase-inhibiting adrenergic receptor signaling pathway [GO:0071881]; cellular response to hormone stimulus [GO:0032870]; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway [GO:0035625]; glucose homeostasis [GO:0042593]; G-protein coupled receptor signaling pathway [GO:0007186]; intestinal absorption [GO:0050892]; movement of cell or subcellular component [GO:0006928]; negative regulation of adenylate cyclase activity [GO:0007194]; negative regulation of adrenergic receptor signaling pathway [GO:0071878]; negative regulation of calcium ion-dependent exocytosis [GO:0045955]; negative regulation of calcium ion transmembrane transporter activity [GO:1901020]; negative regulation of calcium ion transport [GO:0051926]; negative regulation of cAMP biosynthetic process [GO:0030818]; negative regulation of epinephrine secretion [GO:0032811]; negative regulation of insulin secretion [GO:0046676]; negative regulation of insulin secretion involved in cellular response to glucose stimulus [GO:0061179]; negative regulation of lipid catabolic process [GO:0050995]; negative regulation of norepinephrine secretion [GO:0010700]; phospholipase C-activating adrenergic receptor signaling pathway [GO:0071882]; platelet activation [GO:0030168]; positive regulation of cell migration [GO:0030335]; positive regulation of cell proliferation [GO:0008284]; positive regulation of cytokine production [GO:0001819]; positive regulation of epidermal growth factor-activated receptor activity [GO:0045741]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of membrane protein ectodomain proteolysis [GO:0051044]; positive regulation of potassium ion transport [GO:0043268]; positive regulation of wound healing [GO:0090303]; Ras protein signal transduction [GO:0007265]; regulation of insulin secretion [GO:0050796]; regulation of smooth muscle contraction [GO:0006940]; regulation of vasoconstriction [GO:0019229]; Rho protein signal transduction [GO:0007266]; signal transduction [GO:0007165]	alpha-1B adrenergic receptor binding [GO:0031692]; alpha2-adrenergic receptor activity [GO:0004938]; alpha-2C adrenergic receptor binding [GO:0031696]; epinephrine binding [GO:0051379]; heterotrimeric G-protein binding [GO:0032795]; norepinephrine binding [GO:0051380]; protein heterodimerization activity [GO:0046982]; protein homodimerization activity [GO:0042803]; protein kinase binding [GO:0019901]; thioesterase binding [GO:0031996]	basolateral plasma membrane [GO:0016323]; cytoplasm [GO:0005737]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]
P18089	ADA2B_HUMAN	Alpha-2B adrenergic receptor (Alpha-2 adrenergic receptor subtype C2) (Alpha-2B adrenoreceptor) (Alpha-2B adrenoceptor) (Alpha-2BAR)	ADRA2B ADRA2L1 ADRA2RL1	2CVA;	CHEMBL1942;	P18089;	DB00543;DB00182;DB00714;DB00964;DB01238;DB06216;DB00217;DB00484;DB01200;DB00248;DB01136;DB00477;DB00575;DB00363;DB01151;DB01142;DB04855;DB06262;DB01363;DB00668;DB01049;DB00696;DB00292;DB00800;DB00629;DB01018;DB00589;DB00408;DB00934;DB01365;DB01577;DB01403;DB06148;DB00368;DB00540;DB00334;DB00935;DB01267;DB01186;DB00925;DB00413;DB00457;DB01224;DB00734;DB00268;DB05271;DB00697;DB00797;DB00726;DB06694;DB01392;DB00246;		PF00001;	IPR002233;IPR000207;IPR000276;IPR017452;	activation of MAPK activity by adrenergic receptor signaling pathway [GO:0071883]; activation of protein kinase B activity [GO:0032148]; adenylate cyclase-activating adrenergic receptor signaling pathway [GO:0071880]; cell-cell signaling [GO:0007267]; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway [GO:0035625]; G-protein coupled receptor signaling pathway [GO:0007186]; negative regulation of epinephrine secretion [GO:0032811]; negative regulation of norepinephrine secretion [GO:0010700]; platelet activation [GO:0030168]; positive regulation of neuron differentiation [GO:0045666]; regulation of smooth muscle contraction [GO:0006940]; regulation of vasoconstriction [GO:0019229]	alpha2-adrenergic receptor activity [GO:0004938]; epinephrine binding [GO:0051379]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P18825	ADA2C_HUMAN	Alpha-2C adrenergic receptor (Alpha-2 adrenergic receptor subtype C4) (Alpha-2C adrenoreceptor) (Alpha-2C adrenoceptor) (Alpha-2CAR)	ADRA2C ADRA2L2 ADRA2RL2		CHEMBL1916;	P18825;	DB00543;DB00182;DB00714;DB01238;DB06216;DB00217;DB09128;DB00484;DB01200;DB00248;DB01136;DB00477;DB00575;DB00363;DB01151;DB01142;DB04855;DB06262;DB01363;DB00668;DB01049;DB00800;DB04946;DB00589;DB00408;DB08815;DB00934;DB01365;DB01577;DB01403;DB06148;DB00370;DB00368;DB00540;DB00334;DB00935;DB01267;DB01186;DB00925;DB00413;DB01224;DB00734;DB00268;DB00697;DB00797;DB06694;DB01392;DB00246;		PF00001;	IPR002233;IPR000735;IPR000276;IPR017452;	activation of MAPK activity by adrenergic receptor signaling pathway [GO:0071883]; activation of protein kinase B activity [GO:0032148]; adenylate cyclase-activating adrenergic receptor signaling pathway [GO:0071880]; cell-cell signaling [GO:0007267]; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway [GO:0035625]; female pregnancy [GO:0007565]; G-protein coupled receptor signaling pathway [GO:0007186]; negative regulation of epinephrine secretion [GO:0032811]; negative regulation of norepinephrine secretion [GO:0010700]; negative regulation of uterine smooth muscle contraction [GO:0070473]; platelet activation [GO:0030168]; positive regulation of neuron differentiation [GO:0045666]; positive regulation of vasoconstriction [GO:0045907]; regulation of insulin secretion [GO:0050796]; regulation of sensory perception of pain [GO:0051930]	alpha-2A adrenergic receptor binding [GO:0031694]; alpha2-adrenergic receptor activity [GO:0004938]; epinephrine binding [GO:0051379]; protein heterodimerization activity [GO:0046982]; protein homodimerization activity [GO:0042803]	axon terminus [GO:0043679]; cytoplasm [GO:0005737]; endosome [GO:0005768]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
Q9BZ11	ADA33_HUMAN	Disintegrin and metalloproteinase domain-containing protein 33 (ADAM 33) (EC 3.4.24.-)	ADAM33 C20orf153 UNQ873/PRO1891	1R54;1R55;	CHEMBL6121;	Q9BZ11;			PF08516;PF00200;PF01562;PF01421;	IPR006586;IPR018358;IPR001762;IPR013032;IPR000742;IPR024079;IPR001590;IPR002870;	proteolysis [GO:0006508]	metalloendopeptidase activity [GO:0004222]; zinc ion binding [GO:0008270]	integral component of membrane [GO:0016021]
P00813	ADA_HUMAN	Adenosine deaminase (EC 3.5.4.4) (Adenosine aminohydrolase)	ADA ADA1	1M7M;3IAR;	CHEMBL1910;	P00813;	DB00640;DB00975;DB00974;DB01280;DB00552;DB00277;DB00194;		PF00962;	IPR006650;IPR001365;IPR028893;IPR006330;IPR032466;	adenosine catabolic process [GO:0006154]; aging [GO:0007568]; dATP catabolic process [GO:0046061]; deoxyadenosine catabolic process [GO:0006157]; embryonic digestive tract development [GO:0048566]; germinal center B cell differentiation [GO:0002314]; histamine secretion [GO:0001821]; hypoxanthine salvage [GO:0043103]; inosine biosynthetic process [GO:0046103]; liver development [GO:0001889]; lung alveolus development [GO:0048286]; negative regulation of adenosine receptor signaling pathway [GO:0060169]; negative regulation of circadian sleep/wake cycle, non-REM sleep [GO:0042323]; negative regulation of inflammatory response [GO:0050728]; negative regulation of leukocyte migration [GO:0002686]; negative regulation of mature B cell apoptotic process [GO:0002906]; negative regulation of mucus secretion [GO:0070256]; negative regulation of penile erection [GO:0060407]; negative regulation of thymocyte apoptotic process [GO:0070244]; Peyer's patch development [GO:0048541]; placenta development [GO:0001890]; positive regulation of alpha-beta T cell differentiation [GO:0046638]; positive regulation of B cell proliferation [GO:0030890]; positive regulation of calcium-mediated signaling [GO:0050850]; positive regulation of germinal center formation [GO:0002636]; positive regulation of heart rate [GO:0010460]; positive regulation of smooth muscle contraction [GO:0045987]; positive regulation of T cell differentiation in thymus [GO:0033089]; positive regulation of T cell receptor signaling pathway [GO:0050862]; purine-containing compound salvage [GO:0043101]; purine nucleotide salvage [GO:0032261]; purine ribonucleoside monophosphate biosynthetic process [GO:0009168]; regulation of cell-cell adhesion mediated by integrin [GO:0033632]; response to drug [GO:0042493]; response to hydrogen peroxide [GO:0042542]; response to hypoxia [GO:0001666]; response to morphine [GO:0043278]; response to vitamin E [GO:0033197]; T cell activation [GO:0042110]; trophectodermal cell differentiation [GO:0001829]; xanthine biosynthetic process [GO:0046111]	adenosine deaminase activity [GO:0004000]; purine nucleoside binding [GO:0001883]; zinc ion binding [GO:0008270]	cell junction [GO:0030054]; cell surface [GO:0009986]; cytoplasm [GO:0005737]; cytoplasmic membrane-bounded vesicle lumen [GO:0060205]; cytosol [GO:0005829]; dendrite cytoplasm [GO:0032839]; external side of plasma membrane [GO:0009897]; extracellular space [GO:0005615]; lysosome [GO:0005764]; membrane [GO:0016020]; neuronal cell body [GO:0043025]; plasma membrane [GO:0005886]
Q08828	ADCY1_HUMAN	Adenylate cyclase type 1 (EC 4.6.1.1) (ATP pyrophosphate-lyase 1) (Adenylate cyclase type I) (Adenylyl cyclase 1) (Ca(2+)/calmodulin-activated adenylyl cyclase)	ADCY1		CHEMBL2899;	Q08828;	DB00131;DB00171;		PF16214;PF00211;	IPR001054;IPR018297;IPR032628;IPR030672;IPR029787;	activation of adenylate cyclase activity [GO:0007190]; activation of protein kinase A activity [GO:0034199]; adenylate cyclase-activating G-protein coupled receptor signaling pathway [GO:0007189]; adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway [GO:0007193]; axonogenesis [GO:0007409]; cAMP biosynthetic process [GO:0006171]; cAMP-mediated signaling [GO:0019933]; cellular response to calcium ion [GO:0071277]; cellular response to forskolin [GO:1904322]; cellular response to glucagon stimulus [GO:0071377]; circadian rhythm [GO:0007623]; long-term memory [GO:0007616]; regulation of circadian rhythm [GO:0042752]; renal water homeostasis [GO:0003091]; response to drug [GO:0042493]; response to lithium ion [GO:0010226]	adenylate cyclase activity [GO:0004016]; ATP binding [GO:0005524]; calcium- and calmodulin-responsive adenylate cyclase activity [GO:0008294]; metal ion binding [GO:0046872]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; membrane raft [GO:0045121]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
P51828	ADCY7_HUMAN	Adenylate cyclase type 7 (EC 4.6.1.1) (ATP pyrophosphate-lyase 7) (Adenylate cyclase type VII) (Adenylyl cyclase 7)	ADCY7 KIAA0037		CHEMBL2097167;				PF16214;PF06327;PF00211;	IPR001054;IPR018297;IPR032628;IPR030672;IPR009398;IPR029787;	activation of adenylate cyclase activity [GO:0007190]; activation of protein kinase A activity [GO:0034199]; adenylate cyclase-activating G-protein coupled receptor signaling pathway [GO:0007189]; adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway [GO:0007193]; cAMP-mediated signaling [GO:0019933]; cellular response to ethanol [GO:0071361]; cellular response to glucagon stimulus [GO:0071377]; maternal process involved in female pregnancy [GO:0060135]; positive regulation of cAMP biosynthetic process [GO:0030819]; renal water homeostasis [GO:0003091]	adenylate cyclase activity [GO:0004016]; ATP binding [GO:0005524]; metal ion binding [GO:0046872]	integral component of membrane [GO:0016021]; intracellular [GO:0005622]; plasma membrane [GO:0005886]
Q96A70	ADC_HUMAN	Antizyme inhibitor 2 (AzI2) (Arginine decarboxylase) (ADC) (ARGDC) (Ornithine decarboxylase-like protein) (ODC-like protein) (ornithine decarboxylase paralog) (ODC-p)	AZIN2 ADC KIAA1945 ODCP				DB00125;		PF02784;PF00278;	IPR009006;IPR031173;IPR022643;IPR022657;IPR022644;IPR022653;IPR000183;IPR002433;IPR029066;	agmatine biosynthetic process [GO:0097055]; negative regulation of protein catabolic process [GO:0042177]; positive regulation of catalytic activity [GO:0043085]; positive regulation of polyamine transmembrane transport [GO:1902269]; putrescine biosynthetic process from ornithine [GO:0033387]; putrescine transport [GO:0015847]; spermatogenesis [GO:0007283]; trans-Golgi network membrane organization [GO:0098629]	arginine decarboxylase activity [GO:0008792]; ornithine decarboxylase activator activity [GO:0042978]; putrescine transmembrane transporter activity [GO:0015489]	axon [GO:0030424]; cis-Golgi network [GO:0005801]; cytoplasmic vesicle [GO:0031410]; cytosol [GO:0005829]; dendrite [GO:0030425]; endoplasmic reticulum-Golgi intermediate compartment membrane [GO:0033116]; granular vesicle [GO:1990005]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; perikaryon [GO:0043204]; perinuclear region of cytoplasm [GO:0048471]; trans-Golgi network [GO:0005802]; transport vesicle [GO:0030133]
P07327	ADH1A_HUMAN	Alcohol dehydrogenase 1A (EC 1.1.1.1) (Alcohol dehydrogenase subunit alpha)	ADH1A ADH1	1HSO;1U3T;	CHEMBL1970;	P07327;	DB00898;DB01213;		PF08240;PF00107;	IPR013149;IPR013154;IPR002085;IPR002328;IPR011032;IPR016040;IPR020843;	alcohol metabolic process [GO:0006066]; drug metabolic process [GO:0017144]; ethanol oxidation [GO:0006069]	alcohol dehydrogenase (NAD) activity [GO:0004022]; alcohol dehydrogenase activity, zinc-dependent [GO:0004024]; retinol dehydrogenase activity [GO:0004745]; zinc ion binding [GO:0008270]	cytosol [GO:0005829]
P00325	ADH1B_HUMAN	Alcohol dehydrogenase 1B (EC 1.1.1.1) (Alcohol dehydrogenase subunit beta)	ADH1B ADH2	1DEH;1HDX;1HDY;1HDZ;1HSZ;1HTB;1U3U;1U3V;3HUD;	CHEMBL3284;	P00325;	DB00898;DB01213;		PF08240;PF00107;	IPR013149;IPR013154;IPR002328;IPR011032;IPR016040;IPR020843;	ethanol oxidation [GO:0006069]	alcohol dehydrogenase activity, zinc-dependent [GO:0004024]; zinc ion binding [GO:0008270]	cytosol [GO:0005829]
P00326	ADH1G_HUMAN	Alcohol dehydrogenase 1C (EC 1.1.1.1) (Alcohol dehydrogenase subunit gamma)	ADH1C ADH3	1DDA;1HT0;1U3W;	CHEMBL3285;	P00326;	DB02659;DB00898;DB01213;		PF08240;PF00107;	IPR013149;IPR013154;IPR002085;IPR002328;IPR011032;IPR016040;IPR020843;	ethanol oxidation [GO:0006069]	alcohol dehydrogenase (NAD) activity [GO:0004022]; alcohol dehydrogenase activity, zinc-dependent [GO:0004024]; retinol dehydrogenase activity [GO:0004745]; zinc ion binding [GO:0008270]	cytosol [GO:0005829]
P08319	ADH4_HUMAN	Alcohol dehydrogenase 4 (EC 1.1.1.1) (Alcohol dehydrogenase class II pi chain)	ADH4	3COS;	CHEMBL2990;	P08319;	DB00898;		PF08240;PF00107;	IPR013149;IPR013154;IPR002085;IPR002328;IPR011032;IPR016040;IPR020843;IPR028632;	alcohol catabolic process [GO:0046164]; alcohol metabolic process [GO:0006066]; cellular aldehyde metabolic process [GO:0006081]; ethanol oxidation [GO:0006069]; quinone metabolic process [GO:1901661]; retinoid metabolic process [GO:0001523]; retinol metabolic process [GO:0042572]	alcohol dehydrogenase (NAD) activity [GO:0004022]; alcohol dehydrogenase activity, zinc-dependent [GO:0004024]; alditol:NADP+ 1-oxidoreductase activity [GO:0004032]; all-trans retinal binding [GO:0005503]; benzaldehyde dehydrogenase activity [GO:0019115]; ethanol binding [GO:0035276]; NAD binding [GO:0051287]; NADPH:quinone reductase activity [GO:0003960]; oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor [GO:0016620]; retinol binding [GO:0019841]; retinol dehydrogenase activity [GO:0004745]; zinc ion binding [GO:0008270]	cytosol [GO:0005829]
P40394	ADH7_HUMAN	Alcohol dehydrogenase class 4 mu/sigma chain (EC 1.1.1.1) (Alcohol dehydrogenase class IV mu/sigma chain) (Gastric alcohol dehydrogenase) (Retinol dehydrogenase)	ADH7	1AGN;1D1S;1D1T;	CHEMBL3867;	P40394;	DB00898;		PF08240;PF00107;	IPR013149;IPR013154;IPR002085;IPR002328;IPR011032;IPR016040;	ethanol catabolic process [GO:0006068]; ethanol oxidation [GO:0006069]; fatty acid omega-oxidation [GO:0010430]; oxidation-reduction process [GO:0055114]; response to bacterium [GO:0009617]; response to ethanol [GO:0045471]; retinoic acid metabolic process [GO:0042573]; retinoid metabolic process [GO:0001523]; retinol metabolic process [GO:0042572]	alcohol dehydrogenase (NAD) activity [GO:0004022]; alcohol dehydrogenase activity, zinc-dependent [GO:0004024]; aldehyde oxidase activity [GO:0004031]; ethanol binding [GO:0035276]; receptor antagonist activity [GO:0048019]; retinol binding [GO:0019841]; retinol dehydrogenase activity [GO:0004745]; zinc ion binding [GO:0008270]	cytosol [GO:0005829]; extracellular region [GO:0005576]
P11766	ADHX_HUMAN	Alcohol dehydrogenase class-3 (EC 1.1.1.1) (Alcohol dehydrogenase 5) (Alcohol dehydrogenase class chi chain) (Alcohol dehydrogenase class-III) (Glutathione-dependent formaldehyde dehydrogenase) (FALDH) (FDH) (GSH-FDH) (EC 1.1.1.-) (S-(hydroxymethyl)glutathione dehydrogenase) (EC 1.1.1.284)	ADH5 ADHX FDH	1M6H;1M6W;1MA0;1MC5;1MP0;1TEH;2FZE;2FZW;3QJ5;	CHEMBL4116;	P11766;	DB00898;		PF08240;PF00107;	IPR014183;IPR013149;IPR013154;IPR002085;IPR002328;IPR011032;IPR016040;	ethanol oxidation [GO:0006069]; formaldehyde catabolic process [GO:0046294]; peptidyl-cysteine S-nitrosylation [GO:0018119]; positive regulation of blood pressure [GO:0045777]; respiratory system process [GO:0003016]; response to lipopolysaccharide [GO:0032496]; response to nitrosative stress [GO:0051409]; response to redox state [GO:0051775]; retinoid metabolic process [GO:0001523]	alcohol dehydrogenase (NAD) activity [GO:0004022]; electron carrier activity [GO:0009055]; fatty acid binding [GO:0005504]; formaldehyde dehydrogenase activity [GO:0018467]; S-(hydroxymethyl)glutathione dehydrogenase activity [GO:0051903]; zinc ion binding [GO:0008270]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrion [GO:0005739]
P08588	ADRB1_HUMAN	Beta-1 adrenergic receptor (Beta-1 adrenoreceptor) (Beta-1 adrenoceptor)	ADRB1 ADRB1R B1AR	2LSQ;	CHEMBL213;	P08588;	DB01193;DB00866;DB01118;DB00321;DB00182;DB01102;DB06216;DB00335;DB00195;DB00217;DB01295;DB00612;DB08807;DB08808;DB00248;DB00521;DB01136;DB04846;DB01407;DB01151;DB00841;DB04855;DB06262;DB01363;DB00668;DB00187;DB01288;DB00221;DB01064;DB00598;DB01210;DB00408;DB01365;DB01214;DB00264;DB00370;DB01203;DB04861;DB00368;DB00540;DB00334;DB01580;DB01359;DB00397;DB00960;DB01291;DB01297;DB00571;DB00852;DB01001;DB00489;DB00373;DB00726;DB09068;		PF00001;	IPR002233;IPR000507;IPR000276;IPR017452;	activation of adenylate cyclase activity [GO:0007190]; adenylate cyclase-activating adrenergic receptor signaling pathway [GO:0071880]; brown fat cell differentiation [GO:0050873]; cell-cell signaling [GO:0007267]; diet induced thermogenesis [GO:0002024]; fear response [GO:0042596]; heat generation [GO:0031649]; negative regulation of multicellular organism growth [GO:0040015]; positive regulation of cAMP biosynthetic process [GO:0030819]; positive regulation of cAMP-mediated signaling [GO:0043950]; positive regulation of GTPase activity [GO:0043547]; positive regulation of heart rate by epinephrine-norepinephrine [GO:0001996]; positive regulation of the force of heart contraction by epinephrine-norepinephrine [GO:0001997]; response to cold [GO:0009409]; temperature homeostasis [GO:0001659]; vasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressure [GO:0002025]	alpha-2A adrenergic receptor binding [GO:0031694]; beta1-adrenergic receptor activity [GO:0004940]; beta-adrenergic receptor activity [GO:0004939]; epinephrine binding [GO:0051379]; norepinephrine binding [GO:0051380]; PDZ domain binding [GO:0030165]; protein heterodimerization activity [GO:0046982]; Ras guanyl-nucleotide exchange factor activity [GO:0005088]; receptor signaling protein activity [GO:0005057]	early endosome [GO:0005769]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P07550	ADRB2_HUMAN	Beta-2 adrenergic receptor (Beta-2 adrenoreceptor) (Beta-2 adrenoceptor)	ADRB2 ADRB2R B2AR	1GQ4;2R4R;2R4S;2RH1;3D4S;3KJ6;3NY8;3NY9;3NYA;3P0G;3PDS;3SN6;4GBR;4LDE;4LDL;4LDO;4QKX;5D5A;5D5B;5D6L;5JQH;	CHEMBL210;	P07550;	DB01193;DB00866;DB00321;DB00182;DB01102;DB01274;DB06216;DB00335;DB01408;DB00195;DB00217;DB01295;DB00612;DB08807;DB08808;DB00248;DB00521;DB01136;DB04846;DB01407;DB01151;DB00449;DB00841;DB06262;DB01363;DB00668;DB01288;DB00983;DB05039;DB00221;DB01064;DB00598;DB01210;DB01365;DB01214;DB00264;DB00370;DB01203;DB04861;DB00368;DB00540;DB00334;DB09080;DB00816;DB01580;DB01359;DB00925;DB00397;DB00960;DB01291;DB01366;DB00571;DB00852;DB00867;DB01001;DB00938;DB00489;DB00871;DB00373;DB00726;DB09082;		PF00001;	IPR002233;IPR000332;IPR000276;IPR017452;	activation of adenylate cyclase activity [GO:0007190]; activation of transmembrane receptor protein tyrosine kinase activity [GO:0007171]; adenylate cyclase-activating adrenergic receptor signaling pathway [GO:0071880]; adenylate cyclase-modulating G-protein coupled receptor signaling pathway [GO:0007188]; bone resorption [GO:0045453]; brown fat cell differentiation [GO:0050873]; cell-cell signaling [GO:0007267]; cell surface receptor signaling pathway [GO:0007166]; desensitization of G-protein coupled receptor protein signaling pathway by arrestin [GO:0002032]; diet induced thermogenesis [GO:0002024]; endosome to lysosome transport [GO:0008333]; heat generation [GO:0031649]; negative regulation of multicellular organism growth [GO:0040015]; negative regulation of smooth muscle contraction [GO:0045986]; positive regulation of autophagosome maturation [GO:1901098]; positive regulation of bone mineralization [GO:0030501]; positive regulation of lipophagy [GO:1904504]; positive regulation of MAPK cascade [GO:0043410]; positive regulation of protein ubiquitination [GO:0031398]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; receptor-mediated endocytosis [GO:0006898]; regulation of sodium ion transport [GO:0002028]; regulation of vasodilation [GO:0042312]; response to cold [GO:0009409]; vasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressure [GO:0002025]	beta2-adrenergic receptor activity [GO:0004941]; epinephrine binding [GO:0051379]; norepinephrine binding [GO:0051380]; potassium channel regulator activity [GO:0015459]; protein homodimerization activity [GO:0042803]	apical plasma membrane [GO:0016324]; early endosome [GO:0005769]; endosome [GO:0005768]; integral component of plasma membrane [GO:0005887]; lysosome [GO:0005764]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]
P13945	ADRB3_HUMAN	Beta-3 adrenergic receptor (Beta-3 adrenoreceptor) (Beta-3 adrenoceptor)	ADRB3 ADRB3R B3AR	2CDW;	CHEMBL246;	P13945;	DB00321;DB00182;DB01102;DB00217;DB08807;DB08808;DB01407;DB06262;DB01363;DB00668;DB01288;DB01064;DB01365;DB08893;DB00368;DB00540;DB00334;DB00571;DB00726;		PF00001;	IPR002233;IPR000681;IPR000276;IPR017452;	activation of adenylate cyclase activity [GO:0007190]; adenylate cyclase-activating adrenergic receptor signaling pathway [GO:0071880]; adenylate cyclase-modulating G-protein coupled receptor signaling pathway [GO:0007188]; aging [GO:0007568]; brown fat cell differentiation [GO:0050873]; carbohydrate metabolic process [GO:0005975]; cell-cell signaling [GO:0007267]; diet induced thermogenesis [GO:0002024]; eating behavior [GO:0042755]; energy reserve metabolic process [GO:0006112]; generation of precursor metabolites and energy [GO:0006091]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; heat generation [GO:0031649]; negative regulation of multicellular organism growth [GO:0040015]; positive regulation of MAPK cascade [GO:0043410]; response to antibiotic [GO:0046677]; response to cold [GO:0009409]; temperature homeostasis [GO:0001659]; vasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressure [GO:0002025]	beta3-adrenergic receptor activity [GO:0015052]; beta-adrenergic receptor activity [GO:0004939]; epinephrine binding [GO:0051379]; norepinephrine binding [GO:0051380]; protein homodimerization activity [GO:0042803]	integral component of plasma membrane [GO:0005887]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]
P12235	ADT1_HUMAN	ADP/ATP translocase 1 (ADP,ATP carrier protein 1) (ADP,ATP carrier protein, heart/skeletal muscle isoform T1) (Adenine nucleotide translocator 1) (ANT 1) (Solute carrier family 25 member 4)	SLC25A4 ANT1				DB00171;DB00720;		PF00153;	IPR002113;IPR002067;IPR018108;IPR023395;	apoptotic mitochondrial changes [GO:0008637]; generation of precursor metabolites and energy [GO:0006091]; mitochondrial genome maintenance [GO:0000002]; negative regulation of necroptotic process [GO:0060546]; regulation of insulin secretion [GO:0050796]; translation [GO:0006412]; transport [GO:0006810]; viral process [GO:0016032]	adenine transmembrane transporter activity [GO:0015207]; structural constituent of ribosome [GO:0003735]	integral component of plasma membrane [GO:0005887]; mitochondrial inner membrane [GO:0005743]; mitochondrion [GO:0005739]; myelin sheath [GO:0043209]; nucleus [GO:0005634]
P05141	ADT2_HUMAN	ADP/ATP translocase 2 (ADP,ATP carrier protein 2) (ADP,ATP carrier protein, fibroblast isoform) (Adenine nucleotide translocator 2) (ANT 2) (Solute carrier family 25 member 5) [Cleaved into: ADP/ATP translocase 2, N-terminally processed]	SLC25A5 ANT2				DB00720;		PF00153;	IPR002113;IPR002067;IPR018108;IPR023395;	chromosome segregation [GO:0007059]; negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway [GO:1901029]; positive regulation of cell proliferation [GO:0008284]; regulation of insulin secretion [GO:0050796]; translation [GO:0006412]; transport [GO:0006810]; viral process [GO:0016032]	adenine transmembrane transporter activity [GO:0015207]; poly(A) RNA binding [GO:0044822]; structural constituent of ribosome [GO:0003735]; ubiquitin protein ligase binding [GO:0031625]	extracellular exosome [GO:0070062]; extracellular matrix [GO:0031012]; integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; mitochondrial inner membrane [GO:0005743]; mitochondrial nucleoid [GO:0042645]; mitochondrion [GO:0005739]; MMXD complex [GO:0071817]; myelin sheath [GO:0043209]; nucleus [GO:0005634]
P12236	ADT3_HUMAN	ADP/ATP translocase 3 (ADP,ATP carrier protein 3) (ADP,ATP carrier protein, isoform T2) (ANT 2) (Adenine nucleotide translocator 3) (ANT 3) (Solute carrier family 25 member 6) [Cleaved into: ADP/ATP translocase 3, N-terminally processed]	SLC25A6 ANT3 CDABP0051				DB00720;		PF00153;	IPR002113;IPR002067;IPR018108;IPR023395;	active induction of host immune response by virus [GO:0046732]; apoptotic process [GO:0006915]; protein targeting to mitochondrion [GO:0006626]; regulation of insulin secretion [GO:0050796]; translation [GO:0006412]	adenine transmembrane transporter activity [GO:0015207]; ATP:ADP antiporter activity [GO:0005471]; structural constituent of ribosome [GO:0003735]	extracellular matrix [GO:0031012]; integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrial inner membrane presequence translocase complex [GO:0005744]; mitochondrion [GO:0005739]; nucleus [GO:0005634]
P10109	ADX_HUMAN	Adrenodoxin, mitochondrial (Adrenal ferredoxin) (Ferredoxin-1) (Hepatoredoxin)	FDX1 ADX	3N9Y;3N9Z;3NA0;3NA1;3P1M;			DB00648;		PF00111;	IPR001041;IPR001055;IPR018298;IPR012675;	C21-steroid hormone biosynthetic process [GO:0006700]; cholesterol metabolic process [GO:0008203]; hormone biosynthetic process [GO:0042446]; oxidation-reduction process [GO:0055114]; small molecule metabolic process [GO:0044281]; sterol metabolic process [GO:0016125]	2 iron, 2 sulfur cluster binding [GO:0051537]; electron carrier activity [GO:0009055]; iron ion binding [GO:0005506]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
O43931	AFG31_HUMAN	Deleted.
Q9Y4W6	AFG32_HUMAN	AFG3-like protein 2 (EC 3.4.24.-) (Paraplegin-like protein)	AFG3L2	2LNA;			DB00171;		PF00004;PF06480;PF01434;	IPR003593;IPR003959;IPR003960;IPR005936;IPR027417;IPR011546;IPR000642;	axonogenesis [GO:0007409]; cristae formation [GO:0042407]; mitochondrial fusion [GO:0008053]; mitochondrial protein processing [GO:0034982]; muscle fiber development [GO:0048747]; myelination [GO:0042552]; nerve development [GO:0021675]; neuromuscular junction development [GO:0007528]; protein complex assembly [GO:0006461]; protein import into mitochondrial intermembrane space [GO:0045041]; regulation of multicellular organism growth [GO:0040014]; righting reflex [GO:0060013]	ATP binding [GO:0005524]; ATP-dependent peptidase activity [GO:0004176]; metalloendopeptidase activity [GO:0004222]; metallopeptidase activity [GO:0008237]; unfolded protein binding [GO:0051082]; zinc ion binding [GO:0008270]	m-AAA complex [GO:0005745]; mitochondrial inner membrane [GO:0005743]; mitochondrion [GO:0005739]
P06280	AGAL_HUMAN	Alpha-galactosidase A (EC 3.2.1.22) (Alpha-D-galactosidase A) (Alpha-D-galactoside galactohydrolase) (Melibiase) (Agalsidase)	GLA	1R46;1R47;3GXN;3GXP;3GXT;3HG2;3HG3;3HG4;3HG5;3LX9;3LXA;3LXB;3LXC;3S5Y;3S5Z;3TV8;4NXS;	CHEMBL2524;	P06280;			PF16499;	IPR013785;IPR002241;IPR000111;IPR013780;IPR017853;	glycosphingolipid catabolic process [GO:0046479]; glycosphingolipid metabolic process [GO:0006687]; glycosylceramide catabolic process [GO:0046477]; negative regulation of nitric oxide biosynthetic process [GO:0045019]; negative regulation of nitric-oxide synthase activity [GO:0051001]; oligosaccharide metabolic process [GO:0009311]	alpha-galactosidase activity [GO:0004557]; catalytic activity [GO:0003824]; galactoside binding [GO:0016936]; hydrolase activity [GO:0016787]; protein homodimerization activity [GO:0042803]; raffinose alpha-galactosidase activity [GO:0052692]; receptor binding [GO:0005102]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; Golgi apparatus [GO:0005794]; lysosomal lumen [GO:0043202]; lysosome [GO:0005764]
Q9BYV1	AGT2_HUMAN	Alanine--glyoxylate aminotransferase 2, mitochondrial (AGT 2) (EC 2.6.1.44) ((R)-3-amino-2-methylpropionate--pyruvate transaminase) (EC 2.6.1.40) (Beta-ALAAT II) (Beta-alanine-pyruvate aminotransferase) (D-AIBAT)	AGXT2 AGT2				DB00145;DB00160;DB00119;		PF00202;	IPR005814;IPR015424;IPR015421;IPR015422;	glycine biosynthetic process, by transamination of glyoxylate [GO:0019265]; glyoxylate catabolic process [GO:0009436]; glyoxylate metabolic process [GO:0046487]; L-alanine catabolic process, by transamination [GO:0019481]; positive regulation of nitric oxide biosynthetic process [GO:0045429]	(R)-3-amino-2-methylpropionate-pyruvate transaminase activity [GO:0047305]; alanine-glyoxylate transaminase activity [GO:0008453]; beta-alanine-pyruvate transaminase activity [GO:0016223]; identical protein binding [GO:0042802]; pyridoxal phosphate binding [GO:0030170]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
P30556	AGTR1_HUMAN	Type-1 angiotensin II receptor (AT1AR) (AT1BR) (Angiotensin II type-1 receptor) (AT1)	AGTR1 AGTR1A AGTR1B AT2R1 AT2R1B	1ZV0;4YAY;4ZUD;	CHEMBL227;	P30556;	DB08822;DB00796;DB00876;DB01342;DB01029;DB00678;DB00275;DB01347;DB01349;DB00966;DB00177;		PF00001;	IPR000190;IPR000248;IPR000276;IPR017452;	angiotensin-activated signaling pathway [GO:0038166]; calcium-mediated signaling [GO:0019722]; cell chemotaxis [GO:0060326]; G-protein coupled receptor signaling pathway [GO:0007186]; kidney development [GO:0001822]; low-density lipoprotein particle remodeling [GO:0034374]; phospholipase C-activating angiotensin-activated signaling pathway [GO:0086097]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; positive regulation of cellular protein metabolic process [GO:0032270]; positive regulation of cholesterol esterification [GO:0010873]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway [GO:0051482]; positive regulation of inflammatory response [GO:0050729]; positive regulation of macrophage derived foam cell differentiation [GO:0010744]; positive regulation of NAD(P)H oxidase activity [GO:0033864]; positive regulation of phospholipase A2 activity [GO:0032430]; positive regulation of reactive oxygen species metabolic process [GO:2000379]; regulation of blood vessel size by renin-angiotensin [GO:0002034]; regulation of cell growth [GO:0001558]; regulation of cell proliferation [GO:0042127]; regulation of inflammatory response [GO:0050727]; regulation of renal sodium excretion [GO:0035813]; regulation of systemic arterial blood pressure by renin-angiotensin [GO:0003081]; regulation of vasoconstriction [GO:0019229]; regulation of vasodilation [GO:0042312]; renin-angiotensin regulation of aldosterone production [GO:0002018]; Rho protein signal transduction [GO:0007266]	angiotensin type II receptor activity [GO:0004945]; angiotensin type I receptor activity [GO:0001596]; bradykinin receptor binding [GO:0031711]; protein heterodimerization activity [GO:0046982]	integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; intracellular [GO:0005622]; plasma membrane [GO:0005886]
O95831	AIFM1_HUMAN	Apoptosis-inducing factor 1, mitochondrial (EC 1.1.1.-) (Programmed cell death protein 8)	AIFM1 AIF PDCD8	1M6I;4BUR;4BV6;4FDC;4LII;5FS6;5FS7;5FS8;5FS9;			DB03147;		PF14721;PF07992;	IPR029324;IPR023753;IPR016156;IPR004099;	activation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0006919]; apoptotic process [GO:0006915]; cell redox homeostasis [GO:0045454]; cellular response to aldosterone [GO:1904045]; cellular response to estradiol stimulus [GO:0071392]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to nitric oxide [GO:0071732]; cellular response to oxygen-glucose deprivation [GO:0090650]; chromosome condensation [GO:0030261]; DNA catabolic process [GO:0006308]; intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress [GO:0070059]; mitochondrial respiratory chain complex I assembly [GO:0032981]; neuron apoptotic process [GO:0051402]; neuron differentiation [GO:0030182]; positive regulation of apoptotic process [GO:0043065]; positive regulation of neuron apoptotic process [GO:0043525]; regulation of apoptotic DNA fragmentation [GO:1902510]; response to ischemia [GO:0002931]; response to L-glutamate [GO:1902065]; response to toxic substance [GO:0009636]	DNA binding [GO:0003677]; electron carrier activity [GO:0009055]; FAD binding [GO:0071949]; NAD(P)H oxidase activity [GO:0016174]; oxidoreductase activity, acting on NAD(P)H [GO:0016651]	cytosol [GO:0005829]; mitochondrial inner membrane [GO:0005743]; mitochondrial intermembrane space [GO:0005758]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]
Q04828	AK1C1_HUMAN	Aldo-keto reductase family 1 member C1 (EC 1.1.1.-) (20-alpha-hydroxysteroid dehydrogenase) (20-alpha-HSD) (EC 1.1.1.149) (Chlordecone reductase homolog HAKRC) (Dihydrodiol dehydrogenase 1/2) (DD1/DD2) (High-affinity hepatic bile acid-binding protein) (HBAB) (Indanol dehydrogenase) (EC 1.1.1.112) (Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase) (EC 1.3.1.20)	AKR1C1 DDH DDH1	1MRQ;3C3U;3GUG;3NTY;4YVP;	CHEMBL5905;	Q04828;	DB00945;DB00936;		PF00248;	IPR001395;IPR018170;IPR020471;IPR023210;	bile acid and bile salt transport [GO:0015721]; bile acid metabolic process [GO:0008206]; cellular response to jasmonic acid stimulus [GO:0071395]; cholesterol homeostasis [GO:0042632]; daunorubicin metabolic process [GO:0044597]; digestion [GO:0007586]; doxorubicin metabolic process [GO:0044598]; epithelial cell differentiation [GO:0030855]; intestinal cholesterol absorption [GO:0030299]; oxidation-reduction process [GO:0055114]; progesterone metabolic process [GO:0042448]; protein homooligomerization [GO:0051260]; response to organophosphorus [GO:0046683]; retinal metabolic process [GO:0042574]; retinoid metabolic process [GO:0001523]; xenobiotic metabolic process [GO:0006805]	17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase activity [GO:0047006]; alditol:NADP+ 1-oxidoreductase activity [GO:0004032]; aldo-keto reductase (NADP) activity [GO:0004033]; androsterone dehydrogenase (B-specific) activity [GO:0047042]; bile acid binding [GO:0032052]; carboxylic acid binding [GO:0031406]; indanol dehydrogenase activity [GO:0047718]; ketosteroid monooxygenase activity [GO:0047086]; oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor [GO:0016655]; phenanthrene 9,10-monooxygenase activity [GO:0018636]; trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity [GO:0047115]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P52895	AK1C2_HUMAN	Aldo-keto reductase family 1 member C2 (EC 1.-.-.-) (3-alpha-HSD3) (Chlordecone reductase homolog HAKRD) (Dihydrodiol dehydrogenase 2) (DD-2) (DD2) (Dihydrodiol dehydrogenase/bile acid-binding protein) (DD/BABP) (Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase) (EC 1.3.1.20) (Type III 3-alpha-hydroxysteroid dehydrogenase) (EC 1.1.1.357)	AKR1C2 DDH2	1IHI;1J96;1XJB;2HDJ;2IPJ;4JQ1;4JQ2;4JQ3;4JQ4;4JQA;4JTQ;4JTR;4L1W;4L1X;4XO6;4XO7;	CHEMBL5847;	P52895;	DB01586;		PF00248;	IPR001395;IPR018170;IPR020471;IPR023210;	cellular response to jasmonic acid stimulus [GO:0071395]; cellular response to prostaglandin D stimulus [GO:0071799]; daunorubicin metabolic process [GO:0044597]; digestion [GO:0007586]; doxorubicin metabolic process [GO:0044598]; epithelial cell differentiation [GO:0030855]; G-protein coupled receptor signaling pathway [GO:0007186]; oxidation-reduction process [GO:0055114]; positive regulation of cell proliferation [GO:0008284]; positive regulation of protein kinase B signaling [GO:0051897]; progesterone metabolic process [GO:0042448]; prostaglandin metabolic process [GO:0006693]; steroid metabolic process [GO:0008202]	alditol:NADP+ 1-oxidoreductase activity [GO:0004032]; bile acid binding [GO:0032052]; carboxylic acid binding [GO:0031406]; ketosteroid monooxygenase activity [GO:0047086]; oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor [GO:0016655]; phenanthrene 9,10-monooxygenase activity [GO:0018636]; trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity [GO:0047115]	cytoplasm [GO:0005737]
P42330	AK1C3_HUMAN	Aldo-keto reductase family 1 member C3 (EC 1.-.-.-) (17-beta-hydroxysteroid dehydrogenase type 5) (17-beta-HSD 5) (3-alpha-HSD type II, brain) (3-alpha-hydroxysteroid dehydrogenase type 2) (3-alpha-HSD type 2) (EC 1.1.1.357) (Chlordecone reductase homolog HAKRb) (Dihydrodiol dehydrogenase 3) (DD-3) (DD3) (Dihydrodiol dehydrogenase type I) (HA1753) (Indanol dehydrogenase) (EC 1.1.1.112) (Prostaglandin F synthase) (PGFS) (EC 1.1.1.188) (Testosterone 17-beta-dehydrogenase 5) (EC 1.1.1.239) (EC 1.1.1.64) (Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase) (EC 1.3.1.20)	AKR1C3 DDH1 HSD17B5 KIAA0119 PGFS	1RY0;1RY8;1S1P;1S1R;1S2A;1S2C;1XF0;1ZQ5;2F38;2FGB;3R43;3R58;3R6I;3R7M;3R8G;3R8H;3R94;3UFY;3UG8;3UGR;3UWE;4DBS;4DBU;4DBW;4DZ5;4FA3;4FAL;4FAM;4H7C;4HMN;4WDT;4WDU;4WDW;4WDX;4WRH;4XVD;4XVE;4YVV;4YVX;4ZFC;	CHEMBL4681;	P42330;	DB00905;DB00997;		PF00248;	IPR001395;IPR018170;IPR020471;IPR023210;	cellular response to cadmium ion [GO:0071276]; cellular response to calcium ion [GO:0071277]; cellular response to corticosteroid stimulus [GO:0071384]; cellular response to jasmonic acid stimulus [GO:0071395]; cellular response to prostaglandin D stimulus [GO:0071799]; cellular response to prostaglandin stimulus [GO:0071379]; cellular response to reactive oxygen species [GO:0034614]; cellular response to starvation [GO:0009267]; cyclooxygenase pathway [GO:0019371]; daunorubicin metabolic process [GO:0044597]; doxorubicin metabolic process [GO:0044598]; farnesol catabolic process [GO:0016488]; G-protein coupled receptor signaling pathway [GO:0007186]; keratinocyte differentiation [GO:0030216]; male gonad development [GO:0008584]; multicellular organismal macromolecule metabolic process [GO:0044259]; negative regulation of retinoic acid biosynthetic process [GO:1900053]; oxidation-reduction process [GO:0055114]; positive regulation of cell death [GO:0010942]; positive regulation of cell proliferation [GO:0008284]; positive regulation of endothelial cell apoptotic process [GO:2000353]; positive regulation of protein kinase B signaling [GO:0051897]; positive regulation of reactive oxygen species metabolic process [GO:2000379]; progesterone metabolic process [GO:0042448]; prostaglandin metabolic process [GO:0006693]; protein import into nucleus, translocation [GO:0000060]; regulation of retinoic acid receptor signaling pathway [GO:0048385]; regulation of testosterone biosynthetic process [GO:2000224]; renal absorption [GO:0070293]; response to nutrient [GO:0007584]; retinal metabolic process [GO:0042574]; retinoid metabolic process [GO:0001523]; steroid metabolic process [GO:0008202]; testosterone biosynthetic process [GO:0061370]	15-hydroxyprostaglandin-D dehydrogenase (NADP+) activity [GO:0047020]; alditol:NADP+ 1-oxidoreductase activity [GO:0004032]; aldo-keto reductase (NADP) activity [GO:0004033]; androsterone dehydrogenase activity [GO:0047023]; delta4-3-oxosteroid 5beta-reductase activity [GO:0047787]; dihydrotestosterone 17-beta-dehydrogenase activity [GO:0035410]; geranylgeranyl reductase activity [GO:0045550]; indanol dehydrogenase activity [GO:0047718]; ketoreductase activity [GO:0045703]; ketosteroid monooxygenase activity [GO:0047086]; NADP-retinol dehydrogenase activity [GO:0052650]; oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor [GO:0016655]; phenanthrene 9,10-monooxygenase activity [GO:0018636]; prostaglandin D2 11-ketoreductase activity [GO:0036131]; prostaglandin-F synthase activity [GO:0047017]; prostaglandin H2 endoperoxidase reductase activity [GO:0036130]; retinal dehydrogenase activity [GO:0001758]; retinol dehydrogenase activity [GO:0004745]; testosterone 17-beta-dehydrogenase (NADP+) activity [GO:0047045]; testosterone dehydrogenase (NAD+) activity [GO:0047035]; trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity [GO:0047115]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; intracellular [GO:0005622]; nucleus [GO:0005634]
P17516	AK1C4_HUMAN	Aldo-keto reductase family 1 member C4 (EC 1.1.1.-) (3-alpha-HSD1) (3-alpha-hydroxysteroid dehydrogenase type I) (EC 1.1.1.357) (Chlordecone reductase) (CDR) (EC 1.1.1.225) (Dihydrodiol dehydrogenase 4) (DD-4) (DD4) (HAKRA)	AKR1C4 CHDR	2FVL;	CHEMBL4999;	P17516;			PF00248;	IPR001395;IPR018170;IPR020471;IPR023210;	androgen metabolic process [GO:0008209]; bile acid and bile salt transport [GO:0015721]; bile acid biosynthetic process [GO:0006699]; cellular response to jasmonic acid stimulus [GO:0071395]; daunorubicin metabolic process [GO:0044597]; doxorubicin metabolic process [GO:0044598]; retinoid metabolic process [GO:0001523]; steroid metabolic process [GO:0008202]	aldo-keto reductase (NADP) activity [GO:0004033]; androsterone dehydrogenase activity [GO:0047023]; bile acid transmembrane transporter activity [GO:0015125]; chlordecone reductase activity [GO:0047743]; electron carrier activity [GO:0009055]; oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor [GO:0016655]; retinal dehydrogenase activity [GO:0001758]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P31749	AKT1_HUMAN	RAC-alpha serine/threonine-protein kinase (EC 2.7.11.1) (Protein kinase B) (PKB) (Protein kinase B alpha) (PKB alpha) (Proto-oncogene c-Akt) (RAC-PK-alpha)	AKT1 PKB RAC	1H10;1UNP;1UNQ;1UNR;2UVM;2UZR;2UZS;3CQU;3CQW;3MV5;3MVH;3O96;3OCB;3OW4;3QKK;3QKL;3QKM;4EJN;4EKK;4EKL;4GV1;5KCV;	CHEMBL4282;	P31749;	DB00171;DB01169;		PF00169;PF00069;PF00433;	IPR000961;IPR011009;IPR011993;IPR001849;IPR017892;IPR000719;IPR017441;IPR008271;	activation-induced cell death of T cells [GO:0006924]; aging [GO:0007568]; apoptotic mitochondrial changes [GO:0008637]; cell differentiation [GO:0030154]; cell projection organization [GO:0030030]; cell proliferation [GO:0008283]; cellular protein modification process [GO:0006464]; cellular response to DNA damage stimulus [GO:0006974]; cellular response to epidermal growth factor stimulus [GO:0071364]; cellular response to granulocyte macrophage colony-stimulating factor stimulus [GO:0097011]; cellular response to hypoxia [GO:0071456]; cellular response to insulin stimulus [GO:0032869]; cellular response to mechanical stimulus [GO:0071260]; cellular response to nerve growth factor stimulus [GO:1990090]; cellular response to organic cyclic compound [GO:0071407]; cellular response to prostaglandin E stimulus [GO:0071380]; cellular response to vascular endothelial growth factor stimulus [GO:0035924]; chemical synaptic transmission, postsynaptic [GO:0099565]; endocrine pancreas development [GO:0031018]; ERBB2 signaling pathway [GO:0038128]; establishment of protein localization to mitochondrion [GO:0072655]; execution phase of apoptosis [GO:0097194]; germ cell development [GO:0007281]; glucose homeostasis [GO:0042593]; glucose metabolic process [GO:0006006]; glucose transport [GO:0015758]; glycogen biosynthetic process [GO:0005978]; glycogen cell differentiation involved in embryonic placenta development [GO:0060709]; G-protein coupled receptor signaling pathway [GO:0007186]; hyaluronan metabolic process [GO:0030212]; inflammatory response [GO:0006954]; insulin-like growth factor receptor signaling pathway [GO:0048009]; insulin receptor signaling pathway [GO:0008286]; interleukin-18-mediated signaling pathway [GO:0035655]; intracellular signal transduction [GO:0035556]; labyrinthine layer blood vessel development [GO:0060716]; lipopolysaccharide-mediated signaling pathway [GO:0031663]; maintenance of protein location in mitochondrion [GO:0072656]; mammary gland epithelial cell differentiation [GO:0060644]; maternal placenta development [GO:0001893]; negative regulation of apoptotic process [GO:0043066]; negative regulation of autophagy [GO:0010507]; negative regulation of cell size [GO:0045792]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154]; negative regulation of endopeptidase activity [GO:0010951]; negative regulation of extrinsic apoptotic signaling pathway in absence of ligand [GO:2001240]; negative regulation of fatty acid beta-oxidation [GO:0031999]; negative regulation of gene expression [GO:0010629]; negative regulation of JNK cascade [GO:0046329]; negative regulation of neuron death [GO:1901215]; negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway [GO:1902176]; negative regulation of plasma membrane long-chain fatty acid transport [GO:0010748]; negative regulation of protein kinase activity [GO:0006469]; negative regulation of protein kinase activity by protein phosphorylation [GO:0100002]; negative regulation of proteolysis [GO:0045861]; negative regulation of release of cytochrome c from mitochondria [GO:0090201]; nitric oxide biosynthetic process [GO:0006809]; osteoblast differentiation [GO:0001649]; peptidyl-serine phosphorylation [GO:0018105]; peptidyl-threonine phosphorylation [GO:0018107]; peripheral nervous system myelin maintenance [GO:0032287]; phosphatidylinositol-mediated signaling [GO:0048015]; phosphorylation [GO:0016310]; platelet activation [GO:0030168]; positive regulation of apoptotic process [GO:0043065]; positive regulation of blood vessel endothelial cell migration [GO:0043536]; positive regulation of cell growth [GO:0030307]; positive regulation of cellular protein metabolic process [GO:0032270]; positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle [GO:0031659]; positive regulation of endodeoxyribonuclease activity [GO:0032079]; positive regulation of endothelial cell proliferation [GO:0001938]; positive regulation of epidermal growth factor receptor signaling pathway [GO:0045742]; positive regulation of establishment of protein localization to plasma membrane [GO:0090004]; positive regulation of fat cell differentiation [GO:0045600]; positive regulation of fibroblast migration [GO:0010763]; positive regulation of glucose import [GO:0046326]; positive regulation of glucose metabolic process [GO:0010907]; positive regulation of glycogen biosynthetic process [GO:0045725]; positive regulation of lipid biosynthetic process [GO:0046889]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; positive regulation of nitric-oxide synthase activity [GO:0051000]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of proteasomal ubiquitin-dependent protein catabolic process [GO:0032436]; positive regulation of protein localization to nucleus [GO:1900182]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of sequence-specific DNA binding transcription factor activity [GO:0051091]; positive regulation of smooth muscle cell proliferation [GO:0048661]; positive regulation of sodium ion transport [GO:0010765]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of vasoconstriction [GO:0045907]; protein autophosphorylation [GO:0046777]; protein catabolic process [GO:0030163]; protein import into nucleus, translocation [GO:0000060]; protein kinase B signaling [GO:0043491]; protein phosphorylation [GO:0006468]; protein ubiquitination [GO:0016567]; regulation of cell cycle checkpoint [GO:1901976]; regulation of cell migration [GO:0030334]; regulation of glycogen biosynthetic process [GO:0005979]; regulation of mRNA stability [GO:0043488]; regulation of myelination [GO:0031641]; regulation of neuron projection development [GO:0010975]; regulation of nitric-oxide synthase activity [GO:0050999]; regulation of phosphatidylinositol 3-kinase signaling [GO:0014066]; regulation of signal transduction by p53 class mediator [GO:1901796]; regulation of translation [GO:0006417]; response to fluid shear stress [GO:0034405]; response to food [GO:0032094]; response to growth hormone [GO:0060416]; response to heat [GO:0009408]; response to insulin-like growth factor stimulus [GO:1990418]; response to oxidative stress [GO:0006979]; response to UV-A [GO:0070141]; signal transduction [GO:0007165]; spinal cord development [GO:0021510]; striated muscle cell differentiation [GO:0051146]; T cell costimulation [GO:0031295]; translation [GO:0006412]	14-3-3 protein binding [GO:0071889]; ATP binding [GO:0005524]; enzyme binding [GO:0019899]; kinase activity [GO:0016301]; nitric-oxide synthase regulator activity [GO:0030235]; phosphatidylinositol-3,4,5-trisphosphate binding [GO:0005547]; phosphatidylinositol-3,4-bisphosphate binding [GO:0043325]; protein kinase activity [GO:0004672]; protein serine/threonine/tyrosine kinase activity [GO:0004712]; protein serine/threonine kinase activity [GO:0004674]	cell-cell junction [GO:0005911]; ciliary basal body [GO:0036064]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; microtubule cytoskeleton [GO:0015630]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; postsynapse [GO:0098794]; protein complex [GO:0043234]; spindle [GO:0005819]; vesicle [GO:0031982]
P00352	AL1A1_HUMAN	Retinal dehydrogenase 1 (RALDH 1) (RalDH1) (EC 1.2.1.36) (ALDH-E1) (ALHDII) (Aldehyde dehydrogenase family 1 member A1) (Aldehyde dehydrogenase, cytosolic)	ALDH1A1 ALDC ALDH1 PUMB1	4WB9;4WJ9;4WP7;4WPN;4X4L;5AC2;	CHEMBL3577;	P00352;	DB00755;DB00162;	PATHWAY: Cofactor metabolism; retinol metabolism.	PF00171;	IPR016161;IPR016163;IPR016160;IPR029510;IPR016162;IPR015590;	cellular aldehyde metabolic process [GO:0006081]; ethanol oxidation [GO:0006069]; fructose catabolic process to hydroxyacetone phosphate and glyceraldehyde-3-phosphate [GO:0061624]; retinol metabolic process [GO:0042572]	aldehyde dehydrogenase (NAD) activity [GO:0004029]; androgen binding [GO:0005497]; benzaldehyde dehydrogenase (NAD+) activity [GO:0018479]; GTPase activator activity [GO:0005096]; retinal dehydrogenase activity [GO:0001758]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
O94788	AL1A2_HUMAN	Retinal dehydrogenase 2 (RALDH 2) (RalDH2) (EC 1.2.1.36) (Aldehyde dehydrogenase family 1 member A2) (Retinaldehyde-specific dehydrogenase type 2) (RALDH(II))	ALDH1A2 RALDH2	4X2Q;	CHEMBL3112384;	O94788;	DB00755;DB00162;	PATHWAY: Cofactor metabolism; retinol metabolism.	PF00171;	IPR016161;IPR016163;IPR016160;IPR029510;IPR016162;IPR015590;	9-cis-retinoic acid biosynthetic process [GO:0042904]; anterior/posterior pattern specification [GO:0009952]; blood vessel development [GO:0001568]; cardiac muscle tissue development [GO:0048738]; cellular response to retinoic acid [GO:0071300]; determination of bilateral symmetry [GO:0009855]; embryonic camera-type eye development [GO:0031076]; embryonic digestive tract development [GO:0048566]; embryonic forelimb morphogenesis [GO:0035115]; face development [GO:0060324]; heart morphogenesis [GO:0003007]; hindbrain development [GO:0030902]; kidney development [GO:0001822]; liver development [GO:0001889]; lung development [GO:0030324]; midgut development [GO:0007494]; morphogenesis of embryonic epithelium [GO:0016331]; negative regulation of cell proliferation [GO:0008285]; neural crest cell development [GO:0014032]; neural tube development [GO:0021915]; neuron differentiation [GO:0030182]; pancreas development [GO:0031016]; pituitary gland development [GO:0021983]; positive regulation of apoptotic process [GO:0043065]; positive regulation of cell proliferation [GO:0008284]; positive regulation of gene expression [GO:0010628]; proximal/distal pattern formation [GO:0009954]; regulation of endothelial cell proliferation [GO:0001936]; response to cytokine [GO:0034097]; response to estradiol [GO:0032355]; response to vitamin A [GO:0033189]; retinal metabolic process [GO:0042574]; retinoic acid biosynthetic process [GO:0002138]; retinoic acid metabolic process [GO:0042573]; retinoic acid receptor signaling pathway [GO:0048384]; retinol metabolic process [GO:0042572]; ureter maturation [GO:0035799]; vitamin A metabolic process [GO:0006776]	3-chloroallyl aldehyde dehydrogenase activity [GO:0004028]; aldehyde dehydrogenase (NAD) activity [GO:0004029]; retinal binding [GO:0016918]; retinal dehydrogenase activity [GO:0001758]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; perinuclear region of cytoplasm [GO:0048471]
P47895	AL1A3_HUMAN	Aldehyde dehydrogenase family 1 member A3 (EC 1.2.1.5) (Aldehyde dehydrogenase 6) (Retinaldehyde dehydrogenase 3) (RALDH-3) (RalDH3)	ALDH1A3 ALDH6		CHEMBL3579;	P47895;	DB00162;	PATHWAY: Cofactor metabolism; retinol metabolism.	PF00171;	IPR016161;IPR016163;IPR016160;IPR029510;IPR016162;IPR015590;	embryonic eye morphogenesis [GO:0048048]; face development [GO:0060324]; inner ear morphogenesis [GO:0042472]; locomotory behavior [GO:0007626]; neuromuscular process controlling balance [GO:0050885]; nucleus accumbens development [GO:0021768]; olfactory pit development [GO:0060166]; optic cup morphogenesis involved in camera-type eye development [GO:0002072]; positive regulation of apoptotic process [GO:0043065]; retinal metabolic process [GO:0042574]; retinoic acid biosynthetic process [GO:0002138]; retinoic acid metabolic process [GO:0042573]; retinol metabolic process [GO:0042572]; righting reflex [GO:0060013]	aldehyde dehydrogenase (NAD) activity [GO:0004029]; aldehyde dehydrogenase [NAD(P)+] activity [GO:0004030]; NAD+ binding [GO:0070403]; protein homodimerization activity [GO:0042803]; retinal dehydrogenase activity [GO:0001758]; thyroid hormone binding [GO:0070324]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P30837	AL1B1_HUMAN	Aldehyde dehydrogenase X, mitochondrial (EC 1.2.1.3) (Aldehyde dehydrogenase 5) (Aldehyde dehydrogenase family 1 member B1)	ALDH1B1 ALDH5 ALDHX		CHEMBL4881;	P30837;		PATHWAY: Alcohol metabolism; ethanol degradation; acetate from ethanol: step 2/2.	PF00171;	IPR016161;IPR016163;IPR016160;IPR029510;IPR016162;IPR015590;	carbohydrate metabolic process [GO:0005975]; ethanol catabolic process [GO:0006068]; ethanol oxidation [GO:0006069]	aldehyde dehydrogenase (NAD) activity [GO:0004029]	intracellular membrane-bounded organelle [GO:0043231]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]
Q96Q40	AL2S7_HUMAN	Cyclin-dependent kinase 15 (EC 2.7.11.22) (Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 7 protein) (Cell division protein kinase 15) (Serine/threonine-protein kinase ALS2CR7) (Serine/threonine-protein kinase PFTAIRE-2)	CDK15 ALS2CR7 PFTK2		CHEMBL5856;	Q96Q40;	DB00171;		PF00069;	IPR011009;IPR000719;IPR017441;IPR008271;		ATP binding [GO:0005524]; cyclin-dependent protein serine/threonine kinase activity [GO:0004693]; metal ion binding [GO:0046872]; protein serine/threonine kinase activity [GO:0004674]
P30838	AL3A1_HUMAN	Aldehyde dehydrogenase, dimeric NADP-preferring (EC 1.2.1.5) (ALDHIII) (Aldehyde dehydrogenase 3) (Aldehyde dehydrogenase family 3 member A1)	ALDH3A1 ALDH3	3SZA;3SZB;4H80;4L1O;4L2O;	CHEMBL3578;	P30838;			PF00171;	IPR016161;IPR016163;IPR016160;IPR029510;IPR016162;IPR015590;IPR012394;	aging [GO:0007568]; cellular aldehyde metabolic process [GO:0006081]; oxidation-reduction process [GO:0055114]; positive regulation of cell proliferation [GO:0008284]; response to cAMP [GO:0051591]; response to drug [GO:0042493]; response to glucocorticoid [GO:0051384]; response to hypoxia [GO:0001666]; response to nutrient [GO:0007584]; xenobiotic metabolic process [GO:0006805]	3-chloroallyl aldehyde dehydrogenase activity [GO:0004028]; alcohol dehydrogenase (NADP+) activity [GO:0008106]; aldehyde dehydrogenase (NAD) activity [GO:0004029]; aldehyde dehydrogenase [NAD(P)+] activity [GO:0004030]; benzaldehyde dehydrogenase (NAD+) activity [GO:0018479]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; extracellular space [GO:0005615]; integral component of membrane [GO:0016021]; intracellular membrane-bounded organelle [GO:0043231]; nucleoplasm [GO:0005654]; plasma membrane [GO:0005886]
P51648	AL3A2_HUMAN	Fatty aldehyde dehydrogenase (EC 1.2.1.3) (Aldehyde dehydrogenase 10) (Aldehyde dehydrogenase family 3 member A2) (Microsomal aldehyde dehydrogenase)	ALDH3A2 ALDH10 FALDH	4QGK;					PF00171;	IPR016161;IPR016163;IPR016160;IPR029510;IPR016162;IPR015590;IPR012394;	cellular aldehyde metabolic process [GO:0006081]; central nervous system development [GO:0007417]; epidermis development [GO:0008544]; fatty acid alpha-oxidation [GO:0001561]; oxidation-reduction process [GO:0055114]; peripheral nervous system development [GO:0007422]; phytol metabolic process [GO:0033306]; sesquiterpenoid metabolic process [GO:0006714]; sphingolipid biosynthetic process [GO:0030148]	3-chloroallyl aldehyde dehydrogenase activity [GO:0004028]; aldehyde dehydrogenase (NAD) activity [GO:0004029]; aldehyde dehydrogenase [NAD(P)+] activity [GO:0004030]; long-chain-alcohol oxidase activity [GO:0046577]; long-chain-aldehyde dehydrogenase activity [GO:0050061]; medium-chain-aldehyde dehydrogenase activity [GO:0052814]	endoplasmic reticulum membrane [GO:0005789]; extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; intracellular membrane-bounded organelle [GO:0043231]; mitochondrial inner membrane [GO:0005743]; peroxisomal membrane [GO:0005778]; peroxisome [GO:0005777]
P43353	AL3B1_HUMAN	Aldehyde dehydrogenase family 3 member B1 (EC 1.2.1.5) (Aldehyde dehydrogenase 7)	ALDH3B1 ALDH7		CHEMBL3542434;			PATHWAY: Alcohol metabolism; ethanol degradation; acetate from ethanol: step 2/2.	PF00171;	IPR016161;IPR016163;IPR016160;IPR029510;IPR016162;IPR015590;IPR012394;	alcohol metabolic process [GO:0006066]; aldehyde catabolic process [GO:0046185]; cellular response to oxidative stress [GO:0034599]; ethanol catabolic process [GO:0006068]; lipid metabolic process [GO:0006629]; oxidation-reduction process [GO:0055114]; sphingolipid biosynthetic process [GO:0030148]	3-chloroallyl aldehyde dehydrogenase activity [GO:0004028]; aldehyde dehydrogenase (NAD) activity [GO:0004029]; aldehyde dehydrogenase [NAD(P)+] activity [GO:0004030]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; plasma membrane [GO:0005886]; vesicle [GO:0031982]
P48448	AL3B2_HUMAN	Aldehyde dehydrogenase family 3 member B2 (EC 1.2.1.5) (Aldehyde dehydrogenase 8)	ALDH3B2 ALDH8		CHEMBL3542434;			PATHWAY: Alcohol metabolism; ethanol degradation; acetate from ethanol: step 2/2.	PF00171;	IPR016161;IPR016163;IPR016160;IPR029510;IPR016162;IPR015590;	alcohol metabolic process [GO:0006066]; ethanol catabolic process [GO:0006068]; lipid metabolic process [GO:0006629]; sphingolipid biosynthetic process [GO:0030148]	3-chloroallyl aldehyde dehydrogenase activity [GO:0004028]; aldehyde dehydrogenase (NAD) activity [GO:0004029]; aldehyde dehydrogenase [NAD(P)+] activity [GO:0004030]	lipid particle [GO:0005811]
P30038	AL4A1_HUMAN	Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial (P5C dehydrogenase) (EC 1.2.1.88) (Aldehyde dehydrogenase family 4 member A1) (L-glutamate gamma-semialdehyde dehydrogenase)	ALDH4A1 ALDH4 P5CDH	3V9G;3V9H;3V9I;4OE5;	CHEMBL3414418;			PATHWAY: Amino-acid degradation; L-proline degradation into L-glutamate; L-glutamate from L-proline: step 2/2. {ECO:0000269|PubMed:22516612}.	PF00171;	IPR016161;IPR016163;IPR016160;IPR029510;IPR016162;IPR015590;IPR005931;	4-hydroxyproline catabolic process [GO:0019470]; glutamate biosynthetic process [GO:0006537]; proline biosynthetic process [GO:0006561]; proline catabolic process [GO:0006562]; proline catabolic process to glutamate [GO:0010133]; proline metabolic process [GO:0006560]	1-pyrroline-5-carboxylate dehydrogenase activity [GO:0003842]; aldehyde dehydrogenase (NAD) activity [GO:0004029]; electron carrier activity [GO:0009055]	mitochondrial matrix [GO:0005759]
P49419	AL7A1_HUMAN	Alpha-aminoadipic semialdehyde dehydrogenase (Alpha-AASA dehydrogenase) (EC 1.2.1.31) (Aldehyde dehydrogenase family 7 member A1) (EC 1.2.1.3) (Antiquitin-1) (Betaine aldehyde dehydrogenase) (EC 1.2.1.8) (Delta1-piperideine-6-carboxylate dehydrogenase) (P6c dehydrogenase)	ALDH7A1 ATQ1	2J6L;4X0T;4X0U;4ZUK;4ZUL;4ZVW;4ZVX;4ZVY;				PATHWAY: Amine and polyamine biosynthesis; betaine biosynthesis via choline pathway; betaine from betaine aldehyde: step 1/1.	PF00171;	IPR016161;IPR016163;IPR029510;IPR016162;IPR015590;	cellular aldehyde metabolic process [GO:0006081]; choline catabolic process [GO:0042426]; glycine betaine biosynthetic process from choline [GO:0019285]; lysine catabolic process [GO:0006554]; sensory perception of sound [GO:0007605]	aldehyde dehydrogenase (NAD) activity [GO:0004029]; betaine-aldehyde dehydrogenase activity [GO:0008802]; L-aminoadipate-semialdehyde dehydrogenase activity [GO:0004043]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]
P49189	AL9A1_HUMAN	4-trimethylaminobutyraldehyde dehydrogenase (TMABADH) (EC 1.2.1.47) (Aldehyde dehydrogenase E3 isozyme) (Aldehyde dehydrogenase family 9 member A1) (EC 1.2.1.3) (Gamma-aminobutyraldehyde dehydrogenase) (EC 1.2.1.19) (R-aminobutyraldehyde dehydrogenase) [Cleaved into: 4-trimethylaminobutyraldehyde dehydrogenase, N-terminally processed]	ALDH9A1 ALDH4 ALDH7 ALDH9		CHEMBL3542434;			PATHWAY: Amine and polyamine biosynthesis; carnitine biosynthesis.	PF00171;	IPR016161;IPR016163;IPR016160;IPR029510;IPR016162;IPR015590;	carnitine biosynthetic process [GO:0045329]; cellular aldehyde metabolic process [GO:0006081]; hormone metabolic process [GO:0042445]; neurotransmitter biosynthetic process [GO:0042136]; oxidation-reduction process [GO:0055114]	1-pyrroline dehydrogenase activity [GO:0033737]; 3-chloroallyl aldehyde dehydrogenase activity [GO:0004028]; 4-trimethylammoniobutyraldehyde dehydrogenase activity [GO:0047105]; aldehyde dehydrogenase (NAD) activity [GO:0004029]; aminobutyraldehyde dehydrogenase activity [GO:0019145]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P24298	ALAT1_HUMAN	Alanine aminotransferase 1 (ALT1) (EC 2.6.1.2) (Glutamate pyruvate transaminase 1) (GPT 1) (Glutamic--alanine transaminase 1) (Glutamic--pyruvic transaminase 1)	GPT AAT1 GPT1		CHEMBL5929;		DB00160;DB00780;	PATHWAY: Amino-acid degradation; L-alanine degradation via transaminase pathway; pyruvate from L-alanine: step 1/1.	PF00155;	IPR004839;IPR015424;IPR015421;IPR015422;	cellular amino acid biosynthetic process [GO:0008652]; L-alanine catabolic process [GO:0042853]	L-alanine:2-oxoglutarate aminotransferase activity [GO:0004021]; pyridoxal phosphate binding [GO:0030170]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]
Q8TD30	ALAT2_HUMAN	Alanine aminotransferase 2 (ALT2) (EC 2.6.1.2) (Glutamate pyruvate transaminase 2) (GPT 2) (Glutamic--alanine transaminase 2) (Glutamic--pyruvic transaminase 2)	GPT2 AAT2 ALT2	3IHJ;			DB00160;DB00780;	PATHWAY: Amino-acid degradation; L-alanine degradation via transaminase pathway; pyruvate from L-alanine: step 1/1.	PF00155;	IPR004839;IPR015424;IPR015421;IPR015422;	2-oxoglutarate metabolic process [GO:0006103]; cellular amino acid biosynthetic process [GO:0008652]; L-alanine catabolic process [GO:0042853]; L-alanine metabolic process [GO:0042851]	L-alanine:2-oxoglutarate aminotransferase activity [GO:0004021]; pyridoxal phosphate binding [GO:0030170]	mitochondrial matrix [GO:0005759]
P02768	ALBU_HUMAN	Serum albumin	ALB GIG20 GIG42 PRO0903 PRO1708 PRO2044 PRO2619 PRO2675 UNQ696/PRO1341	1AO6;1BJ5;1BKE;1BM0;1E78;1E7A;1E7B;1E7C;1E7E;1E7F;1E7G;1E7H;1E7I;1GNI;1GNJ;1H9Z;1HA2;1HK1;1HK2;1HK3;1HK4;1HK5;1N5U;1O9X;1TF0;1UOR;1YSX;2BX8;2BXA;2BXB;2BXC;2BXD;2BXE;2BXF;2BXG;2BXH;2BXI;2BXK;2BXL;2BXM;2BXN;2BXO;2BXP;2BXQ;2ESG;2I2Z;2I30;2N0X;2VDB;2VUE;2VUF;2XSI;2XVQ;2XVU;2XVV;2XVW;2XW0;2XW1;2YDF;3A73;3B9L;3B9M;3CX9;3JQZ;3JRY;3LU6;3LU7;3LU8;3SQJ;3TDL;3UIV;4BKE;4E99;4EMX;4G03;4G04;4HGK;4HGM;4IW1;4IW2;4K2C;4K71;4L8U;4L9K;4L9Q;4LA0;4LB2;4LB9;4N0F;4N0U;4S1Y;4Z69;5FUO;5ID7;5IFO;5IJF;	CHEMBL3253;	P02768;	DB05812;DB01418;DB01614;DB00945;DB00459;DB00802;DB00321;DB00415;DB00995;DB01294;DB08907;DB01197;DB00456;DB01327;DB00274;DB01328;DB01329;DB00493;DB01330;DB00430;DB01212;DB00482;DB00567;DB00477;DB01242;DB01068;DB01147;DB01189;DB00829;DB00586;DB00861;DB01396;DB04855;DB00228;DB08899;DB00530;DB00199;DB00783;DB00655;DB04574;DB00903;DB00749;DB00573;DB00544;DB00472;DB00712;DB01320;DB06716;DB00695;DB00743;DB06705;DB01044;DB00317;DB01120;DB01016;DB01159;DB00070;DB06205;DB01050;DB00619;DB00328;DB01307;DB04711;DB00762;DB00753;DB08820;DB01587;DB01009;DB00451;DB00279;DB01583;DB00678;DB08932;DB01397;DB00931;DB00563;DB06710;DB08893;DB00688;DB01183;DB00788;DB00731;DB00717;DB00540;DB00334;DB04224;DB00776;DB06412;DB00454;DB00946;DB00252;DB01621;DB00554;DB08860;DB06209;DB00635;DB01032;DB00818;DB00912;DB01045;DB08931;DB00412;DB01098;DB06201;DB00936;DB01232;DB01236;DB06290;DB00815;DB00364;DB01581;DB01582;DB00576;DB01015;DB00605;DB00864;DB05521;DB00624;DB00759;DB01622;DB01623;DB01056;DB08895;DB08867;DB00177;DB00512;DB05294;DB08881;DB08828;DB00682;DB00137;DB00495;		PF00273;	IPR000264;IPR020858;IPR021177;IPR020857;IPR014760;	bile acid and bile salt transport [GO:0015721]; cellular response to starvation [GO:0009267]; hemolysis by symbiont of host erythrocytes [GO:0019836]; lipoprotein metabolic process [GO:0042157]; maintenance of mitochondrion location [GO:0051659]; negative regulation of apoptotic process [GO:0043066]; negative regulation of programmed cell death [GO:0043069]; platelet degranulation [GO:0002576]; receptor-mediated endocytosis [GO:0006898]; retina homeostasis [GO:0001895]; sodium-independent organic anion transport [GO:0043252]; transport [GO:0006810]	antioxidant activity [GO:0016209]; chaperone binding [GO:0051087]; copper ion binding [GO:0005507]; DNA binding [GO:0003677]; drug binding [GO:0008144]; fatty acid binding [GO:0005504]; identical protein binding [GO:0042802]; pyridoxal phosphate binding [GO:0030170]; toxic substance binding [GO:0015643]	blood microparticle [GO:0072562]; endoplasmic reticulum [GO:0005783]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; Golgi apparatus [GO:0005794]; myelin sheath [GO:0043209]; nucleus [GO:0005634]; platelet alpha granule lumen [GO:0031093]; protein complex [GO:0043234]
P05091	ALDH2_HUMAN	Aldehyde dehydrogenase, mitochondrial (EC 1.2.1.3) (ALDH class 2) (ALDH-E2) (ALDHI)	ALDH2 ALDM	1CW3;1NZW;1NZX;1NZZ;1O00;1O01;1O02;1O04;1O05;1ZUM;2ONM;2ONN;2ONO;2ONP;2VLE;3INJ;3INL;3N80;3N81;3N82;3N83;3SZ9;4FQF;4FR8;4KWF;4KWG;	CHEMBL1935;	P05091;	DB01612;DB06770;DB00822;DB00536;DB00435;DB00727;	PATHWAY: Alcohol metabolism; ethanol degradation; acetate from ethanol: step 2/2.	PF00171;	IPR016161;IPR016163;IPR016160;IPR029510;IPR016162;IPR015590;	alcohol metabolic process [GO:0006066]; carbohydrate metabolic process [GO:0005975]; ethanol catabolic process [GO:0006068]; ethanol oxidation [GO:0006069]	aldehyde dehydrogenase (NAD) activity [GO:0004029]; aldehyde dehydrogenase [NAD(P)+] activity [GO:0004030]; electron carrier activity [GO:0009055]	extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]
P04075	ALDOA_HUMAN	Fructose-bisphosphate aldolase A (EC 4.1.2.13) (Lung cancer antigen NY-LU-1) (Muscle-type aldolase)	ALDOA ALDA	1ALD;2ALD;4ALD;	CHEMBL2106;			PATHWAY: Carbohydrate degradation; glycolysis; D-glyceraldehyde 3-phosphate and glycerone phosphate from D-glucose: step 4/4.	PF00274;	IPR029768;IPR013785;IPR000741;	actin filament organization [GO:0007015]; ATP biosynthetic process [GO:0006754]; canonical glycolysis [GO:0061621]; fructose 1,6-bisphosphate metabolic process [GO:0030388]; fructose metabolic process [GO:0006000]; gluconeogenesis [GO:0006094]; glycolytic process [GO:0006096]; muscle cell cellular homeostasis [GO:0046716]; platelet degranulation [GO:0002576]; protein homotetramerization [GO:0051289]; regulation of cell shape [GO:0008360]; striated muscle contraction [GO:0006941]	actin binding [GO:0003779]; cadherin binding involved in cell-cell adhesion [GO:0098641]; cytoskeletal protein binding [GO:0008092]; fructose binding [GO:0070061]; fructose-bisphosphate aldolase activity [GO:0004332]; identical protein binding [GO:0042802]; poly(A) RNA binding [GO:0044822]; tubulin binding [GO:0015631]	actin cytoskeleton [GO:0015629]; cell-cell adherens junction [GO:0005913]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; I band [GO:0031674]; M band [GO:0031430]; membrane [GO:0016020]; nucleus [GO:0005634]; platelet alpha granule lumen [GO:0031093]
P15121	ALDR_HUMAN	Aldose reductase (AR) (EC 1.1.1.21) (Aldehyde reductase) (Aldo-keto reductase family 1 member B1)	AKR1B1 ALDR1	1ABN;1ADS;1AZ1;1AZ2;1EF3;1EL3;1IEI;1MAR;1PWL;1PWM;1T40;1T41;1US0;1X96;1X97;1X98;1XGD;1Z3N;1Z89;1Z8A;2ACQ;2ACR;2ACS;2ACU;2AGT;2DUX;2DUZ;2DV0;2F2K;2FZ8;2FZ9;2FZB;2FZD;2HV5;2HVN;2HVO;2I16;2I17;2IKG;2IKH;2IKI;2IKJ;2INE;2INZ;2IPW;2IQ0;2IQD;2IS7;2ISF;2J8T;2NVC;2NVD;2PD5;2PD9;2PDB;2PDC;2PDF;2PDG;2PDH;2PDI;2PDJ;2PDK;2PDL;2PDM;2PDN;2PDP;2PDQ;2PDU;2PDW;2PDX;2PDY;2PEV;2PF8;2PFH;2PZN;2QXW;2R24;3BCJ;3DN5;3G5E;3GHR;3GHS;3GHT;3GHU;3LBO;3LD5;3LEN;3LEP;3LQG;3LQL;3LZ3;3LZ5;3M0I;3M4H;3M64;3MB9;3MC5;3ONB;3ONC;3P2V;3Q65;3Q67;3RX2;3RX3;3RX4;3S3G;3T42;3U2C;3V35;3V36;4GCA;4GQ0;4IGS;4JIR;4LAU;4LAZ;4LB3;4LB4;4LBR;4LBS;4NKC;4PR4;4PRR;4PRT;4PUU;4PUW;4Q7B;4QBX;4QR6;4QX4;4QXI;4RPQ;4XZH;4XZI;4YS1;4YU1;	CHEMBL1900;	P15121;	DB00605;		PF00248;	IPR001395;IPR018170;IPR020471;IPR023210;	C21-steroid hormone biosynthetic process [GO:0006700]; carbohydrate metabolic process [GO:0005975]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to methylglyoxal [GO:0097238]; cellular response to peptide [GO:1901653]; daunorubicin metabolic process [GO:0044597]; doxorubicin metabolic process [GO:0044598]; fructose biosynthetic process [GO:0046370]; inner medullary collecting duct development [GO:0072061]; maternal process involved in female pregnancy [GO:0060135]; naphthalene metabolic process [GO:0018931]; norepinephrine metabolic process [GO:0042415]; positive regulation of JAK-STAT cascade [GO:0046427]; positive regulation of smooth muscle cell proliferation [GO:0048661]; response to stress [GO:0006950]; response to thyroid hormone [GO:0097066]; response to water deprivation [GO:0009414]; sorbitol biosynthetic process [GO:0006061]; stress-activated protein kinase signaling cascade [GO:0031098]; tissue homeostasis [GO:0001894]	alditol:NADP+ 1-oxidoreductase activity [GO:0004032]; aldo-keto reductase (NADP) activity [GO:0004033]; electron carrier activity [GO:0009055]; glyceraldehyde oxidoreductase activity [GO:0043795]	cell projection cytoplasm [GO:0032838]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; mast cell granule [GO:0042629]; nucleoplasm [GO:0005654]; paranodal junction [GO:0033010]; perinuclear region of cytoplasm [GO:0048471]; Schmidt-Lanterman incisure [GO:0043220]; Schwann cell microvillus [GO:0097454]
Q6NS38	ALKB2_HUMAN	DNA oxidative demethylase ALKBH2 (EC 1.14.11.33) (Alkylated DNA repair protein alkB homolog 2) (Alpha-ketoglutarate-dependent dioxygenase alkB homolog 2) (Oxy DC1)	ALKBH2 ABH2	3BTX;3BTY;3BTZ;3BU0;3BUC;3H8O;3H8R;3H8X;3RZG;3RZH;3RZJ;3RZK;3RZL;3RZM;3S57;3S5A;4MG2;4MGT;			DB00126;		PF13532;	IPR027450;IPR032852;IPR005123;	DNA dealkylation involved in DNA repair [GO:0006307]; DNA demethylation [GO:0080111]; oxidative demethylation [GO:0070989]; oxidative DNA demethylation [GO:0035511]	cytosine C-5 DNA demethylase activity [GO:0051747]; DNA-N1-methyladenine dioxygenase activity [GO:0043734]; ferrous iron binding [GO:0008198]	microtubule cytoskeleton [GO:0015630]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
Q96Q83	ALKB3_HUMAN	Alpha-ketoglutarate-dependent dioxygenase alkB homolog 3 (EC 1.14.11.-) (Alkylated DNA repair protein alkB homolog 3) (hABH3) (DEPC-1) (Prostate cancer antigen 1)	ALKBH3 ABH3 DEPC1	2IUW;	CHEMBL3112376;	Q96Q83;	DB00126;		PF13532;	IPR027450;IPR032854;IPR005123;	cell proliferation [GO:0008283]; DNA dealkylation involved in DNA repair [GO:0006307]; DNA repair [GO:0006281]; oxidative single-stranded DNA demethylation [GO:0035552]; oxidative single-stranded RNA demethylation [GO:0035553]	DNA-N1-methyladenine dioxygenase activity [GO:0043734]; ferrous iron binding [GO:0008198]; L-ascorbic acid binding [GO:0031418]; RNA N1-methyladenosine dioxygenase activity [GO:1990930]	cytoplasm [GO:0005737]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
Q9UM73	ALK_HUMAN	ALK tyrosine kinase receptor (EC 2.7.10.1) (Anaplastic lymphoma kinase) (CD antigen CD246)	ALK	2KUP;2KUQ;2XB7;2XBA;2XP2;2YFX;2YHV;2YJR;2YJS;2YS5;2YT2;3AOX;3L9P;3LCS;3LCT;4ANL;4ANQ;4ANS;4CCB;4CCU;4CD0;4CLI;4CLJ;4CMO;4CMT;4CMU;4CNH;4CTB;4CTC;4DCE;4FNW;4FNX;4FNY;4FNZ;4FOB;4FOC;4FOD;4JOA;4MKC;4TT7;4Z55;5A9U;5AA8;5AA9;5AAA;5AAB;5AAC;5FTO;5FTQ;5IMX;5IUG;5IUH;5IUI;5J7H;5KZ0;	CHEMBL4247;	Q9UM73;	DB00171;DB11363;DB09063;DB08865;		PF00629;PF07714;	IPR026830;IPR013320;IPR011009;IPR002172;IPR000998;IPR000719;IPR017441;IPR001245;IPR008266;IPR020635;IPR002011;	activation of MAPK activity [GO:0000187]; cell proliferation [GO:0008283]; neuron development [GO:0048666]; phosphorylation [GO:0016310]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; protein autophosphorylation [GO:0046777]; regulation of apoptotic process [GO:0042981]; signal transduction [GO:0007165]; transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169]	ATP binding [GO:0005524]; NF-kappaB-inducing kinase activity [GO:0004704]; protein tyrosine kinase activity [GO:0004713]; transmembrane receptor protein tyrosine kinase activity [GO:0004714]	extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; intracellular [GO:0005622]; protein complex [GO:0043234]
P19021	AMD_HUMAN	Peptidyl-glycine alpha-amidating monooxygenase (PAM) [Includes: Peptidylglycine alpha-hydroxylating monooxygenase (PHM) (EC 1.14.17.3); Peptidyl-alpha-hydroxyglycine alpha-amidating lyase (EC 4.3.2.5) (Peptidylamidoglycolate lyase) (PAL)]	PAM		CHEMBL2544;	P19021;	DB00126;		PF03712;PF01082;PF01436;	IPR011042;IPR014784;IPR020611;IPR014783;IPR000323;IPR024548;IPR001258;IPR013017;IPR000720;IPR008977;	central nervous system development [GO:0007417]; heart development [GO:0007507]; lactation [GO:0007595]; limb development [GO:0060173]; long-chain fatty acid metabolic process [GO:0001676]; maternal process involved in female pregnancy [GO:0060135]; odontogenesis [GO:0042476]; ovulation cycle process [GO:0022602]; peptide amidation [GO:0001519]; protein amidation [GO:0018032]; protein homooligomerization [GO:0051260]; regulation of actin cytoskeleton organization [GO:0032956]; regulation of protein secretion [GO:0050708]; regulation of transcription from RNA polymerase II promoter [GO:0006357]; response to copper ion [GO:0046688]; response to drug [GO:0042493]; response to estradiol [GO:0032355]; response to glucocorticoid [GO:0051384]; response to hypoxia [GO:0001666]; response to pH [GO:0009268]; toxin metabolic process [GO:0009404]	calcium ion binding [GO:0005509]; copper ion binding [GO:0005507]; L-ascorbic acid binding [GO:0031418]; peptidylamidoglycolate lyase activity [GO:0004598]; peptidylglycine monooxygenase activity [GO:0004504]; zinc ion binding [GO:0008270]	cell surface [GO:0009986]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; integral component of membrane [GO:0016021]; membrane [GO:0016020]; neuron projection [GO:0043005]; perikaryon [GO:0043204]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; secretory granule membrane [GO:0030667]; trans-Golgi network [GO:0005802]
Q16671	AMHR2_HUMAN	Anti-Muellerian hormone type-2 receptor (EC 2.7.11.30) (Anti-Muellerian hormone type II receptor) (AMH type II receptor) (MIS type II receptor) (MISRII) (MRII)	AMHR2 AMHR MISR2				DB00171;		PF01064;PF00069;	IPR000472;IPR015771;IPR011009;IPR000719;IPR000333;	female gonad development [GO:0008585]; male gonad development [GO:0008584]; Mullerian duct regression [GO:0001880]; negative regulation of anti-Mullerian hormone signaling pathway [GO:1902613]; sex differentiation [GO:0007548]; signal transduction [GO:0007165]; transforming growth factor beta receptor signaling pathway [GO:0007179]	anti-Mullerian hormone receptor activity [GO:1990272]; ATP binding [GO:0005524]; hormone binding [GO:0042562]; metal ion binding [GO:0046872]; receptor activity [GO:0004872]; receptor signaling protein serine/threonine kinase activity [GO:0004702]; transforming growth factor beta receptor activity, type II [GO:0005026]	integral component of plasma membrane [GO:0005887]
Q9BXJ7	AMNLS_HUMAN	Protein amnionless	AMN UNQ513/PRO1028				DB00115;DB00200;			IPR026112;	cobalamin metabolic process [GO:0009235]; cobalamin transport [GO:0015889]; excretion [GO:0007588]; Golgi to plasma membrane protein transport [GO:0043001]; lipoprotein metabolic process [GO:0042157]; multicellular organism development [GO:0007275]; receptor-mediated endocytosis [GO:0006898]	receptor binding [GO:0005102]	apical plasma membrane [GO:0016324]; clathrin-coated pit [GO:0005905]; endocytic vesicle [GO:0030139]; endosome membrane [GO:0010008]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]
P23109	AMPD1_HUMAN	AMP deaminase 1 (EC 3.5.4.6) (AMP deaminase isoform M) (Myoadenylate deaminase)	AMPD1		CHEMBL2869;	P23109;	DB00131;	PATHWAY: Purine metabolism; IMP biosynthesis via salvage pathway; IMP from AMP: step 1/1.	PF00962;	IPR006650;IPR001365;IPR006329;IPR029770;IPR032466;	IMP salvage [GO:0032264]; purine-containing compound salvage [GO:0043101]; response to organic substance [GO:0010033]	AMP deaminase activity [GO:0003876]; metal ion binding [GO:0046872]	cytosol [GO:0005829]
Q01433	AMPD2_HUMAN	AMP deaminase 2 (EC 3.5.4.6) (AMP deaminase isoform L)	AMPD2	4NO3;4NO5;	CHEMBL2997;	Q01433;		PATHWAY: Purine metabolism; IMP biosynthesis via salvage pathway; IMP from AMP: step 1/1.	PF00962;	IPR006650;IPR001365;IPR006329;IPR029749;IPR032466;	AMP metabolic process [GO:0046033]; ATP metabolic process [GO:0046034]; cholesterol homeostasis [GO:0042632]; cyclic purine nucleotide metabolic process [GO:0052652]; energy homeostasis [GO:0097009]; glomerular visceral epithelial cell development [GO:0072015]; GTP metabolic process [GO:0046039]; IMP biosynthetic process [GO:0006188]; IMP salvage [GO:0032264]; purine-containing compound salvage [GO:0043101]	AMP deaminase activity [GO:0003876]; metal ion binding [GO:0046872]	cytosol [GO:0005829]
Q01432	AMPD3_HUMAN	AMP deaminase 3 (EC 3.5.4.6) (AMP deaminase isoform E) (Erythrocyte AMP deaminase)	AMPD3		CHEMBL2912;	Q01432;		PATHWAY: Purine metabolism; IMP biosynthesis via salvage pathway; IMP from AMP: step 1/1.	PF00962;	IPR006650;IPR001365;IPR006329;IPR029771;IPR032466;	ADP metabolic process [GO:0046031]; AMP catabolic process [GO:0006196]; ATP metabolic process [GO:0046034]; energy homeostasis [GO:0097009]; erythrocyte homeostasis [GO:0034101]; GTP metabolic process [GO:0046039]; IMP salvage [GO:0032264]; purine-containing compound salvage [GO:0043101]	AMP deaminase activity [GO:0003876]; metal ion binding [GO:0046872]	cytosol [GO:0005829]
Q07075	AMPE_HUMAN	Glutamyl aminopeptidase (EAP) (EC 3.4.11.7) (Aminopeptidase A) (AP-A) (Differentiation antigen gp160) (CD antigen CD249)	ENPEP	4KX7;4KX8;4KX9;4KXA;4KXB;4KXC;4KXD;	CHEMBL3439;	Q07075;			PF11838;PF01433;	IPR033508;IPR024571;IPR001930;IPR014782;	angiogenesis [GO:0001525]; angiotensin catabolic process in blood [GO:0002005]; angiotensin maturation [GO:0002003]; cell-cell signaling [GO:0007267]; cell migration [GO:0016477]; cell proliferation [GO:0008283]; glomerulus development [GO:0032835]; peptide catabolic process [GO:0043171]; regulation of systemic arterial blood pressure by renin-angiotensin [GO:0003081]	aminopeptidase activity [GO:0004177]; metalloaminopeptidase activity [GO:0070006]; metallopeptidase activity [GO:0008237]; peptide binding [GO:0042277]; zinc ion binding [GO:0008270]	apical part of cell [GO:0045177]; apical plasma membrane [GO:0016324]; brush border [GO:0005903]; cytoplasmic vesicle [GO:0031410]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; lysosomal membrane [GO:0005765]; plasma membrane [GO:0005886]
P15144	AMPN_HUMAN	Aminopeptidase N (AP-N) (hAPN) (EC 3.4.11.2) (Alanyl aminopeptidase) (Aminopeptidase M) (AP-M) (Microsomal aminopeptidase) (Myeloid plasma membrane glycoprotein CD13) (gp150) (CD antigen CD13)	ANPEP APN CD13 PEPN	4FYQ;4FYR;4FYS;4FYT;	CHEMBL1907;	P15144;	DB00973;DB06196;		PF11838;PF01433;	IPR024571;IPR001930;IPR014782;	angiogenesis [GO:0001525]; cell differentiation [GO:0030154]; peptide catabolic process [GO:0043171]	aminopeptidase activity [GO:0004177]; metalloaminopeptidase activity [GO:0070006]; metallopeptidase activity [GO:0008237]; peptide binding [GO:0042277]; receptor activity [GO:0004872]; virus receptor activity [GO:0001618]; zinc ion binding [GO:0008270]	cytosol [GO:0005829]; endoplasmic reticulum-Golgi intermediate compartment [GO:0005793]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; integral component of plasma membrane [GO:0005887]; lysosomal membrane [GO:0005765]
P04746	AMYP_HUMAN	Pancreatic alpha-amylase (PA) (EC 3.2.1.1) (1,4-alpha-D-glucan glucanohydrolase)	AMY2A	1B2Y;1BSI;1CPU;1HNY;1KB3;1KBB;1KBK;1KGU;1KGW;1KGX;1U2Y;1U30;1U33;1XCW;1XCX;1XD0;1XD1;1XGZ;1XH0;1XH1;1XH2;2CPU;2QMK;2QV4;3BAI;3BAJ;3BAK;3BAW;3BAX;3BAY;3CPU;3IJ7;3IJ8;3IJ9;3OLD;3OLE;3OLG;3OLI;4GQQ;4GQR;4W93;4X9Y;5E0F;5EMY;	CHEMBL2045;	P04746;	DB00284;DB00702;DB00491;		PF00128;PF02806;	IPR006048;IPR031319;IPR006046;IPR015902;IPR006047;IPR013780;IPR013781;IPR017853;	carbohydrate catabolic process [GO:0016052]; carbohydrate metabolic process [GO:0005975]; polysaccharide digestion [GO:0044245]	alpha-amylase activity [GO:0004556]; calcium ion binding [GO:0005509]; chloride ion binding [GO:0031404]	extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]
P04745	AMYS_HUMAN	Alpha-amylase 1 (EC 3.2.1.1) (1,4-alpha-D-glucan glucanohydrolase 1) (Salivary alpha-amylase)	AMY1A AMY1; AMY1B AMY1; AMY1C AMY1	1C8Q;1JXJ;1JXK;1MFU;1MFV;1NM9;1Q4N;1SMD;1XV8;1Z32;3BLK;3BLP;3DHP;	CHEMBL2478;	P04745;			PF00128;PF02806;	IPR006048;IPR031319;IPR006046;IPR015902;IPR006047;IPR013780;IPR013781;IPR017853;	carbohydrate metabolic process [GO:0005975]; digestion [GO:0007586]	alpha-amylase activity [GO:0004556]; metal ion binding [GO:0046872]	extracellular exosome [GO:0070062]; extracellular space [GO:0005615]
P54802	ANAG_HUMAN	Alpha-N-acetylglucosaminidase (EC 3.2.1.50) (N-acetyl-alpha-glucosaminidase) (NAG) [Cleaved into: Alpha-N-acetylglucosaminidase 82 kDa form; Alpha-N-acetylglucosaminidase 77 kDa form]	NAGLU UFHSD1	4XWH;			DB00141;		PF05089;PF12972;PF12971;	IPR017853;IPR007781;IPR024732;IPR024240;IPR024733;	cerebellar Purkinje cell layer development [GO:0021680]; glycosaminoglycan catabolic process [GO:0006027]; inner ear receptor cell development [GO:0060119]; locomotor rhythm [GO:0045475]; lysosome organization [GO:0007040]; middle ear morphogenesis [GO:0042474]; nervous system development [GO:0007399]; retinal rod cell development [GO:0046548]	alpha-N-acetylglucosaminidase activity [GO:0004561]	extracellular exosome [GO:0070062]; lysosomal lumen [GO:0043202]; lysosome [GO:0005764]
P10275	ANDR_HUMAN	Androgen receptor (Dihydrotestosterone receptor) (Nuclear receptor subfamily 3 group C member 4)	AR DHTR NR3C4	1E3G;1GS4;1T5Z;1T63;1T65;1XJ7;1XOW;1XQ3;1Z95;2AM9;2AMA;2AMB;2AO6;2AX6;2AX7;2AX8;2AX9;2AXA;2HVC;2OZ7;2PIO;2PIP;2PIQ;2PIR;2PIT;2PIU;2PIV;2PIW;2PIX;2PKL;2PNU;2Q7I;2Q7J;2Q7K;2Q7L;2YHD;2YLO;2YLP;2YLQ;2Z4J;3B5R;3B65;3B66;3B67;3B68;3BTR;3L3X;3L3Z;3RLJ;3RLL;3V49;3V4A;3ZQT;4HLW;4K7A;4OEA;4OED;4OEY;4OEZ;4OFR;4OFU;4OGH;4OH5;4OH6;4OHA;4OIL;4OIU;4OJ9;4OJB;4OK1;4OKB;4OKT;4OKW;4OKX;4OLM;4QL8;5CJ6;	CHEMBL1871;	P10275;	DB01128;DB04839;DB01406;DB01395;DB00858;DB08899;DB00687;DB01185;DB00499;DB01026;DB00367;DB06710;DB08804;DB00984;DB00665;DB00621;DB06412;DB00421;DB00624;DB01420;DB08867;		PF02166;PF00104;PF00105;	IPR001103;IPR000536;IPR001628;IPR013088;	activation of prostate induction by androgen receptor signaling pathway [GO:0060520]; androgen receptor signaling pathway [GO:0030521]; animal organ formation [GO:0048645]; cell-cell signaling [GO:0007267]; cell growth [GO:0016049]; cell proliferation [GO:0008283]; epithelial cell differentiation involved in prostate gland development [GO:0060742]; epithelial cell morphogenesis [GO:0003382]; intracellular receptor signaling pathway [GO:0030522]; in utero embryonic development [GO:0001701]; lateral sprouting involved in mammary gland duct morphogenesis [GO:0060599]; Leydig cell differentiation [GO:0033327]; male genitalia morphogenesis [GO:0048808]; male somatic sex determination [GO:0019102]; mammary gland alveolus development [GO:0060749]; morphogenesis of an epithelial fold [GO:0060571]; multicellular organism growth [GO:0035264]; negative regulation of cell proliferation [GO:0008285]; negative regulation of epithelial cell proliferation [GO:0050680]; negative regulation of extrinsic apoptotic signaling pathway [GO:2001237]; negative regulation of integrin biosynthetic process [GO:0045720]; positive regulation of cell differentiation [GO:0045597]; positive regulation of cell proliferation [GO:0008284]; positive regulation of gene expression [GO:0010628]; positive regulation of insulin-like growth factor receptor signaling pathway [GO:0043568]; positive regulation of integrin biosynthetic process [GO:0045726]; positive regulation of intracellular estrogen receptor signaling pathway [GO:0033148]; positive regulation of MAPK cascade [GO:0043410]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of phosphorylation [GO:0042327]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase III promoter [GO:0045945]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; prostate gland development [GO:0030850]; prostate gland epithelium morphogenesis [GO:0060740]; prostate gland growth [GO:0060736]; protein oligomerization [GO:0051259]; regulation of catalytic activity [GO:0050790]; regulation of developmental growth [GO:0048638]; regulation of establishment of protein localization to plasma membrane [GO:0090003]; regulation of systemic arterial blood pressure [GO:0003073]; seminiferous tubule development [GO:0072520]; sex differentiation [GO:0007548]; signal transduction [GO:0007165]; single fertilization [GO:0007338]; spermatogenesis [GO:0007283]; tertiary branching involved in mammary gland duct morphogenesis [GO:0060748]; transcription, DNA-templated [GO:0006351]; transcription initiation from RNA polymerase II promoter [GO:0006367]; transport [GO:0006810]	androgen binding [GO:0005497]; androgen receptor activity [GO:0004882]; ATPase binding [GO:0051117]; beta-catenin binding [GO:0008013]; chromatin binding [GO:0003682]; DNA binding [GO:0003677]; enzyme binding [GO:0019899]; protein dimerization activity [GO:0046983]; receptor binding [GO:0005102]; RNA polymerase II core promoter proximal region sequence-specific DNA binding [GO:0000978]; RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding [GO:0004879]; RNA polymerase II transcription factor binding [GO:0001085]; steroid binding [GO:0005496]; transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding [GO:0001077]; transcription factor activity, sequence-specific DNA binding [GO:0003700]; transcription factor binding [GO:0008134]; transcription regulatory region DNA binding [GO:0044212]; zinc ion binding [GO:0008270]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nuclear chromatin [GO:0000790]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; protein complex [GO:0043234]
P16860	ANFB_HUMAN	Natriuretic peptides B (Gamma-brain natriuretic peptide) [Cleaved into: Brain natriuretic peptide 32 (BNP(1-32)) (BNP-32); BNP(1-30); BNP(1-29); BNP(1-28); BNP(2-31); BNP(3-32); BNP(3-30); BNP(3-29); BNP(4-32); BNP(4-31); BNP(4-30); BNP(4-29); BNP(4-27); BNP(5-32); BNP(5-31); BNP(5-29)]	NPPB	1YK1;3N56;			DB01136;DB06412;		PF00212;	IPR000663;IPR030480;IPR002408;	body fluid secretion [GO:0007589]; cell surface receptor signaling pathway [GO:0007166]; cGMP biosynthetic process [GO:0006182]; negative regulation of angiogenesis [GO:0016525]; negative regulation of cell growth [GO:0030308]; positive regulation of renal sodium excretion [GO:0035815]; positive regulation of urine volume [GO:0035810]; receptor guanylyl cyclase signaling pathway [GO:0007168]; regulation of blood pressure [GO:0008217]; regulation of vascular permeability [GO:0043114]; regulation of vasodilation [GO:0042312]	diuretic hormone activity [GO:0008613]; hormone activity [GO:0005179]; receptor binding [GO:0005102]	extracellular region [GO:0005576]; extracellular space [GO:0005615]; protein complex [GO:0043234]
P01019	ANGT_HUMAN	Angiotensinogen (Serpin A8) [Cleaved into: Angiotensin-1 (Angiotensin 1-10) (Angiotensin I) (Ang I); Angiotensin-2 (Angiotensin 1-8) (Angiotensin II) (Ang II); Angiotensin-3 (Angiotensin 2-8) (Angiotensin III) (Ang III) (Des-Asp[1]-angiotensin II); Angiotensin-4 (Angiotensin 3-8) (Angiotensin IV) (Ang IV); Angiotensin 1-9; Angiotensin 1-7; Angiotensin 1-5; Angiotensin 1-4]	AGT SERPINA8	1N9U;1N9V;2JP8;2WXW;2X0B;3CK0;3WOO;3WOR;4AA1;4APH;4FYS;5E2Q;					PF00079;	IPR000227;IPR023795;IPR023796;IPR000215;	activation of phospholipase C activity [GO:0007202]; aging [GO:0007568]; angiotensin-activated signaling pathway [GO:0038166]; angiotensin maturation [GO:0002003]; angiotensin-mediated drinking behavior [GO:0003051]; artery smooth muscle contraction [GO:0014824]; blood vessel remodeling [GO:0001974]; catenin import into nucleus [GO:0035411]; cell-cell signaling [GO:0007267]; cell growth involved in cardiac muscle cell development [GO:0061049]; cell surface receptor signaling pathway [GO:0007166]; cellular response to mechanical stimulus [GO:0071260]; cellular sodium ion homeostasis [GO:0006883]; cytokine secretion [GO:0050663]; ERK1 and ERK2 cascade [GO:0070371]; female pregnancy [GO:0007565]; fibroblast proliferation [GO:0048144]; G-protein coupled receptor signaling pathway [GO:0007186]; G-protein coupled receptor signaling pathway coupled to cGMP nucleotide second messenger [GO:0007199]; kidney development [GO:0001822]; low-density lipoprotein particle remodeling [GO:0034374]; negative regulation of angiogenesis [GO:0016525]; negative regulation of cell growth [GO:0030308]; negative regulation of gene expression [GO:0010629]; negative regulation of neurotrophin TRK receptor signaling pathway [GO:0051387]; negative regulation of sodium ion transmembrane transporter activity [GO:2000650]; negative regulation of tissue remodeling [GO:0034104]; nitric oxide mediated signal transduction [GO:0007263]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; positive regulation of activation of JAK2 kinase activity [GO:0010535]; positive regulation of blood pressure [GO:0045777]; positive regulation of branching involved in ureteric bud morphogenesis [GO:0090190]; positive regulation of cardiac muscle cell apoptotic process [GO:0010666]; positive regulation of cardiac muscle hypertrophy [GO:0010613]; positive regulation of cellular protein metabolic process [GO:0032270]; positive regulation of cholesterol esterification [GO:0010873]; positive regulation of cytokine production [GO:0001819]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of endothelial cell migration [GO:0010595]; positive regulation of epidermal growth factor receptor signaling pathway [GO:0045742]; positive regulation of extracellular matrix constituent secretion [GO:0003331]; positive regulation of extrinsic apoptotic signaling pathway [GO:2001238]; positive regulation of fibroblast proliferation [GO:0048146]; positive regulation of gap junction assembly [GO:1903598]; positive regulation of glucose import in response to insulin stimulus [GO:2001275]; positive regulation of inflammatory response [GO:0050729]; positive regulation of L-arginine import into cell [GO:1902828]; positive regulation of L-lysine import into cell [GO:1905010]; positive regulation of macrophage derived foam cell differentiation [GO:0010744]; positive regulation of membrane hyperpolarization [GO:1902632]; positive regulation of NAD(P)H oxidase activity [GO:0033864]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of phosphatidylinositol 3-kinase signaling [GO:0014068]; positive regulation of protein tyrosine kinase activity [GO:0061098]; positive regulation of reactive oxygen species metabolic process [GO:2000379]; positive regulation of renal sodium excretion [GO:0035815]; positive regulation of superoxide anion generation [GO:0032930]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of vascular associated smooth muscle cell migration [GO:1904754]; positive regulation of vascular smooth muscle cell proliferation [GO:1904707]; positive regulation of vasodilation [GO:0045909]; regulation of blood pressure [GO:0008217]; regulation of blood vessel size by renin-angiotensin [GO:0002034]; regulation of blood volume by renin-angiotensin [GO:0002016]; regulation of calcium ion transport [GO:0051924]; regulation of cardiac conduction [GO:1903779]; regulation of cell growth [GO:0001558]; regulation of cell proliferation [GO:0042127]; regulation of extracellular matrix assembly [GO:1901201]; regulation of heart rate [GO:0002027]; regulation of long-term neuronal synaptic plasticity [GO:0048169]; regulation of norepinephrine secretion [GO:0014061]; regulation of renal output by angiotensin [GO:0002019]; regulation of renal sodium excretion [GO:0035813]; regulation of transmission of nerve impulse [GO:0051969]; regulation of vasoconstriction [GO:0019229]; renal system process [GO:0003014]; renin-angiotensin regulation of aldosterone production [GO:0002018]; response to muscle activity involved in regulation of muscle adaptation [GO:0014873]; smooth muscle cell proliferation [GO:0048659]; stress-activated MAPK cascade [GO:0051403]; uterine smooth muscle contraction [GO:0070471]; vasodilation [GO:0042311]	growth factor activity [GO:0008083]; hormone activity [GO:0005179]; receptor agonist activity [GO:0048018]; serine-type endopeptidase inhibitor activity [GO:0004867]; sodium channel regulator activity [GO:0017080]; superoxide-generating NADPH oxidase activator activity [GO:0016176]; type 1 angiotensin receptor binding [GO:0031702]; type 2 angiotensin receptor binding [GO:0031703]	blood microparticle [GO:0072562]; cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]
P16066	ANPRA_HUMAN	Atrial natriuretic peptide receptor 1 (EC 4.6.1.2) (Atrial natriuretic peptide receptor type A) (ANP-A) (ANPR-A) (NPR-A) (Guanylate cyclase A) (GC-A)	NPR1 ANPRA		CHEMBL1988;	P16066;	DB01612;DB01613;DB00883;DB04899;DB00727;DB00325;		PF01094;PF00211;PF07714;	IPR001054;IPR018297;IPR001828;IPR001170;IPR011009;IPR029787;IPR028082;IPR000719;IPR001245;	body fluid secretion [GO:0007589]; cell surface receptor signaling pathway [GO:0007166]; cGMP biosynthetic process [GO:0006182]; dopamine metabolic process [GO:0042417]; intracellular signal transduction [GO:0035556]; negative regulation of angiogenesis [GO:0016525]; negative regulation of cell growth [GO:0030308]; negative regulation of smooth muscle cell proliferation [GO:0048662]; positive regulation of cGMP biosynthetic process [GO:0030828]; positive regulation of renal sodium excretion [GO:0035815]; positive regulation of urine volume [GO:0035810]; receptor guanylyl cyclase signaling pathway [GO:0007168]; regulation of blood pressure [GO:0008217]; regulation of cardiac conduction [GO:1903779]; regulation of vascular permeability [GO:0043114]; regulation of vasodilation [GO:0042312]	ATP binding [GO:0005524]; G-protein coupled peptide receptor activity [GO:0008528]; GTP binding [GO:0005525]; guanylate cyclase activity [GO:0004383]; hormone binding [GO:0042562]; natriuretic peptide receptor activity [GO:0016941]; peptide hormone binding [GO:0017046]; protein kinase activity [GO:0004672]	guanylate cyclase complex, soluble [GO:0008074]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]
P20594	ANPRB_HUMAN	Atrial natriuretic peptide receptor 2 (EC 4.6.1.2) (Atrial natriuretic peptide receptor type B) (ANP-B) (ANPR-B) (NPR-B) (Guanylate cyclase B) (GC-B)	NPR2 ANPRB		CHEMBL2111337;		DB01613;DB04899;		PF01094;PF00211;PF07714;	IPR001054;IPR018297;IPR001828;IPR001170;IPR011009;IPR029787;IPR028082;IPR000719;IPR001245;	bone development [GO:0060348]; cellular response to granulocyte macrophage colony-stimulating factor stimulus [GO:0097011]; cGMP biosynthetic process [GO:0006182]; intracellular signal transduction [GO:0035556]; negative regulation of meiotic cell cycle [GO:0051447]; negative regulation of oocyte maturation [GO:1900194]; ossification [GO:0001503]; receptor guanylyl cyclase signaling pathway [GO:0007168]; regulation of blood pressure [GO:0008217]; regulation of cardiac conduction [GO:1903779]; single organism reproductive process [GO:0044702]	ATP binding [GO:0005524]; GTP binding [GO:0005525]; guanylate cyclase activity [GO:0004383]; hormone binding [GO:0042562]; natriuretic peptide receptor activity [GO:0016941]; peptide hormone binding [GO:0017046]; protein kinase activity [GO:0004672]	guanylate cyclase complex, soluble [GO:0008074]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P17342	ANPRC_HUMAN	Atrial natriuretic peptide receptor 3 (Atrial natriuretic peptide clearance receptor) (Atrial natriuretic peptide receptor type C) (ANP-C) (ANPR-C) (NPR-C)	NPR3 ANPRC C5orf23 NPRC	1JDN;1JDP;1YK0;1YK1;	CHEMBL2247;	P17342;	DB04899;		PF01094;	IPR001828;IPR001170;IPR028082;	adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway [GO:0007193]; cAMP-mediated signaling [GO:0019933]; negative regulation of smooth muscle cell proliferation [GO:0048662]; osteoclast proliferation [GO:0002158]; pancreatic juice secretion [GO:0030157]; phosphatidylinositol-mediated signaling [GO:0048015]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; positive regulation of nitric-oxide synthase activity [GO:0051000]; positive regulation of urine volume [GO:0035810]; regulation of blood pressure [GO:0008217]; regulation of osteoblast proliferation [GO:0033688]; skeletal system development [GO:0001501]	G-protein coupled peptide receptor activity [GO:0008528]; hormone binding [GO:0042562]; natriuretic peptide receptor activity [GO:0016941]; peptide hormone binding [GO:0017046]	extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; intracellular [GO:0005622]; plasma membrane [GO:0005886]
P01008	ANT3_HUMAN	Antithrombin-III (ATIII) (Serpin C1)	SERPINC1 AT3 PRO0309	1ANT;1ATH;1AZX;1BR8;1DZG;1DZH;1E03;1E04;1E05;1JVQ;1LK6;1NQ9;1OYH;1R1L;1SR5;1T1F;1TB6;2ANT;2B4X;2B5T;2BEH;2GD4;2HIJ;2ZNH;3EVJ;3KCG;4EB1;	CHEMBL1950;	P01008;	DB00407;DB06779;DB01225;DB00569;DB01109;DB08813;DB06271;DB06822;		PF00079;	IPR015555;IPR023795;IPR023796;IPR000215;	acute inflammatory response to antigenic stimulus [GO:0002438]; blood coagulation [GO:0007596]; lactation [GO:0007595]; regulation of blood coagulation, intrinsic pathway [GO:2000266]; response to nutrient [GO:0007584]	heparin binding [GO:0008201]; protease binding [GO:0002020]; serine-type endopeptidase inhibitor activity [GO:0004867]	blood microparticle [GO:0072562]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; plasma membrane [GO:0005886]
P58335	ANTR2_HUMAN	Anthrax toxin receptor 2 (Capillary morphogenesis gene 2 protein) (CMG-2)	ANTXR2 CMG2	1SHT;1SHU;1T6B;1TZN;					PF05586;PF05587;PF00092;	IPR017360;IPR008399;IPR008400;IPR002035;	reproductive process [GO:0022414]; toxin transport [GO:1901998]	metal ion binding [GO:0046872]; receptor activity [GO:0004872]	endoplasmic reticulum membrane [GO:0005789]; endosome membrane [GO:0010008]; external side of plasma membrane [GO:0009897]; extracellular region [GO:0005576]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]
P04083	ANXA1_HUMAN	Annexin A1 (Annexin I) (Annexin-1) (Calpactin II) (Calpactin-2) (Chromobindin-9) (Lipocortin I) (Phospholipase A2 inhibitory protein) (p35)	ANXA1 ANX1 LPC1	1AIN;1BO9;1QLS;			DB00288;DB01234;DB00741;		PF00191;	IPR001464;IPR018502;IPR018252;IPR002388;	actin cytoskeleton reorganization [GO:0031532]; adaptive immune response [GO:0002250]; alpha-beta T cell differentiation [GO:0046632]; arachidonic acid secretion [GO:0050482]; cell surface receptor signaling pathway [GO:0007166]; cellular response to glucocorticoid stimulus [GO:0071385]; cellular response to hydrogen peroxide [GO:0070301]; DNA duplex unwinding [GO:0032508]; DNA rewinding [GO:0036292]; endocrine pancreas development [GO:0031018]; estrous cycle [GO:0044849]; gliogenesis [GO:0042063]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; granulocyte chemotaxis [GO:0071621]; hepatocyte differentiation [GO:0070365]; inflammatory response [GO:0006954]; innate immune response [GO:0045087]; insulin secretion [GO:0030073]; keratinocyte differentiation [GO:0030216]; monocyte chemotaxis [GO:0002548]; myoblast migration involved in skeletal muscle regeneration [GO:0014839]; negative regulation of apoptotic process [GO:0043066]; negative regulation of exocytosis [GO:0045920]; negative regulation of interleukin-8 secretion [GO:2000483]; negative regulation of phospholipase A2 activity [GO:1900138]; negative regulation of T-helper 2 cell differentiation [GO:0045629]; neutrophil clearance [GO:0097350]; neutrophil homeostasis [GO:0001780]; peptide cross-linking [GO:0018149]; phagocytosis [GO:0006909]; positive regulation of G1/S transition of mitotic cell cycle [GO:1900087]; positive regulation of interleukin-2 production [GO:0032743]; positive regulation of neutrophil apoptotic process [GO:0033031]; positive regulation of prostaglandin biosynthetic process [GO:0031394]; positive regulation of T cell proliferation [GO:0042102]; positive regulation of T-helper 1 cell differentiation [GO:0045627]; positive regulation of vesicle fusion [GO:0031340]; positive regulation of wound healing [GO:0090303]; prolactin secretion [GO:0070459]; prostate gland development [GO:0030850]; regulation of cell shape [GO:0008360]; regulation of hormone secretion [GO:0046883]; regulation of inflammatory response [GO:0050727]; regulation of interleukin-1 production [GO:0032652]; regulation of leukocyte migration [GO:0002685]; response to drug [GO:0042493]; response to estradiol [GO:0032355]; response to interleukin-1 [GO:0070555]; response to peptide hormone [GO:0043434]; response to X-ray [GO:0010165]; signal transduction [GO:0007165]	annealing helicase activity [GO:0036310]; cadherin binding involved in cell-cell adhesion [GO:0098641]; calcium-dependent phospholipid binding [GO:0005544]; calcium-dependent protein binding [GO:0048306]; calcium ion binding [GO:0005509]; double-stranded DNA-dependent ATPase activity [GO:0033676]; helicase activity [GO:0004386]; phospholipase A2 inhibitor activity [GO:0019834]; phospholipid binding [GO:0005543]; protein binding, bridging [GO:0030674]; receptor binding [GO:0005102]; single-stranded DNA binding [GO:0003697]; single-stranded RNA binding [GO:0003727]; structural molecule activity [GO:0005198]	apical plasma membrane [GO:0016324]; basolateral plasma membrane [GO:0016323]; cell-cell adherens junction [GO:0005913]; cell surface [GO:0009986]; cornified envelope [GO:0001533]; cytoplasm [GO:0005737]; cytoplasmic vesicle membrane [GO:0030659]; early endosome membrane [GO:0031901]; endosome [GO:0005768]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; extrinsic component of endosome membrane [GO:0031313]; extrinsic component of external side of plasma membrane [GO:0031232]; extrinsic component of membrane [GO:0019898]; focal adhesion [GO:0005925]; lateral plasma membrane [GO:0016328]; mast cell granule [GO:0042629]; mitochondrial membrane [GO:0031966]; motile cilium [GO:0031514]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; phagocytic cup [GO:0001891]; plasma membrane [GO:0005886]; protein complex [GO:0043234]; sarcolemma [GO:0042383]; vesicle [GO:0031982]
P12429	ANXA3_HUMAN	Annexin A3 (35-alpha calcimedin) (Annexin III) (Annexin-3) (Inositol 1,2-cyclic phosphate 2-phosphohydrolase) (Lipocortin III) (Placental anticoagulant protein III) (PAP-III)	ANXA3 ANX3	1AII;1AXN;					PF00191;	IPR001464;IPR018502;IPR018252;IPR002390;	animal organ regeneration [GO:0031100]; defense response to bacterium [GO:0042742]; hippocampus development [GO:0021766]; neutrophil degranulation [GO:0043312]; phagocytosis [GO:0006909]; positive regulation of angiogenesis [GO:0045766]; positive regulation of DNA metabolic process [GO:0051054]; positive regulation of endothelial cell migration [GO:0010595]; positive regulation of sequence-specific DNA binding transcription factor activity [GO:0051091]; response to glucocorticoid [GO:0051384]; response to growth factor [GO:0070848]	calcium-dependent phospholipid binding [GO:0005544]; calcium-dependent protein binding [GO:0048306]; calcium ion binding [GO:0005509]; phospholipase A2 inhibitor activity [GO:0019834]	axon [GO:0030424]; cytoplasm [GO:0005737]; dendrite [GO:0030425]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; neuronal cell body [GO:0043025]; phagocytic vesicle membrane [GO:0030670]; plasma membrane [GO:0005886]; specific granule [GO:0042581]
Q16853	AOC3_HUMAN	Membrane primary amine oxidase (EC 1.4.3.21) (Copper amine oxidase) (HPAO) (Semicarbazide-sensitive amine oxidase) (SSAO) (Vascular adhesion protein 1) (VAP-1)	AOC3 VAP1	1PU4;1US1;2C10;2C11;2Y73;2Y74;3ALA;4BTW;4BTX;4BTY;	CHEMBL3437;	Q16853;	DB01275;DB00780;		PF01179;PF02727;PF02728;	IPR000269;IPR015798;IPR016182;IPR015800;IPR015802;	amine metabolic process [GO:0009308]; cell adhesion [GO:0007155]; inflammatory response [GO:0006954]; response to antibiotic [GO:0046677]; xenobiotic metabolic process [GO:0006805]	aliphatic-amine oxidase activity [GO:0052595]; aminoacetone:oxygen oxidoreductase(deaminating) activity [GO:0052594]; calcium ion binding [GO:0005509]; copper ion binding [GO:0005507]; phenethylamine:oxygen oxidoreductase (deaminating) activity [GO:0052596]; primary amine oxidase activity [GO:0008131]; protein heterodimerization activity [GO:0046982]; protein homodimerization activity [GO:0042803]; quinone binding [GO:0048038]; tryptamine:oxygen oxidoreductase (deaminating) activity [GO:0052593]	cell surface [GO:0009986]; cytoplasm [GO:0005737]; early endosome [GO:0005769]; endoplasmic reticulum [GO:0005783]; Golgi apparatus [GO:0005794]; integral component of membrane [GO:0016021]; microvillus [GO:0005902]; plasma membrane [GO:0005886]
P21397	AOFA_HUMAN	Amine oxidase [flavin-containing] A (EC 1.4.3.4) (Monoamine oxidase type A) (MAO-A)	MAOA	1H8Q;2BXR;2BXS;2Z5X;2Z5Y;	CHEMBL1951;	P21397;	DB00918;DB06774;DB00988;DB01363;DB03147;DB00614;DB01247;DB00601;DB01577;DB00805;DB01171;DB08804;DB00952;DB00184;DB06412;DB01626;DB00780;DB00191;DB00388;DB00397;DB00721;DB00852;DB00140;DB00953;DB01037;DB01104;DB00669;DB00624;DB00752;DB00315;DB00909;		PF01593;	IPR002937;IPR023753;IPR001613;	cellular biogenic amine metabolic process [GO:0006576]; dopamine catabolic process [GO:0042420]; neurotransmitter catabolic process [GO:0042135]; neurotransmitter metabolic process [GO:0042133]	primary amine oxidase activity [GO:0008131]	integral component of membrane [GO:0016021]; mitochondrial outer membrane [GO:0005741]; mitochondrion [GO:0005739]
P27338	AOFB_HUMAN	Amine oxidase [flavin-containing] B (EC 1.4.3.4) (Monoamine oxidase type B) (MAO-B)	MAOB	1GOS;1H8R;1OJ9;1OJA;1OJC;1OJD;1S2Q;1S2Y;1S3B;1S3E;2BK3;2BK4;2BK5;2BYB;2C64;2C65;2C66;2C67;2C70;2C72;2C73;2C75;2C76;2V5Z;2V60;2V61;2VRL;2VRM;2VZ2;2XCG;2XFN;2XFO;2XFP;2XFQ;2XFU;3PO7;3ZYX;4A79;4A7A;4CRT;	CHEMBL2039;	P27338;	DB00915;DB00182;DB00988;DB01363;DB03147;DB00614;DB01247;DB00601;DB01577;DB01171;DB08804;DB00184;DB01626;DB00780;DB00191;DB00721;DB01367;DB01037;DB01104;DB00752;DB00909;		PF01593;	IPR002937;IPR023753;IPR001613;	dopamine catabolic process [GO:0042420]; hydrogen peroxide biosynthetic process [GO:0050665]; negative regulation of serotonin secretion [GO:0014063]; neurotransmitter catabolic process [GO:0042135]; positive regulation of dopamine metabolic process [GO:0045964]; response to aluminum ion [GO:0010044]; response to corticosterone [GO:0051412]; response to drug [GO:0042493]; response to ethanol [GO:0045471]; response to lipopolysaccharide [GO:0032496]; response to selenium ion [GO:0010269]; response to toxic substance [GO:0009636]; substantia nigra development [GO:0021762]	electron carrier activity [GO:0009055]; flavin adenine dinucleotide binding [GO:0050660]; primary amine oxidase activity [GO:0008131]	extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; mitochondrial envelope [GO:0005740]; mitochondrial inner membrane [GO:0005743]; mitochondrial outer membrane [GO:0005741]; mitochondrion [GO:0005739]
O14727	APAF_HUMAN	Apoptotic protease-activating factor 1 (APAF-1)	APAF1 KIAA0413	1C15;1CWW;1CY5;1Z6T;2P1H;2YGS;3J2T;3JBT;3YGS;4RHW;	CHEMBL1795093;	O14727;	DB00171;		PF00619;PF00931;PF00400;	IPR017251;IPR001315;IPR011029;IPR020472;IPR002182;IPR027417;IPR015943;IPR001680;IPR019775;IPR017986;	activation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0006919]; activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c [GO:0008635]; aging [GO:0007568]; apoptotic process [GO:0006915]; cardiac muscle cell apoptotic process [GO:0010659]; cell differentiation [GO:0030154]; cellular response to transforming growth factor beta stimulus [GO:0071560]; forebrain development [GO:0030900]; glial cell apoptotic process [GO:0034349]; intrinsic apoptotic signaling pathway [GO:0097193]; intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress [GO:0070059]; nervous system development [GO:0007399]; neural tube closure [GO:0001843]; neuron apoptotic process [GO:0051402]; positive regulation of apoptotic process [GO:0043065]; positive regulation of apoptotic signaling pathway [GO:2001235]; protein homooligomerization [GO:0051260]; regulation of apoptotic DNA fragmentation [GO:1902510]; regulation of apoptotic process [GO:0042981]; response to G1 DNA damage checkpoint signaling [GO:0072432]; response to hypoxia [GO:0001666]; response to nutrient [GO:0007584]	ADP binding [GO:0043531]; ATP binding [GO:0005524]; cysteine-type endopeptidase activator activity involved in apoptotic process [GO:0008656]; nucleotide binding [GO:0000166]	apoptosome [GO:0043293]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleus [GO:0005634]
P27695	APEX1_HUMAN	DNA-(apurinic or apyrimidinic site) lyase (EC 3.1.-.-) (EC 4.2.99.18) (APEX nuclease) (APEN) (Apurinic-apyrimidinic endonuclease 1) (AP endonuclease 1) (APE-1) (REF-1) (Redox factor-1) [Cleaved into: DNA-(apurinic or apyrimidinic site) lyase, mitochondrial]	APEX1 APE APE1 APEX APX HAP1 REF1	1BIX;1CQG;1CQH;1DE8;1DE9;1DEW;1E9N;1HD7;2ISI;2O3H;3U8U;4IEM;4LND;4QH9;4QHD;4QHE;5CFG;5DFF;5DFH;5DFI;5DFJ;5DG0;	CHEMBL5619;	P27695;	DB04967;		PF03372;	IPR004808;IPR020847;IPR020848;IPR005135;	aging [GO:0007568]; base-excision repair [GO:0006284]; base-excision repair, base-free sugar-phosphate removal [GO:0006286]; cell redox homeostasis [GO:0045454]; cellular response to cAMP [GO:0071320]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to peptide hormone stimulus [GO:0071375]; DNA demethylation [GO:0080111]; DNA recombination [GO:0006310]; DNA repair [GO:0006281]; negative regulation of smooth muscle cell migration [GO:0014912]; positive regulation of DNA repair [GO:0045739]; positive regulation of G1/S transition of mitotic cell cycle [GO:1900087]; regulation of mRNA stability [GO:0043488]; regulation of transcription, DNA-templated [GO:0006355]; response to drug [GO:0042493]; telomere maintenance [GO:0000723]; transcription, DNA-templated [GO:0006351]	3'-5' exonuclease activity [GO:0008408]; chromatin DNA binding [GO:0031490]; damaged DNA binding [GO:0003684]; DNA-(apurinic or apyrimidinic site) lyase activity [GO:0003906]; DNA binding [GO:0003677]; double-stranded DNA 3'-5' exodeoxyribonuclease activity [GO:0008311]; double-stranded DNA exodeoxyribonuclease activity [GO:0008309]; double-stranded telomeric DNA binding [GO:0003691]; endodeoxyribonuclease activity [GO:0004520]; endonuclease activity [GO:0004519]; metal ion binding [GO:0046872]; oxidoreductase activity [GO:0016491]; phosphodiesterase I activity [GO:0004528]; phosphoric diester hydrolase activity [GO:0008081]; poly(A) RNA binding [GO:0044822]; RNA-DNA hybrid ribonuclease activity [GO:0004523]; site-specific endodeoxyribonuclease activity, specific for altered base [GO:0016890]; transcription coactivator activity [GO:0003713]; transcription corepressor activity [GO:0003714]; uracil DNA N-glycosylase activity [GO:0004844]	centrosome [GO:0005813]; cytoplasm [GO:0005737]; endoplasmic reticulum [GO:0005783]; mitochondrion [GO:0005739]; nuclear chromosome, telomeric region [GO:0000784]; nuclear speck [GO:0016607]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; ribosome [GO:0005840]; transcription factor complex [GO:0005667]
P02652	APOA2_HUMAN	Apolipoprotein A-II (Apo-AII) (ApoA-II) (Apolipoprotein A2) [Cleaved into: Proapolipoprotein A-II (ProapoA-II); Truncated apolipoprotein A-II (Apolipoprotein A-II(1-76))]	APOA2	1L6L;2OU1;						IPR006801;	acute inflammatory response [GO:0002526]; animal organ regeneration [GO:0031100]; cholesterol efflux [GO:0033344]; cholesterol homeostasis [GO:0042632]; cholesterol metabolic process [GO:0008203]; diacylglycerol catabolic process [GO:0046340]; high-density lipoprotein particle assembly [GO:0034380]; high-density lipoprotein particle clearance [GO:0034384]; high-density lipoprotein particle remodeling [GO:0034375]; lipoprotein biosynthetic process [GO:0042158]; lipoprotein metabolic process [GO:0042157]; low-density lipoprotein particle remodeling [GO:0034374]; negative regulation of cholesterol import [GO:0060621]; negative regulation of cholesterol transport [GO:0032375]; negative regulation of cholesterol transporter activity [GO:0060695]; negative regulation of cytokine secretion involved in immune response [GO:0002740]; negative regulation of lipase activity [GO:0060192]; negative regulation of lipid catabolic process [GO:0050995]; negative regulation of very-low-density lipoprotein particle remodeling [GO:0010903]; peptidyl-methionine modification [GO:0018206]; phosphatidylcholine biosynthetic process [GO:0006656]; phospholipid catabolic process [GO:0009395]; phospholipid efflux [GO:0033700]; positive regulation of cholesterol esterification [GO:0010873]; positive regulation of interleukin-8 biosynthetic process [GO:0045416]; positive regulation of lipid catabolic process [GO:0050996]; protein oxidation [GO:0018158]; regulation of intestinal cholesterol absorption [GO:0030300]; regulation of protein stability [GO:0031647]; response to drug [GO:0042493]; response to estrogen [GO:0043627]; response to glucocorticoid [GO:0051384]; response to glucose [GO:0009749]; retinoid metabolic process [GO:0001523]; reverse cholesterol transport [GO:0043691]; triglyceride metabolic process [GO:0006641]; triglyceride-rich lipoprotein particle remodeling [GO:0034370]; viral process [GO:0016032]	apolipoprotein receptor binding [GO:0034190]; cholesterol binding [GO:0015485]; cholesterol transporter activity [GO:0017127]; high-density lipoprotein particle binding [GO:0008035]; high-density lipoprotein particle receptor binding [GO:0070653]; lipase inhibitor activity [GO:0055102]; lipid binding [GO:0008289]; lipid transporter activity [GO:0005319]; phosphatidylcholine binding [GO:0031210]; phosphatidylcholine-sterol O-acyltransferase activator activity [GO:0060228]; phospholipid binding [GO:0005543]; protein heterodimerization activity [GO:0046982]; protein homodimerization activity [GO:0042803]	blood microparticle [GO:0072562]; chylomicron [GO:0042627]; cytosol [GO:0005829]; early endosome [GO:0005769]; endoplasmic reticulum lumen [GO:0005788]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; high-density lipoprotein particle [GO:0034364]; spherical high-density lipoprotein particle [GO:0034366]; very-low-density lipoprotein particle [GO:0034361]
P08519	APOA_HUMAN	Apolipoprotein(a) (Apo(a)) (Lp(a)) (EC 3.4.21.-)	LPA	1I71;1JFN;1KIV;2FEB;3KIV;4BV5;4BV7;4BVC;4BVD;4BVV;4BVW;4KIV;			DB00513;		PF00051;PF00089;	IPR000001;IPR013806;IPR018056;IPR009003;IPR001314;IPR001254;IPR018114;IPR033116;	blood circulation [GO:0008015]; lipid metabolic process [GO:0006629]; lipid transport [GO:0006869]; lipoprotein metabolic process [GO:0042157]	apolipoprotein binding [GO:0034185]; endopeptidase inhibitor activity [GO:0004866]; fibronectin binding [GO:0001968]; heparin binding [GO:0008201]; serine-type endopeptidase activity [GO:0004252]	extracellular region [GO:0005576]; plasma lipoprotein particle [GO:0034358]
P04114	APOB_HUMAN	Apolipoprotein B-100 (Apo B-100) [Cleaved into: Apolipoprotein B-48 (Apo B-48)]	APOB		CHEMBL4549;	P04114;			PF12491;PF06448;PF09172;PF01347;	IPR022176;IPR016024;IPR015819;IPR001747;IPR009454;IPR015816;IPR015255;IPR015817;IPR015818;IPR011030;	artery morphogenesis [GO:0048844]; cellular protein catabolic process [GO:0044257]; cellular response to prostaglandin stimulus [GO:0071379]; cellular response to tumor necrosis factor [GO:0071356]; cholesterol efflux [GO:0033344]; cholesterol homeostasis [GO:0042632]; cholesterol metabolic process [GO:0008203]; cholesterol transport [GO:0030301]; fertilization [GO:0009566]; flagellated sperm motility [GO:0030317]; in utero embryonic development [GO:0001701]; leukocyte migration [GO:0050900]; lipoprotein biosynthetic process [GO:0042158]; lipoprotein catabolic process [GO:0042159]; lipoprotein metabolic process [GO:0042157]; lipoprotein transport [GO:0042953]; low-density lipoprotein particle clearance [GO:0034383]; low-density lipoprotein particle remodeling [GO:0034374]; nervous system development [GO:0007399]; positive regulation of cholesterol storage [GO:0010886]; positive regulation of gene expression [GO:0010628]; positive regulation of lipid storage [GO:0010884]; positive regulation of macrophage derived foam cell differentiation [GO:0010744]; post-embryonic development [GO:0009791]; receptor-mediated endocytosis [GO:0006898]; regulation of cholesterol biosynthetic process [GO:0045540]; response to carbohydrate [GO:0009743]; response to lipopolysaccharide [GO:0032496]; response to selenium ion [GO:0010269]; response to virus [GO:0009615]; retinoid metabolic process [GO:0001523]; spermatogenesis [GO:0007283]; triglyceride catabolic process [GO:0019433]; triglyceride mobilization [GO:0006642]; very-low-density lipoprotein particle assembly [GO:0034379]	cholesterol transporter activity [GO:0017127]; heparin binding [GO:0008201]; lipase binding [GO:0035473]; low-density lipoprotein particle receptor binding [GO:0050750]; phospholipid binding [GO:0005543]	actin cytoskeleton [GO:0015629]; chylomicron [GO:0042627]; chylomicron remnant [GO:0034360]; clathrin-coated endocytic vesicle membrane [GO:0030669]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; early endosome [GO:0005769]; endocytic vesicle lumen [GO:0071682]; endoplasmic reticulum exit site [GO:0070971]; endoplasmic reticulum lumen [GO:0005788]; endoplasmic reticulum membrane [GO:0005789]; endosome lumen [GO:0031904]; endosome membrane [GO:0010008]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; Golgi apparatus [GO:0005794]; intermediate-density lipoprotein particle [GO:0034363]; intracellular membrane-bounded organelle [GO:0043231]; low-density lipoprotein particle [GO:0034362]; mature chylomicron [GO:0034359]; neuronal cell body [GO:0043025]; plasma membrane [GO:0005886]; very-low-density lipoprotein particle [GO:0034361]
P02749	APOH_HUMAN	Beta-2-glycoprotein 1 (APC inhibitor) (Activated protein C-binding protein) (Anticardiolipin cofactor) (Apolipoprotein H) (Apo-H) (Beta-2-glycoprotein I) (B2GPI) (Beta(2)GPI)	APOH B2G1	1C1Z;1G4F;1G4G;1QUB;2KRI;3OP8;4JHS;					PF00084;PF09014;	IPR015104;IPR000436;	blood coagulation, intrinsic pathway [GO:0007597]; negative regulation of angiogenesis [GO:0016525]; negative regulation of blood coagulation [GO:0030195]; negative regulation of endothelial cell migration [GO:0010596]; negative regulation of endothelial cell proliferation [GO:0001937]; negative regulation of fibrinolysis [GO:0051918]; negative regulation of myeloid cell apoptotic process [GO:0033033]; negative regulation of smooth muscle cell apoptotic process [GO:0034392]; plasminogen activation [GO:0031639]; platelet degranulation [GO:0002576]; positive regulation of blood coagulation [GO:0030194]; positive regulation of lipoprotein lipase activity [GO:0051006]; regulation of fibrinolysis [GO:0051917]; triglyceride metabolic process [GO:0006641]; triglyceride transport [GO:0034197]	glycoprotein binding [GO:0001948]; heparin binding [GO:0008201]; lipid binding [GO:0008289]; lipoprotein lipase activator activity [GO:0060230]; phospholipid binding [GO:0005543]	cell surface [GO:0009986]; chylomicron [GO:0042627]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; high-density lipoprotein particle [GO:0034364]; platelet dense granule lumen [GO:0031089]; very-low-density lipoprotein particle [GO:0034361]
P07741	APT_HUMAN	Adenine phosphoribosyltransferase (APRT) (EC 2.4.2.7)	APRT	1OPU;1ORE;1ZN7;1ZN8;1ZN9;4X44;4X45;			DB00173;DB00131;	PATHWAY: Purine metabolism; AMP biosynthesis via salvage pathway; AMP from adenine: step 1/1.	PF00156;	IPR005764;IPR000836;IPR029057;	adenine salvage [GO:0006168]; AMP salvage [GO:0044209]; cellular response to insulin stimulus [GO:0032869]; grooming behavior [GO:0007625]; lactation [GO:0007595]; purine-containing compound salvage [GO:0043101]	adenine binding [GO:0002055]; adenine phosphoribosyltransferase activity [GO:0003999]; AMP binding [GO:0016208]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleoplasm [GO:0005654]
P29972	AQP1_HUMAN	Aquaporin-1 (AQP-1) (Aquaporin-CHIP) (Urine water channel) (Water channel protein for red blood cells and kidney proximal tubule)	AQP1 CHIP28	1FQY;1H6I;1IH5;4CSK;		P29972;	DB00819;		PF00230;	IPR023271;IPR023274;IPR000425;IPR022357;	ammonium transport [GO:0015696]; bicarbonate transport [GO:0015701]; carbon dioxide transmembrane transport [GO:0035378]; carbon dioxide transport [GO:0015670]; cellular homeostasis [GO:0019725]; cellular hyperosmotic response [GO:0071474]; cellular response to cAMP [GO:0071320]; cellular response to copper ion [GO:0071280]; cellular response to dexamethasone stimulus [GO:0071549]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to hypoxia [GO:0071456]; cellular response to inorganic substance [GO:0071241]; cellular response to mechanical stimulus [GO:0071260]; cellular response to mercury ion [GO:0071288]; cellular response to nitric oxide [GO:0071732]; cellular response to retinoic acid [GO:0071300]; cellular response to salt stress [GO:0071472]; cellular response to stress [GO:0033554]; cellular response to UV [GO:0034644]; cellular water homeostasis [GO:0009992]; cell volume homeostasis [GO:0006884]; cerebrospinal fluid secretion [GO:0033326]; cGMP biosynthetic process [GO:0006182]; establishment or maintenance of actin cytoskeleton polarity [GO:0030950]; glycerol transport [GO:0015793]; lateral ventricle development [GO:0021670]; maintenance of symbiont-containing vacuole by host [GO:0085018]; multicellular organismal water homeostasis [GO:0050891]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154]; nitric oxide transport [GO:0030185]; odontogenesis [GO:0042476]; pancreatic juice secretion [GO:0030157]; positive regulation of angiogenesis [GO:0045766]; positive regulation of fibroblast proliferation [GO:0048146]; positive regulation of saliva secretion [GO:0046878]; potassium ion transport [GO:0006813]; renal water homeostasis [GO:0003091]; renal water transport [GO:0003097]; response to drug [GO:0042493]; transepithelial water transport [GO:0035377]; water transport [GO:0006833]	ammonium transmembrane transporter activity [GO:0008519]; carbon dioxide transmembrane transporter activity [GO:0035379]; glycerol channel activity [GO:0015254]; glycerol transmembrane transporter activity [GO:0015168]; intracellular cGMP activated cation channel activity [GO:0005223]; nitric oxide transmembrane transporter activity [GO:0030184]; potassium channel activity [GO:0005267]; potassium ion transmembrane transporter activity [GO:0015079]; transmembrane transporter activity [GO:0022857]; water channel activity [GO:0015250]; water transmembrane transporter activity [GO:0005372]	apical part of cell [GO:0045177]; apical plasma membrane [GO:0016324]; basal plasma membrane [GO:0009925]; basolateral plasma membrane [GO:0016323]; brush border [GO:0005903]; brush border membrane [GO:0031526]; cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; nuclear membrane [GO:0031965]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; sarcolemma [GO:0042383]; symbiont-containing vacuole [GO:0020003]
P10398	ARAF_HUMAN	Serine/threonine-protein kinase A-Raf (EC 2.7.11.1) (Proto-oncogene A-Raf) (Proto-oncogene A-Raf-1) (Proto-oncogene Pks)	ARAF ARAF1 PKS PKS2	1WXM;2MSE;	CHEMBL1169596;	P10398;	DB00171;		PF00130;PF07714;PF02196;	IPR020454;IPR011009;IPR002219;IPR000719;IPR017441;IPR003116;IPR001245;IPR008271;IPR029071;	cellular protein modification process [GO:0006464]; MAPK cascade [GO:0000165]; negative regulation of apoptotic process [GO:0043066]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; regulation of proteasomal ubiquitin-dependent protein catabolic process [GO:0032434]; regulation of TOR signaling [GO:0032006]	ATP binding [GO:0005524]; metal ion binding [GO:0046872]; protein kinase activity [GO:0004672]; protein serine/threonine kinase activity [GO:0004674]; receptor signaling protein activity [GO:0005057]	cytosol [GO:0005829]
P25098	ARBK1_HUMAN	Beta-adrenergic receptor kinase 1 (Beta-ARK-1) (EC 2.7.11.15) (G-protein coupled receptor kinase 2)	GRK2 ADRBK1 BARK BARK1	1BAK;3CIK;3KRW;3KRX;3V5W;4MK0;4PNK;5HE1;	CHEMBL4079;	P25098;	DB00171;		PF00169;PF00069;PF00615;	IPR000961;IPR000239;IPR011009;IPR011993;IPR001849;IPR000719;IPR017441;IPR016137;IPR008271;	cardiac muscle contraction [GO:0060048]; desensitization of G-protein coupled receptor protein signaling pathway [GO:0002029]; G-protein coupled acetylcholine receptor signaling pathway [GO:0007213]; heart development [GO:0007507]; negative regulation of striated muscle contraction [GO:0045988]; negative regulation of the force of heart contraction by chemical signal [GO:0003108]; peptidyl-serine phosphorylation [GO:0018105]; peptidyl-threonine phosphorylation [GO:0018107]; positive regulation of catecholamine secretion [GO:0033605]; receptor internalization [GO:0031623]; tachykinin receptor signaling pathway [GO:0007217]; viral entry into host cell [GO:0046718]; viral genome replication [GO:0019079]	alpha-2A adrenergic receptor binding [GO:0031694]; ATP binding [GO:0005524]; beta-adrenergic receptor kinase activity [GO:0047696]; Edg-2 lysophosphatidic acid receptor binding [GO:0031755]; G-protein coupled receptor kinase activity [GO:0004703]; protein kinase activity [GO:0004672]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; membrane [GO:0016020]; plasma membrane [GO:0005886]; primary cilium [GO:0072372]
P35626	ARBK2_HUMAN	Beta-adrenergic receptor kinase 2 (Beta-ARK-2) (EC 2.7.11.15) (G-protein-coupled receptor kinase 3)	GRK3 ADRBK2 BARK2		CHEMBL1075166;	P35626;	DB00171;		PF00169;PF00069;PF00615;	IPR000961;IPR000239;IPR011009;IPR011993;IPR001849;IPR000719;IPR017441;IPR016137;IPR008271;	receptor internalization [GO:0031623]; signal transduction [GO:0007165]	ATP binding [GO:0005524]; beta-adrenergic receptor kinase activity [GO:0047696]; G-protein coupled receptor kinase activity [GO:0004703]; protein kinase activity [GO:0004672]	plasma membrane [GO:0005886]
P18085	ARF4_HUMAN	ADP-ribosylation factor 4	ARF4 ARF2	1Z6X;					PF00025;	IPR027417;IPR005225;IPR024156;IPR006689;	activation of phospholipase D activity [GO:0031584]; apical protein localization [GO:0045176]; brain development [GO:0007420]; cell migration [GO:0016477]; dendritic spine development [GO:0060996]; epidermal growth factor receptor signaling pathway [GO:0007173]; ER to Golgi vesicle-mediated transport [GO:0006888]; establishment or maintenance of epithelial cell apical/basal polarity [GO:0045197]; learning [GO:0007612]; negative regulation of apoptotic process [GO:0043066]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; protein ADP-ribosylation [GO:0006471]; protein localization to cilium [GO:0061512]; protein transport [GO:0015031]; regulation of reactive oxygen species metabolic process [GO:2000377]; response to axon injury [GO:0048678]; retrograde vesicle-mediated transport, Golgi to ER [GO:0006890]; small GTPase mediated signal transduction [GO:0007264]	ARF guanyl-nucleotide exchange factor activity [GO:0005086]; epidermal growth factor receptor binding [GO:0005154]; GTPase activity [GO:0003924]; GTP binding [GO:0005525]	cytosol [GO:0005829]; dendritic spine [GO:0043197]; extracellular exosome [GO:0070062]; extracellular matrix [GO:0031012]; Golgi apparatus [GO:0005794]; membrane [GO:0016020]; ruffle membrane [GO:0032587]
P05089	ARGI1_HUMAN	Arginase-1 (EC 3.5.3.1) (Liver-type arginase) (Type I arginase)	ARG1	1WVA;1WVB;2AEB;2PHA;2PHO;2PLL;2ZAV;3DJ8;3E6K;3E6V;3F80;3GMZ;3GN0;3KV2;3LP4;3LP7;3MFV;3MFW;3MJL;3SJT;3SKK;3TF3;3TH7;3THE;3THH;3THJ;4FCI;4FCK;4GSM;4GSV;4GSZ;4GWC;4GWD;4HWW;4HXQ;4IE1;	CHEMBL1075097;	P05089;	DB00129;DB03904;	PATHWAY: Nitrogen metabolism; urea cycle; L-ornithine and urea from L-arginine: step 1/1. {ECO:0000305|PubMed:16141327}.	PF00491;	IPR014033;IPR006035;IPR023696;IPR020855;	aging [GO:0007568]; arginine catabolic process [GO:0006527]; arginine catabolic process to ornithine [GO:0019547]; cellular response to dexamethasone stimulus [GO:0071549]; cellular response to glucagon stimulus [GO:0071377]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to interleukin-4 [GO:0071353]; cellular response to lipopolysaccharide [GO:0071222]; cellular response to transforming growth factor beta stimulus [GO:0071560]; collagen biosynthetic process [GO:0032964]; liver development [GO:0001889]; lung development [GO:0030324]; mammary gland involution [GO:0060056]; maternal process involved in female pregnancy [GO:0060135]; positive regulation of endothelial cell proliferation [GO:0001938]; protein homotrimerization [GO:0070207]; regulation of L-arginine import [GO:0010963]; response to amine [GO:0014075]; response to amino acid [GO:0043200]; response to axon injury [GO:0048678]; response to cadmium ion [GO:0046686]; response to drug [GO:0042493]; response to herbicide [GO:0009635]; response to manganese ion [GO:0010042]; response to methylmercury [GO:0051597]; response to selenium ion [GO:0010269]; response to vitamin A [GO:0033189]; response to vitamin E [GO:0033197]; response to zinc ion [GO:0010043]; urea cycle [GO:0000050]	arginase activity [GO:0004053]; manganese ion binding [GO:0030145]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; mitochondrial outer membrane [GO:0005741]; neuronal cell body [GO:0043025]; neuron projection [GO:0043005]; nucleus [GO:0005634]
P78540	ARGI2_HUMAN	Arginase-2, mitochondrial (EC 3.5.3.1) (Kidney-type arginase) (Non-hepatic arginase) (Type II arginase)	ARG2	1PQ3;4HZE;4I06;4IE2;4IE3;4IXU;4IXV;	CHEMBL1795148;	P78540;	DB00125;DB00129;	PATHWAY: Nitrogen metabolism; urea cycle; L-ornithine and urea from L-arginine: step 1/1. {ECO:0000250|UniProtKB:P05089}.	PF00491;	IPR014033;IPR006035;IPR023696;IPR020855;	arginine metabolic process [GO:0006525]; nitric oxide biosynthetic process [GO:0006809]; striated muscle contraction [GO:0006941]; urea cycle [GO:0000050]; ureteric bud development [GO:0001657]	arginase activity [GO:0004053]; metal ion binding [GO:0046872]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
Q9Y689	ARL5A_HUMAN	ADP-ribosylation factor-like protein 5A	ARL5A ARFLP5 ARL5	1Z6Y;1ZJ6;2H16;2H17;					PF00025;	IPR027417;IPR005225;IPR024156;IPR006689;	small GTPase mediated signal transduction [GO:0007264]	GTP binding [GO:0005525]	intracellular [GO:0005622]
P04424	ARLY_HUMAN	Argininosuccinate lyase (ASAL) (EC 4.3.2.1) (Arginosuccinase)	ASL	1AOS;1K62;			DB00125;	PATHWAY: Amino-acid biosynthesis; L-arginine biosynthesis; L-arginine from L-ornithine and carbamoyl phosphate: step 3/3.; PATHWAY: Nitrogen metabolism; urea cycle; L-arginine and fumarate from (N(omega)-L-arginino)succinate: step 1/1.	PF14698;PF00206;	IPR029419;IPR009049;IPR024083;IPR020557;IPR000362;IPR022761;IPR008948;	arginine biosynthetic process [GO:0006526]; arginine biosynthetic process via ornithine [GO:0042450]; arginine catabolic process [GO:0006527]; internal protein amino acid acetylation [GO:0006475]; protein tetramerization [GO:0051262]; urea cycle [GO:0000050]	argininosuccinate lyase activity [GO:0004056]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
O43681	ARSA1_HUMAN	ATPase ASNA1 (EC 3.6.-.-) (Arsenical pump-driving ATPase) (Arsenite-stimulated ATPase) (Transmembrane domain recognition complex 40 kDa ATPase subunit) (hARSA-I) (hASNA-I)	ASNA1 ARSA TRC40				DB00171;		PF02374;	IPR025723;IPR016300;IPR027542;IPR027417;	IRE1-mediated unfolded protein response [GO:0036498]; protein insertion into ER membrane [GO:0045048]; transport [GO:0006810]	arsenite transmembrane transporter activity [GO:0015105]; ATPase activity, coupled to movement of substances [GO:0043492]; ATP binding [GO:0005524]; metal ion binding [GO:0046872]; transporter activity [GO:0005215]	cytoplasm [GO:0005737]; endoplasmic reticulum membrane [GO:0005789]; extracellular exosome [GO:0070062]; nucleolus [GO:0005730]; nucleus [GO:0005634]
P17405	ASM_HUMAN	Sphingomyelin phosphodiesterase (EC 3.1.4.12) (Acid sphingomyelinase) (aSMase)	SMPD1 ASM	5I81;5I8R;5JG8;	CHEMBL2760;	P17405;	DB00381;DB00477;DB01151;		PF00149;	IPR004843;IPR029052;IPR011001;IPR008139;IPR011160;	ceramide biosynthetic process [GO:0046513]; glycosphingolipid metabolic process [GO:0006687]; negative regulation of MAP kinase activity [GO:0043407]; nervous system development [GO:0007399]; positive regulation of apoptotic process [GO:0043065]; positive regulation of protein dephosphorylation [GO:0035307]; response to cocaine [GO:0042220]; response to drug [GO:0042493]; signal transduction [GO:0007165]; sphingomyelin catabolic process [GO:0006685]; sphingomyelin metabolic process [GO:0006684]; termination of signal transduction [GO:0023021]	acid sphingomyelin phosphodiesterase activity [GO:0061750]; hydrolase activity, acting on glycosyl bonds [GO:0016798]; sphingomyelin phosphodiesterase activity [GO:0004767]; zinc ion binding [GO:0008270]	endosome [GO:0005768]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; lamellar body [GO:0042599]; lysosomal lumen [GO:0043202]; lysosome [GO:0005764]; plasma membrane [GO:0005886]
P08243	ASNS_HUMAN	Asparagine synthetase [glutamine-hydrolyzing] (EC 6.3.5.4) (Cell cycle control protein TS11) (Glutamine-dependent asparagine synthetase)	ASNS TS11		CHEMBL3120;	P08243;	DB00171;DB00174;DB00128;DB00130;	PATHWAY: Amino-acid biosynthesis; L-asparagine biosynthesis; L-asparagine from L-aspartate (L-Gln route): step 1/1.	PF00733;PF13537;	IPR006426;IPR001962;IPR033738;IPR017932;IPR029055;IPR014729;	asparagine biosynthetic process [GO:0006529]; cellular amino acid biosynthetic process [GO:0008652]; cellular response to glucose starvation [GO:0042149]; cellular response to hormone stimulus [GO:0032870]; glutamine metabolic process [GO:0006541]; L-asparagine biosynthetic process [GO:0070981]; liver development [GO:0001889]; negative regulation of apoptotic process [GO:0043066]; PERK-mediated unfolded protein response [GO:0036499]; positive regulation of mitotic cell cycle [GO:0045931]; response to amino acid [GO:0043200]; response to follicle-stimulating hormone [GO:0032354]; response to light stimulus [GO:0009416]; response to mechanical stimulus [GO:0009612]; response to methotrexate [GO:0031427]; response to toxic substance [GO:0009636]	asparagine synthase (glutamine-hydrolyzing) activity [GO:0004066]; ATP binding [GO:0005524]; cofactor binding [GO:0048037]; protein homodimerization activity [GO:0042803]	cytosol [GO:0005829]
Q12797	ASPH_HUMAN	Aspartyl/asparaginyl beta-hydroxylase (EC 1.14.11.16) (Aspartate beta-hydroxylase) (ASP beta-hydroxylase) (Peptide-aspartate beta-dioxygenase)	ASPH BAH	5APA;			DB00128;DB00139;		PF05279;PF05118;	IPR007943;IPR007803;IPR027443;IPR013026;IPR011990;IPR019734;	activation of cysteine-type endopeptidase activity [GO:0097202]; activation of store-operated calcium channel activity [GO:0032237]; calcium ion transmembrane transport [GO:0070588]; cellular response to calcium ion [GO:0071277]; detection of calcium ion [GO:0005513]; ion transmembrane transport [GO:0034220]; muscle contraction [GO:0006936]; peptidyl-amino acid modification [GO:0018193]; positive regulation of calcium ion transport into cytosol [GO:0010524]; positive regulation of intracellular protein transport [GO:0090316]; positive regulation of proteolysis [GO:0045862]; positive regulation of ryanodine-sensitive calcium-release channel activity [GO:0060316]; positive regulation of transcription, DNA-templated [GO:0045893]; regulation of cardiac conduction [GO:1903779]; regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion [GO:0010881]; regulation of cell communication by electrical coupling [GO:0010649]; regulation of inositol 1,4,5-trisphosphate-sensitive calcium-release channel activity [GO:0031585]; regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum [GO:0010880]; regulation of ryanodine-sensitive calcium-release channel activity [GO:0060314]; response to ATP [GO:0033198]	calcium ion binding [GO:0005509]; electron carrier activity [GO:0009055]; ion channel binding [GO:0044325]; peptide-aspartate beta-dioxygenase activity [GO:0004597]; structural constituent of muscle [GO:0008307]; structural molecule activity [GO:0005198]	calcium channel complex [GO:0034704]; cortical endoplasmic reticulum [GO:0032541]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; integral component of endoplasmic reticulum membrane [GO:0030176]; integral component of membrane [GO:0016021]; junctional sarcoplasmic reticulum membrane [GO:0014701]; plasma membrane [GO:0005886]; sarcoplasmic reticulum lumen [GO:0033018]; sarcoplasmic reticulum membrane [GO:0033017]
P00966	ASSY_HUMAN	Argininosuccinate synthase (EC 6.3.4.5) (Citrulline--aspartate ligase)	ASS1 ASS	2NZ2;			DB00171;DB00125;DB00128;DB00155;	PATHWAY: Amino-acid biosynthesis; L-arginine biosynthesis; L-arginine from L-ornithine and carbamoyl phosphate: step 2/3.; PATHWAY: Nitrogen metabolism; urea cycle; (N(omega)-L-arginino)succinate from L-aspartate and L-citrulline: step 1/1.	PF00764;	IPR001518;IPR018223;IPR023434;IPR024074;IPR014729;	acute-phase response [GO:0006953]; aging [GO:0007568]; arginine biosynthetic process [GO:0006526]; argininosuccinate metabolic process [GO:0000053]; aspartate metabolic process [GO:0006531]; cellular response to amine stimulus [GO:0071418]; cellular response to amino acid stimulus [GO:0071230]; cellular response to ammonium ion [GO:0071242]; cellular response to cAMP [GO:0071320]; cellular response to dexamethasone stimulus [GO:0071549]; cellular response to glucagon stimulus [GO:0071377]; cellular response to interferon-gamma [GO:0071346]; cellular response to laminar fluid shear stress [GO:0071499]; cellular response to lipopolysaccharide [GO:0071222]; cellular response to oleic acid [GO:0071400]; cellular response to tumor necrosis factor [GO:0071356]; citrulline metabolic process [GO:0000052]; diaphragm development [GO:0060539]; kidney development [GO:0001822]; liver development [GO:0001889]; midgut development [GO:0007494]; negative regulation of leukocyte cell-cell adhesion [GO:1903038]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; response to drug [GO:0042493]; response to estradiol [GO:0032355]; response to fatty acid [GO:0070542]; response to growth hormone [GO:0060416]; response to mycotoxin [GO:0010046]; response to nutrient [GO:0007584]; response to zinc ion [GO:0010043]; urea cycle [GO:0000050]	amino acid binding [GO:0016597]; argininosuccinate synthase activity [GO:0004055]; ATP binding [GO:0005524]; poly(A) RNA binding [GO:0044822]; toxic substance binding [GO:0015643]	cell body fiber [GO:0070852]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; extracellular exosome [GO:0070062]; lysosome [GO:0005764]; mitochondrial outer membrane [GO:0005741]; nucleus [GO:0005634]; perikaryon [GO:0043204]
P54707	AT12A_HUMAN	Potassium-transporting ATPase alpha chain 2 (EC 3.6.3.10) (Non-gastric H(+)/K(+) ATPase subunit alpha) (Proton pump)	ATP12A ATP1AL1		CHEMBL2933;	P54707;			PF00689;PF00690;PF00122;	IPR030318;IPR006068;IPR004014;IPR023299;IPR018303;IPR023298;IPR008250;IPR023214;IPR005775;IPR001757;	ATP hydrolysis coupled proton transport [GO:0015991]; cellular potassium ion homeostasis [GO:0030007]; cellular sodium ion homeostasis [GO:0006883]; ion transmembrane transport [GO:0034220]; potassium ion import [GO:0010107]; regulation of pH [GO:0006885]; sodium ion export from cell [GO:0036376]	ATP binding [GO:0005524]; hydrogen:potassium-exchanging ATPase activity [GO:0008900]; metal ion binding [GO:0046872]; sodium:potassium-exchanging ATPase activity [GO:0005391]	basolateral plasma membrane [GO:0016323]; hydrogen:potassium-exchanging ATPase complex [GO:0005889]; intracellular membrane-bounded organelle [GO:0043231]; plasma membrane [GO:0005886]
P05023	AT1A1_HUMAN	Sodium/potassium-transporting ATPase subunit alpha-1 (Na(+)/K(+) ATPase alpha-1 subunit) (EC 3.6.3.9) (Sodium pump subunit alpha-1)	ATP1A1		CHEMBL2095186;		DB00511;DB01430;DB01370;DB01244;DB01158;DB01188;DB01078;DB01119;DB01396;DB00390;DB00903;DB00774;DB01092;DB01345;DB01021;		PF00689;PF00690;PF00122;	IPR006068;IPR004014;IPR023299;IPR018303;IPR023298;IPR008250;IPR023214;IPR005775;IPR001757;	ATP hydrolysis coupled proton transport [GO:0015991]; cardiac muscle contraction [GO:0060048]; cell communication by electrical coupling involved in cardiac conduction [GO:0086064]; cellular potassium ion homeostasis [GO:0030007]; cellular response to mechanical stimulus [GO:0071260]; cellular response to steroid hormone stimulus [GO:0071383]; cellular sodium ion homeostasis [GO:0006883]; ion transmembrane transport [GO:0034220]; membrane hyperpolarization [GO:0060081]; membrane repolarization [GO:0086009]; membrane repolarization during cardiac muscle cell action potential [GO:0086013]; negative regulation of glucocorticoid biosynthetic process [GO:0031947]; negative regulation of heart contraction [GO:0045822]; positive regulation of heart contraction [GO:0045823]; positive regulation of striated muscle contraction [GO:0045989]; potassium ion import [GO:0010107]; potassium ion import across plasma membrane [GO:1990573]; regulation of blood pressure [GO:0008217]; regulation of cardiac conduction [GO:1903779]; regulation of cardiac muscle cell contraction [GO:0086004]; regulation of sodium ion transport [GO:0002028]; regulation of the force of heart contraction [GO:0002026]; relaxation of cardiac muscle [GO:0055119]; response to drug [GO:0042493]; response to glycoside [GO:1903416]; sodium ion export from cell [GO:0036376]	ADP binding [GO:0043531]; ATP binding [GO:0005524]; chaperone binding [GO:0051087]; phosphatase activity [GO:0016791]; potassium ion binding [GO:0030955]; sodium:potassium-exchanging ATPase activity [GO:0005391]; sodium ion binding [GO:0031402]; steroid hormone binding [GO:1990239]	apical plasma membrane [GO:0016324]; basolateral plasma membrane [GO:0016323]; caveola [GO:0005901]; endoplasmic reticulum [GO:0005783]; endosome [GO:0005768]; extracellular exosome [GO:0070062]; extracellular vesicle [GO:1903561]; Golgi apparatus [GO:0005794]; integral component of membrane [GO:0016021]; intercalated disc [GO:0014704]; intracellular membrane-bounded organelle [GO:0043231]; melanosome [GO:0042470]; membrane [GO:0016020]; myelin sheath [GO:0043209]; plasma membrane [GO:0005886]; protein complex [GO:0043234]; sarcolemma [GO:0042383]; sodium:potassium-exchanging ATPase complex [GO:0005890]; T-tubule [GO:0030315]
P98194	AT2C1_HUMAN	Calcium-transporting ATPase type 2C member 1 (ATPase 2C1) (EC 3.6.3.8) (ATP-dependent Ca(2+) pump PMR1)	ATP2C1 KIAA1347 PMR1L HUSSY-28				DB01189;DB00228;DB01159;DB00753;DB01028;DB01236;		PF00689;PF00690;PF00122;	IPR030336;IPR006068;IPR004014;IPR018303;IPR023298;IPR008250;IPR023214;IPR006413;IPR001757;	actin cytoskeleton reorganization [GO:0031532]; calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules [GO:0016339]; calcium ion transport [GO:0006816]; cellular calcium ion homeostasis [GO:0006874]; cellular manganese ion homeostasis [GO:0030026]; epidermis development [GO:0008544]; Golgi calcium ion homeostasis [GO:0032468]; Golgi calcium ion transport [GO:0032472]; ion transmembrane transport [GO:0034220]; manganese ion transport [GO:0006828]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]	ATP binding [GO:0005524]; calcium ion binding [GO:0005509]; calcium-transporting ATPase activity [GO:0005388]; manganese ion binding [GO:0030145]; manganese-transporting ATPase activity [GO:0015410]; metal ion binding [GO:0046872]; signal transducer activity [GO:0004871]	Golgi apparatus [GO:0005794]; Golgi membrane [GO:0000139]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; trans-Golgi network [GO:0005802]
Q8IUZ5	AT2L2_HUMAN	5-phosphohydroxy-L-lysine phospho-lyase (EC 4.2.3.134) (Alanine--glyoxylate aminotransferase 2-like 2)	PHYKPL AGXT2L2 PP9286				DB00160;		PF00202;	IPR005814;IPR015424;IPR015421;IPR015422;	collagen catabolic process [GO:0030574]; lysine catabolic process [GO:0006554]	identical protein binding [GO:0042802]; lyase activity [GO:0016829]; pyridoxal phosphate binding [GO:0030170]; transaminase activity [GO:0008483]	mitochondrial matrix [GO:0005759]
Q9Y2Q0	AT8A1_HUMAN	Phospholipid-transporting ATPase IA (EC 3.6.3.1) (ATPase class I type 8A member 1) (Chromaffin granule ATPase II) (P4-ATPase flippase complex alpha subunit ATP8A1)	ATP8A1 ATPIA				DB00144;		PF00122;PF16212;PF16209;	IPR030342;IPR023299;IPR018303;IPR008250;IPR023214;IPR006539;IPR032631;IPR001757;IPR032630;	Golgi vesicle budding [GO:0048194]; ion transmembrane transport [GO:0034220]; learning [GO:0007612]; phospholipid translocation [GO:0045332]; positive regulation of cell migration [GO:0030335]; positive regulation of phospholipid translocation [GO:0061092]	ATP binding [GO:0005524]; cation-transporting ATPase activity [GO:0019829]; magnesium ion binding [GO:0000287]; phospholipid-translocating ATPase activity [GO:0004012]	chromaffin granule membrane [GO:0042584]; endoplasmic reticulum [GO:0005783]; extracellular exosome [GO:0070062]; Golgi apparatus [GO:0005794]; Golgi membrane [GO:0000139]; integral component of membrane [GO:0016021]; intracellular membrane-bounded organelle [GO:0043231]; membrane [GO:0016020]; plasma membrane [GO:0005886]; trans-Golgi network [GO:0005802]
P54710	ATNG_HUMAN	Sodium/potassium-transporting ATPase subunit gamma (Na(+)/K(+) ATPase subunit gamma) (FXYD domain-containing ion transport regulator 2) (Sodium pump gamma chain)	FXYD2 ATP1C ATP1G1	2MKV;	CHEMBL2095186;		DB00606;		PF02038;	IPR000272;	ATP hydrolysis coupled transmembrane transport [GO:0090662]; ion transmembrane transport [GO:0034220]; potassium ion import across plasma membrane [GO:1990573]; regulation of cardiac conduction [GO:1903779]; regulation of cell growth [GO:0001558]; regulation of cell proliferation [GO:0042127]; regulation of sodium ion transmembrane transporter activity [GO:2000649]; sodium ion export from cell [GO:0036376]; transport [GO:0006810]	ion channel activity [GO:0005216]; sodium:potassium-exchanging ATPase activity [GO:0005391]; sodium channel regulator activity [GO:0017080]; transporter activity [GO:0005215]	basolateral plasma membrane [GO:0016323]; extracellular exosome [GO:0070062]; intracellular membrane-bounded organelle [GO:0043231]; plasma membrane [GO:0005886]; sodium:potassium-exchanging ATPase complex [GO:0005890]
O00244	ATOX1_HUMAN	Copper transport protein ATOX1 (Metal transport protein ATX1)	ATOX1 HAH1	1FE0;1FE4;1FEE;1TL4;1TL5;2K1R;2LQ9;3CJK;3IWL;3IWX;4QOT;4YDX;4YEA;					PF00403;	IPR017969;IPR006121;	cellular copper ion homeostasis [GO:0006878]; copper ion transport [GO:0006825]; intracellular copper ion transport [GO:0015680]; response to oxidative stress [GO:0006979]	copper chaperone activity [GO:0016531]; copper-dependent protein binding [GO:0032767]; copper ion binding [GO:0005507]; copper ion transmembrane transporter activity [GO:0005375]; metallochaperone activity [GO:0016530]	cytosol [GO:0005829]
P20648	ATP4A_HUMAN	Potassium-transporting ATPase alpha chain 1 (EC 3.6.3.10) (Gastric H(+)/K(+) ATPase subunit alpha) (Proton pump)	ATP4A		CHEMBL2095173;	P20648;	DB00736;DB00448;DB00338;DB00213;DB01129;		PF00689;PF00690;PF00122;PF09040;	IPR006068;IPR004014;IPR023299;IPR015127;IPR018303;IPR023298;IPR008250;IPR023214;IPR005775;IPR001757;	ATP hydrolysis coupled proton transport [GO:0015991]; cellular potassium ion homeostasis [GO:0030007]; cellular sodium ion homeostasis [GO:0006883]; ion transmembrane transport [GO:0034220]; potassium ion import [GO:0010107]; sodium ion export from cell [GO:0036376]; transport [GO:0006810]	ATP binding [GO:0005524]; hydrogen:potassium-exchanging ATPase activity [GO:0008900]; magnesium ion binding [GO:0000287]; sodium:potassium-exchanging ATPase activity [GO:0005391]	extracellular space [GO:0005615]; integral component of plasma membrane [GO:0005887]; intracellular membrane-bounded organelle [GO:0043231]; plasma membrane [GO:0005886]
P51164	ATP4B_HUMAN	Potassium-transporting ATPase subunit beta (Gastric H(+)/K(+) ATPase subunit beta) (Proton pump beta chain)	ATP4B		CHEMBL2095173;	P51164;			PF00287;	IPR000402;	cell adhesion [GO:0007155]; ion transmembrane transport [GO:0034220]; response to lipopolysaccharide [GO:0032496]; response to organonitrogen compound [GO:0010243]; sodium ion transport [GO:0006814]	hydrogen:potassium-exchanging ATPase activity [GO:0008900]	plasma membrane [GO:0005886]; sodium:potassium-exchanging ATPase complex [GO:0005890]
P30049	ATPD_HUMAN	ATP synthase subunit delta, mitochondrial (F-ATPase delta subunit)	ATP5D				DB01189;DB00228;DB01159;DB00753;DB01028;DB01236;		PF02823;	IPR001469;IPR020546;IPR020547;	ATP biosynthetic process [GO:0006754]; ATP synthesis coupled proton transport [GO:0015986]; mitochondrial ATP synthesis coupled proton transport [GO:0042776]; oxidative phosphorylation [GO:0006119]; response to copper ion [GO:0046688]	proton-transporting ATPase activity, rotational mechanism [GO:0046961]; proton-transporting ATP synthase activity, rotational mechanism [GO:0046933]; transmembrane transporter activity [GO:0022857]; transporter activity [GO:0005215]	mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]; mitochondrial proton-transporting ATP synthase complex [GO:0005753]; mitochondrial proton-transporting ATP synthase complex, catalytic core F(1) [GO:0000275]; mitochondrion [GO:0005739]
P46100	ATRX_HUMAN	Transcriptional regulator ATRX (EC 3.6.4.12) (ATP-dependent helicase ATRX) (X-linked helicase II) (X-linked nuclear protein) (XNP) (Znf-HX)	ATRX RAD54L XH2	2JM1;2LBM;2LD1;3QL9;3QLA;3QLC;3QLN;4W5A;					PF00271;PF00176;	IPR025766;IPR014001;IPR001650;IPR027417;IPR000330;IPR011011;IPR013083;	cellular response to hydroxyurea [GO:0072711]; chromatin modification [GO:0016569]; chromatin remodeling [GO:0006338]; DNA damage response, signal transduction by p53 class mediator [GO:0030330]; DNA methylation [GO:0006306]; DNA recombination [GO:0006310]; DNA repair [GO:0006281]; DNA replication-independent nucleosome assembly [GO:0006336]; forebrain development [GO:0030900]; multicellular organism growth [GO:0035264]; negative regulation of maintenance of mitotic sister chromatid cohesion, telomeric [GO:1904908]; negative regulation of telomeric RNA transcription from RNA pol II promoter [GO:1901581]; nucleosome assembly [GO:0006334]; positive regulation of nuclear cell cycle DNA replication [GO:0010571]; positive regulation of telomere maintenance [GO:0032206]; positive regulation of telomeric RNA transcription from RNA pol II promoter [GO:1901582]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; post-embryonic forelimb morphogenesis [GO:0035128]; protein localization to chromosome, telomeric region [GO:0070198]; regulation of histone H3-K9 trimethylation [GO:1900112]; regulation of transcription, DNA-templated [GO:0006355]; replication fork processing [GO:0031297]; seminiferous tubule development [GO:0072520]; Sertoli cell development [GO:0060009]; spermatogenesis [GO:0007283]; transcription, DNA-templated [GO:0006351]	ATP binding [GO:0005524]; chromatin binding [GO:0003682]; chromo shadow domain binding [GO:0070087]; DNA binding [GO:0003677]; DNA helicase activity [GO:0003678]; DNA translocase activity [GO:0015616]; helicase activity [GO:0004386]; histone binding [GO:0042393]; metal ion binding [GO:0046872]; methylated histone binding [GO:0035064]	nuclear chromosome, telomeric region [GO:0000784]; nuclear heterochromatin [GO:0005720]; nuclear subtelomeric heterochromatin [GO:1990707]; nucleus [GO:0005634]; pericentric heterochromatin [GO:0005721]; PML body [GO:0016605]; SWI/SNF superfamily-type complex [GO:0070603]; telomeric heterochromatin [GO:0031933]
P17735	ATTY_HUMAN	Tyrosine aminotransferase (TAT) (EC 2.6.1.5) (L-tyrosine:2-oxoglutarate aminotransferase)	TAT	3DYD;	CHEMBL3043;		DB00120;DB00135;	PATHWAY: Amino-acid degradation; L-phenylalanine degradation; acetoacetate and fumarate from L-phenylalanine: step 2/6.	PF00155;PF07706;	IPR004839;IPR004838;IPR015424;IPR015421;IPR015422;IPR011715;IPR005958;IPR005957;	2-oxoglutarate metabolic process [GO:0006103]; biosynthetic process [GO:0009058]; glutamate metabolic process [GO:0006536]; L-phenylalanine catabolic process [GO:0006559]; response to glucocorticoid [GO:0051384]; response to mercury ion [GO:0046689]; response to oxidative stress [GO:0006979]; tyrosine catabolic process [GO:0006572]	amino acid binding [GO:0016597]; L-phenylalanine:2-oxoglutarate aminotransferase activity [GO:0080130]; L-tyrosine:2-oxoglutarate aminotransferase activity [GO:0004838]; pyridoxal phosphate binding [GO:0030170]	cytosol [GO:0005829]; mitochondrion [GO:0005739]
O15169	AXN1_HUMAN	Axin-1 (Axis inhibition protein 1) (hAxin)	AXIN1 AXIN	1DK8;1EMU;1O9U;3ZDI;4B7T;4NM0;4NM3;4NM5;4NM7;4NU1;	CHEMBL1255127;				PF16646;PF08833;PF00778;PF00615;	IPR029797;IPR014936;IPR032101;IPR001158;IPR016137;IPR024066;IPR029071;	activation of JUN kinase activity [GO:0007257]; activation of protein kinase activity [GO:0032147]; apoptotic process [GO:0006915]; axial mesoderm formation [GO:0048320]; beta-catenin destruction complex assembly [GO:1904885]; beta-catenin destruction complex disassembly [GO:1904886]; canonical Wnt signaling pathway [GO:0060070]; canonical Wnt signaling pathway involved in neural plate anterior/posterior pattern formation [GO:0060823]; cell death [GO:0008219]; cellular protein complex assembly [GO:0043623]; cellular response to organic cyclic compound [GO:0071407]; cytoplasmic microtubule organization [GO:0031122]; determination of left/right symmetry [GO:0007368]; dorsal/ventral axis specification [GO:0009950]; embryonic eye morphogenesis [GO:0048048]; embryonic skeletal joint morphogenesis [GO:0060272]; forebrain anterior/posterior pattern specification [GO:0021797]; muscle cell development [GO:0055001]; negative regulation of canonical Wnt signaling pathway [GO:0090090]; negative regulation of fat cell differentiation [GO:0045599]; negative regulation of transcription elongation from RNA polymerase II promoter [GO:0034244]; negative regulation of Wnt signaling pathway [GO:0030178]; olfactory placode formation [GO:0030910]; optic placode formation [GO:0001743]; positive regulation of canonical Wnt signaling pathway [GO:0090263]; positive regulation of JNK cascade [GO:0046330]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of peptidyl-threonine phosphorylation [GO:0010800]; positive regulation of protein catabolic process [GO:0045732]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of protein ubiquitination [GO:0031398]; positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process [GO:2000060]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of ubiquitin-protein transferase activity [GO:0051443]; proteasome-mediated ubiquitin-dependent protein catabolic process [GO:0043161]; regulation of catenin import into nucleus [GO:0035412]; Wnt-activated signaling pathway involved in forebrain neuron fate commitment [GO:0021881]; Wnt signaling pathway [GO:0016055]; Wnt signaling pathway involved in somitogenesis [GO:0090244]	armadillo repeat domain binding [GO:0070016]; beta-catenin binding [GO:0008013]; enzyme binding [GO:0019899]; GTPase activator activity [GO:0005096]; identical protein binding [GO:0042802]; I-SMAD binding [GO:0070411]; protein complex scaffold [GO:0032947]; protein homodimerization activity [GO:0042803]; protein kinase binding [GO:0019901]; signal transducer activity [GO:0004871]; SMAD binding [GO:0046332]; ubiquitin protein ligase binding [GO:0031625]	beta-catenin destruction complex [GO:0030877]; cell cortex [GO:0005938]; cell periphery [GO:0071944]; cytoplasm [GO:0005737]; cytoplasmic, membrane-bounded vesicle [GO:0016023]; cytoplasmic microtubule [GO:0005881]; cytoplasmic vesicle [GO:0031410]; cytosol [GO:0005829]; lateral plasma membrane [GO:0016328]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; postsynaptic density [GO:0014069]
Q9P2W7	B3GA1_HUMAN	Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 (EC 2.4.1.135) (Beta-1,3-glucuronyltransferase 1) (Glucuronosyltransferase P) (GlcAT-P) (UDP-GlcUA:glycoprotein beta-1,3-glucuronyltransferase) (GlcUAT-P)	B3GAT1 GLCATP	1V82;1V83;1V84;				PATHWAY: Protein modification; protein glycosylation.	PF03360;	IPR005027;IPR029044;	carbohydrate metabolic process [GO:0005975]; chondroitin sulfate metabolic process [GO:0030204]; chondroitin sulfate proteoglycan biosynthetic process [GO:0050650]; glycosaminoglycan metabolic process [GO:0030203]; protein glycosylation [GO:0006486]	galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase activity [GO:0015018]; metal ion binding [GO:0046872]	endoplasmic reticulum membrane [GO:0005789]; extracellular region [GO:0005576]; Golgi membrane [GO:0000139]; integral component of membrane [GO:0016021]
O94766	B3GA3_HUMAN	Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3 (EC 2.4.1.135) (Beta-1,3-glucuronyltransferase 3) (Glucuronosyltransferase I) (GlcAT-I) (UDP-GlcUA:Gal beta-1,3-Gal-R glucuronyltransferase) (GlcUAT-I)	B3GAT3	1FGG;1KWS;3CU0;				PATHWAY: Protein modification; protein glycosylation.	PF03360;	IPR005027;IPR029044;	carbohydrate metabolic process [GO:0005975]; chondroitin sulfate metabolic process [GO:0030204]; chondroitin sulfate proteoglycan biosynthetic process [GO:0050650]; dermatan sulfate proteoglycan biosynthetic process [GO:0050651]; glycosaminoglycan biosynthetic process [GO:0006024]; glycosaminoglycan metabolic process [GO:0030203]; heparan sulfate proteoglycan biosynthetic process [GO:0015012]; positive regulation of catalytic activity [GO:0043085]; positive regulation of intracellular protein transport [GO:0090316]; protein glycosylation [GO:0006486]	galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase activity [GO:0015018]; glucuronosyltransferase activity [GO:0015020]; metal ion binding [GO:0046872]; protein phosphatase activator activity [GO:0072542]	cis-Golgi network [GO:0005801]; extracellular exosome [GO:0070062]; Golgi apparatus [GO:0005794]; Golgi membrane [GO:0000139]; integral component of membrane [GO:0016021]; membrane [GO:0016020]
P15291	B4GT1_HUMAN	Beta-1,4-galactosyltransferase 1 (Beta-1,4-GalTase 1) (Beta4Gal-T1) (b4Gal-T1) (EC 2.4.1.-) (UDP-Gal:beta-GlcNAc beta-1,4-galactosyltransferase 1) (UDP-galactose:beta-N-acetylglucosamine beta-1,4-galactosyltransferase 1) [Cleaved into: Processed beta-1,4-galactosyltransferase 1] [Includes: Lactose synthase A protein (EC 2.4.1.22); N-acetyllactosamine synthase (EC 2.4.1.90) (Nal synthase); Beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase (EC 2.4.1.38); Beta-N-acetylglucosaminyl-glycolipid beta-1,4-galactosyltransferase (EC 2.4.1.-)]	B4GALT1 GGTB2	2AE7;2AEC;2AES;2AGD;2AH9;2FY7;2FYA;2FYB;3EE5;4EE3;4EE4;4EE5;4EEA;4EEG;4EEM;4EEO;4L41;	CHEMBL4384;	P15291;	DB00141;	PATHWAY: Protein modification; protein glycosylation.	PF02709;PF13733;	IPR003859;IPR027791;IPR027995;IPR029044;	acute inflammatory response [GO:0002526]; angiogenesis involved in wound healing [GO:0060055]; binding of sperm to zona pellucida [GO:0007339]; branching morphogenesis of an epithelial tube [GO:0048754]; cell adhesion [GO:0007155]; development of secondary sexual characteristics [GO:0045136]; epithelial cell development [GO:0002064]; extracellular matrix organization [GO:0030198]; galactose metabolic process [GO:0006012]; keratan sulfate biosynthetic process [GO:0018146]; lactose biosynthetic process [GO:0005989]; leukocyte migration [GO:0050900]; mammary gland development [GO:0030879]; negative regulation of cell proliferation [GO:0008285]; oligosaccharide biosynthetic process [GO:0009312]; penetration of zona pellucida [GO:0007341]; positive regulation of apoptotic process involved in mammary gland involution [GO:0060058]; positive regulation of epithelial cell proliferation involved in wound healing [GO:0060054]; protein N-linked glycosylation [GO:0006487]; regulation of acrosome reaction [GO:0060046]; regulation of cellular component movement [GO:0051270]	alpha-tubulin binding [GO:0043014]; beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity [GO:0003831]; beta-tubulin binding [GO:0048487]; galactosyltransferase activity [GO:0008378]; lactose synthase activity [GO:0004461]; manganese ion binding [GO:0030145]; N-acetyllactosamine synthase activity [GO:0003945]; protein homodimerization activity [GO:0042803]; UDP-galactosyltransferase activity [GO:0035250]	basolateral plasma membrane [GO:0016323]; brush border membrane [GO:0031526]; desmosome [GO:0030057]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; filopodium [GO:0030175]; glycocalyx [GO:0030112]; Golgi apparatus [GO:0005794]; Golgi cisterna membrane [GO:0032580]; Golgi membrane [GO:0000139]; Golgi trans cisterna [GO:0000138]; integral component of membrane [GO:0016021]; membrane [GO:0016020]; plasma membrane [GO:0005886]
O60909	B4GT2_HUMAN	Beta-1,4-galactosyltransferase 2 (Beta-1,4-GalTase 2) (Beta4Gal-T2) (b4Gal-T2) (EC 2.4.1.-) (UDP-Gal:beta-GlcNAc beta-1,4-galactosyltransferase 2) (UDP-galactose:beta-N-acetylglucosamine beta-1,4-galactosyltransferase 2) [Includes: Lactose synthase A protein (EC 2.4.1.22); N-acetyllactosamine synthase (EC 2.4.1.90) (Nal synthase); Beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase (EC 2.4.1.38); Beta-N-acetylglucosaminyl-glycolipid beta-1,4-galactosyltransferase (EC 2.4.1.-)]	B4GALT2				DB00141;	PATHWAY: Protein modification; protein glycosylation.	PF02709;PF13733;	IPR003859;IPR027791;IPR027995;IPR029044;	cerebellar Purkinje cell layer development [GO:0021680]; keratan sulfate biosynthetic process [GO:0018146]; locomotory behavior [GO:0007626]; memory [GO:0007613]; protein glycosylation [GO:0006486]; visual learning [GO:0008542]	beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity [GO:0003831]; galactosyltransferase activity [GO:0008378]; lactose synthase activity [GO:0004461]; metal ion binding [GO:0046872]; N-acetyllactosamine synthase activity [GO:0003945]	Golgi cisterna membrane [GO:0032580]; Golgi membrane [GO:0000139]; integral component of membrane [GO:0016021]
O60512	B4GT3_HUMAN	Beta-1,4-galactosyltransferase 3 (Beta-1,4-GalTase 3) (Beta4Gal-T3) (b4Gal-T3) (EC 2.4.1.-) (UDP-Gal:beta-GlcNAc beta-1,4-galactosyltransferase 3) (UDP-galactose:beta-N-acetylglucosamine beta-1,4-galactosyltransferase 3) [Includes: N-acetyllactosamine synthase (EC 2.4.1.90) (Nal synthase); Beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase (EC 2.4.1.38); Beta-N-acetylglucosaminyl-glycolipid beta-1,4-galactosyltransferase (EC 2.4.1.-)]	B4GALT3				DB00141;	PATHWAY: Protein modification; protein glycosylation.	PF02709;PF13733;	IPR003859;IPR027791;IPR027995;IPR029044;	keratan sulfate biosynthetic process [GO:0018146]; protein glycosylation [GO:0006486]	beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity [GO:0003831]; galactosyltransferase activity [GO:0008378]; metal ion binding [GO:0046872]; N-acetyllactosamine synthase activity [GO:0003945]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; Golgi apparatus [GO:0005794]; Golgi cisterna membrane [GO:0032580]; Golgi membrane [GO:0000139]; integral component of membrane [GO:0016021]
O60513	B4GT4_HUMAN	Beta-1,4-galactosyltransferase 4 (Beta-1,4-GalTase 4) (Beta4Gal-T4) (b4Gal-T4) (EC 2.4.1.-) (UDP-Gal:beta-GlcNAc beta-1,4-galactosyltransferase 4) (UDP-galactose:beta-N-acetylglucosamine beta-1,4-galactosyltransferase 4) [Includes: N-acetyllactosamine synthase (EC 2.4.1.90) (Nal synthase); Lactotriaosylceramide beta-1,4-galactosyltransferase (EC 2.4.1.275) (Beta-N-acetylglucosaminyl-glycolipid beta-1,4-galactosyltransferase)]	B4GALT4 UNQ552/PRO1109				DB00141;	PATHWAY: Protein modification; protein glycosylation.	PF02709;PF13733;	IPR003859;IPR027791;IPR027995;IPR029044;	keratan sulfate biosynthetic process [GO:0018146]; membrane lipid metabolic process [GO:0006643]; protein glycosylation [GO:0006486]	beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase activity [GO:0003831]; galactosyltransferase activity [GO:0008378]; metal ion binding [GO:0046872]; N-acetyllactosamine synthase activity [GO:0003945]	Golgi cisterna membrane [GO:0032580]; Golgi membrane [GO:0000139]; integral component of membrane [GO:0016021]
Q14032	BAAT_HUMAN	Bile acid-CoA:amino acid N-acyltransferase (BACAT) (BAT) (EC 2.3.1.65) (Glycine N-choloyltransferase) (Long-chain fatty-acyl-CoA hydrolase) (EC 3.1.2.2)	BAAT				DB00145;		PF08840;PF04775;	IPR029058;IPR016662;IPR014940;IPR006862;	acyl-CoA metabolic process [GO:0006637]; animal organ regeneration [GO:0031100]; bile acid biosynthetic process [GO:0006699]; bile acid conjugation [GO:0002152]; bile acid metabolic process [GO:0008206]; fatty acid metabolic process [GO:0006631]; glycine metabolic process [GO:0006544]; liver development [GO:0001889]; taurine metabolic process [GO:0019530]	carboxylic ester hydrolase activity [GO:0052689]; glycine N-choloyltransferase activity [GO:0047963]; long-chain acyl-CoA hydrolase activity [GO:0052816]; medium-chain acyl-CoA hydrolase activity [GO:0052815]; N-acyltransferase activity [GO:0016410]; palmitoyl-CoA hydrolase activity [GO:0016290]; receptor binding [GO:0005102]; transferase activity, transferring acyl groups [GO:0016746]; very long chain acyl-CoA hydrolase activity [GO:0052817]	cytosol [GO:0005829]; peroxisomal matrix [GO:0005782]; peroxisome [GO:0005777]
P56817	BACE1_HUMAN	Beta-secretase 1 (EC 3.4.23.46) (Aspartyl protease 2) (ASP2) (Asp 2) (Beta-site amyloid precursor protein cleaving enzyme 1) (Beta-site APP cleaving enzyme 1) (Memapsin-2) (Membrane-associated aspartic protease 2)	BACE1 BACE KIAA1149	1FKN;1M4H;1PY1;1SGZ;1TQF;1UJJ;1UJK;1W50;1W51;1XN2;1XN3;1XS7;1YM2;1YM4;2B8L;2B8V;2F3E;2F3F;2FDP;2G94;2HIZ;2HM1;2IQG;2IRZ;2IS0;2NTR;2OAH;2OF0;2OHK;2OHL;2OHM;2OHN;2OHP;2OHQ;2OHR;2OHS;2OHT;2OHU;2P4J;2P83;2P8H;2PH6;2PH8;2Q11;2Q15;2QK5;2QMD;2QMF;2QMG;2QP8;2QU2;2QU3;2QZK;2QZL;2VA5;2VA6;2VA7;2VIE;2VIJ;2VIY;2VIZ;2VJ6;2VJ7;2VJ9;2VKM;2VNM;2VNN;2WEZ;2WF0;2WF1;2WF2;2WF3;2WF4;2WJO;2XFI;2XFJ;2XFK;2ZDZ;2ZE1;2ZHR;2ZHS;2ZHT;2ZHU;2ZHV;2ZJH;2ZJI;2ZJJ;2ZJK;2ZJL;2ZJM;2ZJN;3BRA;3BUF;3BUG;3BUH;3CIB;3CIC;3CID;3CKP;3CKR;3DM6;3DUY;3DV1;3DV5;3EXO;3FKT;3H0B;3HVG;3HW1;3I25;3IGB;3IN3;3IN4;3IND;3INE;3INF;3INH;3IVH;3IVI;3IXJ;3IXK;3K5C;3K5D;3K5F;3K5G;3KMX;3KMY;3KN0;3KYR;3L38;3L3A;3L58;3L59;3L5B;3L5C;3L5D;3L5E;3L5F;3LHG;3LNK;3LPI;3LPJ;3LPK;3MSJ;3MSK;3MSL;3N4L;3NSH;3OHF;3OHH;3OOZ;3PI5;3QBH;3QI1;3R1G;3R2F;3RSV;3RSX;3RTH;3RTM;3RTN;3RU1;3RVI;3S2O;3S7L;3S7M;3SKF;3SKG;3TPJ;3TPL;3TPP;3TPR;3U6A;3UDH;3UDJ;3UDK;3UDM;3UDN;3UDP;3UDQ;3UDR;3UDY;3UFL;3UQP;3UQR;3UQU;3UQW;3UQX;3VEU;3VF3;3VG1;3VV6;3VV7;3VV8;3WB4;3WB5;3ZMG;3ZOV;4ACU;4ACX;4AZY;4B00;4B05;4B0Q;4B1C;4B1D;4B1E;4B70;4B72;4B77;4B78;4BEK;4BFD;4D83;4D85;4D88;4D89;4D8C;4DH6;4DI2;4DJU;4DJV;4DJW;4DJX;4DJY;4DPF;4DPI;4DUS;4DV9;4DVF;4EWO;4EXG;4FCO;4FGX;4FM7;4FM8;4FRI;4FRJ;4FRK;4FRS;4FS4;4FSE;4FSL;4GID;4GMI;4H1E;4H3F;4H3G;4H3I;4H3J;4HA5;4HZT;4I0D;4I0E;4I0F;4I0G;4I0H;4I0I;4I0J;4I0Z;4I10;4I11;4I12;4I1C;4IVS;4IVT;4J0P;4J0T;4J0V;4J0Y;4J0Z;4J17;4J1C;4J1E;4J1F;4J1H;4J1I;4J1K;4JOO;4JP9;4JPC;4JPE;4K8S;4K9H;4KE0;4KE1;4L7G;4L7H;4L7J;4LC7;4LXA;4LXK;4LXM;4N00;4PZW;4PZX;4R5N;4R8Y;4R91;4R92;4R93;4R95;4RCD;4RCE;4RCF;4RRN;4RRO;4RRS;4TRW;4TRY;4TRZ;4WTU;4WY1;4WY6;4X2L;4X7I;4XKX;4XXS;4YBI;4ZPE;4ZPF;4ZPG;4ZSM;4ZSP;4ZSQ;4ZSR;5CLM;5DQC;5ENK;5EZX;5EZZ;5F00;5F01;5HD0;5HDU;5HDV;5HDX;5HDZ;5HE4;5HE5;5HE7;5I3V;5I3W;5I3X;5I3Y;5IE1;5KQF;5KR8;	CHEMBL4822;	P56817;			PF00026;	IPR001461;IPR001969;IPR009119;IPR009120;IPR033121;IPR021109;	beta-amyloid metabolic process [GO:0050435]; cellular protein metabolic process [GO:0044267]; membrane protein ectodomain proteolysis [GO:0006509]; protein catabolic process [GO:0030163]; proteolysis [GO:0006508]	aspartic-type endopeptidase activity [GO:0004190]; beta-amyloid binding [GO:0001540]; beta-aspartyl-peptidase activity [GO:0008798]; enzyme binding [GO:0019899]; peptidase activity [GO:0008233]	axon [GO:0030424]; cell surface [GO:0009986]; cytoplasmic vesicle membrane [GO:0030659]; endoplasmic reticulum lumen [GO:0005788]; endosome [GO:0005768]; endosome membrane [GO:0010008]; Golgi apparatus [GO:0005794]; Golgi-associated vesicle lumen [GO:0070931]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; late endosome [GO:0005770]; membrane raft [GO:0045121]; multivesicular body [GO:0005771]; plasma membrane [GO:0005886]; trans-Golgi network [GO:0005802]
P82251	BAT1_HUMAN	b(0,+)-type amino acid transporter 1 (b(0,+)AT1) (Glycoprotein-associated amino acid transporter b0,+AT1) (Solute carrier family 7 member 9)	SLC7A9 BAT1				DB00138;		PF13520;	IPR002293;	amino acid transport [GO:0006865]; L-cystine transport [GO:0015811]; leukocyte migration [GO:0050900]; neutral amino acid transport [GO:0015804]; protein complex assembly [GO:0006461]	antiporter activity [GO:0015297]; L-cystine transmembrane transporter activity [GO:0015184]; neutral amino acid transmembrane transporter activity [GO:0015175]; peptide antigen binding [GO:0042605]	apical plasma membrane [GO:0016324]; brush border membrane [GO:0031526]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P56945	BCAR1_HUMAN	Breast cancer anti-estrogen resistance protein 1 (CRK-associated substrate) (Cas scaffolding protein family member 1) (p130cas)	BCAR1 CAS CASS1 CRKAS	1WYX;3T6G;					PF12026;PF08824;PF00018;	IPR028848;IPR021901;IPR014928;IPR001452;IPR013315;	actin filament organization [GO:0007015]; antigen receptor-mediated signaling pathway [GO:0050851]; B cell receptor signaling pathway [GO:0050853]; cell adhesion [GO:0007155]; cell chemotaxis [GO:0060326]; cell division [GO:0051301]; cell migration [GO:0016477]; cell proliferation [GO:0008283]; cellular response to hepatocyte growth factor stimulus [GO:0035729]; epidermal growth factor receptor signaling pathway [GO:0007173]; G-protein coupled receptor signaling pathway [GO:0007186]; hepatocyte growth factor receptor signaling pathway [GO:0048012]; insulin receptor signaling pathway [GO:0008286]; integrin-mediated signaling pathway [GO:0007229]; neurotrophin TRK receptor signaling pathway [GO:0048011]; platelet-derived growth factor receptor signaling pathway [GO:0048008]; positive regulation of cell migration [GO:0030335]; positive regulation of endothelial cell migration [GO:0010595]; regulation of apoptotic process [GO:0042981]; regulation of cell growth [GO:0001558]; T cell receptor signaling pathway [GO:0050852]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]	protein kinase binding [GO:0019901]; signal transducer activity [GO:0004871]	actin cytoskeleton [GO:0015629]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; focal adhesion [GO:0005925]; lamellipodium [GO:0030027]; nucleolus [GO:0005730]; plasma membrane [GO:0005886]; ruffle [GO:0001726]
P54687	BCAT1_HUMAN	Branched-chain-amino-acid aminotransferase, cytosolic (BCAT(c)) (EC 2.6.1.42) (Protein ECA39)	BCAT1 BCT1 ECA39	2ABJ;2COG;2COI;2COJ;	CHEMBL4679;	P54687;	DB00996;DB00167;DB00149;DB00161;		PF01063;	IPR001544;IPR018300;IPR005786;	aspartate biosynthetic process [GO:0006532]; branched-chain amino acid biosynthetic process [GO:0009082]; branched-chain amino acid catabolic process [GO:0009083]; cell proliferation [GO:0008283]; G1/S transition of mitotic cell cycle [GO:0000082]; leucine biosynthetic process [GO:0009098]; valine biosynthetic process [GO:0009099]	branched-chain-amino-acid transaminase activity [GO:0004084]; L-isoleucine transaminase activity [GO:0052656]; L-leucine transaminase activity [GO:0052654]; L-valine transaminase activity [GO:0052655]; pyridoxal phosphate binding [GO:0030170]	cytosol [GO:0005829]; mitochondrion [GO:0005739]
O15382	BCAT2_HUMAN	Branched-chain-amino-acid aminotransferase, mitochondrial (BCAT(m)) (EC 2.6.1.42) (Placental protein 18) (PP18)	BCAT2 BCATM BCT2 ECA40	1EKF;1EKP;1EKV;1KT8;1KTA;2A1H;2HDK;2HG8;2HGW;2HGX;2HHF;5BWR;5BWT;5BWU;5BWV;5BWW;5BWX;5CR5;5HNE;5I5S;5I5T;5I5U;5I5V;5I5W;5I5X;5I5Y;5I60;			DB00167;DB00149;		PF01063;	IPR001544;IPR018300;IPR005786;	aspartate biosynthetic process [GO:0006532]; branched-chain amino acid biosynthetic process [GO:0009082]; branched-chain amino acid catabolic process [GO:0009083]; isoleucine catabolic process [GO:0006550]; leucine biosynthetic process [GO:0009098]; regulation of hormone levels [GO:0010817]; valine biosynthetic process [GO:0009099]	branched-chain-amino-acid transaminase activity [GO:0004084]; L-isoleucine transaminase activity [GO:0052656]; L-leucine transaminase activity [GO:0052654]; L-valine transaminase activity [GO:0052655]; pyridoxal phosphate binding [GO:0030170]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
P10415	BCL2_HUMAN	Apoptosis regulator Bcl-2	BCL2	1G5M;1GJH;1YSW;2O21;2O22;2O2F;2W3L;2XA0;4AQ3;4IEH;4LVT;4LXD;4MAN;5AGW;5AGX;5FCG;	CHEMBL4860;	P10415;	DB01248;DB01050;DB01229;DB01367;		PF00452;PF02180;	IPR013278;IPR002475;IPR004725;IPR020717;IPR020726;IPR020728;IPR003093;IPR020731;IPR026298;	actin filament organization [GO:0007015]; apoptotic process [GO:0006915]; axonogenesis [GO:0007409]; axon regeneration [GO:0031103]; B cell homeostasis [GO:0001782]; B cell lineage commitment [GO:0002326]; B cell proliferation [GO:0042100]; B cell receptor signaling pathway [GO:0050853]; behavioral fear response [GO:0001662]; branching involved in ureteric bud morphogenesis [GO:0001658]; CD8-positive, alpha-beta T cell lineage commitment [GO:0043375]; cell aging [GO:0007569]; cell growth [GO:0016049]; cellular response to DNA damage stimulus [GO:0006974]; cellular response to glucose starvation [GO:0042149]; cellular response to hypoxia [GO:0071456]; cellular response to organic substance [GO:0071310]; cochlear nucleus development [GO:0021747]; defense response to virus [GO:0051607]; digestive tract morphogenesis [GO:0048546]; ear development [GO:0043583]; endoplasmic reticulum calcium ion homeostasis [GO:0032469]; extrinsic apoptotic signaling pathway in absence of ligand [GO:0097192]; extrinsic apoptotic signaling pathway via death domain receptors [GO:0008625]; female pregnancy [GO:0007565]; focal adhesion assembly [GO:0048041]; gland morphogenesis [GO:0022612]; glomerulus development [GO:0032835]; hair follicle morphogenesis [GO:0031069]; homeostasis of number of cells within a tissue [GO:0048873]; humoral immune response [GO:0006959]; intrinsic apoptotic signaling pathway in response to DNA damage [GO:0008630]; intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress [GO:0070059]; intrinsic apoptotic signaling pathway in response to oxidative stress [GO:0008631]; lymphoid progenitor cell differentiation [GO:0002320]; male gonad development [GO:0008584]; melanin metabolic process [GO:0006582]; melanocyte differentiation [GO:0030318]; mesenchymal cell development [GO:0014031]; metanephros development [GO:0001656]; negative regulation of anoikis [GO:2000811]; negative regulation of apoptotic process [GO:0043066]; negative regulation of apoptotic signaling pathway [GO:2001234]; negative regulation of autophagy [GO:0010507]; negative regulation of calcium ion transport into cytosol [GO:0010523]; negative regulation of cell growth [GO:0030308]; negative regulation of cell migration [GO:0030336]; negative regulation of cellular pH reduction [GO:0032848]; negative regulation of extrinsic apoptotic signaling pathway in absence of ligand [GO:2001240]; negative regulation of G1/S transition of mitotic cell cycle [GO:2000134]; negative regulation of intrinsic apoptotic signaling pathway [GO:2001243]; negative regulation of mitochondrial depolarization [GO:0051902]; negative regulation of myeloid cell apoptotic process [GO:0033033]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of ossification [GO:0030279]; negative regulation of osteoblast proliferation [GO:0033689]; negative regulation of reactive oxygen species metabolic process [GO:2000378]; negative regulation of retinal cell programmed cell death [GO:0046671]; neuron apoptotic process [GO:0051402]; oocyte development [GO:0048599]; organ growth [GO:0035265]; ossification [GO:0001503]; ovarian follicle development [GO:0001541]; peptidyl-serine phosphorylation [GO:0018105]; peptidyl-threonine phosphorylation [GO:0018107]; pigment granule organization [GO:0048753]; positive regulation of B cell proliferation [GO:0030890]; positive regulation of catalytic activity [GO:0043085]; positive regulation of cell growth [GO:0030307]; positive regulation of intrinsic apoptotic signaling pathway [GO:2001244]; positive regulation of melanocyte differentiation [GO:0045636]; positive regulation of multicellular organism growth [GO:0040018]; positive regulation of neuron maturation [GO:0014042]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway [GO:1900740]; positive regulation of skeletal muscle fiber development [GO:0048743]; positive regulation of smooth muscle cell migration [GO:0014911]; post-embryonic development [GO:0009791]; protein dephosphorylation [GO:0006470]; protein polyubiquitination [GO:0000209]; reactive oxygen species metabolic process [GO:0072593]; regulation of calcium ion transport [GO:0051924]; regulation of cell-matrix adhesion [GO:0001952]; regulation of gene expression [GO:0010468]; regulation of glycoprotein biosynthetic process [GO:0010559]; regulation of mitochondrial membrane permeability [GO:0046902]; regulation of mitochondrial membrane potential [GO:0051881]; regulation of nitrogen utilization [GO:0006808]; regulation of protein heterodimerization activity [GO:0043497]; regulation of protein homodimerization activity [GO:0043496]; regulation of protein stability [GO:0031647]; regulation of transmembrane transporter activity [GO:0022898]; regulation of viral genome replication [GO:0045069]; release of cytochrome c from mitochondria [GO:0001836]; renal system process [GO:0003014]; response to cytokine [GO:0034097]; response to drug [GO:0042493]; response to gamma radiation [GO:0010332]; response to glucocorticoid [GO:0051384]; response to hydrogen peroxide [GO:0042542]; response to iron ion [GO:0010039]; response to ischemia [GO:0002931]; response to nicotine [GO:0035094]; response to radiation [GO:0009314]; response to toxic substance [GO:0009636]; response to UV-B [GO:0010224]; spleen development [GO:0048536]; T cell differentiation in thymus [GO:0033077]; T cell homeostasis [GO:0043029]; thymus development [GO:0048538]	BH3 domain binding [GO:0051434]; channel activity [GO:0015267]; channel inhibitor activity [GO:0016248]; protease binding [GO:0002020]; protein heterodimerization activity [GO:0046982]; protein homodimerization activity [GO:0042803]; sequence-specific DNA binding [GO:0043565]; ubiquitin protein ligase binding [GO:0031625]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; membrane [GO:0016020]; mitochondrial outer membrane [GO:0005741]; mitochondrion [GO:0005739]; myelin sheath [GO:0043209]; nuclear membrane [GO:0031965]; nucleus [GO:0005634]; pore complex [GO:0046930]
Q02338	BDH_HUMAN	D-beta-hydroxybutyrate dehydrogenase, mitochondrial (EC 1.1.1.30) (3-hydroxybutyrate dehydrogenase) (BDH) (Short chain dehydrogenase/reductase family 9C member 1)	BDH1 BDH SDR9C1						PF00106;	IPR016040;IPR020904;IPR002347;	ketone body biosynthetic process [GO:0046951]; ketone body catabolic process [GO:0046952]	3-hydroxybutyrate dehydrogenase activity [GO:0003858]	cytoplasm [GO:0005737]; matrix side of mitochondrial inner membrane [GO:0099617]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]
P08236	BGLR_HUMAN	Beta-glucuronidase (EC 3.2.1.31) (Beta-G1)	GUSB	1BHG;3HN3;	CHEMBL2728;	P08236;			PF00703;PF02836;PF02837;	IPR008979;IPR006101;IPR013812;IPR023232;IPR006103;IPR023230;IPR006102;IPR006104;IPR013781;IPR017853;	carbohydrate metabolic process [GO:0005975]; glycosaminoglycan catabolic process [GO:0006027]; hyaluronan catabolic process [GO:0030214]	beta-glucuronidase activity [GO:0004566]; protein domain specific binding [GO:0019904]; receptor binding [GO:0005102]	extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; intracellular membrane-bounded organelle [GO:0043231]; lysosomal lumen [GO:0043202]; membrane [GO:0016020]
Q9H2M3	BHMT2_HUMAN	S-methylmethionine--homocysteine S-methyltransferase BHMT2 (SMM-hcy methyltransferase) (EC 2.1.1.10) (Betaine--homocysteine S-methyltransferase 2)	BHMT2		CHEMBL2163167;	Q9H2M3;	DB00134;	PATHWAY: Amino-acid biosynthesis; L-methionine biosynthesis via de novo pathway; L-methionine from L-homocysteine (BhmT route): step 1/1.	PF02574;	IPR017226;IPR003726;	L-methionine salvage [GO:0071267]; S-adenosylmethionine metabolic process [GO:0046500]; S-methylmethionine metabolic process [GO:0033477]; sulfur amino acid metabolic process [GO:0000096]	S-methylmethionine-homocysteine S-methyltransferase activity [GO:0061627]; zinc ion binding [GO:0008270]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]
Q93088	BHMT_HUMAN	Betaine--homocysteine S-methyltransferase 1 (EC 2.1.1.5)	BHMT	1LT7;1LT8;4M3P;	CHEMBL4328;	Q93088;	DB00134;	PATHWAY: Amine and polyamine degradation; betaine degradation; sarcosine from betaine: step 1/2.; PATHWAY: Amino-acid biosynthesis; L-methionine biosynthesis via de novo pathway; L-methionine from L-homocysteine (BhmT route): step 1/1.	PF02574;	IPR017226;IPR003726;	amino-acid betaine catabolic process [GO:0006579]; amino-acid betaine metabolic process [GO:0006577]; choline catabolic process [GO:0042426]; L-methionine salvage [GO:0071267]; protein methylation [GO:0006479]; regulation of homocysteine metabolic process [GO:0050666]; sulfur amino acid metabolic process [GO:0000096]	betaine-homocysteine S-methyltransferase activity [GO:0047150]; S-adenosylmethionine-homocysteine S-methyltransferase activity [GO:0008898]; zinc ion binding [GO:0008270]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P53004	BIEA_HUMAN	Biliverdin reductase A (BVR A) (EC 1.3.1.24) (Biliverdin-IX alpha-reductase)	BLVRA BLVR BVR	2H63;				PATHWAY: Porphyrin-containing compound metabolism; protoheme degradation.	PF09166;PF01408;	IPR017094;IPR015249;IPR016040;IPR000683;	heme catabolic process [GO:0042167]; oxidation-reduction process [GO:0055114]	biliverdin reductase activity [GO:0004074]; zinc ion binding [GO:0008270]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P98170	BIRC4_HUMAN	E3 ubiquitin-protein ligase XIAP (EC 6.3.2.-) (Baculoviral IAP repeat-containing protein 4) (IAP-like protein) (ILP) (hILP) (Inhibitor of apoptosis protein 3) (IAP-3) (hIAP-3) (hIAP3) (X-linked inhibitor of apoptosis protein) (X-linked IAP)	XIAP API3 BIRC4 IAP3	1C9Q;1F9X;1G3F;1G73;1I3O;1I4O;1I51;1KMC;1NW9;1TFQ;1TFT;2ECG;2JK7;2KNA;2OPY;2OPZ;2POI;2POP;2QRA;2VSL;3CLX;3CM2;3CM7;3EYL;3G76;3HL5;3UW4;3UW5;4EC4;4HY0;4IC2;4IC3;4J3Y;4J44;4J45;4J46;4J47;4J48;4KJU;4KJV;4KMP;4MTZ;4OXC;4WVS;4WVT;4WVU;5C0K;5C0L;5C3H;5C3K;5C7A;5C7B;5C7C;5C7D;5C83;5C84;	CHEMBL4198;	P98170;			PF00653;	IPR001370;IPR001841;	cellular response to DNA damage stimulus [GO:0006974]; copper ion homeostasis [GO:0055070]; inhibition of cysteine-type endopeptidase activity involved in apoptotic process [GO:1990001]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154]; positive regulation of canonical Wnt signaling pathway [GO:0090263]; positive regulation of protein linear polyubiquitination [GO:1902530]; positive regulation of protein ubiquitination [GO:0031398]; regulation of BMP signaling pathway [GO:0030510]; regulation of cell proliferation [GO:0042127]; regulation of inflammatory response [GO:0050727]; regulation of innate immune response [GO:0045088]; regulation of nucleotide-binding oligomerization domain containing signaling pathway [GO:0070424]; Wnt signaling pathway [GO:0016055]	cysteine-type endopeptidase inhibitor activity involved in apoptotic process [GO:0043027]; ligase activity [GO:0016874]; ubiquitin protein ligase activity [GO:0061630]; ubiquitin-protein transferase activity [GO:0004842]; zinc ion binding [GO:0008270]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P30411	BKRB2_HUMAN	B2 bradykinin receptor (B2R) (BK-2 receptor)	BDKRB2 BKR2		CHEMBL3157;	P30411;	DB06196;		PF00001;	IPR001504;IPR000496;IPR000276;IPR017452;	arachidonic acid secretion [GO:0050482]; blood circulation [GO:0008015]; cell surface receptor signaling pathway [GO:0007166]; G-protein coupled receptor signaling pathway [GO:0007186]; inflammatory response [GO:0006954]; negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress by p53 class mediator [GO:1902239]; negative regulation of peptidyl-serine phosphorylation [GO:0033137]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; regulation of vascular permeability [GO:0043114]; regulation of vasoconstriction [GO:0019229]; response to salt stress [GO:0009651]; smooth muscle contraction [GO:0006939]; transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169]; vasoconstriction [GO:0042310]; vasodilation [GO:0042311]	bradykinin receptor activity [GO:0004947]; phosphatidylinositol phospholipase C activity [GO:0004435]; protease binding [GO:0002020]; protein heterodimerization activity [GO:0046982]; type 1 angiotensin receptor binding [GO:0031702]	endosome [GO:0005768]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P30043	BLVRB_HUMAN	Flavin reductase (NADPH) (FR) (EC 1.5.1.30) (Biliverdin reductase B) (BVR-B) (EC 1.3.1.24) (Biliverdin-IX beta-reductase) (Green heme-binding protein) (GHBP) (NADPH-dependent diaphorase) (NADPH-flavin reductase) (FLR)	BLVRB FLR	1HDO;1HE2;1HE3;1HE4;1HE5;			DB00140;		PF13460;	IPR016040;	heme catabolic process [GO:0042167]	biliverdin reductase activity [GO:0004074]; riboflavin reductase (NADPH) activity [GO:0042602]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleoplasm [GO:0005654]; plasma membrane [GO:0005886]
P12643	BMP2_HUMAN	Bone morphogenetic protein 2 (BMP-2) (Bone morphogenetic protein 2A) (BMP-2A)	BMP2 BMP2A	1ES7;1REU;1REW;2GOO;2H62;2H64;2QJ9;2QJA;2QJB;3BK3;3BMP;4MID;4N1D;4UHY;4UHZ;4UI0;4UI1;4UI2;	CHEMBL1926496;	P12643;			PF00019;PF00688;	IPR029034;IPR002405;IPR001839;IPR001111;IPR015615;IPR017948;	activation of MAPK activity [GO:0000187]; animal organ morphogenesis [GO:0009887]; atrioventricular valve morphogenesis [GO:0003181]; BMP signaling pathway [GO:0030509]; BMP signaling pathway involved in heart induction [GO:0003130]; bone mineralization [GO:0030282]; bone mineralization involved in bone maturation [GO:0035630]; branching involved in ureteric bud morphogenesis [GO:0001658]; cardiac epithelial to mesenchymal transition [GO:0060317]; cardiac muscle cell differentiation [GO:0055007]; cardiac muscle tissue morphogenesis [GO:0055008]; cardiocyte differentiation [GO:0035051]; cell-cell signaling [GO:0007267]; cell fate commitment [GO:0045165]; cellular response to BMP stimulus [GO:0071773]; cellular response to organic cyclic compound [GO:0071407]; chondrocyte differentiation [GO:0002062]; corticotropin hormone secreting cell differentiation [GO:0060128]; embryo development [GO:0009790]; embryonic heart tube anterior/posterior pattern specification [GO:0035054]; endocardial cushion morphogenesis [GO:0003203]; epithelial to mesenchymal transition [GO:0001837]; growth [GO:0040007]; heart development [GO:0007507]; inflammatory response [GO:0006954]; inner ear development [GO:0048839]; in utero embryonic development [GO:0001701]; mesenchymal cell differentiation [GO:0048762]; mesenchymal cell proliferation involved in ureteric bud development [GO:0072138]; mesenchyme development [GO:0060485]; negative regulation of aldosterone biosynthetic process [GO:0032348]; negative regulation of calcium-independent cell-cell adhesion [GO:0051042]; negative regulation of canonical Wnt signaling pathway [GO:0090090]; negative regulation of cardiac muscle cell differentiation [GO:2000726]; negative regulation of cell cycle [GO:0045786]; negative regulation of cell proliferation [GO:0008285]; negative regulation of cortisol biosynthetic process [GO:2000065]; negative regulation of insulin-like growth factor receptor signaling pathway [GO:0043569]; negative regulation of steroid biosynthetic process [GO:0010894]; negative regulation of transcription, DNA-templated [GO:0045892]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; negative regulation of Wnt signaling pathway involved in heart development [GO:0003308]; Notch signaling pathway [GO:0007219]; odontogenesis of dentin-containing tooth [GO:0042475]; osteoblast differentiation [GO:0001649]; pathway-restricted SMAD protein phosphorylation [GO:0060389]; pericardium development [GO:0060039]; positive regulation of apoptotic process [GO:0043065]; positive regulation of astrocyte differentiation [GO:0048711]; positive regulation of bone mineralization [GO:0030501]; positive regulation of cartilage development [GO:0061036]; positive regulation of cell migration [GO:0030335]; positive regulation of endothelial cell proliferation [GO:0001938]; positive regulation of epithelial to mesenchymal transition [GO:0010718]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of fat cell differentiation [GO:0045600]; positive regulation of gene expression [GO:0010628]; positive regulation of MAPK cascade [GO:0043410]; positive regulation of neuron differentiation [GO:0045666]; positive regulation of odontogenesis [GO:0042482]; positive regulation of ossification [GO:0045778]; positive regulation of osteoblast differentiation [GO:0045669]; positive regulation of osteoblast proliferation [GO:0033690]; positive regulation of p38MAPK cascade [GO:1900745]; positive regulation of pathway-restricted SMAD protein phosphorylation [GO:0010862]; positive regulation of phosphatase activity [GO:0010922]; positive regulation of pri-miRNA transcription from RNA polymerase II promoter [GO:1902895]; positive regulation of protein binding [GO:0032092]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus [GO:1901522]; positive regulation of Wnt signaling pathway [GO:0030177]; positive regulation of Wnt signaling pathway by BMP signaling pathway [GO:0060804]; protein destabilization [GO:0031648]; protein phosphorylation [GO:0006468]; proteoglycan metabolic process [GO:0006029]; regulation of odontogenesis of dentin-containing tooth [GO:0042487]; regulation of transcription, DNA-templated [GO:0006355]; response to hypoxia [GO:0001666]; skeletal system development [GO:0001501]; SMAD protein signal transduction [GO:0060395]; telencephalon development [GO:0021537]; telencephalon regionalization [GO:0021978]; thyroid-stimulating hormone-secreting cell differentiation [GO:0060129]	BMP receptor binding [GO:0070700]; co-receptor binding [GO:0039706]; cytokine activity [GO:0005125]; phosphatase activator activity [GO:0019211]; protein heterodimerization activity [GO:0046982]; receptor binding [GO:0005102]; retinol dehydrogenase activity [GO:0004745]; SMAD binding [GO:0046332]; transforming growth factor beta receptor binding [GO:0005160]	BMP receptor complex [GO:0070724]; cell surface [GO:0009986]; extracellular region [GO:0005576]; extracellular space [GO:0005615]
O75936	BODG_HUMAN	Gamma-butyrobetaine dioxygenase (EC 1.14.11.1) (Gamma-butyrobetaine hydroxylase) (Gamma-BBH) (Gamma-butyrobetaine,2-oxoglutarate dioxygenase)	BBOX1 BBH BBOX	3MS5;3N6W;3O2G;4BG1;4BGK;4BGM;4BHF;4BHG;4BHI;4C5W;4C8R;4CWD;	CHEMBL2163175;	O75936;	DB00139;DB00126;	PATHWAY: Amine and polyamine biosynthesis; carnitine biosynthesis.	PF06155;PF02668;	IPR010376;IPR012775;IPR003819;	carnitine biosynthetic process [GO:0045329]	gamma-butyrobetaine dioxygenase activity [GO:0008336]; iron ion binding [GO:0005506]; zinc ion binding [GO:0008270]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrion [GO:0005739]
P17213	BPI_HUMAN	Bactericidal permeability-increasing protein (BPI) (CAP 57)	BPI	1BP1;1EWF;					PF01273;PF02886;	IPR017943;IPR030181;IPR030675;IPR032942;IPR001124;IPR017954;IPR017942;	defense response to Gram-negative bacterium [GO:0050829]; immune response [GO:0006955]; negative regulation of interleukin-6 production [GO:0032715]; negative regulation of interleukin-8 production [GO:0032717]; negative regulation of macrophage activation [GO:0043031]; negative regulation of tumor necrosis factor production [GO:0032720]	lipopolysaccharide binding [GO:0001530]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; integral component of plasma membrane [GO:0005887]
P50747	BPL1_HUMAN	Biotin--protein ligase (EC 6.3.4.-) (Biotin apo-protein ligase) [Includes: Biotin--[methylmalonyl-CoA-carboxytransferase] ligase (EC 6.3.4.9); Biotin--[propionyl-CoA-carboxylase [ATP-hydrolyzing]] ligase (EC 6.3.4.10) (Holocarboxylase synthetase) (HCS); Biotin--[methylcrotonoyl-CoA-carboxylase] ligase (EC 6.3.4.11); Biotin--[acetyl-CoA-carboxylase] ligase (EC 6.3.4.15)]	HLCS		CHEMBL2062354;	P50747;	DB00121;		PF02237;PF03099;PF09825;	IPR019197;IPR004408;IPR003142;IPR004143;	biotin metabolic process [GO:0006768]; cell proliferation [GO:0008283]; histone biotinylation [GO:0071110]; histone modification [GO:0016570]; protein biotinylation [GO:0009305]; response to biotin [GO:0070781]	ATP binding [GO:0005524]; biotin-[acetyl-CoA-carboxylase] ligase activity [GO:0004077]; biotin-[methylcrotonoyl-CoA-carboxylase] ligase activity [GO:0004078]; biotin-[methylmalonyl-CoA-carboxytransferase] ligase activity [GO:0004079]; biotin-[propionyl-CoA-carboxylase (ATP-hydrolyzing)] ligase activity [GO:0004080]; biotin binding [GO:0009374]; biotin-protein ligase activity [GO:0018271]; enzyme binding [GO:0019899]	chromatin [GO:0000785]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrion [GO:0005739]; nuclear lamina [GO:0005652]; nuclear matrix [GO:0016363]
P15056	BRAF1_HUMAN	Serine/threonine-protein kinase B-raf (EC 2.7.11.1) (Proto-oncogene B-Raf) (p94) (v-Raf murine sarcoma viral oncogene homolog B1)	BRAF BRAF1 RAFB1	1UWH;1UWJ;2FB8;2L05;3C4C;3D4Q;3IDP;3II5;3NY5;3OG7;3PPJ;3PPK;3PRF;3PRI;3PSB;3PSD;3Q4C;3Q96;3SKC;3TV4;3TV6;4CQE;4DBN;4E26;4E4X;4EHE;4EHG;4FC0;4FK3;4G9C;4G9R;4H58;4JVG;4KSP;4KSQ;4MBJ;4MNE;4MNF;4PP7;4R5Y;4RZV;4RZW;4WO5;4XV1;4XV2;4XV3;4XV9;4YHT;5C9C;5CSW;5CSX;5CT7;5FD2;5HI2;5HID;5HIE;5ITA;5J18;5J2R;5JSM;5JT2;	CHEMBL5145;	P15056;	DB08912;DB08896;DB00398;DB08881;		PF00130;PF07714;PF02196;	IPR020454;IPR011009;IPR002219;IPR000719;IPR017441;IPR003116;IPR001245;IPR008271;IPR029071;	animal organ morphogenesis [GO:0009887]; CD4-positive, alpha-beta T cell differentiation [GO:0043367]; cellular response to calcium ion [GO:0071277]; cellular response to drug [GO:0035690]; establishment of protein localization to membrane [GO:0090150]; face development [GO:0060324]; glucose transport [GO:0015758]; head morphogenesis [GO:0060323]; long-term synaptic potentiation [GO:0060291]; MAPK cascade [GO:0000165]; myeloid progenitor cell differentiation [GO:0002318]; negative regulation of apoptotic process [GO:0043066]; negative regulation of endothelial cell apoptotic process [GO:2000352]; negative regulation of fibroblast migration [GO:0010764]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of synaptic vesicle exocytosis [GO:2000301]; positive regulation of axonogenesis [GO:0050772]; positive regulation of axon regeneration [GO:0048680]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of gene expression [GO:0010628]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of stress fiber assembly [GO:0051496]; positive regulation of substrate adhesion-dependent cell spreading [GO:1900026]; positive T cell selection [GO:0043368]; protein heterooligomerization [GO:0051291]; protein phosphorylation [GO:0006468]; regulation of cell proliferation [GO:0042127]; response to cAMP [GO:0051591]; response to peptide hormone [GO:0043434]; somatic stem cell population maintenance [GO:0035019]; thymus development [GO:0048538]; thyroid gland development [GO:0030878]; visual learning [GO:0008542]	ATP binding [GO:0005524]; calcium ion binding [GO:0005509]; identical protein binding [GO:0042802]; MAP kinase kinase kinase activity [GO:0004709]; protein kinase activity [GO:0004672]; protein serine/threonine kinase activity [GO:0004674]	cell body [GO:0044297]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; intracellular membrane-bounded organelle [GO:0043231]; mitochondrion [GO:0005739]; neuron projection [GO:0043005]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
Q10588	BST1_HUMAN	ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 (EC 3.2.2.6) (ADP-ribosyl cyclase 2) (Bone marrow stromal antigen 1) (BST-1) (Cyclic ADP-ribose hydrolase 2) (cADPr hydrolase 2) (CD antigen CD157)	BST1	1ISF;1ISG;1ISH;1ISI;1ISJ;1ISM;			DB02701;		PF02267;	IPR003193;IPR016040;	humoral immune response [GO:0006959]; multicellular organism development [GO:0007275]; positive regulation of B cell proliferation [GO:0030890]	NAD(P)+ nucleosidase activity [GO:0050135]; NAD+ nucleosidase activity [GO:0003953]; phosphorus-oxygen lyase activity [GO:0016849]; transferase activity [GO:0016740]	anchored component of membrane [GO:0031225]; extracellular exosome [GO:0070062]; extrinsic component of membrane [GO:0019898]; plasma membrane [GO:0005886]
Q06187	BTK_HUMAN	Tyrosine-protein kinase BTK (EC 2.7.10.2) (Agammaglobulinemia tyrosine kinase) (ATK) (B-cell progenitor kinase) (BPK) (Bruton tyrosine kinase)	BTK AGMX1 ATK BPK	1AWW;1AWX;1B55;1BTK;1BWN;1K2P;1QLY;2GE9;2Z0P;3GEN;3K54;3OCS;3OCT;3P08;3PIX;3PIY;3PIZ;3PJ1;3PJ2;3PJ3;4NWM;4OT5;4OT6;4OTF;4OTQ;4OTR;4RFY;4RFZ;4RG0;4RX5;4YHF;4Z3V;4ZLY;4ZLZ;5BPY;5BQ0;5FBN;5FBO;5JRS;5KUP;	CHEMBL5251;	Q06187;	DB09053;		PF00779;PF00169;PF07714;PF00017;PF00018;	IPR011009;IPR011993;IPR001849;IPR000719;IPR017441;IPR001245;IPR000980;IPR001452;IPR008266;IPR020635;IPR001562;	adaptive immune response [GO:0002250]; apoptotic signaling pathway [GO:0097190]; B cell activation [GO:0042113]; B cell receptor signaling pathway [GO:0050853]; calcium-mediated signaling [GO:0019722]; cell maturation [GO:0048469]; cellular response to molecule of fungal origin [GO:0071226]; cellular response to reactive oxygen species [GO:0034614]; Fc-epsilon receptor signaling pathway [GO:0038095]; histamine secretion by mast cell [GO:0002553]; I-kappaB kinase/NF-kappaB signaling [GO:0007249]; innate immune response [GO:0045087]; intracellular signal transduction [GO:0035556]; mesoderm development [GO:0007498]; MyD88-dependent toll-like receptor signaling pathway [GO:0002755]; negative regulation of cytokine production [GO:0001818]; peptidyl-tyrosine autophosphorylation [GO:0038083]; peptidyl-tyrosine phosphorylation [GO:0018108]; positive regulation of B cell differentiation [GO:0045579]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of type I hypersensitivity [GO:0001812]; positive regulation of type III hypersensitivity [GO:0001805]; protein phosphorylation [GO:0006468]; regulation of B cell apoptotic process [GO:0002902]; regulation of B cell cytokine production [GO:0002721]; regulation of cell proliferation [GO:0042127]; transcription, DNA-templated [GO:0006351]; transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169]	ATP binding [GO:0005524]; metal ion binding [GO:0046872]; non-membrane spanning protein tyrosine kinase activity [GO:0004715]; phosphatidylinositol-3,4,5-trisphosphate binding [GO:0005547]; protein tyrosine kinase activity [GO:0004713]	cytoplasm [GO:0005737]; cytoplasmic vesicle [GO:0031410]; cytosol [GO:0005829]; extrinsic component of cytoplasmic side of plasma membrane [GO:0031234]; intracellular membrane-bounded organelle [GO:0043231]; mast cell granule [GO:0042629]; membrane raft [GO:0045121]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]
P30536	BZRP_HUMAN	Translocator protein (Mitochondrial benzodiazepine receptor) (PKBS) (Peripheral-type benzodiazepine receptor) (PBR)	TSPO BZRP MBR		CHEMBL5742;	P30536;	DB01178;DB01068;DB00628;DB00829;DB00402;DB01544;DB01587;DB00186;DB00231;DB00897;DB00962;DB01198;		PF03073;	IPR030164;IPR004307;	adrenal gland development [GO:0030325]; aging [GO:0007568]; anion transport [GO:0006820]; apoptotic process [GO:0006915]; behavioral response to pain [GO:0048266]; cell proliferation [GO:0008283]; cellular hypotonic response [GO:0071476]; cellular response to lipopolysaccharide [GO:0071222]; cellular response to zinc ion [GO:0071294]; chloride transport [GO:0006821]; contact inhibition [GO:0060242]; glial cell migration [GO:0008347]; heme biosynthetic process [GO:0006783]; lipid transport [GO:0006869]; maintenance of protein location in mitochondrion [GO:0072656]; negative regulation of ATP metabolic process [GO:1903579]; negative regulation of glial cell proliferation [GO:0060253]; negative regulation of mitophagy [GO:1903147]; negative regulation of nitric oxide biosynthetic process [GO:0045019]; negative regulation of protein ubiquitination [GO:0031397]; negative regulation of tumor necrosis factor production [GO:0032720]; peripheral nervous system axon regeneration [GO:0014012]; positive regulation of apoptotic process [GO:0043065]; positive regulation of calcium ion transport [GO:0051928]; positive regulation of glial cell proliferation [GO:0060252]; positive regulation of mitochondrial depolarization [GO:0051901]; positive regulation of necrotic cell death [GO:0010940]; positive regulation of reactive oxygen species metabolic process [GO:2000379]; protein targeting to mitochondrion [GO:0006626]; regulation of cholesterol transport [GO:0032374]; regulation of steroid biosynthetic process [GO:0050810]; response to drug [GO:0042493]; response to manganese ion [GO:0010042]; response to progesterone [GO:0032570]; response to testosterone [GO:0033574]; response to vitamin B1 [GO:0010266]; steroid biosynthetic process [GO:0006694]; steroid metabolic process [GO:0008202]	androgen binding [GO:0005497]; benzodiazepine receptor activity [GO:0008503]; cholesterol binding [GO:0015485]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; intracellular membrane-bounded organelle [GO:0043231]; mitochondrial outer membrane [GO:0005741]; mitochondrion [GO:0005739]; nuclear membrane [GO:0031965]
P15538	C11B1_HUMAN	Cytochrome P450 11B1, mitochondrial (CYPXIB1) (Cytochrome P-450c11) (Cytochrome P450C11) (Steroid 11-beta-hydroxylase) (EC 1.14.15.4)	CYP11B1 S11BH		CHEMBL1908;	P15538;	DB00501;DB00257;DB00292;DB00196;DB00741;DB01026;DB01233;DB01011;DB01110;DB00648;DB00252;DB00421;		PF00067;	IPR001128;IPR017972;IPR002399;	aldosterone biosynthetic process [GO:0032342]; C21-steroid hormone biosynthetic process [GO:0006700]; cellular response to hormone stimulus [GO:0032870]; cellular response to peptide hormone stimulus [GO:0071375]; cellular response to potassium ion [GO:0035865]; cholesterol metabolic process [GO:0008203]; cortisol biosynthetic process [GO:0034651]; glucocorticoid biosynthetic process [GO:0006704]; glucose homeostasis [GO:0042593]; immune response [GO:0006955]; regulation of blood pressure [GO:0008217]; secondary metabolite biosynthetic process [GO:0044550]; sterol metabolic process [GO:0016125]	corticosterone 18-monooxygenase activity [GO:0047783]; heme binding [GO:0020037]; iron ion binding [GO:0005506]; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen [GO:0016709]; steroid 11-beta-monooxygenase activity [GO:0004507]	mitochondrial inner membrane [GO:0005743]; mitochondrion [GO:0005739]
P00736	C1R_HUMAN	Complement C1r subcomponent (EC 3.4.21.41) (Complement component 1 subcomponent r) [Cleaved into: Complement C1r subcomponent heavy chain; Complement C1r subcomponent light chain]	C1R	1APQ;1GPZ;1MD7;1MD8;2QY0;	CHEMBL4611;	P00736;	DB00054;DB00051;DB00092;DB00087;DB00074;DB00112;DB00002;DB00111;DB00095;DB00005;DB00056;DB00078;DB00075;DB00108;DB00110;DB00073;DB00081;DB00072;		PF00431;PF00084;PF00089;	IPR000859;IPR001881;IPR013032;IPR000742;IPR000152;IPR018097;IPR024175;IPR009003;IPR001314;IPR000436;IPR001254;IPR033116;	complement activation [GO:0006956]; complement activation, classical pathway [GO:0006958]; immune response [GO:0006955]; innate immune response [GO:0045087]	calcium ion binding [GO:0005509]; serine-type endopeptidase activity [GO:0004252]; serine-type peptidase activity [GO:0008236]	blood microparticle [GO:0072562]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]
P09871	C1S_HUMAN	Complement C1s subcomponent (EC 3.4.21.42) (C1 esterase) (Complement component 1 subcomponent s) [Cleaved into: Complement C1s subcomponent heavy chain; Complement C1s subcomponent light chain]	C1S	1ELV;1NZI;4J1Y;4LMF;4LOR;4LOS;4LOT;	CHEMBL3913;	P09871;	DB00054;DB00051;DB00074;DB00002;DB00005;DB00056;DB00078;DB00075;DB00073;DB00072;		PF00431;PF00084;PF00089;	IPR000859;IPR001881;IPR000152;IPR018097;IPR024175;IPR009003;IPR001314;IPR000436;IPR001254;IPR033116;	complement activation [GO:0006956]; complement activation, classical pathway [GO:0006958]; innate immune response [GO:0045087]	calcium ion binding [GO:0005509]; serine-type endopeptidase activity [GO:0004252]	blood microparticle [GO:0072562]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]
P11586	C1TC_HUMAN	C-1-tetrahydrofolate synthase, cytoplasmic (C1-THF synthase) [Cleaved into: C-1-tetrahydrofolate synthase, cytoplasmic, N-terminally processed] [Includes: Methylenetetrahydrofolate dehydrogenase (EC 1.5.1.5); Methenyltetrahydrofolate cyclohydrolase (EC 3.5.4.9); Formyltetrahydrofolate synthetase (EC 6.3.4.3)]	MTHFD1 MTHFC MTHFD	1A4I;1DIA;1DIB;1DIG;	CHEMBL2541;	P11586;	DB00116;	PATHWAY: One-carbon metabolism; tetrahydrofolate interconversion.	PF01268;PF00763;PF02882;	IPR000559;IPR020628;IPR016040;IPR027417;IPR000672;IPR020630;IPR020867;IPR020631;	10-formyltetrahydrofolate biosynthetic process [GO:0009257]; embryonic neurocranium morphogenesis [GO:0048702]; embryonic viscerocranium morphogenesis [GO:0048703]; folic acid metabolic process [GO:0046655]; heart development [GO:0007507]; histidine biosynthetic process [GO:0000105]; methionine biosynthetic process [GO:0009086]; methionine metabolic process [GO:0006555]; neural tube closure [GO:0001843]; neutrophil homeostasis [GO:0001780]; one-carbon metabolic process [GO:0006730]; purine nucleotide biosynthetic process [GO:0006164]; serine family amino acid biosynthetic process [GO:0009070]; serine family amino acid metabolic process [GO:0009069]; somite development [GO:0061053]; tetrahydrofolate interconversion [GO:0035999]; transsulfuration [GO:0019346]	ATP binding [GO:0005524]; formate-tetrahydrofolate ligase activity [GO:0004329]; methenyltetrahydrofolate cyclohydrolase activity [GO:0004477]; methylenetetrahydrofolate dehydrogenase (NAD+) activity [GO:0004487]; methylenetetrahydrofolate dehydrogenase (NADP+) activity [GO:0004488]; methylenetetrahydrofolate dehydrogenase [NAD(P)+] activity [GO:0004486]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; mitochondrion [GO:0005739]
Q99643	C560_HUMAN	Succinate dehydrogenase cytochrome b560 subunit, mitochondrial (Integral membrane protein CII-3) (QPs-1) (QPs1) (Succinate dehydrogenase complex subunit C) (Succinate-ubiquinone oxidoreductase cytochrome B large subunit) (CYBL)	SDHC CYB560 SDH3				DB00139;	PATHWAY: Carbohydrate metabolism; tricarboxylic acid cycle.	PF01127;	IPR018495;IPR014314;IPR000701;	aerobic respiration [GO:0009060]; mitochondrial electron transport, succinate to ubiquinone [GO:0006121]; oxidation-reduction process [GO:0055114]; tricarboxylic acid cycle [GO:0006099]	electron carrier activity [GO:0009055]; heme binding [GO:0020037]; metal ion binding [GO:0046872]; succinate dehydrogenase activity [GO:0000104]	integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone) [GO:0005749]; mitochondrion [GO:0005739]; respiratory chain complex II [GO:0045273]
O00555	CAC1A_HUMAN	Voltage-dependent P/Q-type calcium channel subunit alpha-1A (Brain calcium channel I) (BI) (Calcium channel, L type, alpha-1 polypeptide isoform 4) (Voltage-gated calcium channel subunit alpha Cav2.1)	CACNA1A CACH4 CACN3 CACNL1A4	3BXK;	CHEMBL4266;	O00555;	DB01244;DB00836;DB00230;DB00421;DB00661;		PF08763;PF16905;PF00520;	IPR005448;IPR027359;IPR031649;IPR005821;IPR014873;IPR002077;	adult walking behavior [GO:0007628]; behavioral response to pain [GO:0048266]; calcium ion-regulated exocytosis of neurotransmitter [GO:0048791]; cell death [GO:0008219]; cell growth [GO:0016049]; cellular chloride ion homeostasis [GO:0030644]; cerebellar molecular layer development [GO:0021679]; cerebellar Purkinje cell differentiation [GO:0021702]; cerebellum maturation [GO:0021590]; dendrite morphogenesis [GO:0048813]; gamma-aminobutyric acid secretion [GO:0014051]; gamma-aminobutyric acid signaling pathway [GO:0007214]; glucose metabolic process [GO:0006006]; hormone metabolic process [GO:0042445]; membrane depolarization [GO:0051899]; membrane depolarization during action potential [GO:0086010]; musculoskeletal movement, spinal reflex action [GO:0050883]; negative regulation of hormone biosynthetic process [GO:0032353]; negative regulation of neuron apoptotic process [GO:0043524]; neuromuscular process controlling balance [GO:0050885]; neuromuscular synaptic transmission [GO:0007274]; neurotransmitter metabolic process [GO:0042133]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; receptor clustering [GO:0043113]; regulation of acetylcholine secretion, neurotransmission [GO:0014056]; regulation of axonogenesis [GO:0050770]; regulation of calcium ion-dependent exocytosis [GO:0017158]; regulation of insulin secretion [GO:0050796]; rhythmic synaptic transmission [GO:0060024]; spinal cord motor neuron differentiation [GO:0021522]; sulfur amino acid metabolic process [GO:0000096]; synapse assembly [GO:0007416]; synaptic transmission, glutamatergic [GO:0035249]; transmission of nerve impulse [GO:0019226]; vestibular nucleus development [GO:0021750]	calcium channel activity [GO:0005262]; high voltage-gated calcium channel activity [GO:0008331]; metal ion binding [GO:0046872]; syntaxin binding [GO:0019905]; voltage-gated calcium channel activity [GO:0005245]	cell projection [GO:0042995]; cytoplasm [GO:0005737]; dendrite [GO:0030425]; integral component of membrane [GO:0016021]; neuronal cell body [GO:0043025]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; presynapse [GO:0098793]; voltage-gated calcium channel complex [GO:0005891]
Q00975	CAC1B_HUMAN	Voltage-dependent N-type calcium channel subunit alpha-1B (Brain calcium channel III) (BIII) (Calcium channel, L type, alpha-1 polypeptide isoform 5) (Voltage-gated calcium channel subunit alpha Cav2.2)	CACNA1B CACH5 CACNL1A5	2LCM;	CHEMBL4478;	Q00975;	DB00381;DB00996;DB01202;DB00421;DB00661;		PF08763;PF16905;PF00520;	IPR027359;IPR002048;IPR031649;IPR005821;IPR014873;IPR005447;IPR002077;	chemical synaptic transmission [GO:0007268]; locomotory behavior [GO:0007626]; membrane depolarization [GO:0051899]; membrane depolarization during action potential [GO:0086010]; neurotransmitter secretion [GO:0007269]; regulation of blood pressure [GO:0008217]; regulation of calcium ion transport [GO:0051924]; regulation of heart contraction [GO:0008016]; response to pain [GO:0048265]; transport [GO:0006810]	ATP binding [GO:0005524]; calcium channel activity [GO:0005262]; calcium ion binding [GO:0005509]; high voltage-gated calcium channel activity [GO:0008331]; protein C-terminus binding [GO:0008022]; voltage-gated calcium channel activity [GO:0005245]	dendrite [GO:0030425]; neuronal cell body [GO:0043025]; plasma membrane [GO:0005886]; presynapse [GO:0098793]; voltage-gated calcium channel complex [GO:0005891]
Q13936	CAC1C_HUMAN	Voltage-dependent L-type calcium channel subunit alpha-1C (Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle) (Voltage-gated calcium channel subunit alpha Cav1.2)	CACNA1C CACH2 CACN2 CACNL1A1 CCHL1A1	1T0J;2BE6;2F3Y;2F3Z;2LQC;3G43;3OXQ;	CHEMBL1940;	Q13936;	DB00381;DB00568;DB04920;DB04855;DB06751;DB00898;DB01023;DB00308;DB00270;DB00653;DB00622;DB01115;DB06712;DB00393;DB00401;DB01054;DB00421;DB00661;		PF08763;PF16885;PF16905;PF00520;	IPR031688;IPR027359;IPR031649;IPR005821;IPR014873;IPR005451;IPR005446;IPR002077;	calcium ion transmembrane transport [GO:0070588]; calcium ion transmembrane transport via high voltage-gated calcium channel [GO:0061577]; calcium ion transport into cytosol [GO:0060402]; calcium-mediated signaling using extracellular calcium source [GO:0035585]; camera-type eye development [GO:0043010]; cardiac conduction [GO:0061337]; cardiac muscle cell action potential involved in contraction [GO:0086002]; cell communication by electrical coupling involved in cardiac conduction [GO:0086064]; embryonic forelimb morphogenesis [GO:0035115]; heart development [GO:0007507]; immune system development [GO:0002520]; membrane depolarization during atrial cardiac muscle cell action potential [GO:0098912]; membrane depolarization during AV node cell action potential [GO:0086045]; membrane depolarization during cardiac muscle cell action potential [GO:0086012]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion [GO:0010881]; regulation of heart rate by cardiac conduction [GO:0086091]; regulation of insulin secretion [GO:0050796]; regulation of ventricular cardiac muscle cell action potential [GO:0098911]	alpha-actinin binding [GO:0051393]; calmodulin binding [GO:0005516]; high voltage-gated calcium channel activity [GO:0008331]; metal ion binding [GO:0046872]; voltage-gated calcium channel activity [GO:0005245]; voltage-gated calcium channel activity involved in AV node cell action potential [GO:0086056]; voltage-gated calcium channel activity involved in cardiac muscle cell action potential [GO:0086007]	cytoplasm [GO:0005737]; integral component of membrane [GO:0016021]; L-type voltage-gated calcium channel complex [GO:1990454]; plasma membrane [GO:0005886]; postsynaptic density [GO:0014069]; voltage-gated calcium channel complex [GO:0005891]; Z disc [GO:0030018]
Q01668	CAC1D_HUMAN	Voltage-dependent L-type calcium channel subunit alpha-1D (Calcium channel, L type, alpha-1 polypeptide, isoform 2) (Voltage-gated calcium channel subunit alpha Cav1.3)	CACNA1D CACH3 CACN4 CACNL1A2 CCHL1A2	3LV3;	CHEMBL4138;	Q01668;	DB00381;DB00568;DB04920;DB04855;DB00898;DB01023;DB00270;DB00622;DB01115;DB06712;DB00393;DB00401;DB01054;DB00421;DB00661;		PF08763;PF16885;PF16905;PF00520;	IPR031688;IPR027359;IPR031649;IPR005821;IPR005452;IPR014873;IPR005446;IPR002077;	adenylate cyclase-modulating G-protein coupled receptor signaling pathway [GO:0007188]; calcium ion import [GO:0070509]; calcium ion transmembrane transport [GO:0070588]; calcium ion transport [GO:0006816]; cardiac conduction [GO:0061337]; membrane depolarization during cardiac muscle cell action potential [GO:0086012]; membrane depolarization during SA node cell action potential [GO:0086046]; positive regulation of calcium ion transport [GO:0051928]; regulation of atrial cardiac muscle cell membrane repolarization [GO:0060372]; regulation of heart rate by cardiac conduction [GO:0086091]; regulation of insulin secretion [GO:0050796]; regulation of potassium ion transmembrane transport [GO:1901379]; regulation of potassium ion transmembrane transporter activity [GO:1901016]; sensory perception of sound [GO:0007605]	alpha-actinin binding [GO:0051393]; ankyrin binding [GO:0030506]; high voltage-gated calcium channel activity [GO:0008331]; metal ion binding [GO:0046872]; voltage-gated calcium channel activity [GO:0005245]; voltage-gated calcium channel activity involved in cardiac muscle cell action potential [GO:0086007]; voltage-gated calcium channel activity involved SA node cell action potential [GO:0086059]	L-type voltage-gated calcium channel complex [GO:1990454]; plasma membrane [GO:0005886]; voltage-gated calcium channel complex [GO:0005891]; Z disc [GO:0030018]
O60840	CAC1F_HUMAN	Voltage-dependent L-type calcium channel subunit alpha-1F (Voltage-gated calcium channel subunit alpha Cav1.4)	CACNA1F CACNAF1		CHEMBL5593;	O60840;	DB00568;DB04920;DB04855;DB00393;DB00421;DB00661;		PF08763;PF16885;PF16905;PF00520;	IPR031688;IPR027359;IPR031649;IPR005821;IPR014873;IPR030157;IPR005446;IPR002077;	cardiac conduction [GO:0061337]; detection of light stimulus involved in visual perception [GO:0050908]; membrane depolarization during action potential [GO:0086010]; regulation of T cell receptor signaling pathway [GO:0050856]; T cell homeostasis [GO:0043029]; visual perception [GO:0007601]	high voltage-gated calcium channel activity [GO:0008331]; metal ion binding [GO:0046872]; voltage-gated calcium channel activity [GO:0005245]	integral component of membrane [GO:0016021]; perikaryon [GO:0043204]; photoreceptor outer segment [GO:0001750]; plasma membrane [GO:0005886]; voltage-gated calcium channel complex [GO:0005891]
O43497	CAC1G_HUMAN	Voltage-dependent T-type calcium channel subunit alpha-1G (Cav3.1c) (NBR13) (Voltage-gated calcium channel subunit alpha Cav3.1)	CACNA1G KIAA1123		CHEMBL4641;	O43497;	DB00568;DB00593;DB04841;DB05246;DB00421;DB00347;DB00661;DB00909;		PF00520;	IPR027359;IPR005821;IPR005445;IPR030154;IPR002077;	AV node cell action potential [GO:0086016]; AV node cell to bundle of His cell signaling [GO:0086027]; calcium ion import [GO:0070509]; calcium ion transmembrane transport [GO:0070588]; chemical synaptic transmission [GO:0007268]; membrane depolarization during action potential [GO:0086010]; membrane depolarization during AV node cell action potential [GO:0086045]; membrane depolarization during SA node cell action potential [GO:0086046]; positive regulation of calcium ion-dependent exocytosis [GO:0045956]; regulation of atrial cardiac muscle cell membrane depolarization [GO:0060371]; regulation of heart rate by cardiac conduction [GO:0086091]; regulation of membrane potential [GO:0042391]; response to nickel cation [GO:0010045]; SA node cell action potential [GO:0086015]; SA node cell to atrial cardiac muscle cell signalling [GO:0086018]	low voltage-gated calcium channel activity [GO:0008332]; scaffold protein binding [GO:0097110]; voltage-gated calcium channel activity involved in AV node cell action potential [GO:0086056]; voltage-gated calcium channel activity involved SA node cell action potential [GO:0086059]	cytoplasm [GO:0005737]; plasma membrane [GO:0005886]; voltage-gated calcium channel complex [GO:0005891]
O95180	CAC1H_HUMAN	Voltage-dependent T-type calcium channel subunit alpha-1H (Low-voltage-activated calcium channel alpha1 3.2 subunit) (Voltage-gated calcium channel subunit alpha Cav3.2)	CACNA1H		CHEMBL1859;	O95180;	DB01118;DB01244;DB00568;DB01023;DB04841;DB00270;DB01115;DB01054;DB00421;DB00909;		PF00520;	IPR027359;IPR005821;IPR005445;IPR030160;	aldosterone biosynthetic process [GO:0032342]; calcium ion import [GO:0070509]; cellular response to hormone stimulus [GO:0032870]; cellular response to potassium ion [GO:0035865]; cortisol biosynthetic process [GO:0034651]; membrane depolarization during action potential [GO:0086010]; muscle contraction [GO:0006936]; muscle organ development [GO:0007517]; myoblast fusion [GO:0007520]; positive regulation of acrosome reaction [GO:2000344]; regulation of heart contraction [GO:0008016]; regulation of membrane potential [GO:0042391]; transport [GO:0006810]	low voltage-gated calcium channel activity [GO:0008332]; metal ion binding [GO:0046872]; scaffold protein binding [GO:0097110]	integral component of membrane [GO:0016021]; voltage-gated calcium channel complex [GO:0005891]
Q9P0X4	CAC1I_HUMAN	Voltage-dependent T-type calcium channel subunit alpha-1I (Voltage-gated calcium channel subunit alpha Cav3.3) (Ca(v)3.3)	CACNA1I KIAA1120		CHEMBL5558;	Q9P0X4;	DB00568;DB04841;DB00617;DB00421;DB00661;DB00909;		PF00520;	IPR030162;IPR027359;IPR005821;IPR005445;IPR002077;	calcium ion import [GO:0070509]; flagellated sperm motility [GO:0030317]; membrane depolarization during action potential [GO:0086010]; neuronal action potential [GO:0019228]; positive regulation of calcium ion-dependent exocytosis [GO:0045956]; signal transduction [GO:0007165]; sleep [GO:0030431]; transport [GO:0006810]	low voltage-gated calcium channel activity [GO:0008332]; voltage-gated calcium channel activity [GO:0005245]	plasma membrane [GO:0005886]; voltage-gated calcium channel complex [GO:0005891]
Q13698	CAC1S_HUMAN	Voltage-dependent L-type calcium channel subunit alpha-1S (Calcium channel, L type, alpha-1 polypeptide, isoform 3, skeletal muscle) (Voltage-gated calcium channel subunit alpha Cav1.1)	CACNA1S CACH1 CACN1 CACNL1A3	2VAY;	CHEMBL3805;	Q13698;	DB00381;DB00568;DB04920;DB04855;DB00898;DB01023;DB00270;DB00653;DB01115;DB06712;DB00393;DB00401;DB01054;DB00421;DB00661;		PF08763;PF16905;PF00520;	IPR027359;IPR031649;IPR005821;IPR014873;IPR005450;IPR005446;IPR002077;	calcium ion transport [GO:0006816]; cardiac conduction [GO:0061337]; membrane depolarization during action potential [GO:0086010]; muscle contraction [GO:0006936]	high voltage-gated calcium channel activity [GO:0008331]; metal ion binding [GO:0046872]; voltage-gated calcium channel activity [GO:0005245]	cytoplasm [GO:0005737]; I band [GO:0031674]; plasma membrane [GO:0005886]; T-tubule [GO:0030315]; voltage-gated calcium channel complex [GO:0005891]
P54289	CAC2D_HUMAN	Voltage-dependent calcium channel subunit alpha-2/delta-1 (Voltage-gated calcium channel subunit alpha-2/delta-1) [Cleaved into: Voltage-dependent calcium channel subunit alpha-2-1; Voltage-dependent calcium channel subunit delta-1]	CACNA2D1 CACNL2A CCHL2A MHS3		CHEMBL1919;	P54289;	DB00381;DB04838;DB01023;DB00996;DB00308;DB00270;DB00653;DB00622;DB01115;DB06712;DB00401;DB01054;DB00421;		PF08473;PF00092;PF08399;	IPR013680;IPR013608;IPR002035;	calcium ion transmembrane transport via high voltage-gated calcium channel [GO:0061577]; calcium ion transport [GO:0006816]; calcium ion transport into cytosol [GO:0060402]; cardiac conduction [GO:0061337]; cardiac muscle cell action potential involved in contraction [GO:0086002]; membrane depolarization during cardiac muscle cell action potential [GO:0086012]; positive regulation of high voltage-gated calcium channel activity [GO:1901843]; regulation of calcium ion transport [GO:0051924]; regulation of heart rate by cardiac conduction [GO:0086091]; regulation of membrane repolarization during action potential [GO:0098903]; regulation of ventricular cardiac muscle cell membrane repolarization [GO:0060307]	metal ion binding [GO:0046872]; voltage-gated calcium channel activity [GO:0005245]	extracellular exosome [GO:0070062]; L-type voltage-gated calcium channel complex [GO:1990454]; plasma membrane [GO:0005886]; sarcoplasmic reticulum [GO:0016529]; voltage-gated calcium channel complex [GO:0005891]
Q02641	CACB1_HUMAN	Voltage-dependent L-type calcium channel subunit beta-1 (CAB1) (Calcium channel voltage-dependent subunit beta 1)	CACNB1 CACNLB1		CHEMBL2363032;		DB04855;DB00898;DB00308;DB00653;DB00393;DB00421;DB00661;		PF00625;PF12052;	IPR008145;IPR027417;IPR001452;IPR005443;IPR000584;	cardiac conduction [GO:0061337]; chemical synaptic transmission [GO:0007268]; neuromuscular junction development [GO:0007528]; regulation of voltage-gated calcium channel activity [GO:1901385]; transport [GO:0006810]	high voltage-gated calcium channel activity [GO:0008331]; voltage-gated calcium channel activity [GO:0005245]	plasma membrane [GO:0005886]; sarcolemma [GO:0042383]; voltage-gated calcium channel complex [GO:0005891]
Q08289	CACB2_HUMAN	Voltage-dependent L-type calcium channel subunit beta-2 (CAB2) (Calcium channel voltage-dependent subunit beta 2) (Lambert-Eaton myasthenic syndrome antigen B) (MYSB)	CACNB2 CACNLB2 MYSB		CHEMBL3317336;		DB00381;DB04855;DB01023;DB00270;DB00653;DB00622;DB01115;DB06712;DB00393;DB00401;DB01054;DB00421;DB00661;		PF00625;PF12052;	IPR008145;IPR027417;IPR001452;IPR005444;IPR000584;	calcium ion import [GO:0070509]; cardiac conduction [GO:0061337]; chemical synaptic transmission [GO:0007268]; establishment of protein localization to plasma membrane [GO:0090002]; membrane depolarization during atrial cardiac muscle cell action potential [GO:0098912]; membrane depolarization during AV node cell action potential [GO:0086045]; neuromuscular junction development [GO:0007528]; positive regulation of calcium ion transmembrane transport via high voltage-gated calcium channel [GO:1904879]; positive regulation of calcium ion transport [GO:0051928]; positive regulation of high voltage-gated calcium channel activity [GO:1901843]; regulation of heart rate by cardiac conduction [GO:0086091]; regulation of voltage-gated calcium channel activity [GO:1901385]; visual perception [GO:0007601]	actin filament binding [GO:0051015]; calcium channel activity [GO:0005262]; voltage-gated calcium channel activity [GO:0005245]	integral component of plasma membrane [GO:0005887]; L-type voltage-gated calcium channel complex [GO:1990454]; plasma membrane [GO:0005886]; voltage-gated calcium channel complex [GO:0005891]
P54284	CACB3_HUMAN	Voltage-dependent L-type calcium channel subunit beta-3 (CAB3) (Calcium channel voltage-dependent subunit beta 3)	CACNB3 CACNLB3		CHEMBL2363032;		DB04855;DB00393;DB00421;DB00661;		PF00625;PF12052;	IPR008145;IPR027417;IPR001452;IPR008079;IPR000584;	calcium ion transmembrane transport via high voltage-gated calcium channel [GO:0061577]; calcium ion transport [GO:0006816]; calcium ion transport into cytosol [GO:0060402]; cardiac conduction [GO:0061337]; chemical synaptic transmission [GO:0007268]; membrane depolarization [GO:0051899]; neuromuscular junction development [GO:0007528]; protein localization to plasma membrane [GO:0072659]; regulation of membrane repolarization during action potential [GO:0098903]; regulation of voltage-gated calcium channel activity [GO:1901385]; T cell receptor signaling pathway [GO:0050852]; transport [GO:0006810]	calcium channel activity [GO:0005262]; high voltage-gated calcium channel activity [GO:0008331]; voltage-gated calcium channel activity [GO:0005245]	apical plasma membrane [GO:0016324]; cytosol [GO:0005829]; L-type voltage-gated calcium channel complex [GO:1990454]; membrane [GO:0016020]; plasma membrane [GO:0005886]; voltage-gated calcium channel complex [GO:0005891]
O00305	CACB4_HUMAN	Voltage-dependent L-type calcium channel subunit beta-4 (CAB4) (Calcium channel voltage-dependent subunit beta 4)	CACNB4 CACNLB4	1VYV;2D46;	CHEMBL2363032;		DB04855;DB00393;DB00421;DB00661;		PF00625;PF12052;	IPR008145;IPR027417;IPR001452;IPR000584;	calcium ion transmembrane transport [GO:0070588]; cardiac conduction [GO:0061337]; chemical synaptic transmission [GO:0007268]; membrane depolarization [GO:0051899]; neuromuscular junction development [GO:0007528]; regulation of voltage-gated calcium channel activity [GO:1901385]; transport [GO:0006810]	calcium channel activity [GO:0005262]; voltage-gated calcium channel activity [GO:0005245]	cytoplasmic side of plasma membrane [GO:0009898]; cytosol [GO:0005829]; plasma membrane [GO:0005886]; synapse [GO:0045202]; voltage-gated calcium channel complex [GO:0005891]
P43155	CACP_HUMAN	Carnitine O-acetyltransferase (Carnitine acetylase) (EC 2.3.1.7) (Carnitine acetyltransferase) (CAT) (CrAT)	CRAT CAT1	1NM8;1S5O;	CHEMBL3184;	P43155;	DB00583;		PF00755;	IPR000542;	carnitine metabolic process, CoA-linked [GO:0019254]; fatty acid beta-oxidation using acyl-CoA oxidase [GO:0033540]; transport [GO:0006810]	carnitine O-acetyltransferase activity [GO:0004092]; receptor binding [GO:0005102]	endoplasmic reticulum [GO:0005783]; mitochondrial inner membrane [GO:0005743]; mitochondrion [GO:0005739]; peroxisomal matrix [GO:0005782]; peroxisome [GO:0005777]
O43570	CAH12_HUMAN	Carbonic anhydrase 12 (EC 4.2.1.1) (Carbonate dehydratase XII) (Carbonic anhydrase XII) (CA-XII) (Tumor antigen HOM-RCC-3.1.3)	CA12	1JCZ;1JD0;4HT2;4KP5;4KP8;4Q0L;4QJ0;4QJO;4QJW;4WW8;	CHEMBL3242;	O43570;	DB00562;DB00999;DB00774;DB00909;		PF00194;	IPR001148;IPR023561;IPR018338;IPR018430;	bicarbonate transport [GO:0015701]; chloride ion homeostasis [GO:0055064]; one-carbon metabolic process [GO:0006730]	carbonate dehydratase activity [GO:0004089]; zinc ion binding [GO:0008270]	integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]
P00915	CAH1_HUMAN	Carbonic anhydrase 1 (EC 4.2.1.1) (Carbonate dehydratase I) (Carbonic anhydrase B) (CAB) (Carbonic anhydrase I) (CA-I)	CA1	1AZM;1BZM;1CRM;1CZM;1HCB;1HUG;1HUH;1J9W;1JV0;2CAB;2FOY;2FW4;2IT4;2NMX;2NN1;2NN7;3LXE;3W6H;3W6I;4WR7;4WUP;4WUQ;	CHEMBL261;	P00915;	DB00819;DB00381;DB00436;DB00562;DB01194;DB00880;DB00606;DB01119;DB01144;DB00869;DB01031;DB00999;DB00774;DB00703;DB00423;DB00232;DB01325;DB01021;DB00909;		PF00194;	IPR001148;IPR023561;IPR018338;IPR018442;	bicarbonate transport [GO:0015701]; one-carbon metabolic process [GO:0006730]	arylesterase activity [GO:0004064]; carbonate dehydratase activity [GO:0004089]; hydro-lyase activity [GO:0016836]; zinc ion binding [GO:0008270]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P00918	CAH2_HUMAN	Carbonic anhydrase 2 (EC 4.2.1.1) (Carbonate dehydratase II) (Carbonic anhydrase C) (CAC) (Carbonic anhydrase II) (CA-II)	CA2	12CA;1A42;1AM6;1AVN;1BCD;1BIC;1BN1;1BN3;1BN4;1BNM;1BNN;1BNQ;1BNT;1BNU;1BNV;1BNW;1BV3;1CA2;1CA3;1CAH;1CAI;1CAJ;1CAK;1CAL;1CAM;1CAN;1CAO;1CAY;1CAZ;1CCS;1CCT;1CCU;1CIL;1CIM;1CIN;1CNB;1CNC;1CNG;1CNH;1CNI;1CNJ;1CNK;1CNW;1CNX;1CNY;1CRA;1CVA;1CVB;1CVC;1CVD;1CVE;1CVF;1CVH;1DCA;1DCB;1EOU;1F2W;1FQL;1FQM;1FQN;1FQR;1FR4;1FR7;1FSN;1FSQ;1FSR;1G0E;1G0F;1G1D;1G3Z;1G45;1G46;1G48;1G4J;1G4O;1G52;1G53;1G54;1H4N;1H9N;1H9Q;1HCA;1HEA;1HEB;1HEC;1HED;1HVA;1I8Z;1I90;1I91;1I9L;1I9M;1I9N;1I9O;1I9P;1I9Q;1IF4;1IF5;1IF6;1IF7;1IF8;1IF9;1KWQ;1KWR;1LG5;1LG6;1LGD;1LUG;1LZV;1MOO;1MUA;1OKL;1OKM;1OKN;1OQ5;1RAY;1RAZ;1RZA;1RZB;1RZC;1RZD;1RZE;1T9N;1TB0;1TBT;1TE3;1TEQ;1TEU;1TG3;1TG9;1TH9;1THK;1TTM;1UGA;1UGB;1UGC;1UGD;1UGE;1UGF;1UGG;1XEG;1XEV;1XPZ;1XQ0;1YDA;1YDB;1YDC;1YDD;1YO0;1YO1;1YO2;1Z9Y;1ZE8;1ZFK;1ZFQ;1ZGE;1ZGF;1ZH9;1ZSA;1ZSB;1ZSC;2ABE;2AW1;2AX2;2CA2;2CBA;2CBB;2CBC;2CBD;2CBE;2EU2;2EU3;2EZ7;2F14;2FMG;2FMZ;2FNK;2FNM;2FNN;2FOQ;2FOS;2FOU;2FOV;2GD8;2GEH;2H15;2H4N;2HD6;2HKK;2HL4;2HNC;2HOC;2ILI;2NNG;2NNO;2NNS;2NNV;2NWO;2NWP;2NWY;2NWZ;2NXR;2NXS;2NXT;2O4Z;2OSF;2OSM;2POU;2POV;2POW;2Q1B;2Q1Q;2Q38;2QO8;2QOA;2QP6;2VVA;2VVB;2WD2;2WD3;2WEG;2WEH;2WEJ;2WEO;2X7S;2X7T;2X7U;3B4F;3BET;3BL0;3BL1;3C7P;3CA2;3CAJ;3CYU;3D8W;3D92;3D93;3D9Z;3DAZ;3DBU;3DC3;3DC9;3DCC;3DCS;3DCW;3DD0;3DD8;3DV7;3DVB;3DVC;3DVD;3EFI;3EFT;3F4X;3F8E;3FFP;3GZ0;3HFP;3HKN;3HKQ;3HKT;3HKU;3HLJ;3HS4;3IBI;3IBL;3IBN;3IBU;3IEO;3IGP;3K2F;3K34;3K7K;3KIG;3KKX;3KNE;3KOI;3KOK;3KON;3KS3;3KWA;3L14;3M04;3M14;3M1J;3M1K;3M1Q;3M1W;3M2N;3M2X;3M2Y;3M2Z;3M3X;3M40;3M5E;3M5S;3M5T;3M67;3M96;3M98;3MHC;3MHI;3MHL;3MHM;3MHO;3ML2;3MMF;3MNA;3MNH;3MNI;3MNJ;3MNK;3MNU;3MWO;3MYQ;3MZC;3N0N;3N2P;3N3J;3N4B;3NB5;3NI5;3NJ9;3OIK;3OIL;3OIM;3OKU;3OKV;3OY0;3OYQ;3OYS;3P3H;3P3J;3P44;3P4V;3P55;3P58;3P5A;3P5L;3PJJ;3PO6;3PYK;3QYK;3R16;3R17;3RG3;3RG4;3RGE;3RJ7;3RLD;3RYJ;3RYV;3RYX;3RYY;3RYZ;3RZ0;3RZ1;3RZ5;3RZ7;3RZ8;3S71;3S72;3S73;3S74;3S75;3S76;3S77;3S78;3S8X;3S9T;3SAP;3SAX;3SBH;3SBI;3T5U;3T5Z;3T82;3T83;3T84;3T85;3TMJ;3TVN;3TVO;3U3A;3U45;3U47;3U7C;3V2J;3V2M;3V3F;3V3G;3V3H;3V3I;3V3J;3V5G;3V7X;3VBD;3ZP9;4BCW;4BF1;4BF6;4CA2;4CAC;4CQ0;4DZ7;4DZ9;4E3D;4E3F;4E3G;4E3H;4E49;4E4A;4E5Q;4FIK;4FL7;4FPT;4FRC;4FU5;4FVN;4FVO;4G0C;4GL1;4HBA;4HEW;4HEY;4HEZ;4HF3;4HT0;4IDR;4ILX;4ITO;4ITP;4IWZ;4JS6;4JSA;4JSS;4JSW;4JSZ;4K0S;4K0T;4K0Z;4K13;4K1Q;4KAP;4KNI;4KNJ;4KUV;4KUW;4KUY;4KV0;4L5U;4L5V;4L5W;4LHI;4LP6;4M2R;4M2U;4M2V;4M2W;4MDG;4MDL;4MDM;4MLT;4MLX;4MO8;4MTY;4N0X;4N16;4PQ7;4PXX;4PYX;4PYY;4PZH;4Q06;4Q07;4Q08;4Q09;4Q49;4Q6D;4Q6E;4Q78;4Q7P;4Q7S;4Q7V;4Q7W;4Q81;4Q83;4Q87;4Q8X;4Q8Y;4Q8Z;4Q90;4Q99;4Q9Y;4QEF;4QIY;4QJM;4QK1;4QK2;4QK3;4QSA;4QSB;4QSI;4QTL;4QY3;4R59;4R5A;4R5B;4RFC;4RFD;4RH2;4RIU;4RIV;4RN4;4RUX;4RUY;4RUZ;4WL4;4WW6;4XE1;4Y0J;4YGJ;4YGK;4YGL;4YGN;4YVY;4YWP;4YX4;4YXI;4YXO;4YXU;4YYT;4Z0Q;4Z1E;4Z1J;4Z1K;4Z1N;4ZAO;4ZWI;4ZWX;4ZWY;4ZWZ;4ZX0;4ZX1;5A6H;5AMD;5AMG;5AML;5BNL;5BRU;5BRV;5BRW;5BYI;5C8I;5CA2;5CAC;5CLU;5DSI;5DSJ;5DSK;5DSL;5DSM;5DSN;5DSO;5DSP;5DSQ;5DSR;5E28;5E2K;5E2R;5E2S;5EH5;5EH7;5EH8;5EHV;5EHW;5EKH;5EKJ;5EKM;5FDC;5FDI;5FLO;5FLP;5FLQ;5FLR;5FLS;5FLT;5FNG;5FNH;5FNI;5FNJ;5FNK;5FNM;5G01;5G03;5G0B;5G0C;5J8Z;6CA2;7CA2;8CA2;9CA2;	CHEMBL205;	P00918;	DB00819;DB00436;DB00562;DB01194;DB00880;DB00606;DB01119;DB01144;DB00869;DB01031;DB00695;DB00999;DB00774;DB00703;DB00232;DB01325;DB00273;DB01021;DB03904;DB00909;		PF00194;	IPR018443;IPR001148;IPR023561;IPR018338;	angiotensin-activated signaling pathway [GO:0038166]; bicarbonate transport [GO:0015701]; carbon dioxide transport [GO:0015670]; cellular response to fluid shear stress [GO:0071498]; kidney development [GO:0001822]; morphogenesis of an epithelium [GO:0002009]; odontogenesis of dentin-containing tooth [GO:0042475]; one-carbon metabolic process [GO:0006730]; positive regulation of bone resorption [GO:0045780]; positive regulation of cellular pH reduction [GO:0032849]; positive regulation of dipeptide transmembrane transport [GO:2001150]; positive regulation of osteoclast differentiation [GO:0045672]; positive regulation of synaptic transmission, GABAergic [GO:0032230]; regulation of anion transport [GO:0044070]; regulation of chloride transport [GO:2001225]; regulation of intracellular pH [GO:0051453]; response to estrogen [GO:0043627]; response to pH [GO:0009268]; response to steroid hormone [GO:0048545]; response to zinc ion [GO:0010043]; secretion [GO:0046903]	arylesterase activity [GO:0004064]; carbonate dehydratase activity [GO:0004089]; zinc ion binding [GO:0008270]	apical part of cell [GO:0045177]; axon [GO:0030424]; basolateral plasma membrane [GO:0016323]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; microvillus [GO:0005902]; myelin sheath [GO:0043209]; plasma membrane [GO:0005886]
P22748	CAH4_HUMAN	Carbonic anhydrase 4 (EC 4.2.1.1) (Carbonate dehydratase IV) (Carbonic anhydrase IV) (CA-IV)	CA4	1ZNC;3F7B;3F7U;3FW3;	CHEMBL3729;	P22748;	DB00819;DB00436;DB00562;DB01194;DB00880;DB00606;DB01144;DB00869;DB00999;DB00774;DB00703;DB00232;DB00273;DB01021;DB00909;		PF00194;	IPR001148;IPR023561;IPR018338;IPR018343;	bicarbonate transport [GO:0015701]; one-carbon metabolic process [GO:0006730]	carbonate dehydratase activity [GO:0004089]; zinc ion binding [GO:0008270]	anchored component of external side of plasma membrane [GO:0031362]; apical plasma membrane [GO:0016324]; brush border membrane [GO:0031526]; cell surface [GO:0009986]; endoplasmic reticulum-Golgi intermediate compartment [GO:0005793]; extracellular exosome [GO:0070062]; Golgi apparatus [GO:0005794]; membrane [GO:0016020]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; rough endoplasmic reticulum [GO:0005791]; secretory granule membrane [GO:0030667]; trans-Golgi network [GO:0005802]; transport vesicle membrane [GO:0030658]
P06881	CALCA_HUMAN	Calcitonin gene-related peptide 1 (Alpha-type CGRP) (Calcitonin gene-related peptide I) (CGRP-I)	CALCA CALC1	1LS7;	CHEMBL5293;	P06881;			PF00214;	IPR021117;IPR021116;IPR018360;IPR015476;IPR001693;	activation of adenylate cyclase activity [GO:0007190]; antibacterial humoral response [GO:0019731]; antifungal humoral response [GO:0019732]; cell-cell signaling [GO:0007267]; defense response to Gram-negative bacterium [GO:0050829]; defense response to Gram-positive bacterium [GO:0050830]; endothelial cell migration [GO:0043542]; endothelial cell proliferation [GO:0001935]; G-protein coupled receptor internalization [GO:0002031]; innate immune response [GO:0045087]; leukocyte cell-cell adhesion [GO:0007159]; negative regulation of blood pressure [GO:0045776]; negative regulation of bone resorption [GO:0045779]; negative regulation of calcium ion transport into cytosol [GO:0010523]; negative regulation of osteoclast differentiation [GO:0045671]; neurological system process involved in regulation of systemic arterial blood pressure [GO:0001976]; positive regulation of cAMP biosynthetic process [GO:0030819]; positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway [GO:0051482]; positive regulation of interleukin-1 alpha production [GO:0032730]; positive regulation of interleukin-8 production [GO:0032757]; positive regulation of macrophage differentiation [GO:0045651]; positive regulation of vasodilation [GO:0045909]; protein phosphorylation [GO:0006468]; receptor internalization [GO:0031623]; regulation of blood pressure [GO:0008217]; regulation of cytosolic calcium ion concentration [GO:0051480]; response to yeast [GO:0001878]; vasculature development [GO:0001944]	protein complex binding [GO:0032403]; receptor binding [GO:0005102]	cytoplasm [GO:0005737]; extracellular region [GO:0005576]; extracellular space [GO:0005615]
P30988	CALCR_HUMAN	Calcitonin receptor (CT-R)	CALCR	5II0;	CHEMBL1832;	P30988;	DB01278;DB00017;		PF00002;PF02793;	IPR003287;IPR017981;IPR001688;IPR001879;IPR000832;IPR017983;	adenylate cyclase-activating G-protein coupled receptor signaling pathway [GO:0007189]; cell surface receptor signaling pathway [GO:0007166]; positive regulation of adenylate cyclase activity [GO:0045762]; positive regulation of cAMP biosynthetic process [GO:0030819]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; protein localization to plasma membrane [GO:0072659]; protein transport [GO:0015031]; receptor internalization [GO:0031623]; response to glucocorticoid [GO:0051384]	calcitonin binding [GO:0032841]; calcitonin receptor activity [GO:0004948]; protein transporter activity [GO:0008565]; receptor activity [GO:0004872]	cell [GO:0005623]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P62158	CALM_HUMAN	Calmodulin (CaM)	CALM1 CALM CAM CAM1; CALM2 CAM2 CAMB; CALM3 CALML2 CAM3 CAMC CAMIII	1AJI;1CDL;1CLL;1CTR;1IWQ;1J7O;1J7P;1K90;1K93;1L7Z;1LVC;1NKF;1PK0;1S26;1SK6;1SW8;1WRZ;1XFU;1XFV;1XFW;1XFX;1XFY;1XFZ;1Y6W;1YR5;1YRT;1YRU;1ZOT;1ZUZ;2BE6;2F3Y;2F3Z;2HF5;2I08;2JZI;2K0E;2K0F;2K0J;2K61;2KNE;2KUG;2KUH;2L53;2L7L;2LGF;2LL6;2LL7;2LQC;2LQP;2LV6;2M0J;2M0K;2M55;2MG5;2N27;2N6A;2R28;2V01;2V02;2VAY;2W73;2WEL;2X0G;2Y4V;3BYA;3DVE;3DVJ;3DVK;3DVM;3EWT;3EWV;3G43;3HR4;3J41;3O77;3O78;3OXQ;3SUI;3UCT;3UCW;3UCY;4BW7;4BW8;4BYF;4DCK;4DJC;4GOW;4JPZ;4JQ0;4L79;4LZX;4M1L;4OVN;4Q57;4Q5U;4UMO;4UPU;4V0C;5COC;5DOW;5I0I;5J03;5K7L;5K8Q;	CHEMBL6093;	P62158;	DB01429;DB01244;DB00477;DB00527;DB01023;DB04841;DB00623;DB00753;DB00836;DB01065;DB00622;DB01115;DB00850;DB00925;DB01100;DB01069;DB00831;		PF13499;	IPR011992;IPR018247;IPR002048;	activation of adenylate cyclase activity [GO:0007190]; detection of calcium ion [GO:0005513]; Fc-epsilon receptor signaling pathway [GO:0038095]; G2/M transition of mitotic cell cycle [GO:0000086]; glycogen catabolic process [GO:0005980]; G-protein coupled receptor signaling pathway [GO:0007186]; inositol phosphate metabolic process [GO:0043647]; MAPK cascade [GO:0000165]; muscle contraction [GO:0006936]; negative regulation of peptidyl-threonine phosphorylation [GO:0010801]; negative regulation of ryanodine-sensitive calcium-release channel activity [GO:0060315]; platelet degranulation [GO:0002576]; positive regulation of cyclic nucleotide metabolic process [GO:0030801]; positive regulation of cyclic-nucleotide phosphodiesterase activity [GO:0051343]; positive regulation of DNA binding [GO:0043388]; positive regulation of nitric-oxide synthase activity [GO:0051000]; positive regulation of peptidyl-threonine phosphorylation [GO:0010800]; positive regulation of phosphoprotein phosphatase activity [GO:0032516]; positive regulation of protein autophosphorylation [GO:0031954]; positive regulation of protein dephosphorylation [GO:0035307]; positive regulation of protein serine/threonine kinase activity [GO:0071902]; positive regulation of ryanodine-sensitive calcium-release channel activity [GO:0060316]; regulation of cardiac muscle contraction [GO:0055117]; regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion [GO:0010881]; regulation of cell communication by electrical coupling involved in cardiac conduction [GO:1901844]; regulation of cytokinesis [GO:0032465]; regulation of heart rate [GO:0002027]; regulation of high voltage-gated calcium channel activity [GO:1901841]; regulation of nitric-oxide synthase activity [GO:0050999]; regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum [GO:0010880]; regulation of rhodopsin mediated signaling pathway [GO:0022400]; response to amphetamine [GO:0001975]; response to calcium ion [GO:0051592]; response to corticosterone [GO:0051412]; substantia nigra development [GO:0021762]; Wnt signaling pathway, calcium modulating pathway [GO:0007223]	calcium ion binding [GO:0005509]; inositol-1,4,5-trisphosphate 3-kinase activity [GO:0008440]; ion channel binding [GO:0044325]; ligand-gated ion channel activity [GO:0015276]; nitric-oxide synthase regulator activity [GO:0030235]; N-terminal myristoylation domain binding [GO:0031997]; phospholipase binding [GO:0043274]; protein domain specific binding [GO:0019904]; protein kinase binding [GO:0019901]; protein phosphatase activator activity [GO:0072542]; protein serine/threonine kinase activator activity [GO:0043539]; Ras guanyl-nucleotide exchange factor activity [GO:0005088]; thioesterase binding [GO:0031996]; titin binding [GO:0031432]	centrosome [GO:0005813]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; growth cone [GO:0030426]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; sarcomere [GO:0030017]; spindle microtubule [GO:0005876]; spindle pole [GO:0000922]; vesicle [GO:0031982]; voltage-gated potassium channel complex [GO:0008076]
P49069	CAMLG_HUMAN	Calcium signal-modulating cyclophilin ligand (CAML)	CAMLG CAML				DB00091;		PF14963;	IPR016719;	defense response [GO:0006952]; epidermal growth factor receptor signaling pathway [GO:0007173]; receptor recycling [GO:0001881]; signal transduction [GO:0007165]; viral process [GO:0016032]		endoplasmic reticulum [GO:0005783]; integral component of membrane [GO:0016021]; membrane [GO:0016020]
P07384	CAN1_HUMAN	Calpain-1 catalytic subunit (EC 3.4.22.52) (Calcium-activated neutral proteinase 1) (CANP 1) (Calpain mu-type) (Calpain-1 large subunit) (Cell proliferation-inducing gene 30 protein) (Micromolar-calpain) (muCANP)	CAPN1 CANPL1 PIG30	1ZCM;2ARY;	CHEMBL3891;	P07384;			PF01067;PF13833;PF00648;	IPR022684;IPR022682;IPR022683;IPR029643;IPR011992;IPR018247;IPR002048;IPR000169;IPR001300;	extracellular matrix disassembly [GO:0022617]; mammary gland involution [GO:0060056]; positive regulation of cell proliferation [GO:0008284]; proteolysis [GO:0006508]; receptor catabolic process [GO:0032801]; regulation of macroautophagy [GO:0016241]	calcium-dependent cysteine-type endopeptidase activity [GO:0004198]; calcium ion binding [GO:0005509]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; focal adhesion [GO:0005925]; lysosome [GO:0005764]; membrane [GO:0016020]; mitochondrion [GO:0005739]; plasma membrane [GO:0005886]
P63098	CANB1_HUMAN	Calcineurin subunit B type 1 (Protein phosphatase 2B regulatory subunit 1) (Protein phosphatase 3 regulatory subunit B alpha isoform 1)	PPP3R1 CNA2 CNB	1AUI;1M63;1MF8;2P6B;3LL8;4F0Z;4OR9;4ORA;4ORC;					PF13499;	IPR011992;IPR018247;IPR002048;	calcineurin-NFAT signaling cascade [GO:0033173]; Fc-epsilon receptor signaling pathway [GO:0038095]; positive regulation of NFAT protein import into nucleus [GO:0051533]; positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway [GO:1900740]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; Wnt signaling pathway, calcium modulating pathway [GO:0007223]	calcium-dependent protein serine/threonine phosphatase activity [GO:0004723]; calcium ion binding [GO:0005509]; calmodulin binding [GO:0005516]; protein domain specific binding [GO:0019904]	calcineurin complex [GO:0005955]; cytosol [GO:0005829]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; sarcolemma [GO:0042383]
Q96LZ3	CANB2_HUMAN	Calcineurin subunit B type 2 (Calcineurin B-like protein) (CBLP) (Calcineurin BII) (CNBII) (PPP3R1-like) (Protein phosphatase 2B regulatory subunit 2) (Protein phosphatase 3 regulatory subunit B beta isoform)	PPP3R2 CBLP PPP3RL				DB00091;		PF13499;	IPR011992;IPR018247;IPR002048;		calcium ion binding [GO:0005509]
Q8WVQ1	CANT1_HUMAN	Soluble calcium-activated nucleotidase 1 (SCAN-1) (EC 3.6.1.6) (Apyrase homolog) (Putative MAPK-activating protein PM09) (Putative NF-kappa-B-activating protein 107)	CANT1 SHAPY	1S18;1S1D;2H2N;2H2U;			DB03754;		PF06079;	IPR009283;	positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; proteoglycan biosynthetic process [GO:0030166]	adenosine-diphosphatase activity [GO:0043262]; calcium ion binding [GO:0005509]; guanosine-diphosphatase activity [GO:0004382]; protein homodimerization activity [GO:0042803]; signal transducer activity [GO:0004871]; uridine-diphosphatase activity [GO:0045134]	endoplasmic reticulum membrane [GO:0005789]; extracellular exosome [GO:0070062]; Golgi cisterna membrane [GO:0032580]; integral component of membrane [GO:0016021]; membrane [GO:0016020]
Q16568	CART_HUMAN	Cocaine- and amphetamine-regulated transcript protein [Cleaved into: CART(1-39); CART(42-89)]	CARTPT CART	1HY9;			DB00182;		PF06373;	IPR009106;	activation of MAPKK activity [GO:0000186]; adult feeding behavior [GO:0008343]; cell-cell signaling [GO:0007267]; cellular glucose homeostasis [GO:0001678]; cellular response to starvation [GO:0009267]; chemical synaptic transmission [GO:0007268]; circadian regulation of gene expression [GO:0032922]; G-protein coupled receptor signaling pathway [GO:0007186]; negative regulation of appetite [GO:0032099]; negative regulation of bone resorption [GO:0045779]; negative regulation of glucagon secretion [GO:0070093]; negative regulation of osteoclast differentiation [GO:0045671]; neuropeptide signaling pathway [GO:0007218]; positive regulation of blood pressure [GO:0045777]; positive regulation of epinephrine secretion [GO:0032812]; positive regulation of transmission of nerve impulse [GO:0051971]; regulation of insulin secretion [GO:0050796]; signal transduction [GO:0007165]; somatostatin secretion [GO:0070253]	neuropeptide hormone activity [GO:0005184]	extracellular space [GO:0005615]; secretory granule [GO:0030141]
P29466	CASP1_HUMAN	Caspase-1 (CASP-1) (EC 3.4.22.36) (Interleukin-1 beta convertase) (IL-1BC) (Interleukin-1 beta-converting enzyme) (ICE) (IL-1 beta-converting enzyme) (p45) [Cleaved into: Caspase-1 subunit p20; Caspase-1 subunit p10]	CASP1 IL1BC IL1BCE	1BMQ;1IBC;1ICE;1RWK;1RWM;1RWN;1RWO;1RWP;1RWV;1RWW;1RWX;1SC1;1SC3;1SC4;2FQQ;2H48;2H4W;2H4Y;2H51;2H54;2HBQ;2HBR;2HBY;2HBZ;3D6F;3D6H;3D6M;3E4C;3NS7;5FNA;	CHEMBL4801;	P29466;	DB01017;		PF00619;	IPR001315;IPR029030;IPR033139;IPR016129;IPR011029;IPR002138;IPR001309;IPR015917;IPR017350;	apoptotic process [GO:0006915]; cellular response to mechanical stimulus [GO:0071260]; cellular response to organic substance [GO:0071310]; interleukin-1 beta production [GO:0032611]; membrane hyperpolarization [GO:0060081]; mitochondrial depolarization [GO:0051882]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of interleukin-1 alpha secretion [GO:0050717]; positive regulation of interleukin-1 beta secretion [GO:0050718]; programmed necrotic cell death [GO:0097300]; protein processing [GO:0016485]; proteolysis [GO:0006508]; pyroptosis [GO:0070269]; regulation of apoptotic process [GO:0042981]; regulation of autophagy [GO:0010506]; response to ATP [GO:0033198]; response to hypoxia [GO:0001666]; response to lipopolysaccharide [GO:0032496]; signal transduction [GO:0007165]; toxin transport [GO:1901998]	cysteine-type endopeptidase activator activity involved in apoptotic process [GO:0008656]; cysteine-type endopeptidase activity [GO:0004197]; endopeptidase activity [GO:0004175]	AIM2 inflammasome complex [GO:0097169]; cytosol [GO:0005829]; extracellular region [GO:0005576]; IPAF inflammasome complex [GO:0072557]; mitochondrion [GO:0005739]; NLRP1 inflammasome complex [GO:0072558]; NLRP3 inflammasome complex [GO:0072559]
P42574	CASP3_HUMAN	Caspase-3 (CASP-3) (EC 3.4.22.56) (Apopain) (Cysteine protease CPP32) (CPP-32) (Protein Yama) (SREBP cleavage activity 1) (SCA-1) [Cleaved into: Caspase-3 subunit p17; Caspase-3 subunit p12]	CASP3 CPP32	1CP3;1GFW;1I3O;1NME;1NMQ;1NMS;1PAU;1QX3;1RE1;1RHJ;1RHK;1RHM;1RHQ;1RHR;1RHU;2C1E;2C2K;2C2M;2C2O;2CDR;2CJX;2CJY;2CNK;2CNL;2CNN;2CNO;2DKO;2H5I;2H5J;2H65;2J30;2J31;2J32;2J33;2XYG;2XYH;2XYP;2XZD;2XZT;2Y0B;3DEH;3DEI;3DEJ;3DEK;3EDQ;3GJQ;3GJR;3GJS;3GJT;3H0E;3ITN;3KJF;3PCX;3PD0;3PD1;4DCJ;4DCO;4DCP;4EHA;4EHD;4EHF;4EHH;4EHK;4EHL;4EHN;4JJE;4JQY;4JQZ;4JR0;4PRY;4PS0;4QTX;4QTY;4QU0;4QU5;4QU8;4QU9;4QUA;4QUB;4QUD;4QUE;4QUG;4QUH;4QUI;4QUJ;4QUL;5IC4;	CHEMBL2334;	P42574;	DB01017;			IPR029030;IPR015470;IPR033139;IPR016129;IPR002138;IPR001309;IPR015917;	activation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0006919]; activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c [GO:0008635]; apoptotic DNA fragmentation [GO:0006309]; apoptotic process [GO:0006915]; apoptotic signaling pathway [GO:0097190]; cellular component disassembly involved in execution phase of apoptosis [GO:0006921]; cellular response to organic cyclic compound [GO:0071407]; erythrocyte differentiation [GO:0030218]; execution phase of apoptosis [GO:0097194]; extrinsic apoptotic signaling pathway in absence of ligand [GO:0097192]; glial cell apoptotic process [GO:0034349]; hippocampus development [GO:0021766]; hippo signaling [GO:0035329]; keratinocyte differentiation [GO:0030216]; learning or memory [GO:0007611]; negative regulation of apoptotic process [GO:0043066]; neuron differentiation [GO:0030182]; neurotrophin TRK receptor signaling pathway [GO:0048011]; platelet formation [GO:0030220]; positive regulation of neuron apoptotic process [GO:0043525]; proteolysis [GO:0006508]; regulation of macroautophagy [GO:0016241]; response to amino acid [GO:0043200]; response to antibiotic [GO:0046677]; response to cobalt ion [GO:0032025]; response to drug [GO:0042493]; response to estradiol [GO:0032355]; response to glucocorticoid [GO:0051384]; response to glucose [GO:0009749]; response to hydrogen peroxide [GO:0042542]; response to hypoxia [GO:0001666]; response to lipopolysaccharide [GO:0032496]; response to nicotine [GO:0035094]; response to tumor necrosis factor [GO:0034612]; response to X-ray [GO:0010165]; wound healing [GO:0042060]	aspartic-type endopeptidase activity [GO:0004190]; cysteine-type endopeptidase activator activity involved in apoptotic process [GO:0008656]; cysteine-type endopeptidase activity [GO:0004197]; cysteine-type endopeptidase activity involved in apoptotic process [GO:0097153]; cysteine-type endopeptidase activity involved in execution phase of apoptosis [GO:0097200]; peptidase activity [GO:0008233]; phospholipase A2 activator activity [GO:0016005]	cytosol [GO:0005829]; death-inducing signaling complex [GO:0031264]; membrane raft [GO:0045121]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
P55210	CASP7_HUMAN	Caspase-7 (CASP-7) (EC 3.4.22.60) (Apoptotic protease Mch-3) (CMH-1) (ICE-like apoptotic protease 3) (ICE-LAP3) [Cleaved into: Caspase-7 subunit p20; Caspase-7 subunit p11]	CASP7 MCH3	1F1J;1GQF;1I4O;1I51;1K86;1K88;1KMC;1MIA;1SHJ;1SHL;2QL5;2QL7;2QL9;2QLB;2QLF;2QLJ;3EDR;3H1P;3IBC;3IBF;3R5K;4FDL;4FEA;4HQ0;4HQR;4JB8;4JJ8;4JR1;4JR2;4LSZ;4ZVO;4ZVP;4ZVQ;4ZVR;4ZVS;4ZVT;4ZVU;5IC6;	CHEMBL3468;	P55210;				IPR029030;IPR033139;IPR016129;IPR002138;IPR001309;IPR015917;IPR017350;	activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c [GO:0008635]; apoptotic process [GO:0006915]; cellular component disassembly involved in execution phase of apoptosis [GO:0006921]; execution phase of apoptosis [GO:0097194]; proteolysis [GO:0006508]	cysteine-type endopeptidase activity [GO:0004197]; cysteine-type endopeptidase activity involved in execution phase of apoptosis [GO:0097200]; cysteine-type peptidase activity [GO:0008234]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P41180	CASR_HUMAN	Extracellular calcium-sensing receptor (CaSR) (Parathyroid cell calcium-sensing receptor 1) (PCaR1)	CASR GPRC2A PCAR1	5FBH;5FBK;5K5S;5K5T;	CHEMBL1878;	P41180;	DB01012;		PF00003;PF01094;PF07562;	IPR001828;IPR000337;IPR011500;IPR017978;IPR017979;IPR028082;	anatomical structure morphogenesis [GO:0009653]; calcium ion import [GO:0070509]; cellular calcium ion homeostasis [GO:0006874]; chemosensory behavior [GO:0007635]; detection of calcium ion [GO:0005513]; G-protein coupled receptor signaling pathway [GO:0007186]; ossification [GO:0001503]	G-protein coupled receptor activity [GO:0004930]; phosphatidylinositol phospholipase C activity [GO:0004435]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P04040	CATA_HUMAN	Catalase (EC 1.11.1.6)	CAT	1DGB;1DGF;1DGG;1DGH;1F4J;1QQW;			DB01213;		PF00199;PF06628;	IPR018028;IPR020835;IPR024708;IPR024711;IPR011614;IPR002226;IPR010582;	aerobic respiration [GO:0009060]; aging [GO:0007568]; cellular response to growth factor stimulus [GO:0071363]; cholesterol metabolic process [GO:0008203]; hemoglobin metabolic process [GO:0020027]; hydrogen peroxide catabolic process [GO:0042744]; negative regulation of apoptotic process [GO:0043066]; negative regulation of NF-kappaB transcription factor activity [GO:0032088]; osteoblast differentiation [GO:0001649]; positive regulation of cell division [GO:0051781]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of phosphatidylinositol 3-kinase signaling [GO:0014068]; protein homotetramerization [GO:0051289]; protein tetramerization [GO:0051262]; purine nucleotide catabolic process [GO:0006195]; response to activity [GO:0014823]; response to cadmium ion [GO:0046686]; response to drug [GO:0042493]; response to estradiol [GO:0032355]; response to ethanol [GO:0045471]; response to fatty acid [GO:0070542]; response to hydrogen peroxide [GO:0042542]; response to hyperoxia [GO:0055093]; response to hypoxia [GO:0001666]; response to inactivity [GO:0014854]; response to insulin [GO:0032868]; response to L-ascorbic acid [GO:0033591]; response to lead ion [GO:0010288]; response to light intensity [GO:0009642]; response to ozone [GO:0010193]; response to phenylpropanoid [GO:0080184]; response to reactive oxygen species [GO:0000302]; response to vitamin A [GO:0033189]; response to vitamin E [GO:0033197]; triglyceride metabolic process [GO:0006641]; ureteric bud development [GO:0001657]; UV protection [GO:0009650]	aminoacylase activity [GO:0004046]; antioxidant activity [GO:0016209]; catalase activity [GO:0004096]; enzyme binding [GO:0019899]; heme binding [GO:0020037]; metal ion binding [GO:0046872]; NADP binding [GO:0050661]; oxidoreductase activity, acting on peroxide as acceptor [GO:0016684]; protein homodimerization activity [GO:0042803]; receptor binding [GO:0005102]	cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; focal adhesion [GO:0005925]; Golgi apparatus [GO:0005794]; intracellular membrane-bounded organelle [GO:0043231]; lysosome [GO:0005764]; membrane [GO:0016020]; mitochondrial intermembrane space [GO:0005758]; mitochondrion [GO:0005739]; peroxisomal matrix [GO:0005782]; peroxisomal membrane [GO:0005778]; peroxisome [GO:0005777]; plasma membrane [GO:0005886]
P07858	CATB_HUMAN	Cathepsin B (EC 3.4.22.1) (APP secretase) (APPS) (Cathepsin B1) [Cleaved into: Cathepsin B light chain; Cathepsin B heavy chain]	CTSB CPSB	1CSB;1GMY;1HUC;1PBH;2IPP;2PBH;3AI8;3CBJ;3CBK;3K9M;3PBH;	CHEMBL4072;	P07858;			PF00112;PF08127;	IPR025661;IPR000169;IPR025660;IPR013128;IPR000668;IPR012599;	cellular response to thyroid hormone stimulus [GO:0097067]; collagen catabolic process [GO:0030574]; decidualization [GO:0046697]; epithelial cell differentiation [GO:0030855]; proteolysis [GO:0006508]; proteolysis involved in cellular protein catabolic process [GO:0051603]; regulation of apoptotic process [GO:0042981]; regulation of catalytic activity [GO:0050790]; toll-like receptor signaling pathway [GO:0002224]; viral entry into host cell [GO:0046718]	collagen binding [GO:0005518]; cysteine-type endopeptidase activity [GO:0004197]; cysteine-type peptidase activity [GO:0008234]; peptidase activity [GO:0008233]; proteoglycan binding [GO:0043394]; serine-type endopeptidase activity [GO:0004252]	endolysosome lumen [GO:0036021]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; intracellular [GO:0005622]; intracellular membrane-bounded organelle [GO:0043231]; lysosome [GO:0005764]; melanosome [GO:0042470]; mitochondrion [GO:0005739]; nucleolus [GO:0005730]; perinuclear region of cytoplasm [GO:0048471]
Q9UBX1	CATF_HUMAN	Cathepsin F (CATSF) (EC 3.4.22.41)	CTSF	1D5U;1M6D;	CHEMBL2517;	Q9UBX1;			PF08246;PF00112;	IPR000169;IPR025660;IPR013128;IPR000668;IPR013201;	antigen processing and presentation of exogenous peptide antigen via MHC class II [GO:0019886]; proteolysis [GO:0006508]; proteolysis involved in cellular protein catabolic process [GO:0051603]	cysteine-type endopeptidase activity [GO:0004197]	extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; extracellular vesicle [GO:1903561]; lysosomal lumen [GO:0043202]; lysosome [GO:0005764]
P08311	CATG_HUMAN	Cathepsin G (CG) (EC 3.4.21.20)	CTSG	1AU8;1CGH;1KYN;1T32;	CHEMBL4071;	P08311;			PF00089;	IPR009003;IPR001314;IPR001254;IPR018114;IPR033116;	angiotensin maturation [GO:0002003]; cellular protein metabolic process [GO:0044267]; defense response to fungus [GO:0050832]; extracellular matrix disassembly [GO:0022617]; immune response [GO:0006955]; negative regulation of growth of symbiont in host [GO:0044130]; neutrophil mediated killing of gram-positive bacterium [GO:0070946]; positive regulation of immune response [GO:0050778]; protein phosphorylation [GO:0006468]; protein processing [GO:0016485]; proteolysis [GO:0006508]; response to lipopolysaccharide [GO:0032496]	heparin binding [GO:0008201]; peptidase activity [GO:0008233]; serine-type endopeptidase activity [GO:0004252]	cell surface [GO:0009986]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; secretory granule [GO:0030141]
O60911	CATL2_HUMAN	Cathepsin L2 (EC 3.4.22.43) (Cathepsin U) (Cathepsin V)	CTSV CATL2 CTSL2 CTSU UNQ268/PRO305	1FH0;3H6S;3KFQ;	CHEMBL3272;	O60911;			PF08246;PF00112;	IPR025661;IPR000169;IPR025660;IPR013128;IPR000668;IPR013201;	antigen processing and presentation of exogenous peptide antigen via MHC class II [GO:0019886]; autophagic cell death [GO:0048102]; cellular response to starvation [GO:0009267]; decidualization [GO:0046697]; extracellular matrix disassembly [GO:0022617]; hair follicle morphogenesis [GO:0031069]; multicellular organism aging [GO:0010259]; negative regulation of keratinocyte proliferation [GO:0010839]; nerve development [GO:0021675]; protein autoprocessing [GO:0016540]; proteolysis involved in cellular protein catabolic process [GO:0051603]; regulation of actin cytoskeleton reorganization [GO:2000249]; response to glucocorticoid [GO:0051384]; response to glucose [GO:0009749]; response to gonadotropin [GO:0034698]; Sertoli cell differentiation [GO:0060008]; spermatogenesis [GO:0007283]	aminopeptidase activity [GO:0004177]; cysteine-type carboxypeptidase activity [GO:0016807]; cysteine-type endopeptidase activity [GO:0004197]; cysteine-type peptidase activity [GO:0008234]; peptide binding [GO:0042277]; serine-type endopeptidase activity [GO:0004252]	apical part of cell [GO:0045177]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; lysosomal lumen [GO:0043202]; lysosome [GO:0005764]; microvillus [GO:0005902]; neuron projection [GO:0043005]; nucleolus [GO:0005730]; perikaryon [GO:0043204]; secretory granule [GO:0030141]
P07711	CATL_HUMAN	Cathepsin L1 (EC 3.4.22.15) (Cathepsin L) (Major excreted protein) (MEP) [Cleaved into: Cathepsin L1 heavy chain; Cathepsin L1 light chain]	CTSL CTSL1	1CJL;1CS8;1ICF;1MHW;2NQD;2VHS;2XU1;2XU3;2XU4;2XU5;2YJ2;2YJ8;2YJ9;2YJB;2YJC;3BC3;3H89;3H8B;3H8C;3HHA;3HWN;3IV2;3K24;3KSE;3OF8;3OF9;4AXL;4AXM;5F02;5I4H;	CHEMBL3837;	P07711;			PF08246;PF00112;	IPR025661;IPR000169;IPR025660;IPR013128;IPR000668;IPR013201;	adaptive immune response [GO:0002250]; antigen processing and presentation [GO:0019882]; antigen processing and presentation of exogenous peptide antigen via MHC class II [GO:0019886]; cellular response to thyroid hormone stimulus [GO:0097067]; collagen catabolic process [GO:0030574]; extracellular matrix disassembly [GO:0022617]; macrophage apoptotic process [GO:0071888]; proteolysis [GO:0006508]; proteolysis involved in cellular protein catabolic process [GO:0051603]; toll-like receptor signaling pathway [GO:0002224]	collagen binding [GO:0005518]; cysteine-type endopeptidase activity [GO:0004197]; cysteine-type peptidase activity [GO:0008234]; fibronectin binding [GO:0001968]; histone binding [GO:0042393]; proteoglycan binding [GO:0043394]; serine-type endopeptidase activity [GO:0004252]; serpin family protein binding [GO:0097655]	endolysosome lumen [GO:0036021]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; lysosomal lumen [GO:0043202]; lysosome [GO:0005764]; nucleus [GO:0005634]
P25774	CATS_HUMAN	Cathepsin S (EC 3.4.22.27)	CTSS	1BXF;1GLO;1MS6;1NPZ;1NQC;2C0Y;2F1G;2FQ9;2FRA;2FRQ;2FT2;2FUD;2FYE;2G6D;2G7Y;2H7J;2HH5;2HHN;2HXZ;2OP3;2R9M;2R9N;2R9O;3IEJ;3KWN;3MPE;3MPF;3N3G;3N4C;3OVX;4P6E;4P6G;	CHEMBL2954;	P25774;			PF08246;PF00112;	IPR025661;IPR000169;IPR025660;IPR013128;IPR000668;IPR013201;	adaptive immune response [GO:0002250]; antigen processing and presentation [GO:0019882]; antigen processing and presentation of exogenous peptide antigen via MHC class II [GO:0019886]; antigen processing and presentation of peptide antigen [GO:0048002]; basement membrane disassembly [GO:0034769]; cellular response to thyroid hormone stimulus [GO:0097067]; collagen catabolic process [GO:0030574]; extracellular matrix disassembly [GO:0022617]; immune response [GO:0006955]; positive regulation of cation channel activity [GO:2001259]; protein processing [GO:0016485]; proteolysis [GO:0006508]; proteolysis involved in cellular protein catabolic process [GO:0051603]; response to acidic pH [GO:0010447]; toll-like receptor signaling pathway [GO:0002224]	collagen binding [GO:0005518]; cysteine-type endopeptidase activity [GO:0004197]; fibronectin binding [GO:0001968]; laminin binding [GO:0043236]; proteoglycan binding [GO:0043394]; serine-type endopeptidase activity [GO:0004252]	endolysosome lumen [GO:0036021]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; intracellular membrane-bounded organelle [GO:0043231]; lysosomal lumen [GO:0043202]; lysosome [GO:0005764]
P08185	CBG_HUMAN	Corticosteroid-binding globulin (CBG) (Serpin A6) (Transcortin)	SERPINA6 CBG	2VDX;2VDY;4BB2;4C41;4C49;	CHEMBL2421;		DB00240;DB00394;DB01410;DB00663;DB00180;DB00591;DB01047;DB00324;DB00846;DB00588;DB00596;DB00741;DB00253;DB00648;DB01384;DB00860;DB00896;DB00620;		PF00079;	IPR023795;IPR023796;IPR000215;	glucocorticoid metabolic process [GO:0008211]; transport [GO:0006810]	serine-type endopeptidase inhibitor activity [GO:0004867]; steroid binding [GO:0005496]	extracellular exosome [GO:0070062]; extracellular space [GO:0005615]
P15086	CBPB1_HUMAN	Carboxypeptidase B (EC 3.4.17.2) (Pancreas-specific protein) (PASP)	CPB1 CPB PCPB	1KWM;1ZLI;	CHEMBL2552;	P15086;			PF00246;PF02244;	IPR003146;IPR000834;IPR009020;		carboxypeptidase activity [GO:0004180]; metallocarboxypeptidase activity [GO:0004181]; zinc ion binding [GO:0008270]	extracellular space [GO:0005615]
P16152	CBR1_HUMAN	Carbonyl reductase [NADPH] 1 (EC 1.1.1.184) (15-hydroxyprostaglandin dehydrogenase [NADP(+)]) (EC 1.1.1.197) (NADPH-dependent carbonyl reductase 1) (Prostaglandin 9-ketoreductase) (Prostaglandin-E(2) 9-reductase) (EC 1.1.1.189) (Short chain dehydrogenase/reductase family 21C member 1)	CBR1 CBR CRN SDR21C1	1WMA;2PFG;3BHI;3BHJ;3BHM;4Z3D;	CHEMBL5586;	P16152;	DB00997;DB00502;DB01046;DB04844;		PF00106;	IPR016040;IPR020904;IPR002347;	cyclooxygenase pathway [GO:0019371]; drug metabolic process [GO:0017144]; epithelial cell differentiation [GO:0030855]; oxidation-reduction process [GO:0055114]; vitamin K metabolic process [GO:0042373]	15-hydroxyprostaglandin dehydrogenase (NADP+) activity [GO:0047021]; carbonyl reductase (NADPH) activity [GO:0004090]; oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor [GO:0016655]; prostaglandin-E2 9-reductase activity [GO:0050221]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular vesicle [GO:1903561]
P35520	CBS_HUMAN	Cystathionine beta-synthase (EC 4.2.1.22) (Beta-thionase) (Serine sulfhydrase)	CBS	1JBQ;1M54;4COO;4L0D;4L27;4L28;4L3V;4PCU;4UUU;	CHEMBL3399911;	P35520;	DB00151;DB00133;DB00118;	PATHWAY: Amino-acid biosynthesis; L-cysteine biosynthesis; L-cysteine from L-homocysteine and L-serine: step 1/2. {ECO:0000269|PubMed:20506325, ECO:0000269|PubMed:23974653, ECO:0000269|PubMed:23981774}.	PF00571;PF00291;	IPR000644;IPR005857;IPR001216;IPR001926;	cellular amino acid biosynthetic process [GO:0008652]; cysteine biosynthetic process [GO:0019344]; cysteine biosynthetic process from serine [GO:0006535]; cysteine biosynthetic process via cystathionine [GO:0019343]; DNA protection [GO:0042262]; homocysteine catabolic process [GO:0043418]; homocysteine metabolic process [GO:0050667]; hydrogen sulfide biosynthetic process [GO:0070814]; L-cysteine catabolic process [GO:0019448]; L-serine catabolic process [GO:0006565]; L-serine metabolic process [GO:0006563]; transsulfuration [GO:0019346]	carbon monoxide binding [GO:0070025]; cystathionine beta-synthase activity [GO:0004122]; cysteine synthase activity [GO:0004124]; enzyme binding [GO:0019899]; heme binding [GO:0020037]; metal ion binding [GO:0046872]; modified amino acid binding [GO:0072341]; nitric oxide binding [GO:0070026]; nitrite reductase (NO-forming) activity [GO:0050421]; oxygen binding [GO:0019825]; protein homodimerization activity [GO:0042803]; pyridoxal phosphate binding [GO:0030170]; S-adenosyl-L-methionine binding [GO:1904047]; ubiquitin protein ligase binding [GO:0031625]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleus [GO:0005634]
Q06432	CCG1_HUMAN	Voltage-dependent calcium channel gamma-1 subunit (Dihydropyridine-sensitive L-type, skeletal muscle calcium channel subunit gamma)	CACNG1 CACNLG		CHEMBL2363032;	Q06432;	DB00343;DB00898;DB04842;DB00308;DB00528;DB00653;DB01054;DB00421;		PF13903;	IPR004031;IPR005421;IPR008368;	cardiac conduction [GO:0061337]; muscle contraction [GO:0006936]; sarcoplasmic reticulum calcium ion transport [GO:0070296]; transport [GO:0006810]	voltage-gated calcium channel activity [GO:0005245]	plasma membrane [GO:0005886]; voltage-gated calcium channel complex [GO:0005891]
P32238	CCKAR_HUMAN	Cholecystokinin receptor type A (CCK-A receptor) (CCK-AR) (Cholecystokinin-1 receptor) (CCK1-R)	CCKAR CCKRA	1D6G;1HZN;1PB2;	CHEMBL1901;	P32238;	DB00403;		PF00001;PF09193;	IPR009126;IPR000596;IPR015276;IPR000276;IPR017452;	axonogenesis [GO:0007409]; digestion [GO:0007586]; feeding behavior [GO:0007631]; forebrain development [GO:0030900]; neuron migration [GO:0001764]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; regulation of hormone secretion [GO:0046883]; response to nutrient [GO:0007584]	cholecystokinin receptor activity [GO:0004951]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P06307	CCKN_HUMAN	Cholecystokinin (CCK) [Cleaved into: Cholecystokinin-58 (CCK58); Cholecystokinin-58 desnonopeptide ((1-49)-CCK58); Cholecystokinin-39 (CCK39); Cholecystokinin-33 (CCK33); Cholecystokinin-25 (CCK25); Cholecystokinin-18 (CCK18); Cholecystokinin-12 (CCK12); Cholecystokinin-8 (CCK8); Cholecystokinin-7 (CCK7); Cholecystokinin-5 (CCK5)]	CCK		CHEMBL1649050;	P06307;			PF00918;	IPR015499;IPR001651;IPR013152;	activation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0006919]; axonogenesis [GO:0007409]; behavioral fear response [GO:0001662]; eating behavior [GO:0042755]; negative regulation of appetite [GO:0032099]; neuron migration [GO:0001764]; positive regulation of cell proliferation [GO:0008284]; positive regulation of glutamate secretion [GO:0014049]; positive regulation of mitochondrial depolarization [GO:0051901]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of protein oligomerization [GO:0032461]; protein kinase C-activating G-protein coupled receptor signaling pathway [GO:0007205]; regulation of sensory perception of pain [GO:0051930]; release of cytochrome c from mitochondria [GO:0001836]; signal transduction [GO:0007165]	hormone activity [GO:0005179]; neuropeptide hormone activity [GO:0005184]	axon [GO:0030424]; axon hillock [GO:0043203]; axon initial segment [GO:0043194]; dendrite [GO:0030425]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; perikaryon [GO:0043204]; terminal bouton [GO:0043195]
P78556	CCL20_HUMAN	C-C motif chemokine 20 (Beta-chemokine exodus-1) (CC chemokine LARC) (Liver and activation-regulated chemokine) (Macrophage inflammatory protein 3 alpha) (MIP-3-alpha) (Small-inducible cytokine A20) [Cleaved into: CCL20(1-67); CCL20(1-64); CCL20(2-70)]	CCL20 LARC MIP3A SCYA20	1M8A;2HCI;2JYO;					PF00048;	IPR000827;IPR001811;	calcium-mediated signaling using intracellular calcium source [GO:0035584]; cell-cell signaling [GO:0007267]; cell chemotaxis [GO:0060326]; cellular response to interferon-gamma [GO:0071346]; cellular response to interleukin-1 [GO:0071347]; cellular response to lipopolysaccharide [GO:0071222]; cellular response to lipoteichoic acid [GO:0071223]; cellular response to tumor necrosis factor [GO:0071356]; chemokine-mediated signaling pathway [GO:0070098]; chemotaxis [GO:0006935]; defense response to bacterium [GO:0042742]; G-protein coupled receptor signaling pathway [GO:0007186]; immune response [GO:0006955]; inflammatory response [GO:0006954]; lymphocyte chemotaxis [GO:0048247]; monocyte chemotaxis [GO:0002548]; neutrophil chemotaxis [GO:0030593]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of GTPase activity [GO:0043547]; positive regulation of interleukin-1 alpha biosynthetic process [GO:0050726]; positive regulation of nitric-oxide synthase biosynthetic process [GO:0051770]; positive regulation of T cell migration [GO:2000406]; signal transduction [GO:0007165]; T cell migration [GO:0072678]; thymocyte migration [GO:0072679]; wound healing [GO:0042060]	CCR6 chemokine receptor binding [GO:0031731]; CCR chemokine receptor binding [GO:0048020]; chemokine activity [GO:0008009]	extracellular region [GO:0005576]; extracellular space [GO:0005615]; intracellular [GO:0005622]
P55773	CCL23_HUMAN	C-C motif chemokine 23 (CK-beta-8) (CKB-8) (Macrophage inflammatory protein 3) (MIP-3) (Myeloid progenitor inhibitory factor 1) (MPIF-1) (Small-inducible cytokine A23) [Cleaved into: CCL23(19-99); CCL23(22-99); CCL23(27-99); CCL23(30-99)]	CCL23 MIP3 MPIF1 SCYA23	1G91;					PF00048;	IPR000827;IPR001811;	cell-cell signaling [GO:0007267]; cellular calcium ion homeostasis [GO:0006874]; cellular response to interferon-gamma [GO:0071346]; cellular response to interleukin-1 [GO:0071347]; cellular response to tumor necrosis factor [GO:0071356]; chemokine-mediated signaling pathway [GO:0070098]; chemotaxis [GO:0006935]; G-protein coupled receptor signaling pathway [GO:0007186]; immune response [GO:0006955]; inflammatory response [GO:0006954]; lymphocyte chemotaxis [GO:0048247]; monocyte chemotaxis [GO:0002548]; negative regulation of C-C chemokine binding [GO:2001264]; negative regulation of cell proliferation [GO:0008285]; neutrophil chemotaxis [GO:0030593]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of GTPase activity [GO:0043547]; positive regulation of inflammatory response [GO:0050729]; signal transduction [GO:0007165]	CCR1 chemokine receptor binding [GO:0031726]; chemokine activity [GO:0008009]; heparin binding [GO:0008201]	cell [GO:0005623]; extracellular region [GO:0005576]; extracellular space [GO:0005615]
P13500	CCL2_HUMAN	C-C motif chemokine 2 (HC11) (Monocyte chemoattractant protein 1) (Monocyte chemotactic and activating factor) (MCAF) (Monocyte chemotactic protein 1) (MCP-1) (Monocyte secretory protein JE) (Small-inducible cytokine A2)	CCL2 MCP1 SCYA2	1DOK;1DOL;1DOM;1DON;1MCA;1ML0;2BDN;2NZ1;3IFD;4DN4;4R8I;4ZK9;	CHEMBL1649052;	P13500;	DB01406;DB01055;		PF00048;	IPR000827;IPR001811;	aging [GO:0007568]; angiogenesis [GO:0001525]; animal organ morphogenesis [GO:0009887]; animal organ regeneration [GO:0031100]; astrocyte cell migration [GO:0043615]; cell adhesion [GO:0007155]; cell surface receptor signaling pathway [GO:0007166]; cellular calcium ion homeostasis [GO:0006874]; cellular homeostasis [GO:0019725]; cellular response to ATP [GO:0071318]; cellular response to dexamethasone stimulus [GO:0071549]; cellular response to drug [GO:0035690]; cellular response to fibroblast growth factor stimulus [GO:0044344]; cellular response to high density lipoprotein particle stimulus [GO:0071403]; cellular response to insulin stimulus [GO:0032869]; cellular response to interferon-gamma [GO:0071346]; cellular response to interleukin-1 [GO:0071347]; cellular response to interleukin-6 [GO:0071354]; cellular response to lipopolysaccharide [GO:0071222]; cellular response to macrophage colony-stimulating factor stimulus [GO:0036006]; cellular response to organic cyclic compound [GO:0071407]; cellular response to platelet-derived growth factor stimulus [GO:0036120]; cellular response to retinoic acid [GO:0071300]; cellular response to tumor necrosis factor [GO:0071356]; chemokine-mediated signaling pathway [GO:0070098]; chemotaxis [GO:0006935]; cytokine-mediated signaling pathway [GO:0019221]; cytoskeleton organization [GO:0007010]; G-protein coupled receptor signaling pathway [GO:0007186]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; helper T cell extravasation [GO:0035684]; humoral immune response [GO:0006959]; inflammatory response [GO:0006954]; JAK-STAT cascade [GO:0007259]; leukocyte migration involved in inflammatory response [GO:0002523]; lipopolysaccharide-mediated signaling pathway [GO:0031663]; lymphocyte chemotaxis [GO:0048247]; macrophage chemotaxis [GO:0048246]; MAPK cascade [GO:0000165]; maternal process involved in female pregnancy [GO:0060135]; maternal process involved in parturition [GO:0060137]; monocyte chemotaxis [GO:0002548]; negative regulation of angiogenesis [GO:0016525]; negative regulation of glial cell apoptotic process [GO:0034351]; negative regulation of natural killer cell chemotaxis [GO:2000502]; negative regulation of neuron apoptotic process [GO:0043524]; neutrophil chemotaxis [GO:0030593]; PERK-mediated unfolded protein response [GO:0036499]; positive regulation of apoptotic cell clearance [GO:2000427]; positive regulation of calcium ion import [GO:0090280]; positive regulation of cellular extravasation [GO:0002693]; positive regulation of collagen biosynthetic process [GO:0032967]; positive regulation of endothelial cell proliferation [GO:0001938]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of GTPase activity [GO:0043547]; positive regulation of immune complex clearance by monocytes and macrophages [GO:0090265]; positive regulation of inflammatory response [GO:0050729]; positive regulation of leukocyte mediated cytotoxicity [GO:0001912]; positive regulation of macrophage chemotaxis [GO:0010759]; positive regulation of monocyte chemotaxis [GO:0090026]; positive regulation of nitric-oxide synthase biosynthetic process [GO:0051770]; positive regulation of protein targeting to membrane [GO:0090314]; positive regulation of synaptic transmission [GO:0050806]; positive regulation of T cell activation [GO:0050870]; positive regulation of tumor necrosis factor production [GO:0032760]; protein kinase B signaling [GO:0043491]; protein phosphorylation [GO:0006468]; regulation of cell shape [GO:0008360]; regulation of vascular endothelial growth factor production [GO:0010574]; response to activity [GO:0014823]; response to amino acid [GO:0043200]; response to antibiotic [GO:0046677]; response to bacterium [GO:0009617]; response to ethanol [GO:0045471]; response to gamma radiation [GO:0010332]; response to heat [GO:0009408]; response to hypoxia [GO:0001666]; response to mechanical stimulus [GO:0009612]; response to progesterone [GO:0032570]; response to vitamin B3 [GO:0033552]; response to wounding [GO:0009611]; signal transduction [GO:0007165]; transforming growth factor beta receptor signaling pathway [GO:0007179]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]; viral genome replication [GO:0019079]	CCR2 chemokine receptor binding [GO:0031727]; chemokine activity [GO:0008009]; heparin binding [GO:0008201]; protein kinase activity [GO:0004672]; receptor binding [GO:0005102]	axon terminus [GO:0043679]; C-fiber [GO:0044299]; dendrite [GO:0030425]; endocytic vesicle [GO:0030139]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; perikaryon [GO:0043204]; perinuclear region of cytoplasm [GO:0048471]; rough endoplasmic reticulum [GO:0005791]; synapse [GO:0045202]
P13501	CCL5_HUMAN	C-C motif chemokine 5 (EoCP) (Eosinophil chemotactic cytokine) (SIS-delta) (Small-inducible cytokine A5) (T cell-specific protein P228) (TCP228) (T-cell-specific protein RANTES) [Cleaved into: RANTES(3-68); RANTES(4-68)]	CCL5 D17S136E SCYA5	1B3A;1EQT;1HRJ;1RTN;1RTO;1U4L;1U4M;1U4P;1U4R;2L9H;2VXW;5CMD;5COY;5DNF;	CHEMBL1275217;	P13501;			PF00048;	IPR030595;IPR000827;IPR001811;	activation of phospholipase D activity [GO:0031584]; calcium ion transport [GO:0006816]; cell-cell signaling [GO:0007267]; cellular calcium ion homeostasis [GO:0006874]; cellular protein complex assembly [GO:0043623]; cellular response to fibroblast growth factor stimulus [GO:0044344]; cellular response to interferon-gamma [GO:0071346]; cellular response to interleukin-1 [GO:0071347]; cellular response to organic cyclic compound [GO:0071407]; cellular response to tumor necrosis factor [GO:0071356]; chemokine-mediated signaling pathway [GO:0070098]; chemotaxis [GO:0006935]; dendritic cell chemotaxis [GO:0002407]; eosinophil chemotaxis [GO:0048245]; exocytosis [GO:0006887]; G-protein coupled receptor signaling pathway [GO:0007186]; inflammatory response [GO:0006954]; leukocyte cell-cell adhesion [GO:0007159]; lipopolysaccharide-mediated signaling pathway [GO:0031663]; macrophage chemotaxis [GO:0048246]; MAPK cascade [GO:0000165]; monocyte chemotaxis [GO:0002548]; negative regulation by host of viral transcription [GO:0043922]; negative regulation of G-protein coupled receptor protein signaling pathway [GO:0045744]; negative regulation of macrophage apoptotic process [GO:2000110]; negative regulation of T cell apoptotic process [GO:0070233]; negative regulation of viral genome replication [GO:0045071]; neutrophil activation [GO:0042119]; neutrophil chemotaxis [GO:0030593]; positive regulation of activation of JAK2 kinase activity [GO:0010535]; positive regulation of calcium ion transport [GO:0051928]; positive regulation of cell adhesion [GO:0045785]; positive regulation of cell-cell adhesion mediated by integrin [GO:0033634]; positive regulation of cell migration [GO:0030335]; positive regulation of cellular biosynthetic process [GO:0031328]; positive regulation of epithelial cell proliferation [GO:0050679]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of GTPase activity [GO:0043547]; positive regulation of homotypic cell-cell adhesion [GO:0034112]; positive regulation of inflammatory response [GO:0050729]; positive regulation of innate immune response [GO:0045089]; positive regulation of JAK-STAT cascade [GO:0046427]; positive regulation of macrophage chemotaxis [GO:0010759]; positive regulation of monocyte chemotaxis [GO:0090026]; positive regulation of natural killer cell chemotaxis [GO:2000503]; positive regulation of phosphatidylinositol 3-kinase signaling [GO:0014068]; positive regulation of phosphorylation [GO:0042327]; positive regulation of smooth muscle cell migration [GO:0014911]; positive regulation of smooth muscle cell proliferation [GO:0048661]; positive regulation of T cell apoptotic process [GO:0070234]; positive regulation of T cell chemotaxis [GO:0010820]; positive regulation of T cell migration [GO:2000406]; positive regulation of T cell proliferation [GO:0042102]; positive regulation of translational initiation [GO:0045948]; positive regulation of tyrosine phosphorylation of STAT protein [GO:0042531]; positive regulation of viral genome replication [GO:0045070]; protein kinase B signaling [GO:0043491]; protein tetramerization [GO:0051262]; regulation of chronic inflammatory response [GO:0002676]; regulation of insulin secretion [GO:0050796]; regulation of neuron death [GO:1901214]; regulation of T cell activation [GO:0050863]; response to toxic substance [GO:0009636]; response to virus [GO:0009615]	CCR1 chemokine receptor binding [GO:0031726]; CCR4 chemokine receptor binding [GO:0031729]; CCR5 chemokine receptor binding [GO:0031730]; chemoattractant activity [GO:0042056]; chemokine activity [GO:0008009]; chemokine receptor antagonist activity [GO:0046817]; chemokine receptor binding [GO:0042379]; phosphatidylinositol phospholipase C activity [GO:0004435]; phospholipase activator activity [GO:0016004]; protein homodimerization activity [GO:0042803]; protein kinase activity [GO:0004672]; protein self-association [GO:0043621]; receptor signaling protein tyrosine kinase activator activity [GO:0030298]	cytoplasm [GO:0005737]; extracellular region [GO:0005576]; extracellular space [GO:0005615]
P80075	CCL8_HUMAN	C-C motif chemokine 8 (HC14) (Monocyte chemoattractant protein 2) (Monocyte chemotactic protein 2) (MCP-2) (Small-inducible cytokine A8) [Cleaved into: MCP-2(6-76)]	CCL8 MCP2 SCYA10 SCYA8	1ESR;					PF00048;	IPR033225;IPR000827;IPR001811;	calcium ion transport [GO:0006816]; cell-cell signaling [GO:0007267]; cellular calcium ion homeostasis [GO:0006874]; cellular response to interferon-gamma [GO:0071346]; cellular response to interleukin-1 [GO:0071347]; cellular response to tumor necrosis factor [GO:0071356]; chemokine-mediated signaling pathway [GO:0070098]; chemotaxis [GO:0006935]; exocytosis [GO:0006887]; G-protein coupled receptor signaling pathway [GO:0007186]; inflammatory response [GO:0006954]; lymphocyte chemotaxis [GO:0048247]; monocyte chemotaxis [GO:0002548]; negative regulation of leukocyte proliferation [GO:0070664]; neutrophil chemotaxis [GO:0030593]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of GTPase activity [GO:0043547]; positive regulation of inflammatory response [GO:0050729]; positive regulation of leukocyte migration [GO:0002687]; response to virus [GO:0009615]; signal transduction [GO:0007165]	CCR chemokine receptor binding [GO:0048020]; chemokine activity [GO:0008009]; heparin binding [GO:0008201]; phospholipase activator activity [GO:0016004]; protein kinase activity [GO:0004672]	cell [GO:0005623]; extracellular space [GO:0005615]
P24385	CCND1_HUMAN	G1/S-specific cyclin-D1 (B-cell lymphoma 1 protein) (BCL-1) (BCL-1 oncogene) (PRAD1 oncogene)	CCND1 BCL1 PRAD1	2W96;2W99;2W9F;2W9Z;	CHEMBL3610;	P24385;	DB01169;		PF02984;PF00134;	IPR013763;IPR004367;IPR006671;	canonical Wnt signaling pathway [GO:0060070]; cell division [GO:0051301]; cellular response to DNA damage stimulus [GO:0006974]; endoplasmic reticulum unfolded protein response [GO:0030968]; fat cell differentiation [GO:0045444]; G1/S transition of mitotic cell cycle [GO:0000082]; lactation [GO:0007595]; Leydig cell differentiation [GO:0033327]; liver regeneration [GO:0097421]; mammary gland alveolus development [GO:0060749]; mammary gland epithelial cell proliferation [GO:0033598]; mitotic G1 DNA damage checkpoint [GO:0031571]; negative regulation of cell cycle arrest [GO:0071157]; negative regulation of epithelial cell differentiation [GO:0030857]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; negative regulation of Wnt signaling pathway [GO:0030178]; positive regulation of cell cycle [GO:0045787]; positive regulation of cyclin-dependent protein serine/threonine kinase activity [GO:0045737]; positive regulation of G2/M transition of mitotic cell cycle [GO:0010971]; positive regulation of mammary gland epithelial cell proliferation [GO:0033601]; positive regulation of protein phosphorylation [GO:0001934]; re-entry into mitotic cell cycle [GO:0000320]; response to calcium ion [GO:0051592]; response to corticosterone [GO:0051412]; response to drug [GO:0042493]; response to estradiol [GO:0032355]; response to estrogen [GO:0043627]; response to ethanol [GO:0045471]; response to iron ion [GO:0010039]; response to leptin [GO:0044321]; response to magnesium ion [GO:0032026]; response to organonitrogen compound [GO:0010243]; response to UV-A [GO:0070141]; response to vitamin E [GO:0033197]; response to X-ray [GO:0010165]; transcription, DNA-templated [GO:0006351]	cyclin-dependent protein serine/threonine kinase regulator activity [GO:0016538]; enzyme binding [GO:0019899]; histone deacetylase binding [GO:0042826]; proline-rich region binding [GO:0070064]; protein kinase activity [GO:0004672]; protein kinase binding [GO:0019901]; transcription corepressor activity [GO:0003714]; transcription factor binding [GO:0008134]	bicellular tight junction [GO:0005923]; cyclin-dependent protein kinase holoenzyme complex [GO:0000307]; cytosol [GO:0005829]; intracellular [GO:0005622]; membrane [GO:0016020]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; transcriptional repressor complex [GO:0017053]
P51681	CCR5_HUMAN	C-C chemokine receptor type 5 (C-C CKR-5) (CC-CKR-5) (CCR-5) (CCR5) (CHEMR13) (HIV-1 fusion coreceptor) (CD antigen CD195)	CCR5 CMKBR5	1ND8;1NE0;1OPN;1OPT;1OPW;2L87;2MZX;2RLL;2RRS;4MBS;	CHEMBL274;	P51681;	DB04835;		PF00001;	IPR002240;IPR000355;IPR000276;IPR017452;	calcium ion transport [GO:0006816]; calcium-mediated signaling [GO:0019722]; cell-cell signaling [GO:0007267]; cell surface receptor signaling pathway [GO:0007166]; cellular defense response [GO:0006968]; cellular response to lipopolysaccharide [GO:0071222]; chemotaxis [GO:0006935]; dendritic cell chemotaxis [GO:0002407]; entry into host cell [GO:0030260]; fusion of virus membrane with host plasma membrane [GO:0019064]; G-protein coupled receptor signaling pathway [GO:0007186]; immune response [GO:0006955]; inflammatory response [GO:0006954]; MAPK cascade [GO:0000165]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; release of sequestered calcium ion into cytosol by sarcoplasmic reticulum [GO:0014808]; response to cholesterol [GO:0070723]; signaling [GO:0023052]	actin binding [GO:0003779]; C-C chemokine binding [GO:0019957]; C-C chemokine receptor activity [GO:0016493]; chemokine (C-C motif) ligand 5 binding [GO:0071791]; chemokine receptor activity [GO:0004950]; coreceptor activity [GO:0015026]; phosphatidylinositol phospholipase C activity [GO:0004435]; virus receptor activity [GO:0001618]	cell surface [GO:0009986]; cytoplasm [GO:0005737]; endosome [GO:0005768]; external side of plasma membrane [GO:0009897]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
Q9NNX6	CD209_HUMAN	CD209 antigen (C-type lectin domain family 4 member L) (Dendritic cell-specific ICAM-3-grabbing non-integrin 1) (DC-SIGN) (DC-SIGN1) (CD antigen CD209)	CD209 CLEC4L	1K9I;1SL4;1SL5;2B6B;2IT5;2IT6;2XR5;2XR6;	CHEMBL1795114;	Q9NNX6;			PF00059;	IPR001304;IPR016186;IPR018378;IPR016187;	adaptive immune response [GO:0002250]; antigen processing and presentation [GO:0019882]; cell-cell recognition [GO:0009988]; endocytosis [GO:0006897]; heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules [GO:0007157]; innate immune response [GO:0045087]; intracellular signal transduction [GO:0035556]; intracellular transport of virus [GO:0075733]; leukocyte cell-cell adhesion [GO:0007159]; modulation by virus of host morphology or physiology [GO:0019048]; peptide antigen transport [GO:0046968]; regulation of T cell proliferation [GO:0042129]; stimulatory C-type lectin receptor signaling pathway [GO:0002223]; viral genome replication [GO:0019079]; virion attachment to host cell [GO:0019062]	carbohydrate binding [GO:0030246]; mannose binding [GO:0005537]; metal ion binding [GO:0046872]; peptide antigen binding [GO:0042605]; virion binding [GO:0046790]; virus receptor activity [GO:0001618]	cell surface [GO:0009986]; cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; membrane [GO:0016020]; plasma membrane [GO:0005886]
Q9HCU0	CD248_HUMAN	Endosialin (Tumor endothelial marker 1) (CD antigen CD248)	CD248 CD164L1 TEM1						PF00059;	IPR001304;IPR016186;IPR016187;IPR001881;IPR000742;IPR000152;IPR018097;IPR009030;	anatomical structure regression [GO:0060033]; cell migration [GO:0016477]; lymph node development [GO:0048535]; positive regulation of cell proliferation [GO:0008284]; positive regulation of endothelial cell apoptotic process [GO:2000353]	calcium ion binding [GO:0005509]; carbohydrate binding [GO:0030246]; extracellular matrix binding [GO:0050840]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; proteinaceous extracellular matrix [GO:0005578]
P06729	CD2_HUMAN	T-cell surface antigen CD2 (Erythrocyte receptor) (LFA-2) (LFA-3 receptor) (Rosette receptor) (T-cell surface antigen T11/Leu-5) (CD antigen CD2)	CD2 SRBC	1CDB;1GYA;1HNF;1L2Z;1QA9;2J6O;2J7I;	CHEMBL2040;	P06729;	DB00092;		PF05790;PF07686;	IPR015632;IPR007110;IPR013783;IPR008424;IPR013106;	apoptotic process [GO:0006915]; cell surface receptor signaling pathway [GO:0007166]; heterotypic cell-cell adhesion [GO:0034113]; leukocyte migration [GO:0050900]; membrane raft polarization [GO:0001766]; natural killer cell activation [GO:0030101]; positive regulation of interferon-gamma secretion [GO:1902715]; positive regulation of interleukin-8 secretion [GO:2000484]; positive regulation of myeloid dendritic cell activation [GO:0030887]; positive regulation of tumor necrosis factor production [GO:0032760]; regulation of T cell differentiation [GO:0045580]; single organismal cell-cell adhesion [GO:0016337]; T cell activation [GO:0042110]	receptor activity [GO:0004872]; receptor binding [GO:0005102]	anchored component of plasma membrane [GO:0046658]; cell-cell junction [GO:0005911]; cell surface [GO:0009986]; cytoplasmic side of plasma membrane [GO:0009898]; external side of plasma membrane [GO:0009897]; extracellular region [GO:0005576]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P29965	CD40L_HUMAN	CD40 ligand (CD40-L) (T-cell antigen Gp39) (TNF-related activation protein) (TRAP) (Tumor necrosis factor ligand superfamily member 5) (CD antigen CD154) [Cleaved into: CD40 ligand, membrane form; CD40 ligand, soluble form]	CD40LG CD40L TNFSF5 TRAP	1ALY;1I9R;3LKJ;3QD6;					PF00229;	IPR003263;IPR021184;IPR006052;IPR008983;	activation of JUN kinase activity [GO:0007257]; B cell differentiation [GO:0030183]; B cell proliferation [GO:0042100]; immunoglobulin secretion [GO:0048305]; inflammatory response [GO:0006954]; isotype switching [GO:0045190]; leukocyte cell-cell adhesion [GO:0007159]; negative regulation of apoptotic process [GO:0043066]; platelet activation [GO:0030168]; positive regulation of endothelial cell apoptotic process [GO:2000353]; positive regulation of interleukin-10 production [GO:0032733]; positive regulation of interleukin-12 production [GO:0032735]; positive regulation of interleukin-4 production [GO:0032753]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of T cell proliferation [GO:0042102]; regulation of immune response [GO:0050776]; regulation of immunoglobulin secretion [GO:0051023]; T cell costimulation [GO:0031295]; tumor necrosis factor-mediated signaling pathway [GO:0033209]	CD40 receptor binding [GO:0005174]	cell surface [GO:0009986]; external side of plasma membrane [GO:0009897]; extracellular space [GO:0005615]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; intracellular [GO:0005622]; plasma membrane [GO:0005886]
P13987	CD59_HUMAN	CD59 glycoprotein (1F5 antigen) (20 kDa homologous restriction factor) (HRF-20) (HRF20) (MAC-inhibitory protein) (MAC-IP) (MEM43 antigen) (Membrane attack complex inhibition factor) (MACIF) (Membrane inhibitor of reactive lysis) (MIRL) (Protectin) (CD antigen CD59)	CD59 MIC11 MIN1 MIN2 MIN3 MSK21	1CDQ;1CDR;1CDS;1ERG;1ERH;2J8B;2OFS;2UWR;2UX2;4BIK;5IMT;5IMY;					PF00021;	IPR018363;IPR027101;IPR016054;	blood coagulation [GO:0007596]; cell activation [GO:0001775]; cell surface receptor signaling pathway [GO:0007166]; COPII vesicle coating [GO:0048208]; ER to Golgi vesicle-mediated transport [GO:0006888]; negative regulation of activation of membrane attack complex [GO:0001971]; negative regulation of apoptotic process [GO:0043066]; positive regulation of T cell proliferation [GO:0042102]; regulation of complement activation [GO:0030449]	complement binding [GO:0001848]	anchored component of external side of plasma membrane [GO:0031362]; cell surface [GO:0009986]; compact myelin [GO:0043218]; endoplasmic reticulum-Golgi intermediate compartment membrane [GO:0033116]; endoplasmic reticulum membrane [GO:0005789]; ER to Golgi transport vesicle membrane [GO:0012507]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; focal adhesion [GO:0005925]; Golgi membrane [GO:0000139]; membrane [GO:0016020]; plasma membrane [GO:0005886]; sarcolemma [GO:0042383]; vesicle [GO:0031982]
P06493	CDC2_HUMAN	Cyclin-dependent kinase 1 (CDK1) (EC 2.7.11.22) (EC 2.7.11.23) (Cell division control protein 2 homolog) (Cell division protein kinase 1) (p34 protein kinase)	CDK1 CDC2 CDC28A CDKN1 P34CDC2	1LC9;4Y72;4YC3;4YC6;5HQ0;	CHEMBL308;	P06493;			PF00069;	IPR011009;IPR000719;IPR017441;IPR008271;	activation of MAPK activity [GO:0000187]; anaphase-promoting complex-dependent catabolic process [GO:0031145]; animal organ regeneration [GO:0031100]; apoptotic process [GO:0006915]; cell aging [GO:0007569]; cell division [GO:0051301]; cell migration [GO:0016477]; cell proliferation [GO:0008283]; cellular response to hydrogen peroxide [GO:0070301]; centrosome cycle [GO:0007098]; chromosome condensation [GO:0030261]; DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest [GO:0006977]; DNA repair [GO:0006281]; DNA replication [GO:0006260]; epithelial cell differentiation [GO:0030855]; G1/S transition of mitotic cell cycle [GO:0000082]; G2/M transition of mitotic cell cycle [GO:0000086]; Golgi disassembly [GO:0090166]; microtubule cytoskeleton organization [GO:0000226]; mitotic G2 DNA damage checkpoint [GO:0007095]; mitotic nuclear division [GO:0007067]; mitotic nuclear envelope disassembly [GO:0007077]; negative regulation of apoptotic process [GO:0043066]; negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle [GO:0051436]; peptidyl-serine phosphorylation [GO:0018105]; peptidyl-threonine phosphorylation [GO:0018107]; positive regulation of cardiac muscle cell proliferation [GO:0060045]; positive regulation of DNA replication [GO:0045740]; positive regulation of gene expression [GO:0010628]; positive regulation of mitotic cell cycle [GO:0045931]; positive regulation of protein import into nucleus, translocation [GO:0033160]; positive regulation of protein localization to nucleus [GO:1900182]; positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition [GO:0051437]; pronuclear fusion [GO:0007344]; proteasome-mediated ubiquitin-dependent protein catabolic process [GO:0043161]; protein complex assembly [GO:0006461]; protein localization to kinetochore [GO:0034501]; protein ubiquitination involved in ubiquitin-dependent protein catabolic process [GO:0042787]; regulation of embryonic development [GO:0045995]; regulation of Schwann cell differentiation [GO:0014038]; regulation of transcription involved in G1/S transition of mitotic cell cycle [GO:0000083]; regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle [GO:0051439]; response to activity [GO:0014823]; response to amine [GO:0014075]; response to axon injury [GO:0048678]; response to cadmium ion [GO:0046686]; response to copper ion [GO:0046688]; response to drug [GO:0042493]; response to ethanol [GO:0045471]; response to organic cyclic compound [GO:0014070]; response to toxic substance [GO:0009636]; ventricular cardiac muscle cell development [GO:0055015]	ATP binding [GO:0005524]; chromatin binding [GO:0003682]; cyclin binding [GO:0030332]; cyclin-dependent protein serine/threonine kinase activity [GO:0004693]; histone kinase activity [GO:0035173]; protein kinase activity [GO:0004672]; protein serine/threonine kinase activity [GO:0004674]; RNA polymerase II carboxy-terminal domain kinase activity [GO:0008353]	centrosome [GO:0005813]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; midbody [GO:0030496]; mitochondrion [GO:0005739]; mitotic spindle [GO:0072686]; nuclear chromosome, telomeric region [GO:0000784]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; spindle microtubule [GO:0005876]
Q9Y5I4	CDC2_HUMAN	Protocadherin alpha-C2 (PCDH-alpha-C2)	PCDHAC2						PF00028;PF08266;PF16492;PF15974;	IPR002126;IPR015919;IPR032455;IPR031904;IPR020894;IPR013164;IPR030726;	cell adhesion [GO:0007155]; homophilic cell adhesion via plasma membrane adhesion molecules [GO:0007156]; nervous system development [GO:0007399]	calcium ion binding [GO:0005509]	integral component of plasma membrane [GO:0005887]
P32320	CDD_HUMAN	Cytidine deaminase (EC 3.5.4.5) (Cytidine aminohydrolase)	CDA CDD	1MQ0;	CHEMBL4502;	P32320;	DB00928;DB01101;DB00987;DB00441;		PF00383;	IPR016192;IPR002125;IPR006262;IPR016193;	cell surface receptor signaling pathway [GO:0007166]; cytidine deamination [GO:0009972]; cytosine metabolic process [GO:0019858]; negative regulation of cell growth [GO:0030308]; negative regulation of nucleotide metabolic process [GO:0045980]; protein homotetramerization [GO:0051289]; pyrimidine-containing compound salvage [GO:0008655]; pyrimidine nucleoside salvage [GO:0043097]	cytidine deaminase activity [GO:0004126]; nucleoside binding [GO:0001882]; protein homodimerization activity [GO:0042803]; zinc ion binding [GO:0008270]	cytosol [GO:0005829]; extracellular region [GO:0005576]
O14735	CDIPT_HUMAN	CDP-diacylglycerol--inositol 3-phosphatidyltransferase (EC 2.7.8.11) (Phosphatidylinositol synthase) (PI synthase) (PtdIns synthase)	CDIPT PIS PIS1						PF01066;	IPR000462;IPR014387;	CDP-diacylglycerol metabolic process [GO:0046341]; phosphatidylinositol biosynthetic process [GO:0006661]	alcohol binding [GO:0043178]; carbohydrate binding [GO:0030246]; CDP-diacylglycerol-inositol 3-phosphatidyltransferase activity [GO:0003881]; diacylglycerol binding [GO:0019992]; manganese ion binding [GO:0030145]	endoplasmic reticulum membrane [GO:0005789]; Golgi apparatus [GO:0005794]; Golgi membrane [GO:0000139]; integral component of membrane [GO:0016021]; membrane [GO:0016020]; plasma membrane [GO:0005886]
P11802	CDK4_HUMAN	Cyclin-dependent kinase 4 (EC 2.7.11.22) (Cell division protein kinase 4) (PSK-J3)	CDK4	1LD2;2W96;2W99;2W9F;2W9Z;3G33;5FWK;5FWL;5FWM;	CHEMBL331;	P11802;	DB09073;		PF00069;	IPR011009;IPR000719;IPR017441;IPR008271;	animal organ regeneration [GO:0031100]; cell division [GO:0051301]; circadian rhythm [GO:0007623]; G1/S transition of mitotic cell cycle [GO:0000082]; lens development in camera-type eye [GO:0002088]; negative regulation of cell cycle arrest [GO:0071157]; positive regulation of apoptotic process [GO:0043065]; positive regulation of cell cycle [GO:0045787]; positive regulation of cell proliferation [GO:0008284]; positive regulation of cell size [GO:0045793]; positive regulation of fibroblast proliferation [GO:0048146]; positive regulation of G2/M transition of mitotic cell cycle [GO:0010971]; positive regulation of translation [GO:0045727]; protein phosphorylation [GO:0006468]; regulation of gene expression [GO:0010468]; response to drug [GO:0042493]; response to hyperoxia [GO:0055093]; response to lead ion [GO:0010288]; response to testosterone [GO:0033574]; response to toxic substance [GO:0009636]; signal transduction [GO:0007165]	ATP binding [GO:0005524]; cyclin binding [GO:0030332]; cyclin-dependent protein serine/threonine kinase activity [GO:0004693]; cyclin-dependent protein serine/threonine kinase regulator activity [GO:0016538]	bicellular tight junction [GO:0005923]; chromatin [GO:0000785]; cyclin-dependent protein kinase holoenzyme complex [GO:0000307]; cytosol [GO:0005829]; nuclear membrane [GO:0031965]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; transcription factor complex [GO:0005667]
Q00535	CDK5_HUMAN	Cyclin-dependent-like kinase 5 (EC 2.7.11.1) (Cell division protein kinase 5) (Serine/threonine-protein kinase PSSALRE) (Tau protein kinase II catalytic subunit) (TPKII catalytic subunit)	CDK5 CDKN5	1H4L;1LFR;1UNG;1UNH;1UNL;3O0G;4AU8;	CHEMBL4036;	Q00535;			PF00069;	IPR011009;IPR000719;IPR017441;IPR008271;	axon extension [GO:0048675]; behavioral response to cocaine [GO:0048148]; calcium ion import [GO:0070509]; cell cycle [GO:0007049]; cell division [GO:0051301]; cell-matrix adhesion [GO:0007160]; cell proliferation [GO:0008283]; central nervous system neuron development [GO:0021954]; cerebellar cortex formation [GO:0021697]; chemical synaptic transmission [GO:0007268]; corpus callosum development [GO:0022038]; cortical actin cytoskeleton organization [GO:0030866]; dendrite morphogenesis [GO:0048813]; excitatory postsynaptic potential [GO:0060079]; hippocampus development [GO:0021766]; intracellular protein transport [GO:0006886]; layer formation in cerebral cortex [GO:0021819]; motor neuron axon guidance [GO:0008045]; negative regulation of axon extension [GO:0030517]; negative regulation of cell cycle [GO:0045786]; negative regulation of neuron death [GO:1901215]; negative regulation of protein export from nucleus [GO:0046826]; negative regulation of protein ubiquitination [GO:0031397]; negative regulation of proteolysis [GO:0045861]; negative regulation of synaptic plasticity [GO:0031914]; negative regulation of transcription, DNA-templated [GO:0045892]; neuron apoptotic process [GO:0051402]; neuron differentiation [GO:0030182]; neuron migration [GO:0001764]; neuron projection development [GO:0031175]; nucleocytoplasmic transport [GO:0006913]; oligodendrocyte differentiation [GO:0048709]; peptidyl-serine phosphorylation [GO:0018105]; peptidyl-threonine phosphorylation [GO:0018107]; phosphorylation [GO:0016310]; positive regulation of actin cytoskeleton reorganization [GO:2000251]; positive regulation of calcium ion-dependent exocytosis [GO:0045956]; positive regulation of neuron apoptotic process [GO:0043525]; positive regulation of protein binding [GO:0032092]; positive regulation of protein kinase activity [GO:0045860]; positive regulation of protein targeting to membrane [GO:0090314]; protein autophosphorylation [GO:0046777]; protein localization to synapse [GO:0035418]; receptor catabolic process [GO:0032801]; receptor clustering [GO:0043113]; regulation of apoptotic process [GO:0042981]; regulation of cell cycle arrest [GO:0071156]; regulation of cell migration [GO:0030334]; regulation of dendritic spine morphogenesis [GO:0061001]; regulation of macroautophagy [GO:0016241]; regulation of signal transduction by p53 class mediator [GO:1901796]; regulation of synaptic plasticity [GO:0048167]; regulation of synaptic vesicle recycling [GO:1903421]; response to wounding [GO:0009611]; rhythmic process [GO:0048511]; Schwann cell development [GO:0014044]; sensory perception of pain [GO:0019233]; serine phosphorylation of STAT3 protein [GO:0033136]; skeletal muscle tissue development [GO:0007519]; synapse assembly [GO:0007416]; synaptic transmission, dopaminergic [GO:0001963]; synaptic transmission, glutamatergic [GO:0035249]; synaptic vesicle endocytosis [GO:0048488]; synaptic vesicle exocytosis [GO:0016079]; visual learning [GO:0008542]	acetylcholine receptor activator activity [GO:0030549]; ATP binding [GO:0005524]; cyclin-dependent protein serine/threonine kinase activity [GO:0004693]; ErbB-2 class receptor binding [GO:0005176]; ErbB-3 class receptor binding [GO:0043125]; kinase activity [GO:0016301]; protein kinase activity [GO:0004672]; protein serine/threonine kinase activity [GO:0004674]; tau-protein kinase activity [GO:0050321]	axon [GO:0030424]; cell junction [GO:0030054]; cyclin-dependent protein kinase 5 holoenzyme complex [GO:0016533]; cytoplasm [GO:0005737]; cytoskeleton [GO:0005856]; cytosol [GO:0005829]; dendrite [GO:0030425]; filopodium [GO:0030175]; growth cone [GO:0030426]; lamellipodium [GO:0030027]; membrane [GO:0016020]; neuromuscular junction [GO:0031594]; neuronal cell body [GO:0043025]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; perikaryon [GO:0043204]; plasma membrane [GO:0005886]; postsynaptic density [GO:0014069]; postsynaptic membrane [GO:0045211]; presynapse [GO:0098793]
Q00534	CDK6_HUMAN	Cyclin-dependent kinase 6 (EC 2.7.11.22) (Cell division protein kinase 6) (Serine/threonine-protein kinase PLSTIRE)	CDK6 CDKN6	1BI7;1BI8;1BLX;1G3N;1JOW;1XO2;2EUF;2F2C;3NUP;3NUX;4AUA;4EZ5;4TTH;5L2I;5L2T;	CHEMBL2508;	Q00534;	DB09073;		PF00069;	IPR028788;IPR011009;IPR000719;IPR017441;IPR008271;	astrocyte development [GO:0014002]; cell cycle arrest [GO:0007050]; cell dedifferentiation [GO:0043697]; cell division [GO:0051301]; cellular response to phorbol 13-acetate 12-myristate [GO:1904628]; dentate gyrus development [GO:0021542]; G1/S transition of mitotic cell cycle [GO:0000082]; generation of neurons [GO:0048699]; gliogenesis [GO:0042063]; hematopoietic stem cell differentiation [GO:0060218]; lateral ventricle development [GO:0021670]; negative regulation of cell cycle [GO:0045786]; negative regulation of cell differentiation [GO:0045596]; negative regulation of cell proliferation [GO:0008285]; negative regulation of cellular senescence [GO:2000773]; negative regulation of epithelial cell proliferation [GO:0050680]; negative regulation of monocyte differentiation [GO:0045656]; negative regulation of myeloid cell differentiation [GO:0045638]; negative regulation of osteoblast differentiation [GO:0045668]; Notch signaling pathway [GO:0007219]; positive regulation of cell-matrix adhesion [GO:0001954]; positive regulation of fibroblast proliferation [GO:0048146]; positive regulation of gene expression [GO:0010628]; protein phosphorylation [GO:0006468]; regulation of cell motility [GO:2000145]; regulation of erythrocyte differentiation [GO:0045646]; regulation of gene expression [GO:0010468]; response to virus [GO:0009615]; T cell differentiation in thymus [GO:0033077]; type B pancreatic cell development [GO:0003323]	ATP binding [GO:0005524]; cyclin binding [GO:0030332]; cyclin-dependent protein serine/threonine kinase activity [GO:0004693]	centrosome [GO:0005813]; cyclin-dependent protein kinase holoenzyme complex [GO:0000307]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; ruffle [GO:0001726]
P50613	CDK7_HUMAN	Cyclin-dependent kinase 7 (EC 2.7.11.22) (EC 2.7.11.23) (39 kDa protein kinase) (p39 Mo15) (CDK-activating kinase 1) (Cell division protein kinase 7) (Serine/threonine-protein kinase 1) (TFIIH basal transcription factor complex kinase subunit)	CDK7 CAK CAK1 CDKN7 MO15 STK1	1LG3;1PA8;1UA2;2HIC;	CHEMBL3055;	P50613;			PF00069;	IPR011009;IPR000719;IPR017441;IPR008271;	7-methylguanosine mRNA capping [GO:0006370]; androgen receptor signaling pathway [GO:0030521]; cell cycle arrest [GO:0007050]; cell division [GO:0051301]; cell proliferation [GO:0008283]; G1/S transition of mitotic cell cycle [GO:0000082]; G2/M transition of mitotic cell cycle [GO:0000086]; nucleotide-excision repair, preincision complex assembly [GO:0006294]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; regulation of cyclin-dependent protein serine/threonine kinase activity [GO:0000079]; snRNA transcription from RNA polymerase II promoter [GO:0042795]; termination of RNA polymerase I transcription [GO:0006363]; transcription-coupled nucleotide-excision repair [GO:0006283]; transcription elongation from RNA polymerase II promoter [GO:0006368]; transcription elongation from RNA polymerase I promoter [GO:0006362]; transcription from RNA polymerase II promoter [GO:0006366]; transcription initiation from RNA polymerase II promoter [GO:0006367]; transcription initiation from RNA polymerase I promoter [GO:0006361]	androgen receptor binding [GO:0050681]; ATP binding [GO:0005524]; cyclin-dependent protein serine/threonine kinase activity [GO:0004693]; DNA-dependent ATPase activity [GO:0008094]; kinase activity [GO:0016301]; protein C-terminus binding [GO:0008022]; protein kinase activity [GO:0004672]; protein serine/threonine kinase activity [GO:0004674]; RNA polymerase II carboxy-terminal domain kinase activity [GO:0008353]; transcription coactivator activity [GO:0003713]	cytoplasm [GO:0005737]; holo TFIIH complex [GO:0005675]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]
P49336	CDK8_HUMAN	Cyclin-dependent kinase 8 (EC 2.7.11.22) (EC 2.7.11.23) (Cell division protein kinase 8) (Mediator complex subunit CDK8) (Mediator of RNA polymerase II transcription subunit CDK8) (Protein kinase K35)	CDK8	3RGF;4CRL;4F6S;4F6U;4F6W;4F70;4F7J;4F7L;4F7N;4F7S;4G6L;5BNJ;5CEI;5FGK;5HBE;5HBH;5HBJ;5HNB;5HVY;5I5Z;	CHEMBL5719;	P49336;			PF00069;	IPR011009;IPR000719;IPR017441;IPR008271;	positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; transcription initiation from RNA polymerase II promoter [GO:0006367]	ATP binding [GO:0005524]; cyclin-dependent protein serine/threonine kinase activity [GO:0004693]; protein kinase activity [GO:0004672]; protein serine/threonine kinase activity [GO:0004674]; RNA polymerase II carboxy-terminal domain kinase activity [GO:0008353]	mediator complex [GO:0016592]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; protein complex [GO:0043234]
P50750	CDK9_HUMAN	Cyclin-dependent kinase 9 (EC 2.7.11.22) (EC 2.7.11.23) (C-2K) (Cell division cycle 2-like protein kinase 4) (Cell division protein kinase 9) (Serine/threonine-protein kinase PITALRE) (Tat-associated kinase complex catalytic subunit)	CDK9 CDC2L4 TAK	1PF6;3BLH;3BLQ;3BLR;3LQ5;3MI9;3MIA;3MY1;3TN8;3TNH;3TNI;4BCF;4BCG;4BCH;4BCI;4BCJ;4EC8;4EC9;4IMY;4OGR;4OR5;	CHEMBL3116;	P50750;			PF00069;	IPR011009;IPR000719;IPR017441;IPR008271;	cell proliferation [GO:0008283]; cellular response to cytokine stimulus [GO:0071345]; DNA repair [GO:0006281]; negative regulation of cell cycle arrest [GO:0071157]; negative regulation of mRNA polyadenylation [GO:1900364]; positive regulation of cardiac muscle hypertrophy [GO:0010613]; positive regulation of histone H2B ubiquitination [GO:2001168]; positive regulation of histone phosphorylation [GO:0033129]; positive regulation of mRNA 3'-UTR binding [GO:1903839]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of viral transcription [GO:0050434]; protein phosphorylation [GO:0006468]; regulation of DNA repair [GO:0006282]; regulation of histone modification [GO:0031056]; regulation of muscle cell differentiation [GO:0051147]; replication fork processing [GO:0031297]; response to drug [GO:0042493]; snRNA transcription from RNA polymerase II promoter [GO:0042795]; transcription elongation from RNA polymerase II promoter [GO:0006368]; transcription from RNA polymerase II promoter [GO:0006366]; transcription initiation from RNA polymerase II promoter [GO:0006367]	7SK snRNA binding [GO:0097322]; ATP binding [GO:0005524]; chromatin binding [GO:0003682]; cyclin-dependent protein serine/threonine kinase activity [GO:0004693]; DNA binding [GO:0003677]; kinase activity [GO:0016301]; protein kinase activity [GO:0004672]; protein serine/threonine kinase activity [GO:0004674]; RNA polymerase II carboxy-terminal domain kinase activity [GO:0008353]; RNA polymerase II core promoter sequence-specific DNA binding [GO:0000979]; transcription coactivator binding [GO:0001223]	cyclin/CDK positive transcription elongation factor complex [GO:0008024]; cytoplasm [GO:0005737]; intracellular membrane-bounded organelle [GO:0043231]; membrane [GO:0016020]; nucleoplasm [GO:0005654]; PML body [GO:0016605]; transcription elongation factor complex [GO:0008023]
Q16878	CDO1_HUMAN	Cysteine dioxygenase type 1 (EC 1.13.11.20) (Cysteine dioxygenase type I) (CDO) (CDO-I)	CDO1	2IC1;			DB00151;	PATHWAY: Organosulfur biosynthesis; taurine biosynthesis; hypotaurine from L-cysteine: step 1/2.	PF05995;	IPR010300;IPR014710;IPR011051;	cysteine metabolic process [GO:0006534]; inflammatory response [GO:0006954]; lactation [GO:0007595]; L-cysteine catabolic process [GO:0019448]; L-cysteine catabolic process to pyruvate, using cysteine dioxygenase [GO:0019451]; oxidation-reduction process [GO:0055114]; response to amino acid [GO:0043200]; response to cAMP [GO:0051591]; response to ethanol [GO:0045471]; response to glucagon [GO:0033762]; response to glucocorticoid [GO:0051384]; sulfur amino acid biosynthetic process [GO:0000097]; taurine biosynthetic process [GO:0042412]	cysteine dioxygenase activity [GO:0017172]; ferrous iron binding [GO:0008198]	cytosol [GO:0005829]
Q16739	CEGT_HUMAN	Ceramide glucosyltransferase (EC 2.4.1.80) (GLCT-1) (Glucosylceramide synthase) (GCS) (UDP-glucose ceramide glucosyltransferase) (UDP-glucose:N-acylsphingosine D-glucosyltransferase)	UGCG		CHEMBL2063;	Q16739;	DB09039;DB00419;	PATHWAY: Lipid metabolism; sphingolipid metabolism.	PF13506;	IPR025993;IPR029044;	epidermis development [GO:0008544]; glucosylceramide biosynthetic process [GO:0006679]; glycosphingolipid biosynthetic process [GO:0006688]; glycosphingolipid metabolic process [GO:0006687]; positive regulation of protein targeting to mitochondrion [GO:1903955]	ceramide glucosyltransferase activity [GO:0008120]	Golgi membrane [GO:0000139]; integral component of membrane [GO:0016021]; membrane [GO:0016020]
P00751	CFAB_HUMAN	Complement factor B (EC 3.4.21.47) (C3/C5 convertase) (Glycine-rich beta glycoprotein) (GBG) (PBF2) (Properdin factor B) [Cleaved into: Complement factor B Ba fragment; Complement factor B Bb fragment]	CFB BF BFD	1DLE;1Q0P;1RRK;1RS0;1RTK;2OK5;2WIN;2XWB;2XWJ;3HRZ;3HS0;	CHEMBL5731;	P00751;			PF00084;PF00089;PF00092;	IPR011360;IPR028341;IPR009003;IPR001314;IPR000436;IPR001254;IPR018114;IPR033116;IPR002035;	complement activation [GO:0006956]; complement activation, alternative pathway [GO:0006957]; regulation of complement activation [GO:0030449]	complement binding [GO:0001848]; serine-type endopeptidase activity [GO:0004252]	blood microparticle [GO:0072562]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; plasma membrane [GO:0005886]
P00746	CFAD_HUMAN	Complement factor D (EC 3.4.21.46) (Adipsin) (C3 convertase activator) (Properdin factor D)	CFD DF PFD	1BIO;1DFP;1DIC;1DST;1DSU;1FDP;1HFD;2XW9;2XWA;2XWB;4CBN;4CBO;4D9R;	CHEMBL2176771;	P00746;			PF00089;	IPR009003;IPR001314;IPR001254;IPR018114;IPR033116;	complement activation [GO:0006956]; complement activation, alternative pathway [GO:0006957]; platelet degranulation [GO:0002576]; proteolysis [GO:0006508]	serine-type endopeptidase activity [GO:0004252]; serine-type peptidase activity [GO:0008236]	extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; platelet alpha granule lumen [GO:0031093]
P13569	CFTR_HUMAN	Cystic fibrosis transmembrane conductance regulator (CFTR) (ATP-binding cassette sub-family C member 7) (Channel conductance-controlling ATPase) (EC 3.6.3.49) (cAMP-dependent chloride channel)	CFTR ABCC7	1NBD;1XMI;1XMJ;2BBO;2BBS;2BBT;2LOB;2PZE;2PZF;2PZG;3GD7;3ISW;4WZ6;5D2D;5D3E;	CHEMBL4051;	P13569;	DB00887;DB04941;DB01016;DB01050;DB08820;		PF00664;PF00005;PF14396;	IPR003593;IPR011527;IPR003439;IPR017871;IPR009147;IPR025837;IPR027417;	cellular response to cAMP [GO:0071320]; chloride transmembrane transport [GO:1902476]; cholesterol biosynthetic process [GO:0006695]; cholesterol transport [GO:0030301]; intracellular pH elevation [GO:0051454]; membrane hyperpolarization [GO:0060081]; positive regulation of cyclic nucleotide-gated ion channel activity [GO:1902161]; positive regulation of exocytosis [GO:0045921]; positive regulation of insulin secretion involved in cellular response to glucose stimulus [GO:0035774]; positive regulation of voltage-gated chloride channel activity [GO:1902943]; respiratory gaseous exchange [GO:0007585]; sperm capacitation [GO:0048240]; transmembrane transport [GO:0055085]; transport [GO:0006810]; vesicle docking involved in exocytosis [GO:0006904]	ATPase-coupled anion transmembrane transporter activity [GO:0043225]; ATP binding [GO:0005524]; ATP-binding and phosphorylation-dependent chloride channel activity [GO:0005224]; bicarbonate transmembrane transporter activity [GO:0015106]; channel-conductance-controlling ATPase activity [GO:0005260]; chloride channel activity [GO:0005254]; chloride channel inhibitor activity [GO:0019869]; chloride channel regulator activity [GO:0017081]; chloride transmembrane transporter activity [GO:0015108]; enzyme binding [GO:0019899]; PDZ domain binding [GO:0030165]	apical plasma membrane [GO:0016324]; basolateral plasma membrane [GO:0016323]; cell surface [GO:0009986]; chloride channel complex [GO:0034707]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; early endosome [GO:0005769]; early endosome membrane [GO:0031901]; extracellular exosome [GO:0070062]; Golgi-associated vesicle membrane [GO:0030660]; lysosomal membrane [GO:0005765]; plasma membrane [GO:0005886]; protein complex [GO:0043234]; recycling endosome [GO:0055037]
P32929	CGL_HUMAN	Cystathionine gamma-lyase (EC 4.4.1.1) (Cysteine-protein sulfhydrase) (Gamma-cystathionase)	CTH	2NMP;3COG;3ELP;		P32929;	DB00151;	PATHWAY: Amino-acid biosynthesis; L-cysteine biosynthesis; L-cysteine from L-homocysteine and L-serine: step 2/2.	PF01053;	IPR000277;IPR015424;IPR015421;IPR015422;	'de novo' L-methionine biosynthetic process [GO:0071266]; cysteine biosynthetic process [GO:0019344]; cysteine biosynthetic process via cystathionine [GO:0019343]; cysteine metabolic process [GO:0006534]; endoplasmic reticulum unfolded protein response [GO:0030968]; hydrogen sulfide biosynthetic process [GO:0070814]; negative regulation of apoptotic signaling pathway [GO:2001234]; positive regulation of aortic smooth muscle cell differentiation [GO:1904831]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; protein homotetramerization [GO:0051289]; protein-pyridoxal-5-phosphate linkage via peptidyl-N6-pyridoxal phosphate-L-lysine [GO:0018272]; protein sulfhydration [GO:0044524]; sulfur amino acid catabolic process [GO:0000098]; transsulfuration [GO:0019346]	carbon-sulfur lyase activity [GO:0016846]; cystathionine gamma-lyase activity [GO:0004123]; cystathionine gamma-synthase activity [GO:0003962]; homocysteine desulfhydrase activity [GO:0047982]; L-cysteine desulfhydrase activity [GO:0080146]; L-cystine L-cysteine-lyase (deaminating) [GO:0044540]; pyridoxal phosphate binding [GO:0030170]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleus [GO:0005634]
O14646	CHD1_HUMAN	Chromodomain-helicase-DNA-binding protein 1 (CHD-1) (EC 3.6.4.12) (ATP-dependent helicase CHD1)	CHD1	2B2T;2B2U;2B2V;2B2W;2B2Y;2N39;4B4C;4NW2;4O42;5AFW;			DB00445;		PF00385;PF13907;PF00271;PF00176;	IPR000953;IPR023780;IPR016197;IPR023779;IPR025260;IPR014001;IPR001650;IPR027417;IPR000330;	chromatin modification [GO:0016569]; chromatin remodeling [GO:0006338]; positive regulation by host of viral transcription [GO:0043923]; regulation of transcription from RNA polymerase II promoter [GO:0006357]; transcription, DNA-templated [GO:0006351]	ATP binding [GO:0005524]; ATP-dependent DNA helicase activity [GO:0004003]; DNA binding [GO:0003677]; methylated histone binding [GO:0035064]	cytoplasm [GO:0005737]; nucleus [GO:0005634]
Q8NE62	CHDH_HUMAN	Choline dehydrogenase, mitochondrial (CDH) (CHD) (EC 1.1.99.1)	CHDH				DB00122;	PATHWAY: Amine and polyamine biosynthesis; betaine biosynthesis via choline pathway; betaine aldehyde from choline (cytochrome c reductase route): step 1/1.	PF05199;PF00732;	IPR023753;IPR012132;IPR000172;IPR007867;	choline catabolic process [GO:0042426]; glycine betaine biosynthetic process from choline [GO:0019285]	choline dehydrogenase activity [GO:0008812]; flavin adenine dinucleotide binding [GO:0050660]	mitochondrial inner membrane [GO:0005743]
Q13231	CHIT1_HUMAN	Chitotriosidase-1 (EC 3.2.1.14) (Chitinase-1)	CHIT1	1GUV;1HKI;1HKJ;1HKK;1HKM;1LG1;1LG2;1LQ0;1WAW;1WB0;4WJX;4WK9;4WKA;4WKF;4WKH;5HBF;	CHEMBL3080;	Q13231;	DB02325;		PF01607;PF00704;	IPR002557;IPR011583;IPR029070;IPR001223;IPR001579;IPR013781;IPR017853;	carbohydrate metabolic process [GO:0005975]; chitin catabolic process [GO:0006032]; immune response [GO:0006955]; polysaccharide catabolic process [GO:0000272]; response to bacterium [GO:0009617]	chitinase activity [GO:0004568]; chitin binding [GO:0008061]; endochitinase activity [GO:0008843]; hydrolase activity, hydrolyzing O-glycosyl compounds [GO:0004553]	extracellular region [GO:0005576]; extracellular space [GO:0005615]; lysosome [GO:0005764]
P35790	CHKA_HUMAN	Choline kinase alpha (CK) (EC 2.7.1.32) (CHETK-alpha) (Ethanolamine kinase) (EK) (EC 2.7.1.82)	CHKA CHK CKI	2CKO;2CKP;2CKQ;2I7Q;3F2R;3G15;3ZM9;4BR3;4CG8;4CG9;4CGA;4DA5;5AFV;5EQE;5EQP;5EQY;5FTG;5FUT;	CHEMBL3117;	P35790;	DB00122;	PATHWAY: Phospholipid metabolism; phosphatidylcholine biosynthesis; phosphocholine from choline: step 1/1.; PATHWAY: Phospholipid metabolism; phosphatidylethanolamine biosynthesis; phosphatidylethanolamine from ethanolamine: step 1/3.		IPR011009;	choline metabolic process [GO:0019695]; ethanolamine metabolic process [GO:0006580]; lipid metabolic process [GO:0006629]; lipid transport [GO:0006869]; phosphatidylcholine biosynthetic process [GO:0006656]; phosphatidylethanolamine biosynthetic process [GO:0006646]; response to 3-methylcholanthrene [GO:1904681]; response to toxic substance [GO:0009636]	ATP binding [GO:0005524]; choline binding [GO:0033265]; choline kinase activity [GO:0004103]; cholinesterase activity [GO:0004104]; drug binding [GO:0008144]; ethanolamine kinase activity [GO:0004305]; signal transducer activity [GO:0004871]	cytosol [GO:0005829]
Q9Y259	CHKB_HUMAN	Choline/ethanolamine kinase (Choline kinase beta) (CK) (CKB) (EC 2.7.1.32) (Choline kinase-like protein) (Ethanolamine kinase) (EK) (EC 2.7.1.82) (Ethanolamine kinase beta) (EKB) (choline/ethanolamine kinase beta) (CKEKB)	CHKB CHETK CHKL	2IG7;3FEG;3LQ3;	CHEMBL3112385;	Q9Y259;	DB00122;	PATHWAY: Phospholipid metabolism; phosphatidylethanolamine biosynthesis; phosphatidylethanolamine from ethanolamine: step 1/3.		IPR026712;IPR011009;	phosphatidylcholine biosynthetic process [GO:0006656]; phosphatidylethanolamine biosynthetic process [GO:0006646]	ATP binding [GO:0005524]; choline kinase activity [GO:0004103]; ethanolamine kinase activity [GO:0004305]	cytosol [GO:0005829]
P06276	CHLE_HUMAN	Cholinesterase (EC 3.1.1.8) (Acylcholine acylhydrolase) (Butyrylcholine esterase) (Choline esterase II) (Pseudocholinesterase)	BCHE CHE1	1EHO;1EHQ;1KCJ;1P0I;1P0M;1P0P;1P0Q;1XLU;1XLV;1XLW;2J4C;2PM8;2WID;2WIF;2WIG;2WIJ;2WIK;2WIL;2WSL;2XMB;2XMC;2XMD;2XMG;2XQF;2XQG;2XQI;2XQJ;2XQK;2Y1K;3DJY;3DKK;3O9M;4AQD;4AXB;4B0O;4B0P;4BBZ;4BDS;4TPK;4XII;5K5E;	CHEMBL1914;	P06276;	DB08897;DB01122;DB01408;DB06774;DB01161;DB00856;DB00477;DB00122;DB00527;DB00515;DB04920;DB00979;DB01245;DB00944;DB00711;DB00449;DB01135;DB01395;DB01057;DB01010;DB01364;DB00392;DB00674;DB06756;DB00941;DB00762;DB00677;DB00772;DB00358;DB08893;DB01226;DB01400;DB00585;DB00892;DB01337;DB00082;DB00183;DB00790;DB01338;DB00733;DB01035;DB00721;DB00545;DB00178;DB00989;DB00202;DB00391;DB00871;DB00620;DB00508;DB01116;		PF08674;PF00135;	IPR029058;IPR014788;IPR002018;IPR019826;IPR019819;IPR000997;	choline metabolic process [GO:0019695]; cocaine metabolic process [GO:0050783]; learning [GO:0007612]; negative regulation of cell proliferation [GO:0008285]; negative regulation of synaptic transmission [GO:0050805]; neuroblast differentiation [GO:0014016]; response to alkaloid [GO:0043279]; response to drug [GO:0042493]; response to folic acid [GO:0051593]; response to glucocorticoid [GO:0051384]	acetylcholinesterase activity [GO:0003990]; beta-amyloid binding [GO:0001540]; catalytic activity [GO:0003824]; choline binding [GO:0033265]; cholinesterase activity [GO:0004104]; enzyme binding [GO:0019899]; hydrolase activity, acting on ester bonds [GO:0016788]	blood microparticle [GO:0072562]; endoplasmic reticulum lumen [GO:0005788]; extracellular region [GO:0005576]; membrane [GO:0016020]; nuclear envelope lumen [GO:0005641]
P28329	CLAT_HUMAN	Choline O-acetyltransferase (CHOACTase) (ChAT) (Choline acetylase) (EC 2.3.1.6)	CHAT	2FY2;2FY3;2FY4;2FY5;	CHEMBL4039;	P28329;	DB00122;DB00184;		PF00755;	IPR000542;	neurotransmitter biosynthetic process [GO:0042136]; neurotransmitter secretion [GO:0007269]; phosphatidylcholine biosynthetic process [GO:0006656]	choline O-acetyltransferase activity [GO:0004102]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleus [GO:0005634]; presynapse [GO:0098793]
P51800	CLCKA_HUMAN	Chloride channel protein ClC-Ka (Chloride channel Ka) (ClC-K1)	CLCNKA	2PFI;			DB04552;		PF00571;PF00654;	IPR000644;IPR014743;IPR001807;IPR002250;	chloride transmembrane transport [GO:1902476]; excretion [GO:0007588]; ion transmembrane transport [GO:0034220]; transport [GO:0006810]	chloride ion binding [GO:0031404]; metal ion binding [GO:0046872]; voltage-gated chloride channel activity [GO:0005247]	chloride channel complex [GO:0034707]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P51788	CLCN2_HUMAN	Chloride channel protein 2 (ClC-2)	CLCN2		CHEMBL1628478;		DB01046;		PF00654;	IPR000644;IPR002244;IPR014743;IPR001807;	cell differentiation involved in salivary gland development [GO:0060689]; chloride transmembrane transport [GO:1902476]; ion transmembrane transport [GO:0034220]; retina development in camera-type eye [GO:0060041]; transport [GO:0006810]	chloride ion binding [GO:0031404]; voltage-gated chloride channel activity [GO:0005247]	chloride channel complex [GO:0034707]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P49759	CLK1_HUMAN	Dual specificity protein kinase CLK1 (EC 2.7.12.1) (CDC-like kinase 1)	CLK1 CLK	1Z57;2VAG;5J1V;5J1W;	CHEMBL4224;	P49759;			PF00069;	IPR011009;IPR000719;IPR017441;IPR008271;	cell proliferation [GO:0008283]; peptidyl-serine phosphorylation [GO:0018105]; peptidyl-threonine phosphorylation [GO:0018107]; protein autophosphorylation [GO:0046777]; regulation of RNA splicing [GO:0043484]	ATP binding [GO:0005524]; non-membrane spanning protein tyrosine kinase activity [GO:0004715]; protein serine/threonine/tyrosine kinase activity [GO:0004712]; protein serine/threonine kinase activity [GO:0004674]	cytoplasm [GO:0005737]; nucleus [GO:0005634]
Q16740	CLPP_HUMAN	ATP-dependent Clp protease proteolytic subunit, mitochondrial (EC 3.4.21.92) (Endopeptidase Clp)	CLPP	1TG6;					PF00574;	IPR001907;IPR029045;IPR023562;IPR033135;IPR018215;	protein homooligomerization [GO:0051260]; proteolysis involved in cellular protein catabolic process [GO:0051603]	peptidase activity [GO:0008233]; serine-type endopeptidase activity [GO:0004252]	endopeptidase Clp complex [GO:0009368]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
Q9Y271	CLTR1_HUMAN	Cysteinyl leukotriene receptor 1 (CysLTR1) (Cysteinyl leukotriene D4 receptor) (LTD4 receptor) (G-protein coupled receptor HG55) (HMTMF81)	CYSLTR1 CYSLT1		CHEMBL1798;	Q9Y271;	DB00587;DB00471;DB00716;DB01411;DB00549;		PF00001;	IPR013310;IPR004071;IPR000276;IPR017452;	calcium ion transport [GO:0006816]; cell surface receptor signaling pathway [GO:0007166]; chemotaxis [GO:0006935]; circulatory system process [GO:0003013]; defense response [GO:0006952]; inflammatory response to antigenic stimulus [GO:0002437]; neuropeptide signaling pathway [GO:0007218]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; respiratory gaseous exchange [GO:0007585]	cysteinyl leukotriene receptor activity [GO:0001631]; G-protein coupled peptide receptor activity [GO:0008528]; leukotriene receptor activity [GO:0004974]	integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]
Q9NS75	CLTR2_HUMAN	Cysteinyl leukotriene receptor 2 (CysLTR2) (G-protein coupled receptor GPCR21) (hGPCR21) (G-protein coupled receptor HG57) (HPN321)	CYSLTR2 CYSLT2 CYSLT2R PSEC0146		CHEMBL4330;	Q9NS75;	DB00716;		PF00001;	IPR013311;IPR004071;IPR000276;IPR017452;	immune response [GO:0006955]; neuropeptide signaling pathway [GO:0007218]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; positive regulation of angiogenesis [GO:0045766]; positive regulation of cell death [GO:0010942]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]	cysteinyl leukotriene receptor activity [GO:0001631]; G-protein coupled peptide receptor activity [GO:0008528]; leukotriene receptor activity [GO:0004974]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P23946	CMA1_HUMAN	Chymase (EC 3.4.21.39) (Alpha-chymase) (Mast cell protease I)	CMA1 CYH CYM	1KLT;1NN6;1PJP;1T31;2HVX;3N7O;3S0N;4AFQ;4AFS;4AFU;4AFZ;4AG1;4AG2;4K2Y;4K5Z;4K60;4K69;4KP0;	CHEMBL4068;	P23946;			PF00089;	IPR009003;IPR001314;IPR001254;IPR018114;IPR033116;	angiotensin maturation [GO:0002003]; cellular response to glucose stimulus [GO:0071333]; extracellular matrix disassembly [GO:0022617]; immune response [GO:0006955]; interleukin-1 beta biosynthetic process [GO:0050720]; midbrain development [GO:0030901]; positive regulation of angiogenesis [GO:0045766]; protein processing [GO:0016485]; regulation of inflammatory response [GO:0050727]	endopeptidase activity [GO:0004175]; peptide binding [GO:0042277]; serine-type endopeptidase activity [GO:0004252]; serine-type peptidase activity [GO:0008236]	cytoplasm [GO:0005737]; extracellular region [GO:0005576]; intracellular membrane-bounded organelle [GO:0043231]
O75746	CMC1_HUMAN	Calcium-binding mitochondrial carrier protein Aralar1 (Mitochondrial aspartate glutamate carrier 1) (Solute carrier family 25 member 12)	SLC25A12 ARALAR1	4P5X;4P60;			DB00128;		PF00153;	IPR011992;IPR018247;IPR002048;IPR002067;IPR018108;IPR023395;	aspartate transport [GO:0015810]; gluconeogenesis [GO:0006094]; L-glutamate transport [GO:0015813]; malate-aspartate shuttle [GO:0043490]; response to calcium ion [GO:0051592]; translation [GO:0006412]	acidic amino acid transmembrane transporter activity [GO:0015172]; calcium ion binding [GO:0005509]; L-aspartate transmembrane transporter activity [GO:0015183]; L-glutamate transmembrane transporter activity [GO:0005313]; structural constituent of ribosome [GO:0003735]	integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrion [GO:0005739]; myelin sheath [GO:0043209]
P21554	CNR1_HUMAN	Cannabinoid receptor 1 (CB-R) (CB1) (CANN6)	CNR1 CNR	1LVQ;1LVR;2B0Y;2KOE;2MZ2;2MZ3;2MZA;	CHEMBL218;	P21554;	DB00470;DB00486;DB06155;		PF00001;	IPR000810;IPR002230;IPR000276;IPR017452;	adenylate cyclase-modulating G-protein coupled receptor signaling pathway [GO:0007188]; aging [GO:0007568]; axonal fasciculation [GO:0007413]; glucose homeostasis [GO:0042593]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; maternal process involved in female pregnancy [GO:0060135]; memory [GO:0007613]; negative regulation of action potential [GO:0045759]; negative regulation of blood pressure [GO:0045776]; negative regulation of dopamine secretion [GO:0033602]; negative regulation of fatty acid beta-oxidation [GO:0031999]; negative regulation of ion transport [GO:0043271]; negative regulation of mast cell activation [GO:0033004]; negative regulation of nitric-oxide synthase activity [GO:0051001]; positive regulation of acute inflammatory response to antigenic stimulus [GO:0002866]; positive regulation of apoptotic process [GO:0043065]; positive regulation of blood pressure [GO:0045777]; positive regulation of fever generation [GO:0031622]; positive regulation of neuron projection development [GO:0010976]; regulation of feeding behavior [GO:0060259]; regulation of insulin secretion [GO:0050796]; regulation of penile erection [GO:0060405]; regulation of synaptic transmission, GABAergic [GO:0032228]; regulation of synaptic transmission, glutamatergic [GO:0051966]; response to cocaine [GO:0042220]; response to ethanol [GO:0045471]; response to lipopolysaccharide [GO:0032496]; response to morphine [GO:0043278]; response to nicotine [GO:0035094]; response to nutrient [GO:0007584]; sensory perception of pain [GO:0019233]; spermatogenesis [GO:0007283]	cannabinoid receptor activity [GO:0004949]; drug binding [GO:0008144]	axon [GO:0030424]; growth cone [GO:0030426]; integral component of plasma membrane [GO:0005887]; intracellular membrane-bounded organelle [GO:0043231]; membrane raft [GO:0045121]; plasma membrane [GO:0005886]
P34972	CNR2_HUMAN	Cannabinoid receptor 2 (CB-2) (CB2) (hCB2) (CX5)	CNR2 CB2A CB2B	2KI9;	CHEMBL253;	P34972;	DB00470;DB00486;		PF00001;	IPR001551;IPR002230;IPR000276;IPR017452;	G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; immune response [GO:0006955]; inflammatory response [GO:0006954]; leukocyte chemotaxis [GO:0030595]; negative regulation of action potential [GO:0045759]; negative regulation of inflammatory response [GO:0050728]; negative regulation of mast cell activation [GO:0033004]; negative regulation of nitric-oxide synthase activity [GO:0051001]; negative regulation of synaptic transmission, GABAergic [GO:0032229]; response to amphetamine [GO:0001975]; response to lipopolysaccharide [GO:0032496]; sensory perception of pain [GO:0019233]	cannabinoid receptor activity [GO:0004949]	dendrite [GO:0030425]; extrinsic component of cytoplasmic side of plasma membrane [GO:0031234]; integral component of plasma membrane [GO:0005887]; perikaryon [GO:0043204]; plasma membrane [GO:0005886]
P07360	CO8G_HUMAN	Complement component C8 gamma chain	C8G	1IW2;1LF7;2OVA;2OVD;2OVE;2QOS;2RD7;3OJY;					PF00061;	IPR002968;IPR012674;IPR011038;IPR002345;IPR022272;IPR000566;	complement activation, alternative pathway [GO:0006957]; complement activation, classical pathway [GO:0006958]; cytolysis [GO:0019835]; regulation of complement activation [GO:0030449]	retinol binding [GO:0019841]	blood microparticle [GO:0072562]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; membrane attack complex [GO:0005579]
Q9GZY4	COA1_HUMAN	Cytochrome c oxidase assembly factor 1 homolog (Mitochondrial translation regulation assembly intermediate of cytochrome c oxidase protein of 15 kDa)	COA1 C7orf44 MITRAC15						PF08695;	IPR014807;	mitochondrial respiratory chain complex I assembly [GO:0032981]; mitochondrial respiratory chain complex IV assembly [GO:0033617]; translation [GO:0006412]	RNA binding [GO:0003723]; structural constituent of ribosome [GO:0003735]	cytoplasm [GO:0005737]; cytosolic large ribosomal subunit [GO:0022625]; integral component of mitochondrial inner membrane [GO:0031305]; mitochondrion [GO:0005739]
O00763	COA2_HUMAN	Acetyl-CoA carboxylase 2 (EC 6.4.1.2) (ACC-beta) [Includes: Biotin carboxylase (EC 6.3.4.14)]	ACACB ACC2 ACCB	2DN8;2HJW;2KCC;3FF6;3GID;3GLK;3JRW;3JRX;3TDC;4HQ6;5KKN;	CHEMBL4829;	O00763;	DB00173;DB00121;	PATHWAY: Lipid metabolism; malonyl-CoA biosynthesis; malonyl-CoA from acetyl-CoA: step 1/1.	PF08326;PF02785;PF00289;PF00364;PF01039;PF02786;	IPR013537;IPR011761;IPR013815;IPR013816;IPR005481;IPR011764;IPR005482;IPR000089;IPR000022;IPR005479;IPR029045;IPR011763;IPR011762;IPR016185;IPR011054;IPR011053;	acetyl-CoA metabolic process [GO:0006084]; biotin metabolic process [GO:0006768]; carnitine shuttle [GO:0006853]; energy homeostasis [GO:0097009]; fatty acid biosynthetic process [GO:0006633]; malonyl-CoA biosynthetic process [GO:2001295]; negative regulation of catalytic activity [GO:0043086]; negative regulation of fatty acid beta-oxidation [GO:0031999]; negative regulation of gene expression [GO:0010629]; positive regulation of cellular metabolic process [GO:0031325]; positive regulation of heart growth [GO:0060421]; positive regulation of lipid storage [GO:0010884]; protein homotetramerization [GO:0051289]; regulation of glucose metabolic process [GO:0010906]; response to drug [GO:0042493]; response to nutrient levels [GO:0031667]; response to organic cyclic compound [GO:0014070]	acetyl-CoA carboxylase activity [GO:0003989]; ATP binding [GO:0005524]; biotin binding [GO:0009374]; biotin carboxylase activity [GO:0004075]; metal ion binding [GO:0046872]	cytosol [GO:0005829]; endomembrane system [GO:0012505]; mitochondrial outer membrane [GO:0005741]; mitochondrion [GO:0005739]; nucleus [GO:0005634]
Q96CD2	COAC_HUMAN	Phosphopantothenoylcysteine decarboxylase (PPC-DC) (EC 4.1.1.36) (CoaC)	PPCDC COAC MDS018 UNQ9365/PRO34154	1QZU;				PATHWAY: Cofactor biosynthesis; coenzyme A biosynthesis; CoA from (R)-pantothenate: step 3/5.	PF02441;	IPR003382;	coenzyme A biosynthetic process [GO:0015937]; coenzyme biosynthetic process [GO:0009108]	identical protein binding [GO:0042802]; phosphopantothenoylcysteine decarboxylase activity [GO:0004633]	cytosol [GO:0005829]
Q5TAT6	CODA1_HUMAN	Collagen alpha-1(XIII) chain (COLXIIIA1)	COL13A1						PF01391;	IPR008160;	cell differentiation [GO:0030154]; cell-matrix adhesion [GO:0007160]; collagen catabolic process [GO:0030574]; endochondral ossification [GO:0001958]; extracellular matrix organization [GO:0030198]; morphogenesis of a branching structure [GO:0001763]; single organismal cell-cell adhesion [GO:0016337]	heparin binding [GO:0008201]	cell-cell junction [GO:0005911]; collagen type XIII trimer [GO:0005600]; endoplasmic reticulum lumen [GO:0005788]; extracellular region [GO:0005576]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
P01189	COLI_HUMAN	Pro-opiomelanocortin (POMC) (Corticotropin-lipotropin) [Cleaved into: NPP; Melanotropin gamma (Gamma-MSH); Potential peptide; Corticotropin (Adrenocorticotropic hormone) (ACTH); Melanotropin alpha (Alpha-MSH); Corticotropin-like intermediary peptide (CLIP); Lipotropin beta (Beta-LPH); Lipotropin gamma (Gamma-LPH); Melanotropin beta (Beta-MSH); Beta-endorphin; Met-enkephalin]	POMC	4XNH;4XPD;4Y49;			DB00836;		PF00976;PF08384;PF08035;	IPR001941;IPR013531;IPR013593;IPR013532;	cell-cell signaling [GO:0007267]; cellular pigmentation [GO:0033059]; generation of precursor metabolites and energy [GO:0006091]; glucose homeostasis [GO:0042593]; negative regulation of tumor necrosis factor production [GO:0032720]; neuropeptide signaling pathway [GO:0007218]; peptide hormone processing [GO:0016486]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; regulation of appetite [GO:0032098]; regulation of blood pressure [GO:0008217]; regulation of corticosterone secretion [GO:2000852]; regulation of glycogen metabolic process [GO:0070873]; signal transduction [GO:0007165]	G-protein coupled receptor binding [GO:0001664]; hormone activity [GO:0005179]; neuropeptide hormone activity [GO:0005184]; receptor binding [GO:0005102]; type 1 melanocortin receptor binding [GO:0070996]; type 3 melanocortin receptor binding [GO:0031781]; type 4 melanocortin receptor binding [GO:0031782]	cytoplasm [GO:0005737]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; peroxisomal matrix [GO:0005782]; secretory granule [GO:0030141]; secretory granule lumen [GO:0034774]
P21964	COMT_HUMAN	Catechol O-methyltransferase (EC 2.1.1.6)	COMT	3A7E;3BWM;3BWY;4PYI;4PYJ;4PYK;4XUC;4XUD;4XUE;5LSA;	CHEMBL2023;	P21964;	DB00286;DB00255;DB00841;DB00988;DB00494;DB00968;DB01141;DB00118;DB01420;DB00323;		PF01596;	IPR017128;IPR002935;IPR029063;	cellular response to phosphate starvation [GO:0016036]; developmental process [GO:0032502]; dopamine catabolic process [GO:0042420]; estrogen metabolic process [GO:0008210]; female pregnancy [GO:0007565]; learning [GO:0007612]; methylation [GO:0032259]; multicellular organismal reproductive process [GO:0048609]; negative regulation of dopamine metabolic process [GO:0045963]; negative regulation of renal sodium excretion [GO:0035814]; negative regulation of smooth muscle cell proliferation [GO:0048662]; neurotransmitter catabolic process [GO:0042135]; positive regulation of homocysteine metabolic process [GO:0050668]; regulation of sensory perception of pain [GO:0051930]; response to drug [GO:0042493]; response to lipopolysaccharide [GO:0032496]; response to organic cyclic compound [GO:0014070]; response to pain [GO:0048265]; short-term memory [GO:0007614]	catechol O-methyltransferase activity [GO:0016206]; magnesium ion binding [GO:0000287]; methyltransferase activity [GO:0008168]; O-methyltransferase activity [GO:0008171]	axon [GO:0030424]; cell body [GO:0044297]; cytosol [GO:0005829]; dendritic spine [GO:0043197]; extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; membrane [GO:0016020]; mitochondrion [GO:0005739]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
P00395	COX1_HUMAN	Cytochrome c oxidase subunit 1 (EC 1.9.3.1) (Cytochrome c oxidase polypeptide I)	MT-CO1 COI COXI MTCO1		CHEMBL6173;	P00395;	DB02659;	PATHWAY: Energy metabolism; oxidative phosphorylation.	PF00115;	IPR000883;IPR023615;IPR023616;	aerobic respiration [GO:0009060]; aging [GO:0007568]; cerebellum development [GO:0021549]; mitochondrial electron transport, cytochrome c to oxygen [GO:0006123]; response to copper ion [GO:0046688]; response to electrical stimulus [GO:0051602]; response to oxidative stress [GO:0006979]	cytochrome-c oxidase activity [GO:0004129]; heme binding [GO:0020037]; iron ion binding [GO:0005506]	integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex IV [GO:0005751]; respiratory chain complex IV [GO:0045277]
P05093	CP17A_HUMAN	Steroid 17-alpha-hydroxylase/17,20 lyase (EC 1.14.14.19) (17-alpha-hydroxyprogesterone aldolase) (EC 4.1.2.30) (CYPXVII) (Cytochrome P450 17A1) (Cytochrome P450-C17) (Cytochrome P450c17) (Steroid 17-alpha-monooxygenase)	CYP17A1 CYP17 S17AH	2C17;3RUK;3SWZ;4NKV;4NKW;4NKX;4NKY;4NKZ;	CHEMBL3522;	P05093;	DB05812;DB01424;DB01234;DB01233;DB00396;	PATHWAY: Lipid metabolism; steroid biosynthesis.	PF00067;	IPR033282;IPR001128;IPR017972;IPR002401;	androgen biosynthetic process [GO:0006702]; glucocorticoid biosynthetic process [GO:0006704]; hormone biosynthetic process [GO:0042446]; progesterone metabolic process [GO:0042448]; sex differentiation [GO:0007548]; steroid biosynthetic process [GO:0006694]; steroid metabolic process [GO:0008202]; sterol metabolic process [GO:0016125]	17-alpha-hydroxyprogesterone aldolase activity [GO:0047442]; heme binding [GO:0020037]; iron ion binding [GO:0005506]; oxygen binding [GO:0019825]; steroid 17-alpha-monooxygenase activity [GO:0004508]	axon [GO:0030424]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; mitochondrion [GO:0005739]; neuronal cell body [GO:0043025]
P11511	CP19A_HUMAN	Aromatase (EC 1.14.14.14) (CYPXIX) (Cytochrome P-450AROM) (Cytochrome P450 19A1) (Estrogen synthase)	CYP19A1 ARO1 CYAR CYP19	1TQA;3EQM;3S79;3S7S;4GL5;4GL7;4KQ8;	CHEMBL1978;	P11511;	DB00357;DB01217;DB00443;DB04794;DB06719;DB00389;DB00856;DB00882;DB00257;DB04839;DB01406;DB01234;DB00255;DB00917;DB00858;DB01127;DB00974;DB00292;DB00990;DB01026;DB01006;DB01227;DB00367;DB00358;DB01065;DB00333;DB06710;DB01110;DB08804;DB00984;DB00184;DB01229;DB00481;DB06147;DB00675;DB00857;DB00894;DB00624;DB01007;DB00072;		PF00067;	IPR001128;IPR017972;IPR002401;	androgen metabolic process [GO:0008209]; estrogen biosynthetic process [GO:0006703]; negative regulation of chronic inflammatory response [GO:0002677]; negative regulation of macrophage chemotaxis [GO:0010760]; prostate gland growth [GO:0060736]; steroid biosynthetic process [GO:0006694]; sterol metabolic process [GO:0016125]	aromatase activity [GO:0070330]; electron carrier activity [GO:0009055]; heme binding [GO:0020037]; iron ion binding [GO:0005506]; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen [GO:0016712]; oxygen binding [GO:0019825]; steroid hydroxylase activity [GO:0008395]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; membrane [GO:0016020]
Q16678	CP1B1_HUMAN	Cytochrome P450 1B1 (EC 1.14.14.1) (CYPIB1)	CYP1B1	3PM0;	CHEMBL4878;	Q16678;	DB00613;DB01169;DB00121;DB00201;DB00363;DB01254;DB00694;DB01234;DB01248;DB00997;DB00530;DB00783;DB00655;DB00499;DB01026;DB00448;DB01065;DB01204;DB00338;DB00526;DB01229;DB01174;DB01087;DB01168;DB00396;DB00818;DB00675;DB00624;DB00277;		PF00067;	IPR032971;IPR001128;IPR017972;IPR002401;	angiogenesis [GO:0001525]; arachidonic acid metabolic process [GO:0019369]; blood vessel morphogenesis [GO:0048514]; cell adhesion [GO:0007155]; cellular aromatic compound metabolic process [GO:0006725]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to organic cyclic compound [GO:0071407]; collagen fibril organization [GO:0030199]; endothelial cell-cell adhesion [GO:0071603]; endothelial cell migration [GO:0043542]; epoxygenase P450 pathway [GO:0019373]; estrogen metabolic process [GO:0008210]; intrinsic apoptotic signaling pathway in response to oxidative stress [GO:0008631]; membrane lipid catabolic process [GO:0046466]; negative regulation of cell adhesion mediated by integrin [GO:0033629]; negative regulation of cell migration [GO:0030336]; negative regulation of cell proliferation [GO:0008285]; negative regulation of NF-kappaB transcription factor activity [GO:0032088]; nitric oxide biosynthetic process [GO:0006809]; omega-hydroxylase P450 pathway [GO:0097267]; oxidation-reduction process [GO:0055114]; positive regulation of angiogenesis [GO:0045766]; positive regulation of apoptotic process [GO:0043065]; positive regulation of JAK-STAT cascade [GO:0046427]; positive regulation of vascular endothelial growth factor production [GO:0010575]; regulation of reactive oxygen species metabolic process [GO:2000377]; response to toxic substance [GO:0009636]; retinal blood vessel morphogenesis [GO:0061304]; retinal metabolic process [GO:0042574]; retinol metabolic process [GO:0042572]; steroid metabolic process [GO:0008202]; sterol metabolic process [GO:0016125]; toxin metabolic process [GO:0009404]; trabecular meshwork development [GO:0002930]; visual perception [GO:0007601]; xenobiotic metabolic process [GO:0006805]	aromatase activity [GO:0070330]; heme binding [GO:0020037]; iron ion binding [GO:0005506]; monooxygenase activity [GO:0004497]; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen [GO:0016712]; oxygen binding [GO:0019825]	endoplasmic reticulum membrane [GO:0005789]; intracellular membrane-bounded organelle [GO:0043231]; mitochondrion [GO:0005739]; organelle membrane [GO:0031090]
Q02318	CP27A_HUMAN	Sterol 26-hydroxylase, mitochondrial (EC 1.14.15.15) (5-beta-cholestane-3-alpha,7-alpha,12-alpha-triol 27-hydroxylase) (Cytochrome P-450C27/25) (Cytochrome P450 27) (Sterol 27-hydroxylase) (Vitamin D(3) 25-hydroxylase)	CYP27A1 CYP27	1MFX;	CHEMBL5992;	Q02318;	DB06777;DB00169;DB06410;DB00153;DB00082;	PATHWAY: Hormone biosynthesis; cholecalciferol biosynthesis.	PF00067;	IPR001128;IPR017972;IPR002401;	bile acid biosynthetic process [GO:0006699]; sterol metabolic process [GO:0016125]	heme binding [GO:0020037]; iron ion binding [GO:0005506]; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen [GO:0016705]; steroid hydroxylase activity [GO:0008395]	mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]
O15528	CP27B_HUMAN	25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial (EC 1.14.15.18) (25-OHD-1 alpha-hydroxylase) (25-hydroxyvitamin D(3) 1-alpha-hydroxylase) (VD3 1A hydroxylase) (Calcidiol 1-monooxygenase) (Cytochrome P450 subfamily XXVIIB polypeptide 1) (Cytochrome P450C1 alpha) (Cytochrome P450VD1-alpha) (Cytochrome p450 27B1)	CYP27B1 CYP1ALPHA CYP27B		CHEMBL5993;	O15528;	DB01436;DB00146;DB01285;DB00153;	PATHWAY: Hormone biosynthesis; cholecalciferol biosynthesis.	PF00067;	IPR001128;IPR017972;IPR002401;	bone mineralization [GO:0030282]; calcitriol biosynthetic process from calciol [GO:0036378]; calcium ion homeostasis [GO:0055074]; calcium ion transport [GO:0006816]; decidualization [GO:0046697]; G1 to G0 transition [GO:0070314]; negative regulation of calcidiol 1-monooxygenase activity [GO:0010956]; negative regulation of cell growth [GO:0030308]; negative regulation of cell proliferation [GO:0008285]; positive regulation of keratinocyte differentiation [GO:0045618]; positive regulation of vitamin D 24-hydroxylase activity [GO:0010980]; positive regulation of vitamin D receptor signaling pathway [GO:0070564]; regulation of bone mineralization [GO:0030500]; response to estrogen [GO:0043627]; response to interferon-gamma [GO:0034341]; response to lipopolysaccharide [GO:0032496]; response to vitamin D [GO:0033280]; vitamin D catabolic process [GO:0042369]; vitamin D metabolic process [GO:0042359]; vitamin metabolic process [GO:0006766]	calcidiol 1-monooxygenase activity [GO:0004498]; heme binding [GO:0020037]; iron ion binding [GO:0005506]	cytoplasm [GO:0005737]; mitochondrial outer membrane [GO:0005741]; mitochondrion [GO:0005739]
P11509	CP2A6_HUMAN	Cytochrome P450 2A6 (EC 1.14.13.-) (1,4-cineole 2-exo-monooxygenase) (CYPIIA6) (Coumarin 7-hydroxylase) (Cytochrome P450 IIA3) (Cytochrome P450(I))	CYP2A6 CYP2A3	1Z10;1Z11;2FDU;2FDV;2FDW;2FDY;3EBS;3T3Q;3T3R;4EJJ;4RUI;	CHEMBL5282;	P11509;	DB00316;DB01118;DB00381;DB01351;DB00182;DB01435;DB01274;DB00972;DB00207;DB00921;DB01156;DB00356;DB00568;DB00604;DB00636;DB00882;DB00257;DB00363;DB00531;DB06292;DB01151;DB01234;DB01191;DB00255;DB00470;DB00216;DB04953;DB04841;DB01544;DB00544;DB00690;DB01213;DB00983;DB01159;DB01181;DB00951;DB01026;DB01006;DB00281;DB04871;DB01043;DB00170;DB00763;DB00553;DB01028;DB01011;DB01110;DB00471;DB00238;DB00184;DB01115;DB06712;DB01059;DB00312;DB01174;DB01085;DB00860;DB00396;DB00818;DB01045;DB00412;DB01037;DB01236;DB06729;DB00675;DB00752;DB00755;DB01361;DB00313;DB09068;DB00495;		PF00067;	IPR001128;IPR017972;IPR002401;IPR008067;	coumarin catabolic process [GO:0046226]; coumarin metabolic process [GO:0009804]; drug metabolic process [GO:0017144]; epoxygenase P450 pathway [GO:0019373]; exogenous drug catabolic process [GO:0042738]; steroid metabolic process [GO:0008202]	arachidonic acid epoxygenase activity [GO:0008392]; coumarin 7-hydroxylase activity [GO:0008389]; enzyme binding [GO:0019899]; heme binding [GO:0020037]; iron ion binding [GO:0005506]; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen [GO:0016712]; steroid hydroxylase activity [GO:0008395]	cytoplasmic microtubule [GO:0005881]; endoplasmic reticulum membrane [GO:0005789]; organelle membrane [GO:0031090]
P10632	CP2C8_HUMAN	Cytochrome P450 2C8 (EC 1.14.14.1) (CYPIIC8) (Cytochrome P450 IIC2) (Cytochrome P450 MP-12) (Cytochrome P450 MP-20) (Cytochrome P450 form 1) (S-mephenytoin 4-hydroxylase)	CYP2C8	1PQ2;2NNH;2NNI;2NNJ;2VN0;	CHEMBL3721;	P10632;	DB05812;DB00316;DB00945;DB00918;DB01424;DB01118;DB00321;DB00381;DB00613;DB00701;DB01435;DB06605;DB01076;DB00972;DB06770;DB01393;DB00188;DB00835;DB00921;DB01156;DB06772;DB00201;DB00796;DB00564;DB00748;DB00446;DB00608;DB00169;DB00501;DB00604;DB00758;DB00257;DB00363;DB00907;DB01394;DB00531;DB00091;DB08912;DB00250;DB00705;DB01234;DB00514;DB00647;DB00829;DB00586;DB00255;DB00343;DB01184;DB06210;DB08899;DB00530;DB00783;DB00402;DB00977;DB00773;DB01023;DB01039;DB00544;DB01095;DB01320;DB01241;DB01218;DB00741;DB01050;DB09054;DB01181;DB01029;DB00951;DB09570;DB01221;DB06738;DB01026;DB01009;DB00448;DB01259;DB08918;DB00451;DB00281;DB01583;DB00836;DB00455;DB00678;DB00227;DB00603;DB00784;DB00814;DB00333;DB00916;DB00370;DB00764;DB00471;DB00295;DB00688;DB01183;DB00788;DB00622;DB00184;DB01115;DB04868;DB00665;DB06712;DB09080;DB00338;DB01062;DB01229;DB00617;DB00715;DB06589;DB00738;DB00850;DB00780;DB01174;DB00946;DB00252;DB01132;DB00554;DB08860;DB08901;DB00175;DB00794;DB01032;DB00396;DB01182;DB00818;DB00205;DB00908;DB00468;DB00481;DB08896;DB00912;DB01045;DB01201;DB08931;DB00503;DB00412;DB00938;DB01232;DB00418;DB01037;DB11362;DB00641;DB01261;DB00398;DB00421;DB00359;DB01015;DB06729;DB01138;DB00675;DB00799;DB00231;DB00857;DB00624;DB00277;DB00679;DB00208;DB01007;DB01124;DB00214;DB08911;DB00755;DB00897;DB00347;DB00440;DB01361;DB00313;DB00661;DB08828;DB09068;DB00682;DB00549;DB00495;DB01198;		PF00067;	IPR001128;IPR017972;IPR002401;	drug metabolic process [GO:0017144]; epoxygenase P450 pathway [GO:0019373]; exogenous drug catabolic process [GO:0042738]; lipid hydroxylation [GO:0002933]; omega-hydroxylase P450 pathway [GO:0097267]; organic acid metabolic process [GO:0006082]; oxidation-reduction process [GO:0055114]; oxidative demethylation [GO:0070989]; steroid metabolic process [GO:0008202]; xenobiotic metabolic process [GO:0006805]	arachidonic acid epoxygenase activity [GO:0008392]; aromatase activity [GO:0070330]; caffeine oxidase activity [GO:0034875]; estrogen 16-alpha-hydroxylase activity [GO:0101020]; heme binding [GO:0020037]; iron ion binding [GO:0005506]; monooxygenase activity [GO:0004497]; oxygen binding [GO:0019825]; steroid hydroxylase activity [GO:0008395]	endoplasmic reticulum membrane [GO:0005789]; organelle membrane [GO:0031090]
P11712	CP2C9_HUMAN	Cytochrome P450 2C9 (EC 1.14.13.-) ((R)-limonene 6-monooxygenase) (EC 1.14.13.80) ((S)-limonene 6-monooxygenase) (EC 1.14.13.48) ((S)-limonene 7-monooxygenase) (EC 1.14.13.49) (CYPIIC9) (Cholesterol 25-hydroxylase) (EC 1.14.99.38) (Cytochrome P-450MP) (Cytochrome P450 MP-4) (Cytochrome P450 MP-8) (Cytochrome P450 PB-1) (S-mephenytoin 4-hydroxylase)	CYP2C9 CYP2C10	1OG2;1OG5;1R9O;4NZ2;5A5I;	CHEMBL3397;	P11712;	DB01418;DB00316;DB00945;DB06594;DB00969;DB00404;DB01424;DB01118;DB00321;DB00381;DB00613;DB00701;DB01217;DB01435;DB06605;DB00673;DB01274;DB06413;DB06697;DB01072;DB01076;DB01117;DB00972;DB00307;DB01128;DB00188;DB00559;DB00835;DB00921;DB01156;DB08875;DB00201;DB00796;DB01101;DB00564;DB00748;DB01136;DB00482;DB00446;DB00672;DB00169;DB00501;DB00568;DB00604;DB00515;DB04920;DB00758;DB00257;DB00363;DB00907;DB01394;DB01176;DB00531;DB00091;DB06292;DB00250;DB00705;DB00967;DB01234;DB01191;DB00514;DB00647;DB00829;DB00586;DB01144;DB00266;DB00255;DB00343;DB01075;DB00822;DB00757;DB00843;DB00988;DB00869;DB01142;DB00470;DB00625;DB00216;DB08899;DB00668;DB01240;DB00876;DB00783;DB00655;DB04574;DB00402;DB00898;DB00749;DB01628;DB06414;DB01023;DB01039;DB01195;DB00196;DB04841;DB01544;DB00544;DB00472;DB00712;DB01095;DB00176;DB00983;DB01320;DB00317;DB01241;DB01381;DB01120;DB00222;DB01067;DB01016;DB01018;DB00502;DB01159;DB01355;DB00667;DB00062;DB00327;DB01050;DB01177;DB01181;DB00619;DB00224;DB00328;DB01029;DB00951;DB09570;DB01221;DB06738;DB01026;DB01009;DB00448;DB01097;DB00281;DB01601;DB00455;DB06725;DB00678;DB00227;DB01283;DB00603;DB00784;DB01065;DB00814;DB01357;DB00333;DB00703;DB00763;DB01028;DB00916;DB01110;DB00370;DB01171;DB00745;DB00471;DB00788;DB00731;DB00220;DB09048;DB00238;DB00622;DB06803;DB00184;DB01115;DB04868;DB00665;DB06712;DB00540;DB00334;DB09080;DB00338;DB00904;DB04938;DB00991;DB01229;DB00213;DB00617;DB08439;DB00715;DB00850;DB01174;DB00946;DB00191;DB00812;DB00252;DB01132;DB00554;DB08860;DB01411;DB06209;DB00175;DB00794;DB01032;DB00396;DB01131;DB00420;DB01069;DB01182;DB00818;DB00205;DB01589;DB00908;DB00468;DB01129;DB08896;DB01045;DB01201;DB00503;DB00412;DB01098;DB00936;DB01232;DB00418;DB01037;DB01104;DB00203;DB00641;DB06268;DB00398;DB06820;DB00359;DB06150;DB00576;DB01015;DB08798;DB00259;DB06729;DB00891;DB01138;DB00263;DB00870;DB00675;DB06204;DB00231;DB00444;DB00469;DB00857;DB00624;DB01041;DB00277;DB01154;DB00679;DB00208;DB01007;DB01124;DB00323;DB01036;DB00214;DB05109;DB00752;DB00374;DB00755;DB00897;DB00347;DB00440;DB00726;DB01361;DB00313;DB00177;DB00285;DB00661;DB08828;DB00582;DB09068;DB00682;DB04898;DB00549;DB00943;DB00495;DB00744;DB00425;DB01198;		PF00067;	IPR001128;IPR017972;IPR002401;	cellular amide metabolic process [GO:0043603]; drug catabolic process [GO:0042737]; drug metabolic process [GO:0017144]; epoxygenase P450 pathway [GO:0019373]; exogenous drug catabolic process [GO:0042738]; monocarboxylic acid metabolic process [GO:0032787]; monoterpenoid metabolic process [GO:0016098]; omega-hydroxylase P450 pathway [GO:0097267]; oxidation-reduction process [GO:0055114]; oxidative demethylation [GO:0070989]; steroid metabolic process [GO:0008202]; urea metabolic process [GO:0019627]; xenobiotic metabolic process [GO:0006805]	(R)-limonene 6-monooxygenase activity [GO:0052741]; (S)-limonene 6-monooxygenase activity [GO:0018675]; (S)-limonene 7-monooxygenase activity [GO:0018676]; arachidonic acid epoxygenase activity [GO:0008392]; caffeine oxidase activity [GO:0034875]; cholesterol 25-hydroxylase activity [GO:0001567]; drug binding [GO:0008144]; heme binding [GO:0020037]; iron ion binding [GO:0005506]; monooxygenase activity [GO:0004497]; oxidoreductase activity [GO:0016491]; oxygen binding [GO:0019825]; steroid hydroxylase activity [GO:0008395]	endoplasmic reticulum membrane [GO:0005789]; intracellular membrane-bounded organelle [GO:0043231]; organelle membrane [GO:0031090]
P10635	CP2D6_HUMAN	Cytochrome P450 2D6 (EC 1.14.14.1) (CYPIID6) (Cholesterol 25-hydroxylase) (Cytochrome P450-DB1) (Debrisoquine 4-hydroxylase)	CYP2D6 CYP2DL1	2F9Q;3QM4;3TBG;3TDA;4WNT;4WNU;4WNV;4WNW;4XRY;4XRZ;	CHEMBL289;	P10635;	DB05812;DB01193;DB00316;DB03128;DB01426;DB00918;DB06203;DB00866;DB01424;DB01118;DB00321;DB00381;DB00613;DB00543;DB00182;DB00701;DB00276;DB01435;DB01429;DB01274;DB01238;DB06697;DB06216;DB00637;DB00289;DB01076;DB00972;DB00245;DB06770;DB01244;DB00195;DB01128;DB00810;DB00612;DB00188;DB09128;DB00835;DB00297;DB00921;DB01156;DB00490;DB00201;DB01197;DB00748;DB06016;DB00521;DB01136;DB00482;DB00567;DB00185;DB00475;DB00608;DB01114;DB00477;DB00356;DB00169;DB01410;DB01166;DB00501;DB01012;DB00568;DB00604;DB00215;DB00283;DB04920;DB00349;DB01242;DB00575;DB00257;DB00363;DB09065;DB00907;DB00318;DB00924;DB00531;DB00091;DB06292;DB00496;DB04840;DB00705;DB01151;DB00967;DB01234;DB01191;DB00633;DB06701;DB01576;DB00514;DB00647;DB01551;DB00343;DB01093;DB01075;DB00757;DB01184;DB00843;DB00988;DB00590;DB01142;DB00997;DB04855;DB00476;DB00625;DB00216;DB09039;DB01228;DB08899;DB00751;DB00530;DB01175;DB01466;DB01628;DB01023;DB06702;DB00950;DB08868;DB01195;DB04841;DB00472;DB00623;DB01095;DB00176;DB00983;DB00674;DB00317;DB01437;DB00889;DB01218;DB00502;DB01159;DB00667;DB00956;DB00327;DB01611;DB01005;DB00557;DB09053;DB01177;DB04946;DB00619;DB00458;DB00224;DB00332;DB01029;DB00951;DB01167;DB09570;DB01026;DB00598;DB00448;DB00528;DB01235;DB08918;DB00281;DB00589;DB01206;DB00836;DB01601;DB00455;DB04871;DB00227;DB06708;DB00934;DB00358;DB06691;DB01071;DB00933;DB00333;DB01577;DB00703;DB00763;DB01403;DB01028;DB06800;DB00422;DB01107;DB01233;DB00264;DB00379;DB06148;DB01110;DB00211;DB00834;DB00805;DB08893;DB00370;DB01171;DB00295;DB09049;DB00731;DB04861;DB01149;DB00220;DB09048;DB00238;DB00627;DB00622;DB00699;DB02701;DB00184;DB01115;DB04868;DB00336;DB00540;DB00334;DB00338;DB00904;DB01096;DB01580;DB01062;DB00497;DB06412;DB01192;DB01267;DB00377;DB06603;DB00715;DB06589;DB00738;DB01186;DB01074;DB00850;DB00454;DB00914;DB00191;DB01100;DB00960;DB01132;DB00592;DB01621;DB08901;DB00175;DB01058;DB01087;DB01035;DB00433;DB00396;DB01131;DB01069;DB01182;DB00818;DB00571;DB00344;DB00852;DB00205;DB01224;DB00908;DB00468;DB01129;DB00863;DB00243;DB00234;DB00409;DB01201;DB00734;DB00503;DB00989;DB09291;DB00268;DB00296;DB00412;DB05271;DB01232;DB01037;DB06144;DB01104;DB00203;DB00641;DB00398;DB00259;DB06729;DB00675;DB00706;DB06204;DB00976;DB06287;DB00857;DB04844;DB00277;DB00679;DB01623;DB00208;DB00373;DB01409;DB00932;DB01036;DB05109;DB00193;DB00752;DB00656;DB00726;DB00792;DB00427;DB00209;DB09076;DB08881;DB00285;DB00661;DB06684;DB00570;DB00361;DB09068;DB01392;DB00549;DB00943;DB00246;DB00425;DB01624;		PF00067;	IPR001128;IPR017972;IPR002401;IPR008069;	alkaloid catabolic process [GO:0009822]; alkaloid metabolic process [GO:0009820]; arachidonic acid metabolic process [GO:0019369]; coumarin metabolic process [GO:0009804]; drug catabolic process [GO:0042737]; drug metabolic process [GO:0017144]; heterocycle metabolic process [GO:0046483]; isoquinoline alkaloid metabolic process [GO:0033076]; monoterpenoid metabolic process [GO:0016098]; negative regulation of binding [GO:0051100]; negative regulation of cellular organofluorine metabolic process [GO:0090350]; oxidation-reduction process [GO:0055114]; oxidative demethylation [GO:0070989]; steroid metabolic process [GO:0008202]; xenobiotic metabolic process [GO:0006805]	arachidonic acid epoxygenase activity [GO:0008392]; aromatase activity [GO:0070330]; drug binding [GO:0008144]; heme binding [GO:0020037]; iron ion binding [GO:0005506]; monooxygenase activity [GO:0004497]; oxidoreductase activity [GO:0016491]; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen [GO:0016712]; oxygen binding [GO:0019825]; steroid hydroxylase activity [GO:0008395]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; mitochondrion [GO:0005739]; organelle membrane [GO:0031090]
Q6VVX0	CP2R1_HUMAN	Vitamin D 25-hydroxylase (EC 1.14.14.24) (Cytochrome P450 2R1)	CYP2R1	3C6G;3CZH;3DL9;			DB00169;DB00153;		PF00067;	IPR001128;IPR017972;IPR002401;	response to cesium ion [GO:0010164]; response to ionizing radiation [GO:0010212]; vitamin D metabolic process [GO:0042359]; vitamin metabolic process [GO:0006766]	heme binding [GO:0020037]; iron ion binding [GO:0005506]; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen [GO:0016705]; steroid hydroxylase activity [GO:0008395]; vitamin D3 25-hydroxylase activity [GO:0030343]	endoplasmic reticulum membrane [GO:0005789]; organelle membrane [GO:0031090]
P08684	CP3A3_HUMAN,CP3A4_HUMAN	Cytochrome P450 3A4 (EC 1.14.13.-) (1,8-cineole 2-exo-monooxygenase) (EC 1.14.13.157) (Albendazole monooxygenase) (EC 1.14.13.32) (Albendazole sulfoxidase) (CYPIIIA3) (CYPIIIA4) (Cholesterol 25-hydroxylase) (EC 1.14.14.1) (Cytochrome P450 3A3) (Cytochrome P450 HLp) (Cytochrome P450 NF-25) (Cytochrome P450-PCN1) (Nifedipine oxidase) (Quinine 3-monooxygenase) (EC 1.14.13.67) (Taurochenodeoxycholate 6-alpha-hydroxylase) (EC 1.14.13.97)	CYP3A4 CYP3A3	1TQN;1W0E;1W0F;1W0G;2J0D;2V0M;3NXU;3TJS;3UA1;4D6Z;4D75;4D78;4D7D;4I3Q;4I4G;4I4H;4K9T;4K9U;4K9V;4K9W;4K9X;4NY4;5A1P;5A1R;	CHEMBL340;	P08684;	DB05812;DB01418;DB00316;DB00819;DB00546;DB05773;DB00518;DB00240;DB00041;DB00802;DB00346;DB01246;DB09026;DB01431;DB00918;DB06203;DB00969;DB00404;DB06403;DB06742;DB00357;DB01424;DB01223;DB01118;DB00321;DB00381;DB00701;DB01217;DB01435;DB06605;DB05676;DB00673;DB00278;DB01238;DB06413;DB01169;DB06697;DB06216;DB00637;DB01072;DB00289;DB01076;DB06237;DB06626;DB00719;DB00972;DB00207;DB08903;DB00865;DB06770;DB00443;DB00307;DB01393;DB01128;DB04794;DB00612;DB08873;DB00188;DB00559;DB06616;DB08870;DB09128;DB01194;DB01558;DB01200;DB00835;DB01222;DB00297;DB00921;DB01156;DB00490;DB01008;DB06772;DB00248;DB08875;DB00201;DB00136;DB08907;DB06774;DB00564;DB00748;DB06016;DB01136;DB00520;DB01333;DB00482;DB04846;DB00567;DB00185;DB06777;DB00446;DB00475;DB00608;DB01114;DB00856;DB00477;DB00356;DB00169;DB01410;DB01166;DB00501;DB01012;DB00537;DB00604;DB00215;DB01211;DB00283;DB04920;DB01190;DB00349;DB00845;DB00636;DB00882;DB01242;DB01068;DB00575;DB00758;DB00628;DB01559;DB00257;DB00363;DB05239;DB00907;DB00318;DB01394;DB00872;DB00286;DB01380;DB08865;DB00924;DB00531;DB00091;DB00987;DB08912;DB09102;DB01764;DB01406;DB01219;DB06292;DB00250;DB00496;DB01264;DB01254;DB00694;DB01609;DB00705;DB01151;DB06700;DB01234;DB00514;DB00647;DB00829;DB00586;DB00485;DB00255;DB01396;DB00390;DB01551;DB00320;DB00343;DB01093;DB00280;DB00822;DB01248;DB00204;DB00757;DB08930;DB01184;DB00843;DB00869;DB01142;DB00997;DB00254;DB00470;DB04855;DB01126;DB01127;DB00625;DB00216;DB09039;DB09101;DB00584;DB08899;DB00751;DB00668;DB00700;DB00153;DB01049;DB01253;DB00696;DB00530;DB00199;DB01175;DB09119;DB00736;DB01215;DB00783;DB08866;DB01196;DB00655;DB04574;DB00402;DB00898;DB00977;DB00593;DB01466;DB00294;DB00773;DB01628;DB06414;DB01590;DB00990;DB00973;DB00426;DB00949;DB01023;DB01039;DB00813;DB06702;DB01216;DB08868;DB04908;DB00301;DB00196;DB00180;DB01544;DB00324;DB00472;DB00690;DB00499;DB08906;DB00588;DB01095;DB00176;DB01319;DB01320;DB00947;DB00674;DB00317;DB01241;DB01067;DB01016;DB00889;DB00400;DB01170;DB01018;DB01218;DB00502;DB01159;DB01355;DB00667;DB01275;DB00956;DB00769;DB00741;DB00327;DB06789;DB09053;DB09054;DB01181;DB04946;DB00619;DB00458;DB00724;DB05039;DB00808;DB00224;DB00332;DB01029;DB00762;DB06636;DB00951;DB00883;DB01020;DB00270;DB01167;DB09083;DB08820;DB00602;DB04845;DB09570;DB01321;DB01221;DB01587;DB06738;DB01026;DB00448;DB01259;DB09078;DB00528;DB01006;DB01002;DB06282;DB01137;DB01227;DB08918;DB00367;DB00451;DB00281;DB08882;DB00589;DB08827;DB01206;DB00836;DB01601;DB00455;DB04871;DB00678;DB00227;DB08933;DB06708;DB08815;DB08932;DB04835;DB00643;DB00603;DB00358;DB00814;DB01071;DB00333;DB00703;DB00763;DB00553;DB01028;DB00353;DB00959;DB06710;DB00916;DB01011;DB00379;DB06148;DB01110;DB00683;DB00834;DB08893;DB00370;DB01204;DB00745;DB00471;DB00295;DB00688;DB00607;DB09049;DB01183;DB00731;DB01149;DB00220;DB00238;DB00622;DB02701;DB00184;DB01115;DB04868;DB06712;DB00393;DB00401;DB01595;DB01054;DB00435;DB00717;DB01059;DB00540;DB00334;DB09074;DB00768;DB00338;DB00904;DB01083;DB01173;DB09330;DB04938;DB00842;DB00776;DB00239;DB01062;DB00497;DB01192;DB01229;DB09073;DB01267;DB00377;DB06603;DB00213;DB00617;DB01384;DB08439;DB00910;DB06589;DB00082;DB00738;DB00312;DB08883;DB01186;DB01074;DB04930;DB00850;DB00454;DB00780;DB01174;DB00925;DB00946;DB00812;DB00252;DB01085;DB00337;DB01100;DB01132;DB01621;DB01179;DB08910;DB08901;DB01263;DB01411;DB06209;DB00175;DB01588;DB01058;DB00860;DB00635;DB01087;DB00794;DB01032;DB00433;DB00396;DB01131;DB00420;DB01182;DB00818;DB00571;DB00339;DB00545;DB01589;DB01224;DB01103;DB00908;DB00468;DB01369;DB01129;DB00481;DB00980;DB00863;DB00243;DB00234;DB08896;DB00912;DB01256;DB00615;DB01045;DB01201;DB01220;DB08864;DB06155;DB08931;DB00734;DB00503;DB06228;DB00989;DB09291;DB01301;DB06176;DB00268;DB00296;DB01098;DB05271;DB00778;DB06201;DB08877;DB01001;DB00938;DB01232;DB06335;DB01037;DB11362;DB06144;DB01104;DB01236;DB01105;DB00203;DB06207;DB06290;DB00641;DB00877;DB01261;DB06268;DB01591;DB09143;DB00398;DB00708;DB00359;DB01015;DB00259;DB01138;DB01268;DB00864;DB00820;DB00675;DB00706;DB01349;DB05521;DB00976;DB00231;DB00853;DB06287;DB00444;DB00857;DB00624;DB00759;DB00277;DB00599;DB04572;DB00906;DB08816;DB00208;DB00911;DB01007;DB01409;DB00932;DB08895;DB08811;DB01036;DB06212;DB00273;DB01030;DB00539;DB05109;DB00193;DB08911;DB00752;DB00656;DB00755;DB00620;DB00897;DB00347;DB00440;DB00726;DB01361;DB06267;DB08867;DB00313;DB05294;DB00862;DB08881;DB00285;DB00661;DB09082;DB06684;DB00570;DB00541;DB00309;DB00361;DB08828;DB00582;DB09068;DB00682;DB01392;DB00549;DB00943;DB00962;DB00495;DB00744;DB00246;DB00425;DB00909;DB01198;		PF00067;	IPR001128;IPR017972;IPR008072;IPR002402;	alkaloid catabolic process [GO:0009822]; androgen metabolic process [GO:0008209]; drug catabolic process [GO:0042737]; drug metabolic process [GO:0017144]; exogenous drug catabolic process [GO:0042738]; heterocycle metabolic process [GO:0046483]; lipid hydroxylation [GO:0002933]; lipid metabolic process [GO:0006629]; monoterpenoid metabolic process [GO:0016098]; oxidation-reduction process [GO:0055114]; oxidative demethylation [GO:0070989]; steroid catabolic process [GO:0006706]; steroid metabolic process [GO:0008202]; vitamin D metabolic process [GO:0042359]; xenobiotic metabolic process [GO:0006805]	albendazole monooxygenase activity [GO:0047638]; aromatase activity [GO:0070330]; caffeine oxidase activity [GO:0034875]; enzyme binding [GO:0019899]; estrogen 16-alpha-hydroxylase activity [GO:0101020]; heme binding [GO:0020037]; iron ion binding [GO:0005506]; monooxygenase activity [GO:0004497]; oxidoreductase activity [GO:0016491]; oxygen binding [GO:0019825]; quinine 3-monooxygenase activity [GO:0050591]; steroid binding [GO:0005496]; steroid hydroxylase activity [GO:0008395]; taurochenodeoxycholate 6alpha-hydroxylase activity [GO:0033780]; testosterone 6-beta-hydroxylase activity [GO:0050649]; vitamin D 24-hydroxylase activity [GO:0070576]; vitamin D3 25-hydroxylase activity [GO:0030343]	cytoplasm [GO:0005737]; endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; intracellular membrane-bounded organelle [GO:0043231]; organelle membrane [GO:0031090]
P20815	CP3A5_HUMAN	Cytochrome P450 3A5 (EC 1.14.14.1) (CYPIIIA5) (Cytochrome P450 HLp2) (Cytochrome P450-PCN3)	CYP3A5		CHEMBL3019;	P20815;	DB05773;DB00802;DB00404;DB06403;DB01118;DB00321;DB00381;DB00701;DB06605;DB00673;DB00278;DB01238;DB06413;DB06697;DB00637;DB01076;DB06626;DB00972;DB00394;DB08873;DB08870;DB00921;DB00490;DB06772;DB00201;DB00564;DB00446;DB00608;DB01114;DB01166;DB00501;DB00537;DB00604;DB01211;DB00575;DB00758;DB05239;DB00907;DB00318;DB08865;DB00531;DB00091;DB09102;DB00250;DB01254;DB00694;DB00705;DB01234;DB00514;DB00829;DB00343;DB00822;DB01248;DB08930;DB01184;DB01126;DB08899;DB00700;DB00530;DB00199;DB00783;DB00655;DB00593;DB00773;DB01023;DB00813;DB01216;DB00196;DB00472;DB00499;DB00588;DB01095;DB00176;DB00317;DB06730;DB00889;DB01218;DB00502;DB00741;DB06789;DB09053;DB01181;DB04946;DB00619;DB00224;DB00762;DB01167;DB01026;DB01259;DB00528;DB01227;DB00281;DB00678;DB00227;DB00333;DB00683;DB00834;DB00745;DB00688;DB00731;DB01149;DB00220;DB00238;DB00622;DB01115;DB00393;DB00401;DB01054;DB00717;DB01059;DB00540;DB00904;DB00842;DB00776;DB01062;DB00497;DB01229;DB01267;DB00738;DB08883;DB00780;DB01174;DB00252;DB01100;DB08901;DB00175;DB01058;DB00396;DB00571;DB01224;DB01103;DB00468;DB00863;DB00206;DB01045;DB01201;DB00734;DB00503;DB06228;DB06176;DB01098;DB00938;DB01232;DB06335;DB00203;DB00641;DB00877;DB00398;DB00795;DB01268;DB00864;DB00675;DB00976;DB06287;DB00444;DB00624;DB01041;DB00656;DB00755;DB00897;DB01361;DB06267;DB00313;DB00862;DB00661;DB00541;DB00582;DB09068;DB00943;DB00962;DB00246;DB00425;		PF00067;	IPR001128;IPR017972;IPR008072;IPR002402;	alkaloid catabolic process [GO:0009822]; drug catabolic process [GO:0042737]; lipid hydroxylation [GO:0002933]; oxidative demethylation [GO:0070989]; steroid metabolic process [GO:0008202]; xenobiotic metabolic process [GO:0006805]	aromatase activity [GO:0070330]; estrogen 16-alpha-hydroxylase activity [GO:0101020]; heme binding [GO:0020037]; iron ion binding [GO:0005506]; monooxygenase activity [GO:0004497]; oxidoreductase activity [GO:0016491]; oxygen binding [GO:0019825]	endoplasmic reticulum membrane [GO:0005789]; intracellular membrane-bounded organelle [GO:0043231]; organelle membrane [GO:0031090]
Q02928	CP4AB_HUMAN	Cytochrome P450 4A11 (20-hydroxyeicosatetraenoic acid synthase) (20-HETE synthase) (CYP4AII) (CYPIVA11) (Cytochrome P-450HK-omega) (Cytochrome P450HL-omega) (Fatty acid omega-hydroxylase) (Lauric acid omega-hydroxylase) (Long-chain fatty acid omega-monooxygenase) (EC 1.14.13.205)	CYP4A11 CYP4A2		CHEMBL3978;		DB00515;DB00636;DB01234;DB00655;DB00898;DB00448;DB00082;DB00738;DB01174;DB01045;DB00755;		PF00067;	IPR001128;IPR017972;IPR002401;	arachidonic acid metabolic process [GO:0019369]; epoxygenase P450 pathway [GO:0019373]; fatty acid metabolic process [GO:0006631]; leukotriene metabolic process [GO:0006691]; long-chain fatty acid metabolic process [GO:0001676]; omega-hydroxylase P450 pathway [GO:0097267]; oxidation-reduction process [GO:0055114]; positive regulation of icosanoid secretion [GO:0032305]; pressure natriuresis [GO:0003095]; renal water homeostasis [GO:0003091]; sodium ion homeostasis [GO:0055078]	alkane 1-monooxygenase activity [GO:0018685]; arachidonic acid epoxygenase activity [GO:0008392]; heme binding [GO:0020037]; iron ion binding [GO:0005506]; leukotriene-B4 20-monooxygenase activity [GO:0050051]; monooxygenase activity [GO:0004497]; oxygen binding [GO:0019825]	apical plasma membrane [GO:0016324]; cytoplasm [GO:0005737]; endoplasmic reticulum membrane [GO:0005789]; extracellular exosome [GO:0070062]; intracellular membrane-bounded organelle [GO:0043231]; organelle membrane [GO:0031090]
Q16850	CP51A_HUMAN	Lanosterol 14-alpha demethylase (LDM) (EC 1.14.13.70) (CYPLI) (Cytochrome P450 51A1) (Cytochrome P450-14DM) (Cytochrome P45014DM) (Cytochrome P450LI) (Sterol 14-alpha demethylase)	CYP51A1 CYP51	3JUS;3JUV;3LD6;4UHI;4UHL;	CHEMBL3849;	Q16850;	DB00199;DB01167;DB01026;DB00916;DB01045;DB01153;DB01007;	PATHWAY: Steroid biosynthesis; zymosterol biosynthesis; zymosterol from lanosterol: step 1/6.	PF00067;	IPR001128;IPR017972;IPR002403;	cholesterol biosynthetic process [GO:0006695]; cholesterol biosynthetic process via 24,25-dihydrolanosterol [GO:0033488]; steroid biosynthetic process [GO:0006694]; sterol metabolic process [GO:0016125]	heme binding [GO:0020037]; iron ion binding [GO:0005506]; sterol 14-demethylase activity [GO:0008398]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; membrane [GO:0016020]; organelle membrane [GO:0031090]; plasma membrane [GO:0005886]
P50416	CPT1A_HUMAN	Carnitine O-palmitoyltransferase 1, liver isoform (CPT1-L) (EC 2.3.1.21) (Carnitine O-palmitoyltransferase I, liver isoform) (CPT I) (CPTI-L) (Carnitine palmitoyltransferase 1A)	CPT1A CPT1	2LE3;	CHEMBL1293194;	P50416;	DB01016;DB00583;DB01074;	PATHWAY: Lipid metabolism; fatty acid beta-oxidation.	PF00755;PF16484;	IPR000542;IPR032476;	carnitine metabolic process [GO:0009437]; carnitine shuttle [GO:0006853]; cellular response to fatty acid [GO:0071398]; circadian rhythm [GO:0007623]; eating behavior [GO:0042755]; epithelial cell differentiation [GO:0030855]; fatty acid beta-oxidation [GO:0006635]; glucose metabolic process [GO:0006006]; long-chain fatty acid metabolic process [GO:0001676]; positive regulation of fatty acid beta-oxidation [GO:0032000]; protein homooligomerization [GO:0051260]; regulation of insulin secretion [GO:0050796]; response to drug [GO:0042493]; response to organic cyclic compound [GO:0014070]; triglyceride metabolic process [GO:0006641]	carnitine O-palmitoyltransferase activity [GO:0004095]; palmitoleoyltransferase activity [GO:1990698]	integral component of mitochondrial outer membrane [GO:0031307]; membrane [GO:0016020]; mitochondrial inner membrane [GO:0005743]; mitochondrial outer membrane [GO:0005741]; mitochondrion [GO:0005739]
P23786	CPT2_HUMAN	Carnitine O-palmitoyltransferase 2, mitochondrial (EC 2.3.1.21) (Carnitine palmitoyltransferase II) (CPT II)	CPT2 CPT1		CHEMBL3238;	P23786;	DB00583;DB01074;	PATHWAY: Lipid metabolism; fatty acid beta-oxidation.	PF00755;	IPR000542;	carnitine shuttle [GO:0006853]; fatty acid beta-oxidation [GO:0006635]	carnitine O-palmitoyltransferase activity [GO:0004095]	mitochondrial inner membrane [GO:0005743]; mitochondrion [GO:0005739]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]
P12271	CRAL_HUMAN	Retinaldehyde-binding protein 1 (Cellular retinaldehyde-binding protein)	RLBP1 CRALBP	1XGG;1XGH;3HX3;3HY5;4CIZ;4CJ6;			DB00162;		PF00650;PF03765;	IPR001071;IPR001251;IPR011074;IPR032941;	response to stimulus [GO:0050896]; retinoid metabolic process [GO:0001523]; visual perception [GO:0007601]; vitamin A metabolic process [GO:0006776]	11-cis retinal binding [GO:0005502]; retinol binding [GO:0019841]; transporter activity [GO:0005215]	cell body [GO:0044297]; cytosol [GO:0005829]
P16220	CREB1_HUMAN	Cyclic AMP-responsive element-binding protein 1 (CREB-1) (cAMP-responsive element-binding protein 1)	CREB1	2LXT;	CHEMBL5587;		DB00131;DB01183;		PF00170;PF02173;	IPR004827;IPR003102;IPR001630;	aging [GO:0007568]; axon guidance [GO:0007411]; cellular response to fatty acid [GO:0071398]; cellular response to hepatocyte growth factor stimulus [GO:0035729]; cellular response to insulin-like growth factor stimulus [GO:1990314]; cellular response to nerve growth factor stimulus [GO:1990090]; cellular response to platelet-derived growth factor stimulus [GO:0036120]; cellular response to zinc ion [GO:0071294]; chemotaxis to arachidonic acid [GO:0034670]; circadian rhythm [GO:0007623]; lactation [GO:0007595]; lung saccule development [GO:0060430]; memory [GO:0007613]; negative regulation of neuron death [GO:1901215]; negative regulation of transcription by competitive promoter binding [GO:0010944]; pituitary gland development [GO:0021983]; positive regulation of apoptotic process [GO:0043065]; positive regulation of cardiac muscle tissue development [GO:0055025]; positive regulation of fat cell differentiation [GO:0045600]; positive regulation of hormone secretion [GO:0046887]; positive regulation of lipid biosynthetic process [GO:0046889]; positive regulation of long-term synaptic potentiation [GO:1900273]; positive regulation of multicellular organism growth [GO:0040018]; positive regulation of osteoclast differentiation [GO:0045672]; positive regulation of RNA polymerase II transcriptional preinitiation complex assembly [GO:0045899]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of transforming growth factor beta3 production [GO:0032916]; protein phosphorylation [GO:0006468]; protein stabilization [GO:0050821]; regulation of cell size [GO:0008361]; regulation of circadian rhythm [GO:0042752]; regulation of fibroblast proliferation [GO:0048145]; regulation of glial cell proliferation [GO:0060251]; response to activity [GO:0014823]; response to drug [GO:0042493]; response to glucagon [GO:0033762]; response to hypoxia [GO:0001666]; response to L-glutamate [GO:1902065]; response to nicotine [GO:0035094]; response to organic substance [GO:0010033]; secretory granule organization [GO:0033363]; signal transduction [GO:0007165]; transforming growth factor beta receptor signaling pathway [GO:0007179]; Type I pneumocyte differentiation [GO:0060509]; viral process [GO:0016032]; visual learning [GO:0008542]	cAMP response element binding [GO:0035497]; enzyme binding [GO:0019899]; RNA polymerase II activating transcription factor binding [GO:0001102]; RNA polymerase II core promoter proximal region sequence-specific DNA binding [GO:0000978]; RNA polymerase II distal enhancer sequence-specific DNA binding [GO:0000980]; transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding [GO:0001077]; transcriptional activator activity, RNA polymerase II transcription factor binding [GO:0001190]; transcription cofactor activity [GO:0003712]; transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding [GO:0003705]; transcription factor activity, sequence-specific DNA binding [GO:0003700]	ATF4-CREB1 transcription factor complex [GO:1990589]; axon [GO:0030424]; mitochondrial matrix [GO:0005759]; nuclear euchromatin [GO:0005719]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P02741	CRP_HUMAN	C-reactive protein [Cleaved into: C-reactive protein(1-205)]	CRP PTX1	1B09;1CRV;1GNH;1LJ7;3L2Y;3PVN;3PVO;			DB05278;		PF00354;	IPR013320;IPR001759;IPR030476;	acute-phase response [GO:0006953]; defense response to Gram-positive bacterium [GO:0050830]; inflammatory response [GO:0006954]; negative regulation of lipid storage [GO:0010888]; negative regulation of macrophage derived foam cell differentiation [GO:0010745]; negative regulation of vasodilation [GO:0045908]; opsonization [GO:0008228]; positive regulation of gene expression [GO:0010628]; positive regulation of superoxide anion generation [GO:0032930]; regulation of interleukin-8 secretion [GO:2000482]	calcium ion binding [GO:0005509]; choline binding [GO:0033265]; complement component C1q binding [GO:0001849]; low-density lipoprotein particle binding [GO:0030169]; low-density lipoprotein particle receptor binding [GO:0050750]	extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]
Q14894	CRYM_HUMAN	Ketimine reductase mu-crystallin (EC 1.5.1.25) (NADP-regulated thyroid-hormone-binding protein)	CRYM THBP	2I99;					PF02423;	IPR016040;IPR003462;IPR023401;	lysine catabolic process [GO:0006554]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; sensory perception of sound [GO:0007605]; thyroid hormone metabolic process [GO:0042403]; thyroid hormone transport [GO:0070327]	NADP binding [GO:0050661]; protein homodimerization activity [GO:0042803]; thiomorpholine-carboxylate dehydrogenase activity [GO:0047127]; thyroid hormone binding [GO:0070324]; transcription corepressor activity [GO:0003714]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; peroxisomal matrix [GO:0005782]
Q9Y600	CSAD_HUMAN	Cysteine sulfinic acid decarboxylase (EC 4.1.1.29) (Cysteine-sulfinate decarboxylase) (Sulfinoalanine decarboxylase)	CSAD CSD	2JIS;			DB00151;	PATHWAY: Organosulfur biosynthesis; taurine biosynthesis; hypotaurine from L-cysteine: step 2/2.	PF00282;	IPR002129;IPR015424;IPR015421;IPR015422;	carboxylic acid metabolic process [GO:0019752]; taurine biosynthetic process [GO:0042412]	pyridoxal phosphate binding [GO:0030170]; sulfinoalanine decarboxylase activity [GO:0004782]
P07333	CSF1R_HUMAN	Macrophage colony-stimulating factor 1 receptor (CSF-1 receptor) (CSF-1-R) (CSF-1R) (M-CSF-R) (EC 2.7.10.1) (Proto-oncogene c-Fms) (CD antigen CD115)	CSF1R FMS	2I0V;2I0Y;2I1M;2OGV;3BEA;3DPK;3KRJ;3KRL;3LCD;3LCO;4DKD;4HW7;4LIQ;4R7H;4R7I;4WRL;4WRM;	CHEMBL1844;	P07333;	DB00619;DB01268;		PF00047;PF07714;	IPR030658;IPR007110;IPR013783;IPR003599;IPR003598;IPR013151;IPR011009;IPR000719;IPR017441;IPR001245;IPR008266;IPR020635;IPR016243;IPR001824;	axon guidance [GO:0007411]; cell-cell junction maintenance [GO:0045217]; cell proliferation [GO:0008283]; cellular response to cytokine stimulus [GO:0071345]; cellular response to macrophage colony-stimulating factor stimulus [GO:0036006]; cytokine-mediated signaling pathway [GO:0019221]; forebrain neuron differentiation [GO:0021879]; hemopoiesis [GO:0030097]; inflammatory response [GO:0006954]; innate immune response [GO:0045087]; macrophage colony-stimulating factor signaling pathway [GO:0038145]; macrophage differentiation [GO:0030225]; mammary gland duct morphogenesis [GO:0060603]; monocyte differentiation [GO:0030224]; multicellular organism development [GO:0007275]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cell proliferation [GO:0008285]; olfactory bulb development [GO:0021772]; osteoclast differentiation [GO:0030316]; peptidyl-tyrosine phosphorylation [GO:0018108]; phosphatidylinositol-mediated signaling [GO:0048015]; phosphatidylinositol metabolic process [GO:0046488]; positive regulation of cell migration [GO:0030335]; positive regulation of cell motility [GO:2000147]; positive regulation of cell proliferation [GO:0008284]; positive regulation of chemokine secretion [GO:0090197]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of protein serine/threonine kinase activity [GO:0071902]; positive regulation of protein tyrosine kinase activity [GO:0061098]; positive regulation of tyrosine phosphorylation of Stat3 protein [GO:0042517]; protein autophosphorylation [GO:0046777]; regulation of actin cytoskeleton reorganization [GO:2000249]; regulation of bone resorption [GO:0045124]; regulation of cell shape [GO:0008360]; ruffle organization [GO:0031529]; signal transduction [GO:0007165]; transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169]	ATP binding [GO:0005524]; cytokine binding [GO:0019955]; macrophage colony-stimulating factor receptor activity [GO:0005011]; protein homodimerization activity [GO:0042803]	cell surface [GO:0009986]; CSF1-CSF1R complex [GO:1990682]; integral component of plasma membrane [GO:0005887]; intracellular [GO:0005622]; plasma membrane [GO:0005886]
P68400	CSK21_HUMAN	Casein kinase II subunit alpha (CK II alpha) (EC 2.7.11.1)	CSNK2A1 CK2A1	1JWH;1NA7;1PJK;2PVR;2ZJW;3AMY;3AT2;3AT3;3AT4;3AXW;3BQC;3C13;3FWQ;3H30;3JUH;3MB6;3MB7;3NGA;3NSZ;3OWJ;3OWK;3OWL;3PE1;3PE2;3PE4;3Q04;3Q9W;3Q9X;3Q9Y;3Q9Z;3QA0;3R0T;3RPS;3TAX;3U4U;3U87;3U9C;3W8L;3WAR;3WIK;3WIL;3WOW;4DGL;4FBX;4GRB;4GUB;4GYW;4GYY;4GZ3;4IB5;4KWP;4MD7;4MD8;4MD9;4NH1;4RLL;4UB7;4UBA;5B0X;5CLP;5CQU;5CQW;5CS6;5CSH;5CSP;5CSV;5CU3;5CU4;5CU6;5CVF;5CVG;5CVH;5H8B;5H8E;5H8G;	CHEMBL3629;	P68400;			PF00069;	IPR011009;IPR000719;IPR017441;IPR008271;	apoptotic process [GO:0006915]; chaperone-mediated protein folding [GO:0061077]; mitotic spindle checkpoint [GO:0071174]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154]; positive regulation of cell growth [GO:0030307]; positive regulation of cell proliferation [GO:0008284]; positive regulation of protein catabolic process [GO:0045732]; positive regulation of Wnt signaling pathway [GO:0030177]; protein folding [GO:0006457]; protein phosphorylation [GO:0006468]; regulation of signal transduction by p53 class mediator [GO:1901796]; regulation of transcription, DNA-templated [GO:0006355]; rhythmic process [GO:0048511]; signal transduction [GO:0007165]; transcription, DNA-templated [GO:0006351]; Wnt signaling pathway [GO:0016055]	ATP binding [GO:0005524]; Hsp90 protein binding [GO:0051879]; protein N-terminus binding [GO:0047485]; protein serine/threonine kinase activity [GO:0004674]	cytosol [GO:0005829]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; NuRD complex [GO:0016581]; plasma membrane [GO:0005886]; Sin3 complex [GO:0016580]
O14936	CSKP_HUMAN	Peripheral plasma membrane protein CASK (hCASK) (EC 2.7.11.1) (Calcium/calmodulin-dependent serine protein kinase) (Protein lin-2 homolog)	CASK LIN2	1KGD;1KWA;1ZL8;3C0G;3C0H;3C0I;3MFR;3MFS;3MFT;3MFU;3TAC;	CHEMBL1908381;	O14936;			PF00625;PF02828;PF00595;PF00069;PF07653;	IPR008145;IPR008144;IPR020590;IPR011009;IPR014775;IPR004172;IPR027417;IPR001478;IPR000719;IPR011511;IPR001452;	calcium ion import [GO:0070509]; cell adhesion [GO:0007155]; negative regulation of cell-matrix adhesion [GO:0001953]; negative regulation of cellular response to growth factor stimulus [GO:0090288]; negative regulation of keratinocyte proliferation [GO:0010839]; negative regulation of wound healing [GO:0061045]; neurotransmitter secretion [GO:0007269]; positive regulation of calcium ion import [GO:0090280]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]	ATP binding [GO:0005524]; guanylate kinase activity [GO:0004385]; protein serine/threonine kinase activity [GO:0004674]	actin cytoskeleton [GO:0015629]; basement membrane [GO:0005604]; basolateral plasma membrane [GO:0016323]; cell-cell junction [GO:0005911]; ciliary membrane [GO:0060170]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; focal adhesion [GO:0005925]; nuclear lamina [GO:0005652]; nuclear matrix [GO:0016363]; nucleolus [GO:0005730]; plasma membrane [GO:0005886]; presynaptic membrane [GO:0042734]; vesicle [GO:0031982]
P41240	CSK_HUMAN	Tyrosine-protein kinase CSK (EC 2.7.10.2) (C-Src kinase) (Protein-tyrosine kinase CYL)	CSK	1BYG;1CSK;3D7T;3D7U;3EAC;3EAZ;	CHEMBL2634;	P41240;			PF07714;PF00017;PF00018;	IPR011009;IPR000719;IPR017441;IPR001245;IPR000980;IPR001452;IPR008266;IPR020635;	adaptive immune response [GO:0002250]; adherens junction organization [GO:0034332]; brain development [GO:0007420]; cell differentiation [GO:0030154]; cell migration [GO:0016477]; cellular response to peptide hormone stimulus [GO:0071375]; central nervous system development [GO:0007417]; epidermal growth factor receptor signaling pathway [GO:0007173]; innate immune response [GO:0045087]; negative regulation of bone resorption [GO:0045779]; negative regulation of cell proliferation [GO:0008285]; negative regulation of ERK1 and ERK2 cascade [GO:0070373]; negative regulation of Golgi to plasma membrane protein transport [GO:0042997]; negative regulation of interleukin-6 production [GO:0032715]; negative regulation of kinase activity [GO:0033673]; negative regulation of low-density lipoprotein particle clearance [GO:0010989]; negative regulation of phagocytosis [GO:0050765]; oligodendrocyte differentiation [GO:0048709]; peptidyl-tyrosine autophosphorylation [GO:0038083]; positive regulation of MAP kinase activity [GO:0043406]; protein phosphorylation [GO:0006468]; regulation of cell proliferation [GO:0042127]; regulation of cytokine production [GO:0001817]; regulation of Fc receptor mediated stimulatory signaling pathway [GO:0060368]; T cell costimulation [GO:0031295]; T cell receptor signaling pathway [GO:0050852]; transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169]	ATP binding [GO:0005524]; identical protein binding [GO:0042802]; kinase activity [GO:0016301]; metal ion binding [GO:0046872]; non-membrane spanning protein tyrosine kinase activity [GO:0004715]; protein C-terminus binding [GO:0008022]; protein kinase A catalytic subunit binding [GO:0034236]; protein tyrosine kinase activity [GO:0004713]; receptor binding [GO:0005102]	cell-cell junction [GO:0005911]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extrinsic component of cytoplasmic side of plasma membrane [GO:0031234]; membrane raft [GO:0045121]; plasma membrane [GO:0005886]
Q9NUV7	CT038_HUMAN	Serine palmitoyltransferase 3 (EC 2.3.1.50) (Long chain base biosynthesis protein 2b) (LCB2b) (Long chain base biosynthesis protein 3) (LCB 3) (Serine-palmitoyl-CoA transferase 3) (SPT 3)	SPTLC3 C20orf38 SPTLC2L					PATHWAY: Lipid metabolism; sphingolipid metabolism.	PF00155;	IPR001917;IPR004839;IPR015424;IPR015421;IPR015422;	sphingoid biosynthetic process [GO:0046520]; sphingolipid biosynthetic process [GO:0030148]	pyridoxal phosphate binding [GO:0030170]; serine C-palmitoyltransferase activity [GO:0004758]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; serine C-palmitoyltransferase complex [GO:0017059]
Q13363	CTBP1_HUMAN	C-terminal-binding protein 1 (CtBP1) (EC 1.1.1.-)	CTBP1 CTBP	1MX3;4LCE;4U6Q;4U6S;		Q13363;			PF00389;PF02826;	IPR006139;IPR029753;IPR029752;IPR006140;IPR016040;	negative regulation of cell proliferation [GO:0008285]; negative regulation of histone acetylation [GO:0035067]; negative regulation of histone H4 acetylation [GO:0090241]; negative regulation of transcription, DNA-templated [GO:0045892]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; negative regulation of transcription from RNA polymerase II promoter by histone modification [GO:1903758]; positive regulation of histone deacetylation [GO:0031065]; protein phosphorylation [GO:0006468]; regulation of cell cycle [GO:0051726]; transcription, DNA-templated [GO:0006351]; viral genome replication [GO:0019079]; white fat cell differentiation [GO:0050872]	NAD binding [GO:0051287]; oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor [GO:0016616]; protein C-terminus binding [GO:0008022]; protein domain specific binding [GO:0019904]; protein homodimerization activity [GO:0042803]; repressing transcription factor binding [GO:0070491]; RNA polymerase II transcription corepressor activity [GO:0001106]; transcription factor activity, sequence-specific DNA binding [GO:0003700]; transcription factor binding [GO:0008134]	cytoplasm [GO:0005737]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; transcriptional repressor complex [GO:0017053]; transcription factor complex [GO:0005667]
Q8WWI5	CTL1_HUMAN	Choline transporter-like protein 1 (CDw92) (Solute carrier family 44 member 1) (CD antigen CD92)	SLC44A1 CD92 CDW92 CTL1				DB00122;		PF04515;	IPR007603;	choline catabolic process [GO:0042426]; choline transport [GO:0015871]; phosphatidylcholine biosynthetic process [GO:0006656]; transmembrane transport [GO:0055085]	choline transmembrane transporter activity [GO:0015220]	extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; membrane [GO:0016020]; mitochondrial outer membrane [GO:0005741]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; plasma membrane [GO:0005886]
Q8IWA5	CTL2_HUMAN	Choline transporter-like protein 2 (Solute carrier family 44 member 2)	SLC44A2 CTL2 PSEC0210				DB00122;		PF04515;	IPR007603;	choline transport [GO:0015871]; phosphatidylcholine biosynthetic process [GO:0006656]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; transmembrane transport [GO:0055085]	choline transmembrane transporter activity [GO:0015220]; signal transducer activity [GO:0004871]	extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; lysosomal membrane [GO:0005765]; plasma membrane [GO:0005886]
Q8N4M1	CTL3_HUMAN	Choline transporter-like protein 3 (Solute carrier family 44 member 3)	SLC44A3 CTL3 UNQ558/PRO1115				DB00122;		PF04515;	IPR007603;	phosphatidylcholine biosynthetic process [GO:0006656]; transmembrane transport [GO:0055085]	choline transmembrane transporter activity [GO:0015220]	integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]
Q53GD3	CTL4_HUMAN	Choline transporter-like protein 4 (Solute carrier family 44 member 4)	SLC44A4 C6orf29 CTL4 NG22 UNQ441/PRO874				DB00122;		PF04515;	IPR007603;	acetylcholine biosynthetic process [GO:0008292]; acetylcholine secretion [GO:0061526]; phosphatidylcholine biosynthetic process [GO:0006656]; positive regulation of cell growth [GO:0030307]; transmembrane transport [GO:0055085]	choline transmembrane transporter activity [GO:0015220]	extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]
P16410	CTLA4_HUMAN	Cytotoxic T-lymphocyte protein 4 (Cytotoxic T-lymphocyte-associated antigen 4) (CTLA-4) (CD antigen CD152)	CTLA4 CD152	1AH1;1H6E;1I85;1I8L;2X44;3BX7;3OSK;	CHEMBL2364164;		DB06186;		PF07686;	IPR008096;IPR007110;IPR013783;IPR003599;IPR013106;	adaptive immune response [GO:0002250]; B cell receptor signaling pathway [GO:0050853]; cellular response to DNA damage stimulus [GO:0006974]; immune response [GO:0006955]; negative regulation of B cell proliferation [GO:0030889]; negative regulation of immune response [GO:0050777]; negative regulation of regulatory T cell differentiation [GO:0045590]; negative regulation of T cell proliferation [GO:0042130]; positive regulation of apoptotic process [GO:0043065]; T cell costimulation [GO:0031295]		clathrin-coated endocytic vesicle [GO:0045334]; external side of plasma membrane [GO:0009897]; Golgi apparatus [GO:0005794]; integral component of plasma membrane [GO:0005887]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; protein complex involved in cell adhesion [GO:0098636]
P35222	CTNB1_HUMAN	Catenin beta-1 (Beta-catenin)	CTNNB1 CTNNB OK/SW-cl.35 PRO2286	1G3J;1JDH;1JPW;1LUJ;1P22;1QZ7;1T08;1TH1;2G57;2GL7;2Z6H;3DIW;3FQN;3FQR;3SL9;3SLA;3TX7;4DJS;	CHEMBL5866;	P35222;	DB03904;		PF00514;	IPR011989;IPR016024;IPR000225;IPR013284;	adherens junction assembly [GO:0034333]; androgen receptor signaling pathway [GO:0030521]; anterior/posterior axis specification [GO:0009948]; beta-catenin destruction complex disassembly [GO:1904886]; beta-catenin-TCF complex assembly [GO:1904837]; bone resorption [GO:0045453]; branching involved in ureteric bud morphogenesis [GO:0001658]; canonical Wnt signaling pathway [GO:0060070]; canonical Wnt signaling pathway involved in midbrain dopaminergic neuron differentiation [GO:1904954]; canonical Wnt signaling pathway involved in negative regulation of apoptotic process [GO:0044336]; canonical Wnt signaling pathway involved in positive regulation of cardiac outflow tract cell proliferation [GO:0061324]; canonical Wnt signaling pathway involved in positive regulation of epithelial to mesenchymal transition [GO:0044334]; catenin import into nucleus [GO:0035411]; cell adhesion [GO:0007155]; cell fate specification [GO:0001708]; cell-matrix adhesion [GO:0007160]; cell maturation [GO:0048469]; cellular response to growth factor stimulus [GO:0071363]; cellular response to indole-3-methanol [GO:0071681]; central nervous system vasculogenesis [GO:0022009]; chemical synaptic transmission [GO:0007268]; chromatin-mediated maintenance of transcription [GO:0048096]; cranial ganglion development [GO:0061550]; cranial skeletal system development [GO:1904888]; dorsal/ventral axis specification [GO:0009950]; dorsal root ganglion development [GO:1990791]; ectoderm development [GO:0007398]; embryonic axis specification [GO:0000578]; embryonic brain development [GO:1990403]; embryonic digit morphogenesis [GO:0042733]; embryonic foregut morphogenesis [GO:0048617]; embryonic forelimb morphogenesis [GO:0035115]; embryonic heart tube development [GO:0035050]; embryonic hindlimb morphogenesis [GO:0035116]; embryonic skeletal limb joint morphogenesis [GO:0036023]; endodermal cell fate commitment [GO:0001711]; endothelial tube morphogenesis [GO:0061154]; epithelial cell differentiation involved in prostate gland development [GO:0060742]; epithelial to mesenchymal transition [GO:0001837]; epithelial tube branching involved in lung morphogenesis [GO:0060441]; fungiform papilla formation [GO:0061198]; gastrulation with mouth forming second [GO:0001702]; genitalia morphogenesis [GO:0035112]; glial cell fate determination [GO:0007403]; hair cell differentiation [GO:0035315]; hair follicle morphogenesis [GO:0031069]; hair follicle placode formation [GO:0060789]; hindbrain development [GO:0030902]; in utero embryonic development [GO:0001701]; layer formation in cerebral cortex [GO:0021819]; lens morphogenesis in camera-type eye [GO:0002089]; lung-associated mesenchyme development [GO:0060484]; lung cell differentiation [GO:0060479]; lung induction [GO:0060492]; male genitalia development [GO:0030539]; mesenchymal cell proliferation involved in lung development [GO:0060916]; metanephros morphogenesis [GO:0003338]; midbrain dopaminergic neuron differentiation [GO:1904948]; negative regulation of apoptotic signaling pathway [GO:2001234]; negative regulation of cell proliferation [GO:0008285]; negative regulation of chondrocyte differentiation [GO:0032331]; negative regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis [GO:0003340]; negative regulation of mitotic cell cycle, embryonic [GO:0045976]; negative regulation of neuron death [GO:1901215]; negative regulation of oligodendrocyte differentiation [GO:0048715]; negative regulation of osteoclast differentiation [GO:0045671]; negative regulation of protein sumoylation [GO:0033234]; negative regulation of transcription, DNA-templated [GO:0045892]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; nephron tubule formation [GO:0072079]; neural plate development [GO:0001840]; neuron migration [GO:0001764]; odontogenesis of dentin-containing tooth [GO:0042475]; oocyte development [GO:0048599]; osteoclast differentiation [GO:0030316]; oviduct development [GO:0060066]; pancreas development [GO:0031016]; patterning of blood vessels [GO:0001569]; positive regulation of apoptotic process [GO:0043065]; positive regulation of chromatin-mediated maintenance of transcription [GO:1904501]; positive regulation of determination of dorsal identity [GO:2000017]; positive regulation of DNA-templated transcription, initiation [GO:2000144]; positive regulation of endothelial cell differentiation [GO:0045603]; positive regulation of epithelial cell proliferation involved in prostate gland development [GO:0060769]; positive regulation of epithelial to mesenchymal transition [GO:0010718]; positive regulation of fibroblast growth factor receptor signaling pathway [GO:0045743]; positive regulation of heparan sulfate proteoglycan biosynthetic process [GO:0010909]; positive regulation of histone H3-K4 methylation [GO:0051571]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of MAPK cascade [GO:0043410]; positive regulation of mesenchymal cell proliferation [GO:0002053]; positive regulation of muscle cell differentiation [GO:0051149]; positive regulation of neuroblast proliferation [GO:0002052]; positive regulation of neuron apoptotic process [GO:0043525]; positive regulation of osteoblast differentiation [GO:0045669]; positive regulation of sequence-specific DNA binding transcription factor activity [GO:0051091]; positive regulation of skeletal muscle tissue development [GO:0048643]; positive regulation of telomerase activity [GO:0051973]; positive regulation of telomere maintenance via telomerase [GO:0032212]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of type I interferon production [GO:0032481]; proteasome-mediated ubiquitin-dependent protein catabolic process [GO:0043161]; protein localization to cell surface [GO:0034394]; proximal/distal pattern formation [GO:0009954]; regulation of angiogenesis [GO:0045765]; regulation of calcium ion import [GO:0090279]; regulation of centriole-centriole cohesion [GO:0030997]; regulation of centromeric sister chromatid cohesion [GO:0070602]; regulation of core promoter binding [GO:1904796]; regulation of euchromatin binding [GO:1904793]; regulation of fibroblast proliferation [GO:0048145]; regulation of myelination [GO:0031641]; regulation of nephron tubule epithelial cell differentiation [GO:0072182]; regulation of neurogenesis [GO:0050767]; regulation of protein localization to cell surface [GO:2000008]; regulation of secondary heart field cardioblast proliferation [GO:0003266]; regulation of smooth muscle cell proliferation [GO:0048660]; regulation of T cell proliferation [GO:0042129]; renal inner medulla development [GO:0072053]; renal outer medulla development [GO:0072054]; renal vesicle formation [GO:0072033]; response to drug [GO:0042493]; response to estradiol [GO:0032355]; single organismal cell-cell adhesion [GO:0016337]; smooth muscle cell differentiation [GO:0051145]; stem cell population maintenance [GO:0019827]; sympathetic ganglion development [GO:0061549]; synapse organization [GO:0050808]; synaptic vesicle transport [GO:0048489]; T cell differentiation in thymus [GO:0033077]; thymus development [GO:0048538]; trachea formation [GO:0060440]; transcription, DNA-templated [GO:0006351]; Wnt signaling pathway [GO:0016055]; Wnt signaling pathway, calcium modulating pathway [GO:0007223]	alpha-catenin binding [GO:0045294]; androgen receptor binding [GO:0050681]; cadherin binding [GO:0045296]; cadherin binding involved in cell-cell adhesion [GO:0098641]; double-stranded DNA binding [GO:0003690]; enzyme binding [GO:0019899]; estrogen receptor binding [GO:0030331]; euchromatin binding [GO:1990188]; ion channel binding [GO:0044325]; I-SMAD binding [GO:0070411]; kinase binding [GO:0019900]; nuclear hormone receptor binding [GO:0035257]; protein C-terminus binding [GO:0008022]; protein phosphatase binding [GO:0019903]; RNA polymerase II activating transcription factor binding [GO:0001102]; RNA polymerase II transcription factor binding [GO:0001085]; signal transducer activity [GO:0004871]; SMAD binding [GO:0046332]; transcription coactivator activity [GO:0003713]; transcription factor activity, sequence-specific DNA binding [GO:0003700]; transcription factor binding [GO:0008134]; transcription regulatory region DNA binding [GO:0044212]	adherens junction [GO:0005912]; apical part of cell [GO:0045177]; basolateral plasma membrane [GO:0016323]; beta-catenin destruction complex [GO:0030877]; beta-catenin-TCF7L2 complex [GO:0070369]; beta-catenin-TCF complex [GO:1990907]; bicellular tight junction [GO:0005923]; catenin complex [GO:0016342]; cell-cell adherens junction [GO:0005913]; cell-cell junction [GO:0005911]; cell cortex [GO:0005938]; cell junction [GO:0030054]; cell periphery [GO:0071944]; centrosome [GO:0005813]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; fascia adherens [GO:0005916]; flotillin complex [GO:0016600]; focal adhesion [GO:0005925]; lamellipodium [GO:0030027]; lateral plasma membrane [GO:0016328]; membrane [GO:0016020]; microvillus membrane [GO:0031528]; nuclear euchromatin [GO:0005719]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; protein complex [GO:0043234]; protein-DNA complex [GO:0032993]; Scrib-APC-beta-catenin complex [GO:0034750]; spindle pole [GO:0000922]; transcription factor complex [GO:0005667]; Wnt signalosome [GO:1990909]; Z disc [GO:0030018]
O60931	CTNS_HUMAN	Cystinosin	CTNS				DB00138;		PF04193;	IPR005282;IPR006603;	adult walking behavior [GO:0007628]; ATP metabolic process [GO:0046034]; brain development [GO:0007420]; cellular amino acid metabolic process [GO:0006520]; cognition [GO:0050890]; glutathione metabolic process [GO:0006749]; grooming behavior [GO:0007625]; ion transport [GO:0006811]; L-cystine transport [GO:0015811]; lens development in camera-type eye [GO:0002088]; long-term memory [GO:0007616]; melanin biosynthetic process [GO:0042438]; transmembrane transport [GO:0055085]; visual learning [GO:0008542]	L-cystine transmembrane transporter activity [GO:0015184]	extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; intermediate filament cytoskeleton [GO:0045111]; intracellular membrane-bounded organelle [GO:0043231]; late endosome [GO:0005770]; lysosomal membrane [GO:0005765]; lysosome [GO:0005764]; melanosome [GO:0042470]; plasma membrane [GO:0005886]
P30825	CTR1_HUMAN	High affinity cationic amino acid transporter 1 (CAT-1) (CAT1) (Ecotropic retroviral leukemia receptor homolog) (Ecotropic retrovirus receptor homolog) (ERR) (Solute carrier family 7 member 1) (System Y+ basic amino acid transporter)	SLC7A1 ATRC1 ERR REC1L				DB00125;DB00123;DB00129;		PF13520;PF13906;	IPR002293;IPR004755;IPR029485;	amino acid transport [GO:0006865]; arginine transport [GO:0015809]; L-ornithine transmembrane transport [GO:1903352]; transport [GO:0006810]	amino acid transmembrane transporter activity [GO:0015171]; antiporter activity [GO:0015297]; arginine transmembrane transporter activity [GO:0015181]; L-lysine transmembrane transporter activity [GO:0015189]; L-ornithine transmembrane transporter activity [GO:0000064]	integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]
P52569	CTR2_HUMAN	Cationic amino acid transporter 2 (CAT-2) (CAT2) (Low affinity cationic amino acid transporter 2) (Solute carrier family 7 member 2)	SLC7A2 ATRC2 CAT2				DB00123;DB00129;		PF13520;PF13906;	IPR002293;IPR004755;IPR029485;	amino acid transport [GO:0006865]; arginine transport [GO:0015809]; cellular amino acid metabolic process [GO:0006520]; L-arginine import across plasma membrane [GO:0097638]; L-lysine import across plasma membrane [GO:0097639]; L-ornithine import across plasma membrane [GO:0097640]; macrophage activation [GO:0042116]; nitric oxide biosynthetic process [GO:0006809]; nitric oxide production involved in inflammatory response [GO:0002537]; regulation of inflammatory response [GO:0050727]; regulation of macrophage activation [GO:0043030]; transport [GO:0006810]	amino acid transmembrane transporter activity [GO:0015171]; antiporter activity [GO:0015297]; basic amino acid transmembrane transporter activity [GO:0015174]; high-affinity arginine transmembrane transporter activity [GO:0005289]; high-affinity L-ornithine transmembrane transporter activity [GO:0097627]; high-affinity lysine transmembrane transporter activity [GO:0005292]; L-amino acid transmembrane transporter activity [GO:0015179]; low-affinity L-arginine transmembrane transporter activity [GO:0097626]	integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]
Q8WY07	CTR3_HUMAN	Cationic amino acid transporter 3 (CAT-3) (CAT3) (Cationic amino acid transporter y+) (Solute carrier family 7 member 3)	SLC7A3 ATRC3 CAT3				DB00125;DB00123;DB00129;		PF13520;PF13906;	IPR002293;IPR015606;IPR004755;IPR029485;	amino acid transport [GO:0006865]; arginine transport [GO:0015809]; L-ornithine transmembrane transport [GO:1903352]	amino acid transmembrane transporter activity [GO:0015171]; antiporter activity [GO:0015297]; arginine transmembrane transporter activity [GO:0015181]; L-lysine transmembrane transporter activity [GO:0015189]; L-ornithine transmembrane transporter activity [GO:0000064]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
O43246	CTR4_HUMAN	Cationic amino acid transporter 4 (CAT-4) (CAT4) (Solute carrier family 7 member 4)	SLC7A4				DB00125;DB00123;DB00129;		PF13520;PF13906;	IPR002293;IPR029485;	cellular amino acid metabolic process [GO:0006520]; transport [GO:0006810]	antiporter activity [GO:0015297]; basic amino acid transmembrane transporter activity [GO:0015174]; L-amino acid transmembrane transporter activity [GO:0015179]	integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]
P17538	CTRB1_HUMAN	Chymotrypsinogen B (EC 3.4.21.1) [Cleaved into: Chymotrypsin B chain A; Chymotrypsin B chain B; Chymotrypsin B chain C]	CTRB1 CTRB		CHEMBL4796;	P17538;	DB06692;		PF00089;	IPR009003;IPR001314;IPR001254;IPR018114;IPR033116;	cobalamin metabolic process [GO:0009235]; digestion [GO:0007586]; extracellular matrix disassembly [GO:0022617]	serine-type endopeptidase activity [GO:0004252]; serine-type peptidase activity [GO:0008236]	extracellular region [GO:0005576]; extracellular space [GO:0005615]
O60494	CUBN_HUMAN	Cubilin (460 kDa receptor) (Intestinal intrinsic factor receptor) (Intrinsic factor-cobalamin receptor) (Intrinsic factor-vitamin B12 receptor)	CUBN IFCR	3KQ4;			DB00115;DB00200;		PF00431;PF00008;PF12947;PF07645;	IPR000859;IPR028876;IPR001881;IPR013032;IPR000742;IPR000152;IPR018097;IPR024731;IPR009030;	cholesterol metabolic process [GO:0008203]; cobalamin metabolic process [GO:0009235]; cobalamin transport [GO:0015889]; lipoprotein metabolic process [GO:0042157]; lipoprotein transport [GO:0042953]; protein transport [GO:0015031]; receptor-mediated endocytosis [GO:0006898]; tissue homeostasis [GO:0001894]; vitamin D metabolic process [GO:0042359]	calcium ion binding [GO:0005509]; cobalamin binding [GO:0031419]; protein homodimerization activity [GO:0042803]; receptor activity [GO:0004872]; transporter activity [GO:0005215]	apical plasma membrane [GO:0016324]; brush border membrane [GO:0031526]; clathrin-coated pit [GO:0005905]; cytosol [GO:0005829]; endocytic vesicle [GO:0030139]; endoplasmic reticulum [GO:0005783]; endosome membrane [GO:0010008]; extracellular exosome [GO:0070062]; extrinsic component of external side of plasma membrane [GO:0031232]; Golgi apparatus [GO:0005794]; lysosomal lumen [GO:0043202]; lysosomal membrane [GO:0005765]; membrane [GO:0016020]; plasma membrane [GO:0005886]
P17302	CXA1_HUMAN	Gap junction alpha-1 protein (Connexin-43) (Cx43) (Gap junction 43 kDa heart protein)	GJA1 GJAL	2LL2;			DB01136;		PF00029;PF03508;	IPR000500;IPR002261;IPR013124;IPR019570;IPR017990;IPR013092;	adult heart development [GO:0007512]; apoptotic process [GO:0006915]; ATP transport [GO:0015867]; atrial cardiac muscle cell action potential [GO:0086014]; atrial ventricular junction remodeling [GO:0003294]; blood vessel morphogenesis [GO:0048514]; cell-cell signaling [GO:0007267]; cell communication by chemical coupling [GO:0010643]; cell communication by electrical coupling [GO:0010644]; cell communication by electrical coupling involved in cardiac conduction [GO:0086064]; cellular response to mechanical stimulus [GO:0071260]; chronic inflammatory response [GO:0002544]; embryonic digit morphogenesis [GO:0042733]; endothelium development [GO:0003158]; epithelial cell maturation [GO:0002070]; gap junction assembly [GO:0016264]; heart development [GO:0007507]; heart looping [GO:0001947]; in utero embryonic development [GO:0001701]; ion transmembrane transport [GO:0034220]; lens development in camera-type eye [GO:0002088]; milk ejection [GO:0060156]; muscle contraction [GO:0006936]; negative regulation of cardiac muscle cell proliferation [GO:0060044]; negative regulation of cell growth [GO:0030308]; negative regulation of DNA biosynthetic process [GO:2000279]; negative regulation of endothelial cell proliferation [GO:0001937]; negative regulation of gene expression [GO:0010629]; negative regulation of wound healing [GO:0061045]; neuron migration [GO:0001764]; neuron projection morphogenesis [GO:0048812]; osteoblast differentiation [GO:0001649]; positive regulation of behavioral fear response [GO:2000987]; positive regulation of cell communication by chemical coupling [GO:0010652]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of gene expression [GO:0010628]; positive regulation of glomerular filtration [GO:0003104]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of insulin secretion [GO:0032024]; positive regulation of osteoblast differentiation [GO:0045669]; positive regulation of protein catabolic process [GO:0045732]; positive regulation of striated muscle tissue development [GO:0045844]; positive regulation of vasoconstriction [GO:0045907]; positive regulation of vasodilation [GO:0045909]; protein oligomerization [GO:0051259]; regulation of atrial cardiac muscle cell membrane depolarization [GO:0060371]; regulation of bicellular tight junction assembly [GO:2000810]; regulation of bone mineralization [GO:0030500]; regulation of bone remodeling [GO:0046850]; regulation of calcium ion transport [GO:0051924]; regulation of ventricular cardiac muscle cell membrane depolarization [GO:0060373]; regulation of ventricular cardiac muscle cell membrane repolarization [GO:0060307]; response to fluid shear stress [GO:0034405]; response to glucose [GO:0009749]; response to peptide hormone [GO:0043434]; response to pH [GO:0009268]; signal transduction [GO:0007165]; skeletal muscle tissue regeneration [GO:0043403]; transport [GO:0006810]; vascular transport [GO:0010232]	gap junction channel activity [GO:0005243]; gap junction channel activity involved in cardiac conduction electrical coupling [GO:0086075]; gap junction channel activity involved in cell communication by electrical coupling [GO:1903763]; ion transmembrane transporter activity [GO:0015075]; signal transducer activity [GO:0004871]	apical plasma membrane [GO:0016324]; connexin complex [GO:0005922]; contractile fiber [GO:0043292]; cytosol [GO:0005829]; early endosome [GO:0005769]; endoplasmic reticulum membrane [GO:0005789]; extracellular exosome [GO:0070062]; fascia adherens [GO:0005916]; focal adhesion [GO:0005925]; gap junction [GO:0005921]; Golgi apparatus [GO:0005794]; Golgi-associated vesicle membrane [GO:0030660]; Golgi membrane [GO:0000139]; integral component of plasma membrane [GO:0005887]; intercalated disc [GO:0014704]; intermediate filament [GO:0005882]; lateral plasma membrane [GO:0016328]; lysosome [GO:0005764]; membrane raft [GO:0045121]; mitochondrial outer membrane [GO:0005741]; mitochondrion [GO:0005739]; multivesicular body [GO:0005771]; plasma membrane [GO:0005886]
P61073	CXCR4_HUMAN	C-X-C chemokine receptor type 4 (CXC-R4) (CXCR-4) (FB22) (Fusin) (HM89) (LCR1) (Leukocyte-derived seven transmembrane domain receptor) (LESTR) (Lipopolysaccharide-associated protein 3) (LAP-3) (LPS-associated protein 3) (NPYRL) (Stromal cell-derived factor 1 receptor) (SDF-1 receptor) (CD antigen CD184)	CXCR4	2K03;2K04;2K05;2N55;3ODU;3OE0;3OE6;3OE8;3OE9;4RWS;	CHEMBL2107;	P61073;	DB00452;DB06809;		PF00001;PF12109;	IPR022726;IPR000355;IPR033039;IPR001277;IPR000276;IPR017452;	activation of MAPK activity [GO:0000187]; apoptotic process [GO:0006915]; calcium-mediated signaling [GO:0019722]; cellular response to cytokine stimulus [GO:0071345]; dendritic cell chemotaxis [GO:0002407]; entry into host cell [GO:0030260]; fusion of virus membrane with host plasma membrane [GO:0019064]; G-protein coupled receptor signaling pathway [GO:0007186]; inflammatory response [GO:0006954]; myelin maintenance [GO:0043217]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of oligodendrocyte differentiation [GO:0048714]; regulation of cell migration [GO:0030334]; regulation of chemotaxis [GO:0050920]; response to hypoxia [GO:0001666]; response to virus [GO:0009615]	actin binding [GO:0003779]; coreceptor activity [GO:0015026]; C-X-C chemokine receptor activity [GO:0016494]; G-protein coupled receptor activity [GO:0004930]; myosin light chain binding [GO:0032027]; ubiquitin binding [GO:0043130]; ubiquitin protein ligase binding [GO:0031625]; virus receptor activity [GO:0001618]	cell junction [GO:0030054]; cell leading edge [GO:0031252]; cell surface [GO:0009986]; cytoplasm [GO:0005737]; cytoplasmic, membrane-bounded vesicle [GO:0016023]; cytoplasmic vesicle [GO:0031410]; early endosome [GO:0005769]; extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; late endosome [GO:0005770]; lysosome [GO:0005764]; plasma membrane [GO:0005886]
P00167	CYB5_HUMAN	Cytochrome b5 (Microsomal cytochrome b5 type A) (MCB5)	CYB5A CYB5	2I96;	CHEMBL6170;				PF00173;	IPR001199;IPR018506;	L-ascorbic acid metabolic process [GO:0019852]; response to cadmium ion [GO:0046686]	aldo-keto reductase (NADP) activity [GO:0004033]; cytochrome-c oxidase activity [GO:0004129]; enzyme binding [GO:0019899]; heme binding [GO:0020037]; metal ion binding [GO:0046872]	cytoplasm [GO:0005737]; endoplasmic reticulum membrane [GO:0005789]; extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; intracellular membrane-bounded organelle [GO:0043231]; membrane [GO:0016020]; mitochondrial outer membrane [GO:0005741]
P00156	CYB_HUMAN	Cytochrome b (Complex III subunit 3) (Complex III subunit III) (Cytochrome b-c1 complex subunit 3) (Ubiquinol-cytochrome-c reductase complex cytochrome b subunit)	MT-CYB COB CYTB MTCYB						PF00032;PF00033;	IPR005798;IPR005797;IPR027387;IPR030689;IPR016174;	animal organ regeneration [GO:0031100]; hyperosmotic salinity response [GO:0042538]; mitochondrial electron transport, ubiquinol to cytochrome c [GO:0006122]; response to cadmium ion [GO:0046686]; response to calcium ion [GO:0051592]; response to cobalamin [GO:0033590]; response to copper ion [GO:0046688]; response to drug [GO:0042493]; response to ethanol [GO:0045471]; response to glucagon [GO:0033762]; response to heat [GO:0009408]; response to hyperoxia [GO:0055093]; response to hypoxia [GO:0001666]; response to mercury ion [GO:0046689]; response to toxic substance [GO:0009636]	electron carrier activity [GO:0009055]; metal ion binding [GO:0046872]; ubiquinol-cytochrome-c reductase activity [GO:0008121]	mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex III [GO:0005750]; mitochondrion [GO:0005739]
P99999	CYC_HUMAN	Cytochrome c	CYCS CYC	1J3S;2N9I;2N9J;3NWV;3ZCF;3ZOO;			DB01017;		PF00034;	IPR009056;IPR002327;	activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c [GO:0008635]; cellular respiration [GO:0045333]; intrinsic apoptotic signaling pathway [GO:0097193]; mitochondrial electron transport, cytochrome c to oxygen [GO:0006123]; mitochondrial electron transport, ubiquinol to cytochrome c [GO:0006122]; mitochondrion organization [GO:0007005]; protein dephosphorylation [GO:0006470]; response to reactive oxygen species [GO:0000302]	electron transporter, transferring electrons from CoQH2-cytochrome c reductase complex and cytochrome c oxidase complex activity [GO:0045155]; heme binding [GO:0020037]; metal ion binding [GO:0046872]	cytosol [GO:0005829]; mitochondrial inner membrane [GO:0005743]; mitochondrial intermembrane space [GO:0005758]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; protein phosphatase type 2A complex [GO:0000159]; respiratory chain [GO:0070469]
Q8WWM9	CYGB_HUMAN	Cytoglobin (Histoglobin) (HGb) (Stellate cell activation-associated protein)	CYGB STAP	1UMO;1URV;1URY;1UT0;1UX9;1V5H;2DC3;3AG0;4B3W;					PF00042;	IPR000971;IPR009050;IPR012292;IPR013314;	fatty acid oxidation [GO:0019395]; negative regulation of collagen biosynthetic process [GO:0032966]; negative regulation of fibroblast migration [GO:0010764]; negative regulation of hepatic stellate cell activation [GO:2000490]; oxygen transport [GO:0015671]; regulation of nitric-oxide synthase activity [GO:0050999]; response to hypoxia [GO:0001666]; response to oxidative stress [GO:0006979]	catalase activity [GO:0004096]; fatty acid peroxidase activity [GO:0047888]; heme binding [GO:0020037]; iron ion binding [GO:0005506]; nitric oxide dioxygenase activity [GO:0008941]; oxygen binding [GO:0019825]; oxygen transporter activity [GO:0005344]; peroxidase activity [GO:0004601]	cytosol [GO:0005829]; neuronal cell body [GO:0043025]; neuron projection [GO:0043005]
Q99418	CYH2_HUMAN	Cytohesin-2 (ARF exchange factor) (ARF nucleotide-binding site opener) (Protein ARNO) (PH, SEC7 and coiled-coil domain-containing protein 2)	CYTH2 ARNO PSCD2 PSCD2L	1PBV;1R8M;1R8Q;1R8S;1S9D;4JMI;4JMO;4JWL;4JXH;4L5M;4Z21;	CHEMBL5995;	Q99418;			PF00169;PF01369;	IPR011993;IPR001849;IPR023394;IPR000904;	actin cytoskeleton organization [GO:0030036]; endocytosis [GO:0006897]; regulation of ARF protein signal transduction [GO:0032012]	ARF guanyl-nucleotide exchange factor activity [GO:0005086]; inositol 1,4,5 trisphosphate binding [GO:0070679]; lipid binding [GO:0008289]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; Golgi membrane [GO:0000139]; growth cone [GO:0030426]; membrane [GO:0016020]; plasma membrane [GO:0005886]
Q9NYX4	D1IP_HUMAN	Neuron-specific vesicular protein calcyon	CALY DRD1IP				DB00714;DB00363;DB00831;		PF06387;	IPR009431;	clathrin coat assembly [GO:0048268]; dopamine receptor signaling pathway [GO:0007212]; endocytosis [GO:0006897]; positive regulation of endocytosis [GO:0045807]	clathrin light chain binding [GO:0032051]	cytoplasmic vesicle [GO:0031410]; cytoplasmic vesicle membrane [GO:0030659]; integral component of plasma membrane [GO:0005887]
P42126	D3D2_HUMAN	Enoyl-CoA delta isomerase 1, mitochondrial (EC 5.3.3.8) (3,2-trans-enoyl-CoA isomerase) (Delta(3),Delta(2)-enoyl-CoA isomerase) (D3,D2-enoyl-CoA isomerase) (Dodecenoyl-CoA isomerase)	ECI1 DCI	1SG4;				PATHWAY: Lipid metabolism; fatty acid beta-oxidation.	PF00378;	IPR029045;IPR001753;IPR018376;	fatty acid beta-oxidation [GO:0006635]	dodecenoyl-CoA delta-isomerase activity [GO:0004165]; intramolecular oxidoreductase activity [GO:0016860]	extracellular exosome [GO:0070062]; mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
P08174	DAF_HUMAN	Complement decay-accelerating factor (CD antigen CD55)	CD55 CR DAF	1H03;1H04;1H2P;1H2Q;1M11;1NWV;1OJV;1OJW;1OJY;1OK1;1OK2;1OK3;1OK9;1UOT;1UPN;2C8I;2QZD;2QZF;2QZH;3IYP;3J24;5FOA;			DB00446;		PF00084;	IPR000436;	CD4-positive, alpha-beta T cell cytokine production [GO:0035743]; complement activation, classical pathway [GO:0006958]; ER to Golgi vesicle-mediated transport [GO:0006888]; innate immune response [GO:0045087]; negative regulation of complement activation [GO:0045916]; positive regulation of CD4-positive, alpha-beta T cell activation [GO:2000516]; positive regulation of CD4-positive, alpha-beta T cell proliferation [GO:2000563]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; regulation of complement activation [GO:0030449]; regulation of lipopolysaccharide-mediated signaling pathway [GO:0031664]; respiratory burst [GO:0045730]	lipid binding [GO:0008289]; virus receptor activity [GO:0001618]	anchored component of membrane [GO:0031225]; cell surface [GO:0009986]; endoplasmic reticulum-Golgi intermediate compartment membrane [GO:0033116]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; Golgi membrane [GO:0000139]; integral component of plasma membrane [GO:0005887]; membrane raft [GO:0045121]; plasma membrane [GO:0005886]; transport vesicle [GO:0030133]
P53355	DAPK1_HUMAN	Death-associated protein kinase 1 (DAP kinase 1) (EC 2.7.11.1)	DAPK1 DAPK	1IG1;1JKK;1JKL;1JKS;1JKT;1P4F;1WVW;1WVX;1WVY;1YR5;2W4J;2W4K;2X0G;2XUU;2XZS;2Y0A;2Y4P;2Y4V;2YAK;3DFC;3DGK;3EH9;3EHA;3F5G;3F5U;3GU4;3GU5;3GU6;3GU7;3GU8;3GUB;3ZXT;4B4L;4PF4;4TL0;4TXC;4UV0;4YO4;4YPD;5AUT;5AUU;5AUV;5AUW;5AUX;5AUY;5AUZ;5AV0;5AV1;5AV2;5AV3;5AV4;	CHEMBL2558;	P53355;			PF12796;PF00531;PF00069;	IPR002110;IPR020683;IPR020676;IPR011029;IPR000488;IPR011009;IPR027417;IPR000719;IPR017441;IPR020859;IPR008271;	apoptotic process [GO:0006915]; apoptotic signaling pathway [GO:0097190]; cellular response to interferon-gamma [GO:0071346]; extrinsic apoptotic signaling pathway via death domain receptors [GO:0008625]; intracellular signal transduction [GO:0035556]; negative regulation of extrinsic apoptotic signaling pathway via death domain receptors [GO:1902042]; negative regulation of translation [GO:0017148]; positive regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043280]; protein autophosphorylation [GO:0046777]; protein phosphorylation [GO:0006468]; regulation of apoptotic process [GO:0042981]; regulation of autophagy [GO:0010506]; regulation of N-methyl-D-aspartate selective glutamate receptor activity [GO:2000310]	ATP binding [GO:0005524]; calmodulin binding [GO:0005516]; calmodulin-dependent protein kinase activity [GO:0004683]; GTP binding [GO:0005525]; identical protein binding [GO:0042802]; protein kinase activity [GO:0004672]; protein serine/threonine kinase activity [GO:0004674]; syntaxin-1 binding [GO:0017075]	actin cytoskeleton [GO:0015629]; cytoplasm [GO:0005737]; plasma membrane [GO:0005886]
Q9UN19	DAPP1_HUMAN	Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide (hDAPP1) (B lymphocyte adapter protein Bam32) (B-cell adapter molecule of 32 kDa)	DAPP1 BAM32 HSPC066	1FAO;1FB8;					PF00169;PF00017;	IPR011993;IPR001849;IPR000980;	protein dephosphorylation [GO:0006470]; signal transduction [GO:0007165]	phosphatidylinositol-3,4,5-trisphosphate binding [GO:0005547]; phosphatidylinositol-3,4-bisphosphate binding [GO:0043325]; phospholipid binding [GO:0005543]	cytosol [GO:0005829]; plasma membrane [GO:0005886]
P51843	DAX1_HUMAN	Nuclear receptor subfamily 0 group B member 1 (DSS-AHC critical region on the X chromosome protein 1) (Nuclear receptor DAX-1)	NR0B1 AHC DAX1	4RWV;	CHEMBL1795094;	P51843;	DB01234;DB00755;		PF00104;PF14046;	IPR033544;IPR000536;IPR001723;IPR025900;	adrenal gland development [GO:0030325]; gonad development [GO:0008406]; hypothalamus development [GO:0021854]; Leydig cell differentiation [GO:0033327]; male gonad development [GO:0008584]; male sex determination [GO:0030238]; negative regulation of cell differentiation [GO:0045596]; negative regulation of intracellular steroid hormone receptor signaling pathway [GO:0033144]; negative regulation of sequence-specific DNA binding transcription factor activity [GO:0043433]; negative regulation of transcription, DNA-templated [GO:0045892]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; pituitary gland development [GO:0021983]; protein localization [GO:0008104]; response to immobilization stress [GO:0035902]; Sertoli cell differentiation [GO:0060008]; spermatogenesis [GO:0007283]; steroid biosynthetic process [GO:0006694]; transcription initiation from RNA polymerase II promoter [GO:0006367]	AF-2 domain binding [GO:0050682]; DNA binding [GO:0003677]; DNA hairpin binding [GO:0032448]; protein domain specific binding [GO:0019904]; protein homodimerization activity [GO:0042803]; RNA binding [GO:0003723]; RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding [GO:0004879]; sequence-specific DNA binding [GO:0043565]; steroid hormone receptor activity [GO:0003707]; steroid hormone receptor binding [GO:0035258]; transcription corepressor activity [GO:0003714]; transcription factor binding [GO:0008134]	cytoplasm [GO:0005737]; membrane [GO:0016020]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; polysomal ribosome [GO:0042788]
P17707	DCAM_HUMAN	S-adenosylmethionine decarboxylase proenzyme (AdoMetDC) (SAMDC) (EC 4.1.1.50) [Cleaved into: S-adenosylmethionine decarboxylase alpha chain; S-adenosylmethionine decarboxylase beta chain]	AMD1 AMD	1I72;1I79;1I7B;1I7C;1I7M;1JEN;1JL0;1MSV;3DZ2;3DZ3;3DZ4;3DZ5;3DZ6;3DZ7;3EP3;3EP4;3EP5;3EP6;3EP7;3EP8;3EP9;3EPA;3EPB;3H0V;3H0W;	CHEMBL4181;	P17707;	DB00118;DB03754;	PATHWAY: Amine and polyamine biosynthesis; S-adenosylmethioninamine biosynthesis; S-adenosylmethioninamine from S-adenosyl-L-methionine: step 1/1.	PF01536;	IPR001985;IPR018167;IPR016067;IPR018166;	polyamine metabolic process [GO:0006595]; S-adenosylmethioninamine biosynthetic process [GO:0006557]; S-adenosylmethionine metabolic process [GO:0046500]; spermidine biosynthetic process [GO:0008295]; spermine biosynthetic process [GO:0006597]	adenosylmethionine decarboxylase activity [GO:0004014]; putrescine binding [GO:0019810]	cytosol [GO:0005829]
Q05329	DCE2_HUMAN	Glutamate decarboxylase 2 (EC 4.1.1.15) (65 kDa glutamic acid decarboxylase) (GAD-65) (Glutamate decarboxylase 65 kDa isoform)	GAD2 GAD65	1ES0;2OKK;	CHEMBL2952;				PF00282;	IPR002129;IPR015424;IPR015421;IPR015422;IPR021115;	chemical synaptic transmission [GO:0007268]; glutamate decarboxylation to succinate [GO:0006540]; neurotransmitter biosynthetic process [GO:0042136]; neurotransmitter secretion [GO:0007269]; response to drug [GO:0042493]	glutamate binding [GO:0016595]; glutamate decarboxylase activity [GO:0004351]; pyridoxal phosphate binding [GO:0030170]	anchored component of membrane [GO:0031225]; axon [GO:0030424]; cell junction [GO:0030054]; clathrin-sculpted gamma-aminobutyric acid transport vesicle membrane [GO:0061202]; cytosol [GO:0005829]; Golgi membrane [GO:0000139]; inhibitory synapse [GO:0060077]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; presynaptic membrane [GO:0042734]; synaptic vesicle membrane [GO:0030672]
P19113	DCHS_HUMAN	Histidine decarboxylase (HDC) (EC 4.1.1.22)	HDC	4E1O;			DB00117;	PATHWAY: Amine and polyamine biosynthesis; histamine biosynthesis; histamine from L-histidine: step 1/1.	PF00282;	IPR010977;IPR002129;IPR015424;IPR015421;IPR015422;IPR021115;	catecholamine biosynthetic process [GO:0042423]; histamine biosynthetic process [GO:0001694]; histidine catabolic process [GO:0006548]; histidine metabolic process [GO:0006547]	histidine decarboxylase activity [GO:0004398]; pyridoxal phosphate binding [GO:0030170]	cytosol [GO:0005829]
P27707	DCK_HUMAN	Deoxycytidine kinase (dCK) (EC 2.7.1.74)	DCK	1P5Z;1P60;1P61;1P62;2A2Z;2A30;2A7Q;2NO0;2NO1;2NO6;2NO7;2NO9;2NOA;2QRN;2QRO;2ZI3;2ZI4;2ZI5;2ZI6;2ZI7;2ZI9;2ZIA;3HP1;3IPX;3IPY;3KFX;3MJR;3QEJ;3QEN;3QEO;4JLJ;4JLK;4JLM;4JLN;4KCG;4L5B;4Q18;4Q19;4Q1A;4Q1B;4Q1C;4Q1D;4Q1E;4Q1F;	CHEMBL2447;	P27707;	DB00242;DB00631;DB00987;DB01262;DB00879;DB01073;DB00441;DB00709;DB01280;DB00642;DB00943;		PF01712;	IPR002624;IPR031314;IPR027417;	purine-containing compound salvage [GO:0043101]; pyrimidine nucleoside salvage [GO:0043097]; pyrimidine nucleotide metabolic process [GO:0006220]	ATP binding [GO:0005524]; deoxycytidine kinase activity [GO:0004137]; drug binding [GO:0008144]; nucleoside kinase activity [GO:0019206]; protein homodimerization activity [GO:0042803]	cytosol [GO:0005829]; nucleus [GO:0005634]
P11926	DCOR_HUMAN	Ornithine decarboxylase (ODC) (EC 4.1.1.17)	ODC1	1D7K;2ON3;2OO0;4ZGY;5BWA;	CHEMBL1869;	P11926;	DB06243;DB00127;	PATHWAY: Amine and polyamine biosynthesis; putrescine biosynthesis via L-ornithine pathway; putrescine from L-ornithine: step 1/1.	PF02784;PF00278;	IPR009006;IPR022643;IPR022657;IPR022644;IPR022653;IPR000183;IPR002433;IPR029066;	kidney development [GO:0001822]; polyamine metabolic process [GO:0006595]; positive regulation of cell proliferation [GO:0008284]; putrescine biosynthetic process from ornithine [GO:0033387]; regulation of cellular amino acid metabolic process [GO:0006521]; regulation of protein catabolic process [GO:0042176]; response to virus [GO:0009615]	ornithine decarboxylase activity [GO:0004586]; protein homodimerization activity [GO:0042803]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; perinuclear region of cytoplasm [GO:0048471]
Q96C86	DCPS_HUMAN	m7GpppX diphosphatase (EC 3.6.1.59) (DCS-1) (Decapping scavenger enzyme) (Hint-related 7meGMP-directed hydrolase) (Histidine triad nucleotide-binding protein 5) (Histidine triad protein member 5) (HINT-5) (Scavenger mRNA-decapping enzyme DcpS)	DCPS DCS1 HINT5 HSPC015	1ST0;1ST4;1XML;1XMM;3BL7;3BL9;3BLA;4QDE;4QDV;4QEB;	CHEMBL1949488;	Q96C86;			PF05652;	IPR008594;IPR019808;IPR011146;IPR011145;	cellular response to menadione [GO:0036245]; deadenylation-dependent decapping of nuclear-transcribed mRNA [GO:0000290]; exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay [GO:0043928]; mRNA cis splicing, via spliceosome [GO:0045292]; negative regulation of programmed cell death [GO:0043069]; nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay [GO:0000288]	exoribonuclease activity [GO:0004532]; m7G(5')pppN diphosphatase activity [GO:0050072]; RNA 7-methylguanosine cap binding [GO:0000340]	cytoplasm [GO:0005737]; cytoplasmic mRNA processing body [GO:0000932]; cytosol [GO:0005829]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P06132	DCUP_HUMAN	Uroporphyrinogen decarboxylase (UPD) (URO-D) (EC 4.1.1.37)	UROD	1JPH;1JPI;1JPK;1R3Q;1R3R;1R3S;1R3T;1R3V;1R3W;1R3Y;1URO;2Q6Z;2Q71;3GVQ;3GVR;3GVV;3GVW;3GW0;3GW3;	CHEMBL1681619;			PATHWAY: Porphyrin-containing compound metabolism; protoporphyrin-IX biosynthesis; coproporphyrinogen-III from 5-aminolevulinate: step 4/4.	PF01208;	IPR006361;IPR000257;	heme biosynthetic process [GO:0006783]; protoporphyrinogen IX biosynthetic process [GO:0006782]	uroporphyrinogen decarboxylase activity [GO:0004853]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleoplasm [GO:0005654]
Q7Z4W1	DCXR_HUMAN	L-xylulose reductase (XR) (EC 1.1.1.10) (Carbonyl reductase II) (Dicarbonyl/L-xylulose reductase) (Kidney dicarbonyl reductase) (kiDCR) (Short chain dehydrogenase/reductase family 20C member 1) (Sperm surface protein P34H)	DCXR SDR20C1	1PR9;1WNT;3D3W;	CHEMBL2314;		DB02325;			IPR016040;IPR020904;IPR002347;	D-xylose metabolic process [GO:0042732]; glucose metabolic process [GO:0006006]; glucuronate catabolic process to xylulose 5-phosphate [GO:0019640]; NADP metabolic process [GO:0006739]; oxidation-reduction process [GO:0055114]; protein homotetramerization [GO:0051289]; xylulose metabolic process [GO:0005997]	L-xylulose reductase (NADP+) activity [GO:0050038]; oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor [GO:0016655]	brush border [GO:0005903]; cytoplasmic microtubule [GO:0005881]; extracellular exosome [GO:0070062]; microvillus [GO:0005902]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
O94760	DDAH1_HUMAN	N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 (DDAH-1) (Dimethylarginine dimethylaminohydrolase 1) (EC 3.5.3.18) (DDAHI) (Dimethylargininase-1)	DDAH1 DDAH	2JAI;2JAJ;3I2E;3I4A;3P8E;3P8P;	CHEMBL6036;	O94760;	DB00155;			IPR033199;IPR033197;	arginine catabolic process [GO:0006527]; citrulline metabolic process [GO:0000052]; nitric oxide mediated signal transduction [GO:0007263]; positive regulation of angiogenesis [GO:0045766]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; regulation of nitric-oxide synthase activity [GO:0050999]; regulation of systemic arterial blood pressure [GO:0003073]	amino acid binding [GO:0016597]; catalytic activity [GO:0003824]; dimethylargininase activity [GO:0016403]; metal ion binding [GO:0046872]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrion [GO:0005739]
O95865	DDAH2_HUMAN	N(G),N(G)-dimethylarginine dimethylaminohydrolase 2 (DDAH-2) (Dimethylarginine dimethylaminohydrolase 2) (EC 3.5.3.18) (DDAHII) (Dimethylargininase-2) (Protein G6a) (S-phase protein)	DDAH2 DDAH G6A NG30				DB00155;			IPR033199;IPR033202;	arginine catabolic process [GO:0006527]; citrulline metabolic process [GO:0000052]; negative regulation of apoptotic process [GO:0043066]; nitric oxide biosynthetic process [GO:0006809]; nitric oxide mediated signal transduction [GO:0007263]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; regulation of nitric-oxide synthase activity [GO:0050999]	amino acid binding [GO:0016597]; catalytic activity [GO:0003824]; dimethylargininase activity [GO:0016403]	centrosome [GO:0005813]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrion [GO:0005739]
Q08345	DDR1_HUMAN	Epithelial discoidin domain-containing receptor 1 (Epithelial discoidin domain receptor 1) (EC 2.7.10.1) (CD167 antigen-like family member A) (Cell adhesion kinase) (Discoidin receptor tyrosine kinase) (HGK2) (Mammary carcinoma kinase 10) (MCK-10) (Protein-tyrosine kinase 3A) (Protein-tyrosine kinase RTK-6) (TRK E) (Tyrosine kinase DDR) (Tyrosine-protein kinase CAK) (CD antigen CD167a)	DDR1 CAK EDDR1 NEP NTRK4 PTK3A RTK6 TRKE	3ZOS;4AG4;4BKJ;4CKR;5BVK;5BVN;5BVO;5BVW;5FDP;	CHEMBL5319;	Q08345;	DB00619;		PF00754;PF07714;	IPR029553;IPR000421;IPR008979;IPR011009;IPR000719;IPR001245;IPR008266;IPR020635;IPR002011;	branching involved in mammary gland duct morphogenesis [GO:0060444]; cell adhesion [GO:0007155]; collagen-activated tyrosine kinase receptor signaling pathway [GO:0038063]; ear development [GO:0043583]; embryo implantation [GO:0007566]; extracellular matrix organization [GO:0030198]; lactation [GO:0007595]; mammary gland alveolus development [GO:0060749]; negative regulation of cell proliferation [GO:0008285]; peptidyl-tyrosine autophosphorylation [GO:0038083]; protein autophosphorylation [GO:0046777]; regulation of cell growth [GO:0001558]; regulation of cell-matrix adhesion [GO:0001952]; regulation of extracellular matrix disassembly [GO:0010715]; smooth muscle cell-matrix adhesion [GO:0061302]; smooth muscle cell migration [GO:0014909]; wound healing, spreading of cells [GO:0044319]	ATP binding [GO:0005524]; collagen binding [GO:0005518]; metal ion binding [GO:0046872]; protein tyrosine kinase collagen receptor activity [GO:0038062]; transmembrane receptor protein tyrosine kinase activity [GO:0004714]	extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]
P26196	DDX6_HUMAN	Probable ATP-dependent RNA helicase DDX6 (EC 3.6.4.13) (ATP-dependent RNA helicase p54) (DEAD box protein 6) (Oncogene RCK)	DDX6 HLR2 RCK	1VEC;2WAX;2WAY;4CRW;4CT4;4CT5;5ANR;					PF00270;PF00271;	IPR011545;IPR014001;IPR001650;IPR027417;IPR000629;IPR014014;	cytoplasmic mRNA processing body assembly [GO:0033962]; exonucleolytic nuclear-transcribed mRNA catabolic process involved in deadenylation-dependent decay [GO:0043928]; negative regulation of neuron differentiation [GO:0045665]; regulation of translation [GO:0006417]; RNA secondary structure unwinding [GO:0010501]; spermatogenesis [GO:0007283]; stem cell population maintenance [GO:0019827]; viral RNA genome packaging [GO:0019074]	ATP binding [GO:0005524]; ATP-dependent RNA helicase activity [GO:0004004]; cadherin binding involved in cell-cell adhesion [GO:0098641]; helicase activity [GO:0004386]; poly(A) RNA binding [GO:0044822]; protein domain specific binding [GO:0019904]; RNA helicase activity [GO:0003724]	cell-cell adherens junction [GO:0005913]; cytoplasm [GO:0005737]; cytoplasmic mRNA processing body [GO:0000932]; cytoplasmic stress granule [GO:0010494]; cytosol [GO:0005829]; heterochromatin [GO:0000792]; intracellular membrane-bounded organelle [GO:0043231]; membrane [GO:0016020]; mitochondrion [GO:0005739]; nucleolus [GO:0005730]; nucleus [GO:0005634]; outer dense fiber [GO:0001520]; P granule [GO:0043186]; RISC complex [GO:0016442]; sperm annulus [GO:0097227]
Q16698	DECR_HUMAN	2,4-dienoyl-CoA reductase, mitochondrial (EC 1.3.1.34) (2,4-dienoyl-CoA reductase [NADPH]) (4-enoyl-CoA reductase [NADPH]) (Short chain dehydrogenase/reductase family 18C member 1)	DECR1 DECR SDR18C1	1W6U;1W73;1W8D;						IPR016040;IPR002347;	fatty acid beta-oxidation [GO:0006635]; protein homotetramerization [GO:0051289]	2,4-dienoyl-CoA reductase (NADPH) activity [GO:0008670]; NADPH binding [GO:0070402]; oxidoreductase activity, acting on NAD(P)H [GO:0016651]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
Q9HBH1	DEFM_HUMAN	Peptide deformylase, mitochondrial (EC 3.5.1.88) (Polypeptide deformylase)	PDF PDF1A	3G5K;3G5P;	CHEMBL4647;	Q9HBH1;			PF01327;	IPR023635;	N-terminal protein amino acid modification [GO:0031365]; peptidyl-methionine modification [GO:0018206]; positive regulation of cell proliferation [GO:0008284]; translation [GO:0006412]	metal ion binding [GO:0046872]; peptide deformylase activity [GO:0042586]	mitochondrion [GO:0005739]
P23743	DGKA_HUMAN	Diacylglycerol kinase alpha (DAG kinase alpha) (EC 2.7.1.107) (80 kDa diacylglycerol kinase) (Diglyceride kinase alpha) (DGK-alpha)	DGKA DAGK DAGK1	1TUZ;			DB00163;		PF00130;PF14513;PF00609;PF00781;	IPR029477;IPR000756;IPR001206;IPR011992;IPR018247;IPR002048;IPR016064;IPR002219;	diacylglycerol metabolic process [GO:0046339]; glycerolipid metabolic process [GO:0046486]; intracellular signal transduction [GO:0035556]; lipid phosphorylation [GO:0046834]; phosphatidic acid biosynthetic process [GO:0006654]; platelet activation [GO:0030168]; protein kinase C-activating G-protein coupled receptor signaling pathway [GO:0007205]	ATP binding [GO:0005524]; calcium ion binding [GO:0005509]; diacylglycerol kinase activity [GO:0004143]; kinase activity [GO:0016301]; phospholipid binding [GO:0005543]	cytosol [GO:0005829]; membrane [GO:0016020]; plasma membrane [GO:0005886]
Q9Y6T7	DGKB_HUMAN	Diacylglycerol kinase beta (DAG kinase beta) (EC 2.7.1.107) (90 kDa diacylglycerol kinase) (Diglyceride kinase beta) (DGK-beta)	DGKB DAGK2 KIAA0718						PF00130;PF14513;PF00609;PF00781;PF13499;	IPR029477;IPR000756;IPR001206;IPR011992;IPR018247;IPR002048;IPR016064;IPR002219;	glycerolipid metabolic process [GO:0046486]; intracellular signal transduction [GO:0035556]; lipid phosphorylation [GO:0046834]; platelet activation [GO:0030168]; protein kinase C-activating G-protein coupled receptor signaling pathway [GO:0007205]	ATP binding [GO:0005524]; calcium ion binding [GO:0005509]; diacylglycerol kinase activity [GO:0004143]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; plasma membrane [GO:0005886]
Q16760	DGKD_HUMAN	Diacylglycerol kinase delta (DAG kinase delta) (EC 2.7.1.107) (130 kDa diacylglycerol kinase) (Diglyceride kinase delta) (DGK-delta)	DGKD KIAA0145	1R79;3BQ7;	CHEMBL1075120;		DB00144;		PF00130;PF00609;PF00781;PF00169;PF07647;	IPR000756;IPR001206;IPR016064;IPR002219;IPR011993;IPR001849;IPR001660;IPR013761;	cell growth [GO:0016049]; diacylglycerol metabolic process [GO:0046339]; endocytosis [GO:0006897]; epidermal growth factor receptor signaling pathway [GO:0007173]; lipid phosphorylation [GO:0046834]; multicellular organism development [GO:0007275]; platelet activation [GO:0030168]; protein homooligomerization [GO:0051260]; protein kinase C-activating G-protein coupled receptor signaling pathway [GO:0007205]; protein transport [GO:0015031]; response to organic substance [GO:0010033]; second-messenger-mediated signaling [GO:0019932]; signal transduction [GO:0007165]	ATP binding [GO:0005524]; diacylglycerol binding [GO:0019992]; diacylglycerol kinase activity [GO:0004143]; metal ion binding [GO:0046872]; protein heterodimerization activity [GO:0046982]; protein homodimerization activity [GO:0042803]	cytoplasm [GO:0005737]; cytoplasmic, membrane-bounded vesicle [GO:0016023]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
P49619	DGKG_HUMAN	Diacylglycerol kinase gamma (DAG kinase gamma) (EC 2.7.1.107) (Diglyceride kinase gamma) (DGK-gamma)	DGKG DAGK3		CHEMBL1075157;		DB00144;		PF00130;PF14513;PF00609;PF00781;PF13499;	IPR029477;IPR000756;IPR001206;IPR011992;IPR018247;IPR002048;IPR016064;IPR002219;	glycerolipid metabolic process [GO:0046486]; intracellular signal transduction [GO:0035556]; lipid phosphorylation [GO:0046834]; neuron development [GO:0048666]; platelet activation [GO:0030168]; protein kinase C-activating G-protein coupled receptor signaling pathway [GO:0007205]; signal transduction [GO:0007165]	ATP binding [GO:0005524]; calcium ion binding [GO:0005509]; diacylglycerol kinase activity [GO:0004143]	cytoplasm [GO:0005737]; plasma membrane [GO:0005886]
P14061	DHB1_HUMAN	Estradiol 17-beta-dehydrogenase 1 (EC 1.1.1.62) (17-beta-hydroxysteroid dehydrogenase type 1) (17-beta-HSD 1) (20 alpha-hydroxysteroid dehydrogenase) (20-alpha-HSD) (E2DH) (Placental 17-beta-hydroxysteroid dehydrogenase) (Short chain dehydrogenase/reductase family 28C member 1)	HSD17B1 E17KSR EDH17B1 EDH17B2 EDHB17 SDR28C1	1A27;1BHS;1DHT;1EQU;1FDS;1FDT;1FDU;1FDV;1FDW;1I5R;1IOL;1JTV;1QYV;1QYW;1QYX;3DEY;3DHE;3HB4;3HB5;3KLM;3KLP;3KM0;	CHEMBL3181;	P14061;	DB02187;	PATHWAY: Steroid biosynthesis; estrogen biosynthesis.	PF00106;	IPR011348;IPR016040;IPR020904;IPR002347;	bone development [GO:0060348]; cellular response to metal ion [GO:0071248]; estrogen biosynthetic process [GO:0006703]; estrogen metabolic process [GO:0008210]; steroid biosynthetic process [GO:0006694]; testosterone biosynthetic process [GO:0061370]	catalytic activity [GO:0003824]; estradiol 17-beta-dehydrogenase activity [GO:0004303]; testosterone dehydrogenase (NAD+) activity [GO:0047035]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nuclear membrane [GO:0031965]; nucleoplasm [GO:0005654]
P37059	DHB2_HUMAN	Estradiol 17-beta-dehydrogenase 2 (EC 1.1.1.62) (17-beta-hydroxysteroid dehydrogenase type 2) (17-beta-HSD 2) (20 alpha-hydroxysteroid dehydrogenase) (20-alpha-HSD) (E2DH) (Microsomal 17-beta-hydroxysteroid dehydrogenase) (Short chain dehydrogenase/reductase family 9C member 2) (Testosterone 17-beta-dehydrogenase) (EC 1.1.1.239)	HSD17B2 EDH17B2 SDR9C2		CHEMBL2789;	P37059;			PF00106;	IPR016040;IPR020904;IPR002347;	in utero embryonic development [GO:0001701]; placenta development [GO:0001890]; response to retinoic acid [GO:0032526]; steroid biosynthetic process [GO:0006694]	17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase activity [GO:0047006]; estradiol 17-beta-dehydrogenase activity [GO:0004303]; testosterone dehydrogenase (NAD+) activity [GO:0047035]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]
P37058	DHB3_HUMAN	Testosterone 17-beta-dehydrogenase 3 (EC 1.1.1.64) (17-beta-hydroxysteroid dehydrogenase type 3) (17-beta-HSD 3) (Short chain dehydrogenase/reductase family 12C member 2) (Testicular 17-beta-hydroxysteroid dehydrogenase)	HSD17B3 EDH17B3 SDR12C2		CHEMBL4234;	P37058;		PATHWAY: Hormone biosynthesis; testosterone biosynthesis.	PF00106;	IPR033281;IPR016040;IPR020904;IPR002347;	androgen biosynthetic process [GO:0006702]; male genitalia development [GO:0030539]; testosterone biosynthetic process [GO:0061370]	testosterone 17-beta-dehydrogenase (NADP+) activity [GO:0047045]; testosterone dehydrogenase (NAD+) activity [GO:0047035]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; intracellular membrane-bounded organelle [GO:0043231]
P51659	DHB4_HUMAN	Peroxisomal multifunctional enzyme type 2 (MFE-2) (17-beta-hydroxysteroid dehydrogenase 4) (17-beta-HSD 4) (D-bifunctional protein) (DBP) (Multifunctional protein 2) (MPF-2) (Short chain dehydrogenase/reductase family 8C member 1) [Cleaved into: (3R)-hydroxyacyl-CoA dehydrogenase (EC 1.1.1.n12); Enoyl-CoA hydratase 2 (EC 4.2.1.107) (EC 4.2.1.119) (3-alpha,7-alpha,12-alpha-trihydroxy-5-beta-cholest-24-enoyl-CoA hydratase)]	HSD17B4 EDH17B4 SDR8C1	1IKT;1S9C;1ZBQ;	CHEMBL5814;			PATHWAY: Lipid metabolism; fatty acid beta-oxidation.	PF00106;PF01575;PF02036;	IPR029069;IPR002539;IPR016040;IPR020904;IPR003033;IPR002347;	alpha-linolenic acid metabolic process [GO:0036109]; androgen metabolic process [GO:0008209]; bile acid biosynthetic process [GO:0006699]; estrogen metabolic process [GO:0008210]; fatty acid beta-oxidation [GO:0006635]; fatty acid beta-oxidation using acyl-CoA oxidase [GO:0033540]; medium-chain fatty-acyl-CoA metabolic process [GO:0036112]; osteoblast differentiation [GO:0001649]; Sertoli cell development [GO:0060009]; very long-chain fatty acid metabolic process [GO:0000038]; very long-chain fatty-acyl-CoA metabolic process [GO:0036111]	17-beta-hydroxysteroid dehydrogenase (NAD+) activity [GO:0044594]; 3alpha,7alpha,12alpha-trihydroxy-5beta-cholest-24-enoyl-CoA hydratase activity [GO:0033989]; 3-hydroxyacyl-CoA dehydrogenase activity [GO:0003857]; isomerase activity [GO:0016853]; long-chain-enoyl-CoA hydratase activity [GO:0016508]; protein homodimerization activity [GO:0042803]; receptor binding [GO:0005102]	intracellular membrane-bounded organelle [GO:0043231]; membrane [GO:0016020]; mitochondrion [GO:0005739]; peroxisomal matrix [GO:0005782]; peroxisomal membrane [GO:0005778]; peroxisome [GO:0005777]
P56937	DHB7_HUMAN	3-keto-steroid reductase (EC 1.1.1.270) (17-beta-hydroxysteroid dehydrogenase 7) (17-beta-HSD 7) (Estradiol 17-beta-dehydrogenase 7) (EC 1.1.1.62) (Short chain dehydrogenase/reductase family 37C member 1)	HSD17B7 SDR37C1 UNQ2563/PRO6243		CHEMBL5999;	P56937;		PATHWAY: Steroid biosynthesis; estrogen biosynthesis.; PATHWAY: Steroid biosynthesis; zymosterol biosynthesis; zymosterol from lanosterol: step 5/6.	PF00106;	IPR016040;IPR002347;	cholesterol biosynthetic process [GO:0006695]; estrogen biosynthetic process [GO:0006703]	3-keto sterol reductase activity [GO:0000253]; estradiol 17-beta-dehydrogenase activity [GO:0004303]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]
Q92506	DHB8_HUMAN	Estradiol 17-beta-dehydrogenase 8 (EC 1.1.1.62) (17-beta-hydroxysteroid dehydrogenase 8) (17-beta-HSD 8) (3-ketoacyl-[acyl-carrier-protein] reductase alpha subunit) (KAR alpha subunit) (3-oxoacyl-[acyl-carrier-protein] reductase) (EC 1.1.1.-) (Protein Ke6) (Ke-6) (Really interesting new gene 2 protein) (Short chain dehydrogenase/reductase family 30C member 1) (Testosterone 17-beta-dehydrogenase 8) (EC 1.1.1.239)	HSD17B8 FABGL HKE6 RING2 SDR30C1	2PD6;4CQL;4CQM;				PATHWAY: Steroid biosynthesis; estrogen biosynthesis. {ECO:0000269|PubMed:17978863}.; PATHWAY: Lipid metabolism; fatty acid biosynthesis. {ECO:0000269|PubMed:25203508}.		IPR016040;IPR020904;IPR002347;	androgen metabolic process [GO:0008209]; estrogen biosynthetic process [GO:0006703]; fatty acid biosynthetic process [GO:0006633]; oxidation-reduction process [GO:0055114]; protein heterotetramerization [GO:0051290]; steroid biosynthetic process [GO:0006694]	3-hydroxyacyl-CoA dehydrogenase activity [GO:0003857]; 3-oxoacyl-[acyl-carrier-protein] reductase (NADH) activity [GO:0047025]; estradiol 17-beta-dehydrogenase activity [GO:0004303]; NADH binding [GO:0070404]; testosterone dehydrogenase (NAD+) activity [GO:0047035]	mitochondrial envelope [GO:0005740]; mitochondrial matrix [GO:0005759]; plasma membrane [GO:0005886]
Q9UBM7	DHCR7_HUMAN	7-dehydrocholesterol reductase (7-DHC reductase) (EC 1.3.1.21) (Putative sterol reductase SR-2) (Sterol Delta(7)-reductase)	DHCR7 D7SR		CHEMBL2169735;	Q9UBM7;		PATHWAY: Steroid biosynthesis; cholesterol biosynthesis.	PF01222;	IPR001171;IPR018083;	blood vessel development [GO:0001568]; cell differentiation [GO:0030154]; cholesterol biosynthetic process [GO:0006695]; cholesterol biosynthetic process via desmosterol [GO:0033489]; cholesterol biosynthetic process via lathosterol [GO:0033490]; lung development [GO:0030324]; multicellular organism growth [GO:0035264]; post-embryonic development [GO:0009791]; regulation of cell proliferation [GO:0042127]; regulation of cholesterol biosynthetic process [GO:0045540]	7-dehydrocholesterol reductase activity [GO:0047598]; NADP binding [GO:0050661]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; integral component of endoplasmic reticulum membrane [GO:0030176]; membrane [GO:0016020]; nuclear outer membrane [GO:0005640]
P00367	DHE3_HUMAN	Glutamate dehydrogenase 1, mitochondrial (GDH 1) (EC 1.4.1.3)	GLUD1 GLUD	1L1F;1NR1;			DB00756;		PF00208;PF02812;	IPR006095;IPR033524;IPR006096;IPR006097;IPR016040;	cellular amino acid biosynthetic process [GO:0008652]; glutamate biosynthetic process [GO:0006537]; glutamate catabolic process [GO:0006538]; glutamine metabolic process [GO:0006541]; positive regulation of insulin secretion [GO:0032024]; substantia nigra development [GO:0021762]; tricarboxylic acid metabolic process [GO:0072350]	ADP binding [GO:0043531]; ATP binding [GO:0005524]; glutamate dehydrogenase (NAD+) activity [GO:0004352]; glutamate dehydrogenase [NAD(P)+] activity [GO:0004353]; GTP binding [GO:0005525]; identical protein binding [GO:0042802]; leucine binding [GO:0070728]; NAD+ binding [GO:0070403]	cytoplasm [GO:0005737]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
P49448	DHE4_HUMAN	Glutamate dehydrogenase 2, mitochondrial (GDH 2) (EC 1.4.1.3)	GLUD2 GLUDP1						PF00208;PF02812;	IPR006095;IPR033524;IPR006096;IPR006097;IPR016040;	cellular amino acid metabolic process [GO:0006520]; glutamate biosynthetic process [GO:0006537]; glutamate catabolic process [GO:0006538]; glutamate metabolic process [GO:0006536]; oxidation-reduction process [GO:0055114]	ADP binding [GO:0043531]; glutamate dehydrogenase (NAD+) activity [GO:0004352]; glutamate dehydrogenase [NAD(P)+] activity [GO:0004353]; GTP binding [GO:0005525]; leucine binding [GO:0070728]	mitochondrion [GO:0005739]
P28845	DHI1_HUMAN	Corticosteroid 11-beta-dehydrogenase isozyme 1 (EC 1.1.1.146) (11-beta-hydroxysteroid dehydrogenase 1) (11-DH) (11-beta-HSD1) (Short chain dehydrogenase/reductase family 26C member 1)	HSD11B1 HSD11 HSD11L SDR26C1	1XU7;1XU9;2BEL;2ILT;2IRW;2RBE;3BYZ;3BZU;3CH6;3CZR;3D3E;3D4N;3D5Q;3EY4;3FCO;3FRJ;3H6K;3HFG;3OQ1;3PDJ;3QQP;3TFQ;4BB5;4BB6;4C7J;4C7K;4HFR;4HX5;4IJU;4IJV;4IJW;4K1L;4P38;4YYZ;	CHEMBL4235;	P28845;	DB00635;		PF00106;	IPR016040;IPR020904;IPR002347;	glucocorticoid biosynthetic process [GO:0006704]; lung development [GO:0030324]	11-beta-hydroxysteroid dehydrogenase (NADP+) activity [GO:0070524]; 11-beta-hydroxysteroid dehydrogenase [NAD(P)] activity [GO:0003845]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; membrane [GO:0016020]
P80365	DHI2_HUMAN	Corticosteroid 11-beta-dehydrogenase isozyme 2 (EC 1.1.1.-) (11-beta-hydroxysteroid dehydrogenase type 2) (11-DH2) (11-beta-HSD2) (11-beta-hydroxysteroid dehydrogenase type II) (11-HSD type II) (11-beta-HSD type II) (NAD-dependent 11-beta-hydroxysteroid dehydrogenase) (11-beta-HSD) (Short chain dehydrogenase/reductase family 9C member 3)	HSD11B2 HSD11K SDR9C3		CHEMBL3746;	P80365;			PF00106;	IPR016040;IPR020904;IPR002347;	female pregnancy [GO:0007565]; glucocorticoid biosynthetic process [GO:0006704]; regulation of blood volume by renal aldosterone [GO:0002017]; response to drug [GO:0042493]; response to food [GO:0032094]; response to glucocorticoid [GO:0051384]; response to hypoxia [GO:0001666]; response to insulin [GO:0032868]	11-beta-hydroxysteroid dehydrogenase [NAD(P)] activity [GO:0003845]; NAD binding [GO:0051287]; steroid binding [GO:0005496]	endoplasmic reticulum membrane [GO:0005789]
P09417	DHPR_HUMAN	Dihydropteridine reductase (EC 1.5.1.34) (HDHPR) (Quinoid dihydropteridine reductase) (Short chain dehydrogenase/reductase family 33C member 1)	QDPR DHPR SDR33C1	1HDR;	CHEMBL3730;	P09417;			PF00106;	IPR016040;IPR020904;IPR002347;	cellular amino acid metabolic process [GO:0006520]; cellular response to drug [GO:0035690]; dihydrobiopterin metabolic process [GO:0051066]; liver development [GO:0001889]; L-phenylalanine catabolic process [GO:0006559]; response to aluminum ion [GO:0010044]; response to glucagon [GO:0033762]; response to lead ion [GO:0010288]; tetrahydrobiopterin biosynthetic process [GO:0006729]	6,7-dihydropteridine reductase activity [GO:0004155]; electron carrier activity [GO:0009055]; NADH binding [GO:0070404]; NADPH binding [GO:0070402]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrion [GO:0005739]; neuron projection [GO:0043005]
Q6UWP2	DHR11_HUMAN	Dehydrogenase/reductase SDR family member 11 (EC 1.1.-.-) (Short-chain dehydrogenase/reductase family 24C member 1)	DHRS11 SDR24C1 UNQ836/PRO1774	1XG5;					PF00106;	IPR016040;IPR020904;IPR002347;		oxidoreductase activity [GO:0016491]	extracellular region [GO:0005576]
O75911	DHRS3_HUMAN	Short-chain dehydrogenase/reductase 3 (EC 1.1.1.300) (DD83.1) (Retinal short-chain dehydrogenase/reductase 1) (retSDR1) (Retinol dehydrogenase 17) (Short chain dehydrogenase/reductase family 16C member 1)	DHRS3 RDH17 SDR16C1 UNQ2424/PRO4983				DB00162;		PF00106;	IPR032969;IPR016040;IPR002347;	bone morphogenesis [GO:0060349]; cardiac septum morphogenesis [GO:0060411]; negative regulation of retinoic acid receptor signaling pathway [GO:0048387]; outflow tract morphogenesis [GO:0003151]; palate development [GO:0060021]; regulation of ossification [GO:0030278]; retinoid metabolic process [GO:0001523]; retinol metabolic process [GO:0042572]; visual perception [GO:0007601]	electron carrier activity [GO:0009055]; NADP-retinol dehydrogenase activity [GO:0052650]; nucleotide binding [GO:0000166]; retinol dehydrogenase activity [GO:0004745]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; photoreceptor outer segment membrane [GO:0042622]
Q9BTZ2	DHRS4_HUMAN	Dehydrogenase/reductase SDR family member 4 (EC 1.1.1.184) (NADPH-dependent carbonyl reductase/NADP-retinol dehydrogenase) (CR) (PHCR) (NADPH-dependent retinol dehydrogenase/reductase) (NRDR) (humNRDR) (Peroxisomal short-chain alcohol dehydrogenase) (PSCD) (SCAD-SRL) (Short chain dehydrogenase/reductase family 25C member 2) (Short-chain dehydrogenase/reductase family member 4)	DHRS4 SDR25C2 UNQ851/PRO1800	3O4R;			DB00162;			IPR029511;IPR016040;IPR020904;IPR002347;	alcohol metabolic process [GO:0006066]; cellular ketone metabolic process [GO:0042180]; oxidation-reduction process [GO:0055114]; protein tetramerization [GO:0051262]; steroid metabolic process [GO:0008202]	3-keto sterol reductase activity [GO:0000253]; alcohol dehydrogenase [NAD(P)+] activity [GO:0018455]; carbonyl reductase (NADPH) activity [GO:0004090]; NADP-retinol dehydrogenase activity [GO:0052650]; oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor [GO:0016655]; receptor binding [GO:0005102]	endoplasmic reticulum membrane [GO:0005789]; extracellular exosome [GO:0070062]; intracellular membrane-bounded organelle [GO:0043231]; mitochondrion [GO:0005739]; nuclear membrane [GO:0031965]; nucleus [GO:0005634]; peroxisomal membrane [GO:0005778]; peroxisome [GO:0005777]
Q8NBQ5	DHRS8_HUMAN	Estradiol 17-beta-dehydrogenase 11 (EC 1.1.1.62) (17-beta-hydroxysteroid dehydrogenase 11) (17-beta-HSD 11) (17bHSD11) (17betaHSD11) (17-beta-hydroxysteroid dehydrogenase XI) (17-beta-HSD XI) (17betaHSDXI) (Cutaneous T-cell lymphoma-associated antigen HD-CL-03) (CTCL-associated antigen HD-CL-03) (Dehydrogenase/reductase SDR family member 8) (Retinal short-chain dehydrogenase/reductase 2) (retSDR2) (Short chain dehydrogenase/reductase family 16C member 2)	HSD17B11 DHRS8 PAN1B SDR16C2 PSEC0029 UNQ207/PRO233	1YB1;					PF00106;	IPR016040;IPR002347;	androgen catabolic process [GO:0006710]; estrogen biosynthetic process [GO:0006703]; steroid biosynthetic process [GO:0006694]	estradiol 17-beta-dehydrogenase activity [GO:0004303]; steroid dehydrogenase activity [GO:0016229]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular region [GO:0005576]; intracellular membrane-bounded organelle [GO:0043231]; lipid particle [GO:0005811]
P31040	DHSA_HUMAN	Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial (EC 1.3.5.1) (Flavoprotein subunit of complex II) (Fp)	SDHA SDH2 SDHF		CHEMBL5758;		DB00139;	PATHWAY: Carbohydrate metabolism; tricarboxylic acid cycle; fumarate from succinate (eukaryal route): step 1/1. {ECO:0000305|PubMed:24781757}.	PF00890;PF02910;	IPR003953;IPR023753;IPR003952;IPR015939;IPR030664;IPR027477;IPR011281;IPR014006;	nervous system development [GO:0007399]; oxidation-reduction process [GO:0055114]; respiratory electron transport chain [GO:0022904]; succinate metabolic process [GO:0006105]; tricarboxylic acid cycle [GO:0006099]	flavin adenine dinucleotide binding [GO:0050660]; succinate dehydrogenase (ubiquinone) activity [GO:0008177]	mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone) [GO:0005749]; mitochondrion [GO:0005739]; myelin sheath [GO:0043209]
P21912	DHSB_HUMAN	Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial (EC 1.3.5.1) (Iron-sulfur subunit of complex II) (Ip)	SDHB SDH SDH1				DB00139;	PATHWAY: Carbohydrate metabolism; tricarboxylic acid cycle; fumarate from succinate (eukaryal route): step 1/1.	PF13085;	IPR001041;IPR006058;IPR017896;IPR017900;IPR012675;IPR009051;IPR004489;IPR025192;	aerobic respiration [GO:0009060]; respiratory electron transport chain [GO:0022904]; succinate metabolic process [GO:0006105]; tricarboxylic acid cycle [GO:0006099]	2 iron, 2 sulfur cluster binding [GO:0051537]; 3 iron, 4 sulfur cluster binding [GO:0051538]; 4 iron, 4 sulfur cluster binding [GO:0051539]; electron carrier activity [GO:0009055]; metal ion binding [GO:0046872]; succinate dehydrogenase (ubiquinone) activity [GO:0008177]; succinate dehydrogenase activity [GO:0000104]; ubiquinone binding [GO:0048039]	extracellular exosome [GO:0070062]; mitochondrial inner membrane [GO:0005743]; mitochondrial membrane [GO:0031966]; mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone) [GO:0005749]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; plasma membrane [GO:0005886]; respiratory chain complex II [GO:0045273]
O14521	DHSD_HUMAN	Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial (CybS) (CII-4) (QPs3) (Succinate dehydrogenase complex subunit D) (Succinate-ubiquinone oxidoreductase cytochrome b small subunit) (Succinate-ubiquinone reductase membrane anchor subunit)	SDHD SDH4				DB00756;DB00139;	PATHWAY: Carbohydrate metabolism; tricarboxylic acid cycle.		IPR007992;	tricarboxylic acid cycle [GO:0006099]	electron carrier activity [GO:0009055]; heme binding [GO:0020037]; metal ion binding [GO:0046872]; succinate dehydrogenase activity [GO:0000104]; ubiquinone binding [GO:0048039]	integral component of membrane [GO:0016021]; mitochondrial envelope [GO:0005740]; mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone) [GO:0005749]; mitochondrion [GO:0005739]
Q00796	DHSO_HUMAN	Sorbitol dehydrogenase (EC 1.1.1.14) (L-iditol 2-dehydrogenase)	SORD	1PL6;1PL7;1PL8;	CHEMBL2275;	Q00796;			PF08240;PF00107;	IPR013149;IPR013154;IPR002085;IPR002328;IPR011032;IPR016040;IPR020843;	flagellated sperm motility [GO:0030317]; fructose biosynthetic process [GO:0046370]; glucose metabolic process [GO:0006006]; glucuronate catabolic process to xylulose 5-phosphate [GO:0019640]; L-xylitol catabolic process [GO:0051160]; L-xylitol metabolic process [GO:0051164]; response to cadmium ion [GO:0046686]; response to copper ion [GO:0046688]; response to drug [GO:0042493]; response to hormone [GO:0009725]; response to nutrient levels [GO:0031667]; response to osmotic stress [GO:0006970]; sorbitol catabolic process [GO:0006062]	carbohydrate binding [GO:0030246]; D-xylulose reductase activity [GO:0046526]; L-iditol 2-dehydrogenase activity [GO:0003939]; NAD binding [GO:0051287]; zinc ion binding [GO:0008270]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; membrane [GO:0016020]; mitochondrial membrane [GO:0031966]; motile cilium [GO:0031514]
P49366	DHYS_HUMAN	Deoxyhypusine synthase (DHS) (EC 2.5.1.46)	DHPS DS	1DHS;1RLZ;1ROZ;1RQD;	CHEMBL4415;			PATHWAY: Protein modification; eIF5A hypusination.	PF01916;	IPR002773;IPR029035;	deoxyhypusine biosynthetic process from spermidine [GO:0050983]; glucose homeostasis [GO:0042593]; peptidyl-lysine modification to peptidyl-hypusine [GO:0008612]; positive regulation of cell proliferation [GO:0008284]; positive regulation of T cell proliferation [GO:0042102]; protein homotetramerization [GO:0051289]; translation [GO:0006412]	deoxyhypusine synthase activity [GO:0034038]	cytoplasm [GO:0005737]; cytosol [GO:0005829]
Q9UBX3	DIC_HUMAN	Mitochondrial dicarboxylate carrier (Solute carrier family 25 member 10)	SLC25A10 DIC				DB00139;		PF00153;	IPR002030;IPR018108;IPR023395;	dicarboxylic acid transport [GO:0006835]; gluconeogenesis [GO:0006094]; ion transport [GO:0006811]; mitochondrial transport [GO:0006839]; sulfide oxidation, using sulfide:quinone oxidoreductase [GO:0070221]; translation [GO:0006412]	dicarboxylic acid transmembrane transporter activity [GO:0005310]; structural constituent of ribosome [GO:0003735]	integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; nucleus [GO:0005634]
P09622	DLDH_HUMAN	Dihydrolipoyl dehydrogenase, mitochondrial (EC 1.8.1.4) (Dihydrolipoamide dehydrogenase) (Glycine cleavage system L protein)	DLD GCSL LAD PHE3	1ZMC;1ZMD;1ZY8;2F5Z;3RNM;			DB03147;		PF07992;PF02852;	IPR023753;IPR016156;IPR006258;IPR004099;IPR012999;	2-oxoglutarate metabolic process [GO:0006103]; aging [GO:0007568]; branched-chain amino acid catabolic process [GO:0009083]; cell redox homeostasis [GO:0045454]; dihydrolipoamide metabolic process [GO:0051068]; gastrulation [GO:0007369]; glyoxylate metabolic process [GO:0046487]; lipoate metabolic process [GO:0009106]; lysine catabolic process [GO:0006554]; mitochondrial acetyl-CoA biosynthetic process from pyruvate [GO:0061732]; mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; proteolysis [GO:0006508]; pyruvate metabolic process [GO:0006090]; regulation of acetyl-CoA biosynthetic process from pyruvate [GO:0010510]; regulation of membrane potential [GO:0042391]; sperm capacitation [GO:0048240]; tricarboxylic acid cycle [GO:0006099]	dihydrolipoyl dehydrogenase activity [GO:0004148]; flavin adenine dinucleotide binding [GO:0050660]; lipoamide binding [GO:0043544]; NAD binding [GO:0051287]	acrosomal matrix [GO:0043159]; cilium [GO:0005929]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; myelin sheath [GO:0043209]; nucleoplasm [GO:0005654]; oxoglutarate dehydrogenase complex [GO:0045252]; pyruvate dehydrogenase complex [GO:0045254]
P18858	DNL1_HUMAN	DNA ligase 1 (EC 6.5.1.1) (DNA ligase I) (Polydeoxyribonucleotide synthase [ATP] 1)	LIG1	1X9N;	CHEMBL5694;	P18858;	DB00290;		PF04679;PF01068;PF04675;	IPR000977;IPR012309;IPR012310;IPR016059;IPR012308;IPR012340;	anatomical structure morphogenesis [GO:0009653]; base-excision repair [GO:0006284]; cell division [GO:0051301]; DNA biosynthetic process [GO:0071897]; DNA metabolic process [GO:0006259]; DNA repair [GO:0006281]; mismatch repair [GO:0006298]; nucleotide-excision repair, DNA gap filling [GO:0006297]; Okazaki fragment processing involved in mitotic DNA replication [GO:1903461]; telomere maintenance via recombination [GO:0000722]; transcription-coupled nucleotide-excision repair [GO:0006283]	ATP binding [GO:0005524]; DNA binding [GO:0003677]; DNA ligase (ATP) activity [GO:0003910]; DNA ligase activity [GO:0003909]; metal ion binding [GO:0046872]	Golgi apparatus [GO:0005794]; intracellular membrane-bounded organelle [GO:0043231]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P49916	DNL3_HUMAN	DNA ligase 3 (EC 6.5.1.1) (DNA ligase III) (Polydeoxyribonucleotide synthase [ATP] 3)	LIG3	1IMO;1IN1;1UW0;3L2P;3PC7;3PC8;3QVG;			DB00290;		PF04679;PF01068;PF04675;PF16759;PF00645;	IPR001357;IPR000977;IPR012309;IPR012310;IPR016059;IPR012308;IPR031916;IPR012340;IPR001510;	base-excision repair, DNA ligation [GO:0006288]; cell cycle [GO:0007049]; cell division [GO:0051301]; DNA biosynthetic process [GO:0071897]; DNA ligation [GO:0006266]; DNA replication [GO:0006260]; double-strand break repair [GO:0006302]; double-strand break repair via alternative nonhomologous end joining [GO:0097681]; double-strand break repair via homologous recombination [GO:0000724]; mitochondrial DNA repair [GO:0043504]; mitochondrion organization [GO:0007005]; negative regulation of mitochondrial DNA replication [GO:0090298]; nucleotide-excision repair, DNA gap filling [GO:0006297]; transcription-coupled nucleotide-excision repair [GO:0006283]	ATP binding [GO:0005524]; DNA binding [GO:0003677]; DNA ligase (ATP) activity [GO:0003910]; DNA ligase activity [GO:0003909]; zinc ion binding [GO:0008270]	DNA ligase III-XRCC1 complex [GO:0070421]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P26358	DNMT1_HUMAN	DNA (cytosine-5)-methyltransferase 1 (Dnmt1) (EC 2.1.1.37) (CXXC-type zinc finger protein 9) (DNA methyltransferase HsaI) (DNA MTase HsaI) (M.HsaI) (MCMT)	DNMT1 AIM CXXC9 DNMT	3EPZ;3PTA;3SWR;4WXX;4YOC;	CHEMBL1993;	P26358;	DB00928;DB01262;DB01099;DB01035;		PF01426;PF06464;PF00145;PF12047;PF02008;	IPR001025;IPR018117;IPR001525;IPR031303;IPR022702;IPR010506;IPR017198;IPR029063;IPR002857;	cellular response to amino acid stimulus [GO:0071230]; chromatin modification [GO:0016569]; DNA methylation [GO:0006306]; gene silencing [GO:0016458]; maintenance of DNA methylation [GO:0010216]; negative regulation of gene expression, epigenetic [GO:0045814]; negative regulation of histone H3-K9 methylation [GO:0051573]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; positive regulation of gene expression [GO:0010628]; positive regulation of histone H3-K4 methylation [GO:0051571]; positive regulation of methylation-dependent chromatin silencing [GO:0090309]; Ras protein signal transduction [GO:0007265]; regulation of cell proliferation [GO:0042127]; transcription, DNA-templated [GO:0006351]	DNA (cytosine-5-)-methyltransferase activity [GO:0003886]; DNA binding [GO:0003677]; DNA-methyltransferase activity [GO:0009008]; methyl-CpG binding [GO:0008327]; promoter-specific chromatin binding [GO:1990841]; RNA binding [GO:0003723]; zinc ion binding [GO:0008270]	nucleoplasm [GO:0005654]; nucleus [GO:0005634]; pericentric heterochromatin [GO:0005721]; replication fork [GO:0005657]
Q9ULA0	DNPEP_HUMAN	Aspartyl aminopeptidase (EC 3.4.11.21)	DNPEP ASPEP DAP	4DYO;	CHEMBL2761;	Q9ULA0;			PF02127;	IPR001948;IPR023358;	peptide metabolic process [GO:0006518]	aminopeptidase activity [GO:0004177]; metalloaminopeptidase activity [GO:0070006]; zinc ion binding [GO:0008270]	blood microparticle [GO:0072562]; cytoplasm [GO:0005737]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P09172	DOPO_HUMAN	Dopamine beta-hydroxylase (EC 1.14.17.1) (Dopamine beta-monooxygenase) [Cleaved into: Soluble dopamine beta-hydroxylase]	DBH	4ZEL;	CHEMBL3102;	P09172;	DB06774;DB00822;DB00988;DB00550;DB00126;	PATHWAY: Catecholamine biosynthesis; (R)-noradrenaline biosynthesis; (R)-noradrenaline from dopamine: step 1/1. {ECO:0000269|PubMed:27148966, ECO:0000269|PubMed:3443096, ECO:0000269|PubMed:8546710}.	PF03712;PF01082;PF03351;	IPR014784;IPR020611;IPR014783;IPR000323;IPR024548;IPR000945;IPR005018;IPR008977;IPR028460;	behavioral response to ethanol [GO:0048149]; blood vessel remodeling [GO:0001974]; catecholamine biosynthetic process [GO:0042423]; chemical synaptic transmission [GO:0007268]; cytokine production [GO:0001816]; dopamine catabolic process [GO:0042420]; fear response [GO:0042596]; glucose homeostasis [GO:0042593]; homoiothermy [GO:0042309]; leukocyte mediated immunity [GO:0002443]; leukocyte migration [GO:0050900]; locomotory behavior [GO:0007626]; maternal behavior [GO:0042711]; memory [GO:0007613]; norepinephrine biosynthetic process [GO:0042421]; octopamine biosynthetic process [GO:0006589]; positive regulation of vasoconstriction [GO:0045907]; regulation of cell proliferation [GO:0042127]; regulation of extrinsic apoptotic signaling pathway [GO:2001236]; response to amphetamine [GO:0001975]; response to pain [GO:0048265]; visual learning [GO:0008542]	catalytic activity [GO:0003824]; copper ion binding [GO:0005507]; dopamine beta-monooxygenase activity [GO:0004500]; L-ascorbic acid binding [GO:0031418]	chromaffin granule lumen [GO:0034466]; chromaffin granule membrane [GO:0042584]; cytoplasm [GO:0005737]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; integral component of membrane [GO:0016021]; membrane [GO:0016020]; secretory granule lumen [GO:0034774]; secretory granule membrane [GO:0030667]; transport vesicle membrane [GO:0030658]
Q8TEK3	DOT1L_HUMAN	Histone-lysine N-methyltransferase, H3 lysine-79 specific (EC 2.1.1.43) (DOT1-like protein) (Histone H3-K79 methyltransferase) (H3-K79-HMTase) (Lysine N-methyltransferase 4)	DOT1L KIAA1814 KMT4	1NW3;2MV7;3QOW;3QOX;3SR4;3SX0;3UWP;4EK9;4EKG;4EKI;4EQZ;4ER0;4ER3;4ER5;4ER6;4ER7;4HRA;4WVL;5DRT;5DRY;5DSX;5DT2;5DTM;5DTQ;5DTR;5JUW;	CHEMBL1795117;	Q8TEK3;			PF08123;	IPR025789;IPR021169;IPR030445;IPR029063;	chromatin silencing at telomere [GO:0006348]; DNA damage checkpoint [GO:0000077]; DNA repair [GO:0006281]; histone H3-K79 methylation [GO:0034729]; positive regulation of cell proliferation [GO:0008284]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; regulation of cell cycle [GO:0051726]; regulation of JAK-STAT cascade [GO:0046425]; regulation of transcription regulatory region DNA binding [GO:2000677]; telomere organization [GO:0032200]	DNA binding [GO:0003677]; histone-lysine N-methyltransferase activity [GO:0018024]; histone methyltransferase activity [GO:0042054]; histone methyltransferase activity (H3-K79 specific) [GO:0031151]; transcription factor binding [GO:0008134]	chromosome, telomeric region [GO:0000781]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; protein complex [GO:0043234]
P16444	DPEP1_HUMAN	Dipeptidase 1 (EC 3.4.13.19) (Dehydropeptidase-I) (Microsomal dipeptidase) (Renal dipeptidase) (hRDP)	DPEP1 MDP RDP	1ITQ;1ITU;	CHEMBL1989;	P16444;	DB01597;DB06211;		PF01244;	IPR000180;IPR028536;IPR032466;IPR008257;	antibiotic metabolic process [GO:0016999]; cellular lactam catabolic process [GO:0072340]; cellular response to calcium ion [GO:0071277]; cellular response to drug [GO:0035690]; cellular response to nitric oxide [GO:0071732]; glutathione metabolic process [GO:0006749]; homocysteine metabolic process [GO:0050667]; leukotriene metabolic process [GO:0006691]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cell migration [GO:0030336]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154]; xenobiotic metabolic process [GO:0006805]	cysteine-type endopeptidase inhibitor activity involved in apoptotic process [GO:0043027]; dipeptidase activity [GO:0016805]; dipeptidyl-peptidase activity [GO:0008239]; GPI anchor binding [GO:0034235]; metallodipeptidase activity [GO:0070573]; metalloexopeptidase activity [GO:0008235]; modified amino acid binding [GO:0072341]; zinc ion binding [GO:0008270]	anchored component of membrane [GO:0031225]; apical part of cell [GO:0045177]; apical plasma membrane [GO:0016324]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; microvillus membrane [GO:0031528]; plasma membrane [GO:0005886]
Q14181	DPOA2_HUMAN	DNA polymerase alpha subunit B (DNA polymerase alpha 70 kDa subunit)	POLA2	2KEB;4E2I;4Y97;5EXR;			DB00851;		PF04042;PF08418;	IPR007185;IPR016722;IPR013627;	DNA replication [GO:0006260]; DNA replication initiation [GO:0006270]; DNA strand elongation involved in DNA replication [GO:0006271]; G1/S transition of mitotic cell cycle [GO:0000082]; protein import into nucleus, translocation [GO:0000060]; telomere maintenance via recombination [GO:0000722]	DNA binding [GO:0003677]; DNA-directed DNA polymerase activity [GO:0003887]; protein heterodimerization activity [GO:0046982]	alpha DNA polymerase:primase complex [GO:0005658]; cytoplasm [GO:0005737]; nucleoplasm [GO:0005654]
P09884	DPOLA_HUMAN	DNA polymerase alpha catalytic subunit (EC 2.7.7.7) (DNA polymerase alpha catalytic subunit p180)	POLA1 POLA	1K0P;1K18;1N5G;4Q5V;4QCL;4Y97;5EXR;5IUD;	CHEMBL1828;	P09884;	DB00242;DB00631;DB01073;DB01280;		PF12254;PF00136;PF03104;PF08996;	IPR006172;IPR017964;IPR006133;IPR006134;IPR024647;IPR023211;IPR029702;IPR012337;IPR015088;	cell proliferation [GO:0008283]; DNA replication [GO:0006260]; DNA replication, synthesis of RNA primer [GO:0006269]; DNA replication initiation [GO:0006270]; DNA strand elongation involved in DNA replication [GO:0006271]; double-strand break repair via nonhomologous end joining [GO:0006303]; G1/S transition of mitotic cell cycle [GO:0000082]; lagging strand elongation [GO:0006273]; leading strand elongation [GO:0006272]; regulation of transcription involved in G1/S transition of mitotic cell cycle [GO:0000083]; telomere maintenance via recombination [GO:0000722]; viral process [GO:0016032]	3'-5' exonuclease activity [GO:0008408]; 4 iron, 4 sulfur cluster binding [GO:0051539]; chromatin binding [GO:0003682]; DNA binding [GO:0003677]; DNA-directed DNA polymerase activity [GO:0003887]; metal ion binding [GO:0046872]; nucleoside binding [GO:0001882]; nucleotide binding [GO:0000166]; protein kinase binding [GO:0019901]	alpha DNA polymerase:primase complex [GO:0005658]; cytoplasm [GO:0005737]; nuclear envelope [GO:0005635]; nuclear matrix [GO:0016363]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P06746	DPOLB_HUMAN	DNA polymerase beta (EC 2.7.7.7) (EC 4.2.99.-)	POLB	1BPX;1BPY;1BPZ;1MQ2;1MQ3;1TV9;1TVA;1ZJM;1ZJN;1ZQA;1ZQB;1ZQC;1ZQD;1ZQE;1ZQF;1ZQG;1ZQH;1ZQI;1ZQJ;1ZQK;1ZQL;1ZQM;1ZQN;1ZQO;1ZQP;1ZQQ;1ZQR;1ZQS;1ZQT;2FMP;2FMQ;2FMS;2I9G;2ISO;2ISP;2P66;2PXI;3C2K;3C2L;3C2M;3GDX;3ISB;3ISC;3ISD;3JPN;3JPO;3JPP;3JPQ;3JPR;3JPS;3JPT;3LK9;3MBY;3OGU;3RH4;3RH5;3RH6;3RJE;3RJF;3RJG;3RJH;3RJI;3RJJ;3RJK;3TFR;3TFS;4DO9;4DOA;4DOB;4DOC;4F5N;4F5O;4F5P;4F5Q;4F5R;4GXI;4GXJ;4GXK;4JWM;4JWN;4KLD;4KLE;4KLF;4KLG;4KLH;4KLI;4KLJ;4KLL;4KLM;4KLO;4KLQ;4KLS;4KLT;4KLU;4LVS;4M2Y;4M47;4M9G;4M9H;4M9J;4M9L;4M9N;4MF2;4MF8;4MFA;4MFC;4MFF;4NLK;4NLN;4NLZ;4NM1;4NM2;4NXZ;4NY8;4O5C;4O5E;4O5K;4O9M;4P2H;4PGQ;4PGX;4PGY;4PH5;4PHA;4PHD;4PHE;4PHP;4PPX;4R63;4R64;4R65;4R66;4RPX;4RPY;4RPZ;4RQ0;4RQ1;4RQ2;4RQ3;4RQ4;4RQ5;4RQ6;4RQ7;4RQ8;4RT2;4RT3;4TUP;4TUQ;4TUR;4TUS;4UAW;4UAY;4UAZ;4UB1;4UB2;4UB3;4UB4;4UB5;4UBB;4UBC;4YMM;4YMN;4YMO;4YN4;4Z6C;4Z6D;4Z6E;4Z6F;5BOL;5BOM;5BPC;5DB6;5DB7;5DB8;5DB9;5DBA;5DBB;5DBC;7ICE;7ICF;7ICG;7ICH;7ICI;7ICJ;7ICK;7ICL;7ICM;7ICN;7ICO;7ICP;7ICQ;7ICR;7ICS;7ICT;7ICU;7ICV;8ICA;8ICB;8ICC;8ICE;8ICF;8ICG;8ICH;8ICI;8ICJ;8ICK;8ICL;8ICM;8ICN;8ICO;8ICP;8ICQ;8ICR;8ICS;8ICT;8ICU;8ICV;8ICW;8ICX;8ICY;8ICZ;9ICA;9ICB;9ICC;9ICE;9ICF;9ICG;9ICH;9ICI;9ICJ;9ICK;9ICL;9ICM;9ICN;9ICO;9ICP;9ICQ;9ICR;9ICS;9ICT;9ICU;9ICV;9ICW;9ICX;9ICY;	CHEMBL2392;	P06746;	DB00987;		PF14792;PF14791;PF10391;PF14716;	IPR002054;IPR019843;IPR010996;IPR028207;IPR018944;IPR022312;IPR002008;IPR003583;IPR027420;IPR029398;	aging [GO:0007568]; base-excision repair [GO:0006284]; base-excision repair, base-free sugar-phosphate removal [GO:0006286]; base-excision repair, DNA ligation [GO:0006288]; base-excision repair, gap-filling [GO:0006287]; cellular response to DNA damage stimulus [GO:0006974]; DNA-dependent DNA replication [GO:0006261]; DNA repair [GO:0006281]; homeostasis of number of cells [GO:0048872]; immunoglobulin heavy chain V-D-J recombination [GO:0071707]; inflammatory response [GO:0006954]; intrinsic apoptotic signaling pathway in response to DNA damage [GO:0008630]; lymph node development [GO:0048535]; neuron apoptotic process [GO:0051402]; pyrimidine dimer repair [GO:0006290]; response to ethanol [GO:0045471]; response to gamma radiation [GO:0010332]; response to hyperoxia [GO:0055093]; salivary gland morphogenesis [GO:0007435]; somatic hypermutation of immunoglobulin genes [GO:0016446]; spleen development [GO:0048536]	damaged DNA binding [GO:0003684]; DNA-(apurinic or apyrimidinic site) lyase activity [GO:0003906]; DNA-directed DNA polymerase activity [GO:0003887]; enzyme binding [GO:0019899]; lyase activity [GO:0016829]; metal ion binding [GO:0046872]; microtubule binding [GO:0008017]	cytoplasm [GO:0005737]; microtubule [GO:0005874]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; protein complex [GO:0043234]; spindle microtubule [GO:0005876]
P27487	DPP4_HUMAN	Dipeptidyl peptidase 4 (EC 3.4.14.5) (ADABP) (Adenosine deaminase complexing protein 2) (ADCP-2) (Dipeptidyl peptidase IV) (DPP IV) (T-cell activation antigen CD26) (TP103) (CD antigen CD26) [Cleaved into: Dipeptidyl peptidase 4 membrane form (Dipeptidyl peptidase IV membrane form); Dipeptidyl peptidase 4 soluble form (Dipeptidyl peptidase IV soluble form)]	DPP4 ADCP2 CD26	1J2E;1N1M;1NU6;1NU8;1PFQ;1R9M;1R9N;1RWQ;1TK3;1TKR;1U8E;1W1I;1WCY;1X70;2AJL;2BGN;2BGR;2BUB;2FJP;2G5P;2G5T;2G63;2HHA;2I03;2I78;2IIT;2IIV;2JID;2OAG;2OGZ;2OLE;2ONC;2OPH;2OQI;2OQV;2P8S;2QJR;2QKY;2QOE;2QT9;2QTB;2RGU;2RIP;3BJM;3C43;3C45;3CCB;3CCC;3D4L;3EIO;3F8S;3G0B;3G0C;3G0D;3G0G;3H0C;3HAB;3HAC;3KWF;3KWJ;3NOX;3O95;3O9V;3OC0;3OPM;3Q0T;3Q8W;3QBJ;3SWW;3SX4;3VJK;3VJL;3VJM;3W2T;3WQH;4A5S;4DSA;4DSZ;4DTC;4G1F;4J3J;4JH0;4KR0;4L72;4LKO;4N8D;4N8E;4PNZ;4PV7;4QZV;5I7U;5ISM;5KBY;	CHEMBL284;	P27487;	DB06203;DB01076;DB08882;DB06655;DB06335;DB01261;DB04876;		PF00930;PF00326;	IPR029058;IPR002471;IPR001375;IPR002469;	behavioral fear response [GO:0001662]; endothelial cell migration [GO:0043542]; locomotory exploration behavior [GO:0035641]; negative regulation of extracellular matrix disassembly [GO:0010716]; positive regulation of cell proliferation [GO:0008284]; psychomotor behavior [GO:0036343]; regulation of cell-cell adhesion mediated by integrin [GO:0033632]; response to hypoxia [GO:0001666]; T cell activation [GO:0042110]; T cell costimulation [GO:0031295]	dipeptidyl-peptidase activity [GO:0008239]; identical protein binding [GO:0042802]; protease binding [GO:0002020]; protein homodimerization activity [GO:0042803]; receptor binding [GO:0005102]; serine-type endopeptidase activity [GO:0004252]; serine-type peptidase activity [GO:0008236]; virus receptor activity [GO:0001618]	apical plasma membrane [GO:0016324]; cell surface [GO:0009986]; endocytic vesicle [GO:0030139]; extracellular exosome [GO:0070062]; focal adhesion [GO:0005925]; integral component of membrane [GO:0016021]; intercellular canaliculus [GO:0046581]; invadopodium membrane [GO:0071438]; lamellipodium [GO:0030027]; lamellipodium membrane [GO:0031258]; lysosomal membrane [GO:0005765]; membrane [GO:0016020]; membrane raft [GO:0045121]; plasma membrane [GO:0005886]
P42658	DPP6_HUMAN	Dipeptidyl aminopeptidase-like protein 6 (DPPX) (Dipeptidyl aminopeptidase-related protein) (Dipeptidyl peptidase 6) (Dipeptidyl peptidase IV-like protein) (Dipeptidyl peptidase VI) (DPP VI)	DPP6	1XFD;					PF00930;PF00326;	IPR029058;IPR001375;IPR002469;	protein localization to plasma membrane [GO:0072659]; regulation of potassium ion transmembrane transport [GO:1901379]	potassium channel regulator activity [GO:0015459]; serine-type peptidase activity [GO:0008236]	extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]; voltage-gated potassium channel complex [GO:0008076]
Q12882	DPYD_HUMAN	Dihydropyrimidine dehydrogenase [NADP(+)] (DHPDHase) (DPD) (EC 1.3.1.2) (Dihydrothymine dehydrogenase) (Dihydrouracil dehydrogenase)	DPYD		CHEMBL3172;	Q12882;	DB01101;DB03147;DB00544;	PATHWAY: Amino-acid biosynthesis; beta-alanine biosynthesis.	PF01180;PF14691;PF07992;	IPR017896;IPR017900;IPR013785;IPR005720;IPR028261;IPR023753;IPR009051;	beta-alanine biosynthetic process [GO:0019483]; purine nucleobase catabolic process [GO:0006145]; pyrimidine nucleobase catabolic process [GO:0006208]; pyrimidine nucleoside catabolic process [GO:0046135]; thymidine catabolic process [GO:0006214]; thymine catabolic process [GO:0006210]; uracil catabolic process [GO:0006212]	4 iron, 4 sulfur cluster binding [GO:0051539]; dihydropyrimidine dehydrogenase (NADP+) activity [GO:0017113]; flavin adenine dinucleotide binding [GO:0050660]; metal ion binding [GO:0046872]; NADP binding [GO:0050661]; protein homodimerization activity [GO:0042803]	cytoplasm [GO:0005737]; cytosol [GO:0005829]
P21728	DRD1_HUMAN	D(1A) dopamine receptor (Dopamine D1 receptor)	DRD1	1OZ5;	CHEMBL2056;	P21728;	DB01614;DB01063;DB00543;DB00714;DB01238;DB06216;DB01200;DB00248;DB00477;DB01239;DB00568;DB00363;DB00988;DB01049;DB00696;DB00800;DB00875;DB00623;DB00502;DB04946;DB00458;DB01235;DB00589;DB00408;DB01403;DB00353;DB06148;DB00805;DB00370;DB00334;DB01267;DB01186;DB00850;DB00397;DB01621;DB00413;DB00420;DB01608;DB00777;DB01224;DB00734;DB00268;DB05271;DB01622;DB00679;DB01623;DB00508;DB00726;DB00246;DB01624;		PF00001;	IPR001413;IPR000929;IPR000276;IPR017452;	activation of adenylate cyclase activity [GO:0007190]; adenylate cyclase-activating dopamine receptor signaling pathway [GO:0007191]; adenylate cyclase-activating G-protein coupled receptor signaling pathway [GO:0007189]; adult walking behavior [GO:0007628]; astrocyte development [GO:0014002]; behavioral fear response [GO:0001662]; behavioral response to cocaine [GO:0048148]; cellular response to catecholamine stimulus [GO:0071870]; cerebral cortex GABAergic interneuron migration [GO:0021853]; conditioned taste aversion [GO:0001661]; dentate gyrus development [GO:0021542]; dopamine metabolic process [GO:0042417]; dopamine transport [GO:0015872]; glucose import [GO:0046323]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; grooming behavior [GO:0007625]; habituation [GO:0046959]; learning [GO:0007612]; long term synaptic depression [GO:0060292]; long-term synaptic potentiation [GO:0060291]; maternal behavior [GO:0042711]; mating behavior [GO:0007617]; memory [GO:0007613]; neuronal action potential [GO:0019228]; operant conditioning [GO:0035106]; peristalsis [GO:0030432]; phospholipase C-activating dopamine receptor signaling pathway [GO:0060158]; positive regulation of adenylate cyclase activity involved in G-protein coupled receptor signaling pathway [GO:0010579]; positive regulation of cAMP biosynthetic process [GO:0030819]; positive regulation of cell migration [GO:0030335]; positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway [GO:0051482]; positive regulation of potassium ion transport [GO:0043268]; positive regulation of release of sequestered calcium ion into cytosol [GO:0051281]; positive regulation of synaptic transmission, glutamatergic [GO:0051968]; prepulse inhibition [GO:0060134]; protein import into nucleus [GO:0006606]; regulation of dopamine metabolic process [GO:0042053]; regulation of dopamine uptake involved in synaptic transmission [GO:0051584]; response to amphetamine [GO:0001975]; response to drug [GO:0042493]; sensitization [GO:0046960]; striatum development [GO:0021756]; synapse assembly [GO:0007416]; synaptic transmission, dopaminergic [GO:0001963]; temperature homeostasis [GO:0001659]; transmission of nerve impulse [GO:0019226]; vasodilation [GO:0042311]; visual learning [GO:0008542]	dopamine binding [GO:0035240]; dopamine neurotransmitter receptor activity [GO:0004952]; dopamine neurotransmitter receptor activity, coupled via Gs [GO:0001588]	ciliary membrane [GO:0060170]; endoplasmic reticulum membrane [GO:0005789]; integral component of plasma membrane [GO:0005887]; nonmotile primary cilium [GO:0031513]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
P14416	DRD2_HUMAN	D(2) dopamine receptor (Dopamine D2 receptor)	DRD2	1I15;5AER;	CHEMBL217;	P14416;	DB01614;DB01063;DB01425;DB00915;DB06288;DB00543;DB00182;DB00714;DB01238;DB06216;DB09128;DB01200;DB09018;DB00490;DB00248;DB06016;DB00477;DB01239;DB00568;DB00363;DB01151;DB01184;DB00988;DB01142;DB00450;DB01049;DB00696;DB00875;DB00623;DB04842;DB00502;DB04946;DB00458;DB01221;DB01235;DB00589;DB00408;DB08815;DB00934;DB01043;DB00933;DB01403;DB01233;DB06148;DB00805;DB00370;DB01618;DB00540;DB00334;DB01267;DB01186;DB00850;DB01100;DB01621;DB00413;DB00433;DB00420;DB01069;DB00777;DB01224;DB00409;DB00734;DB00268;DB05271;DB06144;DB00391;DB04844;DB01622;DB00679;DB01623;DB00831;DB00508;DB00726;DB01392;DB00246;DB01624;		PF00001;	IPR001922;IPR000929;IPR000276;IPR017452;	acid secretion [GO:0046717]; activation of protein kinase activity [GO:0032147]; adenohypophysis development [GO:0021984]; adenylate cyclase-inhibiting dopamine receptor signaling pathway [GO:0007195]; adult walking behavior [GO:0007628]; arachidonic acid secretion [GO:0050482]; associative learning [GO:0008306]; auditory behavior [GO:0031223]; axonogenesis [GO:0007409]; behavioral response to cocaine [GO:0048148]; behavioral response to ethanol [GO:0048149]; branching morphogenesis of a nerve [GO:0048755]; cellular calcium ion homeostasis [GO:0006874]; cerebral cortex GABAergic interneuron migration [GO:0021853]; chemical synaptic transmission, postsynaptic [GO:0099565]; circadian regulation of gene expression [GO:0032922]; dopamine metabolic process [GO:0042417]; feeding behavior [GO:0007631]; G-protein coupled receptor internalization [GO:0002031]; grooming behavior [GO:0007625]; intracellular signal transduction [GO:0035556]; locomotory behavior [GO:0007626]; long-term memory [GO:0007616]; negative regulation of adenylate cyclase activity [GO:0007194]; negative regulation of blood pressure [GO:0045776]; negative regulation of cell migration [GO:0030336]; negative regulation of cell proliferation [GO:0008285]; negative regulation of circadian sleep/wake cycle, sleep [GO:0042321]; negative regulation of cytosolic calcium ion concentration [GO:0051481]; negative regulation of dopamine receptor signaling pathway [GO:0060160]; negative regulation of dopamine secretion [GO:0033602]; negative regulation of innate immune response [GO:0045824]; negative regulation of insulin secretion [GO:0046676]; negative regulation of protein kinase B signaling [GO:0051898]; negative regulation of protein secretion [GO:0050709]; negative regulation of synaptic transmission, glutamatergic [GO:0051967]; negative regulation of voltage-gated calcium channel activity [GO:1901386]; neurological system process involved in regulation of systemic arterial blood pressure [GO:0001976]; neuron-neuron synaptic transmission [GO:0007270]; orbitofrontal cortex development [GO:0021769]; peristalsis [GO:0030432]; phosphatidylinositol metabolic process [GO:0046488]; phospholipase C-activating dopamine receptor signaling pathway [GO:0060158]; pigmentation [GO:0043473]; positive regulation of cytokinesis [GO:0032467]; positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway [GO:0051482]; positive regulation of dopamine uptake involved in synaptic transmission [GO:0051586]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of glial cell-derived neurotrophic factor secretion [GO:1900168]; positive regulation of G-protein coupled receptor protein signaling pathway [GO:0045745]; positive regulation of growth hormone secretion [GO:0060124]; positive regulation of long-term synaptic potentiation [GO:1900273]; positive regulation of multicellular organism growth [GO:0040018]; positive regulation of neuroblast proliferation [GO:0002052]; positive regulation of receptor internalization [GO:0002092]; positive regulation of renal sodium excretion [GO:0035815]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of urine volume [GO:0035810]; prepulse inhibition [GO:0060134]; protein localization [GO:0008104]; regulation of cAMP metabolic process [GO:0030814]; regulation of dopamine secretion [GO:0014059]; regulation of dopamine uptake involved in synaptic transmission [GO:0051584]; regulation of heart rate [GO:0002027]; regulation of locomotion involved in locomotory behavior [GO:0090325]; regulation of long-term neuronal synaptic plasticity [GO:0048169]; regulation of phosphoprotein phosphatase activity [GO:0043666]; regulation of potassium ion transport [GO:0043266]; regulation of sodium ion transport [GO:0002028]; regulation of synapse structural plasticity [GO:0051823]; regulation of synaptic transmission, GABAergic [GO:0032228]; release of sequestered calcium ion into cytosol [GO:0051209]; response to amphetamine [GO:0001975]; response to axon injury [GO:0048678]; response to cocaine [GO:0042220]; response to drug [GO:0042493]; response to histamine [GO:0034776]; response to hypoxia [GO:0001666]; response to inactivity [GO:0014854]; response to iron ion [GO:0010039]; response to light stimulus [GO:0009416]; response to morphine [GO:0043278]; response to nicotine [GO:0035094]; response to toxic substance [GO:0009636]; sensory perception of smell [GO:0007608]; striatum development [GO:0021756]; synapse assembly [GO:0007416]; synaptic transmission, dopaminergic [GO:0001963]; temperature homeostasis [GO:0001659]; visual learning [GO:0008542]; Wnt signaling pathway [GO:0016055]	dopamine binding [GO:0035240]; dopamine neurotransmitter receptor activity, coupled via Gi/Go [GO:0001591]; drug binding [GO:0008144]; identical protein binding [GO:0042802]; potassium channel regulator activity [GO:0015459]	acrosomal vesicle [GO:0001669]; axon [GO:0030424]; axon terminus [GO:0043679]; ciliary membrane [GO:0060170]; dendrite [GO:0030425]; dendritic spine [GO:0043197]; endocytic vesicle [GO:0030139]; integral component of plasma membrane [GO:0005887]; intracellular [GO:0005622]; lateral plasma membrane [GO:0016328]; nonmotile primary cilium [GO:0031513]; perikaryon [GO:0043204]; plasma membrane [GO:0005886]; postsynaptic density [GO:0014069]; sperm flagellum [GO:0036126]; synaptic vesicle membrane [GO:0030672]
P35462	DRD3_HUMAN	D(3) dopamine receptor (Dopamine D3 receptor)	DRD3	3PBL;	CHEMBL234;	P35462;	DB06288;DB00543;DB00714;DB01238;DB06216;DB01200;DB00248;DB09014;DB06016;DB00477;DB01239;DB00363;DB01184;DB00988;DB00502;DB04946;DB01235;DB00589;DB00408;DB01403;DB06148;DB00370;DB00334;DB01267;DB01186;DB01100;DB00413;DB01224;DB00409;DB00734;DB00268;DB05271;DB00391;DB01392;DB00246;		PF00001;	IPR001620;IPR000929;IPR000276;IPR017452;	acid secretion [GO:0046717]; adenylate cyclase-activating dopamine receptor signaling pathway [GO:0007191]; adenylate cyclase-inhibiting dopamine receptor signaling pathway [GO:0007195]; arachidonic acid secretion [GO:0050482]; behavioral response to cocaine [GO:0048148]; cellular calcium ion homeostasis [GO:0006874]; circadian regulation of gene expression [GO:0032922]; dopamine metabolic process [GO:0042417]; gastric emptying [GO:0035483]; G-protein coupled receptor internalization [GO:0002031]; G-protein coupled receptor signaling pathway [GO:0007186]; learning [GO:0007612]; learning or memory [GO:0007611]; locomotory behavior [GO:0007626]; musculoskeletal movement, spinal reflex action [GO:0050883]; negative regulation of adenylate cyclase activity [GO:0007194]; negative regulation of blood pressure [GO:0045776]; negative regulation of dopamine receptor signaling pathway [GO:0060160]; negative regulation of oligodendrocyte differentiation [GO:0048715]; negative regulation of protein kinase B signaling [GO:0051898]; negative regulation of protein secretion [GO:0050709]; negative regulation of sodium:proton antiporter activity [GO:0032416]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; positive regulation of cell proliferation [GO:0008284]; positive regulation of cytokinesis [GO:0032467]; positive regulation of dopamine receptor signaling pathway [GO:0060161]; positive regulation of mitotic nuclear division [GO:0045840]; positive regulation of renal sodium excretion [GO:0035815]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; prepulse inhibition [GO:0060134]; regulation of blood volume by renin-angiotensin [GO:0002016]; regulation of cAMP metabolic process [GO:0030814]; regulation of circadian sleep/wake cycle, sleep [GO:0045187]; regulation of dopamine secretion [GO:0014059]; regulation of dopamine uptake involved in synaptic transmission [GO:0051584]; regulation of lipid metabolic process [GO:0019216]; regulation of locomotion involved in locomotory behavior [GO:0090325]; regulation of multicellular organism growth [GO:0040014]; response to amphetamine [GO:0001975]; response to cocaine [GO:0042220]; response to drug [GO:0042493]; response to histamine [GO:0034776]; response to morphine [GO:0043278]; social behavior [GO:0035176]; synaptic transmission, dopaminergic [GO:0001963]; visual learning [GO:0008542]	dopamine binding [GO:0035240]; dopamine neurotransmitter receptor activity, coupled via Gi/Go [GO:0001591]; dopamine neurotransmitter receptor activity, coupled via Gs [GO:0001588]; drug binding [GO:0008144]	apical part of cell [GO:0045177]; cell projection [GO:0042995]; endocytic vesicle [GO:0030139]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P21917	DRD4_HUMAN	D(4) dopamine receptor (D(2C) dopamine receptor) (Dopamine D4 receptor)	DRD4		CHEMBL219;	P21917;	DB00543;DB00714;DB01238;DB06216;DB01200;DB00248;DB00477;DB00363;DB00988;DB04908;DB04946;DB01235;DB00589;DB00408;DB01403;DB00334;DB01267;DB01186;DB00413;DB00420;DB00777;DB01224;DB00409;DB00734;DB00268;DB05271;DB00246;		PF00001;	IPR002185;IPR000929;IPR000276;IPR017452;	activation of MAPK activity [GO:0000187]; adenylate cyclase-inhibiting dopamine receptor signaling pathway [GO:0007195]; adult locomotory behavior [GO:0008344]; arachidonic acid secretion [GO:0050482]; behavioral fear response [GO:0001662]; behavioral response to cocaine [GO:0048148]; behavioral response to ethanol [GO:0048149]; cellular calcium ion homeostasis [GO:0006874]; dopamine metabolic process [GO:0042417]; dopamine receptor signaling pathway [GO:0007212]; fear response [GO:0042596]; inhibitory postsynaptic potential [GO:0060080]; negative regulation of adenylate cyclase activity [GO:0007194]; negative regulation of cAMP biosynthetic process [GO:0030818]; negative regulation of protein secretion [GO:0050709]; negative regulation of voltage-gated calcium channel activity [GO:1901386]; positive regulation of dopamine uptake involved in synaptic transmission [GO:0051586]; positive regulation of kinase activity [GO:0033674]; positive regulation of sodium:proton antiporter activity [GO:0032417]; regulation of circadian rhythm [GO:0042752]; regulation of dopamine metabolic process [GO:0042053]; response to amphetamine [GO:0001975]; response to histamine [GO:0034776]; rhythmic process [GO:0048511]; social behavior [GO:0035176]; synaptic transmission, dopaminergic [GO:0001963]	dopamine binding [GO:0035240]; dopamine neurotransmitter receptor activity [GO:0004952]; dopamine neurotransmitter receptor activity, coupled via Gi/Go [GO:0001591]; dopamine neurotransmitter receptor activity, coupled via Gs [GO:0001588]; drug binding [GO:0008144]; identical protein binding [GO:0042802]; potassium channel regulator activity [GO:0015459]; SH3 domain binding [GO:0017124]	integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]; postsynapse [GO:0098794]
P21918	DRD5_HUMAN	D(1B) dopamine receptor (D(5) dopamine receptor) (D1beta dopamine receptor) (Dopamine D5 receptor)	DRD5 DRD1B DRD1L2		CHEMBL1850;	P21918;	DB00714;DB01238;DB01200;DB00248;DB00477;DB00568;DB00988;DB00696;DB00800;DB00458;DB01235;DB00589;DB00408;DB01403;DB06148;DB00370;DB00334;DB01186;DB00413;DB01224;DB00268;DB05271;DB00726;DB00246;DB01624;		PF00001;	IPR000497;IPR000929;IPR000276;IPR017452;	activation of adenylate cyclase activity [GO:0007190]; adenylate cyclase-activating dopamine receptor signaling pathway [GO:0007191]; adenylate cyclase-activating G-protein coupled receptor signaling pathway [GO:0007189]; associative learning [GO:0008306]; cellular calcium ion homeostasis [GO:0006874]; cellular response to catecholamine stimulus [GO:0071870]; chemical synaptic transmission [GO:0007268]; learning [GO:0007612]; long term synaptic depression [GO:0060292]; negative regulation of blood pressure [GO:0045776]; negative regulation of NAD(P)H oxidase activity [GO:0033861]; norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure [GO:0001994]; phospholipase C-activating dopamine receptor signaling pathway [GO:0060158]; positive regulation of adenylate cyclase activity [GO:0045762]; positive regulation of adenylate cyclase activity involved in G-protein coupled receptor signaling pathway [GO:0010579]; reactive oxygen species metabolic process [GO:0072593]; regulation of female receptivity [GO:0045924]; regulation of systemic arterial blood pressure by vasopressin [GO:0001992]; response to amphetamine [GO:0001975]; response to cocaine [GO:0042220]; sensitization [GO:0046960]; synaptic transmission, dopaminergic [GO:0001963]; transmission of nerve impulse [GO:0019226]; wound healing [GO:0042060]	dopamine binding [GO:0035240]; dopamine neurotransmitter receptor activity [GO:0004952]; dopamine neurotransmitter receptor activity, coupled via Gs [GO:0001588]	brush border membrane [GO:0031526]; ciliary membrane [GO:0060170]; integral component of plasma membrane [GO:0005887]; nonmotile primary cilium [GO:0031513]; plasma membrane [GO:0005886]
P23919	DTYMK_HUMAN	Thymidylate kinase (EC 2.7.4.9) (dTMP kinase)	DTYMK CDC8 TMPK TYMK	1E2D;1E2E;1E2F;1E2G;1E2Q;1E98;1E99;1E9A;1E9B;1E9C;1E9D;1E9E;1E9F;1NMX;1NMY;1NMZ;1NN0;1NN1;1NN3;1NN5;2XX3;	CHEMBL4388;	P23919;		PATHWAY: Pyrimidine metabolism; dTTP biosynthesis.		IPR027417;IPR018095;IPR018094;	cell cycle [GO:0007049]; cell proliferation [GO:0008283]; cellular response to growth factor stimulus [GO:0071363]; dTDP biosynthetic process [GO:0006233]; dTTP biosynthetic process [GO:0006235]; dUDP biosynthetic process [GO:0006227]; myoblast differentiation [GO:0045445]; nucleobase-containing small molecule interconversion [GO:0015949]; response to cadmium ion [GO:0046686]; response to estrogen [GO:0043627]	ATP binding [GO:0005524]; nucleoside phosphate kinase activity [GO:0050145]; thymidylate kinase activity [GO:0004798]; uridylate kinase activity [GO:0009041]	cytosol [GO:0005829]; mitochondrial intermembrane space [GO:0005758]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]
P33316	DUT_HUMAN	Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial (dUTPase) (EC 3.6.1.23) (dUTP pyrophosphatase)	DUT	1Q5H;1Q5U;2HQU;3ARA;3ARN;3EHW;4MZ5;4MZ6;	CHEMBL5203;	P33316;		PATHWAY: Pyrimidine metabolism; dUMP biosynthesis; dUMP from dCTP (dUTP route): step 2/2.	PF00692;	IPR029054;IPR008180;IPR008181;IPR033704;	DNA replication [GO:0006260]; dUMP biosynthetic process [GO:0006226]; dUTP catabolic process [GO:0046081]; nucleobase-containing compound metabolic process [GO:0006139]; pyrimidine nucleoside biosynthetic process [GO:0046134]	dUTP diphosphatase activity [GO:0004170]; magnesium ion binding [GO:0000287]; poly(A) RNA binding [GO:0044822]	extracellular exosome [GO:0070062]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P00374	DYR_HUMAN	Dihydrofolate reductase (EC 1.5.1.3)	DHFR	1BOZ;1DHF;1DLR;1DLS;1DRF;1HFP;1HFQ;1HFR;1KMS;1KMV;1MVS;1MVT;1OHJ;1OHK;1PD8;1PD9;1PDB;1S3U;1S3V;1S3W;1U71;1U72;1YHO;2C2S;2C2T;2DHF;2W3A;2W3B;2W3M;3EIG;3F8Y;3F8Z;3F91;3FS6;3GHC;3GHV;3GHW;3GI2;3GYF;3L3R;3N0H;3NTZ;3NU0;3NXO;3NXR;3NXT;3NXV;3NXX;3NXY;3NZD;3OAF;3S3V;3S7A;4DDR;4G95;4KAK;4KBN;4KD7;4KEB;4KFJ;4M6J;4M6K;4M6L;4QHV;4QJC;	CHEMBL202;	P00374;	DB00798;DB00563;DB00642;DB06813;DB01131;DB00205;DB00440;DB01157;	PATHWAY: Cofactor biosynthesis; tetrahydrofolate biosynthesis; 5,6,7,8-tetrahydrofolate from 7,8-dihydrofolate: step 1/1.	PF00186;	IPR012259;IPR024072;IPR017925;IPR001796;	axon regeneration [GO:0031103]; dihydrofolate metabolic process [GO:0046452]; folic acid metabolic process [GO:0046655]; G1/S transition of mitotic cell cycle [GO:0000082]; glycine biosynthetic process [GO:0006545]; nucleotide biosynthetic process [GO:0009165]; one-carbon metabolic process [GO:0006730]; oxidation-reduction process [GO:0055114]; positive regulation of nitric-oxide synthase activity [GO:0051000]; regulation of removal of superoxide radicals [GO:2000121]; regulation of transcription involved in G1/S transition of mitotic cell cycle [GO:0000083]; response to methotrexate [GO:0031427]; tetrahydrobiopterin biosynthetic process [GO:0006729]; tetrahydrofolate biosynthetic process [GO:0046654]; tetrahydrofolate metabolic process [GO:0046653]	dihydrofolate reductase activity [GO:0004146]; drug binding [GO:0008144]; folate reductase activity [GO:0033560]; folic acid binding [GO:0005542]; methotrexate binding [GO:0051870]; mRNA binding [GO:0003729]; NADPH binding [GO:0070402]	cytosol [GO:0005829]; nucleoplasm [GO:0005654]
P43003	EAA1_HUMAN	Excitatory amino acid transporter 1 (Sodium-dependent glutamate/aspartate transporter 1) (GLAST-1) (Solute carrier family 1 member 3)	SLC1A3 EAAT1 GLAST GLAST1		CHEMBL3085;	P43003;			PF00375;	IPR001991;IPR018107;	auditory behavior [GO:0031223]; cell morphogenesis involved in neuron differentiation [GO:0048667]; chemical synaptic transmission [GO:0007268]; cranial nerve development [GO:0021545]; D-aspartate import [GO:0070779]; gamma-aminobutyric acid biosynthetic process [GO:0009449]; glutamate biosynthetic process [GO:0006537]; glutamate secretion [GO:0014047]; ion transport [GO:0006811]; L-glutamate import [GO:0051938]; neuromuscular process controlling balance [GO:0050885]; neurotransmitter uptake [GO:0001504]; positive regulation of synaptic transmission [GO:0050806]; response to antibiotic [GO:0046677]; response to drug [GO:0042493]; response to light stimulus [GO:0009416]; response to wounding [GO:0009611]; sensory perception of sound [GO:0007605]	amino acid binding [GO:0016597]; amino acid transmembrane transporter activity [GO:0015171]; glutamate binding [GO:0016595]; high-affinity glutamate transmembrane transporter activity [GO:0005314]; L-glutamate transmembrane transporter activity [GO:0005313]	cell surface [GO:0009986]; fibril [GO:0043205]; integral component of membrane [GO:0016021]; membrane [GO:0016020]; neuronal cell body [GO:0043025]; neuron projection [GO:0043005]; plasma membrane [GO:0005886]
P43004	EAA2_HUMAN	Excitatory amino acid transporter 2 (Glutamate/aspartate transporter II) (Sodium-dependent glutamate/aspartate transporter 2) (Solute carrier family 1 member 2)	SLC1A2 EAAT2 GLT1		CHEMBL4973;	P43004;			PF00375;	IPR001991;IPR018107;	adult behavior [GO:0030534]; cellular response to extracellular stimulus [GO:0031668]; chemical synaptic transmission [GO:0007268]; D-aspartate import [GO:0070779]; glutamate secretion [GO:0014047]; ion transport [GO:0006811]; L-glutamate import [GO:0051938]; multicellular organism aging [GO:0010259]; multicellular organism growth [GO:0035264]; positive regulation of glucose import [GO:0046326]; response to amino acid [GO:0043200]; response to drug [GO:0042493]; response to wounding [GO:0009611]; telencephalon development [GO:0021537]; visual behavior [GO:0007632]	amino acid transmembrane transporter activity [GO:0015171]; glutamate:sodium symporter activity [GO:0015501]; high-affinity glutamate transmembrane transporter activity [GO:0005314]; L-glutamate transmembrane transporter activity [GO:0005313]	axolemma [GO:0030673]; cell surface [GO:0009986]; integral component of membrane [GO:0016021]; membrane [GO:0016020]; plasma membrane [GO:0005886]
P43005	EAA3_HUMAN	Excitatory amino acid transporter 3 (Excitatory amino-acid carrier 1) (Neuronal and epithelial glutamate transporter) (Sodium-dependent glutamate/aspartate transporter 3) (Solute carrier family 1 member 1)	SLC1A1 EAAC1 EAAT3		CHEMBL2721;	P43005;	DB00128;DB00230;		PF00375;	IPR001991;IPR018107;	chemical synaptic transmission [GO:0007268]; cysteine transport [GO:0042883]; D-aspartate import [GO:0070779]; glutamate secretion [GO:0014047]; ion transport [GO:0006811]; L-glutamate import [GO:0051938]; L-glutamate transmembrane transport [GO:0089711]; positive regulation of heart rate [GO:0010460]; protein homooligomerization [GO:0051260]	amino acid transmembrane transporter activity [GO:0015171]; cysteine transmembrane transporter activity [GO:0033229]; glutamate:sodium symporter activity [GO:0015501]; glutamate binding [GO:0016595]; high-affinity glutamate transmembrane transporter activity [GO:0005314]; L-glutamate transmembrane transporter activity [GO:0005313]	apical plasma membrane [GO:0016324]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]
P48664	EAA4_HUMAN	Excitatory amino acid transporter 4 (Sodium-dependent glutamate/aspartate transporter) (Solute carrier family 1 member 6)	SLC1A6 EAAT4		CHEMBL3173;				PF00375;	IPR001991;IPR018107;	aspartate transport [GO:0015810]; chemical synaptic transmission [GO:0007268]; glutamate secretion [GO:0014047]; ion transport [GO:0006811]; L-glutamate transport [GO:0015813]; regulation of membrane potential [GO:0042391]	amino acid transmembrane transporter activity [GO:0015171]; high-affinity glutamate transmembrane transporter activity [GO:0005314]; L-aspartate transmembrane transporter activity [GO:0015183]	Golgi apparatus [GO:0005794]; integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]
O00341	EAA5_HUMAN	Excitatory amino acid transporter 5 (Retinal glutamate transporter) (Solute carrier family 1 member 7)	SLC1A7 EAAT5		CHEMBL4390;				PF00375;	IPR001991;IPR018107;	dicarboxylic acid transport [GO:0006835]; glutamate secretion [GO:0014047]; ion transport [GO:0006811]	amino acid transmembrane transporter activity [GO:0015171]; high-affinity glutamate transmembrane transporter activity [GO:0005314]; L-glutamate transmembrane transporter activity [GO:0005313]	integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]
P40939	ECHA_HUMAN	Trifunctional enzyme subunit alpha, mitochondrial (78 kDa gastrin-binding protein) (TP-alpha) [Includes: Long-chain enoyl-CoA hydratase (EC 4.2.1.17); Long chain 3-hydroxyacyl-CoA dehydrogenase (EC 1.1.1.211)]	HADHA HADH					PATHWAY: Lipid metabolism; fatty acid beta-oxidation.	PF00725;PF02737;PF00378;	IPR006180;IPR006176;IPR006108;IPR008927;IPR013328;IPR029045;IPR001753;IPR018376;IPR012803;IPR016040;	cardiolipin acyl-chain remodeling [GO:0035965]; fatty acid beta-oxidation [GO:0006635]; response to drug [GO:0042493]; response to insulin [GO:0032868]	3-hydroxyacyl-CoA dehydrogenase activity [GO:0003857]; acetyl-CoA C-acetyltransferase activity [GO:0003985]; enoyl-CoA hydratase activity [GO:0004300]; fatty-acyl-CoA binding [GO:0000062]; long-chain-3-hydroxyacyl-CoA dehydrogenase activity [GO:0016509]; long-chain-enoyl-CoA hydratase activity [GO:0016508]; NAD binding [GO:0051287]	extracellular matrix [GO:0031012]; mitochondrial fatty acid beta-oxidation multienzyme complex [GO:0016507]; mitochondrial inner membrane [GO:0005743]; mitochondrial nucleoid [GO:0042645]; mitochondrion [GO:0005739]
Q08426	ECHP_HUMAN	Peroxisomal bifunctional enzyme (PBE) (PBFE) [Includes: Enoyl-CoA hydratase/3,2-trans-enoyl-CoA isomerase (EC 4.2.1.17) (EC 5.3.3.8); 3-hydroxyacyl-CoA dehydrogenase (EC 1.1.1.35)]	EHHADH ECHD					PATHWAY: Lipid metabolism; fatty acid beta-oxidation.	PF00725;PF02737;PF00378;	IPR006180;IPR006176;IPR006108;IPR008927;IPR013328;IPR029045;IPR001753;IPR018376;IPR016040;	cellular lipid metabolic process [GO:0044255]; fatty acid beta-oxidation [GO:0006635]; internal protein amino acid acetylation [GO:0006475]	3-hydroxyacyl-CoA dehydrogenase activity [GO:0003857]; dodecenoyl-CoA delta-isomerase activity [GO:0004165]; enoyl-CoA hydratase activity [GO:0004300]; enzyme binding [GO:0019899]; long-chain-enoyl-CoA hydratase activity [GO:0016508]; receptor binding [GO:0005102]	cytosol [GO:0005829]; mitochondrion [GO:0005739]; peroxisomal matrix [GO:0005782]; peroxisome [GO:0005777]
P12724	ECP_HUMAN	Eosinophil cationic protein (ECP) (EC 3.1.27.-) (Ribonuclease 3) (RNase 3)	RNASE3 ECP RNS3	1DYT;1H1H;1QMT;2KB5;2LVZ;4A2O;4A2Y;4OWZ;4OXB;4OXF;4X08;			DB01411;		PF00074;	IPR001427;IPR023411;IPR023412;	antibacterial humoral response [GO:0019731]; defense response to Gram-positive bacterium [GO:0050830]; innate immune response in mucosa [GO:0002227]; RNA catabolic process [GO:0006401]	endonuclease activity [GO:0004519]; nucleic acid binding [GO:0003676]; ribonuclease activity [GO:0004540]	extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]
P25101	EDNRA_HUMAN	Endothelin-1 receptor (Endothelin A receptor) (ET-A) (ETA-R) (hET-AR)	EDNRA ETA ETRA		CHEMBL252;	P25101;	DB00945;DB06403;DB00559;DB08932;DB06268;		PF00001;	IPR000499;IPR002175;IPR000276;IPR017452;	activation of adenylate cyclase activity [GO:0007190]; activation of phospholipase C activity [GO:0007202]; artery smooth muscle contraction [GO:0014824]; cell proliferation [GO:0008283]; enteric nervous system development [GO:0048484]; glucose transport [GO:0015758]; G-protein coupled receptor signaling pathway [GO:0007186]; head development [GO:0060322]; heart development [GO:0007507]; in utero embryonic development [GO:0001701]; negative regulation of cAMP biosynthetic process [GO:0030818]; neural crest cell development [GO:0014032]; patterning of blood vessels [GO:0001569]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; regulation of blood pressure [GO:0008217]; respiratory gaseous exchange [GO:0007585]; response to hypoxia [GO:0001666]; signal transduction [GO:0007165]; smooth muscle contraction [GO:0006939]; vasoconstriction [GO:0042310]	endothelin receptor activity [GO:0004962]; phosphatidylinositol phospholipase C activity [GO:0004435]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P24530	EDNRB_HUMAN	Endothelin B receptor (ET-B) (ET-BR) (Endothelin receptor non-selective type)	EDNRB ETRB		CHEMBL1785;	P24530;	DB06403;DB00559;DB08932;DB06268;		PF00001;	IPR000499;IPR001112;IPR000276;IPR017452;	aging [GO:0007568]; cell surface receptor signaling pathway [GO:0007166]; cellular response to lipopolysaccharide [GO:0071222]; cGMP-mediated signaling [GO:0019934]; endothelin receptor signaling pathway [GO:0086100]; enteric nervous system development [GO:0048484]; enteric smooth muscle cell differentiation [GO:0035645]; epithelial fluid transport [GO:0042045]; macrophage chemotaxis [GO:0048246]; melanocyte differentiation [GO:0030318]; negative regulation of adenylate cyclase activity [GO:0007194]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cellular protein metabolic process [GO:0032269]; negative regulation of neuron maturation [GO:0014043]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; nervous system development [GO:0007399]; neural crest cell migration [GO:0001755]; peripheral nervous system development [GO:0007422]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; positive regulation of cell proliferation [GO:0008284]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of penile erection [GO:0060406]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of renal sodium excretion [GO:0035815]; positive regulation of urine volume [GO:0035810]; posterior midgut development [GO:0007497]; regulation of blood pressure [GO:0008217]; regulation of epithelial cell proliferation [GO:0050678]; regulation of fever generation [GO:0031620]; regulation of pH [GO:0006885]; regulation of sensory perception of pain [GO:0051930]; response to organic cyclic compound [GO:0014070]; response to pain [GO:0048265]; sensory perception of pain [GO:0019233]; vasoconstriction [GO:0042310]; vasodilation [GO:0042311]; vein smooth muscle contraction [GO:0014826]	endothelin receptor activity [GO:0004962]; peptide hormone binding [GO:0017046]	integral component of plasma membrane [GO:0005887]; membrane raft [GO:0045121]; nuclear membrane [GO:0031965]; plasma membrane [GO:0005886]
Q15075	EEA1_HUMAN	Early endosome antigen 1 (Endosome-associated protein p162) (Zinc finger FYVE domain-containing protein 2)	EEA1 ZFYVE2	1HYI;1HYJ;1JOC;3MJH;					PF01363;	IPR007087;IPR000306;IPR017455;IPR011011;IPR013083;	early endosome to late endosome transport [GO:0045022]; endocytosis [GO:0006897]; synaptic vesicle to endosome fusion [GO:0016189]; vesicle fusion [GO:0006906]; viral RNA genome replication [GO:0039694]	1-phosphatidylinositol binding [GO:0005545]; calmodulin binding [GO:0005516]; GTP-dependent protein binding [GO:0030742]; protein homodimerization activity [GO:0042803]; zinc ion binding [GO:0008270]	axonal spine [GO:0044308]; cytoplasm [GO:0005737]; cytoplasmic vesicle [GO:0031410]; cytosol [GO:0005829]; early endosome [GO:0005769]; early endosome membrane [GO:0031901]; extracellular exosome [GO:0070062]; extrinsic component of plasma membrane [GO:0019897]; membrane [GO:0016020]; presynapse [GO:0098793]; recycling endosome [GO:0055037]; serine-pyruvate aminotransferase complex [GO:0005969]
P00533	EGFR_HUMAN	Epidermal growth factor receptor (EC 2.7.10.1) (Proto-oncogene c-ErbB-1) (Receptor tyrosine-protein kinase erbB-1)	EGFR ERBB ERBB1 HER1	1DNQ;1DNR;1IVO;1M14;1M17;1MOX;1NQL;1XKK;1YY9;1Z9I;2EB2;2EB3;2EXP;2EXQ;2GS2;2GS6;2GS7;2ITN;2ITO;2ITP;2ITQ;2ITT;2ITU;2ITV;2ITW;2ITX;2ITY;2ITZ;2J5E;2J5F;2J6M;2JIT;2JIU;2JIV;2KS1;2M0B;2M20;2N5S;2RF9;2RFD;2RFE;2RGP;3B2U;3B2V;3BEL;3BUO;3C09;3G5V;3G5Y;3GOP;3GT8;3IKA;3LZB;3NJP;3OB2;3OP0;3P0Y;3PFV;3POZ;3QWQ;3UG1;3UG2;3VJN;3VJO;3VRP;3VRR;3W2O;3W2P;3W2Q;3W2R;3W2S;3W32;3W33;4G5J;4G5P;4HJO;4I1Z;4I20;4I21;4I22;4I23;4I24;4JQ7;4JQ8;4JR3;4JRV;4KRL;4KRM;4KRO;4KRP;4LI5;4LL0;4LQM;4LRM;4R3P;4R3R;4R5S;4RIW;4RIX;4RIY;4RJ4;4RJ5;4RJ6;4RJ7;4RJ8;4TKS;4UIP;4UV7;4WD5;4WKQ;4WRG;4ZAU;4ZJV;4ZSE;5C8K;5C8M;5C8N;5CAL;5CAN;5CAO;5CAP;5CAQ;5CAS;5CAU;5CAV;5CNN;5CNO;5CZH;5CZI;5D41;5EDP;5EDQ;5EDR;5EM5;5EM6;5EM7;5EM8;5FED;5FEE;5FEQ;5HCX;5HCZ;5HG5;5HG7;5HG8;5HG9;5HIB;5HIC;5J9Z;5JEB;	CHEMBL203;	P00533;	DB08916;DB00002;DB00530;DB00317;DB01259;DB00281;DB09559;DB09330;DB01269;DB00072;DB05294;		PF00757;PF14843;PF07714;PF01030;	IPR006211;IPR006212;IPR032778;IPR009030;IPR011009;IPR032675;IPR000719;IPR017441;IPR000494;IPR001245;IPR008266;IPR020635;IPR016245;	activation of phospholipase A2 activity by calcium-mediated signaling [GO:0043006]; activation of phospholipase C activity [GO:0007202]; astrocyte activation [GO:0048143]; cell proliferation [GO:0008283]; cell surface receptor signaling pathway [GO:0007166]; cellular response to amino acid stimulus [GO:0071230]; cellular response to dexamethasone stimulus [GO:0071549]; cellular response to drug [GO:0035690]; cellular response to epidermal growth factor stimulus [GO:0071364]; cellular response to estradiol stimulus [GO:0071392]; cellular response to mechanical stimulus [GO:0071260]; cerebral cortex cell migration [GO:0021795]; circadian rhythm [GO:0007623]; digestive tract morphogenesis [GO:0048546]; diterpenoid metabolic process [GO:0016101]; embryonic placenta development [GO:0001892]; epidermal growth factor receptor signaling pathway [GO:0007173]; ERBB2 signaling pathway [GO:0038128]; eyelid development in camera-type eye [GO:0061029]; hair follicle development [GO:0001942]; hydrogen peroxide metabolic process [GO:0042743]; learning or memory [GO:0007611]; liver regeneration [GO:0097421]; lung development [GO:0030324]; magnesium ion homeostasis [GO:0010960]; MAPK cascade [GO:0000165]; midgut development [GO:0007494]; morphogenesis of an epithelial fold [GO:0060571]; negative regulation of apoptotic process [GO:0043066]; negative regulation of epidermal growth factor receptor signaling pathway [GO:0042059]; negative regulation of mitotic cell cycle [GO:0045930]; negative regulation of protein catabolic process [GO:0042177]; neuron projection morphogenesis [GO:0048812]; ossification [GO:0001503]; ovulation cycle [GO:0042698]; phosphatidylinositol-mediated signaling [GO:0048015]; positive regulation of bone resorption [GO:0045780]; positive regulation of catenin import into nucleus [GO:0035413]; positive regulation of cell growth [GO:0030307]; positive regulation of cell migration [GO:0030335]; positive regulation of cell proliferation [GO:0008284]; positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle [GO:0031659]; positive regulation of DNA repair [GO:0045739]; positive regulation of DNA replication [GO:0045740]; positive regulation of epithelial cell proliferation [GO:0050679]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of fibroblast proliferation [GO:0048146]; positive regulation of inflammatory response [GO:0050729]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; positive regulation of phosphorylation [GO:0042327]; positive regulation of production of miRNAs involved in gene silencing by miRNA [GO:1903800]; positive regulation of prolactin secretion [GO:1902722]; positive regulation of protein kinase B signaling [GO:0051897]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of smooth muscle cell proliferation [GO:0048661]; positive regulation of superoxide anion generation [GO:0032930]; positive regulation of synaptic transmission, glutamatergic [GO:0051968]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of vasoconstriction [GO:0045907]; positive regulation of vasodilation [GO:0045909]; protein autophosphorylation [GO:0046777]; protein insertion into membrane [GO:0051205]; regulation of cell motility [GO:2000145]; regulation of nitric-oxide synthase activity [GO:0050999]; regulation of peptidyl-tyrosine phosphorylation [GO:0050730]; regulation of phosphatidylinositol 3-kinase signaling [GO:0014066]; response to calcium ion [GO:0051592]; response to cobalamin [GO:0033590]; response to hydroxyisoflavone [GO:0033594]; response to osmotic stress [GO:0006970]; response to oxidative stress [GO:0006979]; response to stress [GO:0006950]; response to UV-A [GO:0070141]; salivary gland morphogenesis [GO:0007435]; signal transduction [GO:0007165]; single organismal cell-cell adhesion [GO:0016337]; tongue development [GO:0043586]; translation [GO:0006412]; wound healing [GO:0042060]	actin filament binding [GO:0051015]; ATP binding [GO:0005524]; cadherin binding involved in cell-cell adhesion [GO:0098641]; chromatin binding [GO:0003682]; double-stranded DNA binding [GO:0003690]; enzyme binding [GO:0019899]; epidermal growth factor-activated receptor activity [GO:0005006]; glycoprotein binding [GO:0001948]; identical protein binding [GO:0042802]; MAP kinase kinase kinase activity [GO:0004709]; phosphatidylinositol-4,5-bisphosphate 3-kinase activity [GO:0046934]; protein heterodimerization activity [GO:0046982]; protein phosphatase binding [GO:0019903]; protein tyrosine kinase activity [GO:0004713]; Ras guanyl-nucleotide exchange factor activity [GO:0005088]; receptor signaling protein tyrosine kinase activity [GO:0004716]; transmembrane receptor protein tyrosine kinase activity [GO:0004714]; transmembrane signaling receptor activity [GO:0004888]; ubiquitin protein ligase binding [GO:0031625]	apical plasma membrane [GO:0016324]; basolateral plasma membrane [GO:0016323]; cell-cell adherens junction [GO:0005913]; cell surface [GO:0009986]; cytoplasm [GO:0005737]; early endosome membrane [GO:0031901]; endocytic vesicle [GO:0030139]; endoplasmic reticulum membrane [GO:0005789]; endosome [GO:0005768]; endosome membrane [GO:0010008]; extracellular space [GO:0005615]; focal adhesion [GO:0005925]; Golgi membrane [GO:0000139]; integral component of membrane [GO:0016021]; membrane [GO:0016020]; membrane raft [GO:0045121]; multivesicular body, internal vesicle lumen [GO:0097489]; nuclear membrane [GO:0031965]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]; Shc-EGFR complex [GO:0070435]; synapse [GO:0045202]
P01133	EGF_HUMAN	Pro-epidermal growth factor (EGF) [Cleaved into: Epidermal growth factor (Urogastrone)]	EGF	1IVO;1JL9;1NQL;1P9J;2KV4;3NJP;	CHEMBL5734;		DB00364;		PF00008;PF07645;PF00058;	IPR011042;IPR001881;IPR013032;IPR000742;IPR000152;IPR018097;IPR023413;IPR009030;IPR000033;IPR016317;	activation of MAPK activity [GO:0000187]; activation of MAPKK activity [GO:0000186]; angiogenesis [GO:0001525]; branching morphogenesis of an epithelial tube [GO:0048754]; canonical Wnt signaling pathway [GO:0060070]; DNA replication [GO:0006260]; epidermal growth factor receptor signaling pathway [GO:0007173]; ERBB2 signaling pathway [GO:0038128]; ERK1 and ERK2 cascade [GO:0070371]; mammary gland alveolus development [GO:0060749]; MAPK cascade [GO:0000165]; negative regulation of cholesterol efflux [GO:0090370]; negative regulation of epidermal growth factor receptor signaling pathway [GO:0042059]; negative regulation of secretion [GO:0051048]; phosphatidylinositol-mediated signaling [GO:0048015]; platelet degranulation [GO:0002576]; positive regulation of catenin import into nucleus [GO:0035413]; positive regulation of cell proliferation [GO:0008284]; positive regulation of cerebellar granule cell precursor proliferation [GO:0021940]; positive regulation of DNA binding [GO:0043388]; positive regulation of epidermal growth factor-activated receptor activity [GO:0045741]; positive regulation of hyaluronan biosynthetic process [GO:1900127]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of mitotic nuclear division [GO:0045840]; positive regulation of peptidyl-threonine phosphorylation [GO:0010800]; positive regulation of phosphorylation [GO:0042327]; positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process [GO:2000060]; positive regulation of transcription, DNA-templated [GO:0045893]; regulation of calcium ion import [GO:0090279]; regulation of cell motility [GO:2000145]; regulation of phosphatidylinositol 3-kinase signaling [GO:0014066]; regulation of protein localization to cell surface [GO:2000008]; signal transduction [GO:0007165]; STAT protein import into nucleus [GO:0007262]; Wnt signaling pathway involved in dorsal/ventral axis specification [GO:0044332]	calcium ion binding [GO:0005509]; epidermal growth factor receptor binding [GO:0005154]; growth factor activity [GO:0008083]; phosphatidylinositol-4,5-bisphosphate 3-kinase activity [GO:0046934]; protein tyrosine kinase activity [GO:0004713]; Ras guanyl-nucleotide exchange factor activity [GO:0005088]; transmembrane receptor protein tyrosine kinase activator activity [GO:0030297]; Wnt-activated receptor activity [GO:0042813]; Wnt-protein binding [GO:0017147]	extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; integral component of membrane [GO:0016021]; lysosomal membrane [GO:0005765]; plasma membrane [GO:0005886]; platelet alpha granule lumen [GO:0031093]; receptor complex [GO:0043235]
Q9GZT9	EGLN1_HUMAN	Egl nine homolog 1 (EC 1.14.11.29) (Hypoxia-inducible factor prolyl hydroxylase 2) (HIF-PH2) (HIF-prolyl hydroxylase 2) (HPH-2) (Prolyl hydroxylase domain-containing protein 2) (PHD2) (SM-20)	EGLN1 C1orf12 PNAS-118 PNAS-137	2G19;2G1M;2HBT;2HBU;2Y33;2Y34;3HQR;3HQU;3OUH;3OUI;3OUJ;4BQW;4BQX;4BQY;4JZR;4KBZ;4UWD;5A3U;5L9B;5L9R;5L9V;5LA9;5LAS;5LAT;5LB6;5LBB;5LBC;5LBE;5LBF;	CHEMBL5697;	Q9GZT9;	DB00126;		PF13640;PF01753;	IPR005123;IPR006620;IPR002893;	cardiac muscle tissue morphogenesis [GO:0055008]; cellular iron ion homeostasis [GO:0006879]; heart trabecula formation [GO:0060347]; labyrinthine layer development [GO:0060711]; negative regulation of cAMP catabolic process [GO:0030821]; negative regulation of cyclic-nucleotide phosphodiesterase activity [GO:0051344]; negative regulation of sequence-specific DNA binding transcription factor activity [GO:0043433]; oxygen homeostasis [GO:0032364]; peptidyl-proline hydroxylation to 4-hydroxy-L-proline [GO:0018401]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; regulation of angiogenesis [GO:0045765]; regulation of neuron death [GO:1901214]; regulation of transcription from RNA polymerase II promoter in response to hypoxia [GO:0061418]; response to hypoxia [GO:0001666]; response to nitric oxide [GO:0071731]; ventricular septum morphogenesis [GO:0060412]	enzyme binding [GO:0019899]; iron ion binding [GO:0005506]; L-ascorbic acid binding [GO:0031418]; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors [GO:0016706]; peptidyl-proline 4-dioxygenase activity [GO:0031545]; peptidyl-proline dioxygenase activity [GO:0031543]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleus [GO:0005634]
Q96KS0	EGLN2_HUMAN	Egl nine homolog 2 (EC 1.14.11.29) (Estrogen-induced tag 6) (HPH-3) (Hypoxia-inducible factor prolyl hydroxylase 1) (HIF-PH1) (HIF-prolyl hydroxylase 1) (HPH-1) (Prolyl hydroxylase domain-containing protein 1) (PHD1)	EGLN2 EIT6		CHEMBL3028;	Q96KS0;	DB00126;		PF13640;	IPR005123;IPR006620;	cell redox homeostasis [GO:0045454]; intracellular estrogen receptor signaling pathway [GO:0030520]; peptidyl-proline hydroxylation to 4-hydroxy-L-proline [GO:0018401]; positive regulation of protein catabolic process [GO:0045732]; regulation of cell growth [GO:0001558]; regulation of neuron apoptotic process [GO:0043523]; regulation of transcription from RNA polymerase II promoter in response to hypoxia [GO:0061418]; response to hypoxia [GO:0001666]	ferrous iron binding [GO:0008198]; L-ascorbic acid binding [GO:0031418]; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors [GO:0016706]; oxygen sensor activity [GO:0019826]; peptidyl-proline 4-dioxygenase activity [GO:0031545]	nucleoplasm [GO:0005654]; nucleus [GO:0005634]
Q9H6Z9	EGLN3_HUMAN	Egl nine homolog 3 (EC 1.14.11.29) (HPH-1) (Hypoxia-inducible factor prolyl hydroxylase 3) (HIF-PH3) (HIF-prolyl hydroxylase 3) (HPH-3) (Prolyl hydroxylase domain-containing protein 3) (PHD3)	EGLN3		CHEMBL5705;	Q9H6Z9;	DB00126;		PF13640;	IPR005123;IPR006620;	activation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0006919]; apoptotic process [GO:0006915]; cellular response to DNA damage stimulus [GO:0006974]; peptidyl-proline hydroxylation to 4-hydroxy-L-proline [GO:0018401]; protein hydroxylation [GO:0018126]; regulation of cell proliferation [GO:0042127]; regulation of neuron apoptotic process [GO:0043523]; regulation of transcription from RNA polymerase II promoter in response to hypoxia [GO:0061418]; response to hypoxia [GO:0001666]	iron ion binding [GO:0005506]; L-ascorbic acid binding [GO:0031418]; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors [GO:0016706]; peptidyl-proline 4-dioxygenase activity [GO:0031545]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
Q9NXG6	EGLX_HUMAN	Transmembrane prolyl 4-hydroxylase (P4H-TM) (EC 1.14.11.-) (Hypoxia-inducible factor prolyl hydroxylase 4) (HIF-PH4) (HIF-prolyl hydroxylase 4) (HPH-4)	P4HTM PH4		CHEMBL3047;	Q9NXG6;	DB00126;		PF13640;PF13499;	IPR011992;IPR018247;IPR002048;IPR005123;IPR006620;	regulation of erythrocyte differentiation [GO:0045646]	calcium ion binding [GO:0005509]; iron ion binding [GO:0005506]; L-ascorbic acid binding [GO:0031418]; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors [GO:0016706]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]
P08246	ELNE_HUMAN	Neutrophil elastase (EC 3.4.21.37) (Bone marrow serine protease) (Elastase-2) (Human leukocyte elastase) (HLE) (Medullasin) (PMN elastase)	ELANE ELA2	1B0F;1H1B;1HNE;1PPF;1PPG;2RG3;2Z7F;3Q76;3Q77;4NZL;4WVP;5A09;5A0A;5A0B;5A0C;5A8X;5A8Y;5A8Z;5ABW;	CHEMBL248;	P08246;	DB00058;DB00099;DB00019;		PF00089;	IPR009003;IPR001314;IPR001254;IPR018114;IPR033116;	acute inflammatory response to antigenic stimulus [GO:0002438]; cellular calcium ion homeostasis [GO:0006874]; defense response to bacterium [GO:0042742]; extracellular matrix disassembly [GO:0022617]; leukocyte migration involved in inflammatory response [GO:0002523]; negative regulation of chemokine biosynthetic process [GO:0045079]; negative regulation of chemotaxis [GO:0050922]; negative regulation of growth of symbiont in host [GO:0044130]; negative regulation of inflammatory response [GO:0050728]; negative regulation of interleukin-8 biosynthetic process [GO:0045415]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; neutrophil mediated killing of fungus [GO:0070947]; phagocytosis [GO:0006909]; positive regulation of immune response [GO:0050778]; positive regulation of interleukin-8 biosynthetic process [GO:0045416]; positive regulation of leukocyte tethering or rolling [GO:1903238]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of smooth muscle cell proliferation [GO:0048661]; protein catabolic process [GO:0030163]; proteolysis [GO:0006508]; response to lipopolysaccharide [GO:0032496]; response to UV [GO:0009411]; response to yeast [GO:0001878]	cytokine binding [GO:0019955]; endopeptidase activity [GO:0004175]; heparin binding [GO:0008201]; peptidase activity [GO:0008233]; protease binding [GO:0002020]; RNA polymerase II transcription corepressor activity [GO:0001106]; serine-type endopeptidase activity [GO:0004252]	cell surface [GO:0009986]; cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; secretory granule [GO:0030141]; transcriptional repressor complex [GO:0017053]
P15502	ELN_HUMAN	Elastin (Tropoelastin)	ELN							IPR003979;	animal organ morphogenesis [GO:0009887]; blood circulation [GO:0008015]; cell proliferation [GO:0008283]; extracellular matrix disassembly [GO:0022617]; extracellular matrix organization [GO:0030198]; respiratory gaseous exchange [GO:0007585]	extracellular matrix structural constituent [GO:0005201]	elastic fiber [GO:0071953]; extracellular region [GO:0005576]; proteinaceous extracellular matrix [GO:0005578]
Q9GZR5	ELOV4_HUMAN	Elongation of very long chain fatty acids protein 4 (EC 2.3.1.199) (3-keto acyl-CoA synthase ELOVL4) (ELOVL fatty acid elongase 4) (ELOVL FA elongase 4) (Very long chain 3-ketoacyl-CoA synthase 4) (Very long chain 3-oxoacyl-CoA synthase 4)	ELOVL4				DB00132;	PATHWAY: Lipid metabolism; fatty acid biosynthesis. {ECO:0000255|HAMAP-Rule:MF_03204, ECO:0000269|PubMed:20937905}.	PF01151;	IPR030457;IPR002076;IPR033678;	fatty acid biosynthetic process [GO:0006633]; fatty acid elongation, monounsaturated fatty acid [GO:0034625]; fatty acid elongation, polyunsaturated fatty acid [GO:0034626]; fatty acid elongation, saturated fatty acid [GO:0019367]; long-chain fatty-acyl-CoA biosynthetic process [GO:0035338]; sphingolipid biosynthetic process [GO:0030148]; unsaturated fatty acid biosynthetic process [GO:0006636]; very long-chain fatty acid biosynthetic process [GO:0042761]	3-oxo-arachidoyl-CoA synthase activity [GO:0102336]; 3-oxo-cerotoyl-CoA synthase activity [GO:0102337]; 3-oxo-lignoceronyl-CoA synthase activity [GO:0102338]; fatty acid elongase activity [GO:0009922]; G-protein coupled photoreceptor activity [GO:0008020]	endoplasmic reticulum [GO:0005783]; integral component of endoplasmic reticulum membrane [GO:0030176]
Q9NX77	ENK13_HUMAN	Endogenous retrovirus group K member 13-1 Env polyprotein (Envelope polyprotein) (HERV-K_16p13.3 provirus ancestral Env polyprotein) [Cleaved into: Surface protein (SU); Transmembrane protein (TM)]	ERVK13-1						PF00517;PF13804;	IPR000328;IPR029104;		structural molecule activity [GO:0005198]	integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]; viral envelope [GO:0019031]
P14625	ENPL_HUMAN	Endoplasmin (94 kDa glucose-regulated protein) (GRP-94) (Heat shock protein 90 kDa beta member 1) (Tumor rejection antigen 1) (gp96 homolog)	HSP90B1 GRP94 TRA1	4NH9;	CHEMBL1075323;	P14625;	DB00615;		PF02518;PF00183;	IPR003594;IPR019805;IPR001404;IPR020575;IPR020568;	actin rod assembly [GO:0031247]; ATF6-mediated unfolded protein response [GO:0036500]; cellular response to ATP [GO:0071318]; ER-associated ubiquitin-dependent protein catabolic process [GO:0030433]; negative regulation of apoptotic process [GO:0043066]; protein folding in endoplasmic reticulum [GO:0034975]; protein transport [GO:0015031]; receptor-mediated endocytosis [GO:0006898]; regulation of phosphoprotein phosphatase activity [GO:0043666]; response to endoplasmic reticulum stress [GO:0034976]; response to hypoxia [GO:0001666]; retrograde protein transport, ER to cytosol [GO:0030970]; sequestering of calcium ion [GO:0051208]; toll-like receptor signaling pathway [GO:0002224]	ATP binding [GO:0005524]; calcium ion binding [GO:0005509]; low-density lipoprotein particle receptor binding [GO:0050750]; protein phosphatase binding [GO:0019903]; RNA binding [GO:0003723]; virion binding [GO:0046790]	cytosol [GO:0005829]; endocytic vesicle lumen [GO:0071682]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum chaperone complex [GO:0034663]; endoplasmic reticulum lumen [GO:0005788]; endoplasmic reticulum membrane [GO:0005789]; extracellular exosome [GO:0070062]; extracellular matrix [GO:0031012]; extracellular region [GO:0005576]; focal adhesion [GO:0005925]; melanosome [GO:0042470]; membrane [GO:0016020]; midbody [GO:0030496]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]
P22413	ENPP1_HUMAN	Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (E-NPP 1) (Membrane component chromosome 6 surface marker 1) (Phosphodiesterase I/nucleotide pyrophosphatase 1) (Plasma-cell membrane glycoprotein PC-1) [Includes: Alkaline phosphodiesterase I (EC 3.1.4.1); Nucleotide pyrophosphatase (NPPase) (EC 3.6.1.9) (Nucleotide diphosphatase)]	ENPP1 M6S1 NPPS PC1 PDNP1	2YS0;	CHEMBL5925;	P22413;	DB01143;DB00811;		PF01223;PF01663;PF01033;	IPR017849;IPR017850;IPR001604;IPR024873;IPR029890;IPR020821;IPR002591;IPR020436;IPR001212;	3'-phosphoadenosine 5'-phosphosulfate metabolic process [GO:0050427]; biomineral tissue development [GO:0031214]; cellular phosphate ion homeostasis [GO:0030643]; cellular response to insulin stimulus [GO:0032869]; generation of precursor metabolites and energy [GO:0006091]; immune response [GO:0006955]; inorganic diphosphate transport [GO:0030505]; negative regulation of cell growth [GO:0030308]; negative regulation of fat cell differentiation [GO:0045599]; negative regulation of glucose import [GO:0046325]; negative regulation of glycogen biosynthetic process [GO:0045719]; negative regulation of insulin receptor signaling pathway [GO:0046627]; negative regulation of protein autophosphorylation [GO:0031953]; nucleoside triphosphate catabolic process [GO:0009143]; phosphate-containing compound metabolic process [GO:0006796]; regulation of bone mineralization [GO:0030500]; riboflavin metabolic process [GO:0006771]; sequestering of triglyceride [GO:0030730]	3'-phosphoadenosine 5'-phosphosulfate binding [GO:0050656]; ATP binding [GO:0005524]; calcium ion binding [GO:0005509]; insulin receptor binding [GO:0005158]; NADH pyrophosphatase activity [GO:0035529]; nucleic acid binding [GO:0003676]; nucleoside-triphosphate diphosphatase activity [GO:0047429]; nucleotide diphosphatase activity [GO:0004551]; phosphodiesterase I activity [GO:0004528]; polysaccharide binding [GO:0030247]; protein homodimerization activity [GO:0042803]; scavenger receptor activity [GO:0005044]; zinc ion binding [GO:0008270]	basolateral plasma membrane [GO:0016323]; cell surface [GO:0009986]; extracellular space [GO:0005615]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; lysosomal membrane [GO:0005765]; plasma membrane [GO:0005886]
P29317	EPHA2_HUMAN	Ephrin type-A receptor 2 (EC 2.7.10.1) (Epithelial cell kinase) (Tyrosine-protein kinase receptor ECK)	EPHA2 ECK	1MQB;2E8N;2K9Y;2KSO;2X10;2X11;3C8X;3CZU;3FL7;3HEI;3HPN;3KKA;3MBW;3MX0;3SKJ;4P2K;4PDO;4TRL;5EK7;	CHEMBL2068;	P29317;	DB01254;DB08896;		PF14575;PF01404;PF00041;PF07714;PF00536;	IPR027936;IPR001090;IPR003961;IPR008979;IPR009030;IPR013783;IPR011009;IPR000719;IPR017441;IPR001660;IPR013761;IPR001245;IPR011641;IPR008266;IPR020635;IPR016257;IPR001426;	activation of GTPase activity [GO:0090630]; axial mesoderm formation [GO:0048320]; blood vessel endothelial cell proliferation involved in sprouting angiogenesis [GO:0002043]; bone remodeling [GO:0046849]; branching involved in mammary gland duct morphogenesis [GO:0060444]; cell chemotaxis [GO:0060326]; cell migration [GO:0016477]; defense response to Gram-positive bacterium [GO:0050830]; ephrin receptor signaling pathway [GO:0048013]; inflammatory response [GO:0006954]; intrinsic apoptotic signaling pathway in response to DNA damage [GO:0008630]; keratinocyte differentiation [GO:0030216]; lens fiber cell morphogenesis [GO:0070309]; mammary gland epithelial cell proliferation [GO:0033598]; multicellular organism development [GO:0007275]; negative regulation of angiogenesis [GO:0016525]; negative regulation of chemokine production [GO:0032682]; negative regulation of lymphangiogenesis [GO:1901491]; negative regulation of protein kinase B signaling [GO:0051898]; neural tube development [GO:0021915]; neuron differentiation [GO:0030182]; notochord cell development [GO:0060035]; notochord formation [GO:0014028]; osteoblast differentiation [GO:0001649]; osteoclast differentiation [GO:0030316]; pericyte cell differentiation [GO:1904238]; positive regulation of establishment of protein localization to plasma membrane [GO:0090004]; post-anal tail morphogenesis [GO:0036342]; protein kinase B signaling [GO:0043491]; regulation of angiogenesis [GO:0045765]; regulation of blood vessel endothelial cell migration [GO:0043535]; regulation of cell adhesion mediated by integrin [GO:0033628]; regulation of ERK1 and ERK2 cascade [GO:0070372]; regulation of lamellipodium assembly [GO:0010591]; response to growth factor [GO:0070848]; skeletal system development [GO:0001501]; vasculogenesis [GO:0001570]; viral process [GO:0016032]	ATP binding [GO:0005524]; cadherin binding involved in cell-cell adhesion [GO:0098641]; ephrin receptor activity [GO:0005003]; transmembrane receptor protein tyrosine kinase activity [GO:0004714]	cell-cell adherens junction [GO:0005913]; cell surface [GO:0009986]; focal adhesion [GO:0005925]; integral component of plasma membrane [GO:0005887]; intracellular [GO:0005622]; lamellipodium membrane [GO:0031258]; leading edge membrane [GO:0031256]; plasma membrane [GO:0005886]; ruffle membrane [GO:0032587]
P04626	ERBB2_HUMAN	Receptor tyrosine-protein kinase erbB-2 (EC 2.7.10.1) (Metastatic lymph node gene 19 protein) (MLN 19) (Proto-oncogene Neu) (Proto-oncogene c-ErbB-2) (Tyrosine kinase-type cell surface receptor HER2) (p185erbB2) (CD antigen CD340)	ERBB2 HER2 MLN19 NEU NGL	1MFG;1MFL;1MW4;1N8Z;1OVC;1QR1;1S78;2A91;2JWA;2KS1;2L4K;2N2A;3BE1;3H3B;3MZW;3N85;3PP0;3RCD;3WLW;3WSQ;4GFU;4HRL;4HRM;4HRN;	CHEMBL1824;	P04626;	DB05773;DB08916;DB01259;DB06366;DB00072;		PF00757;PF14843;PF07714;PF01030;	IPR006211;IPR006212;IPR032778;IPR009030;IPR011009;IPR032675;IPR000719;IPR017441;IPR000494;IPR001245;IPR008266;IPR020635;IPR016245;	cell proliferation [GO:0008283]; cell surface receptor signaling pathway [GO:0007166]; cellular response to epidermal growth factor stimulus [GO:0071364]; cellular response to growth factor stimulus [GO:0071363]; enzyme linked receptor protein signaling pathway [GO:0007167]; ERBB2 signaling pathway [GO:0038128]; heart development [GO:0007507]; MAPK cascade [GO:0000165]; motor neuron axon guidance [GO:0008045]; myelination [GO:0042552]; negative regulation of immature T cell proliferation in thymus [GO:0033088]; neuromuscular junction development [GO:0007528]; oligodendrocyte differentiation [GO:0048709]; peripheral nervous system development [GO:0007422]; phosphatidylinositol 3-kinase signaling [GO:0014065]; phosphatidylinositol-mediated signaling [GO:0048015]; positive regulation of cell adhesion [GO:0045785]; positive regulation of cell growth [GO:0030307]; positive regulation of epithelial cell proliferation [GO:0050679]; positive regulation of GTPase activity [GO:0043547]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of protein targeting to membrane [GO:0090314]; positive regulation of transcription from RNA polymerase III promoter [GO:0045945]; positive regulation of transcription from RNA polymerase I promoter [GO:0045943]; positive regulation of translation [GO:0045727]; protein autophosphorylation [GO:0046777]; protein phosphorylation [GO:0006468]; regulation of angiogenesis [GO:0045765]; regulation of cell motility [GO:2000145]; regulation of ERK1 and ERK2 cascade [GO:0070372]; regulation of microtubule-based process [GO:0032886]; regulation of phosphatidylinositol 3-kinase signaling [GO:0014066]; signal transduction [GO:0007165]; transcription, DNA-templated [GO:0006351]; transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169]; wound healing [GO:0042060]	ATP binding [GO:0005524]; ErbB-3 class receptor binding [GO:0043125]; identical protein binding [GO:0042802]; phosphatidylinositol-4,5-bisphosphate 3-kinase activity [GO:0046934]; protein C-terminus binding [GO:0008022]; protein dimerization activity [GO:0046983]; protein heterodimerization activity [GO:0046982]; protein phosphatase binding [GO:0019903]; protein tyrosine kinase activity [GO:0004713]; Ras guanyl-nucleotide exchange factor activity [GO:0005088]; receptor signaling protein tyrosine kinase activity [GO:0004716]; RNA polymerase I core binding [GO:0001042]; transmembrane receptor protein tyrosine kinase activity [GO:0004714]; transmembrane signaling receptor activity [GO:0004888]	apical plasma membrane [GO:0016324]; basolateral plasma membrane [GO:0016323]; cytoplasm [GO:0005737]; cytoplasmic vesicle [GO:0031410]; endosome membrane [GO:0010008]; integral component of membrane [GO:0016021]; myelin sheath [GO:0043209]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]
Q14534	ERG1_HUMAN	Squalene monooxygenase (EC 1.14.14.17) (Squalene epoxidase) (SE)	SQLE ERG1		CHEMBL3592;	Q14534;	DB01091;DB00735;DB00857;	PATHWAY: Terpene metabolism; lanosterol biosynthesis; lanosterol from farnesyl diphosphate: step 2/3.	PF08491;	IPR023753;IPR013698;	cellular aromatic compound metabolic process [GO:0006725]; cholesterol biosynthetic process [GO:0006695]; response to organic substance [GO:0010033]; sterol biosynthetic process [GO:0016126]	flavin adenine dinucleotide binding [GO:0050660]; squalene monooxygenase activity [GO:0004506]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; organelle membrane [GO:0031090]
Q15800	ERG25_HUMAN	Methylsterol monooxygenase 1 (EC 1.14.13.72) (C-4 methylsterol oxidase)	MSMO1 DESP4 ERG25 SC4MOL					PATHWAY: Steroid biosynthesis; zymosterol biosynthesis; zymosterol from lanosterol: step 3/6.	PF04116;	IPR006694;	cholesterol biosynthetic process [GO:0006695]; fatty acid biosynthetic process [GO:0006633]; fatty acid metabolic process [GO:0006631]; steroid metabolic process [GO:0008202]; sterol biosynthetic process [GO:0016126]	C-4 methylsterol oxidase activity [GO:0000254]; iron ion binding [GO:0005506]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]
P48449	ERG7_HUMAN	Lanosterol synthase (EC 5.4.99.7) (2,3-epoxysqualene--lanosterol cyclase) (Oxidosqualene--lanosterol cyclase) (OSC) (hOSC)	LSS OSC	1W6J;1W6K;	CHEMBL3593;	P48449;		PATHWAY: Terpene metabolism; lanosterol biosynthesis; lanosterol from farnesyl diphosphate: step 3/3.	PF13243;PF13249;	IPR032696;IPR032697;IPR018333;IPR002365;IPR008930;	cholesterol biosynthetic process [GO:0006695]; regulation of protein stability [GO:0031647]; steroid biosynthetic process [GO:0006694]	lanosterol synthase activity [GO:0000250]	endoplasmic reticulum membrane [GO:0005789]; lipid particle [GO:0005811]; membrane [GO:0016020]
Q96RQ1	ERGI2_HUMAN	Endoplasmic reticulum-Golgi intermediate compartment protein 2	ERGIC2 ERV41 PTX1 CDA14						PF07970;	IPR012936;	retrograde vesicle-mediated transport, Golgi to ER [GO:0006890]		cytoplasm [GO:0005737]; endoplasmic reticulum-Golgi intermediate compartment membrane [GO:0033116]; endoplasmic reticulum membrane [GO:0005789]; Golgi apparatus [GO:0005794]; integral component of membrane [GO:0016021]; intracellular membrane-bounded organelle [GO:0043231]; membrane [GO:0016020]; nucleolus [GO:0005730]; nucleus [GO:0005634]
P62508	ERR3_HUMAN	Estrogen-related receptor gamma (ERR gamma-2) (Estrogen receptor-related protein 3) (Nuclear receptor subfamily 3 group B member 3)	ESRRG ERR3 ERRG2 KIAA0832 NR3B3	1KV6;1TFC;1VJB;2E2R;2EWP;2GP7;2GPO;2GPP;2GPU;2GPV;2P7A;2P7G;2P7Z;2ZAS;2ZBS;2ZKC;	CHEMBL4245;	P62508;	DB02659;DB00255;		PF00104;PF00105;	IPR000536;IPR001723;IPR027289;IPR024178;IPR003078;IPR001628;IPR013088;	positive regulation of transcription, DNA-templated [GO:0045893]; regulation of transcription, DNA-templated [GO:0006355]; transcription initiation from RNA polymerase II promoter [GO:0006367]	AF-2 domain binding [GO:0050682]; retinoic acid receptor activity [GO:0003708]; RNA polymerase II regulatory region sequence-specific DNA binding [GO:0000977]; steroid binding [GO:0005496]; steroid hormone receptor activity [GO:0003707]; transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding [GO:0001228]; zinc ion binding [GO:0008270]	nucleoplasm [GO:0005654]
P03372	ESR1_HUMAN	Estrogen receptor (ER) (ER-alpha) (Estradiol receptor) (Nuclear receptor subfamily 3 group A member 1)	ESR1 ESR NR3A1	1A52;1AKF;1ERE;1ERR;1G50;1GWQ;1GWR;1HCP;1HCQ;1L2I;1PCG;1QKT;1QKU;1R5K;1SJ0;1UOM;1X7E;1X7R;1XP1;1XP6;1XP9;1XPC;1XQC;1YIM;1YIN;1ZKY;2AYR;2B1V;2B1Z;2B23;2BJ4;2FAI;2G44;2G5O;2I0J;2IOG;2IOK;2JF9;2JFA;2LLO;2LLQ;2OCF;2OUZ;2P15;2POG;2Q6J;2Q70;2QA6;2QA8;2QAB;2QE4;2QGT;2QGW;2QH6;2QR9;2QSE;2QXM;2QXS;2QZO;2R6W;2R6Y;2YAT;2YJA;3CBM;3CBO;3CBP;3DT3;3ERD;3ERT;3HLV;3HM1;3L03;3OS8;3OS9;3OSA;3Q95;3Q97;3UU7;3UUA;3UUC;3UUD;4AA6;4DMA;4IU7;4IUI;4IV2;4IV4;4IVW;4IVY;4IW6;4IW8;4IWC;4IWF;4JC3;4JDD;4MG5;4MG6;4MG7;4MG8;4MG9;4MGA;4MGB;4MGC;4MGD;4O6F;4PP6;4PPP;4PPS;4PXM;4Q13;4Q50;4TUZ;4TV1;4XI3;4ZN7;4ZN9;4ZNH;4ZNS;4ZNT;4ZNU;4ZNV;4ZNW;4ZUB;4ZUC;4ZWH;4ZWK;5AAU;5AAV;5ACC;5AK2;5BNU;5BP6;5BPR;5BQ4;5DI7;5DID;5DIE;5DIG;5DK9;5DKB;5DKE;5DKG;5DKS;5DL4;5DLR;5DMC;5DMF;5DP0;5DRJ;5DRM;5DTV;5DU5;5DUE;5DUG;5DUH;5DVS;5DVV;5DWE;5DWG;5DWI;5DWJ;5DX3;5DXB;5DXE;5DXG;5DXK;5DXM;5DXP;5DXQ;5DXR;5DY8;5DYB;5DYD;5DZ0;5DZ1;5DZ3;5DZH;5DZI;5E0W;5E0X;5E14;5E15;5E19;5E1C;5EGV;5EHJ;5EI1;5EIT;5FQP;5FQR;5FQS;5FQT;5FQV;5HYR;	CHEMBL206;	P03372;	DB01431;DB06401;DB00882;DB00286;DB01406;DB00304;DB00890;DB00255;DB00783;DB01196;DB04573;DB00655;DB04574;DB00977;DB00823;DB00294;DB01185;DB00947;DB00367;DB00603;DB01065;DB01357;DB01183;DB00957;DB04938;DB00396;DB04575;DB00481;DB00675;DB00539;DB01108;		PF12743;PF00104;PF02159;PF00105;	IPR000536;IPR001723;IPR024178;IPR001292;IPR024736;IPR001628;IPR013088;	androgen metabolic process [GO:0008209]; antral ovarian follicle growth [GO:0001547]; cellular response to estradiol stimulus [GO:0071392]; cellular response to estrogen stimulus [GO:0071391]; chromatin remodeling [GO:0006338]; epithelial cell development [GO:0002064]; epithelial cell proliferation involved in mammary gland duct elongation [GO:0060750]; intracellular estrogen receptor signaling pathway [GO:0030520]; intracellular steroid hormone receptor signaling pathway [GO:0030518]; male gonad development [GO:0008584]; mammary gland alveolus development [GO:0060749]; mammary gland branching involved in pregnancy [GO:0060745]; negative regulation of gene expression [GO:0010629]; negative regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043124]; negative regulation of production of miRNAs involved in gene silencing by miRNA [GO:1903799]; negative regulation of sequence-specific DNA binding transcription factor activity [GO:0043433]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of fibroblast proliferation [GO:0048146]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; positive regulation of nitric-oxide synthase activity [GO:0051000]; positive regulation of phospholipase C activity [GO:0010863]; positive regulation of sequence-specific DNA binding transcription factor activity [GO:0051091]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis [GO:0060527]; prostate epithelial cord elongation [GO:0060523]; protein localization to chromatin [GO:0071168]; regulation of apoptotic process [GO:0042981]; regulation of branching involved in prostate gland morphogenesis [GO:0060687]; regulation of inflammatory response [GO:0050727]; regulation of toll-like receptor signaling pathway [GO:0034121]; regulation of transcription, DNA-templated [GO:0006355]; response to estradiol [GO:0032355]; response to estrogen [GO:0043627]; signal transduction [GO:0007165]; transcription, DNA-templated [GO:0006351]; transcription from RNA polymerase II promoter [GO:0006366]; transcription initiation from RNA polymerase II promoter [GO:0006367]; uterus development [GO:0060065]; vagina development [GO:0060068]	ATPase binding [GO:0051117]; beta-catenin binding [GO:0008013]; chromatin binding [GO:0003682]; core promoter sequence-specific DNA binding [GO:0001046]; enzyme binding [GO:0019899]; estrogen receptor activity [GO:0030284]; estrogen response element binding [GO:0034056]; identical protein binding [GO:0042802]; nitric-oxide synthase regulator activity [GO:0030235]; RNA polymerase II core promoter proximal region sequence-specific DNA binding [GO:0000978]; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding [GO:0038052]; steroid binding [GO:0005496]; steroid hormone receptor activity [GO:0003707]; transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding [GO:0001077]; transcription factor activity, sequence-specific DNA binding [GO:0003700]; transcription factor binding [GO:0008134]; zinc ion binding [GO:0008270]	cytoplasm [GO:0005737]; Golgi apparatus [GO:0005794]; integral component of membrane [GO:0016021]; membrane [GO:0016020]; nuclear chromatin [GO:0000790]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; transcriptionally active chromatin [GO:0035327]
Q92731	ESR2_HUMAN	Estrogen receptor beta (ER-beta) (Nuclear receptor subfamily 3 group A member 2)	ESR2 ESTRB NR3A2	1L2J;1NDE;1QKM;1U3Q;1U3R;1U3S;1U9E;1X76;1X78;1X7B;1X7J;1YY4;1YYE;1ZAF;2FSZ;2GIU;2I0G;2JJ3;2NV7;2QTU;2YJD;2YLY;2Z4B;3OLL;3OLS;3OMO;3OMP;3OMQ;4J24;4J26;4ZI1;	CHEMBL242;	Q92731;	DB00255;DB00783;DB01196;DB04573;DB04574;DB00481;DB00675;DB01108;		PF12497;PF00104;PF00105;	IPR028355;IPR021064;IPR000536;IPR001723;IPR024178;IPR001628;IPR013088;	cell-cell signaling [GO:0007267]; intracellular estrogen receptor signaling pathway [GO:0030520]; negative regulation of cell growth [GO:0030308]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; positive regulation of sequence-specific DNA binding transcription factor activity [GO:0051091]; positive regulation of transcription, DNA-templated [GO:0045893]; regulation of transcription, DNA-templated [GO:0006355]; signal transduction [GO:0007165]; transcription initiation from RNA polymerase II promoter [GO:0006367]	core promoter sequence-specific DNA binding [GO:0001046]; DNA binding [GO:0003677]; enzyme binding [GO:0019899]; estrogen receptor activity [GO:0030284]; estrogen response element binding [GO:0034056]; receptor antagonist activity [GO:0048019]; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding [GO:0038052]; RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding [GO:0004879]; steroid binding [GO:0005496]; steroid hormone receptor activity [GO:0003707]; transcription coactivator activity [GO:0003713]; transcription factor activity, sequence-specific DNA binding [GO:0003700]; zinc ion binding [GO:0008270]	extracellular region [GO:0005576]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P23141	EST1_HUMAN	Liver carboxylesterase 1 (Acyl-coenzyme A:cholesterol acyltransferase) (ACAT) (Brain carboxylesterase hBr1) (Carboxylesterase 1) (CE-1) (hCE-1) (EC 3.1.1.1) (Cocaine carboxylesterase) (Egasyn) (HMSE) (Methylumbelliferyl-acetate deacetylase 1) (EC 3.1.1.56) (Monocyte/macrophage serine esterase) (Retinyl ester hydrolase) (REH) (Serine esterase 1) (Triacylglycerol hydrolase) (TGH)	CES1 CES2 SES1	1MX1;1MX5;1MX9;1YA4;1YA8;1YAH;1YAJ;2DQY;2DQZ;2DR0;2H7C;2HRQ;2HRR;3K9B;4AB1;5A7F;5A7G;5A7H;	CHEMBL2265;	P23141;	DB01086;DB01101;DB02659;DB01410;DB00758;DB04838;DB06695;DB00328;DB00762;DB00583;DB00688;DB00198;DB01599;DB06201;DB11362;DB00675;DB00519;		PF00135;	IPR029058;IPR002018;IPR019826;IPR019819;	cholesterol biosynthetic process [GO:0006695]; cholesterol ester hydrolysis involved in cholesterol transport [GO:0090122]; epithelial cell differentiation [GO:0030855]; medium-chain fatty acid metabolic process [GO:0051791]; metabolic process [GO:0008152]; response to toxic substance [GO:0009636]; xenobiotic metabolic process [GO:0006805]	carboxylic ester hydrolase activity [GO:0052689]; methylumbelliferyl-acetate deacetylase activity [GO:0047374]; sterol esterase activity [GO:0004771]	cytosol [GO:0005829]; endoplasmic reticulum lumen [GO:0005788]; extracellular space [GO:0005615]
P10768	ESTD_HUMAN	S-formylglutathione hydrolase (FGH) (EC 3.1.2.12) (Esterase D) (Methylumbelliferyl-acetate deacetylase) (EC 3.1.1.56)	ESD	3FCX;	CHEMBL2189130;		DB00143;		PF00756;	IPR029058;IPR000801;IPR014186;	formaldehyde catabolic process [GO:0046294]; glutathione derivative biosynthetic process [GO:1901687]	carboxylic ester hydrolase activity [GO:0052689]; hydrolase activity, acting on ester bonds [GO:0016788]; methylumbelliferyl-acetate deacetylase activity [GO:0047374]; S-formylglutathione hydrolase activity [GO:0018738]	cytoplasmic, membrane-bounded vesicle [GO:0016023]; endoplasmic reticulum lumen [GO:0005788]; extracellular exosome [GO:0070062]
P00488	F13A_HUMAN	Coagulation factor XIII A chain (Coagulation factor XIIIa) (EC 2.3.2.13) (Protein-glutamine gamma-glutamyltransferase A chain) (Transglutaminase A chain)	F13A1 F13A	1EVU;1EX0;1F13;1FIE;1GGT;1GGU;1GGY;1QRK;4KTY;	CHEMBL4530;	P00488;	DB00130;		PF00927;PF01841;PF00868;	IPR023608;IPR013783;IPR014756;IPR002931;IPR013808;IPR008958;IPR001102;	blood coagulation [GO:0007596]; peptide cross-linking [GO:0018149]; platelet degranulation [GO:0002576]	metal ion binding [GO:0046872]; protein-glutamine gamma-glutamyltransferase activity [GO:0003810]	blood microparticle [GO:0072562]; extracellular region [GO:0005576]; platelet alpha granule lumen [GO:0031093]
P09467	F16P1_HUMAN	Fructose-1,6-bisphosphatase 1 (FBPase 1) (EC 3.1.3.11) (D-fructose-1,6-bisphosphate 1-phosphohydrolase 1) (Liver FBPase)	FBP1 FBP	1FTA;2FHY;2FIE;2FIX;2JJK;2VT5;2WBB;2WBD;2Y5K;2Y5L;3A29;3KBZ;3KC0;3KC1;4MJO;	CHEMBL3975;	P09467;	DB00131;	PATHWAY: Carbohydrate biosynthesis; gluconeogenesis.	PF00316;	IPR000146;IPR033391;IPR028343;IPR020548;	cellular response to drug [GO:0035690]; cellular response to magnesium ion [GO:0071286]; dephosphorylation [GO:0016311]; fructose 1,6-bisphosphate metabolic process [GO:0030388]; fructose 6-phosphate metabolic process [GO:0006002]; fructose catabolic process [GO:0006001]; fructose metabolic process [GO:0006000]; gluconeogenesis [GO:0006094]; negative regulation of cell growth [GO:0030308]; negative regulation of glycolytic process [GO:0045820]; negative regulation of Ras protein signal transduction [GO:0046580]; protein homotetramerization [GO:0051289]; regulation of gluconeogenesis [GO:0006111]; sucrose biosynthetic process [GO:0005986]	AMP binding [GO:0016208]; fructose 1,6-bisphosphate 1-phosphatase activity [GO:0042132]; identical protein binding [GO:0042802]; metal ion binding [GO:0046872]; monosaccharide binding [GO:0048029]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P16118	F261_HUMAN	6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1 (6PF-2-K/Fru-2,6-P2ase 1) (PFK/FBPase 1) (6PF-2-K/Fru-2,6-P2ase liver isozyme) [Includes: 6-phosphofructo-2-kinase (EC 2.7.1.105); Fructose-2,6-bisphosphatase (EC 3.1.3.46)]	PFKFB1 F6PK PFRX	1K6M;	CHEMBL3421524;	P16118;			PF01591;PF00300;	IPR003094;IPR013079;IPR013078;IPR029033;IPR027417;IPR001345;	animal organ regeneration [GO:0031100]; canonical glycolysis [GO:0061621]; fructose 2,6-bisphosphate metabolic process [GO:0006003]; fructose metabolic process [GO:0006000]; gluconeogenesis [GO:0006094]; glycolytic process [GO:0006096]; positive regulation of glucokinase activity [GO:0033133]; response to cAMP [GO:0051591]; response to glucagon [GO:0033762]; response to glucocorticoid [GO:0051384]; response to insulin [GO:0032868]; response to starvation [GO:0042594]	6-phosphofructo-2-kinase activity [GO:0003873]; ATP binding [GO:0005524]; fructose-2,6-bisphosphate 2-phosphatase activity [GO:0004331]; fructose-6-phosphate binding [GO:0070095]; identical protein binding [GO:0042802]	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex [GO:0043540]; cytosol [GO:0005829]
P00742	FA10_HUMAN	Coagulation factor X (EC 3.4.21.6) (Stuart factor) (Stuart-Prower factor) [Cleaved into: Factor X light chain; Factor X heavy chain; Activated factor Xa heavy chain]	F10	1C5M;1EZQ;1F0R;1F0S;1FAX;1FJS;1FXY;1G2L;1G2M;1HCG;1IOE;1IQE;1IQF;1IQG;1IQH;1IQI;1IQJ;1IQK;1IQL;1IQM;1IQN;1KSN;1LPG;1LPK;1LPZ;1LQD;1MQ5;1MQ6;1MSX;1NFU;1NFW;1NFX;1NFY;1NL8;1P0S;1V3X;1WU1;1XKA;1XKB;1Z6E;2BMG;2BOH;2BOK;2BQ6;2BQ7;2BQW;2CJI;2D1J;2EI6;2EI7;2EI8;2FZZ;2G00;2GD4;2H9E;2J2U;2J34;2J38;2J4I;2J94;2J95;2JKH;2P16;2P3F;2P3T;2P3U;2P93;2P94;2P95;2PHB;2PR3;2Q1J;2RA0;2UWL;2UWO;2UWP;2VH0;2VH6;2VVC;2VVU;2VVV;2VWL;2VWM;2VWN;2VWO;2W26;2W3I;2W3K;2WYG;2WYJ;2XBV;2XBW;2XBX;2XBY;2XC0;2XC4;2XC5;2Y5F;2Y5G;2Y5H;2Y7X;2Y7Z;2Y80;2Y81;2Y82;3CEN;3CS7;3ENS;3FFG;3HPT;3IIT;3K9X;3KL6;3KQB;3KQC;3KQD;3KQE;3LIW;3M36;3M37;3Q3K;3SW2;3TK5;3TK6;4A7I;4BTI;4BTT;4BTU;4Y6D;4Y71;4Y76;4Y79;4Y7A;4Y7B;4ZH8;4ZHA;5K0H;	CHEMBL244;	P00742;	DB00025;DB06605;DB00100;DB00036;DB09075;DB01225;DB00569;DB01109;DB00170;DB06228;		PF00008;PF00594;PF00089;	IPR017857;IPR001881;IPR013032;IPR000742;IPR000152;IPR018097;IPR000294;IPR012224;IPR009003;IPR001314;IPR001254;IPR018114;IPR033116;	blood coagulation [GO:0007596]; blood coagulation, extrinsic pathway [GO:0007598]; blood coagulation, intrinsic pathway [GO:0007597]; ER to Golgi vesicle-mediated transport [GO:0006888]; peptidyl-glutamic acid carboxylation [GO:0017187]; positive regulation of cell migration [GO:0030335]; positive regulation of protein kinase B signaling [GO:0051897]; signal peptide processing [GO:0006465]	calcium ion binding [GO:0005509]; phospholipid binding [GO:0005543]; serine-type endopeptidase activity [GO:0004252]	endoplasmic reticulum lumen [GO:0005788]; extracellular region [GO:0005576]; Golgi lumen [GO:0005796]; intrinsic component of external side of plasma membrane [GO:0031233]; plasma membrane [GO:0005886]
P12259	FA5_HUMAN	Coagulation factor V (Activated protein C cofactor) (Proaccelerin, labile factor) [Cleaved into: Coagulation factor V heavy chain; Coagulation factor V light chain]	F5	1CZS;1CZT;1CZV;1FV4;1Y61;3P6Z;3P70;3S9C;	CHEMBL3618;	P12259;	DB05777;DB00055;		PF07732;PF00754;	IPR011707;IPR033138;IPR008972;IPR000421;IPR024715;IPR029821;IPR008979;	blood circulation [GO:0008015]; blood coagulation [GO:0007596]; COPII vesicle coating [GO:0048208]; ER to Golgi vesicle-mediated transport [GO:0006888]; platelet activation [GO:0030168]; platelet degranulation [GO:0002576]	copper ion binding [GO:0005507]; serine-type endopeptidase activity [GO:0004252]	endoplasmic reticulum-Golgi intermediate compartment membrane [GO:0033116]; endoplasmic reticulum lumen [GO:0005788]; ER to Golgi transport vesicle [GO:0030134]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; extracellular vesicle [GO:1903561]; Golgi membrane [GO:0000139]; membrane [GO:0016020]; plasma membrane [GO:0005886]; platelet alpha granule lumen [GO:0031093]
P08709	FA7_HUMAN	Coagulation factor VII (EC 3.4.21.21) (Proconvertin) (Serum prothrombin conversion accelerator) (SPCA) (Eptacog alfa) [Cleaved into: Factor VII light chain; Factor VII heavy chain]	F7	1BF9;1CVW;1DAN;1DVA;1F7E;1F7M;1FAK;1FF7;1FFM;1J9C;1JBU;1KLI;1KLJ;1NL8;1O5D;1QFK;1W0Y;1W2K;1W7X;1W8B;1WQV;1WSS;1WTG;1WUN;1WV7;1YGC;1Z6J;2A2Q;2AEI;2AER;2B7D;2B8O;2BZ6;2C4F;2EC9;2F9B;2FIR;2FLB;2FLR;2PUQ;2ZP0;2ZWL;2ZZU;3ELA;3TH2;3TH3;3TH4;4IBL;4ISH;4ISI;4JYU;4JYV;4JZD;4JZE;4JZF;4NA9;4NG9;4NGA;4X8S;4X8T;4X8U;4X8V;4YLQ;4YT6;4YT7;4Z6A;4ZMA;4ZXX;4ZXY;5I46;	CHEMBL3991;	P08709;	DB00100;DB00036;DB00170;		PF00008;PF00594;PF00089;	IPR017857;IPR001881;IPR013032;IPR000742;IPR000152;IPR018097;IPR033190;IPR000294;IPR012224;IPR009003;IPR001314;IPR001254;IPR018114;IPR033116;	animal organ regeneration [GO:0031100]; blood coagulation [GO:0007596]; blood coagulation, extrinsic pathway [GO:0007598]; circadian rhythm [GO:0007623]; ER to Golgi vesicle-mediated transport [GO:0006888]; peptidyl-glutamic acid carboxylation [GO:0017187]; positive regulation of blood coagulation [GO:0030194]; positive regulation of cell migration [GO:0030335]; positive regulation of leukocyte chemotaxis [GO:0002690]; positive regulation of platelet-derived growth factor receptor signaling pathway [GO:0010641]; positive regulation of positive chemotaxis [GO:0050927]; positive regulation of protein kinase B signaling [GO:0051897]; protein processing [GO:0016485]; response to 2,3,7,8-tetrachlorodibenzodioxine [GO:1904612]; response to anticoagulant [GO:0061476]; response to carbon dioxide [GO:0010037]; response to cholesterol [GO:0070723]; response to estradiol [GO:0032355]; response to estrogen [GO:0043627]; response to genistein [GO:0033595]; response to growth hormone [GO:0060416]; response to hypoxia [GO:0001666]; response to Thyroid stimulating hormone [GO:1904400]; response to thyroxine [GO:0097068]; response to vitamin K [GO:0032571]; signal peptide processing [GO:0006465]	calcium ion binding [GO:0005509]; glycoprotein binding [GO:0001948]; serine-type endopeptidase activity [GO:0004252]; serine-type peptidase activity [GO:0008236]	endoplasmic reticulum lumen [GO:0005788]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; Golgi lumen [GO:0005796]; plasma membrane [GO:0005886]; serine-type peptidase complex [GO:1905286]; vesicle [GO:0031982]
P00740	FA9_HUMAN	Coagulation factor IX (EC 3.4.21.22) (Christmas factor) (Plasma thromboplastin component) (PTC) [Cleaved into: Coagulation factor IXa light chain; Coagulation factor IXa heavy chain]	F9	1CFH;1CFI;1EDM;1IXA;1MGX;1NL0;1RFN;2WPH;2WPI;2WPJ;2WPK;2WPL;2WPM;3KCG;3LC3;3LC5;4WM0;4WMA;4WMB;4WMI;4WMK;4WN2;4WNH;4YZU;4Z0K;4ZAE;5EGM;5F84;5F85;5F86;5JB8;5JB9;5JBA;5JBB;5JBC;	CHEMBL2016;	P00740;	DB00025;DB00170;		PF00008;PF00594;PF00089;	IPR017857;IPR001881;IPR013032;IPR000742;IPR000152;IPR018097;IPR000294;IPR012224;IPR009003;IPR001314;IPR001254;IPR018114;IPR033116;	blood coagulation [GO:0007596]; blood coagulation, extrinsic pathway [GO:0007598]; blood coagulation, intrinsic pathway [GO:0007597]; ER to Golgi vesicle-mediated transport [GO:0006888]; peptidyl-glutamic acid carboxylation [GO:0017187]; proteolysis [GO:0006508]; signal peptide processing [GO:0006465]; zymogen activation [GO:0031638]	calcium ion binding [GO:0005509]; endopeptidase activity [GO:0004175]; serine-type endopeptidase activity [GO:0004252]	endoplasmic reticulum lumen [GO:0005788]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; Golgi lumen [GO:0005796]; plasma membrane [GO:0005886]
O00519	FAAH_HUMAN	Fatty-acid amide hydrolase 1 (EC 3.5.1.99) (Anandamide amidohydrolase 1) (Oleamide hydrolase 1)	FAAH FAAH1		CHEMBL2243;	O00519;	DB00818;DB00599;		PF01425;	IPR000120;IPR020556;IPR023631;IPR030560;	arachidonic acid metabolic process [GO:0019369]; fatty acid catabolic process [GO:0009062]	acylglycerol lipase activity [GO:0047372]; anandamide amidohydrolase activity [GO:0103073]; carbon-nitrogen ligase activity, with glutamine as amido-N-donor [GO:0016884]; fatty acid amide hydrolase activity [GO:0017064]	cytoskeleton [GO:0005856]; endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; organelle membrane [GO:0031090]
P15090	FABPA_HUMAN	Fatty acid-binding protein, adipocyte (Adipocyte lipid-binding protein) (ALBP) (Adipocyte-type fatty acid-binding protein) (A-FABP) (AFABP) (Fatty acid-binding protein 4)	FABP4	1TOU;1TOW;2HNX;2NNQ;3FR2;3FR4;3FR5;3P6C;3P6D;3P6E;3P6F;3P6G;3P6H;3Q6L;3RZY;4NNS;4NNT;5D45;5D47;5D48;5D4A;5EDB;5EDC;	CHEMBL2083;	P15090;	DB04224;		PF00061;	IPR012674;IPR011038;IPR033073;IPR000463;IPR031259;IPR000566;	brown fat cell differentiation [GO:0050873]; cellular response to lithium ion [GO:0071285]; cholesterol homeostasis [GO:0042632]; cytokine production [GO:0001816]; negative regulation of protein kinase activity [GO:0006469]; negative regulation of transcription, DNA-templated [GO:0045892]; positive regulation of inflammatory response [GO:0050729]; triglyceride catabolic process [GO:0019433]; white fat cell differentiation [GO:0050872]	fatty acid binding [GO:0005504]; transporter activity [GO:0005215]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; lipid particle [GO:0005811]; nucleus [GO:0005634]
O15540	FABPB_HUMAN	Fatty acid-binding protein, brain (Brain lipid-binding protein) (BLBP) (Brain-type fatty acid-binding protein) (B-FABP) (Fatty acid-binding protein 7) (Mammary-derived growth inhibitor related)	FABP7 BLBP FABPB MRG	1FDQ;1FE3;1JJX;			DB00132;DB00154;DB00159;DB04224;		PF00061;	IPR012674;IPR011038;IPR000463;IPR031259;IPR000566;	cell proliferation in forebrain [GO:0021846]; epithelial cell proliferation [GO:0050673]; negative regulation of cell proliferation [GO:0008285]; nervous system development [GO:0007399]; neurogenesis [GO:0022008]; prepulse inhibition [GO:0060134]; triglyceride catabolic process [GO:0019433]	lipid binding [GO:0008289]; transporter activity [GO:0005215]	cell-cell junction [GO:0005911]; cell periphery [GO:0071944]; cell projection [GO:0042995]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; neuronal cell body [GO:0043025]; nucleoplasm [GO:0005654]
Q01469	FABPE_HUMAN	Fatty acid-binding protein, epidermal (Epidermal-type fatty acid-binding protein) (E-FABP) (Fatty acid-binding protein 5) (Psoriasis-associated fatty acid-binding protein homolog) (PA-FABP)	FABP5	1B56;1JJJ;4AZM;4AZR;4LKP;4LKT;	CHEMBL3674;	Q01469;			PF00061;	IPR012674;IPR011038;IPR000463;IPR031259;IPR000566;	epidermis development [GO:0008544]; glucose metabolic process [GO:0006006]; glucose transport [GO:0015758]; lipid metabolic process [GO:0006629]; phosphatidylcholine biosynthetic process [GO:0006656]; response to wounding [GO:0009611]; triglyceride catabolic process [GO:0019433]	fatty acid binding [GO:0005504]; lipid binding [GO:0008289]; transporter activity [GO:0005215]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleoplasm [GO:0005654]
P05413	FABPH_HUMAN	Fatty acid-binding protein, heart (Fatty acid-binding protein 3) (Heart-type fatty acid-binding protein) (H-FABP) (Mammary-derived growth inhibitor) (MDGI) (Muscle fatty acid-binding protein) (M-FABP)	FABP3 FABP11 MDGI	1G5W;1HMR;1HMS;1HMT;2HMB;3RSW;3WBG;3WVM;3WXQ;4TJZ;4TKB;4TKH;4TKJ;4WBK;5CE4;	CHEMBL3344;	P05413;	DB04224;		PF00061;	IPR012674;IPR011038;IPR000463;IPR031259;IPR000566;	cholesterol homeostasis [GO:0042632]; fatty acid metabolic process [GO:0006631]; long-chain fatty acid import [GO:0044539]; negative regulation of cell proliferation [GO:0008285]; phospholipid homeostasis [GO:0055091]; positive regulation of phospholipid biosynthetic process [GO:0071073]; regulation of fatty acid oxidation [GO:0046320]; response to drug [GO:0042493]; response to fatty acid [GO:0070542]; response to insulin [GO:0032868]; triglyceride catabolic process [GO:0019433]	cytoskeletal protein binding [GO:0008092]; icosatetraenoic acid binding [GO:0050543]; long-chain fatty acid binding [GO:0036041]; long-chain fatty acid transporter activity [GO:0005324]; oleic acid binding [GO:0070538]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; sarcoplasm [GO:0016528]
Q05397	FAK1_HUMAN	Focal adhesion kinase 1 (FADK 1) (EC 2.7.10.2) (Focal adhesion kinase-related nonkinase) (FRNK) (Protein phosphatase 1 regulatory subunit 71) (PPP1R71) (Protein-tyrosine kinase 2) (p125FAK) (pp125FAK)	PTK2 FAK FAK1	1K04;1K05;1MP8;1OW6;1OW7;1OW8;2ETM;2IJM;3B71;3BZ3;3PXK;3S9O;4EBV;4EBW;4GU6;4GU9;4I4E;4I4F;4K8A;4K9Y;4KAB;4KAO;4NY0;4Q9S;	CHEMBL2695;	Q05397;			PF00373;PF03623;PF07714;	IPR019749;IPR019748;IPR000299;IPR005189;IPR011009;IPR011993;IPR000719;IPR017441;IPR001245;IPR008266;IPR020635;IPR029071;	angiogenesis [GO:0001525]; axon guidance [GO:0007411]; cell motility [GO:0048870]; cellular component disassembly involved in execution phase of apoptosis [GO:0006921]; central nervous system neuron axonogenesis [GO:0021955]; embryo development [GO:0009790]; endothelial cell migration [GO:0043542]; ephrin receptor signaling pathway [GO:0048013]; epidermal growth factor receptor signaling pathway [GO:0007173]; establishment of cell polarity [GO:0030010]; establishment of nucleus localization [GO:0040023]; extracellular matrix organization [GO:0030198]; Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096]; growth hormone receptor signaling pathway [GO:0060396]; heart morphogenesis [GO:0003007]; innate immune response [GO:0045087]; integrin-mediated signaling pathway [GO:0007229]; MAPK cascade [GO:0000165]; microtubule cytoskeleton organization [GO:0000226]; negative regulation of anoikis [GO:2000811]; negative regulation of apoptotic process [GO:0043066]; negative regulation of axonogenesis [GO:0050771]; negative regulation of cell-cell adhesion [GO:0022408]; negative regulation of organ growth [GO:0046621]; negative regulation of synapse assembly [GO:0051964]; netrin-activated signaling pathway [GO:0038007]; neuron migration [GO:0001764]; peptidyl-tyrosine autophosphorylation [GO:0038083]; peptidyl-tyrosine phosphorylation [GO:0018108]; placenta development [GO:0001890]; positive regulation of cell migration [GO:0030335]; positive regulation of cell proliferation [GO:0008284]; positive regulation of phosphatidylinositol 3-kinase activity [GO:0043552]; positive regulation of phosphatidylinositol 3-kinase signaling [GO:0014068]; positive regulation of protein kinase activity [GO:0045860]; positive regulation of protein kinase B signaling [GO:0051897]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process [GO:2000060]; protein autophosphorylation [GO:0046777]; regulation of cell adhesion mediated by integrin [GO:0033628]; regulation of cell proliferation [GO:0042127]; regulation of cell shape [GO:0008360]; regulation of cytoskeleton organization [GO:0051493]; regulation of endothelial cell migration [GO:0010594]; regulation of epithelial cell migration [GO:0010632]; regulation of focal adhesion assembly [GO:0051893]; regulation of GTPase activity [GO:0043087]; regulation of osteoblast differentiation [GO:0045667]; regulation of protein phosphorylation [GO:0001932]; regulation of substrate adhesion-dependent cell spreading [GO:1900024]; signal complex assembly [GO:0007172]; transforming growth factor beta receptor signaling pathway [GO:0007179]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]; vasculogenesis [GO:0001570]	actin binding [GO:0003779]; ATP binding [GO:0005524]; JUN kinase binding [GO:0008432]; non-membrane spanning protein tyrosine kinase activity [GO:0004715]; protein kinase activity [GO:0004672]; protein kinase binding [GO:0019901]; protein tyrosine kinase activity [GO:0004713]; Ras guanyl-nucleotide exchange factor activity [GO:0005088]; receptor binding [GO:0005102]; SH2 domain binding [GO:0042169]; signal transducer activity [GO:0004871]	apical plasma membrane [GO:0016324]; cell cortex [GO:0005938]; cytoplasm [GO:0005737]; cytoskeleton [GO:0005856]; cytosol [GO:0005829]; extrinsic component of cytoplasmic side of plasma membrane [GO:0031234]; focal adhesion [GO:0005925]; lamellipodium [GO:0030027]; microtubule organizing center [GO:0005815]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; stress fiber [GO:0001725]
Q14289	FAK2_HUMAN	Protein-tyrosine kinase 2-beta (EC 2.7.10.2) (Calcium-dependent tyrosine kinase) (CADTK) (Calcium-regulated non-receptor proline-rich tyrosine kinase) (Cell adhesion kinase beta) (CAK-beta) (CAKB) (Focal adhesion kinase 2) (FADK 2) (Proline-rich tyrosine kinase 2) (Related adhesion focal tyrosine kinase) (RAFTK)	PTK2B FAK2 PYK2 RAFTK	2FO6;2LK4;3CC6;3ET7;3FZO;3FZP;3FZR;3FZS;3FZT;3GM1;3GM2;3GM3;3H3C;3U3F;4EKU;4H1J;4H1M;4R32;4XEF;4XEK;4XEV;	CHEMBL5469;	Q14289;	DB01097;		PF00373;PF03623;PF07714;	IPR019749;IPR014352;IPR019748;IPR000299;IPR005189;IPR011009;IPR011993;IPR000719;IPR017441;IPR030610;IPR001245;IPR008266;IPR020635;IPR029071;	activation of GTPase activity [GO:0090630]; activation of Janus kinase activity [GO:0042976]; adaptive immune response [GO:0002250]; angiogenesis [GO:0001525]; apoptotic process [GO:0006915]; blood vessel endothelial cell migration [GO:0043534]; bone resorption [GO:0045453]; cell surface receptor signaling pathway [GO:0007166]; cellular defense response [GO:0006968]; cellular response to fluid shear stress [GO:0071498]; cellular response to retinoic acid [GO:0071300]; chemokine-mediated signaling pathway [GO:0070098]; epidermal growth factor receptor signaling pathway [GO:0007173]; focal adhesion assembly [GO:0048041]; glial cell proliferation [GO:0014009]; innate immune response [GO:0045087]; integrin-mediated signaling pathway [GO:0007229]; ionotropic glutamate receptor signaling pathway [GO:0035235]; long term synaptic depression [GO:0060292]; long-term synaptic potentiation [GO:0060291]; MAPK cascade [GO:0000165]; marginal zone B cell differentiation [GO:0002315]; negative regulation of apoptotic process [GO:0043066]; negative regulation of bone mineralization [GO:0030502]; negative regulation of cell proliferation [GO:0008285]; negative regulation of muscle cell apoptotic process [GO:0010656]; negative regulation of myeloid cell differentiation [GO:0045638]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of potassium ion transport [GO:0043267]; neuron projection development [GO:0031175]; oocyte maturation [GO:0001556]; peptidyl-tyrosine autophosphorylation [GO:0038083]; peptidyl-tyrosine phosphorylation [GO:0018108]; positive regulation of actin filament polymerization [GO:0030838]; positive regulation of angiogenesis [GO:0045766]; positive regulation of B cell chemotaxis [GO:2000538]; positive regulation of cell growth [GO:0030307]; positive regulation of cell-matrix adhesion [GO:0001954]; positive regulation of cell migration [GO:0030335]; positive regulation of cell proliferation [GO:0008284]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of DNA biosynthetic process [GO:2000573]; positive regulation of endothelial cell migration [GO:0010595]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of excitatory postsynaptic potential [GO:2000463]; positive regulation of JNK cascade [GO:0046330]; positive regulation of JUN kinase activity [GO:0043507]; positive regulation of neuron projection development [GO:0010976]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; positive regulation of nitric-oxide synthase activity [GO:0051000]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of phosphatidylinositol 3-kinase activity [GO:0043552]; positive regulation of protein kinase activity [GO:0045860]; positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process [GO:2000060]; positive regulation of synaptic transmission, glutamatergic [GO:0051968]; positive regulation of translation [GO:0045727]; protein autophosphorylation [GO:0046777]; protein complex assembly [GO:0006461]; protein phosphorylation [GO:0006468]; regulation of actin cytoskeleton reorganization [GO:2000249]; regulation of calcium-mediated signaling [GO:0050848]; regulation of cell adhesion [GO:0030155]; regulation of cell shape [GO:0008360]; regulation of cGMP biosynthetic process [GO:0030826]; regulation of cGMP-mediated signaling [GO:0010752]; regulation of establishment of cell polarity [GO:2000114]; regulation of inositol trisphosphate biosynthetic process [GO:0032960]; regulation of macrophage chemotaxis [GO:0010758]; regulation of N-methyl-D-aspartate selective glutamate receptor activity [GO:2000310]; regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process [GO:2000058]; regulation of release of sequestered calcium ion into cytosol [GO:0051279]; response to calcium ion [GO:0051592]; response to cAMP [GO:0051591]; response to cocaine [GO:0042220]; response to drug [GO:0042493]; response to ethanol [GO:0045471]; response to glucose [GO:0009749]; response to hormone [GO:0009725]; response to hydrogen peroxide [GO:0042542]; response to hypoxia [GO:0001666]; response to immobilization stress [GO:0035902]; response to lithium ion [GO:0010226]; response to mechanical stimulus [GO:0009612]; response to osmotic stress [GO:0006970]; response to stress [GO:0006950]; signal complex assembly [GO:0007172]; signal transduction [GO:0007165]; sprouting angiogenesis [GO:0002040]; stress fiber assembly [GO:0043149]; tumor necrosis factor-mediated signaling pathway [GO:0033209]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]	ATP binding [GO:0005524]; calmodulin-dependent protein kinase activity [GO:0004683]; NMDA glutamate receptor activity [GO:0004972]; non-membrane spanning protein tyrosine kinase activity [GO:0004715]; protein tyrosine kinase activity [GO:0004713]; receptor binding [GO:0005102]; signal transducer activity [GO:0004871]	apical dendrite [GO:0097440]; axon [GO:0030424]; cell body [GO:0044297]; cell cortex [GO:0005938]; cytoplasm [GO:0005737]; cytoskeleton [GO:0005856]; cytosol [GO:0005829]; dendrite [GO:0030425]; extrinsic component of cytoplasmic side of plasma membrane [GO:0031234]; focal adhesion [GO:0005925]; growth cone [GO:0030426]; lamellipodium [GO:0030027]; membrane raft [GO:0045121]; neuronal cell body [GO:0043025]; NMDA selective glutamate receptor complex [GO:0017146]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; postsynaptic density [GO:0014069]
P49327	FAS_HUMAN	Fatty acid synthase (EC 2.3.1.85) [Includes: [Acyl-carrier-protein] S-acetyltransferase (EC 2.3.1.38); [Acyl-carrier-protein] S-malonyltransferase (EC 2.3.1.39); 3-oxoacyl-[acyl-carrier-protein] synthase (EC 2.3.1.41); 3-oxoacyl-[acyl-carrier-protein] reductase (EC 1.1.1.100); 3-hydroxyacyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.59); Enoyl-[acyl-carrier-protein] reductase (EC 1.3.1.39); Oleoyl-[acyl-carrier-protein] hydrolase (EC 3.1.2.14)]	FASN FAS	1XKT;2CG5;2JFD;2JFK;2PX6;3HHD;3TJM;4PIV;4W82;4W9N;4Z49;5C37;	CHEMBL4158;	P49327;	DB01034;DB01083;		PF00698;PF00107;PF16197;PF00109;PF02801;PF08659;PF08242;PF00550;PF14765;PF00975;	IPR029058;IPR001227;IPR014043;IPR016035;IPR013149;IPR023102;IPR011032;IPR032821;IPR018201;IPR014031;IPR014030;IPR016036;IPR013217;IPR016040;IPR020801;IPR020841;IPR020807;IPR020843;IPR013968;IPR020806;IPR009081;IPR006162;IPR029063;IPR001031;IPR016039;	acetyl-CoA metabolic process [GO:0006084]; cellular response to interleukin-4 [GO:0071353]; fatty acid biosynthetic process [GO:0006633]; fatty acid metabolic process [GO:0006631]; long-chain fatty-acyl-CoA biosynthetic process [GO:0035338]; mammary gland development [GO:0030879]; osteoblast differentiation [GO:0001649]; pantothenate metabolic process [GO:0015939]; positive regulation of cellular metabolic process [GO:0031325]	[acyl-carrier-protein] S-acetyltransferase activity [GO:0004313]; [acyl-carrier-protein] S-malonyltransferase activity [GO:0004314]; 3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase activity [GO:0047451]; 3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase activity [GO:0004317]; 3-oxoacyl-[acyl-carrier-protein] reductase (NADPH) activity [GO:0004316]; 3-oxoacyl-[acyl-carrier-protein] synthase activity [GO:0004315]; 3-oxo-pimeloyl-[acp] methyl ester reductase activity [GO:0102132]; cadherin binding involved in cell-cell adhesion [GO:0098641]; drug binding [GO:0008144]; enoyl-[acyl-carrier-protein] reductase (NADPH, A-specific) activity [GO:0047117]; enoyl-[acyl-carrier-protein] reductase (NADPH, B-specific) activity [GO:0004319]; fatty acid synthase activity [GO:0004312]; myristoyl-[acyl-carrier-protein] hydrolase activity [GO:0016295]; NADPH binding [GO:0070402]; oleoyl-[acyl-carrier-protein] hydrolase activity [GO:0004320]; palmitoyl-[acyl-carrier-protein] hydrolase activity [GO:0016296]; phosphopantetheine binding [GO:0031177]; poly(A) RNA binding [GO:0044822]	cell-cell adherens junction [GO:0005913]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; glycogen granule [GO:0042587]; Golgi apparatus [GO:0005794]; melanosome [GO:0042470]; membrane [GO:0016020]; mitochondrion [GO:0005739]; plasma membrane [GO:0005886]
P12319	FCERA_HUMAN	High affinity immunoglobulin epsilon receptor subunit alpha (Fc-epsilon RI-alpha) (FcERI) (IgE Fc receptor subunit alpha)	FCER1A FCE1A	1ALS;1ALT;1F2Q;1F6A;1J86;1J87;1J88;1J89;1RPQ;2Y7Q;	CHEMBL2248;	P12319;	DB00895;DB00043;		PF13895;	IPR007110;IPR013783;IPR003599;IPR003598;	activation of JUN kinase activity [GO:0007257]; Fc-epsilon receptor signaling pathway [GO:0038095]; leukotriene biosynthetic process [GO:0019370]; positive regulation of calcium-mediated signaling [GO:0050850]; positive regulation of granulocyte macrophage colony-stimulating factor biosynthetic process [GO:0045425]; positive regulation of interleukin-3 biosynthetic process [GO:0045401]; positive regulation of mast cell degranulation [GO:0043306]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of type I hypersensitivity [GO:0001812]; serotonin secretion [GO:0001820]	IgE receptor activity [GO:0019767]	cell surface [GO:0009986]; external side of plasma membrane [GO:0009897]; integral component of plasma membrane [GO:0005887]; intracellular [GO:0005622]; plasma membrane [GO:0005886]
P30273	FCERG_HUMAN	High affinity immunoglobulin epsilon receptor subunit gamma (Fc receptor gamma-chain) (FcRgamma) (Fc-epsilon RI-gamma) (IgE Fc receptor subunit gamma) (FceRI gamma)	FCER1G				DB00895;		PF02189;PF11628;	IPR021663;IPR003110;	antigen processing and presentation of exogenous peptide antigen via MHC class I [GO:0042590]; antigen processing and presentation of exogenous peptide antigen via MHC class II [GO:0019886]; blood coagulation [GO:0007596]; cellular response to low-density lipoprotein particle stimulus [GO:0071404]; defense response to bacterium [GO:0042742]; Fc-epsilon receptor signaling pathway [GO:0038095]; Fc-gamma receptor signaling pathway [GO:0038094]; Fc receptor mediated stimulatory signaling pathway [GO:0002431]; immunoglobulin mediated immune response [GO:0016064]; innate immune response [GO:0045087]; integrin-mediated signaling pathway [GO:0007229]; leukocyte migration [GO:0050900]; mast cell activation [GO:0045576]; negative regulation of mast cell apoptotic process [GO:0033026]; neutrophil activation involved in immune response [GO:0002283]; neutrophil chemotaxis [GO:0030593]; phagocytosis, engulfment [GO:0006911]; platelet activation [GO:0030168]; positive regulation of interleukin-10 production [GO:0032733]; positive regulation of interleukin-6 production [GO:0032755]; positive regulation of mast cell cytokine production [GO:0032765]; positive regulation of mast cell degranulation [GO:0043306]; positive regulation of phagocytosis [GO:0050766]; positive regulation of tumor necrosis factor production [GO:0032760]; positive regulation of type I hypersensitivity [GO:0001812]; positive regulation of type IIa hypersensitivity [GO:0001798]; positive regulation of type III hypersensitivity [GO:0001805]; protein localization to plasma membrane [GO:0072659]; receptor internalization [GO:0031623]; regulation of platelet activation [GO:0010543]; serotonin secretion by platelet [GO:0002554]; stimulatory C-type lectin receptor signaling pathway [GO:0002223]; T cell differentiation involved in immune response [GO:0002292]	IgE binding [GO:0019863]; IgE receptor activity [GO:0019767]; IgG binding [GO:0019864]	cell surface [GO:0009986]; external side of plasma membrane [GO:0009897]; Fc-epsilon receptor I complex [GO:0032998]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P12314	FCGR1_HUMAN	High affinity immunoglobulin gamma Fc receptor I (IgG Fc receptor I) (Fc-gamma RI) (FcRI) (Fc-gamma RIA) (FcgammaRIa) (CD antigen CD64)	FCGR1A FCG1 FCGR1 IGFR1	3RJD;4W4O;4X4M;4ZNE;	CHEMBL5349;	P12314;	DB00054;DB00051;DB00092;DB00087;DB00074;DB00112;DB00002;DB00111;DB00095;DB00005;DB00056;DB00078;DB00028;DB00992;DB00075;DB00108;DB00110;DB00707;DB00073;DB00081;DB00072;		PF00047;PF13895;	IPR007110;IPR013783;IPR003599;IPR003598;IPR013151;	antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent [GO:0002479]; Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096]; immune response [GO:0006955]; interferon-gamma-mediated signaling pathway [GO:0060333]; phagocytosis, engulfment [GO:0006911]; receptor-mediated endocytosis [GO:0006898]; regulation of immune response [GO:0050776]; signal transduction [GO:0007165]	receptor signaling protein activity [GO:0005057]	clathrin-coated endocytic vesicle membrane [GO:0030669]; early endosome membrane [GO:0031901]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]
Q13630	FCL_HUMAN	GDP-L-fucose synthase (EC 1.1.1.271) (GDP-4-keto-6-deoxy-D-mannose-3,5-epimerase-4-reductase) (Protein FX) (Red cell NADP(H)-binding protein) (Short-chain dehydrogenase/reductase family 4E member 1)	TSTA3 SDR4E1	4B8W;4B8Z;4BKP;4BL5;4E5Y;				PATHWAY: Nucleotide-sugar biosynthesis; GDP-L-fucose biosynthesis via de novo pathway; GDP-L-fucose from GDP-alpha-D-mannose: step 2/2.	PF01370;	IPR001509;IPR028614;IPR016040;	'de novo' GDP-L-fucose biosynthetic process [GO:0042351]; cytolysis [GO:0019835]; GDP-mannose metabolic process [GO:0019673]; leukocyte cell-cell adhesion [GO:0007159]	coenzyme binding [GO:0050662]; electron carrier activity [GO:0009055]; GDP-4-dehydro-D-rhamnose reductase activity [GO:0042356]; GDP-L-fucose synthase activity [GO:0050577]; isomerase activity [GO:0016853]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
O14842	FFAR1_HUMAN	Free fatty acid receptor 1 (G-protein coupled receptor 40)	FFAR1 GPR40	4PHU;	CHEMBL4422;	O14842;	DB00159;		PF00001;	IPR000276;IPR017452;IPR013312;IPR013313;	glucose homeostasis [GO:0042593]; G-protein coupled receptor signaling pathway [GO:0007186]; insulin secretion [GO:0030073]; positive regulation of calcium ion transport [GO:0051928]; positive regulation of insulin secretion [GO:0032024]; response to fatty acid [GO:0070542]	bioactive lipid receptor activity [GO:0045125]; G-protein coupled receptor activity [GO:0004930]; guanyl-nucleotide exchange factor activity [GO:0005085]; lipid binding [GO:0008289]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P05230	FGF1_HUMAN	Fibroblast growth factor 1 (FGF-1) (Acidic fibroblast growth factor) (aFGF) (Endothelial cell growth factor) (ECGF) (Heparin-binding growth factor 1) (HBGF-1)	FGF1 FGFA	1AXM;1DJS;1DZC;1DZD;1E0O;1EVT;1HKN;1JQZ;1JT3;1JT4;1JT5;1JT7;1JTC;1JY0;1K5U;1K5V;1M16;1NZK;1P63;1PZZ;1Q03;1Q04;1QCT;1RG8;1RML;1RY7;1YTO;1Z2V;1Z4S;2AFG;2AQZ;2AXM;2ERM;2HW9;2HWA;2HWM;2HZ9;2K43;2K4A;2K8R;2KI4;2KI6;2NTD;2Q9X;2RQ9;3B9U;3BA4;3BA5;3BA7;3BAD;3BAG;3BAH;3BAO;3BAQ;3BAU;3BAV;3BB2;3CQA;3CRG;3CRH;3CRI;3CU1;3FGM;3FJ8;3FJ9;3FJA;3FJB;3FJC;3FJD;3FJE;3FJF;3FJH;3FJI;3FJJ;3FJK;3HOM;3JUT;3K1X;3O3Q;3OJ2;3OJM;3OJV;3UD7;3UD8;3UD9;3UDA;4J23;4Q91;4Q9G;4Q9P;4QAL;4QBC;4QBV;4QC4;4QO3;4XKI;4YOL;	CHEMBL2120;	P05230;	DB01025;DB06589;DB00686;		PF00167;	IPR008996;IPR028210;IPR002209;IPR028142;	activation of MAPK activity [GO:0000187]; activation of protein kinase B activity [GO:0032148]; anatomical structure morphogenesis [GO:0009653]; angiogenesis [GO:0001525]; branch elongation involved in ureteric bud branching [GO:0060681]; cell differentiation [GO:0030154]; cell proliferation [GO:0008283]; cellular response to heat [GO:0034605]; fibroblast growth factor receptor signaling pathway [GO:0008543]; lung development [GO:0030324]; MAPK cascade [GO:0000165]; mesonephric epithelium development [GO:0072163]; multicellular organism development [GO:0007275]; organ induction [GO:0001759]; phosphatidylinositol-mediated signaling [GO:0048015]; positive regulation of angiogenesis [GO:0045766]; positive regulation of cell division [GO:0051781]; positive regulation of cell migration [GO:0030335]; positive regulation of cell proliferation [GO:0008284]; positive regulation of cholesterol biosynthetic process [GO:0045542]; positive regulation of endothelial cell migration [GO:0010595]; positive regulation of epithelial cell proliferation [GO:0050679]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of intracellular signal transduction [GO:1902533]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of sprouting angiogenesis [GO:1903672]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; regulation of endothelial cell chemotaxis to fibroblast growth factor [GO:2000544]; regulation of endothelial tube morphogenesis [GO:1901509]; regulation of phosphatidylinositol 3-kinase signaling [GO:0014066]; signal transduction [GO:0007165]	1-phosphatidylinositol-3-kinase activity [GO:0016303]; fibroblast growth factor receptor binding [GO:0005104]; growth factor activity [GO:0008083]; heparin binding [GO:0008201]; integrin binding [GO:0005178]; phosphatidylinositol-4,5-bisphosphate 3-kinase activity [GO:0046934]; protein tyrosine kinase activity [GO:0004713]; Ras guanyl-nucleotide exchange factor activity [GO:0005088]; S100 protein binding [GO:0044548]	cell cortex [GO:0005938]; cytosol [GO:0005829]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; proteinaceous extracellular matrix [GO:0005578]
P09038	FGF2_HUMAN	Fibroblast growth factor 2 (FGF-2) (Basic fibroblast growth factor) (bFGF) (Heparin-binding growth factor 2) (HBGF-2)	FGF2 FGFB	1BAS;1BFB;1BFC;1BFF;1BFG;1BLA;1BLD;1CVS;1EV2;1FGA;1FQ9;1II4;1IIL;2BFH;2FGF;2M49;4FGF;4OEE;4OEF;4OEG;	CHEMBL3107;	P09038;	DB00686;DB00877;DB00364;		PF00167;	IPR008996;IPR028223;IPR002209;IPR028142;	activation of MAPK activity [GO:0000187]; animal organ morphogenesis [GO:0009887]; branching involved in ureteric bud morphogenesis [GO:0001658]; cell migration involved in sprouting angiogenesis [GO:0002042]; chemotaxis [GO:0006935]; chondroblast differentiation [GO:0060591]; embryonic morphogenesis [GO:0048598]; extracellular matrix organization [GO:0030198]; fibroblast growth factor receptor signaling pathway [GO:0008543]; growth factor dependent regulation of skeletal muscle satellite cell proliferation [GO:0014843]; hyaluronan catabolic process [GO:0030214]; inositol phosphate biosynthetic process [GO:0032958]; MAPK cascade [GO:0000165]; negative regulation of blood vessel endothelial cell migration [GO:0043537]; negative regulation of cell death [GO:0060548]; negative regulation of fibroblast migration [GO:0010764]; negative regulation of wound healing [GO:0061045]; nervous system development [GO:0007399]; phosphatidylinositol biosynthetic process [GO:0006661]; phosphatidylinositol-mediated signaling [GO:0048015]; positive regulation of angiogenesis [GO:0045766]; positive regulation of blood vessel endothelial cell migration [GO:0043536]; positive regulation of cardiac muscle cell proliferation [GO:0060045]; positive regulation of cell division [GO:0051781]; positive regulation of cell fate specification [GO:0042660]; positive regulation of cell proliferation [GO:0008284]; positive regulation of endothelial cell chemotaxis to fibroblast growth factor [GO:2000546]; positive regulation of endothelial cell proliferation [GO:0001938]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of phosphatidylinositol 3-kinase activity [GO:0043552]; positive regulation of phospholipase C activity [GO:0010863]; positive regulation of protein complex assembly [GO:0031334]; positive regulation of sprouting angiogenesis [GO:1903672]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; Ras protein signal transduction [GO:0007265]; regulation of angiogenesis [GO:0045765]; regulation of endothelial cell chemotaxis to fibroblast growth factor [GO:2000544]; regulation of phosphatidylinositol 3-kinase signaling [GO:0014066]; release of sequestered calcium ion into cytosol [GO:0051209]; signal transduction [GO:0007165]; somatic stem cell population maintenance [GO:0035019]; wound healing [GO:0042060]	1-phosphatidylinositol-3-kinase activity [GO:0016303]; chemoattractant activity [GO:0042056]; cytokine activity [GO:0005125]; fibroblast growth factor receptor binding [GO:0005104]; growth factor activity [GO:0008083]; heparin binding [GO:0008201]; ligand-dependent nuclear receptor transcription coactivator activity [GO:0030374]; phosphatidylinositol-4,5-bisphosphate 3-kinase activity [GO:0046934]; protein tyrosine kinase activity [GO:0004713]; Ras guanyl-nucleotide exchange factor activity [GO:0005088]	extracellular region [GO:0005576]; extracellular space [GO:0005615]; nucleus [GO:0005634]
P08620	FGF4_HUMAN	Fibroblast growth factor 4 (FGF-4) (Heparin secretory-transforming protein 1) (HST) (HST-1) (HSTF-1) (Heparin-binding growth factor 4) (HBGF-4) (Transforming protein KS3)	FGF4 HST HSTF1 KS3	1IJT;	CHEMBL3286072;	P08620;	DB00686;		PF00167;	IPR008996;IPR028239;IPR002209;IPR028142;	apoptotic process involved in morphogenesis [GO:0060561]; cartilage condensation [GO:0001502]; cell-cell signaling [GO:0007267]; chondroblast differentiation [GO:0060591]; cranial suture morphogenesis [GO:0060363]; embryonic hindlimb morphogenesis [GO:0035116]; fibroblast growth factor receptor signaling pathway [GO:0008543]; MAPK cascade [GO:0000165]; mesenchymal cell proliferation [GO:0010463]; negative regulation of apoptotic process [GO:0043066]; odontogenesis of dentin-containing tooth [GO:0042475]; phosphatidylinositol-mediated signaling [GO:0048015]; positive regulation of cell division [GO:0051781]; positive regulation of cell proliferation [GO:0008284]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; regulation of endothelial cell chemotaxis to fibroblast growth factor [GO:2000544]; regulation of phosphatidylinositol 3-kinase signaling [GO:0014066]; signal transduction [GO:0007165]; stem cell population maintenance [GO:0019827]	1-phosphatidylinositol-3-kinase activity [GO:0016303]; growth factor activity [GO:0008083]; heparin binding [GO:0008201]; phosphatidylinositol-4,5-bisphosphate 3-kinase activity [GO:0046934]; protein tyrosine kinase activity [GO:0004713]; Ras guanyl-nucleotide exchange factor activity [GO:0005088]	extracellular region [GO:0005576]; intracellular [GO:0005622]
P21802	FGFR2_HUMAN	Fibroblast growth factor receptor 2 (FGFR-2) (EC 2.7.10.1) (K-sam) (KGFR) (Keratinocyte growth factor receptor) (CD antigen CD332)	FGFR2 BEK KGFR KSAM	1DJS;1E0O;1EV2;1GJO;1II4;1IIL;1NUN;1OEC;1WVZ;2FDB;2PSQ;2PVF;2PVY;2PWL;2PY3;2PZ5;2PZP;2PZR;2Q0B;3B2T;3CAF;3CLY;3CU1;3DAR;3EUU;3OJ2;3OJM;3RI1;4J23;4J95;4J96;4J97;4J98;4J99;4WV1;5EG3;	CHEMBL4142;	P21802;	DB09078;DB09079;DB00039;DB08901;DB08896;DB01041;		PF07679;PF07714;	IPR016248;IPR007110;IPR013783;IPR013098;IPR003599;IPR003598;IPR011009;IPR000719;IPR017441;IPR001245;IPR008266;IPR020635;	angiogenesis [GO:0001525]; animal organ morphogenesis [GO:0009887]; apoptotic process [GO:0006915]; axonogenesis [GO:0007409]; bone development [GO:0060348]; bone mineralization [GO:0030282]; bone morphogenesis [GO:0060349]; branch elongation involved in salivary gland morphogenesis [GO:0060667]; branching involved in labyrinthine layer morphogenesis [GO:0060670]; branching involved in prostate gland morphogenesis [GO:0060442]; branching involved in salivary gland morphogenesis [GO:0060445]; branching morphogenesis of a nerve [GO:0048755]; bud elongation involved in lung branching [GO:0060449]; cell-cell signaling [GO:0007267]; cell fate commitment [GO:0045165]; digestive tract development [GO:0048565]; embryonic cranial skeleton morphogenesis [GO:0048701]; embryonic digestive tract morphogenesis [GO:0048557]; embryonic organ development [GO:0048568]; embryonic organ morphogenesis [GO:0048562]; embryonic pattern specification [GO:0009880]; epidermis morphogenesis [GO:0048730]; epithelial cell differentiation [GO:0030855]; epithelial cell proliferation involved in salivary gland morphogenesis [GO:0060664]; epithelial to mesenchymal transition [GO:0001837]; fibroblast growth factor receptor signaling pathway [GO:0008543]; fibroblast growth factor receptor signaling pathway involved in hemopoiesis [GO:0035603]; fibroblast growth factor receptor signaling pathway involved in mammary gland specification [GO:0060595]; fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow [GO:0035602]; fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development [GO:0035607]; fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrow [GO:0035604]; gland morphogenesis [GO:0022612]; hair follicle morphogenesis [GO:0031069]; inner ear morphogenesis [GO:0042472]; in utero embryonic development [GO:0001701]; lacrimal gland development [GO:0032808]; lateral sprouting from an epithelium [GO:0060601]; limb bud formation [GO:0060174]; lung alveolus development [GO:0048286]; lung-associated mesenchyme development [GO:0060484]; lung development [GO:0030324]; lung lobe morphogenesis [GO:0060463]; mammary gland bud formation [GO:0060615]; MAPK cascade [GO:0000165]; membranous septum morphogenesis [GO:0003149]; mesenchymal cell differentiation [GO:0048762]; mesenchymal cell differentiation involved in lung development [GO:0060915]; mesenchymal cell proliferation involved in lung development [GO:0060916]; mesodermal cell differentiation [GO:0048333]; midbrain development [GO:0030901]; morphogenesis of embryonic epithelium [GO:0016331]; multicellular organism growth [GO:0035264]; negative regulation of epithelial cell proliferation [GO:0050680]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; odontogenesis [GO:0042476]; orbitofrontal cortex development [GO:0021769]; organ growth [GO:0035265]; otic vesicle formation [GO:0030916]; outflow tract septum morphogenesis [GO:0003148]; peptidyl-tyrosine phosphorylation [GO:0018108]; phosphatidylinositol-mediated signaling [GO:0048015]; positive regulation of canonical Wnt signaling pathway [GO:0090263]; positive regulation of cardiac muscle cell proliferation [GO:0060045]; positive regulation of cell cycle [GO:0045787]; positive regulation of cell division [GO:0051781]; positive regulation of cell proliferation [GO:0008284]; positive regulation of epithelial cell proliferation [GO:0050679]; positive regulation of epithelial cell proliferation involved in lung morphogenesis [GO:0060501]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of MAPK cascade [GO:0043410]; positive regulation of mesenchymal cell proliferation [GO:0002053]; positive regulation of phospholipase activity [GO:0010518]; positive regulation of smooth muscle cell proliferation [GO:0048661]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of Wnt signaling pathway [GO:0030177]; post-embryonic development [GO:0009791]; prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis [GO:0060527]; prostate epithelial cord elongation [GO:0060523]; prostate gland morphogenesis [GO:0060512]; protein autophosphorylation [GO:0046777]; pyramidal neuron development [GO:0021860]; regulation of branching involved in prostate gland morphogenesis [GO:0060687]; regulation of cell fate commitment [GO:0010453]; regulation of ERK1 and ERK2 cascade [GO:0070372]; regulation of fibroblast growth factor receptor signaling pathway [GO:0040036]; regulation of morphogenesis of a branching structure [GO:0060688]; regulation of multicellular organism growth [GO:0040014]; regulation of osteoblast differentiation [GO:0045667]; regulation of osteoblast proliferation [GO:0033688]; regulation of phosphatidylinositol 3-kinase signaling [GO:0014066]; regulation of smoothened signaling pathway [GO:0008589]; regulation of smooth muscle cell differentiation [GO:0051150]; reproductive structure development [GO:0048608]; skeletal system morphogenesis [GO:0048705]; squamous basal epithelial stem cell differentiation involved in prostate gland acinus development [GO:0060529]; ureteric bud development [GO:0001657]; ventricular cardiac muscle tissue morphogenesis [GO:0055010]; ventricular zone neuroblast division [GO:0021847]	1-phosphatidylinositol-3-kinase activity [GO:0016303]; ATP binding [GO:0005524]; fibroblast growth factor-activated receptor activity [GO:0005007]; fibroblast growth factor binding [GO:0017134]; heparin binding [GO:0008201]; phosphatidylinositol-4,5-bisphosphate 3-kinase activity [GO:0046934]; protein homodimerization activity [GO:0042803]; protein tyrosine kinase activity [GO:0004713]; Ras guanyl-nucleotide exchange factor activity [GO:0005088]	cell cortex [GO:0005938]; cell surface [GO:0009986]; cytoplasm [GO:0005737]; cytoplasmic, membrane-bounded vesicle [GO:0016023]; excitatory synapse [GO:0060076]; extracellular region [GO:0005576]; Golgi apparatus [GO:0005794]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; intracellular membrane-bounded organelle [GO:0043231]; membrane [GO:0016020]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
P49789	FHIT_HUMAN	Bis(5'-adenosyl)-triphosphatase (EC 3.6.1.29) (AP3A hydrolase) (AP3Aase) (Diadenosine 5',5'''-P1,P3-triphosphate hydrolase) (Dinucleosidetriphosphatase) (Fragile histidine triad protein)	FHIT	1FHI;1FIT;2FHI;2FIT;3FIT;4FIT;5FIT;6FIT;	CHEMBL1795151;	P49789;			PF01230;	IPR019808;IPR001310;IPR011146;	intrinsic apoptotic signaling pathway by p53 class mediator [GO:0072332]; negative regulation of proteasomal ubiquitin-dependent protein catabolic process [GO:0032435]; nucleotide metabolic process [GO:0009117]; purine nucleotide metabolic process [GO:0006163]; regulation of transcription, DNA-templated [GO:0006355]; transcription, DNA-templated [GO:0006351]	bis(5'-adenosyl)-triphosphatase activity [GO:0047710]; catalytic activity [GO:0003824]; hydrolase activity [GO:0016787]; identical protein binding [GO:0042802]; nucleotide binding [GO:0000166]; ubiquitin protein ligase binding [GO:0031625]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrion [GO:0005739]; nucleus [GO:0005634]
P02671	FIBA_HUMAN	Fibrinogen alpha chain [Cleaved into: Fibrinopeptide A; Fibrinogen alpha chain]	FGA	1BBR;1DM4;1FPH;1FZA;1FZB;1FZC;1FZD;1FZE;1FZF;1FZG;1LT9;1LTJ;1N86;1N8E;1RE3;1RE4;1RF0;1RF1;1YCP;2A45;2FFD;2H43;2HLO;2HOD;2HPC;2OYH;2OYI;2Q9I;2XNX;2XNY;2Z4E;3AT0;3BVH;3E1I;3GHG;3H32;3HUS;4F27;5CFA;	CHEMBL2364709;		DB00009;DB00029;DB00015;DB00364;DB00031;		PF08702;PF12160;PF00147;	IPR014716;IPR014715;IPR002181;IPR012290;IPR021996;IPR020837;	adaptive immune response [GO:0002250]; blood coagulation [GO:0007596]; blood coagulation, common pathway [GO:0072377]; blood coagulation, fibrin clot formation [GO:0072378]; cell-matrix adhesion [GO:0007160]; cellular protein complex assembly [GO:0043623]; cellular protein metabolic process [GO:0044267]; extracellular matrix organization [GO:0030198]; fibrinolysis [GO:0042730]; induction of bacterial agglutination [GO:0043152]; innate immune response [GO:0045087]; negative regulation of blood coagulation, common pathway [GO:2000261]; negative regulation of endothelial cell apoptotic process [GO:2000352]; negative regulation of extrinsic apoptotic signaling pathway via death domain receptors [GO:1902042]; plasminogen activation [GO:0031639]; platelet aggregation [GO:0070527]; platelet degranulation [GO:0002576]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of exocytosis [GO:0045921]; positive regulation of heterotypic cell-cell adhesion [GO:0034116]; positive regulation of peptide hormone secretion [GO:0090277]; positive regulation of protein secretion [GO:0050714]; positive regulation of substrate adhesion-dependent cell spreading [GO:1900026]; positive regulation of vasoconstriction [GO:0045907]; protein complex assembly [GO:0006461]; protein polymerization [GO:0051258]; response to calcium ion [GO:0051592]; signal transduction [GO:0007165]	metal ion binding [GO:0046872]; structural molecule activity [GO:0005198]	blood microparticle [GO:0072562]; cell cortex [GO:0005938]; cell surface [GO:0009986]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; extracellular vesicle [GO:1903561]; fibrinogen complex [GO:0005577]; plasma membrane [GO:0005886]; platelet alpha granule [GO:0031091]; platelet alpha granule lumen [GO:0031093]
P02675	FIBB_HUMAN	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	FGB	1FZA;1FZB;1FZC;1FZE;1FZF;1FZG;1LT9;1LTJ;1N86;1N8E;1RE3;1RE4;1RF0;1RF1;2A45;2FFD;2H43;2HLO;2HOD;2HPC;2OYH;2OYI;2Q9I;2XNX;2XNY;2Z4E;3BVH;3E1I;3GHG;3H32;3HUS;	CHEMBL2364709;		DB00364;		PF08702;PF00147;	IPR014716;IPR014715;IPR002181;IPR012290;IPR020837;	adaptive immune response [GO:0002250]; blood coagulation [GO:0007596]; blood coagulation, fibrin clot formation [GO:0072378]; cell-matrix adhesion [GO:0007160]; cellular protein complex assembly [GO:0043623]; cellular response to interleukin-1 [GO:0071347]; cellular response to leptin stimulus [GO:0044320]; extracellular matrix organization [GO:0030198]; fibrinolysis [GO:0042730]; induction of bacterial agglutination [GO:0043152]; innate immune response [GO:0045087]; negative regulation of endothelial cell apoptotic process [GO:2000352]; negative regulation of extrinsic apoptotic signaling pathway via death domain receptors [GO:1902042]; plasminogen activation [GO:0031639]; platelet aggregation [GO:0070527]; platelet degranulation [GO:0002576]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of exocytosis [GO:0045921]; positive regulation of heterotypic cell-cell adhesion [GO:0034116]; positive regulation of peptide hormone secretion [GO:0090277]; positive regulation of protein secretion [GO:0050714]; positive regulation of substrate adhesion-dependent cell spreading [GO:1900026]; positive regulation of vasoconstriction [GO:0045907]; protein polymerization [GO:0051258]; response to calcium ion [GO:0051592]; signal transduction [GO:0007165]	chaperone binding [GO:0051087]; structural molecule activity [GO:0005198]	blood microparticle [GO:0072562]; cell cortex [GO:0005938]; cell surface [GO:0009986]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; extracellular vesicle [GO:1903561]; fibrinogen complex [GO:0005577]; plasma membrane [GO:0005886]; platelet alpha granule [GO:0031091]; platelet alpha granule lumen [GO:0031093]
P02679	FIBG_HUMAN	Fibrinogen gamma chain	FGG PRO2061	1DUG;1FIB;1FIC;1FID;1FZA;1FZB;1FZC;1FZE;1FZF;1FZG;1LT9;1LTJ;1N86;1N8E;1RE3;1RE4;1RF0;1RF1;2A45;2FFD;2FIB;2H43;2HLO;2HOD;2HPC;2HWL;2OYH;2OYI;2Q9I;2VDO;2VDP;2VDQ;2VDR;2VR3;2XNX;2XNY;2Y7L;2Z4E;3BVH;3E1I;3FIB;3GHG;3H32;3HUS;4B60;	CHEMBL2364709;		DB00364;		PF08702;PF00147;	IPR014716;IPR014715;IPR002181;IPR012290;IPR020837;	blood coagulation [GO:0007596]; blood coagulation, fibrin clot formation [GO:0072378]; cell-matrix adhesion [GO:0007160]; cellular protein complex assembly [GO:0043623]; extracellular matrix organization [GO:0030198]; fibrinolysis [GO:0042730]; negative regulation of endothelial cell apoptotic process [GO:2000352]; negative regulation of extrinsic apoptotic signaling pathway via death domain receptors [GO:1902042]; plasminogen activation [GO:0031639]; platelet aggregation [GO:0070527]; platelet degranulation [GO:0002576]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of exocytosis [GO:0045921]; positive regulation of heterotypic cell-cell adhesion [GO:0034116]; positive regulation of peptide hormone secretion [GO:0090277]; positive regulation of protein secretion [GO:0050714]; positive regulation of substrate adhesion-dependent cell spreading [GO:1900026]; positive regulation of vasoconstriction [GO:0045907]; protein polymerization [GO:0051258]; protein secretion [GO:0009306]; response to calcium ion [GO:0051592]; signal transduction [GO:0007165]	cell adhesion molecule binding [GO:0050839]; metal ion binding [GO:0046872]; receptor binding [GO:0005102]; structural molecule activity [GO:0005198]	blood microparticle [GO:0072562]; cell cortex [GO:0005938]; cell surface [GO:0009986]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; fibrinogen complex [GO:0005577]; plasma membrane [GO:0005886]; platelet alpha granule [GO:0031091]; platelet alpha granule lumen [GO:0031093]
P62942	FKB1A_HUMAN	Peptidyl-prolyl cis-trans isomerase FKBP1A (PPIase FKBP1A) (EC 5.2.1.8) (12 kDa FK506-binding protein) (12 kDa FKBP) (FKBP-12) (Calstabin-1) (FK506-binding protein 1A) (FKBP-1A) (Immunophilin FKBP12) (Rotamase)	FKBP1A FKBP1 FKBP12	1A7X;1B6C;1BKF;1BL4;1D6O;1D7H;1D7I;1D7J;1EYM;1F40;1FAP;1FKB;1FKD;1FKF;1FKG;1FKH;1FKI;1FKJ;1FKR;1FKS;1FKT;1J4H;1J4I;1J4R;1NSG;1QPF;1QPL;2DG3;2DG4;2DG9;2FAP;2FKE;2PPN;2PPO;2PPP;2RSE;3FAP;3H9R;3MDY;4DH0;4FAP;4IPX;4N19;4ODP;4ODQ;4ODR;	CHEMBL1902;	P62942;	DB00337;DB00877;DB00864;		PF00254;	IPR023566;IPR001179;	'de novo' protein folding [GO:0006458]; amyloid fibril formation [GO:1990000]; calcium ion transmembrane transport [GO:0070588]; chaperone-mediated protein folding [GO:0061077]; extracellular fibril organization [GO:0043206]; heart morphogenesis [GO:0003007]; heart trabecula formation [GO:0060347]; negative regulation of protein phosphatase type 2B activity [GO:0032513]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of protein binding [GO:0032092]; positive regulation of protein ubiquitination [GO:0031398]; protein folding [GO:0006457]; protein maturation by protein folding [GO:0022417]; protein peptidyl-prolyl isomerization [GO:0000413]; protein refolding [GO:0042026]; regulation of activin receptor signaling pathway [GO:0032925]; regulation of amyloid precursor protein catabolic process [GO:1902991]; regulation of immune response [GO:0050776]; regulation of protein localization [GO:0032880]; regulation of ryanodine-sensitive calcium-release channel activity [GO:0060314]; SMAD protein complex assembly [GO:0007183]; T cell activation [GO:0042110]; transforming growth factor beta receptor signaling pathway [GO:0007179]; ventricular cardiac muscle tissue morphogenesis [GO:0055010]	activin binding [GO:0048185]; FK506 binding [GO:0005528]; ion channel binding [GO:0044325]; macrolide binding [GO:0005527]; peptidyl-prolyl cis-trans isomerase activity [GO:0003755]; signal transducer activity [GO:0004871]; SMAD binding [GO:0046332]; transforming growth factor beta receptor binding [GO:0005160]; type I transforming growth factor beta receptor binding [GO:0034713]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; endoplasmic reticulum membrane [GO:0005789]; extracellular exosome [GO:0070062]; extracellular matrix [GO:0031012]; membrane [GO:0016020]; terminal cisterna [GO:0014802]; Z disc [GO:0030018]
P68106	FKB1B_HUMAN	Peptidyl-prolyl cis-trans isomerase FKBP1B (PPIase FKBP1B) (EC 5.2.1.8) (12.6 kDa FK506-binding protein) (12.6 kDa FKBP) (FKBP-12.6) (FK506-binding protein 1B) (FKBP-1B) (Immunophilin FKBP12.6) (Rotamase) (h-FKBP-12)	FKBP1B FKBP12.6 FKBP1L FKBP9 OTK4	1C9H;3J8E;4C02;4IQ2;4IQC;	CHEMBL2430;	P68106;			PF00254;	IPR023566;IPR001179;	'de novo' protein folding [GO:0006458]; calcium-mediated signaling using intracellular calcium source [GO:0035584]; cell communication by electrical coupling involved in cardiac conduction [GO:0086064]; chaperone-mediated protein folding [GO:0061077]; insulin secretion [GO:0030073]; ion transmembrane transport [GO:0034220]; negative regulation of heart rate [GO:0010459]; negative regulation of insulin secretion involved in cellular response to glucose stimulus [GO:0061179]; negative regulation of protein phosphatase type 2B activity [GO:0032513]; negative regulation of release of sequestered calcium ion into cytosol [GO:0051280]; negative regulation of ryanodine-sensitive calcium-release channel activity [GO:0060315]; neuronal action potential propagation [GO:0019227]; positive regulation of axon regeneration [GO:0048680]; positive regulation of sequestering of calcium ion [GO:0051284]; protein maturation by protein folding [GO:0022417]; protein peptidyl-prolyl isomerization [GO:0000413]; protein refolding [GO:0042026]; regulation of cardiac conduction [GO:1903779]; regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion [GO:0010881]; regulation of cytosolic calcium ion concentration [GO:0051480]; regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum [GO:0010880]; regulation of ryanodine-sensitive calcium-release channel activity [GO:0060314]; release of sequestered calcium ion into cytosol by sarcoplasmic reticulum [GO:0014808]; response to glucose [GO:0009749]; response to hydrogen peroxide [GO:0042542]; response to redox state [GO:0051775]; response to vitamin E [GO:0033197]; smooth muscle contraction [GO:0006939]; T cell proliferation [GO:0042098]	calcium channel inhibitor activity [GO:0019855]; cyclic nucleotide binding [GO:0030551]; FK506 binding [GO:0005528]; ion channel binding [GO:0044325]; peptidyl-prolyl cis-trans isomerase activity [GO:0003755]; receptor binding [GO:0005102]	calcium channel complex [GO:0034704]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; membrane [GO:0016020]; sarcoplasmic reticulum membrane [GO:0033017]; Z disc [GO:0030018]
Q00688	FKBP3_HUMAN	Peptidyl-prolyl cis-trans isomerase FKBP3 (PPIase FKBP3) (EC 5.2.1.8) (25 kDa FK506-binding protein) (25 kDa FKBP) (FKBP-25) (FK506-binding protein 3) (FKBP-3) (Immunophilin FKBP25) (Rapamycin-selective 25 kDa immunophilin) (Rotamase)	FKBP3 FKBP25	1PBK;2KFV;2MPH;5D75;	CHEMBL4746;	Q00688;			PF00254;	IPR023566;IPR001179;	chaperone-mediated protein folding [GO:0061077]	FK506 binding [GO:0005528]; peptidyl-prolyl cis-trans isomerase activity [GO:0003755]; poly(A) RNA binding [GO:0044822]; receptor activity [GO:0004872]	endoplasmic reticulum membrane [GO:0005789]; nucleus [GO:0005634]
Q02790	FKBP4_HUMAN	Peptidyl-prolyl cis-trans isomerase FKBP4 (PPIase FKBP4) (EC 5.2.1.8) (51 kDa FK506-binding protein) (FKBP51) (52 kDa FK506-binding protein) (52 kDa FKBP) (FKBP-52) (59 kDa immunophilin) (p59) (FK506-binding protein 4) (FKBP-4) (FKBP59) (HSP-binding immunophilin) (HBI) (Immunophilin FKBP52) (Rotamase) [Cleaved into: Peptidyl-prolyl cis-trans isomerase FKBP4, N-terminally processed]	FKBP4 FKBP52	1N1A;1P5Q;1Q1C;1QZ2;4DRJ;4LAV;4LAW;4LAX;4LAY;4TW8;	CHEMBL4050;	Q02790;			PF00254;PF00515;PF07719;	IPR031212;IPR023566;IPR001179;IPR013026;IPR011990;IPR001440;IPR013105;IPR019734;	androgen receptor signaling pathway [GO:0030521]; chaperone-mediated protein folding [GO:0061077]; copper ion transport [GO:0006825]; embryo implantation [GO:0007566]; male sex differentiation [GO:0046661]; negative regulation of microtubule polymerization [GO:0031115]; negative regulation of microtubule polymerization or depolymerization [GO:0031111]; negative regulation of neuron projection development [GO:0010977]; prostate gland development [GO:0030850]; protein complex localization [GO:0031503]; protein folding [GO:0006457]; regulation of cellular response to heat [GO:1900034]; steroid hormone receptor complex assembly [GO:0006463]	ATP binding [GO:0005524]; FK506 binding [GO:0005528]; GTP binding [GO:0005525]; heat shock protein binding [GO:0031072]; peptidyl-prolyl cis-trans isomerase activity [GO:0003755]; poly(A) RNA binding [GO:0044822]; protein binding, bridging [GO:0030674]	axonal growth cone [GO:0044295]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; endoplasmic reticulum membrane [GO:0005789]; extracellular exosome [GO:0070062]; microtubule [GO:0005874]; mitochondrion [GO:0005739]; neuronal cell body [GO:0043025]; nucleoplasm [GO:0005654]; perinuclear region of cytoplasm [GO:0048471]; protein complex [GO:0043234]
P36888	FLT3_HUMAN	Receptor-type tyrosine-protein kinase FLT3 (EC 2.7.10.1) (FL cytokine receptor) (Fetal liver kinase-2) (FLK-2) (Fms-like tyrosine kinase 3) (FLT-3) (Stem cell tyrosine kinase 1) (STK-1) (CD antigen CD135)	FLT3 CD135 FLK2 STK1	1RJB;3QS7;3QS9;4RT7;4XUF;	CHEMBL1974;	P36888;	DB09079;DB08901;DB00398;DB01268;		PF00047;PF07714;	IPR030118;IPR007110;IPR013783;IPR013151;IPR011009;IPR000719;IPR017441;IPR001245;IPR008266;IPR020635;IPR001824;	animal organ regeneration [GO:0031100]; B cell differentiation [GO:0030183]; cellular response to cytokine stimulus [GO:0071345]; cellular response to glucocorticoid stimulus [GO:0071385]; common myeloid progenitor cell proliferation [GO:0035726]; cytokine-mediated signaling pathway [GO:0019221]; dendritic cell differentiation [GO:0097028]; hemopoiesis [GO:0030097]; leukocyte homeostasis [GO:0001776]; lymphocyte proliferation [GO:0046651]; myeloid progenitor cell differentiation [GO:0002318]; peptidyl-tyrosine phosphorylation [GO:0018108]; positive regulation of cell proliferation [GO:0008284]; positive regulation of MAPK cascade [GO:0043410]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of phosphatidylinositol 3-kinase activity [GO:0043552]; positive regulation of phosphatidylinositol 3-kinase signaling [GO:0014068]; positive regulation of tyrosine phosphorylation of STAT protein [GO:0042531]; pro-B cell differentiation [GO:0002328]; protein autophosphorylation [GO:0046777]; regulation of apoptotic process [GO:0042981]; response to organonitrogen compound [GO:0010243]; transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169]	ATP binding [GO:0005524]; cytokine receptor activity [GO:0004896]; protein homodimerization activity [GO:0042803]; transmembrane receptor protein tyrosine kinase activity [GO:0004714]; vascular endothelial growth factor-activated receptor activity [GO:0005021]	cytosol [GO:0005829]; endoplasmic reticulum lumen [GO:0005788]; integral component of plasma membrane [GO:0005887]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; protein complex [GO:0043234]
Q96DP5	FMT_HUMAN	Methionyl-tRNA formyltransferase, mitochondrial (MtFMT) (EC 2.1.2.9)	MTFMT FMT FMT1				DB00116;		PF02911;PF00551;	IPR005794;IPR005793;IPR002376;IPR011034;		methionyl-tRNA formyltransferase activity [GO:0004479]	mitochondrion [GO:0005739]
Q05932	FOLC_HUMAN	Folylpolyglutamate synthase, mitochondrial (EC 6.3.2.17) (Folylpoly-gamma-glutamate synthetase) (FPGS) (Tetrahydrofolylpolyglutamate synthase) (Tetrahydrofolate synthase)	FPGS		CHEMBL3171;	Q05932;	DB00563;DB06813;DB00293;	PATHWAY: Cofactor biosynthesis; tetrahydrofolylpolyglutamate biosynthesis.		IPR001645;IPR018109;IPR023600;IPR004101;IPR013221;	animal organ regeneration [GO:0031100]; brain development [GO:0007420]; cell proliferation [GO:0008283]; folic acid-containing compound metabolic process [GO:0006760]; folic acid metabolic process [GO:0046655]; glutamate metabolic process [GO:0006536]; liver development [GO:0001889]; nucleobase-containing compound metabolic process [GO:0006139]; one-carbon metabolic process [GO:0006730]; tetrahydrofolylpolyglutamate biosynthetic process [GO:0046901]	ATP binding [GO:0005524]; tetrahydrofolylpolyglutamate synthase activity [GO:0004326]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
Q04609	FOLH1_HUMAN	Glutamate carboxypeptidase 2 (EC 3.4.17.21) (Cell growth-inhibiting gene 27 protein) (Folate hydrolase 1) (Folylpoly-gamma-glutamate carboxypeptidase) (FGCP) (Glutamate carboxypeptidase II) (GCPII) (Membrane glutamate carboxypeptidase) (mGCP) (N-acetylated-alpha-linked acidic dipeptidase I) (NAALADase I) (Prostate-specific membrane antigen) (PSM) (PSMA) (Pteroylpoly-gamma-glutamate carboxypeptidase)	FOLH1 FOLH NAALAD1 PSM PSMA GIG27	1Z8L;2C6C;2C6G;2C6P;2CIJ;2JBJ;2JBK;2OOT;2OR4;2PVV;2PVW;2XEF;2XEG;2XEI;2XEJ;3BHX;3BI0;3BI1;3BXM;3D7D;3D7F;3D7G;3D7H;3IWW;3RBU;3SJE;3SJF;3SJG;3SJX;4JYW;4JZ0;4LQG;4MCP;4MCQ;4MCR;4MCS;4NGM;4NGN;4NGP;4NGQ;4NGR;4NGS;4NGT;4OC0;4OC1;4OC2;4OC3;4OC4;4OC5;4OME;4P44;4P45;4P4B;4P4D;4P4E;4P4F;4P4I;4P4J;4W9Y;4X3R;5D29;5ELY;5F09;	CHEMBL1892;	Q04609;	DB00089;		PF02225;PF04389;PF04253;	IPR003137;IPR007484;IPR007365;	cellular amino acid biosynthetic process [GO:0008652]; C-terminal protein deglutamylation [GO:0035609]; folic acid-containing compound metabolic process [GO:0006760]; proteolysis [GO:0006508]	Ac-Asp-Glu binding [GO:1904492]; dipeptidase activity [GO:0016805]; metal ion binding [GO:0046872]; metallocarboxypeptidase activity [GO:0004181]; peptidase activity [GO:0008233]; tetrahydrofolyl-poly(glutamate) polymer binding [GO:1904493]	cell surface [GO:0009986]; cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]
P14207	FOLR2_HUMAN	Folate receptor beta (FR-beta) (Folate receptor 2) (Folate receptor, fetal/placental) (Placental folate-binding protein) (FBP)	FOLR2	4KMY;4KMZ;4KN0;4KN1;4KN2;	CHEMBL5064;	P14207;	DB00158;		PF03024;	IPR004269;IPR018143;IPR032937;	folic acid transport [GO:0015884]; inflammatory response [GO:0006954]; positive regulation of cell proliferation [GO:0008284]; receptor-mediated endocytosis [GO:0006898]; regulation of thymidylate synthase biosynthetic process [GO:0050758]	drug binding [GO:0008144]; folic acid binding [GO:0005542]; folic acid receptor activity [GO:0061714]; folic acid transporter activity [GO:0008517]; methotrexate binding [GO:0051870]	anchored component of external side of plasma membrane [GO:0031362]; cell surface [GO:0009986]; extracellular region [GO:0005576]; membrane [GO:0016020]
P41439	FOLR3_HUMAN	Folate receptor gamma (FR-gamma) (Folate receptor 3)	FOLR3				DB00158;		PF03024;	IPR004269;IPR018143;IPR032934;	folic acid transport [GO:0015884]	folic acid binding [GO:0005542]	extracellular region [GO:0005576]; extrinsic component of membrane [GO:0019898]; membrane [GO:0016020]
P14324	FPPS_HUMAN	Farnesyl pyrophosphate synthase (FPP synthase) (FPS) (EC 2.5.1.10) ((2E,6E)-farnesyl diphosphate synthase) (Dimethylallyltranstransferase) (EC 2.5.1.1) (Farnesyl diphosphate synthase) (Geranyltranstransferase)	FDPS FPS KIAA1293	1YQ7;1YV5;1ZW5;2F7M;2F89;2F8C;2F8Z;2F92;2F94;2F9K;2OPM;2OPN;2QIS;2RAH;2VF6;3B7L;3CP6;3N1V;3N1W;3N3L;3N45;3N46;3N49;3N5H;3N5J;3N6K;3RYE;3S4J;4DEM;4GA3;4H5C;4H5D;4H5E;4JVJ;4KFA;4KPD;4KPJ;4KQ5;4KQS;4KQU;4L2X;4LFV;4LPG;4LPH;4N1Z;4N9U;4NFI;4NFJ;4NFK;4NG6;4NKE;4NKF;4NUA;4OGU;4P0V;4P0W;4P0X;4PVX;4PVY;4Q23;4QPF;4QXS;4RXA;4XQR;4XQS;4XQT;5CG5;5CG6;5DGM;5DGN;5DGS;5DIQ;5DJP;5DJR;5DJV;	CHEMBL1782;	P14324;	DB00630;DB00710;DB00282;DB00884;DB00399;	PATHWAY: Isoprenoid biosynthesis; farnesyl diphosphate biosynthesis; farnesyl diphosphate from geranyl diphosphate and isopentenyl diphosphate: step 1/1.; PATHWAY: Isoprenoid biosynthesis; geranyl diphosphate biosynthesis; geranyl diphosphate from dimethylallyl diphosphate and isopentenyl diphosphate: step 1/1.	PF00348;	IPR008949;IPR000092;	cholesterol biosynthetic process [GO:0006695]; farnesyl diphosphate biosynthetic process [GO:0045337]; geranyl diphosphate biosynthetic process [GO:0033384]; viral process [GO:0016032]	dimethylallyltranstransferase activity [GO:0004161]; geranyltranstransferase activity [GO:0004337]; metal ion binding [GO:0046872]; poly(A) RNA binding [GO:0044822]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleoplasm [GO:0005654]
P21462	FPR1_HUMAN	fMet-Leu-Phe receptor (fMLP receptor) (N-formyl peptide receptor) (FPR) (N-formylpeptide chemoattractant receptor)	FPR1		CHEMBL3359;	P21462;	DB00716;		PF00001;	IPR027345;IPR000826;IPR000276;IPR017452;	activation of MAPK activity [GO:0000187]; adenylate cyclase-modulating G-protein coupled receptor signaling pathway [GO:0007188]; cell chemotaxis [GO:0060326]; chemotaxis [GO:0006935]; complement receptor mediated signaling pathway [GO:0002430]; G-protein coupled receptor signaling pathway [GO:0007186]; inflammatory response [GO:0006954]; leukocyte migration [GO:0050900]; nitric oxide mediated signal transduction [GO:0007263]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; signal transduction [GO:0007165]	complement receptor activity [GO:0004875]; N-formyl peptide receptor activity [GO:0004982]	integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; intracellular [GO:0005622]; plasma membrane [GO:0005886]
P42345	FRAP_HUMAN	Serine/threonine-protein kinase mTOR (EC 2.7.11.1) (FK506-binding protein 12-rapamycin complex-associated protein 1) (FKBP12-rapamycin complex-associated protein) (Mammalian target of rapamycin) (mTOR) (Mechanistic target of rapamycin) (Rapamycin and FKBP12 target 1) (Rapamycin target protein 1)	MTOR FRAP FRAP1 FRAP2 RAFT1 RAPT1	1AUE;1FAP;1NSG;2FAP;2GAQ;2NPU;2RSE;3FAP;4DRH;4DRI;4DRJ;4FAP;4JSN;4JSP;4JSV;4JSX;4JT5;4JT6;5FLC;	CHEMBL2842;	P42345;	DB01590;DB00337;DB00877;DB06287;		PF11865;PF02259;PF02260;PF08771;PF00454;	IPR011989;IPR016024;IPR024585;IPR003152;IPR009076;IPR011009;IPR000403;IPR018936;IPR003151;IPR014009;IPR026683;IPR011990;	'de novo' pyrimidine nucleobase biosynthetic process [GO:0006207]; brain development [GO:0007420]; cardiac muscle cell development [GO:0055013]; cardiac muscle contraction [GO:0060048]; cell aging [GO:0007569]; cell cycle arrest [GO:0007050]; cell growth [GO:0016049]; cellular response to hypoxia [GO:0071456]; cellular response to nutrient levels [GO:0031669]; DNA repair [GO:0006281]; energy reserve metabolic process [GO:0006112]; germ cell development [GO:0007281]; growth [GO:0040007]; heart morphogenesis [GO:0003007]; heart valve morphogenesis [GO:0003179]; long-term memory [GO:0007616]; macroautophagy [GO:0016236]; maternal process involved in female pregnancy [GO:0060135]; mRNA stabilization [GO:0048255]; multicellular organism growth [GO:0035264]; negative regulation of autophagy [GO:0010507]; negative regulation of cell size [GO:0045792]; negative regulation of cholangiocyte apoptotic process [GO:1904193]; negative regulation of iodide transmembrane transport [GO:1904213]; negative regulation of macroautophagy [GO:0016242]; negative regulation of muscle atrophy [GO:0014736]; negative regulation of NFAT protein import into nucleus [GO:0051534]; negative regulation of protein phosphorylation [GO:0001933]; negative regulation of protein ubiquitination [GO:0031397]; peptidyl-serine phosphorylation [GO:0018105]; peptidyl-threonine phosphorylation [GO:0018107]; phosphatidylinositol-mediated signaling [GO:0048015]; phosphorylation [GO:0016310]; positive regulation of actin filament polymerization [GO:0030838]; positive regulation of cell growth involved in cardiac muscle cell development [GO:0061051]; positive regulation of cholangiocyte proliferation [GO:1904056]; positive regulation of dendritic spine development [GO:0060999]; positive regulation of eating behavior [GO:1904000]; positive regulation of endothelial cell proliferation [GO:0001938]; positive regulation of gene expression [GO:0010628]; positive regulation of glial cell proliferation [GO:0060252]; positive regulation of granulosa cell proliferation [GO:1904197]; positive regulation of lamellipodium assembly [GO:0010592]; positive regulation of lipid biosynthetic process [GO:0046889]; positive regulation of myotube differentiation [GO:0010831]; positive regulation of neuron death [GO:1901216]; positive regulation of neuron maturation [GO:0014042]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; positive regulation of oligodendrocyte differentiation [GO:0048714]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of protein kinase B signaling [GO:0051897]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of sensory perception of pain [GO:1904058]; positive regulation of skeletal muscle hypertrophy [GO:1904206]; positive regulation of smooth muscle cell proliferation [GO:0048661]; positive regulation of stress fiber assembly [GO:0051496]; positive regulation of transcription from RNA polymerase III promoter [GO:0045945]; positive regulation of transcription of nuclear large rRNA transcript from RNA polymerase I promoter [GO:1901838]; positive regulation of translation [GO:0045727]; post-embryonic development [GO:0009791]; protein autophosphorylation [GO:0046777]; protein catabolic process [GO:0030163]; protein phosphorylation [GO:0006468]; regulation of actin cytoskeleton organization [GO:0032956]; regulation of brown fat cell differentiation [GO:0090335]; regulation of carbohydrate utilization [GO:0043610]; regulation of cellular response to heat [GO:1900034]; regulation of fatty acid beta-oxidation [GO:0031998]; regulation of glycogen biosynthetic process [GO:0005979]; regulation of GTPase activity [GO:0043087]; regulation of membrane permeability [GO:0090559]; regulation of myelination [GO:0031641]; regulation of osteoclast differentiation [GO:0045670]; regulation of protein kinase activity [GO:0045859]; regulation of response to food [GO:0032095]; response to amino acid [GO:0043200]; response to cocaine [GO:0042220]; response to insulin [GO:0032868]; response to morphine [GO:0043278]; response to nutrient [GO:0007584]; response to stress [GO:0006950]; ruffle organization [GO:0031529]; signal transduction [GO:0007165]; social behavior [GO:0035176]; spinal cord development [GO:0021510]; T cell costimulation [GO:0031295]; TOR signaling [GO:0031929]; visual learning [GO:0008542]; voluntary musculoskeletal movement [GO:0050882]; wound healing [GO:0042060]	ATP binding [GO:0005524]; kinase activity [GO:0016301]; phosphoprotein binding [GO:0051219]; protein kinase activity [GO:0004672]; protein serine/threonine kinase activity [GO:0004674]; ribosome binding [GO:0043022]; RNA polymerase III type 1 promoter DNA binding [GO:0001030]; RNA polymerase III type 2 promoter DNA binding [GO:0001031]; RNA polymerase III type 3 promoter DNA binding [GO:0001032]; TFIIIC-class transcription factor binding [GO:0001156]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; dendrite [GO:0030425]; endomembrane system [GO:0012505]; endoplasmic reticulum membrane [GO:0005789]; Golgi membrane [GO:0000139]; lysosomal membrane [GO:0005765]; lysosome [GO:0005764]; membrane [GO:0016020]; mitochondrial outer membrane [GO:0005741]; neuronal cell body [GO:0043025]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; phosphatidylinositol 3-kinase complex [GO:0005942]; PML body [GO:0016605]; TORC1 complex [GO:0031931]; TORC2 complex [GO:0031932]
P23945	FSHR_HUMAN	Follicle-stimulating hormone receptor (FSH-R) (Follitropin receptor)	FSHR LGR1	1XUN;1XWD;4AY9;4MQW;	CHEMBL2024;	P23945;	DB00097;DB00066;DB00032;DB04786;DB00094;		PF00001;PF12369;PF13306;PF01462;	IPR002272;IPR024635;IPR000276;IPR017452;IPR002131;IPR032675;IPR026906;IPR000372;	activation of adenylate cyclase activity [GO:0007190]; adenylate cyclase-activating G-protein coupled receptor signaling pathway [GO:0007189]; female gamete generation [GO:0007292]; female gonad development [GO:0008585]; gonad development [GO:0008406]; G-protein coupled receptor signaling pathway [GO:0007186]; hormone-mediated signaling pathway [GO:0009755]; male gonad development [GO:0008584]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of phosphatidylinositol 3-kinase signaling [GO:0014068]; primary ovarian follicle growth [GO:0001545]; regulation of osteoclast differentiation [GO:0045670]; regulation of protein kinase A signaling [GO:0010738]; spermatogenesis [GO:0007283]	follicle-stimulating hormone receptor activity [GO:0004963]; G-protein coupled peptide receptor activity [GO:0008528]	integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
O95954	FTCD_HUMAN	Formimidoyltransferase-cyclodeaminase (Formiminotransferase-cyclodeaminase) (FTCD) (LCHC1) [Includes: Glutamate formimidoyltransferase (EC 2.1.2.5) (Glutamate formiminotransferase) (Glutamate formyltransferase); Formimidoyltetrahydrofolate cyclodeaminase (EC 4.3.1.4) (Formiminotetrahydrofolate cyclodeaminase)]	FTCD				DB00116;	PATHWAY: Amino-acid degradation; L-histidine degradation into L-glutamate; L-glutamate from N-formimidoyl-L-glutamate (transferase route): step 1/1.; PATHWAY: One-carbon metabolism; tetrahydrofolate interconversion.	PF02971;PF04961;PF07837;	IPR007044;IPR013802;IPR004227;IPR012886;IPR022384;	cytoskeleton organization [GO:0007010]; folic acid-containing compound metabolic process [GO:0006760]; histidine catabolic process [GO:0006548]; histidine catabolic process to glutamate and formamide [GO:0019556]; histidine catabolic process to glutamate and formate [GO:0019557]; tetrahydrofolate interconversion [GO:0035999]	folic acid binding [GO:0005542]; formimidoyltetrahydrofolate cyclodeaminase activity [GO:0030412]; formimidoyltransferase activity [GO:0030407]; glutamate formimidoyltransferase activity [GO:0030409]; microtubule binding [GO:0008017]	centriole [GO:0005814]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum-Golgi intermediate compartment [GO:0005793]; extracellular exosome [GO:0070062]; Golgi apparatus [GO:0005794]; Golgi membrane [GO:0000139]; smooth endoplasmic reticulum membrane [GO:0030868]
O75891	FTHFD_HUMAN	Cytosolic 10-formyltetrahydrofolate dehydrogenase (10-FTHFDH) (FDH) (EC 1.5.1.6) (Aldehyde dehydrogenase family 1 member L1)	ALDH1L1 FTHFD	2BW0;2CFI;2CQ8;			DB00116;		PF00171;PF02911;PF00551;PF00550;	IPR011407;IPR016161;IPR016163;IPR016160;IPR029510;IPR016162;IPR015590;IPR005793;IPR002376;IPR011034;IPR001555;IPR009081;	10-formyltetrahydrofolate catabolic process [GO:0009258]; biosynthetic process [GO:0009058]; folic acid metabolic process [GO:0046655]; one-carbon metabolic process [GO:0006730]	4-trimethylammoniobutyraldehyde dehydrogenase activity [GO:0047105]; aldehyde dehydrogenase (NAD) activity [GO:0004029]; aminobutyraldehyde dehydrogenase activity [GO:0019145]; catalytic activity [GO:0003824]; formyltetrahydrofolate dehydrogenase activity [GO:0016155]; hydroxymethyl-, formyl- and related transferase activity [GO:0016742]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrion [GO:0005739]
P06241	FYN_HUMAN	Tyrosine-protein kinase Fyn (EC 2.7.10.2) (Proto-oncogene Syn) (Proto-oncogene c-Fyn) (Src-like kinase) (SLK) (p59-Fyn)	FYN	1A0N;1AOT;1AOU;1AVZ;1AZG;1EFN;1FYN;1G83;1M27;1NYF;1NYG;1SHF;1ZBJ;2DQ7;2MQI;2MRJ;2MRK;3H0F;3H0H;3H0I;3UA6;3UA7;4D8D;4EIK;4U17;4U1P;4ZNX;	CHEMBL1841;	P06241;	DB01254;		PF07714;PF00017;PF00018;	IPR011009;IPR000719;IPR017441;IPR001245;IPR000980;IPR001452;IPR008266;IPR020635;	activated T cell proliferation [GO:0050798]; adaptive immune response [GO:0002250]; axon guidance [GO:0007411]; blood coagulation [GO:0007596]; calcium ion transport [GO:0006816]; cell differentiation [GO:0030154]; cell migration [GO:0016477]; cellular response to peptide hormone stimulus [GO:0071375]; cellular response to platelet-derived growth factor stimulus [GO:0036120]; cellular response to transforming growth factor beta stimulus [GO:0071560]; central nervous system development [GO:0007417]; dendrite morphogenesis [GO:0048813]; detection of mechanical stimulus involved in sensory perception of pain [GO:0050966]; ephrin receptor signaling pathway [GO:0048013]; Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096]; feeding behavior [GO:0007631]; forebrain development [GO:0030900]; innate immune response [GO:0045087]; intracellular signal transduction [GO:0035556]; learning [GO:0007612]; leukocyte migration [GO:0050900]; MAPK cascade [GO:0000165]; negative regulation of extrinsic apoptotic signaling pathway in absence of ligand [GO:2001240]; negative regulation of gene expression [GO:0010629]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of protein catabolic process [GO:0042177]; negative regulation of protein ubiquitination [GO:0031397]; neuron migration [GO:0001764]; peptidyl-tyrosine autophosphorylation [GO:0038083]; peptidyl-tyrosine phosphorylation [GO:0018108]; phosphatidylinositol-mediated signaling [GO:0048015]; platelet activation [GO:0030168]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of neuron projection development [GO:0010976]; positive regulation of phosphatidylinositol 3-kinase signaling [GO:0014068]; positive regulation of protein localization to nucleus [GO:1900182]; positive regulation of tyrosine phosphorylation of Stat5 protein [GO:0042523]; protein phosphorylation [GO:0006468]; regulation of apoptotic process [GO:0042981]; regulation of cell proliferation [GO:0042127]; regulation of cell shape [GO:0008360]; regulation of defense response to virus by virus [GO:0050690]; regulation of phosphatidylinositol 3-kinase signaling [GO:0014066]; response to drug [GO:0042493]; response to ethanol [GO:0045471]; stimulatory C-type lectin receptor signaling pathway [GO:0002223]; T cell activation [GO:0042110]; T cell costimulation [GO:0031295]; T cell receptor signaling pathway [GO:0050852]; transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]; viral process [GO:0016032]	ATP binding [GO:0005524]; ephrin receptor binding [GO:0046875]; glycoprotein binding [GO:0001948]; growth factor receptor binding [GO:0070851]; metal ion binding [GO:0046872]; non-membrane spanning protein tyrosine kinase activity [GO:0004715]; phosphatidylinositol-4,5-bisphosphate 3-kinase activity [GO:0046934]; protein tyrosine kinase activity [GO:0004713]; Ras guanyl-nucleotide exchange factor activity [GO:0005088]	actin filament [GO:0005884]; cytosol [GO:0005829]; endosome [GO:0005768]; extrinsic component of cytoplasmic side of plasma membrane [GO:0031234]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; postsynaptic density [GO:0014069]
Q8TDS4	G109A_HUMAN	Hydroxycarboxylic acid receptor 2 (G-protein coupled receptor 109A) (G-protein coupled receptor HM74A) (Niacin receptor 1) (Nicotinic acid receptor)	HCAR2 GPR109A HCA2 HM74A NIACR1		CHEMBL3785;	Q8TDS4;	DB00627;		PF00001;	IPR000276;IPR017452;IPR028017;	negative regulation of lipid catabolic process [GO:0050995]; neutrophil apoptotic process [GO:0001781]; positive regulation of adiponectin secretion [GO:0070165]; positive regulation of neutrophil apoptotic process [GO:0033031]	nicotinic acid receptor activity [GO:0070553]	cell junction [GO:0030054]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]
P49019	G109B_HUMAN	Hydroxycarboxylic acid receptor 3 (G-protein coupled receptor 109B) (G-protein coupled receptor HM74) (G-protein coupled receptor HM74B) (Niacin receptor 2) (Nicotinic acid receptor 2)	HCAR3 GPR109B HCA3 HM74B NIACR2		CHEMBL4421;	P49019;	DB00627;		PF00001;	IPR000276;IPR017452;IPR028017;	G-protein coupled receptor signaling pathway [GO:0007186]	G-protein coupled receptor activity [GO:0004930]	cell junction [GO:0030054]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
O14556	G3PT_HUMAN	Glyceraldehyde-3-phosphate dehydrogenase, testis-specific (EC 1.2.1.12) (Spermatogenic cell-specific glyceraldehyde 3-phosphate dehydrogenase 2) (GAPDH-2) (Spermatogenic glyceraldehyde-3-phosphate dehydrogenase)	GAPDHS GAPD2 GAPDH2 GAPDS HSD-35 HSD35	3H9E;3PFW;5C7L;5C7O;				PATHWAY: Carbohydrate degradation; glycolysis; pyruvate from D-glyceraldehyde 3-phosphate: step 1/5.	PF02800;PF00044;	IPR020831;IPR020830;IPR020829;IPR020828;IPR006424;IPR016040;	canonical glycolysis [GO:0061621]; flagellated sperm motility [GO:0030317]; gluconeogenesis [GO:0006094]; positive regulation of glycolytic process [GO:0045821]	glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity [GO:0004365]; NAD binding [GO:0051287]; NADP binding [GO:0050661]	cytosol [GO:0005829]; nucleus [GO:0005634]
P04406	G3P_HUMAN	Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (EC 1.2.1.12) (Peptidyl-cysteine S-nitrosylase GAPDH) (EC 2.6.99.-)	GAPDH GAPD CDABP0047 OK/SW-cl.12	1U8F;1ZNQ;2FEH;3GPD;4WNC;4WNI;	CHEMBL2284;	P04406;		PATHWAY: Carbohydrate degradation; glycolysis; pyruvate from D-glyceraldehyde 3-phosphate: step 1/5.	PF02800;PF00044;	IPR020831;IPR020830;IPR020829;IPR020828;IPR006424;IPR016040;	canonical glycolysis [GO:0061621]; cellular response to interferon-gamma [GO:0071346]; gluconeogenesis [GO:0006094]; microtubule cytoskeleton organization [GO:0000226]; negative regulation of translation [GO:0017148]; neuron apoptotic process [GO:0051402]; peptidyl-cysteine S-trans-nitrosylation [GO:0035606]; protein stabilization [GO:0050821]; regulation of macroautophagy [GO:0016241]	glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity [GO:0004365]; microtubule binding [GO:0008017]; NAD binding [GO:0051287]; NADP binding [GO:0050661]; peptidyl-cysteine S-nitrosylase activity [GO:0035605]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular matrix [GO:0031012]; GAIT complex [GO:0097452]; intracellular membrane-bounded organelle [GO:0043231]; intracellular ribonucleoprotein complex [GO:0030529]; lipid particle [GO:0005811]; membrane [GO:0016020]; microtubule cytoskeleton [GO:0015630]; nuclear membrane [GO:0031965]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; vesicle [GO:0031982]
P11413	G6PD_HUMAN	Glucose-6-phosphate 1-dehydrogenase (G6PD) (EC 1.1.1.49)	G6PD	1QKI;2BH9;2BHL;	CHEMBL5347;	P11413;		PATHWAY: Carbohydrate degradation; pentose phosphate pathway; D-ribulose 5-phosphate from D-glucose 6-phosphate (oxidative stage): step 1/3.	PF02781;PF00479;	IPR001282;IPR019796;IPR022675;IPR022674;IPR016040;	cellular response to oxidative stress [GO:0034599]; cholesterol biosynthetic process [GO:0006695]; erythrocyte maturation [GO:0043249]; glucose 6-phosphate metabolic process [GO:0051156]; glucose metabolic process [GO:0006006]; glutathione metabolic process [GO:0006749]; lipid metabolic process [GO:0006629]; NADPH regeneration [GO:0006740]; NADP metabolic process [GO:0006739]; negative regulation of cell growth involved in cardiac muscle cell development [GO:0061052]; negative regulation of protein glutathionylation [GO:0010734]; negative regulation of reactive oxygen species metabolic process [GO:2000378]; oxidation-reduction process [GO:0055114]; pentose biosynthetic process [GO:0019322]; pentose-phosphate shunt [GO:0006098]; pentose-phosphate shunt, oxidative branch [GO:0009051]; positive regulation of calcium ion transmembrane transport via high voltage-gated calcium channel [GO:1904879]; regulation of neuron apoptotic process [GO:0043523]; response to ethanol [GO:0045471]; response to food [GO:0032094]; response to iron(III) ion [GO:0010041]; response to organic cyclic compound [GO:0014070]; ribose phosphate biosynthetic process [GO:0046390]; substantia nigra development [GO:0021762]	glucose-6-phosphate dehydrogenase activity [GO:0004345]; glucose binding [GO:0005536]; identical protein binding [GO:0042802]; NADP binding [GO:0050661]; protein homodimerization activity [GO:0042803]	centrosome [GO:0005813]; cytoplasm [GO:0005737]; cytoplasmic side of plasma membrane [GO:0009898]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; intracellular membrane-bounded organelle [GO:0043231]; membrane [GO:0016020]; microtubule organizing center [GO:0005815]; nucleus [GO:0005634]
O95479	G6PE_HUMAN	GDH/6PGL endoplasmic bifunctional protein [Includes: Glucose 1-dehydrogenase (EC 1.1.1.47) (Hexose-6-phosphate dehydrogenase); 6-phosphogluconolactonase (6PGL) (EC 3.1.1.31)]	H6PD GDH						PF02781;PF00479;PF01182;	IPR005900;IPR001282;IPR019796;IPR022675;IPR022674;IPR006148;IPR016040;	glucose metabolic process [GO:0006006]; pentose-phosphate shunt [GO:0006098]	6-phosphogluconolactonase activity [GO:0017057]; glucose 1-dehydrogenase [NAD(P)] activity [GO:0047936]; glucose-6-phosphate dehydrogenase activity [GO:0004345]; NADP binding [GO:0050661]	endoplasmic reticulum lumen [GO:0005788]
P06744	G6PI_HUMAN	Glucose-6-phosphate isomerase (GPI) (EC 5.3.1.9) (Autocrine motility factor) (AMF) (Neuroleukin) (NLK) (Phosphoglucose isomerase) (PGI) (Phosphohexose isomerase) (PHI) (Sperm antigen 36) (SA-36)	GPI	1IAT;1IRI;1JIQ;1JLH;1NUH;				PATHWAY: Carbohydrate degradation; glycolysis; D-glyceraldehyde 3-phosphate and glycerone phosphate from D-glucose: step 2/4.	PF00342;	IPR001672;IPR023096;IPR018189;	aldehyde catabolic process [GO:0046185]; angiogenesis [GO:0001525]; canonical glycolysis [GO:0061621]; carbohydrate metabolic process [GO:0005975]; erythrocyte homeostasis [GO:0034101]; gluconeogenesis [GO:0006094]; glucose 6-phosphate metabolic process [GO:0051156]; glucose homeostasis [GO:0042593]; hemostasis [GO:0007599]; humoral immune response [GO:0006959]; in utero embryonic development [GO:0001701]; learning or memory [GO:0007611]; mesoderm formation [GO:0001707]; methylglyoxal biosynthetic process [GO:0019242]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154]; negative regulation of neuron apoptotic process [GO:0043524]; response to cadmium ion [GO:0046686]; response to estradiol [GO:0032355]; response to immobilization stress [GO:0035902]; response to morphine [GO:0043278]; response to muscle stretch [GO:0035994]; response to progesterone [GO:0032570]; response to testosterone [GO:0033574]	glucose-6-phosphate isomerase activity [GO:0004347]; intramolecular transferase activity [GO:0016866]; monosaccharide binding [GO:0048029]; ubiquitin protein ligase binding [GO:0031625]	ciliary membrane [GO:0060170]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; membrane [GO:0016020]; myelin sheath [GO:0043209]; neuron projection [GO:0043005]; nucleoplasm [GO:0005654]; plasma membrane [GO:0005886]
Q9UBS5	GABR1_HUMAN	Gamma-aminobutyric acid type B receptor subunit 1 (GABA-B receptor 1) (GABA-B-R1) (GABA-BR1) (GABABR1) (Gb1)	GABBR1 GPRC3A	4MQE;4MQF;4MR7;4MR8;4MR9;4MRM;4MS1;4MS3;4MS4;4PAS;	CHEMBL2064;	Q9UBS5;	DB00181;DB00837;DB01080;		PF00003;PF01094;PF00084;	IPR001828;IPR002455;IPR017978;IPR002456;IPR028082;IPR000436;	adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway [GO:0007193]; gamma-aminobutyric acid signaling pathway [GO:0007214]; negative regulation of adenylate cyclase activity [GO:0007194]	G-protein coupled GABA receptor activity [GO:0004965]	cell junction [GO:0030054]; cytoplasm [GO:0005737]; dendrite [GO:0030425]; extracellular region [GO:0005576]; G-protein coupled receptor heterodimeric complex [GO:0038039]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]; presynaptic membrane [GO:0042734]
O75899	GABR2_HUMAN	Gamma-aminobutyric acid type B receptor subunit 2 (GABA-B receptor 2) (GABA-B-R2) (GABA-BR2) (GABABR2) (Gb2) (G-protein coupled receptor 51) (HG20)	GABBR2 GPR51 GPRC3B	4F11;4F12;4MQE;4MQF;4MR7;4MR8;4MR9;4MRM;4MS1;4MS3;4MS4;4PAS;	CHEMBL5034;	O75899;	DB00181;		PF00003;PF01094;	IPR001828;IPR002455;IPR000337;IPR017978;IPR017979;IPR002457;IPR028082;	chemical synaptic transmission [GO:0007268]; gamma-aminobutyric acid signaling pathway [GO:0007214]; G-protein coupled receptor signaling pathway [GO:0007186]; negative regulation of adenylate cyclase activity [GO:0007194]	G-protein coupled GABA receptor activity [GO:0004965]	cell junction [GO:0030054]; cytoplasm [GO:0005737]; G-protein coupled receptor heterodimeric complex [GO:0038039]; integral component of plasma membrane [GO:0005887]; neuron projection [GO:0043005]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
P80404	GABT_HUMAN	4-aminobutyrate aminotransferase, mitochondrial (EC 2.6.1.19) ((S)-3-amino-2-methylpropionate transaminase) (EC 2.6.1.22) (GABA aminotransferase) (GABA-AT) (Gamma-amino-N-butyrate transaminase) (GABA transaminase) (GABA-T) (L-AIBAT)	ABAT GABAT		CHEMBL2044;	P80404;	DB00160;DB00780;DB00119;DB00313;DB01080;		PF00202;	IPR004631;IPR005814;IPR015424;IPR015421;IPR015422;	aging [GO:0007568]; behavioral response to cocaine [GO:0048148]; cerebellum development [GO:0021549]; copulation [GO:0007620]; exploration behavior [GO:0035640]; gamma-aminobutyric acid biosynthetic process [GO:0009449]; gamma-aminobutyric acid catabolic process [GO:0009450]; locomotory behavior [GO:0007626]; negative regulation of blood pressure [GO:0045776]; negative regulation of dopamine secretion [GO:0033602]; negative regulation of gamma-aminobutyric acid secretion [GO:0014053]; negative regulation of platelet aggregation [GO:0090331]; neurotransmitter catabolic process [GO:0042135]; positive regulation of aspartate secretion [GO:1904450]; positive regulation of dopamine metabolic process [GO:0045964]; positive regulation of heat generation [GO:0031652]; positive regulation of inhibitory postsynaptic potential [GO:0097151]; positive regulation of insulin secretion [GO:0032024]; positive regulation of prolactin secretion [GO:1902722]; positive regulation of uterine smooth muscle contraction [GO:0070474]; response to drug [GO:0042493]; response to ethanol [GO:0045471]; response to hypoxia [GO:0001666]; response to iron ion [GO:0010039]; response to nicotine [GO:0035094]	(S)-3-amino-2-methylpropionate transaminase activity [GO:0047298]; 4-aminobutyrate transaminase activity [GO:0003867]; iron-sulfur cluster binding [GO:0051536]; metal ion binding [GO:0046872]; protein homodimerization activity [GO:0042803]; pyridoxal phosphate binding [GO:0030170]; succinate-semialdehyde dehydrogenase binding [GO:0032145]	4-aminobutyrate transaminase complex [GO:0032144]; extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; neuron projection [GO:0043005]
Q14376	GALE_HUMAN	UDP-glucose 4-epimerase (EC 5.1.3.2) (Galactowaldenase) (UDP-N-acetylgalactosamine 4-epimerase) (UDP-GalNAc 4-epimerase) (UDP-N-acetylglucosamine 4-epimerase) (UDP-GlcNAc 4-epimerase) (EC 5.1.3.7) (UDP-galactose 4-epimerase)	GALE	1EK5;1EK6;1HZJ;1I3K;1I3L;1I3M;1I3N;	CHEMBL5843;	Q14376;		PATHWAY: Carbohydrate metabolism; galactose metabolism.	PF16363;	IPR005886;IPR016040;IPR008089;	galactose catabolic process [GO:0019388]	protein homodimerization activity [GO:0042803]; UDP-glucose 4-epimerase activity [GO:0003978]; UDP-N-acetylglucosamine 4-epimerase activity [GO:0003974]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P51570	GALK1_HUMAN	Galactokinase (EC 2.7.1.6) (Galactose kinase)	GALK1 GALK	1WUU;1YH7;	CHEMBL1293257;	P51570;		PATHWAY: Carbohydrate metabolism; galactose metabolism.	PF10509;PF08544;PF00288;	IPR000705;IPR019741;IPR019539;IPR013750;IPR006204;IPR006203;IPR006206;IPR020568;IPR014721;	galactitol metabolic process [GO:0019402]; galactose catabolic process [GO:0019388]; galactose metabolic process [GO:0006012]; glycolytic process from galactose [GO:0061623]	ATP binding [GO:0005524]; galactokinase activity [GO:0004335]; galactose binding [GO:0005534]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]
Q14353	GAMT_HUMAN	Guanidinoacetate N-methyltransferase (EC 2.1.1.2)	GAMT	3ORH;			DB00148;DB00536;	PATHWAY: Amine and polyamine biosynthesis; creatine biosynthesis; creatine from L-arginine and glycine: step 2/2.		IPR016550;IPR026480;IPR029063;	animal organ morphogenesis [GO:0009887]; creatine biosynthetic process [GO:0006601]; creatine metabolic process [GO:0006600]; muscle contraction [GO:0006936]; regulation of multicellular organism growth [GO:0040014]; S-adenosylhomocysteine metabolic process [GO:0046498]; S-adenosylmethionine metabolic process [GO:0046500]; spermatogenesis [GO:0007283]	guanidinoacetate N-methyltransferase activity [GO:0030731]; methyltransferase activity [GO:0008168]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleus [GO:0005634]
Q9H4G4	GAPR1_HUMAN	Golgi-associated plant pathogenesis-related protein 1 (GAPR-1) (Golgi-associated PR-1 protein) (Glioma pathogenesis-related protein 2) (GliPR 2)	GLIPR2 C9orf19 GAPR1	1SMB;4AIW;					PF00188;	IPR001283;IPR018244;IPR014044;	positive regulation of epithelial cell migration [GO:0010634]; positive regulation of epithelial to mesenchymal transition [GO:0010718]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]	protein homodimerization activity [GO:0042803]	extracellular exosome [GO:0070062]; Golgi membrane [GO:0000139]
P32239	GASR_HUMAN	Gastrin/cholecystokinin type B receptor (CCK-B receptor) (CCK-BR) (Cholecystokinin-2 receptor) (CCK2-R)	CCKBR CCKRB	1L4T;	CHEMBL298;	P32239;	DB00183;		PF00001;	IPR009126;IPR000314;IPR000276;IPR017452;	cell proliferation [GO:0008283]; cell surface receptor signaling pathway [GO:0007166]; digestion [GO:0007586]; digestive tract development [GO:0048565]; feeding behavior [GO:0007631]; gastric acid secretion [GO:0001696]; gland development [GO:0048732]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; positive regulation of cell proliferation [GO:0008284]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; sensory perception [GO:0007600]	1-phosphatidylinositol-3-kinase regulator activity [GO:0046935]; cholecystokinin receptor activity [GO:0004951]; gastrin receptor activity [GO:0015054]; phosphatidylinositol phospholipase C activity [GO:0004435]; type B gastrin/cholecystokinin receptor binding [GO:0031741]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
O75879	GATB_HUMAN	Glutamyl-tRNA(Gln) amidotransferase subunit B, mitochondrial (Glu-AdT subunit B) (EC 6.3.5.-) (Cytochrome c oxidase assembly factor PET112 homolog)	GATB PET112 PET112L HSPC199				DB00130;		PF02934;PF02637;	IPR004413;IPR017959;IPR006075;IPR018027;IPR003789;IPR017958;	glutaminyl-tRNAGln biosynthesis via transamidation [GO:0070681]; mitochondrial translation [GO:0032543]; translation [GO:0006412]	ATP binding [GO:0005524]; glutaminyl-tRNA synthase (glutamine-hydrolyzing) activity [GO:0050567]; translation factor activity, RNA binding [GO:0008135]	glutamyl-tRNA(Gln) amidotransferase complex [GO:0030956]; mitochondrion [GO:0005739]
P50440	GATM_HUMAN	Glycine amidinotransferase, mitochondrial (EC 2.1.4.1) (L-arginine:glycine amidinotransferase) (Transamidinase)	GATM AGAT	1JDW;1JDX;2JDW;2JDX;3JDW;4JDW;5JDW;6JDW;7JDW;8JDW;9JDW;			DB00145;DB00129;	PATHWAY: Amine and polyamine biosynthesis; creatine biosynthesis; creatine from L-arginine and glycine: step 1/2.		IPR033195;	creatine biosynthetic process [GO:0006601]; creatine metabolic process [GO:0006600]	glycine amidinotransferase activity [GO:0015068]	extracellular exosome [GO:0070062]; mitochondrial inner membrane [GO:0005743]; mitochondrial intermembrane space [GO:0005758]
P59768	GBG2_HUMAN	Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2 (G gamma-I)	GNG2	4KFM;5HE0;5HE1;5HE2;5HE3;			DB01159;		PF00631;	IPR015898;IPR001770;	adenylate cyclase-activating dopamine receptor signaling pathway [GO:0007191]; cell proliferation [GO:0008283]; cellular response to catecholamine stimulus [GO:0071870]; cellular response to glucagon stimulus [GO:0071377]; cellular response to prostaglandin E stimulus [GO:0071380]; platelet activation [GO:0030168]; protein folding [GO:0006457]; Wnt signaling pathway, calcium modulating pathway [GO:0007223]	G-protein beta-subunit binding [GO:0031681]; signal transducer activity [GO:0004871]	extracellular exosome [GO:0070062]; heterotrimeric G-protein complex [GO:0005834]; membrane [GO:0016020]; plasma membrane [GO:0005886]
P14867	GBRA1_HUMAN	Gamma-aminobutyric acid receptor subunit alpha-1 (GABA(A) receptor subunit alpha-1)	GABRA1		CHEMBL1962;	P14867;	DB00659;DB00546;DB00404;DB01351;DB00543;DB01352;DB01558;DB00237;DB00241;DB01353;DB00475;DB01594;DB00349;DB01068;DB00628;DB01559;DB01189;DB00829;DB00228;DB01049;DB01215;DB00402;DB00898;DB00189;DB00292;DB01567;DB01205;DB00690;DB01381;DB01437;DB00801;DB01159;DB01354;DB01355;DB00753;DB01587;DB00186;DB00371;DB00474;DB01028;DB00849;DB01107;DB00683;DB01595;DB00334;DB00842;DB00312;DB01174;DB01588;DB00794;DB00837;DB00818;DB01589;DB01346;DB00418;DB01236;DB00306;DB00231;DB01154;DB00599;DB00273;DB00897;DB00962;DB00425;DB01198;		PF02931;PF02932;	IPR006028;IPR001390;IPR005431;IPR006202;IPR006201;IPR006029;IPR018000;	cellular response to histamine [GO:0071420]; chloride transmembrane transport [GO:1902476]; gamma-aminobutyric acid signaling pathway [GO:0007214]; ion transmembrane transport [GO:0034220]; synaptic transmission, GABAergic [GO:0051932]; transport [GO:0006810]	drug binding [GO:0008144]; GABA-A receptor activity [GO:0004890]; GABA-gated chloride ion channel activity [GO:0022851]	cell junction [GO:0030054]; chloride channel complex [GO:0034707]; GABA-A receptor complex [GO:1902711]; GABA receptor complex [GO:1902710]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
P47869	GBRA2_HUMAN	Gamma-aminobutyric acid receptor subunit alpha-2 (GABA(A) receptor subunit alpha-2)	GABRA2		CHEMBL4956;	P47869;	DB00659;DB00546;DB00404;DB01351;DB00543;DB01352;DB01558;DB00237;DB00241;DB01353;DB00475;DB01594;DB00349;DB01068;DB00628;DB01559;DB01189;DB00829;DB00228;DB01049;DB01215;DB00402;DB00898;DB00189;DB00292;DB01567;DB01205;DB01544;DB00690;DB01437;DB00801;DB01159;DB01354;DB01355;DB00753;DB00186;DB00371;DB01028;DB00849;DB01107;DB00683;DB01595;DB00334;DB00842;DB00312;DB01588;DB00794;DB00818;DB01589;DB01346;DB00418;DB01236;DB00306;DB00231;DB00599;DB00273;DB00897;DB00425;DB01198;		PF02931;PF02932;	IPR006028;IPR001390;IPR005432;IPR006202;IPR006201;IPR006029;IPR018000;	chloride transmembrane transport [GO:1902476]; gamma-aminobutyric acid signaling pathway [GO:0007214]; ion transmembrane transport [GO:0034220]; neurotransmitter transport [GO:0006836]; regulation of neurotransmitter levels [GO:0001505]	benzodiazepine receptor activity [GO:0008503]; GABA-A receptor activity [GO:0004890]; GABA-gated chloride ion channel activity [GO:0022851]	axon [GO:0030424]; cell junction [GO:0030054]; chloride channel complex [GO:0034707]; dendrite [GO:0030425]; GABA-A receptor complex [GO:1902711]; inhibitory synapse [GO:0060077]; integral component of synaptic vesicle membrane [GO:0030285]; neuronal cell body [GO:0043025]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
P34903	GBRA3_HUMAN	Gamma-aminobutyric acid receptor subunit alpha-3 (GABA(A) receptor subunit alpha-3)	GABRA3		CHEMBL3026;	P34903;	DB00659;DB00546;DB00404;DB01351;DB00543;DB01352;DB01558;DB00237;DB00241;DB01353;DB00475;DB01594;DB00349;DB01068;DB00628;DB01559;DB01189;DB00829;DB00228;DB01049;DB01215;DB00402;DB00898;DB00189;DB00292;DB01567;DB01205;DB01544;DB00690;DB01437;DB00801;DB01159;DB01354;DB01355;DB00753;DB00186;DB00371;DB01028;DB00849;DB01107;DB00683;DB01595;DB00334;DB00842;DB00312;DB01588;DB00794;DB00818;DB01589;DB00418;DB01236;DB00306;DB00231;DB00599;DB00273;DB00897;DB00425;DB01198;		PF02931;PF02932;	IPR006028;IPR001390;IPR005433;IPR006202;IPR006201;IPR006029;IPR018000;	gamma-aminobutyric acid signaling pathway [GO:0007214]; ion transmembrane transport [GO:0034220]; transport [GO:0006810]	benzodiazepine receptor activity [GO:0008503]; chloride channel activity [GO:0005254]; extracellular ligand-gated ion channel activity [GO:0005230]; GABA-A receptor activity [GO:0004890]	cell junction [GO:0030054]; chloride channel complex [GO:0034707]; GABA-A receptor complex [GO:1902711]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
P48169	GBRA4_HUMAN	Gamma-aminobutyric acid receptor subunit alpha-4 (GABA(A) receptor subunit alpha-4)	GABRA4		CHEMBL2472;	P48169;	DB00659;DB00404;DB01351;DB00543;DB01352;DB01558;DB00237;DB00241;DB01353;DB00475;DB00349;DB01068;DB00628;DB01189;DB00829;DB00228;DB01049;DB01215;DB00402;DB00898;DB00189;DB00292;DB01205;DB01544;DB00690;DB01437;DB00801;DB01159;DB01354;DB01355;DB00753;DB00186;DB00371;DB01028;DB00849;DB01107;DB00683;DB01595;DB00334;DB00842;DB00312;DB01588;DB00794;DB00818;DB01589;DB00418;DB01236;DB00306;DB00231;DB00599;DB00273;DB00897;		PF02931;PF02932;	IPR006028;IPR001390;IPR005434;IPR006202;IPR006201;IPR006029;IPR018000;	central nervous system development [GO:0007417]; gamma-aminobutyric acid signaling pathway [GO:0007214]; ion transmembrane transport [GO:0034220]; regulation of response to drug [GO:2001023]; transport [GO:0006810]	benzodiazepine receptor activity [GO:0008503]; chloride channel activity [GO:0005254]; extracellular ligand-gated ion channel activity [GO:0005230]; GABA-A receptor activity [GO:0004890]	cell junction [GO:0030054]; chloride channel complex [GO:0034707]; GABA-A receptor complex [GO:1902711]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
P31644	GBRA5_HUMAN	Gamma-aminobutyric acid receptor subunit alpha-5 (GABA(A) receptor subunit alpha-5)	GABRA5		CHEMBL5112;	P31644;	DB00659;DB00546;DB00404;DB01351;DB00543;DB01352;DB01558;DB00237;DB00241;DB01353;DB00475;DB01594;DB00349;DB01068;DB00628;DB01559;DB01189;DB00829;DB00228;DB01049;DB01215;DB00402;DB00898;DB00189;DB00292;DB01567;DB01205;DB01544;DB00690;DB01437;DB00801;DB01159;DB01354;DB01355;DB00753;DB00186;DB00371;DB01028;DB00849;DB01107;DB00683;DB01595;DB00334;DB00842;DB00312;DB01588;DB00794;DB00818;DB01589;DB00418;DB01236;DB00306;DB00231;DB00599;DB00273;DB00897;DB01198;		PF02931;PF02932;	IPR006028;IPR001390;IPR005435;IPR006202;IPR006201;IPR006029;IPR018000;	associative learning [GO:0008306]; behavioral fear response [GO:0001662]; brain development [GO:0007420]; chemical synaptic transmission [GO:0007268]; cochlea development [GO:0090102]; gamma-aminobutyric acid signaling pathway [GO:0007214]; inner ear receptor cell development [GO:0060119]; innervation [GO:0060384]; ion transmembrane transport [GO:0034220]; negative regulation of neuron apoptotic process [GO:0043524]; sensory perception of sound [GO:0007605]; signal transduction [GO:0007165]; transport [GO:0006810]	chloride channel activity [GO:0005254]; extracellular ligand-gated ion channel activity [GO:0005230]; GABA-A receptor activity [GO:0004890]; receptor activity [GO:0004872]; transporter activity [GO:0005215]	cell junction [GO:0030054]; chloride channel complex [GO:0034707]; dendrite [GO:0030425]; GABA-A receptor complex [GO:1902711]; integral component of plasma membrane [GO:0005887]; neuronal cell body membrane [GO:0032809]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
Q16445	GBRA6_HUMAN	Gamma-aminobutyric acid receptor subunit alpha-6 (GABA(A) receptor subunit alpha-6)	GABRA6		CHEMBL2579;	Q16445;	DB00659;DB00404;DB01351;DB00543;DB01352;DB01558;DB00237;DB00241;DB01353;DB00475;DB00349;DB01068;DB00628;DB01189;DB00829;DB00228;DB01049;DB01215;DB00402;DB00898;DB00189;DB00292;DB01205;DB01544;DB00690;DB01437;DB00801;DB01159;DB01354;DB01355;DB00753;DB00186;DB00371;DB01028;DB00849;DB01107;DB00683;DB01595;DB00334;DB00842;DB00312;DB01588;DB00794;DB00818;DB01589;DB00418;DB01236;DB00306;DB00231;DB00599;DB00273;DB00897;		PF02931;PF02932;	IPR006028;IPR001390;IPR005436;IPR006202;IPR006201;IPR006029;IPR018000;	gamma-aminobutyric acid signaling pathway [GO:0007214]; ion transmembrane transport [GO:0034220]; signal transduction [GO:0007165]; transport [GO:0006810]	benzodiazepine receptor activity [GO:0008503]; chloride channel activity [GO:0005254]; extracellular ligand-gated ion channel activity [GO:0005230]; GABA-A receptor activity [GO:0004890]	cell junction [GO:0030054]; chloride channel complex [GO:0034707]; GABA-A receptor complex [GO:1902711]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
P18505	GBRB1_HUMAN	Gamma-aminobutyric acid receptor subunit beta-1 (GABA(A) receptor subunit beta-1)	GABRB1		CHEMBL2111392;	P18505;	DB00659;DB00546;DB00404;DB00543;DB01558;DB00237;DB00241;DB00475;DB01594;DB00349;DB01068;DB00628;DB01559;DB01189;DB00829;DB00228;DB01049;DB01215;DB00402;DB00898;DB00189;DB00292;DB01567;DB01205;DB00690;DB01440;DB01437;DB00801;DB01159;DB00753;DB01587;DB00431;DB00186;DB00371;DB01028;DB01107;DB00683;DB01595;DB00334;DB00842;DB00312;DB01588;DB00794;DB00818;DB01589;DB01236;DB00306;DB00231;DB00273;DB00897;		PF02931;PF02932;	IPR006028;IPR002289;IPR006202;IPR006201;IPR006029;IPR018000;	cellular response to histamine [GO:0071420]; central nervous system neuron development [GO:0021954]; chloride transmembrane transport [GO:1902476]; ion transmembrane transport [GO:0034220]; ion transport [GO:0006811]; ovulation cycle [GO:0042698]; response to progesterone [GO:0032570]; response to toxic substance [GO:0009636]; signal transduction [GO:0007165]; transport [GO:0006810]	GABA-A receptor activity [GO:0004890]; GABA-gated chloride ion channel activity [GO:0022851]; ligand-gated ion channel activity [GO:0015276]	cell junction [GO:0030054]; chloride channel complex [GO:0034707]; cytoplasm [GO:0005737]; dendrite [GO:0030425]; GABA-A receptor complex [GO:1902711]; integral component of plasma membrane [GO:0005887]; nuclear envelope [GO:0005635]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
P47870	GBRB2_HUMAN	Gamma-aminobutyric acid receptor subunit beta-2 (GABA(A) receptor subunit beta-2)	GABRB2		CHEMBL1920;	P47870;	DB00659;DB00546;DB00404;DB00543;DB01558;DB00237;DB00241;DB00475;DB01594;DB00349;DB01068;DB00628;DB01559;DB01189;DB00829;DB00228;DB01049;DB01215;DB00402;DB00898;DB00189;DB00292;DB01567;DB01205;DB00690;DB06716;DB01381;DB01437;DB00801;DB01159;DB00753;DB00186;DB00371;DB01028;DB01107;DB00683;DB01595;DB00334;DB00842;DB00312;DB01588;DB00794;DB00818;DB01589;DB01236;DB00306;DB00231;DB00273;DB00897;		PF02931;PF02932;	IPR006028;IPR002289;IPR006202;IPR006201;IPR006029;IPR018000;	cellular response to histamine [GO:0071420]; chemical synaptic transmission [GO:0007268]; chloride transmembrane transport [GO:1902476]; cochlea development [GO:0090102]; gamma-aminobutyric acid signaling pathway [GO:0007214]; inner ear receptor cell development [GO:0060119]; innervation [GO:0060384]; ion transmembrane transport [GO:0034220]; negative regulation of neuron apoptotic process [GO:0043524]; sensory perception of sound [GO:0007605]; synaptic transmission, GABAergic [GO:0051932]; transport [GO:0006810]	chloride channel activity [GO:0005254]; GABA-A receptor activity [GO:0004890]; inhibitory extracellular ligand-gated ion channel activity [GO:0005237]	cell junction [GO:0030054]; chloride channel complex [GO:0034707]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; GABA-A receptor complex [GO:1902711]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
P28472	GBRB3_HUMAN	Gamma-aminobutyric acid receptor subunit beta-3 (GABA(A) receptor subunit beta-3)	GABRB3	4COF;	CHEMBL1847;	P28472;	DB00659;DB00546;DB00404;DB00543;DB01558;DB00237;DB00241;DB00475;DB01594;DB00349;DB01068;DB00628;DB01559;DB01189;DB00829;DB00228;DB01049;DB01215;DB00402;DB00898;DB00189;DB00292;DB01567;DB01205;DB00690;DB06716;DB01437;DB00801;DB01159;DB00753;DB00602;DB00186;DB00371;DB01028;DB01107;DB00683;DB01595;DB00334;DB00842;DB00312;DB00592;DB01588;DB00794;DB00818;DB01589;DB01236;DB00306;DB00231;DB00273;DB00897;		PF02931;PF02932;	IPR006028;IPR002289;IPR006202;IPR006201;IPR006029;IPR018000;	cellular response to histamine [GO:0071420]; chloride transmembrane transport [GO:1902476]; cochlea development [GO:0090102]; inhibitory postsynaptic potential [GO:0060080]; inner ear receptor cell development [GO:0060119]; innervation [GO:0060384]; ion transmembrane transport [GO:0034220]; negative regulation of neuron apoptotic process [GO:0043524]; palate development [GO:0060021]; sensory perception of sound [GO:0007605]; signal transduction [GO:0007165]; transport [GO:0006810]	GABA-A receptor activity [GO:0004890]; GABA-gated chloride ion channel activity [GO:0022851]	cell junction [GO:0030054]; chloride channel complex [GO:0034707]; GABA-A receptor complex [GO:1902711]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
P24046	GBRR1_HUMAN	Gamma-aminobutyric acid receptor subunit rho-1 (GABA(A) receptor subunit rho-1) (GABA(C) receptor)	GABRR1		CHEMBL3561;	P24046;	DB00546;DB01558;DB01594;DB01559;DB00829;DB01215;DB01567;DB00690;DB00801;DB00683;DB01595;DB00842;DB01588;DB01589;DB00231;DB00897;		PF02931;PF02932;	IPR006028;IPR008058;IPR008057;IPR006202;IPR006201;IPR006029;IPR018000;	chemical synaptic transmission [GO:0007268]; gamma-aminobutyric acid signaling pathway [GO:0007214]; ion transmembrane transport [GO:0034220]; transport [GO:0006810]	chloride channel activity [GO:0005254]; extracellular ligand-gated ion channel activity [GO:0005230]; GABA-A receptor activity [GO:0004890]	cell junction [GO:0030054]; chloride channel complex [GO:0034707]; GABA-A receptor complex [GO:1902711]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
Q92947	GCDH_HUMAN	Glutaryl-CoA dehydrogenase, mitochondrial (GCD) (EC 1.3.8.6)	GCDH	1SIQ;1SIR;2R0M;2R0N;			DB03147;	PATHWAY: Amino-acid metabolism; lysine degradation.; PATHWAY: Amino-acid metabolism; tryptophan metabolism.	PF00441;PF02770;PF02771;	IPR006089;IPR006091;IPR009075;IPR013786;IPR009100;	fatty acid beta-oxidation using acyl-CoA dehydrogenase [GO:0033539]; fatty-acyl-CoA biosynthetic process [GO:0046949]; lipid homeostasis [GO:0055088]; lysine catabolic process [GO:0006554]; tryptophan metabolic process [GO:0006568]	electron carrier activity [GO:0009055]; fatty-acyl-CoA binding [GO:0000062]; flavin adenine dinucleotide binding [GO:0050660]; glutaryl-CoA dehydrogenase activity [GO:0004361]; oxidoreductase activity, acting on the CH-CH group of donors, with a flavin as acceptor [GO:0052890]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
P30793	GCH1_HUMAN	GTP cyclohydrolase 1 (EC 3.5.4.16) (GTP cyclohydrolase I) (GTP-CH-I)	GCH1 DYT5 GCH	1FB1;			DB02325;	PATHWAY: Cofactor biosynthesis; 7,8-dihydroneopterin triphosphate biosynthesis; 7,8-dihydroneopterin triphosphate from GTP: step 1/1. {ECO:0000305|PubMed:16778797, ECO:0000305|PubMed:2463916, ECO:0000305|PubMed:3753653}.	PF01227;	IPR001474;IPR018234;IPR020602;	7,8-dihydroneopterin 3'-triphosphate biosynthetic process [GO:0035998]; dopamine biosynthetic process [GO:0042416]; negative regulation of blood pressure [GO:0045776]; neuromuscular process controlling posture [GO:0050884]; nitric oxide biosynthetic process [GO:0006809]; positive regulation of nitric-oxide synthase activity [GO:0051000]; protein heterooligomerization [GO:0051291]; protein homooligomerization [GO:0051260]; pteridine-containing compound biosynthetic process [GO:0042559]; regulation of blood pressure [GO:0008217]; regulation of lung blood pressure [GO:0014916]; regulation of nitric-oxide synthase activity [GO:0050999]; regulation of removal of superoxide radicals [GO:2000121]; response to interferon-gamma [GO:0034341]; response to lipopolysaccharide [GO:0032496]; response to pain [GO:0048265]; response to tumor necrosis factor [GO:0034612]; tetrahydrobiopterin biosynthetic process [GO:0006729]; tetrahydrofolate biosynthetic process [GO:0046654]; vasodilation [GO:0042311]	calcium ion binding [GO:0005509]; coenzyme binding [GO:0050662]; GTP binding [GO:0005525]; GTP cyclohydrolase I activity [GO:0003934]; protein homodimerization activity [GO:0042803]; zinc ion binding [GO:0008270]	cytoplasm [GO:0005737]; cytoplasmic vesicle [GO:0031410]; cytosol [GO:0005829]; nuclear membrane [GO:0031965]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; protein complex [GO:0043234]
P04150	GCR_HUMAN	Glucocorticoid receptor (GR) (Nuclear receptor subfamily 3 group C member 1)	NR3C1 GRL	1M2Z;1NHZ;1P93;3BQD;3CLD;3E7C;3H52;3K22;3K23;4CSJ;4HN5;4HN6;4LSJ;4MDD;4P6W;4P6X;4UDC;4UDD;5CBX;5CBY;5CBZ;5CC1;5EMC;5EMP;5EMQ;	CHEMBL2034;	P04150;	DB00240;DB00288;DB00394;DB00443;DB01222;DB01410;DB01013;DB00838;DB01380;DB01260;DB00547;DB01234;DB00223;DB06781;DB00687;DB00663;DB00180;DB00591;DB01047;DB00324;DB01185;DB00846;DB08906;DB00588;DB00596;DB00769;DB00741;DB00873;DB00253;DB00351;DB00959;DB00834;DB00764;DB01384;DB01130;DB00860;DB00635;DB00896;DB00421;DB00620;DB08867;		PF02155;PF00104;PF00105;	IPR001409;IPR000536;IPR001723;IPR001628;IPR013088;	apoptotic process [GO:0006915]; cell division [GO:0051301]; cellular response to steroid hormone stimulus [GO:0071383]; chromatin modification [GO:0016569]; chromosome segregation [GO:0007059]; mitotic nuclear division [GO:0007067]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; regulation of transcription, DNA-templated [GO:0006355]; signal transduction [GO:0007165]; transcription, DNA-templated [GO:0006351]; transcription from RNA polymerase II promoter [GO:0006366]; transcription initiation from RNA polymerase II promoter [GO:0006367]	glucocorticoid-activated RNA polymerase II transcription factor binding transcription factor activity [GO:0038051]; glucocorticoid receptor activity [GO:0004883]; protein complex binding [GO:0032403]; RNA binding [GO:0003723]; RNA polymerase II core promoter proximal region sequence-specific DNA binding [GO:0000978]; steroid binding [GO:0005496]; steroid hormone binding [GO:1990239]; transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding [GO:0001077]; transcription factor activity, sequence-specific DNA binding [GO:0003700]; zinc ion binding [GO:0008270]	cytoplasm [GO:0005737]; microtubule organizing center [GO:0005815]; mitochondrial matrix [GO:0005759]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; protein complex [GO:0043234]; spindle [GO:0005819]
P23434	GCSH_HUMAN	Glycine cleavage system H protein, mitochondrial (Lipoic acid-containing protein)	GCSH				DB00145;			IPR003016;IPR000089;IPR002930;IPR017453;IPR011053;	glycine catabolic process [GO:0006546]; glycine decarboxylation via glycine cleavage system [GO:0019464]; glyoxylate metabolic process [GO:0046487]	aminomethyltransferase activity [GO:0004047]	glycine cleavage complex [GO:0005960]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
P23378	GCSP_HUMAN	Glycine dehydrogenase (decarboxylating), mitochondrial (EC 1.4.4.2) (Glycine cleavage system P protein) (Glycine decarboxylase) (Glycine dehydrogenase (aminomethyl-transferring))	GLDC GCSP				DB00145;		PF01212;PF02347;	IPR001597;IPR003437;IPR020581;IPR015424;IPR015421;	glycine catabolic process [GO:0006546]; glycine decarboxylation via glycine cleavage system [GO:0019464]; glyoxylate metabolic process [GO:0046487]	electron carrier activity [GO:0009055]; glycine binding [GO:0016594]; glycine dehydrogenase (decarboxylating) activity [GO:0004375]; lyase activity [GO:0016829]; pyridoxal phosphate binding [GO:0030170]	glycine cleavage complex [GO:0005960]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
P43026	GDF5_HUMAN	Growth/differentiation factor 5 (GDF-5) (Bone morphogenetic protein 14) (BMP-14) (Cartilage-derived morphogenetic protein 1) (CDMP-1) (Lipopolysaccharide-associated protein 4) (LAP-4) (LPS-associated protein 4) (Radotermin)	GDF5 BMP14 CDMP1	1WAQ;2BHK;3EVS;3QB4;5HK5;			DB02325;		PF00019;PF00688;	IPR029034;IPR001839;IPR001111;IPR015615;IPR017948;	cell-cell signaling [GO:0007267]; cell development [GO:0048468]; chondroblast differentiation [GO:0060591]; chondrocyte differentiation [GO:0002062]; embryonic limb morphogenesis [GO:0030326]; forelimb morphogenesis [GO:0035136]; growth [GO:0040007]; hindlimb morphogenesis [GO:0035137]; negative regulation of chondrocyte differentiation [GO:0032331]; negative regulation of epithelial cell proliferation [GO:0050680]; negative regulation of mesenchymal cell apoptotic process [GO:2001054]; negative regulation of neuron apoptotic process [GO:0043524]; positive regulation of BMP signaling pathway [GO:0030513]; positive regulation of chondrocyte differentiation [GO:0032332]; positive regulation of neuron differentiation [GO:0045666]; positive regulation of pathway-restricted SMAD protein phosphorylation [GO:0010862]; regulation of apoptotic process [GO:0042981]; regulation of MAPK cascade [GO:0043408]; regulation of multicellular organism growth [GO:0040014]; SMAD protein import into nucleus [GO:0007184]; SMAD protein signal transduction [GO:0060395]; transforming growth factor beta receptor signaling pathway [GO:0007179]	BMP binding [GO:0036122]; cytokine activity [GO:0005125]; growth factor activity [GO:0008083]; transforming growth factor beta receptor binding [GO:0005160]	extracellular region [GO:0005576]; extracellular space [GO:0005615]; intracellular [GO:0005622]; plasma membrane [GO:0005886]
Q9NQX3	GEPH_HUMAN	Gephyrin [Includes: Molybdopterin adenylyltransferase (MPT adenylyltransferase) (EC 2.7.7.75) (Domain G); Molybdopterin molybdenumtransferase (MPT Mo-transferase) (EC 2.10.1.1) (Domain E)]	GPHN GPH KIAA1385	1JLJ;				PATHWAY: Cofactor biosynthesis; molybdopterin biosynthesis. {ECO:0000269|PubMed:11095995, ECO:0000269|PubMed:22040219, ECO:0000269|PubMed:26613940}.	PF00994;PF03454;PF03453;	IPR001453;IPR008284;IPR005111;IPR005110;	gamma-aminobutyric acid receptor clustering [GO:0097112]; glycine receptor clustering [GO:0072579]; molybdenum incorporation into molybdenum-molybdopterin complex [GO:0018315]; molybdopterin cofactor biosynthetic process [GO:0032324]; Mo-molybdopterin cofactor biosynthetic process [GO:0006777]	ATP binding [GO:0005524]; metal ion binding [GO:0046872]; molybdopterin adenylyltransferase activity [GO:0061598]; molybdopterin molybdotransferase activity [GO:0061599]	cell junction [GO:0030054]; cytoplasm [GO:0005737]; cytoskeleton [GO:0005856]; dendrite [GO:0030425]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
O94808	GFPT2_HUMAN	Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 2 (EC 2.6.1.16) (D-fructose-6-phosphate amidotransferase 2) (Glutamine:fructose-6-phosphate amidotransferase 2) (GFAT 2) (GFAT2) (Hexosephosphate aminotransferase 2)	GFPT2				DB00130;	PATHWAY: Nucleotide-sugar biosynthesis; UDP-N-acetyl-alpha-D-glucosamine biosynthesis; alpha-D-glucosamine 6-phosphate from D-fructose 6-phosphate: step 1/1. {ECO:0000250|UniProtKB:P82808}.	PF01380;	IPR017932;IPR005855;IPR029055;IPR001347;	carbohydrate metabolic process [GO:0005975]; energy reserve metabolic process [GO:0006112]; fructose 6-phosphate metabolic process [GO:0006002]; glutamine metabolic process [GO:0006541]; UDP-N-acetylglucosamine biosynthetic process [GO:0006048]; UDP-N-acetylglucosamine metabolic process [GO:0006047]	carbohydrate binding [GO:0030246]; glutamine-fructose-6-phosphate transaminase (isomerizing) activity [GO:0004360]	cytosol [GO:0005829]
Q92820	GGH_HUMAN	Gamma-glutamyl hydrolase (EC 3.4.19.9) (Conjugase) (GH) (Gamma-Glu-X carboxypeptidase)	GGH	1L9X;	CHEMBL2223;	Q92820;	DB00158;DB00563;		PF07722;	IPR029062;IPR015527;IPR011697;	glutamine metabolic process [GO:0006541]; response to drug [GO:0042493]; response to ethanol [GO:0045471]; response to insulin [GO:0032868]; response to zinc ion [GO:0010043]; tetrahydrofolylpolyglutamate metabolic process [GO:0046900]	exopeptidase activity [GO:0008238]; gamma-glutamyl-peptidase activity [GO:0034722]; omega peptidase activity [GO:0008242]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; lysosome [GO:0005764]; melanosome [GO:0042470]; nucleus [GO:0005634]; vacuole [GO:0005773]
P19440	GGT1_HUMAN	Gamma-glutamyltranspeptidase 1 (GGT 1) (EC 2.3.2.2) (Gamma-glutamyltransferase 1) (Glutathione hydrolase 1) (EC 3.4.19.13) (Leukotriene-C4 hydrolase) (EC 3.4.19.14) (CD antigen CD224) [Cleaved into: Gamma-glutamyltranspeptidase 1 heavy chain; Gamma-glutamyltranspeptidase 1 light chain]	GGT1 GGT	4GDX;4GG2;4Z9O;4ZBK;4ZC6;4ZCG;	CHEMBL5696;	P19440;	DB00143;	PATHWAY: Sulfur metabolism; glutathione metabolism.	PF01019;	IPR000101;IPR029055;	cellular amino acid metabolic process [GO:0006520]; cysteine biosynthetic process [GO:0019344]; glutamate metabolic process [GO:0006536]; glutathione biosynthetic process [GO:0006750]; glutathione catabolic process [GO:0006751]; glutathione metabolic process [GO:0006749]; leukotriene biosynthetic process [GO:0019370]; leukotriene metabolic process [GO:0006691]; regulation of immune system process [GO:0002682]; regulation of inflammatory response [GO:0050727]; spermatogenesis [GO:0007283]; xenobiotic metabolic process [GO:0006805]; zymogen activation [GO:0031638]	gamma-glutamyltransferase activity [GO:0003840]; glutathione hydrolase activity [GO:0036374]	anchored component of external side of plasma membrane [GO:0031362]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]
Q9H936	GHC1_HUMAN	Mitochondrial glutamate carrier 1 (GC-1) (Glutamate/H(+) symporter 1) (Solute carrier family 25 member 22)	SLC25A22 GC1						PF00153;	IPR002067;IPR018108;IPR023395;	L-glutamate transport [GO:0015813]; translation [GO:0006412]	L-glutamate transmembrane transporter activity [GO:0005313]; structural constituent of ribosome [GO:0003735]; symporter activity [GO:0015293]	integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]
Q9H1K4	GHC2_HUMAN	Mitochondrial glutamate carrier 2 (GC-2) (Glutamate/H(+) symporter 2) (Solute carrier family 25 member 18)	SLC25A18 GC2						PF00153;	IPR002067;IPR018108;IPR023395;	translation [GO:0006412]	structural constituent of ribosome [GO:0003735]; symporter activity [GO:0015293]	integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]
Q02643	GHRHR_HUMAN	Growth hormone-releasing hormone receptor (GHRH receptor) (Growth hormone-releasing factor receptor) (GRF receptor) (GRFR)	GHRHR	2XDG;	CHEMBL2032;	Q02643;	DB00010;DB08869;		PF00002;PF02793;	IPR017981;IPR001879;IPR003288;IPR000832;IPR017983;	activation of adenylate cyclase activity [GO:0007190]; adenylate cyclase-activating G-protein coupled receptor signaling pathway [GO:0007189]; cAMP-mediated signaling [GO:0019933]; cell maturation [GO:0048469]; cell surface receptor signaling pathway [GO:0007166]; cellular response to glucose stimulus [GO:0071333]; cellular response to insulin stimulus [GO:0032869]; determination of adult lifespan [GO:0008340]; growth hormone secretion [GO:0030252]; hormone metabolic process [GO:0042445]; lactation [GO:0007595]; multicellular organismal reproductive process [GO:0048609]; positive regulation of cAMP biosynthetic process [GO:0030819]; positive regulation of cell proliferation [GO:0008284]; positive regulation of circadian sleep/wake cycle, non-REM sleep [GO:0046010]; positive regulation of growth hormone secretion [GO:0060124]; positive regulation of insulin-like growth factor receptor signaling pathway [GO:0043568]; positive regulation of multicellular organism growth [GO:0040018]; regulation of intracellular steroid hormone receptor signaling pathway [GO:0033143]; regulation of protein metabolic process [GO:0051246]; response to estrogen [GO:0043627]; response to glucocorticoid [GO:0051384]; response to insulin [GO:0032868]; somatotropin secreting cell development [GO:0060133]; water homeostasis [GO:0030104]	G-protein coupled receptor activity [GO:0004930]; growth factor binding [GO:0019838]; growth hormone-releasing hormone receptor activity [GO:0016520]; peptide hormone binding [GO:0017046]	cell surface [GO:0009986]; cytoplasm [GO:0005737]; integral component of membrane [GO:0016021]; nuclear inner membrane [GO:0005637]; nuclear matrix [GO:0016363]; nuclear outer membrane [GO:0005640]; plasma membrane [GO:0005886]; sarcolemma [GO:0042383]; secretory granule [GO:0030141]
P04062	GLCM_HUMAN	Glucosylceramidase (EC 3.2.1.45) (Acid beta-glucosidase) (Alglucerase) (Beta-glucocerebrosidase) (Beta-GC) (D-glucosyl-N-acylsphingosine glucohydrolase) (Imiglucerase)	GBA GC GLUC	1OGS;1Y7V;2F61;2J25;2NSX;2NT0;2NT1;2V3D;2V3E;2V3F;2VT0;2WCG;2WKL;2XWD;2XWE;3GXD;3GXF;3GXI;3GXM;3KE0;3KEH;3RIK;3RIL;	CHEMBL2179;	P04062;	DB06720;		PF02055;PF17189;	IPR033452;IPR001139;IPR033453;IPR013780;IPR013781;IPR017853;	carbohydrate metabolic process [GO:0005975]; cellular response to starvation [GO:0009267]; cellular response to tumor necrosis factor [GO:0071356]; ceramide biosynthetic process [GO:0046513]; glucosylceramide catabolic process [GO:0006680]; glycosphingolipid metabolic process [GO:0006687]; negative regulation of gene expression [GO:0010629]; negative regulation of inflammatory response [GO:0050728]; negative regulation of interleukin-6 production [GO:0032715]; negative regulation of MAP kinase activity [GO:0043407]; negative regulation of neuron death [GO:1901215]; negative regulation of protein homooligomerization [GO:0032463]; positive regulation of gene expression [GO:0010628]; positive regulation of macroautophagy [GO:0016239]; positive regulation of neuronal action potential [GO:1904457]; positive regulation of protein complex disassembly [GO:0043243]; positive regulation of protein dephosphorylation [GO:0035307]; positive regulation of protein lipidation [GO:1903061]; positive regulation of proteolysis involved in cellular protein catabolic process [GO:1903052]; regulation of cellular protein metabolic process [GO:0032268]; regulation of lysosomal protein catabolic process [GO:1905165]; regulation of macroautophagy [GO:0016241]; regulation of proteasomal ubiquitin-dependent protein catabolic process [GO:0032434]; regulation of water loss via skin [GO:0033561]; response to estrogen [GO:0043627]; response to glucocorticoid [GO:0051384]; response to pH [GO:0009268]; response to testosterone [GO:0033574]; response to thyroid hormone [GO:0097066]; skin morphogenesis [GO:0043589]; sphingosine biosynthetic process [GO:0046512]; termination of signal transduction [GO:0023021]	glucosylceramidase activity [GO:0004348]; receptor binding [GO:0005102]	extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; lysosomal lumen [GO:0043202]; lysosomal membrane [GO:0005765]
P01215	GLHA_HUMAN	Glycoprotein hormones alpha chain (Anterior pituitary glycoprotein hormones common subunit alpha) (Choriogonadotropin alpha chain) (Chorionic gonadotrophin subunit alpha) (CG-alpha) (Follicle-stimulating hormone alpha chain) (FSH-alpha) (Follitropin alpha chain) (Luteinizing hormone alpha chain) (LSH-alpha) (Lutropin alpha chain) (Thyroid-stimulating hormone alpha chain) (TSH-alpha) (Thyrotropin alpha chain)	CGA	1DZ7;1E9J;1FL7;1HCN;1HD4;1HRP;1QFW;1XUL;1XWD;4AY9;4MQW;	CHEMBL2146305;				PF00236;	IPR029034;IPR000476;	cell-cell signaling [GO:0007267]; peptide hormone processing [GO:0016486]; positive regulation of cell migration [GO:0030335]; positive regulation of cell proliferation [GO:0008284]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; signal transduction [GO:0007165]	hormone activity [GO:0005179]	extracellular region [GO:0005576]; Golgi lumen [GO:0005796]
P15104	GLNA_HUMAN	Glutamine synthetase (GS) (EC 6.3.1.2) (Glutamate decarboxylase) (EC 4.1.1.15) (Glutamate--ammonia ligase)	GLUL GLNS	2OJW;2QC8;	CHEMBL4612;	P15104;	DB06774;DB01212;DB01119;DB00130;DB00134;DB00082;		PF00120;PF03951;	IPR008147;IPR014746;IPR008146;IPR027303;IPR027302;	ammonia assimilation cycle [GO:0019676]; cell proliferation [GO:0008283]; cellular amino acid biosynthetic process [GO:0008652]; cellular response to starvation [GO:0009267]; glutamate catabolic process [GO:0006538]; glutamine biosynthetic process [GO:0006542]; neurotransmitter uptake [GO:0001504]; positive regulation of epithelial cell proliferation [GO:0050679]; positive regulation of insulin secretion [GO:0032024]; positive regulation of synaptic transmission, glutamatergic [GO:0051968]; protein homooligomerization [GO:0051260]; response to glucose [GO:0009749]	ATP binding [GO:0005524]; glutamate-ammonia ligase activity [GO:0004356]; glutamate binding [GO:0016595]; glutamate decarboxylase activity [GO:0004351]; magnesium ion binding [GO:0000287]; manganese ion binding [GO:0030145]	axon terminus [GO:0043679]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; glial cell projection [GO:0097386]; mitochondrion [GO:0005739]; myelin sheath [GO:0043209]; nucleus [GO:0005634]; perikaryon [GO:0043204]; protein complex [GO:0043234]; rough endoplasmic reticulum [GO:0005791]
Q16775	GLO2_HUMAN	Hydroxyacylglutathione hydrolase, mitochondrial (EC 3.1.2.6) (Glyoxalase II) (Glx II)	HAGH GLO2 HAGH1	1QH3;1QH5;2F50;	CHEMBL2261;	Q16775;	DB00143;	PATHWAY: Secondary metabolite metabolism; methylglyoxal degradation; (R)-lactate from methylglyoxal: step 2/2.	PF16123;PF00753;	IPR032282;IPR017782;IPR001279;	glutathione biosynthetic process [GO:0006750]; methylglyoxal catabolic process to D-lactate via S-lactoyl-glutathione [GO:0019243]; pyruvate metabolic process [GO:0006090]	hydroxyacylglutathione hydrolase activity [GO:0004416]; metal ion binding [GO:0046872]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]
P23415	GLRA1_HUMAN	Glycine receptor subunit alpha-1 (Glycine receptor 48 kDa subunit) (Glycine receptor strychnine-binding subunit)	GLRA1	1MOT;1VRY;2M6B;2M6I;4X5T;	CHEMBL5845;	P23415;	DB01189;DB00228;DB00898;DB01381;DB00145;DB01159;DB00753;DB00431;DB01028;DB01236;		PF02931;PF02932;	IPR006028;IPR008127;IPR008128;IPR006202;IPR006201;IPR006029;IPR018000;	acrosome reaction [GO:0007340]; action potential [GO:0001508]; adult walking behavior [GO:0007628]; cellular response to amino acid stimulus [GO:0071230]; cellular response to ethanol [GO:0071361]; cellular response to zinc ion [GO:0071294]; chloride transmembrane transport [GO:1902476]; chloride transport [GO:0006821]; inhibitory postsynaptic potential [GO:0060080]; ion transmembrane transport [GO:0034220]; ion transport [GO:0006811]; muscle contraction [GO:0006936]; negative regulation of transmission of nerve impulse [GO:0051970]; neuromuscular process controlling posture [GO:0050884]; neuropeptide signaling pathway [GO:0007218]; positive regulation of acrosome reaction [GO:2000344]; protein heterooligomerization [GO:0051291]; protein homooligomerization [GO:0051260]; regulation of membrane potential [GO:0042391]; regulation of respiratory gaseous exchange by neurological system process [GO:0002087]; response to alcohol [GO:0097305]; righting reflex [GO:0060013]; startle response [GO:0001964]; synaptic transmission, glycinergic [GO:0060012]; visual perception [GO:0007601]	extracellular-glycine-gated chloride channel activity [GO:0016934]; glycine binding [GO:0016594]; taurine binding [GO:0030977]; transmitter-gated ion channel activity [GO:0022824]; zinc ion binding [GO:0008270]	cell junction [GO:0030054]; chloride channel complex [GO:0034707]; dendrite [GO:0030425]; endoplasmic reticulum [GO:0005783]; external side of plasma membrane [GO:0009897]; inhibitory synapse [GO:0060077]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; intracellular membrane-bounded organelle [GO:0043231]; neuronal cell body [GO:0043025]; neuron projection [GO:0043005]; perikaryon [GO:0043204]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]; synapse [GO:0045202]
P23416	GLRA2_HUMAN	Glycine receptor subunit alpha-2	GLRA2		CHEMBL5871;	P23416;	DB00898;DB00145;DB00431;		PF02931;PF02932;	IPR006028;IPR008127;IPR008129;IPR006202;IPR006201;IPR006029;IPR018000;	cellular response to amino acid stimulus [GO:0071230]; cellular response to ethanol [GO:0071361]; cellular response to zinc ion [GO:0071294]; chloride transmembrane transport [GO:1902476]; ion transmembrane transport [GO:0034220]; neuropeptide signaling pathway [GO:0007218]; synaptic transmission, glycinergic [GO:0060012]	extracellular-glycine-gated chloride channel activity [GO:0016934]; glycine binding [GO:0016594]; glycine-gated chloride ion channel activity [GO:0022852]; metal ion binding [GO:0046872]	cell junction [GO:0030054]; cell projection [GO:0042995]; chloride channel complex [GO:0034707]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
O75311	GLRA3_HUMAN	Glycine receptor subunit alpha-3	GLRA3	5CFB;	CHEMBL1075092;	O75311;	DB00145;DB00602;DB00431;		PF02931;PF02932;	IPR006028;IPR008127;IPR008130;IPR006202;IPR006201;IPR006029;IPR018000;	chloride transmembrane transport [GO:1902476]; ion transmembrane transport [GO:0034220]; neuropeptide signaling pathway [GO:0007218]; protein homooligomerization [GO:0051260]; response to amino acid [GO:0043200]; synaptic transmission, glycinergic [GO:0060012]	extracellular-glycine-gated chloride channel activity [GO:0016934]; glycine binding [GO:0016594]; glycine-gated chloride ion channel activity [GO:0022852]; metal ion binding [GO:0046872]	cell junction [GO:0030054]; dendrite [GO:0030425]; glycine-gated chloride channel complex [GO:0016935]; integral component of plasma membrane [GO:0005887]; perikaryon [GO:0043204]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
P48167	GLRB_HUMAN	Glycine receptor subunit beta (Glycine receptor 58 kDa subunit)	GLRB		CHEMBL2363052;		DB00228;DB00145;DB00431;		PF02931;PF02932;	IPR008060;IPR006202;IPR006201;IPR006029;IPR018000;	acrosome reaction [GO:0007340]; adult walking behavior [GO:0007628]; chemical synaptic transmission [GO:0007268]; chloride transmembrane transport [GO:1902476]; gamma-aminobutyric acid receptor clustering [GO:0097112]; ion transmembrane transport [GO:0034220]; ion transport [GO:0006811]; nervous system development [GO:0007399]; neuropeptide signaling pathway [GO:0007218]; protein heterooligomerization [GO:0051291]; regulation of membrane potential [GO:0042391]; response to amino acid [GO:0043200]; righting reflex [GO:0060013]; startle response [GO:0001964]; synaptic transmission, glycinergic [GO:0060012]; visual perception [GO:0007601]	drug binding [GO:0008144]; extracellular-glycine-gated chloride channel activity [GO:0016934]; extracellular-glycine-gated ion channel activity [GO:0016933]; glycine binding [GO:0016594]	cell junction [GO:0030054]; cytoplasm [GO:0005737]; dendrite [GO:0030425]; glycine-gated chloride channel complex [GO:0016935]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
P35754	GLRX1_HUMAN	Glutaredoxin-1 (Thioltransferase-1) (TTase-1)	GLRX GRX	1B4Q;1JHB;4RQR;			DB00143;		PF00462;	IPR011767;IPR002109;IPR011899;IPR014025;IPR012336;	cell redox homeostasis [GO:0045454]; nucleobase-containing small molecule interconversion [GO:0015949]; positive regulation of membrane potential [GO:0045838]; positive regulation of sodium ion transmembrane transporter activity [GO:2000651]; protein deglutathionylation [GO:0080058]	electron carrier activity [GO:0009055]; glutathione disulfide oxidoreductase activity [GO:0015038]; glutathione oxidoreductase activity [GO:0097573]; protein N-terminus binding [GO:0047485]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrion [GO:0005739]; nucleus [GO:0005634]
Q9NS18	GLRX2_HUMAN	Glutaredoxin-2, mitochondrial	GLRX2 GRX2 CGI-133	2CQ9;2FLS;2HT9;			DB00143;		PF00462;	IPR002109;IPR011899;IPR014025;IPR012336;	aging [GO:0007568]; apoptotic process [GO:0006915]; cell differentiation [GO:0030154]; cell redox homeostasis [GO:0045454]; cellular response to superoxide [GO:0071451]; DNA protection [GO:0042262]; glutathione metabolic process [GO:0006749]; regulation of signal transduction [GO:0009966]; regulation of transcription, DNA-templated [GO:0006355]; response to hydrogen peroxide [GO:0042542]; response to organic substance [GO:0010033]; response to redox state [GO:0051775]; response to temperature stimulus [GO:0009266]	2 iron, 2 sulfur cluster binding [GO:0051537]; arsenate reductase (glutaredoxin) activity [GO:0008794]; electron carrier activity [GO:0009055]; glutathione disulfide oxidoreductase activity [GO:0015038]; metal ion binding [GO:0046872]; protein disulfide isomerase activity [GO:0003756]; protein disulfide oxidoreductase activity [GO:0015035]	dendrite [GO:0030425]; intracellular membrane-bounded organelle [GO:0043231]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; neuronal cell body [GO:0043025]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
O94925	GLSK_HUMAN	Glutaminase kidney isoform, mitochondrial (GLS) (EC 3.5.1.2) (K-glutaminase) (L-glutamine amidohydrolase)	GLS GLS1 KIAA0838	3CZD;3UNW;3UO9;3VOY;3VOZ;3VP0;3VP1;3VP2;3VP3;3VP4;4O7D;5D3O;5FI2;5FI6;5FI7;5HL1;5I94;5JYO;5JYP;	CHEMBL2146302;	O94925;	DB00130;		PF12796;PF04960;	IPR002110;IPR020683;IPR012338;IPR015868;	cellular amino acid biosynthetic process [GO:0008652]; chemical synaptic transmission [GO:0007268]; glutamate biosynthetic process [GO:0006537]; glutamate secretion [GO:0014047]; glutamine catabolic process [GO:0006543]; protein homotetramerization [GO:0051289]; regulation of respiratory gaseous exchange by neurological system process [GO:0002087]; suckling behavior [GO:0001967]	glutaminase activity [GO:0004359]	cytosol [GO:0005829]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
Q9UI32	GLSL_HUMAN	Glutaminase liver isoform, mitochondrial (GLS) (EC 3.5.1.2) (L-glutaminase) (L-glutamine amidohydrolase)	GLS2 GA	4BQM;			DB00130;		PF12796;PF04960;	IPR002110;IPR020683;IPR012338;IPR015868;	cellular amino acid biosynthetic process [GO:0008652]; cellular amino acid metabolic process [GO:0006520]; glutamate biosynthetic process [GO:0006537]; glutamate secretion [GO:0014047]; glutamine catabolic process [GO:0006543]; positive regulation of protein targeting to mitochondrion [GO:1903955]; reactive oxygen species metabolic process [GO:0072593]; regulation of apoptotic process [GO:0042981]	glutaminase activity [GO:0004359]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
Q9NZD2	GLTP_HUMAN	Glycolipid transfer protein (GLTP)	GLTP	1SWX;1SX6;2EUK;2EUM;2EVD;2EVL;2EVS;2EVT;3RIC;3RWV;3RZN;3S0I;3S0K;4GH0;4GHP;4GHS;4GIX;4GJQ;4GVT;4GXD;4GXG;4H2Z;			DB04465;DB04224;		PF08718;	IPR014830;	glycolipid transport [GO:0046836]; glycosphingolipid metabolic process [GO:0006687]	glycolipid binding [GO:0051861]; glycolipid transporter activity [GO:0017089]; lipid binding [GO:0008289]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]
P01275	GLUC_HUMAN	Glucagon [Cleaved into: Glicentin; Glicentin-related polypeptide (GRPP); Oxyntomodulin (OXM) (OXY); Glucagon; Glucagon-like peptide 1 (GLP-1) (Incretin hormone); Glucagon-like peptide 1(7-37) (GLP-1(7-37)); Glucagon-like peptide 1(7-36) (GLP-1(7-36)); Glucagon-like peptide 2 (GLP-2)]	GCG	1BH0;1D0R;1NAU;2G49;2L63;2L64;2M5P;2M5Q;3IOL;4APD;4ZGM;	CHEMBL5736;	P01275;			PF00123;	IPR015550;IPR000532;	adenylate cyclase-modulating G-protein coupled receptor signaling pathway [GO:0007188]; cell proliferation [GO:0008283]; cellular response to glucagon stimulus [GO:0071377]; feeding behavior [GO:0007631]; G-protein coupled receptor signaling pathway [GO:0007186]; negative regulation of apoptotic process [GO:0043066]; negative regulation of execution phase of apoptosis [GO:1900118]; negative regulation of intrinsic apoptotic signaling pathway [GO:2001243]; positive regulation of calcium ion import [GO:0090280]; positive regulation of cAMP biosynthetic process [GO:0030819]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of gluconeogenesis by positive regulation of transcription from RNA polymerase II promoter [GO:0035948]; positive regulation of histone H3-K4 methylation [GO:0051571]; positive regulation of insulin secretion involved in cellular response to glucose stimulus [GO:0035774]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of peptidyl-threonine phosphorylation [GO:0010800]; positive regulation of protein binding [GO:0032092]; positive regulation of protein kinase activity [GO:0045860]; protein kinase A signaling [GO:0010737]; regulation of insulin secretion [GO:0050796]; response to starvation [GO:0042594]; signal transduction [GO:0007165]	glucagon receptor binding [GO:0031769]; hormone activity [GO:0005179]; identical protein binding [GO:0042802]; receptor binding [GO:0005102]	endoplasmic reticulum lumen [GO:0005788]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; plasma membrane [GO:0005886]; secretory granule lumen [GO:0034774]
Q5TDP6	GLUD1_HUMAN	Lengsin (Glutamate-ammonia ligase domain-containing protein 1) (Lens glutamine synthase-like)	LGSN GLULD1 LGS						PF00120;	IPR008147;IPR014746;IPR008146;	glutamine biosynthetic process [GO:0006542]	glutamate-ammonia ligase activity [GO:0004356]	plasma membrane [GO:0005886]
Q6IB77	GLYAT_HUMAN	Glycine N-acyltransferase (EC 2.3.1.13) (Acyl-CoA:glycine N-acyltransferase) (AAc) (Aralkyl acyl-CoA N-acyltransferase) (Aralkyl acyl-CoA:amino acid N-acyltransferase) (Benzoyl-coenzyme A:glycine N-acyltransferase) (Glycine N-benzoyltransferase) (EC 2.3.1.71) (HRP-1(CLP))	GLYAT ACGNAT CAT GAT				DB00145;		PF08444;PF06021;	IPR016181;IPR010313;IPR013652;IPR015938;	acyl-CoA metabolic process [GO:0006637]; glycine metabolic process [GO:0006544]; monocarboxylic acid metabolic process [GO:0032787]; response to toxic substance [GO:0009636]; xenobiotic metabolic process [GO:0006805]	glycine N-acyltransferase activity [GO:0047961]; glycine N-benzoyltransferase activity [GO:0047962]; transferase activity, transferring acyl groups [GO:0016746]	extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
Q969I3	GLYL1_HUMAN	Glycine N-acyltransferase-like protein 1 (EC 2.3.1.68) (Acyl-CoA:glycine N-acyltransferase-like protein 1) (Glutamine N-acyltransferase)	GLYATL1 GNAT				DB00145;		PF08444;PF06021;	IPR016181;IPR010313;IPR013652;IPR015938;		glutamine N-acyltransferase activity [GO:0047946]; glycine N-acyltransferase activity [GO:0047961]	mitochondrion [GO:0005739]
Q8WU03	GLYL2_HUMAN	Glycine N-acyltransferase-like protein 2 (EC 2.3.1.13) (Acyl-CoA:glycine N-acyltransferase-like protein 2)	GLYATL2				DB00145;		PF08444;PF06021;	IPR016181;IPR010313;IPR013652;IPR015938;		glycine N-acyltransferase activity [GO:0047961]	endoplasmic reticulum [GO:0005783]; mitochondrion [GO:0005739]
O60547	GMDS_HUMAN	GDP-mannose 4,6 dehydratase (EC 4.2.1.47) (GDP-D-mannose dehydratase) (GMD)	GMDS	1T2A;5IN4;5IN5;				PATHWAY: Nucleotide-sugar biosynthesis; GDP-L-fucose biosynthesis via de novo pathway; GDP-L-fucose from GDP-alpha-D-mannose: step 1/2.	PF16363;	IPR006368;IPR016040;	'de novo' GDP-L-fucose biosynthetic process [GO:0042351]; GDP-mannose metabolic process [GO:0019673]; Notch signaling pathway [GO:0007219]	GDP-mannose 4,6-dehydratase activity [GO:0008446]; NADP+ binding [GO:0070401]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P36959	GMPR1_HUMAN	GMP reductase 1 (GMPR 1) (EC 1.7.1.7) (Guanosine 5'-monophosphate oxidoreductase 1) (Guanosine monophosphate reductase 1)	GMPR GMPR1	2BLE;2BWG;					PF00478;	IPR013785;IPR005993;IPR015875;IPR001093;	purine-containing compound salvage [GO:0043101]; purine nucleobase metabolic process [GO:0006144]; purine ribonucleotide interconversion [GO:0015951]; response to cold [GO:0009409]	GMP reductase activity [GO:0003920]; metal ion binding [GO:0046872]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; GMP reductase complex [GO:1902560]
Q9P2T1	GMPR2_HUMAN	GMP reductase 2 (GMPR 2) (EC 1.7.1.7) (Guanosine 5'-monophosphate oxidoreductase 2) (Guanosine monophosphate reductase 2)	GMPR2	2A7R;2BZN;2C6Q;					PF00478;	IPR013785;IPR005993;IPR015875;IPR001093;	GMP metabolic process [GO:0046037]; purine-containing compound salvage [GO:0043101]; purine nucleobase metabolic process [GO:0006144]; purine ribonucleotide interconversion [GO:0015951]	GMP reductase activity [GO:0003920]; metal ion binding [GO:0046872]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; GMP reductase complex [GO:1902560]
P22749	GNLY_HUMAN	Granulysin (Lymphokine LAG-2) (Protein NKG5) (T-cell activation protein 519)	GNLY LAG2 NKG5 TLA519	1L9L;					PF03489;	IPR008138;IPR011001;IPR008139;	cellular defense response [GO:0006968]; defense response to bacterium [GO:0042742]; defense response to fungus [GO:0050832]; killing of cells of other organism [GO:0031640]		extracellular space [GO:0005615]
Q14749	GNMT_HUMAN	Glycine N-methyltransferase (EC 2.1.1.20)	GNMT	1R74;2AZT;			DB00145;DB00118;			IPR014369;IPR029063;	cellular protein modification process [GO:0006464]; glycogen metabolic process [GO:0005977]; glyoxylate metabolic process [GO:0046487]; methionine metabolic process [GO:0006555]; one-carbon metabolic process [GO:0006730]; protein homotetramerization [GO:0051289]; regulation of gluconeogenesis [GO:0006111]; S-adenosylmethionine metabolic process [GO:0046500]	folic acid binding [GO:0005542]; glycine binding [GO:0016594]; glycine N-methyltransferase activity [GO:0017174]	cytoplasm [GO:0005737]; cytosol [GO:0005829]
P46926	GNPI_HUMAN	Glucosamine-6-phosphate isomerase 1 (EC 3.5.99.6) (Glucosamine-6-phosphate deaminase 1) (GNPDA 1) (GlcN6P deaminase 1) (Oscillin)	GNPDA1 GNPI HLN KIAA0060	1NE7;					PF01182;	IPR006148;IPR004547;IPR018321;	generation of precursor metabolites and energy [GO:0006091]; glucosamine catabolic process [GO:0006043]; glucose metabolic process [GO:0006006]; N-acetylglucosamine catabolic process [GO:0006046]; N-acetylneuraminate catabolic process [GO:0019262]; single fertilization [GO:0007338]; UDP-N-acetylglucosamine biosynthetic process [GO:0006048]	glucosamine-6-phosphate deaminase activity [GO:0004342]; hydrolase activity [GO:0016787]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P30968	GNRHR_HUMAN	Gonadotropin-releasing hormone receptor (GnRH receptor) (GnRH-R)	GNRHR GRHR		CHEMBL1855;	P30968;	DB00106;DB06719;DB00050;DB01406;DB06699;DB06785;DB00644;DB00014;DB00007;DB00666;DB06825;		PF00001;	IPR000276;IPR017452;IPR001658;IPR027982;	G-protein coupled receptor signaling pathway [GO:0007186]; multicellular organism development [GO:0007275]	gonadotropin-releasing hormone receptor activity [GO:0004968]; peptide binding [GO:0042277]	integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]
Q96P88	GNRR2_HUMAN	Putative gonadotropin-releasing hormone II receptor (GnRH II receptor) (GnRH-II-R) (Type II GnRH receptor)	GNRHR2				DB01406;DB00644;DB00666;		PF00001;	IPR000276;IPR017452;IPR027983;IPR001658;	cellular response to gonadotropin-releasing hormone [GO:0097211]	gonadotropin-releasing hormone receptor activity [GO:0004968]; peptide binding [GO:0042277]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P07359	GP1BA_HUMAN	Platelet glycoprotein Ib alpha chain (GP-Ib alpha) (GPIb-alpha) (GPIbA) (Glycoprotein Ibalpha) (Antigen CD42b-alpha) (CD antigen CD42b) [Cleaved into: Glycocalicin]	GP1BA	1GWB;1K13;1M0Z;1M10;1OOK;1P8V;1P9A;1QYY;1SQ0;1U0N;2BP3;3P72;3PMH;4C2A;4C2B;4CH2;4CH8;4MGX;4YR6;					PF13855;PF01462;	IPR000483;IPR032675;IPR001611;IPR003591;IPR000372;	blood coagulation [GO:0007596]; blood coagulation, intrinsic pathway [GO:0007597]; cell adhesion [GO:0007155]; cell morphogenesis [GO:0000902]; cell surface receptor signaling pathway [GO:0007166]; cytokine-mediated signaling pathway [GO:0019221]; fibrinolysis [GO:0042730]; negative regulation of JAK-STAT cascade [GO:0046426]; negative regulation of protein kinase activity [GO:0006469]; platelet activation [GO:0030168]; platelet aggregation [GO:0070527]; regulation of blood coagulation [GO:0030193]	protein kinase inhibitor activity [GO:0004860]; thrombin receptor activity [GO:0015057]	anchored component of external side of plasma membrane [GO:0031362]; cell surface [GO:0009986]; cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]
P21695	GPDA_HUMAN	Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic (GPD-C) (GPDH-C) (EC 1.1.1.8)	GPD1	1WPQ;1X0V;1X0X;					PF07479;PF01210;	IPR008927;IPR013328;IPR006168;IPR006109;IPR017751;IPR011128;IPR016040;	cellular response to cAMP [GO:0071320]; cellular response to tumor necrosis factor [GO:0071356]; gluconeogenesis [GO:0006094]; glycerol-3-phosphate catabolic process [GO:0046168]; glycerophosphate shuttle [GO:0006127]; phosphatidic acid biosynthetic process [GO:0006654]; positive regulation of glycolytic process [GO:0045821]; triglyceride biosynthetic process [GO:0019432]	glycerol-3-phosphate dehydrogenase [NAD+] activity [GO:0004367]; glycerol-3-phosphate dehydrogenase activity [GO:0004368]; NAD binding [GO:0051287]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; glycerol-3-phosphate dehydrogenase complex [GO:0009331]; mitochondrion [GO:0005739]
P14770	GPIX_HUMAN	Platelet glycoprotein IX (GP-IX) (GPIX) (Glycoprotein 9) (CD antigen CD42a)	GP9	3REZ;			DB00468;		PF13855;PF01462;	IPR000483;IPR032675;IPR001611;IPR000372;	blood coagulation [GO:0007596]; blood coagulation, intrinsic pathway [GO:0007597]; cell adhesion [GO:0007155]; platelet activation [GO:0030168]		integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
Q14330	GPR18_HUMAN	N-arachidonyl glycine receptor (NAGly receptor) (G-protein coupled receptor 18)	GPR18 GPCRW		CHEMBL2384898;	Q14330;	DB00145;		PF00001;	IPR000276;IPR017452;IPR028335;	CD8-positive, alpha-beta intraepithelial T cell differentiation [GO:0002300]; CD8-positive, gamma-delta intraepithelial T cell differentiation [GO:0002305]; G-protein coupled receptor signaling pathway [GO:0007186]; negative regulation of leukocyte chemotaxis [GO:0002689]; negative regulation of tumor necrosis factor production [GO:0032720]	G-protein coupled receptor activity [GO:0004930]	integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]
P07203	GPX1_HUMAN	Glutathione peroxidase 1 (GPx-1) (GSHPx-1) (EC 1.11.1.9) (Cellular glutathione peroxidase)	GPX1	2F8A;	CHEMBL2163186;	P07203;	DB00143;		PF00255;	IPR000889;IPR029759;IPR029760;IPR012336;	angiogenesis involved in wound healing [GO:0060055]; blood vessel endothelial cell migration [GO:0043534]; cell redox homeostasis [GO:0045454]; cellular response to oxidative stress [GO:0034599]; endothelial cell development [GO:0001885]; fat cell differentiation [GO:0045444]; glutathione metabolic process [GO:0006749]; heart contraction [GO:0060047]; hydrogen peroxide catabolic process [GO:0042744]; interaction with symbiont [GO:0051702]; intrinsic apoptotic signaling pathway in response to oxidative stress [GO:0008631]; lipoxygenase pathway [GO:0019372]; myoblast proliferation [GO:0051450]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154]; negative regulation of extrinsic apoptotic signaling pathway via death domain receptors [GO:1902042]; negative regulation of inflammatory response to antigenic stimulus [GO:0002862]; negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway [GO:1902176]; negative regulation of release of cytochrome c from mitochondria [GO:0090201]; positive regulation of fibril organization [GO:1902905]; positive regulation of protein kinase B signaling [GO:0051897]; protein oxidation [GO:0018158]; purine nucleotide catabolic process [GO:0006195]; regulation of gene expression, epigenetic [GO:0040029]; regulation of mammary gland epithelial cell proliferation [GO:0033599]; regulation of neuron apoptotic process [GO:0043523]; regulation of proteasomal protein catabolic process [GO:0061136]; response to gamma radiation [GO:0010332]; response to hydrogen peroxide [GO:0042542]; response to hydroperoxide [GO:0033194]; response to reactive oxygen species [GO:0000302]; response to selenium ion [GO:0010269]; response to symbiotic bacterium [GO:0009609]; response to xenobiotic stimulus [GO:0009410]; sensory perception of sound [GO:0007605]; skeletal muscle fiber development [GO:0048741]; skeletal muscle tissue regeneration [GO:0043403]; temperature homeostasis [GO:0001659]; triglyceride metabolic process [GO:0006641]; UV protection [GO:0009650]; vasodilation [GO:0042311]	glutathione peroxidase activity [GO:0004602]; SH3 domain binding [GO:0017124]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
P18283	GPX2_HUMAN	Glutathione peroxidase 2 (GPx-2) (GSHPx-2) (EC 1.11.1.9) (Gastrointestinal glutathione peroxidase) (Glutathione peroxidase-gastrointestinal) (GPx-GI) (GSHPx-GI) (Glutathione peroxidase-related protein 2) (GPRP-2)	GPX2	2HE3;			DB00143;		PF00255;	IPR000889;IPR029759;IPR029760;IPR012336;	response to reactive oxygen species [GO:0000302]	electron carrier activity [GO:0009055]; glutathione peroxidase activity [GO:0004602]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P22352	GPX3_HUMAN	Glutathione peroxidase 3 (GPx-3) (GSHPx-3) (EC 1.11.1.9) (Extracellular glutathione peroxidase) (Plasma glutathione peroxidase) (GPx-P) (GSHPx-P)	GPX3 GPXP	2R37;			DB00143;		PF00255;	IPR000889;IPR029759;IPR029760;IPR012336;	hydrogen peroxide catabolic process [GO:0042744]; protein homotetramerization [GO:0051289]; response to lipid hydroperoxide [GO:0006982]; response to reactive oxygen species [GO:0000302]	glutathione peroxidase activity [GO:0004602]; selenium binding [GO:0008430]; transcription factor binding [GO:0008134]	extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]
P36969	GPX4_HUMAN	Phospholipid hydroperoxide glutathione peroxidase, mitochondrial (PHGPx) (EC 1.11.1.12) (Glutathione peroxidase 4) (GPx-4) (GSHPx-4)	GPX4	2GS3;2OBI;			DB00143;		PF00255;	IPR000889;IPR029759;IPR029760;IPR012336;	lipoxygenase pathway [GO:0019372]; multicellular organism development [GO:0007275]; oxidation-reduction process [GO:0055114]; phospholipid metabolic process [GO:0006644]; response to oxidative stress [GO:0006979]	glutathione peroxidase activity [GO:0004602]; phospholipid-hydroperoxide glutathione peroxidase activity [GO:0047066]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrion [GO:0005739]; nucleus [GO:0005634]
O75715	GPX5_HUMAN	Epididymal secretory glutathione peroxidase (EC 1.11.1.9) (Epididymis-specific glutathione peroxidase-like protein) (EGLP) (Glutathione peroxidase 5) (GPx-5) (GSHPx-5)	GPX5	2I3Y;			DB00143;		PF00255;	IPR000889;IPR029759;IPR029760;IPR012336;	cellular response to oxidative stress [GO:0034599]; lipid metabolic process [GO:0006629]; response to reactive oxygen species [GO:0000302]	glutathione peroxidase activity [GO:0004602]	extracellular region [GO:0005576]; extracellular space [GO:0005615]; sperm plasma membrane [GO:0097524]
P59796	GPX6_HUMAN	Glutathione peroxidase 6 (GPx-6) (GSHPx-6) (EC 1.11.1.9)	GPX6				DB00143;		PF00255;	IPR000889;IPR029759;IPR029760;IPR012336;	response to oxidative stress [GO:0006979]	glutathione peroxidase activity [GO:0004602]	extracellular region [GO:0005576]
Q96SL4	GPX7_HUMAN	Glutathione peroxidase 7 (GPx-7) (GSHPx-7) (EC 1.11.1.9) (CL683)	GPX7 GPX6 UNQ469/PRO828	2P31;			DB00143;		PF00255;	IPR013376;IPR000889;IPR029759;IPR029760;IPR012336;	response to reactive oxygen species [GO:0000302]	catalase activity [GO:0004096]; glutathione peroxidase activity [GO:0004602]; peroxidase activity [GO:0004601]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum lumen [GO:0005788]; extracellular region [GO:0005576]
P10144	GRAB_HUMAN	Granzyme B (EC 3.4.21.79) (C11) (CTLA-1) (Cathepsin G-like 1) (CTSGL1) (Cytotoxic T-lymphocyte proteinase 2) (Lymphocyte protease) (Fragmentin-2) (Granzyme-2) (Human lymphocyte protein) (HLP) (SECT) (T-cell serine protease 1-3E)	GZMB CGL1 CSPB CTLA1 GRB	1FQ3;1IAU;	CHEMBL2316;	P10144;			PF00089;	IPR009003;IPR001314;IPR001254;IPR018114;IPR033116;	apoptotic process [GO:0006915]; cytolysis [GO:0019835]; natural killer cell mediated cytotoxicity [GO:0042267]; positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway [GO:1900740]; protein processing [GO:0016485]	serine-type endopeptidase activity [GO:0004252]; serine-type peptidase activity [GO:0008236]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; immunological synapse [GO:0001772]; intracellular membrane-bounded organelle [GO:0043231]; membrane [GO:0016020]; mitochondrion [GO:0005739]; nucleus [GO:0005634]
P42261	GRIA1_HUMAN	Glutamate receptor 1 (GluR-1) (AMPA-selective glutamate receptor 1) (GluR-A) (GluR-K1) (Glutamate receptor ionotropic, AMPA 1) (GluA1)	GRIA1 GLUH1 GLUR1		CHEMBL2009;	P42261;	DB01189;DB00228;DB00898;DB00753;DB01028;DB08883;DB01236;		PF01094;PF00060;PF10613;	IPR001828;IPR019594;IPR001508;IPR001320;IPR028082;	chemical synaptic transmission [GO:0007268]; COPII vesicle coating [GO:0048208]; ER to Golgi vesicle-mediated transport [GO:0006888]; long-term memory [GO:0007616]; long term synaptic depression [GO:0060292]; receptor internalization [GO:0031623]; signal transduction [GO:0007165]	AMPA glutamate receptor activity [GO:0004971]; excitatory extracellular ligand-gated ion channel activity [GO:0005231]; extracellular-glutamate-gated ion channel activity [GO:0005234]; glutamate receptor activity [GO:0008066]; PDZ domain binding [GO:0030165]	AMPA glutamate receptor complex [GO:0032281]; axonal spine [GO:0044308]; cell junction [GO:0030054]; cell surface [GO:0009986]; dendrite [GO:0030425]; dendritic spine [GO:0043197]; dendritic spine membrane [GO:0032591]; endocytic vesicle membrane [GO:0030666]; endoplasmic reticulum-Golgi intermediate compartment membrane [GO:0033116]; endoplasmic reticulum membrane [GO:0005789]; ER to Golgi transport vesicle membrane [GO:0012507]; Golgi membrane [GO:0000139]; neuronal cell body [GO:0043025]; neuron spine [GO:0044309]; plasma membrane [GO:0005886]; postsynaptic density [GO:0014069]; postsynaptic membrane [GO:0045211]; recycling endosome [GO:0055037]; synaptic vesicle [GO:0008021]
P42262	GRIA2_HUMAN	Glutamate receptor 2 (GluR-2) (AMPA-selective glutamate receptor 2) (GluR-B) (GluR-K2) (Glutamate receptor ionotropic, AMPA 2) (GluA2)	GRIA2 GLUR2	2WJW;2WJX;2XHD;3R7X;3RN8;3RNN;3UA8;5H8S;	CHEMBL4016;	P42262;	DB01351;DB01352;DB00237;DB00241;DB01353;DB00898;DB01354;DB01355;DB00849;DB00312;DB01174;DB00794;DB01346;DB00418;DB00306;DB00599;		PF01094;PF00060;PF10613;	IPR001828;IPR019594;IPR001508;IPR001320;IPR028082;	chemical synaptic transmission [GO:0007268]; ionotropic glutamate receptor signaling pathway [GO:0035235]; signal transduction [GO:0007165]	AMPA glutamate receptor activity [GO:0004971]; excitatory extracellular ligand-gated ion channel activity [GO:0005231]; extracellular-glutamate-gated ion channel activity [GO:0005234]; ionotropic glutamate receptor activity [GO:0004970]	AMPA glutamate receptor complex [GO:0032281]; cell junction [GO:0030054]; endocytic vesicle membrane [GO:0030666]; endoplasmic reticulum membrane [GO:0005789]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
P42263	GRIA3_HUMAN	Glutamate receptor 3 (GluR-3) (AMPA-selective glutamate receptor 3) (GluR-C) (GluR-K3) (Glutamate receptor ionotropic, AMPA 3) (GluA3)	GRIA3 GLUR3 GLURC		CHEMBL3595;	P42263;	DB00898;DB01356;		PF01094;PF00060;PF10613;	IPR001828;IPR019594;IPR001508;IPR001320;IPR028082;	chemical synaptic transmission [GO:0007268]; glutamate receptor signaling pathway [GO:0007215]; transport [GO:0006810]	AMPA glutamate receptor activity [GO:0004971]; excitatory extracellular ligand-gated ion channel activity [GO:0005231]; extracellular-glutamate-gated ion channel activity [GO:0005234]	AMPA glutamate receptor complex [GO:0032281]; cell junction [GO:0030054]; endocytic vesicle membrane [GO:0030666]; nucleoplasm [GO:0005654]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
P48058	GRIA4_HUMAN	Glutamate receptor 4 (GluR-4) (GluR4) (AMPA-selective glutamate receptor 4) (GluR-D) (Glutamate receptor ionotropic, AMPA 4) (GluA4)	GRIA4 GLUR4		CHEMBL3190;	P48058;	DB00898;		PF01094;PF00060;PF10613;	IPR001828;IPR019594;IPR001508;IPR001320;IPR028082;	chemical synaptic transmission [GO:0007268]; glutamate receptor signaling pathway [GO:0007215]; transport [GO:0006810]	AMPA glutamate receptor activity [GO:0004971]; excitatory extracellular ligand-gated ion channel activity [GO:0005231]; extracellular-glutamate-gated ion channel activity [GO:0005234]; ionotropic glutamate receptor activity [GO:0004970]	AMPA glutamate receptor complex [GO:0032281]; cell junction [GO:0030054]; dendrite [GO:0030425]; endocytic vesicle membrane [GO:0030666]; extracellular vesicle [GO:1903561]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
Q9ULK0	GRID1_HUMAN	Glutamate receptor ionotropic, delta-1 (GluD1) (GluR delta-1 subunit)	GRID1 KIAA1220						PF01094;PF00060;PF10613;	IPR001828;IPR019594;IPR001508;IPR001320;IPR028082;	social behavior [GO:0035176]	extracellular-glutamate-gated ion channel activity [GO:0005234]; ionotropic glutamate receptor activity [GO:0004970]	cell junction [GO:0030054]; extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; postsynaptic membrane [GO:0045211]
O43424	GRID2_HUMAN	Glutamate receptor ionotropic, delta-2 (GluD2) (GluR delta-2 subunit)	GRID2 GLURD2	5KC8;5KCA;					PF01094;PF00060;PF10613;	IPR001828;IPR019594;IPR001508;IPR001320;IPR028082;	cellular protein localization [GO:0034613]; cerebellar granule cell differentiation [GO:0021707]; excitatory postsynaptic potential [GO:0060079]; glutamate receptor signaling pathway [GO:0007215]; heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules [GO:0007157]; prepulse inhibition [GO:0060134]; regulation of neuron apoptotic process [GO:0043523]; regulation of neuron projection development [GO:0010975]; synaptic transmission, glutamatergic [GO:0035249]; transport [GO:0006810]	extracellular-glutamate-gated ion channel activity [GO:0005234]; glutamate receptor activity [GO:0008066]; ionotropic glutamate receptor activity [GO:0004970]; PDZ domain binding [GO:0030165]; scaffold protein binding [GO:0097110]	cell junction [GO:0030054]; dendritic spine [GO:0043197]; integral component of plasma membrane [GO:0005887]; ionotropic glutamate receptor complex [GO:0008328]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]; synapse [GO:0045202]
P39086	GRIK1_HUMAN	Glutamate receptor ionotropic, kainate 1 (GluK1) (Excitatory amino acid receptor 3) (EAA3) (Glutamate receptor 5) (GluR-5) (GluR5)	GRIK1 GLUR5	2ZNS;2ZNT;2ZNU;3FUZ;3FV1;3FV2;3FVG;3FVK;3FVN;3FVO;4MF3;	CHEMBL1918;	P39086;	DB00273;		PF01094;PF00060;PF10613;	IPR001828;IPR019594;IPR001508;IPR001320;IPR028082;	central nervous system development [GO:0007417]; chemical synaptic transmission [GO:0007268]; glutamate receptor signaling pathway [GO:0007215]; nervous system development [GO:0007399]; regulation of synaptic transmission, glutamatergic [GO:0051966]; transport [GO:0006810]	extracellular-glutamate-gated ion channel activity [GO:0005234]; kainate selective glutamate receptor activity [GO:0015277]; ligand-gated ion channel activity [GO:0015276]	cell junction [GO:0030054]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
Q13002	GRIK2_HUMAN	Glutamate receptor ionotropic, kainate 2 (GluK2) (Excitatory amino acid receptor 4) (EAA4) (Glutamate receptor 6) (GluR-6) (GluR6)	GRIK2 GLUR6	3QXM;5CMM;	CHEMBL3683;	Q13002;	DB01351;DB01352;DB00237;DB00241;DB01353;DB01354;DB01355;DB00849;DB00312;DB01174;DB00794;DB00418;DB00306;DB00599;		PF01094;PF00060;PF10613;	IPR001828;IPR019594;IPR001508;IPR001320;IPR028082;	behavioral fear response [GO:0001662]; cellular calcium ion homeostasis [GO:0006874]; chemical synaptic transmission [GO:0007268]; excitatory postsynaptic potential [GO:0060079]; glutamate receptor signaling pathway [GO:0007215]; inhibitory postsynaptic potential [GO:0060080]; intracellular protein transport [GO:0006886]; modulation of synaptic transmission [GO:0050804]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of synaptic transmission, glutamatergic [GO:0051967]; neuronal action potential [GO:0019228]; neuron apoptotic process [GO:0051402]; positive regulation of neuron apoptotic process [GO:0043525]; positive regulation of synaptic transmission [GO:0050806]; receptor clustering [GO:0043113]; regulation of JNK cascade [GO:0046328]; regulation of long-term neuronal synaptic plasticity [GO:0048169]; regulation of short-term neuronal synaptic plasticity [GO:0048172]; synaptic transmission, glutamatergic [GO:0035249]; transport [GO:0006810]	extracellular-glutamate-gated ion channel activity [GO:0005234]; kainate selective glutamate receptor activity [GO:0015277]; ligand-gated ion channel activity [GO:0015276]	cell junction [GO:0030054]; dendrite cytoplasm [GO:0032839]; integral component of plasma membrane [GO:0005887]; kainate selective glutamate receptor complex [GO:0032983]; perikaryon [GO:0043204]; plasma membrane [GO:0005886]; postsynaptic density [GO:0014069]; postsynaptic membrane [GO:0045211]; presynaptic membrane [GO:0042734]; terminal bouton [GO:0043195]
Q13003	GRIK3_HUMAN	Glutamate receptor ionotropic, kainate 3 (GluK3) (Excitatory amino acid receptor 5) (EAA5) (Glutamate receptor 7) (GluR-7) (GluR7)	GRIK3 GLUR7		CHEMBL3684;	Q13003;			PF01094;PF00060;PF10613;	IPR001828;IPR019594;IPR001508;IPR001320;IPR028082;	glutamate receptor signaling pathway [GO:0007215]; G-protein coupled glutamate receptor signaling pathway [GO:0007216]; negative regulation of synaptic transmission, glutamatergic [GO:0051967]; regulation of membrane potential [GO:0042391]	adenylate cyclase inhibiting G-protein coupled glutamate receptor activity [GO:0001640]; extracellular-glutamate-gated ion channel activity [GO:0005234]; glutamate receptor activity [GO:0008066]; G-protein coupled receptor binding [GO:0001664]; ionotropic glutamate receptor activity [GO:0004970]; kainate selective glutamate receptor activity [GO:0015277]; ligand-gated ion channel activity [GO:0015276]	axon [GO:0030424]; cell junction [GO:0030054]; dendrite [GO:0030425]; dendrite cytoplasm [GO:0032839]; integral component of plasma membrane [GO:0005887]; perikaryon [GO:0043204]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]; terminal bouton [GO:0043195]
Q16099	GRIK4_HUMAN	Glutamate receptor ionotropic, kainate 4 (GluK4) (Excitatory amino acid receptor 1) (EAA1) (Glutamate receptor KA-1) (KA1)	GRIK4 GRIK		CHEMBL2109241;	Q16099;			PF01094;PF00060;PF10613;	IPR001828;IPR019594;IPR001508;IPR001320;IPR028082;	chemical synaptic transmission [GO:0007268]; glutamate receptor signaling pathway [GO:0007215]; transport [GO:0006810]	extracellular-glutamate-gated ion channel activity [GO:0005234]; kainate selective glutamate receptor activity [GO:0015277]; ligand-gated ion channel activity [GO:0015276]	cell junction [GO:0030054]; integral component of plasma membrane [GO:0005887]; kainate selective glutamate receptor complex [GO:0032983]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]; presynaptic membrane [GO:0042734]
Q16478	GRIK5_HUMAN	Glutamate receptor ionotropic, kainate 5 (GluK5) (Excitatory amino acid receptor 2) (EAA2) (Glutamate receptor KA-2) (KA2)	GRIK5 GRIK2		CHEMBL2675;	Q16478;			PF01094;PF00060;PF10613;	IPR001828;IPR019594;IPR001508;IPR001320;IPR028082;	cellular response to glucose stimulus [GO:0071333]; establishment of localization in cell [GO:0051649]; excitatory postsynaptic potential [GO:0060079]; positive regulation of neuron apoptotic process [GO:0043525]; protein retention in ER lumen [GO:0006621]; receptor clustering [GO:0043113]; regulation of synaptic vesicle fusion to presynaptic membrane [GO:0031630]; synaptic transmission, glutamatergic [GO:0035249]	extracellular-glutamate-gated ion channel activity [GO:0005234]; kainate selective glutamate receptor activity [GO:0015277]; ligand-gated ion channel activity [GO:0015276]	cell junction [GO:0030054]; dendrite [GO:0030425]; endoplasmic reticulum [GO:0005783]; kainate selective glutamate receptor complex [GO:0032983]; perikaryon [GO:0043204]; plasma membrane [GO:0005886]; postsynaptic density [GO:0014069]; postsynaptic membrane [GO:0045211]; presynaptic membrane [GO:0042734]; terminal bouton [GO:0043195]
P48507	GSH0_HUMAN	Glutamate--cysteine ligase regulatory subunit (GCS light chain) (Gamma-ECS regulatory subunit) (Gamma-glutamylcysteine synthetase regulatory subunit) (Glutamate--cysteine ligase modifier subunit)	GCLM GLCLR				DB00151;	PATHWAY: Sulfur metabolism; glutathione biosynthesis; glutathione from L-cysteine and L-glutamate: step 1/2.	PF00248;	IPR032963;IPR023210;	aging [GO:0007568]; apoptotic mitochondrial changes [GO:0008637]; cellular response to fibroblast growth factor stimulus [GO:0044344]; cellular response to follicle-stimulating hormone stimulus [GO:0071372]; cellular response to glucose stimulus [GO:0071333]; cellular response to hepatocyte growth factor stimulus [GO:0035729]; cellular response to thyroxine stimulus [GO:0097069]; cysteine metabolic process [GO:0006534]; glutamate metabolic process [GO:0006536]; glutathione biosynthetic process [GO:0006750]; hepatic stellate cell activation [GO:0035733]; negative regulation of extrinsic apoptotic signaling pathway [GO:2001237]; negative regulation of neuron apoptotic process [GO:0043524]; positive regulation of glutamate-cysteine ligase activity [GO:0035229]; regulation of blood vessel size [GO:0050880]; regulation of mitochondrial depolarization [GO:0051900]; response to activity [GO:0014823]; response to drug [GO:0042493]; response to human chorionic gonadotropin [GO:0044752]; response to nitrosative stress [GO:0051409]; response to nutrient [GO:0007584]; response to oxidative stress [GO:0006979]; sulfur amino acid metabolic process [GO:0000096]	enzyme regulator activity [GO:0030234]; glutamate-cysteine ligase activity [GO:0004357]; glutamate-cysteine ligase catalytic subunit binding [GO:0035226]	cytosol [GO:0005829]; glutamate-cysteine ligase complex [GO:0017109]
P48506	GSH1_HUMAN	Glutamate--cysteine ligase catalytic subunit (EC 6.3.2.2) (GCS heavy chain) (Gamma-ECS) (Gamma-glutamylcysteine synthetase)	GCLC GLCL GLCLC		CHEMBL4055;	P48506;	DB00151;DB00163;	PATHWAY: Sulfur metabolism; glutathione biosynthesis; glutathione from L-cysteine and L-glutamate: step 1/2.	PF03074;	IPR004308;	aging [GO:0007568]; apoptotic mitochondrial changes [GO:0008637]; cell redox homeostasis [GO:0045454]; cellular response to fibroblast growth factor stimulus [GO:0044344]; cellular response to follicle-stimulating hormone stimulus [GO:0071372]; cellular response to glucose stimulus [GO:0071333]; cellular response to hepatocyte growth factor stimulus [GO:0035729]; cellular response to insulin stimulus [GO:0032869]; cellular response to mechanical stimulus [GO:0071260]; cellular response to thyroxine stimulus [GO:0097069]; cysteine metabolic process [GO:0006534]; glutamate metabolic process [GO:0006536]; glutathione biosynthetic process [GO:0006750]; L-ascorbic acid metabolic process [GO:0019852]; negative regulation of apoptotic process [GO:0043066]; negative regulation of extrinsic apoptotic signaling pathway [GO:2001237]; negative regulation of hepatic stellate cell activation [GO:2000490]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of protein ubiquitination [GO:0031397]; negative regulation of transcription, DNA-templated [GO:0045892]; positive regulation of proteasomal ubiquitin-dependent protein catabolic process [GO:0032436]; regulation of blood vessel size [GO:0050880]; regulation of mitochondrial depolarization [GO:0051900]; response to activity [GO:0014823]; response to arsenic-containing substance [GO:0046685]; response to cadmium ion [GO:0046686]; response to heat [GO:0009408]; response to hormone [GO:0009725]; response to human chorionic gonadotropin [GO:0044752]; response to interleukin-1 [GO:0070555]; response to nitrosative stress [GO:0051409]; response to nutrient [GO:0007584]; response to oxidative stress [GO:0006979]; response to xenobiotic stimulus [GO:0009410]; sulfur amino acid metabolic process [GO:0000096]	ADP binding [GO:0043531]; ATP binding [GO:0005524]; coenzyme binding [GO:0050662]; glutamate binding [GO:0016595]; glutamate-cysteine ligase activity [GO:0004357]; magnesium ion binding [GO:0000287]	cytosol [GO:0005829]; glutamate-cysteine ligase complex [GO:0017109]
P48637	GSHB_HUMAN	Glutathione synthetase (GSH synthetase) (GSH-S) (EC 6.3.2.3) (Glutathione synthase)	GSS	2HGS;			DB06151;DB00143;DB00145;DB00151;	PATHWAY: Sulfur metabolism; glutathione biosynthesis; glutathione from L-cysteine and L-glutamate: step 2/2.	PF03917;PF03199;	IPR004887;IPR014042;IPR014709;IPR005615;IPR014049;IPR016185;	aging [GO:0007568]; cellular amino acid metabolic process [GO:0006520]; glutathione biosynthetic process [GO:0006750]; nervous system development [GO:0007399]; response to amino acid [GO:0043200]; response to cadmium ion [GO:0046686]; response to nutrient levels [GO:0031667]; response to oxidative stress [GO:0006979]; response to tumor necrosis factor [GO:0034612]; response to xenobiotic stimulus [GO:0009410]	ATP binding [GO:0005524]; glutathione binding [GO:0043295]; glutathione synthase activity [GO:0004363]; glycine binding [GO:0016594]; magnesium ion binding [GO:0000287]; protein homodimerization activity [GO:0042803]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P00390	GSHR_HUMAN	Glutathione reductase, mitochondrial (GR) (GRase) (EC 1.8.1.7)	GSR GLUR GRD1	1ALG;1BWC;1DNC;1GRA;1GRB;1GRE;1GRF;1GRG;1GRH;1GRT;1GSN;1K4Q;1XAN;2AAQ;2GH5;2GRT;3DJG;3DJJ;3DK4;3DK8;3DK9;3GRS;3GRT;3SQP;4GR1;4GRT;5GRT;	CHEMBL2755;	P00390;	DB00262;DB03147;DB00143;		PF07992;PF02852;	IPR023753;IPR016156;IPR006322;IPR004099;IPR012999;	cell redox homeostasis [GO:0045454]; glutathione metabolic process [GO:0006749]; nucleobase-containing small molecule interconversion [GO:0015949]; response to reactive oxygen species [GO:0000302]	electron carrier activity [GO:0009055]; flavin adenine dinucleotide binding [GO:0050660]; glutathione-disulfide reductase activity [GO:0004362]; NADP binding [GO:0050661]	cytosol [GO:0005829]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]
P49841	GSK3B_HUMAN	Glycogen synthase kinase-3 beta (GSK-3 beta) (EC 2.7.11.26) (Serine/threonine-protein kinase GSK3B) (EC 2.7.11.1)	GSK3B	1GNG;1H8F;1I09;1J1B;1J1C;1O6K;1O6L;1O9U;1PYX;1Q3D;1Q3W;1Q41;1Q4L;1Q5K;1R0E;1UV5;2JDO;2JDR;2JLD;2O5K;2OW3;2UW9;2X39;2XH5;3CQU;3CQW;3DU8;3E87;3E88;3E8D;3F7Z;3F88;3GB2;3I4B;3L1S;3M1S;3MV5;3OW4;3PUP;3Q3B;3QKK;3SAY;3SD0;3ZDI;3ZRK;3ZRL;3ZRM;4ACC;4ACD;4ACG;4ACH;4AFJ;4B7T;4DIT;4EKK;4IQ6;4J1R;4J71;4NM0;4NM3;4NM5;4NM7;4PTC;4PTE;4PTG;5F94;5F95;5HLN;5HLP;5K5N;	CHEMBL262;	P49841;	DB01356;		PF00069;	IPR033573;IPR011009;IPR000719;IPR017441;IPR008271;	animal organ morphogenesis [GO:0009887]; axonogenesis [GO:0007409]; beta-catenin destruction complex assembly [GO:1904885]; beta-catenin destruction complex disassembly [GO:1904886]; canonical Wnt signaling pathway [GO:0060070]; canonical Wnt signaling pathway involved in positive regulation of apoptotic process [GO:0044337]; cell migration [GO:0016477]; cellular response to hepatocyte growth factor stimulus [GO:0035729]; cellular response to interleukin-3 [GO:0036016]; chemical synaptic transmission, postsynaptic [GO:0099565]; circadian rhythm [GO:0007623]; dopamine receptor signaling pathway [GO:0007212]; epithelial to mesenchymal transition [GO:0001837]; ER overload response [GO:0006983]; extrinsic apoptotic signaling pathway in absence of ligand [GO:0097192]; fat cell differentiation [GO:0045444]; glycogen metabolic process [GO:0005977]; hippocampus development [GO:0021766]; hypermethylation of CpG island [GO:0044027]; intracellular signal transduction [GO:0035556]; intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress [GO:0070059]; myoblast fusion [GO:0007520]; negative regulation of apoptotic process [GO:0043066]; negative regulation of canonical Wnt signaling pathway [GO:0090090]; negative regulation of cardiac muscle hypertrophy [GO:0010614]; negative regulation of dopaminergic neuron differentiation [GO:1904339]; negative regulation of glycogen (starch) synthase activity [GO:2000466]; negative regulation of glycogen biosynthetic process [GO:0045719]; negative regulation of neuron maturation [GO:0014043]; negative regulation of neuron projection development [GO:0010977]; negative regulation of NFAT protein import into nucleus [GO:0051534]; negative regulation of protein binding [GO:0032091]; negative regulation of protein complex assembly [GO:0031333]; negative regulation of protein localization to nucleus [GO:1900181]; negative regulation of type B pancreatic cell development [GO:2000077]; peptidyl-serine phosphorylation [GO:0018105]; peptidyl-threonine phosphorylation [GO:0018107]; positive regulation of axon extension [GO:0045773]; positive regulation of cell-matrix adhesion [GO:0001954]; positive regulation of GTPase activity [GO:0043547]; positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway [GO:1901030]; positive regulation of neuron death [GO:1901216]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of peptidyl-threonine phosphorylation [GO:0010800]; positive regulation of proteasomal ubiquitin-dependent protein catabolic process [GO:0032436]; positive regulation of protein binding [GO:0032092]; positive regulation of protein catabolic process [GO:0045732]; positive regulation of protein complex assembly [GO:0031334]; positive regulation of protein export from nucleus [GO:0046827]; positive regulation of stem cell differentiation [GO:2000738]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; proteasome-mediated ubiquitin-dependent protein catabolic process [GO:0043161]; protein autophosphorylation [GO:0046777]; protein export from nucleus [GO:0006611]; protein localization to microtubule [GO:0035372]; protein phosphorylation [GO:0006468]; re-entry into mitotic cell cycle [GO:0000320]; regulation of cellular response to heat [GO:1900034]; regulation of gene expression by genetic imprinting [GO:0006349]; regulation of microtubule-based process [GO:0032886]; superior temporal gyrus development [GO:0071109]; Wnt signaling pathway [GO:0016055]	ATP binding [GO:0005524]; beta-catenin binding [GO:0008013]; kinase activity [GO:0016301]; NF-kappaB binding [GO:0051059]; p53 binding [GO:0002039]; protein kinase A catalytic subunit binding [GO:0034236]; protein kinase activity [GO:0004672]; protein kinase binding [GO:0019901]; protein serine/threonine kinase activity [GO:0004674]; RNA polymerase II transcription factor binding [GO:0001085]; tau-protein kinase activity [GO:0050321]; ubiquitin protein ligase binding [GO:0031625]	beta-catenin destruction complex [GO:0030877]; centrosome [GO:0005813]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; dendritic shaft [GO:0043198]; growth cone [GO:0030426]; intracellular ribonucleoprotein complex [GO:0030529]; mitochondrion [GO:0005739]; neuronal cell body [GO:0043025]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; postsynapse [GO:0098794]; Wnt signalosome [GO:1990909]
P08263	GSTA1_HUMAN	Glutathione S-transferase A1 (EC 2.5.1.18) (GST HA subunit 1) (GST class-alpha member 1) (GST-epsilon) (GSTA1-1) (GTH1) [Cleaved into: Glutathione S-transferase A1, N-terminally processed]	GSTA1	1GSD;1GSE;1GSF;1GUH;1K3L;1K3O;1K3Y;1LBK;1PKW;1PKZ;1PL1;1PL2;1USB;1XWG;1YDK;2R3X;2R6K;3I69;3I6A;3IK9;3KTL;3L0H;3Q74;3U6V;3ZFB;3ZFL;4HJ2;5LCZ;	CHEMBL3409;	P08263;	DB00993;DB01008;DB00143;		PF00043;PF02798;	IPR010987;IPR004045;IPR003080;IPR004046;IPR012336;	epithelial cell differentiation [GO:0030855]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; linoleic acid metabolic process [GO:0043651]; metabolic process [GO:0008152]	glutathione peroxidase activity [GO:0004602]; glutathione transferase activity [GO:0004364]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P09210	GSTA2_HUMAN	Glutathione S-transferase A2 (EC 2.5.1.18) (GST HA subunit 2) (GST class-alpha member 2) (GST-gamma) (GSTA2-2) (GTH2)	GSTA2 GST2	1AGS;2VCT;2WJU;4ACS;	CHEMBL2241;	P09210;	DB00993;DB01008;DB00608;DB00636;DB00903;DB00143;DB00163;		PF14497;PF02798;	IPR010987;IPR004045;IPR003080;IPR004046;IPR012336;	epithelial cell differentiation [GO:0030855]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]	glutathione transferase activity [GO:0004364]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]
Q16772	GSTA3_HUMAN	Glutathione S-transferase A3 (EC 2.5.1.18) (GST class-alpha member 3) (Glutathione S-transferase A3-3)	GSTA3	1TDI;2VCV;	CHEMBL4866;		DB00143;		PF14497;PF02798;	IPR010987;IPR004045;IPR003080;IPR004046;IPR012336;	glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]	glutathione transferase activity [GO:0004364]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]
O15217	GSTA4_HUMAN	Glutathione S-transferase A4 (EC 2.5.1.18) (GST class-alpha member 4) (Glutathione S-transferase A4-4)	GSTA4	1GUL;1GUM;3IK7;	CHEMBL4933;		DB00143;		PF14497;PF02798;	IPR010987;IPR004045;IPR003080;IPR004046;IPR012336;	glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; xenobiotic metabolic process [GO:0006805]	glutathione transferase activity [GO:0004364]; protein homodimerization activity [GO:0042803]	cytosol [GO:0005829]
Q7RTV2	GSTA5_HUMAN	Glutathione S-transferase A5 (EC 2.5.1.18) (GST class-alpha member 5) (Glutathione S-transferase A5-5)	GSTA5				DB00143;		PF14497;PF02798;	IPR010987;IPR004045;IPR003080;IPR004046;IPR012336;	glutathione metabolic process [GO:0006749]	glutathione transferase activity [GO:0004364]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]
Q9Y2Q3	GSTK1_HUMAN	Glutathione S-transferase kappa 1 (EC 2.5.1.18) (GST 13-13) (GST class-kappa) (GSTK1-1) (hGSTK1) (Glutathione S-transferase subunit 13)	GSTK1 HDCMD47P	1YZX;3RPN;3RPP;	CHEMBL4491;	Q9Y2Q3;	DB00143;		PF01323;	IPR001853;IPR014440;IPR012336;	epithelial cell differentiation [GO:0030855]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]	glutathione peroxidase activity [GO:0004602]; glutathione transferase activity [GO:0004364]; protein disulfide oxidoreductase activity [GO:0015035]; receptor binding [GO:0005102]	extracellular exosome [GO:0070062]; intracellular [GO:0005622]; intracellular membrane-bounded organelle [GO:0043231]; membrane [GO:0016020]; mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]; peroxisome [GO:0005777]
P09488	GSTM1_HUMAN	Glutathione S-transferase Mu 1 (EC 2.5.1.18) (GST HB subunit 4) (GST class-mu 1) (GSTM1-1) (GSTM1a-1a) (GSTM1b-1b) (GTH4)	GSTM1 GST1	1GTU;1XW6;1XWK;1YJ6;2F3M;	CHEMBL2081;	P09488;	DB00993;DB01008;DB00958;DB00515;DB00143;DB00526;		PF14497;PF02798;	IPR010987;IPR004045;IPR004046;IPR003081;IPR012336;	cellular detoxification of nitrogen compound [GO:0070458]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; nitrobenzene metabolic process [GO:0018916]; xenobiotic catabolic process [GO:0042178]	enzyme binding [GO:0019899]; glutathione binding [GO:0043295]; glutathione transferase activity [GO:0004364]; protein homodimerization activity [GO:0042803]	cytoplasm [GO:0005737]; cytosol [GO:0005829]
P28161	GSTM2_HUMAN	Glutathione S-transferase Mu 2 (EC 2.5.1.18) (GST class-mu 2) (GSTM2-2)	GSTM2 GST4	1HNA;1HNB;1HNC;1XW5;1YKC;2AB6;2C4J;2GTU;3GTU;3GUR;	CHEMBL4589;	P28161;	DB00143;		PF00043;PF02798;	IPR010987;IPR004045;IPR004046;IPR003081;IPR012336;	cellular detoxification of nitrogen compound [GO:0070458]; cellular response to caffeine [GO:0071313]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; linoleic acid metabolic process [GO:0043651]; negative regulation of ryanodine-sensitive calcium-release channel activity [GO:0060315]; nitrobenzene metabolic process [GO:0018916]; positive regulation of ryanodine-sensitive calcium-release channel activity [GO:0060316]; regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion [GO:0010881]; regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum [GO:0010880]; regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion [GO:0014809]; relaxation of cardiac muscle [GO:0055119]; xenobiotic catabolic process [GO:0042178]	enzyme binding [GO:0019899]; glutathione binding [GO:0043295]; glutathione peroxidase activity [GO:0004602]; glutathione transferase activity [GO:0004364]; protein homodimerization activity [GO:0042803]; receptor binding [GO:0005102]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; sarcoplasmic reticulum [GO:0016529]
P21266	GSTM3_HUMAN	Glutathione S-transferase Mu 3 (EC 2.5.1.18) (GST class-mu 3) (GSTM3-3) (hGSTM3-3)	GSTM3 GST5	3GTU;	CHEMBL2242;		DB00143;DB00163;		PF00043;PF02798;	IPR010987;IPR004045;IPR004046;IPR003081;IPR012336;	cellular detoxification of nitrogen compound [GO:0070458]; establishment of blood-nerve barrier [GO:0008065]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; nitrobenzene metabolic process [GO:0018916]; response to estrogen [GO:0043627]; xenobiotic catabolic process [GO:0042178]	enzyme binding [GO:0019899]; glutathione binding [GO:0043295]; glutathione transferase activity [GO:0004364]; identical protein binding [GO:0042802]; protein homodimerization activity [GO:0042803]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleus [GO:0005634]; sperm fibrous sheath [GO:0035686]
Q03013	GSTM4_HUMAN	Glutathione S-transferase Mu 4 (EC 2.5.1.18) (GST class-mu 4) (GST-Mu2) (GSTM4-4)	GSTM4	4GTU;	CHEMBL2100;		DB00143;		PF14497;PF02798;	IPR010987;IPR004045;IPR004046;IPR003081;IPR012336;	glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; nitrobenzene metabolic process [GO:0018916]; xenobiotic catabolic process [GO:0042178]	enzyme binding [GO:0019899]; glutathione binding [GO:0043295]; glutathione transferase activity [GO:0004364]; protein homodimerization activity [GO:0042803]	cytoplasm [GO:0005737]; cytosol [GO:0005829]
P46439	GSTM5_HUMAN	Glutathione S-transferase Mu 5 (EC 2.5.1.18) (GST class-mu 5) (GSTM5-5)	GSTM5		CHEMBL2819;		DB00143;		PF00043;PF02798;	IPR010987;IPR004045;IPR004046;IPR003081;IPR012336;	glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]	glutathione transferase activity [GO:0004364]	cytosol [GO:0005829]
P78417	GSTO1_HUMAN	Glutathione S-transferase omega-1 (GSTO-1) (EC 2.5.1.18) (Glutathione S-transferase omega 1-1) (GSTO 1-1) (Glutathione-dependent dehydroascorbate reductase) (EC 1.8.5.1) (Monomethylarsonic acid reductase) (MMA(V) reductase) (EC 1.20.4.2) (S-(Phenacyl)glutathione reductase) (SPG-R)	GSTO1 GSTTLP28	1EEM;3LFL;3VLN;4IS0;	CHEMBL3174;	P78417;	DB00143;DB00163;		PF14497;PF13417;	IPR010987;IPR004045;IPR004046;IPR005442;IPR012336;	cellular response to arsenic-containing substance [GO:0071243]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; L-ascorbic acid metabolic process [GO:0019852]; methylation [GO:0032259]; negative regulation of ryanodine-sensitive calcium-release channel activity [GO:0060315]; positive regulation of ryanodine-sensitive calcium-release channel activity [GO:0060316]; positive regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion [GO:0014810]; regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion [GO:0010881]; regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum [GO:0010880]; xenobiotic catabolic process [GO:0042178]	glutathione dehydrogenase (ascorbate) activity [GO:0045174]; glutathione transferase activity [GO:0004364]; methylarsonate reductase activity [GO:0050610]; oxidoreductase activity [GO:0016491]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
Q9H4Y5	GSTO2_HUMAN	Glutathione S-transferase omega-2 (GSTO-2) (EC 2.5.1.18) (Glutathione S-transferase omega 2-2) (GSTO 2-2) (Glutathione-dependent dehydroascorbate reductase) (EC 1.8.5.1) (Monomethylarsonic acid reductase) (MMA(V) reductase) (EC 1.20.4.2)	GSTO2	3Q18;3Q19;3QAG;	CHEMBL2161;		DB00143;		PF13417;	IPR010987;IPR004045;IPR005442;IPR012336;	cellular response to arsenic-containing substance [GO:0071243]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; L-ascorbic acid metabolic process [GO:0019852]; oxidation-reduction process [GO:0055114]; xenobiotic metabolic process [GO:0006805]	glutathione dehydrogenase (ascorbate) activity [GO:0045174]; glutathione transferase activity [GO:0004364]; methylarsonate reductase activity [GO:0050610]; oxidoreductase activity [GO:0016491]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P30711	GSTT1_HUMAN	Glutathione S-transferase theta-1 (EC 2.5.1.18) (GST class-theta-1) (Glutathione transferase T1-1)	GSTT1	2C3N;2C3Q;2C3T;	CHEMBL2141;		DB00958;DB00515;DB00773;DB00143;DB00526;		PF00043;PF13417;	IPR010987;IPR004045;IPR004046;IPR012336;	glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]	glutathione peroxidase activity [GO:0004602]; glutathione transferase activity [GO:0004364]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P0CG30	GSTT2_HUMAN	Glutathione S-transferase theta-2B (EC 2.5.1.18) (GST class-theta-2) (Glutathione S-transferase theta-2)	GSTT2B GSTT2	1LJR;2LJR;3LJR;4MPG;					PF00043;PF02798;	IPR010987;IPR004045;IPR004046;IPR012336;	glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]	glutathione transferase activity [GO:0004364]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P11166	GTR1_HUMAN	Solute carrier family 2, facilitated glucose transporter member 1 (Glucose transporter type 1, erythrocyte/brain) (GLUT-1) (HepG2 glucose transporter)	SLC2A1 GLUT1	1SUK;4PYP;5EQG;5EQH;5EQI;	CHEMBL2535;	P11166;	DB00292;		PF00083;	IPR002439;IPR020846;IPR005828;IPR003663;IPR005829;	cellular response to glucose starvation [GO:0042149]; glucose transmembrane transport [GO:1904659]; glucose transport [GO:0015758]; lactose biosynthetic process [GO:0005989]; L-ascorbic acid metabolic process [GO:0019852]; protein complex assembly [GO:0006461]; regulation of insulin secretion [GO:0050796]; response to osmotic stress [GO:0006970]	dehydroascorbic acid transporter activity [GO:0033300]; D-glucose transmembrane transporter activity [GO:0055056]; glucose transmembrane transporter activity [GO:0005355]; protein self-association [GO:0043621]; xenobiotic transporter activity [GO:0042910]	apical plasma membrane [GO:0016324]; basolateral plasma membrane [GO:0016323]; blood microparticle [GO:0072562]; caveola [GO:0005901]; cell-cell junction [GO:0005911]; cortical actin cytoskeleton [GO:0030864]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; female pronucleus [GO:0001939]; Golgi membrane [GO:0000139]; integral component of plasma membrane [GO:0005887]; melanosome [GO:0042470]; membrane [GO:0016020]; midbody [GO:0030496]; plasma membrane [GO:0005886]
P49915	GUAA_HUMAN	GMP synthase [glutamine-hydrolyzing] (EC 6.3.5.2) (GMP synthetase) (Glutamine amidotransferase)	GMPS	2VPI;2VXO;	CHEMBL5721;		DB00130;	PATHWAY: Purine metabolism; GMP biosynthesis; GMP from XMP (L-Gln route): step 1/1.	PF00117;PF00958;PF02540;	IPR029062;IPR017926;IPR001674;IPR004739;IPR025777;IPR022310;IPR014729;	glutamine metabolic process [GO:0006541]; purine nucleobase biosynthetic process [GO:0009113]; purine ribonucleoside monophosphate biosynthetic process [GO:0009168]	ATP binding [GO:0005524]; GMP synthase (glutamine-hydrolyzing) activity [GO:0003922]; GMP synthase activity [GO:0003921]; pyrophosphatase activity [GO:0016462]	cytoplasm [GO:0005737]; cytosol [GO:0005829]
P69905	HBA_HUMAN	Hemoglobin subunit alpha (Alpha-globin) (Hemoglobin alpha chain)	HBA1; HBA2	1A00;1A01;1A0U;1A0Z;1A3N;1A3O;1A9W;1ABW;1ABY;1AJ9;1B86;1BAB;1BBB;1BIJ;1BUW;1BZ0;1BZ1;1BZZ;1C7B;1C7C;1C7D;1CLS;1CMY;1COH;1DKE;1DXT;1DXU;1DXV;1FDH;1FN3;1G9V;1GBU;1GBV;1GLI;1GZX;1HAB;1HAC;1HBA;1HBB;1HBS;1HCO;1HDB;1HGA;1HGB;1HGC;1HHO;1IRD;1J3Y;1J3Z;1J40;1J41;1J7S;1J7W;1J7Y;1JY7;1K0Y;1K1K;1KD2;1LFL;1LFQ;1LFT;1LFV;1LFY;1LFZ;1LJW;1M9P;1MKO;1NEJ;1NIH;1NQP;1O1I;1O1J;1O1K;1O1L;1O1M;1O1N;1O1O;1O1P;1QI8;1QSH;1QSI;1QXD;1QXE;1R1X;1R1Y;1RPS;1RQ3;1RQ4;1RQA;1RVW;1SDK;1SDL;1SHR;1SI4;1THB;1UIW;1VWT;1XXT;1XY0;1XYE;1XZ2;1XZ4;1XZ5;1XZ7;1XZU;1XZV;1Y01;1Y09;1Y0A;1Y0C;1Y0D;1Y0T;1Y0W;1Y22;1Y2Z;1Y31;1Y35;1Y45;1Y46;1Y4B;1Y4F;1Y4G;1Y4P;1Y4Q;1Y4R;1Y4V;1Y5F;1Y5J;1Y5K;1Y7C;1Y7D;1Y7G;1Y7Z;1Y83;1Y85;1Y8W;1YDZ;1YE0;1YE1;1YE2;1YEN;1YEO;1YEQ;1YEU;1YEV;1YFF;1YG5;1YGD;1YGF;1YH9;1YHE;1YHR;1YIE;1YIH;1YVQ;1YVT;1YZI;1Z8U;2D5Z;2D60;2DN1;2DN2;2DN3;2DXM;2H35;2HBC;2HBD;2HBE;2HBF;2HBS;2HCO;2HHB;2HHD;2HHE;2M6Z;2W6V;2W72;2YRS;3B75;3D17;3D7O;3DUT;3HHB;3HXN;3IA3;3IC0;3IC2;3KMF;3NL7;3NMM;3ODQ;3ONZ;3OO4;3OO5;3OVU;3P5Q;3QJB;3QJC;3QJD;3QJE;3R5I;3S48;3S65;3S66;3SZK;3WCP;3WHM;4FC3;4HHB;4IJ2;4L7Y;4M4A;4M4B;4MQC;4MQG;4MQH;4MQI;4MQJ;4MQK;4N7N;4N7O;4N7P;4N8T;4NI0;4NI1;4ROL;4ROM;4WJG;4X0L;4XS0;5E29;5E6E;5E83;5EE4;5HU6;5JDO;5KDQ;5SW7;6HBW;	CHEMBL2887;		DB00893;DB00358;		PF00042;	IPR000971;IPR009050;IPR012292;IPR002338;IPR002339;	bicarbonate transport [GO:0015701]; cellular oxidant detoxification [GO:0098869]; hydrogen peroxide catabolic process [GO:0042744]; oxygen transport [GO:0015671]; positive regulation of cell death [GO:0010942]; protein heterooligomerization [GO:0051291]; receptor-mediated endocytosis [GO:0006898]; response to hydrogen peroxide [GO:0042542]	heme binding [GO:0020037]; iron ion binding [GO:0005506]; oxygen binding [GO:0019825]; oxygen transporter activity [GO:0005344]	blood microparticle [GO:0072562]; cytosol [GO:0005829]; cytosolic small ribosomal subunit [GO:0022627]; endocytic vesicle lumen [GO:0071682]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; haptoglobin-hemoglobin complex [GO:0031838]; hemoglobin complex [GO:0005833]; membrane [GO:0016020]
P68871	HBB_HUMAN	Hemoglobin subunit beta (Beta-globin) (Hemoglobin beta chain) [Cleaved into: LVV-hemorphin-7; Spinorphin]	HBB	1A00;1A01;1A0U;1A0Z;1A3N;1A3O;1ABW;1ABY;1AJ9;1B86;1BAB;1BBB;1BIJ;1BUW;1BZ0;1BZ1;1BZZ;1C7B;1C7C;1C7D;1CBL;1CBM;1CH4;1CLS;1CMY;1COH;1DKE;1DXT;1DXU;1DXV;1FN3;1G9V;1GBU;1GBV;1GLI;1GZX;1HAB;1HAC;1HBA;1HBB;1HBS;1HCO;1HDB;1HGA;1HGB;1HGC;1HHO;1IRD;1J3Y;1J3Z;1J40;1J41;1J7S;1J7W;1J7Y;1JY7;1K0Y;1K1K;1KD2;1LFL;1LFQ;1LFT;1LFV;1LFY;1LFZ;1LJW;1M9P;1MKO;1NEJ;1NIH;1NQP;1O1I;1O1J;1O1K;1O1L;1O1M;1O1N;1O1O;1O1P;1QI8;1QSH;1QSI;1QXD;1QXE;1R1X;1R1Y;1RPS;1RQ3;1RQ4;1RQA;1RVW;1SDK;1SDL;1THB;1UIW;1VWT;1XXT;1XY0;1XYE;1XZ2;1XZ4;1XZ5;1XZ7;1XZU;1XZV;1Y09;1Y0A;1Y0C;1Y0D;1Y0T;1Y0W;1Y22;1Y2Z;1Y31;1Y35;1Y45;1Y46;1Y4B;1Y4F;1Y4G;1Y4P;1Y4Q;1Y4R;1Y4V;1Y5F;1Y5J;1Y5K;1Y7C;1Y7D;1Y7G;1Y7Z;1Y83;1Y85;1Y8W;1YDZ;1YE0;1YE1;1YE2;1YEN;1YEO;1YEQ;1YEU;1YEV;1YFF;1YG5;1YGD;1YGF;1YH9;1YHE;1YHR;1YIE;1YIH;1YVQ;1YVT;1YZI;2D5Z;2D60;2DN1;2DN2;2DN3;2DXM;2H35;2HBC;2HBD;2HBE;2HBF;2HBS;2HCO;2HHB;2HHD;2HHE;2M6Z;2W6V;2W72;2YRS;3B75;3D17;3D7O;3DUT;3HHB;3HXN;3IC0;3IC2;3KMF;3NL7;3NMM;3ODQ;3ONZ;3OO4;3OO5;3P5Q;3QJB;3QJC;3QJD;3QJE;3R5I;3S65;3S66;3SZK;3W4U;3WCP;3WHM;4FC3;4HHB;4IJ2;4L7Y;4M4A;4M4B;4MQC;4MQG;4MQH;4MQI;4N7N;4N7O;4N7P;4N8T;4NI0;4NI1;4ROL;4ROM;4WJG;4X0L;4XS0;5E29;5E6E;5E83;5EE4;5HU6;5JDO;5KDQ;5SW7;6HBW;	CHEMBL4331;		DB00893;		PF00042;	IPR000971;IPR009050;IPR012292;IPR002337;	bicarbonate transport [GO:0015701]; blood coagulation [GO:0007596]; cellular oxidant detoxification [GO:0098869]; hydrogen peroxide catabolic process [GO:0042744]; nitric oxide transport [GO:0030185]; oxygen transport [GO:0015671]; platelet aggregation [GO:0070527]; positive regulation of cell death [GO:0010942]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; protein heterooligomerization [GO:0051291]; receptor-mediated endocytosis [GO:0006898]; regulation of blood pressure [GO:0008217]; regulation of blood vessel size [GO:0050880]; renal absorption [GO:0070293]; response to hydrogen peroxide [GO:0042542]	heme binding [GO:0020037]; hemoglobin binding [GO:0030492]; iron ion binding [GO:0005506]; oxygen binding [GO:0019825]; oxygen transporter activity [GO:0005344]	blood microparticle [GO:0072562]; cytosol [GO:0005829]; endocytic vesicle lumen [GO:0071682]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; haptoglobin-hemoglobin complex [GO:0031838]; hemoglobin complex [GO:0005833]
Q99714	HCD2_HUMAN	3-hydroxyacyl-CoA dehydrogenase type-2 (EC 1.1.1.35) (17-beta-hydroxysteroid dehydrogenase 10) (17-beta-HSD 10) (EC 1.1.1.51) (3-hydroxy-2-methylbutyryl-CoA dehydrogenase) (EC 1.1.1.178) (3-hydroxyacyl-CoA dehydrogenase type II) (Endoplasmic reticulum-associated amyloid beta-peptide-binding protein) (Mitochondrial ribonuclease P protein 2) (Mitochondrial RNase P protein 2) (Short chain dehydrogenase/reductase family 5C member 1) (Short-chain type dehydrogenase/reductase XH98G2) (Type II HADH)	HSD17B10 ERAB HADH2 MRPP2 SCHAD SDR5C1 XH98G2	1F67;1SO8;1U7T;2O23;	CHEMBL4159;				PF00106;	IPR016040;IPR020904;IPR002347;	branched-chain amino acid catabolic process [GO:0009083]; lipid metabolic process [GO:0006629]; mitochondrial tRNA methylation [GO:0070901]; mitochondrial tRNA processing [GO:0090646]	3-hydroxy-2-methylbutyryl-CoA dehydrogenase activity [GO:0047015]; 3-hydroxyacyl-CoA dehydrogenase activity [GO:0003857]; cholate 7-alpha-dehydrogenase activity [GO:0008709]; poly(A) RNA binding [GO:0044822]; testosterone dehydrogenase [NAD(P)] activity [GO:0030283]	cytoplasm [GO:0005737]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; plasma membrane [GO:0005886]
Q16836	HCDH_HUMAN	Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial (HCDH) (EC 1.1.1.35) (Medium and short-chain L-3-hydroxyacyl-coenzyme A dehydrogenase) (Short-chain 3-hydroxyacyl-CoA dehydrogenase)	HADH HAD HADHSC SCHAD	1F0Y;1F12;1F14;1F17;1IL0;1LSJ;1LSO;1M75;1M76;2HDH;3HAD;3RQS;				PATHWAY: Lipid metabolism; fatty acid beta-oxidation.	PF00725;PF02737;	IPR022694;IPR006180;IPR006176;IPR006108;IPR008927;IPR013328;IPR016040;	fatty acid beta-oxidation [GO:0006635]; negative regulation of insulin secretion [GO:0046676]; response to activity [GO:0014823]; response to drug [GO:0042493]; response to insulin [GO:0032868]	3-hydroxyacyl-CoA dehydrogenase activity [GO:0003857]; NAD+ binding [GO:0070403]	cytoplasm [GO:0005737]; mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]
P08631	HCK_HUMAN	Tyrosine-protein kinase HCK (EC 2.7.10.2) (Hematopoietic cell kinase) (Hemopoietic cell kinase) (p59-HCK/p60-HCK) (p59Hck) (p61Hck)	HCK	1AD5;1BU1;1QCF;2C0I;2C0O;2C0T;2HCK;2HK5;2OI3;2OJ2;3HCK;3NHN;3RBB;3REA;3REB;3VRY;3VRZ;3VS0;3VS1;3VS2;3VS3;3VS4;3VS5;3VS6;3VS7;4HCK;4LUD;4LUE;4ORZ;4U5W;5HCK;	CHEMBL3234;	P08631;	DB06616;		PF07714;PF00017;PF00018;	IPR011009;IPR000719;IPR017441;IPR001245;IPR000980;IPR001452;IPR008266;IPR020635;	cell adhesion [GO:0007155]; cell differentiation [GO:0030154]; cytokine-mediated signaling pathway [GO:0019221]; Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096]; inflammatory response [GO:0006954]; innate immune response-activating signal transduction [GO:0002758]; integrin-mediated signaling pathway [GO:0007229]; interferon-gamma-mediated signaling pathway [GO:0060333]; leukocyte degranulation [GO:0043299]; leukocyte migration involved in immune response [GO:0002522]; lipopolysaccharide-mediated signaling pathway [GO:0031663]; mesoderm development [GO:0007498]; negative regulation of apoptotic process [GO:0043066]; peptidyl-tyrosine autophosphorylation [GO:0038083]; peptidyl-tyrosine phosphorylation [GO:0018108]; positive regulation of actin cytoskeleton reorganization [GO:2000251]; positive regulation of actin filament polymerization [GO:0030838]; positive regulation of cell proliferation [GO:0008284]; protein autophosphorylation [GO:0046777]; protein phosphorylation [GO:0006468]; regulation of cell shape [GO:0008360]; regulation of defense response to virus by virus [GO:0050690]; regulation of inflammatory response [GO:0050727]; regulation of phagocytosis [GO:0050764]; regulation of podosome assembly [GO:0071801]; regulation of sequence-specific DNA binding transcription factor activity [GO:0051090]; respiratory burst after phagocytosis [GO:0045728]; transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169]; viral process [GO:0016032]	ATP binding [GO:0005524]; non-membrane spanning protein tyrosine kinase activity [GO:0004715]; protein tyrosine kinase activity [GO:0004713]; receptor binding [GO:0005102]	caveola [GO:0005901]; cell projection [GO:0042995]; cytoskeleton [GO:0005856]; cytosol [GO:0005829]; extrinsic component of cytoplasmic side of plasma membrane [GO:0031234]; focal adhesion [GO:0005925]; Golgi apparatus [GO:0005794]; lysosome [GO:0005764]; nucleus [GO:0005634]; transport vesicle [GO:0030133]
Q96NT5	HCP1_HUMAN	Proton-coupled folate transporter (G21) (Heme carrier protein 1) (PCFT/HCP1) (Solute carrier family 46 member 1)	SLC46A1 HCP1 PCFT		CHEMBL1795188;	Q96NT5;	DB00158;DB00563;DB00795;		PF07690;	IPR011701;IPR020846;IPR005829;	cellular iron ion homeostasis [GO:0006879]; folic acid import into cell [GO:1904447]; folic acid metabolic process [GO:0046655]; folic acid transport [GO:0015884]; hydrogen ion transmembrane transport [GO:1902600]; intestinal folate absorption [GO:0098829]; methotrexate transport [GO:0051958]	folic acid binding [GO:0005542]; folic acid transporter activity [GO:0008517]; heme transporter activity [GO:0015232]; hydrogen ion transmembrane transporter activity [GO:0015078]; methotrexate transporter activity [GO:0015350]	apical plasma membrane [GO:0016324]; brush border membrane [GO:0031526]; cell surface [GO:0009986]; cytoplasm [GO:0005737]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]
Q13547	HDAC1_HUMAN	Histone deacetylase 1 (HD1) (EC 3.5.1.98)	HDAC1 RPD3L1	1TYI;4BKX;5ICN;	CHEMBL325;	Q13547;	DB06603;DB06176;DB02546;		PF00850;	IPR000286;IPR003084;IPR023801;	ATP-dependent chromatin remodeling [GO:0043044]; beta-catenin-TCF complex assembly [GO:1904837]; blood coagulation [GO:0007596]; cellular response to oxidative stress [GO:0034599]; cellular response to tumor necrosis factor [GO:0071356]; chromatin organization [GO:0006325]; chromatin remodeling [GO:0006338]; circadian regulation of gene expression [GO:0032922]; embryonic digit morphogenesis [GO:0042733]; epidermal cell differentiation [GO:0009913]; eyelid development in camera-type eye [GO:0061029]; fungiform papilla formation [GO:0061198]; hair follicle placode formation [GO:0060789]; histone deacetylation [GO:0016575]; histone H3 deacetylation [GO:0070932]; histone H4 deacetylation [GO:0070933]; methylation-dependent chromatin silencing [GO:0006346]; negative regulation by host of viral transcription [GO:0043922]; negative regulation of androgen receptor signaling pathway [GO:0060766]; negative regulation of apoptotic process [GO:0043066]; negative regulation of canonical Wnt signaling pathway [GO:0090090]; negative regulation of cell proliferation [GO:0008285]; negative regulation of gene expression [GO:0010629]; negative regulation of insulin secretion [GO:0046676]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of peptidyl-lysine acetylation [GO:2000757]; negative regulation of transcription, DNA-templated [GO:0045892]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; odontogenesis of dentin-containing tooth [GO:0042475]; positive regulation of cell proliferation [GO:0008284]; positive regulation of chemokine (C-X-C motif) ligand 2 production [GO:2000343]; positive regulation of interleukin-1 production [GO:0032732]; positive regulation of oligodendrocyte differentiation [GO:0048714]; positive regulation of receptor biosynthetic process [GO:0010870]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of tumor necrosis factor production [GO:0032760]; positive regulation of type B pancreatic cell apoptotic process [GO:2000676]; positive regulation of tyrosine phosphorylation of Stat3 protein [GO:0042517]; protein deacetylation [GO:0006476]; regulation of signal transduction by p53 class mediator [GO:1901796]; response to amphetamine [GO:0001975]; response to caffeine [GO:0031000]; response to drug [GO:0042493]; response to hyperoxia [GO:0055093]; response to lipopolysaccharide [GO:0032496]; transcription, DNA-templated [GO:0006351]; viral process [GO:0016032]	activating transcription factor binding [GO:0033613]; chromatin binding [GO:0003682]; core promoter binding [GO:0001047]; deacetylase activity [GO:0019213]; enzyme binding [GO:0019899]; histone deacetylase activity [GO:0004407]; histone deacetylase binding [GO:0042826]; NAD-dependent histone deacetylase activity (H3-K14 specific) [GO:0032041]; NF-kappaB binding [GO:0051059]; protein deacetylase activity [GO:0033558]; protein N-terminus binding [GO:0047485]; repressing transcription factor binding [GO:0070491]; RNA polymerase II repressing transcription factor binding [GO:0001103]; RNA polymerase II transcription corepressor activity [GO:0001106]; RNA polymerase II transcription factor binding [GO:0001085]; transcription factor activity, sequence-specific DNA binding [GO:0003700]; transcription factor binding [GO:0008134]; transcription regulatory region DNA binding [GO:0044212]; transcription regulatory region sequence-specific DNA binding [GO:0000976]	chromatin [GO:0000785]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; histone deacetylase complex [GO:0000118]; neuron projection [GO:0043005]; nuclear chromatin [GO:0000790]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; NuRD complex [GO:0016581]; perinuclear region of cytoplasm [GO:0048471]; protein complex [GO:0043234]; Sin3 complex [GO:0016580]
Q92769	HDAC2_HUMAN	Histone deacetylase 2 (HD2) (EC 3.5.1.98)	HDAC2	3MAX;4LXZ;4LY1;5IWG;5IX0;	CHEMBL1937;	Q92769;	DB01223;DB00227;DB01303;DB06603;DB06176;DB00277;DB00313;DB02546;		PF00850;	IPR000286;IPR003084;IPR023801;	ATP-dependent chromatin remodeling [GO:0043044]; behavioral response to ethanol [GO:0048149]; blood coagulation [GO:0007596]; cardiac muscle hypertrophy [GO:0003300]; cellular response to dopamine [GO:1903351]; cellular response to heat [GO:0034605]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to retinoic acid [GO:0071300]; cellular response to transforming growth factor beta stimulus [GO:0071560]; chromatin remodeling [GO:0006338]; circadian regulation of gene expression [GO:0032922]; dendrite development [GO:0016358]; embryonic digit morphogenesis [GO:0042733]; epidermal cell differentiation [GO:0009913]; eyelid development in camera-type eye [GO:0061029]; fungiform papilla formation [GO:0061198]; hair follicle placode formation [GO:0060789]; histone deacetylation [GO:0016575]; histone H3 deacetylation [GO:0070932]; histone H4 deacetylation [GO:0070933]; maintenance of chromatin silencing [GO:0006344]; negative regulation of apoptotic process [GO:0043066]; negative regulation of dendritic spine development [GO:0061000]; negative regulation of DNA binding [GO:0043392]; negative regulation of MHC class II biosynthetic process [GO:0045347]; negative regulation of neuron projection development [GO:0010977]; negative regulation of peptidyl-lysine acetylation [GO:2000757]; negative regulation of sequence-specific DNA binding transcription factor activity [GO:0043433]; negative regulation of transcription, DNA-templated [GO:0045892]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; odontogenesis of dentin-containing tooth [GO:0042475]; positive regulation of cell proliferation [GO:0008284]; positive regulation of collagen biosynthetic process [GO:0032967]; positive regulation of epithelial to mesenchymal transition [GO:0010718]; positive regulation of interleukin-1 production [GO:0032732]; positive regulation of oligodendrocyte differentiation [GO:0048714]; positive regulation of proteolysis [GO:0045862]; positive regulation of receptor biosynthetic process [GO:0010870]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of tumor necrosis factor production [GO:0032760]; positive regulation of tyrosine phosphorylation of Stat3 protein [GO:0042517]; regulation of signal transduction by p53 class mediator [GO:1901796]; response to amphetamine [GO:0001975]; response to caffeine [GO:0031000]; response to cocaine [GO:0042220]; response to drug [GO:0042493]; response to hyperoxia [GO:0055093]; response to lipopolysaccharide [GO:0032496]; response to nicotine [GO:0035094]; transcription, DNA-templated [GO:0006351]	chromatin binding [GO:0003682]; core promoter binding [GO:0001047]; deacetylase activity [GO:0019213]; enzyme binding [GO:0019899]; histone deacetylase activity [GO:0004407]; NAD-dependent histone deacetylase activity (H3-K14 specific) [GO:0032041]; NF-kappaB binding [GO:0051059]; poly(A) RNA binding [GO:0044822]; protein deacetylase activity [GO:0033558]; RNA polymerase II repressing transcription factor binding [GO:0001103]; sequence-specific DNA binding [GO:0043565]; transcription factor binding [GO:0008134]	cytoplasm [GO:0005737]; ESC/E(Z) complex [GO:0035098]; nuclear chromatin [GO:0000790]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; NuRD complex [GO:0016581]; protein complex [GO:0043234]; Sin3 complex [GO:0016580]
O15379	HDAC3_HUMAN	Histone deacetylase 3 (HD3) (EC 3.5.1.98) (RPD3-2) (SMAP45)	HDAC3	4A69;	CHEMBL1829;	O15379;	DB06603;DB02546;		PF00850;	IPR000286;IPR003084;IPR023801;	cellular lipid metabolic process [GO:0044255]; cellular response to fluid shear stress [GO:0071498]; chromatin organization [GO:0006325]; circadian rhythm [GO:0007623]; negative regulation of apoptotic process [GO:0043066]; negative regulation of JNK cascade [GO:0046329]; negative regulation of transcription, DNA-templated [GO:0045892]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of TOR signaling [GO:0032008]; positive regulation of transcription factor import into nucleus [GO:0042993]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; protein deacetylation [GO:0006476]; regulation of protein stability [GO:0031647]; spindle assembly [GO:0051225]; transcription, DNA-templated [GO:0006351]	chromatin binding [GO:0003682]; cyclin binding [GO:0030332]; enzyme binding [GO:0019899]; histone deacetylase activity [GO:0004407]; histone deacetylase binding [GO:0042826]; NAD-dependent histone deacetylase activity (H3-K14 specific) [GO:0032041]; NF-kappaB binding [GO:0051059]; protein deacetylase activity [GO:0033558]; transcription corepressor activity [GO:0003714]; transcription factor binding [GO:0008134]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; Golgi apparatus [GO:0005794]; histone deacetylase complex [GO:0000118]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; spindle microtubule [GO:0005876]; transcriptional repressor complex [GO:0017053]
Q9UBN7	HDAC6_HUMAN	Histone deacetylase 6 (HD6) (EC 3.5.1.98)	HDAC6 KIAA0901 JM21	3C5K;3GV4;3PHD;5B8D;5EDU;5KH3;5KH7;5KH9;	CHEMBL1865;	Q9UBN7;	DB06603;DB06176;DB02546;		PF00850;PF02148;	IPR000286;IPR023801;IPR013083;IPR001607;	aggresome assembly [GO:0070842]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to misfolded protein [GO:0071218]; cellular response to topologically incorrect protein [GO:0035967]; collateral sprouting [GO:0048668]; dendritic spine morphogenesis [GO:0060997]; histone deacetylation [GO:0016575]; Hsp90 deacetylation [GO:0070846]; intracellular protein transport [GO:0006886]; lysosome localization [GO:0032418]; macroautophagy [GO:0016236]; misfolded or incompletely synthesized protein catabolic process [GO:0006515]; mitochondrion localization [GO:0051646]; mitophagy in response to mitochondrial depolarization [GO:0098779]; negative regulation of hydrogen peroxide metabolic process [GO:0010727]; negative regulation of microtubule depolymerization [GO:0007026]; negative regulation of oxidoreductase activity [GO:0051354]; negative regulation of protein complex disassembly [GO:0043242]; negative regulation of proteolysis [GO:0045861]; negative regulation of transcription, DNA-templated [GO:0045892]; organelle organization [GO:0006996]; peptidyl-lysine deacetylation [GO:0034983]; polyubiquitinated misfolded protein transport [GO:0070845]; positive regulation of chaperone-mediated protein complex assembly [GO:0090035]; positive regulation of epithelial cell migration [GO:0010634]; positive regulation of hydrogen peroxide-mediated programmed cell death [GO:1901300]; positive regulation of receptor biosynthetic process [GO:0010870]; positive regulation of signal transduction [GO:0009967]; protein complex disassembly [GO:0043241]; protein deacetylation [GO:0006476]; protein polyubiquitination [GO:0000209]; regulation of androgen receptor signaling pathway [GO:0060765]; regulation of autophagy [GO:0010506]; regulation of establishment of protein localization [GO:0070201]; regulation of fat cell differentiation [GO:0045598]; regulation of gene expression, epigenetic [GO:0040029]; regulation of microtubule-based movement [GO:0060632]; regulation of mitophagy [GO:1903146]; regulation of protein stability [GO:0031647]; regulation of receptor activity [GO:0010469]; response to growth factor [GO:0070848]; response to misfolded protein [GO:0051788]; response to organic substance [GO:0010033]; response to toxic substance [GO:0009636]; transcription, DNA-templated [GO:0006351]; tubulin deacetylation [GO:0090042]; ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway [GO:0043162]	alpha-tubulin binding [GO:0043014]; beta-catenin binding [GO:0008013]; core promoter binding [GO:0001047]; dynein complex binding [GO:0070840]; enzyme binding [GO:0019899]; histone deacetylase activity [GO:0004407]; histone deacetylase binding [GO:0042826]; Hsp90 protein binding [GO:0051879]; microtubule binding [GO:0008017]; misfolded protein binding [GO:0051787]; NAD-dependent histone deacetylase activity (H3-K14 specific) [GO:0032041]; polyubiquitin binding [GO:0031593]; tau protein binding [GO:0048156]; tubulin deacetylase activity [GO:0042903]; ubiquitin protein ligase binding [GO:0031625]; zinc ion binding [GO:0008270]	aggresome [GO:0016235]; axon [GO:0030424]; caveola [GO:0005901]; cell leading edge [GO:0031252]; cytoplasm [GO:0005737]; cytoplasmic microtubule [GO:0005881]; cytosol [GO:0005829]; dendrite [GO:0030425]; histone deacetylase complex [GO:0000118]; inclusion body [GO:0016234]; microtubule [GO:0005874]; microtubule associated complex [GO:0005875]; multivesicular body [GO:0005771]; nucleus [GO:0005634]; perikaryon [GO:0043204]; perinuclear region of cytoplasm [GO:0048471]
Q9BY41	HDAC8_HUMAN	Histone deacetylase 8 (HD8) (EC 3.5.1.98)	HDAC8 HDACL1 CDA07	1T64;1T67;1T69;1VKG;1W22;2V5W;2V5X;3EW8;3EWF;3EZP;3EZT;3F06;3F07;3F0R;3MZ3;3MZ4;3MZ6;3MZ7;3RQD;3SFF;3SFH;4QA0;4QA1;4QA2;4QA3;4QA4;4QA5;4QA6;4QA7;4RN0;4RN1;4RN2;5BWZ;5D1B;5D1C;5D1D;5DC5;5DC6;5DC7;5DC8;	CHEMBL3192;	Q9BY41;	DB06603;DB02546;		PF00850;	IPR000286;IPR003084;IPR023801;	chromatin assembly or disassembly [GO:0006333]; chromatin organization [GO:0006325]; negative regulation of protein ubiquitination [GO:0031397]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; regulation of cohesin loading [GO:0071922]; regulation of protein stability [GO:0031647]; regulation of telomere maintenance [GO:0032204]; sister chromatid cohesion [GO:0007062]; transcription, DNA-templated [GO:0006351]	histone deacetylase activity [GO:0004407]; Hsp70 protein binding [GO:0030544]; Hsp90 protein binding [GO:0051879]; metal ion binding [GO:0046872]; NAD-dependent histone deacetylase activity (H3-K14 specific) [GO:0032041]; transcription factor binding [GO:0008134]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; histone deacetylase complex [GO:0000118]; nuclear chromosome [GO:0000228]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
Q9UKV0	HDAC9_HUMAN	Histone deacetylase 9 (HD9) (EC 3.5.1.98) (Histone deacetylase 7B) (HD7) (HD7b) (Histone deacetylase-related protein) (MEF2-interacting transcription repressor MITR)	HDAC9 HDAC7 HDAC7B HDRP KIAA0744 MITR		CHEMBL4145;	Q9UKV0;	DB06603;DB00313;		PF12203;PF00850;	IPR000286;IPR023801;IPR024643;IPR017320;	B cell activation [GO:0042113]; B cell differentiation [GO:0030183]; cellular response to insulin stimulus [GO:0032869]; heart development [GO:0007507]; histone deacetylation [GO:0016575]; histone H3 deacetylation [GO:0070932]; histone H4 deacetylation [GO:0070933]; inflammatory response [GO:0006954]; negative regulation of transcription, DNA-templated [GO:0045892]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; neuron differentiation [GO:0030182]; peptidyl-lysine deacetylation [GO:0034983]; positive regulation of cell migration involved in sprouting angiogenesis [GO:0090050]; regulation of skeletal muscle fiber development [GO:0048742]; regulation of striated muscle cell differentiation [GO:0051153]; response to amphetamine [GO:0001975]; transcription, DNA-templated [GO:0006351]	histone deacetylase activity [GO:0004407]; histone deacetylase binding [GO:0042826]; metal ion binding [GO:0046872]; NAD-dependent histone deacetylase activity (H3-K14 specific) [GO:0032041]; protein deacetylase activity [GO:0033558]; protein kinase C binding [GO:0005080]; repressing transcription factor binding [GO:0070491]; transcription corepressor activity [GO:0003714]; transcription factor binding [GO:0008134]	cytoplasm [GO:0005737]; histone deacetylase complex [GO:0000118]; histone methyltransferase complex [GO:0035097]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; transcription factor complex [GO:0005667]
P13196	HEM1_HUMAN	5-aminolevulinate synthase, nonspecific, mitochondrial (ALAS-H) (EC 2.3.1.37) (5-aminolevulinic acid synthase 1) (Delta-ALA synthase 1) (Delta-aminolevulinate synthase 1)	ALAS1 ALAS3 ALASH OK/SW-cl.121				DB00145;	PATHWAY: Porphyrin-containing compound metabolism; protoporphyrin-IX biosynthesis; 5-aminolevulinate from glycine: step 1/1.	PF00155;PF09029;	IPR010961;IPR015118;IPR001917;IPR004839;IPR015424;IPR015421;IPR015422;	heme biosynthetic process [GO:0006783]; mitochondrion organization [GO:0007005]; protoporphyrinogen IX biosynthetic process [GO:0006782]	5-aminolevulinate synthase activity [GO:0003870]; pyridoxal phosphate binding [GO:0030170]	cytoplasm [GO:0005737]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]
P13716	HEM2_HUMAN	Delta-aminolevulinic acid dehydratase (ALADH) (EC 4.2.1.24) (Porphobilinogen synthase)	ALAD	1E51;1PV8;5HMS;5HNR;	CHEMBL3126;	P13716;	DB00855;	PATHWAY: Porphyrin-containing compound metabolism; protoporphyrin-IX biosynthesis; coproporphyrinogen-III from 5-aminolevulinate: step 1/4.	PF00490;	IPR001731;IPR030656;IPR013785;	cellular response to interleukin-4 [GO:0071353]; cellular response to lead ion [GO:0071284]; heme biosynthetic process [GO:0006783]; protein homooligomerization [GO:0051260]; protoporphyrinogen IX biosynthetic process [GO:0006782]; response to activity [GO:0014823]; response to aluminum ion [GO:0010044]; response to amino acid [GO:0043200]; response to arsenic-containing substance [GO:0046685]; response to cadmium ion [GO:0046686]; response to cobalt ion [GO:0032025]; response to drug [GO:0042493]; response to ethanol [GO:0045471]; response to fatty acid [GO:0070542]; response to glucocorticoid [GO:0051384]; response to herbicide [GO:0009635]; response to hypoxia [GO:0001666]; response to ionizing radiation [GO:0010212]; response to iron ion [GO:0010039]; response to lipopolysaccharide [GO:0032496]; response to mercury ion [GO:0046689]; response to methylmercury [GO:0051597]; response to oxidative stress [GO:0006979]; response to platinum ion [GO:0070541]; response to selenium ion [GO:0010269]; response to vitamin B1 [GO:0010266]; response to vitamin E [GO:0033197]; response to zinc ion [GO:0010043]	catalytic activity [GO:0003824]; identical protein binding [GO:0042802]; lead ion binding [GO:0032791]; porphobilinogen synthase activity [GO:0004655]; zinc ion binding [GO:0008270]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; nucleus [GO:0005634]
P22830	HEMH_HUMAN	Ferrochelatase, mitochondrial (EC 4.99.1.1) (Heme synthase) (Protoheme ferro-lyase)	FECH	1HRK;2HRC;2HRE;2PNJ;2PO5;2PO7;2QD1;2QD2;2QD3;2QD4;2QD5;3AQI;3HCN;3HCO;3HCP;3HCR;3W1W;4F4D;4KLA;4KLC;4KLR;4KMM;4MK4;			DB02659;	PATHWAY: Porphyrin-containing compound metabolism; protoheme biosynthesis; protoheme from protoporphyrin-IX: step 1/1.	PF00762;	IPR001015;IPR019772;IPR033644;IPR033659;	cellular response to dexamethasone stimulus [GO:0071549]; generation of precursor metabolites and energy [GO:0006091]; heme biosynthetic process [GO:0006783]; protoporphyrinogen IX metabolic process [GO:0046501]; response to arsenic-containing substance [GO:0046685]; response to drug [GO:0042493]; response to ethanol [GO:0045471]; response to insecticide [GO:0017085]; response to lead ion [GO:0010288]; response to light stimulus [GO:0009416]; response to methylmercury [GO:0051597]; response to platinum ion [GO:0070541]	2 iron, 2 sulfur cluster binding [GO:0051537]; ferrochelatase activity [GO:0004325]; ferrous iron binding [GO:0008198]	mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
P05546	HEP2_HUMAN	Heparin cofactor 2 (Heparin cofactor II) (HC-II) (Protease inhibitor leuserpin-2) (HLS2) (Serpin D1)	SERPIND1 HCF2	1JMJ;1JMO;2NAT;			DB00407;DB06271;		PF00079;	IPR023795;IPR023796;IPR000215;	bioluminescence [GO:0008218]; blood coagulation [GO:0007596]; chemotaxis [GO:0006935]	endopeptidase inhibitor activity [GO:0004866]; heparin binding [GO:0008201]; serine-type endopeptidase inhibitor activity [GO:0004867]	extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]
P07686	HEXB_HUMAN	Beta-hexosaminidase subunit beta (EC 3.2.1.52) (Beta-N-acetylhexosaminidase subunit beta) (Hexosaminidase subunit B) (Cervical cancer proto-oncogene 7 protein) (HCC-7) (N-acetyl-beta-glucosaminidase subunit beta) [Cleaved into: Beta-hexosaminidase subunit beta chain B; Beta-hexosaminidase subunit beta chain A]	HEXB HCC7	1NOU;1NOW;1NP0;1O7A;1QBD;2GJX;2GK1;3LMY;5BRO;	CHEMBL5877;	P07686;			PF00728;PF14845;	IPR025705;IPR029018;IPR015883;IPR013781;IPR017853;IPR029019;	astrocyte cell migration [GO:0043615]; cellular calcium ion homeostasis [GO:0006874]; cellular protein metabolic process [GO:0044267]; chondroitin sulfate catabolic process [GO:0030207]; ganglioside catabolic process [GO:0006689]; glycosphingolipid metabolic process [GO:0006687]; hyaluronan catabolic process [GO:0030214]; keratan sulfate catabolic process [GO:0042340]; lipid storage [GO:0019915]; locomotory behavior [GO:0007626]; lysosome organization [GO:0007040]; male courtship behavior [GO:0008049]; myelination [GO:0042552]; neuromuscular process controlling balance [GO:0050885]; oligosaccharide catabolic process [GO:0009313]; oogenesis [GO:0048477]; penetration of zona pellucida [GO:0007341]; phospholipid biosynthetic process [GO:0008654]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; regulation of cell shape [GO:0008360]; sensory perception of sound [GO:0007605]; skeletal system development [GO:0001501]	acetylglucosaminyltransferase activity [GO:0008375]; beta-N-acetylhexosaminidase activity [GO:0004563]; protein heterodimerization activity [GO:0046982]; protein homodimerization activity [GO:0042803]	acrosomal vesicle [GO:0001669]; azurophil granule [GO:0042582]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; lysosomal lumen [GO:0043202]; membrane [GO:0016020]
P14210	HGF_HUMAN	Hepatocyte growth factor (Hepatopoietin-A) (Scatter factor) (SF) [Cleaved into: Hepatocyte growth factor alpha chain; Hepatocyte growth factor beta chain]	HGF HPTA	1BHT;1GMN;1GMO;1GP9;1NK1;1SHY;1SI5;2HGF;2QJ2;3HMS;3HMT;3HN4;3MKP;3SP8;4D3C;4K3J;4O3T;4O3U;5COE;5CP9;5CS1;5CS3;5CS5;5CS9;5CSQ;5CT1;5CT2;5CT3;	CHEMBL5479;	P14210;			PF00051;PF00024;PF00089;	IPR027284;IPR024174;IPR000001;IPR013806;IPR018056;IPR003609;IPR009003;IPR001314;IPR001254;	activation of MAPK activity [GO:0000187]; animal organ regeneration [GO:0031100]; cell chemotaxis [GO:0060326]; cellular response to hepatocyte growth factor stimulus [GO:0035729]; epithelial to mesenchymal transition [GO:0001837]; hepatocyte growth factor receptor signaling pathway [GO:0048012]; hyaluronan metabolic process [GO:0030212]; liver development [GO:0001889]; mitotic nuclear division [GO:0007067]; myoblast proliferation [GO:0051450]; negative regulation of autophagy [GO:0010507]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154]; negative regulation of extrinsic apoptotic signaling pathway via death domain receptors [GO:1902042]; negative regulation of hydrogen peroxide-mediated programmed cell death [GO:1901299]; negative regulation of inflammatory response [GO:0050728]; negative regulation of interleukin-6 production [GO:0032715]; negative regulation of peptidyl-serine phosphorylation [GO:0033137]; negative regulation of release of cytochrome c from mitochondria [GO:0090201]; platelet degranulation [GO:0002576]; positive regulation of angiogenesis [GO:0045766]; positive regulation of cell migration [GO:0030335]; positive regulation of cell proliferation [GO:0008284]; positive regulation of DNA biosynthetic process [GO:2000573]; positive regulation of interleukin-10 production [GO:0032733]; positive regulation of myelination [GO:0031643]; positive regulation of neuron projection regeneration [GO:0070572]; positive regulation of osteoblast differentiation [GO:0045669]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of phosphatidylinositol 3-kinase signaling [GO:0014068]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling [GO:0060665]; regulation of p38MAPK cascade [GO:1900744]; regulation of tau-protein kinase activity [GO:1902947]	chemoattractant activity [GO:0042056]; growth factor activity [GO:0008083]; identical protein binding [GO:0042802]	extracellular region [GO:0005576]; extracellular space [GO:0005615]; membrane [GO:0016020]; platelet alpha granule lumen [GO:0031093]
Q9NWT6	HIF1N_HUMAN	Hypoxia-inducible factor 1-alpha inhibitor (EC 1.14.11.30) (EC 1.14.11.n4) (Factor inhibiting HIF-1) (FIH-1) (Hypoxia-inducible factor asparagine hydroxylase)	HIF1AN FIH1	1H2K;1H2L;1H2M;1H2N;1IZ3;1MZE;1MZF;1YCI;2CGN;2CGO;2ILM;2W0X;2WA3;2WA4;2XUM;2Y0I;2YC0;2YDE;3D8C;3KCX;3KCY;3OD4;3P3N;3P3P;4AI8;4B7E;4B7K;4BIO;4JAA;4NR1;4Z1V;4Z2W;	CHEMBL5909;	Q9NWT6;				IPR027445;IPR027452;IPR003347;	negative regulation of Notch signaling pathway [GO:0045746]; negative regulation of transcription from RNA polymerase II promoter in response to hypoxia [GO:0061428]; oxidation-reduction process [GO:0055114]; peptidyl-asparagine hydroxylation [GO:0042265]; peptidyl-aspartic acid hydroxylation [GO:0042264]; peptidyl-histidine hydroxylation [GO:0036138]; positive regulation of myoblast differentiation [GO:0045663]; positive regulation of vasculogenesis [GO:2001214]; regulation of transcription from RNA polymerase II promoter in response to hypoxia [GO:0061418]; transcription, DNA-templated [GO:0006351]	ankyrin repeat binding [GO:0071532]; carboxylic acid binding [GO:0031406]; cofactor binding [GO:0048037]; iron ion binding [GO:0005506]; NF-kappaB binding [GO:0051059]; Notch binding [GO:0005112]; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors [GO:0016706]; oxygen sensor activity [GO:0019826]; peptidyl-asparagine 3-dioxygenase activity [GO:0036140]; peptidyl-histidine dioxygenase activity [GO:0036139]; protein homodimerization activity [GO:0042803]; zinc ion binding [GO:0008270]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleoplasm [GO:0005654]; perinuclear region of cytoplasm [GO:0048471]
P49773	HINT1_HUMAN	Histidine triad nucleotide-binding protein 1 (EC 3.-.-.-) (Adenosine 5'-monophosphoramidase) (Protein kinase C inhibitor 1) (Protein kinase C-interacting protein 1) (PKCI-1)	HINT1 HINT PKCI1 PRKCNH1	1AV5;1KPA;1KPB;1KPC;1KPE;1KPF;3TW2;4EQE;4EQG;4EQH;4ZKL;4ZKV;5I2E;5I2F;	CHEMBL5878;	P49773;	DB00131;		PF01230;	IPR019808;IPR001310;IPR011146;	intrinsic apoptotic signaling pathway by p53 class mediator [GO:0072332]; positive regulation of calcium-mediated signaling [GO:0050850]; purine ribonucleotide catabolic process [GO:0009154]; regulation of transcription, DNA-templated [GO:0006355]; signal transduction [GO:0007165]; transcription, DNA-templated [GO:0006351]	hydrolase activity [GO:0016787]; nucleotide binding [GO:0000166]; protein kinase C binding [GO:0005080]	cytoplasm [GO:0005737]; cytoskeleton [GO:0005856]; extracellular exosome [GO:0070062]; histone deacetylase complex [GO:0000118]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
P04035	HMDH_HUMAN	3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) (EC 1.1.1.34)	HMGCR	1DQ8;1DQ9;1DQA;1HW8;1HW9;1HWI;1HWJ;1HWK;1HWL;2Q1L;2Q6B;2Q6C;2R4F;3BGL;3CCT;3CCW;3CCZ;3CD0;3CD5;3CD7;3CDA;3CDB;	CHEMBL402;	P04035;	DB01076;DB01095;DB00227;DB08860;DB00175;DB01098;DB00641;	PATHWAY: Metabolic intermediate biosynthesis; (R)-mevalonate biosynthesis; (R)-mevalonate from acetyl-CoA: step 3/3.	PF00368;PF12349;	IPR002202;IPR023074;IPR023076;IPR004554;IPR004816;IPR023282;IPR009023;IPR009029;IPR000731;	aging [GO:0007568]; cholesterol biosynthetic process [GO:0006695]; coenzyme A metabolic process [GO:0015936]; isoprenoid biosynthetic process [GO:0008299]; myoblast differentiation [GO:0045445]; negative regulation of insulin secretion involved in cellular response to glucose stimulus [GO:0061179]; negative regulation of MAP kinase activity [GO:0043407]; negative regulation of striated muscle cell apoptotic process [GO:0010664]; negative regulation of vasodilation [GO:0045908]; negative regulation of wound healing [GO:0061045]; positive regulation of cardiac muscle cell apoptotic process [GO:0010666]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of skeletal muscle tissue development [GO:0048643]; positive regulation of smooth muscle cell proliferation [GO:0048661]; positive regulation of stress-activated MAPK cascade [GO:0032874]; protein tetramerization [GO:0051262]; response to ethanol [GO:0045471]; response to nutrient [GO:0007584]; ubiquinone metabolic process [GO:0006743]; visual learning [GO:0008542]	coenzyme binding [GO:0050662]; hydroxymethylglutaryl-CoA reductase (NADPH) activity [GO:0004420]; hydroxymethylglutaryl-CoA reductase activity [GO:0042282]; NADPH binding [GO:0070402]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; peroxisomal membrane [GO:0005778]
P35914	HMGCL_HUMAN	Hydroxymethylglutaryl-CoA lyase, mitochondrial (HL) (HMG-CoA lyase) (EC 4.1.3.4) (3-hydroxy-3-methylglutarate-CoA lyase)	HMGCL	2CW6;3MP3;3MP4;3MP5;				PATHWAY: Metabolic intermediate metabolism; (S)-3-hydroxy-3-methylglutaryl-CoA degradation; acetoacetate from (S)-3-hydroxy-3-methylglutaryl-CoA: step 1/1.	PF00682;	IPR013785;IPR030020;IPR000138;IPR000891;	acyl-CoA metabolic process [GO:0006637]; ketone body biosynthetic process [GO:0046951]; leucine catabolic process [GO:0006552]; lipid metabolic process [GO:0006629]; liver development [GO:0001889]; mitochondrion organization [GO:0007005]; protein tetramerization [GO:0051262]; response to fatty acid [GO:0070542]; response to nutrient [GO:0007584]; response to starvation [GO:0042594]	carboxylic acid binding [GO:0031406]; fatty-acyl-CoA binding [GO:0000062]; hydroxymethylglutaryl-CoA lyase activity [GO:0004419]; magnesium ion binding [GO:0000287]; manganese ion binding [GO:0030145]; metal ion binding [GO:0046872]; protein homodimerization activity [GO:0042803]; receptor binding [GO:0005102]	mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; peroxisome [GO:0005777]
P09601	HMOX1_HUMAN	Heme oxygenase 1 (HO-1) (EC 1.14.14.18)	HMOX1 HO HO1	1N3U;1N45;1NI6;1OYK;1OYL;1OZE;1OZL;1OZR;1OZW;1S13;1S8C;1T5P;1TWN;1TWR;1XJZ;1XK0;1XK1;1XK2;1XK3;3CZY;3HOK;3K4F;3TGM;4WD4;5BTQ;	CHEMBL2823;	P09601;	DB00163;		PF01126;	IPR002051;IPR016053;IPR016084;IPR018207;	angiogenesis [GO:0001525]; cell death [GO:0008219]; cellular iron ion homeostasis [GO:0006879]; cellular response to arsenic-containing substance [GO:0071243]; cellular response to cadmium ion [GO:0071276]; cellular response to cisplatin [GO:0072719]; cellular response to heat [GO:0034605]; cellular response to hypoxia [GO:0071456]; cellular response to nutrient [GO:0031670]; endothelial cell proliferation [GO:0001935]; erythrocyte homeostasis [GO:0034101]; excretion [GO:0007588]; heme catabolic process [GO:0042167]; heme oxidation [GO:0006788]; intracellular signal transduction [GO:0035556]; intrinsic apoptotic signaling pathway in response to DNA damage [GO:0008630]; iron ion homeostasis [GO:0055072]; liver regeneration [GO:0097421]; low-density lipoprotein particle clearance [GO:0034383]; negative regulation of DNA binding [GO:0043392]; negative regulation of epithelial cell apoptotic process [GO:1904036]; negative regulation of extrinsic apoptotic signaling pathway via death domain receptors [GO:1902042]; negative regulation of leukocyte migration [GO:0002686]; negative regulation of mast cell cytokine production [GO:0032764]; negative regulation of mast cell degranulation [GO:0043305]; negative regulation of muscle cell apoptotic process [GO:0010656]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of sequence-specific DNA binding transcription factor activity [GO:0043433]; negative regulation of smooth muscle cell proliferation [GO:0048662]; negative regulation of vascular smooth muscle cell proliferation [GO:1904706]; positive regulation of angiogenesis [GO:0045766]; positive regulation of apoptotic process [GO:0043065]; positive regulation of chemokine biosynthetic process [GO:0045080]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of macroautophagy [GO:0016239]; positive regulation of smooth muscle cell proliferation [GO:0048661]; positive regulation of vasodilation [GO:0045909]; protein homooligomerization [GO:0051260]; regulation of angiogenesis [GO:0045765]; regulation of blood pressure [GO:0008217]; regulation of sequence-specific DNA binding transcription factor activity [GO:0051090]; regulation of transcription from RNA polymerase II promoter in response to iron [GO:0034395]; regulation of transcription from RNA polymerase II promoter in response to oxidative stress [GO:0043619]; response to estrogen [GO:0043627]; response to hydrogen peroxide [GO:0042542]; response to nicotine [GO:0035094]; response to oxidative stress [GO:0006979]; small GTPase mediated signal transduction [GO:0007264]; smooth muscle hyperplasia [GO:0014806]; wound healing involved in inflammatory response [GO:0002246]	enzyme binding [GO:0019899]; heme binding [GO:0020037]; heme oxygenase (decyclizing) activity [GO:0004392]; metal ion binding [GO:0046872]; phospholipase D activity [GO:0004630]; protein homodimerization activity [GO:0042803]; signal transducer activity [GO:0004871]	caveola [GO:0005901]; cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; extracellular space [GO:0005615]; membrane [GO:0016020]; nucleolus [GO:0005730]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]
P30519	HMOX2_HUMAN	Heme oxygenase 2 (HO-2) (EC 1.14.14.18)	HMOX2 HO2	2Q32;2QPP;2RGZ;4WMH;	CHEMBL2546;				PF01126;	IPR002051;IPR016053;IPR016084;IPR018207;	cellular iron ion homeostasis [GO:0006879]; heme catabolic process [GO:0042167]; heme oxidation [GO:0006788]; response to hypoxia [GO:0001666]	heme oxygenase (decyclizing) activity [GO:0004392]; metal ion binding [GO:0046872]	endoplasmic reticulum membrane [GO:0005789]; membrane [GO:0016020]; plasma membrane [GO:0005886]
Q14541	HNF4G_HUMAN	Hepatocyte nuclear factor 4-gamma (HNF-4-gamma) (Nuclear receptor subfamily 2 group A member 2)	HNF4G NR2A2	1LV2;	CHEMBL1961786;				PF00104;PF00105;	IPR003068;IPR000536;IPR001723;IPR001628;IPR013088;	regulation of transcription from RNA polymerase II promoter [GO:0006357]; transcription initiation from RNA polymerase II promoter [GO:0006367]	RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding [GO:0004879]; sequence-specific DNA binding [GO:0043565]; steroid hormone receptor activity [GO:0003707]; transcription factor activity, sequence-specific DNA binding [GO:0003700]; zinc ion binding [GO:0008270]	nucleoplasm [GO:0005654]
P50135	HNMT_HUMAN	Histamine N-methyltransferase (HMT) (EC 2.1.1.8)	HNMT	1ICZ;1JQD;1JQE;2AOT;2AOU;2AOV;2AOW;2AOX;	CHEMBL2190;	P50135;	DB00613;DB00878;DB00667;DB01103;			IPR016673;IPR029063;	brain development [GO:0007420]; histamine catabolic process [GO:0001695]; histidine catabolic process [GO:0006548]; hyperosmotic response [GO:0006972]; methylation [GO:0032259]; positive regulation of protein targeting to mitochondrion [GO:1903955]; respiratory gaseous exchange [GO:0007585]; response to amine [GO:0014075]; response to cocaine [GO:0042220]; response to glucocorticoid [GO:0051384]; response to immobilization stress [GO:0035902]; response to interleukin-1 [GO:0070555]; response to tumor cell [GO:0002347]	histamine N-methyltransferase activity [GO:0046539]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; neuron projection [GO:0043005]; nucleoplasm [GO:0005654]
P32754	HPPD_HUMAN	4-hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27) (4-hydroxyphenylpyruvic acid oxidase) (4HPPD) (HPD) (HPPDase)	HPD PPD	3ISQ;5EC3;	CHEMBL1861;	P32754;	DB00348;	PATHWAY: Amino-acid degradation; L-phenylalanine degradation; acetoacetate and fumarate from L-phenylalanine: step 3/6.	PF00903;	IPR005956;IPR029068;IPR004360;	L-phenylalanine catabolic process [GO:0006559]; tyrosine catabolic process [GO:0006572]	4-hydroxyphenylpyruvate dioxygenase activity [GO:0003868]; metal ion binding [GO:0046872]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P00492	HPRT_HUMAN	Hypoxanthine-guanine phosphoribosyltransferase (HGPRT) (HGPRTase) (EC 2.4.2.8)	HPRT1 HPRT	1BZY;1D6N;1HMP;1Z7G;2VFA;3GEP;3GGC;3GGJ;4IJQ;4KN6;4RAB;4RAC;4RAD;4RAN;4RAO;4RAQ;5BRN;5BSK;	CHEMBL2360;	P00492;	DB00993;DB01033;DB00352;	PATHWAY: Purine metabolism; IMP biosynthesis via salvage pathway; IMP from hypoxanthine: step 1/1.	PF00156;	IPR005904;IPR000836;IPR029057;	adenine salvage [GO:0006168]; central nervous system neuron development [GO:0021954]; cerebral cortex neuron differentiation [GO:0021895]; cytolysis [GO:0019835]; dendrite morphogenesis [GO:0048813]; dopamine metabolic process [GO:0042417]; GMP catabolic process [GO:0046038]; GMP salvage [GO:0032263]; grooming behavior [GO:0007625]; guanine salvage [GO:0006178]; hypoxanthine metabolic process [GO:0046100]; hypoxanthine salvage [GO:0043103]; IMP metabolic process [GO:0046040]; IMP salvage [GO:0032264]; locomotory behavior [GO:0007626]; lymphocyte proliferation [GO:0046651]; positive regulation of dopamine metabolic process [GO:0045964]; protein homotetramerization [GO:0051289]; purine-containing compound salvage [GO:0043101]; purine nucleotide biosynthetic process [GO:0006164]; purine ribonucleoside salvage [GO:0006166]; response to amphetamine [GO:0001975]; striatum development [GO:0021756]	guanine phosphoribosyltransferase activity [GO:0052657]; hypoxanthine phosphoribosyltransferase activity [GO:0004422]; magnesium ion binding [GO:0000287]; nucleotide binding [GO:0000166]; protein homodimerization activity [GO:0042803]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
Q9Y251	HPSE_HUMAN	Heparanase (EC 3.2.1.166) (Endo-glucoronidase) (Heparanase-1) (Hpa1) [Cleaved into: Heparanase 8 kDa subunit; Heparanase 50 kDa subunit]	HPSE HEP HPA HPA1 HPR1 HPSE1 HSE1	5E8M;5E97;5E98;5E9B;5E9C;	CHEMBL3921;	Q9Y251;	DB06779;DB01109;		PF03662;	IPR005199;IPR013781;IPR017853;	angiogenesis involved in wound healing [GO:0060055]; carbohydrate metabolic process [GO:0005975]; cell-matrix adhesion [GO:0007160]; extracellular matrix organization [GO:0030198]; glycosaminoglycan catabolic process [GO:0006027]; heparan sulfate proteoglycan catabolic process [GO:0030200]; positive regulation of blood coagulation [GO:0030194]; positive regulation of hair follicle development [GO:0051798]; positive regulation of osteoblast proliferation [GO:0033690]; positive regulation of protein kinase B signaling [GO:0051897]; positive regulation of vascular endothelial growth factor production [GO:0010575]; proteoglycan metabolic process [GO:0006029]; regulation of hair follicle development [GO:0051797]; vascular wound healing [GO:0061042]	beta-glucuronidase activity [GO:0004566]; heparanase activity [GO:0030305]; heparan sulfate proteoglycan binding [GO:0043395]; protein dimerization activity [GO:0046983]; syndecan binding [GO:0045545]	intracellular membrane-bounded organelle [GO:0043231]; lysosomal lumen [GO:0043202]; lysosomal membrane [GO:0005765]; lysosome [GO:0005764]; membrane raft [GO:0045121]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; proteinaceous extracellular matrix [GO:0005578]
P35367	HRH1_HUMAN	Histamine H1 receptor (H1R) (HH1R)	HRH1	3RZE;	CHEMBL231;	P35367;	DB01615;DB06766;DB01246;DB00321;DB00543;DB08799;DB01238;DB06216;DB00637;DB00719;DB00972;DB00245;DB04890;DB06698;DB01237;DB00835;DB00354;DB09016;DB00748;DB06016;DB00341;DB08936;DB08800;DB01114;DB00477;DB01239;DB00568;DB00215;DB00283;DB04837;DB00363;DB01176;DB00434;DB01151;DB00967;DB00405;DB00985;DB08801;DB01075;DB01146;DB01142;DB00366;DB01084;DB00751;DB01175;DB00950;DB04841;DB00667;DB00557;DB04946;DB00458;DB08802;DB00920;DB01106;DB06282;DB00455;DB00408;DB00934;DB00737;DB06691;DB01071;DB00902;DB01403;DB06148;DB00370;DB00540;DB00334;DB00768;DB01173;DB01267;DB01619;DB01620;DB00420;DB01069;DB00777;DB01224;DB00734;DB00797;DB00656;DB00726;DB00792;DB00427;DB00246;DB01624;		PF00001;	IPR000276;IPR017452;IPR000921;	cellular response to histamine [GO:0071420]; eosinophil chemotaxis [GO:0048245]; G-protein coupled receptor signaling pathway [GO:0007186]; inflammatory response [GO:0006954]; inositol phosphate-mediated signaling [GO:0048016]; memory [GO:0007613]; modulation of synaptic transmission [GO:0050804]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; positive regulation of inositol trisphosphate biosynthetic process [GO:0032962]; positive regulation of vasoconstriction [GO:0045907]; regulation of synaptic plasticity [GO:0048167]; regulation of vascular permeability [GO:0043114]; regulation of vasoconstriction [GO:0019229]; visual learning [GO:0008542]	G-protein coupled receptor activity [GO:0004930]; histamine receptor activity [GO:0004969]	cytoplasm [GO:0005737]; integral component of plasma membrane [GO:0005887]; nucleoplasm [GO:0005654]; plasma membrane [GO:0005886]
P25021	HRH2_HUMAN	Histamine H2 receptor (H2R) (HH2R) (Gastric receptor I)	HRH2		CHEMBL1941;	P25021;	DB00321;DB06216;DB00272;DB00501;DB01142;DB00751;DB00927;DB00667;DB00408;DB00940;DB00585;DB00334;DB00863;DB08806;DB00797;		PF00001;	IPR000276;IPR017452;IPR000503;	digestive tract development [GO:0048565]; epithelial cell morphogenesis [GO:0003382]; gastrin-induced gastric acid secretion [GO:0001698]; gland development [GO:0048732]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; histamine-induced gastric acid secretion [GO:0001697]; immune response [GO:0006955]; memory [GO:0007613]; positive regulation of vasoconstriction [GO:0045907]; regulation of synaptic plasticity [GO:0048167]; toxin transport [GO:1901998]; visual learning [GO:0008542]	histamine receptor activity [GO:0004969]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
Q9Y5N1	HRH3_HUMAN	Histamine H3 receptor (H3R) (HH3R) (G-protein coupled receptor 97)	HRH3 GPCR97		CHEMBL264;	Q9Y5N1;	DB06698;DB00667;DB00370;		PF00001;	IPR000276;IPR017452;IPR003980;	adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway [GO:0007197]; cognition [GO:0050890]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; negative regulation of glutamate secretion [GO:0014050]; negative regulation of serotonin secretion [GO:0014063]; neurotransmitter secretion [GO:0007269]; phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway [GO:0007207]; regulation of norepinephrine secretion [GO:0014061]; synaptic transmission, cholinergic [GO:0007271]	G-protein coupled acetylcholine receptor activity [GO:0016907]; histamine receptor activity [GO:0004969]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; presynapse [GO:0098793]
Q9H3N8	HRH4_HUMAN	Histamine H4 receptor (H4R) (HH4R) (AXOR35) (G-protein coupled receptor 105) (GPRv53) (Pfi-013) (SP9144)	HRH4 GPCR105		CHEMBL3759;	Q9H3N8;	DB00321;DB00543;DB00477;DB00363;DB01142;DB00667;DB00408;DB06148;DB00334;		PF00001;	IPR000276;IPR017452;IPR008102;	adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway [GO:0007197]; inflammatory response [GO:0006954]; phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway [GO:0007207]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; regulation of MAPK cascade [GO:0043408]; synaptic transmission, cholinergic [GO:0007271]	G-protein coupled acetylcholine receptor activity [GO:0016907]; histamine receptor activity [GO:0004969]	integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]; synapse [GO:0045202]
P07900	HS90A_HUMAN	Heat shock protein HSP 90-alpha (Heat shock 86 kDa) (HSP 86) (HSP86) (Lipopolysaccharide-associated protein 2) (LAP-2) (LPS-associated protein 2) (Renal carcinoma antigen NY-REN-38)	HSP90AA1 HSP90A HSPC1 HSPCA	1BYQ;1OSF;1UY6;1UY7;1UY8;1UY9;1UYC;1UYD;1UYE;1UYF;1UYG;1UYH;1UYI;1UYK;1UYL;1YC1;1YC3;1YC4;1YER;1YES;1YET;2BSM;2BT0;2BUG;2BYH;2BYI;2BZ5;2C2L;2CCS;2CCT;2CCU;2FWY;2FWZ;2H55;2JJC;2K5B;2QF6;2QFO;2QG0;2QG2;2UWD;2VCI;2VCJ;2WI1;2WI2;2WI3;2WI4;2WI5;2WI6;2WI7;2XAB;2XDK;2XDL;2XDS;2XDU;2XDX;2XHR;2XHT;2XHX;2XJG;2XJJ;2XJX;2XK2;2YE2;2YE3;2YE4;2YE5;2YE6;2YE7;2YE8;2YE9;2YEA;2YEB;2YEC;2YED;2YEE;2YEF;2YEG;2YEH;2YEI;2YEJ;2YI0;2YI5;2YI6;2YI7;2YJW;2YJX;2YK2;2YK9;2YKB;2YKC;2YKE;2YKI;2YKJ;3B24;3B25;3B26;3B27;3B28;3BM9;3BMY;3D0B;3EKO;3EKR;3FT5;3FT8;3HEK;3HHU;3HYY;3HYZ;3HZ1;3HZ5;3INW;3INX;3K97;3K98;3K99;3MNR;3O0I;3OW6;3OWB;3OWD;3Q6M;3Q6N;3QDD;3QTF;3R4M;3R4N;3R4O;3R4P;3R91;3R92;3RKZ;3RLP;3RLQ;3RLR;3T0H;3T0Z;3T10;3T1K;3T2S;3TUH;3VHA;3VHC;3VHD;3WHA;3WQ9;4AIF;4AWO;4AWP;4AWQ;4B7P;4BQG;4BQJ;4CGQ;4CGU;4CGV;4CGW;4CWF;4CWN;4CWO;4CWP;4CWQ;4CWR;4CWS;4CWT;4EEH;4EFT;4EFU;4EGH;4EGI;4EGK;4FCP;4FCQ;4FCR;4HY6;4JQL;4L8Z;4L90;4L91;4L93;4L94;4LWE;4LWF;4LWG;4LWH;4LWI;4NH7;4NH8;4O04;4O05;4O07;4O09;4O0B;4R3M;4U93;4W7T;4XIP;4XIQ;4XIR;4XIT;4YKQ;4YKR;4YKT;4YKU;4YKW;4YKX;4YKY;4YKZ;5CF0;	CHEMBL3880;	P07900;	DB00716;DB00615;		PF02518;PF00183;	IPR003594;IPR019805;IPR001404;IPR020575;IPR020568;	cardiac muscle cell apoptotic process [GO:0010659]; chaperone-mediated autophagy [GO:0061684]; chaperone-mediated protein complex assembly [GO:0051131]; ERBB2 signaling pathway [GO:0038128]; Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096]; G2/M transition of mitotic cell cycle [GO:0000086]; mitochondrial transport [GO:0006839]; neuron migration [GO:0001764]; positive regulation of cardiac muscle contraction [GO:0060452]; positive regulation of cell size [GO:0045793]; positive regulation of lamellipodium assembly [GO:0010592]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; positive regulation of protein import into nucleus, translocation [GO:0033160]; protein import into mitochondrial outer membrane [GO:0045040]; protein refolding [GO:0042026]; protein stabilization [GO:0050821]; protein unfolding [GO:0043335]; receptor-mediated endocytosis [GO:0006898]; regulation of cellular response to heat [GO:1900034]; regulation of nitric-oxide synthase activity [GO:0050999]; regulation of protein complex assembly [GO:0043254]; regulation of protein ubiquitination [GO:0031396]; response to antibiotic [GO:0046677]; response to cocaine [GO:0042220]; response to cold [GO:0009409]; response to drug [GO:0042493]; response to estrogen [GO:0043627]; response to heat [GO:0009408]; response to salt stress [GO:0009651]; response to unfolded protein [GO:0006986]; signal transduction [GO:0007165]; skeletal muscle contraction [GO:0003009]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]	ATPase activity [GO:0016887]; ATP binding [GO:0005524]; CTP binding [GO:0002135]; dATP binding [GO:0032564]; glycoprotein binding [GO:0001948]; GTPase binding [GO:0051020]; GTP binding [GO:0005525]; histone deacetylase binding [GO:0042826]; identical protein binding [GO:0042802]; MHC class II protein complex binding [GO:0023026]; mRNA binding [GO:0003729]; nitric-oxide synthase regulator activity [GO:0030235]; nucleotide binding [GO:0000166]; poly(A) RNA binding [GO:0044822]; protein homodimerization activity [GO:0042803]; protein tyrosine kinase activity [GO:0004713]; TPR domain binding [GO:0030911]; UTP binding [GO:0002134]	apical plasma membrane [GO:0016324]; basolateral plasma membrane [GO:0016323]; brush border membrane [GO:0031526]; cell surface [GO:0009986]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; endocytic vesicle lumen [GO:0071682]; extracellular exosome [GO:0070062]; extracellular matrix [GO:0031012]; extracellular region [GO:0005576]; lysosomal lumen [GO:0043202]; melanosome [GO:0042470]; membrane [GO:0016020]; myelin sheath [GO:0043209]; neuronal cell body [GO:0043025]; neuron projection [GO:0043005]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; protein complex [GO:0043234]; ruffle membrane [GO:0032587]; sperm mitochondrial sheath [GO:0097226]; sperm plasma membrane [GO:0097524]
P08238	HS90B_HUMAN	Heat shock protein HSP 90-beta (HSP 90) (Heat shock 84 kDa) (HSP 84) (HSP84)	HSP90AB1 HSP90B HSPC2 HSPCB	1QZ2;1UYM;2L6J;3FWV;3NMQ;3PRY;3UQ3;5FWK;5FWL;5FWM;	CHEMBL4303;	P08238;			PF02518;PF00183;	IPR003594;IPR019805;IPR001404;IPR020575;IPR020568;	cellular response to drug [GO:0035690]; cellular response to interleukin-4 [GO:0071353]; cellular response to organic cyclic compound [GO:0071407]; Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096]; fibril organization [GO:0097435]; negative regulation of complement-dependent cytotoxicity [GO:1903660]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of proteasomal ubiquitin-dependent protein catabolic process [GO:0032435]; placenta development [GO:0001890]; positive regulation of cell size [GO:0045793]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; positive regulation of phosphoprotein phosphatase activity [GO:0032516]; positive regulation of protein binding [GO:0032092]; positive regulation of protein import into nucleus, translocation [GO:0033160]; positive regulation of protein serine/threonine kinase activity [GO:0071902]; protein folding [GO:0006457]; protein stabilization [GO:0050821]; regulation of cellular response to heat [GO:1900034]; regulation of interferon-gamma-mediated signaling pathway [GO:0060334]; regulation of protein ubiquitination [GO:0031396]; regulation of type I interferon-mediated signaling pathway [GO:0060338]; response to cocaine [GO:0042220]; response to salt stress [GO:0009651]; response to unfolded protein [GO:0006986]; virion attachment to host cell [GO:0019062]	ATP binding [GO:0005524]; cadherin binding involved in cell-cell adhesion [GO:0098641]; CTP binding [GO:0002135]; dATP binding [GO:0032564]; double-stranded RNA binding [GO:0003725]; drug binding [GO:0008144]; glycoprotein binding [GO:0001948]; GTP binding [GO:0005525]; histone deacetylase binding [GO:0042826]; kinase binding [GO:0019900]; MHC class II protein complex binding [GO:0023026]; nitric-oxide synthase regulator activity [GO:0030235]; poly(A) RNA binding [GO:0044822]; protein kinase regulator activity [GO:0019887]; TPR domain binding [GO:0030911]; UTP binding [GO:0002134]	apical plasma membrane [GO:0016324]; basolateral plasma membrane [GO:0016323]; brush border membrane [GO:0031526]; cell-cell adherens junction [GO:0005913]; cell surface [GO:0009986]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; inclusion body [GO:0016234]; lysosomal membrane [GO:0005765]; melanosome [GO:0042470]; membrane [GO:0016020]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; ooplasm [GO:1990917]; sperm head plasma membrane [GO:1990913]
P0DMV8	HSP71_HUMAN	Heat shock 70 kDa protein 1A (Heat shock 70 kDa protein 1) (HSP70-1) (HSP70.1)	HSPA1A HSPA1 HSX70	1HJO;1S3X;1XQS;2E88;2E8A;2LMG;3A8Y;3ATU;3ATV;3AY9;3D2E;3D2F;3JXU;3LOF;3Q49;4IO8;4J8F;4PO2;4WV5;4WV7;5AQZ;5AR0;5BN8;5BPL;5BPN;	CHEMBL5460;	P0DMV8;			PF00012;	IPR018181;IPR029048;IPR029047;IPR013126;	ATP metabolic process [GO:0046034]; cellular heat acclimation [GO:0070370]; cellular response to heat [GO:0034605]; cellular response to oxidative stress [GO:0034599]; negative regulation of cell death [GO:0060548]; negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway [GO:1902236]; negative regulation of extrinsic apoptotic signaling pathway in absence of ligand [GO:2001240]; negative regulation of inclusion body assembly [GO:0090084]; negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway [GO:1901029]; negative regulation of protein ubiquitination [GO:0031397]; positive regulation of endoribonuclease activity [GO:1902380]; positive regulation of gene expression [GO:0010628]; positive regulation of interleukin-8 production [GO:0032757]; positive regulation of mRNA endonucleolytic cleavage involved in unfolded protein response [GO:1904722]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway [GO:0070434]; positive regulation of tumor necrosis factor-mediated signaling pathway [GO:1903265]; protein refolding [GO:0042026]; protein stabilization [GO:0050821]; regulation of cellular response to heat [GO:1900034]; regulation of mRNA stability [GO:0043488]; regulation of protein ubiquitination [GO:0031396]	ATPase activity [GO:0016887]; ATPase activity, coupled [GO:0042623]; ATP binding [GO:0005524]; C3HC4-type RING finger domain binding [GO:0055131]; cadherin binding involved in cell-cell adhesion [GO:0098641]; enzyme binding [GO:0019899]; G-protein coupled receptor binding [GO:0001664]; heat shock protein binding [GO:0031072]; histone deacetylase binding [GO:0042826]; protein binding involved in protein folding [GO:0044183]; receptor binding [GO:0005102]; ubiquitin protein ligase binding [GO:0031625]; unfolded protein binding [GO:0051082]; virus receptor activity [GO:0001618]	blood microparticle [GO:0072562]; cell-cell adherens junction [GO:0005913]; centriole [GO:0005814]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; focal adhesion [GO:0005925]; inclusion body [GO:0016234]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; perinuclear region of cytoplasm [GO:0048471]
P0DMV9	HSP71_HUMAN	Heat shock 70 kDa protein 1B (Heat shock 70 kDa protein 2) (HSP70-2) (HSP70.2)	HSPA1B	4J8F;		P0DMV9;			PF00012;	IPR018181;IPR029048;IPR029047;IPR013126;	ATP metabolic process [GO:0046034]; cellular heat acclimation [GO:0070370]; cellular response to heat [GO:0034605]; cellular response to oxidative stress [GO:0034599]; negative regulation of cell death [GO:0060548]; negative regulation of extrinsic apoptotic signaling pathway in absence of ligand [GO:2001240]; negative regulation of inclusion body assembly [GO:0090084]; negative regulation of protein ubiquitination [GO:0031397]; positive regulation of gene expression [GO:0010628]; positive regulation of interleukin-8 production [GO:0032757]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway [GO:0070434]; positive regulation of tumor necrosis factor-mediated signaling pathway [GO:1903265]; protein refolding [GO:0042026]; protein stabilization [GO:0050821]; regulation of cellular response to heat [GO:1900034]; regulation of protein ubiquitination [GO:0031396]	ATPase activity [GO:0016887]; ATPase activity, coupled [GO:0042623]; ATP binding [GO:0005524]; C3HC4-type RING finger domain binding [GO:0055131]; enzyme binding [GO:0019899]; G-protein coupled receptor binding [GO:0001664]; heat shock protein binding [GO:0031072]; histone deacetylase binding [GO:0042826]; protein binding involved in protein folding [GO:0044183]; receptor binding [GO:0005102]; ubiquitin protein ligase binding [GO:0031625]; unfolded protein binding [GO:0051082]; virus receptor activity [GO:0001618]	blood microparticle [GO:0072562]; centriole [GO:0005814]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; focal adhesion [GO:0005925]; inclusion body [GO:0016234]; nucleoplasm [GO:0005654]; perinuclear region of cytoplasm [GO:0048471]
P48741	HSP71_HUMAN	Putative heat shock 70 kDa protein 7 (Heat shock 70 kDa protein B)	HSPA7 HSP70B						PF00012;	IPR018181;IPR013126;		ATP binding [GO:0005524]	blood microparticle [GO:0072562]; extracellular exosome [GO:0070062]
Q9BUP3	HTAI2_HUMAN	Oxidoreductase HTATIP2 (EC 1.1.1.-) (30 kDa HIV-1 TAT-interacting protein) (HIV-1 TAT-interactive protein 2)	HTATIP2 CC3 TIP30	2BKA;					PF13460;	IPR016040;	angiogenesis [GO:0001525]; apoptotic process [GO:0006915]; cell differentiation [GO:0030154]; negative regulation of apoptotic process [GO:0043066]; nuclear import [GO:0051170]; regulation of angiogenesis [GO:0045765]; regulation of transcription from RNA polymerase II promoter [GO:0006357]; viral process [GO:0016032]	oxidoreductase activity [GO:0016491]; transcription coactivator activity [GO:0003713]	cytoplasm [GO:0005737]; membrane [GO:0016020]; nuclear envelope [GO:0005635]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P42357	HUTH_HUMAN	Histidine ammonia-lyase (Histidase) (EC 4.3.1.3)	HAL HIS		CHEMBL4003;		DB00117;	PATHWAY: Amino-acid degradation; L-histidine degradation into L-glutamate; N-formimidoyl-L-glutamate from L-histidine: step 1/3.	PF00221;	IPR001106;IPR024083;IPR005921;IPR008948;IPR022313;	histidine catabolic process [GO:0006548]; histidine catabolic process to glutamate and formamide [GO:0019556]; histidine catabolic process to glutamate and formate [GO:0019557]	histidine ammonia-lyase activity [GO:0004397]	cytosol [GO:0005829]
P19367	HXK1_HUMAN	Hexokinase-1 (EC 2.7.1.1) (Brain form hexokinase) (Hexokinase type I) (HK I)	HK1	1CZA;1DGK;1HKB;1HKC;1QHA;4F9O;4FOE;4FOI;4FPA;4FPB;	CHEMBL2688;	P19367;		PATHWAY: Carbohydrate metabolism; hexose metabolism.	PF00349;PF03727;	IPR001312;IPR019807;IPR022673;IPR022672;	canonical glycolysis [GO:0061621]; cellular glucose homeostasis [GO:0001678]; establishment of protein localization to mitochondrion [GO:0072655]; glucose transport [GO:0015758]; glycolytic process [GO:0006096]; maintenance of protein location in mitochondrion [GO:0072656]	ATP binding [GO:0005524]; fructokinase activity [GO:0008865]; glucokinase activity [GO:0004340]; glucose binding [GO:0005536]; hexokinase activity [GO:0004396]; mannokinase activity [GO:0019158]	cytosol [GO:0005829]; membrane raft [GO:0045121]; mitochondrial outer membrane [GO:0005741]; mitochondrion [GO:0005739]; sperm principal piece [GO:0097228]
P35557	HXK4_HUMAN	Glucokinase (EC 2.7.1.2) (Hexokinase type IV) (HK IV) (Hexokinase-4) (HK4) (Hexokinase-D)	GCK	1GLK;1V4S;1V4T;3A0I;3F9M;3FGU;3FR0;3GOI;3H1V;3ID8;3IDH;3IMX;3QIC;3S41;3VEV;3VEY;3VF6;4DCH;4DHY;4ISE;4ISF;4ISG;4IWV;4IXC;4L3Q;4LC9;4MLE;4MLH;4NO7;4RCH;	CHEMBL3820;	P35557;			PF00349;PF03727;	IPR001312;IPR019807;IPR022673;IPR022672;	calcium ion import [GO:0070509]; canonical glycolysis [GO:0061621]; cellular glucose homeostasis [GO:0001678]; cellular response to insulin stimulus [GO:0032869]; cellular response to leptin stimulus [GO:0044320]; detection of glucose [GO:0051594]; glucose homeostasis [GO:0042593]; glucose transport [GO:0015758]; glycolytic process [GO:0006096]; NADP metabolic process [GO:0006739]; negative regulation of gluconeogenesis [GO:0045721]; positive regulation of glycogen biosynthetic process [GO:0045725]; positive regulation of insulin secretion [GO:0032024]; regulation of glucose transport [GO:0010827]; regulation of glycolytic process [GO:0006110]; regulation of insulin secretion [GO:0050796]; regulation of potassium ion transport [GO:0043266]	ATP binding [GO:0005524]; glucokinase activity [GO:0004340]; glucose binding [GO:0005536]	cytosol [GO:0005829]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]
P34913	HYES_HUMAN	Bifunctional epoxide hydrolase 2 [Includes: Cytosolic epoxide hydrolase 2 (CEH) (EC 3.3.2.10) (Epoxide hydratase) (Soluble epoxide hydrolase) (SEH); Lipid-phosphate phosphatase (EC 3.1.3.76)]	EPHX2	1S8O;1VJ5;1ZD2;1ZD3;1ZD4;1ZD5;3ANS;3ANT;3I1Y;3I28;3KOO;3OTQ;3PDC;3WK4;3WK5;3WK6;3WK7;3WK8;3WK9;3WKA;3WKB;3WKC;3WKD;3WKE;4C4X;4C4Y;4C4Z;4HAI;4J03;4JNC;4OCZ;4OD0;4X6X;4X6Y;4Y2J;4Y2P;4Y2Q;4Y2R;4Y2S;4Y2T;4Y2U;4Y2V;4Y2X;4Y2Y;5AHX;5AI0;5AI4;5AI5;5AI6;5AI8;5AI9;5AIA;5AIB;5AIC;5AK3;5AK4;5AK5;5AK6;5AKE;5AKG;5AKH;5AKI;5AKJ;5AKK;5AKL;5AKX;5AKY;5AKZ;5ALD;5ALE;5ALF;5ALG;5ALH;5ALI;5ALJ;5ALK;5ALL;5ALM;5ALN;5ALO;5ALP;5ALQ;5ALR;5ALS;5ALT;5ALU;5ALV;5ALW;5ALX;5ALY;5ALZ;5AM0;5AM1;5AM2;5AM3;5AM4;5AM5;5FP0;	CHEMBL2409;	P34913;			PF00561;PF13419;	IPR029058;IPR000073;IPR000639;IPR023214;IPR006439;IPR011945;IPR023198;	cellular calcium ion homeostasis [GO:0006874]; cholesterol homeostasis [GO:0042632]; dephosphorylation [GO:0016311]; drug metabolic process [GO:0017144]; epoxygenase P450 pathway [GO:0019373]; inflammatory response [GO:0006954]; phospholipid dephosphorylation [GO:0046839]; positive regulation of gene expression [GO:0010628]; positive regulation of vasodilation [GO:0045909]; reactive oxygen species metabolic process [GO:0072593]; regulation of blood pressure [GO:0008217]; regulation of cholesterol metabolic process [GO:0090181]; response to toxic substance [GO:0009636]; stilbene catabolic process [GO:0046272]; xenobiotic metabolic process [GO:0006805]	10-hydroxy-9-(phosphonooxy)octadecanoate phosphatase activity [GO:0033885]; epoxide hydrolase activity [GO:0004301]; lipid phosphatase activity [GO:0042577]; magnesium ion binding [GO:0000287]; phosphatase activity [GO:0016791]; protein homodimerization activity [GO:0042803]; receptor binding [GO:0005102]; toxic substance binding [GO:0015643]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; peroxisome [GO:0005777]
P14902	I23O_HUMAN	Indoleamine 2,3-dioxygenase 1 (IDO-1) (EC 1.13.11.52) (Indoleamine-pyrrole 2,3-dioxygenase)	IDO1 IDO INDO	2D0T;2D0U;4PK5;4PK6;4U72;4U74;5EK2;5EK3;5EK4;5ETW;	CHEMBL4685;	P14902;	DB00150;DB01065;	PATHWAY: Amino-acid degradation; L-tryptophan degradation via kynurenine pathway; L-kynurenine from L-tryptophan: step 1/2.	PF01231;	IPR000898;	cytokine production involved in inflammatory response [GO:0002534]; female pregnancy [GO:0007565]; immune system process [GO:0002376]; kynurenic acid biosynthetic process [GO:0034276]; multicellular organismal response to stress [GO:0033555]; negative regulation of interleukin-10 production [GO:0032693]; negative regulation of T cell apoptotic process [GO:0070233]; negative regulation of T cell proliferation [GO:0042130]; positive regulation of chronic inflammatory response [GO:0002678]; positive regulation of interleukin-12 production [GO:0032735]; positive regulation of T cell apoptotic process [GO:0070234]; positive regulation of T cell tolerance induction [GO:0002666]; positive regulation of type 2 immune response [GO:0002830]; response to lipopolysaccharide [GO:0032496]; swimming behavior [GO:0036269]; tryptophan catabolic process [GO:0006569]; tryptophan catabolic process to kynurenine [GO:0019441]	electron carrier activity [GO:0009055]; heme binding [GO:0020037]; indoleamine 2,3-dioxygenase activity [GO:0033754]; metal ion binding [GO:0046872]; tryptophan 2,3-dioxygenase activity [GO:0004833]	cytosol [GO:0005829]; smooth muscle contractile fiber [GO:0030485]; stereocilium bundle [GO:0032421]
P10997	IAPP_HUMAN	Islet amyloid polypeptide (Amylin) (Diabetes-associated peptide) (DAP) (Insulinoma amyloid peptide)	IAPP	1KUW;2G48;2KB8;2L86;3DG1;3FPO;3FR1;3FTH;3FTK;3FTL;3FTR;3G7V;3G7W;3HGZ;	CHEMBL1914266;				PF00214;	IPR021117;IPR021116;IPR018360;IPR001693;IPR000443;	apoptotic process [GO:0006915]; cell-cell signaling [GO:0007267]; cellular protein metabolic process [GO:0044267]; eating behavior [GO:0042755]; negative regulation of bone resorption [GO:0045779]; negative regulation of cell differentiation [GO:0045596]; sensory perception of pain [GO:0019233]; signal transduction [GO:0007165]	identical protein binding [GO:0042802]; receptor binding [GO:0005102]	extracellular region [GO:0005576]; extracellular space [GO:0005615]; neuronal cell body [GO:0043025]
P05362	ICAM1_HUMAN	Intercellular adhesion molecule 1 (ICAM-1) (Major group rhinovirus receptor) (CD antigen CD54)	ICAM1	1D3E;1D3I;1D3L;1IAM;1IC1;1IJ4;1MQ8;1P53;1Z7Z;2OZ4;3TCX;	CHEMBL3070;	P05362;	DB08818;DB00108;		PF03921;	IPR003988;IPR013768;IPR003987;IPR007110;IPR013783;IPR003599;	acute inflammatory response to antigenic stimulus [GO:0002438]; adhesion of symbiont to host [GO:0044406]; cell adhesion [GO:0007155]; cell adhesion mediated by integrin [GO:0033627]; cell aging [GO:0007569]; cellular response to alkaloid [GO:0071312]; cellular response to glucose stimulus [GO:0071333]; cellular response to hypoxia [GO:0071456]; cellular response to interleukin-1 [GO:0071347]; cellular response to lipopolysaccharide [GO:0071222]; cellular response to nutrient levels [GO:0031669]; cellular response to tumor necrosis factor [GO:0071356]; establishment of endothelial barrier [GO:0061028]; establishment of Sertoli cell barrier [GO:0097368]; extracellular matrix organization [GO:0030198]; heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules [GO:0007157]; interferon-gamma-mediated signaling pathway [GO:0060333]; leukocyte cell-cell adhesion [GO:0007159]; leukocyte migration [GO:0050900]; membrane to membrane docking [GO:0022614]; negative regulation of calcium ion transport [GO:0051926]; negative regulation of endothelial cell apoptotic process [GO:2000352]; negative regulation of extrinsic apoptotic signaling pathway via death domain receptors [GO:1902042]; ovarian follicle development [GO:0001541]; positive regulation of actin filament polymerization [GO:0030838]; positive regulation of cellular extravasation [GO:0002693]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of GTPase activity [GO:0043547]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of vasoconstriction [GO:0045907]; receptor-mediated virion attachment to host cell [GO:0046813]; regulation of cell adhesion [GO:0030155]; regulation of cell shape [GO:0008360]; regulation of immune response [GO:0050776]; regulation of leukocyte mediated cytotoxicity [GO:0001910]; regulation of ruffle assembly [GO:1900027]; response to amino acid [GO:0043200]; response to amphetamine [GO:0001975]; response to copper ion [GO:0046688]; response to drug [GO:0042493]; response to ethanol [GO:0045471]; response to gonadotropin [GO:0034698]; response to ionizing radiation [GO:0010212]; response to organic cyclic compound [GO:0014070]; response to sulfur dioxide [GO:0010477]; sensory perception of sound [GO:0007605]; T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell [GO:0002291]; T cell antigen processing and presentation [GO:0002457]	integrin binding [GO:0005178]; receptor activity [GO:0004872]; transmembrane signaling receptor activity [GO:0004888]; virus receptor activity [GO:0001618]	cell surface [GO:0009986]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; focal adhesion [GO:0005925]; immunological synapse [GO:0001772]; integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; membrane raft [GO:0045121]; plasma membrane [GO:0005886]
P14735	IDE_HUMAN	Insulin-degrading enzyme (EC 3.4.24.56) (Abeta-degrading protease) (Insulin protease) (Insulinase) (Insulysin)	IDE	2G47;2G48;2G49;2G54;2G56;2JBU;2JG4;2WBY;2WC0;2WK3;2YPU;3CWW;3E4A;3E4Z;3E50;3H44;3HGZ;3N56;3N57;3OFI;3QZ2;4DTT;4DWK;4GS8;4GSC;4GSF;4IFH;4IOF;4LTE;4M1C;4NXO;4PES;4PF7;4PF9;4PFC;4Q5Z;4QIA;4RAL;4RE9;5CJO;	CHEMBL1293287;	P14735;	DB00626;DB00030;		PF00675;PF05193;PF16187;	IPR011249;IPR011237;IPR011765;IPR001431;IPR007863;IPR032632;	beta-amyloid metabolic process [GO:0050435]; bradykinin catabolic process [GO:0010815]; determination of adult lifespan [GO:0008340]; hormone catabolic process [GO:0042447]; insulin catabolic process [GO:1901143]; insulin metabolic process [GO:1901142]; insulin receptor signaling pathway [GO:0008286]; negative regulation of proteolysis [GO:0045861]; positive regulation of protein oligomerization [GO:0032461]; protein heterooligomerization [GO:0051291]; protein homooligomerization [GO:0051260]; protein homotetramerization [GO:0051289]; protein processing [GO:0016485]; proteolysis [GO:0006508]; proteolysis involved in cellular protein catabolic process [GO:0051603]; ubiquitin homeostasis [GO:0010992]	ATPase activity [GO:0016887]; ATP binding [GO:0005524]; beta-amyloid binding [GO:0001540]; beta-endorphin binding [GO:0031626]; glycoprotein binding [GO:0001948]; insulin binding [GO:0043559]; metalloendopeptidase activity [GO:0004222]; peptide binding [GO:0042277]; protein homodimerization activity [GO:0042803]; receptor binding [GO:0005102]; ubiquitin binding [GO:0043130]; virus receptor activity [GO:0001618]; zinc ion binding [GO:0008270]	cell surface [GO:0009986]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; cytosolic proteasome complex [GO:0031597]; extracellular space [GO:0005615]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; peroxisomal matrix [GO:0005782]; peroxisome [GO:0005777]; plasma membrane [GO:0005886]
P50213	IDH3A_HUMAN	Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial (EC 1.1.1.41) (Isocitric dehydrogenase subunit alpha) (NAD(+)-specific ICDH subunit alpha)	IDH3A						PF00180;	IPR019818;IPR001804;IPR004434;IPR024084;	carbohydrate metabolic process [GO:0005975]; tricarboxylic acid cycle [GO:0006099]	isocitrate dehydrogenase (NAD+) activity [GO:0004449]; magnesium ion binding [GO:0000287]; NAD binding [GO:0051287]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; myelin sheath [GO:0043209]; nucleus [GO:0005634]
O43837	IDH3B_HUMAN	Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial (EC 1.1.1.41) (Isocitric dehydrogenase subunit beta) (NAD(+)-specific ICDH subunit beta)	IDH3B						PF00180;	IPR019818;IPR001804;IPR004434;IPR024084;	2-oxoglutarate metabolic process [GO:0006103]; isocitrate metabolic process [GO:0006102]; NADH metabolic process [GO:0006734]; tricarboxylic acid cycle [GO:0006099]	electron carrier activity [GO:0009055]; isocitrate dehydrogenase (NAD+) activity [GO:0004449]; magnesium ion binding [GO:0000287]; NAD binding [GO:0051287]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]
P51553	IDH3G_HUMAN	Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial (EC 1.1.1.41) (Isocitric dehydrogenase subunit gamma) (NAD(+)-specific ICDH subunit gamma)	IDH3G						PF00180;	IPR019818;IPR001804;IPR004434;IPR024084;	carbohydrate metabolic process [GO:0005975]; isocitrate metabolic process [GO:0006102]; tricarboxylic acid cycle [GO:0006099]	ATP binding [GO:0005524]; isocitrate dehydrogenase (NAD+) activity [GO:0004449]; magnesium ion binding [GO:0000287]; NAD binding [GO:0051287]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]
O75874	IDHC_HUMAN	Isocitrate dehydrogenase [NADP] cytoplasmic (IDH) (EC 1.1.1.42) (Cytosolic NADP-isocitrate dehydrogenase) (IDP) (NADP(+)-specific ICDH) (Oxalosuccinate decarboxylase)	IDH1 PICD	1T09;1T0L;3INM;3MAP;3MAR;3MAS;4I3K;4I3L;4KZO;4L03;4L04;4L06;4UMX;4UMY;4XRX;4XS3;5DE1;5K10;5K11;	CHEMBL2007625;	O75874;			PF00180;	IPR019818;IPR004790;IPR024084;	2-oxoglutarate metabolic process [GO:0006103]; female gonad development [GO:0008585]; glutathione metabolic process [GO:0006749]; glyoxylate cycle [GO:0006097]; isocitrate metabolic process [GO:0006102]; NADPH regeneration [GO:0006740]; regulation of phospholipid biosynthetic process [GO:0071071]; regulation of phospholipid catabolic process [GO:0060696]; response to oxidative stress [GO:0006979]; response to steroid hormone [GO:0048545]; tricarboxylic acid cycle [GO:0006099]	(R)-2-hydroxyglutarate dehydrogenase activity [GO:0051990]; cadherin binding involved in cell-cell adhesion [GO:0098641]; isocitrate dehydrogenase (NADP+) activity [GO:0004450]; magnesium ion binding [GO:0000287]; NAD binding [GO:0051287]; NADP binding [GO:0050661]; protein homodimerization activity [GO:0042803]; receptor binding [GO:0005102]	cell-cell adherens junction [GO:0005913]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrion [GO:0005739]; peroxisomal matrix [GO:0005782]; peroxisome [GO:0005777]
P06730	IF4E_HUMAN	Eukaryotic translation initiation factor 4E (eIF-4E) (eIF4E) (eIF-4F 25 kDa subunit) (mRNA cap-binding protein)	EIF4E EIF4EL1 EIF4F	1IPB;1IPC;1WKW;2GPQ;2V8W;2V8X;2V8Y;2W97;3AM7;3TF2;3U7X;4AZA;4BEA;4DT6;4DUM;4TPW;4TQB;4TQC;4UED;5ABI;5EHC;5EI3;5EIR;5EKV;	CHEMBL4848;	P06730;			PF01652;	IPR023398;IPR001040;IPR019770;	behavioral fear response [GO:0001662]; G1/S transition of mitotic cell cycle [GO:0000082]; lung development [GO:0030324]; mRNA export from nucleus [GO:0006406]; negative regulation of neuron differentiation [GO:0045665]; negative regulation of translation [GO:0017148]; nuclear-transcribed mRNA poly(A) tail shortening [GO:0000289]; positive regulation of mitotic cell cycle [GO:0045931]; regulation of translation [GO:0006417]; RNA export from nucleus [GO:0006405]; stem cell population maintenance [GO:0019827]; translational initiation [GO:0006413]; viral process [GO:0016032]	enzyme binding [GO:0019899]; eukaryotic initiation factor 4G binding [GO:0031370]; poly(A) RNA binding [GO:0044822]; repressing transcription factor binding [GO:0070491]; RNA cap binding [GO:0000339]; translation initiation factor activity [GO:0003743]	chromatoid body [GO:0033391]; cytoplasm [GO:0005737]; cytoplasmic mRNA processing body [GO:0000932]; cytoplasmic stress granule [GO:0010494]; cytosol [GO:0005829]; eukaryotic translation initiation factor 4F complex [GO:0016281]; extracellular exosome [GO:0070062]; mRNA cap binding complex [GO:0005845]; perinuclear region of cytoplasm [GO:0048471]; RISC complex [GO:0016442]
P01574	IFNB_HUMAN	Interferon beta (IFN-beta) (Fibroblast interferon)	IFNB1 IFB IFNB	1AU1;					PF00143;	IPR009079;IPR012351;IPR000471;IPR015588;	adaptive immune response [GO:0002250]; B cell activation involved in immune response [GO:0002312]; B cell differentiation [GO:0030183]; B cell proliferation [GO:0042100]; blood coagulation [GO:0007596]; cell surface receptor signaling pathway [GO:0007166]; cellular response to dexamethasone stimulus [GO:0071549]; cellular response to exogenous dsRNA [GO:0071360]; cellular response to interferon-beta [GO:0035458]; cellular response to virus [GO:0098586]; defense response to bacterium [GO:0042742]; defense response to virus [GO:0051607]; humoral immune response [GO:0006959]; natural killer cell activation [GO:0030101]; natural killer cell activation involved in immune response [GO:0002323]; negative regulation of T cell differentiation [GO:0045581]; negative regulation of T-helper 2 cell cytokine production [GO:2000552]; negative regulation of viral genome replication [GO:0045071]; positive regulation of apoptotic signaling pathway [GO:2001235]; positive regulation of innate immune response [GO:0045089]; positive regulation of peptidyl-serine phosphorylation of STAT protein [GO:0033141]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; regulation of MHC class I biosynthetic process [GO:0045343]; regulation of type I interferon-mediated signaling pathway [GO:0060338]; response to exogenous dsRNA [GO:0043330]; response to virus [GO:0009615]; T cell activation involved in immune response [GO:0002286]; type I interferon signaling pathway [GO:0060337]	chloramphenicol O-acetyltransferase activity [GO:0008811]; cytokine activity [GO:0005125]; type I interferon receptor binding [GO:0005132]	extracellular region [GO:0005576]; extracellular space [GO:0005615]
P01579	IFNG_HUMAN	Interferon gamma (IFN-gamma) (Immune interferon)	IFNG	1EKU;1FG9;1FYH;1HIG;3BES;	CHEMBL3286073;	P01579;	DB05676;DB01296;DB01250;		PF00714;	IPR009079;IPR012351;IPR002069;	adaptive immune response [GO:0002250]; antigen processing and presentation [GO:0019882]; apoptotic process [GO:0006915]; CD8-positive, alpha-beta T cell differentiation involved in immune response [GO:0002302]; cell cycle arrest [GO:0007050]; cell surface receptor signaling pathway [GO:0007166]; cellular response to interleukin-18 [GO:0071351]; cellular response to lipopolysaccharide [GO:0071222]; defense response to bacterium [GO:0042742]; defense response to protozoan [GO:0042832]; defense response to virus [GO:0051607]; endoplasmic reticulum unfolded protein response [GO:0030968]; extrinsic apoptotic signaling pathway [GO:0097191]; humoral immune response [GO:0006959]; interferon-gamma-mediated signaling pathway [GO:0060333]; movement of cell or subcellular component [GO:0006928]; negative regulation of epithelial cell differentiation [GO:0030857]; negative regulation of fibroblast proliferation [GO:0048147]; negative regulation of gene expression [GO:0010629]; negative regulation of glomerular mesangial cell proliferation [GO:0072125]; negative regulation of growth of symbiont in host [GO:0044130]; negative regulation of interleukin-17 production [GO:0032700]; negative regulation of myelination [GO:0031642]; negative regulation of smooth muscle cell proliferation [GO:0048662]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; neutrophil apoptotic process [GO:0001781]; neutrophil chemotaxis [GO:0030593]; positive regulation of autophagy [GO:0010508]; positive regulation of calcidiol 1-monooxygenase activity [GO:0060559]; positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation involved in immune response [GO:0032834]; positive regulation of cell proliferation [GO:0008284]; positive regulation of chemokine biosynthetic process [GO:0045080]; positive regulation of epithelial cell migration [GO:0010634]; positive regulation of establishment of protein localization to plasma membrane [GO:0090004]; positive regulation of exosomal secretion [GO:1903543]; positive regulation of fructose 1,6-bisphosphate 1-phosphatase activity [GO:0060550]; positive regulation of fructose 1,6-bisphosphate metabolic process [GO:0060552]; positive regulation of gene expression [GO:0010628]; positive regulation of interleukin-12 biosynthetic process [GO:0045084]; positive regulation of interleukin-12 production [GO:0032735]; positive regulation of interleukin-1 beta secretion [GO:0050718]; positive regulation of interleukin-23 production [GO:0032747]; positive regulation of interleukin-6 biosynthetic process [GO:0045410]; positive regulation of isotype switching to IgG isotypes [GO:0048304]; positive regulation of killing of cells of other organism [GO:0051712]; positive regulation of membrane protein ectodomain proteolysis [GO:0051044]; positive regulation of MHC class II biosynthetic process [GO:0045348]; positive regulation of neuron differentiation [GO:0045666]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; positive regulation of osteoclast differentiation [GO:0045672]; positive regulation of peptidyl-serine phosphorylation of STAT protein [GO:0033141]; positive regulation of smooth muscle cell apoptotic process [GO:0034393]; positive regulation of synaptic transmission, cholinergic [GO:0032224]; positive regulation of T cell proliferation [GO:0042102]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of tumor necrosis factor (ligand) superfamily member 11 production [GO:2000309]; positive regulation of tumor necrosis factor production [GO:0032760]; positive regulation of tyrosine phosphorylation of Stat1 protein [GO:0042511]; positive regulation of vitamin D biosynthetic process [GO:0060557]; protein import into nucleus, translocation [GO:0000060]; regulation of glial cell proliferation [GO:0060251]; regulation of hepatocyte proliferation [GO:2000345]; regulation of insulin secretion [GO:0050796]; regulation of interferon-gamma-mediated signaling pathway [GO:0060334]; regulation of neuronal action potential [GO:0098908]; regulation of the force of heart contraction [GO:0002026]; response to drug [GO:0042493]; response to virus [GO:0009615]; sensory perception of mechanical stimulus [GO:0050954]; T cell receptor signaling pathway [GO:0050852]	cytokine activity [GO:0005125]; interferon-gamma receptor binding [GO:0005133]	cytoplasm [GO:0005737]; external side of plasma membrane [GO:0009897]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; neuron projection [GO:0043005]; perikaryon [GO:0043204]
P08069	IGF1R_HUMAN	Insulin-like growth factor 1 receptor (EC 2.7.10.1) (Insulin-like growth factor I receptor) (IGF-I receptor) (CD antigen CD221) [Cleaved into: Insulin-like growth factor 1 receptor alpha chain; Insulin-like growth factor 1 receptor beta chain]	IGF1R	1IGR;1JQH;1K3A;1M7N;1P4O;2OJ9;2ZM3;3D94;3F5P;3I81;3LVP;3LW0;3NW5;3NW6;3NW7;3O23;3QQU;4D2R;4XSS;5HZN;	CHEMBL1957;	P08069;	DB00047;DB00046;DB00030;DB01277;		PF00757;PF07714;PF01030;	IPR003961;IPR006211;IPR006212;IPR009030;IPR013783;IPR011009;IPR032675;IPR000719;IPR017441;IPR000494;IPR001245;IPR008266;IPR020635;IPR016246;IPR002011;	immune response [GO:0006955]; inactivation of MAPKK activity [GO:0051389]; insulin-like growth factor receptor signaling pathway [GO:0048009]; insulin receptor signaling pathway [GO:0008286]; negative regulation of apoptotic process [GO:0043066]; peptidyl-tyrosine autophosphorylation [GO:0038083]; phosphatidylinositol 3-kinase signaling [GO:0014065]; phosphatidylinositol-mediated signaling [GO:0048015]; positive regulation of cell migration [GO:0030335]; positive regulation of cell proliferation [GO:0008284]; positive regulation of DNA replication [GO:0045740]; protein autophosphorylation [GO:0046777]; protein tetramerization [GO:0051262]; regulation of JNK cascade [GO:0046328]; signal transduction [GO:0007165]	ATP binding [GO:0005524]; insulin binding [GO:0043559]; insulin-like growth factor-activated receptor activity [GO:0005010]; insulin-like growth factor binding [GO:0005520]; insulin-like growth factor I binding [GO:0031994]; insulin receptor binding [GO:0005158]; insulin receptor substrate binding [GO:0043560]; phosphatidylinositol 3-kinase binding [GO:0043548]; protein tyrosine kinase activity [GO:0004713]	alphav-beta3 integrin-IGF-1-IGF1R complex [GO:0035867]; integral component of plasma membrane [GO:0005887]; intracellular membrane-bounded organelle [GO:0043231]; membrane [GO:0016020]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]
P01854	IGHE_HUMAN	Ig epsilon chain C region	IGHE	1F6A;1FP5;1G84;1IGE;1O0V;2WQR;2Y7Q;3H9Y;3H9Z;3HA0;4EZM;4GKO;4GRG;4GT7;4J4P;4KI1;5ANM;5HYS;	CHEMBL1834;				PF07654;	IPR007110;IPR013783;IPR003006;IPR003597;	B cell receptor signaling pathway [GO:0050853]; complement activation, classical pathway [GO:0006958]; defense response to bacterium [GO:0042742]; Fc-epsilon receptor signaling pathway [GO:0038095]; immune response [GO:0006955]; innate immune response [GO:0045087]; phagocytosis, engulfment [GO:0006911]; phagocytosis, recognition [GO:0006910]; positive regulation of B cell activation [GO:0050871]	antigen binding [GO:0003823]; immunoglobulin receptor binding [GO:0034987]	blood microparticle [GO:0072562]; external side of plasma membrane [GO:0009897]; extracellular region [GO:0005576]; immunoglobulin complex, circulating [GO:0042571]
P01857	IGHG1_HUMAN	Ig gamma-1 chain C region	IGHG1	1AJ7;1AQK;1BEY;1D5B;1D5I;1D6V;1DFB;1DN2;1E4K;1FC1;1FC2;1FCC;1GAF;1H3T;1H3U;1H3V;1H3W;1H3X;1H3Y;1HKL;1HZH;1I7Z;1L6X;1N7M;1OP3;1OQO;1OQX;1T83;1T89;1VGE;2DTS;2GJ7;2I5Y;2IWG;2J6E;2JB5;2JB6;2O5X;2O5Y;2O5Z;2OSL;2QAD;2QL1;2QQK;2QQL;2QQN;2QR0;2R56;2RCJ;2RCS;2VXQ;2WAH;3AGV;3AVE;3AY4;3B2U;3B2V;3BDY;3BE1;3BKY;3BN9;3BQU;3C08;3C09;3C2S;3CFJ;3CFK;3CSY;3D0L;3D0V;3D6G;3D85;3DJ9;3DNK;3DO3;3DRO;3DRQ;3DVG;3DVN;3EYF;3EYO;3EYQ;3FJT;3O11;3RY6;3S7G;3SGJ;3SGK;3TV3;3TWC;3TYG;3U0W;3U7W;3U7Y;3V7M;3V8C;3V95;3WJJ;3WJL;3WKN;3WN5;4ACP;4B7I;4BM7;4BSV;4BSW;4BYH;4CDH;4D9Q;4D9R;4DAG;4DZ8;4EOW;4J12;4KU1;4LLD;4LLM;4LLQ;4N0U;4NQS;4NQT;4NQU;4NWT;4NWU;4O4Y;4O51;4Q6Y;4Q74;4Q7D;4W4N;4W4O;4WI2;4WI3;4WI4;4WI5;4WI6;4WI7;4WI8;4WI9;4X4M;4X98;4X99;4ZNE;5BW7;5D4Q;5D6D;5DI8;5DJ0;5DJ2;5DJ6;5DJ8;5DJA;5DJC;5DJD;5DJX;5DJY;5DJZ;5DK0;5DK2;5DVK;5DVL;5DVM;5DVN;5DVO;5HSF;5IQ7;5IQ9;					PF07654;	IPR007110;IPR013783;IPR003006;IPR003597;	B cell receptor signaling pathway [GO:0050853]; complement activation [GO:0006956]; complement activation, classical pathway [GO:0006958]; defense response to bacterium [GO:0042742]; Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096]; innate immune response [GO:0045087]; phagocytosis, engulfment [GO:0006911]; phagocytosis, recognition [GO:0006910]; positive regulation of B cell activation [GO:0050871]	antigen binding [GO:0003823]; immunoglobulin receptor binding [GO:0034987]; serine-type endopeptidase activity [GO:0004252]	blood microparticle [GO:0072562]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; immunoglobulin complex, circulating [GO:0042571]
O14920	IKKB_HUMAN	Inhibitor of nuclear factor kappa-B kinase subunit beta (I-kappa-B-kinase beta) (IKK-B) (IKK-beta) (IkBKB) (EC 2.7.11.10) (I-kappa-B kinase 2) (IKK2) (Nuclear factor NF-kappa-B inhibitor kinase beta) (NFKBIKB)	IKBKB IKKB	3BRT;3BRV;4E3C;4KIK;	CHEMBL1991;	O14920;	DB06151;DB00945;DB01169;DB00995;DB00244;DB00795;		PF12179;PF00069;	IPR022007;IPR011009;IPR000719;IPR008271;IPR029071;IPR000626;	cellular response to tumor necrosis factor [GO:0071356]; cortical actin cytoskeleton organization [GO:0030866]; establishment of protein localization to plasma membrane [GO:0090002]; Fc-epsilon receptor signaling pathway [GO:0038095]; I-kappaB kinase/NF-kappaB signaling [GO:0007249]; inflammatory response [GO:0006954]; innate immune response [GO:0045087]; interleukin-1-mediated signaling pathway [GO:0070498]; negative regulation of apoptotic process [GO:0043066]; negative regulation of bicellular tight junction assembly [GO:1903347]; negative regulation of myosin-light-chain-phosphatase activity [GO:0035509]; nucleotide-binding oligomerization domain containing signaling pathway [GO:0070423]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; protein phosphorylation [GO:0006468]; regulation of establishment of endothelial barrier [GO:1903140]; regulation of phosphorylation [GO:0042325]; regulation of tumor necrosis factor-mediated signaling pathway [GO:0010803]; response to virus [GO:0009615]; serine phosphorylation of STAT protein [GO:0042501]; stimulatory C-type lectin receptor signaling pathway [GO:0002223]; stress-activated MAPK cascade [GO:0051403]; T cell receptor signaling pathway [GO:0050852]; TRIF-dependent toll-like receptor signaling pathway [GO:0035666]; tumor necrosis factor-mediated signaling pathway [GO:0033209]	ATP binding [GO:0005524]; IkappaB kinase activity [GO:0008384]; protein heterodimerization activity [GO:0046982]; protein homodimerization activity [GO:0042803]; protein kinase activity [GO:0004672]; protein kinase binding [GO:0019901]; protein serine/threonine kinase activity [GO:0004674]; scaffold protein binding [GO:0097110]	CD40 receptor complex [GO:0035631]; cytoplasm [GO:0005737]; cytoplasmic side of plasma membrane [GO:0009898]; cytosol [GO:0005829]; IkappaB kinase complex [GO:0008385]; membrane raft [GO:0045121]; nucleus [GO:0005634]
P29460	IL12B_HUMAN	Interleukin-12 subunit beta (IL-12B) (Cytotoxic lymphocyte maturation factor 40 kDa subunit) (CLMF p40) (IL-12 subunit p40) (NK cell stimulatory factor chain 2) (NKSF2)	IL12B NKSF2	1F42;1F45;3D85;3D87;3DUH;3HMX;3QWR;4GRW;4OE8;4OG9;	CHEMBL2364154;		DB05679;		PF10420;	IPR003961;IPR003530;IPR007110;IPR013783;IPR003598;IPR015528;IPR019482;	cell cycle arrest [GO:0007050]; cell migration [GO:0016477]; cellular response to interferon-gamma [GO:0071346]; cellular response to lipopolysaccharide [GO:0071222]; defense response to Gram-negative bacterium [GO:0050829]; defense response to protozoan [GO:0042832]; defense response to virus [GO:0051607]; interferon-gamma biosynthetic process [GO:0042095]; natural killer cell activation [GO:0030101]; natural killer cell activation involved in immune response [GO:0002323]; negative regulation of growth of symbiont in host [GO:0044130]; negative regulation of inflammatory response to antigenic stimulus [GO:0002862]; negative regulation of interleukin-10 production [GO:0032693]; negative regulation of interleukin-17 production [GO:0032700]; negative regulation of smooth muscle cell proliferation [GO:0048662]; positive regulation of activated T cell proliferation [GO:0042104]; positive regulation of activation of JAK2 kinase activity [GO:0010535]; positive regulation of cell adhesion [GO:0045785]; positive regulation of defense response to virus by host [GO:0002230]; positive regulation of granulocyte macrophage colony-stimulating factor production [GO:0032725]; positive regulation of inflammatory response [GO:0050729]; positive regulation of interferon-gamma biosynthetic process [GO:0045078]; positive regulation of interferon-gamma production [GO:0032729]; positive regulation of interleukin-10 production [GO:0032733]; positive regulation of interleukin-12 production [GO:0032735]; positive regulation of interleukin-17 production [GO:0032740]; positive regulation of lymphocyte proliferation [GO:0050671]; positive regulation of memory T cell differentiation [GO:0043382]; positive regulation of mononuclear cell proliferation [GO:0032946]; positive regulation of natural killer cell activation [GO:0032816]; positive regulation of natural killer cell mediated cytotoxicity directed against tumor cell target [GO:0002860]; positive regulation of natural killer cell proliferation [GO:0032819]; positive regulation of NF-kappaB import into nucleus [GO:0042346]; positive regulation of NK T cell activation [GO:0051135]; positive regulation of NK T cell proliferation [GO:0051142]; positive regulation of osteoclast differentiation [GO:0045672]; positive regulation of smooth muscle cell apoptotic process [GO:0034393]; positive regulation of T cell mediated cytotoxicity [GO:0001916]; positive regulation of T cell proliferation [GO:0042102]; positive regulation of T-helper 17 cell lineage commitment [GO:2000330]; positive regulation of T-helper 17 type immune response [GO:2000318]; positive regulation of T-helper 1 type immune response [GO:0002827]; positive regulation of tissue remodeling [GO:0034105]; positive regulation of tumor necrosis factor production [GO:0032760]; positive regulation of tyrosine phosphorylation of Stat3 protein [GO:0042517]; positive regulation of tyrosine phosphorylation of Stat4 protein [GO:0042520]; positive regulation of tyrosine phosphorylation of Stat5 protein [GO:0042523]; regulation of cytokine biosynthetic process [GO:0042035]; regulation of tyrosine phosphorylation of Stat1 protein [GO:0042510]; response to UV-B [GO:0010224]; sensory perception of pain [GO:0019233]; sexual reproduction [GO:0019953]; T-helper 1 type immune response [GO:0042088]; T-helper cell differentiation [GO:0042093]	cytokine receptor activity [GO:0004896]; interleukin-12 alpha subunit binding [GO:0042164]; interleukin-12 receptor binding [GO:0005143]; protein heterodimerization activity [GO:0046982]	cytoplasm [GO:0005737]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; interleukin-12 complex [GO:0043514]; interleukin-23 complex [GO:0070743]; membrane [GO:0016020]
P01584	IL1B_HUMAN	Interleukin-1 beta (IL-1 beta) (Catabolin)	IL1B IL1F2	1HIB;1I1B;1IOB;1ITB;1L2H;1S0L;1T4Q;1TOO;1TP0;1TWE;1TWM;21BI;2I1B;2KH2;2NVH;31BI;3LTQ;3O4O;3POK;41BI;4DEP;4G6J;4G6M;4GAF;4GAI;4I1B;5BVP;5I1B;6I1B;7I1B;9ILB;	CHEMBL1909490;	P01584;	DB06168;DB05260;DB01017;DB06372;		PF00340;PF02394;	IPR008996;IPR003294;IPR003296;IPR020877;IPR000975;IPR028142;IPR003502;	activation of MAPK activity [GO:0000187]; apoptotic process [GO:0006915]; cell-cell signaling [GO:0007267]; cellular response to drug [GO:0035690]; cellular response to mechanical stimulus [GO:0071260]; cellular response to organic cyclic compound [GO:0071407]; cellular response to organic substance [GO:0071310]; cytokine-mediated signaling pathway [GO:0019221]; ectopic germ cell programmed cell death [GO:0035234]; embryo implantation [GO:0007566]; extrinsic apoptotic signaling pathway in absence of ligand [GO:0097192]; fever generation [GO:0001660]; hyaluronan biosynthetic process [GO:0030213]; immune response [GO:0006955]; inflammatory response [GO:0006954]; interleukin-1 beta production [GO:0032611]; lipopolysaccharide-mediated signaling pathway [GO:0031663]; MAPK cascade [GO:0000165]; monocyte aggregation [GO:0070487]; negative regulation of adiponectin secretion [GO:0070164]; negative regulation of cell proliferation [GO:0008285]; negative regulation of extrinsic apoptotic signaling pathway in absence of ligand [GO:2001240]; negative regulation of glucose transport [GO:0010829]; negative regulation of insulin receptor signaling pathway [GO:0046627]; negative regulation of lipid catabolic process [GO:0050995]; negative regulation of lipid metabolic process [GO:0045833]; negative regulation of MAP kinase activity [GO:0043407]; neutrophil chemotaxis [GO:0030593]; positive regulation of angiogenesis [GO:0045766]; positive regulation of calcidiol 1-monooxygenase activity [GO:0060559]; positive regulation of cell adhesion molecule production [GO:0060355]; positive regulation of cell division [GO:0051781]; positive regulation of chemokine biosynthetic process [GO:0045080]; positive regulation of fever generation [GO:0031622]; positive regulation of gene expression [GO:0010628]; positive regulation of granulocyte macrophage colony-stimulating factor production [GO:0032725]; positive regulation of heterotypic cell-cell adhesion [GO:0034116]; positive regulation of histone acetylation [GO:0035066]; positive regulation of histone phosphorylation [GO:0033129]; positive regulation of interferon-gamma production [GO:0032729]; positive regulation of interleukin-2 biosynthetic process [GO:0045086]; positive regulation of interleukin-6 biosynthetic process [GO:0045410]; positive regulation of interleukin-6 production [GO:0032755]; positive regulation of interleukin-6 secretion [GO:2000778]; positive regulation of interleukin-8 production [GO:0032757]; positive regulation of JNK cascade [GO:0046330]; positive regulation of lipid catabolic process [GO:0050996]; positive regulation of membrane protein ectodomain proteolysis [GO:0051044]; positive regulation of mitotic nuclear division [GO:0045840]; positive regulation of monocyte chemotactic protein-1 production [GO:0071639]; positive regulation of myosin light chain kinase activity [GO:0035505]; positive regulation of NF-kappaB import into nucleus [GO:0042346]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; positive regulation of phagocytosis [GO:0050766]; positive regulation of prostaglandin secretion [GO:0032308]; positive regulation of protein export from nucleus [GO:0046827]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of sequence-specific DNA binding transcription factor activity [GO:0051091]; positive regulation of T cell mediated immunity [GO:0002711]; positive regulation of T cell proliferation [GO:0042102]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of vascular endothelial growth factor production [GO:0010575]; positive regulation of vascular endothelial growth factor receptor signaling pathway [GO:0030949]; protein kinase B signaling [GO:0043491]; regulation of establishment of endothelial barrier [GO:1903140]; regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043122]; regulation of insulin secretion [GO:0050796]; regulation of nitric-oxide synthase activity [GO:0050999]; response to ATP [GO:0033198]; response to carbohydrate [GO:0009743]; sequestering of triglyceride [GO:0030730]; signal transduction [GO:0007165]; smooth muscle adaptation [GO:0014805]	cytokine activity [GO:0005125]; interleukin-1 receptor binding [GO:0005149]; protein domain specific binding [GO:0019904]	autophagosome [GO:0005776]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; lysosome [GO:0005764]; secretory granule [GO:0030141]
P32927	IL3RB_HUMAN	Cytokine receptor common subunit beta (CDw131) (GM-CSF/IL-3/IL-5 receptor common beta subunit) (CD antigen CD131)	CSF2RB IL3RB IL5RB	1C8P;1EGJ;1GH7;2GYS;2NA8;2NA9;4NKQ;5DWU;	CHEMBL2364169;		DB00020;		PF09240;PF09294;	IPR003961;IPR003531;IPR013783;IPR011365;IPR015373;IPR015321;	cellular protein metabolic process [GO:0044267]; cellular response to interleukin-3 [GO:0036016]; interleukin-3-mediated signaling pathway [GO:0038156]; interleukin-5-mediated signaling pathway [GO:0038043]; MAPK cascade [GO:0000165]; respiratory gaseous exchange [GO:0007585]; response to lipopolysaccharide [GO:0032496]; signal transduction [GO:0007165]	cytokine receptor activity [GO:0004896]; protein tyrosine kinase activity [GO:0004713]; Ras guanyl-nucleotide exchange factor activity [GO:0005088]; receptor activity [GO:0004872]	granulocyte macrophage colony-stimulating factor receptor complex [GO:0030526]; integral component of plasma membrane [GO:0005887]; intracellular [GO:0005622]; plasma membrane [GO:0005886]
P08700	IL3_HUMAN	Interleukin-3 (IL-3) (Hematopoietic growth factor) (Mast cell growth factor) (MCGF) (Multipotential colony-stimulating factor) (P-cell-stimulating factor)	IL3	1JLI;			DB01025;		PF02059;	IPR009079;IPR012351;IPR002183;	cell-cell signaling [GO:0007267]; cytokine-mediated signaling pathway [GO:0019221]; embryonic hemopoiesis [GO:0035162]; immune response [GO:0006955]; MAPK cascade [GO:0000165]; nervous system development [GO:0007399]; positive regulation of cell proliferation [GO:0008284]; positive regulation of DNA replication [GO:0045740]; positive regulation of mast cell proliferation [GO:0070668]; positive regulation of myeloid leukocyte differentiation [GO:0002763]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of tyrosine phosphorylation of Stat5 protein [GO:0042523]	cytokine activity [GO:0005125]; interleukin-3 receptor binding [GO:0005135]; protein tyrosine kinase activity [GO:0004713]; Ras guanyl-nucleotide exchange factor activity [GO:0005088]	extracellular region [GO:0005576]; extracellular space [GO:0005615]; intracellular [GO:0005622]
P05113	IL5_HUMAN	Interleukin-5 (IL-5) (B-cell differentiation factor I) (Eosinophil differentiation factor) (T-cell replacing factor) (TRF)	IL5	1HUL;3QT2;3VA2;	CHEMBL1169600;	P05113;	DB06612;DB01411;		PF02025;	IPR009079;IPR012351;IPR000186;	cytokine-mediated signaling pathway [GO:0019221]; immune response [GO:0006955]; inflammatory response [GO:0006954]; MAPK cascade [GO:0000165]; positive regulation of B cell proliferation [GO:0030890]; positive regulation of eosinophil differentiation [GO:0045645]; positive regulation of immunoglobulin secretion [GO:0051024]; positive regulation of JAK-STAT cascade [GO:0046427]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of podosome assembly [GO:0071803]; positive regulation of sequence-specific DNA binding transcription factor activity [GO:0051091]; positive regulation of transcription, DNA-templated [GO:0045893]	cytokine activity [GO:0005125]; interleukin-5 receptor binding [GO:0005137]; protein tyrosine kinase activity [GO:0004713]; Ras guanyl-nucleotide exchange factor activity [GO:0005088]	extracellular region [GO:0005576]; extracellular space [GO:0005615]; intracellular [GO:0005622]
P08887	IL6RA_HUMAN	Interleukin-6 receptor subunit alpha (IL-6 receptor subunit alpha) (IL-6R subunit alpha) (IL-6R-alpha) (IL-6RA) (IL-6R 1) (Membrane glycoprotein 80) (gp80) (CD antigen CD126)	IL6R	1N26;1N2Q;1P9M;2ARW;	CHEMBL2364155;		DB06273;		PF00047;PF09240;	IPR003961;IPR003530;IPR007110;IPR013783;IPR003599;IPR003598;IPR013151;IPR015321;	acute-phase response [GO:0006953]; ciliary neurotrophic factor-mediated signaling pathway [GO:0070120]; cytokine-mediated signaling pathway [GO:0019221]; defense response to Gram-negative bacterium [GO:0050829]; defense response to Gram-positive bacterium [GO:0050830]; endocrine pancreas development [GO:0031018]; extrinsic apoptotic signaling pathway [GO:0097191]; hepatic immune response [GO:0002384]; interleukin-6-mediated signaling pathway [GO:0070102]; monocyte chemotaxis [GO:0002548]; negative regulation of collagen biosynthetic process [GO:0032966]; negative regulation of interleukin-8 production [GO:0032717]; neutrophil mediated immunity [GO:0002446]; positive regulation of activation of Janus kinase activity [GO:0010536]; positive regulation of cell proliferation [GO:0008284]; positive regulation of chemokine production [GO:0032722]; positive regulation of interleukin-6 production [GO:0032755]; positive regulation of leukocyte chemotaxis [GO:0002690]; positive regulation of MAPK cascade [GO:0043410]; positive regulation of osteoblast differentiation [GO:0045669]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of smooth muscle cell proliferation [GO:0048661]; positive regulation of tyrosine phosphorylation of Stat3 protein [GO:0042517]; response to cytokine [GO:0034097]	ciliary neurotrophic factor binding [GO:0070119]; enzyme binding [GO:0019899]; interleukin-6 binding [GO:0019981]; interleukin-6 receptor activity [GO:0004915]; protein homodimerization activity [GO:0042803]	apical plasma membrane [GO:0016324]; basolateral plasma membrane [GO:0016323]; cell surface [GO:0009986]; ciliary neurotrophic factor receptor complex [GO:0070110]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; interleukin-6 receptor complex [GO:0005896]; plasma membrane [GO:0005886]
P05231	IL6_HUMAN	Interleukin-6 (IL-6) (B-cell stimulatory factor 2) (BSF-2) (CTL differentiation factor) (CDF) (Hybridoma growth factor) (Interferon beta-2) (IFN-beta-2)	IL6 IFNB2	1ALU;1IL6;1N2Q;1P9M;2IL6;4CNI;4J4L;4NI7;4NI9;4O9H;4ZS7;	CHEMBL1795129;	P05231;	DB01404;DB09036;		PF00489;	IPR009079;IPR012351;IPR003574;IPR030474;IPR030473;	acute-phase response [GO:0006953]; aging [GO:0007568]; bone remodeling [GO:0046849]; branching involved in salivary gland morphogenesis [GO:0060445]; cell growth [GO:0016049]; cell redox homeostasis [GO:0045454]; cellular response to dexamethasone stimulus [GO:0071549]; cellular response to estradiol stimulus [GO:0071392]; cellular response to hepatocyte growth factor stimulus [GO:0035729]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to interleukin-1 [GO:0071347]; cellular response to lipopolysaccharide [GO:0071222]; cellular response to nutrient levels [GO:0031669]; cellular response to prolactin [GO:1990646]; cellular response to tumor necrosis factor [GO:0071356]; cytokine-mediated signaling pathway [GO:0019221]; defense response to Gram-negative bacterium [GO:0050829]; defense response to Gram-positive bacterium [GO:0050830]; defense response to protozoan [GO:0042832]; defense response to virus [GO:0051607]; endocrine pancreas development [GO:0031018]; epithelial cell proliferation involved in salivary gland morphogenesis [GO:0060664]; glucagon secretion [GO:0070091]; glucose homeostasis [GO:0042593]; hepatic immune response [GO:0002384]; humoral immune response [GO:0006959]; inflammatory response [GO:0006954]; interleukin-6-mediated signaling pathway [GO:0070102]; monocyte chemotaxis [GO:0002548]; muscle cell cellular homeostasis [GO:0046716]; negative regulation of apoptotic process [GO:0043066]; negative regulation of bone resorption [GO:0045779]; negative regulation of cell proliferation [GO:0008285]; negative regulation of chemokine biosynthetic process [GO:0045079]; negative regulation of collagen biosynthetic process [GO:0032966]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154]; negative regulation of cytokine secretion [GO:0050710]; negative regulation of fat cell differentiation [GO:0045599]; negative regulation of gluconeogenesis [GO:0045721]; negative regulation of hormone secretion [GO:0046888]; negative regulation of interleukin-1-mediated signaling pathway [GO:2000660]; negative regulation of lipid storage [GO:0010888]; negative regulation of membrane potential [GO:0045837]; negative regulation of muscle organ development [GO:0048635]; negative regulation of neuron death [GO:1901215]; negative regulation of protein kinase activity [GO:0006469]; neuron projection development [GO:0031175]; neutrophil apoptotic process [GO:0001781]; neutrophil mediated immunity [GO:0002446]; platelet activation [GO:0030168]; positive regulation of acute inflammatory response [GO:0002675]; positive regulation of apoptotic process [GO:0043065]; positive regulation of B cell activation [GO:0050871]; positive regulation of cell proliferation [GO:0008284]; positive regulation of cell proliferation in bone marrow [GO:0071864]; positive regulation of chemokine production [GO:0032722]; positive regulation of DNA replication [GO:0045740]; positive regulation of epithelial cell proliferation [GO:0050679]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of gene expression [GO:0010628]; positive regulation of immunoglobulin secretion [GO:0051024]; positive regulation of interleukin-6 production [GO:0032755]; positive regulation of JAK-STAT cascade [GO:0046427]; positive regulation of leukocyte chemotaxis [GO:0002690]; positive regulation of MAPK cascade [GO:0043410]; positive regulation of neuron projection development [GO:0010976]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; positive regulation of osteoblast differentiation [GO:0045669]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of protein import into nucleus, translocation [GO:0033160]; positive regulation of protein kinase B signaling [GO:0051897]; positive regulation of sequence-specific DNA binding transcription factor activity [GO:0051091]; positive regulation of smooth muscle cell proliferation [GO:0048661]; positive regulation of STAT protein import into nucleus [GO:2000366]; positive regulation of T cell proliferation [GO:0042102]; positive regulation of T-helper 2 cell cytokine production [GO:2000553]; positive regulation of T-helper 2 cell differentiation [GO:0045630]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of translation [GO:0045727]; positive regulation of transmission of nerve impulse [GO:0051971]; positive regulation of type B pancreatic cell apoptotic process [GO:2000676]; positive regulation of tyrosine phosphorylation of Stat3 protein [GO:0042517]; regulation of angiogenesis [GO:0045765]; regulation of cell shape [GO:0008360]; regulation of circadian sleep/wake cycle, non-REM sleep [GO:0045188]; regulation of vascular endothelial growth factor production [GO:0010574]; response to amino acid [GO:0043200]; response to antibiotic [GO:0046677]; response to auditory stimulus [GO:0010996]; response to caffeine [GO:0031000]; response to calcium ion [GO:0051592]; response to cold [GO:0009409]; response to drug [GO:0042493]; response to electrical stimulus [GO:0051602]; response to glucocorticoid [GO:0051384]; response to heat [GO:0009408]; response to insulin [GO:0032868]; response to peptidoglycan [GO:0032494]; response to yeast [GO:0001878]; T-helper 17 cell lineage commitment [GO:0072540]	cytokine activity [GO:0005125]; growth factor activity [GO:0008083]; interleukin-6 receptor binding [GO:0005138]	cytoplasm [GO:0005737]; external side of plasma membrane [GO:0009897]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; interleukin-6 receptor complex [GO:0005896]
P10145	IL8_HUMAN	Interleukin-8 (IL-8) (C-X-C motif chemokine 8) (Chemokine (C-X-C motif) ligand 8) (Emoctakin) (Granulocyte chemotactic protein 1) (GCP-1) (Monocyte-derived neutrophil chemotactic factor) (MDNCF) (Monocyte-derived neutrophil-activating peptide) (MONAP) (Neutrophil-activating protein 1) (NAP-1) (Protein 3-10C) (T-cell chemotactic factor) [Cleaved into: MDNCF-a (GCP/IL-8 protein IV) (IL8/NAP1 form I); Interleukin-8 ((Ala-IL-8)77) (GCP/IL-8 protein II) (IL-8(1-77)) (IL8/NAP1 form II) (MDNCF-b); IL-8(5-77); IL-8(6-77) ((Ser-IL-8)72) (GCP/IL-8 protein I) (IL8/NAP1 form III) (Lymphocyte-derived neutrophil-activating factor) (LYNAP) (MDNCF-c) (Neutrophil-activating factor) (NAF); IL-8(7-77) (GCP/IL-8 protein V) (IL8/NAP1 form IV); IL-8(8-77) (GCP/IL-8 protein VI) (IL8/NAP1 form V); IL-8(9-77) (GCP/IL-8 protein III) (IL8/NAP1 form VI)]	CXCL8 IL8	1ICW;1IKL;1IKM;1IL8;1ILP;1ILQ;1QE6;1ROD;2IL8;3IL8;4XDX;5D14;	CHEMBL2157;	P10145;			PF00048;	IPR001089;IPR018048;IPR001811;IPR028469;	angiogenesis [GO:0001525]; calcium-mediated signaling [GO:0019722]; cell cycle arrest [GO:0007050]; cellular response to fibroblast growth factor stimulus [GO:0044344]; cellular response to interleukin-1 [GO:0071347]; cellular response to lipopolysaccharide [GO:0071222]; cellular response to tumor necrosis factor [GO:0071356]; chemokine-mediated signaling pathway [GO:0070098]; chemotaxis [GO:0006935]; embryonic digestive tract development [GO:0048566]; G-protein coupled receptor signaling pathway [GO:0007186]; immune response [GO:0006955]; induction of positive chemotaxis [GO:0050930]; inflammatory response [GO:0006954]; intracellular signal transduction [GO:0035556]; movement of cell or subcellular component [GO:0006928]; negative regulation of cell proliferation [GO:0008285]; negative regulation of G-protein coupled receptor protein signaling pathway [GO:0045744]; neutrophil activation [GO:0042119]; neutrophil chemotaxis [GO:0030593]; PERK-mediated unfolded protein response [GO:0036499]; positive regulation of angiogenesis [GO:0045766]; positive regulation of neutrophil chemotaxis [GO:0090023]; receptor internalization [GO:0031623]; regulation of cell adhesion [GO:0030155]; regulation of entry of bacterium into host cell [GO:2000535]; regulation of single stranded viral RNA replication via double stranded DNA intermediate [GO:0045091]; response to endoplasmic reticulum stress [GO:0034976]; response to molecule of bacterial origin [GO:0002237]; signal transduction [GO:0007165]	chemokine activity [GO:0008009]; interleukin-8 receptor binding [GO:0005153]	extracellular region [GO:0005576]; extracellular space [GO:0005615]; intracellular [GO:0005622]
P51161	ILBP_HUMAN	Gastrotropin (GT) (Fatty acid-binding protein 6) (Ileal lipid-binding protein) (ILBP) (Intestinal 15 kDa protein) (I-15P) (Intestinal bile acid-binding protein) (I-BABP)	FABP6 ILBP ILLBP	1O1U;1O1V;2MM3;5L8I;5L8N;5L8O;			DB02659;			IPR012674;IPR011038;IPR000463;IPR031257;IPR031259;	bile acid and bile salt transport [GO:0015721]; bile acid metabolic process [GO:0008206]; lipid metabolic process [GO:0006629]; negative regulation of cell proliferation [GO:0008285]; triglyceride catabolic process [GO:0019433]	bile acid binding [GO:0032052]; lipid binding [GO:0008289]; transporter activity [GO:0005215]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; membrane [GO:0016020]
P20839	IMDH1_HUMAN	Inosine-5'-monophosphate dehydrogenase 1 (IMP dehydrogenase 1) (IMPD 1) (IMPDH 1) (EC 1.1.1.205) (IMPDH-I)	IMPDH1 IMPD1	1JCN;	CHEMBL1822;	P20839;	DB01033;DB00688;DB01024;DB00811;	PATHWAY: Purine metabolism; XMP biosynthesis via de novo pathway; XMP from IMP: step 1/1. {ECO:0000255|HAMAP-Rule:MF_03156}.	PF00571;PF00478;	IPR013785;IPR000644;IPR005990;IPR015875;IPR001093;	GMP biosynthetic process [GO:0006177]; GTP biosynthetic process [GO:0006183]; lymphocyte proliferation [GO:0046651]; purine ribonucleoside monophosphate biosynthetic process [GO:0009168]	DNA binding [GO:0003677]; IMP dehydrogenase activity [GO:0003938]; metal ion binding [GO:0046872]; nucleic acid binding [GO:0003676]; nucleotide binding [GO:0000166]; RNA binding [GO:0003723]	cell junction [GO:0030054]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P12268	IMDH2_HUMAN	Inosine-5'-monophosphate dehydrogenase 2 (IMP dehydrogenase 2) (IMPD 2) (IMPDH 2) (EC 1.1.1.205) (IMPDH-II)	IMPDH2 IMPD2	1B3O;1NF7;1NFB;	CHEMBL2002;	P12268;	DB01033;DB00688;DB01024;	PATHWAY: Purine metabolism; XMP biosynthesis via de novo pathway; XMP from IMP: step 1/1. {ECO:0000255|HAMAP-Rule:MF_03156}.	PF00571;PF00478;	IPR013785;IPR000644;IPR005990;IPR015875;IPR001093;	cellular response to interleukin-4 [GO:0071353]; GMP biosynthetic process [GO:0006177]; GTP biosynthetic process [GO:0006183]; lymphocyte proliferation [GO:0046651]; protein homotetramerization [GO:0051289]; purine ribonucleoside monophosphate biosynthetic process [GO:0009168]; retina development in camera-type eye [GO:0060041]	DNA binding [GO:0003677]; IMP dehydrogenase activity [GO:0003938]; metal ion binding [GO:0046872]; nucleotide binding [GO:0000166]; RNA binding [GO:0003723]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; nucleus [GO:0005634]; peroxisomal membrane [GO:0005778]
P29218	IMPA1_HUMAN	Inositol monophosphatase 1 (IMP 1) (IMPase 1) (EC 3.1.3.25) (D-galactose 1-phosphate phosphatase) (EC 3.1.3.94) (Inositol-1(or 4)-monophosphatase 1) (Lithium-sensitive myo-inositol monophosphatase A1)	IMPA1 IMPA	1AWB;1IMA;1IMB;1IMC;1IMD;1IME;1IMF;2HHM;4AS4;	CHEMBL1786;	P29218;	DB01356;	PATHWAY: Polyol metabolism; myo-inositol biosynthesis; myo-inositol from D-glucose 6-phosphate: step 2/2.	PF00459;	IPR020583;IPR020552;IPR000760;IPR020550;	inositol biosynthetic process [GO:0006021]; inositol metabolic process [GO:0006020]; inositol phosphate dephosphorylation [GO:0046855]; inositol phosphate metabolic process [GO:0043647]; phosphate-containing compound metabolic process [GO:0006796]; phosphatidylinositol biosynthetic process [GO:0006661]; phosphatidylinositol phosphorylation [GO:0046854]; signal transduction [GO:0007165]	inositol monophosphate 1-phosphatase activity [GO:0008934]; inositol monophosphate 3-phosphatase activity [GO:0052832]; inositol monophosphate 4-phosphatase activity [GO:0052833]; inositol monophosphate phosphatase activity [GO:0052834]; lithium ion binding [GO:0031403]; magnesium ion binding [GO:0000287]; manganese ion binding [GO:0030145]; protein homodimerization activity [GO:0042803]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
O14732	IMPA2_HUMAN	Inositol monophosphatase 2 (IMP 2) (IMPase 2) (EC 3.1.3.25) (Inositol-1(or 4)-monophosphatase 2) (Myo-inositol monophosphatase A2)	IMPA2 IMP.18P	2CZH;2CZI;2CZK;2DDK;2FVZ;	CHEMBL1776;		DB01356;	PATHWAY: Polyol metabolism; myo-inositol biosynthesis; myo-inositol from D-glucose 6-phosphate: step 2/2.	PF00459;	IPR020583;IPR020552;IPR000760;IPR020550;	inositol biosynthetic process [GO:0006021]; inositol metabolic process [GO:0006020]; inositol phosphate dephosphorylation [GO:0046855]; inositol phosphate metabolic process [GO:0043647]; phosphate-containing compound metabolic process [GO:0006796]; phosphatidylinositol phosphorylation [GO:0046854]; signal transduction [GO:0007165]	inositol monophosphate 1-phosphatase activity [GO:0008934]; inositol monophosphate 3-phosphatase activity [GO:0052832]; inositol monophosphate 4-phosphatase activity [GO:0052833]; magnesium ion binding [GO:0000287]; protein homodimerization activity [GO:0042803]	cytoplasm [GO:0005737]; cytosol [GO:0005829]
P49441	INPP_HUMAN	Inositol polyphosphate 1-phosphatase (IPP) (IPPase) (EC 3.1.3.57)	INPP1					PATHWAY: Signal transduction; phosphatidylinositol signaling pathway.	PF00459;	IPR020583;IPR000760;IPR020550;	inositol phosphate dephosphorylation [GO:0046855]; inositol phosphate metabolic process [GO:0043647]; phosphate-containing compound metabolic process [GO:0006796]; phosphatidylinositol phosphorylation [GO:0046854]; signal transduction [GO:0007165]	inositol-1,3,4-trisphosphate 1-phosphatase activity [GO:0052829]; inositol-1,4-bisphosphate 1-phosphatase activity [GO:0004441]; magnesium ion binding [GO:0000287]	cytoplasm [GO:0005737]; cytosol [GO:0005829]
P06213	INSR_HUMAN	Insulin receptor (IR) (EC 2.7.10.1) (CD antigen CD220) [Cleaved into: Insulin receptor subunit alpha; Insulin receptor subunit beta]	INSR	1GAG;1I44;1IR3;1IRK;1P14;1RQQ;2AUH;2B4S;2HR7;2MFR;2Z8C;3BU3;3BU5;3BU6;3EKK;3EKN;3ETA;3W11;3W12;3W13;3W14;4IBM;4OGA;4XLV;4XSS;4XST;4ZXB;5E1S;5HHW;5J3H;	CHEMBL1981;	P06213;	DB01306;DB01307;DB00047;DB01309;DB00046;DB00030;DB01277;		PF00757;PF07714;PF01030;	IPR003961;IPR006211;IPR006212;IPR009030;IPR013783;IPR011009;IPR032675;IPR000719;IPR017441;IPR000494;IPR001245;IPR008266;IPR020635;IPR016246;IPR002011;	activation of MAPK activity [GO:0000187]; activation of protein kinase activity [GO:0032147]; activation of protein kinase B activity [GO:0032148]; adrenal gland development [GO:0030325]; carbohydrate metabolic process [GO:0005975]; cellular response to growth factor stimulus [GO:0071363]; cellular response to insulin stimulus [GO:0032869]; epidermis development [GO:0008544]; exocrine pancreas development [GO:0031017]; glucose homeostasis [GO:0042593]; G-protein coupled receptor signaling pathway [GO:0007186]; heart morphogenesis [GO:0003007]; insulin receptor signaling pathway [GO:0008286]; male gonad development [GO:0008584]; male sex determination [GO:0030238]; peptidyl-tyrosine autophosphorylation [GO:0038083]; peptidyl-tyrosine phosphorylation [GO:0018108]; positive regulation of cell migration [GO:0030335]; positive regulation of cell proliferation [GO:0008284]; positive regulation of developmental growth [GO:0048639]; positive regulation of DNA replication [GO:0045740]; positive regulation of glucose import [GO:0046326]; positive regulation of glycogen biosynthetic process [GO:0045725]; positive regulation of glycolytic process [GO:0045821]; positive regulation of MAPK cascade [GO:0043410]; positive regulation of meiotic cell cycle [GO:0051446]; positive regulation of mitotic nuclear division [GO:0045840]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; positive regulation of protein kinase B signaling [GO:0051897]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of respiratory burst [GO:0060267]; positive regulation of transcription, DNA-templated [GO:0045893]; protein autophosphorylation [GO:0046777]; protein heterotetramerization [GO:0051290]; regulation of embryonic development [GO:0045995]; regulation of female gonad development [GO:2000194]; regulation of transcription, DNA-templated [GO:0006355]; transformation of host cell by virus [GO:0019087]	ATP binding [GO:0005524]; GTP binding [GO:0005525]; insulin-activated receptor activity [GO:0005009]; insulin binding [GO:0043559]; insulin-like growth factor I binding [GO:0031994]; insulin-like growth factor II binding [GO:0031995]; insulin-like growth factor receptor binding [GO:0005159]; insulin receptor substrate binding [GO:0043560]; phosphatidylinositol 3-kinase binding [GO:0043548]; protein tyrosine kinase activity [GO:0004713]; PTB domain binding [GO:0051425]; receptor signaling protein tyrosine kinase activity [GO:0004716]	caveola [GO:0005901]; endosome membrane [GO:0010008]; extracellular exosome [GO:0070062]; insulin receptor complex [GO:0005899]; integral component of plasma membrane [GO:0005887]; intracellular membrane-bounded organelle [GO:0043231]; membrane [GO:0016020]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]
P23677	IP3KA_HUMAN	Inositol-trisphosphate 3-kinase A (EC 2.7.1.127) (Inositol 1,4,5-trisphosphate 3-kinase A) (IP3 3-kinase A) (IP3K A) (InsP 3-kinase A)	ITPKA	1W2C;1W2D;1W2F;4UPU;		P23677;			PF03770;	IPR005522;	actin cytoskeleton organization [GO:0030036]; dendritic spine maintenance [GO:0097062]; inositol metabolic process [GO:0006020]; inositol phosphate metabolic process [GO:0043647]; positive regulation of dendritic spine morphogenesis [GO:0061003]; regulation of synaptic plasticity [GO:0048167]; signal transduction [GO:0007165]	ATP binding [GO:0005524]; calmodulin-dependent protein kinase activity [GO:0004683]; inositol-1,4,5-trisphosphate 3-kinase activity [GO:0008440]	cytosol [GO:0005829]; dendritic spine [GO:0043197]
P10745	IRBP_HUMAN	Retinol-binding protein 3 (Interphotoreceptor retinoid-binding protein) (IRBP) (Interstitial retinol-binding protein)	RBP3				DB00162;		PF03572;	IPR029045;IPR032956;IPR005151;	lipid metabolic process [GO:0006629]; retinoid metabolic process [GO:0001523]; transport [GO:0006810]; visual perception [GO:0007601]	retinal binding [GO:0016918]; retinoid binding [GO:0005501]; retinol binding [GO:0019841]; serine-type peptidase activity [GO:0008236]	extracellular region [GO:0005576]; extracellular space [GO:0005615]; extracellular vesicle [GO:1903561]; interphotoreceptor matrix [GO:0033165]
Q14654	IRK11_HUMAN	ATP-sensitive inward rectifier potassium channel 11 (IKATP) (Inward rectifier K(+) channel Kir6.2) (Potassium channel, inwardly rectifying subfamily J member 11)	KCNJ11		CHEMBL1886;	Q14654;	DB01119;DB00222;DB01016;DB00308;DB00922;DB01154;DB00661;DB01392;		PF01007;	IPR014756;IPR016449;IPR003279;IPR013518;	cellular response to glucose stimulus [GO:0071333]; cellular response to nicotine [GO:0071316]; cellular response to tumor necrosis factor [GO:0071356]; glucose metabolic process [GO:0006006]; negative regulation of insulin secretion [GO:0046676]; neurological system process [GO:0050877]; positive regulation of cation channel activity [GO:2001259]; potassium ion import [GO:0010107]; potassium ion transmembrane transport [GO:0071805]; regulation of cardiac conduction [GO:1903779]; regulation of insulin secretion [GO:0050796]; regulation of membrane potential [GO:0042391]; response to ATP [GO:0033198]; response to drug [GO:0042493]; response to estradiol [GO:0032355]; response to ischemia [GO:0002931]; response to testosterone [GO:0033574]; transmembrane transport [GO:0055085]	ankyrin binding [GO:0030506]; ATP-activated inward rectifier potassium channel activity [GO:0015272]; ATP binding [GO:0005524]; ion channel binding [GO:0044325]; potassium ion binding [GO:0030955]; voltage-gated potassium channel activity [GO:0005249]	ATP-sensitive potassium channel complex [GO:0008282]; axolemma [GO:0030673]; cell body fiber [GO:0070852]; cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; endosome [GO:0005768]; integral component of plasma membrane [GO:0005887]; intercalated disc [GO:0014704]; mitochondrion [GO:0005739]; myelin sheath [GO:0043209]; neuronal cell body [GO:0043025]; nuclear envelope [GO:0005635]; plasma membrane [GO:0005886]; T-tubule [GO:0030315]; voltage-gated potassium channel complex [GO:0008076]
Q14500	IRK12_HUMAN	ATP-sensitive inward rectifier potassium channel 12 (Inward rectifier K(+) channel Kir2.2) (IRK-2) (Inward rectifier K(+) channel Kir2.2v) (Potassium channel, inwardly rectifying subfamily J member 12)	KCNJ12 IRK2 KCNJN1				DB00204;DB01392;		PF01007;PF08466;	IPR014756;IPR016449;IPR003272;IPR013518;IPR013673;	cardiac conduction [GO:0061337]; muscle contraction [GO:0006936]; potassium ion import [GO:0010107]; potassium ion transport [GO:0006813]; protein homotetramerization [GO:0051289]; regulation of heart contraction [GO:0008016]	G-protein activated inward rectifier potassium channel activity [GO:0015467]; inward rectifier potassium channel activity [GO:0005242]	integral component of plasma membrane [GO:0005887]; intrinsic component of membrane [GO:0031224]; plasma membrane [GO:0005886]
P48048	IRK1_HUMAN	ATP-sensitive inward rectifier potassium channel 1 (ATP-regulated potassium channel ROM-K) (Inward rectifier K(+) channel Kir1.1) (Potassium channel, inwardly rectifying subfamily J member 1)	KCNJ1 ROMK1		CHEMBL1293292;	P48048;	DB00217;DB00222;DB01016;DB01382;DB00350;DB00839;DB01124;DB01392;		PF01007;	IPR014756;IPR016449;IPR003268;IPR013518;	excretion [GO:0007588]; potassium ion import [GO:0010107]; potassium ion transport [GO:0006813]	ATP-activated inward rectifier potassium channel activity [GO:0015272]; ATP binding [GO:0005524]; inward rectifier potassium channel activity [GO:0005242]; phosphatidylinositol-4,5-bisphosphate binding [GO:0005546]	plasma membrane [GO:0005886]; voltage-gated potassium channel complex [GO:0008076]
P48549	IRK3_HUMAN	G protein-activated inward rectifier potassium channel 1 (GIRK-1) (Inward rectifier K(+) channel Kir3.1) (Potassium channel, inwardly rectifying subfamily J member 3)	KCNJ3 GIRK1		CHEMBL3038489;	P48549;	DB00898;DB01159;		PF01007;	IPR014756;IPR016449;IPR003274;IPR013518;	potassium ion import [GO:0010107]; potassium ion transport [GO:0006813]; response to electrical stimulus [GO:0051602]	G-protein activated inward rectifier potassium channel activity [GO:0015467]	external side of plasma membrane [GO:0009897]; plasma membrane [GO:0005886]; T-tubule [GO:0030315]; voltage-gated potassium channel complex [GO:0008076]
P48544	IRK5_HUMAN	G protein-activated inward rectifier potassium channel 4 (GIRK-4) (Cardiac inward rectifier) (CIR) (Heart KATP channel) (Inward rectifier K(+) channel Kir3.4) (IRK-4) (KATP-1) (Potassium channel, inwardly rectifying subfamily J member 5)	KCNJ5 GIRK4		CHEMBL3038488;	P48544;	DB00898;DB01016;		PF01007;	IPR014756;IPR016449;IPR003277;IPR013518;	potassium ion import [GO:0010107]; potassium ion transport [GO:0006813]	G-protein activated inward rectifier potassium channel activity [GO:0015467]	external side of plasma membrane [GO:0009897]; plasma membrane [GO:0005886]; T-tubule [GO:0030315]; voltage-gated potassium channel complex [GO:0008076]
P48051	IRK6_HUMAN	G protein-activated inward rectifier potassium channel 2 (GIRK-2) (BIR1) (Inward rectifier K(+) channel Kir3.2) (KATP-2) (Potassium channel, inwardly rectifying subfamily J member 6)	KCNJ6 GIRK2 KATP2 KCNJ7		CHEMBL2406895;	P48051;	DB00898;DB01159;		PF01007;	IPR014756;IPR016449;IPR003275;IPR013518;	potassium ion import [GO:0010107]; potassium ion transport [GO:0006813]	G-protein activated inward rectifier potassium channel activity [GO:0015467]; inward rectifier potassium channel activity [GO:0005242]	Golgi apparatus [GO:0005794]; plasma membrane [GO:0005886]; voltage-gated potassium channel complex [GO:0008076]
Q15842	IRK8_HUMAN	ATP-sensitive inward rectifier potassium channel 8 (Inward rectifier K(+) channel Kir6.1) (Potassium channel, inwardly rectifying subfamily J member 8) (uKATP-1)	KCNJ8		CHEMBL4770;		DB01251;DB01289;DB01016;DB00922;DB00914;DB01154;DB01392;		PF01007;	IPR014756;IPR016449;IPR003278;IPR013518;	defense response to virus [GO:0051607]; heart development [GO:0007507]; kidney development [GO:0001822]; potassium ion import [GO:0010107]; potassium ion transport [GO:0006813]; response to exogenous dsRNA [GO:0043330]; response to lipopolysaccharide [GO:0032496]; response to pH [GO:0009268]; vasodilation [GO:0042311]	ATP-activated inward rectifier potassium channel activity [GO:0015272]; ATP binding [GO:0005524]; inward rectifier potassium channel activity [GO:0005242]	ATP-sensitive potassium channel complex [GO:0008282]; mitochondrion [GO:0005739]; myofibril [GO:0030016]; plasma membrane [GO:0005886]; sarcolemma [GO:0042383]; voltage-gated potassium channel complex [GO:0008076]
Q96AZ6	ISG20_HUMAN	Interferon-stimulated gene 20 kDa protein (EC 3.1.13.1) (Estrogen-regulated transcript 45 protein) (Promyelocytic leukemia nuclear body-associated protein ISG20)	ISG20 HEM45	1WLJ;					PF00929;	IPR013520;IPR012337;	cell proliferation [GO:0008283]; defense response to virus [GO:0051607]; DNA catabolic process, exonucleolytic [GO:0000738]; negative regulation of viral genome replication [GO:0045071]; response to virus [GO:0009615]; RNA catabolic process [GO:0006401]; rRNA processing [GO:0006364]; type I interferon signaling pathway [GO:0060337]	3'-5'-exoribonuclease activity [GO:0000175]; exonuclease activity [GO:0004527]; exoribonuclease II activity [GO:0008859]; metal ion binding [GO:0046872]; single-stranded DNA 3'-5' exodeoxyribonuclease activity [GO:0008310]; U1 snRNA binding [GO:0030619]; U2 snRNA binding [GO:0030620]; U3 snoRNA binding [GO:0034511]	Cajal body [GO:0015030]; cytoplasm [GO:0005737]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; PML body [GO:0016605]
Q9UKX5	ITA11_HUMAN	Integrin alpha-11	ITGA11 MSTP018		CHEMBL5883;				PF01839;PF08441;PF00092;	IPR013517;IPR013519;IPR000413;IPR013649;IPR032695;IPR002035;	cell adhesion [GO:0007155]; cell adhesion mediated by integrin [GO:0033627]; cell-matrix adhesion [GO:0007160]; collagen-activated signaling pathway [GO:0038065]; extracellular matrix organization [GO:0030198]; integrin-mediated signaling pathway [GO:0007229]; muscle organ development [GO:0007517]; osteoblast differentiation [GO:0001649]; substrate-dependent cell migration [GO:0006929]	collagen binding [GO:0005518]; collagen binding involved in cell-matrix adhesion [GO:0098639]; collagen receptor activity [GO:0038064]; metal ion binding [GO:0046872]	focal adhesion [GO:0005925]; integrin alpha11-beta1 complex [GO:0034681]; integrin complex [GO:0008305]; membrane [GO:0016020]; plasma membrane [GO:0005886]
P08514	ITA2B_HUMAN	Integrin alpha-IIb (GPalpha IIb) (GPIIb) (Platelet membrane glycoprotein IIb) (CD antigen CD41) [Cleaved into: Integrin alpha-IIb heavy chain; Integrin alpha-IIb light chain, form 1; Integrin alpha-IIb light chain, form 2]	ITGA2B GP2B ITGAB	1DPK;1DPQ;1JX5;1KUP;1KUZ;1M8O;1RN0;1S4W;1TYE;1UV9;2K1A;2K9J;2KNC;2MTP;2N9Y;2VC2;2VDK;2VDL;2VDM;2VDN;2VDO;2VDP;2VDQ;2VDR;3FCS;3FCU;3NID;3NIF;3NIG;3T3M;3T3P;3ZDX;3ZDY;3ZDZ;3ZE0;3ZE1;3ZE2;4CAK;4Z7N;4Z7O;4Z7Q;5HDB;	CHEMBL212;	P08514;	DB00054;DB00775;		PF01839;PF00357;PF08441;	IPR013517;IPR013519;IPR000413;IPR013649;IPR018184;IPR032695;	cell adhesion [GO:0007155]; cell-matrix adhesion [GO:0007160]; extracellular matrix organization [GO:0030198]; integrin-mediated signaling pathway [GO:0007229]; platelet aggregation [GO:0070527]; platelet degranulation [GO:0002576]; positive regulation of leukocyte migration [GO:0002687]	extracellular matrix binding [GO:0050840]; identical protein binding [GO:0042802]; metal ion binding [GO:0046872]	blood microparticle [GO:0072562]; cell surface [GO:0009986]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; focal adhesion [GO:0005925]; integral component of plasma membrane [GO:0005887]; integrin complex [GO:0008305]; plasma membrane [GO:0005886]; platelet alpha granule membrane [GO:0031092]
P20701	ITAL_HUMAN	Integrin alpha-L (CD11 antigen-like family member A) (Leukocyte adhesion glycoprotein LFA-1 alpha chain) (LFA-1A) (Leukocyte function-associated molecule 1 alpha chain) (CD antigen CD11a)	ITGAL CD11A	1CQP;1DGQ;1IJ4;1LFA;1MJN;1MQ8;1MQ9;1MQA;1RD4;1T0P;1XDD;1XDG;1XUO;1ZON;1ZOO;1ZOP;2ICA;2K8O;2M3E;2O7N;3BN3;3BQM;3BQN;3E2M;3EOA;3EOB;3F74;3F78;3HI6;3M6F;3TCX;4IXD;5E6R;5E6S;5E6U;	CHEMBL1803;	P20701;	DB00098;DB00095;DB00227;		PF01839;PF00357;PF08441;PF00092;	IPR013517;IPR013519;IPR000413;IPR013649;IPR018184;IPR032695;IPR002035;	cell adhesion [GO:0007155]; cell-matrix adhesion [GO:0007160]; extracellular matrix organization [GO:0030198]; heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules [GO:0007157]; inflammatory response [GO:0006954]; integrin-mediated signaling pathway [GO:0007229]; leukocyte cell-cell adhesion [GO:0007159]; leukocyte migration [GO:0050900]; movement of cell or subcellular component [GO:0006928]; phagocytosis [GO:0006909]; receptor clustering [GO:0043113]; regulation of immune response [GO:0050776]; signal transduction [GO:0007165]; T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell [GO:0002291]	cell adhesion molecule binding [GO:0050839]; ICAM-3 receptor activity [GO:0030369]; metal ion binding [GO:0046872]	cell surface [GO:0009986]; extracellular exosome [GO:0070062]; integrin alphaL-beta2 complex [GO:0034687]; integrin complex [GO:0008305]; membrane [GO:0016020]; plasma membrane [GO:0005886]
P05107	ITB2_HUMAN	Integrin beta-2 (Cell surface adhesion glycoproteins LFA-1/CR3/p150,95 subunit beta) (Complement receptor C3 subunit beta) (CD antigen CD18)	ITGB2 CD18 MFI7	1JX3;1L3Y;1YUK;2JF1;2P26;2P28;2V7D;3K6S;3K71;3K72;4NEH;4NEN;5E6R;5E6S;5E6U;5E6V;5E6W;5E6X;5ES4;	CHEMBL2096661;	P05107;	DB00641;		PF08725;PF07965;PF00362;	IPR015812;IPR015439;IPR014836;IPR012896;IPR002369;IPR032695;IPR016201;IPR002035;	aging [GO:0007568]; apoptotic process [GO:0006915]; cell adhesion [GO:0007155]; cell-cell signaling [GO:0007267]; cell-matrix adhesion [GO:0007160]; cellular extravasation [GO:0045123]; cellular response to low-density lipoprotein particle stimulus [GO:0071404]; endodermal cell differentiation [GO:0035987]; endothelial cell migration [GO:0043542]; extracellular matrix organization [GO:0030198]; heterotypic cell-cell adhesion [GO:0034113]; inflammatory response [GO:0006954]; integrin-mediated signaling pathway [GO:0007229]; leukocyte cell-cell adhesion [GO:0007159]; leukocyte migration [GO:0050900]; leukocyte migration involved in inflammatory response [GO:0002523]; natural killer cell activation [GO:0030101]; neutrophil chemotaxis [GO:0030593]; phagocytosis [GO:0006909]; positive regulation of angiogenesis [GO:0045766]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; receptor clustering [GO:0043113]; receptor internalization [GO:0031623]; regulation of cell shape [GO:0008360]; regulation of immune response [GO:0050776]; regulation of peptidyl-tyrosine phosphorylation [GO:0050730]; toll-like receptor 4 signaling pathway [GO:0034142]	cell adhesion molecule binding [GO:0050839]; glycoprotein binding [GO:0001948]; ICAM-3 receptor activity [GO:0030369]; metal ion binding [GO:0046872]; protein kinase binding [GO:0019901]	cell surface [GO:0009986]; extracellular exosome [GO:0070062]; extracellular vesicle [GO:1903561]; integrin alphaL-beta2 complex [GO:0034687]; integrin complex [GO:0008305]; membrane [GO:0016020]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]
P16144	ITB4_HUMAN	Integrin beta-4 (GP150) (CD antigen CD104)	ITGB4	1QG3;2YRZ;3F7P;3F7Q;3F7R;3FQ4;3FSO;3H6A;4Q58;4WTW;4WTX;					PF03160;PF07974;PF00041;PF07965;PF00362;	IPR003644;IPR013032;IPR013111;IPR003961;IPR013783;IPR015812;IPR012013;IPR012896;IPR002369;IPR016201;IPR002035;	amelogenesis [GO:0097186]; autophagy [GO:0006914]; cell adhesion [GO:0007155]; cell-matrix adhesion [GO:0007160]; cell motility [GO:0048870]; digestive tract development [GO:0048565]; extracellular matrix organization [GO:0030198]; hemidesmosome assembly [GO:0031581]; integrin-mediated signaling pathway [GO:0007229]; mesodermal cell differentiation [GO:0048333]; nail development [GO:0035878]; renal system development [GO:0072001]; response to wounding [GO:0009611]; skin development [GO:0043588]	G-protein coupled receptor binding [GO:0001664]; receptor activity [GO:0004872]	cell junction [GO:0030054]; cell leading edge [GO:0031252]; cell surface [GO:0009986]; extracellular exosome [GO:0070062]; hemidesmosome [GO:0030056]; integrin complex [GO:0008305]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]
Q08881	ITK_HUMAN	Tyrosine-protein kinase ITK/TSK (EC 2.7.10.2) (Interleukin-2-inducible T-cell kinase) (IL-2-inducible T-cell kinase) (Kinase EMT) (T-cell-specific kinase) (Tyrosine-protein kinase Lyk)	ITK EMT LYK	1SM2;1SNU;1SNX;2E6I;2LMJ;2YUQ;3MIY;3MJ1;3MJ2;3QGW;3QGY;3T9T;3V5J;3V5L;3V8T;3V8W;4HCT;4HCU;4HCV;4KIO;4L7S;4M0Y;4M0Z;4M12;4M13;4M14;4M15;4MF0;4MF1;4PP9;4PPA;4PPB;4PPC;4PQN;4QD6;4RFM;	CHEMBL2959;	Q08881;	DB06589;		PF00779;PF00169;PF07714;PF00017;PF00018;	IPR011009;IPR011993;IPR001849;IPR000719;IPR017441;IPR001245;IPR000980;IPR001452;IPR008266;IPR020635;IPR001562;	activation of phospholipase C activity [GO:0007202]; adaptive immune response [GO:0002250]; cellular defense response [GO:0006968]; cytokine production [GO:0001816]; Fc-epsilon receptor signaling pathway [GO:0038095]; innate immune response [GO:0045087]; interferon-gamma production [GO:0032609]; interleukin-4 production [GO:0032633]; intracellular signal transduction [GO:0035556]; NK T cell differentiation [GO:0001865]; peptidyl-tyrosine autophosphorylation [GO:0038083]; regulation of cell proliferation [GO:0042127]; signal transduction [GO:0007165]; T cell activation [GO:0042110]; T cell receptor signaling pathway [GO:0050852]; transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169]	ATP binding [GO:0005524]; metal ion binding [GO:0046872]; non-membrane spanning protein tyrosine kinase activity [GO:0004715]	cell-cell junction [GO:0005911]; cytosol [GO:0005829]; extrinsic component of cytoplasmic side of plasma membrane [GO:0031234]
P26440	IVD_HUMAN	Isovaleryl-CoA dehydrogenase, mitochondrial (IVD) (EC 1.3.8.4)	IVD	1IVH;			DB03147;	PATHWAY: Amino-acid degradation; L-leucine degradation; (S)-3-hydroxy-3-methylglutaryl-CoA from 3-isovaleryl-CoA: step 1/3.	PF00441;PF02770;PF02771;	IPR006089;IPR006091;IPR009075;IPR013786;IPR009100;	branched-chain amino acid catabolic process [GO:0009083]; fatty acid beta-oxidation using acyl-CoA dehydrogenase [GO:0033539]; leucine catabolic process [GO:0006552]; lipid homeostasis [GO:0055088]	electron carrier activity [GO:0009055]; fatty-acyl-CoA binding [GO:0000062]; flavin adenine dinucleotide binding [GO:0050660]; isovaleryl-CoA dehydrogenase activity [GO:0008470]; oxidoreductase activity, acting on the CH-CH group of donors, with a flavin as acceptor [GO:0052890]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
Q9BY66	JAD1D_HUMAN	Lysine-specific demethylase 5D (EC 1.14.11.-) (Histocompatibility Y antigen) (H-Y) (Histone demethylase JARID1D) (Jumonji/ARID domain-containing protein 1D) (Protein SmcY)	KDM5D HY HYA JARID1D KIAA0234 SMCY	2E6R;2YQE;			DB00126;		PF01388;PF02373;PF02375;PF00628;PF08429;PF02928;	IPR001606;IPR003347;IPR003349;IPR013637;IPR019786;IPR004198;IPR011011;IPR001965;IPR019787;IPR013083;	histone H3-K4 demethylation [GO:0034720]; T cell antigen processing and presentation [GO:0002457]	DNA binding [GO:0003677]; histone demethylase activity [GO:0032452]; histone demethylase activity (H3-K4 specific) [GO:0032453]; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors [GO:0016706]; zinc ion binding [GO:0008270]	nucleoplasm [GO:0005654]
O60674	JAK2_HUMAN	Tyrosine-protein kinase JAK2 (EC 2.7.10.2) (Janus kinase 2) (JAK-2)	JAK2	2B7A;2W1I;2XA4;3E62;3E63;3E64;3FUP;3IO7;3IOK;3JY9;3KCK;3KRR;3LPB;3Q32;3RVG;3TJC;3TJD;3UGC;3ZMM;4AQC;4BBE;4BBF;4C61;4C62;4D0W;4D0X;4D1S;4E4M;4E6D;4E6Q;4F08;4F09;4FVP;4FVQ;4FVR;4GFM;4GMY;4HGE;4IVA;4JI9;4JIA;4P7E;4YTC;4YTF;4YTH;4YTI;4Z32;4ZIM;5AEP;5CF4;5CF5;5CF6;5CF8;5I4N;5L3A;	CHEMBL2971;	O60674;	DB08877;DB08895;		PF07714;PF00017;	IPR019749;IPR019748;IPR000299;IPR011009;IPR011993;IPR000719;IPR017441;IPR001245;IPR000980;IPR008266;IPR020635;IPR016251;IPR020693;	actin filament polymerization [GO:0030041]; activation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0006919]; activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway [GO:0097296]; activation of JAK2 kinase activity [GO:0042977]; activation of MAPKK activity [GO:0000186]; adaptive immune response [GO:0002250]; apoptotic process [GO:0006915]; axon regeneration [GO:0031103]; blood coagulation [GO:0007596]; cell differentiation [GO:0030154]; cell migration [GO:0016477]; cytokine-mediated signaling pathway [GO:0019221]; enzyme linked receptor protein signaling pathway [GO:0007167]; erythrocyte differentiation [GO:0030218]; extrinsic apoptotic signaling pathway [GO:0097191]; G-protein coupled receptor signaling pathway [GO:0007186]; growth hormone receptor signaling pathway [GO:0060396]; histone H3-Y41 phosphorylation [GO:0035409]; innate immune response [GO:0045087]; interferon-gamma-mediated signaling pathway [GO:0060333]; interleukin-12-mediated signaling pathway [GO:0035722]; intracellular signal transduction [GO:0035556]; intrinsic apoptotic signaling pathway in response to oxidative stress [GO:0008631]; JAK-STAT cascade [GO:0007259]; JAK-STAT cascade involved in growth hormone signaling pathway [GO:0060397]; mammary gland epithelium development [GO:0061180]; MAPK cascade [GO:0000165]; mesoderm development [GO:0007498]; mineralocorticoid receptor signaling pathway [GO:0031959]; movement of cell or subcellular component [GO:0006928]; negative regulation of cardiac muscle cell apoptotic process [GO:0010667]; negative regulation of cell-cell adhesion [GO:0022408]; negative regulation of cell proliferation [GO:0008285]; negative regulation of DNA binding [GO:0043392]; negative regulation of heart contraction [GO:0045822]; negative regulation of neuron apoptotic process [GO:0043524]; peptidyl-tyrosine autophosphorylation [GO:0038083]; peptidyl-tyrosine phosphorylation [GO:0018108]; platelet-derived growth factor receptor signaling pathway [GO:0048008]; positive regulation of cell activation [GO:0050867]; positive regulation of cell differentiation [GO:0045597]; positive regulation of cell migration [GO:0030335]; positive regulation of cell-substrate adhesion [GO:0010811]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of DNA binding [GO:0043388]; positive regulation of epithelial cell apoptotic process [GO:1904037]; positive regulation of growth factor dependent skeletal muscle satellite cell proliferation [GO:1902728]; positive regulation of growth hormone receptor signaling pathway [GO:0060399]; positive regulation of inflammatory response [GO:0050729]; positive regulation of insulin secretion [GO:0032024]; positive regulation of interleukin-1 beta production [GO:0032731]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; positive regulation of nitric-oxide synthase biosynthetic process [GO:0051770]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of phosphatidylinositol 3-kinase signaling [GO:0014068]; positive regulation of phosphoprotein phosphatase activity [GO:0032516]; positive regulation of protein import into nucleus, translocation [GO:0033160]; positive regulation of sequence-specific DNA binding transcription factor activity [GO:0051091]; positive regulation of tumor necrosis factor production [GO:0032760]; positive regulation of tyrosine phosphorylation of Stat3 protein [GO:0042517]; positive regulation of tyrosine phosphorylation of Stat5 protein [GO:0042523]; positive regulation of vascular smooth muscle cell proliferation [GO:1904707]; protein autophosphorylation [GO:0046777]; protein phosphorylation [GO:0006468]; regulation of apoptotic process [GO:0042981]; regulation of cell proliferation [GO:0042127]; regulation of inflammatory response [GO:0050727]; regulation of interferon-gamma-mediated signaling pathway [GO:0060334]; response to antibiotic [GO:0046677]; response to hydroperoxide [GO:0033194]; response to interleukin-12 [GO:0070671]; response to lipopolysaccharide [GO:0032496]; response to tumor necrosis factor [GO:0034612]; signal transduction [GO:0007165]; STAT protein import into nucleus [GO:0007262]; tumor necrosis factor-mediated signaling pathway [GO:0033209]; tyrosine phosphorylation of Stat1 protein [GO:0042508]; tyrosine phosphorylation of Stat3 protein [GO:0042503]; tyrosine phosphorylation of Stat5 protein [GO:0042506]; tyrosine phosphorylation of STAT protein [GO:0007260]	ATP binding [GO:0005524]; growth hormone receptor binding [GO:0005131]; heme binding [GO:0020037]; histone binding [GO:0042393]; histone kinase activity (H3-Y41 specific) [GO:0035401]; interleukin-12 receptor binding [GO:0005143]; metal ion binding [GO:0046872]; non-membrane spanning protein tyrosine kinase activity [GO:0004715]; protein kinase activity [GO:0004672]; protein kinase binding [GO:0019901]; protein tyrosine kinase activity [GO:0004713]; Ras guanyl-nucleotide exchange factor activity [GO:0005088]; receptor binding [GO:0005102]; SH2 domain binding [GO:0042169]	caveola [GO:0005901]; cytoplasm [GO:0005737]; cytoskeleton [GO:0005856]; cytosol [GO:0005829]; endosome lumen [GO:0031904]; extrinsic component of cytoplasmic side of plasma membrane [GO:0031234]; membrane raft [GO:0045121]; nuclear matrix [GO:0016363]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P05412	JUN_HUMAN	Transcription factor AP-1 (Activator protein 1) (AP1) (Proto-oncogene c-Jun) (V-jun avian sarcoma virus 17 oncogene homolog) (p39)	JUN	1A02;1FOS;1JNM;1JUN;1S9K;1T2K;	CHEMBL4977;	P05412;	DB01169;DB01029;DB00852;DB00570;		PF00170;PF03957;	IPR004827;IPR015558;IPR005643;IPR002112;IPR008917;	aging [GO:0007568]; angiogenesis [GO:0001525]; axon regeneration [GO:0031103]; cellular response to calcium ion [GO:0071277]; cellular response to hormone stimulus [GO:0032870]; cellular response to potassium ion starvation [GO:0051365]; circadian rhythm [GO:0007623]; eyelid development in camera-type eye [GO:0061029]; Fc-epsilon receptor signaling pathway [GO:0038095]; leading edge cell differentiation [GO:0035026]; learning [GO:0007612]; liver development [GO:0001889]; membrane depolarization [GO:0051899]; microglial cell activation [GO:0001774]; monocyte differentiation [GO:0030224]; negative regulation by host of viral transcription [GO:0043922]; negative regulation of cell proliferation [GO:0008285]; negative regulation of DNA binding [GO:0043392]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of protein autophosphorylation [GO:0031953]; negative regulation of transcription, DNA-templated [GO:0045892]; negative regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress [GO:1990441]; outflow tract morphogenesis [GO:0003151]; positive regulation by host of viral transcription [GO:0043923]; positive regulation of cell differentiation [GO:0045597]; positive regulation of DNA replication [GO:0045740]; positive regulation of DNA-templated transcription, initiation [GO:2000144]; positive regulation of endothelial cell proliferation [GO:0001938]; positive regulation of epithelial cell migration [GO:0010634]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of fibroblast proliferation [GO:0048146]; positive regulation of monocyte differentiation [GO:0045657]; positive regulation of neuron apoptotic process [GO:0043525]; positive regulation of pri-miRNA transcription from RNA polymerase II promoter [GO:1902895]; positive regulation of smooth muscle cell proliferation [GO:0048661]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; Ras protein signal transduction [GO:0007265]; regulation of cell cycle [GO:0051726]; regulation of cell death [GO:0010941]; regulation of cell proliferation [GO:0042127]; regulation of sequence-specific DNA binding transcription factor activity [GO:0051090]; release of cytochrome c from mitochondria [GO:0001836]; response to cAMP [GO:0051591]; response to cytokine [GO:0034097]; response to drug [GO:0042493]; response to hydrogen peroxide [GO:0042542]; response to lipopolysaccharide [GO:0032496]; response to mechanical stimulus [GO:0009612]; response to muscle stretch [GO:0035994]; response to radiation [GO:0009314]; SMAD protein import into nucleus [GO:0007184]; SMAD protein signal transduction [GO:0060395]; transforming growth factor beta receptor signaling pathway [GO:0007179]	cAMP response element binding [GO:0035497]; chromatin binding [GO:0003682]; DNA binding [GO:0003677]; enzyme binding [GO:0019899]; GTPase activator activity [GO:0005096]; identical protein binding [GO:0042802]; poly(A) RNA binding [GO:0044822]; RNA polymerase II activating transcription factor binding [GO:0001102]; RNA polymerase II core promoter proximal region sequence-specific DNA binding [GO:0000978]; RNA polymerase II distal enhancer sequence-specific DNA binding [GO:0000980]; RNA polymerase II transcription factor activity, sequence-specific DNA binding [GO:0000981]; R-SMAD binding [GO:0070412]; transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding [GO:0001077]; transcriptional activator activity, RNA polymerase II transcription factor binding [GO:0001190]; transcription coactivator activity [GO:0003713]; transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding [GO:0000982]; transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding [GO:0003705]; transcription factor activity, sequence-specific DNA binding [GO:0003700]; transcription factor binding [GO:0008134]; transcription regulatory region DNA binding [GO:0044212]	cytosol [GO:0005829]; nuclear chromosome [GO:0000228]; nuclear euchromatin [GO:0005719]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; transcriptional repressor complex [GO:0017053]; transcription factor complex [GO:0005667]
P00568	KAD1_HUMAN	Adenylate kinase isoenzyme 1 (AK 1) (EC 2.7.4.3) (EC 2.7.4.6) (ATP-AMP transphosphorylase 1) (ATP:AMP phosphotransferase) (Adenylate monophosphate kinase) (Myokinase)	AK1	1Z83;2C95;	CHEMBL4925;					IPR000850;IPR028582;IPR006267;IPR027417;	ADP biosynthetic process [GO:0006172]; AMP metabolic process [GO:0046033]; ATP metabolic process [GO:0046034]; cell cycle arrest [GO:0007050]; nucleobase-containing small molecule interconversion [GO:0015949]; nucleoside diphosphate phosphorylation [GO:0006165]; nucleoside triphosphate biosynthetic process [GO:0009142]	adenylate kinase activity [GO:0004017]; ATP binding [GO:0005524]; nucleoside diphosphate kinase activity [GO:0004550]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; outer dense fiber [GO:0001520]; plasma membrane [GO:0005886]
Q16773	KAT1_HUMAN	Kynurenine--oxoglutarate transaminase 1 (EC 2.6.1.7) (Cysteine-S-conjugate beta-lyase) (EC 4.4.1.13) (Glutamine transaminase K) (GTK) (Glutamine--phenylpyruvate transaminase) (EC 2.6.1.64) (Kynurenine aminotransferase 1) (Kynurenine aminotransferase I) (KATI) (Kynurenine--oxoglutarate transaminase I)	KYAT1 CCBL1	1W7L;1W7M;1W7N;3FVS;3FVU;3FVX;4WLH;4WLJ;4WP0;	CHEMBL3962;	Q16773;	DB00130;	PATHWAY: Amino-acid degradation; L-kynurenine degradation; kynurenate from L-kynurenine: step 1/2.	PF00155;	IPR004839;IPR015424;IPR015421;IPR015422;	cellular amino acid biosynthetic process [GO:0008652]; cellular modified amino acid metabolic process [GO:0006575]; kynurenine metabolic process [GO:0070189]; L-kynurenine catabolic process [GO:0097053]; L-phenylalanine catabolic process [GO:0006559]; tryptophan catabolic process [GO:0006569]	cysteine-S-conjugate beta-lyase activity [GO:0047804]; glutamine-phenylpyruvate transaminase activity [GO:0047316]; kynurenine-oxoglutarate transaminase activity [GO:0016212]; L-glutamine:pyruvate aminotransferase activity [GO:0047945]; L-phenylalanine:pyruvate aminotransferase activity [GO:0047312]; protein homodimerization activity [GO:0042803]; pyridoxal phosphate binding [GO:0030170]; transaminase activity [GO:0008483]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleoplasm [GO:0005654]
Q6YP21	KAT3_HUMAN	Kynurenine--oxoglutarate transaminase 3 (EC 2.6.1.7) (Cysteine-S-conjugate beta-lyase 2) (EC 4.4.1.13) (Kynurenine aminotransferase 3) (Kynurenine aminotransferase III) (KATIII) (Kynurenine--glyoxylate transaminase) (EC 2.6.1.63) (Kynurenine--oxoglutarate transaminase III)	KYAT3 CCBL2 KAT3		CHEMBL2046260;	Q6YP21;			PF00155;	IPR004839;IPR015424;IPR015421;IPR015422;	2-oxoglutarate metabolic process [GO:0006103]; biosynthetic process [GO:0009058]; cellular amino acid metabolic process [GO:0006520]; kynurenine metabolic process [GO:0070189]	cysteine-S-conjugate beta-lyase activity [GO:0047804]; kynurenine-glyoxylate transaminase activity [GO:0047315]; kynurenine-oxoglutarate transaminase activity [GO:0016212]; poly(A) RNA binding [GO:0044822]; pyridoxal phosphate binding [GO:0030170]	mitochondrion [GO:0005739]
O75600	KBL_HUMAN	2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial (AKB ligase) (EC 2.3.1.29) (Aminoacetone synthase) (Glycine acetyltransferase)	GCAT KBL				DB00145;	PATHWAY: Amino-acid degradation; L-threonine degradation via oxydo-reductase pathway; glycine from L-threonine: step 2/2.	PF00155;	IPR011282;IPR001917;IPR004839;IPR015424;IPR015421;IPR015422;	biosynthetic process [GO:0009058]; cellular amino acid metabolic process [GO:0006520]; L-threonine catabolic process to glycine [GO:0019518]	glycine C-acetyltransferase activity [GO:0008890]; pyridoxal phosphate binding [GO:0030170]	mitochondrial inner membrane [GO:0005743]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]
P78368	KC1G2_HUMAN	Casein kinase I isoform gamma-2 (CKI-gamma 2) (EC 2.7.11.1)	CSNK1G2 CK1G2	2C47;	CHEMBL2543;	P78368;			PF12605;PF00069;	IPR022247;IPR011009;IPR000719;IPR017441;IPR008271;	endocytosis [GO:0006897]; peptidyl-serine phosphorylation [GO:0018105]; protein autophosphorylation [GO:0046777]; protein phosphorylation [GO:0006468]; regulation of cell shape [GO:0008360]; signal transduction [GO:0007165]; sphingolipid biosynthetic process [GO:0030148]; Wnt signaling pathway [GO:0016055]	ATP binding [GO:0005524]; glycoprotein binding [GO:0001948]; magnesium ion binding [GO:0000287]; peptide binding [GO:0042277]; protein serine/threonine kinase activity [GO:0004674]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; membrane [GO:0016020]; nucleus [GO:0005634]
Q9Y691	KCMB2_HUMAN	Calcium-activated potassium channel subunit beta-2 (BK channel subunit beta-2) (BKbeta2) (Hbeta2) (Calcium-activated potassium channel, subfamily M subunit beta-2) (Charybdotoxin receptor subunit beta-2) (Hbeta3) (K(VCA)beta-2) (Maxi K channel subunit beta-2) (Slo-beta-2)	KCNMB2	1JO6;			DB01110;DB00721;		PF03185;PF09303;	IPR003930;IPR015382;	action potential [GO:0001508]; chemical synaptic transmission [GO:0007268]; detection of calcium ion [GO:0005513]; neuronal action potential [GO:0019228]; potassium ion transport [GO:0006813]; regulation of vasoconstriction [GO:0019229]	calcium-activated potassium channel activity [GO:0015269]; ion channel inhibitor activity [GO:0008200]; potassium channel regulator activity [GO:0015459]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; voltage-gated potassium channel complex [GO:0008076]
Q09470	KCNA1_HUMAN	Potassium voltage-gated channel subfamily A member 1 (Voltage-gated K(+) channel HuKI) (Voltage-gated potassium channel HBK1) (Voltage-gated potassium channel subunit Kv1.1)	KCNA1	2AFL;	CHEMBL2309;	Q09470;	DB00321;DB06637;DB01189;DB00228;DB00753;DB01028;DB01115;DB01236;		PF02214;PF00520;	IPR000210;IPR027359;IPR005821;IPR003968;IPR003972;IPR004048;IPR011333;IPR003131;IPR028325;	cell communication by electrical coupling [GO:0010644]; cellular protein localization [GO:0034613]; cellular response to magnesium ion [GO:0071286]; chemical synaptic transmission [GO:0007268]; detection of mechanical stimulus involved in sensory perception of pain [GO:0050966]; detection of mechanical stimulus involved in sensory perception of touch [GO:0050976]; hippocampus development [GO:0021766]; magnesium ion homeostasis [GO:0010960]; neuroblast proliferation [GO:0007405]; neuromuscular process [GO:0050905]; neuronal action potential [GO:0019228]; neuronal signal transduction [GO:0023041]; potassium ion transmembrane transport [GO:0071805]; potassium ion transport [GO:0006813]; protein homooligomerization [GO:0051260]; regulation of membrane potential [GO:0042391]; regulation of muscle contraction [GO:0006937]; startle response [GO:0001964]	delayed rectifier potassium channel activity [GO:0005251]; potassium channel activity [GO:0005267]; potassium ion transmembrane transporter activity [GO:0015079]; voltage-gated potassium channel activity [GO:0005249]	apical plasma membrane [GO:0016324]; axon terminus [GO:0043679]; cell junction [GO:0030054]; cell surface [GO:0009986]; cytoplasmic, membrane-bounded vesicle [GO:0016023]; cytosol [GO:0005829]; dendrite [GO:0030425]; endoplasmic reticulum [GO:0005783]; integral component of plasma membrane [GO:0005887]; juxtaparanode region of axon [GO:0044224]; neuronal cell body [GO:0043025]; paranode region of axon [GO:0033270]; perikaryon [GO:0043204]; plasma membrane [GO:0005886]; presynaptic membrane [GO:0042734]; synapse [GO:0045202]; voltage-gated potassium channel complex [GO:0008076]
Q03721	KCNC4_HUMAN	Potassium voltage-gated channel subfamily C member 4 (KSHIIIC) (Voltage-gated potassium channel subunit Kv3.4)	KCNC4	1B4G;1B4I;1ZTN;	CHEMBL2362996;				PF02214;PF00520;PF11404;	IPR000210;IPR027359;IPR005821;IPR003968;IPR003974;IPR005405;IPR021105;IPR011333;IPR003131;IPR028325;	chemical synaptic transmission [GO:0007268]; potassium ion transport [GO:0006813]; protein homooligomerization [GO:0051260]; regulation of neurotransmitter secretion [GO:0046928]	delayed rectifier potassium channel activity [GO:0005251]; potassium channel activity [GO:0005267]; voltage-gated potassium channel activity [GO:0005249]	axon terminus [GO:0043679]; neuromuscular junction [GO:0031594]; plasma membrane [GO:0005886]; voltage-gated potassium channel complex [GO:0008076]
P15382	KCNE1_HUMAN	Potassium voltage-gated channel subfamily E member 1 (Delayed rectifier potassium channel subunit IsK) (IKs producing slow voltage-gated potassium channel subunit beta Mink) (Minimal potassium channel)	KCNE1	2K21;	CHEMBL4872;	P15382;	DB00808;		PF02060;	IPR000369;IPR005424;	cardiac conduction [GO:0061337]; cardiac muscle cell action potential involved in contraction [GO:0086002]; cellular response to cAMP [GO:0071320]; membrane repolarization [GO:0086009]; membrane repolarization during action potential [GO:0086011]; membrane repolarization during cardiac muscle cell action potential [GO:0086013]; membrane repolarization during ventricular cardiac muscle cell action potential [GO:0098915]; negative regulation of delayed rectifier potassium channel activity [GO:1902260]; negative regulation of protein targeting to membrane [GO:0090315]; positive regulation of potassium ion transmembrane transport [GO:1901381]; potassium ion export [GO:0071435]; potassium ion transmembrane transport [GO:0071805]; protein N-linked glycosylation [GO:0006487]; protein O-linked glycosylation [GO:0006493]; regulation of delayed rectifier potassium channel activity [GO:1902259]; regulation of heart rate by cardiac conduction [GO:0086091]; regulation of potassium ion transmembrane transport [GO:1901379]; regulation of ventricular cardiac muscle cell membrane repolarization [GO:0060307]; sensory perception of sound [GO:0007605]; ventricular cardiac muscle cell action potential [GO:0086005]	delayed rectifier potassium channel activity [GO:0005251]; potassium channel regulator activity [GO:0015459]; telethonin binding [GO:0031433]	apical plasma membrane [GO:0016324]; cell surface [GO:0009986]; lysosome [GO:0005764]; membrane raft [GO:0045121]; plasma membrane [GO:0005886]; voltage-gated potassium channel complex [GO:0008076]; Z disc [GO:0030018]
Q12809	KCNH2_HUMAN	Potassium voltage-gated channel subfamily H member 2 (Eag homolog) (Ether-a-go-go-related gene potassium channel 1) (ERG-1) (Eag-related protein 1) (Ether-a-go-go-related protein 1) (H-ERG) (hERG-1) (hERG1) (Voltage-gated potassium channel subunit Kv11.1)	KCNH2 ERG ERG1 HERG	1BYW;1UJL;2L0W;2L1M;2L4R;2LE7;2N7G;4HP9;4HQA;	CHEMBL240;	Q12809;	DB00346;DB01118;DB00276;DB00637;DB01136;DB00477;DB00537;DB00604;DB01211;DB00204;DB00590;DB01142;DB04855;DB00199;DB01218;DB00308;DB00458;DB01110;DB01100;DB00457;DB01182;DB00908;DB06144;DB00489;DB01162;DB00679;DB00661;		PF00027;PF00520;PF13426;	IPR018490;IPR000595;IPR005821;IPR003938;IPR003967;IPR001610;IPR000014;IPR000700;IPR014710;	cardiac conduction [GO:0061337]; cardiac muscle contraction [GO:0060048]; cellular response to drug [GO:0035690]; membrane depolarization during action potential [GO:0086010]; membrane repolarization during action potential [GO:0086011]; membrane repolarization during cardiac muscle cell action potential [GO:0086013]; membrane repolarization during ventricular cardiac muscle cell action potential [GO:0098915]; negative regulation of potassium ion export [GO:1902303]; negative regulation of potassium ion transmembrane transport [GO:1901380]; positive regulation of potassium ion transmembrane transport [GO:1901381]; potassium ion export [GO:0071435]; potassium ion export across plasma membrane [GO:0097623]; potassium ion homeostasis [GO:0055075]; potassium ion transmembrane transport [GO:0071805]; regulation of heart rate by cardiac conduction [GO:0086091]; regulation of heart rate by hormone [GO:0003064]; regulation of membrane potential [GO:0042391]; regulation of membrane repolarization [GO:0060306]; regulation of potassium ion transmembrane transport [GO:1901379]; regulation of ventricular cardiac muscle cell membrane repolarization [GO:0060307]; ventricular cardiac muscle cell action potential [GO:0086005]	C3HC4-type RING finger domain binding [GO:0055131]; delayed rectifier potassium channel activity [GO:0005251]; identical protein binding [GO:0042802]; inward rectifier potassium channel activity [GO:0005242]; phosphorelay sensor kinase activity [GO:0000155]; protein homodimerization activity [GO:0042803]; scaffold protein binding [GO:0097110]; ubiquitin protein ligase binding [GO:0031625]; voltage-gated potassium channel activity [GO:0005249]; voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization [GO:0086008]; voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization [GO:1902282]	cell surface [GO:0009986]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; voltage-gated potassium channel complex [GO:0008076]
Q9H252	KCNH6_HUMAN	Potassium voltage-gated channel subfamily H member 6 (Ether-a-go-go-related gene potassium channel 2) (ERG-2) (Eag-related protein 2) (Ether-a-go-go-related protein 2) (hERG-2) (hERG2) (Voltage-gated potassium channel subunit Kv11.2)	KCNH6 ERG2		CHEMBL2362996;		DB00590;DB00308;DB01110;DB00457;DB01162;		PF00027;PF00520;PF13426;	IPR018490;IPR000595;IPR005821;IPR003938;IPR003967;IPR030172;IPR000014;IPR014710;	regulation of membrane potential [GO:0042391]	voltage-gated potassium channel activity [GO:0005249]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
Q9NS40	KCNH7_HUMAN	Potassium voltage-gated channel subfamily H member 7 (Ether-a-go-go-related gene potassium channel 3) (ERG-3) (Eag-related protein 3) (Ether-a-go-go-related protein 3) (hERG-3) (Voltage-gated potassium channel subunit Kv11.3)	KCNH7 ERG3		CHEMBL2362996;		DB00590;DB00308;DB01110;DB00457;DB01162;		PF00027;PF00520;PF13426;	IPR018490;IPR000595;IPR005821;IPR003938;IPR003967;IPR000014;IPR014710;	regulation of membrane potential [GO:0042391]	voltage-gated potassium channel activity [GO:0005249]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
O00180	KCNK1_HUMAN	Potassium channel subfamily K member 1 (Inward rectifying potassium channel protein TWIK-1) (Potassium channel K2P1) (Potassium channel KCNO1)	KCNK1 HOHO1 KCNO1 TWIK1	3UKM;			DB00308;DB00908;DB01346;		PF07885;	IPR003280;IPR003092;IPR005408;IPR001779;IPR013099;	cardiac conduction [GO:0061337]; potassium ion transmembrane transport [GO:0071805]; potassium ion transport [GO:0006813]; regulation of resting membrane potential [GO:0060075]; response to nicotine [GO:0035094]; sodium ion transmembrane transport [GO:0035725]; stabilization of membrane potential [GO:0030322]	inward rectifier potassium channel activity [GO:0005242]; potassium channel activity [GO:0005267]; potassium ion leak channel activity [GO:0022841]; sodium channel activity [GO:0005272]	apical plasma membrane [GO:0016324]; brush border membrane [GO:0031526]; cell junction [GO:0030054]; cytoplasmic, membrane-bounded vesicle [GO:0016023]; dendrite [GO:0030425]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; inward rectifier potassium channel complex [GO:1902937]; perikaryon [GO:0043204]; plasma membrane [GO:0005886]; potassium channel complex [GO:0034705]; recycling endosome [GO:0055037]; synapse [GO:0045202]; voltage-gated potassium channel complex [GO:0008076]
O95069	KCNK2_HUMAN	Potassium channel subfamily K member 2 (Outward rectifying potassium channel protein TREK-1) (TREK-1 K(+) channel subunit) (Two pore domain potassium channel TREK-1) (Two pore potassium channel TPKC1)	KCNK2 TREK TREK1	4TWK;	CHEMBL2321615;	O95069;	DB00204;DB04855;		PF07885;	IPR003280;IPR003976;IPR013099;	cardiac ventricle development [GO:0003231]; cellular response to hypoxia [GO:0071456]; cochlea development [GO:0090102]; G-protein coupled receptor signaling pathway [GO:0007186]; memory [GO:0007613]; negative regulation of cardiac muscle cell proliferation [GO:0060044]; negative regulation of DNA biosynthetic process [GO:2000279]; positive regulation of cell death [GO:0010942]; positive regulation of cellular response to hypoxia [GO:1900039]; potassium ion transmembrane transport [GO:0071805]; response to axon injury [GO:0048678]; response to mechanical stimulus [GO:0009612]; stabilization of membrane potential [GO:0030322]	outward rectifier potassium channel activity [GO:0015271]; potassium channel inhibitor activity [GO:0019870]; potassium ion leak channel activity [GO:0022841]	apical plasma membrane [GO:0016324]; astrocyte projection [GO:0097449]; calyx of Held [GO:0044305]; cell surface [GO:0009986]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; integral component of plasma membrane [GO:0005887]; neuronal cell body [GO:0043025]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; voltage-gated potassium channel complex [GO:0008076]
Q9Y257	KCNK6_HUMAN	Potassium channel subfamily K member 6 (Inward rectifying potassium channel protein TWIK-2) (TWIK-originated similarity sequence)	KCNK6 TOSS TWIK2				DB00308;DB00908;		PF07885;	IPR003280;IPR003092;IPR005408;IPR005409;IPR013099;	cardiac conduction [GO:0061337]; negative regulation of systemic arterial blood pressure [GO:0003085]; potassium ion transport [GO:0006813]; regulation of resting membrane potential [GO:0060075]; stabilization of membrane potential [GO:0030322]	inward rectifier potassium channel activity [GO:0005242]; potassium channel activity [GO:0005267]; potassium ion leak channel activity [GO:0022841]	plasma membrane [GO:0005886]; voltage-gated potassium channel complex [GO:0008076]
O15554	KCNN4_HUMAN	Intermediate conductance calcium-activated potassium channel protein 4 (SK4) (SKCa 4) (SKCa4) (IKCa1) (IK1) (KCa3.1) (KCa4) (Putative Gardos channel)	KCNN4 IK1 IKCA1 KCA4 SK4		CHEMBL4305;	O15554;	DB00257;DB00228;DB01159;DB01110;DB00721;DB00468;		PF02888;PF07885;PF03530;	IPR004178;IPR015449;IPR013099;	calcium ion transport [GO:0006816]; cell volume homeostasis [GO:0006884]; defense response [GO:0006952]; immune system process [GO:0002376]; phospholipid translocation [GO:0045332]; positive regulation of protein secretion [GO:0050714]; positive regulation of T cell receptor signaling pathway [GO:0050862]; potassium ion transport [GO:0006813]; saliva secretion [GO:0046541]; stabilization of membrane potential [GO:0030322]	calcium-activated potassium channel activity [GO:0015269]; potassium channel activity [GO:0005267]; protein phosphatase binding [GO:0019903]; small conductance calcium-activated potassium channel activity [GO:0016286]	plasma membrane [GO:0005886]; vesicle [GO:0031982]; voltage-gated potassium channel complex [GO:0008076]
P51787	KCNQ1_HUMAN	Potassium voltage-gated channel subfamily KQT member 1 (IKs producing slow voltage-gated potassium channel subunit alpha KvLQT1) (KQT-like 1) (Voltage-gated potassium channel subunit Kv7.1)	KCNQ1 KCNA8 KCNA9 KVLQT1	3BJ4;3HFC;3HFE;4UMO;4V0C;	CHEMBL1866;	P51787;	DB01244;DB00808;		PF00520;PF03520;	IPR005821;IPR003937;IPR013821;IPR005827;IPR028325;	atrial cardiac muscle cell action potential [GO:0086014]; cardiac conduction [GO:0061337]; cardiac muscle contraction [GO:0060048]; cardiovascular system development [GO:0072358]; cellular response to cAMP [GO:0071320]; cellular response to drug [GO:0035690]; cellular response to epinephrine stimulus [GO:0071872]; gene silencing [GO:0016458]; inner ear development [GO:0048839]; intestinal absorption [GO:0050892]; membrane repolarization during action potential [GO:0086011]; membrane repolarization during cardiac muscle cell action potential [GO:0086013]; membrane repolarization during ventricular cardiac muscle cell action potential [GO:0098915]; negative regulation of delayed rectifier potassium channel activity [GO:1902260]; negative regulation of voltage-gated potassium channel activity [GO:1903817]; positive regulation of cardiac muscle contraction [GO:0060452]; positive regulation of heart rate [GO:0010460]; positive regulation of potassium ion transmembrane transport [GO:1901381]; potassium ion export [GO:0071435]; potassium ion export across plasma membrane [GO:0097623]; potassium ion transmembrane transport [GO:0071805]; regulation of atrial cardiac muscle cell membrane repolarization [GO:0060372]; regulation of gastric acid secretion [GO:0060453]; regulation of gene expression by genetic imprinting [GO:0006349]; regulation of heart contraction [GO:0008016]; regulation of heart rate by cardiac conduction [GO:0086091]; regulation of membrane repolarization [GO:0060306]; regulation of ventricular cardiac muscle cell membrane repolarization [GO:0060307]; renal absorption [GO:0070293]; sensory perception of sound [GO:0007605]; ventricular cardiac muscle cell action potential [GO:0086005]	calmodulin binding [GO:0005516]; delayed rectifier potassium channel activity [GO:0005251]; ion channel binding [GO:0044325]; outward rectifier potassium channel activity [GO:0015271]; phosphatidylinositol-4,5-bisphosphate binding [GO:0005546]; protein kinase A catalytic subunit binding [GO:0034236]; protein kinase A regulatory subunit binding [GO:0034237]; protein phosphatase 1 binding [GO:0008157]; scaffold protein binding [GO:0097110]; voltage-gated potassium channel activity [GO:0005249]; voltage-gated potassium channel activity involved in atrial cardiac muscle cell action potential repolarization [GO:0086089]; voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization [GO:0086008]; voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization [GO:1902282]	basolateral plasma membrane [GO:0016323]; cytoplasm [GO:0005737]; cytoplasmic vesicle membrane [GO:0030659]; early endosome [GO:0005769]; endoplasmic reticulum [GO:0005783]; ion channel complex [GO:0034702]; late endosome [GO:0005770]; lysosome [GO:0005764]; membrane raft [GO:0045121]; plasma membrane [GO:0005886]; voltage-gated potassium channel complex [GO:0008076]
O43526	KCNQ2_HUMAN	Potassium voltage-gated channel subfamily KQT member 2 (KQT-like 2) (Neuroblastoma-specific potassium channel subunit alpha KvLQT2) (Voltage-gated potassium channel subunit Kv7.2)	KCNQ2	5J03;	CHEMBL2476;	O43526;	DB00321;DB00586;DB04953;DB00939;		PF00520;PF03520;PF11956;	IPR020969;IPR005821;IPR003937;IPR003947;IPR013821;IPR028325;	chemical synaptic transmission [GO:0007268]; nervous system development [GO:0007399]; potassium ion transport [GO:0006813]	ankyrin binding [GO:0030506]; delayed rectifier potassium channel activity [GO:0005251]; potassium channel activity [GO:0005267]; voltage-gated potassium channel activity [GO:0005249]	axon initial segment [GO:0043194]; node of Ranvier [GO:0033268]; plasma membrane [GO:0005886]; voltage-gated potassium channel complex [GO:0008076]
P12277	KCRB_HUMAN	Creatine kinase B-type (EC 2.7.3.2) (B-CK) (Creatine kinase B chain)	CKB CKBB	3B6R;3DRB;3DRE;	CHEMBL6049;		DB00148;		PF00217;PF02807;	IPR000749;IPR022415;IPR022414;IPR022413;IPR014746;	cellular chloride ion homeostasis [GO:0030644]; creatine metabolic process [GO:0006600]; substantia nigra development [GO:0021762]	ATP binding [GO:0005524]; creatine kinase activity [GO:0004111]; ubiquitin protein ligase binding [GO:0031625]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; mitochondrion [GO:0005739]; myelin sheath [GO:0043209]
P06732	KCRM_HUMAN	Creatine kinase M-type (EC 2.7.3.2) (Creatine kinase M chain) (M-CK) [Cleaved into: Creatine kinase M-type, N-terminally processed]	CKM CKMM	1I0E;	CHEMBL2656;	P06732;	DB00148;		PF00217;PF02807;	IPR000749;IPR022415;IPR022414;IPR022413;IPR014746;	creatine metabolic process [GO:0006600]; phosphocreatine biosynthetic process [GO:0046314]	ATP binding [GO:0005524]; creatine kinase activity [GO:0004111]	cytosol [GO:0005829]
P17540	KCRS_HUMAN	Creatine kinase S-type, mitochondrial (EC 2.7.3.2) (Basic-type mitochondrial creatine kinase) (Mib-CK) (Sarcomeric mitochondrial creatine kinase) (S-MtCK)	CKMT2	4Z9M;			DB00148;		PF00217;PF02807;	IPR000749;IPR022415;IPR022414;IPR022413;IPR014746;	creatine metabolic process [GO:0006600]; muscle contraction [GO:0006936]	ATP binding [GO:0005524]; creatine kinase activity [GO:0004111]	mitochondrial inner membrane [GO:0005743]; mitochondrion [GO:0005739]
P12532	KCRU_HUMAN	Creatine kinase U-type, mitochondrial (EC 2.7.3.2) (Acidic-type mitochondrial creatine kinase) (Mia-CK) (Ubiquitous mitochondrial creatine kinase) (U-MtCK)	CKMT1A CKMT; CKMT1B CKMT	1QK1;			DB00148;		PF00217;PF02807;	IPR000749;IPR022415;IPR022414;IPR022413;IPR014746;	creatine metabolic process [GO:0006600]	ATP binding [GO:0005524]; creatine kinase activity [GO:0004111]	extracellular exosome [GO:0070062]; mitochondrial inner membrane [GO:0005743]; mitochondrion [GO:0005739]
P30085	KCY_HUMAN	UMP-CMP kinase (EC 2.7.4.14) (Deoxycytidylate kinase) (CK) (dCMP kinase) (Nucleoside-diphosphate kinase) (EC 2.7.4.6) (Uridine monophosphate/cytidine monophosphate kinase) (UMP/CMP kinase) (UMP/CMPK)	CMPK1 CMK CMPK UCK UMK UMPK	1TEV;	CHEMBL5681;		DB00441;DB00709;			IPR000850;IPR027417;IPR006266;	'de novo' pyrimidine nucleobase biosynthetic process [GO:0006207]; nucleobase-containing small molecule interconversion [GO:0015949]; nucleoside diphosphate phosphorylation [GO:0006165]; nucleoside triphosphate biosynthetic process [GO:0009142]; pyrimidine ribonucleotide biosynthetic process [GO:0009220]	ATP binding [GO:0005524]; cytidylate kinase activity [GO:0004127]; nucleoside diphosphate kinase activity [GO:0004550]; nucleoside phosphate kinase activity [GO:0050145]; uridine kinase activity [GO:0004849]; uridylate kinase activity [GO:0009041]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleus [GO:0005634]
P43631	KI2S2_HUMAN	Killer cell immunoglobulin-like receptor 2DS2 (CD158 antigen-like family member J) (MHC class I NK cell receptor) (NK receptor 183 ActI) (Natural killer-associated transcript 5) (NKAT-5) (p58 natural killer cell receptor clone CL-49) (p58 NK receptor CL-49) (CD antigen CD158j)	KIR2DS2 CD158J NKAT5	1M4K;4N8V;					PF00047;	IPR007110;IPR013783;IPR003599;IPR013151;	immune response [GO:0006955]; innate immune response [GO:0045087]; regulation of immune response [GO:0050776]	transmembrane signaling receptor activity [GO:0004888]	integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]
P52732	KIF11_HUMAN	Kinesin-like protein KIF11 (Kinesin-like protein 1) (Kinesin-like spindle protein HKSP) (Kinesin-related motor protein Eg5) (Thyroid receptor-interacting protein 5) (TR-interacting protein 5) (TRIP-5)	KIF11 EG5 KNSL1 TRIP5	1II6;1Q0B;1X88;1YRS;2FKY;2FL2;2FL6;2FME;2G1Q;2GM1;2IEH;2PG2;2Q2Y;2Q2Z;2UYI;2UYM;2WOG;2X2R;2X7C;2X7D;2X7E;2XAE;3CJO;3HQD;3K3B;3K5E;3KEN;3L9H;3WPN;3ZCW;4A1Z;4A28;4A50;4A51;4A5Y;4AP0;4AQV;4AQW;4AS7;4B7B;4BBG;4BXN;4CK5;4CK6;4CK7;4ZCA;4ZHI;5JV3;	CHEMBL4581;	P52732;			PF00225;PF13931;	IPR025901;IPR027640;IPR019821;IPR001752;IPR027417;	antigen processing and presentation of exogenous peptide antigen via MHC class II [GO:0019886]; cell division [GO:0051301]; chromosome segregation [GO:0007059]; microtubule-based movement [GO:0007018]; mitotic centrosome separation [GO:0007100]; mitotic nuclear division [GO:0007067]; mitotic spindle assembly [GO:0090307]; mitotic spindle organization [GO:0007052]; regulation of mitotic centrosome separation [GO:0046602]; retrograde vesicle-mediated transport, Golgi to ER [GO:0006890]; spindle organization [GO:0007051]	ATP binding [GO:0005524]; ATP-dependent microtubule motor activity, plus-end-directed [GO:0008574]; microtubule motor activity [GO:0003777]; protein complex binding [GO:0032403]; protein kinase binding [GO:0019901]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; kinesin complex [GO:0005871]; membrane [GO:0016020]; microtubule [GO:0005874]; spindle [GO:0005819]; spindle pole [GO:0000922]
Q12756	KIF1A_HUMAN	Kinesin-like protein KIF1A (Axonal transporter of synaptic vesicles) (Microtubule-based motor KIF1A) (Unc-104- and KIF1A-related protein) (hUnc-104)	KIF1A ATSV C2orf20	4EGX;4EJQ;4UXO;4UXP;4UXR;4UXS;					PF12473;PF00498;PF12423;PF00225;PF16183;PF00169;	IPR000253;IPR022164;IPR027640;IPR022140;IPR032405;IPR019821;IPR001752;IPR027417;IPR011993;IPR001849;IPR008984;	anterograde axonal transport [GO:0008089]	ATPase activity [GO:0016887]; ATP binding [GO:0005524]; microtubule motor activity [GO:0003777]; motor activity [GO:0003774]	axon cytoplasm [GO:1904115]; kinesin complex [GO:0005871]; microtubule [GO:0005874]
P33176	KINH_HUMAN	Kinesin-1 heavy chain (Conventional kinesin heavy chain) (Ubiquitous kinesin heavy chain) (UKHC)	KIF5B KNS KNS1	1BG2;1MKJ;2P4N;3J8X;3J8Y;4HNA;4LNU;	CHEMBL5864;	P33176;			PF00225;	IPR027640;IPR019821;IPR001752;IPR027417;	axon guidance [GO:0007411]; cytoplasm organization [GO:0007028]; cytoskeleton-dependent intracellular transport [GO:0030705]; microtubule-based movement [GO:0007018]; plus-end-directed vesicle transport along microtubule [GO:0072383]; positive regulation of establishment of protein localization to plasma membrane [GO:0090004]; positive regulation of insulin secretion involved in cellular response to glucose stimulus [GO:0035774]; positive regulation of intracellular protein transport [GO:0090316]; positive regulation of potassium ion transport [GO:0043268]; positive regulation of synaptic transmission, GABAergic [GO:0032230]; positive regulation of vesicle fusion [GO:0031340]; positive regulation of voltage-gated sodium channel activity [GO:1905152]; regulation of membrane potential [GO:0042391]; stress granule disassembly [GO:0035617]; vesicle transport along microtubule [GO:0047496]	ATP binding [GO:0005524]; ATP-dependent microtubule motor activity, plus-end-directed [GO:0008574]; cadherin binding involved in cell-cell adhesion [GO:0098641]; microtubule binding [GO:0008017]; microtubule motor activity [GO:0003777]	axonal growth cone [GO:0044295]; cell-cell adherens junction [GO:0005913]; ciliary rootlet [GO:0035253]; cytoplasm [GO:0005737]; endocytic vesicle [GO:0030139]; kinesin complex [GO:0005871]; membrane [GO:0016020]; microtubule [GO:0005874]; microtubule organizing center [GO:0005815]; perinuclear region of cytoplasm [GO:0048471]; vesicle [GO:0031982]
P04183	KITH_HUMAN	Thymidine kinase, cytosolic (EC 2.7.1.21)	TK1	1W4R;1XBT;2ORV;2WVJ;	CHEMBL2883;	P04183;	DB00432;DB00495;		PF00265;	IPR027417;IPR001267;IPR020633;	DNA biosynthetic process [GO:0071897]; DNA metabolic process [GO:0006259]; nucleobase-containing compound metabolic process [GO:0006139]; protein homotetramerization [GO:0051289]; pyrimidine nucleoside salvage [GO:0043097]; thymidine metabolic process [GO:0046104]	ATP binding [GO:0005524]; nucleoside kinase activity [GO:0019206]; thymidine kinase activity [GO:0004797]; zinc ion binding [GO:0008270]	cytosol [GO:0005829]
P10721	KIT_HUMAN	Mast/stem cell growth factor receptor Kit (SCFR) (EC 2.7.10.1) (Piebald trait protein) (PBT) (Proto-oncogene c-Kit) (Tyrosine-protein kinase Kit) (p145 c-kit) (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (CD antigen CD117)	KIT SCFR	1PKG;1QZJ;1QZK;1R01;1T45;1T46;2E9W;2EC8;2IUH;2VIF;3G0E;3G0F;4HVS;4K94;4K9E;4PGZ;4U0I;	CHEMBL1936;	P10721;	DB01254;DB00619;DB09078;DB04868;DB06589;DB08901;DB08896;DB00398;DB01268;		PF00047;PF07714;	IPR007110;IPR013783;IPR003599;IPR003598;IPR013151;IPR011009;IPR000719;IPR017441;IPR027263;IPR001245;IPR008266;IPR020635;IPR016243;IPR001824;	actin cytoskeleton reorganization [GO:0031532]; activation of MAPK activity [GO:0000187]; cell chemotaxis [GO:0060326]; cellular response to thyroid hormone stimulus [GO:0097067]; cytokine-mediated signaling pathway [GO:0019221]; dendritic cell cytokine production [GO:0002371]; detection of mechanical stimulus involved in sensory perception of sound [GO:0050910]; digestive tract development [GO:0048565]; ectopic germ cell programmed cell death [GO:0035234]; embryonic hemopoiesis [GO:0035162]; epithelial cell proliferation [GO:0050673]; erythrocyte differentiation [GO:0030218]; erythropoietin-mediated signaling pathway [GO:0038162]; Fc receptor signaling pathway [GO:0038093]; germ cell migration [GO:0008354]; glycosphingolipid metabolic process [GO:0006687]; hematopoietic stem cell migration [GO:0035701]; hemopoiesis [GO:0030097]; immature B cell differentiation [GO:0002327]; inflammatory response [GO:0006954]; Kit signaling pathway [GO:0038109]; lamellipodium assembly [GO:0030032]; lymphoid progenitor cell differentiation [GO:0002320]; male gonad development [GO:0008584]; MAPK cascade [GO:0000165]; mast cell chemotaxis [GO:0002551]; mast cell cytokine production [GO:0032762]; mast cell degranulation [GO:0043303]; mast cell differentiation [GO:0060374]; mast cell proliferation [GO:0070662]; megakaryocyte development [GO:0035855]; melanocyte adhesion [GO:0097326]; melanocyte differentiation [GO:0030318]; melanocyte migration [GO:0097324]; myeloid progenitor cell differentiation [GO:0002318]; negative regulation of programmed cell death [GO:0043069]; ovarian follicle development [GO:0001541]; peptidyl-tyrosine phosphorylation [GO:0018108]; phosphatidylinositol-mediated signaling [GO:0048015]; pigmentation [GO:0043473]; positive regulation of cell migration [GO:0030335]; positive regulation of cell proliferation [GO:0008284]; positive regulation of gene expression [GO:0010628]; positive regulation of JAK-STAT cascade [GO:0046427]; positive regulation of long-term neuronal synaptic plasticity [GO:0048170]; positive regulation of MAPK cascade [GO:0043410]; positive regulation of Notch signaling pathway [GO:0045747]; positive regulation of phosphatidylinositol 3-kinase activity [GO:0043552]; positive regulation of phosphatidylinositol 3-kinase signaling [GO:0014068]; positive regulation of phospholipase C activity [GO:0010863]; positive regulation of pseudopodium assembly [GO:0031274]; positive regulation of sequence-specific DNA binding transcription factor activity [GO:0051091]; positive regulation of tyrosine phosphorylation of Stat1 protein [GO:0042511]; positive regulation of tyrosine phosphorylation of Stat3 protein [GO:0042517]; positive regulation of tyrosine phosphorylation of Stat5 protein [GO:0042523]; positive regulation of vascular smooth muscle cell differentiation [GO:1905065]; protein autophosphorylation [GO:0046777]; regulation of cell proliferation [GO:0042127]; regulation of cell shape [GO:0008360]; regulation of developmental pigmentation [GO:0048070]; regulation of phosphatidylinositol 3-kinase signaling [GO:0014066]; signal transduction [GO:0007165]; somatic stem cell division [GO:0048103]; somatic stem cell population maintenance [GO:0035019]; spermatid development [GO:0007286]; spermatogenesis [GO:0007283]; stem cell differentiation [GO:0048863]; stem cell population maintenance [GO:0019827]; T cell differentiation [GO:0030217]; visual learning [GO:0008542]	ATP binding [GO:0005524]; cytokine binding [GO:0019955]; metal ion binding [GO:0046872]; phosphatidylinositol-4,5-bisphosphate 3-kinase activity [GO:0046934]; protein homodimerization activity [GO:0042803]; protein tyrosine kinase activity [GO:0004713]; Ras guanyl-nucleotide exchange factor activity [GO:0005088]; receptor signaling protein tyrosine kinase activity [GO:0004716]; stem cell factor receptor activity [GO:0005020]; transmembrane receptor protein tyrosine kinase activity [GO:0004714]	acrosomal vesicle [GO:0001669]; cell-cell junction [GO:0005911]; cytoplasmic side of plasma membrane [GO:0009898]; external side of plasma membrane [GO:0009897]; extracellular space [GO:0005615]; integral component of membrane [GO:0016021]; mast cell granule [GO:0042629]; plasma membrane [GO:0005886]
P06870	KLK1_HUMAN	Kallikrein-1 (EC 3.4.21.35) (Kidney/pancreas/salivary gland kallikrein) (Tissue kallikrein)	KLK1	1SPJ;	CHEMBL2319;	P06870;	DB06692;		PF00089;	IPR009003;IPR001314;IPR001254;IPR018114;IPR033116;		serine-type endopeptidase activity [GO:0004252]	extracellular exosome [GO:0070062]; nucleus [GO:0005634]
Q92876	KLK6_HUMAN	Kallikrein-6 (EC 3.4.21.-) (Neurosin) (Protease M) (SP59) (Serine protease 18) (Serine protease 9) (Zyme)	KLK6 PRSS18 PRSS9	1GVL;1L2E;1LO6;3VFE;4D8N;	CHEMBL4448;	Q92876;			PF00089;	IPR009003;IPR001314;IPR001254;IPR018114;IPR033116;	amyloid precursor protein metabolic process [GO:0042982]; central nervous system development [GO:0007417]; collagen catabolic process [GO:0030574]; hormone metabolic process [GO:0042445]; myelination [GO:0042552]; neuron death [GO:0070997]; positive regulation of G-protein coupled receptor protein signaling pathway [GO:0045745]; protein autoprocessing [GO:0016540]; protein processing [GO:0016485]; regulation of cell differentiation [GO:0045595]; regulation of neuron projection development [GO:0010975]; response to wounding [GO:0009611]; tissue regeneration [GO:0042246]	serine-type endopeptidase activity [GO:0004252]	cytoplasm [GO:0005737]; endoplasmic reticulum [GO:0005783]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; intercellular bridge [GO:0045171]; microtubule cytoskeleton [GO:0015630]; mitochondrion [GO:0005739]; nuclear membrane [GO:0031965]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]
P01042	KNG1_HUMAN	Kininogen-1 (Alpha-2-thiol proteinase inhibitor) (Fitzgerald factor) (High molecular weight kininogen) (HMWK) (Williams-Fitzgerald-Flaujeac factor) [Cleaved into: Kininogen-1 heavy chain; T-kinin (Ile-Ser-Bradykinin); Bradykinin (Kallidin I); Lysyl-bradykinin (Kallidin II); Kininogen-1 light chain; Low molecular weight growth-promoting factor]	KNG1 BDK KNG	1NY2;2WOK;4ASQ;4ASR;4ECB;4ECC;5I25;		P01042;			PF00031;	IPR000010;IPR002395;IPR027358;IPR018073;	blood coagulation, intrinsic pathway [GO:0007597]; inflammatory response [GO:0006954]; negative regulation of blood coagulation [GO:0030195]; negative regulation of cell adhesion [GO:0007162]; negative regulation of proteolysis [GO:0045861]; platelet degranulation [GO:0002576]; positive regulation of apoptotic process [GO:0043065]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; vasodilation [GO:0042311]	cysteine-type endopeptidase inhibitor activity [GO:0004869]; heparin binding [GO:0008201]; receptor binding [GO:0005102]; zinc ion binding [GO:0008270]	blood microparticle [GO:0072562]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; plasma membrane [GO:0005886]; platelet alpha granule lumen [GO:0031093]
P17252	KPCA_HUMAN	Protein kinase C alpha type (PKC-A) (PKC-alpha) (EC 2.7.11.13)	PRKCA PKCA PRKACA	2ELI;3IW4;4DNL;4RA4;	CHEMBL299;	P17252;	DB05013;DB00144;DB00675;DB00163;		PF00130;PF00168;PF00069;PF00433;	IPR000961;IPR000008;IPR020454;IPR011009;IPR002219;IPR017892;IPR000719;IPR017441;IPR014375;IPR008271;	activation of adenylate cyclase activity [GO:0007190]; angiogenesis [GO:0001525]; apoptotic signaling pathway [GO:0097190]; cell adhesion [GO:0007155]; desmosome assembly [GO:0002159]; histone H3-T6 phosphorylation [GO:0035408]; intracellular signal transduction [GO:0035556]; mitotic nuclear envelope disassembly [GO:0007077]; negative regulation of adenylate cyclase activity [GO:0007194]; negative regulation of glial cell apoptotic process [GO:0034351]; peptidyl-serine phosphorylation [GO:0018105]; platelet activation [GO:0030168]; positive regulation of angiogenesis [GO:0045766]; positive regulation of blood vessel endothelial cell migration [GO:0043536]; positive regulation of cardiac muscle hypertrophy [GO:0010613]; positive regulation of cell adhesion [GO:0045785]; positive regulation of cell migration [GO:0030335]; positive regulation of dense core granule biogenesis [GO:2000707]; positive regulation of endothelial cell migration [GO:0010595]; positive regulation of endothelial cell proliferation [GO:0001938]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of lipopolysaccharide-mediated signaling pathway [GO:0031666]; positive regulation of macrophage differentiation [GO:0045651]; positive regulation of mitotic cell cycle [GO:0045931]; protein phosphorylation [GO:0006468]; regulation of insulin secretion [GO:0050796]; regulation of mRNA stability [GO:0043488]; regulation of platelet aggregation [GO:0090330]; response to interleukin-1 [GO:0070555]	ATP binding [GO:0005524]; calcium-dependent protein kinase C activity [GO:0004698]; enzyme binding [GO:0019899]; histone kinase activity (H3-T6 specific) [GO:0035403]; protein kinase activity [GO:0004672]; protein kinase C activity [GO:0004697]; protein serine/threonine kinase activity [GO:0004674]; zinc ion binding [GO:0008270]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; extracellular exosome [GO:0070062]; mitochondrial membrane [GO:0031966]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]
P05771	KPCB_HUMAN	Protein kinase C beta type (PKC-B) (PKC-beta) (EC 2.7.11.13)	PRKCB PKCB PRKCB1	2I0E;	CHEMBL3045;	P05771;	DB00675;DB00163;		PF00130;PF00168;PF00069;PF00433;	IPR000961;IPR000008;IPR020454;IPR011009;IPR002219;IPR017892;IPR000719;IPR017441;IPR014375;IPR008271;	adaptive immune response [GO:0002250]; apoptotic process [GO:0006915]; B cell activation [GO:0042113]; B cell receptor signaling pathway [GO:0050853]; calcium ion transport [GO:0006816]; cellular calcium ion homeostasis [GO:0006874]; cellular response to carbohydrate stimulus [GO:0071322]; histone H3-T6 phosphorylation [GO:0035408]; intracellular signal transduction [GO:0035556]; lipoprotein transport [GO:0042953]; mitotic nuclear envelope disassembly [GO:0007077]; negative regulation of glucose transport [GO:0010829]; negative regulation of insulin receptor signaling pathway [GO:0046627]; peptidyl-serine phosphorylation [GO:0018105]; platelet activation [GO:0030168]; positive regulation of angiogenesis [GO:0045766]; positive regulation of B cell receptor signaling pathway [GO:0050861]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of vascular endothelial growth factor receptor signaling pathway [GO:0030949]; protein phosphorylation [GO:0006468]; regulation of transcription from RNA polymerase II promoter [GO:0006357]; response to hypoxia [GO:0001666]; signal transduction [GO:0007165]; transcription, DNA-templated [GO:0006351]	androgen receptor binding [GO:0050681]; ATP binding [GO:0005524]; calcium channel regulator activity [GO:0005246]; calcium-dependent protein kinase C activity [GO:0004698]; chromatin binding [GO:0003682]; histone binding [GO:0042393]; histone kinase activity (H3-T6 specific) [GO:0035403]; ligand-dependent nuclear receptor transcription coactivator activity [GO:0030374]; protein kinase C activity [GO:0004697]; protein kinase C binding [GO:0005080]; protein serine/threonine kinase activity [GO:0004674]; zinc ion binding [GO:0008270]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
Q04759	KPCT_HUMAN	Protein kinase C theta type (EC 2.7.11.13) (nPKC-theta)	PRKCQ PRKCT	1XJD;2ENJ;2ENN;2ENZ;2JED;4Q9Z;4RA5;5F9E;	CHEMBL3920;	Q04759;	DB00675;		PF00130;PF00069;PF00433;	IPR000961;IPR000008;IPR020454;IPR011009;IPR002219;IPR027264;IPR017892;IPR014376;IPR000719;IPR017441;IPR008271;	axon guidance [GO:0007411]; cell chemotaxis [GO:0060326]; cellular component disassembly involved in execution phase of apoptosis [GO:0006921]; Fc-epsilon receptor signaling pathway [GO:0038095]; inflammatory response [GO:0006954]; intracellular signal transduction [GO:0035556]; membrane protein ectodomain proteolysis [GO:0006509]; negative regulation of insulin receptor signaling pathway [GO:0046627]; negative regulation of T cell apoptotic process [GO:0070233]; peptidyl-serine phosphorylation [GO:0018105]; platelet activation [GO:0030168]; positive regulation of interleukin-17 production [GO:0032740]; positive regulation of interleukin-2 biosynthetic process [GO:0045086]; positive regulation of interleukin-4 production [GO:0032753]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of T cell activation [GO:0050870]; positive regulation of T cell proliferation [GO:0042102]; positive regulation of telomerase activity [GO:0051973]; positive regulation of telomere capping [GO:1904355]; positive regulation of telomere maintenance via telomerase [GO:0032212]; positive regulation of T-helper 17 type immune response [GO:2000318]; positive regulation of T-helper 2 cell activation [GO:2000570]; regulation of cell growth [GO:0001558]; regulation of platelet aggregation [GO:0090330]; regulation of transcription, DNA-templated [GO:0006355]; T cell receptor signaling pathway [GO:0050852]	ATP binding [GO:0005524]; metal ion binding [GO:0046872]; protein kinase activity [GO:0004672]; protein kinase C activity [GO:0004697]; protein serine/threonine kinase activity [GO:0004674]	cytosol [GO:0005829]; immunological synapse [GO:0001772]; intracellular [GO:0005622]; plasma membrane [GO:0005886]
P14618	KPYM_HUMAN	Pyruvate kinase PKM (EC 2.7.1.40) (Cytosolic thyroid hormone-binding protein) (CTHBP) (Opa-interacting protein 3) (OIP-3) (Pyruvate kinase 2/3) (Pyruvate kinase muscle isozyme) (Thyroid hormone-binding protein 1) (THBP1) (Tumor M2-PK) (p58)	PKM OIP3 PK2 PK3 PKM2	1T5A;1ZJH;3BJF;3BJT;3G2G;3GQY;3GR4;3H6O;3ME3;3SRD;3SRF;3SRH;3U2Z;4B2D;4FXF;4FXJ;4G1N;4JPG;4QG6;4QG8;4QG9;4QGC;4RPP;4WJ8;4YJ5;	CHEMBL1075189;	P14618;	DB00119;	PATHWAY: Carbohydrate degradation; glycolysis; pyruvate from D-glyceraldehyde 3-phosphate: step 5/5.	PF00224;PF02887;	IPR001697;IPR015813;IPR011037;IPR015794;IPR018209;IPR015793;IPR015795;IPR015806;	canonical glycolysis [GO:0061621]; programmed cell death [GO:0012501]	ATP binding [GO:0005524]; cadherin binding involved in cell-cell adhesion [GO:0098641]; kinase activity [GO:0016301]; magnesium ion binding [GO:0000287]; MHC class II protein complex binding [GO:0023026]; poly(A) RNA binding [GO:0044822]; potassium ion binding [GO:0030955]; pyruvate kinase activity [GO:0004743]	cell-cell adherens junction [GO:0005913]; cilium [GO:0005929]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular matrix [GO:0031012]; extracellular vesicle [GO:1903561]; mitochondrion [GO:0005739]; myelin sheath [GO:0043209]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; vesicle [GO:0031982]
P30613	KPYR_HUMAN	Pyruvate kinase PKLR (EC 2.7.1.40) (Pyruvate kinase 1) (Pyruvate kinase isozymes L/R) (R-type/L-type pyruvate kinase) (Red cell/liver pyruvate kinase)	PKLR PK1 PKL	2VGB;2VGF;2VGG;2VGI;4IMA;4IP7;	CHEMBL1075126;	P30613;	DB00119;	PATHWAY: Carbohydrate degradation; glycolysis; pyruvate from D-glyceraldehyde 3-phosphate: step 5/5.	PF00224;PF02887;	IPR001697;IPR015813;IPR011037;IPR015794;IPR018209;IPR015793;IPR015795;IPR015806;	ATP biosynthetic process [GO:0006754]; canonical glycolysis [GO:0061621]; cellular response to insulin stimulus [GO:0032869]; pyruvate biosynthetic process [GO:0042866]; response to ATP [GO:0033198]; response to cAMP [GO:0051591]; response to glucose [GO:0009749]; response to heat [GO:0009408]; response to hypoxia [GO:0001666]; response to lithium ion [GO:0010226]; response to nutrient [GO:0007584]	ATP binding [GO:0005524]; kinase activity [GO:0016301]; magnesium ion binding [GO:0000287]; potassium ion binding [GO:0030955]; pyruvate kinase activity [GO:0004743]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]
O75582	KS6A5_HUMAN	Ribosomal protein S6 kinase alpha-5 (S6K-alpha-5) (EC 2.7.11.1) (90 kDa ribosomal protein S6 kinase 5) (Nuclear mitogen- and stress-activated protein kinase 1) (RSK-like protein kinase) (RSKL)	RPS6KA5 MSK1	1VZO;3KN5;3KN6;	CHEMBL4237;	O75582;			PF00069;PF00433;	IPR000961;IPR011009;IPR017892;IPR000719;IPR017441;IPR016239;IPR008271;	axon guidance [GO:0007411]; epidermal growth factor receptor signaling pathway [GO:0007173]; histone H2A-S1 phosphorylation [GO:0043990]; histone H3-S10 phosphorylation [GO:0043987]; histone H3-S28 phosphorylation [GO:0043988]; histone phosphorylation [GO:0016572]; inflammatory response [GO:0006954]; interleukin-1-mediated signaling pathway [GO:0070498]; intracellular signal transduction [GO:0035556]; negative regulation of cytokine production [GO:0001818]; negative regulation of transcription, DNA-templated [GO:0045892]; positive regulation of CREB transcription factor activity [GO:0032793]; positive regulation of histone acetylation [GO:0035066]; positive regulation of histone phosphorylation [GO:0033129]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; protein phosphorylation [GO:0006468]; regulation of transcription, DNA-templated [GO:0006355]; stimulatory C-type lectin receptor signaling pathway [GO:0002223]	ATP binding [GO:0005524]; histone kinase activity (H3-S10 specific) [GO:0035175]; magnesium ion binding [GO:0000287]; protein kinase activity [GO:0004672]; protein serine/threonine kinase activity [GO:0004674]	cytoplasm [GO:0005737]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P43405	KSYK_HUMAN	Tyrosine-protein kinase SYK (EC 2.7.10.2) (Spleen tyrosine kinase) (p72-Syk)	SYK	1A81;1CSY;1CSZ;1XBA;1XBB;1XBC;3BUW;3EMG;3FQE;3FQH;3FQS;3SRV;3TUB;3TUC;3TUD;3VF8;3VF9;4DFL;4DFN;4F4P;4FL1;4FL2;4FL3;4FYN;4FYO;4FZ6;4FZ7;4GFG;4I0R;4I0S;4I0T;4PUZ;4PV0;4PX6;4RSS;4RX7;4RX8;4RX9;4WNM;4XG2;4XG3;4XG4;4XG6;4XG7;4XG8;4XG9;4YJO;4YJP;4YJQ;4YJR;4YJS;4YJT;4YJU;4YJV;5C26;5C27;5CXH;5CXZ;5CY3;5GHV;5LMA;5LMB;	CHEMBL2599;	P43405;			PF07714;PF00017;	IPR011009;IPR023420;IPR000719;IPR017441;IPR001245;IPR000980;IPR008266;IPR020635;IPR012234;	activation of JUN kinase activity [GO:0007257]; adaptive immune response [GO:0002250]; angiogenesis [GO:0001525]; animal organ morphogenesis [GO:0009887]; B cell receptor signaling pathway [GO:0050853]; beta selection [GO:0043366]; blood vessel morphogenesis [GO:0048514]; cell proliferation [GO:0008283]; cellular response to low-density lipoprotein particle stimulus [GO:0071404]; cellular response to molecule of fungal origin [GO:0071226]; defense response to bacterium [GO:0042742]; Fc-epsilon receptor signaling pathway [GO:0038095]; Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096]; inflammatory response [GO:0006954]; innate immune response [GO:0045087]; integrin-mediated signaling pathway [GO:0007229]; leukocyte activation involved in immune response [GO:0002366]; leukocyte cell-cell adhesion [GO:0007159]; leukotriene biosynthetic process [GO:0019370]; lymph vessel development [GO:0001945]; macrophage activation involved in immune response [GO:0002281]; neutrophil activation involved in immune response [GO:0002283]; neutrophil chemotaxis [GO:0030593]; peptidyl-serine phosphorylation [GO:0018105]; peptidyl-tyrosine autophosphorylation [GO:0038083]; platelet activation [GO:0030168]; positive regulation of alpha-beta T cell differentiation [GO:0046638]; positive regulation of alpha-beta T cell proliferation [GO:0046641]; positive regulation of B cell differentiation [GO:0045579]; positive regulation of bone resorption [GO:0045780]; positive regulation of calcium-mediated signaling [GO:0050850]; positive regulation of cell adhesion mediated by integrin [GO:0033630]; positive regulation of cytokine secretion [GO:0050715]; positive regulation of gamma-delta T cell differentiation [GO:0045588]; positive regulation of granulocyte macrophage colony-stimulating factor biosynthetic process [GO:0045425]; positive regulation of interleukin-3 biosynthetic process [GO:0045401]; positive regulation of mast cell degranulation [GO:0043306]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of receptor internalization [GO:0002092]; positive regulation of type I interferon production [GO:0032481]; protein phosphorylation [GO:0006468]; receptor internalization [GO:0031623]; regulation of arachidonic acid secretion [GO:0090237]; regulation of ERK1 and ERK2 cascade [GO:0070372]; regulation of neutrophil degranulation [GO:0043313]; regulation of phagocytosis [GO:0050764]; regulation of platelet activation [GO:0010543]; regulation of platelet aggregation [GO:0090330]; regulation of sequence-specific DNA binding transcription factor activity [GO:0051090]; regulation of superoxide anion generation [GO:0032928]; regulation of tumor necrosis factor-mediated signaling pathway [GO:0010803]; serotonin secretion by platelet [GO:0002554]; stimulatory C-type lectin receptor signaling pathway [GO:0002223]; transcription factor import into nucleus [GO:0042991]; transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169]; viral process [GO:0016032]	ATP binding [GO:0005524]; integrin binding [GO:0005178]; non-membrane spanning protein tyrosine kinase activity [GO:0004715]; protein kinase activity [GO:0004672]; protein serine/threonine kinase activity [GO:0004674]; protein tyrosine kinase activity [GO:0004713]; receptor signaling protein tyrosine kinase activity [GO:0004716]	B cell receptor complex [GO:0019815]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; early phagosome [GO:0032009]; extrinsic component of cytoplasmic side of plasma membrane [GO:0031234]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; protein complex [GO:0043234]; T cell receptor complex [GO:0042101]
P01619	KV3G_HUMAN	Immunoglobulin kappa variable 3-20 (Ig kappa chain V-III region B6) (Ig kappa chain V-III region GOL) (Ig kappa chain V-III region HAH) (Ig kappa chain V-III region HIC) (Ig kappa chain V-III region IARC/BL41) (Ig kappa chain V-III region NG9) (Ig kappa chain V-III region SIE) (Ig kappa chain V-III region Ti) (Ig kappa chain V-III region WOL)	IGKV3-20	1DH5;4LRN;4M62;4M8Q;4OB5;4ODX;					PF07686;	IPR007110;IPR013783;IPR003599;IPR013106;	complement activation [GO:0006956]; complement activation, classical pathway [GO:0006958]; Fc-epsilon receptor signaling pathway [GO:0038095]; Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096]; receptor-mediated endocytosis [GO:0006898]; regulation of immune response [GO:0050776]	antigen binding [GO:0003823]; serine-type endopeptidase activity [GO:0004252]	extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; plasma membrane [GO:0005886]
P06312	KV402_HUMAN	Immunoglobulin kappa variable 4-1 (Ig kappa chain V-IV region B17) (Ig kappa chain V-IV region JI) (Ig kappa chain V-IV region Len) (Ig kappa chain V-IV region STH)	IGKV4-1	1DH6;1EEQ;1EEU;1EFQ;1EK3;1LVE;1QAC;2LVE;3LVE;4LVE;5LVE;			DB02325;		PF07686;	IPR007110;IPR013783;IPR003599;IPR013106;	complement activation [GO:0006956]; complement activation, classical pathway [GO:0006958]; Fc-epsilon receptor signaling pathway [GO:0038095]; Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096]; immune response [GO:0006955]; immunoglobulin production [GO:0002377]; receptor-mediated endocytosis [GO:0006898]; regulation of immune response [GO:0050776]	antigen binding [GO:0003823]; serine-type endopeptidase activity [GO:0004252]	blood microparticle [GO:0072562]; extracellular region [GO:0005576]; plasma membrane [GO:0005886]
Q16719	KYNU_HUMAN	Kynureninase (EC 3.7.1.3) (L-kynurenine hydrolase)	KYNU	2HZP;3E9K;	CHEMBL5100;	Q16719;	DB00160;	PATHWAY: Amino-acid degradation; L-kynurenine degradation; L-alanine and anthranilate from L-kynurenine: step 1/1. {ECO:0000255|HAMAP-Rule:MF_03017}.; PATHWAY: Cofactor biosynthesis; NAD(+) biosynthesis; quinolinate from L-kynurenine: step 2/3. {ECO:0000255|HAMAP-Rule:MF_03017}.	PF00266;	IPR000192;IPR010111;IPR015424;IPR015421;IPR015422;	'de novo' NAD biosynthetic process from tryptophan [GO:0034354]; anthranilate metabolic process [GO:0043420]; L-kynurenine catabolic process [GO:0097053]; quinolinate biosynthetic process [GO:0019805]; response to interferon-gamma [GO:0034341]; response to vitamin B6 [GO:0034516]; tryptophan catabolic process [GO:0006569]; tryptophan catabolic process to acetyl-CoA [GO:0019442]; tryptophan catabolic process to kynurenine [GO:0019441]	kynureninase activity [GO:0030429]; protein homodimerization activity [GO:0042803]; pyridoxal phosphate binding [GO:0030170]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]
P0CG06	LAC_HUMAN	Ig lambda-3 chain C regions	IGLC3	1AQK;7FAB;					PF07654;	IPR007110;IPR013783;IPR003006;IPR003597;	B cell receptor signaling pathway [GO:0050853]; complement activation [GO:0006956]; complement activation, classical pathway [GO:0006958]; defense response to bacterium [GO:0042742]; Fc-epsilon receptor signaling pathway [GO:0038095]; Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096]; innate immune response [GO:0045087]; phagocytosis, engulfment [GO:0006911]; phagocytosis, recognition [GO:0006910]; positive regulation of B cell activation [GO:0050871]; receptor-mediated endocytosis [GO:0006898]; regulation of immune response [GO:0050776]	antigen binding [GO:0003823]; immunoglobulin receptor binding [GO:0034987]; serine-type endopeptidase activity [GO:0004252]	blood microparticle [GO:0072562]; external side of plasma membrane [GO:0009897]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; immunoglobulin complex, circulating [GO:0042571]; plasma membrane [GO:0005886]
P0CG05	LAC_HUMAN	Ig lambda-2 chain C regions	IGLC2	1JVK;1LIL;1ZVO;2JB5;2JB6;3C2A;3TV3;3TWC;3TYG;4EOW;4LLD;4LLM;4LLQ;4LLU;4LLW;4LLY;4O58;4O5I;5IQ7;5IQ9;					PF07654;	IPR007110;IPR013783;IPR003006;IPR003597;	B cell receptor signaling pathway [GO:0050853]; complement activation [GO:0006956]; complement activation, classical pathway [GO:0006958]; defense response to bacterium [GO:0042742]; Fc-epsilon receptor signaling pathway [GO:0038095]; Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096]; innate immune response [GO:0045087]; phagocytosis, engulfment [GO:0006911]; phagocytosis, recognition [GO:0006910]; positive regulation of B cell activation [GO:0050871]; receptor-mediated endocytosis [GO:0006898]; regulation of immune response [GO:0050776]	antigen binding [GO:0003823]; immunoglobulin receptor binding [GO:0034987]; serine-type endopeptidase activity [GO:0004252]	blood microparticle [GO:0072562]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; immunoglobulin complex, circulating [GO:0042571]; plasma membrane [GO:0005886]
P0CG04	LAC_HUMAN	Ig lambda-1 chain C regions	IGLC1	1ZVO;2FB4;2IG2;					PF07654;	IPR007110;IPR013783;IPR003006;IPR003597;	B cell receptor signaling pathway [GO:0050853]; complement activation [GO:0006956]; complement activation, classical pathway [GO:0006958]; defense response to bacterium [GO:0042742]; Fc-epsilon receptor signaling pathway [GO:0038095]; Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096]; immune response [GO:0006955]; innate immune response [GO:0045087]; phagocytosis, engulfment [GO:0006911]; phagocytosis, recognition [GO:0006910]; positive regulation of B cell activation [GO:0050871]; receptor-mediated endocytosis [GO:0006898]; regulation of immune response [GO:0050776]	antigen binding [GO:0003823]; immunoglobulin receptor binding [GO:0034987]; serine-type endopeptidase activity [GO:0004252]	blood microparticle [GO:0072562]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; immunoglobulin complex, circulating [GO:0042571]; plasma membrane [GO:0005886]
Q9UHI5	LAT2_HUMAN	Large neutral amino acids transporter small subunit 2 (L-type amino acid transporter 2) (hLAT2) (Solute carrier family 7 member 8)	SLC7A8 LAT2				DB00160;DB00130;DB00120;DB01235;		PF13520;	IPR002293;IPR004760;	amino acid transport [GO:0006865]; cellular amino acid metabolic process [GO:0006520]; leukocyte migration [GO:0050900]; metal ion homeostasis [GO:0055065]; neutral amino acid transport [GO:0015804]; response to toxic substance [GO:0009636]; transport [GO:0006810]	amino acid transmembrane transporter activity [GO:0015171]; antiporter activity [GO:0015297]; L-amino acid transmembrane transporter activity [GO:0015179]; neutral amino acid transmembrane transporter activity [GO:0015175]; organic cation transmembrane transporter activity [GO:0015101]; peptide antigen binding [GO:0042605]; toxin transporter activity [GO:0019534]	basolateral plasma membrane [GO:0016323]; cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
O15269	LCB1_HUMAN	Serine palmitoyltransferase 1 (EC 2.3.1.50) (Long chain base biosynthesis protein 1) (LCB 1) (Serine-palmitoyl-CoA transferase 1) (SPT 1) (SPT1)	SPTLC1 LCB1		CHEMBL1250343;	O15269;	DB00133;	PATHWAY: Lipid metabolism; sphingolipid metabolism.	PF00155;	IPR004839;IPR015424;IPR015421;IPR015422;	ceramide biosynthetic process [GO:0046513]; positive regulation of lipophagy [GO:1904504]; sphinganine biosynthetic process [GO:0046511]; sphingolipid biosynthetic process [GO:0030148]; sphingolipid metabolic process [GO:0006665]; sphingomyelin biosynthetic process [GO:0006686]; sphingosine biosynthetic process [GO:0046512]	pyridoxal phosphate binding [GO:0030170]; serine C-palmitoyltransferase activity [GO:0004758]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; serine C-palmitoyltransferase complex [GO:0017059]; SPOTS complex [GO:0035339]
O15270	LCB2_HUMAN	Serine palmitoyltransferase 2 (EC 2.3.1.50) (Long chain base biosynthesis protein 2) (LCB 2) (Long chain base biosynthesis protein 2a) (LCB2a) (Serine-palmitoyl-CoA transferase 2) (SPT 2)	SPTLC2 KIAA0526 LCB2		CHEMBL1250344;	O15270;	DB00133;	PATHWAY: Lipid metabolism; sphingolipid metabolism.	PF00155;	IPR001917;IPR004839;IPR015424;IPR015421;IPR015422;	ceramide biosynthetic process [GO:0046513]; positive regulation of lipophagy [GO:1904504]; sphinganine biosynthetic process [GO:0046511]; sphingolipid biosynthetic process [GO:0030148]; sphingomyelin biosynthetic process [GO:0006686]; sphingosine biosynthetic process [GO:0046512]	pyridoxal phosphate binding [GO:0030170]; serine C-palmitoyltransferase activity [GO:0004758]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; mitochondrion [GO:0005739]; serine C-palmitoyltransferase complex [GO:0017059]
P06239	LCK_HUMAN	Tyrosine-protein kinase Lck (EC 2.7.10.2) (Leukocyte C-terminal Src kinase) (LSK) (Lymphocyte cell-specific protein-tyrosine kinase) (Protein YT16) (Proto-oncogene Lck) (T cell-specific protein-tyrosine kinase) (p56-LCK)	LCK	1BHF;1BHH;1CWD;1CWE;1FBZ;1H92;1IJR;1KIK;1LCJ;1LCK;1LKK;1LKL;1Q68;1Q69;1QPC;1QPD;1QPE;1QPJ;1X27;2IIM;2OF2;2OF4;2OFU;2OFV;2OG8;2PL0;2ZM1;2ZM4;2ZYB;3AC1;3AC2;3AC3;3AC4;3AC5;3AC8;3ACJ;3ACK;3AD4;3AD5;3AD6;3B2W;3BRH;3BYM;3BYO;3BYS;3BYU;3KMM;3KXZ;3LCK;3MPM;4C3F;4D8K;	CHEMBL258;	P06239;	DB01254;DB09079;DB08901;		PF07714;PF00017;PF00018;	IPR011009;IPR000719;IPR017441;IPR001245;IPR000980;IPR001452;IPR008266;IPR020635;	activation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0006919]; B cell receptor signaling pathway [GO:0050853]; cellular zinc ion homeostasis [GO:0006882]; hemopoiesis [GO:0030097]; innate immune response [GO:0045087]; leukocyte migration [GO:0050900]; peptidyl-tyrosine autophosphorylation [GO:0038083]; phosphatidylinositol-mediated signaling [GO:0048015]; platelet activation [GO:0030168]; positive regulation of intrinsic apoptotic signaling pathway [GO:2001244]; positive regulation of T cell activation [GO:0050870]; positive regulation of T cell receptor signaling pathway [GO:0050862]; protein phosphorylation [GO:0006468]; regulation of cell proliferation [GO:0042127]; regulation of defense response to virus by virus [GO:0050690]; regulation of lymphocyte activation [GO:0051249]; regulation of phosphatidylinositol 3-kinase signaling [GO:0014066]; release of sequestered calcium ion into cytosol [GO:0051209]; response to drug [GO:0042493]; T cell costimulation [GO:0031295]; T cell differentiation [GO:0030217]; T cell receptor signaling pathway [GO:0050852]; transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169]; viral process [GO:0016032]	ATPase binding [GO:0051117]; ATP binding [GO:0005524]; CD4 receptor binding [GO:0042609]; CD8 receptor binding [GO:0042610]; glycoprotein binding [GO:0001948]; identical protein binding [GO:0042802]; kinase activity [GO:0016301]; non-membrane spanning protein tyrosine kinase activity [GO:0004715]; phosphatidylinositol 3-kinase binding [GO:0043548]; phosphatidylinositol-4,5-bisphosphate 3-kinase activity [GO:0046934]; protein C-terminus binding [GO:0008022]; protein kinase binding [GO:0019901]; protein phosphatase binding [GO:0019903]; protein serine/threonine phosphatase activity [GO:0004722]; protein tyrosine kinase activity [GO:0004713]; SH2 domain binding [GO:0042169]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extrinsic component of cytoplasmic side of plasma membrane [GO:0031234]; immunological synapse [GO:0001772]; membrane raft [GO:0045121]; pericentriolar material [GO:0000242]; plasma membrane [GO:0005886]
Q9UIC8	LCMT1_HUMAN	Leucine carboxyl methyltransferase 1 (EC 2.1.1.233) (Protein-leucine O-methyltransferase) ([Phosphatase 2A protein]-leucine-carboxy methyltransferase 1)	LCMT1 LCMT CGI-68	3IEI;3O7W;3P71;			DB00149;		PF04072;	IPR016651;IPR007213;IPR029063;	cellular protein modification process [GO:0006464]; C-terminal protein methylation [GO:0006481]; negative regulation of protein complex assembly [GO:0031333]; protein methylation [GO:0006479]; regulation of apoptotic process [GO:0042981]; regulation of glucose metabolic process [GO:0010906]; regulation of mitotic cell cycle spindle assembly checkpoint [GO:0090266]	protein C-terminal carboxyl O-methyltransferase activity [GO:0003880]; protein C-terminal leucine carboxyl O-methyltransferase activity [GO:0018423]; S-adenosylmethionine-dependent methyltransferase activity [GO:0008757]	cytosol [GO:0005829]
O60294	LCMT2_HUMAN	tRNA wybutosine-synthesizing protein 4 (tRNA yW-synthesizing protein 4) (EC 2.1.1.290) (EC 2.3.1.231) (Leucine carboxyl methyltransferase 2) (tRNA(Phe) (7-(3-amino-3-(methoxycarbonyl)propyl)wyosine(37)-N)-methoxycarbonyltransferase) (tRNA(Phe) (7-(3-amino-3-carboxypropyl)wyosine(37)-O)-methyltransferase)	LCMT2 KIAA0547 TYW4				DB00149;	PATHWAY: tRNA modification; wybutosine-tRNA(Phe) biosynthesis.	PF04072;	IPR015915;IPR007213;IPR029063;	tRNA methylation [GO:0030488]; tRNA modification [GO:0006400]; wybutosine biosynthetic process [GO:0031591]	S-adenosylmethionine-dependent methyltransferase activity [GO:0008757]; tRNA methyltransferase activity [GO:0008175]	cytoplasm [GO:0005737]; cytosol [GO:0005829]
Q6ZMR3	LDH6A_HUMAN	L-lactate dehydrogenase A-like 6A (EC 1.1.1.27)	LDHAL6A LDHL2					PATHWAY: Fermentation; pyruvate fermentation to lactate; (S)-lactate from pyruvate: step 1/1.	PF02866;PF00056;	IPR001557;IPR011304;IPR018177;IPR022383;IPR001236;IPR015955;IPR016040;	carbohydrate metabolic process [GO:0005975]; carboxylic acid metabolic process [GO:0019752]	L-lactate dehydrogenase activity [GO:0004459]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]
Q9BYZ2	LDH6B_HUMAN	L-lactate dehydrogenase A-like 6B (EC 1.1.1.27)	LDHAL6B LDHAL6 LDHL					PATHWAY: Fermentation; pyruvate fermentation to lactate; (S)-lactate from pyruvate: step 1/1.	PF02866;PF00056;	IPR001557;IPR011304;IPR018177;IPR022383;IPR001236;IPR015955;IPR016040;	carbohydrate metabolic process [GO:0005975]; pyruvate metabolic process [GO:0006090]	L-lactate dehydrogenase activity [GO:0004459]	mitochondrial matrix [GO:0005759]; nucleus [GO:0005634]
P00338	LDHA_HUMAN	L-lactate dehydrogenase A chain (LDH-A) (EC 1.1.1.27) (Cell proliferation-inducing gene 19 protein) (LDH muscle subunit) (LDH-M) (Renal carcinoma antigen NY-REN-59)	LDHA PIG19	1I10;4AJP;4JNK;4L4R;4L4S;4M49;4OJN;4OKN;4QO7;4QO8;4QSM;4QT0;4R68;4R69;4RLS;4ZVV;5IXS;5IXY;	CHEMBL4835;	P00338;	DB02701;	PATHWAY: Fermentation; pyruvate fermentation to lactate; (S)-lactate from pyruvate: step 1/1.	PF02866;PF00056;	IPR001557;IPR011304;IPR018177;IPR022383;IPR001236;IPR015955;IPR016040;	glycolytic process [GO:0006096]; lactate metabolic process [GO:0006089]; NAD metabolic process [GO:0019674]; positive regulation of apoptotic process [GO:0043065]; post-embryonic animal organ development [GO:0048569]; pyruvate metabolic process [GO:0006090]; response to cAMP [GO:0051591]; response to drug [GO:0042493]; response to estrogen [GO:0043627]; response to glucose [GO:0009749]; response to hydrogen peroxide [GO:0042542]; response to hypoxia [GO:0001666]; response to nutrient [GO:0007584]; substantia nigra development [GO:0021762]	cadherin binding involved in cell-cell adhesion [GO:0098641]; L-lactate dehydrogenase activity [GO:0004459]; NAD binding [GO:0051287]	cell-cell adherens junction [GO:0005913]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; nucleus [GO:0005634]
P07195	LDHB_HUMAN	L-lactate dehydrogenase B chain (LDH-B) (EC 1.1.1.27) (LDH heart subunit) (LDH-H) (Renal carcinoma antigen NY-REN-46)	LDHB	1I0Z;1T2F;	CHEMBL4940;	P07195;		PATHWAY: Fermentation; pyruvate fermentation to lactate; (S)-lactate from pyruvate: step 1/1.	PF02866;PF00056;	IPR001557;IPR011304;IPR018177;IPR022383;IPR001236;IPR015955;IPR016040;	carbohydrate metabolic process [GO:0005975]; lactate metabolic process [GO:0006089]; NAD metabolic process [GO:0019674]; pyruvate metabolic process [GO:0006090]	L-lactate dehydrogenase activity [GO:0004459]; NAD binding [GO:0051287]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; membrane raft [GO:0045121]; mitochondrion [GO:0005739]; myelin sheath [GO:0043209]
P07864	LDHC_HUMAN	L-lactate dehydrogenase C chain (LDH-C) (EC 1.1.1.27) (Cancer/testis antigen 32) (CT32) (LDH testis subunit) (LDH-X)	LDHC LDH3 LDHX					PATHWAY: Fermentation; pyruvate fermentation to lactate; (S)-lactate from pyruvate: step 1/1.	PF02866;PF00056;	IPR001557;IPR011304;IPR018177;IPR022383;IPR001236;IPR015955;IPR016040;	ATP biosynthetic process [GO:0006754]; carbohydrate metabolic process [GO:0005975]; flagellated sperm motility [GO:0030317]; lactate biosynthetic process from pyruvate [GO:0019244]; lactate oxidation [GO:0019516]; pyruvate metabolic process [GO:0006090]	L-lactate dehydrogenase activity [GO:0004459]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; motile cilium [GO:0031514]; nucleus [GO:0005634]
P01130	LDLR_HUMAN	Low-density lipoprotein receptor (LDL receptor)	LDLR	1AJJ;1D2J;1F5Y;1F8Z;1HJ7;1HZ8;1I0U;1IJQ;1LDL;1LDR;1LRX;1N7D;1XFE;2FCW;2KRI;2LGP;2M7P;2MG9;2W2M;2W2N;2W2O;2W2P;2W2Q;3BPS;3GCW;3GCX;3M0C;3P5B;3P5C;3SO6;4NE9;	CHEMBL3311;	P01130;	DB00707;		PF07645;PF00057;PF00058;	IPR011042;IPR001881;IPR013032;IPR000742;IPR000152;IPR018097;IPR009030;IPR023415;IPR000033;IPR002172;	cellular response to fatty acid [GO:0071398]; cholesterol homeostasis [GO:0042632]; cholesterol import [GO:0070508]; cholesterol metabolic process [GO:0008203]; cholesterol transport [GO:0030301]; endocytosis [GO:0006897]; intestinal cholesterol absorption [GO:0030299]; lipid metabolic process [GO:0006629]; lipoprotein catabolic process [GO:0042159]; low-density lipoprotein particle clearance [GO:0034383]; negative regulation of gene expression [GO:0010629]; phospholipid transport [GO:0015914]; positive regulation of gene expression [GO:0010628]; positive regulation of inflammatory response [GO:0050729]; positive regulation of triglyceride biosynthetic process [GO:0010867]; receptor-mediated endocytosis [GO:0006898]; regulation of cholesterol homeostasis [GO:2000188]; regulation of phosphatidylcholine catabolic process [GO:0010899]	calcium ion binding [GO:0005509]; clathrin heavy chain binding [GO:0032050]; glycoprotein binding [GO:0001948]; identical protein binding [GO:0042802]; low-density lipoprotein particle binding [GO:0030169]; low-density lipoprotein receptor activity [GO:0005041]; protease binding [GO:0002020]; receptor activity [GO:0004872]; very-low-density lipoprotein particle receptor activity [GO:0030229]; virus receptor activity [GO:0001618]	apical part of cell [GO:0045177]; basolateral plasma membrane [GO:0016323]; cell surface [GO:0009986]; clathrin-coated endocytic vesicle membrane [GO:0030669]; clathrin-coated pit [GO:0005905]; early endosome [GO:0005769]; endosome membrane [GO:0010008]; external side of plasma membrane [GO:0009897]; Golgi apparatus [GO:0005794]; integral component of plasma membrane [GO:0005887]; late endosome [GO:0005770]; low-density lipoprotein particle [GO:0034362]; lysosome [GO:0005764]; membrane [GO:0016020]; PCSK9-LDLR complex [GO:1990666]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]
P05162	LEG2_HUMAN	Galectin-2 (Gal-2) (Beta-galactoside-binding lectin L-14-II) (HL14) (Lactose-binding lectin 2) (S-Lac lectin 2)	LGALS2	1HLC;5DG1;5DG2;5EWS;	CHEMBL5977;	P05162;			PF00337;	IPR013320;IPR001079;		carbohydrate binding [GO:0030246]; galactoside binding [GO:0016936]
P17931	LEG3_HUMAN	Galectin-3 (Gal-3) (35 kDa lectin) (Carbohydrate-binding protein 35) (CBP 35) (Galactose-specific lectin 3) (Galactoside-binding protein) (GALBP) (IgE-binding protein) (L-31) (Laminin-binding protein) (Lectin L-29) (Mac-2 antigen)	LGALS3 MAC2	1A3K;1KJL;1KJR;2NMN;2NMO;2NN8;2XG3;3AYA;3AYC;3AYD;3AYE;3T1L;3T1M;3ZSJ;3ZSK;3ZSL;3ZSM;4BLI;4BLJ;4BM8;4JC1;4JCK;4LBJ;4LBK;4LBL;4LBM;4LBN;4LBO;4R9A;4R9B;4R9C;4R9D;4RL7;4XBN;5E88;5E89;5E8A;5H9P;5H9R;	CHEMBL4531;	P17931;			PF00337;	IPR013320;IPR001079;	eosinophil chemotaxis [GO:0048245]; epithelial cell differentiation [GO:0030855]; innate immune response [GO:0045087]; macrophage chemotaxis [GO:0048246]; monocyte chemotaxis [GO:0002548]; mononuclear cell migration [GO:0071674]; mRNA processing [GO:0006397]; negative regulation of endocytosis [GO:0045806]; negative regulation of extrinsic apoptotic signaling pathway [GO:2001237]; negative regulation of immunological synapse formation [GO:2000521]; negative regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell [GO:2001189]; negative regulation of T cell receptor signaling pathway [GO:0050860]; neutrophil chemotaxis [GO:0030593]; positive chemotaxis [GO:0050918]; positive regulation of calcium ion import [GO:0090280]; positive regulation of mononuclear cell migration [GO:0071677]; regulation of extrinsic apoptotic signaling pathway via death domain receptors [GO:1902041]; regulation of T cell apoptotic process [GO:0070232]; regulation of T cell proliferation [GO:0042129]; RNA splicing [GO:0008380]	carbohydrate binding [GO:0030246]; chemoattractant activity [GO:0042056]; IgE binding [GO:0019863]; laminin binding [GO:0043236]; poly(A) RNA binding [GO:0044822]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; immunological synapse [GO:0001772]; membrane [GO:0016020]; mitochondrial inner membrane [GO:0005743]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; spliceosomal complex [GO:0005681]
P47929	LEG7_HUMAN	Galectin-7 (Gal-7) (HKL-14) (PI7) (p53-induced gene 1 protein)	LGALS7 PIG1; LGALS7B	1BKZ;2GAL;3GAL;3ZXE;3ZXF;4GAL;4UW3;4UW4;4UW5;4UW6;4XBQ;4Y26;5GAL;5H9Q;5H9S;	CHEMBL5008;	P47929;			PF00337;	IPR013320;IPR030640;IPR001079;	apoptotic process [GO:0006915]; heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules [GO:0007157]	carbohydrate binding [GO:0030246]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; nucleus [GO:0005634]
Q04760	LGUL_HUMAN	Lactoylglutathione lyase (EC 4.4.1.5) (Aldoketomutase) (Glyoxalase I) (Glx I) (Ketone-aldehyde mutase) (Methylglyoxalase) (S-D-lactoylglutathione methylglyoxal lyase)	GLO1	1BH5;1FRO;1QIN;1QIP;3VW9;3W0T;3W0U;	CHEMBL2424;	Q04760;	DB00143;DB00328;	PATHWAY: Secondary metabolite metabolism; methylglyoxal degradation; (R)-lactate from methylglyoxal: step 1/2.	PF00903;	IPR029068;IPR004360;IPR004361;IPR018146;	carbohydrate metabolic process [GO:0005975]; glutathione metabolic process [GO:0006749]; methylglyoxal metabolic process [GO:0009438]; negative regulation of apoptotic process [GO:0043066]; osteoclast differentiation [GO:0030316]; pyruvate metabolic process [GO:0006090]; regulation of transcription from RNA polymerase II promoter [GO:0006357]	lactoylglutathione lyase activity [GO:0004462]; zinc ion binding [GO:0008270]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
O43766	LIAS_HUMAN	Lipoyl synthase, mitochondrial (EC 2.8.1.8) (Lipoate synthase) (LS) (Lip-syn) (Lipoic acid synthase)	LIAS LAS HUSSY-01				DB00166;	PATHWAY: Protein modification; protein lipoylation via endogenous pathway; protein N(6)-(lipoyl)lysine from octanoyl-[acyl-carrier-protein]: step 2/2. {ECO:0000255|HAMAP-Rule:MF_03123}.	PF16881;PF04055;	IPR013785;IPR006638;IPR031691;IPR003698;IPR007197;	glyoxylate metabolic process [GO:0046487]; inflammatory response [GO:0006954]; lipoate biosynthetic process [GO:0009107]; neural tube closure [GO:0001843]; protein lipoylation [GO:0009249]; response to lipopolysaccharide [GO:0032496]; response to oxidative stress [GO:0006979]	4 iron, 4 sulfur cluster binding [GO:0051539]; lipoate synthase activity [GO:0016992]; metal ion binding [GO:0046872]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
Q9Y234	LIPB_HUMAN	Lipoyltransferase 1, mitochondrial (EC 2.3.1.-) (Lipoate biosynthesis protein) (Lipoate-protein ligase) (Lipoyl ligase)	LIPT1				DB00166;	PATHWAY: Protein modification; protein lipoylation via exogenous pathway; protein N(6)-(lipoyl)lysine from lipoate: step 2/2.		IPR004143;IPR004562;	cellular protein modification process [GO:0006464]; glyoxylate metabolic process [GO:0046487]; lipid metabolic process [GO:0006629]; protein lipoylation [GO:0009249]	transferase activity, transferring acyl groups [GO:0016746]	mitochondrial matrix [GO:0005759]
A6NK58	LIPB_HUMAN	Putative lipoyltransferase 2, mitochondrial (EC 2.3.1.181) (Lipoate-protein ligase B) (Lipoyl/octanoyl transferase) (Octanoyl-[acyl-carrier-protein]-protein N-octanoyltransferase)	LIPT2					PATHWAY: Protein modification; protein lipoylation via endogenous pathway; protein N(6)-(lipoyl)lysine from octanoyl-[acyl-carrier-protein]: step 1/2.	PF03099;	IPR004143;IPR000544;	glyoxylate metabolic process [GO:0046487]; lipoate biosynthetic process [GO:0009107]; protein lipoylation [GO:0009249]	ligase activity [GO:0016874]; lipoyl(octanoyl) transferase activity [GO:0033819]; octanoyltransferase activity [GO:0016415]	mitochondrial matrix [GO:0005759]
P06858	LIPL_HUMAN	Lipoprotein lipase (LPL) (EC 3.1.1.34)	LPL LIPD		CHEMBL2060;	P06858;	DB05269;DB06439;		PF00151;PF01477;	IPR029058;IPR016272;IPR013818;IPR002330;IPR001024;IPR000734;	cholesterol homeostasis [GO:0042632]; chylomicron remodeling [GO:0034371]; fatty acid biosynthetic process [GO:0006633]; lipoprotein metabolic process [GO:0042157]; phospholipid metabolic process [GO:0006644]; positive regulation of chemokine secretion [GO:0090197]; positive regulation of cholesterol storage [GO:0010886]; positive regulation of inflammatory response [GO:0050729]; positive regulation of macrophage derived foam cell differentiation [GO:0010744]; positive regulation of sequestering of triglyceride [GO:0010890]; response to cold [GO:0009409]; response to drug [GO:0042493]; response to glucose [GO:0009749]; retinoid metabolic process [GO:0001523]; triglyceride biosynthetic process [GO:0019432]; triglyceride catabolic process [GO:0019433]; triglyceride homeostasis [GO:0070328]; triglyceride metabolic process [GO:0006641]; very-low-density lipoprotein particle remodeling [GO:0034372]	apolipoprotein binding [GO:0034185]; heparin binding [GO:0008201]; lipoprotein lipase activity [GO:0004465]; phospholipase activity [GO:0004620]; receptor binding [GO:0005102]; triglyceride binding [GO:0017129]; triglyceride lipase activity [GO:0004806]	anchored component of membrane [GO:0031225]; cell surface [GO:0009986]; chylomicron [GO:0042627]; extracellular exosome [GO:0070062]; extracellular matrix [GO:0031012]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; plasma membrane [GO:0005886]; very-low-density lipoprotein particle [GO:0034361]
P16233	LIPP_HUMAN	Pancreatic triacylglycerol lipase (PL) (PTL) (Pancreatic lipase) (EC 3.1.1.3)	PNLIP	1LPA;1LPB;1N8S;	CHEMBL1812;	P16233;	DB08909;DB01083;		PF00151;PF01477;	IPR029058;IPR016272;IPR013818;IPR002331;IPR001024;IPR000734;	intestinal cholesterol absorption [GO:0030299]; lipid catabolic process [GO:0016042]; lipid digestion [GO:0044241]; positive regulation of triglyceride lipase activity [GO:0061365]; retinoid metabolic process [GO:0001523]	metal ion binding [GO:0046872]; triglyceride lipase activity [GO:0004806]	extracellular region [GO:0005576]
P09960	LKHA4_HUMAN	Leukotriene A-4 hydrolase (LTA-4 hydrolase) (EC 3.3.2.6) (Leukotriene A(4) hydrolase)	LTA4H LTA4	1GW6;1H19;1HS6;1SQM;2R59;2VJ8;3B7R;3B7S;3B7T;3B7U;3CHO;3CHP;3CHQ;3CHR;3CHS;3FH5;3FH7;3FH8;3FHE;3FTS;3FTU;3FTV;3FTW;3FTX;3FTY;3FTZ;3FU0;3FU3;3FU5;3FU6;3FUD;3FUE;3FUF;3FUH;3FUI;3FUJ;3FUK;3FUL;3FUM;3FUN;3U9W;4DPR;4L2L;4MKT;4MS6;4R7L;4RSY;4RVB;5AEN;5BPP;	CHEMBL4618;	P09960;	DB01197;	PATHWAY: Lipid metabolism; leukotriene B4 biosynthesis.	PF09127;PF01433;	IPR016024;IPR012777;IPR001930;IPR015211;IPR014782;	leukotriene biosynthetic process [GO:0019370]; leukotriene metabolic process [GO:0006691]; peptide catabolic process [GO:0043171]	aminopeptidase activity [GO:0004177]; epoxide hydrolase activity [GO:0004301]; leukotriene-A4 hydrolase activity [GO:0004463]; metalloaminopeptidase activity [GO:0070006]; peptidase activity [GO:0008233]; peptide binding [GO:0042277]; poly(A) RNA binding [GO:0044822]; zinc ion binding [GO:0008270]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
Q9Y468	LMBTL_HUMAN	Lethal(3)malignant brain tumor-like protein 1 (H-l(3)mbt) (H-l(3)mbt protein) (L(3)mbt-like) (L(3)mbt protein homolog) (L3MBTL1)	L3MBTL1 KIAA0681 L3MBT L3MBTL	1OYX;1OZ2;1OZ3;2PQW;2RHI;2RHU;2RHX;2RHY;2RHZ;2RI2;2RI3;2RI5;2RJC;2RJD;2RJE;2RJF;3OQ5;3P8H;3UWN;	CHEMBL1287622;	Q9Y468;			PF02820;PF00536;PF01530;	IPR004092;IPR001660;IPR013761;IPR002515;	chromatin modification [GO:0016569]; chromatin organization [GO:0006325]; hemopoiesis [GO:0030097]; negative regulation of transcription, DNA-templated [GO:0045892]; regulation of cell cycle [GO:0051726]; regulation of megakaryocyte differentiation [GO:0045652]; regulation of mitotic nuclear division [GO:0007088]; regulation of signal transduction by p53 class mediator [GO:1901796]; transcription, DNA-templated [GO:0006351]	chromatin binding [GO:0003682]; histone binding [GO:0042393]; identical protein binding [GO:0042802]; methylated histone binding [GO:0035064]; nucleosomal histone binding [GO:0031493]; nucleosome binding [GO:0031491]; SAM domain binding [GO:0032093]; transcription factor activity, sequence-specific DNA binding [GO:0003700]; zinc ion binding [GO:0008270]	chromatin [GO:0000785]; condensed chromosome [GO:0000793]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
P16050	LOX15_HUMAN	Arachidonate 15-lipoxygenase (15-LOX) (15-LOX-1) (EC 1.13.11.33) (12/15-lipoxygenase) (Arachidonate 12-lipoxygenase, leukocyte-type) (12-LOX) (EC 1.13.11.31) (Arachidonate omega-6 lipoxygenase)	ALOX15 LOG15	2ABT;	CHEMBL2903;	P16050;		PATHWAY: Lipid metabolism; hydroperoxy eicosatetraenoic acid biosynthesis.	PF00305;PF01477;	IPR000907;IPR013819;IPR020834;IPR020833;IPR001885;IPR001024;	apoptotic cell clearance [GO:0043277]; arachidonic acid metabolic process [GO:0019369]; bone mineralization [GO:0030282]; cellular response to calcium ion [GO:0071277]; cellular response to interleukin-13 [GO:0035963]; hepoxilin biosynthetic process [GO:0051122]; inflammatory response [GO:0006954]; leukotriene metabolic process [GO:0006691]; lipoxin A4 biosynthetic process [GO:2001303]; lipoxygenase pathway [GO:0019372]; negative regulation of adaptive immune response [GO:0002820]; ossification [GO:0001503]; phosphatidylethanolamine biosynthetic process [GO:0006646]; positive regulation of actin filament polymerization [GO:0030838]; positive regulation of cell-substrate adhesion [GO:0010811]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of heterotypic cell-cell adhesion [GO:0034116]; regulation of engulfment of apoptotic cell [GO:1901074]; regulation of peroxisome proliferator activated receptor signaling pathway [GO:0035358]; response to endoplasmic reticulum stress [GO:0034976]; wound healing [GO:0042060]	arachidonate 12-lipoxygenase activity [GO:0004052]; arachidonate 15-lipoxygenase activity [GO:0050473]; eoxin A4 synthase activity [GO:0097260]; hepoxilin A3 synthase activity [GO:0051120]; hepoxilin-epoxide hydrolase activity [GO:0047977]; iron ion binding [GO:0005506]; phosphatidylinositol-4,5-bisphosphate binding [GO:0005546]	cytosol [GO:0005829]; extrinsic component of cytoplasmic side of plasma membrane [GO:0031234]; lipid particle [GO:0005811]; membrane [GO:0016020]; plasma membrane [GO:0005886]
P09917	LOX5_HUMAN	Arachidonate 5-lipoxygenase (5-LO) (5-lipoxygenase) (EC 1.13.11.34)	ALOX5 LOG5	2ABV;3O8Y;3V92;3V98;3V99;	CHEMBL215;	P09917;	DB00233;DB01014;DB00586;DB00711;DB00179;DB00939;DB00244;DB01017;DB00471;DB00795;DB00163;DB00744;	PATHWAY: Lipid metabolism; leukotriene A4 biosynthesis.	PF00305;PF01477;	IPR000907;IPR013819;IPR020834;IPR020833;IPR001885;IPR001024;	leukotriene biosynthetic process [GO:0019370]; leukotriene metabolic process [GO:0006691]; leukotriene production involved in inflammatory response [GO:0002540]; lipoxin metabolic process [GO:2001300]; lipoxygenase pathway [GO:0019372]	arachidonate 5-lipoxygenase activity [GO:0004051]; iron ion binding [GO:0005506]	cytosol [GO:0005829]; extracellular space [GO:0005615]; nuclear envelope [GO:0005635]; nuclear envelope lumen [GO:0005641]; nuclear matrix [GO:0016363]; nuclear membrane [GO:0031965]
Q05315	LPPL_HUMAN	Galectin-10 (Gal-10) (Charcot-Leyden crystal protein) (CLC) (Eosinophil lysophospholipase) (Lysolecithin acylhydrolase)	CLC LGALS10 LGALS10A	1G86;1HDK;1LCL;1QKQ;					PF00337;	IPR013320;IPR030648;IPR001079;	multicellular organism development [GO:0007275]; regulation of activated T cell proliferation [GO:0046006]; regulation of T cell anergy [GO:0002667]; regulation of T cell cytokine production [GO:0002724]; T cell apoptotic process [GO:0070231]	carbohydrate binding [GO:0030246]; cysteine-type endopeptidase activity involved in apoptotic process [GO:0097153]	cytosol [GO:0005829]
O95237	LRAT_HUMAN	Lecithin retinol acyltransferase (EC 2.3.1.135) (Phosphatidylcholine--retinol O-acyltransferase)	LRAT		CHEMBL2202;	O95237;	DB00162;	PATHWAY: Cofactor metabolism; retinol metabolism.	PF04970;	IPR007053;	positive regulation of lipid transport [GO:0032370]; response to stimulus [GO:0050896]; retinoic acid metabolic process [GO:0042573]; retinoid metabolic process [GO:0001523]; retinol metabolic process [GO:0042572]; visual perception [GO:0007601]; vitamin A metabolic process [GO:0006776]	lecithin:11-cis retinol acyltransferase activity [GO:0102279]; O-palmitoyltransferase activity [GO:0016416]; phosphatidylcholine-retinol O-acyltransferase activity [GO:0047173]; retinoic acid binding [GO:0001972]; retinol binding [GO:0019841]; transferase activity, transferring acyl groups [GO:0016746]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; multivesicular body [GO:0005771]; perinuclear region of cytoplasm [GO:0048471]; rough endoplasmic reticulum [GO:0005791]
P98164	LRP2_HUMAN	Low-density lipoprotein receptor-related protein 2 (LRP-2) (Glycoprotein 330) (gp330) (Megalin)	LRP2	2M0P;			DB00798;DB00030;DB00013;		PF12662;PF07645;PF00057;PF00058;	IPR011042;IPR026823;IPR001881;IPR013032;IPR000742;IPR000152;IPR018097;IPR009030;IPR023415;IPR000033;IPR002172;IPR019825;	aorta development [GO:0035904]; cell proliferation [GO:0008283]; coronary vasculature development [GO:0060976]; endocytosis [GO:0006897]; forebrain development [GO:0030900]; lipid metabolic process [GO:0006629]; protein glycosylation [GO:0006486]; receptor-mediated endocytosis [GO:0006898]; retinoid metabolic process [GO:0001523]; ventricular septum development [GO:0003281]; vitamin D metabolic process [GO:0042359]	calcium ion binding [GO:0005509]; lipoprotein transporter activity [GO:0042954]; low-density lipoprotein receptor activity [GO:0005041]	apical plasma membrane [GO:0016324]; brush border membrane [GO:0031526]; clathrin-coated pit [GO:0005905]; endocytic vesicle [GO:0030139]; endoplasmic reticulum [GO:0005783]; endosome [GO:0005768]; extracellular exosome [GO:0070062]; Golgi apparatus [GO:0005794]; integral component of membrane [GO:0016021]; lysosomal membrane [GO:0005765]; lysosome [GO:0005764]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]
P22888	LSHR_HUMAN	Lutropin-choriogonadotropic hormone receptor (LH/CG-R) (Luteinizing hormone receptor) (LHR) (LSH-R)	LHCGR LCGR LGR2 LHRHR	1LUT;1XUL;	CHEMBL1854;	P22888;	DB06719;DB00050;DB00097;DB00014;DB00044;DB00032;		PF00001;PF13306;	IPR000276;IPR017452;IPR002131;IPR032675;IPR026906;IPR002273;	activation of adenylate cyclase activity [GO:0007190]; adenylate cyclase-activating G-protein coupled receptor signaling pathway [GO:0007189]; cellular response to gonadotropin stimulus [GO:0071371]; cognition [GO:0050890]; G-protein coupled receptor signaling pathway [GO:0007186]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; hormone-mediated signaling pathway [GO:0009755]; male genitalia development [GO:0030539]; male gonad development [GO:0008584]; ovulation cycle process [GO:0022602]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; positive regulation of cAMP-mediated signaling [GO:0043950]; positive regulation of inositol trisphosphate biosynthetic process [GO:0032962]	choriogonadotropin hormone binding [GO:0038106]; choriogonadotropin hormone receptor activity [GO:0035472]; G-protein coupled peptide receptor activity [GO:0008528]; luteinizing hormone receptor activity [GO:0004964]	endosome [GO:0005768]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
Q16873	LTC4S_HUMAN	Leukotriene C4 synthase (LTC4 synthase) (EC 4.4.1.20) (Leukotriene-C(4) synthase)	LTC4S	2PNO;2UUH;2UUI;3B29;3HKK;3LEO;3PCV;4J7T;4J7Y;4JC7;4JCZ;4JRZ;4WAB;5HV9;	CHEMBL1743183;	Q16873;	DB00143;		PF01124;	IPR001446;IPR018295;IPR023352;IPR001129;	leukotriene biosynthetic process [GO:0019370]; leukotriene metabolic process [GO:0006691]; lipoxin metabolic process [GO:2001300]; lipoxygenase pathway [GO:0019372]	enzyme activator activity [GO:0008047]; glutathione peroxidase activity [GO:0004602]; glutathione transferase activity [GO:0004364]; leukotriene-C4 synthase activity [GO:0004464]; lipid binding [GO:0008289]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; intracellular membrane-bounded organelle [GO:0043231]; nuclear envelope [GO:0005635]; nuclear outer membrane [GO:0005640]
P01709	LV206_HUMAN	Immunoglobulin lambda variable 2-8 (Ig lambda chain V-II region BO) (Ig lambda chain V-II region MGC)	IGLV2-8	1A8J;1DCL;1MCW;2MCG;3MCG;4UNT;4UNU;4UNV;5ACL;5ACM;					PF07686;	IPR007110;IPR013783;IPR003599;IPR013106;	complement activation [GO:0006956]; complement activation, classical pathway [GO:0006958]; Fc-epsilon receptor signaling pathway [GO:0038095]; Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096]; immune response [GO:0006955]; receptor-mediated endocytosis [GO:0006898]; regulation of immune response [GO:0050776]	antigen binding [GO:0003823]; serine-type endopeptidase activity [GO:0004252]	extracellular region [GO:0005576]; plasma membrane [GO:0005886]
P10253	LYAG_HUMAN	Lysosomal alpha-glucosidase (EC 3.2.1.20) (Acid maltase) (Aglucosidase alfa) [Cleaved into: 76 kDa lysosomal alpha-glucosidase; 70 kDa lysosomal alpha-glucosidase]	GAA		CHEMBL2608;	P10253;	DB00284;DB00491;		PF13802;PF01055;PF16863;PF00088;	IPR031727;IPR011013;IPR000322;IPR030458;IPR030459;IPR025887;IPR017853;IPR017957;IPR000519;	cardiac muscle contraction [GO:0060048]; diaphragm contraction [GO:0002086]; glucose metabolic process [GO:0006006]; glycogen catabolic process [GO:0005980]; heart morphogenesis [GO:0003007]; locomotory behavior [GO:0007626]; lysosome organization [GO:0007040]; maltose metabolic process [GO:0000023]; muscle cell cellular homeostasis [GO:0046716]; neuromuscular process controlling balance [GO:0050885]; neuromuscular process controlling posture [GO:0050884]; regulation of the force of heart contraction [GO:0002026]; sucrose metabolic process [GO:0005985]; tissue development [GO:0009888]; vacuolar sequestering [GO:0043181]	alpha-1,4-glucosidase activity [GO:0004558]; carbohydrate binding [GO:0030246]; maltose alpha-glucosidase activity [GO:0032450]; oligo-1,6-glucosidase activity [GO:0004574]	extracellular exosome [GO:0070062]; lysosomal lumen [GO:0043202]; lysosomal membrane [GO:0005765]; lysosome [GO:0005764]; membrane [GO:0016020]
P16581	LYAM2_HUMAN	E-selectin (CD62 antigen-like family member E) (Endothelial leukocyte adhesion molecule 1) (ELAM-1) (Leukocyte-endothelial cell adhesion molecule 2) (LECAM2) (CD antigen CD62E)	SELE ELAM1	1ESL;1G1T;1KJA;4C16;4CSY;	CHEMBL3890;	P16581;	DB01136;		PF00008;PF00059;PF00084;	IPR001304;IPR016186;IPR018378;IPR016187;IPR013032;IPR000742;IPR002396;IPR000436;	actin filament-based process [GO:0030029]; activation of phospholipase C activity [GO:0007202]; calcium-mediated signaling [GO:0019722]; heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules [GO:0007157]; inflammatory response [GO:0006954]; leukocyte cell-cell adhesion [GO:0007159]; leukocyte migration [GO:0050900]; leukocyte migration involved in inflammatory response [GO:0002523]; leukocyte tethering or rolling [GO:0050901]; positive regulation of receptor internalization [GO:0002092]; regulation of inflammatory response [GO:0050727]; response to interleukin-1 [GO:0070555]; response to lipopolysaccharide [GO:0032496]; response to tumor necrosis factor [GO:0034612]	oligosaccharide binding [GO:0070492]; phospholipase binding [GO:0043274]; sialic acid binding [GO:0033691]; transmembrane signaling receptor activity [GO:0004888]	caveola [GO:0005901]; clathrin-coated pit [GO:0005905]; cortical cytoskeleton [GO:0030863]; extracellular space [GO:0005615]; integral component of membrane [GO:0016021]; membrane raft [GO:0045121]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]
P16109	LYAM3_HUMAN	P-selectin (CD62 antigen-like family member P) (Granule membrane protein 140) (GMP-140) (Leukocyte-endothelial cell adhesion molecule 3) (LECAM3) (Platelet activation dependent granule-external membrane protein) (PADGEM) (CD antigen CD62P)	SELP GMRP GRMP	1FSB;1G1Q;1G1R;1G1S;1HES;1KJD;	CHEMBL5378;	P16109;	DB06779;DB01109;DB08813;		PF00059;PF00084;	IPR001304;IPR016186;IPR018378;IPR016187;IPR013032;IPR000742;IPR002396;IPR000436;	calcium-mediated signaling using intracellular calcium source [GO:0035584]; cell adhesion [GO:0007155]; defense response to Gram-negative bacterium [GO:0050829]; heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules [GO:0007157]; inflammatory response [GO:0006954]; leukocyte cell-cell adhesion [GO:0007159]; leukocyte migration [GO:0050900]; leukocyte tethering or rolling [GO:0050901]; platelet degranulation [GO:0002576]; positive regulation of leukocyte migration [GO:0002687]; positive regulation of phosphatidylinositol 3-kinase signaling [GO:0014068]; positive regulation of platelet activation [GO:0010572]; regulation of integrin activation [GO:0033623]; response to lipopolysaccharide [GO:0032496]	fucose binding [GO:0042806]; glycoprotein binding [GO:0001948]; glycosphingolipid binding [GO:0043208]; heparin binding [GO:0008201]; lipopolysaccharide binding [GO:0001530]; oligosaccharide binding [GO:0070492]; sialic acid binding [GO:0033691]	cytoplasm [GO:0005737]; external side of plasma membrane [GO:0009897]; extracellular space [GO:0005615]; integral component of plasma membrane [GO:0005887]; nucleoplasm [GO:0005654]; plasma membrane [GO:0005886]; platelet alpha granule membrane [GO:0031092]; platelet dense granule membrane [GO:0031088]
Q9UKM7	MA1B1_HUMAN	Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase (EC 3.2.1.113) (ER alpha-1,2-mannosidase) (ER mannosidase 1) (ERMan1) (Man9GlcNAc2-specific-processing alpha-mannosidase) (Mannosidase alpha class 1B member 1)	MAN1B1 UNQ747/PRO1477	1FMI;1FO2;1FO3;1X9D;	CHEMBL2308;	Q9UKM7;		PATHWAY: Protein modification; protein glycosylation. {ECO:0000250|UniProtKB:P32906}.	PF01532;	IPR001382;	endoplasmic reticulum mannose trimming [GO:1904380]; ER-associated ubiquitin-dependent protein catabolic process [GO:0030433]; mannose trimming involved in glycoprotein ERAD pathway [GO:1904382]; N-glycan processing [GO:0006491]; oligosaccharide metabolic process [GO:0009311]; protein alpha-1,2-demannosylation [GO:0036508]; trimming of terminal mannose on B branch [GO:0036509]	alpha-mannosidase activity [GO:0004559]; calcium ion binding [GO:0005509]; mannosyl-oligosaccharide 1,2-alpha-mannosidase activity [GO:0004571]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; endoplasmic reticulum quality control compartment [GO:0044322]; extracellular vesicle [GO:1903561]; Golgi apparatus [GO:0005794]; integral component of membrane [GO:0016021]; membrane [GO:0016020]
O43708	MAAI_HUMAN	Maleylacetoacetate isomerase (MAAI) (EC 5.2.1.2) (GSTZ1-1) (Glutathione S-transferase zeta 1) (EC 2.5.1.18)	GSTZ1 MAAI	1FW1;	CHEMBL4949;		DB00143;	PATHWAY: Amino-acid degradation; L-phenylalanine degradation; acetoacetate and fumarate from L-phenylalanine: step 5/6.	PF14497;PF13417;	IPR010987;IPR004045;IPR004046;IPR005955;IPR012336;	glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; L-phenylalanine catabolic process [GO:0006559]; tyrosine catabolic process [GO:0006572]	glutathione peroxidase activity [GO:0004602]; glutathione transferase activity [GO:0004364]; maleylacetoacetate isomerase activity [GO:0016034]; protein homodimerization activity [GO:0042803]	cytosol [GO:0005829]; mitochondrion [GO:0005739]
P23368	MAOM_HUMAN	NAD-dependent malic enzyme, mitochondrial (NAD-ME) (EC 1.1.1.38) (Malic enzyme 2)	ME2	1DO8;1EFK;1EFL;1GZ3;1GZ4;1PJ2;1PJ3;1PJ4;1PJL;1QR6;					PF00390;PF03949;	IPR015884;IPR012301;IPR012302;IPR001891;IPR016040;	malate metabolic process [GO:0006108]; regulation of NADP metabolic process [GO:1902031]	electron carrier activity [GO:0009055]; malate dehydrogenase (decarboxylating) (NAD+) activity [GO:0004471]; malic enzyme activity [GO:0004470]; metal ion binding [GO:0046872]; NAD binding [GO:0051287]; oxaloacetate decarboxylase activity [GO:0008948]	intracellular membrane-bounded organelle [GO:0043231]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
Q16798	MAON_HUMAN	NADP-dependent malic enzyme, mitochondrial (NADP-ME) (EC 1.1.1.40) (Malic enzyme 3)	ME3		CHEMBL6182;				PF00390;PF03949;	IPR015884;IPR012301;IPR012302;IPR001891;IPR016040;	aerobic respiration [GO:0009060]; malate metabolic process [GO:0006108]; oxidation-reduction process [GO:0055114]; oxygen metabolic process [GO:0072592]; pyruvate metabolic process [GO:0006090]	cofactor binding [GO:0048037]; malate dehydrogenase (decarboxylating) (NAD+) activity [GO:0004471]; malate dehydrogenase (decarboxylating) (NADP+) activity [GO:0004473]; malic enzyme activity [GO:0004470]; metal ion binding [GO:0046872]; NAD binding [GO:0051287]; oxaloacetate decarboxylase activity [GO:0008948]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
P48163	MAOX_HUMAN	NADP-dependent malic enzyme (NADP-ME) (EC 1.1.1.40) (Malic enzyme 1)	ME1	2AW5;3WJA;	CHEMBL3495;	P48163;			PF00390;PF03949;	IPR015884;IPR012301;IPR012302;IPR001891;IPR016040;	carbohydrate metabolic process [GO:0005975]; malate metabolic process [GO:0006108]; NADP biosynthetic process [GO:0006741]; protein tetramerization [GO:0051262]; regulation of NADP metabolic process [GO:1902031]; response to carbohydrate [GO:0009743]; response to hormone [GO:0009725]	ADP binding [GO:0043531]; electron carrier activity [GO:0009055]; malate dehydrogenase (decarboxylating) (NAD+) activity [GO:0004471]; malate dehydrogenase (decarboxylating) (NADP+) activity [GO:0004473]; malic enzyme activity [GO:0004470]; manganese ion binding [GO:0030145]; NAD binding [GO:0051287]; NADP binding [GO:0050661]; oxaloacetate decarboxylase activity [GO:0008948]	cytosol [GO:0005829]; mitochondrion [GO:0005739]
P78559	MAP1A_HUMAN	Microtubule-associated protein 1A (MAP-1A) (Proliferation-related protein p80) [Cleaved into: MAP1A heavy chain; MAP1 light chain LC2]	MAP1A MAP1L				DB01196;			IPR026074;IPR015656;IPR001279;	microtubule cytoskeleton organization [GO:0000226]	structural molecule activity [GO:0005198]	cytoplasm [GO:0005737]; microtubule [GO:0005874]; microtubule associated complex [GO:0005875]
P50579	AMPM2_HUMAN,MAP2_HUMAN	Methionine aminopeptidase 2 (MAP 2) (MetAP 2) (EC 3.4.11.18) (Initiation factor 2-associated 67 kDa glycoprotein) (p67) (p67eIF2) (Peptidase M)	METAP2 MNPEP P67EIF2	1B59;1B6A;1BN5;1BOA;1KQ0;1KQ9;1QZY;1R58;1R5G;1R5H;1YW7;1YW8;1YW9;2ADU;2EA2;2EA4;2GA2;2OAZ;5CLS;5D6E;5D6F;5JFR;5JHU;5JI6;	CHEMBL3922;	P50579;	DB00134;DB01422;		PF00557;	IPR001714;IPR000994;IPR002468;IPR018349;IPR011991;	N-terminal protein amino acid modification [GO:0031365]; peptidyl-methionine modification [GO:0018206]; protein initiator methionine removal [GO:0070084]; protein processing [GO:0016485]; regulation of rhodopsin mediated signaling pathway [GO:0022400]	aminopeptidase activity [GO:0004177]; metal ion binding [GO:0046872]; metalloaminopeptidase activity [GO:0070006]; metalloexopeptidase activity [GO:0008235]; poly(A) RNA binding [GO:0044822]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; plasma membrane [GO:0005886]
P49137	MAPK2_HUMAN	MAP kinase-activated protein kinase 2 (MAPK-activated protein kinase 2) (MAPKAP kinase 2) (MAPKAP-K2) (MAPKAPK-2) (MK-2) (MK2) (EC 2.7.11.1)	MAPKAPK2	1KWP;1NXK;1NY3;2JBO;2JBP;2OKR;2ONL;2OZA;2P3G;2PZY;3A2C;3FPM;3FYJ;3FYK;3GOK;3KA0;3KC3;3KGA;3M2W;3M42;3R2B;3R2Y;3R30;3WI6;4TYH;	CHEMBL2208;	P49137;			PF00069;	IPR011009;IPR027442;IPR000719;IPR017441;IPR008271;	3'-UTR-mediated mRNA stabilization [GO:0070935]; activation of MAPK activity [GO:0000187]; cellular response to DNA damage stimulus [GO:0006974]; cellular response to vascular endothelial growth factor stimulus [GO:0035924]; G2 DNA damage checkpoint [GO:0031572]; inflammatory response [GO:0006954]; inner ear development [GO:0048839]; leukotriene metabolic process [GO:0006691]; macropinocytosis [GO:0044351]; MAPK cascade [GO:0000165]; p38MAPK cascade [GO:0038066]; peptidyl-serine phosphorylation [GO:0018105]; positive regulation of tumor necrosis factor biosynthetic process [GO:0042535]; protein autophosphorylation [GO:0046777]; protein phosphorylation [GO:0006468]; Ras protein signal transduction [GO:0007265]; regulation of cellular response to heat [GO:1900034]; regulation of interleukin-6 production [GO:0032675]; regulation of mRNA stability [GO:0043488]; regulation of tumor necrosis factor production [GO:0032680]; response to cytokine [GO:0034097]; response to lipopolysaccharide [GO:0032496]; response to stress [GO:0006950]; toll-like receptor signaling pathway [GO:0002224]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]	ATP binding [GO:0005524]; calcium-dependent protein serine/threonine kinase activity [GO:0009931]; calmodulin binding [GO:0005516]; calmodulin-dependent protein kinase activity [GO:0004683]; protein kinase activity [GO:0004672]; protein serine/threonine kinase activity [GO:0004674]; signal transducer activity [GO:0004871]	centrosome [GO:0005813]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
Q9NZL9	MAT2B_HUMAN	Methionine adenosyltransferase 2 subunit beta (Methionine adenosyltransferase II beta) (MAT II beta) (Putative dTDP-4-keto-6-deoxy-D-glucose 4-reductase)	MAT2B TGR MSTP045 Nbla02999 UNQ2435/PRO4995	2YDX;2YDY;4KTT;4KTV;4NDN;			DB00134;	PATHWAY: Amino-acid biosynthesis; S-adenosyl-L-methionine biosynthesis; S-adenosyl-L-methionine from L-methionine: step 1/1. {ECO:0000269|PubMed:10644686, ECO:0000269|PubMed:23189196, ECO:0000269|PubMed:25075345}.	PF04321;	IPR005913;IPR016040;IPR029903;	methylation [GO:0032259]; one-carbon metabolic process [GO:0006730]; S-adenosylmethionine biosynthetic process [GO:0006556]	enzyme binding [GO:0019899]; methionine adenosyltransferase regulator activity [GO:0048270]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; intracellular [GO:0005622]; methionine adenosyltransferase complex [GO:0048269]; mitochondrion [GO:0005739]; nucleus [GO:0005634]
Q9UBB5	MBD2_HUMAN	Methyl-CpG-binding domain protein 2 (Demethylase) (DMTase) (Methyl-CpG-binding protein MBD2)	MBD2	2L2L;		Q9UBB5;			PF01429;PF14048;PF16564;	IPR016177;IPR032343;IPR025884;IPR001739;	aging [GO:0007568]; ATP-dependent chromatin remodeling [GO:0043044]; cellular protein complex assembly [GO:0043623]; cellular response to organic cyclic compound [GO:0071407]; chromatin silencing at rDNA [GO:0000183]; embryonic organ development [GO:0048568]; heart development [GO:0007507]; maternal behavior [GO:0042711]; methylation-dependent chromatin silencing [GO:0006346]; negative regulation of transcription, DNA-templated [GO:0045892]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; positive regulation of chromatin binding [GO:0035563]; positive regulation of Wnt signaling pathway [GO:0030177]; regulation of cell proliferation [GO:0042127]; regulation of DNA methylation [GO:0044030]; response to estradiol [GO:0032355]; response to mechanical stimulus [GO:0009612]; response to nutrient levels [GO:0031667]; transcription, DNA-templated [GO:0006351]	C2H2 zinc finger domain binding [GO:0070742]; chromatin binding [GO:0003682]; methyl-CpG binding [GO:0008327]; mRNA binding [GO:0003729]; protein domain specific binding [GO:0019904]; satellite DNA binding [GO:0003696]; siRNA binding [GO:0035197]	cytoplasm [GO:0005737]; heterochromatin [GO:0000792]; histone deacetylase complex [GO:0000118]; nuclear chromatin [GO:0000790]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; protein complex [GO:0043234]
Q8N8R3	MCATL_HUMAN	Mitochondrial basic amino acids transporter (Carnitine/acylcarnitine translocase-like) (CACT-like) (Mitochondrial carnitine/acylcarnitine carrier protein CACL) (Mitochondrial ornithine transporter 3) (Solute carrier family 25 member 29)	SLC25A29 C14orf69 ORNT3				DB00583;		PF00153;	IPR002067;IPR018108;IPR023395;	translation [GO:0006412]	acyl carnitine transmembrane transporter activity [GO:0015227]; structural constituent of ribosome [GO:0003735]	integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]
O43772	MCAT_HUMAN	Mitochondrial carnitine/acylcarnitine carrier protein (Carnitine/acylcarnitine translocase) (CAC) (Solute carrier family 25 member 20)	SLC25A20 CAC CACT		CHEMBL2216740;	O43772;	DB00583;		PF00153;	IPR018108;IPR023395;	carnitine shuttle [GO:0006853]; translation [GO:0006412]	acyl carnitine transmembrane transporter activity [GO:0015227]; structural constituent of ribosome [GO:0003735]	cytoplasm [GO:0005737]; integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrion [GO:0005739]
Q96RQ3	MCCA_HUMAN	Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial (MCCase subunit alpha) (EC 6.4.1.4) (3-methylcrotonyl-CoA carboxylase 1) (3-methylcrotonyl-CoA carboxylase biotin-containing subunit) (3-methylcrotonyl-CoA:carbon dioxide ligase subunit alpha)	MCCC1 MCCA	2EJM;			DB00121;	PATHWAY: Amino-acid degradation; L-leucine degradation; (S)-3-hydroxy-3-methylglutaryl-CoA from 3-isovaleryl-CoA: step 2/3.	PF02785;PF00289;PF00364;PF02786;	IPR011761;IPR013815;IPR013816;IPR005481;IPR001882;IPR011764;IPR005482;IPR000089;IPR005479;IPR016185;IPR011054;IPR011053;	biotin metabolic process [GO:0006768]; branched-chain amino acid catabolic process [GO:0009083]; leucine catabolic process [GO:0006552]; protein heterooligomerization [GO:0051291]	ATP binding [GO:0005524]; biotin binding [GO:0009374]; biotin carboxylase activity [GO:0004075]; metal ion binding [GO:0046872]; methylcrotonoyl-CoA carboxylase activity [GO:0004485]	3-methylcrotonyl-CoA carboxylase complex, mitochondrial [GO:0002169]; cytosol [GO:0005829]; methylcrotonoyl-CoA carboxylase complex [GO:1905202]; mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
Q9HCC0	MCCC2_HUMAN	Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial (MCCase subunit beta) (EC 6.4.1.4) (3-methylcrotonyl-CoA carboxylase 2) (3-methylcrotonyl-CoA carboxylase non-biotin-containing subunit) (3-methylcrotonyl-CoA:carbon dioxide ligase subunit beta)	MCCC2 MCCB				DB00121;	PATHWAY: Amino-acid degradation; L-leucine degradation; (S)-3-hydroxy-3-methylglutaryl-CoA from 3-isovaleryl-CoA: step 2/3.	PF01039;	IPR000022;IPR029045;IPR011763;IPR011762;	biotin metabolic process [GO:0006768]; branched-chain amino acid catabolic process [GO:0009083]; coenzyme A metabolic process [GO:0015936]; leucine catabolic process [GO:0006552]; protein heterooligomerization [GO:0051291]	ATP binding [GO:0005524]; methylcrotonoyl-CoA carboxylase activity [GO:0004485]	3-methylcrotonyl-CoA carboxylase complex, mitochondrial [GO:0002169]; cytosol [GO:0005829]; methylcrotonoyl-CoA carboxylase complex [GO:1905202]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
Q14566	MCM6_HUMAN	DNA replication licensing factor MCM6 (EC 3.6.4.12) (p105MCM)	MCM6	2KLQ;2LE8;					PF00493;PF14551;	IPR031327;IPR008049;IPR018525;IPR001208;IPR027925;IPR012340;IPR027417;IPR004039;	DNA replication [GO:0006260]; DNA replication initiation [GO:0006270]; DNA unwinding involved in DNA replication [GO:0006268]; G1/S transition of mitotic cell cycle [GO:0000082]	ATP binding [GO:0005524]; DNA helicase activity [GO:0003678]; single-stranded DNA binding [GO:0003697]	MCM complex [GO:0042555]; nuclear chromosome, telomeric region [GO:0000784]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P33993	MCM7_HUMAN	DNA replication licensing factor MCM7 (EC 3.6.4.12) (CDC47 homolog) (P1.1-MCM3)	MCM7 CDC47 MCM2						PF00493;PF14551;	IPR003593;IPR031327;IPR008050;IPR018525;IPR001208;IPR027925;IPR012340;IPR027417;	cell proliferation [GO:0008283]; cellular response to DNA damage stimulus [GO:0006974]; cellular response to epidermal growth factor stimulus [GO:0071364]; cellular response to xenobiotic stimulus [GO:0071466]; DNA replication [GO:0006260]; DNA replication initiation [GO:0006270]; DNA unwinding involved in DNA replication [GO:0006268]; G1/S transition of mitotic cell cycle [GO:0000082]; regulation of phosphorylation [GO:0042325]; response to drug [GO:0042493]	ATP binding [GO:0005524]; DNA helicase activity [GO:0003678]; single-stranded DNA binding [GO:0003697]	chromatin [GO:0000785]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; MCM complex [GO:0042555]; membrane [GO:0016020]; nuclear chromosome, telomeric region [GO:0000784]; nucleoplasm [GO:0005654]
P15529	MCP_HUMAN	Membrane cofactor protein (TLX) (Trophoblast leukocyte common antigen) (CD antigen CD46)	CD46 MCP MIC10	1CKL;1HR4;2O39;3INB;3L89;3O8E;5FO8;					PF00084;	IPR017341;IPR000436;	adaptive immune response [GO:0002250]; complement activation, classical pathway [GO:0006958]; innate immune response [GO:0045087]; interleukin-10 production [GO:0032613]; negative regulation of gene expression [GO:0010629]; positive regulation of gene expression [GO:0010628]; positive regulation of interleukin-10 production [GO:0032733]; positive regulation of memory T cell differentiation [GO:0043382]; positive regulation of regulatory T cell differentiation [GO:0045591]; positive regulation of T cell proliferation [GO:0042102]; positive regulation of transforming growth factor beta production [GO:0071636]; regulation of complement activation [GO:0030449]; regulation of Notch signaling pathway [GO:0008593]; sequestering of extracellular ligand from receptor [GO:0035581]; single fertilization [GO:0007338]; T cell mediated immunity [GO:0002456]	cadherin binding [GO:0045296]; receptor activity [GO:0004872]; virus receptor activity [GO:0001618]	cell surface [GO:0009986]; extracellular exosome [GO:0070062]; focal adhesion [GO:0005925]; inner acrosomal membrane [GO:0002079]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P08235	MCR_HUMAN	Mineralocorticoid receptor (MR) (Nuclear receptor subfamily 3 group C member 2)	NR3C2 MCR MLR	1Y9R;1YA3;2A3I;2AA2;2AA5;2AA6;2AA7;2AAX;2AB2;2ABI;2OAX;3VHU;3VHV;3WFF;3WFG;4PF3;4TNT;4UDA;4UDB;5HCV;	CHEMBL1994;	P08235;	DB01395;DB00700;DB01023;DB00687;DB00588;DB00393;DB00396;DB00421;		PF00104;PF00105;	IPR000536;IPR001628;IPR013088;	signal transduction [GO:0007165]; transcription initiation from RNA polymerase II promoter [GO:0006367]	sequence-specific DNA binding [GO:0043565]; steroid binding [GO:0005496]; steroid hormone receptor activity [GO:0003707]; transcription factor activity, sequence-specific DNA binding [GO:0003700]; zinc ion binding [GO:0008270]	endoplasmic reticulum membrane [GO:0005789]; nucleoplasm [GO:0005654]; receptor complex [GO:0043235]
P40925	MDHC_HUMAN	Malate dehydrogenase, cytoplasmic (EC 1.1.1.37) (Cytosolic malate dehydrogenase) (Diiodophenylpyruvate reductase) (EC 1.1.1.96)	MDH1 MDHA		CHEMBL3560;	P40925;			PF02866;PF00056;	IPR001557;IPR022383;IPR001236;IPR015955;IPR001252;IPR011274;IPR010945;IPR016040;	gluconeogenesis [GO:0006094]; malate metabolic process [GO:0006108]; NADH metabolic process [GO:0006734]; oxaloacetate metabolic process [GO:0006107]; tricarboxylic acid cycle [GO:0006099]	diiodophenylpyruvate reductase activity [GO:0047860]; L-malate dehydrogenase activity [GO:0030060]; malic enzyme activity [GO:0004470]; NAD binding [GO:0051287]	centrosome [GO:0005813]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; mitochondrion [GO:0005739]; myelin sheath [GO:0043209]
P40926	MDHM_HUMAN	Malate dehydrogenase, mitochondrial (EC 1.1.1.37)	MDH2	2DFD;4WLE;4WLF;4WLN;4WLO;4WLU;4WLV;	CHEMBL5917;	P40926;			PF02866;PF00056;	IPR001557;IPR022383;IPR001236;IPR015955;IPR001252;IPR010097;IPR016040;	gluconeogenesis [GO:0006094]; internal protein amino acid acetylation [GO:0006475]; malate metabolic process [GO:0006108]; NADH metabolic process [GO:0006734]; oxaloacetate metabolic process [GO:0006107]; tricarboxylic acid cycle [GO:0006099]	L-malate dehydrogenase activity [GO:0030060]; malate dehydrogenase (NADP+) activity [GO:0046554]; poly(A) RNA binding [GO:0044822]	extracellular exosome [GO:0070062]; mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; myelin sheath [GO:0043209]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
Q00987	MDM2_HUMAN	E3 ubiquitin-protein ligase Mdm2 (EC 6.3.2.-) (Double minute 2 protein) (Hdm2) (Oncoprotein Mdm2) (p53-binding protein Mdm2)	MDM2	1RV1;1T4E;1T4F;1YCR;1Z1M;2AXI;2C6A;2C6B;2F1Y;2FOP;2GV2;2HDP;2LZG;2M86;2MPS;2RUH;2VJE;2VJF;3EQS;3G03;3IUX;3IWY;3JZK;3JZR;3JZS;3LBK;3LBL;3LNJ;3LNZ;3MQS;3TJ2;3TPX;3TU1;3V3B;3VBG;3VZV;3W69;4DIJ;4ERE;4ERF;4HBM;4HFZ;4HG7;4JV7;4JV9;4JVE;4JVR;4JWR;4MDN;4MDQ;4OAS;4OBA;4OCC;4ODE;4ODF;4OGN;4OGT;4OGV;4OQ3;4QO4;4QOC;4UD7;4UE1;4UMN;4WT2;4XXB;4ZYC;4ZYF;4ZYI;5AFG;5C5A;5HMH;5HMI;5HMK;5LN2;	CHEMBL5023;	Q00987;			PF02201;PF00641;	IPR028340;IPR015459;IPR016495;IPR003121;IPR001876;IPR001841;IPR013083;	atrial septum development [GO:0003283]; atrioventricular valve morphogenesis [GO:0003181]; blood vessel development [GO:0001568]; blood vessel remodeling [GO:0001974]; cardiac septum morphogenesis [GO:0060411]; cellular response to alkaloid [GO:0071312]; cellular response to antibiotic [GO:0071236]; cellular response to estrogen stimulus [GO:0071391]; cellular response to growth factor stimulus [GO:0071363]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to hypoxia [GO:0071456]; cellular response to peptide hormone stimulus [GO:0071375]; cellular response to UV-C [GO:0071494]; cellular response to vitamin B1 [GO:0071301]; DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest [GO:0006977]; endocardial cushion morphogenesis [GO:0003203]; establishment of protein localization [GO:0045184]; negative regulation of cell cycle arrest [GO:0071157]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154]; negative regulation of DNA damage response, signal transduction by p53 class mediator [GO:0043518]; negative regulation of neuron projection development [GO:0010977]; negative regulation of protein processing [GO:0010955]; negative regulation of signal transduction by p53 class mediator [GO:1901797]; negative regulation of transcription, DNA-templated [GO:0045892]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; peptidyl-lysine modification [GO:0018205]; positive regulation of cell proliferation [GO:0008284]; positive regulation of gene expression [GO:0010628]; positive regulation of mitotic cell cycle [GO:0045931]; positive regulation of proteasomal ubiquitin-dependent protein catabolic process [GO:0032436]; positive regulation of protein export from nucleus [GO:0046827]; positive regulation of vascular associated smooth muscle cell migration [GO:1904754]; positive regulation of vascular smooth muscle cell proliferation [GO:1904707]; protein complex assembly [GO:0006461]; protein destabilization [GO:0031648]; protein localization to nucleus [GO:0034504]; protein sumoylation [GO:0016925]; protein ubiquitination [GO:0016567]; protein ubiquitination involved in ubiquitin-dependent protein catabolic process [GO:0042787]; regulation of heart rate [GO:0002027]; regulation of protein catabolic process [GO:0042176]; regulation of signal transduction by p53 class mediator [GO:1901796]; response to antibiotic [GO:0046677]; response to carbohydrate [GO:0009743]; response to cocaine [GO:0042220]; response to drug [GO:0042493]; response to ether [GO:0045472]; response to iron ion [GO:0010039]; response to magnesium ion [GO:0032026]; response to morphine [GO:0043278]; response to steroid hormone [GO:0048545]; response to toxic substance [GO:0009636]; response to water-immersion restraint stress [GO:1990785]; traversing start control point of mitotic cell cycle [GO:0007089]; ventricular septum development [GO:0003281]; viral process [GO:0016032]	enzyme binding [GO:0019899]; ligase activity [GO:0016874]; p53 binding [GO:0002039]; SUMO transferase activity [GO:0019789]; ubiquitin protein ligase activity [GO:0061630]; ubiquitin protein ligase binding [GO:0031625]; ubiquitin-protein transferase activity [GO:0004842]; zinc ion binding [GO:0008270]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; endocytic vesicle membrane [GO:0030666]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; protein complex [GO:0043234]; synapse [GO:0045202]
P08183	MDR1_HUMAN	Multidrug resistance protein 1 (EC 3.6.3.44) (ATP-binding cassette sub-family B member 1) (P-glycoprotein 1) (CD antigen CD243)	ABCB1 MDR1 PGY1		CHEMBL4302;	P08183;	DB01193;DB00316;DB00945;DB00171;DB05773;DB08916;DB00518;DB11363;DB00802;DB00523;DB00915;DB06403;DB00345;DB01118;DB00321;DB00381;DB00701;DB00276;DB06605;DB01169;DB00637;DB01072;DB00335;DB01076;DB06626;DB00972;DB00207;DB01086;DB01244;DB00443;DB00810;DB08873;DB06616;DB08870;DB01200;DB00921;DB00490;DB06772;DB00201;DB08907;DB00796;DB01197;DB00564;DB08889;DB01136;DB00520;DB09063;DB00608;DB00477;DB00672;DB01239;DB02659;DB01340;DB00501;DB00537;DB00515;DB00215;DB01211;DB00349;DB00845;DB00882;DB01242;DB00575;DB00758;DB00257;DB00363;DB09065;DB05239;DB01394;DB00286;DB08865;DB00531;DB00091;DB06695;DB08912;DB09102;DB00970;DB06292;DB01254;DB00694;DB04840;DB01151;DB00967;DB01234;DB00514;DB00829;DB00586;DB00255;DB01396;DB00390;DB00320;DB00343;DB00975;DB01248;DB01184;DB00590;DB01142;DB00997;DB00470;DB04855;DB09075;DB00216;DB00584;DB08899;DB00751;DB01253;DB00696;DB00530;DB00199;DB00783;DB01196;DB04573;DB00655;DB00977;DB00773;DB06414;DB00973;DB01023;DB00813;DB06702;DB00950;DB08874;DB00196;DB00472;DB00875;DB00623;DB00690;DB08906;DB00176;DB00317;DB00441;DB01016;DB00027;DB00502;DB00741;DB01050;DB09054;DB00619;DB00458;DB05039;DB00224;DB00328;DB00762;DB06636;DB01167;DB08820;DB00602;DB01221;DB01587;DB01026;DB00709;DB00555;DB00448;DB01259;DB00480;DB09078;DB01202;DB01137;DB08918;DB00451;DB00281;DB08882;DB00279;DB01583;DB00722;DB08827;DB00836;DB01601;DB00455;DB00678;DB00227;DB00742;DB00934;DB00643;DB00358;DB00351;DB00371;DB00333;DB00563;DB00959;DB00264;DB01110;DB00683;DB00834;DB08893;DB00305;DB01204;DB00295;DB00688;DB01203;DB01183;DB00704;DB01149;DB00220;DB01400;DB00622;DB01115;DB04868;DB09079;DB00401;DB01595;DB01054;DB00585;DB00717;DB00334;DB00338;DB09330;DB01229;DB06603;DB00213;DB00715;DB06589;DB00790;DB01174;DB00252;DB01100;DB08860;DB08910;DB08901;DB01263;DB00175;DB00457;DB00860;DB00635;DB01032;DB00396;DB01069;DB01182;DB00571;DB00344;DB01224;DB01103;DB00908;DB00468;DB00863;DB00234;DB08896;DB00206;DB01045;DB08864;DB00734;DB00503;DB06228;DB09291;DB06176;DB00778;DB00936;DB01232;DB00747;DB01037;DB11362;DB01104;DB06207;DB06290;DB00641;DB00877;DB01261;DB08934;DB00398;DB01208;DB00421;DB00428;DB01138;DB00669;DB01268;DB00864;DB00675;DB05521;DB00966;DB06287;DB01162;DB00624;DB08816;DB00373;DB06212;DB01030;DB00539;DB00656;DB00831;DB00508;DB00440;DB00726;DB01361;DB08867;DB09076;DB01339;DB00285;DB00661;DB00570;DB00541;DB00361;DB08828;DB04877;DB00495;		PF00664;PF00005;	IPR003593;IPR011527;IPR003439;IPR017871;IPR027417;	antigen processing and presentation of endogenous peptide antigen via MHC class Ib via ER pathway, TAP-dependent [GO:0002489]; antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-dependent [GO:0002485]; antigen processing and presentation of exogenous protein antigen via MHC class Ib, TAP-dependent [GO:0002481]; ceramide translocation [GO:0099040]; G2/M transition of mitotic cell cycle [GO:0000086]; phospholipid translocation [GO:0045332]; positive regulation of antigen processing and presentation of peptide antigen via MHC class I [GO:0002591]; response to drug [GO:0042493]; stem cell proliferation [GO:0072089]; transmembrane transport [GO:0055085]; transport [GO:0006810]	ATPase activity, coupled to transmembrane movement of substances [GO:0042626]; ATP binding [GO:0005524]; ceramide-translocating ATPase activity [GO:0099038]; phosphatidylcholine-translocating ATPase activity [GO:0090554]; phosphatidylethanolamine-translocating ATPase activity [GO:0090555]; transporter activity [GO:0005215]; xenobiotic-transporting ATPase activity [GO:0008559]	apical plasma membrane [GO:0016324]; cell surface [GO:0009986]; extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; membrane [GO:0016020]; plasma membrane [GO:0005886]
O15553	MEFV_HUMAN	Pyrin (Marenostrin)	MEFV MEF TRIM20	2MPC;2WL1;4CG4;					PF13765;PF02758;PF00622;PF00643;	IPR001870;IPR003879;IPR013320;IPR004020;IPR011029;IPR006574;IPR003877;IPR000315;	inflammatory response [GO:0006954]; negative regulation of cytokine production involved in inflammatory response [GO:1900016]; negative regulation of inflammatory response [GO:0050728]; negative regulation of interleukin-12 production [GO:0032695]; negative regulation of interleukin-1 beta production [GO:0032691]; negative regulation of macrophage inflammatory protein 1 alpha production [GO:0071641]; negative regulation of NLRP3 inflammasome complex assembly [GO:1900226]; positive regulation of autophagy [GO:0010508]; positive regulation of cysteine-type endopeptidase activity [GO:2001056]; response to interferon-gamma [GO:0034341]	actin binding [GO:0003779]; zinc ion binding [GO:0008270]	autophagosome [GO:0005776]; cytoplasm [GO:0005737]; cytoplasmic vesicle [GO:0031410]; cytosol [GO:0005829]; lamellipodium [GO:0030027]; microtubule [GO:0005874]; microtubule associated complex [GO:0005875]; nucleus [GO:0005634]; ruffle [GO:0001726]
Q99707	METH_HUMAN	Methionine synthase (EC 2.1.1.13) (5-methyltetrahydrofolate--homocysteine methyltransferase) (Vitamin-B12 dependent methionine synthase) (MS)	MTR	2O2K;4CCZ;	CHEMBL2150844;	Q99707;	DB00115;DB00200;DB00134;DB00116;	PATHWAY: Amino-acid biosynthesis; L-methionine biosynthesis via de novo pathway; L-methionine from L-homocysteine (MetH route): step 1/1.	PF02310;PF02607;PF02965;PF00809;PF02574;	IPR003759;IPR006158;IPR011005;IPR003726;IPR033706;IPR011822;IPR000489;IPR004223;	axon regeneration [GO:0031103]; cellular response to nitric oxide [GO:0071732]; cobalamin metabolic process [GO:0009235]; methionine biosynthetic process [GO:0009086]; methylation [GO:0032259]; nervous system development [GO:0007399]; pteridine-containing compound metabolic process [GO:0042558]; response to axon injury [GO:0048678]; sulfur amino acid metabolic process [GO:0000096]	cobalamin binding [GO:0031419]; methionine synthase activity [GO:0008705]; S-adenosylmethionine-homocysteine S-methyltransferase activity [GO:0008898]; zinc ion binding [GO:0008270]	cytoplasm [GO:0005737]; cytosol [GO:0005829]
Q00266	METK1_HUMAN	S-adenosylmethionine synthase isoform type-1 (AdoMet synthase 1) (EC 2.5.1.6) (Methionine adenosyltransferase 1) (MAT 1) (Methionine adenosyltransferase I/III) (MAT-I/III)	MAT1A AMS1 MATA1	2OBV;			DB00134;DB00118;	PATHWAY: Amino-acid biosynthesis; S-adenosyl-L-methionine biosynthesis; S-adenosyl-L-methionine from L-methionine: step 1/1. {ECO:0000269|PubMed:10677294}.	PF02773;PF02772;PF00438;	IPR022631;IPR022630;IPR022629;IPR022628;IPR002133;IPR022636;	methionine catabolic process [GO:0009087]; methylation [GO:0032259]; one-carbon metabolic process [GO:0006730]; protein homotetramerization [GO:0051289]; S-adenosylmethionine biosynthetic process [GO:0006556]; selenium compound metabolic process [GO:0001887]; sulfur amino acid metabolic process [GO:0000096]	ATP binding [GO:0005524]; metal ion binding [GO:0046872]; methionine adenosyltransferase activity [GO:0004478]; selenomethionine adenosyltransferase activity [GO:0098601]	cytosol [GO:0005829]
P31153	METK2_HUMAN	S-adenosylmethionine synthase isoform type-2 (AdoMet synthase 2) (EC 2.5.1.6) (Methionine adenosyltransferase 2) (MAT 2) (Methionine adenosyltransferase II) (MAT-II)	MAT2A AMS2 MATA2	2P02;4KTT;4KTV;4NDN;5A19;5A1G;5A1I;	CHEMBL3313835;		DB00134;DB00118;	PATHWAY: Amino-acid biosynthesis; S-adenosyl-L-methionine biosynthesis; S-adenosyl-L-methionine from L-methionine: step 1/1. {ECO:0000269|PubMed:10644686, ECO:0000269|PubMed:23189196, ECO:0000269|PubMed:25075345}.	PF02773;PF02772;PF00438;	IPR022631;IPR022630;IPR022629;IPR022628;IPR002133;IPR022636;	methylation [GO:0032259]; one-carbon metabolic process [GO:0006730]; protein heterooligomerization [GO:0051291]; protein hexamerization [GO:0034214]; S-adenosylmethionine biosynthetic process [GO:0006556]	ATP binding [GO:0005524]; metal ion binding [GO:0046872]; methionine adenosyltransferase activity [GO:0004478]	cytosol [GO:0005829]; methionine adenosyltransferase complex [GO:0048269]
P08581	MET_HUMAN	Hepatocyte growth factor receptor (HGF receptor) (EC 2.7.10.1) (HGF/SF receptor) (Proto-oncogene c-Met) (Scatter factor receptor) (SF receptor) (Tyrosine-protein kinase Met)	MET	1FYR;1R0P;1R1W;1SHY;1SSL;1UX3;2G15;2RFN;2RFS;2UZX;2UZY;2WD1;2WGJ;2WKM;3A4P;3BUX;3C1X;3CCN;3CD8;3CE3;3CTH;3CTJ;3DKC;3DKF;3DKG;3EFJ;3EFK;3F66;3F82;3I5N;3L8V;3LQ8;3Q6U;3Q6W;3QTI;3R7O;3RHK;3U6H;3U6I;3VW8;3ZBX;3ZC5;3ZCL;3ZXZ;3ZZE;4AOI;4AP7;4DEG;4DEH;4DEI;4EEV;4GG5;4GG7;4IWD;4K3J;4KNB;4MXC;4O3T;4O3U;4R1V;4R1Y;4XMO;4XYF;5DG5;5EYC;5EYD;	CHEMBL3717;	P08581;	DB08875;DB08865;		PF07714;PF01437;PF01403;PF01833;	IPR013783;IPR014756;IPR002909;IPR011009;IPR016201;IPR002165;IPR000719;IPR017441;IPR001627;IPR001245;IPR008266;IPR020635;IPR016244;IPR015943;	branching morphogenesis of an epithelial tube [GO:0048754]; cell proliferation [GO:0008283]; cell surface receptor signaling pathway [GO:0007166]; endothelial cell morphogenesis [GO:0001886]; negative regulation of autophagy [GO:0010507]; negative regulation of hydrogen peroxide-mediated programmed cell death [GO:1901299]; positive chemotaxis [GO:0050918]; positive regulation of endothelial cell chemotaxis [GO:2001028]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; semaphorin-plexin signaling pathway [GO:0071526]; signal transduction [GO:0007165]	ATP binding [GO:0005524]; hepatocyte growth factor-activated receptor activity [GO:0005008]; protein phosphatase binding [GO:0019903]; protein tyrosine kinase activity [GO:0004713]	basal plasma membrane [GO:0009925]; cell surface [GO:0009986]; extracellular region [GO:0005576]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
Q9H2D1	MFTC_HUMAN	Mitochondrial folate transporter/carrier (Solute carrier family 25 member 32)	SLC25A32 MFT MFTC				DB00158;		PF00153;	IPR002030;IPR018108;IPR023395;	folic acid import into mitochondrion [GO:1904947]; folic acid metabolic process [GO:0046655]; folic acid transport [GO:0015884]; glycine metabolic process [GO:0006544]; translation [GO:0006412]	folic acid transporter activity [GO:0008517]; structural constituent of ribosome [GO:0003735]	integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrion [GO:0005739]
O43451	MGA_HUMAN	Maltase-glucoamylase, intestinal [Includes: Maltase (EC 3.2.1.20) (Alpha-glucosidase); Glucoamylase (EC 3.2.1.3) (Glucan 1,4-alpha-glucosidase)]	MGAM MGA MGAML	2QLY;2QMJ;3CTT;3L4T;3L4U;3L4V;3L4W;3L4X;3L4Y;3L4Z;3TON;3TOP;	CHEMBL2074;	O43451;	DB00284;DB00491;DB04878;		PF01055;PF16863;PF00088;	IPR031727;IPR011013;IPR000322;IPR030458;IPR030459;IPR017853;IPR017957;IPR000519;	polysaccharide digestion [GO:0044245]; starch catabolic process [GO:0005983]	alpha-1,4-glucosidase activity [GO:0004558]; amylase activity [GO:0016160]; carbohydrate binding [GO:0030246]; catalytic activity [GO:0003824]; glucan 1,4-alpha-glucosidase activity [GO:0004339]; maltose alpha-glucosidase activity [GO:0032450]	apical plasma membrane [GO:0016324]; extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]
P16455	MGMT_HUMAN	Methylated-DNA--protein-cysteine methyltransferase (EC 2.1.1.63) (6-O-methylguanine-DNA methyltransferase) (MGMT) (O-6-methylguanine-DNA-alkyltransferase)	MGMT	1EH6;1EH7;1EH8;1QNT;1T38;1T39;1YFH;	CHEMBL2864;	P16455;	DB00151;		PF01035;PF02870;	IPR001497;IPR014048;IPR008332;IPR011991;	cellular response to ionizing radiation [GO:0071479]; cellular response to organic cyclic compound [GO:0071407]; cellular response to oxidative stress [GO:0034599]; DNA dealkylation involved in DNA repair [GO:0006307]; DNA ligation [GO:0006266]; mammary gland epithelial cell differentiation [GO:0060644]; negative regulation of apoptotic process [GO:0043066]; positive regulation of double-strand break repair [GO:2000781]; regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043281]; response to drug [GO:0042493]; response to ethanol [GO:0045471]; response to folic acid [GO:0051593]; response to toxic substance [GO:0009636]	calcium ion binding [GO:0005509]; damaged DNA binding [GO:0003684]; DNA binding [GO:0003677]; DNA-methyltransferase activity [GO:0009008]; methylated-DNA-[protein]-cysteine S-methyltransferase activity [GO:0003908]; methyltransferase activity [GO:0008168]	membrane [GO:0016020]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
Q13255	MGR1_HUMAN	Metabotropic glutamate receptor 1 (mGluR1)	GRM1 GPRC1A MGLUR1	3KS9;4OR2;	CHEMBL3772;	Q13255;			PF00003;PF01094;PF10606;PF07562;	IPR001828;IPR000337;IPR011500;IPR017978;IPR017979;IPR000162;IPR001256;IPR019588;IPR028082;	activation of MAPK activity [GO:0000187]; activation of MAPKK activity [GO:0000186]; cellular response to electrical stimulus [GO:0071257]; chemical synaptic transmission [GO:0007268]; dimeric G-protein coupled receptor signaling pathway [GO:0038042]; G-protein coupled glutamate receptor signaling pathway [GO:0007216]; G-protein coupled receptor signaling pathway [GO:0007186]; locomotory behavior [GO:0007626]; positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway [GO:0051482]; protein kinase C-activating G-protein coupled receptor signaling pathway [GO:0007205]; regulation of sensory perception of pain [GO:0051930]; regulation of synaptic transmission, glutamatergic [GO:0051966]; sensory perception of pain [GO:0019233]	glutamate receptor activity [GO:0008066]; G-protein coupled receptor activity [GO:0004930]	dendrite [GO:0030425]; G-protein coupled receptor dimeric complex [GO:0038037]; G-protein coupled receptor homodimeric complex [GO:0038038]; integral component of plasma membrane [GO:0005887]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; postsynaptic density [GO:0014069]
Q14416	MGR2_HUMAN	Metabotropic glutamate receptor 2 (mGluR2)	GRM2 GPRC1B MGLUR2	4XAQ;4XAS;5CNI;5CNJ;	CHEMBL5137;	Q14416;			PF00003;PF01094;PF07562;	IPR001828;IPR000337;IPR011500;IPR017978;IPR017979;IPR000162;IPR001458;IPR028082;	adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway [GO:0007196]; chemical synaptic transmission [GO:0007268]; glutamate secretion [GO:0014047]; negative regulation of adenylate cyclase activity [GO:0007194]; regulation of synaptic transmission, glutamatergic [GO:0051966]	calcium channel regulator activity [GO:0005246]; glutamate receptor activity [GO:0008066]; G-protein coupled receptor activity [GO:0004930]; group II metabotropic glutamate receptor activity [GO:0001641]	axon [GO:0030424]; cell junction [GO:0030054]; dendrite [GO:0030425]; integral component of plasma membrane [GO:0005887]; intracellular [GO:0005622]; plasma membrane [GO:0005886]; presynaptic membrane [GO:0042734]
P60602	MGR2_HUMAN	Reactive oxygen species modulator 1 (ROS modulator 1) (Epididymis tissue protein Li 175) (Glyrichin) (Mitochondrial targeting GxxxG motif protein) (MTGM) (Protein MGR2 homolog)	ROMO1 C20orf52						PF10247;	IPR018450;	cellular response to reactive oxygen species [GO:0034614]; defense response to bacterium [GO:0042742]; positive regulation of cell proliferation [GO:0008284]; positive regulation of reactive oxygen species metabolic process [GO:2000379]; replicative cell aging [GO:0001302]		integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrion [GO:0005739]
Q14832	MGR3_HUMAN	Metabotropic glutamate receptor 3 (mGluR3)	GRM3 GPRC1C MGLUR3	1S8M;3SM9;4XAR;5CNK;5CNM;	CHEMBL2888;	Q14832;			PF00003;PF01094;PF07562;	IPR001828;IPR000337;IPR011500;IPR017978;IPR017979;IPR000162;IPR001234;IPR028082;	adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway [GO:0007196]; chemical synaptic transmission [GO:0007268]; negative regulation of adenylate cyclase activity [GO:0007194]; regulation of synaptic transmission, glutamatergic [GO:0051966]	calcium channel regulator activity [GO:0005246]; glutamate receptor activity [GO:0008066]; G-protein coupled receptor activity [GO:0004930]; group II metabotropic glutamate receptor activity [GO:0001641]	axon [GO:0030424]; dendritic spine [GO:0043197]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; postsynaptic density [GO:0014069]; postsynaptic membrane [GO:0045211]; presynaptic membrane [GO:0042734]
Q14833	MGR4_HUMAN	Metabotropic glutamate receptor 4 (mGluR4)	GRM4 GPRC1D MGLUR4		CHEMBL2736;	Q14833;			PF00003;PF01094;PF07562;	IPR001828;IPR000337;IPR011500;IPR017978;IPR017979;IPR000162;IPR001786;IPR028082;	activation of MAPK activity [GO:0000187]; adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway [GO:0007196]; chemical synaptic transmission [GO:0007268]; neurotransmitter secretion [GO:0007269]; positive regulation of MAPK cascade [GO:0043410]; regulation of neuron apoptotic process [GO:0043523]; regulation of synaptic transmission, glutamatergic [GO:0051966]	glutamate receptor activity [GO:0008066]; G-protein coupled receptor activity [GO:0004930]; group III metabotropic glutamate receptor activity [GO:0001642]	cytoplasmic vesicle [GO:0031410]; integral component of plasma membrane [GO:0005887]; intracellular [GO:0005622]; plasma membrane [GO:0005886]; presynaptic membrane [GO:0042734]
P41594	MGR5_HUMAN	Metabotropic glutamate receptor 5 (mGluR5)	GRM5 GPRC1E MGLUR5	3LMK;4OO9;5CGC;5CGD;	CHEMBL3227;	P41594;	DB00659;DB06201;		PF00003;PF01094;PF10606;PF07562;	IPR001828;IPR000337;IPR011500;IPR017978;IPR017979;IPR000162;IPR000202;IPR019588;IPR028082;	chemical synaptic transmission [GO:0007268]; cognition [GO:0050890]; G-protein coupled glutamate receptor signaling pathway [GO:0007216]; learning [GO:0007612]; locomotory behavior [GO:0007626]; phospholipase C-activating G-protein coupled glutamate receptor signaling pathway [GO:0007206]; protein kinase C-activating G-protein coupled receptor signaling pathway [GO:0007205]; regulation of long-term neuronal synaptic plasticity [GO:0048169]; regulation of synaptic transmission, glutamatergic [GO:0051966]	glutamate receptor activity [GO:0008066]; G-protein coupled receptor activity [GO:0004930]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; neuron projection [GO:0043005]; plasma membrane [GO:0005886]; postsynaptic density [GO:0014069]
Q14831	MGR7_HUMAN	Metabotropic glutamate receptor 7 (mGluR7)	GRM7 GPRC1G MGLUR7	3MQ4;5C5C;	CHEMBL3777;	Q14831;			PF00003;PF01094;PF07562;	IPR001828;IPR000337;IPR011500;IPR017978;IPR017979;IPR000162;IPR001883;IPR028082;	adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway [GO:0007196]; adult behavior [GO:0030534]; chemical synaptic transmission [GO:0007268]; conditioned taste aversion [GO:0001661]; multicellular organismal response to stress [GO:0033555]; negative regulation of adenylate cyclase activity [GO:0007194]; negative regulation of cAMP biosynthetic process [GO:0030818]; negative regulation of glutamate secretion [GO:0014050]; regulation of synaptic transmission, glutamatergic [GO:0051966]; sensory perception of smell [GO:0007608]; sensory perception of sound [GO:0007605]; short-term memory [GO:0007614]; transmission of nerve impulse [GO:0019226]	adenylate cyclase inhibitor activity [GO:0010855]; calcium channel regulator activity [GO:0005246]; calcium ion binding [GO:0005509]; glutamate binding [GO:0016595]; glutamate receptor activity [GO:0008066]; group III metabotropic glutamate receptor activity [GO:0001642]; PDZ domain binding [GO:0030165]; serine binding [GO:0070905]; voltage-gated calcium channel activity [GO:0005245]	asymmetric synapse [GO:0032279]; axon [GO:0030424]; cell cortex [GO:0005938]; dendrite [GO:0030425]; dendritic shaft [GO:0043198]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]; presynaptic active zone [GO:0048786]; presynaptic membrane [GO:0042734]; receptor complex [GO:0043235]
O00222	MGR8_HUMAN	Metabotropic glutamate receptor 8 (mGluR8)	GRM8 GPRC1H MGLUR8		CHEMBL3228;	O00222;			PF00003;PF01094;PF07562;	IPR001828;IPR000337;IPR011500;IPR017978;IPR017979;IPR000162;IPR000144;IPR028082;	adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway [GO:0007196]; negative regulation of cAMP biosynthetic process [GO:0030818]; regulation of synaptic transmission, glutamatergic [GO:0051966]; sensory perception of smell [GO:0007608]; visual perception [GO:0007601]	glutamate receptor activity [GO:0008066]; G-protein coupled receptor activity [GO:0004930]; group III metabotropic glutamate receptor activity [GO:0001642]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; presynaptic membrane [GO:0042734]
P10620	MGST1_HUMAN	Microsomal glutathione S-transferase 1 (Microsomal GST-1) (EC 2.5.1.18) (Microsomal GST-I)	MGST1 GST12 MGST		CHEMBL1743184;		DB00143;		PF01124;	IPR023352;IPR001129;	cellular response to lipid hydroperoxide [GO:0071449]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; Leydig cell differentiation [GO:0033327]; oxidation-reduction process [GO:0055114]; protein homotrimerization [GO:0070207]; response to drug [GO:0042493]; response to lipopolysaccharide [GO:0032496]; response to organonitrogen compound [GO:0010243]; xenobiotic metabolic process [GO:0006805]	glutathione binding [GO:0043295]; glutathione peroxidase activity [GO:0004602]; glutathione transferase activity [GO:0004364]	apical part of cell [GO:0045177]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrial outer membrane [GO:0005741]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; peroxisomal membrane [GO:0005778]
Q99735	MGST2_HUMAN	Microsomal glutathione S-transferase 2 (Microsomal GST-2) (EC 2.5.1.18) (Microsomal GST-II)	MGST2 GST2		CHEMBL1743185;		DB01008;DB00143;		PF01124;	IPR001446;IPR018295;IPR023352;IPR001129;	glutathione biosynthetic process [GO:0006750]; glutathione derivative biosynthetic process [GO:1901687]; leukotriene biosynthetic process [GO:0019370]; response to lipopolysaccharide [GO:0032496]; response to organonitrogen compound [GO:0010243]; xenobiotic metabolic process [GO:0006805]	enzyme activator activity [GO:0008047]; glutathione peroxidase activity [GO:0004602]; glutathione transferase activity [GO:0004364]; leukotriene-C4 synthase activity [GO:0004464]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; intracellular membrane-bounded organelle [GO:0043231]; nuclear envelope [GO:0005635]; organelle membrane [GO:0031090]; plasma membrane [GO:0005886]
O14880	MGST3_HUMAN	Microsomal glutathione S-transferase 3 (Microsomal GST-3) (EC 2.5.1.18) (Microsomal GST-III)	MGST3		CHEMBL1743186;		DB00143;		PF01124;	IPR023352;IPR001129;	glutathione derivative biosynthetic process [GO:1901687]; lipid metabolic process [GO:0006629]; response to organonitrogen compound [GO:0010243]; signal transduction [GO:0007165]; xenobiotic metabolic process [GO:0006805]	glutathione peroxidase activity [GO:0004602]; glutathione transferase activity [GO:0004364]; peroxidase activity [GO:0004601]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; intracellular membrane-bounded organelle [GO:0043231]; membrane [GO:0016020]; nuclear envelope [GO:0005635]; organelle membrane [GO:0031090]
P14174	MIF_HUMAN	Macrophage migration inhibitory factor (MIF) (EC 5.3.2.1) (Glycosylation-inhibiting factor) (GIF) (L-dopachrome isomerase) (L-dopachrome tautomerase) (EC 5.3.3.12) (Phenylpyruvate tautomerase)	MIF GLIF MMIF	1CA7;1CGQ;1GCZ;1GD0;1GIF;1LJT;1MIF;1P1G;2OOH;2OOW;2OOZ;3B9S;3CE4;3DJH;3DJI;3HOF;3IJG;3IJJ;3JSF;3JSG;3JTU;3L5P;3L5R;3L5S;3L5T;3L5U;3L5V;3SMB;3SMC;3U18;3WNR;3WNS;3WNT;4ETG;4EUI;4EVG;4F2K;4GRN;4GRO;4GRP;4GRQ;4GRR;4GRU;4GUM;4K9G;4OSF;4OYQ;4P01;4P0H;4PKK;4PKZ;4PLU;4TRF;4TRU;4WR8;4WRB;4XX7;4XX8;5B4O;5BS9;5BSC;5BSI;5BSJ;5CG4;5EIZ;5HVS;5HVT;5HVV;5J7P;5J7Q;	CHEMBL2085;	P14174;			PF01187;	IPR001398;IPR019829;IPR014347;	carboxylic acid metabolic process [GO:0019752]; cell aging [GO:0007569]; cell proliferation [GO:0008283]; cell surface receptor signaling pathway [GO:0007166]; DNA damage response, signal transduction by p53 class mediator [GO:0030330]; inflammatory response [GO:0006954]; innate immune response [GO:0045087]; leukocyte migration [GO:0050900]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cell aging [GO:0090344]; negative regulation of cell cycle arrest [GO:0071157]; negative regulation of cellular protein metabolic process [GO:0032269]; negative regulation of DNA damage response, signal transduction by p53 class mediator [GO:0043518]; negative regulation of gene expression [GO:0010629]; negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator [GO:1902166]; negative regulation of mature B cell apoptotic process [GO:0002906]; negative regulation of myeloid cell apoptotic process [GO:0033033]; positive regulation of arachidonic acid secretion [GO:0090238]; positive regulation of B cell proliferation [GO:0030890]; positive regulation of chemokine (C-X-C motif) ligand 2 production [GO:2000343]; positive regulation of cytokine secretion [GO:0050715]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of fibroblast proliferation [GO:0048146]; positive regulation of lipopolysaccharide-mediated signaling pathway [GO:0031666]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of myeloid leukocyte cytokine production involved in immune response [GO:0061081]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of phosphorylation [GO:0042327]; positive regulation of prostaglandin secretion involved in immune response [GO:0061078]; positive regulation of protein kinase A signaling [GO:0010739]; prostaglandin biosynthetic process [GO:0001516]; protein homotrimerization [GO:0070207]; regulation of macrophage activation [GO:0043030]	chemoattractant activity [GO:0042056]; cytokine activity [GO:0005125]; cytokine receptor binding [GO:0005126]; dopachrome isomerase activity [GO:0004167]; phenylpyruvate tautomerase activity [GO:0050178]; receptor binding [GO:0005102]	cell surface [GO:0009986]; cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; myelin sheath [GO:0043209]; nucleoplasm [GO:0005654]; vesicle [GO:0031982]
P28482	MK01_HUMAN	Mitogen-activated protein kinase 1 (MAP kinase 1) (MAPK 1) (EC 2.7.11.24) (ERT1) (Extracellular signal-regulated kinase 2) (ERK-2) (MAP kinase isoform p42) (p42-MAPK) (Mitogen-activated protein kinase 2) (MAP kinase 2) (MAPK 2)	MAPK1 ERK2 PRKM1 PRKM2	1PME;1TVO;1WZY;2OJG;2OJI;2OJJ;2Y9Q;3D42;3D44;3I5Z;3I60;3SA0;3TEI;3W55;4FMQ;4FUX;4FUY;4FV0;4FV1;4FV2;4FV3;4FV4;4FV5;4FV6;4FV7;4FV8;4FV9;4G6N;4G6O;4H3P;4H3Q;4IZ5;4IZ7;4IZA;4N0S;4NIF;4O6E;4QP1;4QP2;4QP3;4QP4;4QP6;4QP7;4QP8;4QP9;4QPA;4QTA;4QTE;4XJ0;4ZXT;4ZZM;4ZZN;4ZZO;5AX3;5BUE;5BUI;5BUJ;5BVD;5BVE;5BVF;5K4I;5LCJ;5LCK;	CHEMBL4040;	P28482;	DB01169;DB01064;		PF00069;	IPR011009;IPR003527;IPR008349;IPR000719;IPR017441;IPR008271;	activation of MAPK activity [GO:0000187]; apoptotic process [GO:0006915]; axon guidance [GO:0007411]; B cell receptor signaling pathway [GO:0050853]; Bergmann glial cell differentiation [GO:0060020]; cardiac neural crest cell development involved in heart development [GO:0061308]; caveolin-mediated endocytosis [GO:0072584]; cell cycle [GO:0007049]; cellular response to DNA damage stimulus [GO:0006974]; cellular response to granulocyte macrophage colony-stimulating factor stimulus [GO:0097011]; chemical synaptic transmission [GO:0007268]; chemotaxis [GO:0006935]; cytosine metabolic process [GO:0019858]; ERBB signaling pathway [GO:0038127]; ERK1 and ERK2 cascade [GO:0070371]; face development [GO:0060324]; Fc-epsilon receptor signaling pathway [GO:0038095]; Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096]; fibroblast growth factor receptor signaling pathway [GO:0008543]; JAK-STAT cascade involved in growth hormone signaling pathway [GO:0060397]; labyrinthine layer blood vessel development [GO:0060716]; lipopolysaccharide-mediated signaling pathway [GO:0031663]; long-term synaptic potentiation [GO:0060291]; lung morphogenesis [GO:0060425]; mammary gland epithelial cell proliferation [GO:0033598]; MAPK cascade [GO:0000165]; MAPK import into nucleus [GO:0000189]; negative regulation of cell differentiation [GO:0045596]; outer ear morphogenesis [GO:0042473]; peptidyl-serine phosphorylation [GO:0018105]; peptidyl-threonine phosphorylation [GO:0018107]; platelet activation [GO:0030168]; positive regulation of cell migration [GO:0030335]; positive regulation of cell proliferation [GO:0008284]; positive regulation of peptidyl-threonine phosphorylation [GO:0010800]; positive regulation of telomerase activity [GO:0051973]; positive regulation of telomere capping [GO:1904355]; positive regulation of telomere maintenance via telomerase [GO:0032212]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of translation [GO:0045727]; protein phosphorylation [GO:0006468]; regulation of cellular response to heat [GO:1900034]; regulation of cytoskeleton organization [GO:0051493]; regulation of early endosome to late endosome transport [GO:2000641]; regulation of Golgi inheritance [GO:0090170]; regulation of ossification [GO:0030278]; regulation of phosphatidylinositol 3-kinase signaling [GO:0014066]; regulation of protein stability [GO:0031647]; regulation of sequence-specific DNA binding transcription factor activity [GO:0051090]; regulation of stress-activated MAPK cascade [GO:0032872]; response to epidermal growth factor [GO:0070849]; response to estrogen [GO:0043627]; response to exogenous dsRNA [GO:0043330]; response to stress [GO:0006950]; response to toxic substance [GO:0009636]; sensory perception of pain [GO:0019233]; signal transduction [GO:0007165]; T cell receptor signaling pathway [GO:0050852]; thymus development [GO:0048538]; thyroid gland development [GO:0030878]; trachea formation [GO:0060440]; transcription, DNA-templated [GO:0006351]; viral process [GO:0016032]	ATP binding [GO:0005524]; DNA binding [GO:0003677]; kinase activity [GO:0016301]; MAP kinase activity [GO:0004707]; phosphatase binding [GO:0019902]; protein serine/threonine kinase activity [GO:0004674]; RNA polymerase II carboxy-terminal domain kinase activity [GO:0008353]	axon [GO:0030424]; caveola [GO:0005901]; cytoplasm [GO:0005737]; cytoskeleton [GO:0005856]; cytosol [GO:0005829]; dendrite cytoplasm [GO:0032839]; early endosome [GO:0005769]; extracellular exosome [GO:0070062]; focal adhesion [GO:0005925]; Golgi apparatus [GO:0005794]; late endosome [GO:0005770]; microtubule cytoskeleton [GO:0015630]; microtubule organizing center [GO:0005815]; mitochondrion [GO:0005739]; mitotic spindle [GO:0072686]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; perikaryon [GO:0043204]; protein complex [GO:0043234]; pseudopodium [GO:0031143]
P27361	MK03_HUMAN	Mitogen-activated protein kinase 3 (MAP kinase 3) (MAPK 3) (EC 2.7.11.24) (ERT2) (Extracellular signal-regulated kinase 1) (ERK-1) (Insulin-stimulated MAP2 kinase) (MAP kinase isoform p44) (p44-MAPK) (Microtubule-associated protein 2 kinase) (p44-ERK1)	MAPK3 ERK1 PRKM3	2ZOQ;4QTB;	CHEMBL3385;	P27361;	DB01169;DB00605;		PF00069;	IPR011009;IPR003527;IPR008349;IPR000719;IPR017441;IPR008271;	activation of MAPK activity [GO:0000187]; apoptotic process [GO:0006915]; arachidonic acid metabolic process [GO:0019369]; axon guidance [GO:0007411]; Bergmann glial cell differentiation [GO:0060020]; BMP signaling pathway [GO:0030509]; cardiac neural crest cell development involved in heart development [GO:0061308]; cartilage development [GO:0051216]; caveolin-mediated endocytosis [GO:0072584]; cell cycle [GO:0007049]; cellular response to mechanical stimulus [GO:0071260]; DNA damage induced protein phosphorylation [GO:0006975]; ERK1 and ERK2 cascade [GO:0070371]; face development [GO:0060324]; Fc-epsilon receptor signaling pathway [GO:0038095]; Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096]; fibroblast growth factor receptor signaling pathway [GO:0008543]; interleukin-1-mediated signaling pathway [GO:0070498]; JAK-STAT cascade involved in growth hormone signaling pathway [GO:0060397]; lipopolysaccharide-mediated signaling pathway [GO:0031663]; lung morphogenesis [GO:0060425]; MAPK cascade [GO:0000165]; MAPK import into nucleus [GO:0000189]; negative regulation of apolipoprotein binding [GO:2000657]; outer ear morphogenesis [GO:0042473]; peptidyl-serine phosphorylation [GO:0018105]; peptidyl-tyrosine autophosphorylation [GO:0038083]; phosphorylation [GO:0016310]; platelet activation [GO:0030168]; positive regulation of cyclase activity [GO:0031281]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of histone acetylation [GO:0035066]; positive regulation of histone phosphorylation [GO:0033129]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of telomerase activity [GO:0051973]; positive regulation of telomere capping [GO:1904355]; positive regulation of telomere maintenance via telomerase [GO:0032212]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of translation [GO:0045727]; positive regulation of xenophagy [GO:1904417]; protein complex assembly [GO:0006461]; protein phosphorylation [GO:0006468]; regulation of cellular response to heat [GO:1900034]; regulation of cytoskeleton organization [GO:0051493]; regulation of early endosome to late endosome transport [GO:2000641]; regulation of Golgi inheritance [GO:0090170]; regulation of ossification [GO:0030278]; regulation of phosphatidylinositol 3-kinase signaling [GO:0014066]; regulation of sequence-specific DNA binding transcription factor activity [GO:0051090]; regulation of stress-activated MAPK cascade [GO:0032872]; response to epidermal growth factor [GO:0070849]; response to exogenous dsRNA [GO:0043330]; response to toxic substance [GO:0009636]; sensory perception of pain [GO:0019233]; thymus development [GO:0048538]; thyroid gland development [GO:0030878]; trachea formation [GO:0060440]; transcription initiation from RNA polymerase I promoter [GO:0006361]; viral process [GO:0016032]	ATP binding [GO:0005524]; kinase activity [GO:0016301]; MAP kinase activity [GO:0004707]; phosphatase binding [GO:0019902]; protein serine/threonine kinase activity [GO:0004674]	caveola [GO:0005901]; cytoskeleton [GO:0005856]; cytosol [GO:0005829]; early endosome [GO:0005769]; extracellular exosome [GO:0070062]; focal adhesion [GO:0005925]; Golgi apparatus [GO:0005794]; late endosome [GO:0005770]; microtubule cytoskeleton [GO:0015630]; mitochondrion [GO:0005739]; nuclear envelope [GO:0005635]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; protein complex [GO:0043234]; pseudopodium [GO:0031143]
P53779	MK10_HUMAN	Mitogen-activated protein kinase 10 (MAP kinase 10) (MAPK 10) (EC 2.7.11.24) (MAP kinase p49 3F12) (Stress-activated protein kinase 1b) (SAPK1b) (Stress-activated protein kinase JNK3) (c-Jun N-terminal kinase 3)	MAPK10 JNK3 JNK3A PRKM10 SAPK1B	1JNK;1PMN;1PMU;1PMV;2B1P;2EXC;2O0U;2O2U;2OK1;2P33;2R9S;2WAJ;2ZDT;2ZDU;3CGF;3CGO;3DA6;3FI2;3FI3;3FV8;3G90;3G9L;3G9N;3KVX;3OXI;3OY1;3PTG;3RTP;3TTI;3TTJ;3V6R;3V6S;4H36;4H39;4H3B;4KKE;4KKG;4KKH;4U79;4W4V;4W4W;4W4X;4W4Y;4WHZ;4X21;4Y46;4Y5H;4Z9L;	CHEMBL2637;	P53779;			PF00069;	IPR011009;IPR003527;IPR008351;IPR000719;IPR008271;	Fc-epsilon receptor signaling pathway [GO:0038095]; JNK cascade [GO:0007254]; protein phosphorylation [GO:0006468]; regulation of circadian rhythm [GO:0042752]; regulation of sequence-specific DNA binding transcription factor activity [GO:0051090]; response to light stimulus [GO:0009416]; rhythmic process [GO:0048511]; signal transduction [GO:0007165]	ATP binding [GO:0005524]; JUN kinase activity [GO:0004705]; MAP kinase kinase activity [GO:0004708]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; plasma membrane [GO:0005886]
P53778	MK12_HUMAN	Mitogen-activated protein kinase 12 (MAP kinase 12) (MAPK 12) (EC 2.7.11.24) (Extracellular signal-regulated kinase 6) (ERK-6) (Mitogen-activated protein kinase p38 gamma) (MAP kinase p38 gamma) (Stress-activated protein kinase 3)	MAPK12 ERK6 SAPK3	1CM8;4QUM;	CHEMBL4674;	P53778;			PF00069;	IPR011009;IPR003527;IPR008352;IPR000719;IPR017441;	cell cycle arrest [GO:0007050]; DNA damage induced protein phosphorylation [GO:0006975]; muscle organ development [GO:0007517]; myoblast differentiation [GO:0045445]; peptidyl-serine phosphorylation [GO:0018105]; positive regulation of muscle cell differentiation [GO:0051149]; positive regulation of peptidase activity [GO:0010952]; regulation of transcription, DNA-templated [GO:0006355]; signal transduction [GO:0007165]; transcription, DNA-templated [GO:0006351]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]	ATP binding [GO:0005524]; magnesium ion binding [GO:0000287]; MAP kinase activity [GO:0004707]; protein serine/threonine kinase activity [GO:0004674]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]
Q16539	MK14_HUMAN	Mitogen-activated protein kinase 14 (MAP kinase 14) (MAPK 14) (EC 2.7.11.24) (Cytokine suppressive anti-inflammatory drug-binding protein) (CSAID-binding protein) (CSBP) (MAP kinase MXI2) (MAX-interacting protein 2) (Mitogen-activated protein kinase p38 alpha) (MAP kinase p38 alpha) (Stress-activated protein kinase 2a) (SAPK2a)	MAPK14 CSBP CSBP1 CSBP2 CSPB1 MXI2 SAPK2A	1A9U;1BL6;1BL7;1BMK;1DI9;1IAN;1KV1;1KV2;1M7Q;1OUK;1OUY;1OVE;1OZ1;1R39;1R3C;1W7H;1W82;1W83;1W84;1WBN;1WBO;1WBS;1WBT;1WBV;1WBW;1WFC;1YQJ;1ZYJ;1ZZ2;1ZZL;2BAJ;2BAK;2BAL;2BAQ;2FSL;2FSM;2FSO;2FST;2GFS;2I0H;2LGC;2NPQ;2OKR;2ONL;2QD9;2RG5;2RG6;2Y8O;2YIS;2YIW;2YIX;2ZAZ;2ZB0;2ZB1;3BV2;3BV3;3BX5;3C5U;3CTQ;3D7Z;3D83;3DS6;3DT1;3E92;3E93;3FC1;3FI4;3FKL;3FKN;3FKO;3FL4;3FLN;3FLQ;3FLS;3FLW;3FLY;3FLZ;3FMH;3FMJ;3FMK;3FML;3FMM;3FMN;3FSF;3FSK;3GC7;3GCP;3GCQ;3GCS;3GCU;3GCV;3GFE;3GI3;3HA8;3HEC;3HEG;3HL7;3HLL;3HP2;3HP5;3HRB;3HUB;3HUC;3HV3;3HV4;3HV5;3HV6;3HV7;3HVC;3IPH;3ITZ;3IW5;3IW6;3IW7;3IW8;3K3I;3K3J;3KF7;3KQ7;3L8S;3L8X;3LFA;3LFB;3LFC;3LFD;3LFE;3LFF;3LHJ;3MGY;3MH0;3MH1;3MH2;3MH3;3MPA;3MPT;3MVL;3MVM;3MW1;3NEW;3NNU;3NNV;3NNW;3NNX;3NWW;3O8P;3O8T;3O8U;3OBG;3OBJ;3OC1;3OCG;3OD6;3ODY;3ODZ;3OEF;3PG3;3QUD;3QUE;3RIN;3ROC;3S3I;3S4Q;3U8W;3UVP;3UVQ;3UVR;3ZS5;3ZSG;3ZSH;3ZSI;3ZYA;4A9Y;4AA0;4AA4;4AA5;4AAC;4DLI;4DLJ;4E5A;4E5B;4E6A;4E6C;4E8A;4EH2;4EH3;4EH4;4EH5;4EH6;4EH7;4EH8;4EH9;4EHV;4EWQ;4F9W;4F9Y;4FA2;4GEO;4KIN;4KIP;4KIQ;4L8M;4R3C;4ZTH;5ETC;5ETI;	CHEMBL260;	Q16539;			PF00069;	IPR011009;IPR003527;IPR008352;IPR000719;IPR017441;	3'-UTR-mediated mRNA stabilization [GO:0070935]; activation of MAPK activity [GO:0000187]; angiogenesis [GO:0001525]; apoptotic process [GO:0006915]; cartilage condensation [GO:0001502]; cell morphogenesis [GO:0000902]; cell surface receptor signaling pathway [GO:0007166]; cellular response to ionizing radiation [GO:0071479]; cellular response to lipopolysaccharide [GO:0071222]; cellular response to vascular endothelial growth factor stimulus [GO:0035924]; cellular response to virus [GO:0098586]; chemotaxis [GO:0006935]; chondrocyte differentiation [GO:0002062]; DNA damage checkpoint [GO:0000077]; fatty acid oxidation [GO:0019395]; glucose metabolic process [GO:0006006]; intracellular signal transduction [GO:0035556]; lipopolysaccharide-mediated signaling pathway [GO:0031663]; movement of cell or subcellular component [GO:0006928]; myoblast differentiation involved in skeletal muscle regeneration [GO:0014835]; negative regulation of canonical Wnt signaling pathway [GO:0090090]; osteoclast differentiation [GO:0030316]; p38MAPK cascade [GO:0038066]; peptidyl-serine phosphorylation [GO:0018105]; placenta development [GO:0001890]; positive regulation of brown fat cell differentiation [GO:0090336]; positive regulation of cardiac muscle cell proliferation [GO:0060045]; positive regulation of cyclase activity [GO:0031281]; positive regulation of erythrocyte differentiation [GO:0045648]; positive regulation of gene expression [GO:0010628]; positive regulation of glucose import [GO:0046326]; positive regulation of interleukin-12 secretion [GO:2001184]; positive regulation of muscle cell differentiation [GO:0051149]; positive regulation of myoblast differentiation [GO:0045663]; positive regulation of myoblast fusion [GO:1901741]; positive regulation of myotube differentiation [GO:0010831]; positive regulation of protein import into nucleus [GO:0042307]; positive regulation of reactive oxygen species metabolic process [GO:2000379]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; Ras protein signal transduction [GO:0007265]; regulation of cytokine production involved in inflammatory response [GO:1900015]; regulation of ossification [GO:0030278]; regulation of sequence-specific DNA binding transcription factor activity [GO:0051090]; regulation of signal transduction by p53 class mediator [GO:1901796]; regulation of transcription from RNA polymerase II promoter [GO:0006357]; response to muramyl dipeptide [GO:0032495]; response to muscle stretch [GO:0035994]; signal transduction [GO:0007165]; signal transduction in response to DNA damage [GO:0042770]; skeletal muscle tissue development [GO:0007519]; stress-induced premature senescence [GO:0090400]; striated muscle cell differentiation [GO:0051146]; transcription, DNA-templated [GO:0006351]; transmembrane receptor protein serine/threonine kinase signaling pathway [GO:0007178]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]	ATP binding [GO:0005524]; enzyme binding [GO:0019899]; MAP kinase activity [GO:0004707]; MAP kinase kinase activity [GO:0004708]; NFAT protein binding [GO:0051525]; protein phosphatase binding [GO:0019903]; protein serine/threonine kinase activity [GO:0004674]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; spindle pole [GO:0000922]
Q8IVH4	MMAA_HUMAN	Methylmalonic aciduria type A protein, mitochondrial (EC 3.6.-.-)	MMAA	2WWW;			DB00115;DB00200;	PATHWAY: Cofactor biosynthesis; adenosylcobalamin biosynthesis.		IPR005129;IPR027417;	cobalamin biosynthetic process [GO:0009236]; cobalamin metabolic process [GO:0009235]; short-chain fatty acid catabolic process [GO:0019626]	GTPase activity [GO:0003924]; GTP binding [GO:0005525]	mitochondrial matrix [GO:0005759]
Q96EY8	MMAB_HUMAN	Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial (EC 2.5.1.17) (Cob(I)alamin adenosyltransferase) (Methylmalonic aciduria type B protein)	MMAB	2IDX;			DB00115;DB00200;	PATHWAY: Cofactor biosynthesis; adenosylcobalamin biosynthesis; adenosylcobalamin from cob(II)yrinate a,c-diamide: step 2/7.	PF01923;	IPR016030;IPR029499;	cobalamin biosynthetic process [GO:0009236]; cobalamin metabolic process [GO:0009235]	ATP binding [GO:0005524]; cob(I)yrinic acid a,c-diamide adenosyltransferase activity [GO:0008817]	mitochondrial matrix [GO:0005759]
Q9Y4U1	MMAC_HUMAN	Methylmalonic aciduria and homocystinuria type C protein (EC 1.16.1.-) (CblC) (Cyanocobalamin reductase (cyanide-eliminating))	MMACHC	3SBY;3SBZ;3SC0;3SOM;			DB00115;DB00200;	PATHWAY: Cofactor biosynthesis; adenosylcobalamin biosynthesis. {ECO:0000269|PubMed:19700356, ECO:0000269|PubMed:22642810, ECO:0000269|PubMed:25809485}.	PF16690;	IPR032037;	cobalamin biosynthetic process [GO:0009236]; cobalamin metabolic process [GO:0009235]; demethylation [GO:0070988]; glutathione metabolic process [GO:0006749]; oxidation-reduction process [GO:0055114]	cobalamin binding [GO:0031419]; cyanocobalamin reductase (cyanide-eliminating) activity [GO:0033787]; demethylase activity [GO:0032451]; FAD binding [GO:0071949]; glutathione binding [GO:0043295]; oxidoreductase activity [GO:0016491]; protein homodimerization activity [GO:0042803]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrion [GO:0005739]
P39900	MMP12_HUMAN	Macrophage metalloelastase (MME) (EC 3.4.24.65) (Macrophage elastase) (ME) (hME) (Matrix metalloproteinase-12) (MMP-12)	MMP12 HME	1JIZ;1JK3;1OS2;1OS9;1RMZ;1ROS;1UTT;1UTZ;1Y93;1YCM;1Z3J;2HU6;2JXY;2K2G;2K9C;2KRJ;2MLR;2MLS;2N8R;2OXU;2OXW;2OXZ;2POJ;2W0D;2WO8;2WO9;2WOA;2Z2D;3BA0;3EHX;3EHY;3F15;3F16;3F17;3F18;3F19;3F1A;3LIK;3LIL;3LIR;3LJG;3LK8;3LKA;3N2U;3N2V;3NX7;3RTS;3RTT;3TS4;3TSK;3UVC;4EFS;4GQL;4GR0;4GR3;4GR8;4GUY;4H30;4H49;4H76;4H84;4I03;4IJO;5CXA;5CZM;5D2B;5D3C;5I0L;5I2Z;5I3M;5I43;5I4O;5L79;5L7F;5LAB;	CHEMBL4393;	P39900;	DB00551;DB00786;		PF00045;PF00413;PF01471;	IPR000585;IPR018487;IPR018486;IPR033739;IPR024079;IPR028718;IPR001818;IPR021190;IPR016293;IPR021158;IPR006026;IPR002477;	collagen catabolic process [GO:0030574]; extracellular matrix disassembly [GO:0022617]; positive regulation of epithelial cell proliferation involved in wound healing [GO:0060054]; proteolysis [GO:0006508]; wound healing, spreading of epidermal cells [GO:0035313]	calcium ion binding [GO:0005509]; endopeptidase activity [GO:0004175]; metalloendopeptidase activity [GO:0004222]; serine-type endopeptidase activity [GO:0004252]; zinc ion binding [GO:0008270]	extracellular region [GO:0005576]; proteinaceous extracellular matrix [GO:0005578]
P45452	MMP13_HUMAN	Collagenase 3 (EC 3.4.24.-) (Matrix metalloproteinase-13) (MMP-13)	MMP13	1EUB;1FLS;1FM1;1PEX;1UC1;1XUC;1XUD;1XUR;1YOU;1ZTQ;2D1N;2E2D;2OW9;2OZR;2PJT;2YIG;3ELM;3I7G;3I7I;3KEC;3KEJ;3KEK;3KRY;3LJZ;3O2X;3TVC;3WV1;3WV2;3WV3;3ZXH;456C;4A7B;4FU4;4FVL;4G0D;4JP4;4JPA;4L19;5BOT;5BOY;5BPA;830C;	CHEMBL280;	P45452;	DB00786;		PF00045;PF00413;PF01471;	IPR028711;IPR000585;IPR018487;IPR018486;IPR033739;IPR024079;IPR001818;IPR021190;IPR016293;IPR021158;IPR006026;IPR002477;	bone mineralization [GO:0030282]; bone morphogenesis [GO:0060349]; cellular protein metabolic process [GO:0044267]; collagen catabolic process [GO:0030574]; endochondral ossification [GO:0001958]; extracellular matrix disassembly [GO:0022617]; growth plate cartilage development [GO:0003417]; proteolysis [GO:0006508]	calcium ion binding [GO:0005509]; collagen binding [GO:0005518]; metalloendopeptidase activity [GO:0004222]; serine-type endopeptidase activity [GO:0004252]; zinc ion binding [GO:0008270]	extracellular region [GO:0005576]; extracellular space [GO:0005615]; proteinaceous extracellular matrix [GO:0005578]
P51512	MMP16_HUMAN	Matrix metalloproteinase-16 (MMP-16) (EC 3.4.24.-) (MMP-X2) (Membrane-type matrix metalloproteinase 3) (MT-MMP 3) (MTMMP3) (Membrane-type-3 matrix metalloproteinase) (MT3-MMP) (MT3MMP)	MMP16 MMPX2	1RM8;	CHEMBL2200;	P51512;	DB00786;		PF11857;PF00045;PF00413;PF01471;	IPR000585;IPR018487;IPR018486;IPR033739;IPR024079;IPR028697;IPR001818;IPR021190;IPR021805;IPR016293;IPR021158;IPR006026;IPR002477;	chondrocyte proliferation [GO:0035988]; collagen catabolic process [GO:0030574]; craniofacial suture morphogenesis [GO:0097094]; embryonic cranial skeleton morphogenesis [GO:0048701]; endochondral ossification [GO:0001958]; extracellular matrix disassembly [GO:0022617]; protein metabolic process [GO:0019538]; protein processing [GO:0016485]; proteolysis [GO:0006508]	calcium ion binding [GO:0005509]; enzyme activator activity [GO:0008047]; metalloaminopeptidase activity [GO:0070006]; metalloendopeptidase activity [GO:0004222]; zinc ion binding [GO:0008270]	cell surface [GO:0009986]; Golgi lumen [GO:0005796]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; proteinaceous extracellular matrix [GO:0005578]
P08253	MMP2_HUMAN	72 kDa type IV collagenase (EC 3.4.24.24) (72 kDa gelatinase) (Gelatinase A) (Matrix metalloproteinase-2) (MMP-2) (TBE-1) [Cleaved into: PEX]	MMP2 CLG4A	1CK7;1CXW;1EAK;1GEN;1GXD;1HOV;1J7M;1KS0;1QIB;1RTG;3AYU;	CHEMBL333;	P08253;	DB01197;DB00786;		PF00040;PF00045;PF00413;PF01471;	IPR028708;IPR000562;IPR000585;IPR018487;IPR018486;IPR013806;IPR033739;IPR024079;IPR001818;IPR021190;IPR021158;IPR006026;IPR002477;	angiogenesis [GO:0001525]; blood vessel maturation [GO:0001955]; bone trabecula formation [GO:0060346]; cellular protein metabolic process [GO:0044267]; cellular response to amino acid stimulus [GO:0071230]; collagen catabolic process [GO:0030574]; embryo implantation [GO:0007566]; endodermal cell differentiation [GO:0035987]; ephrin receptor signaling pathway [GO:0048013]; extracellular matrix disassembly [GO:0022617]; face morphogenesis [GO:0060325]; intramembranous ossification [GO:0001957]; positive regulation of innate immune response [GO:0045089]; positive regulation of vascular smooth muscle cell proliferation [GO:1904707]; proteolysis [GO:0006508]; response to hypoxia [GO:0001666]	metalloendopeptidase activity [GO:0004222]; metallopeptidase activity [GO:0008237]; serine-type endopeptidase activity [GO:0004252]; zinc ion binding [GO:0008270]	extracellular matrix [GO:0031012]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; proteinaceous extracellular matrix [GO:0005578]; sarcomere [GO:0030017]
P08254	MMP3_HUMAN	Stromelysin-1 (SL-1) (EC 3.4.24.17) (Matrix metalloproteinase-3) (MMP-3) (Transin-1)	MMP3 STMY1	1B3D;1B8Y;1BIW;1BM6;1BQO;1C3I;1C8T;1CAQ;1CIZ;1CQR;1D5J;1D7X;1D8F;1D8M;1G05;1G49;1G4K;1HFS;1HY7;1M1W;1OO9;1QIA;1QIC;1SLM;1SLN;1UEA;1UMS;1UMT;1USN;2D1O;2JNP;2JT5;2JT6;2SRT;2USN;3OHL;3OHO;3USN;4DPE;4G9L;4JA1;	CHEMBL283;	P08254;	DB00786;		PF00045;PF00413;PF01471;	IPR000585;IPR018487;IPR018486;IPR033739;IPR024079;IPR001818;IPR021190;IPR016293;IPR021158;IPR006026;IPR002477;IPR028700;	cellular response to nitric oxide [GO:0071732]; collagen catabolic process [GO:0030574]; extracellular matrix disassembly [GO:0022617]; negative regulation of hydrogen peroxide metabolic process [GO:0010727]; positive regulation of oxidative stress-induced cell death [GO:1903209]; positive regulation of protein oligomerization [GO:0032461]; proteolysis [GO:0006508]	calcium ion binding [GO:0005509]; endopeptidase activity [GO:0004175]; metalloendopeptidase activity [GO:0004222]; serine-type endopeptidase activity [GO:0004252]; zinc ion binding [GO:0008270]	extracellular region [GO:0005576]; extracellular space [GO:0005615]; proteinaceous extracellular matrix [GO:0005578]
P22894	MMP8_HUMAN	Neutrophil collagenase (EC 3.4.24.34) (Matrix metalloproteinase-8) (MMP-8) (PMNL collagenase) (PMNL-CL)	MMP8 CLG1	1A85;1A86;1BZS;1I73;1I76;1JAN;1JAO;1JAP;1JAQ;1JH1;1JJ9;1KBC;1MMB;1MNC;1ZP5;1ZS0;1ZVX;2OY2;2OY4;3DNG;3DPE;3DPF;3TT4;4QKZ;	CHEMBL4588;	P22894;	DB00786;		PF00045;PF00413;PF01471;	IPR000585;IPR018487;IPR018486;IPR033739;IPR024079;IPR028709;IPR001818;IPR021190;IPR016293;IPR021158;IPR006026;IPR002477;	collagen catabolic process [GO:0030574]; endodermal cell differentiation [GO:0035987]; extracellular matrix disassembly [GO:0022617]; proteolysis [GO:0006508]	calcium ion binding [GO:0005509]; metalloendopeptidase activity [GO:0004222]; serine-type endopeptidase activity [GO:0004252]; zinc ion binding [GO:0008270]	extracellular region [GO:0005576]; extracellular space [GO:0005615]; proteinaceous extracellular matrix [GO:0005578]
P14780	MMP9_HUMAN	Matrix metalloproteinase-9 (MMP-9) (EC 3.4.24.35) (92 kDa gelatinase) (92 kDa type IV collagenase) (Gelatinase B) (GELB) [Cleaved into: 67 kDa matrix metalloproteinase-9; 82 kDa matrix metalloproteinase-9]	MMP9 CLG4B	1GKC;1GKD;1ITV;1L6J;1LKG;2OVX;2OVZ;2OW0;2OW1;2OW2;4H1Q;4H2E;4H3X;4H82;4HMA;4JIJ;4JQG;4WZV;4XCT;5CUH;5I12;	CHEMBL321;	P14780;	DB01197;DB01296;DB00786;DB01017;		PF00040;PF00045;PF00413;PF01471;	IPR000562;IPR000585;IPR018487;IPR018486;IPR013806;IPR033739;IPR024079;IPR028688;IPR001818;IPR021190;IPR021158;IPR006026;IPR002477;	collagen catabolic process [GO:0030574]; embryo implantation [GO:0007566]; endodermal cell differentiation [GO:0035987]; ephrin receptor signaling pathway [GO:0048013]; extracellular matrix disassembly [GO:0022617]; leukocyte migration [GO:0050900]; macrophage differentiation [GO:0030225]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cation channel activity [GO:2001258]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway [GO:2001268]; negative regulation of intrinsic apoptotic signaling pathway [GO:2001243]; ossification [GO:0001503]; positive regulation of DNA binding [GO:0043388]; positive regulation of epidermal growth factor receptor signaling pathway [GO:0045742]; positive regulation of keratinocyte migration [GO:0051549]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of receptor binding [GO:1900122]; positive regulation of release of cytochrome c from mitochondria [GO:0090200]; positive regulation of vascular smooth muscle cell proliferation [GO:1904707]; proteolysis [GO:0006508]; skeletal system development [GO:0001501]	collagen binding [GO:0005518]; endopeptidase activity [GO:0004175]; metalloendopeptidase activity [GO:0004222]; metallopeptidase activity [GO:0008237]; serine-type endopeptidase activity [GO:0004252]; zinc ion binding [GO:0008270]	extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; proteinaceous extracellular matrix [GO:0005578]
Q02252	MMSA_HUMAN	Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial (MMSDH) (Malonate-semialdehyde dehydrogenase [acylating]) (EC 1.2.1.18) (EC 1.2.1.27) (Aldehyde dehydrogenase family 6 member A1)	ALDH6A1 MMSDH						PF00171;	IPR016161;IPR016163;IPR016160;IPR016162;IPR015590;IPR010061;	branched-chain amino acid catabolic process [GO:0009083]; brown fat cell differentiation [GO:0050873]; thymine catabolic process [GO:0006210]; thymine metabolic process [GO:0019859]; valine catabolic process [GO:0006574]; valine metabolic process [GO:0006573]	aldehyde dehydrogenase (NAD) activity [GO:0004029]; fatty-acyl-CoA binding [GO:0000062]; malonate-semialdehyde dehydrogenase (acetylating) activity [GO:0018478]; methylmalonate-semialdehyde dehydrogenase (acylating) activity [GO:0004491]; poly(A) RNA binding [GO:0044822]	extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]
Q96EN8	MOCOS_HUMAN	Molybdenum cofactor sulfurase (MCS) (MOS) (MoCo sulfurase) (hMCS) (EC 2.8.1.9) (Molybdenum cofactor sulfurtransferase)	MOCOS						PF00266;PF03473;PF03476;	IPR000192;IPR005302;IPR028886;IPR005303;IPR015424;IPR015421;IPR015422;IPR011037;	molybdopterin cofactor biosynthetic process [GO:0032324]; molybdopterin cofactor metabolic process [GO:0043545]; Mo-molybdopterin cofactor biosynthetic process [GO:0006777]	lyase activity [GO:0016829]; molybdenum ion binding [GO:0030151]; Mo-molybdopterin cofactor sulfurase activity [GO:0008265]; pyridoxal phosphate binding [GO:0030170]; transferase activity [GO:0016740]	cytosol [GO:0005829]
P53985	MOT1_HUMAN	Monocarboxylate transporter 1 (MCT 1) (Solute carrier family 16 member 1)	SLC16A1 MCT1		CHEMBL4360;	P53985;	DB03166;DB00345;DB00415;DB03793;DB00529;DB01440;DB04398;DB00563;DB00731;DB00627;DB04552;DB00175;DB01032;DB00119;DB00936;DB00313;		PF07690;	IPR004743;IPR030757;IPR011701;IPR020846;	behavioral response to nutrient [GO:0051780]; cellular response to organic cyclic compound [GO:0071407]; centrosome organization [GO:0051297]; glucose homeostasis [GO:0042593]; leukocyte migration [GO:0050900]; lipid metabolic process [GO:0006629]; mevalonate transport [GO:0015728]; monocarboxylic acid transport [GO:0015718]; plasma membrane lactate transport [GO:0035879]; pyruvate metabolic process [GO:0006090]; regulation of insulin secretion [GO:0050796]; response to food [GO:0032094]	lactate transmembrane transporter activity [GO:0015129]; mevalonate transmembrane transporter activity [GO:0015130]; monocarboxylic acid transmembrane transporter activity [GO:0008028]; organic cyclic compound binding [GO:0097159]; symporter activity [GO:0015293]	centrosome [GO:0005813]; extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; mitochondrion [GO:0005739]; plasma membrane [GO:0005886]
O60669	MOT2_HUMAN	Monocarboxylate transporter 2 (MCT 2) (Solute carrier family 16 member 7)	SLC16A7 MCT2		CHEMBL2073704;		DB01440;DB04398;DB04552;DB01032;DB00119;		PF07690;	IPR004743;IPR027178;IPR011701;IPR020846;	lactate transmembrane transport [GO:0035873]; plasma membrane lactate transport [GO:0035879]; pyruvate transmembrane transport [GO:1901475]	lactate transmembrane transporter activity [GO:0015129]; monocarboxylic acid transmembrane transporter activity [GO:0008028]; pyruvate secondary active transmembrane transporter activity [GO:0005477]; pyruvate transmembrane transporter activity [GO:0050833]; symporter activity [GO:0015293]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
O95907	MOT3_HUMAN	Monocarboxylate transporter 3 (MCT 3) (Solute carrier family 16 member 8)	SLC16A8 MCT3				DB00119;		PF07690;	IPR004743;IPR030759;IPR011701;IPR020846;	lactate transport [GO:0015727]; leukocyte migration [GO:0050900]; plasma membrane lactate transport [GO:0035879]; pyruvate metabolic process [GO:0006090]	lactate transmembrane transporter activity [GO:0015129]; monocarboxylic acid transmembrane transporter activity [GO:0008028]; symporter activity [GO:0015293]	integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]
O15427	MOT4_HUMAN	Monocarboxylate transporter 4 (MCT 4) (Solute carrier family 16 member 3)	SLC16A3 MCT4		CHEMBL2073663;	O15427;	DB01440;DB04398;DB00627;DB00119;		PF07690;	IPR004743;IPR030756;IPR011701;IPR020846;	leukocyte migration [GO:0050900]; monocarboxylic acid transport [GO:0015718]; plasma membrane lactate transport [GO:0035879]; pyruvate metabolic process [GO:0006090]	lactate transmembrane transporter activity [GO:0015129]; monocarboxylic acid transmembrane transporter activity [GO:0008028]; poly(A) RNA binding [GO:0044822]; symporter activity [GO:0015293]	actin cytoskeleton [GO:0015629]; integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; nuclear membrane [GO:0031965]; plasma membrane [GO:0005886]
O15374	MOT5_HUMAN	Monocarboxylate transporter 5 (MCT 5) (Monocarboxylate transporter 4) (MCT 4) (Solute carrier family 16 member 4)	SLC16A4 MCT4 MCT5				DB00119;		PF07690;	IPR011701;IPR020846;	monocarboxylic acid transport [GO:0015718]; plasma membrane lactate transport [GO:0035879]	lactate transmembrane transporter activity [GO:0015129]; monocarboxylic acid transmembrane transporter activity [GO:0008028]; symporter activity [GO:0015293]	integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]
O15375	MOT6_HUMAN	Monocarboxylate transporter 6 (MCT 6) (Monocarboxylate transporter 5) (MCT 5) (Solute carrier family 16 member 5)	SLC16A5 MCT5 MCT6				DB00119;		PF07690;	IPR004743;IPR030760;IPR011701;IPR020846;	monocarboxylic acid transport [GO:0015718]; plasma membrane lactate transport [GO:0035879]	lactate transmembrane transporter activity [GO:0015129]; monocarboxylic acid transmembrane transporter activity [GO:0008028]; symporter activity [GO:0015293]	integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]
O15403	MOT7_HUMAN	Monocarboxylate transporter 7 (MCT 7) (Monocarboxylate transporter 6) (MCT 6) (Solute carrier family 16 member 6)	SLC16A6 MCT6 MCT7				DB00119;		PF07690;	IPR030766;IPR011701;IPR020846;	monocarboxylic acid transport [GO:0015718]; plasma membrane lactate transport [GO:0035879]	lactate transmembrane transporter activity [GO:0015129]; monocarboxylic acid transmembrane transporter activity [GO:0008028]; symporter activity [GO:0015293]	integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]
P36021	MOT8_HUMAN	Monocarboxylate transporter 8 (MCT 8) (Monocarboxylate transporter 7) (MCT 7) (Solute carrier family 16 member 2) (X-linked PEST-containing transporter)	SLC16A2 MCT8 XPCT				DB00149;DB00150;DB00135;DB00451;DB01583;DB00119;		PF07690;	IPR030761;IPR011701;IPR020846;	monocarboxylic acid transport [GO:0015718]; thyroid hormone transport [GO:0070327]; transport [GO:0006810]	monocarboxylic acid transmembrane transporter activity [GO:0008028]; symporter activity [GO:0015293]; thyroid hormone transmembrane transporter activity [GO:0015349]; transporter activity [GO:0005215]	integral component of plasma membrane [GO:0005887]
Q02750	MP2K1_HUMAN	Dual specificity mitogen-activated protein kinase kinase 1 (MAP kinase kinase 1) (MAPKK 1) (MKK1) (EC 2.7.12.2) (ERK activator kinase 1) (MAPK/ERK kinase 1) (MEK 1)	MAP2K1 MEK1 PRKMK1	1S9J;2P55;3DV3;3DY7;3E8N;3EQB;3EQC;3EQD;3EQF;3EQG;3EQH;3EQI;3MBL;3ORN;3OS3;3PP1;3SLS;3V01;3V04;3VVH;3W8Q;3WIG;3ZLS;3ZLW;3ZLX;3ZLY;3ZM4;4AN2;4AN3;4AN9;4ANB;4ARK;4LMN;4MNE;4U7Z;4U80;4U81;5BX0;5EYM;	CHEMBL3587;	Q02750;	DB06616;DB05239;DB08911;		PF00069;	IPR011009;IPR000719;IPR017441;IPR008271;	activation of MAPK activity [GO:0000187]; Bergmann glial cell differentiation [GO:0060020]; cell cycle arrest [GO:0007050]; cell motility [GO:0048870]; cellular senescence [GO:0090398]; cerebellar cortex formation [GO:0021697]; chemotaxis [GO:0006935]; epithelial cell proliferation involved in lung morphogenesis [GO:0060502]; ERK1 and ERK2 cascade [GO:0070371]; face development [GO:0060324]; heart development [GO:0007507]; keratinocyte differentiation [GO:0030216]; labyrinthine layer development [GO:0060711]; MAPK cascade [GO:0000165]; movement of cell or subcellular component [GO:0006928]; negative regulation of cell proliferation [GO:0008285]; negative regulation of gene expression [GO:0010629]; neuron differentiation [GO:0030182]; placenta blood vessel development [GO:0060674]; positive regulation of axonogenesis [GO:0050772]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of gene expression [GO:0010628]; positive regulation of production of miRNAs involved in gene silencing by miRNA [GO:1903800]; positive regulation of protein serine/threonine kinase activity [GO:0071902]; positive regulation of transcription, DNA-templated [GO:0045893]; proteolysis in other organism [GO:0035897]; regulation of axon regeneration [GO:0048679]; regulation of early endosome to late endosome transport [GO:2000641]; regulation of Golgi inheritance [GO:0090170]; regulation of stress-activated MAPK cascade [GO:0032872]; signal transduction [GO:0007165]; thymus development [GO:0048538]; thyroid gland development [GO:0030878]; trachea formation [GO:0060440]	ATP binding [GO:0005524]; MAP kinase kinase activity [GO:0004708]; protein C-terminus binding [GO:0008022]; protein kinase activity [GO:0004672]; protein kinase binding [GO:0019901]; protein N-terminus binding [GO:0047485]; protein serine/threonine/tyrosine kinase activity [GO:0004712]; protein serine/threonine kinase activator activity [GO:0043539]; protein serine/threonine kinase activity [GO:0004674]; protein tyrosine kinase activity [GO:0004713]; receptor signaling protein serine/threonine kinase activity [GO:0004702]; receptor signaling protein tyrosine phosphatase activity [GO:0004728]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; early endosome [GO:0005769]; endoplasmic reticulum [GO:0005783]; extracellular exosome [GO:0070062]; focal adhesion [GO:0005925]; Golgi apparatus [GO:0005794]; late endosome [GO:0005770]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; spindle pole body [GO:0005816]
O14733	MP2K7_HUMAN	Dual specificity mitogen-activated protein kinase kinase 7 (MAP kinase kinase 7) (MAPKK 7) (EC 2.7.12.2) (JNK-activating kinase 2) (MAPK/ERK kinase 7) (MEK 7) (Stress-activated protein kinase kinase 4) (SAPK kinase 4) (SAPKK-4) (SAPKK4) (c-Jun N-terminal kinase kinase 2) (JNK kinase 2) (JNKK 2)	MAP2K7 JNKK2 MEK7 MKK7 PRKMK7 SKK4	2DYL;3WZU;4UX9;5B2K;5B2L;5B2M;	CHEMBL3530;	O14733;			PF00069;	IPR011009;IPR000719;IPR008271;	activation of JUN kinase activity [GO:0007257]; apoptotic process [GO:0006915]; Fc-epsilon receptor signaling pathway [GO:0038095]; JNK cascade [GO:0007254]; positive regulation of telomerase activity [GO:0051973]; positive regulation of telomere capping [GO:1904355]; positive regulation of telomere maintenance via telomerase [GO:0032212]; proteolysis in other organism [GO:0035897]; response to heat [GO:0009408]; response to osmotic stress [GO:0006970]; response to tumor necrosis factor [GO:0034612]; response to UV [GO:0009411]; signal transduction [GO:0007165]; stress-activated MAPK cascade [GO:0051403]	ATP binding [GO:0005524]; enzyme binding [GO:0019899]; magnesium ion binding [GO:0000287]; MAP kinase kinase activity [GO:0004708]; protein kinase binding [GO:0019901]; protein phosphatase binding [GO:0019903]; protein tyrosine kinase activity [GO:0004713]; receptor signaling protein serine/threonine kinase activity [GO:0004702]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleus [GO:0005634]
P30305	MPIP2_HUMAN	M-phase inducer phosphatase 2 (EC 3.1.3.48) (Dual specificity phosphatase Cdc25B)	CDC25B CDC25HU2	1CWR;1CWS;1CWT;1QB0;1YM9;1YMD;1YMK;1YML;1YS0;2A2K;2IFD;2IFV;2UZQ;3FQT;3FQU;4WH7;4WH9;	CHEMBL4804;	P30305;			PF06617;PF00581;	IPR000751;IPR001763;	cell division [GO:0051301]; female meiosis I [GO:0007144]; G2/M transition of mitotic cell cycle [GO:0000086]; mitotic cell cycle [GO:0000278]; mitotic nuclear division [GO:0007067]; oocyte maturation [GO:0001556]; positive regulation of cell proliferation [GO:0008284]; positive regulation of cytokinesis [GO:0032467]; positive regulation of mitotic cell cycle [GO:0045931]; positive regulation of protein kinase activity [GO:0045860]; protein phosphorylation [GO:0006468]	phosphoprotein phosphatase activity [GO:0004721]; protein kinase binding [GO:0019901]; protein tyrosine phosphatase activity [GO:0004725]	centrosome [GO:0005813]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleoplasm [GO:0005654]; spindle pole [GO:0000922]
P33527	MRP1_HUMAN	Multidrug resistance-associated protein 1 (ATP-binding cassette sub-family C member 1) (Leukotriene C(4) transporter) (LTC4 transporter)	ABCC1 MRP MRP1	2CBZ;4C3Z;	CHEMBL3004;	P33527;	DB05812;DB00345;DB00701;DB01072;DB01076;DB02659;DB01394;DB00286;DB00091;DB00970;DB00694;DB00586;DB01248;DB00997;DB00445;DB00199;DB00773;DB00693;DB00143;DB01016;DB01050;DB01177;DB00224;DB00328;DB00762;DB00602;DB00709;DB00563;DB00834;DB01204;DB01165;DB01229;DB01174;DB01032;DB00396;DB01045;DB00503;DB01098;DB01232;DB06335;DB01138;DB05294;DB08881;DB00661;DB00570;DB00541;DB00399;		PF00664;PF00005;	IPR003593;IPR011527;IPR003439;IPR017871;IPR030241;IPR005292;IPR027417;	cobalamin metabolic process [GO:0009235]; leukotriene metabolic process [GO:0006691]; response to drug [GO:0042493]; transmembrane transport [GO:0055085]; transport [GO:0006810]	ATPase activity [GO:0016887]; ATPase activity, coupled to transmembrane movement of substances [GO:0042626]; ATPase-coupled anion transmembrane transporter activity [GO:0043225]; ATP binding [GO:0005524]; cobalamin-transporting ATPase activity [GO:0015420]; transporter activity [GO:0005215]	basolateral plasma membrane [GO:0016323]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]
Q92887	MRP2_HUMAN	Canalicular multispecific organic anion transporter 1 (ATP-binding cassette sub-family C member 2) (Canalicular multidrug resistance protein) (Multidrug resistance-associated protein 2)	ABCC2 CMOAT CMOAT1 CMRP MRP2		CHEMBL5748;	Q92887;	DB00171;DB00345;DB01169;DB01076;DB09060;DB08907;DB00564;DB00958;DB02659;DB00515;DB00257;DB00286;DB00091;DB00694;DB01234;DB01248;DB00997;DB09272;DB00876;DB00977;DB00773;DB00973;DB00695;DB02703;DB08884;DB00143;DB01016;DB00224;DB00328;DB00762;DB00602;DB00709;DB00650;DB01202;DB00978;DB00227;DB00563;DB00688;DB01115;DB00957;DB01165;DB00275;DB00526;DB01229;DB01174;DB00252;DB08860;DB01411;DB00175;DB01032;DB00908;DB00206;DB01045;DB00503;DB01232;DB00641;DB00398;DB01208;DB00421;DB00795;DB01138;DB01268;DB00675;DB00966;DB00300;DB00116;DB01586;DB00067;DB00661;DB00570;DB00541;		PF00664;PF00005;	IPR003593;IPR011527;IPR003439;IPR017871;IPR030247;IPR005292;IPR027417;	cellular chloride ion homeostasis [GO:0030644]; drug transmembrane transport [GO:0006855]; prostaglandin transport [GO:0015732]; response to arsenic-containing substance [GO:0046685]; response to estrogen [GO:0043627]; response to heat [GO:0009408]; response to methotrexate [GO:0031427]; response to oxidative stress [GO:0006979]; response to steroid hormone [GO:0048545]; thyroid hormone transport [GO:0070327]; transmembrane transport [GO:0055085]; transport [GO:0006810]	ATPase activity, coupled to transmembrane movement of substances [GO:0042626]; ATPase-coupled anion transmembrane transporter activity [GO:0043225]; ATP binding [GO:0005524]; bilirubin transmembrane transporter activity [GO:0015127]; organic anion transmembrane transporter activity [GO:0008514]	apical plasma membrane [GO:0016324]; cell surface [GO:0009986]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
O15438	MRP3_HUMAN	Canalicular multispecific organic anion transporter 2 (ATP-binding cassette sub-family C member 3) (Multi-specific organic anion transporter D) (MOAT-D) (Multidrug resistance-associated protein 3)	ABCC3 CMOAT2 MLP2 MRP3		CHEMBL5918;	O15438;	DB02659;DB00515;DB00257;DB00286;DB00091;DB00997;DB00773;DB00973;DB00544;DB00158;DB08884;DB00143;DB01016;DB00328;DB00709;DB00650;DB00563;DB01011;DB01115;DB00338;DB01174;DB01032;DB01045;DB01138;DB00661;DB00541;		PF00664;PF00005;	IPR003593;IPR011527;IPR003439;IPR017871;IPR030242;IPR005292;IPR027417;	bile acid and bile salt transport [GO:0015721]; transmembrane transport [GO:0055085]; transport [GO:0006810]	ATPase activity, coupled to transmembrane movement of substances [GO:0042626]; ATPase-coupled anion transmembrane transporter activity [GO:0043225]; ATP binding [GO:0005524]; bile acid-exporting ATPase activity [GO:0015432]; organic anion transmembrane transporter activity [GO:0008514]	integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]
O15439	MRP4_HUMAN	Multidrug resistance-associated protein 4 (ATP-binding cassette sub-family C member 4) (MRP/cMOAT-related ABC transporter) (Multi-specific organic anion transporter B) (MOAT-B)	ABCC4 MRP4		CHEMBL1743128;	O15439;	DB00718;DB00770;DB01076;DB01327;DB00482;DB02659;DB00286;DB00586;DB00917;DB00975;DB00544;DB00712;DB00158;DB08884;DB00143;DB01050;DB00328;DB01009;DB00709;DB00650;DB00814;DB01033;DB00563;DB00731;DB00198;DB01032;DB01098;DB00203;DB00398;DB01138;DB01268;DB00300;DB00352;DB01586;DB00661;DB00495;		PF00664;PF00005;	IPR003593;IPR011527;IPR003439;IPR017871;IPR030240;IPR027417;	cilium assembly [GO:0042384]; platelet degranulation [GO:0002576]; positive regulation of smooth muscle cell proliferation [GO:0048661]; prostaglandin secretion [GO:0032310]; response to drug [GO:0042493]; response to organic cyclic compound [GO:0014070]; response to organonitrogen compound [GO:0010243]; transmembrane transport [GO:0055085]	15-hydroxyprostaglandin dehydrogenase (NAD+) activity [GO:0016404]; ATPase activity, coupled to transmembrane movement of ions, phosphorylative mechanism [GO:0015662]; ATPase-coupled anion transmembrane transporter activity [GO:0043225]; ATP binding [GO:0005524]	basolateral plasma membrane [GO:0016323]; integral component of membrane [GO:0016021]; membrane [GO:0016020]; plasma membrane [GO:0005886]; platelet dense granule membrane [GO:0031088]
Q9UJ68	MSRA_HUMAN	Mitochondrial peptide methionine sulfoxide reductase (EC 1.8.4.11) (Peptide-methionine (S)-S-oxide reductase) (Peptide Met(O) reductase) (Protein-methionine-S-oxide reductase) (PMSR)	MSRA				DB00134;		PF01625;	IPR028427;IPR002569;	cellular protein modification process [GO:0006464]; methionine metabolic process [GO:0006555]; protein repair [GO:0030091]; response to oxidative stress [GO:0006979]	peptide-methionine (S)-S-oxide reductase activity [GO:0008113]	actin cytoskeleton [GO:0015629]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]
Q9Y3D2	MSRB2_HUMAN	Methionine-R-sulfoxide reductase B2, mitochondrial (MsrB2) (EC 1.8.4.-)	MSRB2 CBS-1 MSRB CGI-131		CHEMBL3509603;		DB00134;		PF01641;	IPR028427;IPR002579;IPR011057;	actin filament polymerization [GO:0030041]; protein repair [GO:0030091]; response to oxidative stress [GO:0006979]	actin binding [GO:0003779]; peptide-methionine (R)-S-oxide reductase activity [GO:0033743]; transcription factor activity, sequence-specific DNA binding [GO:0003700]; zinc ion binding [GO:0008270]	cytosol [GO:0005829]; mitochondrion [GO:0005739]
Q9NZV6	MSRX_HUMAN	Methionine-R-sulfoxide reductase B1 (MsrB1) (EC 1.8.4.-) (Selenoprotein X) (SelX)	MSRB1 SEPX1 HSPC270	3MAO;			DB00134;		PF01641;	IPR028427;IPR002579;IPR011057;	actin filament polymerization [GO:0030041]; innate immune response [GO:0045087]; protein repair [GO:0030091]; response to oxidative stress [GO:0006979]	actin binding [GO:0003779]; methionine-R-sulfoxide reductase activity [GO:0070191]; peptide-methionine (R)-S-oxide reductase activity [GO:0033743]; zinc ion binding [GO:0008270]	actin cytoskeleton [GO:0015629]; cytosol [GO:0005829]; nucleus [GO:0005634]
Q13126	MTAP_HUMAN	S-methyl-5'-thioadenosine phosphorylase (EC 2.4.2.28) (5'-methylthioadenosine phosphorylase) (MTA phosphorylase) (MTAP) (MTAPase)	MTAP MSAP	1CB0;1CG6;1K27;1SD1;1SD2;3LN5;3OZC;3OZD;3OZE;	CHEMBL4941;	Q13126;	DB00173;	PATHWAY: Amino-acid biosynthesis; L-methionine biosynthesis via salvage pathway; S-methyl-5-thio-alpha-D-ribose 1-phosphate from S-methyl-5'-thioadenosine (phosphorylase route): step 1/1. {ECO:0000255|HAMAP-Rule:MF_03155}.	PF01048;	IPR010044;IPR000845;IPR001369;IPR018099;	L-methionine biosynthetic process from methylthioadenosine [GO:0019509]; methylation [GO:0032259]; nucleobase-containing compound metabolic process [GO:0006139]; purine-containing compound salvage [GO:0043101]; purine ribonucleoside salvage [GO:0006166]; response to testosterone [GO:0033574]	phosphorylase activity [GO:0004645]; S-methyl-5-thioadenosine phosphorylase activity [GO:0017061]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleus [GO:0005634]
P13995	MTDC_HUMAN	Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial [Includes: NAD-dependent methylenetetrahydrofolate dehydrogenase (EC 1.5.1.15); Methenyltetrahydrofolate cyclohydrolase (EC 3.5.4.9)]	MTHFD2 NMDMC	1ZN4;			DB00116;		PF00763;PF02882;	IPR016040;IPR000672;IPR020630;IPR020867;IPR020631;	folic acid-containing compound biosynthetic process [GO:0009396]; folic acid metabolic process [GO:0046655]; one-carbon metabolic process [GO:0006730]; tetrahydrofolate metabolic process [GO:0046653]	magnesium ion binding [GO:0000287]; methenyltetrahydrofolate cyclohydrolase activity [GO:0004477]; methylenetetrahydrofolate dehydrogenase (NAD+) activity [GO:0004487]; methylenetetrahydrofolate dehydrogenase (NADP+) activity [GO:0004488]; phosphate ion binding [GO:0042301]	extracellular space [GO:0005615]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
P42898	MTHR_HUMAN	Methylenetetrahydrofolate reductase (EC 1.5.1.20)	MTHFR				DB00542;DB00115;DB00544;DB00158;DB00134;DB00170;DB00563;DB00140;DB00116;	PATHWAY: One-carbon metabolism; tetrahydrofolate interconversion.	PF02219;	IPR029041;IPR004621;IPR003171;	blood circulation [GO:0008015]; cellular amino acid metabolic process [GO:0006520]; folic acid metabolic process [GO:0046655]; heterochromatin maintenance [GO:0070829]; homocysteine metabolic process [GO:0050667]; methionine metabolic process [GO:0006555]; regulation of histone methylation [GO:0031060]; response to amino acid [GO:0043200]; response to drug [GO:0042493]; response to folic acid [GO:0051593]; response to hypoxia [GO:0001666]; response to interleukin-1 [GO:0070555]; response to vitamin B2 [GO:0033274]; S-adenosylmethionine metabolic process [GO:0046500]; tetrahydrofolate interconversion [GO:0035999]	flavin adenine dinucleotide binding [GO:0050660]; methylenetetrahydrofolate reductase (NAD(P)H) activity [GO:0004489]; modified amino acid binding [GO:0072341]; NADP binding [GO:0050661]; protein complex binding [GO:0032403]	cytosol [GO:0005829]; synapse [GO:0045202]
P55157	MTP_HUMAN	Microsomal triglyceride transfer protein large subunit	MTTP MTP		CHEMBL2569;	P55157;	DB01094;DB08827;		PF01347;	IPR015819;IPR001747;IPR015816;IPR011030;	lipid metabolic process [GO:0006629]; lipoprotein biosynthetic process [GO:0042158]; phospholipid transport [GO:0015914]; plasma lipoprotein particle assembly [GO:0034377]; triglyceride transport [GO:0034197]	lipid binding [GO:0008289]; lipid transporter activity [GO:0005319]; phospholipid transporter activity [GO:0005548]; protein heterodimerization activity [GO:0046982]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum lumen [GO:0005788]; receptor complex [GO:0043235]
P48039	MTR1A_HUMAN	Melatonin receptor type 1A (Mel-1A-R) (Mel1a receptor)	MTNR1A		CHEMBL1945;	P48039;	DB06594;DB01065;DB00980;DB09071;		PF00001;	IPR000276;IPR017452;IPR002278;IPR000025;	cell surface receptor signaling pathway [GO:0007166]; circadian rhythm [GO:0007623]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; mating behavior [GO:0007617]; positive regulation of cGMP biosynthetic process [GO:0030828]	hormone binding [GO:0042562]; melatonin receptor activity [GO:0008502]; organic cyclic compound binding [GO:0097159]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]
P49286	MTR1B_HUMAN	Melatonin receptor type 1B (Mel-1B-R) (Mel1b receptor)	MTNR1B		CHEMBL1946;	P49286;	DB06594;DB01065;DB00980;DB09071;		PF00001;	IPR000276;IPR017452;IPR002278;IPR027459;IPR000025;	cell surface receptor signaling pathway [GO:0007166]; chemical synaptic transmission [GO:0007268]; circadian rhythm [GO:0007623]; glucose homeostasis [GO:0042593]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; regulation of insulin secretion [GO:0050796]	G-protein coupled receptor activity [GO:0004930]; melatonin receptor activity [GO:0008502]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
Q9UBK8	MTRR_HUMAN	Methionine synthase reductase (MSR) (EC 1.16.1.8)	MTRR	2QTL;2QTZ;			DB00115;DB00200;DB00134;		PF00667;PF00258;PF00175;	IPR003097;IPR017927;IPR001094;IPR008254;IPR001709;IPR029039;IPR023173;IPR001433;IPR017938;	cobalamin metabolic process [GO:0009235]; DNA methylation [GO:0006306]; folic acid metabolic process [GO:0046655]; homocysteine catabolic process [GO:0043418]; methionine biosynthetic process [GO:0009086]; methionine metabolic process [GO:0006555]; methylation [GO:0032259]; negative regulation of cystathionine beta-synthase activity [GO:1904042]; oxidation-reduction process [GO:0055114]; S-adenosylmethionine cycle [GO:0033353]; sulfur amino acid metabolic process [GO:0000096]	[methionine synthase] reductase activity [GO:0030586]; aquacobalamin reductase (NADPH) activity [GO:0050444]; FAD binding [GO:0071949]; flavin adenine dinucleotide binding [GO:0050660]; FMN binding [GO:0010181]; NADP binding [GO:0050661]; NADPH binding [GO:0070402]; NADPH-hemoprotein reductase activity [GO:0003958]; oxidoreductase activity, oxidizing metal ions, NAD or NADP as acceptor [GO:0016723]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; intermediate filament cytoskeleton [GO:0045111]; nucleoplasm [GO:0005654]
Q02817	MUC2_HUMAN	Mucin-2 (MUC-2) (Intestinal mucin-2)	MUC2 SMUC				DB01411;		PF08742;PF13330;PF01826;PF00094;	IPR006207;IPR028580;IPR002919;IPR014853;IPR001007;IPR001846;IPR025155;	maintenance of gastrointestinal epithelium [GO:0030277]; O-glycan processing [GO:0016266]		Golgi lumen [GO:0005796]; inner mucus layer [GO:0070702]; outer mucus layer [GO:0070703]
P22033	MUTA_HUMAN	Methylmalonyl-CoA mutase, mitochondrial (MCM) (EC 5.4.99.2) (Methylmalonyl-CoA isomerase)	MUT	2XIJ;2XIQ;3BIC;			DB00115;DB00200;		PF02310;PF01642;	IPR006159;IPR016176;IPR014348;IPR006158;IPR006099;IPR006098;	cobalamin metabolic process [GO:0009235]; homocysteine metabolic process [GO:0050667]; post-embryonic development [GO:0009791]; short-chain fatty acid catabolic process [GO:0019626]	cobalamin binding [GO:0031419]; metal ion binding [GO:0046872]; methylmalonyl-CoA mutase activity [GO:0004494]; modified amino acid binding [GO:0072341]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
P32418	NAC1_HUMAN	Sodium/calcium exchanger 1 (Na(+)/Ca(2+)-exchange protein 1) (Solute carrier family 8 member 1)	SLC8A1 CNC NCX1		CHEMBL4076;	P32418;	DB00132;DB00159;		PF03160;PF01699;PF16494;	IPR003644;IPR001623;IPR004836;IPR032452;IPR002987;IPR004837;	calcium ion export [GO:1901660]; calcium ion homeostasis [GO:0055074]; calcium ion import [GO:0070509]; calcium ion transmembrane transport [GO:0070588]; calcium ion transport into cytosol [GO:0060402]; cardiac muscle cell development [GO:0055013]; cardiac muscle contraction [GO:0060048]; cell communication by electrical coupling involved in cardiac conduction [GO:0086064]; cellular response to caffeine [GO:0071313]; cellular response to cAMP [GO:0071320]; cellular response to hypoxia [GO:0071456]; cellular response to reactive oxygen species [GO:0034614]; cellular sodium ion homeostasis [GO:0006883]; cytosolic calcium ion transport [GO:0060401]; ion transport [GO:0006811]; membrane depolarization during cardiac muscle cell action potential [GO:0086012]; muscle contraction [GO:0006936]; negative regulation of cytosolic calcium ion concentration [GO:0051481]; positive regulation of bone mineralization [GO:0030501]; positive regulation of fibroblast migration [GO:0010763]; positive regulation of the force of heart contraction [GO:0098735]; regulation of cardiac conduction [GO:1903779]; regulation of cardiac muscle contraction by calcium ion signaling [GO:0010882]; regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion [GO:0010881]; regulation of cell communication by electrical coupling [GO:0010649]; regulation of heart rate [GO:0002027]; regulation of sodium ion transport [GO:0002028]; regulation of the force of heart contraction [GO:0002026]; relaxation of cardiac muscle [GO:0055119]; relaxation of smooth muscle [GO:0044557]; response to ATP [GO:0033198]; response to drug [GO:0042493]; response to glucose [GO:0009749]; response to hydrogen peroxide [GO:0042542]; response to immobilization stress [GO:0035902]; response to muscle stretch [GO:0035994]; response to nutrient [GO:0007584]; sodium ion export [GO:0071436]; sodium ion import [GO:0097369]; sodium ion transmembrane transport [GO:0035725]; telencephalon development [GO:0021537]; vascular smooth muscle contraction [GO:0014829]	ankyrin binding [GO:0030506]; calcium:sodium antiporter activity [GO:0005432]; calcium ion binding [GO:0005509]; cytoskeletal protein binding [GO:0008092]; ion channel binding [GO:0044325]	dendritic shaft [GO:0043198]; dendritic spine [GO:0043197]; integral component of plasma membrane [GO:0005887]; intercalated disc [GO:0014704]; microtubule [GO:0005874]; mitochondrion [GO:0005739]; plasma membrane [GO:0005886]; sarcolemma [GO:0042383]; T-tubule [GO:0030315]; Z disc [GO:0030018]
Q15274	NADC_HUMAN	Nicotinate-nucleotide pyrophosphorylase [carboxylating] (EC 2.4.2.19) (Quinolinate phosphoribosyltransferase [decarboxylating]) (QAPRTase) (QPRTase)	QPRT	2JBM;4KWV;4KWW;5AYX;5AYY;5AYZ;			DB00627;	PATHWAY: Cofactor biosynthesis; NAD(+) biosynthesis; nicotinate D-ribonucleotide from quinolinate: step 1/1.	PF01729;PF02749;	IPR013785;IPR004393;IPR027277;IPR002638;IPR022412;	NAD biosynthetic process [GO:0009435]; NAD metabolic process [GO:0019674]; protein oligomerization [GO:0051259]; quinolinate catabolic process [GO:0034213]	nicotinate-nucleotide diphosphorylase (carboxylating) activity [GO:0004514]; protein homodimerization activity [GO:0042803]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
Q6IA69	NADE1_HUMAN	Glutamine-dependent NAD(+) synthetase (EC 6.3.5.1) (NAD(+) synthase [glutamine-hydrolyzing]) (NAD(+) synthetase)	NADSYN1			Q6IA69;	DB00130;	PATHWAY: Cofactor biosynthesis; NAD(+) biosynthesis; NAD(+) from deamido-NAD(+) (L-Gln route): step 1/1.	PF00795;PF02540;	IPR003010;IPR014445;IPR022310;IPR003694;IPR014729;	NAD biosynthetic process [GO:0009435]; NAD metabolic process [GO:0019674]	ATP binding [GO:0005524]; glutaminase activity [GO:0004359]; NAD+ synthase (glutamine-hydrolyzing) activity [GO:0003952]	cytoplasm [GO:0005737]; cytosol [GO:0005829]
Q9UJ70	NAGK_HUMAN	N-acetyl-D-glucosamine kinase (N-acetylglucosamine kinase) (EC 2.7.1.59) (GlcNAc kinase)	NAGK	2CH5;2CH6;			DB00141;	PATHWAY: Amino-sugar metabolism; N-acetylneuraminate degradation. {ECO:0000269|PubMed:22692205}.	PF01869;	IPR002731;	N-acetylglucosamine metabolic process [GO:0006044]; N-acetylmannosamine metabolic process [GO:0006051]; N-acetylneuraminate catabolic process [GO:0019262]; UDP-N-acetylglucosamine biosynthetic process [GO:0006048]	ATP binding [GO:0005524]; N-acetylglucosamine kinase activity [GO:0045127]; N-acylmannosamine kinase activity [GO:0009384]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]
Q9UK23	NAGPA_HUMAN	N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase (EC 3.1.4.45) (Mannose 6-phosphate-uncovering enzyme) (Phosphodiester alpha-GlcNAcase)	NAGPA		CHEMBL5920;		DB00141;	PATHWAY: Protein modification; protein glycosylation.	PF09992;	IPR013032;IPR000742;IPR018711;	carbohydrate metabolic process [GO:0005975]; cellular protein modification process [GO:0006464]; lysosome organization [GO:0007040]; protein glycosylation [GO:0006486]; protein targeting to lysosome [GO:0006622]; secretion of lysosomal enzymes [GO:0033299]	N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase activity [GO:0003944]	Golgi cisterna membrane [GO:0032580]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]
Q8N159	NAGS_HUMAN	N-acetylglutamate synthase, mitochondrial (EC 2.3.1.1) (Amino-acid acetyltransferase) [Cleaved into: N-acetylglutamate synthase long form; N-acetylglutamate synthase short form; N-acetylglutamate synthase conserved domain form]	NAGS	4K30;				PATHWAY: Amino-acid biosynthesis; L-arginine biosynthesis; N(2)-acetyl-L-ornithine from L-glutamate: step 1/4.	PF04768;	IPR016181;IPR001048;IPR011243;IPR006855;	arginine biosynthetic process [GO:0006526]; glutamate metabolic process [GO:0006536]; urea cycle [GO:0000050]	acetyl-CoA:L-glutamate N-acetyltransferase activity [GO:0004042]; arginine binding [GO:0034618]	mitochondrial matrix [GO:0005759]
P00387	NCB5R_HUMAN	NADH-cytochrome b5 reductase 3 (B5R) (Cytochrome b5 reductase) (EC 1.6.2.2) (Diaphorase-1) [Cleaved into: NADH-cytochrome b5 reductase 3 membrane-bound form; NADH-cytochrome b5 reductase 3 soluble form]	CYB5R3 DIA1	1M91;1UMK;	CHEMBL2146;		DB03147;		PF00970;PF00175;	IPR017927;IPR001709;IPR001834;IPR008333;IPR001433;IPR017938;	blood circulation [GO:0008015]; cholesterol biosynthetic process [GO:0006695]; L-ascorbic acid metabolic process [GO:0019852]	ADP binding [GO:0043531]; AMP binding [GO:0016208]; cytochrome-b5 reductase activity, acting on NAD(P)H [GO:0004128]; FAD binding [GO:0071949]; flavin adenine dinucleotide binding [GO:0050660]; NAD binding [GO:0051287]	cytoplasm [GO:0005737]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; extracellular exosome [GO:0070062]; hemoglobin complex [GO:0005833]; lipid particle [GO:0005811]; membrane [GO:0016020]; mitochondrial inner membrane [GO:0005743]; mitochondrial outer membrane [GO:0005741]; mitochondrion [GO:0005739]
P16435	NCPR_HUMAN	NADPH--cytochrome P450 reductase (CPR) (P450R) (EC 1.6.2.4)	POR CYPOR	1B1C;3FJO;3QE2;3QFC;3QFR;3QFS;3QFT;5EMN;5FA6;	CHEMBL2169731;		DB00865;DB00694;DB00997;DB01466;DB03147;DB00166;DB00305;DB00665;DB00698;		PF00667;PF00258;PF00175;	IPR003097;IPR017927;IPR001094;IPR008254;IPR001709;IPR029039;IPR023173;IPR001433;IPR023208;IPR017938;	carnitine metabolic process [GO:0009437]; cellular organofluorine metabolic process [GO:0090346]; cellular response to follicle-stimulating hormone stimulus [GO:0071372]; cellular response to peptide hormone stimulus [GO:0071375]; demethylation [GO:0070988]; fatty acid oxidation [GO:0019395]; flavonoid metabolic process [GO:0009812]; internal peptidyl-lysine acetylation [GO:0018393]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154]; negative regulation of lipase activity [GO:0060192]; nitrate catabolic process [GO:0043602]; nitric oxide catabolic process [GO:0046210]; oxidation-reduction process [GO:0055114]; positive regulation of cholesterol biosynthetic process [GO:0045542]; positive regulation of chondrocyte differentiation [GO:0032332]; positive regulation of monooxygenase activity [GO:0032770]; positive regulation of smoothened signaling pathway [GO:0045880]; positive regulation of steroid hormone biosynthetic process [GO:0090031]; regulation of growth plate cartilage chondrocyte proliferation [GO:0003420]; response to drug [GO:0042493]; response to nutrient [GO:0007584]; xenobiotic metabolic process [GO:0006805]	[methionine synthase] reductase activity [GO:0030586]; cytochrome-b5 reductase activity, acting on NAD(P)H [GO:0004128]; electron carrier activity [GO:0009055]; flavin adenine dinucleotide binding [GO:0050660]; FMN binding [GO:0010181]; hydrolase activity [GO:0016787]; iron-cytochrome-c reductase activity [GO:0047726]; NADP binding [GO:0050661]; NADPH-hemoprotein reductase activity [GO:0003958]; nitric oxide dioxygenase activity [GO:0008941]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; intracellular membrane-bounded organelle [GO:0043231]; membrane [GO:0016020]; mitochondrion [GO:0005739]
O76036	NCTR1_HUMAN	Natural cytotoxicity triggering receptor 1 (Lymphocyte antigen 94 homolog) (NK cell-activating receptor) (Natural killer cell p46-related protein) (NK-p46) (NKp46) (hNKp46) (CD antigen CD335)	NCR1 LY94	1OLL;1P6F;						IPR007110;IPR013783;IPR003599;	cellular defense response [GO:0006968]; natural killer cell activation [GO:0030101]; regulation of immune response [GO:0050776]; regulation of natural killer cell mediated cytotoxicity [GO:0042269]; signal transduction [GO:0007165]	receptor signaling protein activity [GO:0005057]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; SWI/SNF complex [GO:0016514]
P15531	NDKA_HUMAN	Nucleoside diphosphate kinase A (NDK A) (NDP kinase A) (EC 2.7.4.6) (Granzyme A-activated DNase) (GAAD) (Metastasis inhibition factor nm23) (NM23-H1) (Tumor metastatic process-associated protein)	NME1 NDPKA NM23	1JXV;1UCN;2HVD;2HVE;3L7U;4ENO;	CHEMBL2159;		DB00718;DB00709;DB00300;		PF00334;	IPR001564;IPR023005;	cellular response to drug [GO:0035690]; cellular response to fatty acid [GO:0071398]; cellular response to glucose stimulus [GO:0071333]; CTP biosynthetic process [GO:0006241]; endocytosis [GO:0006897]; GTP biosynthetic process [GO:0006183]; hippocampus development [GO:0021766]; negative regulation of cell proliferation [GO:0008285]; negative regulation of gene expression [GO:0010629]; negative regulation of myeloid leukocyte differentiation [GO:0002762]; nucleobase-containing small molecule interconversion [GO:0015949]; nucleoside triphosphate biosynthetic process [GO:0009142]; positive regulation of DNA binding [GO:0043388]; positive regulation of epithelial cell proliferation [GO:0050679]; positive regulation of neuron projection development [GO:0010976]; purine nucleotide metabolic process [GO:0006163]; pyrimidine nucleotide metabolic process [GO:0006220]; regulation of apoptotic process [GO:0042981]; response to amine [GO:0014075]; response to cAMP [GO:0051591]; response to testosterone [GO:0033574]; UTP biosynthetic process [GO:0006228]	ATP binding [GO:0005524]; deoxyribonuclease activity [GO:0004536]; GTP binding [GO:0005525]; identical protein binding [GO:0042802]; magnesium ion binding [GO:0000287]; nucleoside diphosphate kinase activity [GO:0004550]; poly(A) RNA binding [GO:0044822]; ribosomal small subunit binding [GO:0043024]; RNA polymerase II regulatory region sequence-specific DNA binding [GO:0000977]; single-stranded DNA binding [GO:0003697]	centrosome [GO:0005813]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; intermediate filament [GO:0005882]; membrane [GO:0016020]; mitochondrial outer membrane [GO:0005741]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; ruffle membrane [GO:0032587]
P22392	NDKB_HUMAN	Nucleoside diphosphate kinase B (NDK B) (NDP kinase B) (EC 2.7.4.6) (C-myc purine-binding transcription factor PUF) (Histidine protein kinase NDKB) (EC 2.7.13.3) (nm23-H2)	NME2 NM23B	1NSK;1NUE;3BBB;3BBC;3BBF;	CHEMBL2160;		DB00718;DB00709;DB00300;		PF00334;	IPR001564;IPR023005;	cell adhesion [GO:0007155]; cellular response to fatty acid [GO:0071398]; cellular response to glucose stimulus [GO:0071333]; cellular response to oxidative stress [GO:0034599]; CTP biosynthetic process [GO:0006241]; GTP biosynthetic process [GO:0006183]; integrin-mediated signaling pathway [GO:0007229]; negative regulation of apoptotic process [GO:0043066]; negative regulation of myeloid leukocyte differentiation [GO:0002762]; nucleobase-containing small molecule interconversion [GO:0015949]; nucleoside triphosphate biosynthetic process [GO:0009142]; positive regulation of cAMP biosynthetic process [GO:0030819]; positive regulation of epithelial cell proliferation [GO:0050679]; positive regulation of keratinocyte differentiation [GO:0045618]; positive regulation of neuron projection development [GO:0010976]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; protein autophosphorylation [GO:0046777]; protein oligomerization [GO:0051259]; purine nucleotide metabolic process [GO:0006163]; pyrimidine nucleotide metabolic process [GO:0006220]; regulation of epidermis development [GO:0045682]; regulation of transcription, DNA-templated [GO:0006355]; response to growth hormone [GO:0060416]; transcription, DNA-templated [GO:0006351]; UTP biosynthetic process [GO:0006228]	ATP binding [GO:0005524]; DNA binding [GO:0003677]; drug binding [GO:0008144]; fatty acid binding [GO:0005504]; metal ion binding [GO:0046872]; nucleoside diphosphate kinase activity [GO:0004550]; protein histidine kinase activity [GO:0004673]; protein serine/threonine kinase activity [GO:0004674]; transcription factor activity, sequence-specific DNA binding [GO:0003700]	cell periphery [GO:0071944]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; intermediate filament [GO:0005882]; lamellipodium [GO:0030027]; mitochondrial membrane [GO:0031966]; myelin sheath [GO:0043209]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; ruffle [GO:0001726]
P52848	NDST1_HUMAN	Bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 1 (EC 2.8.2.8) (Glucosaminyl N-deacetylase/N-sulfotransferase 1) (NDST-1) (N-heparan sulfate sulfotransferase 1) (N-HSST 1) ([Heparan sulfate]-glucosamine N-sulfotransferase 1) (HSNST 1) [Includes: Heparan sulfate N-deacetylase 1 (EC 3.-.-.-); Heparan sulfate N-sulfotransferase 1 (EC 2.8.2.-)]	NDST1 HSST HSST1	1NST;				PATHWAY: Glycan metabolism; heparan sulfate biosynthesis.; PATHWAY: Glycan metabolism; heparin biosynthesis.	PF12062;PF00685;	IPR021930;IPR027417;IPR000863;	aorta development [GO:0035904]; cardiac septum development [GO:0003279]; coronary vasculature development [GO:0060976]; embryonic neurocranium morphogenesis [GO:0048702]; embryonic viscerocranium morphogenesis [GO:0048703]; fibroblast growth factor receptor signaling pathway [GO:0008543]; forebrain development [GO:0030900]; glycosaminoglycan biosynthetic process [GO:0006024]; heparan sulfate proteoglycan biosynthetic process [GO:0015012]; heparin biosynthetic process [GO:0030210]; inflammatory response [GO:0006954]; MAPK cascade [GO:0000165]; midbrain development [GO:0030901]; polysaccharide biosynthetic process [GO:0000271]; protein sulfation [GO:0006477]; respiratory gaseous exchange [GO:0007585]; smoothened signaling pathway [GO:0007224]	[heparan sulfate]-glucosamine N-sulfotransferase activity [GO:0015016]; N-acetylglucosamine deacetylase activity [GO:0050119]	Golgi membrane [GO:0000139]; integral component of membrane [GO:0016021]
O15239	NDUA1_HUMAN	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 1 (Complex I-MWFE) (CI-MWFE) (NADH-ubiquinone oxidoreductase MWFE subunit)	NDUFA1		CHEMBL2363065;				PF15879;	IPR017384;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrial membrane [GO:0031966]; mitochondrial respiratory chain complex I [GO:0005747]; mitochondrion [GO:0005739]
O43678	NDUA2_HUMAN	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2 (Complex I-B8) (CI-B8) (NADH-ubiquinone oxidoreductase B8 subunit)	NDUFA2	1S3A;	CHEMBL2363065;				PF05047;	IPR016464;IPR007741;IPR012336;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	mitochondrial inner membrane [GO:0005743]; mitochondrial membrane [GO:0031966]; mitochondrial respiratory chain complex I [GO:0005747]
O95167	NDUA3_HUMAN	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 3 (Complex I-B9) (CI-B9) (NADH-ubiquinone oxidoreductase B9 subunit)	NDUFA3		CHEMBL2363065;				PF14987;	IPR026626;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]; mitochondrion [GO:0005739]
O00483	NDUA4_HUMAN	Cytochrome c oxidase subunit NDUFA4 (Complex I-MLRQ) (CI-MLRQ) (NADH-ubiquinone oxidoreductase MLRQ subunit)	NDUFA4		CHEMBL2317;	O00483;			PF06522;	IPR010530;	hydrogen ion transmembrane transport [GO:1902600]; mitochondrial electron transport, cytochrome c to oxygen [GO:0006123]; mitochondrial electron transport, NADH to ubiquinone [GO:0006120]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]; protein complex binding [GO:0032403]	extracellular exosome [GO:0070062]; mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]; mitochondrial respiratory chain complex IV [GO:0005751]; mitochondrion [GO:0005739]
Q16718	NDUA5_HUMAN	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 (Complex I subunit B13) (Complex I-13kD-B) (CI-13kD-B) (NADH-ubiquinone oxidoreductase 13 kDa-B subunit)	NDUFA5		CHEMBL2363065;				PF04716;	IPR006806;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]
P56556	NDUA6_HUMAN	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6 (Complex I-B14) (CI-B14) (LYR motif-containing protein 6) (NADH-ubiquinone oxidoreductase B14 subunit)	NDUFA6 LYRM6 NADHB14		CHEMBL2363065;				PF05347;	IPR008011;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]; response to oxidative stress [GO:0006979]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	mitochondrial inner membrane [GO:0005743]; mitochondrial membrane [GO:0031966]; mitochondrial respiratory chain complex I [GO:0005747]
O95182	NDUA7_HUMAN	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 7 (Complex I-B14.5a) (CI-B14.5a) (NADH-ubiquinone oxidoreductase subunit B14.5a)	NDUFA7		CHEMBL2363065;				PF07347;	IPR009947;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]; mitochondrial translation [GO:0032543]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]; structural constituent of ribosome [GO:0003735]	mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]; mitochondrial ribosome [GO:0005761]; mitochondrion [GO:0005739]
P51970	NDUA8_HUMAN	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8 (Complex I-19kD) (CI-19kD) (Complex I-PGIV) (CI-PGIV) (NADH-ubiquinone oxidoreductase 19 kDa subunit)	NDUFA8		CHEMBL2363065;				PF06747;	IPR010625;IPR016680;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]; protein complex binding [GO:0032403]	mitochondrial inner membrane [GO:0005743]; mitochondrial intermembrane space [GO:0005758]; mitochondrial respiratory chain complex I [GO:0005747]; mitochondrion [GO:0005739]
Q16795	NDUA9_HUMAN	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial (Complex I-39kD) (CI-39kD) (NADH-ubiquinone oxidoreductase 39 kDa subunit)	NDUFA9 NDUFS2L		CHEMBL2363065;				PF01370;	IPR001509;IPR016040;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]; sodium ion transport [GO:0006814]; ubiquinone-6 biosynthetic process [GO:1901006]	coenzyme binding [GO:0050662]; NADH dehydrogenase (ubiquinone) activity [GO:0008137]; NADH dehydrogenase activity [GO:0003954]; protein complex binding [GO:0032403]	mitochondrial matrix [GO:0005759]; mitochondrial membrane [GO:0031966]; mitochondrial respiratory chain complex I [GO:0005747]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
O95299	NDUAA_HUMAN	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial (Complex I-42kD) (CI-42kD) (NADH-ubiquinone oxidoreductase 42 kDa subunit)	NDUFA10		CHEMBL2363065;				PF01712;	IPR031314;IPR015828;IPR027417;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]; response to drug [GO:0042493]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]; mitochondrial respiratory chain complex I [GO:0005747]; myelin sheath [GO:0043209]
Q86Y39	NDUAB_HUMAN	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 11 (Complex I-B14.7) (CI-B14.7) (NADH-ubiquinone oxidoreductase subunit B14.7)	NDUFA11		CHEMBL2363065;						mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]		integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]; mitochondrion [GO:0005739]
Q9UI09	NDUAC_HUMAN	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 (13 kDa differentiation-associated protein) (Complex I-B17.2) (CI-B17.2) (CIB17.2) (NADH-ubiquinone oxidoreductase subunit B17.2)	NDUFA12 DAP13		CHEMBL2363065;				PF05071;	IPR007763;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]; respiratory gaseous exchange [GO:0007585]; response to oxidative stress [GO:0006979]	electron carrier activity [GO:0009055]; NADH dehydrogenase (ubiquinone) activity [GO:0008137]	mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]
Q9P0J0	NDUAD_HUMAN	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 (Cell death regulatory protein GRIM-19) (Complex I-B16.6) (CI-B16.6) (Gene associated with retinoic and interferon-induced mortality 19 protein) (GRIM-19) (Gene associated with retinoic and IFN-induced mortality 19 protein) (NADH-ubiquinone oxidoreductase B16.6 subunit)	NDUFA13 GRIM19 CDA016 CGI-39		CHEMBL2363065;				PF06212;	IPR009346;	apoptotic signaling pathway [GO:0097190]; cellular response to interferon-beta [GO:0035458]; cellular response to retinoic acid [GO:0071300]; extrinsic apoptotic signaling pathway [GO:0097191]; mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]; negative regulation of cell growth [GO:0030308]; negative regulation of intrinsic apoptotic signaling pathway [GO:2001243]; negative regulation of transcription, DNA-templated [GO:0045892]; positive regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043280]; positive regulation of peptidase activity [GO:0010952]; positive regulation of protein catabolic process [GO:0045732]; protein import into mitochondrial inner membrane [GO:0045039]; reactive oxygen species metabolic process [GO:0072593]	ATP binding [GO:0005524]; NADH dehydrogenase (ubiquinone) activity [GO:0008137]; NADH dehydrogenase activity [GO:0003954]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrial membrane [GO:0031966]; mitochondrial respiratory chain [GO:0005746]; mitochondrial respiratory chain complex I [GO:0005747]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]
O75438	NDUB1_HUMAN	NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 1 (Complex I-MNLL) (CI-MNLL) (NADH-ubiquinone oxidoreductase MNLL subunit) [Cleaved into: NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 1, N-terminally processed]	NDUFB1		CHEMBL2363065;				PF08040;	IPR012575;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]
O95178	NDUB2_HUMAN	NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial (Complex I-AGGG) (CI-AGGG) (NADH-ubiquinone oxidoreductase AGGG subunit)	NDUFB2		CHEMBL2363065;					IPR026627;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]
O43676	NDUB3_HUMAN	NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3 (Complex I-B12) (CI-B12) (NADH-ubiquinone oxidoreductase B12 subunit)	NDUFB3		CHEMBL2363065;				PF08122;	IPR012576;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]
O95168	NDUB4_HUMAN	NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 (Complex I-B15) (CI-B15) (NADH-ubiquinone oxidoreductase B15 subunit)	NDUFB4		CHEMBL2363065;				PF07225;	IPR009866;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]; response to oxidative stress [GO:0006979]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]; mitochondrion [GO:0005739]; nuclear membrane [GO:0031965]; nucleoplasm [GO:0005654]
O43674	NDUB5_HUMAN	NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 5, mitochondrial (Complex I-SGDH) (CI-SGDH) (NADH-ubiquinone oxidoreductase SGDH subunit)	NDUFB5		CHEMBL2363065;				PF09781;	IPR019173;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]
O95139	NDUB6_HUMAN	NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6 (Complex I-B17) (CI-B17) (NADH-ubiquinone oxidoreductase B17 subunit)	NDUFB6		CHEMBL2363065;				PF09782;	IPR019174;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrial membrane [GO:0031966]; mitochondrial respiratory chain complex I [GO:0005747]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]
P17568	NDUB7_HUMAN	NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7 (Cell adhesion protein SQM1) (Complex I-B18) (CI-B18) (NADH-ubiquinone oxidoreductase B18 subunit)	NDUFB7		CHEMBL2363065;				PF05676;	IPR008698;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	mitochondrial inner membrane [GO:0005743]; mitochondrial intermembrane space [GO:0005758]; mitochondrial respiratory chain complex I [GO:0005747]; mitochondrion [GO:0005739]
O95169	NDUB8_HUMAN	NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial (Complex I-ASHI) (CI-ASHI) (NADH-ubiquinone oxidoreductase ASHI subunit)	NDUFB8		CHEMBL2363065;				PF05821;	IPR008699;IPR016551;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	endoplasmic reticulum [GO:0005783]; integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]
Q9Y6M9	NDUB9_HUMAN	NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 (Complex I-B22) (CI-B22) (LYR motif-containing protein 3) (NADH-ubiquinone oxidoreductase B22 subunit)	NDUFB9 LYRM3 UQOR22		CHEMBL2363065;				PF05347;	IPR008011;IPR033034;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]; sensory perception of sound [GO:0007605]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	extracellular exosome [GO:0070062]; mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]; mitochondrion [GO:0005739]
O96000	NDUBA_HUMAN	NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 (Complex I-PDSW) (CI-PDSW) (NADH-ubiquinone oxidoreductase PDSW subunit)	NDUFB10		CHEMBL2363065;				PF10249;	IPR019377;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	extracellular exosome [GO:0070062]; mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]
O43677	NDUC1_HUMAN	NADH dehydrogenase [ubiquinone] 1 subunit C1, mitochondrial (Complex I-KFYI) (CI-KFYI) (NADH-ubiquinone oxidoreductase KFYI subunit)	NDUFC1		CHEMBL2363065;				PF15088;	IPR026192;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]; mitochondrion [GO:0005739]
O95298	NDUC2_HUMAN	NADH dehydrogenase [ubiquinone] 1 subunit C2 (Complex I-B14.5b) (CI-B14.5b) (Human lung cancer oncogene 1 protein) (HLC-1) (NADH-ubiquinone oxidoreductase subunit B14.5b)	NDUFC2 HLC1		CHEMBL2363065;		DB01136;		PF06374;	IPR009423;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	cytoplasm [GO:0005737]; integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]
P28331	NDUS1_HUMAN	NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial (EC 1.6.5.3) (EC 1.6.99.3) (Complex I-75kD) (CI-75kD)	NDUFS1		CHEMBL2363065;				PF00384;PF10588;PF09326;	IPR001041;IPR012675;IPR006656;IPR006963;IPR000283;IPR010228;IPR019574;IPR015405;	apoptotic mitochondrial changes [GO:0008637]; ATP metabolic process [GO:0046034]; cellular respiration [GO:0045333]; mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]; reactive oxygen species metabolic process [GO:0072593]; regulation of mitochondrial membrane potential [GO:0051881]	2 iron, 2 sulfur cluster binding [GO:0051537]; 4 iron, 4 sulfur cluster binding [GO:0051539]; electron carrier activity [GO:0009055]; metal ion binding [GO:0046872]; NADH dehydrogenase (ubiquinone) activity [GO:0008137]	mitochondrial intermembrane space [GO:0005758]; mitochondrial matrix [GO:0005759]; mitochondrial respiratory chain complex I [GO:0005747]; mitochondrion [GO:0005739]; myelin sheath [GO:0043209]
O75306	NDUS2_HUMAN	NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial (EC 1.6.5.3) (EC 1.6.99.3) (Complex I-49kD) (CI-49kD) (NADH-ubiquinone oxidoreductase 49 kDa subunit)	NDUFS2		CHEMBL2363065;		DB00997;		PF00346;	IPR001135;IPR014029;IPR022885;IPR029014;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]; response to oxidative stress [GO:0006979]	4 iron, 4 sulfur cluster binding [GO:0051539]; electron carrier activity [GO:0009055]; metal ion binding [GO:0046872]; NAD binding [GO:0051287]; NADH dehydrogenase (ubiquinone) activity [GO:0008137]; quinone binding [GO:0048038]; ubiquitin protein ligase binding [GO:0031625]	mitochondrial matrix [GO:0005759]; mitochondrial respiratory chain complex I [GO:0005747]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]
O75489	NDUS3_HUMAN	NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial (EC 1.6.5.3) (EC 1.6.99.3) (Complex I-30kD) (CI-30kD) (NADH-ubiquinone oxidoreductase 30 kDa subunit)	NDUFS3		CHEMBL2363065;		DB00997;		PF00329;	IPR010218;IPR001268;IPR020396;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]; negative regulation of cell growth [GO:0030308]; negative regulation of intrinsic apoptotic signaling pathway [GO:2001243]; reactive oxygen species metabolic process [GO:0072593]; substantia nigra development [GO:0021762]	electron carrier activity [GO:0009055]; NADH dehydrogenase (ubiquinone) activity [GO:0008137]; NADH dehydrogenase activity [GO:0003954]	mitochondrial matrix [GO:0005759]; mitochondrial membrane [GO:0031966]; mitochondrial respiratory chain complex I [GO:0005747]; mitochondrion [GO:0005739]; myelin sheath [GO:0043209]; nucleus [GO:0005634]
O43181	NDUS4_HUMAN	NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial (Complex I-18 kDa) (CI-18 kDa) (Complex I-AQDQ) (CI-AQDQ) (NADH-ubiquinone oxidoreductase 18 kDa subunit)	NDUFS4		CHEMBL2363065;				PF04800;	IPR006885;	brain development [GO:0007420]; cAMP-mediated signaling [GO:0019933]; cellular respiration [GO:0045333]; mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]; positive regulation of fibroblast proliferation [GO:0048146]; reactive oxygen species metabolic process [GO:0072593]; regulation of protein phosphorylation [GO:0001932]; response to cAMP [GO:0051591]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]; mitochondrion [GO:0005739]
O43920	NDUS5_HUMAN	NADH dehydrogenase [ubiquinone] iron-sulfur protein 5 (Complex I-15 kDa) (CI-15 kDa) (NADH-ubiquinone oxidoreductase 15 kDa subunit)	NDUFS5		CHEMBL2363065;				PF10200;	IPR019342;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	mitochondrial inner membrane [GO:0005743]; mitochondrial intermembrane space [GO:0005758]; mitochondrial respiratory chain complex I [GO:0005747]; mitochondrion [GO:0005739]
O75380	NDUS6_HUMAN	NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial (Complex I-13kD-A) (CI-13kD-A) (NADH-ubiquinone oxidoreductase 13 kDa-A subunit)	NDUFS6		CHEMBL2363065;				PF10276;	IPR016668;IPR019401;	cardiovascular system development [GO:0072358]; fatty acid metabolic process [GO:0006631]; mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]; mitochondrion morphogenesis [GO:0070584]; multicellular organism aging [GO:0010259]; multicellular organism growth [GO:0035264]; muscle contraction [GO:0006936]; reproductive system development [GO:0061458]	electron carrier activity [GO:0009055]; NADH dehydrogenase (ubiquinone) activity [GO:0008137]	mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]
O75251	NDUS7_HUMAN	NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial (EC 1.6.5.3) (EC 1.6.99.3) (Complex I-20kD) (CI-20kD) (NADH-ubiquinone oxidoreductase 20 kDa subunit) (PSST subunit)	NDUFS7		CHEMBL2363065;		DB00997;		PF01058;	IPR006137;IPR006138;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]	4 iron, 4 sulfur cluster binding [GO:0051539]; metal ion binding [GO:0046872]; NADH dehydrogenase (ubiquinone) activity [GO:0008137]; oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor [GO:0016655]; quinone binding [GO:0048038]	mitochondrial matrix [GO:0005759]; mitochondrial respiratory chain complex I [GO:0005747]; neuronal cell body [GO:0043025]; neuron projection [GO:0043005]; synaptic membrane [GO:0097060]
O00217	NDUS8_HUMAN	NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial (EC 1.6.5.3) (EC 1.6.99.3) (Complex I-23kD) (CI-23kD) (NADH-ubiquinone oxidoreductase 23 kDa subunit) (TYKY subunit)	NDUFS8		CHEMBL2363065;				PF12838;	IPR017896;IPR017900;IPR010226;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]; response to oxidative stress [GO:0006979]	4 iron, 4 sulfur cluster binding [GO:0051539]; metal ion binding [GO:0046872]; NADH dehydrogenase (ubiquinone) activity [GO:0008137]	mitochondrial matrix [GO:0005759]; mitochondrial respiratory chain complex I [GO:0005747]; mitochondrion [GO:0005739]
P49821	NDUV1_HUMAN	NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial (EC 1.6.5.3) (EC 1.6.99.3) (Complex I-51kD) (CI-51kD) (NADH dehydrogenase flavoprotein 1) (NADH-ubiquinone oxidoreductase 51 kDa subunit)	NDUFV1 UQOR1		CHEMBL2363065;				PF01512;PF10589;PF10531;	IPR001949;IPR011537;IPR011538;IPR019575;IPR019554;	aerobic respiration [GO:0009060]; mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]	4 iron, 4 sulfur cluster binding [GO:0051539]; FMN binding [GO:0010181]; metal ion binding [GO:0046872]; NAD binding [GO:0051287]; NADH dehydrogenase (ubiquinone) activity [GO:0008137]	mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]
P19404	NDUV2_HUMAN	NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial (EC 1.6.5.3) (EC 1.6.99.3) (NADH-ubiquinone oxidoreductase 24 kDa subunit)	NDUFV2		CHEMBL2363065;					IPR002023;IPR012336;	cardiac muscle tissue development [GO:0048738]; mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]; nervous system development [GO:0007399]	2 iron, 2 sulfur cluster binding [GO:0051537]; electron carrier activity [GO:0009055]; metal ion binding [GO:0046872]; NADH dehydrogenase (ubiquinone) activity [GO:0008137]	mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]; mitochondrion [GO:0005739]; myelin sheath [GO:0043209]
P56181	NDUV3_HUMAN	NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial (Complex I-9kD) (CI-9kD) (NADH-ubiquinone oxidoreductase 9 kDa subunit) (Renal carcinoma antigen NY-REN-4)	NDUFV3		CHEMBL2363065;				PF15880;	IPR026193;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]; poly(A) RNA binding [GO:0044822]	mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]
Q96FI4	NEIL1_HUMAN	Endonuclease 8-like 1 (EC 3.2.2.-) (EC 4.2.99.18) (DNA glycosylase/AP lyase Neil1) (DNA-(apurinic or apyrimidinic site) lyase Neil1) (Endonuclease VIII-like 1) (FPG1) (Nei homolog 1) (NEH1) (Nei-like protein 1)	NEIL1	1TDH;4NRV;5ITQ;5ITR;5ITT;5ITU;5ITX;5ITY;			DB03754;		PF01149;PF06831;PF09292;	IPR015886;IPR015371;IPR012319;IPR010979;	base-excision repair [GO:0006284]; depyrimidination [GO:0045008]; negative regulation of nuclease activity [GO:0032074]; nucleotide-excision repair [GO:0006289]; response to oxidative stress [GO:0006979]	damaged DNA binding [GO:0003684]; DNA-(apurinic or apyrimidinic site) lyase activity [GO:0003906]; DNA N-glycosylase activity [GO:0019104]; hydrolase activity, acting on glycosyl bonds [GO:0016798]; protein C-terminus binding [GO:0008022]; zinc ion binding [GO:0008270]	chromosome [GO:0005694]; cytoplasm [GO:0005737]; microtubule organizing center [GO:0005815]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P08473	NEP_HUMAN	Neprilysin (EC 3.4.24.11) (Atriopeptidase) (Common acute lymphocytic leukemia antigen) (CALLA) (Enkephalinase) (Neutral endopeptidase 24.11) (NEP) (Neutral endopeptidase) (Skin fibroblast elastase) (SFE) (CD antigen CD10)	MME EPN	1DL9;1DMT;1QVD;1R1H;1R1I;1R1J;1Y8J;2QPJ;2YB9;4CTH;5JMY;	CHEMBL1944;	P08473;	DB00616;DB06655;DB09292;		PF01431;PF05649;	IPR024079;IPR029727;IPR000718;IPR018497;IPR008753;	angiotensin maturation [GO:0002003]; beta-amyloid metabolic process [GO:0050435]; cellular response to cytokine stimulus [GO:0071345]; cellular response to UV-A [GO:0071492]; cellular response to UV-B [GO:0071493]; creatinine metabolic process [GO:0046449]; kidney development [GO:0001822]; peptide metabolic process [GO:0006518]; proteolysis [GO:0006508]; replicative senescence [GO:0090399]; sensory perception of pain [GO:0019233]	endopeptidase activity [GO:0004175]; exopeptidase activity [GO:0008238]; metalloendopeptidase activity [GO:0004222]; metallopeptidase activity [GO:0008237]; peptide binding [GO:0042277]; zinc ion binding [GO:0008270]	axon [GO:0030424]; brush border [GO:0005903]; cytoplasm [GO:0005737]; dendrite [GO:0030425]; extracellular exosome [GO:0070062]; focal adhesion [GO:0005925]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; neuron projection terminus [GO:0044306]; plasma membrane [GO:0005886]; synapse [GO:0045202]; synaptic vesicle [GO:0008021]
P01178	NEU1_HUMAN	Oxytocin-neurophysin 1 (OT-NPI) [Cleaved into: Oxytocin (Ocytocin); Neurophysin 1]	OXT OT				DB00107;		PF00220;PF00184;	IPR000981;IPR022423;	drinking behavior [GO:0042756]; eating behavior [GO:0042755]; female pregnancy [GO:0007565]; grooming behavior [GO:0007625]; heart development [GO:0007507]; hyperosmotic salinity response [GO:0042538]; male mating behavior [GO:0060179]; maternal aggressive behavior [GO:0002125]; maternal behavior [GO:0042711]; memory [GO:0007613]; negative regulation of blood pressure [GO:0045776]; negative regulation of gastric acid secretion [GO:0060455]; negative regulation of urine volume [GO:0035811]; positive regulation of blood pressure [GO:0045777]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of female receptivity [GO:0045925]; positive regulation of hindgut contraction [GO:0060450]; positive regulation of norepinephrine secretion [GO:0010701]; positive regulation of ossification [GO:0045778]; positive regulation of penile erection [GO:0060406]; positive regulation of prostaglandin secretion [GO:0032308]; positive regulation of renal sodium excretion [GO:0035815]; positive regulation of synapse assembly [GO:0051965]; positive regulation of synaptic transmission [GO:0050806]; positive regulation of uterine smooth muscle contraction [GO:0070474]; regulation of heart rate [GO:0002027]; regulation of sensory perception of pain [GO:0051930]; response to activity [GO:0014823]; response to amphetamine [GO:0001975]; response to cAMP [GO:0051591]; response to cocaine [GO:0042220]; response to electrical stimulus [GO:0051602]; response to estradiol [GO:0032355]; response to ether [GO:0045472]; response to food [GO:0032094]; response to glucocorticoid [GO:0051384]; response to peptide hormone [GO:0043434]; response to progesterone [GO:0032570]; response to prostaglandin E [GO:0034695]; response to retinoic acid [GO:0032526]; response to sucrose [GO:0009744]; signal transduction [GO:0007165]; sleep [GO:0030431]; social behavior [GO:0035176]; sperm ejaculation [GO:0042713]		extracellular region [GO:0005576]; extracellular space [GO:0005615]; secretory granule [GO:0030141]; terminal bouton [GO:0043195]
Q99519	NEUR1_HUMAN	Sialidase-1 (EC 3.2.1.18) (Acetylneuraminyl hydrolase) (G9 sialidase) (Lysosomal sialidase) (N-acetyl-alpha-neuraminidase 1)	NEU1 NANH		CHEMBL2726;	Q99519;	DB00198;		PF13088;	IPR026856;IPR011040;	ganglioside catabolic process [GO:0006689]; glycosphingolipid metabolic process [GO:0006687]; oligosaccharide catabolic process [GO:0009313]	exo-alpha-(2->3)-sialidase activity [GO:0052794]; exo-alpha-(2->6)-sialidase activity [GO:0052795]; exo-alpha-(2->8)-sialidase activity [GO:0052796]; exo-alpha-sialidase activity [GO:0004308]	cell junction [GO:0030054]; cytoplasmic, membrane-bounded vesicle [GO:0016023]; extracellular exosome [GO:0070062]; intracellular membrane-bounded organelle [GO:0043231]; lysosomal lumen [GO:0043202]; lysosomal membrane [GO:0005765]; lysosome [GO:0005764]; membrane [GO:0016020]; plasma membrane [GO:0005886]
Q9Y3R4	NEUR2_HUMAN	Sialidase-2 (EC 3.2.1.18) (Cytosolic sialidase) (N-acetyl-alpha-neuraminidase 2)	NEU2	1SNT;1SO7;1VCU;2F0Z;2F10;2F11;2F12;2F13;2F24;2F25;2F26;2F27;2F28;2F29;4NC5;4NCS;	CHEMBL3200;	Q9Y3R4;	DB00198;DB00558;		PF13088;	IPR026945;IPR026856;IPR011040;	ganglioside catabolic process [GO:0006689]; glycosphingolipid metabolic process [GO:0006687]; oligosaccharide catabolic process [GO:0009313]	exo-alpha-(2->3)-sialidase activity [GO:0052794]; exo-alpha-(2->6)-sialidase activity [GO:0052795]; exo-alpha-(2->8)-sialidase activity [GO:0052796]; exo-alpha-sialidase activity [GO:0004308]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; intracellular membrane-bounded organelle [GO:0043231]; membrane [GO:0016020]
P19838	NFKB1_HUMAN	Nuclear factor NF-kappa-B p105 subunit (DNA-binding factor KBF1) (EBP-1) (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) [Cleaved into: Nuclear factor NF-kappa-B p50 subunit]	NFKB1	1MDI;1MDJ;1MDK;1NFI;1SVC;2DBF;2O61;3GUT;	CHEMBL3251;	P19838;	DB00945;DB01411;DB01041;DB08814;		PF12796;PF00531;PF16179;PF00554;	IPR002110;IPR020683;IPR011029;IPR000488;IPR013783;IPR014756;IPR002909;IPR030503;IPR000451;IPR008967;IPR030492;IPR032397;IPR011539;	apoptotic process [GO:0006915]; cellular response to dsRNA [GO:0071359]; cellular response to interleukin-1 [GO:0071347]; cellular response to interleukin-6 [GO:0071354]; cellular response to lipopolysaccharide [GO:0071222]; cellular response to mechanical stimulus [GO:0071260]; cellular response to nicotine [GO:0071316]; cellular response to peptide hormone stimulus [GO:0071375]; Fc-epsilon receptor signaling pathway [GO:0038095]; I-kappaB kinase/NF-kappaB signaling [GO:0007249]; inflammatory response [GO:0006954]; innate immune response [GO:0045087]; membrane protein intracellular domain proteolysis [GO:0031293]; negative regulation of apoptotic process [GO:0043066]; negative regulation of calcidiol 1-monooxygenase activity [GO:0010956]; negative regulation of cellular protein metabolic process [GO:0032269]; negative regulation of cholesterol transport [GO:0032375]; negative regulation of gene expression [GO:0010629]; negative regulation of inflammatory response [GO:0050728]; negative regulation of interleukin-12 biosynthetic process [GO:0045083]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; negative regulation of vitamin D biosynthetic process [GO:0010957]; NIK/NF-kappaB signaling [GO:0038061]; positive regulation of canonical Wnt signaling pathway [GO:0090263]; positive regulation of hyaluronan biosynthetic process [GO:1900127]; positive regulation of lipid storage [GO:0010884]; positive regulation of macrophage derived foam cell differentiation [GO:0010744]; positive regulation of miRNA metabolic process [GO:2000630]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of type I interferon production [GO:0032481]; response to muscle stretch [GO:0035994]; stimulatory C-type lectin receptor signaling pathway [GO:0002223]; stress-activated MAPK cascade [GO:0051403]; T cell receptor signaling pathway [GO:0050852]; transcription from RNA polymerase II promoter [GO:0006366]	actinin binding [GO:0042805]; chromatin binding [GO:0003682]; identical protein binding [GO:0042802]; protein heterodimerization activity [GO:0046982]; regulatory region DNA binding [GO:0000975]; RNA polymerase II distal enhancer sequence-specific DNA binding [GO:0000980]; RNA polymerase II regulatory region sequence-specific DNA binding [GO:0000977]; transcriptional activator activity, RNA polymerase II distal enhancer sequence-specific binding [GO:0001205]; transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding [GO:0001227]; transcription factor activity, sequence-specific DNA binding [GO:0003700]; transcription factor binding [GO:0008134]; transcription regulatory region DNA binding [GO:0044212]; transcription regulatory region sequence-specific DNA binding [GO:0000976]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; I-kappaB/NF-kappaB complex [GO:0033256]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
Q9Y697	NFS1_HUMAN	Cysteine desulfurase, mitochondrial (EC 2.8.1.7)	NFS1 NIFS HUSSY-08	5KZ5;			DB00160;DB00151;		PF00266;	IPR000192;IPR020578;IPR010240;IPR016454;IPR015424;IPR015421;IPR015422;	[2Fe-2S] cluster assembly [GO:0044571]; iron incorporation into metallo-sulfur cluster [GO:0018283]; molybdopterin cofactor biosynthetic process [GO:0032324]; Mo-molybdopterin cofactor biosynthetic process [GO:0006777]; protein complex assembly [GO:0006461]; small molecule metabolic process [GO:0044281]; sulfur amino acid metabolic process [GO:0000096]	cysteine desulfurase activity [GO:0031071]; iron-sulfur cluster binding [GO:0051536]; metal ion binding [GO:0046872]; protein homodimerization activity [GO:0042803]; pyridoxal phosphate binding [GO:0030170]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; intracellular membrane-bounded organelle [GO:0043231]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P80188	NGAL_HUMAN	Neutrophil gelatinase-associated lipocalin (NGAL) (25 kDa alpha-2-microglobulin-related subunit of MMP-9) (Lipocalin-2) (Oncogene 24p3) (Siderocalin LCN2) (p25)	LCN2 HNL NGAL	1DFV;1L6M;1NGL;1QQS;1X71;1X89;1X8U;3BY0;3CBC;3CMP;3DSZ;3DTQ;3FW4;3FW5;3HWD;3HWE;3HWF;3HWG;3I0A;3K3L;3PEC;3PED;3T1D;3TF6;3TZS;3U03;3U0D;4GH7;4IAW;4IAX;4K19;4MVI;4MVK;4MVL;4QAE;4ZFX;4ZHC;4ZHD;4ZHF;4ZHG;4ZHH;		P80188;			PF00061;	IPR012674;IPR011038;IPR003087;IPR002345;IPR022272;IPR000566;	apoptotic process [GO:0006915]; cellular iron ion homeostasis [GO:0006879]; innate immune response [GO:0045087]; ion transport [GO:0006811]; siderophore transport [GO:0015891]	iron ion binding [GO:0005506]; small molecule binding [GO:0036094]; transporter activity [GO:0005215]	cell [GO:0005623]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]
Q9NPG2	NGB_HUMAN	Neuroglobin	NGB	1OJ6;4MPM;					PF00042;	IPR000971;IPR009050;IPR012292;	apoptotic process [GO:0006915]; oxygen transport [GO:0015671]	heme binding [GO:0020037]; metal ion binding [GO:0046872]; oxygen binding [GO:0019825]; oxygen transporter activity [GO:0005344]	mitochondrion [GO:0005739]; perikaryon [GO:0043204]
P01138	NGF_HUMAN	Beta-nerve growth factor (Beta-NGF)	NGF NGFB	1SG1;1WWW;2IFG;4EDW;4EDX;4ZBN;	CHEMBL1649058;	P01138;	DB01407;		PF00243;	IPR029034;IPR020408;IPR002072;IPR020425;IPR020437;IPR019846;	activation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0006919]; activation of MAPKK activity [GO:0000186]; cell-cell signaling [GO:0007267]; extrinsic apoptotic signaling pathway via death domain receptors [GO:0008625]; microtubule-based movement [GO:0007018]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154]; negative regulation of neuron apoptotic process [GO:0043524]; nerve growth factor processing [GO:0032455]; neuron projection morphogenesis [GO:0048812]; neurotrophin TRK receptor signaling pathway [GO:0048011]; phosphatidylinositol-mediated signaling [GO:0048015]; positive regulation of apoptotic process [GO:0043065]; positive regulation of axonogenesis [GO:0050772]; positive regulation of gene expression [GO:0010628]; positive regulation of Ras protein signal transduction [GO:0046579]; regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043281]; regulation of neuron differentiation [GO:0045664]; transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169]	growth factor activity [GO:0008083]; metalloendopeptidase inhibitor activity [GO:0008191]; nerve growth factor receptor binding [GO:0005163]	cytoplasmic, membrane-bounded vesicle [GO:0016023]; endosome [GO:0005768]; extracellular region [GO:0005576]; Golgi lumen [GO:0005796]
P25103	NK1R_HUMAN	Substance-P receptor (SPR) (NK-1 receptor) (NK-1R) (Tachykinin receptor 1)	TACR1 NK1R TAC1R	2KS9;2KSA;2KSB;	CHEMBL249;	P25103;	DB00673;DB01221;DB09048;DB04894;		PF00001;	IPR000276;IPR017452;IPR001681;IPR000046;	cell surface receptor signaling pathway [GO:0007166]; chemical synaptic transmission [GO:0007268]; detection of abiotic stimulus [GO:0009582]; inflammatory response [GO:0006954]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; positive regulation of smooth muscle contraction [GO:0045987]; regulation of uterine smooth muscle contraction [GO:0070472]; response to pain [GO:0048265]; tachykinin receptor signaling pathway [GO:0007217]	substance P receptor activity [GO:0016496]; tachykinin receptor activity [GO:0004995]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P21452	NK2R_HUMAN	Substance-K receptor (SKR) (NK-2 receptor) (NK-2R) (Neurokinin A receptor) (Tachykinin receptor 2)	TACR2 NK2R NKNAR TAC2R		CHEMBL2327;	P21452;			PF00001;	IPR000276;IPR017452;IPR001681;IPR000913;	cell surface receptor signaling pathway [GO:0007166]; chemical synaptic transmission [GO:0007268]; excretion [GO:0007588]; intestine smooth muscle contraction [GO:0014827]; muscle contraction [GO:0006936]; negative regulation of luteinizing hormone secretion [GO:0033685]; operant conditioning [GO:0035106]; positive regulation of acetylcholine secretion, neurotransmission [GO:0014057]; positive regulation of smooth muscle contraction [GO:0045987]; positive regulation of uterine smooth muscle contraction [GO:0070474]; positive regulation of vascular permeability [GO:0043117]; prolactin secretion [GO:0070459]; response to electrical stimulus [GO:0051602]; tachykinin receptor signaling pathway [GO:0007217]	substance K receptor activity [GO:0016497]; tachykinin receptor activity [GO:0004995]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
Q8TCU5	NMD3A_HUMAN	Glutamate receptor ionotropic, NMDA 3A (GluN3A) (N-methyl-D-aspartate receptor subtype 3A) (NMDAR3A) (NR3A) (NMDAR-L)	GRIN3A KIAA1973		CHEMBL4787;		DB00659;DB06151;DB00915;DB00289;DB01161;DB00514;DB00898;DB00392;DB00949;DB00996;DB01159;DB01221;DB06738;DB01043;DB00333;DB04896;DB01173;DB00312;DB01174;DB00721;DB00418;DB00193;		PF00060;PF10613;	IPR019594;IPR001508;IPR001320;IPR028082;	calcium ion transport [GO:0006816]; dendrite development [GO:0016358]; prepulse inhibition [GO:0060134]; response to ethanol [GO:0045471]	calcium channel activity [GO:0005262]; extracellular-glutamate-gated ion channel activity [GO:0005234]; glycine binding [GO:0016594]; identical protein binding [GO:0042802]; NMDA glutamate receptor activity [GO:0004972]; protein phosphatase 2A binding [GO:0051721]	cell junction [GO:0030054]; integral component of membrane [GO:0016021]; membrane [GO:0016020]; neuronal cell body [GO:0043025]; neuron projection [GO:0043005]; NMDA selective glutamate receptor complex [GO:0017146]; postsynaptic density [GO:0014069]; postsynaptic membrane [GO:0045211]; synapse [GO:0045202]
O60391	NMD3B_HUMAN	Glutamate receptor ionotropic, NMDA 3B (GluN3B) (N-methyl-D-aspartate receptor subtype 3B) (NMDAR3B) (NR3B)	GRIN3B		CHEMBL2094124;		DB00659;DB00289;DB00996;DB00145;DB01159;DB06738;DB04896;DB01173;DB00312;DB01174;DB00418;		PF00060;PF10613;	IPR019594;IPR001508;IPR001320;IPR028082;	ionotropic glutamate receptor signaling pathway [GO:0035235]; protein insertion into membrane [GO:0051205]; regulation of calcium ion transport [GO:0051924]	calcium channel activity [GO:0005262]; cation channel activity [GO:0005261]; extracellular-glutamate-gated ion channel activity [GO:0005234]; glycine binding [GO:0016594]; neurotransmitter binding [GO:0042165]; neurotransmitter receptor activity [GO:0030594]; NMDA glutamate receptor activity [GO:0004972]	cell junction [GO:0030054]; neuronal cell body [GO:0043025]; NMDA selective glutamate receptor complex [GO:0017146]; postsynaptic membrane [GO:0045211]
Q12879	NMDE1_HUMAN	Glutamate receptor ionotropic, NMDA 2A (GluN2A) (Glutamate [NMDA] receptor subunit epsilon-1) (N-methyl D-aspartate receptor subtype 2A) (NMDAR2A) (NR2A) (hNR2A)	GRIN2A NMDAR2A	3NFL;5H8F;5H8H;5H8N;5H8Q;5I2K;5I2N;5KCJ;5KDT;	CHEMBL1972;	Q12879;	DB00659;DB06151;DB00289;DB00949;DB00996;DB00145;DB01159;DB06738;DB01043;DB04896;DB00312;DB00454;DB01174;DB00418;		PF01094;PF00060;PF10613;PF10565;	IPR001828;IPR019594;IPR001508;IPR001320;IPR018884;IPR028082;	chemical synaptic transmission [GO:0007268]; directional locomotion [GO:0033058]; dopamine metabolic process [GO:0042417]; excitatory postsynaptic potential [GO:0060079]; glutamate receptor signaling pathway [GO:0007215]; learning or memory [GO:0007611]; long-term synaptic potentiation [GO:0060291]; MAPK cascade [GO:0000165]; memory [GO:0007613]; negative regulation of protein catabolic process [GO:0042177]; neurogenesis [GO:0022008]; positive regulation of apoptotic process [GO:0043065]; positive regulation of long-term synaptic potentiation [GO:1900273]; protein localization [GO:0008104]; regulation of sensory perception of pain [GO:0051930]; response to amphetamine [GO:0001975]; response to drug [GO:0042493]; response to ethanol [GO:0045471]; response to wounding [GO:0009611]; sensory perception of pain [GO:0019233]; serotonin metabolic process [GO:0042428]; sleep [GO:0030431]; startle response [GO:0001964]; transport [GO:0006810]; visual learning [GO:0008542]	calcium channel activity [GO:0005262]; extracellular-glutamate-gated ion channel activity [GO:0005234]; NMDA glutamate receptor activity [GO:0004972]; Ras guanyl-nucleotide exchange factor activity [GO:0005088]; zinc ion binding [GO:0008270]	cell junction [GO:0030054]; cell surface [GO:0009986]; endoplasmic reticulum [GO:0005783]; integral component of plasma membrane [GO:0005887]; neuron projection [GO:0043005]; NMDA selective glutamate receptor complex [GO:0017146]; plasma membrane [GO:0005886]; postsynaptic density [GO:0014069]; postsynaptic membrane [GO:0045211]; presynaptic membrane [GO:0042734]; synaptic vesicle [GO:0008021]
Q13224	NMDE2_HUMAN	Glutamate receptor ionotropic, NMDA 2B (GluN2B) (Glutamate [NMDA] receptor subunit epsilon-2) (N-methyl D-aspartate receptor subtype 2B) (NMDAR2B) (NR2B) (N-methyl-D-aspartate receptor subunit 3) (NR3) (hNR3)	GRIN2B NMDAR2B	1S11;1S2S;2IPV;5EWJ;5EWL;5EWM;	CHEMBL1904;	Q13224;	DB00659;DB06151;DB00289;DB00949;DB00996;DB00502;DB08954;DB06738;DB01043;DB04896;DB00312;DB00454;DB01174;DB00418;		PF01094;PF00060;PF10613;PF10565;	IPR001828;IPR019594;IPR001508;IPR001320;IPR018884;IPR028082;	chemical synaptic transmission [GO:0007268]; ephrin receptor signaling pathway [GO:0048013]; glutamate receptor signaling pathway [GO:0007215]; learning or memory [GO:0007611]; MAPK cascade [GO:0000165]; response to ethanol [GO:0045471]; transport [GO:0006810]	extracellular-glutamate-gated ion channel activity [GO:0005234]; glycine binding [GO:0016594]; NMDA glutamate receptor activity [GO:0004972]; Ras guanyl-nucleotide exchange factor activity [GO:0005088]; zinc ion binding [GO:0008270]	cell junction [GO:0030054]; cell surface [GO:0009986]; integral component of plasma membrane [GO:0005887]; intracellular [GO:0005622]; neuron projection [GO:0043005]; NMDA selective glutamate receptor complex [GO:0017146]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
Q14957	NMDE3_HUMAN	Glutamate receptor ionotropic, NMDA 2C (GluN2C) (Glutamate [NMDA] receptor subunit epsilon-3) (N-methyl D-aspartate receptor subtype 2C) (NMDAR2C) (NR2C)	GRIN2C NMDAR2C		CHEMBL4109;	Q14957;	DB00659;DB00289;DB00996;DB00145;DB06738;DB04896;DB00312;DB00454;DB01174;DB00418;		PF01094;PF00060;PF10613;PF10565;	IPR001828;IPR019594;IPR001508;IPR001320;IPR018884;IPR028082;	chemical synaptic transmission [GO:0007268]; directional locomotion [GO:0033058]; excitatory postsynaptic potential [GO:0060079]; glutamate receptor signaling pathway [GO:0007215]; MAPK cascade [GO:0000165]; negative regulation of protein catabolic process [GO:0042177]; neuromuscular process controlling balance [GO:0050885]; protein localization [GO:0008104]; response to wounding [GO:0009611]; transport [GO:0006810]	cation channel activity [GO:0005261]; extracellular-glutamate-gated ion channel activity [GO:0005234]; NMDA glutamate receptor activity [GO:0004972]; Ras guanyl-nucleotide exchange factor activity [GO:0005088]	cell junction [GO:0030054]; integral component of plasma membrane [GO:0005887]; NMDA selective glutamate receptor complex [GO:0017146]; plasma membrane [GO:0005886]; postsynaptic density [GO:0014069]; postsynaptic membrane [GO:0045211]
O15399	NMDE4_HUMAN	Glutamate receptor ionotropic, NMDA 2D (GluN2D) (EB11) (Glutamate [NMDA] receptor subunit epsilon-4) (N-methyl D-aspartate receptor subtype 2D) (NMDAR2D) (NR2D)	GRIN2D GluN2D NMDAR2D		CHEMBL2591;	O15399;	DB00659;DB06151;DB00289;DB00996;DB06738;DB04896;DB01173;DB00312;DB00454;DB01174;DB00418;		PF01094;PF00060;PF10613;	IPR001828;IPR019594;IPR001508;IPR001320;IPR028082;	adult locomotory behavior [GO:0008344]; chemical synaptic transmission [GO:0007268]; MAPK cascade [GO:0000165]; regulation of sensory perception of pain [GO:0051930]; signal transduction [GO:0007165]; startle response [GO:0001964]	extracellular-glutamate-gated ion channel activity [GO:0005234]; NMDA glutamate receptor activity [GO:0004972]; Ras guanyl-nucleotide exchange factor activity [GO:0005088]	cell junction [GO:0030054]; intracellular [GO:0005622]; NMDA selective glutamate receptor complex [GO:0017146]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
Q05586	NMDZ1_HUMAN	Glutamate receptor ionotropic, NMDA 1 (GluN1) (Glutamate [NMDA] receptor subunit zeta-1) (N-methyl-D-aspartate receptor subunit NR1) (NMD-R1)	GRIN1 NMDAR1	2HQW;2NR1;3BYA;5H8F;5H8H;5H8N;5H8Q;5I2K;5I2N;5KCJ;5KDT;	CHEMBL2015;	Q05586;	DB00659;DB06151;DB00289;DB00996;DB08954;DB06738;DB01043;DB04896;DB01173;DB00312;DB00454;DB01174;DB00418;		PF01094;PF10562;PF00060;PF10613;	IPR001828;IPR018882;IPR019594;IPR001508;IPR001320;IPR028082;	adult locomotory behavior [GO:0008344]; calcium ion homeostasis [GO:0055074]; cation transport [GO:0006812]; cellular calcium ion homeostasis [GO:0006874]; cerebral cortex development [GO:0021987]; chemical synaptic transmission [GO:0007268]; conditioned taste aversion [GO:0001661]; ephrin receptor signaling pathway [GO:0048013]; excitatory postsynaptic potential [GO:0060079]; ionotropic glutamate receptor signaling pathway [GO:0035235]; long-term memory [GO:0007616]; male mating behavior [GO:0060179]; MAPK cascade [GO:0000165]; negative regulation of neuron apoptotic process [GO:0043524]; olfactory learning [GO:0008355]; pons maturation [GO:0021586]; positive regulation of apoptotic process [GO:0043065]; positive regulation of excitatory postsynaptic potential [GO:2000463]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; prepulse inhibition [GO:0060134]; propylene metabolic process [GO:0018964]; regulation of axonogenesis [GO:0050770]; regulation of dendrite morphogenesis [GO:0048814]; regulation of long-term neuronal synaptic plasticity [GO:0048169]; regulation of membrane potential [GO:0042391]; regulation of respiratory gaseous exchange [GO:0043576]; regulation of synapse assembly [GO:0051963]; respiratory gaseous exchange [GO:0007585]; response to amphetamine [GO:0001975]; response to ethanol [GO:0045471]; response to morphine [GO:0043278]; sensory perception of pain [GO:0019233]; social behavior [GO:0035176]; suckling behavior [GO:0001967]; synaptic transmission, glutamatergic [GO:0035249]; visual learning [GO:0008542]	calcium channel activity [GO:0005262]; calcium ion binding [GO:0005509]; calmodulin binding [GO:0005516]; extracellular-glutamate-gated ion channel activity [GO:0005234]; glutamate binding [GO:0016595]; glycine binding [GO:0016594]; neurotransmitter binding [GO:0042165]; NMDA glutamate receptor activity [GO:0004972]; Ras guanyl-nucleotide exchange factor activity [GO:0005088]	cell junction [GO:0030054]; cell surface [GO:0009986]; dendrite [GO:0030425]; dendritic spine [GO:0043197]; endoplasmic reticulum [GO:0005783]; excitatory synapse [GO:0060076]; integral component of plasma membrane [GO:0005887]; neuron projection [GO:0043005]; NMDA selective glutamate receptor complex [GO:0017146]; plasma membrane [GO:0005886]; postsynaptic density [GO:0014069]; postsynaptic membrane [GO:0045211]; synapse [GO:0045202]; synaptic cleft [GO:0043083]; synaptic vesicle [GO:0008021]; terminal bouton [GO:0043195]
Q9HAN9	NMNA1_HUMAN	Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 (NMN/NaMN adenylyltransferase 1) (EC 2.7.7.1) (EC 2.7.7.18) (Nicotinamide-nucleotide adenylyltransferase 1) (NMN adenylyltransferase 1) (Nicotinate-nucleotide adenylyltransferase 1) (NaMN adenylyltransferase 1)	NMNAT1 NMNAT	1GZU;1KKU;1KQN;1KQO;1KR2;				PATHWAY: Cofactor biosynthesis; NAD(+) biosynthesis; NAD(+) from nicotinamide D-ribonucleotide: step 1/1.; PATHWAY: Cofactor biosynthesis; NAD(+) biosynthesis; deamido-NAD(+) from nicotinate D-ribonucleotide: step 1/1.	PF01467;	IPR004821;IPR005248;IPR014729;	'de novo' NAD biosynthetic process from aspartate [GO:0034628]; ATP generation from poly-ADP-D-ribose [GO:1990966]; NAD biosynthetic process [GO:0009435]; NAD metabolic process [GO:0019674]; response to wounding [GO:0009611]	ATP binding [GO:0005524]; nicotinamide-nucleotide adenylyltransferase activity [GO:0000309]; nicotinate-nucleotide adenylyltransferase activity [GO:0004515]	nucleoplasm [GO:0005654]; nucleus [GO:0005634]
Q96T66	NMNA3_HUMAN	Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 3 (NMN/NaMN adenylyltransferase 3) (Nicotinamide-nucleotide adenylyltransferase 3) (NMN adenylyltransferase 3) (Nicotinate-nucleotide adenylyltransferase 3) (NaMN adenylyltransferase 3) (EC 2.7.7.18) (Pyridine nucleotide adenylyltransferase 3) (PNAT-3) (EC 2.7.7.1)	NMNAT3 FKSG76	1NUP;1NUQ;1NUR;1NUS;1NUT;1NUU;				PATHWAY: Cofactor biosynthesis; NAD(+) biosynthesis; NAD(+) from nicotinamide D-ribonucleotide: step 1/1.; PATHWAY: Cofactor biosynthesis; NAD(+) biosynthesis; deamido-NAD(+) from nicotinate D-ribonucleotide: step 1/1.	PF01467;	IPR004821;IPR005248;IPR014729;	'de novo' NAD biosynthetic process from aspartate [GO:0034628]; NAD biosynthetic process [GO:0009435]; NAD metabolic process [GO:0019674]; response to wounding [GO:0009611]	ATP binding [GO:0005524]; nicotinamide-nucleotide adenylyltransferase activity [GO:0000309]; nicotinate-nucleotide adenylyltransferase activity [GO:0004515]	cytosol [GO:0005829]; mitochondrion [GO:0005739]
P40261	NNMT_HUMAN	Nicotinamide N-methyltransferase (EC 2.1.1.1)	NNMT	2IIP;3ROD;	CHEMBL2346486;	P40261;	DB00627;		PF01234;	IPR025820;IPR000940;IPR029063;	animal organ regeneration [GO:0031100]; methylation [GO:0032259]; response to drug [GO:0042493]; response to organonitrogen compound [GO:0010243]	nicotinamide N-methyltransferase activity [GO:0008112]; pyridine N-methyltransferase activity [GO:0030760]	cytosol [GO:0005829]
Q13423	NNTM_HUMAN	NAD(P) transhydrogenase, mitochondrial (EC 1.6.1.2) (Nicotinamide nucleotide transhydrogenase) (Pyridine nucleotide transhydrogenase)	NNT	1DJL;1PT9;1U31;					PF01262;PF05222;PF02233;PF12769;	IPR008143;IPR008142;IPR007886;IPR007698;IPR029035;IPR016040;IPR012136;IPR026255;IPR024605;IPR030168;	cell redox homeostasis [GO:0045454]; NADPH regeneration [GO:0006740]; oxidation-reduction process [GO:0055114]; proton transport [GO:0015992]; reactive oxygen species metabolic process [GO:0072593]; tricarboxylic acid cycle [GO:0006099]	NAD(P)+ transhydrogenase (AB-specific) activity [GO:0008750]; NAD(P)+ transhydrogenase (B-specific) activity [GO:0003957]; NAD(P)+ transhydrogenase activity [GO:0008746]; NAD binding [GO:0051287]; NADP binding [GO:0050661]	integral component of membrane [GO:0016021]; membrane [GO:0016020]; mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain [GO:0005746]; mitochondrion [GO:0005739]
P29475	NOS1_HUMAN	Nitric oxide synthase, brain (EC 1.14.13.39) (Constitutive NOS) (NC-NOS) (NOS type I) (Neuronal NOS) (N-NOS) (nNOS) (Peptidyl-cysteine S-nitrosylase NOS1) (bNOS)	NOS1	4D1N;4UCH;4UH5;4UH6;4V3U;5ADF;5ADG;5ADI;5FVU;5FVV;5FVW;5FVX;	CHEMBL3568;	P29475;	DB00997;DB03147;DB00155;		PF00667;PF00258;PF00175;PF02898;PF00595;	IPR003097;IPR017927;IPR001094;IPR008254;IPR001709;IPR029039;IPR023173;IPR012144;IPR004030;IPR001433;IPR001478;IPR017938;	arginine catabolic process [GO:0006527]; cell redox homeostasis [GO:0045454]; cellular response to growth factor stimulus [GO:0071363]; exogenous drug catabolic process [GO:0042738]; multicellular organismal response to stress [GO:0033555]; myoblast fusion [GO:0007520]; negative regulation of adrenergic receptor signaling pathway involved in heart process [GO:1901205]; negative regulation of blood pressure [GO:0045776]; negative regulation of calcium ion transport [GO:0051926]; negative regulation of calcium ion transport into cytosol [GO:0010523]; negative regulation of hydrolase activity [GO:0051346]; negative regulation of potassium ion transport [GO:0043267]; negative regulation of serotonin uptake [GO:0051612]; neurotransmitter biosynthetic process [GO:0042136]; nitric oxide biosynthetic process [GO:0006809]; nitric oxide mediated signal transduction [GO:0007263]; peptidyl-cysteine S-nitrosylation [GO:0018119]; positive regulation of adrenergic receptor signaling pathway involved in heart process [GO:1901206]; positive regulation of guanylate cyclase activity [GO:0031284]; positive regulation of histone acetylation [GO:0035066]; positive regulation of sodium ion transmembrane transport [GO:1902307]; positive regulation of the force of heart contraction [GO:0098735]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of vasodilation [GO:0045909]; regulation of calcium ion transmembrane transport via high voltage-gated calcium channel [GO:1902514]; regulation of cardiac conduction [GO:1903779]; regulation of cardiac muscle contraction [GO:0055117]; regulation of neurogenesis [GO:0050767]; regulation of ryanodine-sensitive calcium-release channel activity [GO:0060314]; regulation of sodium ion transport [GO:0002028]; response to heat [GO:0009408]; response to hypoxia [GO:0001666]; striated muscle contraction [GO:0006941]	arginine binding [GO:0034618]; cadmium ion binding [GO:0046870]; flavin adenine dinucleotide binding [GO:0050660]; FMN binding [GO:0010181]; heme binding [GO:0020037]; ion channel binding [GO:0044325]; iron ion binding [GO:0005506]; NADP binding [GO:0050661]; nitric-oxide synthase activity [GO:0004517]; scaffold protein binding [GO:0097110]; sodium channel regulator activity [GO:0017080]; tetrahydrobiopterin binding [GO:0034617]	caveola [GO:0005901]; cytoplasm [GO:0005737]; cytoskeleton [GO:0005856]; cytosol [GO:0005829]; dendritic spine [GO:0043197]; membrane raft [GO:0045121]; mitochondrion [GO:0005739]; perinuclear region of cytoplasm [GO:0048471]; photoreceptor inner segment [GO:0001917]; protein complex [GO:0043234]; sarcolemma [GO:0042383]; sarcoplasmic reticulum [GO:0016529]; sarcoplasmic reticulum membrane [GO:0033017]; synapse [GO:0045202]; T-tubule [GO:0030315]; Z disc [GO:0030018]
P35228	NOS2A_HUMAN	Nitric oxide synthase, inducible (EC 1.14.13.39) (Hepatocyte NOS) (HEP-NOS) (Inducible NO synthase) (Inducible NOS) (iNOS) (NOS type II) (Peptidyl-cysteine S-nitrosylase NOS2)	NOS2 NOS2A	1NSI;2LL6;2NSI;3E7G;3EJ8;3HR4;4CX7;4NOS;	CHEMBL4481;	P35228;	DB01234;DB00997;DB00125;DB00155;DB01110;DB08814;		PF00667;PF00258;PF00175;PF02898;	IPR003097;IPR017927;IPR001094;IPR008254;IPR001709;IPR029039;IPR023173;IPR004030;IPR001433;IPR017938;	arginine catabolic process [GO:0006527]; cell redox homeostasis [GO:0045454]; cellular response to drug [GO:0035690]; cellular response to interferon-gamma [GO:0071346]; cellular response to lipopolysaccharide [GO:0071222]; circadian rhythm [GO:0007623]; defense response to bacterium [GO:0042742]; defense response to Gram-negative bacterium [GO:0050829]; innate immune response in mucosa [GO:0002227]; interleukin-6 secretion [GO:0072604]; interleukin-8 secretion [GO:0072606]; negative regulation of blood pressure [GO:0045776]; negative regulation of gene expression [GO:0010629]; negative regulation of protein catabolic process [GO:0042177]; nitric oxide biosynthetic process [GO:0006809]; nitric oxide mediated signal transduction [GO:0007263]; peptidyl-cysteine S-nitrosylation [GO:0018119]; positive regulation of guanylate cyclase activity [GO:0031284]; positive regulation of killing of cells of other organism [GO:0051712]; positive regulation of leukocyte mediated cytotoxicity [GO:0001912]; positive regulation of vasodilation [GO:0045909]; prostaglandin secretion [GO:0032310]; regulation of cell proliferation [GO:0042127]; regulation of cellular respiration [GO:0043457]; regulation of cytokine production involved in inflammatory response [GO:1900015]; regulation of insulin secretion [GO:0050796]; response to bacterium [GO:0009617]; response to hypoxia [GO:0001666]; superoxide metabolic process [GO:0006801]	arginine binding [GO:0034618]; flavin adenine dinucleotide binding [GO:0050660]; FMN binding [GO:0010181]; heme binding [GO:0020037]; metal ion binding [GO:0046872]; NADP binding [GO:0050661]; nitric-oxide synthase activity [GO:0004517]; protein homodimerization activity [GO:0042803]; receptor binding [GO:0005102]; tetrahydrobiopterin binding [GO:0034617]	cortical cytoskeleton [GO:0030863]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; intracellular [GO:0005622]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; peroxisome [GO:0005777]
P81272	NOS2B_HUMAN	Deleted.
Q14961	NOS2C_HUMAN	Deleted.
P29474	NOS3_HUMAN	Nitric oxide synthase, endothelial (EC 1.14.13.39) (Constitutive NOS) (cNOS) (EC-NOS) (Endothelial NOS) (eNOS) (NOS type III) (NOSIII)	NOS3	1M9J;1M9K;1M9M;1M9Q;1M9R;1NIW;2LL7;2MG5;3EAH;3NOS;4D1O;4D1P;	CHEMBL4803;	P29474;	DB05676;DB00997;DB00125;DB00155;DB01110;DB00360;		PF00667;PF00258;PF00175;PF02898;	IPR003097;IPR017927;IPR001094;IPR008254;IPR001709;IPR029039;IPR023173;IPR012144;IPR004030;IPR001433;IPR017938;	angiogenesis [GO:0001525]; arginine catabolic process [GO:0006527]; blood vessel remodeling [GO:0001974]; cell redox homeostasis [GO:0045454]; endothelial cell migration [GO:0043542]; in utero embryonic development [GO:0001701]; lipopolysaccharide-mediated signaling pathway [GO:0031663]; lung development [GO:0030324]; mitochondrion organization [GO:0007005]; negative regulation of blood pressure [GO:0045776]; negative regulation of calcium ion transport [GO:0051926]; negative regulation of cell proliferation [GO:0008285]; negative regulation of extrinsic apoptotic signaling pathway via death domain receptors [GO:1902042]; negative regulation of hydrolase activity [GO:0051346]; negative regulation of muscle hyperplasia [GO:0014740]; negative regulation of platelet activation [GO:0010544]; negative regulation of potassium ion transport [GO:0043267]; nitric oxide biosynthetic process [GO:0006809]; nitric oxide mediated signal transduction [GO:0007263]; ovulation from ovarian follicle [GO:0001542]; positive regulation of angiogenesis [GO:0045766]; positive regulation of guanylate cyclase activity [GO:0031284]; positive regulation of vasodilation [GO:0045909]; regulation of blood pressure [GO:0008217]; regulation of blood vessel size [GO:0050880]; regulation of nitric-oxide synthase activity [GO:0050999]; regulation of sodium ion transport [GO:0002028]; regulation of systemic arterial blood pressure by endothelin [GO:0003100]; regulation of the force of heart contraction by chemical signal [GO:0003057]; removal of superoxide radicals [GO:0019430]; response to fluid shear stress [GO:0034405]; response to heat [GO:0009408]; smooth muscle hyperplasia [GO:0014806]	actin monomer binding [GO:0003785]; arginine binding [GO:0034618]; cadmium ion binding [GO:0046870]; flavin adenine dinucleotide binding [GO:0050660]; FMN binding [GO:0010181]; heme binding [GO:0020037]; iron ion binding [GO:0005506]; NADP binding [GO:0050661]; nitric-oxide synthase activity [GO:0004517]; tetrahydrobiopterin binding [GO:0034617]	caveola [GO:0005901]; cytoplasm [GO:0005737]; cytoskeleton [GO:0005856]; cytosol [GO:0005829]; endocytic vesicle membrane [GO:0030666]; Golgi membrane [GO:0000139]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
Q9UHC9	NPCL1_HUMAN	Niemann-Pick C1-like protein 1	NPC1L1	3QNT;	CHEMBL2027;	Q9UHC9;	DB00973;		PF16414;PF02460;PF12349;	IPR032190;IPR003392;IPR000731;	cholesterol biosynthetic process [GO:0006695]; cholesterol transport [GO:0030301]; intestinal cholesterol absorption [GO:0030299]; lipoprotein metabolic process [GO:0042157]; response to drug [GO:0042493]; sterol transport [GO:0015918]	drug binding [GO:0008144]; myosin V binding [GO:0031489]; Rab GTPase binding [GO:0017137]	apical plasma membrane [GO:0016324]; brush border membrane [GO:0031526]; cytoplasmic vesicle membrane [GO:0030659]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]
Q6W5P4	NPSR1_HUMAN	Neuropeptide S receptor (G-protein coupled receptor 154) (G-protein coupled receptor PGR14) (G-protein coupled receptor for asthma susceptibility)	NPSR1 GPR154 GPRA PGR14		CHEMBL5162;	Q6W5P4;	DB01159;		PF00001;	IPR000276;IPR017452;IPR027294;IPR001817;	neuropeptide signaling pathway [GO:0007218]; positive regulation of release of sequestered calcium ion into cytosol [GO:0051281]	neuropeptide receptor activity [GO:0008188]; vasopressin receptor activity [GO:0005000]	cytoplasm [GO:0005737]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P15559	NQO1_HUMAN	NAD(P)H dehydrogenase [quinone] 1 (EC 1.6.5.2) (Azoreductase) (DT-diaphorase) (DTD) (Menadione reductase) (NAD(P)H:quinone oxidoreductase 1) (Phylloquinone reductase) (Quinone reductase 1) (QR1)	NQO1 DIA4 NMOR1	1D4A;1DXO;1GG5;1H66;1H69;1KBO;1KBQ;1QBG;2F1O;3JSX;4CET;4CF6;5A4K;5EA2;5EAI;	CHEMBL3623;	P15559;	DB00958;DB00515;DB00266;DB00997;DB03147;DB00170;DB00526;DB00163;		PF02525;	IPR003680;IPR029039;	aging [GO:0007568]; negative regulation of apoptotic process [GO:0043066]; negative regulation of catalytic activity [GO:0043086]; nitric oxide biosynthetic process [GO:0006809]; positive regulation of neuron apoptotic process [GO:0043525]; regulation of cellular amino acid metabolic process [GO:0006521]; response to estradiol [GO:0032355]; response to ethanol [GO:0045471]; response to nutrient [GO:0007584]; response to toxic substance [GO:0009636]; synaptic transmission, cholinergic [GO:0007271]; xenobiotic metabolic process [GO:0006805]	cytochrome-b5 reductase activity, acting on NAD(P)H [GO:0004128]; identical protein binding [GO:0042802]; NAD(P)H dehydrogenase (quinone) activity [GO:0003955]; poly(A) RNA binding [GO:0044822]; superoxide dismutase activity [GO:0004784]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; neuronal cell body [GO:0043025]
P16083	NQO2_HUMAN	Ribosyldihydronicotinamide dehydrogenase [quinone] (EC 1.10.5.1) (NRH dehydrogenase [quinone] 2) (NRH:quinone oxidoreductase 2) (Quinone reductase 2) (QR2)	NQO2 NMOR2	1QR2;1SG0;1XI2;1ZX1;2BZS;2QMY;2QMZ;2QR2;2QWX;2QX4;2QX6;2QX8;2QX9;3FW1;3G5M;3GAM;3NFR;3NHF;3NHJ;3NHK;3NHL;3NHP;3NHR;3NHS;3NHU;3NHW;3NHY;3O2N;3O73;3OVM;3OWH;3OWX;3OX1;3OX2;3OX3;3TE7;3TEM;3TZB;3UXE;3UXH;4FGJ;4FGK;4FGL;4GQI;4GR9;4QOD;4QOE;4QOF;4QOG;4QOH;4QOI;4QOJ;4U7F;4U7G;4U7H;4XDG;4XDH;4ZVK;4ZVL;4ZVM;4ZVN;5BUC;5LBT;5LBU;	CHEMBL3959;	P16083;	DB06695;DB03147;DB01065;DB00170;DB01087;		PF02525;	IPR003680;IPR029039;	memory [GO:0007613]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of neuron apoptotic process [GO:0043525]; positive regulation of reactive oxygen species metabolic process [GO:2000379]; positive regulation of vascular smooth muscle cell proliferation [GO:1904707]	electron carrier activity [GO:0009055]; metal ion binding [GO:0046872]; NADPH dehydrogenase (quinone) activity [GO:0008753]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; nucleoplasm [GO:0005654]
P55055	NR1H2_HUMAN	Oxysterols receptor LXR-beta (Liver X receptor beta) (Nuclear receptor NER) (Nuclear receptor subfamily 1 group H member 2) (Ubiquitously-expressed nuclear receptor)	NR1H2 LXRB NER UNR	1P8D;1PQ6;1PQ9;1PQC;1UPV;1UPW;3KFC;3L0E;4DK7;4DK8;4NQA;4RAK;5HJP;5I4V;5KYA;5KYJ;	CHEMBL4093;	P55055;			PF00104;PF00105;	IPR023257;IPR000536;IPR001723;IPR001628;IPR013088;	cellular lipid metabolic process [GO:0044255]; cholesterol homeostasis [GO:0042632]; negative regulation of cholesterol storage [GO:0010887]; negative regulation of interferon-gamma-mediated signaling pathway [GO:0060336]; negative regulation of lipid transport [GO:0032369]; negative regulation of macrophage derived foam cell differentiation [GO:0010745]; negative regulation of pinocytosis [GO:0048550]; negative regulation of proteolysis [GO:0045861]; negative regulation of transcription, DNA-templated [GO:0045892]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; positive regulation of cellular protein metabolic process [GO:0032270]; positive regulation of cholesterol efflux [GO:0010875]; positive regulation of cholesterol transport [GO:0032376]; positive regulation of fatty acid biosynthetic process [GO:0045723]; positive regulation of high-density lipoprotein particle assembly [GO:0090108]; positive regulation of lipid storage [GO:0010884]; positive regulation of lipoprotein lipase activity [GO:0051006]; positive regulation of pancreatic juice secretion [GO:0090187]; positive regulation of secretion of lysosomal enzymes [GO:0090340]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of triglyceride biosynthetic process [GO:0010867]; regulation of cholesterol homeostasis [GO:2000188]; retinoic acid receptor signaling pathway [GO:0048384]; transcription initiation from RNA polymerase II promoter [GO:0006367]	apolipoprotein A-I receptor binding [GO:0034191]; ATPase binding [GO:0051117]; DNA binding [GO:0003677]; RNA polymerase II core promoter proximal region sequence-specific DNA binding [GO:0000978]; RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding [GO:0004879]; RNA polymerase II transcription factor activity, sequence-specific transcription regulatory region DNA binding [GO:0001133]; steroid hormone receptor activity [GO:0003707]; transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding [GO:0001077]; zinc ion binding [GO:0008270]	cytoplasm [GO:0005737]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
Q96RI1	NR1H4_HUMAN	Bile acid receptor (Farnesoid X-activated receptor) (Farnesol receptor HRR-1) (Nuclear receptor subfamily 1 group H member 4) (Retinoid X receptor-interacting protein 14) (RXR-interacting protein 14)	NR1H4 BAR FXR HRR1 RIP14	1OSH;1OSK;3BEJ;3DCT;3DCU;3FLI;3FXV;3GD2;3HC5;3HC6;3L1B;3OKH;3OKI;3OLF;3OMK;3OMM;3OOF;3OOK;3P88;3P89;3RUT;3RUU;3RVF;4OIV;4QE6;4QE8;4WVD;	CHEMBL2047;	Q96RI1;	DB06777;		PF00104;PF00105;	IPR000536;IPR001723;IPR001728;IPR001628;IPR013088;	bile acid and bile salt transport [GO:0015721]; bile acid metabolic process [GO:0008206]; bile acid signaling pathway [GO:0038183]; cell-cell junction assembly [GO:0007043]; cellular response to fatty acid [GO:0071398]; cellular response to lipopolysaccharide [GO:0071222]; cellular response to organonitrogen compound [GO:0071417]; cellular triglyceride homeostasis [GO:0035356]; defense response to bacterium [GO:0042742]; fatty acid homeostasis [GO:0055089]; glucose homeostasis [GO:0042593]; histone H3-R17 methylation [GO:0034971]; inflammatory response [GO:0006954]; innate immune response [GO:0045087]; interleukin-17 secretion [GO:0072615]; intracellular bile acid receptor signaling pathway [GO:0038185]; intracellular receptor signaling pathway [GO:0030522]; negative regulation of apoptotic process [GO:0043066]; negative regulation of bile acid biosynthetic process [GO:0070858]; negative regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043124]; negative regulation of inflammatory response [GO:0050728]; negative regulation of interferon-gamma secretion [GO:1902714]; negative regulation of interleukin-1 production [GO:0032692]; negative regulation of interleukin-2 production [GO:0032703]; negative regulation of interleukin-6 production [GO:0032715]; negative regulation of monocyte chemotactic protein-1 production [GO:0071638]; negative regulation of NF-kappaB transcription factor activity [GO:0032088]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; negative regulation of tumor necrosis factor-mediated signaling pathway [GO:0010804]; negative regulation of tumor necrosis factor secretion [GO:1904468]; nitrogen catabolite activation of transcription from RNA polymerase II promoter [GO:0001080]; Notch signaling pathway [GO:0007219]; positive regulation of adipose tissue development [GO:1904179]; positive regulation of ammonia assimilation cycle [GO:2001250]; positive regulation of glucose import in response to insulin stimulus [GO:2001275]; positive regulation of glutamate metabolic process [GO:2000213]; positive regulation of insulin receptor signaling pathway [GO:0046628]; positive regulation of insulin secretion involved in cellular response to glucose stimulus [GO:0035774]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; regulation of bile acid biosynthetic process [GO:0070857]; regulation of cholesterol homeostasis [GO:2000188]; regulation of cholesterol metabolic process [GO:0090181]; regulation of insulin secretion involved in cellular response to glucose stimulus [GO:0061178]; regulation of low-density lipoprotein particle clearance [GO:0010988]; regulation of urea metabolic process [GO:0034255]; signal transduction [GO:0007165]; toll-like receptor 4 signaling pathway [GO:0034142]; toll-like receptor 9 signaling pathway [GO:0034162]; transcription initiation from RNA polymerase II promoter [GO:0006367]	bile acid binding [GO:0032052]; bile acid receptor activity [GO:0038181]; chenodeoxycholic acid binding [GO:1902122]; ligand-dependent nuclear receptor binding [GO:0016922]; RNA polymerase II distal enhancer sequence-specific DNA binding [GO:0000980]; RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding [GO:0004879]; sequence-specific DNA binding [GO:0043565]; steroid hormone receptor activity [GO:0003707]; thyroid hormone receptor activity [GO:0004887]; transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding [GO:0001077]; transcriptional activator activity, RNA polymerase II transcription factor binding [GO:0001190]; transcription coactivator activity [GO:0003713]; transcription corepressor activity [GO:0003714]; transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding [GO:0003705]; transcription factor activity, sequence-specific DNA binding [GO:0003700]; zinc ion binding [GO:0008270]	nuclear euchromatin [GO:0005719]; nucleoplasm [GO:0005654]
Q15738	NSDHL_HUMAN	Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating (EC 1.1.1.170) (Protein H105e3)	NSDHL H105E3					PATHWAY: Steroid biosynthesis; zymosterol biosynthesis; zymosterol from lanosterol: step 4/6.	PF01073;	IPR002225;IPR016040;	cholesterol biosynthetic process [GO:0006695]; hair follicle development [GO:0001942]; labyrinthine layer blood vessel development [GO:0060716]; smoothened signaling pathway [GO:0007224]	3-beta-hydroxy-delta5-steroid dehydrogenase activity [GO:0003854]; C-3 sterol dehydrogenase (C-4 sterol decarboxylase) activity [GO:0000252]; sterol-4-alpha-carboxylate 3-dehydrogenase (decarboxylating) activity [GO:0047012]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; intracellular membrane-bounded organelle [GO:0043231]; lipid particle [GO:0005811]
Q9NY59	NSMA2_HUMAN	Sphingomyelin phosphodiesterase 3 (EC 3.1.4.12) (Neutral sphingomyelinase 2) (nSMase-2) (nSMase2) (Neutral sphingomyelinase II)	SMPD3				DB00144;	PATHWAY: Lipid metabolism; sphingolipid metabolism.	PF03372;	IPR005135;	cell cycle [GO:0007049]; glycosphingolipid metabolic process [GO:0006687]; hematopoietic progenitor cell differentiation [GO:0002244]; peptide hormone secretion [GO:0030072]; positive regulation of ceramide biosynthetic process [GO:2000304]; positive regulation of exosomal secretion [GO:1903543]; sphingomyelin catabolic process [GO:0006685]	metal ion binding [GO:0046872]; sphingomyelin phosphodiesterase activity [GO:0004767]	Golgi cis cisterna [GO:0000137]; Golgi membrane [GO:0000139]; plasma membrane [GO:0005886]
Q9NXE4	NSMA3_HUMAN	Sphingomyelin phosphodiesterase 4 (EC 3.1.4.12) (Neutral sphingomyelinase 3) (nSMase-3) (nSMase3) (Neutral sphingomyelinase III)	SMPD4 KIAA1418				DB00144;		PF14724;	IPR024129;	cellular response to tumor necrosis factor [GO:0071356]; ceramide biosynthetic process [GO:0046513]; glycerophospholipid catabolic process [GO:0046475]; glycosphingolipid metabolic process [GO:0006687]; sphingomyelin catabolic process [GO:0006685]	metal ion binding [GO:0046872]; sphingomyelin phosphodiesterase activity [GO:0004767]; sphingomyelin phosphodiesterase D activity [GO:0050290]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; Golgi apparatus [GO:0005794]; Golgi membrane [GO:0000139]; integral component of membrane [GO:0016021]; trans-Golgi network [GO:0005802]
Q9NPB1	NT5M_HUMAN	5'(3')-deoxyribonucleotidase, mitochondrial (5',3'-nucleotidase, mitochondrial) (EC 3.1.3.-) (Deoxy-5'-nucleotidase 2) (dNT-2)	NT5M DNT2	1MH9;1Q91;1Q92;1Z4I;1Z4J;1Z4K;1Z4L;1Z4M;1Z4P;1Z4Q;2JAU;2JAW;4L6A;4L6C;4MUM;4MWO;4NFL;4YIK;					PF06941;	IPR010708;IPR023214;	DNA replication [GO:0006260]; dUMP catabolic process [GO:0046079]; pyrimidine deoxyribonucleotide catabolic process [GO:0009223]; pyrimidine nucleoside catabolic process [GO:0046135]	5'-nucleotidase activity [GO:0008253]; metal ion binding [GO:0046872]; nucleotidase activity [GO:0008252]; nucleotide binding [GO:0000166]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
O95665	NTR2_HUMAN	Neurotensin receptor type 2 (NT-R-2) (NTR2) (Levocabastine-sensitive neurotensin receptor)	NTSR2		CHEMBL2514;	O95665;	DB01106;		PF00001;	IPR000276;IPR017452;IPR003986;IPR003984;	cell surface receptor signaling pathway [GO:0007166]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; regulation of membrane potential [GO:0042391]; sensory perception [GO:0007600]	G-protein coupled neurotensin receptor activity [GO:0016492]; G-protein coupled receptor activity [GO:0004930]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P04629	NTRK1_HUMAN	High affinity nerve growth factor receptor (EC 2.7.10.1) (Neurotrophic tyrosine kinase receptor type 1) (TRK1-transforming tyrosine kinase protein) (Tropomyosin-related kinase A) (Tyrosine kinase receptor) (Tyrosine kinase receptor A) (Trk-A) (gp140trk) (p140-TrkA)	NTRK1 MTC TRK TRKA	1HE7;1SHC;1WWA;1WWW;2IFG;4AOJ;4CRP;4F0I;4GT5;4PMM;4PMP;4PMS;4PMT;4YNE;4YPS;	CHEMBL2815;	P04629;	DB00321;DB00619;DB08896;		PF13855;PF07714;PF16920;	IPR000483;IPR007110;IPR013783;IPR011009;IPR032675;IPR001611;IPR031635;IPR000719;IPR017441;IPR001245;IPR008266;IPR020635;IPR020461;IPR020777;IPR002011;	activation of MAPKK activity [GO:0000186]; aging [GO:0007568]; axon guidance [GO:0007411]; axonogenesis involved in innervation [GO:0060385]; B cell differentiation [GO:0030183]; behavioral response to formalin induced pain [GO:0061368]; cellular response to nerve growth factor stimulus [GO:1990090]; cellular response to nicotine [GO:0071316]; circadian rhythm [GO:0007623]; detection of mechanical stimulus involved in sensory perception of pain [GO:0050966]; detection of temperature stimulus involved in sensory perception of pain [GO:0050965]; learning or memory [GO:0007611]; mechanoreceptor differentiation [GO:0042490]; microtubule-based movement [GO:0007018]; negative regulation of cell proliferation [GO:0008285]; negative regulation of neuron apoptotic process [GO:0043524]; neurotrophin TRK receptor signaling pathway [GO:0048011]; olfactory nerve development [GO:0021553]; phosphatidylinositol-mediated signaling [GO:0048015]; positive regulation of angiogenesis [GO:0045766]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of GTPase activity [GO:0043547]; positive regulation of neuron projection development [GO:0010976]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of programmed cell death [GO:0043068]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of Ras protein signal transduction [GO:0046579]; positive regulation of synapse assembly [GO:0051965]; positive regulation of synaptic transmission, glutamatergic [GO:0051968]; programmed cell death involved in cell development [GO:0010623]; protein autophosphorylation [GO:0046777]; protein phosphorylation [GO:0006468]; response to activity [GO:0014823]; response to axon injury [GO:0048678]; response to drug [GO:0042493]; response to electrical stimulus [GO:0051602]; response to ethanol [GO:0045471]; response to hydrostatic pressure [GO:0051599]; response to nutrient levels [GO:0031667]; response to radiation [GO:0009314]; Sertoli cell development [GO:0060009]; sympathetic nervous system development [GO:0048485]	ATP binding [GO:0005524]; GPI-linked ephrin receptor activity [GO:0005004]; nerve growth factor binding [GO:0048406]; nerve growth factor receptor activity [GO:0010465]; neurotrophin binding [GO:0043121]; protein homodimerization activity [GO:0042803]; transmembrane receptor protein tyrosine kinase activity [GO:0004714]	axon [GO:0030424]; cell surface [GO:0009986]; cytoplasmic vesicle [GO:0031410]; dendrite [GO:0030425]; early endosome [GO:0005769]; early endosome membrane [GO:0031901]; endosome [GO:0005768]; integral component of plasma membrane [GO:0005887]; late endosome [GO:0005770]; late endosome membrane [GO:0031902]; neuronal cell body [GO:0043025]; plasma membrane [GO:0005886]; protein complex [GO:0043234]; receptor complex [GO:0043235]
P03886	NU1M_HUMAN	NADH-ubiquinone oxidoreductase chain 1 (EC 1.6.5.3) (NADH dehydrogenase subunit 1)	MT-ND1 MTND1 NADH1 ND1		CHEMBL2363065;		DB01189;DB01159;DB00753;DB01028;DB01236;		PF00146;	IPR001694;IPR018086;	cellular respiration [GO:0045333]; mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]; response to drug [GO:0042493]; response to hydroperoxide [GO:0033194]; response to organic cyclic compound [GO:0014070]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	dendrite [GO:0030425]; integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrial membrane [GO:0031966]; mitochondrial respiratory chain complex I [GO:0005747]; neuronal cell body [GO:0043025]
P03891	NU2M_HUMAN	NADH-ubiquinone oxidoreductase chain 2 (EC 1.6.5.3) (NADH dehydrogenase subunit 2)	MT-ND2 MTND2 NADH2 ND2		CHEMBL2363065;				PF06444;PF00361;	IPR010933;IPR003917;IPR001750;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]; reactive oxygen species metabolic process [GO:0072593]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]; postsynaptic density [GO:0014069]
P03897	NU3M_HUMAN	NADH-ubiquinone oxidoreductase chain 3 (EC 1.6.5.3) (NADH dehydrogenase subunit 3)	MT-ND3 MTND3 NADH3 ND3		CHEMBL2363065;				PF00507;	IPR000440;	cellular response to glucocorticoid stimulus [GO:0071385]; mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]; response to light intensity [GO:0009642]; response to oxidative stress [GO:0006979]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]
P03901	NU4LM_HUMAN	NADH-ubiquinone oxidoreductase chain 4L (EC 1.6.5.3) (NADH dehydrogenase subunit 4L)	MT-ND4L MTND4L NADH4L ND4L		CHEMBL2363065;				PF00420;	IPR001133;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	integral component of membrane [GO:0016021]; mitochondrial respiratory chain complex I [GO:0005747]
P03905	NU4M_HUMAN	NADH-ubiquinone oxidoreductase chain 4 (EC 1.6.5.3) (NADH dehydrogenase subunit 4)	MT-ND4 MTND4 NADH4 ND4		CHEMBL4499;	P03905;			PF01059;PF00361;	IPR000260;IPR010227;IPR003918;IPR001750;	aging [GO:0007568]; cerebellum development [GO:0021549]; in utero embryonic development [GO:0001701]; mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]; response to ethanol [GO:0045471]; response to hypoxia [GO:0001666]; response to nicotine [GO:0035094]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]
P03915	NU5M_HUMAN	NADH-ubiquinone oxidoreductase chain 5 (EC 1.6.5.3) (NADH dehydrogenase subunit 5)	MT-ND5 MTND5 NADH5 ND5		CHEMBL2363065;				PF06455;PF00361;PF00662;	IPR010934;IPR003945;IPR001750;IPR001516;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]; response to hydrogen peroxide [GO:0042542]; response to hypoxia [GO:0001666]; response to organonitrogen compound [GO:0010243]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain complex I [GO:0005747]; neuron projection [GO:0043005]
P03923	NU6M_HUMAN	NADH-ubiquinone oxidoreductase chain 6 (EC 1.6.5.3) (NADH dehydrogenase subunit 6)	MT-ND6 MTND6 NADH6 ND6		CHEMBL2363065;				PF00499;	IPR001457;	mitochondrial electron transport, NADH to ubiquinone [GO:0006120]; mitochondrial respiratory chain complex I assembly [GO:0032981]; response to cocaine [GO:0042220]; response to hydrogen peroxide [GO:0042542]; response to nicotine [GO:0035094]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrion [GO:0005739]; respiratory chain [GO:0070469]
Q9NRX3	NUA4L_HUMAN	NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4-like 2 (NADH-ubiquinone oxidoreductase MLRQ subunit homolog) (NUOMS)	NDUFA4L2		CHEMBL2363065;				PF06522;	IPR010530;	hydrogen ion transmembrane transport [GO:1902600]	NADH dehydrogenase (ubiquinone) activity [GO:0008137]	mitochondrial respiratory chain complex IV [GO:0005751]
Q9BW91	NUDT9_HUMAN	ADP-ribose pyrophosphatase, mitochondrial (EC 3.6.1.13) (ADP-ribose diphosphatase) (ADP-ribose phosphohydrolase) (Adenosine diphosphoribose pyrophosphatase) (ADPR-PPase) (Nucleoside diphosphate-linked moiety X motif 9) (Nudix motif 9)	NUDT9 NUDT10 PSEC0099 UNQ3012/PRO9771	1Q33;1QVJ;					PF00293;	IPR000086;IPR015797;	ADP catabolic process [GO:0046032]; IDP catabolic process [GO:0046709]; nucleobase-containing small molecule catabolic process [GO:0034656]	adenosine-diphosphatase activity [GO:0043262]; ADP-ribose diphosphatase activity [GO:0047631]; ADP-sugar diphosphatase activity [GO:0019144]	extracellular exosome [GO:0070062]; intracellular [GO:0005622]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
Q30154	O00157_HUMAN	HLA class II histocompatibility antigen, DR beta 5 chain (DR beta-5) (DR2-beta-2) (Dw2) (MHC class II antigen DRB5)	HLA-DRB5	1FV1;1H15;1HQR;1ZGL;					PF07654;PF00969;	IPR007110;IPR013783;IPR003006;IPR003597;IPR011162;IPR014745;IPR000353;	antigen processing and presentation of exogenous peptide antigen via MHC class II [GO:0019886]; interferon-gamma-mediated signaling pathway [GO:0060333]; T cell costimulation [GO:0031295]; T cell receptor signaling pathway [GO:0050852]	peptide antigen binding [GO:0042605]	clathrin-coated endocytic vesicle membrane [GO:0030669]; endocytic vesicle membrane [GO:0030666]; ER to Golgi transport vesicle membrane [GO:0012507]; extracellular exosome [GO:0070062]; Golgi membrane [GO:0000139]; integral component of lumenal side of endoplasmic reticulum membrane [GO:0071556]; late endosome membrane [GO:0031902]; lysosomal membrane [GO:0005765]; MHC class II protein complex [GO:0042613]; plasma membrane [GO:0005886]; trans-Golgi network membrane [GO:0032588]; transport vesicle membrane [GO:0030658]
O14756	O14756_HUMAN	17-beta-hydroxysteroid dehydrogenase type 6 (17-beta-HSD 6) (17-beta-HSD6) (EC 1.1.1.105) (EC 1.1.1.239) (EC 1.1.1.62) (3-alpha->beta-hydroxysteroid epimerase) (3-alpha->beta-HSE) (Oxidative 3-alpha hydroxysteroid dehydrogenase) (Short chain dehydrogenase/reductase family 9C member 6)	HSD17B6 RODH SDR9C6				DB00139;		PF00106;	IPR016040;IPR020904;IPR002347;	androgen biosynthetic process [GO:0006702]; androgen catabolic process [GO:0006710]; steroid metabolic process [GO:0008202]	catalytic activity [GO:0003824]; electron carrier activity [GO:0009055]; estradiol 17-beta-dehydrogenase activity [GO:0004303]; oxidoreductase activity [GO:0016491]; retinol dehydrogenase activity [GO:0004745]; testosterone dehydrogenase (NAD+) activity [GO:0047035]	early endosome membrane [GO:0031901]; endoplasmic reticulum [GO:0005783]; intracellular [GO:0005622]
O43519	O43519_HUMAN	RET proto-oncogene (Fragment)	RET				DB00619;
O43923	O43923_HUMAN	Matrix metalloproteinase-25 (Metalloproteinase)	mmp20 MMP20 MMP25				DB01039;		PF00413;	IPR024079;IPR028733;IPR001818;IPR021190;IPR006026;	inflammatory response [GO:0006954]	metalloendopeptidase activity [GO:0004222]; zinc ion binding [GO:0008270]	extracellular matrix [GO:0031012]; integral component of membrane [GO:0016021]
O60427	O60427_HUMAN	Fatty acid desaturase 1 (EC 1.14.19.-) (Delta(5) fatty acid desaturase) (D5D) (Delta(5) desaturase) (Delta-5 desaturase)	FADS1 FADSD5		CHEMBL5840;	O60427;	DB00132;DB00159;	PATHWAY: Lipid metabolism; polyunsaturated fatty acid biosynthesis.	PF00173;PF00487;	IPR001199;IPR012171;IPR005804;	alpha-linolenic acid metabolic process [GO:0036109]; cell-cell signaling [GO:0007267]; cellular response to starvation [GO:0009267]; icosanoid biosynthetic process [GO:0046456]; linoleic acid metabolic process [GO:0043651]; phospholipid biosynthetic process [GO:0008654]; regulation of cell differentiation [GO:0045595]; regulation of transcription, DNA-templated [GO:0006355]; unsaturated fatty acid biosynthetic process [GO:0006636]	C-5 sterol desaturase activity [GO:0000248]; omega-6 fatty acid desaturase activity [GO:0045485]; oxidoreductase activity [GO:0016491]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; intracellular membrane-bounded organelle [GO:0043231]; membrane [GO:0016020]; mitochondrion [GO:0005739]
P24941	CDK2_HUMAN,O75100_HUMAN	Cyclin-dependent kinase 2 (EC 2.7.11.22) (Cell division protein kinase 2) (p33 protein kinase)	CDK2 CDKN2	1AQ1;1B38;1B39;1BUH;1CKP;1DI8;1DM2;1E1V;1E1X;1E9H;1F5Q;1FIN;1FQ1;1FVT;1FVV;1G5S;1GIH;1GII;1GIJ;1GY3;1GZ8;1H00;1H01;1H07;1H08;1H0V;1H0W;1H1P;1H1Q;1H1R;1H1S;1H24;1H25;1H26;1H27;1H28;1HCK;1HCL;1JST;1JSU;1JSV;1JVP;1KE5;1KE6;1KE7;1KE8;1KE9;1OGU;1OI9;1OIQ;1OIR;1OIT;1OIU;1OIY;1OKV;1OKW;1OL1;1OL2;1P2A;1P5E;1PF8;1PKD;1PW2;1PXI;1PXJ;1PXK;1PXL;1PXM;1PXN;1PXO;1PXP;1PYE;1QMZ;1R78;1URC;1URW;1V1K;1VYW;1VYZ;1W0X;1W8C;1W98;1WCC;1Y8Y;1Y91;1YKR;2A0C;2A4L;2B52;2B53;2B54;2B55;2BHE;2BHH;2BKZ;2BPM;2BTR;2BTS;2C4G;2C5N;2C5O;2C5V;2C5X;2C5Y;2C68;2C69;2C6I;2C6K;2C6L;2C6M;2C6O;2C6T;2CCH;2CCI;2CJM;2CLX;2DS1;2DUV;2EXM;2FVD;2G9X;2HIC;2I40;2IW6;2IW8;2IW9;2J9M;2JGZ;2R3F;2R3G;2R3H;2R3I;2R3J;2R3K;2R3L;2R3M;2R3N;2R3O;2R3P;2R3Q;2R3R;2R64;2UUE;2UZB;2UZD;2UZE;2UZL;2UZN;2UZO;2V0D;2V22;2VTA;2VTH;2VTI;2VTJ;2VTL;2VTM;2VTN;2VTO;2VTP;2VTQ;2VTR;2VTS;2VTT;2VU3;2VV9;2W05;2W06;2W17;2W1H;2WEV;2WFY;2WHB;2WIH;2WIP;2WMA;2WMB;2WPA;2WXV;2X1N;2XMY;2XNB;3BHT;3BHU;3BHV;3DDP;3DDQ;3DOG;3EID;3EJ1;3EOC;3EZR;3EZV;3F5X;3FZ1;3IG7;3IGG;3LE6;3LFN;3LFQ;3LFS;3MY5;3NS9;3PJ8;3PXF;3PXQ;3PXR;3PXY;3PXZ;3PY0;3PY1;3QHR;3QHW;3QL8;3QQF;3QQG;3QQH;3QQJ;3QQK;3QQL;3QRT;3QRU;3QTQ;3QTR;3QTS;3QTU;3QTW;3QTX;3QTZ;3QU0;3QWJ;3QWK;3QX2;3QX4;3QXO;3QXP;3QZF;3QZG;3QZH;3QZI;3R1Q;3R1S;3R1Y;3R28;3R6X;3R71;3R73;3R7E;3R7I;3R7U;3R7V;3R7Y;3R83;3R8L;3R8M;3R8P;3R8U;3R8V;3R8Z;3R9D;3R9H;3R9N;3R9O;3RAH;3RAI;3RAK;3RAL;3RJC;3RK5;3RK7;3RK9;3RKB;3RM6;3RM7;3RMF;3RNI;3ROY;3RPO;3RPR;3RPV;3RPY;3RZB;3S00;3S0O;3S1H;3S2P;3SQQ;3SW4;3SW7;3TI1;3TIY;3TIZ;3TNW;3ULI;3UNJ;3UNK;3WBL;4ACM;4BCK;4BCM;4BCN;4BCO;4BCP;4BCQ;4BGH;4BZD;4CFM;4CFN;4CFU;4CFV;4CFW;4CFX;4D1X;4D1Z;4EK3;4EK4;4EK5;4EK6;4EK8;4EOI;4EOJ;4EOK;4EOL;4EOM;4EON;4EOO;4EOP;4EOQ;4EOR;4EOS;4ERW;4EZ3;4EZ7;4FKG;4FKI;4FKJ;4FKL;4FKO;4FKP;4FKQ;4FKR;4FKS;4FKT;4FKU;4FKV;4FKW;4FX3;4GCJ;4I3Z;4II5;4KD1;4LYN;4NJ3;4RJ3;5A14;5AND;5ANE;5ANG;5ANI;5ANJ;5ANK;5ANO;5CYI;5D1J;5FP5;5FP6;5IEV;5IEX;5IEY;5IF1;5K4J;5L2W;	CHEMBL301;	P24941;	DB06616;		PF00069;	IPR011009;IPR000719;IPR017441;IPR008271;	cell division [GO:0051301]; cellular response to nitric oxide [GO:0071732]; centriole replication [GO:0007099]; centrosome duplication [GO:0051298]; DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest [GO:0006977]; DNA repair [GO:0006281]; DNA replication [GO:0006260]; G1/S transition of mitotic cell cycle [GO:0000082]; G2/M transition of mitotic cell cycle [GO:0000086]; histone phosphorylation [GO:0016572]; meiotic nuclear division [GO:0007126]; mitotic G1 DNA damage checkpoint [GO:0031571]; mitotic nuclear division [GO:0007067]; negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle [GO:0051436]; peptidyl-serine phosphorylation [GO:0018105]; positive regulation of cell proliferation [GO:0008284]; positive regulation of DNA-dependent DNA replication initiation [GO:0032298]; positive regulation of transcription, DNA-templated [GO:0045893]; potassium ion transport [GO:0006813]; Ras protein signal transduction [GO:0007265]; regulation of gene silencing [GO:0060968]; regulation of signal transduction by p53 class mediator [GO:1901796]; regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle [GO:0051439]	ATP binding [GO:0005524]; cyclin binding [GO:0030332]; cyclin-dependent protein serine/threonine kinase activity [GO:0004693]; kinase activity [GO:0016301]; metal ion binding [GO:0046872]; protein serine/threonine kinase activity [GO:0004674]	Cajal body [GO:0015030]; centrosome [GO:0005813]; chromosome, telomeric region [GO:0000781]; condensed chromosome [GO:0000793]; cyclin-dependent protein kinase holoenzyme complex [GO:0000307]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; endosome [GO:0005768]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; transcription factor complex [GO:0005667]; X chromosome [GO:0000805]; Y chromosome [GO:0000806]
Q4U2R8	O95742_HUMAN	Solute carrier family 22 member 6 (Organic anion transporter 1) (hOAT1) (PAH transporter) (hPAHT) (Renal organic anion transporter 1) (hROAT1)	SLC22A6 OAT1 PAHT		CHEMBL1641347;	Q4U2R8;	DB00316;DB00819;DB06151;DB00945;DB00787;DB00718;DB00345;DB01424;DB01060;DB01435;DB00168;DB01053;DB01237;DB00887;DB01197;DB00578;DB00821;DB00520;DB01414;DB01140;DB00456;DB01326;DB01327;DB01329;DB00493;DB00229;DB01333;DB00438;DB01212;DB00567;DB00446;DB00880;DB00672;DB00369;DB01597;DB00501;DB00827;DB01147;DB00286;DB00091;DB00606;DB08912;DB00586;DB00900;DB00861;DB01160;DB00917;DB00254;DB00584;DB00903;DB00749;DB00693;DB00712;DB00158;DB00529;DB00695;DB01004;DB00798;DB01016;DB00999;DB01050;DB00328;DB01009;DB00709;DB01137;DB00678;DB00939;DB00703;DB00563;DB01017;DB00607;DB00779;DB00788;DB00731;DB01059;DB01051;DB01165;DB00595;DB00812;DB00319;DB00554;DB00175;DB01032;DB00140;DB00936;DB00649;DB01082;DB00605;DB00300;DB00759;DB01124;DB00500;DB00432;DB00577;DB00313;DB00512;DB00943;DB00495;		PF00083;	IPR020846;IPR005828;IPR004749;	alpha-ketoglutarate transport [GO:0015742]; organic anion transport [GO:0015711]; protein homooligomerization [GO:0051260]; renal tubular secretion [GO:0097254]; response to methotrexate [GO:0031427]; sodium-independent organic anion transport [GO:0043252]	anion:anion antiporter activity [GO:0015301]; chloride ion binding [GO:0031404]; inorganic anion exchanger activity [GO:0005452]; organic anion transmembrane transporter activity [GO:0008514]; sodium-independent organic anion transmembrane transporter activity [GO:0015347]	basolateral plasma membrane [GO:0016323]; caveola [GO:0005901]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; protein complex [GO:0043234]
Q8TCC7	O95820_HUMAN	Solute carrier family 22 member 8 (Organic anion transporter 3) (hOAT3)	SLC22A8 OAT3		CHEMBL1641348;	Q8TCC7;	DB00787;DB00718;DB00437;DB00345;DB00168;DB09060;DB00181;DB03793;DB01053;DB00887;DB01414;DB01140;DB00456;DB01326;DB01327;DB01329;DB00493;DB01212;DB00567;DB02659;DB01597;DB00501;DB00286;DB08912;DB00586;DB00390;DB01160;DB00917;DB00254;DB09272;DB00584;DB00783;DB00927;DB00695;DB01004;DB00536;DB01050;DB00328;DB01009;DB00583;DB00279;DB01583;DB01065;DB01033;DB00563;DB06710;DB01017;DB01051;DB00198;DB01092;DB00595;DB00812;DB00554;DB00175;DB01032;DB00908;DB00863;DB00936;DB06335;DB00139;DB00300;DB00469;DB00624;DB00759;DB00577;DB00313;DB00495;		PF00083;	IPR020846;IPR005828;IPR004749;IPR005829;	response to toxic substance [GO:0009636]; sodium-independent organic anion transport [GO:0043252]	anion:anion antiporter activity [GO:0015301]; inorganic anion exchanger activity [GO:0005452]; sodium-independent organic anion transmembrane transporter activity [GO:0015347]	basolateral plasma membrane [GO:0016323]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
O95864	O95864_HUMAN	Fatty acid desaturase 2 (EC 1.14.19.3) (Acyl-CoA 6-desaturase) (Delta(6) fatty acid desaturase) (D6D) (Delta(6) desaturase) (Delta-6 desaturase)	FADS2		CHEMBL6097;	O95864;	DB00132;	PATHWAY: Lipid metabolism; polyunsaturated fatty acid biosynthesis.	PF00173;PF00487;	IPR001199;IPR012171;IPR005804;	alpha-linolenic acid metabolic process [GO:0036109]; linoleic acid metabolic process [GO:0043651]; unsaturated fatty acid biosynthetic process [GO:0006636]	linoleoyl-CoA desaturase activity [GO:0016213]; stearoyl-CoA 9-desaturase activity [GO:0004768]	endoplasmic reticulum membrane [GO:0005789]; integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]
Q9NSA0	OAT4_HUMAN	Solute carrier family 22 member 11 (Organic anion transporter 4)	SLC22A11 OAT4		CHEMBL2073677;	Q9NSA0;	DB00345;DB00168;DB01053;DB00887;DB00456;DB01326;DB01327;DB01329;DB00493;DB01212;DB00501;DB00286;DB00586;DB01160;DB00917;DB00254;DB00783;DB00695;DB01050;DB00328;DB01009;DB00563;DB01017;DB01051;DB00595;DB00812;DB00554;DB00175;DB01032;DB00936;DB00759;DB00495;		PF00083;	IPR020846;IPR005828;	organic anion transport [GO:0015711]; sodium-independent organic anion transport [GO:0043252]; urate metabolic process [GO:0046415]	inorganic anion exchanger activity [GO:0005452]; organic anion transmembrane transporter activity [GO:0008514]; sodium-independent organic anion transmembrane transporter activity [GO:0015347]	apical plasma membrane [GO:0016324]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P54368	OAZ1_HUMAN	Ornithine decarboxylase antizyme 1 (ODC-Az)	OAZ1 OAZ	4ZGY;4ZGZ;5BWA;			DB00129;		PF02100;	IPR016181;IPR029914;IPR002993;	negative regulation of polyamine transmembrane transport [GO:1902268]; polyamine biosynthetic process [GO:0006596]; positive regulation of intracellular protein transport [GO:0090316]; positive regulation of protein catabolic process [GO:0045732]; regulation of cellular amino acid metabolic process [GO:0006521]; transport [GO:0006810]	ornithine decarboxylase inhibitor activity [GO:0008073]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleus [GO:0005634]
O95190	OAZ2_HUMAN	Ornithine decarboxylase antizyme 2 (AZ2) (ODC-Az 2)	OAZ2				DB00129;		PF02100;	IPR016181;IPR029916;IPR002993;	negative regulation of polyamine transmembrane transport [GO:1902268]; polyamine biosynthetic process [GO:0006596]; polyamine metabolic process [GO:0006595]; positive regulation of intracellular protein transport [GO:0090316]; positive regulation of protein catabolic process [GO:0045732]; regulation of cellular amino acid metabolic process [GO:0006521]	ornithine decarboxylase inhibitor activity [GO:0008073]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleus [GO:0005634]
Q9UMX2	OAZ3_HUMAN	Ornithine decarboxylase antizyme 3 (AZ3) (ODC-Az 3)	OAZ3				DB00129;		PF02100;	IPR016181;IPR029913;IPR002993;	negative regulation of polyamine transmembrane transport [GO:1902268]; polyamine biosynthetic process [GO:0006596]; polyamine metabolic process [GO:0006595]; positive regulation of protein catabolic process [GO:0045732]; regulation of cellular amino acid metabolic process [GO:0006521]; spermatogenesis [GO:0007283]	ornithine decarboxylase inhibitor activity [GO:0008073]; putrescine transmembrane transporter activity [GO:0015489]	blood microparticle [GO:0072562]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleus [GO:0005634]
Q9UKG9	OCTC_HUMAN	Peroxisomal carnitine O-octanoyltransferase (COT) (EC 2.3.1.137)	CROT COT		CHEMBL2206;	Q9UKG9;	DB00583;	PATHWAY: Lipid metabolism; fatty acid beta-oxidation.	PF00755;	IPR000542;	carnitine metabolic process [GO:0009437]; coenzyme A metabolic process [GO:0015936]; fatty acid beta-oxidation [GO:0006635]; fatty acid beta-oxidation using acyl-CoA oxidase [GO:0033540]; fatty acid metabolic process [GO:0006631]; fatty acid transport [GO:0015908]; generation of precursor metabolites and energy [GO:0006091]; medium-chain fatty acid metabolic process [GO:0051791]	carnitine O-octanoyltransferase activity [GO:0008458]; receptor binding [GO:0005102]	intracellular membrane-bounded organelle [GO:0043231]; mitochondrion [GO:0005739]; peroxisomal matrix [GO:0005782]; peroxisome [GO:0005777]
Q02218	ODO1_HUMAN	2-oxoglutarate dehydrogenase, mitochondrial (EC 1.2.4.2) (2-oxoglutarate dehydrogenase complex component E1) (OGDC-E1) (Alpha-ketoglutarate dehydrogenase)	OGDH	3ERY;	CHEMBL2816;		DB00313;		PF16078;PF00676;PF16870;PF02779;	IPR032106;IPR011603;IPR001017;IPR031717;IPR029061;IPR005475;	2-oxoglutarate metabolic process [GO:0006103]; cerebellar cortex development [GO:0021695]; generation of precursor metabolites and energy [GO:0006091]; glycolytic process [GO:0006096]; glyoxylate metabolic process [GO:0046487]; hippocampus development [GO:0021766]; lysine catabolic process [GO:0006554]; NADH metabolic process [GO:0006734]; olfactory bulb mitral cell layer development [GO:0061034]; pyramidal neuron development [GO:0021860]; striatum development [GO:0021756]; succinyl-CoA metabolic process [GO:0006104]; tangential migration from the subventricular zone to the olfactory bulb [GO:0022028]; thalamus development [GO:0021794]; tricarboxylic acid cycle [GO:0006099]	metal ion binding [GO:0046872]; oxoglutarate dehydrogenase (NAD+) activity [GO:0034602]; oxoglutarate dehydrogenase (succinyl-transferring) activity [GO:0004591]; thiamine pyrophosphate binding [GO:0030976]	mitochondrial matrix [GO:0005759]; mitochondrial membrane [GO:0031966]; mitochondrion [GO:0005739]; oxoglutarate dehydrogenase complex [GO:0045252]
P10515	ODP2_HUMAN	Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial (EC 2.3.1.12) (70 kDa mitochondrial autoantigen of primary biliary cirrhosis) (PBC) (Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex) (M2 antigen complex 70 kDa subunit) (Pyruvate dehydrogenase complex component E2) (PDC-E2) (PDCE2)	DLAT DLTA	1FYC;1Y8N;1Y8O;1Y8P;2DNE;2PNR;2Q8I;3B8K;3CRK;3CRL;					PF00198;PF00364;PF02817;	IPR003016;IPR001078;IPR000089;IPR023213;IPR004167;IPR006257;IPR011053;	acetyl-CoA biosynthetic process from pyruvate [GO:0006086]; glucose metabolic process [GO:0006006]; glyoxylate metabolic process [GO:0046487]; pyruvate metabolic process [GO:0006090]; regulation of acetyl-CoA biosynthetic process from pyruvate [GO:0010510]; sleep [GO:0030431]; tricarboxylic acid cycle [GO:0006099]	dihydrolipoyllysine-residue acetyltransferase activity [GO:0004742]	mitochondrial matrix [GO:0005759]; mitochondrial pyruvate dehydrogenase complex [GO:0005967]; mitochondrion [GO:0005739]; myelin sheath [GO:0043209]; pyruvate dehydrogenase complex [GO:0045254]
P29803	ODPAT_HUMAN	Pyruvate dehydrogenase E1 component subunit alpha, testis-specific form, mitochondrial (EC 1.2.4.1) (PDHE1-A type II)	PDHA2 PDHAL						PF00676;	IPR001017;IPR017597;IPR029061;	glucose metabolic process [GO:0006006]; pyruvate metabolic process [GO:0006090]; tricarboxylic acid cycle [GO:0006099]	pyruvate dehydrogenase (acetyl-transferring) activity [GO:0004739]; pyruvate dehydrogenase (NAD+) activity [GO:0034604]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; pyruvate dehydrogenase complex [GO:0045254]
P08559	ODPA_HUMAN	Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial (EC 1.2.4.1) (PDHE1-A type I)	PDHA1 PHE1A	1NI4;2OZL;3EXE;3EXF;3EXG;3EXH;3EXI;					PF00676;	IPR001017;IPR017597;IPR029061;	acetyl-CoA biosynthetic process from pyruvate [GO:0006086]; glucose metabolic process [GO:0006006]; glyoxylate metabolic process [GO:0046487]; mitochondrial acetyl-CoA biosynthetic process from pyruvate [GO:0061732]; pyruvate metabolic process [GO:0006090]; regulation of acetyl-CoA biosynthetic process from pyruvate [GO:0010510]; tricarboxylic acid cycle [GO:0006099]	pyruvate dehydrogenase (acetyl-transferring) activity [GO:0004739]; pyruvate dehydrogenase (NAD+) activity [GO:0034604]; pyruvate dehydrogenase activity [GO:0004738]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; myelin sheath [GO:0043209]; nucleus [GO:0005634]; pyruvate dehydrogenase complex [GO:0045254]
P11177	ODPB_HUMAN	Pyruvate dehydrogenase E1 component subunit beta, mitochondrial (PDHE1-B) (EC 1.2.4.1)	PDHB PHE1B	1NI4;2OZL;3EXE;3EXF;3EXG;3EXH;3EXI;			DB00119;		PF02779;PF02780;	IPR027110;IPR029061;IPR009014;IPR005475;IPR033248;IPR033247;	acetyl-CoA biosynthetic process from pyruvate [GO:0006086]; glucose metabolic process [GO:0006006]; glyoxylate metabolic process [GO:0046487]; mitochondrial acetyl-CoA biosynthetic process from pyruvate [GO:0061732]; pyruvate metabolic process [GO:0006090]; regulation of acetyl-CoA biosynthetic process from pyruvate [GO:0010510]; tricarboxylic acid cycle [GO:0006099]	pyruvate dehydrogenase (acetyl-transferring) activity [GO:0004739]; pyruvate dehydrogenase activity [GO:0004738]	extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; pyruvate dehydrogenase complex [GO:0045254]
O14841	OPLA_HUMAN	5-oxoprolinase (EC 3.5.2.9) (5-oxo-L-prolinase) (5-OPase) (Pyroglutamase)	OPLAH						PF05378;PF01968;PF02538;	IPR008040;IPR002821;IPR003692;	glutathione biosynthetic process [GO:0006750]; glutathione metabolic process [GO:0006749]	5-oxoprolinase (ATP-hydrolyzing) activity [GO:0017168]; ATP binding [GO:0005524]	cytosol [GO:0005829]
P41143	OPRD_HUMAN	Delta-type opioid receptor (D-OR-1) (DOR-1)	OPRD1 OPRD	1OZC;2IQM;4N6H;4RWA;4RWD;	CHEMBL236;	P41143;	DB06274;DB00321;DB00921;DB00611;DB00318;DB00514;DB00647;DB01081;DB09272;DB00813;DB01452;DB00956;DB00327;DB01221;DB06738;DB00854;DB00836;DB00333;DB00295;DB00844;DB01183;DB00704;DB00497;DB01192;DB00899;DB00708;DB06204;DB00193;		PF00001;	IPR000321;IPR000276;IPR017452;IPR001418;	adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway [GO:0007193]; adult locomotory behavior [GO:0008344]; cellular response to growth factor stimulus [GO:0071363]; cellular response to hypoxia [GO:0071456]; cellular response to toxic substance [GO:0097237]; chemical synaptic transmission [GO:0007268]; eating behavior [GO:0042755]; G-protein coupled receptor signaling pathway [GO:0007186]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; immune response [GO:0006955]; negative regulation of gene expression [GO:0010629]; negative regulation of protein oligomerization [GO:0032460]; neuropeptide signaling pathway [GO:0007218]; opioid receptor signaling pathway [GO:0038003]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; positive regulation of CREB transcription factor activity [GO:0032793]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; protein import into nucleus, translocation [GO:0000060]; regulation of calcium ion transport [GO:0051924]; regulation of mitochondrial membrane potential [GO:0051881]; regulation of sensory perception of pain [GO:0051930]; sensory perception of pain [GO:0019233]	enkephalin receptor activity [GO:0038046]; neuropeptide binding [GO:0042923]; opioid receptor activity [GO:0004985]	axon terminus [GO:0043679]; cytoplasm [GO:0005737]; dendrite membrane [GO:0032590]; integral component of plasma membrane [GO:0005887]; intrinsic component of plasma membrane [GO:0031226]; membrane raft [GO:0045121]; neuron projection [GO:0043005]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]; vesicle [GO:0031982]
P41145	OPRK_HUMAN	Kappa-type opioid receptor (K-OR-1) (KOR-1)	OPRK1 OPRK	2A0D;2IQN;4DJH;	CHEMBL237;	P41145;	DB06274;DB00321;DB00921;DB00611;DB00318;DB00514;DB00647;DB01209;DB09272;DB00813;DB01452;DB00327;DB01221;DB06738;DB00854;DB00836;DB00825;DB06800;DB06148;DB00370;DB00295;DB00844;DB01183;DB00704;DB00497;DB00652;DB00454;DB00396;DB00899;DB00708;DB06204;DB00193;		PF00001;	IPR000276;IPR017452;IPR000452;IPR001418;	adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway [GO:0007193]; adenylate cyclase-inhibiting opioid receptor signaling pathway [GO:0031635]; behavior [GO:0007610]; behavioral response to cocaine [GO:0048148]; cellular response to lipopolysaccharide [GO:0071222]; chemical synaptic transmission [GO:0007268]; conditioned place preference [GO:1990708]; defense response to virus [GO:0051607]; eating behavior [GO:0042755]; estrous cycle [GO:0044849]; immune response [GO:0006955]; locomotory behavior [GO:0007626]; maternal behavior [GO:0042711]; negative regulation of luteinizing hormone secretion [GO:0033685]; neuropeptide signaling pathway [GO:0007218]; opioid receptor signaling pathway [GO:0038003]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; positive regulation of dopamine secretion [GO:0033603]; positive regulation of locomotion [GO:0040017]; positive regulation of p38MAPK cascade [GO:1900745]; positive regulation of potassium ion transmembrane transport [GO:1901381]; regulation of aerobic respiration [GO:1903715]; regulation of energy homeostasis [GO:2000505]; regulation of saliva secretion [GO:0046877]; regulation of sensory perception of pain [GO:0051930]; response to acrylamide [GO:1903937]; response to estrogen [GO:0043627]; response to ethanol [GO:0045471]; response to insulin [GO:0032868]; response to morphine [GO:0043278]; response to radiation [GO:0009314]; sensory perception [GO:0007600]; sensory perception of pain [GO:0019233]; sensory perception of temperature stimulus [GO:0050951]	dynorphin receptor activity [GO:0038048]; neuropeptide binding [GO:0042923]; opioid receptor activity [GO:0004985]	axon terminus [GO:0043679]; dendrite [GO:0030425]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; neuron projection [GO:0043005]; perikaryon [GO:0043204]; plasma membrane [GO:0005886]; synapse [GO:0045202]
P35372	OPRM_HUMAN	Mu-type opioid receptor (M-OR-1) (MOR-1) (Mu opiate receptor) (Mu opioid receptor) (MOP) (hMOP)	OPRM1 MOR1		CHEMBL233;	P35372;	DB00802;DB06274;DB00321;DB00913;DB00921;DB00611;DB00318;DB00514;DB00647;DB01209;DB01081;DB09272;DB01466;DB00813;DB01452;DB00956;DB00327;DB01221;DB06738;DB00504;DB01227;DB00854;DB00836;DB00333;DB01433;DB06800;DB00295;DB00844;DB09049;DB01183;DB00704;DB00904;DB00497;DB01192;DB00652;DB00454;DB00899;DB00708;DB06204;DB00193;		PF00001;	IPR000276;IPR017452;IPR000105;IPR001418;	acute inflammatory response to antigenic stimulus [GO:0002438]; adenylate cyclase-activating dopamine receptor signaling pathway [GO:0007191]; adenylate cyclase-inhibiting opioid receptor signaling pathway [GO:0031635]; behavioral response to ethanol [GO:0048149]; cellular response to morphine [GO:0071315]; cellular response to stress [GO:0033554]; chemical synaptic transmission [GO:0007268]; eating behavior [GO:0042755]; estrous cycle [GO:0044849]; excitatory postsynaptic potential [GO:0060079]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; locomotory behavior [GO:0007626]; negative regulation of adenylate cyclase activity [GO:0007194]; negative regulation of cAMP-mediated signaling [GO:0043951]; negative regulation of cell proliferation [GO:0008285]; negative regulation of cytosolic calcium ion concentration [GO:0051481]; negative regulation of nitric oxide biosynthetic process [GO:0045019]; negative regulation of Wnt protein secretion [GO:0061358]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; positive regulation of appetite [GO:0032100]; positive regulation of cAMP-mediated signaling [GO:0043950]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of neurogenesis [GO:0050769]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; regulation of N-methyl-D-aspartate selective glutamate receptor activity [GO:2000310]; regulation of sensory perception of pain [GO:0051930]; response to cocaine [GO:0042220]; response to food [GO:0032094]; response to growth factor [GO:0070848]; response to lipopolysaccharide [GO:0032496]; response to radiation [GO:0009314]; sensory perception [GO:0007600]; sensory perception of pain [GO:0019233]; wound healing [GO:0042060]	beta-endorphin receptor activity [GO:0004979]; G-protein alpha-subunit binding [GO:0001965]; G-protein beta-subunit binding [GO:0031681]; G-protein coupled receptor activity [GO:0004930]; morphine receptor activity [GO:0038047]; neuropeptide binding [GO:0042923]; voltage-gated calcium channel activity [GO:0005245]	cell [GO:0005623]; dendrite cytoplasm [GO:0032839]; dendrite membrane [GO:0032590]; endoplasmic reticulum [GO:0005783]; focal adhesion [GO:0005925]; Golgi apparatus [GO:0005794]; integral component of plasma membrane [GO:0005887]; membrane raft [GO:0045121]; neuron projection [GO:0043005]; perikaryon [GO:0043204]; plasma membrane [GO:0005886]; postsynapse [GO:0098794]; sarcolemma [GO:0042383]
P41146	OPRX_HUMAN	Nociceptin receptor (Kappa-type 3 opioid receptor) (KOR-3) (Orphanin FQ receptor)	OPRL1 OOR ORL1	4EA3;5DHG;5DHH;	CHEMBL2014;	P41146;			PF00001;	IPR000276;IPR017452;IPR001418;IPR001420;	adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway [GO:0007193]; chemical synaptic transmission [GO:0007268]; eating behavior [GO:0042755]; estrous cycle [GO:0044849]; negative regulation of blood pressure [GO:0045776]; negative regulation of cAMP biosynthetic process [GO:0030818]; negative regulation of voltage-gated calcium channel activity [GO:1901386]; neuropeptide signaling pathway [GO:0007218]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of gastric acid secretion [GO:0060454]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of sensory perception of pain [GO:1904058]; positive regulation of urine volume [GO:0035810]; regulation of locomotor rhythm [GO:1904059]; response to estradiol [GO:0032355]; sensory perception [GO:0007600]; sensory perception of pain [GO:0019233]	G-protein coupled receptor activity [GO:0004930]; neuropeptide binding [GO:0042923]; nociceptin receptor activity [GO:0001626]	cytoplasmic, membrane-bounded vesicle [GO:0016023]; integral component of plasma membrane [GO:0005887]; neuron projection [GO:0043005]; plasma membrane [GO:0005886]
P08100	OPSD_HUMAN	Rhodopsin (Opsin-2)	RHO OPN2	4ZWJ;5DGY;			DB01159;		PF00001;PF10413;	IPR000276;IPR017452;IPR001760;IPR027430;IPR000732;IPR019477;	absorption of visible light [GO:0016038]; G-protein coupled receptor signaling pathway [GO:0007186]; photoreceptor cell maintenance [GO:0045494]; phototransduction, visible light [GO:0007603]; protein-chromophore linkage [GO:0018298]; protein phosphorylation [GO:0006468]; regulation of rhodopsin mediated signaling pathway [GO:0022400]; retina development in camera-type eye [GO:0060041]; retinoid metabolic process [GO:0001523]; rhodopsin mediated signaling pathway [GO:0016056]; visual perception [GO:0007601]	G-protein coupled photoreceptor activity [GO:0008020]; G-protein coupled receptor activity [GO:0004930]; metal ion binding [GO:0046872]	cell-cell junction [GO:0005911]; ciliary membrane [GO:0060170]; Golgi apparatus [GO:0005794]; Golgi-associated vesicle membrane [GO:0030660]; Golgi membrane [GO:0000139]; integral component of plasma membrane [GO:0005887]; photoreceptor disc membrane [GO:0097381]; photoreceptor inner segment [GO:0001917]; photoreceptor inner segment membrane [GO:0060342]; photoreceptor outer segment [GO:0001750]; photoreceptor outer segment membrane [GO:0042622]; plasma membrane [GO:0005886]
Q9Y619	ORNT1_HUMAN	Mitochondrial ornithine transporter 1 (Solute carrier family 25 member 15)	SLC25A15 ORNT1 SP1855				DB00129;		PF00153;	IPR018108;IPR023395;	cellular amino acid metabolic process [GO:0006520]; mitochondrial ornithine transport [GO:0000066]; translation [GO:0006412]; urea cycle [GO:0000050]	L-ornithine transmembrane transporter activity [GO:0000064]; structural constituent of ribosome [GO:0003735]	integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]
Q9BXI2	ORNT2_HUMAN	Mitochondrial ornithine transporter 2 (Solute carrier family 25 member 2)	SLC25A2 ORNT2				DB00129;		PF00153;	IPR018108;IPR023395;	translation [GO:0006412]; urea cycle [GO:0000050]	L-ornithine transmembrane transporter activity [GO:0000064]; structural constituent of ribosome [GO:0003735]	integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]
Q9Y663	OST3A_HUMAN	Heparan sulfate glucosamine 3-O-sulfotransferase 3A1 (EC 2.8.2.30) (Heparan sulfate D-glucosaminyl 3-O-sulfotransferase 3A1) (3-OST-3A) (Heparan sulfate 3-O-sulfotransferase 3A1) (h3-OST-3A)	HS3ST3A1 3OST3A1 HS3ST3A UNQ2551/PRO6180	1T8T;1T8U;					PF00685;	IPR027417;IPR000863;	glycosaminoglycan biosynthetic process [GO:0006024]	[heparan sulfate]-glucosamine 3-sulfotransferase 1 activity [GO:0008467]; [heparan sulfate]-glucosamine 3-sulfotransferase 3 activity [GO:0033872]; sulfotransferase activity [GO:0008146]	Golgi membrane [GO:0000139]; integral component of membrane [GO:0016021]
Q9NRP0	OSTC_HUMAN	Oligosaccharyltransferase complex subunit OSTC (Hydrophobic protein HSF-28)	OSTC DC2 HDCMD45P HSPC307						PF04756;	IPR021149;	protein N-linked glycosylation via asparagine [GO:0018279]		integral component of membrane [GO:0016021]; oligosaccharyltransferase complex [GO:0008250]
P00480	OTC_HUMAN	Ornithine carbamoyltransferase, mitochondrial (EC 2.1.3.3) (Ornithine transcarbamylase) (OTCase)	OTC	1C9Y;1EP9;1FVO;1OTH;	CHEMBL2222;	P00480;	DB00155;DB00129;	PATHWAY: Nitrogen metabolism; urea cycle; L-citrulline from L-ornithine and carbamoyl phosphate: step 1/1.	PF00185;PF02729;	IPR006132;IPR006130;IPR006131;IPR002292;	ammonia homeostasis [GO:0097272]; anion homeostasis [GO:0055081]; arginine biosynthetic process via ornithine [GO:0042450]; citrulline biosynthetic process [GO:0019240]; liver development [GO:0001889]; midgut development [GO:0007494]; ornithine catabolic process [GO:0006593]; protein homotrimerization [GO:0070207]; response to biotin [GO:0070781]; response to drug [GO:0042493]; response to insulin [GO:0032868]; response to zinc ion [GO:0010043]; urea cycle [GO:0000050]	amino acid binding [GO:0016597]; ornithine carbamoyltransferase activity [GO:0004585]; phosphate ion binding [GO:0042301]; phospholipid binding [GO:0005543]	mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
P30559	OXYR_HUMAN	Oxytocin receptor (OT-R)	OXTR		CHEMBL2049;	P30559;	DB01282;DB00107;		PF00001;	IPR000276;IPR017452;IPR002062;IPR001817;	cell surface receptor signaling pathway [GO:0007166]; cellular response to hormone stimulus [GO:0032870]; digestive tract development [GO:0048565]; eating behavior [GO:0042755]; ERK1 and ERK2 cascade [GO:0070371]; estrous cycle [GO:0044849]; female pregnancy [GO:0007565]; heart development [GO:0007507]; lactation [GO:0007595]; maternal behavior [GO:0042711]; maternal process involved in parturition [GO:0060137]; memory [GO:0007613]; muscle contraction [GO:0006936]; negative regulation of gastric acid secretion [GO:0060455]; positive regulation of blood pressure [GO:0045777]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of norepinephrine secretion [GO:0010701]; positive regulation of penile erection [GO:0060406]; positive regulation of synapse assembly [GO:0051965]; positive regulation of synaptic transmission, GABAergic [GO:0032230]; positive regulation of synaptic transmission, glutamatergic [GO:0051968]; positive regulation of uterine smooth muscle contraction [GO:0070474]; positive regulation of vasoconstriction [GO:0045907]; regulation of systemic arterial blood pressure by vasopressin [GO:0001992]; response to amphetamine [GO:0001975]; response to anoxia [GO:0034059]; response to cocaine [GO:0042220]; response to cytokine [GO:0034097]; response to drug [GO:0042493]; response to estradiol [GO:0032355]; response to peptide [GO:1901652]; response to peptide hormone [GO:0043434]; response to progesterone [GO:0032570]; sleep [GO:0030431]; social behavior [GO:0035176]; sperm ejaculation [GO:0042713]; suckling behavior [GO:0001967]; telencephalon development [GO:0021537]	oxytocin receptor activity [GO:0004990]; peptide binding [GO:0042277]; peptide hormone binding [GO:0017046]; vasopressin receptor activity [GO:0005000]	apical plasma membrane [GO:0016324]; cell-cell adherens junction [GO:0005913]; integral component of plasma membrane [GO:0005887]; intracellular [GO:0005622]; microvillus [GO:0005902]; plasma membrane [GO:0005886]
P41231	P2RY2_HUMAN	P2Y purinoceptor 2 (P2Y2) (ATP receptor) (P2U purinoceptor 1) (P2U1) (P2U receptor 1) (Purinergic receptor)	P2RY2 P2RU1	1Z8E;	CHEMBL4398;	P41231;	DB04786;		PF00001;	IPR000276;IPR017452;IPR000356;	cellular ion homeostasis [GO:0006873]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; positive regulation of mucus secretion [GO:0070257]; regulation of vasodilation [GO:0042312]	G-protein coupled purinergic nucleotide receptor activity [GO:0045028]; receptor activity [GO:0004872]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
Q9H244	P2Y12_HUMAN	P2Y purinoceptor 12 (P2Y12) (ADP-glucose receptor) (ADPG-R) (P2T(AC)) (P2Y(AC)) (P2Y(cyc)) (P2Y12 platelet ADP receptor) (P2Y(ADP)) (SP1999)	P2RY12 HORK3	1T78;1VZ1;1Y9C;4NTJ;4PXZ;4PY0;	CHEMBL2001;	Q9H244;	DB06441;DB00758;DB01240;DB06209;DB08816;DB00208;DB00374;		PF00001;	IPR000276;IPR017452;IPR005394;	adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway [GO:0007193]; calcium ion transmembrane transport [GO:0070588]; cellular response to ATP [GO:0071318]; glial cell migration [GO:0008347]; G-protein coupled receptor signaling pathway [GO:0007186]; hemostasis [GO:0007599]; negative regulation of cell differentiation [GO:0045596]; negative regulation of norepinephrine secretion [GO:0010700]; platelet aggregation [GO:0070527]; positive regulation of ion transport [GO:0043270]; potassium ion transmembrane transport [GO:0071805]; protein kinase B signaling [GO:0043491]; regulation of calcium ion transport [GO:0051924]; regulation of microglial cell migration [GO:1904139]; substrate-dependent cell migration, cell extension [GO:0006930]	ADP receptor activity [GO:0001621]; G-protein coupled adenosine receptor activity [GO:0001609]; guanyl-nucleotide exchange factor activity [GO:0005085]	basal plasma membrane [GO:0009925]; caveola [GO:0005901]; cell surface [GO:0009986]; external side of plasma membrane [GO:0009897]; integral component of plasma membrane [GO:0005887]; intrinsic component of membrane [GO:0031224]; mitochondrion [GO:0005739]; plasma membrane [GO:0005886]
O00443	P3C2A_HUMAN	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha (PI3K-C2-alpha) (PtdIns-3-kinase C2 subunit alpha) (EC 2.7.1.154) (Phosphoinositide 3-kinase-C2-alpha)	PIK3C2A	2AR5;2IWL;2REA;2RED;	CHEMBL1075102;	O00443;			PF00168;PF00454;PF00792;PF00794;PF00613;PF00787;	IPR016024;IPR000008;IPR011009;IPR001683;IPR000403;IPR018936;IPR002420;IPR000341;IPR015433;IPR001263;IPR029071;	clathrin coat assembly [GO:0048268]; endocytosis [GO:0006897]; epidermal growth factor receptor signaling pathway [GO:0007173]; exocytosis [GO:0006887]; insulin receptor signaling pathway [GO:0008286]; phosphatidylinositol biosynthetic process [GO:0006661]; phosphatidylinositol-mediated signaling [GO:0048015]; platelet-derived growth factor receptor signaling pathway [GO:0048008]; vascular smooth muscle contraction [GO:0014829]	1-phosphatidylinositol-3-kinase activity [GO:0016303]; 1-phosphatidylinositol-4-phosphate 3-kinase activity [GO:0035005]; ATP binding [GO:0005524]; phosphatidylinositol 3-kinase activity [GO:0035004]; phosphatidylinositol binding [GO:0035091]	clathrin-coated vesicle [GO:0030136]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; Golgi apparatus [GO:0005794]; membrane [GO:0016020]; nucleus [GO:0005634]; phosphatidylinositol 3-kinase complex [GO:0005942]; plasma membrane [GO:0005886]; vesicle [GO:0031982]
Q32P28	P3H1_HUMAN	Prolyl 3-hydroxylase 1 (EC 1.14.11.7) (Growth suppressor 1) (Leucine- and proline-enriched proteoglycan 1) (Leprecan-1)	P3H1 GROS1 LEPRE1 PSEC0109				DB00172;DB00139;DB00126;		PF13640;	IPR005123;IPR006620;IPR011990;	bone development [GO:0060348]; chaperone-mediated protein folding [GO:0061077]; collagen metabolic process [GO:0032963]; negative regulation of cell proliferation [GO:0008285]; negative regulation of post-translational protein modification [GO:1901874]; protein folding [GO:0006457]; protein hydroxylation [GO:0018126]; protein stabilization [GO:0050821]; regulation of protein secretion [GO:0050708]	iron ion binding [GO:0005506]; L-ascorbic acid binding [GO:0031418]; procollagen-proline 3-dioxygenase activity [GO:0019797]; protein complex binding [GO:0032403]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum lumen [GO:0005788]; extracellular exosome [GO:0070062]; macromolecular complex [GO:0032991]; membrane [GO:0016020]; proteinaceous extracellular matrix [GO:0005578]
Q8IVL5	P3H2_HUMAN	Prolyl 3-hydroxylase 2 (EC 1.14.11.7) (Leprecan-like protein 1) (Myxoid liposarcoma-associated protein 4)	P3H2 LEPREL1 MLAT4				DB00172;DB00139;DB00126;		PF13640;	IPR005123;IPR006620;IPR011990;	collagen metabolic process [GO:0032963]; negative regulation of cell proliferation [GO:0008285]; peptidyl-proline hydroxylation [GO:0019511]	iron ion binding [GO:0005506]; L-ascorbic acid binding [GO:0031418]; procollagen-proline 3-dioxygenase activity [GO:0019797]	basement membrane [GO:0005604]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum lumen [GO:0005788]; Golgi apparatus [GO:0005794]
Q8IVL6	P3H3_HUMAN	Prolyl 3-hydroxylase 3 (EC 1.14.11.7) (Leprecan-like protein 2) (Protein B)	P3H3 LEPREL2				DB00172;DB00139;DB00126;		PF13640;	IPR005123;IPR006620;IPR011990;	collagen metabolic process [GO:0032963]; negative regulation of cell proliferation [GO:0008285]	iron ion binding [GO:0005506]; L-ascorbic acid binding [GO:0031418]; procollagen-proline 3-dioxygenase activity [GO:0019797]	endoplasmic reticulum [GO:0005783]
P13674	P4HA1_HUMAN	Prolyl 4-hydroxylase subunit alpha-1 (4-PH alpha-1) (EC 1.14.11.2) (Procollagen-proline,2-oxoglutarate-4-dioxygenase subunit alpha-1)	P4HA1 P4HA	1TJC;2V5F;2YQ8;4BT8;4BT9;4BTA;4BTB;	CHEMBL1250350;		DB01275;DB00172;DB00139;DB00126;		PF13640;PF08336;	IPR005123;IPR006620;IPR013547;IPR013026;IPR011990;IPR019734;	collagen fibril organization [GO:0030199]; peptidyl-proline hydroxylation to 4-hydroxy-L-proline [GO:0018401]	iron ion binding [GO:0005506]; L-ascorbic acid binding [GO:0031418]; oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen [GO:0016702]; procollagen-proline 4-dioxygenase activity [GO:0004656]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum lumen [GO:0005788]; intracellular membrane-bounded organelle [GO:0043231]; membrane [GO:0016020]; mitochondrion [GO:0005739]; procollagen-proline 4-dioxygenase complex [GO:0016222]
O15460	P4HA2_HUMAN	Prolyl 4-hydroxylase subunit alpha-2 (4-PH alpha-2) (EC 1.14.11.2) (Procollagen-proline,2-oxoglutarate-4-dioxygenase subunit alpha-2)	P4HA2 UNQ290/PRO330		CHEMBL5640;		DB00172;DB00139;		PF13640;PF08336;	IPR005123;IPR006620;IPR013547;IPR013026;IPR011990;IPR019734;		electron carrier activity [GO:0009055]; iron ion binding [GO:0005506]; L-ascorbic acid binding [GO:0031418]; oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen [GO:0016702]; procollagen-proline 4-dioxygenase activity [GO:0004656]	cytoplasm [GO:0005737]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum lumen [GO:0005788]; intracellular membrane-bounded organelle [GO:0043231]; nucleus [GO:0005634]
P32322	P5CR1_HUMAN	Pyrroline-5-carboxylate reductase 1, mitochondrial (P5C reductase 1) (P5CR 1) (EC 1.5.1.2)	PYCR1	2GER;2GR9;2GRA;2IZZ;			DB00172;	PATHWAY: Amino-acid biosynthesis; L-proline biosynthesis; L-proline from L-glutamate 5-semialdehyde: step 1/1.	PF03807;PF14748;	IPR008927;IPR016040;IPR029036;IPR028939;IPR000304;	cellular amino acid biosynthetic process [GO:0008652]; cellular response to oxidative stress [GO:0034599]; L-proline biosynthetic process [GO:0055129]; negative regulation of hydrogen peroxide-induced cell death [GO:1903206]; proline biosynthetic process [GO:0006561]; regulation of mitochondrial membrane potential [GO:0051881]	identical protein binding [GO:0042802]; pyrroline-5-carboxylate reductase activity [GO:0004735]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
Q96C36	P5CR2_HUMAN	Pyrroline-5-carboxylate reductase 2 (P5C reductase 2) (P5CR 2) (EC 1.5.1.2)	PYCR2				DB00172;	PATHWAY: Amino-acid biosynthesis; L-proline biosynthesis; L-proline from L-glutamate 5-semialdehyde: step 1/1.	PF03807;PF14748;	IPR008927;IPR016040;IPR029036;IPR028939;IPR000304;	cellular amino acid biosynthetic process [GO:0008652]; cellular response to oxidative stress [GO:0034599]; L-proline biosynthetic process [GO:0055129]; proline biosynthetic process [GO:0006561]	pyrroline-5-carboxylate reductase activity [GO:0004735]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
P54886	P5CS_HUMAN	Delta-1-pyrroline-5-carboxylate synthase (P5CS) (Aldehyde dehydrogenase family 18 member A1) [Includes: Glutamate 5-kinase (GK) (EC 2.7.2.11) (Gamma-glutamyl kinase); Gamma-glutamyl phosphate reductase (GPR) (EC 1.2.1.41) (Glutamate-5-semialdehyde dehydrogenase) (Glutamyl-gamma-semialdehyde dehydrogenase)]	ALDH18A1 GSAS P5CS PYCS	2H5G;				PATHWAY: Amino-acid biosynthesis; L-proline biosynthesis; L-glutamate 5-semialdehyde from L-glutamate: step 1/2. {ECO:0000269|PubMed:26297558}.; PATHWAY: Amino-acid biosynthesis; L-proline biosynthesis; L-glutamate 5-semialdehyde from L-glutamate: step 2/2. {ECO:0000269|PubMed:26297558}.	PF00696;PF00171;	IPR016161;IPR016163;IPR016162;IPR015590;IPR001048;IPR020593;IPR001057;IPR005715;IPR019797;IPR000965;IPR005766;	cellular amino acid biosynthetic process [GO:0008652]; citrulline biosynthetic process [GO:0019240]; glutamate metabolic process [GO:0006536]; L-proline biosynthetic process [GO:0055129]; ornithine biosynthetic process [GO:0006592]; proline biosynthetic process [GO:0006561]	ATP binding [GO:0005524]; delta1-pyrroline-5-carboxylate synthetase activity [GO:0017084]; glutamate 5-kinase activity [GO:0004349]; glutamate-5-semialdehyde dehydrogenase activity [GO:0004350]; identical protein binding [GO:0042802]; poly(A) RNA binding [GO:0044822]	cytoplasm [GO:0005737]; mitochondrial inner membrane [GO:0005743]; mitochondrion [GO:0005739]
P27986	P85A_HUMAN	Phosphatidylinositol 3-kinase regulatory subunit alpha (PI3-kinase regulatory subunit alpha) (PI3K regulatory subunit alpha) (PtdIns-3-kinase regulatory subunit alpha) (Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha) (PI3-kinase subunit p85-alpha) (PtdIns-3-kinase regulatory subunit p85-alpha)	PIK3R1 GRB1	1A0N;1AZG;1H9O;1PBW;1PHT;1PIC;1PKS;1PKT;2IUG;2IUH;2IUI;2RD0;2V1Y;3HHM;3HIZ;3I5R;3I5S;4A55;4JPS;4L1B;4L23;4L2Y;4OVU;4OVV;4WAF;4YKN;4ZOP;5AUL;5FI4;5ITD;	CHEMBL2506;	P27986;	DB01064;		PF16454;PF00620;PF00017;	IPR032498;IPR001720;IPR008936;IPR000198;IPR000980;IPR001452;	B cell differentiation [GO:0030183]; cellular glucose homeostasis [GO:0001678]; cellular response to insulin stimulus [GO:0032869]; cellular response to UV [GO:0034644]; epidermal growth factor receptor signaling pathway [GO:0007173]; ERBB2 signaling pathway [GO:0038128]; extrinsic apoptotic signaling pathway via death domain receptors [GO:0008625]; Fc-epsilon receptor signaling pathway [GO:0038095]; Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096]; growth hormone receptor signaling pathway [GO:0060396]; insulin-like growth factor receptor signaling pathway [GO:0048009]; insulin receptor signaling pathway [GO:0008286]; intrinsic apoptotic signaling pathway in response to DNA damage [GO:0008630]; leukocyte migration [GO:0050900]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cell-matrix adhesion [GO:0001953]; negative regulation of osteoclast differentiation [GO:0045671]; NFAT protein import into nucleus [GO:0051531]; phosphatidylinositol 3-kinase signaling [GO:0014065]; phosphatidylinositol biosynthetic process [GO:0006661]; phosphatidylinositol-mediated signaling [GO:0048015]; phosphatidylinositol phosphorylation [GO:0046854]; platelet activation [GO:0030168]; positive regulation of cell migration [GO:0030335]; positive regulation of endoplasmic reticulum unfolded protein response [GO:1900103]; positive regulation of establishment of protein localization to plasma membrane [GO:0090004]; positive regulation of glucose import [GO:0046326]; positive regulation of glucose import in response to insulin stimulus [GO:2001275]; positive regulation of RNA splicing [GO:0033120]; positive regulation of transcription factor import into nucleus [GO:0042993]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of tumor necrosis factor production [GO:0032760]; protein phosphorylation [GO:0006468]; protein stabilization [GO:0050821]; regulation of phosphatidylinositol 3-kinase activity [GO:0043551]; regulation of phosphatidylinositol 3-kinase signaling [GO:0014066]; regulation of stress fiber assembly [GO:0051492]; response to endoplasmic reticulum stress [GO:0034976]; T cell costimulation [GO:0031295]; T cell receptor signaling pathway [GO:0050852]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]; viral process [GO:0016032]	1-phosphatidylinositol-3-kinase activity [GO:0016303]; 1-phosphatidylinositol-3-kinase regulator activity [GO:0046935]; ErbB-3 class receptor binding [GO:0043125]; insulin binding [GO:0043559]; insulin-like growth factor receptor binding [GO:0005159]; insulin receptor binding [GO:0005158]; insulin receptor substrate binding [GO:0043560]; neurotrophin TRKA receptor binding [GO:0005168]; phosphatidylinositol 3-kinase binding [GO:0043548]; phosphatidylinositol 3-kinase regulator activity [GO:0035014]; phosphatidylinositol-4,5-bisphosphate 3-kinase activity [GO:0046934]; protein phosphatase binding [GO:0019903]; transcription factor binding [GO:0008134]; transmembrane receptor protein tyrosine kinase adaptor activity [GO:0005068]	cell-cell junction [GO:0005911]; cis-Golgi network [GO:0005801]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; membrane [GO:0016020]; nucleus [GO:0005634]; perinuclear endoplasmic reticulum membrane [GO:1990578]; phosphatidylinositol 3-kinase complex [GO:0005942]; phosphatidylinositol 3-kinase complex, class IA [GO:0005943]; plasma membrane [GO:0005886]
P47712	PA24A_HUMAN	Cytosolic phospholipase A2 (cPLA2) (Phospholipase A2 group IVA) [Includes: Phospholipase A2 (EC 3.1.1.4) (Phosphatidylcholine 2-acylhydrolase); Lysophospholipase (EC 3.1.1.5)]	PLA2G4A CPLA2 PLA2G4	1BCI;1CJY;1RLW;	CHEMBL3816;	P47712;	DB00041;DB00411;DB00578;DB00445;DB00591;DB00588;DB04552;DB01083;DB01103;DB00086;DB04786;		PF00168;PF01735;	IPR016035;IPR000008;IPR002642;	arachidonic acid metabolic process [GO:0019369]; arachidonic acid secretion [GO:0050482]; cardiolipin acyl-chain remodeling [GO:0035965]; cellular response to antibiotic [GO:0071236]; icosanoid biosynthetic process [GO:0046456]; icosanoid metabolic process [GO:0006690]; phosphatidic acid biosynthetic process [GO:0006654]; phosphatidylcholine acyl-chain remodeling [GO:0036151]; phosphatidylethanolamine acyl-chain remodeling [GO:0036152]; phosphatidylglycerol acyl-chain remodeling [GO:0036148]; phosphatidylinositol acyl-chain remodeling [GO:0036149]; phosphatidylserine acyl-chain remodeling [GO:0036150]; phospholipid catabolic process [GO:0009395]; phospholipid metabolic process [GO:0006644]; platelet activating factor biosynthetic process [GO:0006663]; regulation of cell proliferation [GO:0042127]	calcium-dependent phospholipase A2 activity [GO:0047498]; calcium-dependent phospholipid binding [GO:0005544]; calcium ion binding [GO:0005509]; lysophospholipase activity [GO:0004622]; phosphatidylcholine 1-acylhydrolase activity [GO:0008970]; phospholipase A2 activity [GO:0004623]	cytoplasm [GO:0005737]; cytoplasmic, membrane-bounded vesicle [GO:0016023]; cytosol [GO:0005829]; endoplasmic reticulum membrane [GO:0005789]; Golgi apparatus [GO:0005794]; mitochondrial inner membrane [GO:0005743]
O60733	PA2G6_HUMAN	85/88 kDa calcium-independent phospholipase A2 (CaI-PLA2) (EC 3.1.1.4) (Group VI phospholipase A2) (GVI PLA2) (Intracellular membrane-associated calcium-independent phospholipase A2 beta) (iPLA2-beta) (Patatin-like phospholipase domain-containing protein 9) (PNPLA9)	PLA2G6 PLPLA9		CHEMBL3213;	O60733;	DB01103;		PF12796;PF01734;	IPR016035;IPR002110;IPR020683;IPR002641;	antibacterial humoral response [GO:0019731]; cardiolipin biosynthetic process [GO:0032049]; chemotaxis [GO:0006935]; Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096]; lipid catabolic process [GO:0016042]; maternal process involved in female pregnancy [GO:0060135]; memory [GO:0007613]; negative regulation of synaptic transmission, glutamatergic [GO:0051967]; phosphatidylcholine acyl-chain remodeling [GO:0036151]; phosphatidylethanolamine acyl-chain remodeling [GO:0036152]; positive regulation of arachidonic acid secretion [GO:0090238]; positive regulation of ceramide biosynthetic process [GO:2000304]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of exocytosis [GO:0045921]; positive regulation of insulin secretion involved in cellular response to glucose stimulus [GO:0035774]; positive regulation of protein kinase C signaling [GO:0090037]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of release of cytochrome c from mitochondria [GO:0090200]; positive regulation of vasodilation [GO:0045909]; regulation of store-operated calcium channel activity [GO:1901339]; response to endoplasmic reticulum stress [GO:0034976]; urinary bladder smooth muscle contraction [GO:0014832]	calcium-independent phospholipase A2 activity [GO:0047499]; hydrolase activity [GO:0016787]; phospholipase A2 activity [GO:0004623]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular space [GO:0005615]; membrane [GO:0016020]; microtubule organizing center [GO:0005815]; mitochondrion [GO:0005739]
P14555	PA2GA_HUMAN	Phospholipase A2, membrane associated (EC 3.1.1.4) (GIIC sPLA2) (Group IIA phospholipase A2) (Non-pancreatic secretory phospholipase A2) (NPS-PLA2) (Phosphatidylcholine 2-acylhydrolase 2A)	PLA2G2A PLA2B PLA2L RASF-A	1AYP;1BBC;1DB4;1DB5;1DCY;1J1A;1KQU;1KVO;1N28;1N29;1POD;1POE;2GNY;3U8B;3U8D;3U8H;3U8I;5G3N;	CHEMBL3474;	P14555;	DB00586;DB01381;DB00328;DB02325;DB04786;		PF00068;	IPR001211;IPR033112;IPR016090;IPR033113;	arachidonic acid secretion [GO:0050482]; defense response to Gram-positive bacterium [GO:0050830]; lipid catabolic process [GO:0016042]; low-density lipoprotein particle remodeling [GO:0034374]; phosphatidic acid biosynthetic process [GO:0006654]; phosphatidic acid metabolic process [GO:0046473]; phosphatidylcholine acyl-chain remodeling [GO:0036151]; phosphatidylethanolamine acyl-chain remodeling [GO:0036152]; phosphatidylglycerol acyl-chain remodeling [GO:0036148]; phosphatidylinositol acyl-chain remodeling [GO:0036149]; phosphatidylserine acyl-chain remodeling [GO:0036150]; phospholipid metabolic process [GO:0006644]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of inflammatory response [GO:0050729]; positive regulation of macrophage derived foam cell differentiation [GO:0010744]	calcium-dependent phospholipase A2 activity [GO:0047498]; calcium ion binding [GO:0005509]; phospholipase A2 activity [GO:0004623]; phospholipid binding [GO:0005543]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; secretory granule [GO:0030141]
O15496	PA2GX_HUMAN	Group 10 secretory phospholipase A2 (EC 3.1.1.4) (Group X secretory phospholipase A2) (GX sPLA2) (sPLA2-X) (Phosphatidylcholine 2-acylhydrolase 10)	PLA2G10	1LE6;1LE7;4UY1;5G3M;	CHEMBL4342;	O15496;			PF00068;	IPR001211;IPR033112;IPR016090;IPR033113;	arachidonic acid metabolic process [GO:0019369]; arachidonic acid secretion [GO:0050482]; axon guidance [GO:0007411]; cholesterol homeostasis [GO:0042632]; lipid catabolic process [GO:0016042]; lysophospholipid transport [GO:0051977]; negative regulation of cholesterol efflux [GO:0090370]; negative regulation of sequence-specific DNA binding transcription factor activity [GO:0043433]; phosphatidic acid biosynthetic process [GO:0006654]; phosphatidylcholine acyl-chain remodeling [GO:0036151]; phosphatidylethanolamine acyl-chain remodeling [GO:0036152]; phosphatidylglycerol acyl-chain remodeling [GO:0036148]; phosphatidylinositol acyl-chain remodeling [GO:0036149]; phosphatidylserine acyl-chain remodeling [GO:0036150]; positive regulation of arachidonic acid secretion [GO:0090238]; positive regulation of cellular protein metabolic process [GO:0032270]; positive regulation of lipid storage [GO:0010884]; positive regulation of macrophage derived foam cell differentiation [GO:0010744]; positive regulation of prostaglandin secretion [GO:0032308]; regulation of macrophage activation [GO:0043030]	calcium ion binding [GO:0005509]; phospholipase A2 activity [GO:0004623]; phospholipase activity [GO:0004620]	extracellular region [GO:0005576]
Q9ULC6	PADI1_HUMAN	Protein-arginine deiminase type-1 (EC 3.5.3.15) (Peptidylarginine deiminase I) (Protein-arginine deiminase type I)	PADI1 PAD1 PDI1	5HP5;	CHEMBL1909486;	Q9ULC6;	DB00155;		PF03068;PF08527;PF08526;	IPR008972;IPR004303;IPR013530;IPR013732;IPR013733;	chromatin organization [GO:0006325]; protein citrullination [GO:0018101]	calcium ion binding [GO:0005509]; protein-arginine deiminase activity [GO:0004668]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]
Q9Y2J8	PADI2_HUMAN	Protein-arginine deiminase type-2 (EC 3.5.3.15) (PAD-H19) (Peptidylarginine deiminase II) (Protein-arginine deiminase type II)	PADI2 KIAA0994 PAD2 PDI2	4N20;4N22;4N24;4N25;4N26;4N28;4N2A;4N2B;4N2C;4N2D;4N2E;4N2F;4N2G;4N2H;4N2I;4N2K;4N2L;4N2M;4N2N;	CHEMBL1909487;	Q9Y2J8;	DB00155;		PF03068;PF08527;PF08526;	IPR008972;IPR004303;IPR013530;IPR013732;IPR013733;	chromatin-mediated maintenance of transcription [GO:0048096]; chromatin organization [GO:0006325]; histone H3-R26 citrullination [GO:0036413]; intracellular estrogen receptor signaling pathway [GO:0030520]; negative regulation of chemokine-mediated signaling pathway [GO:0070100]; negative regulation of lymphocyte chemotaxis [GO:1901624]; protein citrullination [GO:0018101]; regulation of chromatin disassembly [GO:0010848]; substantia nigra development [GO:0021762]	calcium ion binding [GO:0005509]; estrogen receptor binding [GO:0030331]; protein-arginine deiminase activity [GO:0004668]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; transcriptionally active chromatin [GO:0035327]
Q9ULW8	PADI3_HUMAN	Protein-arginine deiminase type-3 (EC 3.5.3.15) (Peptidylarginine deiminase III) (Protein-arginine deiminase type III)	PADI3 PAD3 PDI3		CHEMBL1909488;	Q9ULW8;	DB00155;		PF03068;PF08527;PF08526;	IPR008972;IPR004303;IPR013530;IPR013732;IPR013733;	chromatin organization [GO:0006325]; protein citrullination [GO:0018101]	calcium ion binding [GO:0005509]; protein-arginine deiminase activity [GO:0004668]	cytosol [GO:0005829]
Q9UM07	PADI4_HUMAN	Protein-arginine deiminase type-4 (EC 3.5.3.15) (HL-60 PAD) (Peptidylarginine deiminase IV) (Protein-arginine deiminase type IV)	PADI4 PAD4 PADI5 PDI5	1WD8;1WD9;1WDA;2DEW;2DEX;2DEY;2DW5;3APM;3APN;3B1T;3B1U;4DKT;4X8C;4X8G;	CHEMBL6111;	Q9UM07;	DB00207;DB00254;DB00155;DB01082;DB00759;		PF03068;PF08527;PF08526;	IPR008972;IPR004303;IPR013530;IPR013732;IPR013733;	cellular protein modification process [GO:0006464]; chromatin organization [GO:0006325]; chromatin remodeling [GO:0006338]; histone citrullination [GO:0036414]; histone H3-R26 citrullination [GO:0036413]; innate immune response [GO:0045087]; nucleosome assembly [GO:0006334]; protein citrullination [GO:0018101]; regulation of transcription, DNA-templated [GO:0006355]; stem cell population maintenance [GO:0019827]; transcription, DNA-templated [GO:0006351]	arginine deiminase activity [GO:0016990]; calcium ion binding [GO:0005509]; protein-arginine deiminase activity [GO:0004668]	cytosol [GO:0005829]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
Q6TGC4	PADI6_HUMAN	Protein-arginine deiminase type-6 (EC 3.5.3.15) (Peptidyl arginine deiminase-like protein) (Peptidylarginine deiminase VI) (hPADVI) (Protein-arginine deiminase type VI)	PADI6 PAD6	4DAT;4DAU;		Q6TGC4;	DB00155;		PF03068;PF08527;PF08526;	IPR008972;IPR004303;IPR013530;IPR013732;IPR013733;	cytoplasm organization [GO:0007028]; cytoskeleton organization [GO:0007010]; protein citrullination [GO:0018101]; regulation of translation by machinery localization [GO:0043143]	calcium ion binding [GO:0005509]; protein-arginine deiminase activity [GO:0004668]	cytoplasm [GO:0005737]; intermediate filament cytoskeleton [GO:0045111]; nucleus [GO:0005634]
O14832	PAHX_HUMAN	Phytanoyl-CoA dioxygenase, peroxisomal (EC 1.14.11.18) (Phytanic acid oxidase) (Phytanoyl-CoA alpha-hydroxylase) (PhyH)	PHYH PAHX	2A1X;			DB00025;DB00126;	PATHWAY: Lipid metabolism; fatty acid metabolism.	PF05721;	IPR008775;	fatty acid alpha-oxidation [GO:0001561]; isoprenoid metabolic process [GO:0006720]; methyl-branched fatty acid metabolic process [GO:0097089]	cofactor binding [GO:0048037]; L-ascorbic acid binding [GO:0031418]; metal ion binding [GO:0046872]; phytanoyl-CoA dioxygenase activity [GO:0048244]	mitochondrion [GO:0005739]; peroxisomal matrix [GO:0005782]; peroxisome [GO:0005777]
P05121	PAI1_HUMAN	Plasminogen activator inhibitor 1 (PAI) (PAI-1) (Endothelial plasminogen activator inhibitor) (Serpin E1)	SERPINE1 PAI1 PLANH1	1A7C;1B3K;1C5G;1DB2;1DVM;1DVN;1LJ5;1OC0;3CVM;3EOX;3PB1;3Q02;3Q03;3R4L;3UT3;4AQH;4G8O;4G8R;4IC0;5BRR;9PAI;	CHEMBL3475;	P05121;	DB00009;DB00029;DB00055;DB00015;DB00031;DB00013;		PF00079;	IPR023795;IPR023796;IPR000215;	angiogenesis [GO:0001525]; cellular response to lipopolysaccharide [GO:0071222]; chronological cell aging [GO:0001300]; circadian rhythm [GO:0007623]; defense response to Gram-negative bacterium [GO:0050829]; extracellular matrix organization [GO:0030198]; fibrinolysis [GO:0042730]; negative regulation of blood coagulation [GO:0030195]; negative regulation of cell adhesion mediated by integrin [GO:0033629]; negative regulation of cell migration [GO:0030336]; negative regulation of endopeptidase activity [GO:0010951]; negative regulation of endothelial cell apoptotic process [GO:2000352]; negative regulation of extrinsic apoptotic signaling pathway via death domain receptors [GO:1902042]; negative regulation of fibrinolysis [GO:0051918]; negative regulation of plasminogen activation [GO:0010757]; negative regulation of smooth muscle cell-matrix adhesion [GO:2000098]; negative regulation of smooth muscle cell migration [GO:0014912]; negative regulation of vascular wound healing [GO:0061044]; negative regulation of wound healing [GO:0061045]; platelet degranulation [GO:0002576]; positive regulation of angiogenesis [GO:0045766]; positive regulation of blood coagulation [GO:0030194]; positive regulation of inflammatory response [GO:0050729]; positive regulation of interleukin-8 production [GO:0032757]; positive regulation of leukotriene production involved in inflammatory response [GO:0035491]; positive regulation of monocyte chemotaxis [GO:0090026]; positive regulation of receptor-mediated endocytosis [GO:0048260]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; regulation of receptor activity [GO:0010469]	protease binding [GO:0002020]; receptor binding [GO:0005102]; serine-type endopeptidase inhibitor activity [GO:0004867]	extracellular exosome [GO:0070062]; extracellular matrix [GO:0031012]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; plasma membrane [GO:0005886]; platelet alpha granule lumen [GO:0031093]
Q8TE04	PANK1_HUMAN	Pantothenate kinase 1 (hPanK) (hPanK1) (EC 2.7.1.33) (Pantothenic acid kinase 1)	PANK1 PANK	2I7N;3SMP;	CHEMBL3407326;	Q8TE04;		PATHWAY: Cofactor biosynthesis; coenzyme A biosynthesis; CoA from (R)-pantothenate: step 1/5.	PF03630;	IPR004567;	coenzyme A biosynthetic process [GO:0015937]; coenzyme biosynthetic process [GO:0009108]	ATP binding [GO:0005524]; pantothenate kinase activity [GO:0004594]	cell periphery [GO:0071944]; clathrin coat [GO:0030118]; cytosol [GO:0005829]; nucleus [GO:0005634]; recycling endosome [GO:0055037]
O43252	PAPS1_HUMAN	Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1 (PAPS synthase 1) (PAPSS 1) (Sulfurylase kinase 1) (SK 1) (SK1) [Includes: Sulfate adenylyltransferase (EC 2.7.7.4) (ATP-sulfurylase) (Sulfate adenylate transferase) (SAT); Adenylyl-sulfate kinase (EC 2.7.1.25) (3'-phosphoadenosine-5'-phosphosulfate synthase) (APS kinase) (Adenosine-5'-phosphosulfate 3'-phosphotransferase) (Adenylylsulfate 3'-phosphotransferase)]	PAPSS1 ATPSK1 PAPSS	1X6V;1XJQ;1XNJ;2OFW;2OFX;2PEY;2PEZ;2QJF;				PATHWAY: Sulfur metabolism; sulfate assimilation.	PF01747;PF14306;	IPR002891;IPR025980;IPR027417;IPR015947;IPR014729;IPR024951;IPR002650;	3'-phosphoadenosine 5'-phosphosulfate biosynthetic process [GO:0050428]; skeletal system development [GO:0001501]; sulfate assimilation [GO:0000103]	adenylylsulfate kinase activity [GO:0004020]; ATP binding [GO:0005524]; nucleotidyltransferase activity [GO:0016779]; sulfate adenylyltransferase (ATP) activity [GO:0004781]	cytosol [GO:0005829]
P09874	PARP1_HUMAN	Poly [ADP-ribose] polymerase 1 (PARP-1) (EC 2.4.2.30) (ADP-ribosyltransferase diphtheria toxin-like 1) (ARTD1) (NAD(+) ADP-ribosyltransferase 1) (ADPRT 1) (Poly[ADP-ribose] synthase 1)	PARP1 ADPRT PPOL	1UK0;1UK1;1WOK;2COK;2CR9;2CS2;2DMJ;2JVN;2L30;2L31;2N8A;2RCW;2RD6;2RIQ;3GJW;3GN7;3L3L;3L3M;3OD8;3ODA;3ODC;3ODE;4AV1;4DQY;4GV7;4HHY;4HHZ;4L6S;4OPX;4OQA;4OQB;4PJT;4R5W;4R6E;4RV6;4UND;4UXB;4XHU;4ZZZ;5A00;5DS3;5HA9;	CHEMBL3105;	P09874;	DB02701;DB09074;		PF00533;PF08063;PF00644;PF02877;PF05406;PF00645;	IPR001357;IPR012982;IPR008288;IPR012317;IPR004102;IPR008893;IPR001510;	ATP generation from poly-ADP-D-ribose [GO:1990966]; cellular response to beta-amyloid [GO:1904646]; cellular response to DNA damage stimulus [GO:0006974]; cellular response to insulin stimulus [GO:0032869]; cellular response to oxidative stress [GO:0034599]; cellular response to zinc ion [GO:0071294]; DNA damage response, detection of DNA damage [GO:0042769]; DNA ligation involved in DNA repair [GO:0051103]; DNA repair [GO:0006281]; double-strand break repair [GO:0006302]; double-strand break repair via homologous recombination [GO:0000724]; global genome nucleotide-excision repair [GO:0070911]; lagging strand elongation [GO:0006273]; macrophage differentiation [GO:0030225]; mitochondrial DNA metabolic process [GO:0032042]; mitochondrial DNA repair [GO:0043504]; mitochondrion organization [GO:0007005]; negative regulation of telomere maintenance via telomere lengthening [GO:1904357]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; nucleotide-excision repair, DNA damage recognition [GO:0000715]; nucleotide-excision repair, DNA duplex unwinding [GO:0000717]; nucleotide-excision repair, DNA incision [GO:0033683]; nucleotide-excision repair, DNA incision, 3'-to lesion [GO:0006295]; nucleotide-excision repair, DNA incision, 5'-to lesion [GO:0006296]; nucleotide-excision repair, preincision complex assembly [GO:0006294]; nucleotide-excision repair, preincision complex stabilization [GO:0006293]; positive regulation of cardiac muscle hypertrophy [GO:0010613]; positive regulation of intracellular estrogen receptor signaling pathway [GO:0033148]; positive regulation of mitochondrial depolarization [GO:0051901]; positive regulation of myofibroblast differentiation [GO:1904762]; positive regulation of neuron death [GO:1901216]; positive regulation of SMAD protein import into nucleus [GO:0060391]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of transcription regulatory region DNA binding [GO:2000679]; protein ADP-ribosylation [GO:0006471]; protein autoprocessing [GO:0016540]; protein modification process [GO:0036211]; protein poly-ADP-ribosylation [GO:0070212]; protein sumoylation [GO:0016925]; regulation of cellular protein localization [GO:1903827]; regulation of DNA methylation [GO:0044030]; regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway [GO:1903376]; regulation of SMAD protein complex assembly [GO:0010990]; response to aldosterone [GO:1904044]; response to gamma radiation [GO:0010332]; signal transduction involved in regulation of gene expression [GO:0023019]; transcription from RNA polymerase II promoter [GO:0006366]; transforming growth factor beta receptor signaling pathway [GO:0007179]	DNA binding [GO:0003677]; DNA ligase (ATP) activity [GO:0003910]; enzyme binding [GO:0019899]; NAD+ ADP-ribosyltransferase activity [GO:0003950]; NAD binding [GO:0051287]; poly(A) RNA binding [GO:0044822]; protein kinase binding [GO:0019901]; protein N-terminus binding [GO:0047485]; transcription factor binding [GO:0008134]; zinc ion binding [GO:0008270]	membrane [GO:0016020]; mitochondrion [GO:0005739]; nuclear chromosome, telomeric region [GO:0000784]; nuclear envelope [GO:0005635]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; protein complex [GO:0043234]; transcription factor complex [GO:0005667]
Q92831	PCAF_HUMAN	Histone acetyltransferase KAT2B (EC 2.3.1.48) (Histone acetyltransferase PCAF) (Histone acetylase PCAF) (Lysine acetyltransferase 2B) (P300/CBP-associated factor) (P/CAF)	KAT2B PCAF	1CM0;1JM4;1N72;1WUG;1WUM;1ZS5;2RNW;2RNX;3GG3;4NSQ;5FDZ;5FE0;5FE1;5FE2;5FE3;5FE4;5FE5;5FE6;5FE7;5FE8;5FE9;	CHEMBL5500;	Q92831;			PF00583;PF00439;PF06466;	IPR016181;IPR001487;IPR018359;IPR000182;IPR016376;IPR009464;	cell cycle arrest [GO:0007050]; cellular response to insulin stimulus [GO:0032869]; chromatin remodeling [GO:0006338]; histone H3 acetylation [GO:0043966]; histone H3-K9 acetylation [GO:0043970]; internal peptidyl-lysine acetylation [GO:0018393]; negative regulation of cell proliferation [GO:0008285]; negative regulation of cyclin-dependent protein serine/threonine kinase activity [GO:0045736]; Notch signaling pathway [GO:0007219]; N-terminal peptidyl-lysine acetylation [GO:0018076]; peptidyl-lysine acetylation [GO:0018394]; positive regulation of gene expression, epigenetic [GO:0045815]; positive regulation of gluconeogenesis by positive regulation of transcription from RNA polymerase II promoter [GO:0035948]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; protein acetylation [GO:0006473]; regulation of protein ADP-ribosylation [GO:0010835]; rhythmic process [GO:0048511]; transcription initiation from RNA polymerase II promoter [GO:0006367]; viral process [GO:0016032]	acetyltransferase activity [GO:0016407]; chromatin binding [GO:0003682]; cyclin-dependent protein serine/threonine kinase inhibitor activity [GO:0004861]; histone acetyltransferase activity [GO:0004402]; histone deacetylase binding [GO:0042826]; lysine N-acetyltransferase activity, acting on acetyl phosphate as donor [GO:0004468]; protein complex binding [GO:0032403]; protein kinase binding [GO:0019901]; RNA polymerase II regulatory region sequence-specific DNA binding [GO:0000977]; transcription coactivator activity [GO:0003713]; transcription cofactor activity [GO:0003712]; transcription factor binding [GO:0008134]	A band [GO:0031672]; actomyosin [GO:0042641]; Ada2/Gcn5/Ada3 transcription activator complex [GO:0005671]; I band [GO:0031674]; kinetochore [GO:0000776]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; PCAF complex [GO:0000125]
P05165	PCCA_HUMAN	Propionyl-CoA carboxylase alpha chain, mitochondrial (PCCase subunit alpha) (EC 6.4.1.3) (Propanoyl-CoA:carbon dioxide ligase subunit alpha)	PCCA	2CQY;2JKU;			DB00121;	PATHWAY: Metabolic intermediate metabolism; propanoyl-CoA degradation; succinyl-CoA from propanoyl-CoA: step 1/3.	PF02785;PF00289;PF00364;PF02786;	IPR011761;IPR013815;IPR013816;IPR005481;IPR001882;IPR011764;IPR005482;IPR000089;IPR005479;IPR016185;IPR011054;IPR011053;	biotin metabolic process [GO:0006768]; short-chain fatty acid catabolic process [GO:0019626]	ATP binding [GO:0005524]; biotin binding [GO:0009374]; biotin carboxylase activity [GO:0004075]; enzyme binding [GO:0019899]; metal ion binding [GO:0046872]; propionyl-CoA carboxylase activity [GO:0004658]	cytosol [GO:0005829]; mitochondrial matrix [GO:0005759]
P05166	PCCB_HUMAN	Propionyl-CoA carboxylase beta chain, mitochondrial (PCCase subunit beta) (EC 6.4.1.3) (Propanoyl-CoA:carbon dioxide ligase subunit beta)	PCCB				DB00121;DB00161;	PATHWAY: Metabolic intermediate metabolism; propanoyl-CoA degradation; succinyl-CoA from propanoyl-CoA: step 1/3.	PF01039;	IPR000022;IPR029045;IPR011763;IPR011762;	biotin metabolic process [GO:0006768]; short-chain fatty acid catabolic process [GO:0019626]	ATP binding [GO:0005524]; propionyl-CoA carboxylase activity [GO:0004658]	cytosol [GO:0005829]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
P49585	PCY1A_HUMAN	Choline-phosphate cytidylyltransferase A (EC 2.7.7.15) (CCT-alpha) (CTP:phosphocholine cytidylyltransferase A) (CCT A) (CT A) (Phosphorylcholine transferase A)	PCYT1A CTPCT PCYT1				DB00122;DB00709;	PATHWAY: Phospholipid metabolism; phosphatidylcholine biosynthesis; phosphatidylcholine from phosphocholine: step 1/2. {ECO:0000250|UniProtKB:P19836}.	PF01467;	IPR004821;IPR014729;	CDP-choline pathway [GO:0006657]; phosphatidylcholine biosynthetic process [GO:0006656]; phospholipid biosynthetic process [GO:0008654]	choline-phosphate cytidylyltransferase activity [GO:0004105]; lipid binding [GO:0008289]; phosphatidylcholine binding [GO:0031210]	cytosol [GO:0005829]; endoplasmic reticulum membrane [GO:0005789]; glycogen granule [GO:0042587]; nuclear envelope [GO:0005635]; plasma membrane [GO:0005886]
Q9Y5K3	PCY1B_HUMAN	Choline-phosphate cytidylyltransferase B (EC 2.7.7.15) (CCT-beta) (CTP:phosphocholine cytidylyltransferase B) (CCT B) (CT B) (Phosphorylcholine transferase B)	PCYT1B CCTB				DB00122;	PATHWAY: Phospholipid metabolism; phosphatidylcholine biosynthesis; phosphatidylcholine from phosphocholine: step 1/2. {ECO:0000250|UniProtKB:P19836}.	PF01467;	IPR004821;IPR014729;	ovarian follicle development [GO:0001541]; phosphatidylcholine biosynthetic process [GO:0006656]; phospholipid biosynthetic process [GO:0008654]; spermatogenesis [GO:0007283]	choline-phosphate cytidylyltransferase activity [GO:0004105]	cytoplasm [GO:0005737]; endoplasmic reticulum membrane [GO:0005789]
Q13258	PD2R_HUMAN	Prostaglandin D2 receptor (PGD receptor) (PGD2 receptor) (Prostanoid DP receptor)	PTGDR		CHEMBL4427;	Q13258;	DB00716;		PF00001;	IPR000276;IPR017452;IPR000376;IPR008365;	adenosine metabolic process [GO:0046085]; cellular response to prostaglandin D stimulus [GO:0071799]; G-protein coupled receptor signaling pathway [GO:0007186]; inflammatory response [GO:0006954]; male sex determination [GO:0030238]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of vasodilation [GO:0045909]; sleep [GO:0030431]	prostacyclin receptor activity [GO:0016501]; prostaglandin D receptor activity [GO:0004956]; prostaglandin J receptor activity [GO:0001785]	integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
Q9Y233	PDE10_HUMAN	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (EC 3.1.4.17) (EC 3.1.4.35)	PDE10A	1LRB;2OUN;2OUP;2OUQ;2OUR;2OUS;2OUU;2OUV;2OUY;2WEY;2Y0J;2ZMF;3SN7;3SNI;3SNL;3UI7;3UUO;3WI2;3WS8;3WS9;3WYK;3WYL;3WYM;4AEL;4AJD;4AJF;4AJG;4AJM;4BBX;4DDL;4DFF;4FCB;4FCD;4HEU;4HF4;4LKQ;4LLJ;4LLK;4LLP;4LLX;4LM0;4LM1;4LM2;4LM3;4LM4;4MRW;4MRZ;4MS0;4MSA;4MSC;4MSE;4MSH;4MSN;4MUW;4MVH;4P0N;4P1R;4PHW;4TPM;4TPP;4WN1;4XY2;4YQH;4YS7;4ZO5;5AXP;5AXQ;5B4K;5B4L;5C1W;5C28;5C29;5C2A;5C2E;5C2H;5DH4;5DH5;5EDE;5EDG;5EDH;5EDI;5I2R;5K9R;	CHEMBL4409;	Q9Y233;	DB00201;DB00975;DB01113;DB08811;DB08814;	PATHWAY: Purine metabolism; 3',5'-cyclic AMP degradation; AMP from 3',5'-cyclic AMP: step 1/1.; PATHWAY: Purine metabolism; 3',5'-cyclic GMP degradation; GMP from 3',5'-cyclic GMP: step 1/1.	PF01590;PF00233;	IPR003018;IPR029016;IPR003607;IPR023088;IPR002073;IPR023174;	cAMP catabolic process [GO:0006198]; cGMP catabolic process [GO:0046069]; regulation of cAMP-mediated signaling [GO:0043949]; regulation of protein kinase A signaling [GO:0010738]; signal transduction [GO:0007165]	3',5'-cyclic-AMP phosphodiesterase activity [GO:0004115]; 3',5'-cyclic-GMP phosphodiesterase activity [GO:0047555]; 3',5'-cyclic-nucleotide phosphodiesterase activity [GO:0004114]; cAMP binding [GO:0030552]; cGMP binding [GO:0030553]; cGMP-stimulated cyclic-nucleotide phosphodiesterase activity [GO:0004118]; drug binding [GO:0008144]; metal ion binding [GO:0046872]	cytosol [GO:0005829]; membrane [GO:0016020]; perikaryon [GO:0043204]
Q01064	PDE1B_HUMAN	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B (Cam-PDE 1B) (EC 3.1.4.17) (63 kDa Cam-PDE)	PDE1B PDE1B1 PDES1B	1LXR;1TAZ;4NPV;4NPW;5B25;	CHEMBL4425;	Q01064;	DB01244;DB00201;DB01023;DB00622;		PF00233;PF08499;	IPR003607;IPR023088;IPR002073;IPR023174;IPR013706;	apoptotic process [GO:0006915]; cAMP catabolic process [GO:0006198]; cellular response to granulocyte macrophage colony-stimulating factor stimulus [GO:0097011]; cellular response to macrophage colony-stimulating factor stimulus [GO:0036006]; cGMP catabolic process [GO:0046069]; locomotory behavior [GO:0007626]; monocyte differentiation [GO:0030224]; regulation of dopamine metabolic process [GO:0042053]; regulation of neurotransmitter levels [GO:0001505]; response to amphetamine [GO:0001975]; serotonin metabolic process [GO:0042428]; signal transduction [GO:0007165]; visual learning [GO:0008542]	3',5'-cyclic-AMP phosphodiesterase activity [GO:0004115]; 3',5'-cyclic-GMP phosphodiesterase activity [GO:0047555]; calcium- and calmodulin-regulated 3',5'-cyclic-GMP phosphodiesterase activity [GO:0048101]; calmodulin-dependent cyclic-nucleotide phosphodiesterase activity [GO:0004117]; metal ion binding [GO:0046872]	cytosol [GO:0005829]; neuronal cell body [GO:0043025]
O00408	PDE2A_HUMAN	cGMP-dependent 3',5'-cyclic phosphodiesterase (EC 3.1.4.17) (Cyclic GMP-stimulated phosphodiesterase) (CGS-PDE) (cGSPDE)	PDE2A	1Z1L;3IBJ;3ITM;3ITU;4C1I;4D08;4D09;4HTX;4HTZ;4JIB;	CHEMBL2652;	O00408;	DB00201;DB08811;		PF01590;PF13185;PF00233;	IPR003018;IPR029016;IPR003607;IPR023088;IPR002073;IPR023174;	cAMP catabolic process [GO:0006198]; cAMP-mediated signaling [GO:0019933]; cellular response to cGMP [GO:0071321]; cellular response to drug [GO:0035690]; cellular response to granulocyte macrophage colony-stimulating factor stimulus [GO:0097011]; cellular response to macrophage colony-stimulating factor stimulus [GO:0036006]; cellular response to mechanical stimulus [GO:0071260]; cellular response to transforming growth factor beta stimulus [GO:0071560]; cGMP catabolic process [GO:0046069]; cGMP-mediated signaling [GO:0019934]; establishment of endothelial barrier [GO:0061028]; metabolic process [GO:0008152]; monocyte differentiation [GO:0030224]; negative regulation of cAMP biosynthetic process [GO:0030818]; negative regulation of protein import into nucleus, translocation [GO:0033159]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; negative regulation of vascular permeability [GO:0043116]; positive regulation of inflammatory response [GO:0050729]; positive regulation of vascular permeability [GO:0043117]; protein targeting to mitochondrion [GO:0006626]	3',5'-cyclic-AMP phosphodiesterase activity [GO:0004115]; 3',5'-cyclic-GMP phosphodiesterase activity [GO:0047555]; calcium channel activity [GO:0005262]; cAMP binding [GO:0030552]; cGMP binding [GO:0030553]; cGMP-stimulated cyclic-nucleotide phosphodiesterase activity [GO:0004118]; cyclic-nucleotide phosphodiesterase activity [GO:0004112]; drug binding [GO:0008144]; metal ion binding [GO:0046872]; protein homodimerization activity [GO:0042803]; TPR domain binding [GO:0030911]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; Golgi apparatus [GO:0005794]; mitochondrial matrix [GO:0005759]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; presynaptic membrane [GO:0042734]
Q14432	PDE3A_HUMAN	cGMP-inhibited 3',5'-cyclic phosphodiesterase A (EC 3.1.4.17) (Cyclic GMP-inhibited phosphodiesterase A) (CGI-PDE A)	PDE3A	1LRC;	CHEMBL241;	Q14432;	DB01223;DB01427;DB00261;DB00201;DB01166;DB04880;DB05266;DB00922;DB00235;DB01303;DB00277;DB08811;		PF00233;	IPR003607;IPR002073;IPR023174;	cAMP catabolic process [GO:0006198]; cAMP-mediated signaling [GO:0019933]; cellular response to cGMP [GO:0071321]; cellular response to transforming growth factor beta stimulus [GO:0071560]; cGMP-mediated signaling [GO:0019934]; diterpenoid metabolic process [GO:0016101]; lipid metabolic process [GO:0006629]; negative regulation of apoptotic process [GO:0043066]; negative regulation of vascular permeability [GO:0043116]; oocyte maturation [GO:0001556]; positive regulation of oocyte development [GO:0060282]; positive regulation of vascular permeability [GO:0043117]; regulation of meiotic nuclear division [GO:0040020]; response to cAMP [GO:0051591]; response to drug [GO:0042493]	3',5'-cyclic-AMP phosphodiesterase activity [GO:0004115]; 3',5'-cyclic-GMP phosphodiesterase activity [GO:0047555]; cAMP binding [GO:0030552]; cGMP-inhibited cyclic-nucleotide phosphodiesterase activity [GO:0004119]; metal ion binding [GO:0046872]	cytosol [GO:0005829]; integral component of membrane [GO:0016021]
Q13370	PDE3B_HUMAN	cGMP-inhibited 3',5'-cyclic phosphodiesterase B (EC 3.1.4.17) (CGIPDE1) (CGIP1) (Cyclic GMP-inhibited phosphodiesterase B) (CGI-PDE B)	PDE3B	1SO2;1SOJ;	CHEMBL290;	Q13370;	DB00201;		PF00233;	IPR003607;IPR002073;IPR023174;	angiogenesis [GO:0001525]; cAMP catabolic process [GO:0006198]; cellular response to insulin stimulus [GO:0032869]; negative regulation of angiogenesis [GO:0016525]; negative regulation of cAMP-mediated signaling [GO:0043951]; negative regulation of cell adhesion [GO:0007162]; negative regulation of cell adhesion mediated by integrin [GO:0033629]; negative regulation of lipid catabolic process [GO:0050995]; signal transduction [GO:0007165]	3',5'-cyclic-AMP phosphodiesterase activity [GO:0004115]; 3',5'-cyclic-GMP phosphodiesterase activity [GO:0047555]; 3',5'-cyclic-nucleotide phosphodiesterase activity [GO:0004114]; cGMP-inhibited cyclic-nucleotide phosphodiesterase activity [GO:0004119]; metal ion binding [GO:0046872]; protein kinase B binding [GO:0043422]	cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; Golgi apparatus [GO:0005794]; guanyl-nucleotide exchange factor complex [GO:0032045]; integral component of membrane [GO:0016021]; membrane [GO:0016020]
P27815	PDE4A_HUMAN	cAMP-specific 3',5'-cyclic phosphodiesterase 4A (EC 3.1.4.53) (DPDE2) (PDE46)	PDE4A DPDE2	2QYK;3I8V;3TVX;	CHEMBL254;	P27815;	DB05676;DB00201;DB00975;DB06751;DB00651;DB00824;DB05266;DB01088;DB00920;DB01303;DB00806;DB01656;DB00277;DB08811;	PATHWAY: Purine metabolism; 3',5'-cyclic AMP degradation; AMP from 3',5'-cyclic AMP: step 1/1.	PF00233;	IPR003607;IPR023088;IPR002073;IPR023174;	cAMP catabolic process [GO:0006198]; cellular response to drug [GO:0035690]; regulation of cAMP-mediated signaling [GO:0043949]; regulation of protein kinase A signaling [GO:0010738]; sensory perception of smell [GO:0007608]; signal transduction [GO:0007165]	3',5'-cyclic-AMP phosphodiesterase activity [GO:0004115]; cAMP binding [GO:0030552]; metal ion binding [GO:0046872]	cytosol [GO:0005829]; membrane [GO:0016020]; perinuclear region of cytoplasm [GO:0048471]; ruffle membrane [GO:0032587]
Q07343	PDE4B_HUMAN	cAMP-specific 3',5'-cyclic phosphodiesterase 4B (EC 3.1.4.53) (DPDE4) (PDE32)	PDE4B DPDE4	1F0J;1JP1;1JP2;1RO6;1RO9;1ROR;1TB5;1XLX;1XLZ;1XM4;1XM6;1XMU;1XMY;1XN0;1XOS;1XOT;1Y2H;1Y2J;2CHM;2QYL;3D3P;3FRG;3G45;3GWT;3HC8;3HDZ;3HMV;3KKT;3LY2;3O0J;3O56;3O57;3W5E;3WD9;4KP6;4MYQ;4NW7;4WZI;4X0F;	CHEMBL275;	Q07343;	DB00131;DB01427;DB05676;DB00201;DB00651;DB00824;DB05266;DB01088;DB00920;DB01113;DB00806;DB01656;DB01412;DB00277;	PATHWAY: Purine metabolism; 3',5'-cyclic AMP degradation; AMP from 3',5'-cyclic AMP: step 1/1.	PF00233;	IPR003607;IPR023088;IPR002073;IPR023174;	cAMP catabolic process [GO:0006198]; cellular response to drug [GO:0035690]; cellular response to epinephrine stimulus [GO:0071872]; cellular response to lipopolysaccharide [GO:0071222]; leukocyte migration [GO:0050900]; negative regulation of relaxation of cardiac muscle [GO:1901898]; neutrophil chemotaxis [GO:0030593]; neutrophil homeostasis [GO:0001780]; positive regulation of interferon-gamma production [GO:0032729]; positive regulation of interleukin-2 production [GO:0032743]; regulation of cardiac muscle cell contraction [GO:0086004]; regulation of high voltage-gated calcium channel activity [GO:1901841]; T cell receptor signaling pathway [GO:0050852]	3',5'-cyclic-AMP phosphodiesterase activity [GO:0004115]; cAMP binding [GO:0030552]; ion channel binding [GO:0044325]; metal ion binding [GO:0046872]	cell periphery [GO:0071944]; centrosome [GO:0005813]; cytosol [GO:0005829]; dendritic spine [GO:0043197]; gamma-tubulin complex [GO:0000930]; membrane [GO:0016020]; postsynaptic density [GO:0014069]; synaptic vesicle [GO:0008021]; Z disc [GO:0030018]
Q08493	PDE4C_HUMAN	cAMP-specific 3',5'-cyclic phosphodiesterase 4C (EC 3.1.4.53) (DPDE1) (PDE21)	PDE4C DPDE1	1LXU;2QYM;	CHEMBL291;	Q08493;	DB00201;DB00651;DB05266;DB01088;DB00920;DB01656;	PATHWAY: Purine metabolism; 3',5'-cyclic AMP degradation; AMP from 3',5'-cyclic AMP: step 1/1.	PF00233;	IPR003607;IPR023088;IPR002073;IPR023174;	cAMP catabolic process [GO:0006198]; signal transduction [GO:0007165]	3',5'-cyclic-AMP phosphodiesterase activity [GO:0004115]; metal ion binding [GO:0046872]	cytosol [GO:0005829]; extracellular space [GO:0005615]; primary cilium [GO:0072372]
Q08499	PDE4D_HUMAN	cAMP-specific 3',5'-cyclic phosphodiesterase 4D (EC 3.1.4.53) (DPDE3) (PDE43)	PDE4D DPDE3	1E9K;1MKD;1OYN;1PTW;1Q9M;1TB7;1TBB;1XOM;1XON;1XOQ;1XOR;1Y2B;1Y2C;1Y2D;1Y2E;1Y2K;1ZKN;2FM0;2FM5;2PW3;2QYN;3G4G;3G4I;3G4K;3G4L;3G58;3IAD;3IAK;3K4S;3SL3;3SL4;3SL5;3SL6;3SL8;3V9B;4OGB;4W1O;4WCU;	CHEMBL288;	Q08499;	DB00131;DB05676;DB00201;DB00651;DB05266;DB01088;DB00920;DB01656;	PATHWAY: Purine metabolism; 3',5'-cyclic AMP degradation; AMP from 3',5'-cyclic AMP: step 1/1.	PF00233;	IPR023088;IPR002073;IPR023174;	adrenergic receptor signaling pathway [GO:0071875]; adrenergic receptor signaling pathway involved in positive regulation of heart rate [GO:0086024]; aging [GO:0007568]; cAMP catabolic process [GO:0006198]; cAMP-mediated signaling [GO:0019933]; cellular response to cAMP [GO:0071320]; cellular response to epinephrine stimulus [GO:0071872]; cellular response to lipopolysaccharide [GO:0071222]; establishment of endothelial barrier [GO:0061028]; multicellular organism growth [GO:0035264]; negative regulation of heart contraction [GO:0045822]; negative regulation of peptidyl-serine phosphorylation [GO:0033137]; negative regulation of relaxation of cardiac muscle [GO:1901898]; neutrophil chemotaxis [GO:0030593]; positive regulation of interferon-gamma production [GO:0032729]; positive regulation of interleukin-2 production [GO:0032743]; positive regulation of interleukin-5 production [GO:0032754]; regulation of cAMP metabolic process [GO:0030814]; regulation of cardiac muscle cell contraction [GO:0086004]; regulation of cell communication by electrical coupling involved in cardiac conduction [GO:1901844]; regulation of heart rate [GO:0002027]; regulation of receptor activity [GO:0010469]; regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum [GO:0010880]; regulation of ryanodine-sensitive calcium-release channel activity [GO:0060314]; smooth muscle contraction [GO:0006939]; T cell receptor signaling pathway [GO:0050852]	3',5'-cyclic-AMP phosphodiesterase activity [GO:0004115]; 3',5'-cyclic-nucleotide phosphodiesterase activity [GO:0004114]; ATPase binding [GO:0051117]; beta-2 adrenergic receptor binding [GO:0031698]; cAMP binding [GO:0030552]; drug binding [GO:0008144]; enzyme binding [GO:0019899]; ion channel binding [GO:0044325]; metal ion binding [GO:0046872]; scaffold protein binding [GO:0097110]; ubiquitin protein ligase binding [GO:0031625]	apical plasma membrane [GO:0016324]; calcium channel complex [GO:0034704]; centrosome [GO:0005813]; cytosol [GO:0005829]; membrane [GO:0016020]; voltage-gated calcium channel complex [GO:0005891]
O76074	PDE5A_HUMAN	cGMP-specific 3',5'-cyclic phosphodiesterase (EC 3.1.4.35) (cGMP-binding cGMP-specific phosphodiesterase) (CGB-PDE)	PDE5A PDE5	1RKP;1T9R;1T9S;1TBF;1UDT;1UDU;1UHO;1XOZ;1XP0;2CHM;2H40;2H42;2H44;2XSS;3B2R;3BJC;3HC8;3HDZ;3JWQ;3JWR;3LFV;3MF0;3SHY;3SHZ;3SIE;3TGE;3TGG;4G2W;4G2Y;4I9Z;4IA0;4MD6;4OEW;4OEX;	CHEMBL1827;	O76074;	DB06237;DB00201;DB00975;DB00806;DB00203;DB00820;DB00277;DB06267;DB00862;	PATHWAY: Purine metabolism; 3',5'-cyclic GMP degradation; GMP from 3',5'-cyclic GMP: step 1/1.	PF01590;PF00233;	IPR003018;IPR029016;IPR003607;IPR023088;IPR002073;IPR023174;	cGMP catabolic process [GO:0046069]; negative regulation of cardiac muscle contraction [GO:0055118]; negative regulation of T cell proliferation [GO:0042130]; positive regulation of cardiac muscle hypertrophy [GO:0010613]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of oocyte development [GO:0060282]; regulation of cGMP metabolic process [GO:0030823]; relaxation of cardiac muscle [GO:0055119]; signal transduction [GO:0007165]	3',5'-cyclic-GMP phosphodiesterase activity [GO:0047555]; 3',5'-cyclic-nucleotide phosphodiesterase activity [GO:0004114]; cGMP binding [GO:0030553]; metal ion binding [GO:0046872]	cytosol [GO:0005829]
Q13946	PDE7A_HUMAN	High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A (EC 3.1.4.53) (HCP1) (TM22)	PDE7A	1ZKL;3G3N;4PM0;4Y2B;	CHEMBL3012;	Q13946;	DB00201;DB00651;DB00920;	PATHWAY: Purine metabolism; 3',5'-cyclic AMP degradation; AMP from 3',5'-cyclic AMP: step 1/1.	PF00233;	IPR003607;IPR023088;IPR002073;IPR023174;	cAMP catabolic process [GO:0006198]; signal transduction [GO:0007165]	3',5'-cyclic-AMP phosphodiesterase activity [GO:0004115]; metal ion binding [GO:0046872]	cytosol [GO:0005829]
Q9NP56	PDE7B_HUMAN	cAMP-specific 3',5'-cyclic phosphodiesterase 7B (EC 3.1.4.53)	PDE7B	1LXW;	CHEMBL4716;	Q9NP56;	DB00201;DB00651;DB00920;	PATHWAY: Purine metabolism; 3',5'-cyclic AMP degradation; AMP from 3',5'-cyclic AMP: step 1/1.	PF00233;	IPR003607;IPR023088;IPR002073;IPR023174;	cAMP catabolic process [GO:0006198]; chemical synaptic transmission [GO:0007268]; signal transduction [GO:0007165]	3',5'-cyclic-AMP phosphodiesterase activity [GO:0004115]; metal ion binding [GO:0046872]	cytosol [GO:0005829]
O76083	PDE9A_HUMAN	High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A (EC 3.1.4.35)	PDE9A	2HD1;2YY2;3DY8;3DYL;3DYN;3DYQ;3DYS;3JSI;3JSW;3K3E;3K3H;3N3Z;3QI3;3QI4;4E90;4G2J;4G2L;4GH6;4Y86;4Y87;4Y8C;	CHEMBL3535;	O76083;	DB00201;	PATHWAY: Purine metabolism; 3',5'-cyclic GMP degradation; GMP from 3',5'-cyclic GMP: step 1/1.	PF00233;	IPR003607;IPR023088;IPR002073;IPR023174;	cGMP catabolic process [GO:0046069]; cGMP-mediated signaling [GO:0019934]; cGMP metabolic process [GO:0046068]; positive regulation of cardiac muscle hypertrophy [GO:0010613]; signal transduction [GO:0007165]	3',5'-cyclic-GMP phosphodiesterase activity [GO:0047555]; 3',5'-cyclic-nucleotide phosphodiesterase activity [GO:0004114]; metal ion binding [GO:0046872]	cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; Golgi apparatus [GO:0005794]; perikaryon [GO:0043204]; perinuclear region of cytoplasm [GO:0048471]; ruffle membrane [GO:0032587]; sarcolemma [GO:0042383]
P07237	PDIA1_HUMAN	Protein disulfide-isomerase (PDI) (EC 5.3.4.1) (Cellular thyroid hormone-binding protein) (Prolyl 4-hydroxylase subunit beta) (p55)	P4HB ERBA2L PDI PDIA1 PO4DB	1BJX;1MEK;1X5C;2BJX;2K18;3BJ5;3UEM;4EKZ;4EL1;4JU5;	CHEMBL5422;	P07237;	DB03615;		PF00085;	IPR005788;IPR005792;IPR012336;IPR017937;IPR013766;	cell redox homeostasis [GO:0045454]; cellular response to hypoxia [GO:0071456]; lipoprotein biosynthetic process [GO:0042158]; peptidyl-proline hydroxylation to 4-hydroxy-L-proline [GO:0018401]; positive regulation of viral entry into host cell [GO:0046598]; regulation of oxidative stress-induced intrinsic apoptotic signaling pathway [GO:1902175]; response to endoplasmic reticulum stress [GO:0034976]; response to reactive oxygen species [GO:0000302]	integrin binding [GO:0005178]; poly(A) RNA binding [GO:0044822]; procollagen-proline 4-dioxygenase activity [GO:0004656]; protein disulfide isomerase activity [GO:0003756]; protein heterodimerization activity [GO:0046982]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum chaperone complex [GO:0034663]; endoplasmic reticulum-Golgi intermediate compartment [GO:0005793]; endoplasmic reticulum lumen [GO:0005788]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; extracellular matrix [GO:0031012]; extracellular region [GO:0005576]; focal adhesion [GO:0005925]; melanosome [GO:0042470]; procollagen-proline 4-dioxygenase complex [GO:0016222]
O15530	PDPK1_HUMAN	3-phosphoinositide-dependent protein kinase 1 (hPDK1) (EC 2.7.11.1)	PDPK1 PDK1	1H1W;1OKY;1OKZ;1UU3;1UU7;1UU8;1UU9;1UVR;1W1D;1W1G;1W1H;1Z5M;2BIY;2PE0;2PE1;2PE2;2R7B;2VKI;2XCH;2XCK;3H9O;3HRC;3HRF;3ION;3IOP;3NAX;3NAY;3NUN;3NUS;3NUU;3NUY;3ORX;3ORZ;3OTU;3PWY;3QC4;3QCQ;3QCS;3QCX;3QCY;3QD0;3QD3;3QD4;3RCJ;3RWP;3RWQ;3SC1;4A06;4A07;4AW0;4AW1;4CT1;4CT2;4RQK;4RQV;4RRV;4XX9;5ACK;5HKM;5HNG;5HO7;5HO8;	CHEMBL2534;	O15530;	DB00482;		PF00069;	IPR011009;IPR011993;IPR000719;IPR017441;IPR008271;	actin cytoskeleton organization [GO:0030036]; activation of protein kinase B activity [GO:0032148]; calcium-mediated signaling [GO:0019722]; cell migration [GO:0016477]; cellular response to brain-derived neurotrophic factor stimulus [GO:1990416]; cellular response to epidermal growth factor stimulus [GO:0071364]; cellular response to insulin stimulus [GO:0032869]; epidermal growth factor receptor signaling pathway [GO:0007173]; extrinsic apoptotic signaling pathway [GO:0097191]; Fc-epsilon receptor signaling pathway [GO:0038095]; focal adhesion assembly [GO:0048041]; hyperosmotic response [GO:0006972]; intracellular signal transduction [GO:0035556]; negative regulation of cardiac muscle cell apoptotic process [GO:0010667]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of protein kinase activity [GO:0006469]; negative regulation of toll-like receptor signaling pathway [GO:0034122]; negative regulation of transforming growth factor beta receptor signaling pathway [GO:0030512]; peptidyl-serine phosphorylation [GO:0018105]; peptidyl-threonine phosphorylation [GO:0018107]; phosphatidylinositol-mediated signaling [GO:0048015]; platelet activation [GO:0030168]; positive regulation of establishment of protein localization to plasma membrane [GO:0090004]; positive regulation of phospholipase activity [GO:0010518]; positive regulation of release of sequestered calcium ion into cytosol [GO:0051281]; protein autophosphorylation [GO:0046777]; protein phosphorylation [GO:0006468]; regulation of endothelial cell migration [GO:0010594]; regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043122]; regulation of mast cell degranulation [GO:0043304]; regulation of transcription, DNA-templated [GO:0006355]; stimulatory C-type lectin receptor signaling pathway [GO:0002223]; T cell costimulation [GO:0031295]; T cell receptor signaling pathway [GO:0050852]; transcription, DNA-templated [GO:0006351]; type B pancreatic cell development [GO:0003323]	3-phosphoinositide-dependent protein kinase activity [GO:0004676]; ATP binding [GO:0005524]; kinase activity [GO:0016301]; phospholipase activator activity [GO:0016004]; phospholipase binding [GO:0043274]; protein serine/threonine kinase activity [GO:0004674]	cell projection [GO:0042995]; cytoplasm [GO:0005737]; cytoplasmic, membrane-bounded vesicle [GO:0016023]; cytosol [GO:0005829]; focal adhesion [GO:0005925]; nucleoplasm [GO:0005654]; perikaryon [GO:0043204]; plasma membrane [GO:0005886]
O00764	PDXK_HUMAN	Pyridoxal kinase (EC 2.7.1.35) (Pyridoxine kinase)	PDXK C21orf124 C21orf97 PKH PNK PRED79	2AJP;2F7K;2YXT;2YXU;3FHX;3FHY;3KEU;4EN4;4EOH;	CHEMBL1075181;	O00764;	DB00147;DB00165;		PF08543;	IPR013749;IPR004625;IPR029056;	cell proliferation [GO:0008283]; pyridoxal 5'-phosphate salvage [GO:0009443]; pyridoxal phosphate biosynthetic process [GO:0042823]; vitamin B6 metabolic process [GO:0042816]	ATP binding [GO:0005524]; lithium ion binding [GO:0031403]; magnesium ion binding [GO:0000287]; potassium ion binding [GO:0030955]; protein homodimerization activity [GO:0042803]; pyridoxal kinase activity [GO:0008478]; pyridoxal phosphate binding [GO:0030170]; sodium ion binding [GO:0031402]; zinc ion binding [GO:0008270]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P01213	PDYN_HUMAN	Proenkephalin-B (Beta-neoendorphin-dynorphin) (Preprodynorphin) [Cleaved into: Alpha-neoendorphin; Beta-neoendorphin; Big dynorphin (Big Dyn); Dynorphin A(1-17) (Dyn-A17) (Dynorphin A); Dynorphin A(1-13); Dynorphin A(1-8); Leu-enkephalin; Rimorphin (Dynorphin B) (Dyn-B) (Dynorphin B(1-13)); Leumorphin (Dynorphin B-29)]	PDYN	2N2F;	CHEMBL2227;	P01213;			PF01160;	IPR006024;IPR000750;	chemical synaptic transmission [GO:0007268]; neuropeptide signaling pathway [GO:0007218]; sensory perception [GO:0007600]	neuropeptide hormone activity [GO:0005184]; opioid receptor binding [GO:0031628]	axon terminus [GO:0043679]; dendrite [GO:0030425]; extracellular region [GO:0005576]; neuronal cell body [GO:0043025]; plasma membrane [GO:0005886]
P34995	PE2R1_HUMAN	Prostaglandin E2 receptor EP1 subtype (PGE receptor EP1 subtype) (PGE2 receptor EP1 subtype) (Prostanoid EP1 receptor)	PTGER1		CHEMBL1811;	P34995;	DB00770;DB00905;DB00297;DB00429;DB00917;DB01088;		PF00001;	IPR000276;IPR017452;IPR008365;IPR001244;IPR000708;	adenylate cyclase-activating G-protein coupled receptor signaling pathway [GO:0007189]; G-protein coupled receptor signaling pathway [GO:0007186]; inflammatory response [GO:0006954]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; response to lipopolysaccharide [GO:0032496]	prostaglandin E receptor activity [GO:0004957]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P43116	PE2R2_HUMAN	Prostaglandin E2 receptor EP2 subtype (PGE receptor EP2 subtype) (PGE2 receptor EP2 subtype) (Prostanoid EP2 receptor)	PTGER2		CHEMBL1881;	P43116;	DB00770;DB00917;DB00929;		PF00001;	IPR000276;IPR017452;IPR008365;IPR001923;	adenylate cyclase-activating G-protein coupled receptor signaling pathway [GO:0007189]; cellular response to prostaglandin E stimulus [GO:0071380]; G-protein coupled receptor signaling pathway [GO:0007186]; inflammatory response [GO:0006954]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; regulation of cell proliferation [GO:0042127]; response to lipopolysaccharide [GO:0032496]; response to progesterone [GO:0032570]	prostaglandin E receptor activity [GO:0004957]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P43115	PE2R3_HUMAN	Prostaglandin E2 receptor EP3 subtype (PGE receptor EP3 subtype) (PGE2 receptor EP3 subtype) (PGE2-R) (Prostanoid EP3 receptor)	PTGER3		CHEMBL3710;	P43115;	DB00905;DB00917;DB00929;		PF00001;	IPR001481;IPR000276;IPR017452;IPR008365;IPR001244;IPR000265;	cell death [GO:0008219]; G-protein coupled receptor signaling pathway [GO:0007186]; inflammatory response [GO:0006954]; intestine smooth muscle contraction [GO:0014827]; negative regulation of gastric acid secretion [GO:0060455]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of fever generation [GO:0031622]	prostaglandin E receptor activity [GO:0004957]	integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; nuclear envelope [GO:0005635]; plasma membrane [GO:0005886]
P35408	PE2R4_HUMAN	Prostaglandin E2 receptor EP4 subtype (PGE receptor EP4 subtype) (PGE2 receptor EP4 subtype) (Prostanoid EP4 receptor)	PTGER4 PTGER2		CHEMBL1836;	P35408;	DB00917;DB00929;		PF00001;	IPR000276;IPR017452;IPR001758;IPR008365;IPR001244;	adenylate cyclase-activating G-protein coupled receptor signaling pathway [GO:0007189]; adenylate cyclase-modulating G-protein coupled receptor signaling pathway [GO:0007188]; bone development [GO:0060348]; cellular response to mechanical stimulus [GO:0071260]; cellular response to prostaglandin E stimulus [GO:0071380]; ERK1 and ERK2 cascade [GO:0070371]; immune response [GO:0006955]; JNK cascade [GO:0007254]; negative regulation of cytokine secretion [GO:0050710]; negative regulation of eosinophil extravasation [GO:2000420]; negative regulation of inflammatory response [GO:0050728]; negative regulation of integrin activation [GO:0033624]; positive regulation of cytokine secretion [GO:0050715]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of inflammatory response [GO:0050729]; regulation of ossification [GO:0030278]; regulation of stress fiber assembly [GO:0051492]; response to lipopolysaccharide [GO:0032496]; response to mechanical stimulus [GO:0009612]; T-helper cell differentiation [GO:0042093]	prostaglandin E receptor activity [GO:0004957]	integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; intracellular [GO:0005622]; plasma membrane [GO:0005886]
P30086	PEBP1_HUMAN	Phosphatidylethanolamine-binding protein 1 (PEBP-1) (HCNPpp) (Neuropolypeptide h3) (Prostatic-binding protein) (Raf kinase inhibitor protein) (RKIP) [Cleaved into: Hippocampal cholinergic neurostimulating peptide (HCNP)]	PEBP1 PBP PEBP	1BD9;1BEH;2L7W;2QYQ;					PF01161;	IPR008914;IPR001858;	MAPK cascade [GO:0000165]	ATP binding [GO:0005524]; enzyme binding [GO:0019899]; phosphatidylethanolamine binding [GO:0008429]; poly(A) RNA binding [GO:0044822]; protein kinase binding [GO:0019901]; serine-type endopeptidase inhibitor activity [GO:0004867]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleus [GO:0005634]
Q9BY49	PECR_HUMAN	Peroxisomal trans-2-enoyl-CoA reductase (TERP) (EC 1.3.1.38) (2,4-dienoyl-CoA reductase-related protein) (DCR-RP) (HPDHase) (Short chain dehydrogenase/reductase family 29C member 1) (pVI-ARL)	PECR SDR29C1 PRO1004	1YXM;			DB00173;	PATHWAY: Lipid metabolism; fatty acid biosynthesis.		IPR016040;IPR002347;	cellular lipid metabolic process [GO:0044255]; fatty acid biosynthetic process [GO:0006633]; oxidation-reduction process [GO:0055114]; phytol metabolic process [GO:0033306]	receptor binding [GO:0005102]; trans-2-enoyl-CoA reductase (NADPH) activity [GO:0019166]	intracellular membrane-bounded organelle [GO:0043231]; mitochondrion [GO:0005739]; peroxisomal membrane [GO:0005778]; peroxisome [GO:0005777]
P05164	PERM_HUMAN	Myeloperoxidase (MPO) (EC 1.11.2.2) [Cleaved into: Myeloperoxidase; 89 kDa myeloperoxidase; 84 kDa myeloperoxidase; Myeloperoxidase light chain; Myeloperoxidase heavy chain]	MPO	1CXP;1D2V;1D5L;1D7W;1DNU;1DNW;1MHL;1MYP;3F9P;3ZS0;3ZS1;4C1M;4DL1;4EJX;5FIW;	CHEMBL2439;	P05164;	DB00233;DB00006;DB02300;DB06774;DB00958;DB00833;DB00535;DB00515;DB00847;DB00250;DB01225;DB00062;DB00583;DB01065;DB00244;DB00461;DB00104;DB00526;DB00550;DB00208;DB06823;DB00500;		PF03098;	IPR010255;IPR019791;IPR029609;	aging [GO:0007568]; defense response [GO:0006952]; defense response to bacterium [GO:0042742]; defense response to fungus [GO:0050832]; hydrogen peroxide catabolic process [GO:0042744]; hypochlorous acid biosynthetic process [GO:0002149]; low-density lipoprotein particle remodeling [GO:0034374]; negative regulation of apoptotic process [GO:0043066]; negative regulation of growth of symbiont in host [GO:0044130]; oxidation-reduction process [GO:0055114]; removal of superoxide radicals [GO:0019430]; respiratory burst involved in defense response [GO:0002679]; response to food [GO:0032094]; response to gold nanoparticle [GO:1990268]; response to lipopolysaccharide [GO:0032496]; response to mechanical stimulus [GO:0009612]; response to oxidative stress [GO:0006979]; response to yeast [GO:0001878]	chromatin binding [GO:0003682]; heme binding [GO:0020037]; heparin binding [GO:0008201]; metal ion binding [GO:0046872]; peroxidase activity [GO:0004601]	azurophil granule [GO:0042582]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; lysosome [GO:0005764]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; secretory granule [GO:0030141]
P07202	PERT_HUMAN	Thyroid peroxidase (TPO) (EC 1.11.1.8)	TPO		CHEMBL1839;		DB00389;DB00509;DB00763;DB00550;	PATHWAY: Hormone biosynthesis; thyroid hormone biosynthesis.	PF03098;PF07645;PF00084;	IPR001881;IPR013032;IPR000742;IPR000152;IPR018097;IPR010255;IPR019791;IPR000436;IPR029589;	embryonic hemopoiesis [GO:0035162]; hormone biosynthetic process [GO:0042446]; hydrogen peroxide catabolic process [GO:0042744]; response to oxidative stress [GO:0006979]; thyroid hormone generation [GO:0006590]	calcium ion binding [GO:0005509]; heme binding [GO:0020037]; iodide peroxidase activity [GO:0004447]; peroxidase activity [GO:0004601]	cell surface [GO:0009986]; extracellular space [GO:0005615]; integral component of plasma membrane [GO:0005887]; mitochondrion [GO:0005739]; plasma membrane [GO:0005886]
P43088	PF2R_HUMAN	Prostaglandin F2-alpha receptor (PGF receptor) (PGF2-alpha receptor) (Prostanoid FP receptor)	PTGFR		CHEMBL1987;	P43088;	DB00905;DB01160;DB00654;DB08819;DB00287;		PF00001;	IPR000276;IPR017452;IPR000141;IPR008365;	adenylate cyclase-activating G-protein coupled receptor signaling pathway [GO:0007189]; calcium-mediated signaling using intracellular calcium source [GO:0035584]; cellular response to prostaglandin D stimulus [GO:0071799]; G-protein coupled receptor signaling pathway [GO:0007186]; inflammatory response [GO:0006954]; negative regulation of apoptotic process [GO:0043066]; parturition [GO:0007567]; positive regulation of cell proliferation [GO:0008284]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of gene expression [GO:0010628]; response to estradiol [GO:0032355]; response to lipopolysaccharide [GO:0032496]	prostaglandin F receptor activity [GO:0004958]	cytoplasm [GO:0005737]; extracellular region [GO:0005576]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P15428	PGDH_HUMAN	15-hydroxyprostaglandin dehydrogenase [NAD(+)] (15-PGDH) (EC 1.1.1.141) (Prostaglandin dehydrogenase 1) (Short chain dehydrogenase/reductase family 36C member 1)	HPGD PGDH1 SDR36C1	2GDZ;	CHEMBL1293255;	P15428;			PF00106;	IPR016040;IPR020904;IPR002347;	ductus arteriosus closure [GO:0097070]; female pregnancy [GO:0007565]; lipoxin metabolic process [GO:2001300]; lipoxygenase pathway [GO:0019372]; negative regulation of cell cycle [GO:0045786]; ovulation [GO:0030728]; parturition [GO:0007567]; prostaglandin metabolic process [GO:0006693]; thrombin receptor signaling pathway [GO:0070493]; transforming growth factor beta receptor signaling pathway [GO:0007179]	15-hydroxyprostaglandin dehydrogenase (NAD+) activity [GO:0016404]; catalytic activity [GO:0003824]; NAD+ binding [GO:0070403]; NAD binding [GO:0051287]; prostaglandin E receptor activity [GO:0004957]; protein homodimerization activity [GO:0042803]	basolateral plasma membrane [GO:0016323]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleoplasm [GO:0005654]
P16234	PGFRA_HUMAN	Platelet-derived growth factor receptor alpha (PDGF-R-alpha) (PDGFR-alpha) (EC 2.7.10.1) (Alpha platelet-derived growth factor receptor) (Alpha-type platelet-derived growth factor receptor) (CD140 antigen-like family member A) (CD140a antigen) (Platelet-derived growth factor alpha receptor) (Platelet-derived growth factor receptor 2) (PDGFR-2) (CD antigen CD140a)	PDGFRA PDGFR2 RHEPDGFRA	1GQ5;5K5X;	CHEMBL2007;	P16234;	DB00102;DB00619;DB06589;DB08901;DB08896;DB01268;		PF07679;PF07714;	IPR007110;IPR013783;IPR013098;IPR003599;IPR003598;IPR011009;IPR027290;IPR000719;IPR017441;IPR001245;IPR008266;IPR020635;IPR016243;IPR001824;	cardiac myofibril assembly [GO:0055003]; cell activation [GO:0001775]; cell chemotaxis [GO:0060326]; cellular response to reactive oxygen species [GO:0034614]; embryonic cranial skeleton morphogenesis [GO:0048701]; embryonic digestive tract morphogenesis [GO:0048557]; embryonic skeletal system morphogenesis [GO:0048704]; luteinization [GO:0001553]; MAPK cascade [GO:0000165]; metanephric glomerular capillary formation [GO:0072277]; negative regulation of platelet activation [GO:0010544]; peptidyl-tyrosine phosphorylation [GO:0018108]; phosphatidylinositol-mediated signaling [GO:0048015]; platelet aggregation [GO:0070527]; platelet-derived growth factor receptor-alpha signaling pathway [GO:0035790]; platelet-derived growth factor receptor signaling pathway [GO:0048008]; positive regulation of cell migration [GO:0030335]; positive regulation of cell proliferation [GO:0008284]; positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway [GO:0038091]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of DNA replication [GO:0045740]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of fibroblast proliferation [GO:0048146]; positive regulation of phosphatidylinositol 3-kinase activity [GO:0043552]; positive regulation of phosphatidylinositol 3-kinase signaling [GO:0014068]; positive regulation of phospholipase C activity [GO:0010863]; protein autophosphorylation [GO:0046777]; regulation of actin cytoskeleton reorganization [GO:2000249]; regulation of chemotaxis [GO:0050920]; regulation of mesenchymal stem cell differentiation [GO:2000739]; regulation of phosphatidylinositol 3-kinase signaling [GO:0014066]; retina vasculature development in camera-type eye [GO:0061298]; viral process [GO:0016032]; wound healing [GO:0042060]	ATP binding [GO:0005524]; phosphatidylinositol-4,5-bisphosphate 3-kinase activity [GO:0046934]; platelet-derived growth factor alpha-receptor activity [GO:0005018]; platelet-derived growth factor binding [GO:0048407]; platelet-derived growth factor receptor binding [GO:0005161]; protein homodimerization activity [GO:0042803]; protein kinase activity [GO:0004672]; Ras guanyl-nucleotide exchange factor activity [GO:0005088]; transmembrane receptor protein tyrosine kinase activity [GO:0004714]; vascular endothelial growth factor-activated receptor activity [GO:0005021]; vascular endothelial growth factor binding [GO:0038085]	cytoplasm [GO:0005737]; integral component of plasma membrane [GO:0005887]; intrinsic component of plasma membrane [GO:0031226]; membrane [GO:0016020]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; protein complex [GO:0043234]
P09619	PGFRB_HUMAN	Platelet-derived growth factor receptor beta (PDGF-R-beta) (PDGFR-beta) (EC 2.7.10.1) (Beta platelet-derived growth factor receptor) (Beta-type platelet-derived growth factor receptor) (CD140 antigen-like family member B) (Platelet-derived growth factor receptor 1) (PDGFR-1) (CD antigen CD140b)	PDGFRB PDGFR PDGFR1	1GQ5;1H9O;1LWP;1SHA;2L6W;2PLD;2PLE;3MJG;	CHEMBL1913;	P09619;	DB00102;DB01254;DB00619;DB06589;DB08896;DB00398;DB01268;		PF07679;PF00047;PF07714;	IPR007110;IPR013783;IPR013098;IPR003599;IPR003598;IPR013151;IPR011009;IPR027288;IPR000719;IPR017441;IPR001245;IPR008266;IPR020635;IPR016243;IPR001824;	aorta morphogenesis [GO:0035909]; cardiac myofibril assembly [GO:0055003]; cell chemotaxis [GO:0060326]; cell migration [GO:0016477]; cell migration involved in coronary angiogenesis [GO:0060981]; cell migration involved in vasculogenesis [GO:0035441]; glycosaminoglycan biosynthetic process [GO:0006024]; inner ear development [GO:0048839]; MAPK cascade [GO:0000165]; metanephric comma-shaped body morphogenesis [GO:0072278]; metanephric glomerular capillary formation [GO:0072277]; metanephric glomerular mesangial cell proliferation involved in metanephros development [GO:0072262]; metanephric mesenchymal cell migration [GO:0035789]; metanephric mesenchyme development [GO:0072075]; metanephric S-shaped body morphogenesis [GO:0072284]; negative regulation of apoptotic process [GO:0043066]; peptidyl-tyrosine phosphorylation [GO:0018108]; phosphatidylinositol-mediated signaling [GO:0048015]; phosphatidylinositol metabolic process [GO:0046488]; platelet-derived growth factor receptor-beta signaling pathway [GO:0035791]; platelet-derived growth factor receptor signaling pathway [GO:0048008]; positive regulation of apoptotic process [GO:0043065]; positive regulation of calcium ion import [GO:0090280]; positive regulation of cell migration [GO:0030335]; positive regulation of cell proliferation [GO:0008284]; positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway [GO:0038091]; positive regulation of chemotaxis [GO:0050921]; positive regulation of collagen biosynthetic process [GO:0032967]; positive regulation of DNA biosynthetic process [GO:2000573]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of fibroblast proliferation [GO:0048146]; positive regulation of hepatic stellate cell activation [GO:2000491]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway [GO:0035793]; positive regulation of mitotic nuclear division [GO:0045840]; positive regulation of phosphatidylinositol 3-kinase activity [GO:0043552]; positive regulation of phosphatidylinositol 3-kinase signaling [GO:0014068]; positive regulation of phospholipase C activity [GO:0010863]; positive regulation of phosphoprotein phosphatase activity [GO:0032516]; positive regulation of reactive oxygen species metabolic process [GO:2000379]; positive regulation of Rho protein signal transduction [GO:0035025]; positive regulation of smooth muscle cell migration [GO:0014911]; positive regulation of smooth muscle cell proliferation [GO:0048661]; protein autophosphorylation [GO:0046777]; regulation of actin cytoskeleton organization [GO:0032956]; regulation of phosphatidylinositol 3-kinase signaling [GO:0014066]; response to estradiol [GO:0032355]; response to estrogen [GO:0043627]; response to fluid shear stress [GO:0034405]; response to hydrogen peroxide [GO:0042542]; response to hyperoxia [GO:0055093]; response to retinoic acid [GO:0032526]; response to toxic substance [GO:0009636]; retina vasculature development in camera-type eye [GO:0061298]; signal transduction [GO:0007165]; smooth muscle cell chemotaxis [GO:0071670]; wound healing [GO:0042060]	ATP binding [GO:0005524]; enzyme binding [GO:0019899]; phosphatidylinositol-4,5-bisphosphate 3-kinase activity [GO:0046934]; platelet activating factor receptor activity [GO:0004992]; platelet-derived growth factor-activated receptor activity [GO:0005017]; platelet-derived growth factor beta-receptor activity [GO:0005019]; platelet-derived growth factor binding [GO:0048407]; platelet-derived growth factor receptor binding [GO:0005161]; protein kinase binding [GO:0019901]; protein tyrosine kinase activity [GO:0004713]; Ras guanyl-nucleotide exchange factor activity [GO:0005088]; receptor binding [GO:0005102]; vascular endothelial growth factor binding [GO:0038085]	apical plasma membrane [GO:0016324]; cell surface [GO:0009986]; cytoplasm [GO:0005737]; cytoplasmic, membrane-bounded vesicle [GO:0016023]; extracellular exosome [GO:0070062]; focal adhesion [GO:0005925]; integral component of membrane [GO:0016021]; intrinsic component of plasma membrane [GO:0031226]; lysosomal lumen [GO:0043202]; membrane [GO:0016020]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
P23219	PGH1_HUMAN	Prostaglandin G/H synthase 1 (EC 1.14.99.1) (Cyclooxygenase-1) (COX-1) (Prostaglandin H2 synthase 1) (PGH synthase 1) (PGHS-1) (PHS 1) (Prostaglandin-endoperoxide synthase 1)	PTGS1 COX1		CHEMBL221;	P23219;	DB00316;DB00945;DB01435;DB01419;DB01014;DB00188;DB00963;DB00796;DB00821;DB01136;DB00672;DB00250;DB00035;DB00829;DB00586;DB00711;DB00861;DB00154;DB01075;DB00470;DB00216;DB00402;DB00749;DB00773;DB00573;DB00712;DB01355;DB00327;DB01050;DB00159;DB01181;DB00619;DB00328;DB01029;DB01221;DB06738;DB01009;DB00465;DB06725;DB01283;DB01397;DB00939;DB00784;DB00814;DB00244;DB00350;DB00471;DB00461;DB00788;DB00731;DB06802;DB04552;DB00540;DB00991;DB00812;DB01132;DB00554;DB00412;DB00936;DB01399;DB01015;DB00795;DB00605;DB00870;DB00469;DB00857;DB01041;DB01600;DB00500;DB00214;DB05109;DB08814;DB01401;DB00313;DB00582;DB00549;DB00744;DB00425;DB01198;	PATHWAY: Lipid metabolism; prostaglandin biosynthesis.	PF03098;PF00008;	IPR029580;IPR000742;IPR010255;IPR019791;	cyclooxygenase pathway [GO:0019371]; inflammatory response [GO:0006954]; lipid metabolic process [GO:0006629]; prostaglandin biosynthetic process [GO:0001516]; regulation of blood pressure [GO:0008217]; regulation of cell proliferation [GO:0042127]; response to oxidative stress [GO:0006979]; xenobiotic metabolic process [GO:0006805]	dioxygenase activity [GO:0051213]; heme binding [GO:0020037]; metal ion binding [GO:0046872]; peroxidase activity [GO:0004601]; prostaglandin-endoperoxide synthase activity [GO:0004666]	cytoplasm [GO:0005737]; endoplasmic reticulum membrane [GO:0005789]; extracellular exosome [GO:0070062]; Golgi apparatus [GO:0005794]; intracellular membrane-bounded organelle [GO:0043231]; nucleus [GO:0005634]; organelle membrane [GO:0031090]; photoreceptor outer segment [GO:0001750]
P35354	PGH2_HUMAN	Prostaglandin G/H synthase 2 (EC 1.14.99.1) (Cyclooxygenase-2) (COX-2) (PHS II) (Prostaglandin H2 synthase 2) (PGH synthase 2) (PGHS-2) (Prostaglandin-endoperoxide synthase 2)	PTGS2 COX2	1V0X;5F19;5F1A;5IKQ;5IKR;5IKT;5IKV;	CHEMBL230;	P35354;	DB00316;DB00945;DB00041;DB00233;DB01435;DB01419;DB01014;DB00963;DB00887;DB06774;DB00821;DB00482;DB00856;DB00515;DB00720;DB00250;DB00035;DB00586;DB00861;DB00154;DB01395;DB00005;DB00749;DB00773;DB01628;DB00573;DB00712;DB01404;DB01050;DB00159;DB00328;DB01009;DB00465;DB00480;DB06725;DB01283;DB01397;DB00939;DB00784;DB00814;DB00244;DB00461;DB00788;DB06802;DB04552;DB04743;DB06804;DB00991;DB08439;DB00812;DB00554;DB08910;DB00884;DB00936;DB01399;DB00795;DB00605;DB00870;DB08819;DB00469;DB00360;DB01041;DB01600;DB00500;DB00620;DB01401;	PATHWAY: Lipid metabolism; prostaglandin biosynthesis.	PF03098;PF00008;	IPR029576;IPR000742;IPR010255;IPR019791;	angiogenesis [GO:0001525]; bone mineralization [GO:0030282]; brown fat cell differentiation [GO:0050873]; cellular response to ATP [GO:0071318]; cellular response to fluid shear stress [GO:0071498]; cellular response to hypoxia [GO:0071456]; cellular response to mechanical stimulus [GO:0071260]; cellular response to UV [GO:0034644]; cyclooxygenase pathway [GO:0019371]; decidualization [GO:0046697]; embryo implantation [GO:0007566]; hair cycle [GO:0042633]; inflammatory response [GO:0006954]; learning [GO:0007612]; lipoxygenase pathway [GO:0019372]; maintenance of blood-brain barrier [GO:0035633]; memory [GO:0007613]; movement of cell or subcellular component [GO:0006928]; negative regulation of calcium ion transport [GO:0051926]; negative regulation of cell cycle [GO:0045786]; negative regulation of cell proliferation [GO:0008285]; negative regulation of smooth muscle contraction [GO:0045986]; negative regulation of synaptic transmission, dopaminergic [GO:0032227]; nicotinamide metabolic process [GO:0006769]; ovulation [GO:0030728]; positive regulation of apoptotic process [GO:0043065]; positive regulation of brown fat cell differentiation [GO:0090336]; positive regulation of cell migration involved in sprouting angiogenesis [GO:0090050]; positive regulation of fever generation [GO:0031622]; positive regulation of fibroblast growth factor production [GO:0090271]; positive regulation of NF-kappaB import into nucleus [GO:0042346]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; positive regulation of platelet-derived growth factor production [GO:0090362]; positive regulation of prostaglandin biosynthetic process [GO:0031394]; positive regulation of smooth muscle cell proliferation [GO:0048661]; positive regulation of smooth muscle contraction [GO:0045987]; positive regulation of synaptic plasticity [GO:0031915]; positive regulation of synaptic transmission, glutamatergic [GO:0051968]; positive regulation of transforming growth factor beta production [GO:0071636]; positive regulation of vascular endothelial growth factor production [GO:0010575]; positive regulation of vasoconstriction [GO:0045907]; prostaglandin biosynthetic process [GO:0001516]; prostaglandin metabolic process [GO:0006693]; regulation of blood pressure [GO:0008217]; regulation of inflammatory response [GO:0050727]; response to drug [GO:0042493]; response to estradiol [GO:0032355]; response to fatty acid [GO:0070542]; response to fructose [GO:0009750]; response to glucocorticoid [GO:0051384]; response to lipopolysaccharide [GO:0032496]; response to lithium ion [GO:0010226]; response to manganese ion [GO:0010042]; response to oxidative stress [GO:0006979]; response to tumor necrosis factor [GO:0034612]; response to vitamin D [GO:0033280]; sensory perception of pain [GO:0019233]	arachidonate 15-lipoxygenase activity [GO:0050473]; enzyme binding [GO:0019899]; heme binding [GO:0020037]; lipid binding [GO:0008289]; metal ion binding [GO:0046872]; peroxidase activity [GO:0004601]; prostaglandin-endoperoxide synthase activity [GO:0004666]	caveola [GO:0005901]; cytoplasm [GO:0005737]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum lumen [GO:0005788]; endoplasmic reticulum membrane [GO:0005789]; neuron projection [GO:0043005]; nucleus [GO:0005634]; organelle membrane [GO:0031090]; protein complex [GO:0043234]
P53609	PGT1_HUMAN	Geranylgeranyl transferase type-1 subunit beta (EC 2.5.1.59) (Geranylgeranyl transferase type I subunit beta) (GGTase-I-beta) (Type I protein geranyl-geranyltransferase subunit beta)	PGGT1B		CHEMBL4135;	P53609;			PF00432;	IPR001330;IPR008930;	negative regulation of nitric-oxide synthase biosynthetic process [GO:0051771]; positive regulation of cell cycle [GO:0045787]; positive regulation of cell proliferation [GO:0008284]; protein geranylgeranylation [GO:0018344]; response to cytokine [GO:0034097]	CAAX-protein geranylgeranyltransferase activity [GO:0004662]; drug binding [GO:0008144]; isoprenoid binding [GO:0019840]; peptide binding [GO:0042277]; protein geranylgeranyltransferase activity [GO:0004661]; zinc ion binding [GO:0008270]	CAAX-protein geranylgeranyltransferase complex [GO:0005953]
P00439	PH4H_HUMAN	Phenylalanine-4-hydroxylase (PAH) (EC 1.14.16.1) (Phe-4-monooxygenase)	PAH	1DMW;1J8T;1J8U;1KW0;1LRM;1MMK;1MMT;1PAH;1TDW;1TG2;2PAH;3PAH;4ANP;4PAH;5FII;5PAH;6PAH;	CHEMBL3076;	P00439;	DB06262;DB00668;DB00120;DB00368;DB00360;	PATHWAY: Amino-acid degradation; L-phenylalanine degradation; acetoacetate and fumarate from L-phenylalanine: step 1/6.	PF01842;PF00351;	IPR002912;IPR001273;IPR018301;IPR019774;IPR005961;IPR019773;	aromatic amino acid family metabolic process [GO:0009072]; catecholamine biosynthetic process [GO:0042423]; cellular amino acid biosynthetic process [GO:0008652]; L-phenylalanine catabolic process [GO:0006559]; neurotransmitter biosynthetic process [GO:0042136]	amino acid binding [GO:0016597]; iron ion binding [GO:0005506]; phenylalanine 4-monooxygenase activity [GO:0004505]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]
Q8TCT1	PHOP1_HUMAN	Phosphoethanolamine/phosphocholine phosphatase (EC 3.1.3.75)	PHOSPHO1		CHEMBL6113;	Q8TCT1;	DB00122;		PF06888;	IPR023214;IPR006383;IPR016965;IPR006384;	bone mineralization involved in bone maturation [GO:0035630]; endochondral ossification [GO:0001958]; phosphatidylcholine biosynthetic process [GO:0006656]; phosphatidylethanolamine biosynthetic process [GO:0006646]; regulation of bone mineralization [GO:0030500]	metal ion binding [GO:0046872]; phosphatase activity [GO:0016791]; phosphocholine phosphatase activity [GO:0052731]; phosphoethanolamine phosphatase activity [GO:0052732]; pyrophosphatase activity [GO:0016462]	cytosol [GO:0005829]; extracellular membrane-bounded organelle [GO:0065010]; proteinaceous extracellular matrix [GO:0005578]
P43119	PI2R_HUMAN	Prostacyclin receptor (Prostaglandin I2 receptor) (PGI receptor) (PGI2 receptor) (Prostanoid IP receptor)	PTGIR PRIPR		CHEMBL1995;	P43119;	DB01160;DB01240;DB01088;DB11362;DB00374;		PF00001;	IPR000276;IPR017452;IPR008365;IPR000370;	adenylate cyclase-activating G-protein coupled receptor signaling pathway [GO:0007189]; cell-cell signaling [GO:0007267]; cellular response to prostaglandin D stimulus [GO:0071799]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; inflammatory response [GO:0006954]; negative regulation of platelet-derived growth factor receptor signaling pathway [GO:0010642]; negative regulation of smooth muscle cell proliferation [GO:0048662]; positive regulation of cAMP biosynthetic process [GO:0030819]; positive regulation of cAMP-mediated signaling [GO:0043950]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; response to lipopolysaccharide [GO:0032496]	guanyl-nucleotide exchange factor activity [GO:0005085]; prostacyclin receptor activity [GO:0016501]	cytosol [GO:0005829]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P11309	PIM1_HUMAN	Serine/threonine-protein kinase pim-1 (EC 2.7.11.1)	PIM1	1XQZ;1XR1;1XWS;1YHS;1YI3;1YI4;1YWV;1YXS;1YXT;1YXU;1YXV;1YXX;2BIK;2BIL;2BZH;2BZI;2BZJ;2BZK;2C3I;2J2I;2O3P;2O63;2O64;2O65;2OBJ;2OI4;2XIX;2XIY;2XIZ;2XJ0;2XJ1;2XJ2;3A99;3BGP;3BGQ;3BGZ;3BWF;3C4E;3CXW;3CY2;3CY3;3DCV;3F2A;3JPV;3JXW;3JY0;3JYA;3MA3;3QF9;3R00;3R01;3R02;3R04;3T9I;3UIX;3UMW;3UMX;3VBQ;3VBT;3VBV;3VBW;3VBX;3VBY;3VC4;3WE8;4A7C;4ALU;4ALV;4ALW;4AS0;4BZN;4BZO;4DTK;4ENX;4ENY;4GW8;4I41;4IAA;4JX3;4JX7;4K0Y;4K18;4K1B;4LL5;4LM5;4LMU;4MBI;4MBL;4MED;4MTA;4N6Y;4N6Z;4N70;4RBL;4RC2;4RC3;4RC4;4RPV;4TY1;4WRS;4WSY;4WT6;4XH6;4XHK;5C1Q;5DGZ;5DHJ;5DIA;5DWR;5EOL;5IIS;5IPJ;	CHEMBL2147;	P11309;	DB00131;		PF00069;	IPR011009;IPR017348;IPR000719;IPR017441;IPR008271;	apoptotic process [GO:0006915]; cell cycle [GO:0007049]; cell proliferation [GO:0008283]; hyaluronan metabolic process [GO:0030212]; multicellular organism development [GO:0007275]; negative regulation of apoptotic process [GO:0043066]; negative regulation of sequence-specific DNA binding transcription factor activity [GO:0043433]; positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle [GO:0031659]; protein autophosphorylation [GO:0046777]; protein phosphorylation [GO:0006468]; vitamin D receptor signaling pathway [GO:0070561]	ATP binding [GO:0005524]; manganese ion binding [GO:0030145]; protein serine/threonine kinase activity [GO:0004674]; ribosomal small subunit binding [GO:0043024]; transcription factor binding [GO:0008134]	cytoplasm [GO:0005737]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
P22061	PIMT_HUMAN	Protein-L-isoaspartate(D-aspartate) O-methyltransferase (PIMT) (EC 2.1.1.77) (L-isoaspartyl protein carboxyl methyltransferase) (Protein L-isoaspartyl/D-aspartyl methyltransferase) (Protein-beta-aspartate methyltransferase)	PCMT1	1I1N;1KR5;	CHEMBL4240;	P22061;				IPR000682;IPR029063;	protein methylation [GO:0006479]; protein repair [GO:0030091]	cadherin binding involved in cell-cell adhesion [GO:0098641]; protein-L-isoaspartate (D-aspartate) O-methyltransferase activity [GO:0004719]	cell-cell adherens junction [GO:0005913]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular vesicle [GO:1903561]
Q00169	PIPNA_HUMAN	Phosphatidylinositol transfer protein alpha isoform (PI-TP-alpha) (PtdIns transfer protein alpha) (PtdInsTP alpha)	PITPNA PITPN	1UW5;					PF02121;	IPR001666;IPR023393;	lipid metabolic process [GO:0006629]; phospholipid transport [GO:0015914]; transport [GO:0006810]; visual perception [GO:0007601]	phosphatidylcholine binding [GO:0031210]; phosphatidylcholine transporter activity [GO:0008525]; phosphatidylglycerol binding [GO:1901611]; phosphatidylinositol binding [GO:0035091]; phosphatidylinositol transporter activity [GO:0008526]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; myelin sheath [GO:0043209]
Q9UG56	PISD_HUMAN	Phosphatidylserine decarboxylase proenzyme, mitochondrial (EC 4.1.1.65) [Cleaved into: Phosphatidylserine decarboxylase beta chain; Phosphatidylserine decarboxylase alpha chain]	PISD				DB00144;		PF02666;	IPR003817;IPR033177;IPR033661;	phosphatidylethanolamine biosynthetic process [GO:0006646]; protein autoprocessing [GO:0016540]	phosphatidylserine decarboxylase activity [GO:0004609]	integral component of mitochondrial inner membrane [GO:0031305]; nucleus [GO:0005634]
P48736	PK3CG_HUMAN	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (PI3-kinase subunit gamma) (PI3K-gamma) (PI3Kgamma) (PtdIns-3-kinase subunit gamma) (EC 2.7.1.153) (Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit gamma) (PtdIns-3-kinase subunit p110-gamma) (p110gamma) (Phosphoinositide-3-kinase catalytic gamma polypeptide) (Serine/threonine protein kinase PIK3CG) (EC 2.7.11.1) (p120-PI3K)	PIK3CG	1E8Y;1E8Z;1HE8;2A4Z;2A5U;2CHW;2CHX;2CHZ;2V4L;3APC;3APD;3APF;3CSF;3CST;3DBS;3DPD;3ENE;3IBE;3L08;3L13;3L16;3L17;3L54;3LJ3;3MJW;3ML8;3ML9;3NZS;3NZU;3OAW;3P2B;3PRE;3PRZ;3PS6;3QAQ;3QAR;3QJZ;3QK0;3R7Q;3R7R;3S2A;3SD5;3T8M;3TJP;3TL5;3ZVV;3ZW3;4ANU;4ANV;4ANW;4ANX;4AOF;4DK5;4EZJ;4EZK;4EZL;4F1S;4FA6;4FAD;4FHJ;4FHK;4FJY;4FJZ;4FLH;4FUL;4G11;4GB9;4HLE;4HVB;4J6I;4KZ0;4KZC;4PS3;4PS7;4PS8;4URK;4WWN;4WWO;4WWP;4XX5;4XZ4;5EDS;5G2N;	CHEMBL3267;	P48736;		PATHWAY: Phospholipid metabolism; phosphatidylinositol phosphate biosynthesis.	PF00454;PF00792;PF00794;PF00613;	IPR016024;IPR000008;IPR011009;IPR000403;IPR018936;IPR003113;IPR002420;IPR000341;IPR015433;IPR001263;IPR029071;	adaptive immune response [GO:0002250]; angiogenesis [GO:0001525]; cellular response to cAMP [GO:0071320]; cytokine production [GO:0001816]; dendritic cell chemotaxis [GO:0002407]; endocytosis [GO:0006897]; G-protein coupled receptor signaling pathway [GO:0007186]; hepatocyte apoptotic process [GO:0097284]; inflammatory response [GO:0006954]; innate immune response [GO:0045087]; mast cell degranulation [GO:0043303]; natural killer cell chemotaxis [GO:0035747]; negative regulation of cardiac muscle contraction [GO:0055118]; negative regulation of fibroblast apoptotic process [GO:2000270]; negative regulation of triglyceride catabolic process [GO:0010897]; neutrophil chemotaxis [GO:0030593]; neutrophil extravasation [GO:0072672]; phosphatidylinositol 3-kinase signaling [GO:0014065]; phosphatidylinositol biosynthetic process [GO:0006661]; phosphorylation [GO:0016310]; platelet activation [GO:0030168]; platelet aggregation [GO:0070527]; positive regulation of acute inflammatory response [GO:0002675]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of protein kinase B signaling [GO:0051897]; regulation of calcium ion transmembrane transport [GO:1903169]; regulation of cell adhesion mediated by integrin [GO:0033628]; respiratory burst involved in defense response [GO:0002679]; secretory granule localization [GO:0032252]; T cell activation [GO:0042110]; T cell chemotaxis [GO:0010818]; T cell proliferation [GO:0042098]	1-phosphatidylinositol-3-kinase activity [GO:0016303]; 1-phosphatidylinositol-4-phosphate 3-kinase activity [GO:0035005]; ATP binding [GO:0005524]; ephrin receptor binding [GO:0046875]; kinase activity [GO:0016301]; phosphatidylinositol 3-kinase activity [GO:0035004]; phosphatidylinositol-4,5-bisphosphate 3-kinase activity [GO:0046934]; protein kinase activity [GO:0004672]; protein serine/threonine kinase activity [GO:0004674]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mast cell granule [GO:0042629]; membrane [GO:0016020]; phosphatidylinositol 3-kinase complex, class IB [GO:0005944]; plasma membrane [GO:0005886]
Q9HB21	PKHA1_HUMAN	Pleckstrin homology domain-containing family A member 1 (PH domain-containing family A member 1) (Tandem PH domain-containing protein 1) (TAPP-1)	PLEKHA1 TAPP1	1EAZ;					PF00169;	IPR011993;IPR001849;	androgen metabolic process [GO:0008209]; B cell receptor signaling pathway [GO:0050853]; cellular response to hydrogen peroxide [GO:0070301]; establishment of protein localization [GO:0045184]; estrogen metabolic process [GO:0008210]; face morphogenesis [GO:0060325]; Leydig cell differentiation [GO:0033327]; luteinization [GO:0001553]; multicellular organism growth [GO:0035264]; negative regulation of protein kinase B signaling [GO:0051898]; palate development [GO:0060021]; phosphatidylinositol 3-kinase signaling [GO:0014065]; platelet-derived growth factor receptor signaling pathway [GO:0048008]; post-embryonic development [GO:0009791]; ruffle organization [GO:0031529]; skeletal system morphogenesis [GO:0048705]; spermatogenesis [GO:0007283]	lipid binding [GO:0008289]; PDZ domain binding [GO:0030165]; phosphatidylinositol-3,4-bisphosphate binding [GO:0043325]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; nucleoplasm [GO:0005654]; plasma membrane [GO:0005886]; ruffle membrane [GO:0032587]
Q9H4M7	PKHA4_HUMAN	Pleckstrin homology domain-containing family A member 4 (PH domain-containing family A member 4) (Phosphoinositol 3-phosphate-binding protein 1) (PEPP-1)	PLEKHA4 PEPP1	1UPQ;1UPR;					PF00169;	IPR011993;IPR001849;		1-phosphatidylinositol binding [GO:0005545]	cytoplasm [GO:0005737]; membrane [GO:0016020]
Q13393	PLD1_HUMAN	Phospholipase D1 (PLD 1) (hPLD1) (EC 3.1.4.4) (Choline phosphatase 1) (Phosphatidylcholine-hydrolyzing phospholipase D1)	PLD1		CHEMBL2536;	Q13393;	DB00122;DB09031;		PF00169;PF00614;PF13091;PF00787;	IPR011993;IPR001849;IPR001683;IPR025202;IPR001736;IPR016555;IPR015679;	cell motility [GO:0048870]; chemotaxis [GO:0006935]; inositol lipid-mediated signaling [GO:0048017]; lipid catabolic process [GO:0016042]; phosphatidic acid biosynthetic process [GO:0006654]; Ras protein signal transduction [GO:0007265]; regulation of microvillus assembly [GO:0032534]; small GTPase mediated signal transduction [GO:0007264]	N-acylphosphatidylethanolamine-specific phospholipase D activity [GO:0070290]; phosphatidylinositol binding [GO:0035091]; phospholipase D activity [GO:0004630]	apical plasma membrane [GO:0016324]; endocytic vesicle [GO:0030139]; endoplasmic reticulum membrane [GO:0005789]; endosome [GO:0005768]; Golgi apparatus [GO:0005794]; Golgi membrane [GO:0000139]; late endosome membrane [GO:0031902]; lysosomal membrane [GO:0005765]; membrane [GO:0016020]; perinuclear region of cytoplasm [GO:0048471]
O14939	PLD2_HUMAN	Phospholipase D2 (PLD 2) (hPLD2) (EC 3.1.4.4) (Choline phosphatase 2) (PLD1C) (Phosphatidylcholine-hydrolyzing phospholipase D2)	PLD2		CHEMBL2734;	O14939;	DB00122;		PF00614;PF13091;PF00787;	IPR011993;IPR001849;IPR001683;IPR025202;IPR001736;IPR016555;IPR015679;	cell motility [GO:0048870]; cytoskeleton organization [GO:0007010]; Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096]; inositol lipid-mediated signaling [GO:0048017]; lipid catabolic process [GO:0016042]; phosphatidic acid biosynthetic process [GO:0006654]; small GTPase mediated signal transduction [GO:0007264]; synaptic vesicle recycling [GO:0036465]	N-acylphosphatidylethanolamine-specific phospholipase D activity [GO:0070290]; phosphatidylinositol binding [GO:0035091]; phospholipase D activity [GO:0004630]	endoplasmic reticulum membrane [GO:0005789]; Golgi apparatus [GO:0005794]; plasma membrane [GO:0005886]; presynapse [GO:0098793]
Q96BZ4	PLD4_HUMAN	Phospholipase D4 (PLD 4) (EC 3.1.4.4) (Choline phosphatase 4) (Phosphatidylcholine-hydrolyzing phospholipase D4)	PLD4 C14orf175 UNQ2488/PRO5775						PF00614;PF13918;	IPR032803;IPR001736;	inositol phosphate metabolic process [GO:0043647]; lipid catabolic process [GO:0016042]	N-acylphosphatidylethanolamine-specific phospholipase D activity [GO:0070290]; phosphatidylinositol phospholipase C activity [GO:0004435]; phospholipase D activity [GO:0004630]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]
P49763	PLGF_HUMAN	Placenta growth factor (PlGF)	PGF PGFL PLGF	1FZV;1RV6;	CHEMBL1697671;	P49763;	DB08885;		PF00341;	IPR029034;IPR023581;IPR000072;	angiogenesis [GO:0001525]; animal organ regeneration [GO:0031100]; branching involved in ureteric bud morphogenesis [GO:0001658]; cell-cell signaling [GO:0007267]; cell differentiation [GO:0030154]; cellular response to hormone stimulus [GO:0032870]; female pregnancy [GO:0007565]; induction of positive chemotaxis [GO:0050930]; positive regulation of angiogenesis [GO:0045766]; positive regulation of cell division [GO:0051781]; positive regulation of cell proliferation [GO:0008284]; positive regulation of endothelial cell proliferation [GO:0001938]; positive regulation of mast cell chemotaxis [GO:0060754]; regulation of morphogenesis of a branching structure [GO:0060688]; response to drug [GO:0042493]; response to hypoxia [GO:0001666]; signal transduction [GO:0007165]; sprouting angiogenesis [GO:0002040]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]	growth factor activity [GO:0008083]; heparin binding [GO:0008201]; vascular endothelial growth factor receptor binding [GO:0005172]	extracellular region [GO:0005576]; extracellular space [GO:0005615]; membrane [GO:0016020]
P00747	PLMN_HUMAN	Plasminogen (EC 3.4.21.7) [Cleaved into: Plasmin heavy chain A; Activation peptide; Angiostatin; Plasmin heavy chain A, short form; Plasmin light chain B]	PLG	1B2I;1BML;1BUI;1CEA;1CEB;1DDJ;1HPJ;1HPK;1I5K;1KI0;1KRN;1L4D;1L4Z;1PK4;1PKR;1PMK;1QRZ;1RJX;2DOH;2DOI;2KNF;2L0S;2PK4;3UIR;4A5T;4CIK;4DCB;4DUR;4DUU;5HPG;	CHEMBL1801;	P00747;	DB00009;DB00513;DB00029;DB06692;DB00015;DB00086;DB00031;DB00302;DB00013;		PF00051;PF00024;PF00089;	IPR000001;IPR013806;IPR018056;IPR003609;IPR023317;IPR009003;IPR001314;IPR001254;IPR018114;IPR033116;	blood coagulation [GO:0007596]; cellular protein metabolic process [GO:0044267]; extracellular matrix disassembly [GO:0022617]; fibrinolysis [GO:0042730]; negative regulation of cell-cell adhesion mediated by cadherin [GO:2000048]; negative regulation of cell proliferation [GO:0008285]; negative regulation of cell-substrate adhesion [GO:0010812]; negative regulation of fibrinolysis [GO:0051918]; platelet degranulation [GO:0002576]; positive regulation of fibrinolysis [GO:0051919]; tissue remodeling [GO:0048771]	apolipoprotein binding [GO:0034185]; protein domain specific binding [GO:0019904]; receptor binding [GO:0005102]; serine-type endopeptidase activity [GO:0004252]; serine-type peptidase activity [GO:0008236]	blood microparticle [GO:0072562]; cell surface [GO:0009986]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; extrinsic component of external side of plasma membrane [GO:0031232]; plasma membrane [GO:0005886]; platelet alpha granule lumen [GO:0031093]
Q02809	PLOD1_HUMAN	Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 (EC 1.14.11.4) (Lysyl hydroxylase 1) (LH1)	PLOD1 LLH PLOD				DB00139;DB00126;		PF03171;	IPR029044;IPR005123;IPR006620;IPR001006;	cellular protein modification process [GO:0006464]; epidermis development [GO:0008544]; hydroxylysine biosynthetic process [GO:0046947]; oxidation-reduction process [GO:0055114]; response to hypoxia [GO:0001666]	iron ion binding [GO:0005506]; L-ascorbic acid binding [GO:0031418]; procollagen-lysine 5-dioxygenase activity [GO:0008475]; protein homodimerization activity [GO:0042803]	endoplasmic reticulum membrane [GO:0005789]; extracellular exosome [GO:0070062]; rough endoplasmic reticulum membrane [GO:0030867]
O00469	PLOD2_HUMAN	Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 (EC 1.14.11.4) (Lysyl hydroxylase 2) (LH2)	PLOD2				DB00126;		PF03171;	IPR029044;IPR005123;IPR006620;IPR001006;	cellular protein modification process [GO:0006464]; response to hypoxia [GO:0001666]	iron ion binding [GO:0005506]; L-ascorbic acid binding [GO:0031418]; procollagen-lysine 5-dioxygenase activity [GO:0008475]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; extracellular exosome [GO:0070062]; rough endoplasmic reticulum membrane [GO:0030867]
O60568	PLOD3_HUMAN	Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 (EC 1.14.11.4) (Lysyl hydroxylase 3) (LH3)	PLOD3				DB00139;DB00126;		PF03171;	IPR029044;IPR005123;IPR006620;IPR001006;	basement membrane assembly [GO:0070831]; cellular response to hormone stimulus [GO:0032870]; collagen fibril organization [GO:0030199]; endothelial cell morphogenesis [GO:0001886]; epidermis morphogenesis [GO:0048730]; in utero embryonic development [GO:0001701]; lung morphogenesis [GO:0060425]; neural tube development [GO:0021915]; protein localization [GO:0008104]; vasodilation [GO:0042311]	iron ion binding [GO:0005506]; L-ascorbic acid binding [GO:0031418]; procollagen galactosyltransferase activity [GO:0050211]; procollagen glucosyltransferase activity [GO:0033823]; procollagen-lysine 5-dioxygenase activity [GO:0008475]	endoplasmic reticulum membrane [GO:0005789]; extracellular exosome [GO:0070062]; rough endoplasmic reticulum membrane [GO:0030867]
Q96GD0	PLPP_HUMAN	Pyridoxal phosphate phosphatase (PLP phosphatase) (EC 3.1.3.3) (EC 3.1.3.74) (Chronophin)	PDXP CIN PLP PLPP	2CFR;2CFS;2CFT;2OYC;2P27;2P69;					PF13344;	IPR023214;IPR006357;IPR023215;IPR006349;	actin rod assembly [GO:0031247]; cellular response to ATP [GO:0071318]; positive regulation of actin filament depolymerization [GO:0030836]; protein dephosphorylation [GO:0006470]; pyridoxal phosphate catabolic process [GO:0032361]; regulation of cytokinesis [GO:0032465]; regulation of mitotic nuclear division [GO:0007088]	heat shock protein binding [GO:0031072]; magnesium ion binding [GO:0000287]; phosphoprotein phosphatase activity [GO:0004721]; phosphoserine phosphatase activity [GO:0004647]; pyridoxal phosphatase activity [GO:0033883]	cytoskeleton [GO:0005856]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; lamellipodium membrane [GO:0031258]; ruffle membrane [GO:0032587]
P54278	PMS2_HUMAN	Mismatch repair endonuclease PMS2 (EC 3.1.-.-) (DNA mismatch repair protein PMS2) (PMS1 protein homolog 2)	PMS2 PMSL2	1EA6;1H7S;1H7U;					PF01119;PF08676;	IPR013507;IPR014762;IPR002099;IPR003594;IPR014790;IPR028831;IPR020568;IPR014721;	mismatch repair [GO:0006298]; response to drug [GO:0042493]; somatic hypermutation of immunoglobulin genes [GO:0016446]	ATPase activity [GO:0016887]; ATP binding [GO:0005524]; DNA binding [GO:0003677]; endonuclease activity [GO:0004519]; single base insertion or deletion binding [GO:0032138]	cytoplasm [GO:0005737]; microtubule cytoskeleton [GO:0015630]; MutLalpha complex [GO:0032389]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P11086	PNMT_HUMAN	Phenylethanolamine N-methyltransferase (PNMTase) (EC 2.1.1.28) (Noradrenaline N-methyltransferase)	PNMT PENT	1HNN;1N7I;1N7J;1YZ3;2AN3;2AN4;2AN5;2G70;2G71;2G72;2G8N;2OBF;2ONY;2ONZ;2OPB;3HCA;3HCB;3HCC;3HCD;3HCE;3HCF;3KPJ;3KPU;3KPV;3KPW;3KPY;3KQM;3KQO;3KQP;3KQQ;3KQS;3KQT;3KQV;3KQW;3KQY;3KR0;3KR1;3KR2;4DM3;4MIK;4MQ4;	CHEMBL4617;	P11086;		PATHWAY: Catecholamine biosynthesis; (R)-adrenaline biosynthesis; (R)-adrenaline from (R)-noradrenaline: step 1/1.	PF01234;	IPR025820;IPR000940;IPR029063;	catecholamine biosynthetic process [GO:0042423]; epinephrine biosynthetic process [GO:0042418]	phenylethanolamine N-methyltransferase activity [GO:0004603]	cytosol [GO:0005829]
P00491	PNPH_HUMAN	Purine nucleoside phosphorylase (PNP) (EC 2.4.2.1) (Inosine phosphorylase) (Inosine-guanosine phosphorylase)	PNP NP	1M73;1PF7;1PWY;1RCT;1RFG;1RR6;1RSZ;1RT9;1ULA;1ULB;1V2H;1V3Q;1V41;1V45;1YRY;2A0W;2A0X;2A0Y;2OC4;2OC9;2ON6;2Q7O;3BGS;3D1V;3GB9;3GGS;3INY;3K8O;3K8Q;3PHB;4EAR;4EB8;4ECE;4GKA;5ETJ;	CHEMBL4338;	P00491;	DB00242;DB00900;	PATHWAY: Purine metabolism; purine nucleoside salvage.	PF01048;	IPR000845;IPR001369;IPR011270;IPR011268;IPR018099;	immune response [GO:0006955]; inosine catabolic process [GO:0006148]; interleukin-2 secretion [GO:0070970]; NAD biosynthesis via nicotinamide riboside salvage pathway [GO:0034356]; nicotinamide riboside catabolic process [GO:0006738]; nucleobase-containing compound metabolic process [GO:0006139]; positive regulation of alpha-beta T cell differentiation [GO:0046638]; positive regulation of T cell proliferation [GO:0042102]; purine-containing compound salvage [GO:0043101]; purine nucleotide catabolic process [GO:0006195]; response to drug [GO:0042493]; urate biosynthetic process [GO:0034418]	drug binding [GO:0008144]; nucleoside binding [GO:0001882]; phosphate ion binding [GO:0042301]; purine nucleobase binding [GO:0002060]; purine-nucleoside phosphorylase activity [GO:0004731]	cytoplasm [GO:0005737]; cytoskeleton [GO:0005856]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; intracellular [GO:0005622]; nucleus [GO:0005634]
Q9NVS9	PNPO_HUMAN	Pyridoxine-5'-phosphate oxidase (EC 1.4.3.5) (Pyridoxamine-phosphate oxidase)	PNPO	1NRG;3HY8;	CHEMBL3271932;	Q9NVS9;		PATHWAY: Cofactor metabolism; pyridoxal 5'-phosphate salvage; pyridoxal 5'-phosphate from pyridoxamine 5'-phosphate: step 1/1.; PATHWAY: Cofactor metabolism; pyridoxal 5'-phosphate salvage; pyridoxal 5'-phosphate from pyridoxine 5'-phosphate: step 1/1.	PF10590;PF01243;	IPR000659;IPR019740;IPR011576;IPR019576;IPR012349;	pyridoxal phosphate biosynthetic process [GO:0042823]; pyridoxine biosynthetic process [GO:0008615]; vitamin B6 metabolic process [GO:0042816]	FMN binding [GO:0010181]; pyridoxamine-phosphate oxidase activity [GO:0004733]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleoplasm [GO:0005654]
P27169	PON1_HUMAN	Serum paraoxonase/arylesterase 1 (PON 1) (EC 3.1.1.2) (EC 3.1.1.81) (EC 3.1.8.1) (Aromatic esterase 1) (A-esterase 1) (K-45) (Serum aryldialkylphosphatase 1)	PON1 PON	1V04;1XHR;	CHEMBL3167;	P27169;	DB01327;		PF01731;	IPR011042;IPR002640;IPR008363;	aromatic compound catabolic process [GO:0019439]; carboxylic acid catabolic process [GO:0046395]; cholesterol metabolic process [GO:0008203]; organophosphate catabolic process [GO:0046434]; phosphatidylcholine metabolic process [GO:0046470]; positive regulation of binding [GO:0051099]; positive regulation of cholesterol efflux [GO:0010875]; positive regulation of transporter activity [GO:0032411]; response to external stimulus [GO:0009605]; response to fatty acid [GO:0070542]; response to fluoride [GO:1902617]; response to nutrient levels [GO:0031667]; response to toxic substance [GO:0009636]	acyl-L-homoserine-lactone lactonohydrolase activity [GO:0102007]; aryldialkylphosphatase activity [GO:0004063]; arylesterase activity [GO:0004064]; calcium ion binding [GO:0005509]; phospholipid binding [GO:0005543]; protein homodimerization activity [GO:0042803]	blood microparticle [GO:0072562]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; high-density lipoprotein particle [GO:0034364]; intracellular membrane-bounded organelle [GO:0043231]; spherical high-density lipoprotein particle [GO:0034366]
P36873	PP1G_HUMAN	Serine/threonine-protein phosphatase PP1-gamma catalytic subunit (PP-1G) (EC 3.1.3.16) (Protein phosphatase 1C catalytic subunit)	PPP1CC	1IT6;1JK7;1U32;2BCD;2BDX;4UT2;4UT3;	CHEMBL4438;	P36873;			PF00149;PF16891;	IPR004843;IPR029052;IPR006186;IPR031675;	cell division [GO:0051301]; circadian regulation of gene expression [GO:0032922]; entrainment of circadian clock by photoperiod [GO:0043153]; glycogen metabolic process [GO:0005977]; neuron differentiation [GO:0030182]; protein dephosphorylation [GO:0006470]; regulation of circadian rhythm [GO:0042752]; regulation of nucleocytoplasmic transport [GO:0046822]; sister chromatid cohesion [GO:0007062]	metal ion binding [GO:0046872]; phosphatase activity [GO:0016791]; phosphoprotein phosphatase activity [GO:0004721]; poly(A) RNA binding [GO:0044822]; protein kinase binding [GO:0019901]; protein N-terminus binding [GO:0047485]; protein serine/threonine phosphatase activity [GO:0004722]	cleavage furrow [GO:0032154]; condensed chromosome kinetochore [GO:0000777]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; dendritic spine [GO:0043197]; focal adhesion [GO:0005925]; midbody [GO:0030496]; mitochondrial outer membrane [GO:0005741]; mitochondrion [GO:0005739]; MLL5-L complex [GO:0070688]; nuclear speck [GO:0016607]; nucleolus [GO:0005730]; nucleus [GO:0005634]; protein complex [GO:0043234]; PTW/PP1 phosphatase complex [GO:0072357]
P67775	PP2AA_HUMAN	Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform (PP2A-alpha) (EC 3.1.3.16) (Replication protein C) (RP-C)	PPP2CA	2IAE;2IE3;2IE4;2NPP;2NYL;2NYM;3C5W;3DW8;3FGA;3K7V;3K7W;3P71;4I5L;4I5N;4IYP;4LAC;	CHEMBL4703;	P67775;	DB00163;		PF00149;	IPR004843;IPR029052;IPR006186;	apoptotic process [GO:0006915]; ceramide metabolic process [GO:0006672]; inactivation of MAPK activity [GO:0000188]; meiotic cell cycle [GO:0051321]; mesoderm development [GO:0007498]; mitotic nuclear envelope reassembly [GO:0007084]; negative regulation of cell growth [GO:0030308]; negative regulation of epithelial to mesenchymal transition [GO:0010719]; negative regulation of tyrosine phosphorylation of Stat3 protein [GO:0042518]; nuclear-transcribed mRNA catabolic process, nonsense-mediated decay [GO:0000184]; positive regulation of protein serine/threonine kinase activity [GO:0071902]; protein dephosphorylation [GO:0006470]; regulation of cell adhesion [GO:0030155]; regulation of cell differentiation [GO:0045595]; regulation of DNA replication [GO:0006275]; regulation of growth [GO:0040008]; regulation of transcription, DNA-templated [GO:0006355]; regulation of Wnt signaling pathway [GO:0030111]; response to organic substance [GO:0010033]; RNA splicing [GO:0008380]; second-messenger-mediated signaling [GO:0019932]	metal ion binding [GO:0046872]; phosphoprotein phosphatase activity [GO:0004721]	chromosome, centromeric region [GO:0000775]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; microtubule cytoskeleton [GO:0015630]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; protein phosphatase type 2A complex [GO:0000159]; spindle pole [GO:0000922]
P62714	PP2AB_HUMAN	Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform (PP2A-beta) (EC 3.1.3.16)	PPP2CB				DB00163;		PF00149;	IPR004843;IPR029052;IPR006186;	apoptotic mitochondrial changes [GO:0008637]; negative regulation of Ras protein signal transduction [GO:0046580]; proteasome-mediated ubiquitin-dependent protein catabolic process [GO:0043161]; protein dephosphorylation [GO:0006470]; regulation of gene expression [GO:0010468]; response to antibiotic [GO:0046677]; response to endoplasmic reticulum stress [GO:0034976]; response to hydrogen peroxide [GO:0042542]	metal ion binding [GO:0046872]; protein serine/threonine phosphatase activity [GO:0004722]	chromosome, centromeric region [GO:0000775]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleus [GO:0005634]; protein phosphatase type 2A complex [GO:0000159]; spindle pole [GO:0000922]
P15309	PPAP_HUMAN	Prostatic acid phosphatase (PAP) (EC 3.1.3.2) (5'-nucleotidase) (5'-NT) (EC 3.1.3.5) (Ecto-5'-nucleotidase) (Thiamine monophosphatase) (TMPase) [Cleaved into: PAPf39]	ACPP	1CVI;1ND5;1ND6;2HPA;2L3H;2L77;2L79;2MG0;3PPD;	CHEMBL2633;	P15309;	DB06688;		PF00328;	IPR033379;IPR000560;IPR029033;	adenosine metabolic process [GO:0046085]; dephosphorylation [GO:0016311]; nucleotide metabolic process [GO:0009117]; positive regulation of adenosine receptor signaling pathway [GO:0060168]; purine nucleobase metabolic process [GO:0006144]; regulation of sensory perception of pain [GO:0051930]; thiamine metabolic process [GO:0006772]	5'-nucleotidase activity [GO:0008253]; acid phosphatase activity [GO:0003993]; identical protein binding [GO:0042802]; lysophosphatidic acid phosphatase activity [GO:0052642]; phosphatase activity [GO:0016791]; thiamine phosphate phosphatase activity [GO:0042131]	extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; filopodium [GO:0030175]; integral component of membrane [GO:0016021]; intracellular [GO:0005622]; lysosomal membrane [GO:0005765]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; vesicle membrane [GO:0012506]
Q07869	PPARA_HUMAN	Peroxisome proliferator-activated receptor alpha (PPAR-alpha) (Nuclear receptor subfamily 1 group C member 1)	PPARA NR1C1 PPAR	1I7G;1K7L;1KKQ;2NPA;2P54;2REW;2ZNN;3ET1;3FEI;3G8I;3KDT;3KDU;3SP6;3VI8;4BCR;4CI4;5AZT;	CHEMBL239;	Q07869;	DB01393;DB00636;DB01039;DB01241;DB00328;		PF00104;PF00105;	IPR003074;IPR003076;IPR000536;IPR001723;IPR001628;IPR013088;	behavioral response to nicotine [GO:0035095]; cellular lipid metabolic process [GO:0044255]; circadian regulation of gene expression [GO:0032922]; enamel mineralization [GO:0070166]; epidermis development [GO:0008544]; fatty acid metabolic process [GO:0006631]; fatty acid transport [GO:0015908]; heart development [GO:0007507]; lipid metabolic process [GO:0006629]; lipoprotein metabolic process [GO:0042157]; negative regulation of appetite [GO:0032099]; negative regulation of blood pressure [GO:0045776]; negative regulation of cholesterol storage [GO:0010887]; negative regulation of glycolytic process [GO:0045820]; negative regulation of inflammatory response [GO:0050728]; negative regulation of leukocyte cell-cell adhesion [GO:1903038]; negative regulation of macrophage derived foam cell differentiation [GO:0010745]; negative regulation of neuron death [GO:1901215]; negative regulation of pri-miRNA transcription from RNA polymerase II promoter [GO:1902894]; negative regulation of protein binding [GO:0032091]; negative regulation of receptor biosynthetic process [GO:0010871]; negative regulation of sequestering of triglyceride [GO:0010891]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; negative regulation of transcription regulatory region DNA binding [GO:2000678]; positive regulation of fatty acid beta-oxidation [GO:0032000]; positive regulation of fatty acid oxidation [GO:0046321]; positive regulation of gluconeogenesis [GO:0045722]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; regulation of cellular ketone metabolic process by positive regulation of transcription from RNA polymerase II promoter [GO:0072366]; regulation of circadian rhythm [GO:0042752]; regulation of glycolytic process by positive regulation of transcription from RNA polymerase II promoter [GO:0072363]; regulation of lipid transport by positive regulation of transcription from RNA polymerase II promoter [GO:0072369]; response to hypoxia [GO:0001666]; response to insulin [GO:0032868]; transcription initiation from RNA polymerase II promoter [GO:0006367]; wound healing [GO:0042060]	DNA binding [GO:0003677]; drug binding [GO:0008144]; lipid binding [GO:0008289]; RNA polymerase II core promoter proximal region sequence-specific DNA binding [GO:0000978]; RNA polymerase II repressing transcription factor binding [GO:0001103]; RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding [GO:0004879]; sequence-specific DNA binding [GO:0043565]; steroid hormone receptor activity [GO:0003707]; transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding [GO:0001077]; transcriptional activator activity, RNA polymerase II transcription factor binding [GO:0001190]; transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding [GO:0001078]; transcription factor activity, sequence-specific DNA binding [GO:0003700]; transcription factor binding [GO:0008134]; ubiquitin conjugating enzyme binding [GO:0031624]; zinc ion binding [GO:0008270]	nucleoplasm [GO:0005654]; nucleus [GO:0005634]
Q03181	PPARD_HUMAN	Peroxisome proliferator-activated receptor delta (PPAR-delta) (NUCI) (Nuclear hormone receptor 1) (NUC1) (Nuclear receptor subfamily 1 group C member 2) (Peroxisome proliferator-activated receptor beta) (PPAR-beta)	PPARD NR1C2 PPARB	1GWX;1Y0S;2AWH;2B50;2BAW;2ENV;2GWX;2J14;2Q5G;2XYJ;2XYW;2XYX;2ZNP;2ZNQ;3D5F;3DY6;3ET2;3GWX;3GZ9;3OZ0;3PEQ;3SP9;3TKM;	CHEMBL3979;	Q03181;	DB01393;DB00159;DB00605;DB00374;		PF00104;PF00105;	IPR003074;IPR003075;IPR000536;IPR001723;IPR001628;IPR013088;	adipose tissue development [GO:0060612]; apoptotic process [GO:0006915]; apoptotic signaling pathway [GO:0097190]; axon ensheathment [GO:0008366]; cell differentiation [GO:0030154]; cell proliferation [GO:0008283]; cell-substrate adhesion [GO:0031589]; cellular response to hypoxia [GO:0071456]; cellular response to lipopolysaccharide [GO:0071222]; cholesterol metabolic process [GO:0008203]; decidualization [GO:0046697]; embryo implantation [GO:0007566]; fatty acid beta-oxidation [GO:0006635]; fatty acid catabolic process [GO:0009062]; fatty acid transport [GO:0015908]; generation of precursor metabolites and energy [GO:0006091]; glucose metabolic process [GO:0006006]; glucose transport [GO:0015758]; heart development [GO:0007507]; keratinocyte migration [GO:0051546]; keratinocyte proliferation [GO:0043616]; lipid metabolic process [GO:0006629]; mRNA transcription [GO:0009299]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cell growth [GO:0030308]; negative regulation of collagen biosynthetic process [GO:0032966]; negative regulation of epithelial cell proliferation [GO:0050680]; negative regulation of inflammatory response [GO:0050728]; negative regulation of myoblast differentiation [GO:0045662]; negative regulation of pri-miRNA transcription from RNA polymerase II promoter [GO:1902894]; negative regulation of smooth muscle cell migration [GO:0014912]; negative regulation of smooth muscle cell proliferation [GO:0048662]; negative regulation of transcription, DNA-templated [GO:0045892]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; phospholipid biosynthetic process [GO:0008654]; positive regulation of epidermis development [GO:0045684]; positive regulation of fat cell differentiation [GO:0045600]; positive regulation of insulin secretion [GO:0032024]; positive regulation of myoblast proliferation [GO:2000288]; positive regulation of phosphatidylinositol 3-kinase signaling [GO:0014068]; positive regulation of skeletal muscle tissue regeneration [GO:0043415]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of vasodilation [GO:0045909]; proteoglycan metabolic process [GO:0006029]; regulation of skeletal muscle satellite cell proliferation [GO:0014842]; regulation of transcription from RNA polymerase II promoter [GO:0006357]; response to activity [GO:0014823]; response to glucose [GO:0009749]; response to vitamin A [GO:0033189]; transcription initiation from RNA polymerase II promoter [GO:0006367]; vitamin A metabolic process [GO:0006776]; wound healing [GO:0042060]	DNA binding [GO:0003677]; drug binding [GO:0008144]; linoleic acid binding [GO:0070539]; lipid binding [GO:0008289]; RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding [GO:0004879]; sequence-specific DNA binding [GO:0043565]; steroid hormone receptor activity [GO:0003707]; transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding [GO:0001227]; transcription coactivator activity [GO:0003713]; transcription factor activity, sequence-specific DNA binding [GO:0003700]; transcription factor binding [GO:0008134]; zinc ion binding [GO:0008270]	nuclear chromatin [GO:0000790]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P37231	PPARG_HUMAN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma) (Nuclear receptor subfamily 1 group C member 3)	PPARG NR1C3	1FM6;1FM9;1I7I;1K74;1KNU;1NYX;1PRG;1RDT;1WM0;1ZEO;1ZGY;2ATH;2F4B;2FVJ;2G0G;2G0H;2GTK;2HFP;2HWQ;2HWR;2I4J;2I4P;2I4Z;2OM9;2P4Y;2POB;2PRG;2Q59;2Q5P;2Q5S;2Q61;2Q6R;2Q6S;2Q8S;2QMV;2VSR;2VST;2VV0;2VV1;2VV2;2VV3;2VV4;2XKW;2YFE;2ZK0;2ZK1;2ZK2;2ZK3;2ZK4;2ZK5;2ZK6;2ZNO;2ZVT;3ADS;3ADT;3ADU;3ADV;3ADW;3ADX;3AN3;3AN4;3B0Q;3B0R;3B1M;3B3K;3BC5;3CDP;3CDS;3CS8;3CWD;3D6D;3DZU;3DZY;3E00;3ET0;3ET3;3FEJ;3FUR;3G9E;3GBK;3H0A;3HO0;3HOD;3IA6;3K8S;3KMG;3LMP;3NOA;3OSI;3OSW;3PBA;3PO9;3PRG;3QT0;3R5N;3R8A;3R8I;3S9S;3SZ1;3T03;3TY0;3U9Q;3V9T;3V9V;3V9Y;3VJH;3VJI;3VN2;3VSO;3VSP;3WJ4;3WJ5;3WMH;3X1H;3X1I;4A4V;4A4W;4CI5;4E4K;4E4Q;4EM9;4EMA;4F9M;4FGY;4HEE;4JAZ;4JL4;4L96;4L98;4O8F;4OJ4;4PRG;4PVU;4PWL;4R06;4R2U;4R6S;4XLD;4XTA;4XUH;4XUM;4Y29;4YT1;5AZV;5DSH;5DV3;5DV6;5DV8;5DWL;5F9B;	CHEMBL235;	P37231;	DB01014;DB01393;DB01067;DB01050;DB00159;DB00328;DB00244;DB01252;DB00731;DB01132;DB00912;DB00412;DB00795;DB00966;		PF00104;PF12577;PF00105;	IPR003074;IPR003077;IPR000536;IPR001723;IPR022590;IPR001628;IPR013088;	activation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0006919]; animal organ regeneration [GO:0031100]; cell fate commitment [GO:0045165]; cell maturation [GO:0048469]; cellular response to hyperoxia [GO:0071455]; cellular response to insulin stimulus [GO:0032869]; cellular response to prostaglandin E stimulus [GO:0071380]; cellular response to retinoic acid [GO:0071300]; cellular response to vitamin E [GO:0071306]; epithelial cell differentiation [GO:0030855]; fatty acid oxidation [GO:0019395]; glucose homeostasis [GO:0042593]; heart development [GO:0007507]; innate immune response [GO:0045087]; lipid homeostasis [GO:0055088]; lipid metabolic process [GO:0006629]; lipoprotein transport [GO:0042953]; long-chain fatty acid transport [GO:0015909]; low-density lipoprotein particle receptor biosynthetic process [GO:0045713]; macrophage derived foam cell differentiation [GO:0010742]; monocyte differentiation [GO:0030224]; negative regulation of acute inflammatory response [GO:0002674]; negative regulation of cell growth [GO:0030308]; negative regulation of cholesterol storage [GO:0010887]; negative regulation of collagen biosynthetic process [GO:0032966]; negative regulation of interferon-gamma-mediated signaling pathway [GO:0060336]; negative regulation of macrophage derived foam cell differentiation [GO:0010745]; negative regulation of pancreatic stellate cell proliferation [GO:2000230]; negative regulation of receptor biosynthetic process [GO:0010871]; negative regulation of sequestering of triglyceride [GO:0010891]; negative regulation of smooth muscle cell proliferation [GO:0048662]; negative regulation of telomerase activity [GO:0051974]; negative regulation of transcription, DNA-templated [GO:0045892]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; peroxisome proliferator activated receptor signaling pathway [GO:0035357]; placenta development [GO:0001890]; positive regulation of fat cell differentiation [GO:0045600]; positive regulation of fatty acid oxidation [GO:0046321]; positive regulation of oligodendrocyte differentiation [GO:0048714]; positive regulation of phagocytosis, engulfment [GO:0060100]; positive regulation of sequence-specific DNA binding transcription factor activity [GO:0051091]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; regulation of blood pressure [GO:0008217]; regulation of cholesterol transporter activity [GO:0060694]; regulation of circadian rhythm [GO:0042752]; regulation of transcription involved in cell fate commitment [GO:0060850]; response to caffeine [GO:0031000]; response to cold [GO:0009409]; response to drug [GO:0042493]; response to estrogen [GO:0043627]; response to immobilization stress [GO:0035902]; response to lipid [GO:0033993]; response to low-density lipoprotein particle [GO:0055098]; response to mechanical stimulus [GO:0009612]; response to metformin [GO:1901558]; response to nutrient [GO:0007584]; response to retinoic acid [GO:0032526]; response to starvation [GO:0042594]; response to vitamin A [GO:0033189]; rhythmic process [GO:0048511]; signal transduction [GO:0007165]; transcription initiation from RNA polymerase II promoter [GO:0006367]; white fat cell differentiation [GO:0050872]	activating transcription factor binding [GO:0033613]; alpha-actinin binding [GO:0051393]; arachidonic acid binding [GO:0050544]; chromatin binding [GO:0003682]; core promoter sequence-specific DNA binding [GO:0001046]; DNA binding [GO:0003677]; drug binding [GO:0008144]; enzyme binding [GO:0019899]; ligand-dependent nuclear receptor transcription coactivator activity [GO:0030374]; prostaglandin receptor activity [GO:0004955]; retinoid X receptor binding [GO:0046965]; RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding [GO:0004879]; steroid hormone receptor activity [GO:0003707]; transcription factor activity, sequence-specific DNA binding [GO:0003700]; transcription factor binding [GO:0008134]; transcription regulatory region DNA binding [GO:0044212]; zinc ion binding [GO:0008270]	cytosol [GO:0005829]; Golgi apparatus [GO:0005794]; intracellular membrane-bounded organelle [GO:0043231]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; RNA polymerase II transcription factor complex [GO:0090575]
P10696	PPBN_HUMAN	Alkaline phosphatase, placental-like (EC 3.1.3.1) (ALP-1) (Alkaline phosphatase Nagao isozyme) (Germ cell alkaline phosphatase) (GCAP) (Placental alkaline phosphatase-like) (PLAP-like)	ALPPL2 ALPPL		CHEMBL3402;	P10696;	DB01143;		PF00245;	IPR017849;IPR001952;IPR018299;IPR017850;		alkaline phosphatase activity [GO:0004035]; metal ion binding [GO:0046872]	anchored component of membrane [GO:0031225]; plasma membrane [GO:0005886]
P48147	PPCE_HUMAN	Prolyl endopeptidase (PE) (EC 3.4.21.26) (Post-proline cleaving enzyme)	PREP PEP	3DDU;	CHEMBL3202;	P48147;	DB00107;		PF00326;PF02897;	IPR029058;IPR002471;IPR023302;IPR001375;IPR002470;	proteolysis [GO:0006508]	serine-type endopeptidase activity [GO:0004252]; serine-type exopeptidase activity [GO:0070008]; serine-type peptidase activity [GO:0008236]	cytoplasm [GO:0005737]; membrane [GO:0016020]; nucleus [GO:0005634]
P35558	PPCKC_HUMAN	Phosphoenolpyruvate carboxykinase, cytosolic [GTP] (PEPCK-C) (EC 4.1.1.32)	PCK1 PEPCK1	1KHB;1KHE;1KHF;1KHG;1M51;1NHX;2GMV;	CHEMBL2911;	P35558;		PATHWAY: Carbohydrate biosynthesis; gluconeogenesis.	PF00821;	IPR018091;IPR013035;IPR008209;IPR008210;	aging [GO:0007568]; cellular response to cAMP [GO:0071320]; cellular response to fructose stimulus [GO:0071332]; cellular response to glucagon stimulus [GO:0071377]; cellular response to hypoxia [GO:0071456]; cellular response to insulin stimulus [GO:0032869]; cellular response to interleukin-1 [GO:0071347]; cellular response to potassium ion starvation [GO:0051365]; cellular response to retinoic acid [GO:0071300]; cellular response to tumor necrosis factor [GO:0071356]; gluconeogenesis [GO:0006094]; glucose homeostasis [GO:0042593]; glucose metabolic process [GO:0006006]; glycerol biosynthetic process from pyruvate [GO:0046327]; internal protein amino acid acetylation [GO:0006475]; oxaloacetate metabolic process [GO:0006107]; positive regulation of transcription from RNA polymerase II promoter in response to acidic pH [GO:0061402]; response to activity [GO:0014823]; response to insulin [GO:0032868]; response to interleukin-6 [GO:0070741]; response to lipopolysaccharide [GO:0032496]; response to methionine [GO:1904640]	carboxylic acid binding [GO:0031406]; GDP binding [GO:0019003]; GTP binding [GO:0005525]; magnesium ion binding [GO:0000287]; manganese ion binding [GO:0030145]; nucleoside diphosphate kinase activity [GO:0004550]; phosphoenolpyruvate carboxykinase (GTP) activity [GO:0004613]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
Q9UKL6	PPCT_HUMAN	Phosphatidylcholine transfer protein (PC-TP) (START domain-containing protein 2) (StARD2) (StAR-related lipid transfer protein 2)	PCTP STARD2	1LN1;1LN2;1LN3;					PF01852;	IPR023393;IPR002913;	lipid transport [GO:0006869]; phospholipid transport [GO:0015914]	lipid binding [GO:0008289]; phosphatidylcholine binding [GO:0031210]; phosphatidylcholine transporter activity [GO:0008525]	cytosol [GO:0005829]
P62937	PPIA_HUMAN	Peptidyl-prolyl cis-trans isomerase A (PPIase A) (EC 5.2.1.8) (Cyclophilin A) (Cyclosporin A-binding protein) (Rotamase A) [Cleaved into: Peptidyl-prolyl cis-trans isomerase A, N-terminally processed]	PPIA CYPA	1AK4;1AWQ;1AWR;1AWS;1AWT;1AWU;1AWV;1BCK;1CWA;1CWB;1CWC;1CWF;1CWH;1CWI;1CWJ;1CWK;1CWL;1CWM;1CWO;1FGL;1M63;1M9C;1M9D;1M9E;1M9F;1M9X;1M9Y;1MF8;1MIK;1NMK;1OCA;1RMH;1VBS;1VBT;1W8L;1W8M;1W8V;1YND;1ZKF;2ALF;2CPL;2CYH;2MS4;2MZU;2N0T;2RMA;2RMB;2X25;2X2A;2X2C;2X2D;2XGY;3CYH;3CYS;3K0M;3K0N;3K0O;3K0P;3K0Q;3K0R;3ODI;3ODL;3RDD;4CYH;4IPZ;4N1M;4N1N;4N1O;4N1P;4N1Q;4N1R;4N1S;4YUG;4YUH;4YUI;4YUJ;4YUK;4YUL;4YUM;4YUN;4YUO;4YUP;5CYH;5F66;5FJB;5KUL;5KUN;5KUO;5KUQ;5KUR;5KUS;5KUU;5KUV;5KUW;5KUZ;5KV0;5KV1;5KV2;5KV3;5KV4;5KV5;5KV6;5KV7;	CHEMBL1949;	P62937;	DB00091;DB00172;		PF00160;	IPR029000;IPR024936;IPR020892;IPR002130;	entry into host cell [GO:0030260]; establishment of integrated proviral latency [GO:0075713]; fusion of virus membrane with host plasma membrane [GO:0019064]; leukocyte migration [GO:0050900]; lipid particle organization [GO:0034389]; positive regulation of protein secretion [GO:0050714]; positive regulation of viral genome replication [GO:0045070]; protein folding [GO:0006457]; protein peptidyl-prolyl isomerization [GO:0000413]; regulation of viral genome replication [GO:0045069]; RNA-dependent DNA biosynthetic process [GO:0006278]; uncoating of virus [GO:0019061]; viral life cycle [GO:0019058]; viral release from host cell [GO:0019076]; virion assembly [GO:0019068]	peptide binding [GO:0042277]; peptidyl-prolyl cis-trans isomerase activity [GO:0003755]; poly(A) RNA binding [GO:0044822]; unfolded protein binding [GO:0051082]; virion binding [GO:0046790]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; focal adhesion [GO:0005925]; membrane [GO:0016020]; nucleus [GO:0005634]
P23284	PPIB_HUMAN	Peptidyl-prolyl cis-trans isomerase B (PPIase B) (EC 5.2.1.8) (CYP-S1) (Cyclophilin B) (Rotamase B) (S-cyclophilin) (SCYLP)	PPIB CYPB	1CYN;3ICH;3ICI;	CHEMBL2075;	P23284;	DB00172;		PF00160;	IPR029000;IPR024936;IPR020892;IPR002130;	bone development [GO:0060348]; chaperone-mediated protein folding [GO:0061077]; positive regulation by host of viral genome replication [GO:0044829]; positive regulation by host of viral process [GO:0044794]; positive regulation of multicellular organism growth [GO:0040018]; protein peptidyl-prolyl isomerization [GO:0000413]; protein stabilization [GO:0050821]	peptide binding [GO:0042277]; peptidyl-prolyl cis-trans isomerase activity [GO:0003755]; poly(A) RNA binding [GO:0044822]; protein complex binding [GO:0032403]; RNA polymerase binding [GO:0070063]; unfolded protein binding [GO:0051082]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum chaperone complex [GO:0034663]; endoplasmic reticulum lumen [GO:0005788]; extracellular exosome [GO:0070062]; focal adhesion [GO:0005925]; macromolecular complex [GO:0032991]; melanosome [GO:0042470]; membrane [GO:0016020]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; smooth endoplasmic reticulum [GO:0005790]
P45877	PPIC_HUMAN	Peptidyl-prolyl cis-trans isomerase C (PPIase C) (EC 5.2.1.8) (Cyclophilin C) (Rotamase C)	PPIC CYPC	2ESL;	CHEMBL2424505;	P45877;	DB00172;		PF00160;	IPR029000;IPR024936;IPR020892;IPR002130;	protein folding [GO:0006457]	cyclosporin A binding [GO:0016018]; peptidyl-prolyl cis-trans isomerase activity [GO:0003755]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]
P30405	PPIF_HUMAN	Peptidyl-prolyl cis-trans isomerase F, mitochondrial (PPIase F) (EC 5.2.1.8) (Cyclophilin D) (CyP-D) (CypD) (Cyclophilin F) (Mitochondrial cyclophilin) (CyP-M) (Rotamase F)	PPIF CYP3	2BIT;2BIU;2Z6W;3QYU;3R49;3R4G;3R54;3R56;3R57;3R59;3RCF;3RCG;3RCI;3RCK;3RCL;3RD9;3RDA;3RDB;3RDC;4J58;4J59;4J5A;4J5B;4J5C;4J5D;4J5E;4O8H;4O8I;4XNC;4ZSC;4ZSD;5A0E;5CBT;5CBU;5CBV;5CBW;5CCN;5CCQ;5CCR;5CCS;	CHEMBL3325306;	P30405;	DB00091;DB00172;		PF00160;	IPR029000;IPR024936;IPR020892;IPR002130;	apoptotic mitochondrial changes [GO:0008637]; cellular response to arsenic-containing substance [GO:0071243]; cellular response to calcium ion [GO:0071277]; cellular response to hydrogen peroxide [GO:0070301]; necroptotic process [GO:0070266]; negative regulation of apoptotic process [GO:0043066]; negative regulation of ATPase activity [GO:0032780]; negative regulation of intrinsic apoptotic signaling pathway [GO:2001243]; negative regulation of oxidative phosphorylation [GO:0090324]; negative regulation of oxidative phosphorylation uncoupler activity [GO:2000276]; negative regulation of release of cytochrome c from mitochondria [GO:0090201]; positive regulation of release of cytochrome c from mitochondria [GO:0090200]; protein folding [GO:0006457]; regulation of mitochondrial membrane permeability [GO:0046902]; regulation of mitochondrial membrane permeability involved in programmed necrotic cell death [GO:1902445]; regulation of necrotic cell death [GO:0010939]; regulation of proton-transporting ATPase activity, rotational mechanism [GO:0010849]; response to ischemia [GO:0002931]	cyclosporin A binding [GO:0016018]; peptidyl-prolyl cis-trans isomerase activity [GO:0003755]	membrane [GO:0016020]; mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]
Q13427	PPIG_HUMAN	Peptidyl-prolyl cis-trans isomerase G (PPIase G) (Peptidyl-prolyl isomerase G) (EC 5.2.1.8) (CASP10) (Clk-associating RS-cyclophilin) (CARS-Cyp) (CARS-cyclophilin) (SR-cyclophilin) (SR-cyp) (SRcyp) (Cyclophilin G) (Rotamase G)	PPIG	2GW2;2WFI;2WFJ;		Q13427;	DB00172;		PF00160;	IPR029000;IPR024936;IPR020892;IPR002130;	protein folding [GO:0006457]; RNA splicing [GO:0008380]	cyclosporin A binding [GO:0016018]; peptidyl-prolyl cis-trans isomerase activity [GO:0003755]; poly(A) RNA binding [GO:0044822]	cytoplasm [GO:0005737]; nuclear matrix [GO:0016363]; nuclear speck [GO:0016607]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
O43447	PPIH_HUMAN	Peptidyl-prolyl cis-trans isomerase H (PPIase H) (EC 5.2.1.8) (Rotamase H) (Small nuclear ribonucleoprotein particle-specific cyclophilin H) (CypH) (U-snRNP-associated cyclophilin SnuCyp-20) (USA-CYP)	PPIH CYP20 CYPH	1MZW;1QOI;		O43447;	DB00172;		PF00160;	IPR029000;IPR024936;IPR020892;IPR002130;	mRNA splicing, via spliceosome [GO:0000398]; positive regulation of viral genome replication [GO:0045070]; protein complex assembly [GO:0006461]; protein folding [GO:0006457]	cyclosporin A binding [GO:0016018]; peptidyl-prolyl cis-trans isomerase activity [GO:0003755]; ribonucleoprotein complex binding [GO:0043021]	cytoplasm [GO:0005737]; nuclear speck [GO:0016607]; nucleoplasm [GO:0005654]; spliceosomal complex [GO:0005681]; U4/U6 snRNP [GO:0071001]; U4/U6 x U5 tri-snRNP complex [GO:0046540]
P53041	PPP5_HUMAN	Serine/threonine-protein phosphatase 5 (PP5) (EC 3.1.3.16) (Protein phosphatase T) (PP-T) (PPT)	PPP5C PPP5	1A17;1S95;1WAO;2BUG;3H60;3H61;3H62;3H63;3H64;3H66;3H67;3H68;3H69;4ZVZ;4ZX2;5HPE;	CHEMBL3425389;	P53041;			PF00149;PF08321;PF00515;	IPR004843;IPR029052;IPR013235;IPR006186;IPR011236;IPR013026;IPR011990;IPR001440;IPR019734;	cellular response to cadmium ion [GO:0071276]; cellular response to hydrogen peroxide [GO:0070301]; DNA repair [GO:0006281]; histone dephosphorylation [GO:0016576]; MAPK cascade [GO:0000165]; mitotic nuclear division [GO:0007067]; negative regulation of neuron death [GO:1901215]; negative regulation of protein phosphorylation [GO:0001933]; positive regulation of glucocorticoid receptor signaling pathway [GO:2000324]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; protein dephosphorylation [GO:0006470]; protein heterooligomerization [GO:0051291]; response to lead ion [GO:0010288]; response to morphine [GO:0043278]; transcription, DNA-templated [GO:0006351]	ADP binding [GO:0043531]; ATP binding [GO:0005524]; lipid binding [GO:0008289]; metal ion binding [GO:0046872]; phosphoprotein phosphatase activity [GO:0004721]; protein serine/threonine phosphatase activity [GO:0004722]; RNA binding [GO:0003723]; signal transducer activity [GO:0004871]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; intracellular membrane-bounded organelle [GO:0043231]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; perikaryon [GO:0043204]; plasma membrane [GO:0005886]; protein complex [GO:0043234]; proximal dendrite [GO:1990635]
P32119	PRDX2_HUMAN	Peroxiredoxin-2 (EC 1.11.1.15) (Natural killer cell-enhancing factor B) (NKEF-B) (PRP) (Thiol-specific antioxidant protein) (TSA) (Thioredoxin peroxidase 1) (Thioredoxin-dependent peroxide reductase 1)	PRDX2 NKEFB TDPX1	1QMV;					PF10417;PF00578;	IPR000866;IPR024706;IPR019479;IPR033046;IPR012336;IPR013766;	cell redox homeostasis [GO:0045454]; cellular response to oxidative stress [GO:0034599]; hydrogen peroxide catabolic process [GO:0042744]; negative regulation of apoptotic process [GO:0043066]; regulation of apoptotic process [GO:0042981]; removal of superoxide radicals [GO:0019430]; response to oxidative stress [GO:0006979]; response to reactive oxygen species [GO:0000302]	antioxidant activity [GO:0016209]; thioredoxin peroxidase activity [GO:0008379]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P30044	PRDX5_HUMAN	Peroxiredoxin-5, mitochondrial (EC 1.11.1.15) (Alu corepressor 1) (Antioxidant enzyme B166) (AOEB166) (Liver tissue 2D-page spot 71B) (PLP) (Peroxiredoxin V) (Prx-V) (Peroxisomal antioxidant enzyme) (TPx type VI) (Thioredoxin peroxidase PMP20) (Thioredoxin reductase)	PRDX5 ACR1 SBBI10	1H4O;1HD2;1OC3;1URM;2VL2;2VL3;2VL9;3MNG;4K7I;4K7N;4K7O;4MMM;			DB00995;DB03793;		PF08534;	IPR013740;IPR012336;IPR013766;	cell redox homeostasis [GO:0045454]; cellular response to reactive oxygen species [GO:0034614]; hydrogen peroxide catabolic process [GO:0042744]; inflammatory response [GO:0006954]; NADPH oxidation [GO:0070995]; negative regulation of apoptotic process [GO:0043066]; negative regulation of oxidoreductase activity [GO:0051354]; negative regulation of transcription from RNA polymerase III promoter [GO:0016480]; positive regulation of collagen biosynthetic process [GO:0032967]; reactive nitrogen species metabolic process [GO:2001057]; regulation of apoptosis involved in tissue homeostasis [GO:0060785]; response to oxidative stress [GO:0006979]; response to reactive oxygen species [GO:0000302]	antioxidant activity [GO:0016209]; cysteine-type endopeptidase inhibitor activity involved in apoptotic process [GO:0043027]; peroxidase activity [GO:0004601]; peroxiredoxin activity [GO:0051920]; peroxynitrite reductase activity [GO:0072541]; protein dimerization activity [GO:0046983]; receptor binding [GO:0005102]; RNA polymerase III regulatory region DNA binding [GO:0001016]; thioredoxin peroxidase activity [GO:0008379]	cytoplasm [GO:0005737]; cytoplasmic vesicle [GO:0031410]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; intracellular membrane-bounded organelle [GO:0043231]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; peroxisomal matrix [GO:0005782]; peroxisome [GO:0005777]
P06401	PRGR_HUMAN	Progesterone receptor (PR) (Nuclear receptor subfamily 3 group C member 3)	PGR NR3C3	1A28;1E3K;1SQN;1SR7;1ZUC;2C7A;2OVH;2OVM;2W8Y;3D90;3G8O;3HQ5;3KBA;3ZR7;3ZRA;3ZRB;4A2J;4APU;4OAR;5CC0;	CHEMBL208;	P06401;	DB01431;DB01406;DB00304;DB01395;DB00378;DB00823;DB00294;DB00588;DB06789;DB00367;DB00603;DB00351;DB00834;DB06713;DB00717;DB00957;DB00396;DB00421;DB08867;		PF00104;PF02161;PF00105;	IPR000536;IPR001723;IPR000128;IPR001628;IPR013088;	cell-cell signaling [GO:0007267]; negative regulation of gene expression [GO:0010629]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; signal transduction [GO:0007165]; transcription initiation from RNA polymerase II promoter [GO:0006367]	ATPase binding [GO:0051117]; DNA binding [GO:0003677]; enzyme binding [GO:0019899]; receptor binding [GO:0005102]; RNA polymerase II core promoter proximal region sequence-specific DNA binding [GO:0000978]; steroid binding [GO:0005496]; steroid hormone receptor activity [GO:0003707]; transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding [GO:0001077]; zinc ion binding [GO:0008270]	mitochondrial outer membrane [GO:0005741]; nucleoplasm [GO:0005654]
P04156	PRIO_HUMAN	Major prion protein (PrP) (ASCR) (PrP27-30) (PrP33-35C) (CD antigen CD230)	PRNP ALTPRP PRIP PRP	1E1G;1E1J;1E1P;1E1S;1E1U;1E1W;1FKC;1FO7;1H0L;1HJM;1HJN;1I4M;1OEH;1OEI;1QLX;1QLZ;1QM0;1QM1;1QM2;1QM3;2IV4;2IV5;2IV6;2K1D;2KUN;2LBG;2LEJ;2LFT;2LSB;2LV1;2M8T;2OL9;2W9E;3HAF;3HAK;3HEQ;3HER;3HES;3HJ5;3HJX;3MD4;3MD5;3NHC;3NHD;3NVF;4DGI;4E1H;4E1I;4KML;4N9O;	CHEMBL4869;	P04156;	DB00759;		PF00377;PF11587;	IPR000817;IPR022416;IPR025860;	cell cycle arrest [GO:0007050]; cellular copper ion homeostasis [GO:0006878]; cellular response to copper ion [GO:0071280]; cellular response to drug [GO:0035690]; learning or memory [GO:0007611]; metabolic process [GO:0008152]; negative regulation of activated T cell proliferation [GO:0046007]; negative regulation of apoptotic process [GO:0043066]; negative regulation of calcineurin-NFAT signaling cascade [GO:0070885]; negative regulation of interferon-gamma production [GO:0032689]; negative regulation of interleukin-17 production [GO:0032700]; negative regulation of interleukin-2 production [GO:0032703]; negative regulation of protein phosphorylation [GO:0001933]; negative regulation of sequence-specific DNA binding transcription factor activity [GO:0043433]; negative regulation of T cell receptor signaling pathway [GO:0050860]; protein homooligomerization [GO:0051260]; regulation of potassium ion transmembrane transport [GO:1901379]; regulation of protein localization [GO:0032880]; response to cadmium ion [GO:0046686]; response to oxidative stress [GO:0006979]	copper ion binding [GO:0005507]; identical protein binding [GO:0042802]; microtubule binding [GO:0008017]; tubulin binding [GO:0015631]	anchored component of membrane [GO:0031225]; cell surface [GO:0009986]; cytoplasm [GO:0005737]; endoplasmic reticulum [GO:0005783]; extracellular exosome [GO:0070062]; extrinsic component of membrane [GO:0019898]; Golgi apparatus [GO:0005794]; membrane raft [GO:0045121]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
P16471	PRLR_HUMAN	Prolactin receptor (PRL-R)	PRLR	1BP3;2LFG;2N7I;3D48;3MZG;3N06;3N0P;3NCB;3NCC;3NCE;3NCF;4I18;	CHEMBL5588;	P16471;	DB01185;DB00052;		PF09067;	IPR003961;IPR015152;IPR013783;IPR003528;IPR033230;	activation of JAK2 kinase activity [GO:0042977]; activation of transmembrane receptor protein tyrosine kinase activity [GO:0007171]; cell surface receptor signaling pathway [GO:0007166]; embryo implantation [GO:0007566]; JAK-STAT cascade involved in growth hormone signaling pathway [GO:0060397]; lactation [GO:0007595]; mammary gland alveolus development [GO:0060749]; mammary gland epithelial cell differentiation [GO:0060644]; negative regulation of apoptotic process [GO:0043066]; prostate gland growth [GO:0060736]; regulation of cell adhesion [GO:0030155]; regulation of epithelial cell differentiation [GO:0030856]; steroid biosynthetic process [GO:0006694]; T cell activation [GO:0042110]	metal ion binding [GO:0046872]; ornithine decarboxylase activator activity [GO:0042978]; peptide hormone binding [GO:0017046]; prolactin receptor activity [GO:0004925]; protein homodimerization activity [GO:0042803]	cell surface [GO:0009986]; endosome lumen [GO:0031904]; extracellular region [GO:0005576]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]
P04070	PROC_HUMAN	Vitamin K-dependent protein C (EC 3.4.21.69) (Anticoagulant protein C) (Autoprothrombin IIA) (Blood coagulation factor XIV) [Cleaved into: Vitamin K-dependent protein C light chain; Vitamin K-dependent protein C heavy chain; Activation peptide]	PROC	1AUT;1LQV;1PCU;2PCT;3F6U;3JTC;4DT7;	CHEMBL4444;	P04070;	DB00025;DB00170;DB00464;		PF00008;PF00594;PF00089;	IPR017857;IPR001881;IPR013032;IPR000742;IPR000152;IPR018097;IPR000294;IPR012224;IPR009003;IPR001314;IPR001254;IPR018114;IPR033116;	blood coagulation [GO:0007596]; ER to Golgi vesicle-mediated transport [GO:0006888]; leukocyte migration [GO:0050900]; negative regulation of apoptotic process [GO:0043066]; negative regulation of blood coagulation [GO:0030195]; negative regulation of coagulation [GO:0050819]; negative regulation of inflammatory response [GO:0050728]; peptidyl-glutamic acid carboxylation [GO:0017187]; positive regulation of establishment of endothelial barrier [GO:1903142]; proteolysis [GO:0006508]; signal peptide processing [GO:0006465]	calcium ion binding [GO:0005509]; serine-type endopeptidase activity [GO:0004252]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum lumen [GO:0005788]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; Golgi apparatus [GO:0005794]; Golgi lumen [GO:0005796]
O43272	PROD_HUMAN	Proline dehydrogenase 1, mitochondrial (EC 1.5.5.2) (Proline oxidase) (Proline oxidase 2) (p53-induced gene 6 protein)	PRODH PIG6 POX2				DB06756;DB00172;	PATHWAY: Amino-acid degradation; L-proline degradation into L-glutamate; L-glutamate from L-proline: step 1/2.	PF01619;	IPR029041;IPR002872;IPR015659;	4-hydroxyproline catabolic process [GO:0019470]; intrinsic apoptotic signaling pathway in response to oxidative stress [GO:0008631]; positive regulation of cell death [GO:0010942]; proline catabolic process [GO:0006562]; proline catabolic process to glutamate [GO:0010133]; proline metabolic process [GO:0006560]	FAD binding [GO:0071949]; proline dehydrogenase activity [GO:0004657]	mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]
O94903	PROSC_HUMAN	Proline synthase co-transcribed bacterial homolog protein	PROSC				DB00172;		PF01168;	IPR001608;IPR029066;IPR011078;		pyridoxal phosphate binding [GO:0030170]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; intracellular [GO:0005622]; mitochondrion [GO:0005739]
P07225	PROS_HUMAN	Vitamin K-dependent protein S	PROS1 PROS	1Z6C;			DB00055;DB00170;DB00464;		PF00008;PF07645;PF00594;PF00054;PF02210;	IPR017857;IPR013320;IPR001881;IPR013032;IPR000742;IPR000152;IPR018097;IPR000294;IPR009030;IPR001791;IPR033189;	blood coagulation [GO:0007596]; ER to Golgi vesicle-mediated transport [GO:0006888]; fibrinolysis [GO:0042730]; leukocyte migration [GO:0050900]; peptidyl-glutamic acid carboxylation [GO:0017187]; platelet degranulation [GO:0002576]; regulation of complement activation [GO:0030449]; signal peptide processing [GO:0006465]	calcium ion binding [GO:0005509]; endopeptidase inhibitor activity [GO:0004866]	blood microparticle [GO:0072562]; endoplasmic reticulum membrane [GO:0005789]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; Golgi lumen [GO:0005796]; Golgi membrane [GO:0000139]; plasma membrane [GO:0005886]; platelet alpha granule lumen [GO:0031093]
P22891	PROZ_HUMAN	Vitamin K-dependent protein Z	PROZ	3F1S;3H5C;			DB00170;		PF00008;PF00594;PF00089;	IPR017857;IPR001881;IPR013032;IPR000742;IPR000152;IPR000294;IPR012224;IPR009003;IPR001254;	blood coagulation [GO:0007596]; ER to Golgi vesicle-mediated transport [GO:0006888]; peptidyl-glutamic acid carboxylation [GO:0017187]; signal peptide processing [GO:0006465]	calcium ion binding [GO:0005509]; serine-type endopeptidase activity [GO:0004252]	endoplasmic reticulum lumen [GO:0005788]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; Golgi lumen [GO:0005796]
P24158	PRTN3_HUMAN	Myeloblastin (EC 3.4.21.76) (AGP7) (C-ANCA antigen) (Leukocyte proteinase 3) (PR-3) (PR3) (Neutrophil proteinase 4) (NP-4) (P29) (Wegener autoantigen)	PRTN3 MBN	1FUJ;	CHEMBL3900;	P24158;			PF00089;	IPR009003;IPR001314;IPR001254;IPR018114;IPR033116;	blood coagulation [GO:0007596]; collagen catabolic process [GO:0030574]; mature conventional dendritic cell differentiation [GO:0097029]; negative regulation of phagocytosis [GO:0050765]; positive regulation of cell proliferation [GO:0008284]	enzyme binding [GO:0019899]; serine-type endopeptidase activity [GO:0004252]; serine-type peptidase activity [GO:0008236]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; plasma membrane [GO:0005886]
P20618	PSB1_HUMAN	Proteasome subunit beta type-1 (EC 3.4.25.1) (Macropain subunit C5) (Multicatalytic endopeptidase complex subunit C5) (Proteasome component C5) (Proteasome gamma chain)	PSMB1 PSC5	4R3O;4R67;5A0Q;5GJQ;5GJR;5L4G;5LE5;5LEX;5LEY;5LEZ;5LF0;5LF1;5LF3;5LF4;5LF6;5LF7;	CHEMBL4208;	P20618;	DB00188;DB08889;		PF00227;	IPR029055;IPR016050;IPR001353;IPR023333;	anaphase-promoting complex-dependent catabolic process [GO:0031145]; antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent [GO:0002479]; Fc-epsilon receptor signaling pathway [GO:0038095]; MAPK cascade [GO:0000165]; negative regulation of canonical Wnt signaling pathway [GO:0090090]; negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle [GO:0051436]; NIK/NF-kappaB signaling [GO:0038061]; positive regulation of canonical Wnt signaling pathway [GO:0090263]; positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition [GO:0051437]; proteasome-mediated ubiquitin-dependent protein catabolic process [GO:0043161]; protein polyubiquitination [GO:0000209]; regulation of cellular amino acid metabolic process [GO:0006521]; regulation of mRNA stability [GO:0043488]; stimulatory C-type lectin receptor signaling pathway [GO:0002223]; T cell receptor signaling pathway [GO:0050852]; tumor necrosis factor-mediated signaling pathway [GO:0033209]; viral process [GO:0016032]; Wnt signaling pathway, planar cell polarity pathway [GO:0060071]	threonine-type endopeptidase activity [GO:0004298]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; proteasome complex [GO:0000502]; proteasome core complex [GO:0005839]
P49721	PSB2_HUMAN	Proteasome subunit beta type-2 (EC 3.4.25.1) (Macropain subunit C7-I) (Multicatalytic endopeptidase complex subunit C7-I) (Proteasome component C7-I)	PSMB2	4R3O;4R67;5A0Q;5GJQ;5GJR;5L4G;5LE5;5LEX;5LEY;5LEZ;5LF0;5LF1;5LF3;5LF4;5LF6;5LF7;	CHEMBL3492;	P49721;	DB00188;DB08889;		PF00227;	IPR029055;IPR016050;IPR001353;IPR023333;	anaphase-promoting complex-dependent catabolic process [GO:0031145]; antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent [GO:0002479]; Fc-epsilon receptor signaling pathway [GO:0038095]; MAPK cascade [GO:0000165]; negative regulation of canonical Wnt signaling pathway [GO:0090090]; negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle [GO:0051436]; NIK/NF-kappaB signaling [GO:0038061]; positive regulation of canonical Wnt signaling pathway [GO:0090263]; positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition [GO:0051437]; proteasome-mediated ubiquitin-dependent protein catabolic process [GO:0043161]; protein polyubiquitination [GO:0000209]; regulation of cellular amino acid metabolic process [GO:0006521]; regulation of mRNA stability [GO:0043488]; response to organic cyclic compound [GO:0014070]; response to organonitrogen compound [GO:0010243]; stimulatory C-type lectin receptor signaling pathway [GO:0002223]; T cell receptor signaling pathway [GO:0050852]; tumor necrosis factor-mediated signaling pathway [GO:0033209]; viral process [GO:0016032]; Wnt signaling pathway, planar cell polarity pathway [GO:0060071]	threonine-type endopeptidase activity [GO:0004298]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; proteasome complex [GO:0000502]; proteasome core complex [GO:0005839]
P28074	PSB5_HUMAN	Proteasome subunit beta type-5 (EC 3.4.25.1) (Macropain epsilon chain) (Multicatalytic endopeptidase complex epsilon chain) (Proteasome chain 6) (Proteasome epsilon chain) (Proteasome subunit MB1) (Proteasome subunit X)	PSMB5 LMPX MB1 X	4R3O;4R67;5A0Q;5GJQ;5GJR;5L4G;5LE5;5LEX;5LEY;5LEZ;5LF0;5LF1;5LF3;5LF4;5LF6;5LF7;	CHEMBL4662;	P28074;	DB00188;DB08889;		PF00227;	IPR029055;IPR000243;IPR016050;IPR001353;IPR023333;	anaphase-promoting complex-dependent catabolic process [GO:0031145]; antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent [GO:0002479]; Fc-epsilon receptor signaling pathway [GO:0038095]; MAPK cascade [GO:0000165]; negative regulation of canonical Wnt signaling pathway [GO:0090090]; negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle [GO:0051436]; NIK/NF-kappaB signaling [GO:0038061]; positive regulation of canonical Wnt signaling pathway [GO:0090263]; positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition [GO:0051437]; proteasome-mediated ubiquitin-dependent protein catabolic process [GO:0043161]; protein polyubiquitination [GO:0000209]; proteolysis [GO:0006508]; regulation of cellular amino acid metabolic process [GO:0006521]; regulation of mRNA stability [GO:0043488]; response to oxidative stress [GO:0006979]; stimulatory C-type lectin receptor signaling pathway [GO:0002223]; T cell receptor signaling pathway [GO:0050852]; tumor necrosis factor-mediated signaling pathway [GO:0033209]; viral process [GO:0016032]; Wnt signaling pathway, planar cell polarity pathway [GO:0060071]	peptidase activity [GO:0008233]; threonine-type endopeptidase activity [GO:0004298]	centrosome [GO:0005813]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; proteasome complex [GO:0000502]; proteasome core complex [GO:0005839]
Q99460	PSMD1_HUMAN	26S proteasome non-ATPase regulatory subunit 1 (26S proteasome regulatory subunit RPN2) (26S proteasome regulatory subunit S1) (26S proteasome subunit p112)	PSMD1	5GJQ;5GJR;5L4K;			DB00188;		PF01851;	IPR016642;IPR011989;IPR016024;IPR002015;	anaphase-promoting complex-dependent catabolic process [GO:0031145]; antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent [GO:0002479]; Fc-epsilon receptor signaling pathway [GO:0038095]; MAPK cascade [GO:0000165]; negative regulation of canonical Wnt signaling pathway [GO:0090090]; negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle [GO:0051436]; NIK/NF-kappaB signaling [GO:0038061]; positive regulation of canonical Wnt signaling pathway [GO:0090263]; positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition [GO:0051437]; proteasome-mediated ubiquitin-dependent protein catabolic process [GO:0043161]; protein polyubiquitination [GO:0000209]; regulation of cellular amino acid metabolic process [GO:0006521]; regulation of mRNA stability [GO:0043488]; stimulatory C-type lectin receptor signaling pathway [GO:0002223]; T cell receptor signaling pathway [GO:0050852]; tumor necrosis factor-mediated signaling pathway [GO:0033209]; Wnt signaling pathway, planar cell polarity pathway [GO:0060071]	enzyme regulator activity [GO:0030234]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; proteasome accessory complex [GO:0022624]; proteasome complex [GO:0000502]; proteasome regulatory particle [GO:0005838]; proteasome regulatory particle, base subcomplex [GO:0008540]; proteasome storage granule [GO:0034515]
Q13200	PSMD2_HUMAN	26S proteasome non-ATPase regulatory subunit 2 (26S proteasome regulatory subunit RPN1) (26S proteasome regulatory subunit S2) (26S proteasome subunit p97) (Protein 55.11) (Tumor necrosis factor type 1 receptor-associated protein 2)	PSMD2 TRAP2	5GJQ;5GJR;5L4K;			DB00188;		PF01851;	IPR016643;IPR016024;IPR002015;	anaphase-promoting complex-dependent catabolic process [GO:0031145]; antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent [GO:0002479]; Fc-epsilon receptor signaling pathway [GO:0038095]; MAPK cascade [GO:0000165]; negative regulation of canonical Wnt signaling pathway [GO:0090090]; negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle [GO:0051436]; NIK/NF-kappaB signaling [GO:0038061]; positive regulation of canonical Wnt signaling pathway [GO:0090263]; positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition [GO:0051437]; proteasome-mediated ubiquitin-dependent protein catabolic process [GO:0043161]; protein polyubiquitination [GO:0000209]; regulation of cellular amino acid metabolic process [GO:0006521]; regulation of mRNA stability [GO:0043488]; stimulatory C-type lectin receptor signaling pathway [GO:0002223]; T cell receptor signaling pathway [GO:0050852]; tumor necrosis factor-mediated signaling pathway [GO:0033209]; Wnt signaling pathway, planar cell polarity pathway [GO:0060071]	enzyme regulator activity [GO:0030234]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; proteasome accessory complex [GO:0022624]; proteasome complex [GO:0000502]; proteasome regulatory particle [GO:0005838]; proteasome regulatory particle, base subcomplex [GO:0008540]; proteasome storage granule [GO:0034515]
O60760	PTGD2_HUMAN	Hematopoietic prostaglandin D synthase (H-PGDS) (EC 5.3.99.2) (GST class-sigma) (Glutathione S-transferase) (EC 2.5.1.18) (Glutathione-dependent PGD synthase) (Glutathione-requiring prostaglandin D synthase) (Prostaglandin-H2 D-isomerase)	HPGDS GSTS PGDS PTGDS2	1IYH;1IYI;1V40;2CVD;2VCQ;2VCW;2VCX;2VCZ;2VD0;2VD1;3EE2;3KXO;3VI5;3VI7;4EC0;4EDY;4EDZ;4EE0;5AIS;5AIV;5AIX;	CHEMBL5879;	O60760;	DB00143;DB07615;		PF14497;PF02798;	IPR010987;IPR004045;IPR004046;IPR012336;	cyclooxygenase pathway [GO:0019371]; glutathione derivative biosynthetic process [GO:1901687]; locomotory behavior [GO:0007626]; negative regulation of male germ cell proliferation [GO:2000255]; prostaglandin metabolic process [GO:0006693]; signal transduction [GO:0007165]	calcium ion binding [GO:0005509]; glutathione transferase activity [GO:0004364]; magnesium ion binding [GO:0000287]; prostaglandin-D synthase activity [GO:0004667]; protein homodimerization activity [GO:0042803]	cytoplasm [GO:0005737]; cytosol [GO:0005829]
Q16647	PTGIS_HUMAN	Prostacyclin synthase (EC 5.3.99.4) (Prostaglandin I2 synthase)	PTGIS CYP8 CYP8A1	2IAG;3B6H;	CHEMBL4428;	Q16647;	DB01240;DB00812;		PF00067;	IPR001128;IPR024204;IPR002403;IPR027286;	apoptotic signaling pathway [GO:0097190]; cellular response to hypoxia [GO:0071456]; cellular response to interleukin-1 [GO:0071347]; cellular response to interleukin-6 [GO:0071354]; cyclooxygenase pathway [GO:0019371]; decidualization [GO:0046697]; embryo implantation [GO:0007566]; icosanoid metabolic process [GO:0006690]; negative regulation of inflammatory response [GO:0050728]; negative regulation of NF-kappaB transcription factor activity [GO:0032088]; negative regulation of nitric oxide biosynthetic process [GO:0045019]; nicotinamide metabolic process [GO:0006769]; positive regulation of angiogenesis [GO:0045766]; positive regulation of execution phase of apoptosis [GO:1900119]; positive regulation of peroxisome proliferator activated receptor signaling pathway [GO:0035360]; prostaglandin biosynthetic process [GO:0001516]	heme binding [GO:0020037]; iron ion binding [GO:0005506]; monooxygenase activity [GO:0004497]; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen [GO:0016705]; prostaglandin-I synthase activity [GO:0008116]	caveola [GO:0005901]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; extracellular space [GO:0005615]; integral component of membrane [GO:0016021]; nucleus [GO:0005634]
Q03431	PTHR1_HUMAN	Parathyroid hormone/parathyroid hormone-related peptide receptor (PTH/PTHrP type I receptor) (PTH/PTHr receptor) (Parathyroid hormone 1 receptor) (PTH1 receptor)	PTH1R PTHR PTHR1	1BL1;1ET2;1ET3;3C4M;3H3G;3L2J;4Z8J;	CHEMBL1793;	Q03431;	DB05829;DB06285;		PF00002;PF02793;	IPR017981;IPR001879;IPR002170;IPR000832;IPR017983;	adenylate cyclase-activating G-protein coupled receptor signaling pathway [GO:0007189]; adenylate cyclase-modulating G-protein coupled receptor signaling pathway [GO:0007188]; aging [GO:0007568]; bone mineralization [GO:0030282]; bone resorption [GO:0045453]; cell maturation [GO:0048469]; cell surface receptor signaling pathway [GO:0007166]; chondrocyte differentiation [GO:0002062]; G-protein coupled receptor signaling pathway [GO:0007186]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; negative regulation of cell proliferation [GO:0008285]; osteoblast development [GO:0002076]; phospholipase C-activating G-protein coupled receptor signaling pathway [GO:0007200]; positive regulation of cell proliferation [GO:0008284]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of inositol phosphate biosynthetic process [GO:0060732]; skeletal system development [GO:0001501]	parathyroid hormone receptor activity [GO:0004991]; peptide hormone binding [GO:0017046]; protein self-association [GO:0043621]	apical plasma membrane [GO:0016324]; basolateral plasma membrane [GO:0016323]; brush border membrane [GO:0031526]; cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]
P01270	PTHY_HUMAN	Parathyroid hormone (PTH) (Parathormone) (Parathyrin)	PTH	1BWX;1ET1;1ET2;1FVY;1HPH;1HPY;1HTH;1ZWA;1ZWB;1ZWD;1ZWE;1ZWF;1ZWG;2L1X;3C4M;					PF01279;	IPR003625;IPR001415;	adenylate cyclase-activating G-protein coupled receptor signaling pathway [GO:0007189]; bone resorption [GO:0045453]; cAMP metabolic process [GO:0046058]; cell-cell signaling [GO:0007267]; cellular calcium ion homeostasis [GO:0006874]; cellular macromolecule biosynthetic process [GO:0034645]; G-protein coupled receptor signaling pathway [GO:0007186]; homeostasis of number of cells within a tissue [GO:0048873]; hormone-mediated apoptotic signaling pathway [GO:0008628]; negative regulation of apoptotic process in bone marrow [GO:0071866]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; positive regulation of bone mineralization [GO:0030501]; positive regulation of cAMP biosynthetic process [GO:0030819]; positive regulation of cell proliferation in bone marrow [GO:0071864]; positive regulation of glucose import [GO:0046326]; positive regulation of glycogen biosynthetic process [GO:0045725]; positive regulation of osteoclast proliferation [GO:0090290]; positive regulation of signal transduction [GO:0009967]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; regulation of gene expression [GO:0010468]; response to cadmium ion [GO:0046686]; response to drug [GO:0042493]; response to ethanol [GO:0045471]; response to fibroblast growth factor [GO:0071774]; response to lead ion [GO:0010288]; response to parathyroid hormone [GO:0071107]; response to vitamin D [GO:0033280]; Rho protein signal transduction [GO:0007266]; skeletal system development [GO:0001501]	hormone activity [GO:0005179]; parathyroid hormone receptor binding [GO:0031856]; peptide hormone receptor binding [GO:0051428]; transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding [GO:0003705]	extracellular region [GO:0005576]; extracellular space [GO:0005615]; intracellular [GO:0005622]
Q06124	PTN11_HUMAN	Tyrosine-protein phosphatase non-receptor type 11 (EC 3.1.3.48) (Protein-tyrosine phosphatase 1D) (PTP-1D) (Protein-tyrosine phosphatase 2C) (PTP-2C) (SH-PTP2) (SHP-2) (Shp2) (SH-PTP3)	PTPN11 PTP2C SHPTP2	2SHP;3B7O;3MOW;3O5X;3TKZ;3TL0;3ZM0;3ZM1;3ZM2;3ZM3;4DGP;4DGX;4GWF;4H1O;4H34;4JE4;4JEG;4JMG;4NWF;4NWG;4OHD;4OHE;4OHH;4OHI;4OHL;4PVG;4QSY;4RDD;5DF6;5EHP;5EHR;5I6V;5IBM;5IBS;	CHEMBL3864;	Q06124;			PF00017;PF00102;	IPR029021;IPR000242;IPR000980;IPR016130;IPR003595;IPR012152;IPR000387;	abortive mitotic cell cycle [GO:0033277]; activation of MAPK activity [GO:0000187]; atrioventricular canal development [GO:0036302]; axonogenesis [GO:0007409]; Bergmann glial cell differentiation [GO:0060020]; brain development [GO:0007420]; cerebellar cortex formation [GO:0021697]; DNA damage checkpoint [GO:0000077]; ephrin receptor signaling pathway [GO:0048013]; epidermal growth factor receptor signaling pathway [GO:0007173]; ERBB signaling pathway [GO:0038127]; face morphogenesis [GO:0060325]; fibroblast growth factor receptor signaling pathway [GO:0008543]; genitalia development [GO:0048806]; glucose homeostasis [GO:0042593]; heart development [GO:0007507]; homeostasis of number of cells within a tissue [GO:0048873]; hormone-mediated signaling pathway [GO:0009755]; hormone metabolic process [GO:0042445]; inner ear development [GO:0048839]; integrin-mediated signaling pathway [GO:0007229]; intestinal epithelial cell migration [GO:0061582]; leukocyte migration [GO:0050900]; megakaryocyte development [GO:0035855]; microvillus organization [GO:0032528]; multicellular organismal reproductive process [GO:0048609]; multicellular organism growth [GO:0035264]; negative regulation of cell adhesion mediated by integrin [GO:0033629]; negative regulation of cortisol secretion [GO:0051463]; negative regulation of growth hormone secretion [GO:0060125]; negative regulation of insulin secretion [GO:0046676]; neurotrophin TRK receptor signaling pathway [GO:0048011]; organ growth [GO:0035265]; peptidyl-tyrosine dephosphorylation [GO:0035335]; phosphatidylinositol-mediated signaling [GO:0048015]; platelet activation [GO:0030168]; platelet-derived growth factor receptor signaling pathway [GO:0048008]; platelet formation [GO:0030220]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of glucose import in response to insulin stimulus [GO:2001275]; positive regulation of hormone secretion [GO:0046887]; positive regulation of mitotic cell cycle [GO:0045931]; regulation of cell adhesion mediated by integrin [GO:0033628]; regulation of multicellular organism growth [GO:0040014]; regulation of phosphatidylinositol 3-kinase signaling [GO:0014066]; regulation of protein complex assembly [GO:0043254]; regulation of protein export from nucleus [GO:0046825]; regulation of type I interferon-mediated signaling pathway [GO:0060338]; T cell costimulation [GO:0031295]; triglyceride metabolic process [GO:0006641]	1-phosphatidylinositol-3-kinase activity [GO:0016303]; insulin receptor binding [GO:0005158]; non-membrane spanning protein tyrosine phosphatase activity [GO:0004726]; phosphatidylinositol-4,5-bisphosphate 3-kinase activity [GO:0046934]; phosphoprotein phosphatase activity [GO:0004721]; protein tyrosine phosphatase activity [GO:0004725]; SH3/SH2 adaptor activity [GO:0005070]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; protein complex [GO:0043234]
P18031	PTN1_HUMAN	Tyrosine-protein phosphatase non-receptor type 1 (EC 3.1.3.48) (Protein-tyrosine phosphatase 1B) (PTP-1B)	PTPN1 PTP1B	1A5Y;1AAX;1BZC;1BZH;1BZJ;1C83;1C84;1C85;1C86;1C87;1C88;1ECV;1EEN;1EEO;1G1F;1G1G;1G1H;1G7F;1G7G;1GFY;1I57;1JF7;1KAK;1KAV;1L8G;1LQF;1NL9;1NNY;1NO6;1NWE;1NWL;1NZ7;1OEM;1OEO;1OES;1OET;1OEU;1OEV;1ONY;1ONZ;1PA1;1PH0;1PTT;1PTU;1PTV;1PTY;1PXH;1PYN;1Q1M;1Q6J;1Q6M;1Q6N;1Q6P;1Q6S;1Q6T;1QXK;1SUG;1T48;1T49;1T4J;1WAX;1XBO;2AZR;2B07;2B4S;2BGD;2BGE;2CM2;2CM3;2CM7;2CM8;2CMA;2CMB;2CMC;2CNE;2CNF;2CNG;2CNH;2CNI;2F6F;2F6T;2F6V;2F6W;2F6Y;2F6Z;2F70;2F71;2FJM;2FJN;2H4G;2H4K;2HB1;2HNP;2HNQ;2NT7;2NTA;2QBP;2QBQ;2QBR;2QBS;2VEU;2VEV;2VEW;2VEX;2VEY;2ZMM;2ZN7;3A5J;3A5K;3CWE;3D9C;3EAX;3EB1;3EU0;3I7Z;3I80;3QKP;3QKQ;3SME;3ZMP;3ZMQ;3ZV2;4BJO;4I8N;4QAH;4QAP;4QBE;4QBW;4Y14;4ZRT;	CHEMBL335;	P18031;	DB01133;		PF00102;	IPR029021;IPR000242;IPR012265;IPR016130;IPR003595;IPR000387;	actin cytoskeleton reorganization [GO:0031532]; activation of JUN kinase activity [GO:0007257]; activation of signaling protein activity involved in unfolded protein response [GO:0006987]; endoplasmic reticulum unfolded protein response [GO:0030968]; insulin receptor signaling pathway [GO:0008286]; IRE1-mediated unfolded protein response [GO:0036498]; JAK-STAT cascade involved in growth hormone signaling pathway [GO:0060397]; negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway [GO:1902236]; negative regulation of ERK1 and ERK2 cascade [GO:0070373]; negative regulation of insulin receptor signaling pathway [GO:0046627]; negative regulation of MAP kinase activity [GO:0043407]; negative regulation of PERK-mediated unfolded protein response [GO:1903898]; negative regulation of signal transduction [GO:0009968]; negative regulation of vascular endothelial growth factor receptor signaling pathway [GO:0030948]; peptidyl-tyrosine dephosphorylation [GO:0035335]; peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activity [GO:1990264]; platelet-derived growth factor receptor-beta signaling pathway [GO:0035791]; positive regulation of IRE1-mediated unfolded protein response [GO:1903896]; positive regulation of protein tyrosine kinase activity [GO:0061098]; positive regulation of receptor catabolic process [GO:2000646]; protein dephosphorylation [GO:0006470]; regulation of endocytosis [GO:0030100]; regulation of hepatocyte growth factor receptor signaling pathway [GO:1902202]; regulation of intracellular protein transport [GO:0033157]; regulation of signal transduction [GO:0009966]; regulation of type I interferon-mediated signaling pathway [GO:0060338]	cadherin binding involved in cell-cell adhesion [GO:0098641]; enzyme binding [GO:0019899]; ephrin receptor binding [GO:0046875]; poly(A) RNA binding [GO:0044822]; protein kinase binding [GO:0019901]; protein tyrosine phosphatase activity [GO:0004725]; receptor tyrosine kinase binding [GO:0030971]; zinc ion binding [GO:0008270]	cell-cell adherens junction [GO:0005913]; cytoplasmic side of endoplasmic reticulum membrane [GO:0098554]; cytoplasmic vesicle [GO:0031410]; cytosol [GO:0005829]; early endosome [GO:0005769]; endoplasmic reticulum [GO:0005783]; sorting endosome [GO:0097443]
P29074	PTN4_HUMAN	Tyrosine-protein phosphatase non-receptor type 4 (EC 3.1.3.48) (Protein-tyrosine phosphatase MEG1) (MEG) (PTPase-MEG1)	PTPN4	2CS5;2I75;2VPH;3NFK;3NFL;5EYZ;5EZ0;	CHEMBL3165;	P29074;	DB00630;		PF08736;PF09380;PF00373;PF09379;PF00595;PF00102;	IPR019749;IPR014847;IPR014352;IPR019748;IPR019747;IPR000299;IPR018979;IPR018980;IPR001478;IPR011993;IPR029021;IPR000242;IPR016130;IPR003595;IPR012151;IPR000387;IPR029071;	protein dephosphorylation [GO:0006470]	non-membrane spanning protein tyrosine phosphatase activity [GO:0004726]	cytoplasm [GO:0005737]; cytoplasmic side of plasma membrane [GO:0009898]; cytoskeleton [GO:0005856]
P48651	PTSS1_HUMAN	Phosphatidylserine synthase 1 (PSS-1) (PtdSer synthase 1) (EC 2.7.8.29) (Serine-exchange enzyme I)	PTDSS1 KIAA0024 PSSA				DB00144;	PATHWAY: Phospholipid metabolism; phosphatidylserine biosynthesis.	PF03034;	IPR004277;	phosphatidylserine biosynthetic process [GO:0006659]; phospholipid biosynthetic process [GO:0008654]	transferase activity [GO:0016740]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; membrane [GO:0016020]
Q9BVG9	PTSS2_HUMAN	Phosphatidylserine synthase 2 (PSS-2) (PtdSer synthase 2) (EC 2.7.8.29) (Serine-exchange enzyme II)	PTDSS2 PSS2				DB00144;	PATHWAY: Phospholipid metabolism; phosphatidylserine biosynthesis.	PF03034;	IPR004277;	phosphatidylserine biosynthetic process [GO:0006659]; phospholipid biosynthetic process [GO:0008654]	CDP-diacylglycerol-serine O-phosphatidyltransferase activity [GO:0003882]; transferase activity [GO:0016740]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; membrane [GO:0016020]
Q14671	PUM1_HUMAN	Pumilio homolog 1 (HsPUM) (Pumilio-1)	PUM1 KIAA0099 PUMH1	1IB2;1M8W;1M8X;1M8Y;1M8Z;2YJY;3BSB;3BSX;3Q0L;3Q0M;3Q0N;3Q0O;3Q0P;					PF00806;	IPR011989;IPR016024;IPR033133;IPR033712;IPR001313;	adult locomotory behavior [GO:0008344]; mRNA destabilization [GO:0061157]; positive regulation of gene silencing by miRNA [GO:2000637]; positive regulation of RIG-I signaling pathway [GO:1900246]; posttranscriptional gene silencing [GO:0016441]; posttranscriptional regulation of gene expression [GO:0010608]; regulation of cell cycle [GO:0051726]; regulation of chromosome segregation [GO:0051983]; regulation of gene silencing by miRNA [GO:0060964]; regulation of mRNA stability [GO:0043488]; spermatogenesis [GO:0007283]; stem cell differentiation [GO:0048863]	mRNA 3'-UTR binding [GO:0003730]; poly(A) RNA binding [GO:0044822]; RNA binding [GO:0003723]	cytoplasmic mRNA processing body [GO:0000932]; cytoplasmic stress granule [GO:0010494]; cytosol [GO:0005829]
Q06203	PUR1_HUMAN	Amidophosphoribosyltransferase (ATase) (EC 2.4.2.14) (Glutamine phosphoribosylpyrophosphate amidotransferase) (GPAT)	PPAT GPAT		CHEMBL2362992;		DB00544;DB00130;DB01033;	PATHWAY: Purine metabolism; IMP biosynthesis via de novo pathway; N(1)-(5-phospho-D-ribosyl)glycinamide from 5-phospho-alpha-D-ribose 1-diphosphate: step 1/2.	PF00156;	IPR017932;IPR029055;IPR000836;IPR029057;IPR005854;	'de novo' IMP biosynthetic process [GO:0006189]; animal organ regeneration [GO:0031100]; cellular response to drug [GO:0035690]; cellular response to insulin stimulus [GO:0032869]; G1/S transition of mitotic cell cycle [GO:0000082]; glutamine catabolic process [GO:0006543]; kidney development [GO:0001822]; lactation [GO:0007595]; maternal process involved in female pregnancy [GO:0060135]; nucleoside metabolic process [GO:0009116]; protein homotetramerization [GO:0051289]; purine nucleobase biosynthetic process [GO:0009113]; purine nucleotide biosynthetic process [GO:0006164]; purine ribonucleoside monophosphate biosynthetic process [GO:0009168]	4 iron, 4 sulfur cluster binding [GO:0051539]; amidophosphoribosyltransferase activity [GO:0004044]; metal ion binding [GO:0046872]	cytosol [GO:0005829]
P22102	O14659_HUMAN,PUR2_HUMAN	Trifunctional purine biosynthetic protein adenosine-3 [Includes: Phosphoribosylamine--glycine ligase (EC 6.3.4.13) (Glycinamide ribonucleotide synthetase) (GARS) (Phosphoribosylglycinamide synthetase); Phosphoribosylformylglycinamidine cyclo-ligase (EC 6.3.3.1) (AIR synthase) (AIRS) (Phosphoribosyl-aminoimidazole synthetase); Phosphoribosylglycinamide formyltransferase (EC 2.1.2.2) (5'-phosphoribosylglycinamide transformylase) (GAR transformylase) (GART)]	GART PGFT PRGS	1MEJ;1MEN;1MEO;1NJS;1RBM;1RBQ;1RBY;1RBZ;1RC0;1RC1;1ZLX;1ZLY;2QK4;2V9Y;4EW1;4EW2;4EW3;4ZYT;4ZYU;4ZYV;4ZYW;4ZYX;4ZYY;4ZYZ;4ZZ0;4ZZ1;4ZZ2;4ZZ3;5J9F;	CHEMBL3972;	P22102;	DB00642;	PATHWAY: Purine metabolism; IMP biosynthesis via de novo pathway; 5-amino-1-(5-phospho-D-ribosyl)imidazole from N(2)-formyl-N(1)-(5-phospho-D-ribosyl)glycinamide: step 2/2.; PATHWAY: Purine metabolism; IMP biosynthesis via de novo pathway; N(1)-(5-phospho-D-ribosyl)glycinamide from 5-phospho-alpha-D-ribose 1-diphosphate: step 2/2.; PATHWAY: Purine metabolism; IMP biosynthesis via de novo pathway; N(2)-formyl-N(1)-(5-phospho-D-ribosyl)glycinamide from N(1)-(5-phospho-D-ribosyl)glycinamide (10-formyl THF route): step 1/1.	PF00586;PF02769;PF00551;PF01071;PF02843;PF02844;	IPR010918;IPR011761;IPR013815;IPR013816;IPR002376;IPR001555;IPR016185;IPR020561;IPR000115;IPR020560;IPR020559;IPR020562;IPR016188;IPR004733;IPR004607;IPR011054;	'de novo' IMP biosynthetic process [GO:0006189]; brainstem development [GO:0003360]; cerebellum development [GO:0021549]; cerebral cortex development [GO:0021987]; glycine metabolic process [GO:0006544]; purine nucleobase biosynthetic process [GO:0009113]; purine ribonucleoside monophosphate biosynthetic process [GO:0009168]; response to inorganic substance [GO:0010035]; response to organic substance [GO:0010033]; tetrahydrofolate biosynthetic process [GO:0046654]	ATP binding [GO:0005524]; metal ion binding [GO:0046872]; phosphoribosylamine-glycine ligase activity [GO:0004637]; phosphoribosylformylglycinamidine cyclo-ligase activity [GO:0004641]; phosphoribosylglycinamide formyltransferase activity [GO:0004644]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]
O15067	PUR4_HUMAN	Phosphoribosylformylglycinamidine synthase (FGAM synthase) (FGAMS) (EC 6.3.5.3) (Formylglycinamide ribonucleotide amidotransferase) (FGAR amidotransferase) (FGAR-AT) (Formylglycinamide ribotide amidotransferase)	PFAS KIAA0361				DB00130;	PATHWAY: Purine metabolism; IMP biosynthesis via de novo pathway; 5-amino-1-(5-phospho-D-ribosyl)imidazole from N(2)-formyl-N(1)-(5-phospho-D-ribosyl)glycinamide: step 1/2.	PF02769;	IPR010918;IPR029062;IPR017926;IPR010073;IPR016188;	'de novo' IMP biosynthetic process [GO:0006189]; glutamine metabolic process [GO:0006541]; purine nucleotide biosynthetic process [GO:0006164]; purine ribonucleoside monophosphate biosynthetic process [GO:0009168]; response to drug [GO:0042493]; ribonucleoside monophosphate biosynthetic process [GO:0009156]	ATP binding [GO:0005524]; metal ion binding [GO:0046872]; phosphoribosylformylglycinamidine synthase activity [GO:0004642]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P22234	PUR6_HUMAN	Multifunctional protein ADE2 [Includes: Phosphoribosylaminoimidazole-succinocarboxamide synthase (EC 6.3.2.6) (SAICAR synthetase); Phosphoribosylaminoimidazole carboxylase (EC 4.1.1.21) (AIR carboxylase) (AIRC)]	PAICS ADE2 AIRC PAIS	2H31;	CHEMBL5922;		DB00128;	PATHWAY: Purine metabolism; IMP biosynthesis via de novo pathway; 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide from 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxylate: step 1/2.; PATHWAY: Purine metabolism; IMP biosynthesis via de novo pathway; 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxylate from 5-amino-1-(5-phospho-D-ribosyl)imidazole (carboxylase route): step 1/1.	PF00731;PF01259;	IPR013816;IPR033626;IPR000031;IPR028923;IPR018236;	'de novo' IMP biosynthetic process [GO:0006189]; adenine biosynthetic process [GO:0046084]; purine nucleobase biosynthetic process [GO:0009113]; purine ribonucleoside monophosphate biosynthetic process [GO:0009168]	ATP binding [GO:0005524]; cadherin binding involved in cell-cell adhesion [GO:0098641]; identical protein binding [GO:0042802]; phosphoribosylaminoimidazole carboxylase activity [GO:0004638]; phosphoribosylaminoimidazolesuccinocarboxamide synthase activity [GO:0004639]	cell-cell adherens junction [GO:0005913]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]
P30566	PUR8_HUMAN	Adenylosuccinate lyase (ADSL) (ASL) (EC 4.3.2.2) (Adenylosuccinase) (ASase)	ADSL AMPS	2J91;2VD6;4FFX;4FLC;				PATHWAY: Purine metabolism; AMP biosynthesis via de novo pathway; AMP from IMP: step 2/2.; PATHWAY: Purine metabolism; IMP biosynthesis via de novo pathway; 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide from 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxylate: step 2/2.	PF10397;PF00206;	IPR019468;IPR024083;IPR020557;IPR000362;IPR022761;IPR008948;IPR004769;	'de novo' AMP biosynthetic process [GO:0044208]; 'de novo' IMP biosynthetic process [GO:0006189]; aerobic respiration [GO:0009060]; AMP biosynthetic process [GO:0006167]; protein tetramerization [GO:0051262]; purine nucleotide biosynthetic process [GO:0006164]; purine ribonucleoside monophosphate biosynthetic process [GO:0009168]; response to hypoxia [GO:0001666]; response to muscle activity [GO:0014850]; response to nutrient [GO:0007584]; response to starvation [GO:0042594]	(S)-2-(5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamido)succinate AMP-lyase (fumarate-forming) activity [GO:0070626]; N6-(1,2-dicarboxyethyl)AMP AMP-lyase (fumarate-forming) activity [GO:0004018]	cytosol [GO:0005829]; mitochondrion [GO:0005739]
P31939	PUR9_HUMAN	Bifunctional purine biosynthesis protein PURH [Cleaved into: Bifunctional purine biosynthesis protein PURH, N-terminally processed] [Includes: Phosphoribosylaminoimidazolecarboxamide formyltransferase (EC 2.1.2.3) (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase) (AICAR transformylase); IMP cyclohydrolase (EC 3.5.4.10) (ATIC) (IMP synthase) (Inosinicase)]	ATIC PURH OK/SW-cl.86	1P4R;1PKX;1PL0;	CHEMBL2518;	P31939;	DB00563;DB00642;DB00116;	PATHWAY: Purine metabolism; IMP biosynthesis via de novo pathway; 5-formamido-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide from 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide (10-formyl THF route): step 1/1.; PATHWAY: Purine metabolism; IMP biosynthesis via de novo pathway; IMP from 5-formamido-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide: step 1/1.	PF01808;PF02142;	IPR024051;IPR024050;IPR002695;IPR016193;IPR011607;	'de novo' IMP biosynthetic process [GO:0006189]; animal organ regeneration [GO:0031100]; brainstem development [GO:0003360]; cerebellum development [GO:0021549]; cerebral cortex development [GO:0021987]; dihydrofolate metabolic process [GO:0046452]; nucleobase-containing compound metabolic process [GO:0006139]; nucleoside metabolic process [GO:0009116]; purine ribonucleoside monophosphate biosynthetic process [GO:0009168]; response to inorganic substance [GO:0010035]; tetrahydrofolate biosynthetic process [GO:0046654]	cadherin binding involved in cell-cell adhesion [GO:0098641]; IMP cyclohydrolase activity [GO:0003937]; phosphoribosylaminoimidazolecarboxamide formyltransferase activity [GO:0004643]; protein homodimerization activity [GO:0042803]	cell-cell adherens junction [GO:0005913]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; mitochondrion [GO:0005739]
Q8N142	PURA1_HUMAN	Adenylosuccinate synthetase isozyme 1 (AMPSase 1) (AdSS 1) (EC 6.3.4.4) (Adenylosuccinate synthetase, basic isozyme) (Adenylosuccinate synthetase, muscle isozyme) (M-type adenylosuccinate synthetase) (IMP--aspartate ligase 1)	ADSSL1 ADSS1	2GJO;			DB00128;	PATHWAY: Purine metabolism; AMP biosynthesis via de novo pathway; AMP from IMP: step 1/2. {ECO:0000255|HAMAP-Rule:MF_03126}.	PF00709;	IPR018220;IPR033128;IPR001114;IPR027509;IPR027417;	'de novo' AMP biosynthetic process [GO:0044208]; AMP biosynthetic process [GO:0006167]; aspartate metabolic process [GO:0006531]; cellular response to drug [GO:0035690]; cellular response to electrical stimulus [GO:0071257]; glutamine metabolic process [GO:0006541]; immune system process [GO:0002376]; IMP metabolic process [GO:0046040]; purine ribonucleoside monophosphate biosynthetic process [GO:0009168]; response to muscle activity [GO:0014850]; response to starvation [GO:0042594]	adenylosuccinate synthase activity [GO:0004019]; GTPase activity [GO:0003924]; GTP binding [GO:0005525]; magnesium ion binding [GO:0000287]; phosphate ion binding [GO:0042301]	cytoplasm [GO:0005737]; cytosol [GO:0005829]
P30520	B1AQM5_HUMAN,PURA2_HUMAN	Adenylosuccinate synthetase isozyme 2 (AMPSase 2) (AdSS 2) (EC 6.3.4.4) (Adenylosuccinate synthetase, acidic isozyme) (Adenylosuccinate synthetase, liver isozyme) (L-type adenylosuccinate synthetase) (IMP--aspartate ligase 2)	ADSS ADSS2	2V40;	CHEMBL4875;	P30520;	DB00128;	PATHWAY: Purine metabolism; AMP biosynthesis via de novo pathway; AMP from IMP: step 1/2. {ECO:0000255|HAMAP-Rule:MF_03127}.	PF00709;	IPR018220;IPR033128;IPR001114;IPR027529;IPR027417;	'de novo' AMP biosynthetic process [GO:0044208]; AMP biosynthetic process [GO:0006167]; aspartate metabolic process [GO:0006531]; cellular response to electrical stimulus [GO:0071257]; immune system process [GO:0002376]; IMP metabolic process [GO:0046040]; purine ribonucleoside monophosphate biosynthetic process [GO:0009168]; response to ammonium ion [GO:0060359]; response to purine-containing compound [GO:0014074]	adenylosuccinate synthase activity [GO:0004019]; GTP binding [GO:0005525]; magnesium ion binding [GO:0000287]; phosphate ion binding [GO:0042301]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; plasma membrane [GO:0005886]
O75469	PXR_HUMAN	Nuclear receptor subfamily 1 group I member 2 (Orphan nuclear receptor PAR1) (Orphan nuclear receptor PXR) (Pregnane X receptor) (Steroid and xenobiotic receptor) (SXR)	NR1I2 PXR	1ILG;1ILH;1M13;1NRL;1SKX;2O9I;2QNV;3CTB;3HVL;3R8D;4J5W;4J5X;4NY9;4S0S;4S0T;4X1F;4X1G;4XAO;4XHD;5A86;	CHEMBL3401;	O75469;	DB01248;DB00530;DB00783;DB00977;DB01229;DB01045;DB01220;DB08864;DB00163;		PF00104;PF00105;	IPR000536;IPR001723;IPR001628;IPR013088;	drug export [GO:0046618]; exogenous drug catabolic process [GO:0042738]; negative regulation of transcription, DNA-templated [GO:0045892]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; signal transduction [GO:0007165]; steroid metabolic process [GO:0008202]; transcription initiation from RNA polymerase II promoter [GO:0006367]; xenobiotic metabolic process [GO:0006805]; xenobiotic transport [GO:0042908]	drug binding [GO:0008144]; RNA polymerase II regulatory region sequence-specific DNA binding [GO:0000977]; RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding [GO:0004879]; steroid hormone receptor activity [GO:0003707]; transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding [GO:0001228]; transcription coactivator activity [GO:0003713]; zinc ion binding [GO:0008270]	nucleoplasm [GO:0005654]
P11498	PYC_HUMAN	Pyruvate carboxylase, mitochondrial (EC 6.4.1.1) (Pyruvic carboxylase) (PCB)	PC	3BG3;3BG9;			DB00121;DB00119;	PATHWAY: Carbohydrate biosynthesis; gluconeogenesis.	PF02785;PF00289;PF00364;PF02786;PF00682;PF02436;	IPR013785;IPR011761;IPR013815;IPR013816;IPR005481;IPR001882;IPR011764;IPR005482;IPR000089;IPR003379;IPR005479;IPR009057;IPR016185;IPR000891;IPR005930;IPR011054;IPR011053;	biotin metabolic process [GO:0006768]; gluconeogenesis [GO:0006094]; lipid metabolic process [GO:0006629]; negative regulation of gene expression [GO:0010629]; positive regulation by host of viral process [GO:0044794]; positive regulation by host of viral release from host cell [GO:0044791]; pyruvate metabolic process [GO:0006090]; viral RNA genome packaging [GO:0019074]	ATP binding [GO:0005524]; biotin binding [GO:0009374]; biotin carboxylase activity [GO:0004075]; DNA binding [GO:0003677]; metal ion binding [GO:0046872]; pyruvate carboxylase activity [GO:0004736]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
P11216	PYGB_HUMAN	Glycogen phosphorylase, brain form (EC 2.4.1.1)	PYGB	5IKO;5IKP;	CHEMBL3856;	P11216;			PF00343;	IPR011833;IPR000811;	glycogen catabolic process [GO:0005980]	glycogen phosphorylase activity [GO:0008184]; pyridoxal phosphate binding [GO:0030170]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; membrane [GO:0016020]
P06737	PYGL_HUMAN	Glycogen phosphorylase, liver form (EC 2.4.1.1)	PYGL	1EM6;1EXV;1FA9;1FC0;1L5Q;1L5R;1L5S;1L7X;1XOI;2ATI;2QLL;2ZB2;3CEH;3CEJ;3CEM;3DD1;3DDS;3DDW;	CHEMBL2568;	P06737;	DB00131;		PF00343;	IPR011833;IPR000811;	5-phosphoribose 1-diphosphate biosynthetic process [GO:0006015]; glucose homeostasis [GO:0042593]; glycogen catabolic process [GO:0005980]; glycogen metabolic process [GO:0005977]; necroptotic process [GO:0070266]	AMP binding [GO:0016208]; ATP binding [GO:0005524]; bile acid binding [GO:0032052]; drug binding [GO:0008144]; glucose binding [GO:0005536]; glycogen phosphorylase activity [GO:0008184]; protein homodimerization activity [GO:0042803]; purine nucleobase binding [GO:0002060]; pyridoxal phosphate binding [GO:0030170]; vitamin binding [GO:0019842]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; plasma membrane [GO:0005886]
P11217	PYGM_HUMAN	Glycogen phosphorylase, muscle form (EC 2.4.1.1) (Myophosphorylase)	PYGM	1Z8D;	CHEMBL3526;	P11217;			PF00343;	IPR011833;IPR000811;	glycogen catabolic process [GO:0005980]; glycogen metabolic process [GO:0005977]	glycogen phosphorylase activity [GO:0008184]; nucleotide binding [GO:0000166]; pyridoxal phosphate binding [GO:0030170]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P27708	PYR1_HUMAN	CAD protein [Includes: Glutamine-dependent carbamoyl-phosphate synthase (EC 6.3.5.5); Aspartate carbamoyltransferase (EC 2.1.3.2); Dihydroorotase (EC 3.5.2.3)]	CAD	4BY3;4C6B;4C6C;4C6D;4C6E;4C6F;4C6I;4C6J;4C6K;4C6L;4C6M;4C6N;4C6O;4C6P;4C6Q;5G1N;5G1O;5G1P;	CHEMBL3093;	P27708;	DB00128;DB00130;	PATHWAY: Pyrimidine metabolism; UMP biosynthesis via de novo pathway; (S)-dihydroorotate from bicarbonate: step 1/3.; PATHWAY: Pyrimidine metabolism; UMP biosynthesis via de novo pathway; (S)-dihydroorotate from bicarbonate: step 2/3.; PATHWAY: Pyrimidine metabolism; UMP biosynthesis via de novo pathway; (S)-dihydroorotate from bicarbonate: step 3/3.	PF01979;PF02786;PF02787;PF00988;PF00117;PF02142;PF00185;PF02729;	IPR006680;IPR006132;IPR006130;IPR002082;IPR006131;IPR011761;IPR013815;IPR013816;IPR006275;IPR005480;IPR006274;IPR002474;IPR005479;IPR005483;IPR029062;IPR002195;IPR017926;IPR011059;IPR032466;IPR011607;IPR016185;	'de novo' pyrimidine nucleobase biosynthetic process [GO:0006207]; 'de novo' UMP biosynthetic process [GO:0044205]; animal organ regeneration [GO:0031100]; arginine biosynthetic process [GO:0006526]; cellular response to drug [GO:0035690]; cellular response to epidermal growth factor stimulus [GO:0071364]; citrulline biosynthetic process [GO:0019240]; drug metabolic process [GO:0017144]; female pregnancy [GO:0007565]; glutamine metabolic process [GO:0006541]; heart development [GO:0007507]; lactation [GO:0007595]; liver development [GO:0001889]; peptidyl-threonine phosphorylation [GO:0018107]; protein autophosphorylation [GO:0046777]; pyrimidine nucleoside biosynthetic process [GO:0046134]; response to amine [GO:0014075]; response to caffeine [GO:0031000]; response to cortisol [GO:0051414]; response to insulin [GO:0032868]; response to starvation [GO:0042594]; response to testosterone [GO:0033574]; urea cycle [GO:0000050]; UTP biosynthetic process [GO:0006228]	aspartate binding [GO:0070335]; aspartate carbamoyltransferase activity [GO:0004070]; ATP binding [GO:0005524]; carbamoyl-phosphate synthase (ammonia) activity [GO:0004087]; carbamoyl-phosphate synthase (glutamine-hydrolyzing) activity [GO:0004088]; dihydroorotase activity [GO:0004151]; enzyme binding [GO:0019899]; identical protein binding [GO:0042802]; protein kinase activity [GO:0004672]; zinc ion binding [GO:0008270]	cell projection [GO:0042995]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; neuronal cell body [GO:0043025]; nuclear matrix [GO:0016363]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; protein complex [GO:0043234]; terminal bouton [GO:0043195]
Q02127	PYRD_HUMAN	Dihydroorotate dehydrogenase (quinone), mitochondrial (DHOdehase) (EC 1.3.5.2) (Dihydroorotate oxidase)	DHODH	1D3G;1D3H;2B0M;2BXV;2FPT;2FPV;2FPY;2FQI;2PRH;2PRL;2PRM;2WV8;3F1Q;3FJ6;3FJL;3G0U;3G0X;3KVJ;3KVK;3KVL;3KVM;3U2O;3W7R;3ZWS;3ZWT;4IGH;4JGD;4JS3;4JTS;4JTT;4JTU;4LS0;4LS1;4LS2;4OQV;4RK8;4RKA;4RLI;4RR4;4YLW;4ZL1;4ZMG;5HIN;	CHEMBL1966;	Q02127;	DB01117;DB01097;DB08880;	PATHWAY: Pyrimidine metabolism; UMP biosynthesis via de novo pathway; orotate from (S)-dihydroorotate (quinone route): step 1/1.	PF01180;	IPR013785;IPR005720;IPR005719;IPR001295;	'de novo' pyrimidine nucleobase biosynthetic process [GO:0006207]; 'de novo' UMP biosynthetic process [GO:0044205]; female pregnancy [GO:0007565]; lactation [GO:0007595]; positive regulation of apoptotic process [GO:0043065]; pyrimidine nucleoside biosynthetic process [GO:0046134]; regulation of mitochondrial fission [GO:0090140]; response to caffeine [GO:0031000]; response to drug [GO:0042493]; response to L-arginine [GO:1903576]; response to starvation [GO:0042594]	dihydroorotate dehydrogenase activity [GO:0004152]; drug binding [GO:0008144]; FMN binding [GO:0010181]; ubiquinone binding [GO:0048039]	cytoplasm [GO:0005737]; integral component of membrane [GO:0016021]; mitochondrial inner membrane [GO:0005743]; mitochondrion [GO:0005739]; neuronal cell body [GO:0043025]; nucleoplasm [GO:0005654]
P17812	PYRG1_HUMAN	CTP synthase 1 (EC 6.3.4.2) (CTP synthetase 1) (UTP--ammonia ligase 1)	CTPS1 CTPS	2VO1;			DB00130;	PATHWAY: Pyrimidine metabolism; CTP biosynthesis via de novo pathway; CTP from UDP: step 2/2. {ECO:0000269|PubMed:16179339, ECO:0000269|PubMed:24870241}.	PF06418;PF00117;	IPR029062;IPR004468;IPR017456;IPR017926;IPR027417;	'de novo' CTP biosynthetic process [GO:0044210]; B cell proliferation [GO:0042100]; CTP biosynthetic process [GO:0006241]; glutamine metabolic process [GO:0006541]; nucleobase-containing compound metabolic process [GO:0006139]; nucleobase-containing small molecule interconversion [GO:0015949]; response to drug [GO:0042493]; T cell proliferation [GO:0042098]	ATP binding [GO:0005524]; CTP synthase activity [GO:0003883]	cytosol [GO:0005829]; membrane [GO:0016020]
P05106	ITB3_HUMAN,Q12806_HUMAN	Integrin beta-3 (Platelet membrane glycoprotein IIIa) (GPIIIa) (CD antigen CD61)	ITGB3 GP3A	1JV2;1KUP;1KUZ;1L5G;1M1X;1M8O;1MIZ;1MK7;1MK9;1RN0;1S4X;1TYE;1U8C;2INI;2K9J;2KNC;2KV9;2L1C;2L91;2LJD;2LJE;2LJF;2MTP;2N9Y;2Q6W;2RMZ;2RN0;2VC2;2VDK;2VDL;2VDM;2VDN;2VDO;2VDP;2VDQ;2VDR;3FCS;3FCU;3IJE;3NID;3NIF;3NIG;3T3M;3T3P;3ZDX;3ZDY;3ZDZ;3ZE0;3ZE1;3ZE2;4CAK;4G1E;4G1M;4MMX;4MMY;4MMZ;4O02;4Z7N;4Z7O;4Z7Q;5HDB;	CHEMBL2093869;	P05106;	DB00054;DB00098;DB00063;DB00775;		PF07974;PF08725;PF07965;PF00362;	IPR013111;IPR027068;IPR015812;IPR014836;IPR012896;IPR002369;IPR032695;IPR016201;IPR002035;	activation of protein kinase activity [GO:0032147]; angiogenesis involved in wound healing [GO:0060055]; apolipoprotein A-I-mediated signaling pathway [GO:0038027]; blood coagulation [GO:0007596]; cell adhesion [GO:0007155]; cell adhesion mediated by integrin [GO:0033627]; cell growth [GO:0016049]; cell-matrix adhesion [GO:0007160]; cell migration [GO:0016477]; cell-substrate adhesion [GO:0031589]; cell-substrate junction assembly [GO:0007044]; extracellular matrix organization [GO:0030198]; heterotypic cell-cell adhesion [GO:0034113]; integrin-mediated signaling pathway [GO:0007229]; leukocyte migration [GO:0050900]; mesodermal cell differentiation [GO:0048333]; negative chemotaxis [GO:0050919]; negative regulation of lipid storage [GO:0010888]; negative regulation of lipid transport [GO:0032369]; negative regulation of lipoprotein metabolic process [GO:0050748]; negative regulation of low-density lipoprotein particle receptor biosynthetic process [GO:0045715]; negative regulation of macrophage derived foam cell differentiation [GO:0010745]; platelet activation [GO:0030168]; platelet aggregation [GO:0070527]; platelet degranulation [GO:0002576]; positive regulation of endothelial cell migration [GO:0010595]; positive regulation of endothelial cell proliferation [GO:0001938]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of vascular endothelial growth factor receptor signaling pathway [GO:0030949]; regulation of bone resorption [GO:0045124]; smooth muscle cell migration [GO:0014909]; substrate adhesion-dependent cell spreading [GO:0034446]; tube development [GO:0035295]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]; viral entry into host cell [GO:0046718]; wound healing [GO:0042060]	cell adhesion molecule binding [GO:0050839]; coreceptor activity [GO:0015026]; enzyme binding [GO:0019899]; extracellular matrix binding [GO:0050840]; fibronectin binding [GO:0001968]; identical protein binding [GO:0042802]; platelet-derived growth factor receptor binding [GO:0005161]; protease binding [GO:0002020]; protein disulfide isomerase activity [GO:0003756]; vascular endothelial growth factor receptor 2 binding [GO:0043184]; virus receptor activity [GO:0001618]	alphav-beta3 integrin-IGF-1-IGF1R complex [GO:0035867]; alphav-beta3 integrin-vitronectin complex [GO:0071062]; cell surface [GO:0009986]; extracellular exosome [GO:0070062]; filopodium membrane [GO:0031527]; focal adhesion [GO:0005925]; integral component of plasma membrane [GO:0005887]; integrin alphav-beta3 complex [GO:0034683]; integrin complex [GO:0008305]; lamellipodium membrane [GO:0031258]; melanosome [GO:0042470]; microvillus membrane [GO:0031528]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; platelet alpha granule membrane [GO:0031092]; receptor complex [GO:0043235]; ruffle membrane [GO:0032587]
Q14097	Q14097_HUMAN	CYP2B protein (Cytochrome P450 2B7 short isoform)	CYP2B CYP2B7				DB00856;DB00366;DB00472;DB01149;DB01104;		PF00067;	IPR001128;IPR002401;IPR008068;		heme binding [GO:0020037]; iron ion binding [GO:0005506]; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen [GO:0016712]
Q15111	Q15111_HUMAN	Inactive phospholipase C-like protein 1 (PLC-L1) (Phospholipase C-deleted in lung carcinoma) (Phospholipase C-related but catalytically inactive protein) (PRIP)	PLCL1				DB01103;		PF00168;PF09279;PF16457;PF00388;PF00387;	IPR000008;IPR011992;IPR011993;IPR001849;IPR001192;IPR017946;IPR015359;IPR028382;IPR000909;IPR001711;	gamma-aminobutyric acid signaling pathway [GO:0007214]; intracellular signal transduction [GO:0035556]; lipid metabolic process [GO:0006629]; positive regulation of receptor binding [GO:1900122]; regulation of peptidyl-serine phosphorylation [GO:0033135]; regulation of synaptic transmission, GABAergic [GO:0032228]	inositol 1,4,5 trisphosphate binding [GO:0070679]; phosphatidylinositol phospholipase C activity [GO:0004435]; phospholipase C activity [GO:0004629]; signal transducer activity [GO:0004871]	cytoplasm [GO:0005737]; plasma membrane [GO:0005886]
Q16857	Q16857_HUMAN	Deleted.
Q2TU84	Q2TU84_HUMAN	Aspartate aminotransferase (EC 2.6.1.1)	GIG18				DB00128;		PF00155;	IPR004839;IPR000796;IPR004838;IPR015424;IPR015421;	biosynthetic process [GO:0009058]; cellular amino acid metabolic process [GO:0006520]	L-aspartate:2-oxoglutarate aminotransferase activity [GO:0004069]; L-phenylalanine:2-oxoglutarate aminotransferase activity [GO:0080130]; pyridoxal phosphate binding [GO:0030170]
Q99259	DCE1_HUMAN,Q49AK1_HUMAN	Glutamate decarboxylase 1 (EC 4.1.1.15) (67 kDa glutamic acid decarboxylase) (GAD-67) (Glutamate decarboxylase 67 kDa isoform)	GAD1 GAD GAD67	2OKJ;3VP6;	CHEMBL2614;				PF00282;	IPR002129;IPR015424;IPR015421;IPR015422;IPR021115;	chemical synaptic transmission [GO:0007268]; gamma-aminobutyric acid biosynthetic process [GO:0009449]; glutamate catabolic process [GO:0006538]; glutamate decarboxylation to succinate [GO:0006540]; neurotransmitter biosynthetic process [GO:0042136]; neurotransmitter secretion [GO:0007269]; protein-pyridoxal-5-phosphate linkage [GO:0018352]; response to drug [GO:0042493]	glutamate binding [GO:0016595]; glutamate decarboxylase activity [GO:0004351]; pyridoxal phosphate binding [GO:0030170]	clathrin-sculpted gamma-aminobutyric acid transport vesicle membrane [GO:0061202]; intracellular [GO:0005622]; plasma membrane [GO:0005886]; presynaptic active zone [GO:0048786]; vesicle membrane [GO:0012506]
Q4W8W1	Q4W8W1_HUMAN	Pyrroline-5-carboxylate reductase (EC 1.5.1.2)	P5CR2				DB00172;	PATHWAY: Amino-acid biosynthesis; L-proline biosynthesis; L-proline from L-glutamate 5-semialdehyde: step 1/1. {ECO:0000256|RuleBase:RU003903}.	PF14748;	IPR008927;IPR016040;IPR029036;IPR000304;	L-proline biosynthetic process [GO:0055129]	pyrroline-5-carboxylate reductase activity [GO:0004735]
Q53ET4	Q53ET4_HUMAN	Serine hydroxymethyltransferase (EC 2.1.2.1) (Fragment)					DB00145;DB00116;	PATHWAY: One-carbon metabolism; tetrahydrofolate interconversion. {ECO:0000256|RuleBase:RU000585}.	PF00464;	IPR015424;IPR015421;IPR015422;IPR001085;IPR019798;	glycine metabolic process [GO:0006544]; L-serine metabolic process [GO:0006563]; tetrahydrofolate interconversion [GO:0035999]	glycine hydroxymethyltransferase activity [GO:0004372]; methyltransferase activity [GO:0008168]; pyridoxal phosphate binding [GO:0030170]
Q53ET7	Q53ET7_HUMAN	Serine hydroxymethyltransferase (EC 2.1.2.1) (Fragment)						PATHWAY: One-carbon metabolism; tetrahydrofolate interconversion. {ECO:0000256|RuleBase:RU000585}.	PF00464;	IPR015424;IPR015421;IPR015422;IPR001085;IPR019798;	glycine metabolic process [GO:0006544]; L-serine metabolic process [GO:0006563]; tetrahydrofolate interconversion [GO:0035999]	glycine hydroxymethyltransferase activity [GO:0004372]; methyltransferase activity [GO:0008168]; pyridoxal phosphate binding [GO:0030170]
P00505	AATM_HUMAN,Q53FL3_HUMAN	Aspartate aminotransferase, mitochondrial (mAspAT) (EC 2.6.1.1) (EC 2.6.1.7) (Fatty acid-binding protein) (FABP-1) (Glutamate oxaloacetate transaminase 2) (Kynurenine aminotransferase 4) (Kynurenine aminotransferase IV) (Kynurenine--oxoglutarate transaminase 4) (Kynurenine--oxoglutarate transaminase IV) (Plasma membrane-associated fatty acid-binding protein) (FABPpm) (Transaminase A)	GOT2	5AX8;			DB00128;		PF00155;	IPR004839;IPR000796;IPR004838;IPR015424;IPR015421;	2-oxoglutarate metabolic process [GO:0006103]; 4-hydroxyproline catabolic process [GO:0019470]; aspartate biosynthetic process [GO:0006532]; aspartate catabolic process [GO:0006533]; aspartate metabolic process [GO:0006531]; cellular amino acid biosynthetic process [GO:0008652]; fatty acid transport [GO:0015908]; gluconeogenesis [GO:0006094]; glutamate catabolic process to 2-oxoglutarate [GO:0019551]; glutamate catabolic process to aspartate [GO:0019550]; glutamate metabolic process [GO:0006536]; oxaloacetate metabolic process [GO:0006107]; response to ethanol [GO:0045471]	amino acid binding [GO:0016597]; identical protein binding [GO:0042802]; kynurenine-oxoglutarate transaminase activity [GO:0016212]; L-aspartate:2-oxoglutarate aminotransferase activity [GO:0004069]; L-phenylalanine:2-oxoglutarate aminotransferase activity [GO:0080130]; phospholipid binding [GO:0005543]; poly(A) RNA binding [GO:0044822]; pyridoxal phosphate binding [GO:0030170]	cell surface [GO:0009986]; extracellular exosome [GO:0070062]; mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; myelin sheath [GO:0043209]; perikaryon [GO:0043204]; plasma membrane [GO:0005886]; protein complex [GO:0043234]
P03950	ANGI_HUMAN,Q53X86_HUMAN	Angiogenin (EC 3.1.27.-) (Ribonuclease 5) (RNase 5)	ANG RNASE5	1A4Y;1ANG;1AWZ;1B1E;1B1I;1B1J;1GV7;1H0D;1H52;1H53;1HBY;1K58;1K59;1K5A;1K5B;1UN3;1UN4;1UN5;2ANG;4AHD;4AHE;4AHF;4AHG;4AHH;4AHI;4AHJ;4AHK;4AHL;4AHM;4AHN;4AOH;4B36;5EOP;5EPZ;5EQO;	CHEMBL5829;	P03950;			PF00074;	IPR001427;IPR023411;IPR023412;	actin filament polymerization [GO:0030041]; activation of phospholipase A2 activity [GO:0032431]; activation of phospholipase C activity [GO:0007202]; activation of protein kinase B activity [GO:0032148]; adherens junction organization [GO:0034332]; angiogenesis [GO:0001525]; antibacterial humoral response [GO:0019731]; antifungal humoral response [GO:0019732]; cell communication [GO:0007154]; cell migration [GO:0016477]; defense response to Gram-positive bacterium [GO:0050830]; diacylglycerol biosynthetic process [GO:0006651]; homeostatic process [GO:0042592]; innate immune response [GO:0045087]; negative regulation of smooth muscle cell proliferation [GO:0048662]; negative regulation of translation [GO:0017148]; oocyte maturation [GO:0001556]; ovarian follicle development [GO:0001541]; placenta development [GO:0001890]; positive regulation of endothelial cell proliferation [GO:0001938]; positive regulation of phosphorylation [GO:0042327]; positive regulation of protein secretion [GO:0050714]; response to hormone [GO:0009725]; response to hypoxia [GO:0001666]; response to yeast [GO:0001878]; rRNA transcription [GO:0009303]	actin binding [GO:0003779]; copper ion binding [GO:0005507]; DNA binding [GO:0003677]; endonuclease activity [GO:0004519]; heparin binding [GO:0008201]; peptide binding [GO:0042277]; protein homodimerization activity [GO:0042803]; receptor binding [GO:0005102]; ribonuclease activity [GO:0004540]; rRNA binding [GO:0019843]	angiogenin-PRI complex [GO:0032311]; basal lamina [GO:0005605]; cytoplasmic, membrane-bounded vesicle [GO:0016023]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; growth cone [GO:0030426]; neuronal cell body [GO:0043025]; nucleolus [GO:0005730]; nucleus [GO:0005634]
Q9UJS0	CMC2_HUMAN,Q546F9_HUMAN	Calcium-binding mitochondrial carrier protein Aralar2 (Citrin) (Mitochondrial aspartate glutamate carrier 2) (Solute carrier family 25 member 13)	SLC25A13 ARALAR2	4P5W;			DB00128;		PF00153;	IPR029658;IPR011992;IPR002048;IPR002067;IPR018108;IPR023395;	aspartate transport [GO:0015810]; ATP biosynthetic process [GO:0006754]; cellular respiration [GO:0045333]; gluconeogenesis [GO:0006094]; L-glutamate transport [GO:0015813]; malate-aspartate shuttle [GO:0043490]; response to calcium ion [GO:0051592]; translation [GO:0006412]; transport [GO:0006810]	acidic amino acid transmembrane transporter activity [GO:0015172]; calcium ion binding [GO:0005509]; L-aspartate transmembrane transporter activity [GO:0015183]; L-glutamate transmembrane transporter activity [GO:0005313]; structural constituent of ribosome [GO:0003735]; transporter activity [GO:0005215]	integral component of plasma membrane [GO:0005887]; mitochondrial inner membrane [GO:0005743]; mitochondrion [GO:0005739]
Q59FK2	Q59FK2_HUMAN	Selenocysteine lyase variant (Fragment)							PF00266;	IPR000192;IPR015424;IPR015421;		lyase activity [GO:0016829]
Q59GM9	Q59GM9_HUMAN	Alpha-1,4 glucan phosphorylase (EC 2.4.1.1) (Fragment)							PF00343;	IPR011833;IPR000811;	carbohydrate metabolic process [GO:0005975]	glycogen phosphorylase activity [GO:0008184]; pyridoxal phosphate binding [GO:0030170]
Q59HE2	Q59HE2_HUMAN	Ornithine aminotransferase variant (Fragment)							PF00202;	IPR005814;IPR010164;IPR015424;IPR015421;IPR015422;		pyridoxal phosphate binding [GO:0030170]; transaminase activity [GO:0008483]
Q5BJF5	Q5BJF5_HUMAN	Serine hydroxymethyltransferase (EC 2.1.2.1) (Fragment)	SHMT2					PATHWAY: One-carbon metabolism; tetrahydrofolate interconversion. {ECO:0000256|RuleBase:RU000585}.	PF00464;	IPR015424;IPR015421;IPR015422;IPR001085;IPR019798;	glycine metabolic process [GO:0006544]; L-serine metabolic process [GO:0006563]; tetrahydrofolate interconversion [GO:0035999]	glycine hydroxymethyltransferase activity [GO:0004372]; pyridoxal phosphate binding [GO:0030170]
Q5HYG8	Q5HYG8_HUMAN	Serine hydroxymethyltransferase (EC 2.1.2.1)	DKFZp686P09201					PATHWAY: One-carbon metabolism; tetrahydrofolate interconversion. {ECO:0000256|RuleBase:RU000585}.	PF00464;	IPR015424;IPR015421;IPR015422;IPR001085;IPR019798;	glycine metabolic process [GO:0006544]; L-serine metabolic process [GO:0006563]; tetrahydrofolate interconversion [GO:0035999]	glycine hydroxymethyltransferase activity [GO:0004372]; pyridoxal phosphate binding [GO:0030170]
Q5JAM2	Q5JAM2_HUMAN	5-aminolevulinate synthase (EC 2.3.1.37) (5-aminolevulinic acid synthase) (Delta-ALA synthase) (Delta-aminolevulinate synthase)	ALAS1 hCG_42575					PATHWAY: Porphyrin-containing compound metabolism; protoporphyrin-IX biosynthesis; 5-aminolevulinate from glycine: step 1/1. {ECO:0000256|RuleBase:RU910713}.	PF00155;PF09029;	IPR010961;IPR015118;IPR001917;IPR004839;IPR015424;IPR015421;IPR015422;	protoporphyrinogen IX biosynthetic process [GO:0006782]	5-aminolevulinate synthase activity [GO:0003870]; pyridoxal phosphate binding [GO:0030170]	cytoplasm [GO:0005737]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]
Q5JWL9	Q5JWL9_HUMAN	Deleted.
Q5SNW5	Q5SNW5_HUMAN	Methylenetetrahydrofolate reductase (Fragment)	MTHFR					PATHWAY: One-carbon metabolism; tetrahydrofolate interconversion. {ECO:0000256|RuleBase:RU004254}.	PF02219;	IPR029041;IPR003171;	methionine metabolic process [GO:0006555]; tetrahydrofolate interconversion [GO:0035999]	methylenetetrahydrofolate reductase (NAD(P)H) activity [GO:0004489]
Q5SQC4	Q5SQC4_HUMAN	Deleted.
Q12791	KCMA1_HUMAN,Q5SQR9_HUMAN	Calcium-activated potassium channel subunit alpha-1 (BK channel) (BKCA alpha) (Calcium-activated potassium channel, subfamily M subunit alpha-1) (K(VCA)alpha) (KCa1.1) (Maxi K channel) (MaxiK) (Slo-alpha) (Slo1) (Slowpoke homolog) (Slo homolog) (hSlo)	KCNMA1 KCNMA SLO	2K44;3MT5;3NAF;	CHEMBL4304;	Q12791;	DB00436;DB00356;DB01003;DB01119;DB01159;DB00999;DB00774;DB01110;DB00721;		PF03493;PF00520;	IPR005821;IPR003929;IPR016040;IPR028325;	cellular potassium ion homeostasis [GO:0030007]; micturition [GO:0060073]; negative regulation of cell volume [GO:0045794]; positive regulation of apoptotic process [GO:0043065]; potassium ion transport [GO:0006813]; regulation of membrane potential [GO:0042391]; response to calcium ion [GO:0051592]; response to carbon monoxide [GO:0034465]; response to hypoxia [GO:0001666]; response to osmotic stress [GO:0006970]; smooth muscle contraction involved in micturition [GO:0060083]	actin binding [GO:0003779]; calcium-activated potassium channel activity [GO:0015269]; large conductance calcium-activated potassium channel activity [GO:0060072]; metal ion binding [GO:0046872]; voltage-gated potassium channel activity [GO:0005249]	apical plasma membrane [GO:0016324]; caveola [GO:0005901]; extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]; voltage-gated potassium channel complex [GO:0008076]
Q5SVJ2	Q5SVJ2_HUMAN	Deleted.
Q5SY84	Q5SY84_HUMAN	Deleted.
Q5T1J1	Q5T1J1_HUMAN	HCG20471, isoform CRA_c (Sigma non-opioid intracellular receptor 1)	SIGMAR1 hCG_20471				DB00514;DB00704;		PF04622;	IPR006716;
Q5T6L4	Q5T6L4_HUMAN	Argininosuccinate synthase 1 isoform 1 (Argininosuccinate synthetase, isoform CRA_a) (cDNA, FLJ96050, highly similar to Homo sapiens argininosuccinate synthetase (ASS), transcript variant1, mRNA)	ASS ASS1 hCG_31245				DB00128;DB00155;		PF00764;	IPR001518;IPR018223;IPR023434;IPR024074;IPR014729;	acute-phase response [GO:0006953]; aging [GO:0007568]; arginine biosynthetic process [GO:0006526]; argininosuccinate metabolic process [GO:0000053]; cellular response to amine stimulus [GO:0071418]; cellular response to amino acid stimulus [GO:0071230]; cellular response to ammonium ion [GO:0071242]; cellular response to cAMP [GO:0071320]; cellular response to dexamethasone stimulus [GO:0071549]; cellular response to glucagon stimulus [GO:0071377]; cellular response to interferon-gamma [GO:0071346]; cellular response to lipopolysaccharide [GO:0071222]; cellular response to oleic acid [GO:0071400]; cellular response to tumor necrosis factor [GO:0071356]; diaphragm development [GO:0060539]; kidney development [GO:0001822]; liver development [GO:0001889]; midgut development [GO:0007494]; response to drug [GO:0042493]; response to estradiol [GO:0032355]; response to fatty acid [GO:0070542]; response to growth hormone [GO:0060416]; response to mycotoxin [GO:0010046]; response to nutrient [GO:0007584]; response to zinc ion [GO:0010043]; urea cycle [GO:0000050]	argininosuccinate synthase activity [GO:0004055]; ATP binding [GO:0005524]; toxic substance binding [GO:0015643]	cell body fiber [GO:0070852]; endoplasmic reticulum [GO:0005783]; lysosome [GO:0005764]; mitochondrial outer membrane [GO:0005741]; nucleus [GO:0005634]; perikaryon [GO:0043204]
Q5TCD1	Q5TCD1_HUMAN	Isoleucine--tRNA ligase, cytoplasmic (Fragment)	IARS						PF00133;	IPR001412;IPR002300;IPR002301;IPR014729;IPR009008;	isoleucyl-tRNA aminoacylation [GO:0006428]	aminoacyl-tRNA editing activity [GO:0002161]; ATP binding [GO:0005524]; isoleucine-tRNA ligase activity [GO:0004822]	cytoplasm [GO:0005737]
Q5TER2	Q5TER2_HUMAN	Deleted.
P09211	GSTP1_HUMAN,Q5TZY3_HUMAN	Glutathione S-transferase P (EC 2.5.1.18) (GST class-pi) (GSTP1-1)	GSTP1 FAEES3 GST3	10GS;11GS;12GS;13GS;14GS;16GS;17GS;18GS;19GS;1AQV;1AQW;1AQX;1EOG;1EOH;1GSS;1KBN;1LBK;1MD3;1MD4;1PGT;1PX6;1PX7;1ZGN;20GS;22GS;2A2R;2A2S;2GSS;2J9H;2PGT;3CSH;3CSI;3CSJ;3DD3;3DGQ;3GSS;3GUS;3HJM;3HJO;3HKR;3IE3;3KM6;3KMN;3KMO;3N9J;3PGT;4GSS;4PGT;5GSS;6GSS;7GSS;8GSS;9GSS;	CHEMBL3902;	P09211;	DB01008;DB04339;DB00958;DB00291;DB00515;DB01242;DB00773;DB00143;DB00526;DB00163;		PF14497;PF02798;	IPR010987;IPR004045;IPR004046;IPR003082;IPR012336;	animal organ regeneration [GO:0031100]; cellular response to cell-matrix adhesion [GO:0071460]; cellular response to epidermal growth factor stimulus [GO:0071364]; cellular response to glucocorticoid stimulus [GO:0071385]; cellular response to insulin stimulus [GO:0032869]; cellular response to lipopolysaccharide [GO:0071222]; central nervous system development [GO:0007417]; common myeloid progenitor cell proliferation [GO:0035726]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; linoleic acid metabolic process [GO:0043651]; negative regulation of acute inflammatory response [GO:0002674]; negative regulation of apoptotic process [GO:0043066]; negative regulation of biosynthetic process [GO:0009890]; negative regulation of ERK1 and ERK2 cascade [GO:0070373]; negative regulation of extrinsic apoptotic signaling pathway [GO:2001237]; negative regulation of fibroblast proliferation [GO:0048147]; negative regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043124]; negative regulation of interleukin-1 beta production [GO:0032691]; negative regulation of JUN kinase activity [GO:0043508]; negative regulation of leukocyte proliferation [GO:0070664]; negative regulation of MAPK cascade [GO:0043409]; negative regulation of MAP kinase activity [GO:0043407]; negative regulation of monocyte chemotactic protein-1 production [GO:0071638]; negative regulation of nitric-oxide synthase biosynthetic process [GO:0051771]; negative regulation of protein kinase activity [GO:0006469]; negative regulation of smooth muscle cell chemotaxis [GO:0071672]; negative regulation of stress-activated MAPK cascade [GO:0032873]; negative regulation of tumor necrosis factor-mediated signaling pathway [GO:0010804]; negative regulation of tumor necrosis factor production [GO:0032720]; negative regulation of vascular smooth muscle cell proliferation [GO:1904706]; nitric oxide storage [GO:0035732]; oligodendrocyte development [GO:0014003]; positive regulation of superoxide anion generation [GO:0032930]; regulation of ERK1 and ERK2 cascade [GO:0070372]; regulation of stress-activated MAPK cascade [GO:0032872]; response to amino acid [GO:0043200]; response to estradiol [GO:0032355]; response to ethanol [GO:0045471]; response to L-ascorbic acid [GO:0033591]; response to reactive oxygen species [GO:0000302]; xenobiotic metabolic process [GO:0006805]	dinitrosyl-iron complex binding [GO:0035731]; drug binding [GO:0008144]; glutathione binding [GO:0043295]; glutathione peroxidase activity [GO:0004602]; glutathione transferase activity [GO:0004364]; JUN kinase binding [GO:0008432]; kinase regulator activity [GO:0019207]; nitric oxide binding [GO:0070026]; S-nitrosoglutathione binding [GO:0035730]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; intracellular [GO:0005622]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; TRAF2-GSTP1 complex [GO:0097057]; vesicle [GO:0031982]
Q5VZ30	Q5VZ30_HUMAN	Glutamate decarboxylase 2 (Pancreatic islets and brain, 65kDa) (Glutamate decarboxylase 2 (Pancreatic islets and brain, 65kDa), isoform CRA_b)	GAD2 hCG_23434						PF00282;	IPR002129;IPR015424;IPR015421;IPR015422;IPR021115;	glutamate decarboxylation to succinate [GO:0006540]; response to drug [GO:0042493]	glutamate binding [GO:0016595]; glutamate decarboxylase activity [GO:0004351]; pyridoxal phosphate binding [GO:0030170]	anchored component of membrane [GO:0031225]; axon [GO:0030424]; cytosol [GO:0005829]; inhibitory synapse [GO:0060077]; perinuclear region of cytoplasm [GO:0048471]; synaptic vesicle membrane [GO:0030672]
P20711	DDC_HUMAN,Q5W5T9_HUMAN	Aromatic-L-amino-acid decarboxylase (AADC) (EC 4.1.1.28) (DOPA decarboxylase) (DDC)	DDC AADC	3RBF;3RBL;3RCH;	CHEMBL1843;	P20711;	DB00915;DB00190;DB00260;DB06262;DB00875;DB00150;DB01235;DB00968;	PATHWAY: Catecholamine biosynthesis; dopamine biosynthesis; dopamine from L-tyrosine: step 2/2.	PF00282;	IPR010977;IPR002129;IPR015424;IPR015421;IPR015422;IPR021115;	aminergic neurotransmitter loading into synaptic vesicle [GO:0015842]; catecholamine biosynthetic process [GO:0042423]; cellular amino acid metabolic process [GO:0006520]; cellular response to alkaloid [GO:0071312]; cellular response to drug [GO:0035690]; cellular response to growth factor stimulus [GO:0071363]; circadian rhythm [GO:0007623]; dopamine biosynthetic process [GO:0042416]; indolalkylamine biosynthetic process [GO:0046219]; isoquinoline alkaloid metabolic process [GO:0033076]; multicellular organism aging [GO:0010259]; phytoalexin metabolic process [GO:0052314]; response to pyrethroid [GO:0046684]; serotonin biosynthetic process [GO:0042427]	amino acid binding [GO:0016597]; aromatic-L-amino-acid decarboxylase activity [GO:0004058]; enzyme binding [GO:0019899]; L-dopa decarboxylase activity [GO:0036468]; pyridoxal phosphate binding [GO:0030170]	axon [GO:0030424]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; neuronal cell body [GO:0043025]; synaptic vesicle [GO:0008021]
P04181	OAT_HUMAN,Q6IAV9_HUMAN	Ornithine aminotransferase, mitochondrial (EC 2.6.1.13) (Ornithine delta-aminotransferase) (Ornithine--oxo-acid aminotransferase) [Cleaved into: Ornithine aminotransferase, hepatic form; Ornithine aminotransferase, renal form]	OAT	1GBN;1OAT;2BYJ;2BYL;2CAN;2OAT;	CHEMBL5954;		DB00129;	PATHWAY: Amino-acid biosynthesis; L-proline biosynthesis; L-glutamate 5-semialdehyde from L-ornithine: step 1/1.	PF00202;	IPR005814;IPR010164;IPR015424;IPR015421;IPR015422;	arginine catabolic process to glutamate [GO:0019544]; arginine catabolic process to proline via ornithine [GO:0010121]; cellular amino acid biosynthetic process [GO:0008652]; L-proline biosynthetic process [GO:0055129]; protein hexamerization [GO:0034214]; visual perception [GO:0007601]	identical protein binding [GO:0042802]; ornithine-oxo-acid transaminase activity [GO:0004587]; pyridoxal phosphate binding [GO:0030170]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
Q6IBS8	Q6IBS8_HUMAN	DDC protein	DDC						PF00282;	IPR010977;IPR002129;IPR015424;IPR015421;IPR015422;IPR021115;	cellular amino acid metabolic process [GO:0006520]	carboxy-lyase activity [GO:0016831]; pyridoxal phosphate binding [GO:0030170]
Q6N063	Q6N063_HUMAN	2-oxoglutarate and iron-dependent oxygenase domain-containing protein 2 (EC 1.14.11.-)	OGFOD2				DB00126;			IPR005123;IPR006620;		dioxygenase activity [GO:0051213]; iron ion binding [GO:0005506]; L-ascorbic acid binding [GO:0031418]; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen [GO:0016705]
Q6NSD4	Q6NSD4_HUMAN	Glutathione peroxidase	GPX1				DB00143;		PF00255;	IPR000889;IPR029760;IPR012336;	response to oxidative stress [GO:0006979]	glutathione peroxidase activity [GO:0004602]
Q6P996	Q6P996_HUMAN	Pyridoxal-dependent decarboxylase domain-containing protein 1 (EC 4.1.1.-)	PDXDC1 KIAA0251						PF00282;	IPR002129;IPR015424;IPR015421;IPR015422;	carboxylic acid metabolic process [GO:0019752]	cadherin binding involved in cell-cell adhesion [GO:0098641]; carboxy-lyase activity [GO:0016831]; pyridoxal phosphate binding [GO:0030170]	cell-cell adherens junction [GO:0005913]; Golgi apparatus [GO:0005794]; intracellular membrane-bounded organelle [GO:0043231]
Q6PI42	Q6PI42_HUMAN	Glutathione peroxidase	GPX4						PF00255;	IPR000889;IPR029760;IPR012336;	response to oxidative stress [GO:0006979]	glutathione peroxidase activity [GO:0004602]
Q6ZQY3	Q6ZQY3_HUMAN	Acidic amino acid decarboxylase GADL1 (Aspartate 1-decarboxylase) (ADC) (HuADC) (EC 4.1.1.11) (Cysteine sulfinic acid decarboxylase) (CSADC) (HuCSADC) (EC 4.1.1.29) (Glutamate decarboxylase-like protein 1)	GADL1						PF00282;	IPR002129;IPR015424;IPR015421;IPR015422;IPR021115;	cellular amino acid biosynthetic process [GO:0008652]	aspartate 1-decarboxylase activity [GO:0004068]; carboxy-lyase activity [GO:0016831]; pyridoxal phosphate binding [GO:0030170]; sulfinoalanine decarboxylase activity [GO:0004782]	cytosol [GO:0005829]
Q7L266	Q7L266_HUMAN	Isoaspartyl peptidase/L-asparaginase (EC 3.4.19.5) (EC 3.5.1.1) (Asparaginase-like protein 1) (Beta-aspartyl-peptidase) (Isoaspartyl dipeptidase) (L-asparagine amidohydrolase) [Cleaved into: Isoaspartyl peptidase/L-asparaginase alpha chain; Isoaspartyl peptidase/L-asparaginase beta chain]	ASRGL1 ALP CRASH	3TKJ;4ET0;4O0C;4O0D;4O0E;4O0F;4O0G;4O0H;4OSX;4OSY;4PVP;4PVQ;4PVR;4PVS;4ZM9;			DB00174;DB00128;		PF01112;	IPR029055;IPR000246;	asparagine catabolic process via L-aspartate [GO:0033345]; L-phenylalanine catabolic process [GO:0006559]	asparaginase activity [GO:0004067]; beta-aspartyl-peptidase activity [GO:0008798]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleus [GO:0005634]
Q6WRI0	Q86YJ9_HUMAN	Immunoglobulin superfamily member 10 (IgSF10) (Calvaria mechanical force protein 608) (CMF608)	IGSF10 CMF608						PF07679;PF13855;	IPR000483;IPR007110;IPR013783;IPR013098;IPR003599;IPR003598;IPR013106;IPR032675;IPR001611;IPR003591;IPR000372;	cell differentiation [GO:0030154]; multicellular organism development [GO:0007275]; ossification [GO:0001503]		extracellular region [GO:0005576]
Q8IVA8	Q8IVA8_HUMAN	Glutamate decarboxylase 1 (Brain, 67kDa)	GAD1						PF00282;	IPR002129;IPR015424;IPR015421;IPR015422;IPR021115;	carboxylic acid metabolic process [GO:0019752]	glutamate decarboxylase activity [GO:0004351]; pyridoxal phosphate binding [GO:0030170]	intracellular [GO:0005622]
P34897	GLYM_HUMAN,Q8N1A5_HUMAN	Serine hydroxymethyltransferase, mitochondrial (SHMT) (EC 2.1.2.1) (Glycine hydroxymethyltransferase) (Serine methylase)	SHMT2	3OU5;4PVF;			DB00145;DB00116;	PATHWAY: One-carbon metabolism; tetrahydrofolate interconversion. {ECO:0000305|PubMed:25619277}.	PF00464;	IPR015424;IPR015421;IPR015422;IPR001085;IPR019798;	folic acid metabolic process [GO:0046655]; glycine biosynthetic process from serine [GO:0019264]; glycine metabolic process [GO:0006544]; L-serine biosynthetic process [GO:0006564]; L-serine metabolic process [GO:0006563]; one-carbon metabolic process [GO:0006730]; positive regulation of cell proliferation [GO:0008284]; protein homotetramerization [GO:0051289]; protein K63-linked deubiquitination [GO:0070536]; protein tetramerization [GO:0051262]; response to type I interferon [GO:0034340]; tetrahydrofolate interconversion [GO:0035999]; tetrahydrofolate metabolic process [GO:0046653]	amino acid binding [GO:0016597]; chromatin binding [GO:0003682]; glycine hydroxymethyltransferase activity [GO:0004372]; L-allo-threonine aldolase activity [GO:0008732]; pyridoxal phosphate binding [GO:0030170]	BRISC complex [GO:0070552]; cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; microtubule cytoskeleton [GO:0015630]; mitochondrial inner membrane [GO:0005743]; mitochondrial intermembrane space [GO:0005758]; mitochondrial matrix [GO:0005759]; mitochondrial nucleoid [GO:0042645]; mitochondrion [GO:0005739]; nucleus [GO:0005634]
Q8N3E9	Q8N3E9_HUMAN	1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-3 (EC 3.1.4.11) (Phosphoinositide phospholipase C-delta-3) (Phospholipase C-delta-3) (PLC-delta-3)	PLCD3 KIAA1964						PF00168;PF00388;PF00387;	IPR000008;IPR011992;IPR018247;IPR011993;IPR001849;IPR001192;IPR028406;IPR017946;IPR000909;IPR001711;	angiogenesis [GO:0001525]; inositol phosphate metabolic process [GO:0043647]; intracellular signal transduction [GO:0035556]; labyrinthine layer blood vessel development [GO:0060716]; lipid catabolic process [GO:0016042]; regulation of cell proliferation [GO:0042127]	metal ion binding [GO:0046872]; phosphatidylinositol phospholipase C activity [GO:0004435]; signal transducer activity [GO:0004871]	cleavage furrow [GO:0032154]; cytosol [GO:0005829]; plasma membrane [GO:0005886]
Q8N4L9	Q8N4L9_HUMAN	Deleted.
Q8N543	Q8N543_HUMAN	Prolyl 3-hydroxylase OGFOD1 (EC 1.14.11.-) (2-oxoglutarate and iron-dependent oxygenase domain-containing protein 1) (Termination and polyadenylation 1 homolog)	OGFOD1 KIAA1612 TPA1	4NHX;4NHY;			DB00126;		PF10637;	IPR005123;IPR019601;IPR006620;	cell proliferation [GO:0008283]; peptidyl-proline hydroxylation [GO:0019511]; protein hydroxylation [GO:0018126]; regulation of translational termination [GO:0006449]; stress granule assembly [GO:0034063]	iron ion binding [GO:0005506]; L-ascorbic acid binding [GO:0031418]; peptidyl-proline 3-dioxygenase activity [GO:0031544]; peptidyl-proline dioxygenase activity [GO:0031543]	cytoplasm [GO:0005737]; cytoplasmic stress granule [GO:0010494]; nucleus [GO:0005634]
P22557	HEM0_HUMAN,Q8N6H3_HUMAN	5-aminolevulinate synthase, erythroid-specific, mitochondrial (ALAS-E) (EC 2.3.1.37) (5-aminolevulinic acid synthase 2) (Delta-ALA synthase 2) (Delta-aminolevulinate synthase 2)	ALAS2 ALASE ASB				DB00145;	PATHWAY: Porphyrin-containing compound metabolism; protoporphyrin-IX biosynthesis; 5-aminolevulinate from glycine: step 1/1.	PF00155;PF09029;	IPR010961;IPR015118;IPR001917;IPR004839;IPR015424;IPR015421;IPR015422;	cellular iron ion homeostasis [GO:0006879]; erythrocyte differentiation [GO:0030218]; heme biosynthetic process [GO:0006783]; hemoglobin biosynthetic process [GO:0042541]; oxygen homeostasis [GO:0032364]; protoporphyrinogen IX biosynthetic process [GO:0006782]; response to hypoxia [GO:0001666]	5-aminolevulinate synthase activity [GO:0003870]; coenzyme binding [GO:0050662]; glycine binding [GO:0016594]; pyridoxal phosphate binding [GO:0030170]	mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
Q8TED1	Q8TED1_HUMAN	Probable glutathione peroxidase 8 (GPx-8) (GSHPx-8) (EC 1.11.1.9)	GPX8 UNQ847/PRO1785	3CYN;3KIJ;			DB00143;		PF00255;	IPR013376;IPR000889;IPR029760;IPR012336;	response to reactive oxygen species [GO:0000302]	glutathione peroxidase activity [GO:0004602]; peroxidase activity [GO:0004601]	endoplasmic reticulum lumen [GO:0005788]; integral component of membrane [GO:0016021]
Q96EM0	Q96EM0_HUMAN	Trans-3-hydroxy-L-proline dehydratase (EC 4.2.1.77) (Trans-L-3-hydroxyproline dehydratase)	L3HYPDH C14orf149				DB00172;		PF05544;	IPR008794;	metabolic process [GO:0008152]	hydro-lyase activity [GO:0016836]; trans-L-3-hydroxyproline dehydratase activity [GO:0050346]
Q53H96	Q8N3N9_HUMAN,Q96HX4_HUMAN	Pyrroline-5-carboxylate reductase 3 (P5C reductase 3) (P5CR 3) (EC 1.5.1.2) (Pyrroline-5-carboxylate reductase-like protein)	PYCRL				DB00172;	PATHWAY: Amino-acid biosynthesis; L-proline biosynthesis; L-proline from L-glutamate 5-semialdehyde: step 1/1. {ECO:0000269|PubMed:23024808}.	PF03807;PF14748;	IPR008927;IPR016040;IPR029036;IPR028939;IPR000304;	cellular amino acid biosynthetic process [GO:0008652]; L-proline biosynthetic process [GO:0055129]	pyrroline-5-carboxylate reductase activity [GO:0004735]	cytosol [GO:0005829]
P34896	GLYC_HUMAN,Q96HY0_HUMAN	Serine hydroxymethyltransferase, cytosolic (SHMT) (EC 2.1.2.1) (Glycine hydroxymethyltransferase) (Serine methylase)	SHMT1	1BJ4;	CHEMBL1772927;	P34896;	DB00145;DB01055;DB00116;	PATHWAY: One-carbon metabolism; tetrahydrofolate interconversion. {ECO:0000305|PubMed:24698160}.	PF00464;	IPR015424;IPR015421;IPR015422;IPR001085;IPR019798;	carnitine biosynthetic process [GO:0045329]; cellular response to tetrahydrofolate [GO:1904482]; dTMP biosynthetic process [GO:0006231]; folic acid metabolic process [GO:0046655]; glycine biosynthetic process from serine [GO:0019264]; glycine metabolic process [GO:0006544]; L-serine catabolic process [GO:0006565]; L-serine metabolic process [GO:0006563]; protein homotetramerization [GO:0051289]; protein tetramerization [GO:0051262]; purine nucleobase biosynthetic process [GO:0009113]; tetrahydrofolate interconversion [GO:0035999]; tetrahydrofolate metabolic process [GO:0046653]	amino acid binding [GO:0016597]; glycine hydroxymethyltransferase activity [GO:0004372]; L-allo-threonine aldolase activity [GO:0008732]; protein homodimerization activity [GO:0042803]; pyridoxal phosphate binding [GO:0030170]; serine binding [GO:0070905]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrion [GO:0005739]; nucleus [GO:0005634]
P48728	GCST_HUMAN,Q96IG6_HUMAN	Aminomethyltransferase, mitochondrial (EC 2.1.2.10) (Glycine cleavage system T protein) (GCVT)	AMT GCST	1WSR;1WSV;			DB00116;		PF01571;PF08669;	IPR006223;IPR028896;IPR013977;IPR006222;IPR029043;IPR027266;	glycine catabolic process [GO:0006546]; glycine decarboxylation via glycine cleavage system [GO:0019464]; glyoxylate metabolic process [GO:0046487]	aminomethyltransferase activity [GO:0004047]; transaminase activity [GO:0008483]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
Q96JQ3	Q96JQ3_HUMAN	P-selectin cytoplasmic tail-associated protein (PCAP)	pcap						PF00282;	IPR002129;IPR015424;IPR015421;IPR015422;	carboxylic acid metabolic process [GO:0019752]	carbohydrate binding [GO:0030246]; carboxy-lyase activity [GO:0016831]; pyridoxal phosphate binding [GO:0030170]
Q96QU6	Q96QU6_HUMAN	1-aminocyclopropane-1-carboxylate synthase-like protein 1 (ACC synthase-like protein 1)	ACCS PHACS						PF00155;	IPR004839;IPR015424;IPR015421;IPR015422;	biosynthetic process [GO:0009058]	catalytic activity [GO:0003824]; protein homodimerization activity [GO:0042803]; pyridoxal phosphate binding [GO:0030170]
P29590	Q96S41_HUMAN	Protein PML (Promyelocytic leukemia protein) (RING finger protein 71) (Tripartite motif-containing protein 19)	PML MYL PP8675 RNF71 TRIM19	1BOR;2MVW;2MWX;4WJN;4WJO;					PF12126;PF00643;	IPR021978;IPR000315;IPR001841;IPR013083;IPR017907;	activation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0006919]; apoptotic process [GO:0006915]; branching involved in mammary gland duct morphogenesis [GO:0060444]; cell cycle arrest [GO:0007050]; cell fate commitment [GO:0045165]; cellular response to interleukin-4 [GO:0071353]; cellular senescence [GO:0090398]; circadian regulation of gene expression [GO:0032922]; common-partner SMAD protein phosphorylation [GO:0007182]; defense response to virus [GO:0051607]; DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest [GO:0006977]; endoplasmic reticulum calcium ion homeostasis [GO:0032469]; entrainment of circadian clock by photoperiod [GO:0043153]; extrinsic apoptotic signaling pathway [GO:0097191]; fibroblast migration [GO:0010761]; innate immune response [GO:0045087]; interferon-gamma-mediated signaling pathway [GO:0060333]; intrinsic apoptotic signaling pathway in response to DNA damage [GO:0008630]; intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator [GO:0042771]; intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress [GO:0070059]; intrinsic apoptotic signaling pathway in response to oxidative stress [GO:0008631]; maintenance of protein location in nucleus [GO:0051457]; myeloid cell differentiation [GO:0030099]; negative regulation of angiogenesis [GO:0016525]; negative regulation of cell growth [GO:0030308]; negative regulation of cell proliferation [GO:0008285]; negative regulation of interleukin-1 beta secretion [GO:0050713]; negative regulation of mitotic cell cycle [GO:0045930]; negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process [GO:2000059]; negative regulation of telomerase activity [GO:0051974]; negative regulation of telomere maintenance via telomerase [GO:0032211]; negative regulation of transcription, DNA-templated [GO:0045892]; negative regulation of translation in response to oxidative stress [GO:0032938]; negative regulation of viral release from host cell [GO:1902187]; PML body organization [GO:0030578]; positive regulation of apoptotic process involved in mammary gland involution [GO:0060058]; positive regulation of defense response to virus by host [GO:0002230]; positive regulation of extrinsic apoptotic signaling pathway [GO:2001238]; positive regulation of fibroblast proliferation [GO:0048146]; positive regulation of histone deacetylation [GO:0031065]; positive regulation of MHC class I biosynthetic process [GO:0045345]; positive regulation of protein localization to chromosome, telomeric region [GO:1904816]; positive regulation of telomere maintenance [GO:0032206]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; proteasome-mediated ubiquitin-dependent protein catabolic process [GO:0043161]; protein complex assembly [GO:0006461]; protein stabilization [GO:0050821]; protein sumoylation [GO:0016925]; protein targeting [GO:0006605]; regulation of calcium ion transport into cytosol [GO:0010522]; regulation of cell adhesion [GO:0030155]; regulation of circadian rhythm [GO:0042752]; regulation of double-strand break repair [GO:2000779]; regulation of protein phosphorylation [GO:0001932]; regulation of signal transduction by p53 class mediator [GO:1901796]; regulation of transcription, DNA-templated [GO:0006355]; response to cytokine [GO:0034097]; response to gamma radiation [GO:0010332]; response to hypoxia [GO:0001666]; response to UV [GO:0009411]; retinoic acid receptor signaling pathway [GO:0048384]; SMAD protein import into nucleus [GO:0007184]; transcription, DNA-templated [GO:0006351]; transforming growth factor beta receptor signaling pathway [GO:0007179]	cobalt ion binding [GO:0050897]; DNA binding [GO:0003677]; protein heterodimerization activity [GO:0046982]; protein homodimerization activity [GO:0042803]; SUMO binding [GO:0032183]; transcription coactivator activity [GO:0003713]; ubiquitin protein ligase binding [GO:0031625]; zinc ion binding [GO:0008270]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; early endosome membrane [GO:0031901]; extrinsic component of endoplasmic reticulum membrane [GO:0042406]; nuclear chromosome, telomeric region [GO:0000784]; nuclear matrix [GO:0016363]; nuclear membrane [GO:0031965]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; PML body [GO:0016605]
Q99720	Q99720_HUMAN	Sigma non-opioid intracellular receptor 1 (Aging-associated gene 8 protein) (SR31747-binding protein) (SR-BP) (Sigma 1-type opioid receptor) (SIG-1R) (Sigma1-receptor) (Sigma1R) (hSigmaR1)	SIGMAR1 OPRS1 SRBP AAG8	5HK1;5HK2;	CHEMBL287;	Q99720;	DB00321;DB09014;DB00514;DB00540;DB00652;DB00409;		PF04622;	IPR006716;	lipid transport [GO:0006869]; nervous system development [GO:0007399]; protein homotrimerization [GO:0070207]; regulation of neuron apoptotic process [GO:0043523]	drug binding [GO:0008144]; opioid receptor activity [GO:0004985]	cell junction [GO:0030054]; cytoplasmic, membrane-bounded vesicle [GO:0016023]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; growth cone [GO:0030426]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; lipid particle [GO:0005811]; nuclear envelope [GO:0005635]; nuclear inner membrane [GO:0005637]; nuclear outer membrane [GO:0005640]; postsynaptic density [GO:0014069]; postsynaptic membrane [GO:0045211]
Q9BXA1	Q9BXA1_HUMAN	Hepatic peroxysomal alanine:glyoxylate aminotransferase (Fragment)							PF00266;	IPR000192;IPR020578;IPR015424;IPR015421;IPR015422;IPR024169;		transaminase activity [GO:0008483]
P16442	BGAT_HUMAN,Q9NY01_HUMAN	Histo-blood group ABO system transferase (Fucosylglycoprotein 3-alpha-galactosyltransferase) (Fucosylglycoprotein alpha-N-acetylgalactosaminyltransferase) (Glycoprotein-fucosylgalactoside alpha-N-acetylgalactosaminyltransferase) (EC 2.4.1.40) (Glycoprotein-fucosylgalactoside alpha-galactosyltransferase) (EC 2.4.1.37) (Histo-blood group A transferase) (A transferase) (Histo-blood group B transferase) (B transferase) (NAGAT) [Cleaved into: Fucosylglycoprotein alpha-N-acetylgalactosaminyltransferase soluble form]	ABO	1LZ0;1LZ7;1LZI;1LZJ;1R7T;1R7U;1R7V;1R7X;1R7Y;1R80;1R81;1R82;1WSZ;1WT0;1WT1;1WT2;1WT3;1XZ6;1ZHJ;1ZI1;1ZI3;1ZI4;1ZI5;1ZIZ;1ZJ0;1ZJ1;1ZJ2;1ZJ3;1ZJO;1ZJP;2A8U;2A8W;2I7B;2O1F;2O1G;2O1H;2PGV;2PGY;2RIT;2RIX;2RIY;2RIZ;2RJ0;2RJ1;2RJ4;2RJ5;2RJ6;2RJ7;2RJ8;2RJ9;2Y7A;3I0C;3I0D;3I0E;3I0F;3I0G;3I0H;3I0I;3I0J;3I0K;3I0L;3IOH;3IOI;3IOJ;3SX3;3SX5;3SX7;3SX8;3SXA;3SXB;3SXC;3SXD;3SXE;3SXG;3U0X;3U0Y;3V0L;3V0M;3V0N;3V0O;3V0P;3V0Q;3ZGF;3ZGG;4C2S;4FQW;4FRA;4FRB;4FRD;4FRE;4FRH;4FRL;4FRM;4FRO;4FRP;4FRQ;4GBP;4KC1;4KC2;4KC4;4KXO;4Y62;4Y63;4Y64;5BXC;5C1G;5C1H;5C1L;5C36;5C38;5C3A;5C3B;5C3D;5C47;5C48;5C49;5C4B;5C4C;5C4D;5C4E;5C4F;5C8R;5CMF;5CMG;5CMH;5CMI;5CMJ;	CHEMBL2321639;	P16442;		PATHWAY: Protein modification; protein glycosylation. {ECO:0000305}.	PF03414;	IPR005076;IPR029044;	protein glycosylation [GO:0006486]	fucosylgalactoside 3-alpha-galactosyltransferase activity [GO:0004381]; glycoprotein-fucosylgalactoside alpha-N-acetylgalactosaminyltransferase activity [GO:0004380]; metal ion binding [GO:0046872]	extracellular region [GO:0005576]; Golgi cisterna membrane [GO:0032580]; integral component of membrane [GO:0016021]
Q9NY47	Q9NY47_HUMAN	Voltage-dependent calcium channel subunit alpha-2/delta-2 (Voltage-gated calcium channel subunit alpha-2/delta-2) [Cleaved into: Voltage-dependent calcium channel subunit alpha-2-2; Voltage-dependent calcium channel subunit delta-2]	CACNA2D2 KIAA0558		CHEMBL3896;	Q9NY47;	DB01118;DB01244;DB01023;DB00996;DB00270;DB01054;DB00421;		PF08473;PF00092;PF08399;	IPR013680;IPR013608;IPR002035;	cardiac conduction [GO:0061337]; muscle fiber development [GO:0048747]; neuromuscular junction development [GO:0007528]; positive regulation of organ growth [GO:0046622]; regulation of insulin secretion [GO:0050796]; regulation of multicellular organism growth [GO:0040014]; rhythmic synaptic transmission [GO:0060024]	metal ion binding [GO:0046872]; voltage-gated calcium channel activity [GO:0005245]	plasma membrane [GO:0005886]; voltage-gated calcium channel complex [GO:0005891]
Q9NY62	Q9NY62_HUMAN	Methylenetetrahydrofolate reductase (Methylenetetrahydrofolate reductase intermediate form) (Fragment)	MTHFR					PATHWAY: One-carbon metabolism; tetrahydrofolate interconversion. {ECO:0000256|RuleBase:RU004254}.	PF02219;	IPR029041;IPR003171;	methionine metabolic process [GO:0006555]; tetrahydrofolate interconversion [GO:0035999]	methylenetetrahydrofolate reductase (NAD(P)H) activity [GO:0004489]
Q9NYR8	Q9NYR8_HUMAN	Retinol dehydrogenase 8 (EC 1.1.1.300) (Photoreceptor outer segment all-trans retinol dehydrogenase) (Short chain dehydrogenase/reductase family 28C member 2)	RDH8 PRRDH SDR28C2				DB00162;		PF00106;	IPR011348;IPR016040;IPR020904;IPR002347;	estrogen biosynthetic process [GO:0006703]; response to stimulus [GO:0050896]; steroid biosynthetic process [GO:0006694]; visual perception [GO:0007601]	estradiol 17-beta-dehydrogenase activity [GO:0004303]; NADP-retinol dehydrogenase activity [GO:0052650]; retinol dehydrogenase activity [GO:0004745]	cytoplasm [GO:0005737]; integral component of plasma membrane [GO:0005887]
Q96I15	Q7L670_HUMAN,Q9NZR7_HUMAN	Selenocysteine lyase (hSCL) (EC 4.4.1.16)	SCLY SCL	3GZC;3GZD;					PF00266;	IPR000192;IPR016454;IPR015424;IPR015421;IPR015422;	cellular amino acid metabolic process [GO:0006520]; selenium compound metabolic process [GO:0001887]	selenocysteine lyase activity [GO:0009000]; transferase activity [GO:0016740]	cytosol [GO:0005829]
Q9UGI5	Q9UGI5_HUMAN	Glutamic acid decarboxylase (EC 4.1.1.15) (Fragment)	GAD65				DB00780;		PF00282;	IPR002129;IPR015424;IPR015421;IPR015422;IPR021115;	carboxylic acid metabolic process [GO:0019752]	glutamate decarboxylase activity [GO:0004351]; pyridoxal phosphate binding [GO:0030170]
Q9UJX1	Q9UJX1_HUMAN	Alanine-glyoxylate aminotransferase homolog	TLH6						PF00266;	IPR000192;IPR015424;IPR015422;		transaminase activity [GO:0008483]
Q9Y646	Q9Y5X6_HUMAN	Carboxypeptidase Q (EC 3.4.17.-) (Lysosomal dipeptidase) (Plasma glutamate carboxypeptidase)	CPQ LCH1 PGCP						PF04389;	IPR007484;	peptide catabolic process [GO:0043171]; proteolysis [GO:0006508]; thyroid hormone generation [GO:0006590]; tissue regeneration [GO:0042246]	carboxypeptidase activity [GO:0004180]; metal ion binding [GO:0046872]; metallodipeptidase activity [GO:0070573]; protein homodimerization activity [GO:0042803]	cytoplasm [GO:0005737]; endoplasmic reticulum [GO:0005783]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; Golgi apparatus [GO:0005794]; lysosome [GO:0005764]
Q9Y602	Q9Y602_HUMAN	Cysteine sulfinic acid decarboxylase (Cysteine sulfinic acid decarboxylase, isoform CRA_c) (Cysteine sulfinic acid decarboxylase-related protein 1)	CSAD hCG_43754						PF00282;	IPR002129;IPR015424;IPR015421;	carboxylic acid metabolic process [GO:0019752]	carboxy-lyase activity [GO:0016831]; pyridoxal phosphate binding [GO:0030170]
Q9Y6K0	Q9Y6K0_HUMAN	Choline/ethanolaminephosphotransferase 1 (hCEPT1) (EC 2.7.8.1) (EC 2.7.8.2)	CEPT1 PRO1101				DB00122;	PATHWAY: Phospholipid metabolism; phosphatidylethanolamine biosynthesis; phosphatidylethanolamine from ethanolamine: step 3/3.; PATHWAY: Phospholipid metabolism; phosphatidylcholine biosynthesis; phosphatidylcholine from phosphocholine: step 2/2.	PF01066;	IPR000462;IPR014472;	lipid metabolic process [GO:0006629]; phosphatidylcholine biosynthetic process [GO:0006656]; phosphatidylethanolamine biosynthetic process [GO:0006646]	diacylglycerol cholinephosphotransferase activity [GO:0004142]; ethanolaminephosphotransferase activity [GO:0004307]; metal ion binding [GO:0046872]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; nuclear membrane [GO:0031965]
Q08257	QOR_HUMAN	Quinone oxidoreductase (EC 1.6.5.5) (NADPH:quinone reductase) (Zeta-crystallin)	CRYZ	1YB5;	CHEMBL6118;		DB00266;		PF08240;PF00107;	IPR013149;IPR013154;IPR011032;IPR016040;IPR020843;IPR002364;	protein homotetramerization [GO:0051289]; visual perception [GO:0007601]; xenobiotic catabolic process [GO:0042178]	mRNA 3'-UTR binding [GO:0003730]; NADPH:quinone reductase activity [GO:0003960]; NADPH binding [GO:0070402]; zinc ion binding [GO:0008270]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
Q16769	QPCT_HUMAN	Glutaminyl-peptide cyclotransferase (EC 2.3.2.5) (Glutaminyl cyclase) (QC) (sQC) (Glutaminyl-tRNA cyclotransferase) (Glutamyl cyclase) (EC)	QPCT	1MOI;2AFM;2AFO;2AFS;2AFU;2AFW;2AFX;2AFZ;2ZED;2ZEE;2ZEF;2ZEG;2ZEH;2ZEL;2ZEM;2ZEN;2ZEO;2ZEP;3PBB;3PBE;3SI0;4YU9;4YWY;	CHEMBL4508;	Q16769;			PF04389;	IPR007484;	cellular protein modification process [GO:0006464]; peptidyl-pyroglutamic acid biosynthetic process, using glutaminyl-peptide cyclotransferase [GO:0017186]	glutaminyl-peptide cyclotransferase activity [GO:0016603]; zinc ion binding [GO:0008270]	extracellular exosome [GO:0070062]
P51151	RAB9_HUMAN	Ras-related protein Rab-9A	RAB9A RAB9	1WMS;	CHEMBL1293294;		DB03793;		PF00071;	IPR027417;IPR005225;IPR001806;	negative regulation by host of symbiont molecular function [GO:0052405]; positive regulation of exocytosis [GO:0045921]; protein transport [GO:0015031]; regulation of protein localization [GO:0032880]; retrograde transport, endosome to Golgi [GO:0042147]; small GTPase mediated signal transduction [GO:0007264]	GDP binding [GO:0019003]; GTPase activity [GO:0003924]; GTP binding [GO:0005525]	cytosol [GO:0005829]; endoplasmic reticulum membrane [GO:0005789]; extracellular exosome [GO:0070062]; late endosome [GO:0005770]; lysosome [GO:0005764]; melanosome [GO:0042470]; phagocytic vesicle [GO:0045335]; phagocytic vesicle membrane [GO:0030670]; plasma membrane [GO:0005886]; trans-Golgi network membrane [GO:0032588]; transport vesicle [GO:0030133]
P29762	RABP1_HUMAN	Cellular retinoic acid-binding protein 1 (Cellular retinoic acid-binding protein I) (CRABP-I)	CRABP1 RBP5		CHEMBL2079;		DB00523;DB00755;		PF00061;	IPR012674;IPR011038;IPR031279;IPR000463;IPR031259;IPR000566;	multicellular organism development [GO:0007275]; retinoic acid catabolic process [GO:0034653]; signal transduction [GO:0007165]	retinal binding [GO:0016918]; retinoic acid binding [GO:0001972]; retinoid binding [GO:0005501]; retinol binding [GO:0019841]; transporter activity [GO:0005215]	cytosol [GO:0005829]
P29373	RABP2_HUMAN	Cellular retinoic acid-binding protein 2 (Cellular retinoic acid-binding protein II) (CRABP-II)	CRABP2	1BLR;1BM5;1CBQ;1CBS;1XCA;2CBS;2FR3;2FRS;2FS6;2FS7;2G78;2G79;2G7B;3CBS;3CR6;3CWK;3D95;3D96;3D97;3F8A;3F9D;3FA6;3FA7;3FA8;3FA9;3FEK;3FEL;3FEN;3FEP;3I17;4I9R;4I9S;4M6S;4M7M;4QGV;4QGW;4QGX;4YBP;4YBU;4YCE;4YCH;4YDA;4YDB;4YFP;4YFQ;4YFR;4YGG;4YGH;4YGZ;4YH0;4YKM;4YKO;5HZQ;	CHEMBL2221342;		DB00523;DB00755;		PF00061;	IPR012674;IPR011038;IPR031281;IPR000463;IPR031259;IPR000566;	embryonic forelimb morphogenesis [GO:0035115]; epidermis development [GO:0008544]; positive regulation of collateral sprouting [GO:0048672]; regulation of retinoic acid receptor signaling pathway [GO:0048385]; regulation of transcription, DNA-templated [GO:0006355]; retinoic acid metabolic process [GO:0042573]; signal transduction [GO:0007165]	retinal binding [GO:0016918]; retinoic acid binding [GO:0001972]; retinoid binding [GO:0005501]; retinol binding [GO:0019841]; transporter activity [GO:0005215]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; extracellular exosome [GO:0070062]; nucleoplasm [GO:0005654]
P63000	RAC1_HUMAN	Ras-related C3 botulinum toxin substrate 1 (Cell migration-inducing gene 5 protein) (Ras-like protein TC25) (p21-Rac1)	RAC1 TC25 MIG5	1E96;1FOE;1G4U;1HE1;1HH4;1I4D;1I4L;1I4T;1MH1;1RYF;1RYH;2FJU;2H7V;2NZ8;2P2L;2RMK;2VRW;2WKP;2WKQ;2WKR;2YIN;3B13;3BJI;3RYT;3SBD;3SBE;3SU8;3SUA;3TH5;4GZL;4GZM;4YON;5FI0;	CHEMBL6094;	P63000;	DB00514;		PF00071;	IPR027417;IPR005225;IPR001806;	actin cytoskeleton organization [GO:0030036]; actin filament polymerization [GO:0030041]; anatomical structure arrangement [GO:0048532]; anatomical structure morphogenesis [GO:0009653]; auditory receptor cell morphogenesis [GO:0002093]; axon guidance [GO:0007411]; blood coagulation [GO:0007596]; bone resorption [GO:0045453]; cell adhesion [GO:0007155]; cell-cell junction organization [GO:0045216]; cell-matrix adhesion [GO:0007160]; cell motility [GO:0048870]; cell proliferation [GO:0008283]; cellular response to mechanical stimulus [GO:0071260]; cerebral cortex GABAergic interneuron development [GO:0021894]; cerebral cortex radially oriented cell migration [GO:0021799]; cochlea morphogenesis [GO:0090103]; dendrite morphogenesis [GO:0048813]; embryonic olfactory bulb interneuron precursor migration [GO:0021831]; engulfment of apoptotic cell [GO:0043652]; ephrin receptor signaling pathway [GO:0048013]; epithelial cell morphogenesis [GO:0003382]; Fc-epsilon receptor signaling pathway [GO:0038095]; Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096]; G-protein coupled receptor signaling pathway [GO:0007186]; homeostasis of number of cells within a tissue [GO:0048873]; hyperosmotic response [GO:0006972]; inflammatory response [GO:0006954]; intracellular signal transduction [GO:0035556]; lamellipodium assembly [GO:0030032]; localization within membrane [GO:0051668]; mast cell chemotaxis [GO:0002551]; midbrain dopaminergic neuron differentiation [GO:1904948]; movement of cell or subcellular component [GO:0006928]; negative regulation of interleukin-23 production [GO:0032707]; negative regulation of receptor-mediated endocytosis [GO:0048261]; platelet activation [GO:0030168]; positive regulation of actin filament polymerization [GO:0030838]; positive regulation of apoptotic process [GO:0043065]; positive regulation of cell-substrate adhesion [GO:0010811]; positive regulation of DNA replication [GO:0045740]; positive regulation of focal adhesion assembly [GO:0051894]; positive regulation of GTPase activity [GO:0043547]; positive regulation of lamellipodium assembly [GO:0010592]; positive regulation of neutrophil chemotaxis [GO:0090023]; positive regulation of phosphatidylinositol 3-kinase activity [GO:0043552]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of Rho protein signal transduction [GO:0035025]; positive regulation of stress fiber assembly [GO:0051496]; positive regulation of substrate adhesion-dependent cell spreading [GO:1900026]; protein localization to plasma membrane [GO:0072659]; regulation of cell migration [GO:0030334]; regulation of cell size [GO:0008361]; regulation of defense response to virus by virus [GO:0050690]; regulation of fibroblast migration [GO:0010762]; regulation of hydrogen peroxide metabolic process [GO:0010310]; regulation of neuron maturation [GO:0014041]; regulation of respiratory burst [GO:0060263]; regulation of small GTPase mediated signal transduction [GO:0051056]; response to wounding [GO:0009611]; ruffle assembly [GO:0097178]; ruffle organization [GO:0031529]; semaphorin-plexin signaling pathway [GO:0071526]; small GTPase mediated signal transduction [GO:0007264]; substrate adhesion-dependent cell spreading [GO:0034446]; synaptic transmission, GABAergic [GO:0051932]; T cell costimulation [GO:0031295]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]; Wnt signaling pathway, planar cell polarity pathway [GO:0060071]	enzyme binding [GO:0019899]; GTPase activity [GO:0003924]; GTP binding [GO:0005525]; Rho GDP-dissociation inhibitor binding [GO:0051022]; thioesterase binding [GO:0031996]	cytoplasm [GO:0005737]; cytoplasmic ribonucleoprotein granule [GO:0036464]; cytosol [GO:0005829]; early endosome membrane [GO:0031901]; endoplasmic reticulum membrane [GO:0005789]; extracellular exosome [GO:0070062]; extracellular matrix [GO:0031012]; extrinsic component of plasma membrane [GO:0019897]; focal adhesion [GO:0005925]; Golgi membrane [GO:0000139]; lamellipodium [GO:0030027]; melanosome [GO:0042470]; membrane [GO:0016020]; nucleus [GO:0005634]; phagocytic cup [GO:0001891]; plasma membrane [GO:0005886]; ruffle membrane [GO:0032587]; trans-Golgi network [GO:0005802]
P04049	RAF1_HUMAN	RAF proto-oncogene serine/threonine-protein kinase (EC 2.7.11.1) (Proto-oncogene c-RAF) (cRaf) (Raf-1)	RAF1 RAF	1C1Y;1FAQ;1FAR;1GUA;1RFA;3CU8;3IQJ;3IQU;3IQV;3KUC;3KUD;3NKX;3O8I;3OMV;4FJ3;4G0N;4G3X;4IEA;4IHL;	CHEMBL1906;	P04049;	DB08912;DB08896;DB00398;		PF00130;PF07714;PF02196;	IPR020454;IPR011009;IPR002219;IPR000719;IPR017441;IPR003116;IPR001245;IPR008271;IPR029071;	activation of adenylate cyclase activity [GO:0007190]; activation of MAPKK activity [GO:0000186]; apoptotic process [GO:0006915]; cell differentiation [GO:0030154]; cell proliferation [GO:0008283]; death-inducing signaling complex assembly [GO:0071550]; face development [GO:0060324]; heart development [GO:0007507]; insulin secretion involved in cellular response to glucose stimulus [GO:0035773]; intermediate filament cytoskeleton organization [GO:0045104]; ion transmembrane transport [GO:0034220]; MAPK cascade [GO:0000165]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cell proliferation [GO:0008285]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154]; negative regulation of extrinsic apoptotic signaling pathway via death domain receptors [GO:1902042]; negative regulation of protein complex assembly [GO:0031333]; neurotrophin TRK receptor signaling pathway [GO:0048011]; platelet activation [GO:0030168]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; protein phosphorylation [GO:0006468]; regulation of apoptotic process [GO:0042981]; regulation of cell differentiation [GO:0045595]; regulation of cell motility [GO:2000145]; regulation of Rho protein signal transduction [GO:0035023]; response to hypoxia [GO:0001666]; response to muscle stretch [GO:0035994]; signal transduction [GO:0007165]; somatic stem cell population maintenance [GO:0035019]; stimulatory C-type lectin receptor signaling pathway [GO:0002223]; thymus development [GO:0048538]; thyroid gland development [GO:0030878]; wound healing [GO:0042060]	ATP binding [GO:0005524]; kinase activity [GO:0016301]; MAP kinase kinase kinase activity [GO:0004709]; metal ion binding [GO:0046872]; protein kinase activity [GO:0004672]; protein serine/threonine kinase activity [GO:0004674]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; Golgi apparatus [GO:0005794]; mitochondrial outer membrane [GO:0005741]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; pseudopodium [GO:0031143]
Q8NFJ5	RAI3_HUMAN	Retinoic acid-induced protein 3 (G-protein coupled receptor family C group 5 member A) (Phorbol ester induced gene 1) (PEIG-1) (Retinoic acid-induced gene 1 protein) (RAIG-1)	GPRC5A GPCR5A RAI3 RAIG1				DB00755;		PF00003;	IPR017978;	negative regulation of epidermal growth factor-activated receptor activity [GO:0007175]; signal transduction [GO:0007165]	cadherin binding involved in cell-cell adhesion [GO:0098641]; G-protein coupled receptor activity [GO:0004930]	cell-cell adherens junction [GO:0005913]; cytoplasmic vesicle membrane [GO:0030659]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; intracellular membrane-bounded organelle [GO:0043231]; plasma membrane [GO:0005886]; vesicle [GO:0031982]
P10114	RAP2A_HUMAN	Ras-related protein Rap-2a (RbBP-30)	RAP2A	1KAO;2RAP;3RAP;					PF00071;	IPR027417;IPR005225;IPR001806;IPR020849;	actin cytoskeleton reorganization [GO:0031532]; cellular protein localization [GO:0034613]; cellular response to drug [GO:0035690]; establishment of protein localization [GO:0045184]; microvillus assembly [GO:0030033]; negative regulation of cell migration [GO:0030336]; positive regulation of protein autophosphorylation [GO:0031954]; positive regulation of protein phosphorylation [GO:0001934]; protein localization to plasma membrane [GO:0072659]; Rap protein signal transduction [GO:0032486]; regulation of dendrite morphogenesis [GO:0048814]; regulation of JNK cascade [GO:0046328]	GTPase activity [GO:0003924]; GTP binding [GO:0005525]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; midbody [GO:0030496]; plasma membrane [GO:0005886]; recycling endosome [GO:0055037]; recycling endosome membrane [GO:0055038]
P10276	Q96S41_HUMAN,RARA_HUMAN	Retinoic acid receptor alpha (RAR-alpha) (Nuclear receptor subfamily 1 group B member 1)	RARA NR1B1	1DKF;1DSZ;3A9E;3KMR;3KMZ;4DQM;5K13;	CHEMBL2055;	P10276;	DB00459;DB00210;DB00523;DB00982;DB04942;DB00799;		PF00104;PF00105;	IPR000536;IPR001723;IPR003078;IPR001628;IPR013088;	apoptotic cell clearance [GO:0043277]; cellular response to estrogen stimulus [GO:0071391]; cellular response to lipopolysaccharide [GO:0071222]; cellular response to retinoic acid [GO:0071300]; chondroblast differentiation [GO:0060591]; embryonic camera-type eye development [GO:0031076]; face development [GO:0060324]; female pregnancy [GO:0007565]; germ cell development [GO:0007281]; glandular epithelial cell development [GO:0002068]; growth plate cartilage development [GO:0003417]; hippocampus development [GO:0021766]; limb development [GO:0060173]; liver development [GO:0001889]; multicellular organism growth [GO:0035264]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cartilage development [GO:0061037]; negative regulation of cell proliferation [GO:0008285]; negative regulation of granulocyte differentiation [GO:0030853]; negative regulation of interferon-gamma production [GO:0032689]; negative regulation of transcription, DNA-templated [GO:0045892]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; negative regulation of translational initiation [GO:0045947]; negative regulation of tumor necrosis factor production [GO:0032720]; neural tube closure [GO:0001843]; outflow tract septum morphogenesis [GO:0003148]; positive regulation of binding [GO:0051099]; positive regulation of cell cycle [GO:0045787]; positive regulation of cell proliferation [GO:0008284]; positive regulation of interleukin-13 production [GO:0032736]; positive regulation of interleukin-4 production [GO:0032753]; positive regulation of interleukin-5 production [GO:0032754]; positive regulation of neuron differentiation [GO:0045666]; positive regulation of T-helper 2 cell differentiation [GO:0045630]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; prostate gland development [GO:0030850]; protein phosphorylation [GO:0006468]; regulation of myelination [GO:0031641]; regulation of synaptic plasticity [GO:0048167]; response to cytokine [GO:0034097]; response to estradiol [GO:0032355]; response to ethanol [GO:0045471]; response to retinoic acid [GO:0032526]; response to vitamin A [GO:0033189]; retinoic acid receptor signaling pathway [GO:0048384]; Sertoli cell fate commitment [GO:0060010]; signal transduction [GO:0007165]; spermatogenesis [GO:0007283]; trachea cartilage development [GO:0060534]; transcription initiation from RNA polymerase II promoter [GO:0006367]; ureteric bud development [GO:0001657]; ventricular cardiac muscle cell differentiation [GO:0055012]	alpha-actinin binding [GO:0051393]; chromatin DNA binding [GO:0031490]; drug binding [GO:0008144]; enzyme binding [GO:0019899]; mRNA 5'-UTR binding [GO:0048027]; protein domain specific binding [GO:0019904]; protein heterodimerization activity [GO:0046982]; protein kinase A binding [GO:0051018]; protein kinase B binding [GO:0043422]; receptor binding [GO:0005102]; retinoic acid binding [GO:0001972]; retinoic acid receptor activity [GO:0003708]; retinoic acid-responsive element binding [GO:0044323]; RNA polymerase II regulatory region sequence-specific DNA binding [GO:0000977]; steroid hormone receptor activity [GO:0003707]; transcription coactivator activity [GO:0003713]; transcription corepressor activity [GO:0003714]; transcription factor activity, sequence-specific DNA binding [GO:0003700]; transcription factor binding [GO:0008134]; translation repressor activity, nucleic acid binding [GO:0000900]; zinc ion binding [GO:0008270]	actin cytoskeleton [GO:0015629]; cell surface [GO:0009986]; cytoplasm [GO:0005737]; dendrite [GO:0030425]; neuronal cell body [GO:0043025]; nuclear chromatin [GO:0000790]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]
P10826	RARB_HUMAN	Retinoic acid receptor beta (RAR-beta) (HBV-activated protein) (Nuclear receptor subfamily 1 group B member 2) (RAR-epsilon)	RARB HAP NR1B2	1HRA;1XAP;4DM6;4DM8;4JYG;4JYH;4JYI;	CHEMBL2008;	P10826;	DB00459;DB00210;DB00523;DB04942;DB00799;		PF00104;PF00105;	IPR000536;IPR001723;IPR003078;IPR001628;IPR013088;	embryonic digestive tract development [GO:0048566]; embryonic eye morphogenesis [GO:0048048]; embryonic hindlimb morphogenesis [GO:0035116]; glandular epithelial cell development [GO:0002068]; growth plate cartilage development [GO:0003417]; multicellular organism growth [GO:0035264]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cell proliferation [GO:0008285]; negative regulation of chondrocyte differentiation [GO:0032331]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; outflow tract septum morphogenesis [GO:0003148]; positive regulation of apoptotic process [GO:0043065]; positive regulation of cell proliferation [GO:0008284]; positive regulation of neuron differentiation [GO:0045666]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; regulation of myelination [GO:0031641]; retinal pigment epithelium development [GO:0003406]; signal transduction [GO:0007165]; striatum development [GO:0021756]; transcription initiation from RNA polymerase II promoter [GO:0006367]; ureteric bud development [GO:0001657]; ventricular cardiac muscle cell differentiation [GO:0055012]	DNA binding [GO:0003677]; drug binding [GO:0008144]; retinoic acid receptor activity [GO:0003708]; RNA polymerase II regulatory region sequence-specific DNA binding [GO:0000977]; steroid hormone receptor activity [GO:0003707]; zinc ion binding [GO:0008270]	cytoplasm [GO:0005737]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P13631	RARG1_HUMAN,RARG2_HUMAN	Retinoic acid receptor gamma (RAR-gamma) (Nuclear receptor subfamily 1 group B member 3)	RARG NR1B3	1EXA;1EXX;1FCX;1FCY;1FCZ;1FD0;2LBD;3LBD;4LBD;	CHEMBL2003;	P13631;	DB00459;DB00210;DB00523;DB00799;DB00755;		PF00104;PF00105;	IPR000536;IPR001723;IPR003078;IPR001628;IPR013088;	anterior/posterior pattern specification [GO:0009952]; canonical Wnt signaling pathway [GO:0060070]; cellular response to retinoic acid [GO:0071300]; embryonic camera-type eye development [GO:0031076]; embryonic eye morphogenesis [GO:0048048]; embryonic hindlimb morphogenesis [GO:0035116]; face development [GO:0060324]; glandular epithelial cell development [GO:0002068]; growth plate cartilage chondrocyte growth [GO:0003430]; Harderian gland development [GO:0070384]; multicellular organism growth [GO:0035264]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cell proliferation [GO:0008285]; negative regulation of chondrocyte differentiation [GO:0032331]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; neural tube closure [GO:0001843]; positive regulation of apoptotic process [GO:0043065]; positive regulation of cell proliferation [GO:0008284]; positive regulation of programmed cell death [GO:0043068]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; prostate gland epithelium morphogenesis [GO:0060740]; regulation of cell size [GO:0008361]; regulation of myelination [GO:0031641]; regulation of myeloid cell differentiation [GO:0045637]; response to retinoic acid [GO:0032526]; retinal pigment epithelium development [GO:0003406]; retinoic acid receptor signaling pathway [GO:0048384]; trachea cartilage development [GO:0060534]; transcription initiation from RNA polymerase II promoter [GO:0006367]	DNA binding [GO:0003677]; retinoic acid receptor activity [GO:0003708]; retinoid X receptor binding [GO:0046965]; RNA polymerase II regulatory region sequence-specific DNA binding [GO:0000977]; steroid hormone receptor activity [GO:0003707]; transcription factor activity, sequence-specific DNA binding [GO:0003700]; zinc ion binding [GO:0008270]	integral component of membrane [GO:0016021]; nuclear chromatin [GO:0000790]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; transcription factor complex [GO:0005667]
P01112	RASH_HUMAN	GTPase HRas (H-Ras-1) (Ha-Ras) (Transforming protein p21) (c-H-ras) (p21ras) [Cleaved into: GTPase HRas, N-terminally processed]	HRAS HRAS1	121P;1AA9;1AGP;1BKD;1CLU;1CRP;1CRQ;1CRR;1CTQ;1GNP;1GNQ;1GNR;1HE8;1IAQ;1IOZ;1JAH;1JAI;1K8R;1LF0;1LF5;1LFD;1NVU;1NVV;1NVW;1NVX;1P2S;1P2T;1P2U;1P2V;1PLJ;1PLK;1PLL;1Q21;1QRA;1RVD;1WQ1;1XCM;1XD2;1XJ0;1ZVQ;1ZW6;221P;2C5L;2CE2;2CL0;2CL6;2CL7;2CLC;2CLD;2EVW;2GDP;2LCF;2LWI;2N42;2N46;2Q21;2QUZ;2RGA;2RGB;2RGC;2RGD;2RGE;2RGG;2UZI;2VH5;2X1V;3DDC;3I3S;3K8Y;3K9L;3K9N;3KKM;3KKN;3KUD;3L8Y;3L8Z;3LBH;3LBI;3LBN;3LO5;3OIU;3OIV;3OIW;3RRY;3RRZ;3RS0;3RS2;3RS3;3RS4;3RS5;3RS7;3RSL;3RSO;3TGP;421P;4DLR;4DLS;4DLT;4DLU;4DLV;4DLW;4DLX;4DLY;4DLZ;4DST;4DSU;4EFL;4EFM;4EFN;4G0N;4G3X;4K81;4L9S;4L9W;4NYI;4NYJ;4NYM;4Q21;4RSG;4URU;4URV;4URW;4URX;4URY;4URZ;4US0;4US1;4US2;4XVQ;4XVR;521P;5B2Z;5B30;5P21;621P;6Q21;721P;821P;	CHEMBL2167;	P01112;			PF00071;	IPR027417;IPR005225;IPR001806;IPR020849;	animal organ morphogenesis [GO:0009887]; axon guidance [GO:0007411]; cell cycle arrest [GO:0007050]; cell proliferation [GO:0008283]; cell surface receptor signaling pathway [GO:0007166]; cellular senescence [GO:0090398]; chemotaxis [GO:0006935]; defense response to protozoan [GO:0042832]; endocytosis [GO:0006897]; ephrin receptor signaling pathway [GO:0048013]; epidermal growth factor receptor signaling pathway [GO:0007173]; ERBB2 signaling pathway [GO:0038128]; Fc-epsilon receptor signaling pathway [GO:0038095]; intrinsic apoptotic signaling pathway [GO:0097193]; leukocyte migration [GO:0050900]; MAPK cascade [GO:0000165]; mitotic cell cycle checkpoint [GO:0007093]; negative regulation of cell proliferation [GO:0008285]; negative regulation of gene expression [GO:0010629]; negative regulation of GTPase activity [GO:0034260]; negative regulation of neuron apoptotic process [GO:0043524]; positive regulation of actin cytoskeleton reorganization [GO:2000251]; positive regulation of cell migration [GO:0030335]; positive regulation of cell proliferation [GO:0008284]; positive regulation of DNA replication [GO:0045740]; positive regulation of epithelial cell proliferation [GO:0050679]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of GTPase activity [GO:0043547]; positive regulation of interferon-gamma production [GO:0032729]; positive regulation of JNK cascade [GO:0046330]; positive regulation of MAPK cascade [GO:0043410]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of miRNA metabolic process [GO:2000630]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of Ras protein signal transduction [GO:0046579]; positive regulation of ruffle assembly [GO:1900029]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of wound healing [GO:0090303]; protein heterooligomerization [GO:0051291]; Ras protein signal transduction [GO:0007265]; regulation of long-term neuronal synaptic plasticity [GO:0048169]; signal transduction [GO:0007165]; social behavior [GO:0035176]; stimulatory C-type lectin receptor signaling pathway [GO:0002223]; T cell receptor signaling pathway [GO:0050852]; T-helper 1 type immune response [GO:0042088]	GTPase activity [GO:0003924]; GTP binding [GO:0005525]; protein C-terminus binding [GO:0008022]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; Golgi apparatus [GO:0005794]; Golgi membrane [GO:0000139]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]
Q8TC12	RDH11_HUMAN	Retinol dehydrogenase 11 (EC 1.1.1.300) (Androgen-regulated short-chain dehydrogenase/reductase 1) (HCV core-binding protein HCBP12) (Prostate short-chain dehydrogenase/reductase 1) (Retinal reductase 1) (RalR1) (Short chain dehydrogenase/reductase family 7C member 1)	RDH11 ARSDR1 PSDR1 SDR7C1 CGI-82				DB00162;		PF00106;	IPR016040;IPR002347;	adaptation of rhodopsin mediated signaling [GO:0016062]; retinal metabolic process [GO:0042574]; retinoid metabolic process [GO:0001523]; retinol metabolic process [GO:0042572]	NADP-retinol dehydrogenase activity [GO:0052650]; oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor [GO:0016616]; retinol dehydrogenase activity [GO:0004745]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; intracellular [GO:0005622]; photoreceptor inner segment [GO:0001917]
Q96NR8	RDH12_HUMAN	Retinol dehydrogenase 12 (EC 1.1.1.-) (All-trans and 9-cis retinol dehydrogenase) (Short chain dehydrogenase/reductase family 7C member 2)	RDH12 SDR7C2				DB00162;		PF00106;	IPR016040;IPR002347;	photoreceptor cell maintenance [GO:0045494]; response to stimulus [GO:0050896]; retinoid metabolic process [GO:0001523]; retinol metabolic process [GO:0042572]; visual perception [GO:0007601]	NADP-retinol dehydrogenase activity [GO:0052650]; retinol dehydrogenase activity [GO:0004745]	intracellular [GO:0005622]; photoreceptor inner segment membrane [GO:0060342]
Q8NBN7	RDH13_HUMAN	Retinol dehydrogenase 13 (EC 1.1.1.-) (Short chain dehydrogenase/reductase family 7C member 3)	RDH13 SDR7C3 PSEC0082 UNQ736/PRO1430				DB00162;		PF00106;	IPR016040;IPR020904;IPR002347;	eye photoreceptor cell development [GO:0042462]; response to high light intensity [GO:0009644]; retina layer formation [GO:0010842]	NADP-retinol dehydrogenase activity [GO:0052650]; oxidoreductase activity [GO:0016491]	mitochondrial inner membrane [GO:0005743]
Q9HBH5	RDH14_HUMAN	Retinol dehydrogenase 14 (EC 1.1.1.-) (Alcohol dehydrogenase PAN2) (Short chain dehydrogenase/reductase family 7C member 4)	RDH14 PAN2 SDR7C4 UNQ529/PRO1072				DB00162;		PF00106;	IPR016040;IPR002347;	osteoblast differentiation [GO:0001649]	NADP-retinol dehydrogenase activity [GO:0052650]; oxidoreductase activity [GO:0016491]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; lysosomal membrane [GO:0005765]; membrane [GO:0016020]; mitochondrion [GO:0005739]; nucleus [GO:0005634]
Q92781	RDH1_HUMAN	11-cis retinol dehydrogenase (11-cis RDH) (11-cis RoDH) (EC 1.1.1.315) (9-cis retinol dehydrogenase) (9cRDH) (Retinol dehydrogenase 5) (Short chain dehydrogenase/reductase family 9C member 5)	RDH5 HSD17B9 RDH1 SDR9C5				DB00162;	PATHWAY: Cofactor metabolism; retinol metabolism. {ECO:0000269|PubMed:9115228}.	PF00106;	IPR016040;IPR032968;IPR002347;	response to stimulus [GO:0050896]; retinoid metabolic process [GO:0001523]; retinol metabolic process [GO:0042572]; visual perception [GO:0007601]	retinol dehydrogenase activity [GO:0004745]	cell body [GO:0044297]; endoplasmic reticulum lumen [GO:0005788]; endoplasmic reticulum membrane [GO:0005789]
P05451	REG1A_HUMAN	Lithostathine-1-alpha (Islet cells regeneration factor) (ICRF) (Islet of Langerhans regenerating protein) (REG) (Pancreatic stone protein) (PSP) (Pancreatic thread protein) (PTP) (Regenerating islet-derived protein 1-alpha) (REG-1-alpha) (Regenerating protein I alpha)	REG1A PSPS PSPS1 REG	1LIT;1QDD;					PF00059;	IPR001304;IPR016186;IPR018378;IPR016187;	positive regulation of cell proliferation [GO:0008284]	carbohydrate binding [GO:0030246]; growth factor activity [GO:0008083]	extracellular exosome [GO:0070062]
P51606	RENBP_HUMAN	N-acylglucosamine 2-epimerase (AGE) (EC 5.1.3.8) (GlcNAc 2-epimerase) (N-acetyl-D-glucosamine 2-epimerase) (Renin-binding protein) (RnBP)	RENBP				DB00141;	PATHWAY: Amino-sugar metabolism; N-acetylneuraminate degradation. {ECO:0000269|PubMed:22692205}.		IPR008928;IPR012341;	N-acetylglucosamine metabolic process [GO:0006044]; N-acetylmannosamine metabolic process [GO:0006051]; N-acetylneuraminate catabolic process [GO:0019262]; regulation of blood pressure [GO:0008217]; UDP-N-acetylglucosamine biosynthetic process [GO:0006048]	ATP binding [GO:0005524]; endopeptidase inhibitor activity [GO:0004866]; N-acylglucosamine 2-epimerase activity [GO:0050121]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P00797	RENI_HUMAN	Renin (EC 3.4.23.15) (Angiotensinogenase)	REN	1BBS;1BIL;1BIM;1HRN;1RNE;2BKS;2BKT;2FS4;2G1N;2G1O;2G1R;2G1S;2G1Y;2G20;2G21;2G22;2G24;2G26;2G27;2I4Q;2IKO;2IKU;2IL2;2REN;2V0Z;2V10;2V11;2V12;2V13;2V16;2X0B;3D91;3G6Z;3G70;3G72;3GW5;3K1W;3KM4;3O9L;3OAD;3OAG;3OOT;3OQF;3OQK;3OWN;3Q3T;3Q4B;3Q5H;3SFC;3VCM;3VSW;3VSX;3VUC;3VYD;3VYE;3VYF;4AMT;4GJ5;4GJ6;4GJ7;4GJ8;4GJ9;4GJA;4GJB;4GJC;4GJD;4PYV;4Q1N;4RYC;4RYG;4RZ1;4S1G;4XX3;4XX4;	CHEMBL286;	P00797;	DB09026;DB00212;		PF07966;PF00026;	IPR001461;IPR001969;IPR012848;IPR033121;IPR021109;	angiotensin maturation [GO:0002003]; beta-amyloid metabolic process [GO:0050435]; cell maturation [GO:0048469]; cellular response to drug [GO:0035690]; drinking behavior [GO:0042756]; hormone-mediated signaling pathway [GO:0009755]; kidney development [GO:0001822]; male gonad development [GO:0008584]; mesonephros development [GO:0001823]; proteolysis [GO:0006508]; regulation of blood pressure [GO:0008217]; regulation of MAPK cascade [GO:0043408]; renin-angiotensin regulation of aldosterone production [GO:0002018]; response to cAMP [GO:0051591]; response to cGMP [GO:0070305]; response to immobilization stress [GO:0035902]; response to lipopolysaccharide [GO:0032496]	aspartic-type endopeptidase activity [GO:0004190]; peptidase activity [GO:0008233]; receptor binding [GO:0005102]	extracellular region [GO:0005576]; extracellular space [GO:0005615]; lysosome [GO:0005764]; plasma membrane [GO:0005886]
P09455	RET1_HUMAN	Retinol-binding protein 1 (Cellular retinol-binding protein) (CRBP) (Cellular retinol-binding protein I) (CRBP-I)	RBP1 CRBP1	5H8T;5H9A;5HA1;5HBS;			DB00459;DB00162;		PF00061;	IPR012674;IPR011038;IPR031264;IPR000463;IPR031259;IPR000566;	retinoic acid biosynthetic process [GO:0002138]; retinoid metabolic process [GO:0001523]; vitamin A metabolic process [GO:0006776]	retinal binding [GO:0016918]; retinoid binding [GO:0005501]; retinol binding [GO:0019841]; transporter activity [GO:0005215]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleoplasm [GO:0005654]
P50120	RET2_HUMAN	Retinol-binding protein 2 (Cellular retinol-binding protein II) (CRBP-II)	RBP2 CRBP2	2RCQ;2RCT;4EDE;4EEJ;4EFG;4EXZ;4GKC;4QYN;4QYP;4QZT;4QZU;4RUU;4ZCB;4ZGU;4ZH6;4ZH9;4ZJ0;4ZR2;5DG4;5DPQ;			DB00162;		PF00061;	IPR012674;IPR011038;IPR031266;IPR000463;IPR031259;IPR000566;	epidermis development [GO:0008544]; retinoid metabolic process [GO:0001523]; vitamin A metabolic process [GO:0006776]	retinal binding [GO:0016918]; retinoid binding [GO:0005501]; retinol binding [GO:0019841]; transporter activity [GO:0005215]	cytosol [GO:0005829]
P82980	RET5_HUMAN	Retinol-binding protein 5 (Cellular retinol-binding protein III) (CRBP-III) (HRBPiso)	RBP5	1GGL;			DB00162;		PF00061;	IPR012674;IPR011038;IPR031270;IPR000463;IPR031259;IPR000566;		retinal binding [GO:0016918]; retinoid binding [GO:0005501]; retinol binding [GO:0019841]; transporter activity [GO:0005215]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]
Q96R05	RET7_HUMAN	Retinoid-binding protein 7 (Cellular retinoic acid-binding protein 4) (CRABP4) (CRBP4) (Cellular retinoic acid-binding protein IV) (CRABP-IV)	RBP7	1LPJ;			DB00162;		PF00061;	IPR012674;IPR011038;IPR000463;IPR031259;IPR000566;IPR033075;		retinal binding [GO:0016918]; retinol binding [GO:0019841]; transporter activity [GO:0005215]	cytoplasm [GO:0005737]
P02753	RETBP_HUMAN	Retinol-binding protein 4 (Plasma retinol-binding protein) (PRBP) (RBP) [Cleaved into: Plasma retinol-binding protein(1-182); Plasma retinol-binding protein(1-181); Plasma retinol-binding protein(1-179); Plasma retinol-binding protein(1-176)]	RBP4 PRO2222	1BRP;1BRQ;1JYD;1JYJ;1QAB;1RBP;1RLB;2WQ9;2WQA;2WR6;3BSZ;3FMZ;4O9S;4PSQ;	CHEMBL3100;	P02753;	DB00162;		PF00061;	IPR012674;IPR011038;IPR002345;IPR022271;IPR022272;IPR000566;IPR002449;	cardiac muscle tissue development [GO:0048738]; embryonic organ morphogenesis [GO:0048562]; embryonic retina morphogenesis in camera-type eye [GO:0060059]; embryonic skeletal system development [GO:0048706]; eye development [GO:0001654]; female genitalia morphogenesis [GO:0048807]; gluconeogenesis [GO:0006094]; glucose homeostasis [GO:0042593]; heart development [GO:0007507]; heart trabecula formation [GO:0060347]; lung development [GO:0030324]; maintenance of gastrointestinal epithelium [GO:0030277]; negative regulation of cardiac muscle cell proliferation [GO:0060044]; positive regulation of immunoglobulin secretion [GO:0051024]; positive regulation of insulin secretion [GO:0032024]; response to ethanol [GO:0045471]; response to retinoic acid [GO:0032526]; retinoid metabolic process [GO:0001523]; retinol metabolic process [GO:0042572]; retinol transport [GO:0034633]; urinary bladder development [GO:0060157]; uterus development [GO:0060065]; vagina development [GO:0060068]; visual perception [GO:0007601]	retinal binding [GO:0016918]; retinol binding [GO:0019841]; retinol transporter activity [GO:0034632]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; protein complex [GO:0043234]
Q6NUM9	RETST_HUMAN	All-trans-retinol 13,14-reductase (EC 1.3.99.23) (All-trans-13,14-dihydroretinol saturase) (RetSat) (PPAR-alpha-regulated and starvation-induced gene protein)	RETSAT PPSIG UNQ439/PRO872				DB00162;			IPR023753;	oxidation-reduction process [GO:0055114]; retinol metabolic process [GO:0042572]	all-trans-retinol 13,14-reductase activity [GO:0051786]; oxidoreductase activity [GO:0016491]	endoplasmic reticulum membrane [GO:0005789]; membrane [GO:0016020]; nuclear membrane [GO:0031965]; nuclear outer membrane [GO:0005640]
P07949	RET_HUMAN	Proto-oncogene tyrosine-protein kinase receptor Ret (EC 2.7.10.1) (Cadherin family member 12) (Proto-oncogene c-Ret) [Cleaved into: Soluble RET kinase fragment; Extracellular cell-membrane anchored RET cadherin 120 kDa fragment]	RET CDHF12 CDHR16 PTC RET51	1XPD;2IVS;2IVT;2IVU;2IVV;2X2K;2X2L;2X2M;2X2U;4CKI;4CKJ;4UX8;5AMN;	CHEMBL2041;	P07949;	DB08875;DB08901;DB08896;DB00398;		PF00028;PF07714;	IPR002126;IPR015919;IPR011009;IPR000719;IPR017441;IPR001245;IPR008266;IPR020635;IPR016249;	activation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0006919]; cellular response to retinoic acid [GO:0071300]; embryonic epithelial tube formation [GO:0001838]; enteric nervous system development [GO:0048484]; homophilic cell adhesion via plasma membrane adhesion molecules [GO:0007156]; innervation [GO:0060384]; lymphocyte migration into lymphoid organs [GO:0097021]; MAPK cascade [GO:0000165]; membrane protein proteolysis [GO:0033619]; neural crest cell migration [GO:0001755]; neuron cell-cell adhesion [GO:0007158]; neuron maturation [GO:0042551]; Peyer's patch morphogenesis [GO:0061146]; positive regulation of cell adhesion mediated by integrin [GO:0033630]; positive regulation of cell migration [GO:0030335]; positive regulation of cell size [GO:0045793]; positive regulation of extrinsic apoptotic signaling pathway in absence of ligand [GO:2001241]; positive regulation of metanephric glomerulus development [GO:0072300]; positive regulation of neuron maturation [GO:0014042]; positive regulation of neuron projection development [GO:0010976]; positive regulation of serine phosphorylation of STAT3 protein [GO:1903263]; positive regulation of transcription, DNA-templated [GO:0045893]; posterior midgut development [GO:0007497]; protein phosphorylation [GO:0006468]; regulation of axonogenesis [GO:0050770]; regulation of cell adhesion [GO:0030155]; response to drug [GO:0042493]; response to pain [GO:0048265]; retina development in camera-type eye [GO:0060041]; signal transduction [GO:0007165]; transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169]; ureteric bud development [GO:0001657]; ureter maturation [GO:0035799]	ATP binding [GO:0005524]; calcium ion binding [GO:0005509]; protein tyrosine kinase activity [GO:0004713]; Ras guanyl-nucleotide exchange factor activity [GO:0005088]; receptor activity [GO:0004872]; transmembrane receptor protein tyrosine kinase activity [GO:0004714]	axon [GO:0030424]; cytoplasm [GO:0005737]; dendrite [GO:0030425]; early endosome [GO:0005769]; endosome membrane [GO:0010008]; integral component of plasma membrane [GO:0005887]; intracellular membrane-bounded organelle [GO:0043231]; membrane raft [GO:0045121]; neuronal cell body [GO:0043025]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]
P47736	RGP2_HUMAN	Rap1 GTPase-activating protein 1 (Rap1GAP) (Rap1GAP1)	RAP1GAP KIAA0474 RAP1GA1	1SRQ;3BRW;					PF02188;PF02145;	IPR003109;IPR000331;	cellular response to glial cell derived neurotrophic factor [GO:1990792]; negative regulation of GTP binding [GO:1904425]; negative regulation of microvillus assembly [GO:1903697]; negative regulation of neuron differentiation [GO:0045665]; negative regulation of thyroid gland epithelial cell proliferation [GO:1904442]; positive regulation of GTPase activity [GO:0043547]; regulation of GTPase activity [GO:0043087]; regulation of small GTPase mediated signal transduction [GO:0051056]; signal transduction [GO:0007165]	GTPase activator activity [GO:0005096]; GTPase activity [GO:0003924]; protein homodimerization activity [GO:0042803]; Ras GTPase binding [GO:0017016]	axon [GO:0030424]; cytosol [GO:0005829]; dendrite [GO:0030425]; early endosome [GO:0005769]; Golgi membrane [GO:0000139]; membrane [GO:0016020]; neuronal cell body [GO:0043025]
P61586	RHOA_HUMAN	Transforming protein RhoA (Rho cDNA clone 12) (h12)	RHOA ARH12 ARHA RHO12	1A2B;1CC0;1CXZ;1DPF;1FTN;1KMQ;1LB1;1OW3;1S1C;1TX4;1X86;1XCG;2RGN;3KZ1;3LW8;3LWN;3LXR;3MSX;3T06;4D0N;4XH9;4XOI;4XSG;4XSH;5A0F;5BWM;5C2K;5C4M;5FR1;5FR2;5HPY;5IRC;5JCP;	CHEMBL6052;	P61586;			PF00071;	IPR027417;IPR005225;IPR001806;	actin cytoskeleton organization [GO:0030036]; actin cytoskeleton reorganization [GO:0031532]; apical junction assembly [GO:0043297]; apolipoprotein A-I-mediated signaling pathway [GO:0038027]; cell migration [GO:0016477]; cleavage furrow formation [GO:0036089]; endothelial cell migration [GO:0043542]; endothelial tube lumen extension [GO:0097498]; ephrin receptor signaling pathway [GO:0048013]; mitotic cleavage furrow formation [GO:1903673]; mitotic spindle assembly [GO:0090307]; negative chemotaxis [GO:0050919]; negative regulation of axonogenesis [GO:0050771]; negative regulation of cell migration involved in sprouting angiogenesis [GO:0090051]; ossification involved in bone maturation [GO:0043931]; phosphatidylinositol-mediated signaling [GO:0048015]; platelet activation [GO:0030168]; positive regulation of axonogenesis [GO:0050772]; positive regulation of cytokinesis [GO:0032467]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of lipase activity [GO:0060193]; positive regulation of neuron differentiation [GO:0045666]; positive regulation of NF-kappaB import into nucleus [GO:0042346]; positive regulation of protein serine/threonine kinase activity [GO:0071902]; positive regulation of stress fiber assembly [GO:0051496]; regulation of actin cytoskeleton organization [GO:0032956]; regulation of cell migration [GO:0030334]; regulation of cell motility [GO:2000145]; regulation of osteoblast proliferation [GO:0033688]; regulation of small GTPase mediated signal transduction [GO:0051056]; Rho protein signal transduction [GO:0007266]; Roundabout signaling pathway [GO:0035385]; skeletal muscle satellite cell migration [GO:1902766]; stress fiber assembly [GO:0043149]; substantia nigra development [GO:0021762]; trabecula morphogenesis [GO:0061383]; transforming growth factor beta receptor signaling pathway [GO:0007179]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]; viral process [GO:0016032]; Wnt signaling pathway, planar cell polarity pathway [GO:0060071]; wound healing, spreading of cells [GO:0044319]	GTPase activity [GO:0003924]; GTP binding [GO:0005525]; myosin binding [GO:0017022]	apical junction complex [GO:0043296]; cell cortex [GO:0005938]; cell junction [GO:0030054]; cell periphery [GO:0071944]; cleavage furrow [GO:0032154]; cytoskeleton [GO:0005856]; cytosol [GO:0005829]; endoplasmic reticulum membrane [GO:0005789]; endosome [GO:0005768]; extracellular exosome [GO:0070062]; extrinsic component of cytoplasmic side of plasma membrane [GO:0031234]; focal adhesion [GO:0005925]; lamellipodium [GO:0030027]; midbody [GO:0030496]; plasma membrane [GO:0005886]; vesicle [GO:0031982]
Q969G6	RIFK_HUMAN	Riboflavin kinase (EC 2.7.1.26) (ATP:riboflavin 5'-phosphotransferase) (Flavokinase)	RFK	1NB0;1NB9;1P4M;1Q9S;			DB00140;	PATHWAY: Cofactor biosynthesis; FMN biosynthesis; FMN from riboflavin (ATP route): step 1/1.	PF01687;	IPR023468;IPR015865;IPR023465;	apoptotic process [GO:0006915]; FMN biosynthetic process [GO:0009398]; positive regulation of NAD(P)H oxidase activity [GO:0033864]; reactive oxygen species metabolic process [GO:0072593]; riboflavin biosynthetic process [GO:0009231]; riboflavin metabolic process [GO:0006771]	ATP binding [GO:0005524]; metal ion binding [GO:0046872]; riboflavin kinase activity [GO:0008531]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrion [GO:0005739]
P23921	RIR1_HUMAN	Ribonucleoside-diphosphate reductase large subunit (EC 1.17.4.1) (Ribonucleoside-diphosphate reductase subunit M1) (Ribonucleotide reductase large subunit)	RRM1 RR1	2WGH;3HNC;3HND;3HNE;3HNF;4X3V;5D1Y;	CHEMBL1830;	P23921;	DB00242;DB00631;DB01073;DB00441;DB01005;	PATHWAY: Genetic information processing; DNA replication.	PF03477;PF02867;PF00317;	IPR005144;IPR013346;IPR000788;IPR013509;IPR008926;	cell proliferation in forebrain [GO:0021846]; deoxyribonucleotide biosynthetic process [GO:0009263]; DNA replication [GO:0006260]; male gonad development [GO:0008584]; mitotic cell cycle [GO:0000278]; nucleobase-containing small molecule interconversion [GO:0015949]; protein heterotetramerization [GO:0051290]; pyrimidine nucleobase metabolic process [GO:0006206]; response to ionizing radiation [GO:0010212]; retina development in camera-type eye [GO:0060041]	ATP binding [GO:0005524]; ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor [GO:0004748]	cell projection [GO:0042995]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; neuronal cell body [GO:0043025]; nuclear envelope [GO:0005635]; nucleoplasm [GO:0005654]; ribonucleoside-diphosphate reductase complex [GO:0005971]
P07998	RNAS1_HUMAN	Ribonuclease pancreatic (EC 3.1.27.5) (HP-RNase) (RIB-1) (RNase UpI-1) (Ribonuclease 1) (RNase 1) (Ribonuclease A) (RNase A)	RNASE1 RIB1 RNS1	1DZA;1E21;1H8X;1Z7X;2E0J;2E0L;2E0M;2E0O;2K11;2Q4G;3F8G;4KXH;	CHEMBL5425;	P07998;	DB00536;DB02325;DB00128;		PF00074;	IPR001427;IPR023411;IPR023412;		nucleic acid binding [GO:0003676]; ribonuclease A activity [GO:0004522]	extracellular exosome [GO:0070062]
P10153	RNAS2_HUMAN	Non-secretory ribonuclease (EC 3.1.27.5) (Eosinophil-derived neurotoxin) (RNase UpI-2) (Ribonuclease 2) (RNase 2) (Ribonuclease US)	RNASE2 EDN RNS2	1GQV;1HI2;1HI3;1HI4;1HI5;1K2A;2BEX;2BZZ;2C01;2C02;2C05;5E13;	CHEMBL5120;	P10153;			PF00074;	IPR001427;IPR023411;IPR023412;	chemotaxis [GO:0006935]; positive regulation of protein targeting to mitochondrion [GO:1903955]; RNA catabolic process [GO:0006401]	endonuclease activity [GO:0004519]; nucleic acid binding [GO:0003676]; ribonuclease A activity [GO:0004522]; ribonuclease activity [GO:0004540]	extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; lysosome [GO:0005764]
P34096	RNAS4_HUMAN	Ribonuclease 4 (RNase 4) (EC 3.1.27.-)	RNASE4 RNS4	1RNF;2RNF;					PF00074;	IPR001427;IPR023411;IPR023412;	mRNA cleavage [GO:0006379]	endonuclease activity [GO:0004519]; nucleic acid binding [GO:0003676]; ribonuclease A activity [GO:0004522]; ribonuclease activity [GO:0004540]	extracellular exosome [GO:0070062]; extracellular region [GO:0005576]
Q13464	ROCK1_HUMAN	Rho-associated protein kinase 1 (EC 2.7.11.1) (Renal carcinoma antigen NY-REN-35) (Rho-associated, coiled-coil-containing protein kinase 1) (Rho-associated, coiled-coil-containing protein kinase I) (ROCK-I) (p160 ROCK-1) (p160ROCK)	ROCK1	1S1C;2ESM;2ETK;2ETR;2V55;3D9V;3NCZ;3NDM;3O0Z;3TV7;3TWJ;3V8S;4L2W;4W7P;4YVC;4YVE;5BML;	CHEMBL3231;	Q13464;			PF00069;PF08912;	IPR000961;IPR011009;IPR002219;IPR011993;IPR001849;IPR000719;IPR017441;IPR015008;IPR029876;IPR020684;IPR008271;	actin cytoskeleton organization [GO:0030036]; apical constriction [GO:0003383]; bleb assembly [GO:0032060]; cellular component disassembly involved in execution phase of apoptosis [GO:0006921]; cortical actin cytoskeleton organization [GO:0030866]; ephrin receptor signaling pathway [GO:0048013]; establishment of protein localization to plasma membrane [GO:0090002]; I-kappaB kinase/NF-kappaB signaling [GO:0007249]; leukocyte cell-cell adhesion [GO:0007159]; leukocyte migration [GO:0050900]; leukocyte tethering or rolling [GO:0050901]; membrane to membrane docking [GO:0022614]; myoblast migration [GO:0051451]; negative regulation of angiogenesis [GO:0016525]; negative regulation of bicellular tight junction assembly [GO:1903347]; negative regulation of myosin-light-chain-phosphatase activity [GO:0035509]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of protein binding [GO:0032091]; positive regulation of focal adhesion assembly [GO:0051894]; protein phosphorylation [GO:0006468]; regulation of actin cytoskeleton organization [GO:0032956]; regulation of cell adhesion [GO:0030155]; regulation of cell motility [GO:2000145]; regulation of establishment of cell polarity [GO:2000114]; regulation of establishment of endothelial barrier [GO:1903140]; regulation of focal adhesion assembly [GO:0051893]; regulation of keratinocyte differentiation [GO:0045616]; regulation of stress fiber assembly [GO:0051492]; Rho protein signal transduction [GO:0007266]; signal transduction [GO:0007165]; smooth muscle contraction [GO:0006939]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]	ATP binding [GO:0005524]; metal ion binding [GO:0046872]; protein kinase activity [GO:0004672]; protein serine/threonine kinase activity [GO:0004674]	bleb [GO:0032059]; centriole [GO:0005814]; cytoskeleton [GO:0005856]; cytosol [GO:0005829]; Golgi membrane [GO:0000139]; lamellipodium [GO:0030027]; plasma membrane [GO:0005886]; ruffle [GO:0001726]
Q9BZR6	RTN4R_HUMAN	Reticulon-4 receptor (Nogo receptor) (NgR) (Nogo-66 receptor)	RTN4R NOGOR UNQ330/PRO526	1OZN;1P8T;					PF13855;	IPR000483;IPR032675;IPR001611;IPR003591;	axonogenesis [GO:0007409]; cytokine-mediated signaling pathway [GO:0019221]; negative regulation of axon extension [GO:0030517]; negative regulation of axonogenesis [GO:0050771]; negative regulation of JAK-STAT cascade [GO:0046426]; negative regulation of protein kinase activity [GO:0006469]; neuronal signal transduction [GO:0023041]; positive regulation of GTPase activity [GO:0043547]	neuregulin receptor activity [GO:0038131]; protein kinase inhibitor activity [GO:0004860]; receptor activity [GO:0004872]	anchored component of membrane [GO:0031225]; axonal growth cone [GO:0044295]; cell surface [GO:0009986]; cytoplasm [GO:0005737]; endoplasmic reticulum [GO:0005783]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; neuronal cell body [GO:0043025]; neuron projection [GO:0043005]; plasma membrane [GO:0005886]
P19793	RXRA_HUMAN	Retinoic acid receptor RXR-alpha (Nuclear receptor subfamily 2 group B member 1) (Retinoid X receptor alpha)	RXRA NR2B1	1BY4;1DSZ;1FBY;1FM6;1FM9;1G1U;1G5Y;1K74;1LBD;1MV9;1MVC;1MZN;1R0N;1RDT;1RXR;1XLS;1XV9;1XVP;1YNW;2ACL;2NLL;2P1T;2P1U;2P1V;2ZXZ;2ZY0;3DZU;3DZY;3E00;3E94;3FAL;3FC6;3FUG;3H0A;3KWY;3NSP;3NSQ;3OAP;3OZJ;3PCU;3R29;3R2A;3R5M;3UVV;4CN2;4CN3;4CN5;4CN7;4J5W;4J5X;4K4J;4K6I;4M8E;4M8H;4N5G;4N8R;4NQA;4OC7;4POH;4POJ;4PP3;4PP5;4RFW;4RMC;4RMD;4RME;4ZO1;4ZSH;5EC9;	CHEMBL2061;	P19793;	DB00459;DB00210;DB00523;DB00307;DB00749;		PF00104;PF11825;PF00105;	IPR021780;IPR000536;IPR001723;IPR000003;IPR001628;IPR013088;	bile acid and bile salt transport [GO:0015721]; camera-type eye development [GO:0043010]; cardiac muscle cell proliferation [GO:0060038]; cellular lipid metabolic process [GO:0044255]; cholesterol metabolic process [GO:0008203]; embryo implantation [GO:0007566]; in utero embryonic development [GO:0001701]; maternal placenta development [GO:0001893]; modulation by virus of host morphology or physiology [GO:0019048]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; peroxisome proliferator activated receptor signaling pathway [GO:0035357]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus [GO:1901522]; positive regulation of translational initiation by iron [GO:0045994]; protein homotetramerization [GO:0051289]; regulation of branching involved in prostate gland morphogenesis [GO:0060687]; response to retinoic acid [GO:0032526]; retinoic acid receptor signaling pathway [GO:0048384]; secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development [GO:0060528]; transcription initiation from RNA polymerase II promoter [GO:0006367]; ventricular cardiac muscle cell differentiation [GO:0055012]; ventricular cardiac muscle tissue morphogenesis [GO:0055010]; vitamin metabolic process [GO:0006766]	9-cis retinoic acid receptor activity [GO:0004886]; chromatin DNA binding [GO:0031490]; DNA binding [GO:0003677]; enzyme binding [GO:0019899]; protein heterodimerization activity [GO:0046982]; retinoic acid receptor activity [GO:0003708]; retinoic acid-responsive element binding [GO:0044323]; RNA polymerase II regulatory region sequence-specific DNA binding [GO:0000977]; RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding [GO:0004879]; sequence-specific DNA binding [GO:0043565]; steroid hormone receptor activity [GO:0003707]; transcription coactivator activity [GO:0003713]; transcription factor activity, sequence-specific DNA binding [GO:0003700]; vitamin D receptor binding [GO:0042809]; zinc ion binding [GO:0008270]	nuclear chromatin [GO:0000790]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; receptor complex [GO:0043235]; RNA polymerase II transcription factor complex [GO:0090575]
P28702	RXRB_HUMAN	Retinoic acid receptor RXR-beta (Nuclear receptor subfamily 2 group B member 2) (Retinoid X receptor beta)	RXRB NR2B2	1H9U;1UHL;5HJP;5I4V;5KYA;5KYJ;	CHEMBL1870;	P28702;	DB00459;DB00210;DB00523;DB00307;DB00799;DB00755;		PF00104;PF00105;	IPR000536;IPR001723;IPR000003;IPR001628;IPR013088;	positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; transcription initiation from RNA polymerase II promoter [GO:0006367]	9-cis retinoic acid receptor activity [GO:0004886]; RNA polymerase II regulatory region sequence-specific DNA binding [GO:0000977]; RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding [GO:0004879]; steroid hormone receptor activity [GO:0003707]; transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding [GO:0001228]; transcription coactivator activity [GO:0003713]; transcription factor activity, sequence-specific DNA binding [GO:0003700]; zinc ion binding [GO:0008270]	nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P48443	RXRG_HUMAN	Retinoic acid receptor RXR-gamma (Nuclear receptor subfamily 2 group B member 3) (Retinoid X receptor gamma)	RXRG NR2B3	2GL8;	CHEMBL2004;	P48443;	DB00459;DB00210;DB00523;DB00307;DB00755;		PF00104;PF11825;PF00105;	IPR021780;IPR000536;IPR001723;IPR000003;IPR001628;IPR013088;	positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus [GO:1901522]; protein homotetramerization [GO:0051289]; transcription initiation from RNA polymerase II promoter [GO:0006367]	9-cis retinoic acid receptor activity [GO:0004886]; RNA polymerase II regulatory region sequence-specific DNA binding [GO:0000977]; steroid hormone receptor activity [GO:0003707]; zinc ion binding [GO:0008270]	nucleoplasm [GO:0005654]
P21817	RYR1_HUMAN	Ryanodine receptor 1 (RYR-1) (RyR1) (Skeletal muscle calcium release channel) (Skeletal muscle ryanodine receptor) (Skeletal muscle-type ryanodine receptor) (Type 1 ryanodine receptor)	RYR1 RYDR		CHEMBL1846;	P21817;	DB00201;DB01219;DB04786;		PF13833;PF08709;PF00520;PF02815;PF08454;PF06459;PF01365;PF02026;PF00622;	IPR001870;IPR013320;IPR011992;IPR002048;IPR014821;IPR005821;IPR016093;IPR013662;IPR000699;IPR013333;IPR003032;IPR015925;IPR009460;IPR033215;IPR003877;	calcium ion transport [GO:0006816]; cellular response to caffeine [GO:0071313]; ion transmembrane transport [GO:0034220]; muscle contraction [GO:0006936]; ossification involved in bone maturation [GO:0043931]; outflow tract morphogenesis [GO:0003151]; regulation of cardiac conduction [GO:1903779]; regulation of cytosolic calcium ion concentration [GO:0051480]; release of sequestered calcium ion into cytosol [GO:0051209]; release of sequestered calcium ion into cytosol by sarcoplasmic reticulum [GO:0014808]; response to caffeine [GO:0031000]; response to hypoxia [GO:0001666]; skeletal muscle fiber development [GO:0048741]; skin development [GO:0043588]	calcium channel activity [GO:0005262]; calcium-induced calcium release activity [GO:0048763]; calcium ion binding [GO:0005509]; calcium-release channel activity [GO:0015278]; calmodulin binding [GO:0005516]; ryanodine-sensitive calcium-release channel activity [GO:0005219]; voltage-gated calcium channel activity [GO:0005245]	calcium channel complex [GO:0034704]; cell cortex [GO:0005938]; cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; I band [GO:0031674]; integral component of plasma membrane [GO:0005887]; junctional membrane complex [GO:0030314]; junctional sarcoplasmic reticulum membrane [GO:0014701]; plasma membrane [GO:0005886]; sarcolemma [GO:0042383]; sarcoplasmic reticulum [GO:0016529]; sarcoplasmic reticulum membrane [GO:0033017]; smooth endoplasmic reticulum [GO:0005790]; terminal cisterna [GO:0014802]; T-tubule [GO:0030315]; Z disc [GO:0030018]
P25815	S100P_HUMAN	Protein S100-P (Migration-inducing gene 9 protein) (MIG9) (Protein S100-E) (S100 calcium-binding protein P)	S100P S100E	1J55;1OZO;2MJW;			DB01003;		PF01023;	IPR011992;IPR002048;IPR001751;IPR013787;IPR028494;	endothelial cell migration [GO:0043542]; response to organic substance [GO:0010033]	cadherin binding involved in cell-cell adhesion [GO:0098641]; calcium-dependent protein binding [GO:0048306]; calcium ion binding [GO:0005509]; magnesium ion binding [GO:0000287]	cell-cell adherens junction [GO:0005913]; cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; microvillus membrane [GO:0031528]; nucleus [GO:0005634]
P23297	S10A1_HUMAN	Protein S100-A1 (S-100 protein alpha chain) (S-100 protein subunit alpha) (S100 calcium-binding protein A1)	S100A1 S100A	2L0P;2LHL;2LLS;2LLT;2LLU;2LP2;2LP3;2LUX;2M3W;			DB00768;		PF00036;PF01023;	IPR011992;IPR018247;IPR002048;IPR028486;IPR001751;IPR013787;	intracellular signal transduction [GO:0035556]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; positive regulation of voltage-gated calcium channel activity [GO:1901387]; regulation of heart contraction [GO:0008016]; substantia nigra development [GO:0021762]	ATPase binding [GO:0051117]; calcium ion binding [GO:0005509]; identical protein binding [GO:0042802]; protein homodimerization activity [GO:0042803]; S100 protein binding [GO:0044548]	M band [GO:0031430]; neuron projection [GO:0043005]; nucleus [GO:0005634]; protein complex [GO:0043234]; sarcoplasmic reticulum [GO:0016529]; Z disc [GO:0030018]
P06703	S10A6_HUMAN	Protein S100-A6 (Calcyclin) (Growth factor-inducible protein 2A9) (MLN 4) (Prolactin receptor-associated protein) (PRA) (S100 calcium-binding protein A6)	S100A6 CACY	1K8U;1K96;1K9K;1K9P;2M1K;4YBH;					PF01023;	IPR011992;IPR018247;IPR002048;IPR001751;IPR013787;	axonogenesis [GO:0007409]; positive regulation of fibroblast proliferation [GO:0048146]; signal transduction [GO:0007165]	calcium-dependent protein binding [GO:0048306]; calcium ion binding [GO:0005509]; ion transmembrane transporter activity [GO:0015075]; protein homodimerization activity [GO:0042803]; S100 protein binding [GO:0044548]; tropomyosin binding [GO:0005523]; zinc ion binding [GO:0008270]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extrinsic component of cytoplasmic side of plasma membrane [GO:0031234]; nuclear envelope [GO:0005635]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; ruffle [GO:0001726]
P31949	S10AB_HUMAN	Protein S100-A11 (Calgizzarin) (Metastatic lymph node gene 70 protein) (MLN 70) (Protein S100-C) (S100 calcium-binding protein A11) [Cleaved into: Protein S100-A11, N-terminally processed]	S100A11 MLN70 S100C	1V4Z;1V50;2LUC;					PF00036;PF01023;	IPR011992;IPR018247;IPR002048;IPR001751;IPR013787;IPR028482;	negative regulation of cell proliferation [GO:0008285]; negative regulation of DNA replication [GO:0008156]; signal transduction [GO:0007165]	cadherin binding involved in cell-cell adhesion [GO:0098641]; calcium-dependent protein binding [GO:0048306]; calcium ion binding [GO:0005509]; protein homodimerization activity [GO:0042803]; S100 protein binding [GO:0044548]	cell-cell adherens junction [GO:0005913]; cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; nucleus [GO:0005634]; ruffle [GO:0001726]
P80511	S10AC_HUMAN	Protein S100-A12 (CGRP) (Calcium-binding protein in amniotic fluid 1) (CAAF1) (Calgranulin-C) (CAGC) (Extracellular newly identified RAGE-binding protein) (EN-RAGE) (Migration inhibitory factor-related protein 6) (MRP-6) (p6) (Neutrophil S100 protein) (S100 calcium-binding protein A12) [Cleaved into: Calcitermin]	S100A12	1E8A;1GQM;1ODB;2M9G;2WC8;2WCB;2WCE;2WCF;			DB01025;DB00768;		PF01023;	IPR011992;IPR002048;IPR001751;IPR013787;	cytokine secretion [GO:0050663]; defense response to bacterium [GO:0042742]; defense response to fungus [GO:0050832]; inflammatory response [GO:0006954]; innate immune response [GO:0045087]; killing of cells of other organism [GO:0031640]; mast cell activation [GO:0045576]; monocyte chemotaxis [GO:0002548]; neutrophil chemotaxis [GO:0030593]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of inflammatory response [GO:0050729]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; xenobiotic metabolic process [GO:0006805]	calcium ion binding [GO:0005509]; copper ion binding [GO:0005507]; RAGE receptor binding [GO:0050786]; zinc ion binding [GO:0008270]	cytoplasm [GO:0005737]; cytoskeleton [GO:0005856]; cytosol [GO:0005829]; extracellular region [GO:0005576]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
Q99584	S10AD_HUMAN	Protein S100-A13 (S100 calcium-binding protein A13)	S100A13	1YUR;1YUS;1YUT;1YUU;2EGD;2H2K;2K8M;2KI4;2KI6;2KOT;2L5X;2LE9;			DB01025;DB00768;		PF01023;	IPR011992;IPR013787;IPR028487;	cytokine secretion [GO:0050663]; interleukin-1 alpha secretion [GO:0050703]; mast cell degranulation [GO:0043303]; positive regulation of cell proliferation [GO:0008284]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; regulation of cell shape [GO:0008360]; response to copper ion [GO:0046688]; response to electrical stimulus [GO:0051602]	calcium ion binding [GO:0005509]; copper ion binding [GO:0005507]; fibroblast growth factor binding [GO:0017134]; lipid binding [GO:0008289]; protein homodimerization activity [GO:0042803]; RAGE receptor binding [GO:0050786]; zinc ion binding [GO:0008270]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; mast cell granule [GO:0042629]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]
Q13621	S12A1_HUMAN	Solute carrier family 12 member 1 (Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2) (Kidney-specific Na-K-Cl symporter)	SLC12A1 NKCC2		CHEMBL1874;		DB00887;DB00534;DB00310;DB00903;DB00695;DB00774;DB00232;DB00761;DB01325;DB00214;DB01021;		PF00324;PF08403;PF03522;	IPR004841;IPR013612;IPR002443;IPR018491;IPR002445;IPR004842;	ion transmembrane transport [GO:0034220]; ion transport [GO:0006811]; potassium ion transport [GO:0006813]; sodium ion transport [GO:0006814]; transport [GO:0006810]	sodium:potassium:chloride symporter activity [GO:0008511]	apical plasma membrane [GO:0016324]; extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; membrane [GO:0016020]; plasma membrane [GO:0005886]
P55011	S12A2_HUMAN	Solute carrier family 12 member 2 (Basolateral Na-K-Cl symporter) (Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1)	SLC12A2 NKCC1		CHEMBL1615383;	P55011;	DB00887;DB00761;DB01325;		PF00324;PF08403;PF03522;	IPR004841;IPR013612;IPR002443;IPR002444;IPR018491;IPR004842;	aging [GO:0007568]; ammonium transport [GO:0015696]; gamma-aminobutyric acid signaling pathway [GO:0007214]; hyperosmotic response [GO:0006972]; ion transport [GO:0006811]; positive regulation of cell volume [GO:0045795]; potassium ion transport [GO:0006813]; sodium ion transport [GO:0006814]; transepithelial ammonium transport [GO:0070634]; transepithelial chloride transport [GO:0030321]; transport [GO:0006810]	ammonium transmembrane transporter activity [GO:0008519]; protein kinase binding [GO:0019901]; sodium:potassium:chloride symporter activity [GO:0008511]	apical plasma membrane [GO:0016324]; extracellular exosome [GO:0070062]; extracellular vesicle [GO:1903561]; integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]
P55017	S12A3_HUMAN	Solute carrier family 12 member 3 (Na-Cl cotransporter) (NCC) (Na-Cl symporter) (Thiazide-sensitive sodium-chloride cotransporter)	SLC12A3 NCC TSC		CHEMBL1876;		DB00436;DB00562;DB00880;DB01119;DB00999;DB00524;DB01324;DB01325;		PF00324;PF08403;PF03522;	IPR004841;IPR013612;IPR018491;IPR002948;IPR004842;	ion transport [GO:0006811]; sodium ion transmembrane transport [GO:0035725]; sodium ion transport [GO:0006814]; transport [GO:0006810]	sodium:chloride symporter activity [GO:0015378]; transporter activity [GO:0005215]	apical plasma membrane [GO:0016324]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]
Q9UP95	S12A4_HUMAN	Solute carrier family 12 member 4 (Electroneutral potassium-chloride cotransporter 1) (Erythroid K-Cl cotransporter 1) (hKCC1)	SLC12A4 KCC1				DB00887;DB00761;		PF00324;PF03522;	IPR004841;IPR000622;IPR000076;IPR018491;IPR004842;	cell volume homeostasis [GO:0006884]; chemical synaptic transmission [GO:0007268]; ion transport [GO:0006811]; transport [GO:0006810]	potassium:chloride symporter activity [GO:0015379]; potassium ion symporter activity [GO:0022820]; protein kinase binding [GO:0019901]	integral component of plasma membrane [GO:0005887]; lysosomal membrane [GO:0005765]; membrane [GO:0016020]; plasma membrane [GO:0005886]
Q9H2X9	S12A5_HUMAN	Solute carrier family 12 member 5 (Electroneutral potassium-chloride cotransporter 2) (K-Cl cotransporter 2) (hKCC2) (Neuronal K-Cl cotransporter)	SLC12A5 KCC2 KIAA1176		CHEMBL1615384;	Q9H2X9;	DB00887;DB00761;		PF00324;PF03522;	IPR004841;IPR030358;IPR000076;IPR018491;IPR004842;	cellular chloride ion homeostasis [GO:0030644]; cellular ion homeostasis [GO:0006873]; chemical synaptic transmission [GO:0007268]; dendritic spine development [GO:0060996]; ion transport [GO:0006811]; learning [GO:0007612]; multicellular organism growth [GO:0035264]; response to drug [GO:0042493]; thermosensory behavior [GO:0040040]; transport [GO:0006810]	chloride transmembrane transporter activity [GO:0015108]; potassium:chloride symporter activity [GO:0015379]; potassium ion symporter activity [GO:0022820]; protein kinase binding [GO:0019901]	dendritic shaft [GO:0043198]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; neuronal cell body [GO:0043025]; plasma membrane [GO:0005886]
Q9UHW9	S12A6_HUMAN	Solute carrier family 12 member 6 (Electroneutral potassium-chloride cotransporter 3) (K-Cl cotransporter 3)	SLC12A6 KCC3				DB00761;		PF00324;PF03522;	IPR004841;IPR030364;IPR000076;IPR018491;IPR004842;	angiogenesis [GO:0001525]; cellular hypotonic response [GO:0071476]; cellular hypotonic salinity response [GO:0071477]; chemical synaptic transmission [GO:0007268]; ion transport [GO:0006811]; potassium ion import [GO:0010107]; rubidium ion transport [GO:0035826]	potassium:chloride symporter activity [GO:0015379]; potassium ion symporter activity [GO:0022820]; potassium ion transmembrane transporter activity [GO:0015079]; protein kinase binding [GO:0019901]; rubidium ion transmembrane transporter activity [GO:0035827]	basolateral plasma membrane [GO:0016323]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
Q9Y666	S12A7_HUMAN	Solute carrier family 12 member 7 (Electroneutral potassium-chloride cotransporter 4) (K-Cl cotransporter 4)	SLC12A7 KCC4				DB00761;		PF00324;PF03522;	IPR004841;IPR030354;IPR000076;IPR018491;IPR004842;	cell volume homeostasis [GO:0006884]; chemical synaptic transmission [GO:0007268]; ion transport [GO:0006811]; transport [GO:0006810]	potassium:chloride symporter activity [GO:0015379]; potassium ion symporter activity [GO:0022820]; protein kinase binding [GO:0019901]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
Q9BZW2	S13A1_HUMAN	Solute carrier family 13 member 1 (Renal sodium/sulfate cotransporter) (Na(+)/sulfate cotransporter) (hNaSi-1)	SLC13A1 NAS1 NASI1				DB00139;		PF00939;	IPR001898;IPR031312;	sodium ion transmembrane transport [GO:0035725]; sulfate transport [GO:0008272]	sodium:sulfate symporter activity [GO:0015382]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
Q13183	S13A2_HUMAN	Solute carrier family 13 member 2 (Na(+)/dicarboxylate cotransporter 1) (NaDC-1) (Renal sodium/dicarboxylate cotransporter)	SLC13A2 NADC1 SDCT1				DB00139;		PF00939;	IPR001898;IPR031312;	transport [GO:0006810]	low-affinity sodium:dicarboxylate symporter activity [GO:0015361]	extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]
Q8WWT9	S13A3_HUMAN	Solute carrier family 13 member 3 (Na(+)/dicarboxylate cotransporter 3) (NaDC-3) (hNaDC3) (Sodium-dependent high-affinity dicarboxylate transporter 2)	SLC13A3 NADC3 SDCT2				DB00139;		PF00939;	IPR001898;	citrate transport [GO:0015746]	citrate transmembrane transporter activity [GO:0015137]; high-affinity sodium:dicarboxylate symporter activity [GO:0015362]; sodium:dicarboxylate symporter activity [GO:0017153]; succinate transmembrane transporter activity [GO:0015141]	extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
O76054	S14L2_HUMAN	SEC14-like protein 2 (Alpha-tocopherol-associated protein) (TAP) (hTAP) (Squalene transfer protein) (Supernatant protein factor) (SPF)	SEC14L2 C22orf6 KIAA1186 KIAA1658	1O6U;1OLM;4OMJ;4OMK;			DB00163;		PF00650;	IPR001071;IPR001251;IPR011074;IPR009038;	positive regulation of transcription, DNA-templated [GO:0045893]; regulation of cholesterol biosynthetic process [GO:0045540]; transcription, DNA-templated [GO:0006351]	phospholipid binding [GO:0005543]; transporter activity [GO:0005215]; vitamin E binding [GO:0008431]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; nucleus [GO:0005634]
Q9UDX4	S14L3_HUMAN	SEC14-like protein 3 (Tocopherol-associated protein 2)	SEC14L3 TAP2	4UYB;			DB00163;		PF00650;	IPR001071;IPR001251;IPR011074;IPR009038;		lipid binding [GO:0008289]; transporter activity [GO:0005215]	extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; intracellular [GO:0005622]
Q9UDX3	S14L4_HUMAN	SEC14-like protein 4 (Tocopherol-associated protein 3)	SEC14L4 TAP3	4TLG;			DB00163;		PF00650;	IPR001071;IPR001251;IPR011074;IPR009038;		lipid binding [GO:0008289]; transporter activity [GO:0005215]	integral component of membrane [GO:0016021]; intracellular [GO:0005622]
P46059	S15A1_HUMAN	Solute carrier family 15 member 1 (Intestinal H(+)/peptide cotransporter) (Oligopeptide transporter, small intestine isoform) (Peptide transporter 1)	SLC15A1 PEPT1		CHEMBL4605;	P46059;	DB00855;DB01060;DB00415;DB08795;DB00542;DB01053;DB01197;DB00833;DB01140;DB00456;DB00535;DB01413;DB00671;DB00274;DB00493;DB01333;DB00438;DB01415;DB01332;DB01212;DB01112;DB00567;DB00672;DB01340;DB01147;DB01000;DB00485;DB00584;DB01095;DB00492;DB01016;DB01235;DB00722;DB00968;DB00211;DB00691;DB00731;DB00198;DB00713;DB00790;DB00417;DB00881;DB00178;DB01348;DB01124;DB00519;DB00577;DB01610;		PF00854;	IPR020846;IPR004768;IPR000109;IPR018456;	digestion [GO:0007586]; ion transport [GO:0006811]; protein transport [GO:0015031]; transport [GO:0006810]	peptide:proton symporter activity [GO:0015333]; proton-dependent oligopeptide secondary active transmembrane transporter activity [GO:0005427]	brush border [GO:0005903]; integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]
Q16348	S15A2_HUMAN	Solute carrier family 15 member 2 (Kidney H(+)/peptide cotransporter) (Oligopeptide transporter, kidney isoform) (Peptide transporter 2)	SLC15A2 PEPT2		CHEMBL1743125;	Q16348;	DB00855;DB01060;DB00415;DB08795;DB00542;DB01053;DB00833;DB01140;DB00456;DB00535;DB01413;DB00671;DB00274;DB00493;DB01333;DB00438;DB01415;DB01212;DB01112;DB00567;DB00672;DB01340;DB01147;DB01000;DB00485;DB00492;DB01016;DB00691;DB00731;DB00713;DB00790;DB00881;DB00178;DB01348;DB01124;DB00519;DB00302;DB00577;DB01610;		PF00854;	IPR029028;IPR020846;IPR004768;IPR000109;IPR018456;	drug transport [GO:0015893]; ion transport [GO:0006811]; protein transport [GO:0015031]; transport [GO:0006810]	oligopeptide transporter activity [GO:0015198]; peptide:proton symporter activity [GO:0015333]	extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
O60779	S19A2_HUMAN	Thiamine transporter 1 (ThTr-1) (ThTr1) (Solute carrier family 19 member 2) (Thiamine carrier 1) (TC1)	SLC19A2 THT1 TRMA		CHEMBL3079;	O60779;	DB00152;		PF01770;	IPR002666;IPR020846;IPR028338;	thiamine-containing compound metabolic process [GO:0042723]; thiamine transport [GO:0015888]	folic acid transporter activity [GO:0008517]; thiamine transmembrane transporter activity [GO:0015234]; thiamine uptake transmembrane transporter activity [GO:0015403]	integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
Q9BZV2	S19A3_HUMAN	Thiamine transporter 2 (ThTr-2) (ThTr2) (Solute carrier family 19 member 3)	SLC19A3				DB00151;		PF01770;	IPR002666;IPR020846;IPR028337;	thiamine-containing compound metabolic process [GO:0042723]; thiamine transmembrane transport [GO:0071934]	thiamine transmembrane transporter activity [GO:0015234]; thiamine uptake transmembrane transporter activity [GO:0015403]	integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
Q9H015	S22A4_HUMAN	Solute carrier family 22 member 4 (Ergothioneine transporter) (ET transporter) (Organic cation/carnitine transporter 1)	SLC22A4 ETT OCTN1 UT2H		CHEMBL2073668;		DB00594;DB00345;DB01053;DB00122;DB00501;DB00575;DB01151;DB00536;DB00458;DB00332;DB00125;DB00583;DB00123;DB01137;DB06691;DB00184;DB01165;DB01035;DB00908;DB00468;DB00127;DB00624;DB01409;DB00661;		PF00083;	IPR020846;IPR005828;IPR004749;IPR005829;	body fluid secretion [GO:0007589]; carnitine metabolic process [GO:0009437]; carnitine transport [GO:0015879]; organic cation transport [GO:0015695]; quaternary ammonium group transport [GO:0015697]; sodium ion transport [GO:0006814]; triglyceride metabolic process [GO:0006641]	ATP binding [GO:0005524]; carnitine transmembrane transporter activity [GO:0015226]; cation:cation antiporter activity [GO:0015491]; nucleotide binding [GO:0000166]; PDZ domain binding [GO:0030165]; quaternary ammonium group transmembrane transporter activity [GO:0015651]; secondary active organic cation transmembrane transporter activity [GO:0008513]; symporter activity [GO:0015293]	apical plasma membrane [GO:0016324]; integral component of plasma membrane [GO:0005887]; mitochondrion [GO:0005739]; plasma membrane [GO:0005886]
O76082	S22A5_HUMAN	Solute carrier family 22 member 5 (High-affinity sodium-dependent carnitine cotransporter) (Organic cation/carnitine transporter 2)	SLC22A5 OCTN2		CHEMBL2073693;		DB08842;DB03128;DB00345;DB00182;DB00415;DB08795;DB01053;DB01140;DB00456;DB00535;DB01413;DB00671;DB01333;DB00438;DB00567;DB00689;DB00122;DB00501;DB00575;DB00148;DB01000;DB00970;DB01151;DB01075;DB00988;DB00668;DB00695;DB00536;DB00667;DB00332;DB00125;DB00583;DB00281;DB00978;DB06691;DB01577;DB00627;DB00184;DB00368;DB01059;DB01165;DB01032;DB01035;DB00908;DB00468;DB01208;DB00152;DB01409;DB00313;DB00661;		PF00083;	IPR020846;IPR005828;IPR004749;IPR005829;	carnitine metabolic process [GO:0009437]; carnitine transport [GO:0015879]; drug transport [GO:0015893]; positive regulation of intestinal epithelial structure maintenance [GO:0060731]; quaternary ammonium group transport [GO:0015697]; quorum sensing involved in interaction with host [GO:0052106]; sodium-dependent organic cation transport [GO:0070715]; sodium ion transport [GO:0006814]	ATP binding [GO:0005524]; carnitine transmembrane transporter activity [GO:0015226]; cation:cation antiporter activity [GO:0015491]; drug transmembrane transporter activity [GO:0015238]; PDZ domain binding [GO:0030165]; quaternary ammonium group transmembrane transporter activity [GO:0015651]; symporter activity [GO:0015293]	apical plasma membrane [GO:0016324]; brush border membrane [GO:0031526]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
Q9UHI7	S23A1_HUMAN	Solute carrier family 23 member 1 (Na(+)/L-ascorbic acid transporter 1) (Sodium-dependent vitamin C transporter 1) (hSVCT1) (Yolk sac permease-like molecule 3)	SLC23A1 SVCT1 YSPL3				DB00126;		PF00860;	IPR029954;IPR006043;	brain development [GO:0007420]; dehydroascorbic acid transport [GO:0070837]; L-ascorbic acid metabolic process [GO:0019852]; L-ascorbic acid transport [GO:0015882]; lung development [GO:0030324]; nucleobase-containing compound metabolic process [GO:0006139]; nucleobase transport [GO:0015851]; response to toxic substance [GO:0009636]; sodium ion transport [GO:0006814]; transepithelial L-ascorbic acid transport [GO:0070904]	dehydroascorbic acid transporter activity [GO:0033300]; L-ascorbate:sodium symporter activity [GO:0008520]; L-ascorbic acid transporter activity [GO:0015229]; nucleobase transmembrane transporter activity [GO:0015205]; sodium-dependent L-ascorbate transmembrane transporter activity [GO:0070890]; sodium ion transmembrane transporter activity [GO:0015081]	apical plasma membrane [GO:0016324]; basal plasma membrane [GO:0009925]; cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; intracellular organelle [GO:0043229]; membrane [GO:0016020]; plasma membrane [GO:0005886]
Q99808	S29A1_HUMAN	Equilibrative nucleoside transporter 1 (Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter) (Equilibrative NBMPR-sensitive nucleoside transporter) (Nucleoside transporter, es-type) (Solute carrier family 29 member 1)	SLC29A1 ENT1		CHEMBL1997;	Q99808;	DB00987;DB00900;DB00898;DB01073;DB00544;DB00441;DB01033;DB00642;DB00811;DB00943;		PF01733;	IPR030195;IPR002259;IPR020846;	cellular response to glucose stimulus [GO:0071333]; cellular response to hypoxia [GO:0071456]; excitatory postsynaptic potential [GO:0060079]; lactation [GO:0007595]; nucleobase-containing compound metabolic process [GO:0006139]; nucleoside transport [GO:0015858]; sleep [GO:0030431]; uridine transport [GO:0015862]	nucleoside transmembrane transporter activity [GO:0005337]	apical plasma membrane [GO:0016324]; basolateral plasma membrane [GO:0016323]; integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]; postsynapse [GO:0098794]
Q7Z2H8	S36A1_HUMAN	Proton-coupled amino acid transporter 1 (Proton/amino acid transporter 1) (hPAT1) (Solute carrier family 36 member 1)	SLC36A1 PAT1		CHEMBL1914279;	Q7Z2H8;	DB00659;DB00145;DB08847;DB00160;DB08835;DB01080;		PF01490;	IPR013057;	amino acid transport [GO:0006865]; glycine transport [GO:0015816]; ion transport [GO:0006811]; proline transport [GO:0015824]	amino acid transmembrane transporter activity [GO:0015171]; glycine transmembrane transporter activity [GO:0015187]; hydrogen:amino acid symporter activity [GO:0005280]; hydrogen ion transmembrane transporter activity [GO:0015078]; L-alanine transmembrane transporter activity [GO:0015180]; L-proline transmembrane transporter activity [GO:0015193]	endoplasmic reticulum [GO:0005783]; integral component of membrane [GO:0016021]; lysosomal membrane [GO:0005765]; plasma membrane [GO:0005886]
Q99624	S38A3_HUMAN	Sodium-coupled neutral amino acid transporter 3 (N-system amino acid transporter 1) (Na(+)-coupled neutral amino acid transporter 3) (Solute carrier family 38 member 3) (System N amino acid transporter 1)	SLC38A3 G17 NAT1 SN1 SNAT3				DB00174;DB00130;DB00117;		PF01490;	IPR013057;	amino acid transport [GO:0006865]; asparagine transport [GO:0006867]; brain development [GO:0007420]; cellular response to potassium ion starvation [GO:0051365]; female pregnancy [GO:0007565]; glutamine transport [GO:0006868]; histidine transport [GO:0015817]; L-alanine transport [GO:0015808]; positive regulation of glutamine transport [GO:2000487]; positive regulation of transcription from RNA polymerase II promoter in response to acidic pH [GO:0061402]; sodium ion transport [GO:0006814]	amino acid transmembrane transporter activity [GO:0015171]; antiporter activity [GO:0015297]; L-alanine transmembrane transporter activity [GO:0015180]; L-asparagine transmembrane transporter activity [GO:0015182]; L-glutamine transmembrane transporter activity [GO:0015186]; L-histidine transmembrane transporter activity [GO:0005290]; symporter activity [GO:0015293]	basolateral plasma membrane [GO:0016323]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P18405	S5A1_HUMAN	3-oxo-5-alpha-steroid 4-dehydrogenase 1 (EC 1.3.1.22) (SR type 1) (Steroid 5-alpha-reductase 1) (S5AR 1)	SRD5A1		CHEMBL1787;	P18405;	DB01126;DB01216;DB00367;DB06412;DB00421;		PF02544;	IPR016636;IPR001104;	androgen biosynthetic process [GO:0006702]; bone development [GO:0060348]; cell differentiation [GO:0030154]; cellular response to cAMP [GO:0071320]; cellular response to dexamethasone stimulus [GO:0071549]; cellular response to epinephrine stimulus [GO:0071872]; cellular response to estradiol stimulus [GO:0071392]; cellular response to growth factor stimulus [GO:0071363]; cellular response to insulin stimulus [GO:0032869]; cellular response to starvation [GO:0009267]; cellular response to testosterone stimulus [GO:0071394]; cerebral cortex development [GO:0021987]; circadian sleep/wake cycle, REM sleep [GO:0042747]; diterpenoid metabolic process [GO:0016101]; female genitalia development [GO:0030540]; hippocampus development [GO:0021766]; hypothalamus development [GO:0021854]; liver development [GO:0001889]; male genitalia development [GO:0030539]; male gonad development [GO:0008584]; pituitary gland development [GO:0021983]; progesterone metabolic process [GO:0042448]; response to drug [GO:0042493]; response to estrogen [GO:0043627]; response to follicle-stimulating hormone [GO:0032354]; response to fungicide [GO:0060992]; response to growth hormone [GO:0060416]; response to muscle activity [GO:0014850]; serotonin metabolic process [GO:0042428]; sex determination [GO:0007530]; spinal cord development [GO:0021510]; steroid biosynthetic process [GO:0006694]; thalamus development [GO:0021794]; urogenital system development [GO:0001655]	3-oxo-5-alpha-steroid 4-dehydrogenase activity [GO:0003865]; amide binding [GO:0033218]; cholestenone 5-alpha-reductase activity [GO:0047751]; electron carrier activity [GO:0009055]; NADPH binding [GO:0070402]	cell body fiber [GO:0070852]; endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; myelin sheath [GO:0043209]; neuronal cell body [GO:0043025]; organelle membrane [GO:0031090]; perinuclear region of cytoplasm [GO:0048471]
P31213	S5A2_HUMAN	3-oxo-5-alpha-steroid 4-dehydrogenase 2 (EC 1.3.1.22) (5 alpha-SR2) (SR type 2) (Steroid 5-alpha-reductase 2) (S5AR 2) (Type II 5-alpha reductase)	SRD5A2		CHEMBL1856;	P31213;	DB00548;DB01126;DB01216;DB00421;		PF02544;	IPR016636;IPR001104;	androgen biosynthetic process [GO:0006702]; androgen metabolic process [GO:0008209]; biphenyl metabolic process [GO:0018879]; bone development [GO:0060348]; cell-cell signaling [GO:0007267]; cell differentiation [GO:0030154]; dibenzo-p-dioxin metabolic process [GO:0018894]; female genitalia development [GO:0030540]; hippocampus development [GO:0021766]; hypothalamus development [GO:0021854]; male genitalia development [GO:0030539]; male gonad development [GO:0008584]; phthalate metabolic process [GO:0018963]; response to drug [GO:0042493]; response to follicle-stimulating hormone [GO:0032354]; response to nutrient levels [GO:0031667]; response to peptide hormone [GO:0043434]; response to steroid hormone [GO:0048545]; response to testosterone [GO:0033574]; steroid biosynthetic process [GO:0006694]; steroid catabolic process [GO:0006706]	3-oxo-5-alpha-steroid 4-dehydrogenase activity [GO:0003865]; amide binding [GO:0033218]; cholestenone 5-alpha-reductase activity [GO:0047751]; sterol 5-alpha reductase activity [GO:0009917]	cell body fiber [GO:0070852]; endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; neuronal cell body [GO:0043025]; organelle membrane [GO:0031090]
Q9UN76	S6A14_HUMAN	Sodium- and chloride-dependent neutral and basic amino acid transporter B(0+) (Amino acid transporter ATB0+) (Solute carrier family 6 member 14)	SLC6A14				DB00172;DB00577;DB01610;		PF00209;	IPR000175;	amino acid transport [GO:0006865]; cellular amino acid metabolic process [GO:0006520]; response to toxic substance [GO:0009636]; transport [GO:0006810]	amino acid transmembrane transporter activity [GO:0015171]; neurotransmitter:sodium symporter activity [GO:0005328]	brush border membrane [GO:0031526]; extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; vesicle [GO:0031982]
P23526	SAHH_HUMAN	Adenosylhomocysteinase (AdoHcyase) (EC 3.3.1.1) (S-adenosyl-L-homocysteine hydrolase)	AHCY SAHH	1A7A;1LI4;3NJ4;4PFJ;4PGF;4YVF;	CHEMBL2664;	P23526;	DB02325;	PATHWAY: Amino-acid biosynthesis; L-homocysteine biosynthesis; L-homocysteine from S-adenosyl-L-homocysteine: step 1/1.	PF05221;PF00670;	IPR000043;IPR015878;IPR016040;IPR020082;	chronic inflammatory response to antigenic stimulus [GO:0002439]; circadian sleep/wake cycle [GO:0042745]; homocysteine biosynthetic process [GO:0071268]; methylation [GO:0032259]; one-carbon metabolic process [GO:0006730]; response to hypoxia [GO:0001666]; response to nutrient [GO:0007584]; S-adenosylhomocysteine catabolic process [GO:0019510]; S-adenosylmethionine cycle [GO:0033353]; sulfur amino acid metabolic process [GO:0000096]	adenosylhomocysteinase activity [GO:0004013]; adenyl nucleotide binding [GO:0030554]; NAD binding [GO:0051287]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; melanosome [GO:0042470]; neuron projection [GO:0043005]; nucleus [GO:0005634]
P02743	SAMP_HUMAN	Serum amyloid P-component (SAP) (9.5S alpha-1-glycoprotein) [Cleaved into: Serum amyloid P-component(1-203)]	APCS PTX2	1GYK;1LGN;1SAC;2A3W;2A3X;2A3Y;2W08;3D5O;3KQR;4AVS;4AVT;4AVV;4AYU;	CHEMBL4929;				PF00354;	IPR013320;IPR001759;IPR030476;	acute-phase response [GO:0006953]; cellular protein metabolic process [GO:0044267]; chaperone-mediated protein complex assembly [GO:0051131]; innate immune response [GO:0045087]; negative regulation by host of viral exo-alpha-sialidase activity [GO:0044869]; negative regulation by host of viral glycoprotein metabolic process [GO:0044871]; negative regulation of acute inflammatory response [GO:0002674]; negative regulation of exo-alpha-sialidase activity [GO:1903016]; negative regulation of glycoprotein metabolic process [GO:1903019]; negative regulation of monocyte differentiation [GO:0045656]; negative regulation of viral entry into host cell [GO:0046597]; negative regulation of viral process [GO:0048525]; negative regulation of wound healing [GO:0061045]; protein folding [GO:0006457]	calcium ion binding [GO:0005509]; carbohydrate binding [GO:0030246]; complement component C1q binding [GO:0001849]; unfolded protein binding [GO:0051082]; virion binding [GO:0046790]	blood microparticle [GO:0072562]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; nucleus [GO:0005634]
P17900	SAP3_HUMAN	Ganglioside GM2 activator (Cerebroside sulfate activator protein) (GM2-AP) (Sphingolipid activator protein 3) (SAP-3) [Cleaved into: Ganglioside GM2 activator isoform short]	GM2A	1G13;1PU5;1PUB;1TJJ;2AF9;2AG2;2AG4;2AG9;			DB02325;		PF02221;	IPR028996;IPR003172;	ganglioside catabolic process [GO:0006689]; glycosphingolipid metabolic process [GO:0006687]; learning or memory [GO:0007611]; lipid storage [GO:0019915]; neuromuscular process controlling balance [GO:0050885]; oligosaccharide catabolic process [GO:0009313]; positive regulation of hydrolase activity [GO:0051345]	beta-N-acetylgalactosaminidase activity [GO:0032428]; lipid transporter activity [GO:0005319]; phospholipase activator activity [GO:0016004]; sphingolipid activator protein activity [GO:0030290]	apical cortex [GO:0045179]; cytoplasmic side of plasma membrane [GO:0009898]; extracellular exosome [GO:0070062]; hydrogen:potassium-exchanging ATPase complex [GO:0005889]; lysosomal lumen [GO:0043202]; mitochondrion [GO:0005739]
P07602	SAP_HUMAN	Prosaposin (Proactivator polypeptide) [Cleaved into: Saposin-A (Protein A); Saposin-B-Val; Saposin-B (Cerebroside sulfate activator) (CSAct) (Dispersin) (Sphingolipid activator protein 1) (SAP-1) (Sulfatide/GM1 activator); Saposin-C (A1 activator) (Co-beta-glucosidase) (Glucosylceramidase activator) (Sphingolipid activator protein 2) (SAP-2); Saposin-D (Component C) (Protein C)]	PSAP GLBA SAP1	1M12;1N69;1SN6;2DOB;2GTG;2QYP;2R0R;2R1Q;2RB3;2Z9A;3BQP;3BQQ;4DDJ;4UEX;4V2O;					PF02199;PF05184;PF03489;	IPR003119;IPR007856;IPR008138;IPR008373;IPR011001;IPR021165;IPR008139;	adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway [GO:0007193]; cellular response to organic substance [GO:0071310]; epithelial cell differentiation involved in prostate gland development [GO:0060742]; glycosphingolipid metabolic process [GO:0006687]; lipid transport [GO:0006869]; negative regulation of hydrogen peroxide-induced cell death [GO:1903206]; platelet degranulation [GO:0002576]; positive regulation of MAPK cascade [GO:0043410]; prostate gland growth [GO:0060736]; regulation of autophagy [GO:0010506]; regulation of lipid metabolic process [GO:0019216]	enzyme activator activity [GO:0008047]; G-protein coupled receptor binding [GO:0001664]; lipid binding [GO:0008289]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; integral component of membrane [GO:0016021]; lysosomal lumen [GO:0043202]; lysosomal membrane [GO:0005765]; lysosome [GO:0005764]; mitochondrion [GO:0005739]
P21673	SAT1_HUMAN	Diamine acetyltransferase 1 (EC 2.3.1.57) (Polyamine N-acetyltransferase 1) (Putrescine acetyltransferase) (Spermidine/spermine N(1)-acetyltransferase 1) (SSAT) (SSAT-1)	SAT1 SAT	2B3U;2B3V;2B4B;2B4D;2B58;2B5G;2F5I;2FXF;2G3T;2JEV;	CHEMBL4286;	P21673;	DB00127;	PATHWAY: Amine and polyamine degradation; putrescine degradation; N-acetylputrescine from putrescine: step 1/1.	PF00583;	IPR016181;IPR000182;IPR032957;	angiogenesis [GO:0001525]; nor-spermidine metabolic process [GO:0046204]; polyamine biosynthetic process [GO:0006596]; putrescine acetylation [GO:0032920]; putrescine catabolic process [GO:0009447]; regulation of cell proliferation [GO:0042127]; spermidine acetylation [GO:0032918]; spermine acetylation [GO:0032919]; spermine catabolic process [GO:0046208]	diamine N-acetyltransferase activity [GO:0004145]; spermidine binding [GO:0019809]	cytosol [GO:0005829]; intracellular [GO:0005622]
Q96F10	SAT2_HUMAN	Diamine acetyltransferase 2 (EC 2.3.1.57) (Polyamine N-acetyltransferase 2) (Spermidine/spermine N(1)-acetyltransferase 2) (Thialysine N-epsilon-acetyltransferase)	SAT2 SSAT2	2BEI;2Q4V;	CHEMBL3509592;		DB00127;	PATHWAY: Amine and polyamine degradation; putrescine degradation; N-acetylputrescine from putrescine: step 1/1.	PF00583;	IPR016181;IPR000182;IPR032959;	nor-spermidine metabolic process [GO:0046204]; putrescine acetylation [GO:0032920]; putrescine catabolic process [GO:0009447]; spermidine acetylation [GO:0032918]; spermine acetylation [GO:0032919]; spermine catabolic process [GO:0046208]	diamine N-acetyltransferase activity [GO:0004145]; spermidine binding [GO:0019809]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]
P43007	SATT_HUMAN	Neutral amino acid transporter A (Alanine/serine/cysteine/threonine transporter 1) (ASCT-1) (SATT) (Solute carrier family 1 member 4)	SLC1A4 ASCT1 SATT				DB00160;		PF00375;	IPR001991;IPR018107;	amino acid transport [GO:0006865]; cognition [GO:0050890]; glutamine transport [GO:0006868]; hydroxyproline transport [GO:0034589]; L-alanine transport [GO:0015808]; L-cystine transport [GO:0015811]; L-serine transport [GO:0015825]; proline transport [GO:0015824]; synaptic transmission, glutamatergic [GO:0035249]; threonine transport [GO:0015826]	amino acid transmembrane transporter activity [GO:0015171]; chloride channel activity [GO:0005254]; L-alanine transmembrane transporter activity [GO:0015180]; L-cystine transmembrane transporter activity [GO:0015184]; L-glutamine transmembrane transporter activity [GO:0015186]; L-hydroxyproline transmembrane transporter activity [GO:0034590]; L-proline transmembrane transporter activity [GO:0015193]; L-serine transmembrane transporter activity [GO:0015194]; L-threonine transmembrane transporter activity [GO:0015195]; symporter activity [GO:0015293]	cell surface [GO:0009986]; centrosome [GO:0005813]; dendrite [GO:0030425]; extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; intermediate filament [GO:0005882]; melanosome [GO:0042470]; membrane [GO:0016020]; microtubule organizing center [GO:0005815]; neuronal cell body [GO:0043025]; plasma membrane [GO:0005886]
Q9Y5Y9	SC10A_HUMAN	Sodium channel protein type 10 subunit alpha (Peripheral nerve sodium channel 3) (PN3) (hPN3) (Sodium channel protein type X subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.8)	SCN10A		CHEMBL5451;	Q9Y5Y9;	DB01086;DB00297;DB01161;DB00527;DB00907;DB00645;DB00473;DB06218;DB01002;DB00281;DB00961;DB01173;DB00892;DB00721;DB00807;DB00296;DB00313;		PF00520;PF06512;	IPR027359;IPR005821;IPR028809;IPR001696;IPR010526;	AV node cell action potential [GO:0086016]; bundle of His cell action potential [GO:0086043]; membrane depolarization during action potential [GO:0086010]; neuronal action potential [GO:0019228]; odontogenesis of dentin-containing tooth [GO:0042475]; regulation of atrial cardiac muscle cell membrane depolarization [GO:0060371]; regulation of cardiac muscle contraction [GO:0055117]; regulation of heart rate [GO:0002027]; regulation of ion transmembrane transport [GO:0034765]; sensory perception [GO:0007600]; sensory perception of pain [GO:0019233]; sodium ion transmembrane transport [GO:0035725]	ion channel binding [GO:0044325]; voltage-gated sodium channel activity [GO:0005248]	clathrin complex [GO:0071439]; extracellular exosome [GO:0070062]; voltage-gated sodium channel complex [GO:0001518]
P67812	SC11A_HUMAN	Signal peptidase complex catalytic subunit SEC11A (EC 3.4.21.89) (Endopeptidase SP18) (Microsomal signal peptidase 18 kDa subunit) (SPase 18 kDa subunit) (SEC11 homolog A) (SEC11-like protein 1) (SPC18)	SEC11A SEC11L1 SPC18 SPCS4A						PF00717;	IPR019758;IPR019756;IPR028360;IPR019759;IPR015927;IPR001733;	signal peptide processing [GO:0006465]	serine-type peptidase activity [GO:0008236]	endoplasmic reticulum membrane [GO:0005789]; extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; organelle membrane [GO:0031090]
Q9Y289	SC5A6_HUMAN	Sodium-dependent multivitamin transporter (Na(+)-dependent multivitamin transporter) (Solute carrier family 5 member 6)	SLC5A6 SMVT				DB00121;DB08872;DB00166;		PF00474;	IPR001734;IPR018212;	biotin metabolic process [GO:0006768]; biotin transport [GO:0015878]; pantothenate metabolic process [GO:0015939]; pantothenate transmembrane transport [GO:0015887]; transmembrane transport [GO:0055085]; transport [GO:0006810]	sodium-dependent multivitamin transmembrane transporter activity [GO:0008523]	brush border membrane [GO:0031526]; integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]; vesicle membrane [GO:0012506]
Q9GZV3	SC5A7_HUMAN	High affinity choline transporter 1 (Hemicholinium-3-sensitive choline transporter) (CHT) (Solute carrier family 5 member 7)	SLC5A7 CHT1		CHEMBL4507;	Q9GZV3;	DB00122;		PF00474;	IPR001734;	acetylcholine biosynthetic process [GO:0008292]; neuromuscular synaptic transmission [GO:0007274]; neurotransmitter secretion [GO:0007269]; synaptic transmission, cholinergic [GO:0007271]; transmembrane transport [GO:0055085]	choline:sodium symporter activity [GO:0005307]; choline binding [GO:0033265]; choline transmembrane transporter activity [GO:0015220]	axon [GO:0030424]; dendrite [GO:0030425]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; perikaryon [GO:0043204]; plasma membrane [GO:0005886]; presynapse [GO:0098793]; synapse [GO:0045202]
P30531	SC6A1_HUMAN	Sodium- and chloride-dependent GABA transporter 1 (GAT-1) (Solute carrier family 6 member 1)	SLC6A1 GABATR GABT1 GAT1		CHEMBL1903;	P30531;	DB00349;DB00906;		PF00209;	IPR000175;IPR002980;	chemical synaptic transmission [GO:0007268]; gamma-aminobutyric acid import [GO:0051939]; gamma-aminobutyric acid transport [GO:0015812]; learning [GO:0007612]; negative regulation of synaptic transmission, GABAergic [GO:0032229]; neurotransmitter transport [GO:0006836]; positive regulation of gamma-aminobutyric acid secretion [GO:0014054]; protein homooligomerization [GO:0051260]; response to calcium ion [GO:0051592]; response to cocaine [GO:0042220]; response to estradiol [GO:0032355]; response to lead ion [GO:0010288]; response to purine-containing compound [GO:0014074]; response to sucrose [GO:0009744]; response to toxic substance [GO:0009636]; transport [GO:0006810]	gamma-aminobutyric acid:sodium symporter activity [GO:0005332]; metal ion binding [GO:0046872]; neurotransmitter:sodium symporter activity [GO:0005328]	axon [GO:0030424]; cell surface [GO:0009986]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; neuron projection [GO:0043005]; plasma membrane [GO:0005886]
P23975	SC6A2_HUMAN	Sodium-dependent noradrenaline transporter (Norepinephrine transporter) (NET) (Solute carrier family 6 member 2)	SLC6A2 NAT1 NET1 SLC6A5		CHEMBL222;	P23975;	DB00321;DB00543;DB00182;DB00289;DB01156;DB01114;DB00215;DB01242;DB00907;DB04840;DB01151;DB06700;DB06701;DB01576;DB00514;DB00937;DB00988;DB01142;DB06262;DB00476;DB01363;DB01364;DB00696;DB01175;DB01381;DB00226;DB01170;DB00458;DB06704;DB01221;DB08918;DB06707;DB00408;DB00934;DB00579;DB01577;DB00422;DB06148;DB04896;DB00370;DB01149;DB00368;DB00540;DB01173;DB00715;DB00454;DB01579;DB00830;DB00191;DB00344;DB00852;DB00234;DB01105;DB06204;DB00193;DB00726;DB00285;		PF00209;	IPR000175;IPR002435;	chemical synaptic transmission [GO:0007268]; monoamine transport [GO:0015844]; norepinephrine transport [GO:0015874]; response to drug [GO:0042493]; response to pain [GO:0048265]; transport [GO:0006810]	metal ion binding [GO:0046872]; monoamine transmembrane transporter activity [GO:0008504]; norepinephrine:sodium symporter activity [GO:0005334]	cell surface [GO:0009986]; integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; membrane raft [GO:0045121]; neuron projection [GO:0043005]; plasma membrane [GO:0005886]
Q01959	SC6A3_HUMAN	Sodium-dependent dopamine transporter (DA transporter) (DAT) (Solute carrier family 6 member 3)	SLC6A3 DAT1		CHEMBL238;	Q01959;	DB00543;DB00182;DB06413;DB00289;DB00245;DB00865;DB01156;DB01161;DB01114;DB00215;DB00907;DB06701;DB01576;DB00937;DB01146;DB00988;DB00476;DB01363;DB01175;DB01463;DB00458;DB08824;DB01255;DB00408;DB00579;DB01577;DB00422;DB06148;DB00370;DB00745;DB01149;DB00454;DB00830;DB00191;DB00721;DB00852;DB01104;DB01105;DB00726;DB00285;		PF00209;	IPR000175;IPR002436;	adenohypophysis development [GO:0021984]; aging [GO:0007568]; dopamine biosynthetic process [GO:0042416]; dopamine catabolic process [GO:0042420]; dopamine transport [GO:0015872]; dopamine uptake [GO:0090494]; dopamine uptake involved in synaptic transmission [GO:0051583]; lactation [GO:0007595]; locomotory behavior [GO:0007626]; monoamine transport [GO:0015844]; neurotransmitter biosynthetic process [GO:0042136]; positive regulation of multicellular organism growth [GO:0040018]; prepulse inhibition [GO:0060134]; regulation of dopamine metabolic process [GO:0042053]; response to cAMP [GO:0051591]; response to cocaine [GO:0042220]; response to drug [GO:0042493]; response to ethanol [GO:0045471]; response to iron ion [GO:0010039]; response to nicotine [GO:0035094]; sensory perception of smell [GO:0007608]	dopamine:sodium symporter activity [GO:0005330]; dopamine binding [GO:0035240]; dopamine transmembrane transporter activity [GO:0005329]; drug binding [GO:0008144]; metal ion binding [GO:0046872]; monoamine transmembrane transporter activity [GO:0008504]	axon [GO:0030424]; cell surface [GO:0009986]; cytoplasm [GO:0005737]; flotillin complex [GO:0016600]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; membrane raft [GO:0045121]; neuronal cell body [GO:0043025]; neuron projection [GO:0043005]; plasma membrane [GO:0005886]; presynapse [GO:0098793]
P31645	SC6A4_HUMAN	Sodium-dependent serotonin transporter (SERT) (5HT transporter) (5HTT) (Solute carrier family 6 member 4)	SLC6A4 HTT SERT	5I6X;5I6Z;5I71;5I73;5I74;5I75;	CHEMBL228;	P31645;	DB00321;DB00543;DB00182;DB00289;DB09016;DB01114;DB00215;DB01242;DB00907;DB01151;DB06700;DB01191;DB06701;DB00514;DB00988;DB01142;DB00476;DB01363;DB01175;DB00472;DB00176;DB00458;DB08918;DB00408;DB00579;DB01577;DB00422;DB06148;DB04896;DB00805;DB00370;DB01149;DB00540;DB00715;DB00454;DB00191;DB00344;DB00852;DB01104;DB01105;DB06204;DB00193;DB00656;DB00726;DB00285;DB00661;DB06684;DB09068;		PF03491;PF00209;	IPR000175;IPR013086;	brain morphogenesis [GO:0048854]; cellular response to cGMP [GO:0071321]; cellular response to retinoic acid [GO:0071300]; chemical synaptic transmission [GO:0007268]; circadian rhythm [GO:0007623]; memory [GO:0007613]; monoamine transport [GO:0015844]; negative regulation of cerebellar granule cell precursor proliferation [GO:0021941]; negative regulation of neuron differentiation [GO:0045665]; negative regulation of organ growth [GO:0046621]; negative regulation of synaptic transmission, dopaminergic [GO:0032227]; positive regulation of cell cycle [GO:0045787]; positive regulation of gene expression [GO:0010628]; protein homooligomerization [GO:0051260]; protein oligomerization [GO:0051259]; response to drug [GO:0042493]; response to estradiol [GO:0032355]; response to hypoxia [GO:0001666]; response to nutrient [GO:0007584]; response to toxic substance [GO:0009636]; serotonin transport [GO:0006837]; serotonin uptake [GO:0051610]; social behavior [GO:0035176]; sperm ejaculation [GO:0042713]; thalamus development [GO:0021794]; vasoconstriction [GO:0042310]	actin filament binding [GO:0051015]; cocaine binding [GO:0019811]; metal ion binding [GO:0046872]; monoamine transmembrane transporter activity [GO:0008504]; Rab GTPase binding [GO:0017137]; serotonin:sodium symporter activity [GO:0005335]; serotonin transmembrane transporter activity [GO:0015222]	cytosol [GO:0005829]; endomembrane system [GO:0012505]; endosome membrane [GO:0010008]; integral component of plasma membrane [GO:0005887]; membrane raft [GO:0045121]; neuron projection [GO:0043005]; plasma membrane [GO:0005886]; presynapse [GO:0098793]
Q9Y345	SC6A5_HUMAN	Sodium- and chloride-dependent glycine transporter 2 (GlyT-2) (GlyT2) (Solute carrier family 6 member 5)	SLC6A5 GLYT2 NET1		CHEMBL3060;	Q9Y345;	DB00145;		PF00209;	IPR000175;	chemical synaptic transmission [GO:0007268]; glycine import [GO:0036233]; synaptic transmission, glycinergic [GO:0060012]; transport [GO:0006810]	glycine:sodium symporter activity [GO:0015375]; metal ion binding [GO:0046872]; neurotransmitter:sodium symporter activity [GO:0005328]	integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
Q99884	SC6A7_HUMAN	Sodium-dependent proline transporter (Solute carrier family 6 member 7)	SLC6A7 PROT		CHEMBL3317335;	Q99884;	DB00172;		PF00209;	IPR000175;	proline transport [GO:0015824]; transport [GO:0006810]	L-proline transmembrane transporter activity [GO:0015193]; neurotransmitter:sodium symporter activity [GO:0005328]; proline:sodium symporter activity [GO:0005298]	integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]
P48029	SC6A8_HUMAN	Sodium- and chloride-dependent creatine transporter 1 (CT1) (Creatine transporter 1) (Solute carrier family 6 member 8)	SLC6A8				DB00148;		PF00209;	IPR000175;IPR002984;	creatine metabolic process [GO:0006600]; creatine transport [GO:0015881]; muscle contraction [GO:0006936]; transport [GO:0006810]	creatine:sodium symporter activity [GO:0005309]; creatine transmembrane transporter activity [GO:0005308]; neurotransmitter:sodium symporter activity [GO:0005328]	integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P48067	SC6A9_HUMAN	Sodium- and chloride-dependent glycine transporter 1 (GlyT-1) (GlyT1) (Solute carrier family 6 member 9)	SLC6A9		CHEMBL2337;	P48067;	DB00145;		PF00209;	IPR000175;IPR003028;	glycine import [GO:0036233]; glycine secretion, neurotransmission [GO:0061537]; synaptic transmission, glycinergic [GO:0060012]; transport [GO:0006810]	glycine:sodium symporter activity [GO:0015375]; neurotransmitter:sodium symporter activity [GO:0005328]	integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]; presynapse [GO:0098793]
P35498	SCN1A_HUMAN	Sodium channel protein type 1 subunit alpha (Sodium channel protein brain I subunit alpha) (Sodium channel protein type I subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.1)	SCN1A NAC1 SCN1		CHEMBL1845;	P35498;	DB04855;DB01595;DB04930;DB01121;DB01438;DB00252;DB00273;DB00313;DB00909;		PF00520;PF06512;PF11933;	IPR027359;IPR005821;IPR008051;IPR001696;IPR010526;IPR024583;	adult walking behavior [GO:0007628]; detection of mechanical stimulus involved in sensory perception of pain [GO:0050966]; membrane depolarization during action potential [GO:0086010]; neuromuscular process controlling posture [GO:0050884]; neuronal action potential [GO:0019228]; neuronal action potential propagation [GO:0019227]; sodium ion transport [GO:0006814]	voltage-gated sodium channel activity [GO:0005248]	axon initial segment [GO:0043194]; intercalated disc [GO:0014704]; neuronal cell body [GO:0043025]; node of Ranvier [GO:0033268]; plasma membrane [GO:0005886]; T-tubule [GO:0030315]; voltage-gated sodium channel complex [GO:0001518]; Z disc [GO:0030018]
Q99250	SCN2A_HUMAN	Sodium channel protein type 2 subunit alpha (HBSC II) (Sodium channel protein brain II subunit alpha) (Sodium channel protein type II subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.2)	SCN2A NAC2 SCN2A1 SCN2A2	2KAV;4JPZ;	CHEMBL4187;	Q99250;	DB00555;DB00818;DB00313;DB00909;		PF00520;PF06512;PF11933;	IPR027359;IPR005821;IPR000048;IPR001696;IPR010526;IPR024583;	membrane depolarization during action potential [GO:0086010]; myelination [GO:0042552]; neuronal action potential [GO:0019228]; sodium ion transmembrane transport [GO:0035725]; sodium ion transport [GO:0006814]	voltage-gated sodium channel activity [GO:0005248]	axon [GO:0030424]; integral component of plasma membrane [GO:0005887]; intrinsic component of plasma membrane [GO:0031226]; node of Ranvier [GO:0033268]; sodium channel complex [GO:0034706]; voltage-gated sodium channel complex [GO:0001518]
Q9NY46	SCN3A_HUMAN	Sodium channel protein type 3 subunit alpha (Sodium channel protein brain III subunit alpha) (Sodium channel protein type III subunit alpha) (Voltage-gated sodium channel subtype III) (Voltage-gated sodium channel subunit alpha Nav1.3)	SCN3A KIAA1356 NAC3		CHEMBL5163;	Q9NY46;	DB06218;DB00313;DB00909;		PF00520;PF06512;PF11933;	IPR027359;IPR005821;IPR000048;IPR001696;IPR010526;IPR024583;	membrane depolarization during action potential [GO:0086010]; neuronal action potential [GO:0019228]; sodium ion transport [GO:0006814]	voltage-gated sodium channel activity [GO:0005248]	cytoplasm [GO:0005737]; plasma membrane [GO:0005886]; voltage-gated sodium channel complex [GO:0001518]
P35499	SCN4A_HUMAN	Sodium channel protein type 4 subunit alpha (SkM1) (Sodium channel protein skeletal muscle subunit alpha) (Sodium channel protein type IV subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.4)	SCN4A		CHEMBL2072;	P35499;	DB00586;DB01195;DB00818;DB00313;DB00909;		PF00520;PF06512;	IPR027359;IPR005821;IPR000048;IPR028826;IPR008052;IPR001696;IPR010526;	membrane depolarization during action potential [GO:0086010]; muscle contraction [GO:0006936]; neuronal action potential [GO:0019228]; sodium ion transport [GO:0006814]	voltage-gated sodium channel activity [GO:0005248]	integral component of plasma membrane [GO:0005887]; voltage-gated sodium channel complex [GO:0001518]
Q14524	SCN5A_HUMAN	Sodium channel protein type 5 subunit alpha (HH1) (Sodium channel protein cardiac muscle subunit alpha) (Sodium channel protein type V subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.5)	SCN5A	2KBI;2L53;4DCK;4DJC;4JQ0;4OVN;	CHEMBL1980;	Q14524;	DB01426;DB01429;DB00868;DB00564;DB00527;DB00907;DB00280;DB01228;DB00754;DB01195;DB01320;DB00473;DB00192;DB00281;DB00379;DB00680;DB00776;DB00252;DB00750;DB01035;DB01182;DB00908;DB01346;DB00243;DB00740;DB01056;DB00313;DB00661;DB00909;		PF00520;PF06512;PF11933;	IPR027359;IPR005821;IPR008053;IPR001696;IPR010526;IPR024583;	AV node cell action potential [GO:0086016]; AV node cell to bundle of His cell communication [GO:0086067]; brainstem development [GO:0003360]; bundle of His cell action potential [GO:0086043]; cardiac conduction [GO:0061337]; cardiac muscle cell action potential involved in contraction [GO:0086002]; cardiac muscle contraction [GO:0060048]; cardiac ventricle development [GO:0003231]; cellular response to calcium ion [GO:0071277]; cerebellum development [GO:0021549]; membrane depolarization [GO:0051899]; membrane depolarization during action potential [GO:0086010]; membrane depolarization during AV node cell action potential [GO:0086045]; membrane depolarization during bundle of His cell action potential [GO:0086048]; membrane depolarization during cardiac muscle cell action potential [GO:0086012]; membrane depolarization during Purkinje myocyte cell action potential [GO:0086047]; membrane depolarization during SA node cell action potential [GO:0086046]; neuronal action potential [GO:0019228]; odontogenesis of dentin-containing tooth [GO:0042475]; positive regulation of action potential [GO:0045760]; positive regulation of epithelial cell proliferation [GO:0050679]; positive regulation of sodium ion transport [GO:0010765]; regulation of atrial cardiac muscle cell membrane depolarization [GO:0060371]; regulation of atrial cardiac muscle cell membrane repolarization [GO:0060372]; regulation of cardiac muscle cell contraction [GO:0086004]; regulation of heart rate [GO:0002027]; regulation of heart rate by cardiac conduction [GO:0086091]; regulation of sodium ion transmembrane transport [GO:1902305]; regulation of ventricular cardiac muscle cell membrane depolarization [GO:0060373]; regulation of ventricular cardiac muscle cell membrane repolarization [GO:0060307]; response to denervation involved in regulation of muscle adaptation [GO:0014894]; SA node cell action potential [GO:0086015]; sodium ion transmembrane transport [GO:0035725]; sodium ion transport [GO:0006814]; telencephalon development [GO:0021537]; ventricular cardiac muscle cell action potential [GO:0086005]	ankyrin binding [GO:0030506]; calmodulin binding [GO:0005516]; enzyme binding [GO:0019899]; fibroblast growth factor binding [GO:0017134]; ion channel binding [GO:0044325]; nitric-oxide synthase binding [GO:0050998]; protein domain specific binding [GO:0019904]; protein kinase binding [GO:0019901]; scaffold protein binding [GO:0097110]; ubiquitin protein ligase binding [GO:0031625]; voltage-gated sodium channel activity [GO:0005248]; voltage-gated sodium channel activity involved in AV node cell action potential [GO:0086060]; voltage-gated sodium channel activity involved in bundle of His cell action potential [GO:0086061]; voltage-gated sodium channel activity involved in cardiac muscle cell action potential [GO:0086006]; voltage-gated sodium channel activity involved in Purkinje myocyte action potential [GO:0086062]; voltage-gated sodium channel activity involved in SA node cell action potential [GO:0086063]	caveola [GO:0005901]; cell surface [GO:0009986]; endoplasmic reticulum [GO:0005783]; integral component of membrane [GO:0016021]; intercalated disc [GO:0014704]; intracellular [GO:0005622]; lateral plasma membrane [GO:0016328]; plasma membrane [GO:0005886]; sarcolemma [GO:0042383]; T-tubule [GO:0030315]; voltage-gated sodium channel complex [GO:0001518]; Z disc [GO:0030018]
Q9UQD0	SCN8A_HUMAN	Sodium channel protein type 8 subunit alpha (Sodium channel protein type VIII subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.6)	SCN8A MED		CHEMBL5202;	Q9UQD0;	DB00313;		PF00520;PF00612;PF06512;PF11933;	IPR027359;IPR005821;IPR000048;IPR008054;IPR001696;IPR010526;IPR024583;	membrane depolarization during action potential [GO:0086010]; myelination [GO:0042552]; nervous system development [GO:0007399]; neuronal action potential [GO:0019228]; peripheral nervous system development [GO:0007422]; sodium ion transport [GO:0006814]	ATP binding [GO:0005524]; voltage-gated sodium channel activity [GO:0005248]	axon initial segment [GO:0043194]; cytoplasmic, membrane-bounded vesicle [GO:0016023]; integral component of membrane [GO:0016021]; node of Ranvier [GO:0033268]; plasma membrane [GO:0005886]; voltage-gated sodium channel complex [GO:0001518]; Z disc [GO:0030018]
Q15858	SCN9A_HUMAN	Sodium channel protein type 9 subunit alpha (Neuroendocrine sodium channel) (hNE-Na) (Peripheral sodium channel 1) (PN1) (Sodium channel protein type IX subunit alpha) (Voltage-gated sodium channel subunit alpha Nav1.7)	SCN9A NENA	5EK0;	CHEMBL4296;	Q15858;	DB06218;DB00281;DB00243;DB06201;DB00313;DB00909;		PF00520;PF06512;PF11933;	IPR027359;IPR005821;IPR000048;IPR001696;IPR010526;IPR024583;IPR028803;	behavioral response to pain [GO:0048266]; inflammatory response [GO:0006954]; membrane depolarization during action potential [GO:0086010]; neuronal action potential [GO:0019228]; post-embryonic development [GO:0009791]; response to toxic substance [GO:0009636]; sensory perception of pain [GO:0019233]; sodium ion transmembrane transport [GO:0035725]; sodium ion transport [GO:0006814]	sodium ion binding [GO:0031402]; voltage-gated sodium channel activity [GO:0005248]	cell projection [GO:0042995]; integral component of plasma membrane [GO:0005887]; voltage-gated sodium channel complex [GO:0001518]
P37088	SCNNA_HUMAN	Amiloride-sensitive sodium channel subunit alpha (Alpha-NaCH) (Epithelial Na(+) channel subunit alpha) (Alpha-ENaC) (ENaCA) (Nonvoltage-gated sodium channel 1 subunit alpha) (SCNEA)	SCNN1A SCNN1	2M3O;	CHEMBL1791;	P37088;	DB00594;DB00384;		PF00858;	IPR004724;IPR001873;IPR020903;	ion transmembrane transport [GO:0034220]; multicellular organismal water homeostasis [GO:0050891]; response to stimulus [GO:0050896]; sensory perception of taste [GO:0050909]; sodium ion homeostasis [GO:0055078]; sodium ion transmembrane transport [GO:0035725]	ligand-gated sodium channel activity [GO:0015280]; WW domain binding [GO:0050699]	apical plasma membrane [GO:0016324]; ciliary membrane [GO:0060170]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; motile cilium [GO:0031514]; plasma membrane [GO:0005886]; sodium channel complex [GO:0034706]
P51168	SCNNB_HUMAN	Amiloride-sensitive sodium channel subunit beta (Beta-NaCH) (Epithelial Na(+) channel subunit beta) (Beta-ENaC) (ENaCB) (Nonvoltage-gated sodium channel 1 subunit beta) (SCNEB)	SCNN1B		CHEMBL1628483;		DB00594;DB00384;		PF00858;	IPR004724;IPR001873;IPR020903;	excretion [GO:0007588]; ion transmembrane transport [GO:0034220]; multicellular organismal water homeostasis [GO:0050891]; response to stimulus [GO:0050896]; sensory perception of taste [GO:0050909]; sodium ion homeostasis [GO:0055078]; sodium ion transmembrane transport [GO:0035725]; sodium ion transport [GO:0006814]	ligand-gated sodium channel activity [GO:0015280]; WW domain binding [GO:0050699]	apical plasma membrane [GO:0016324]; cytoplasmic vesicle membrane [GO:0030659]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; sodium channel complex [GO:0034706]
P51172	SCNND_HUMAN	Amiloride-sensitive sodium channel subunit delta (Delta-NaCH) (Epithelial Na(+) channel subunit delta) (Delta-ENaC) (ENaCD) (Nonvoltage-gated sodium channel 1 subunit delta) (SCNED)	SCNN1D DNACH				DB00594;DB00384;		PF00858;	IPR004724;IPR001873;IPR020903;	ion transmembrane transport [GO:0034220]; response to stimulus [GO:0050896]; sensory perception of taste [GO:0050909]; sodium ion transport [GO:0006814]	ligand-gated sodium channel activity [GO:0015280]	actin cytoskeleton [GO:0015629]; integral component of membrane [GO:0016021]; membrane [GO:0016020]; plasma membrane [GO:0005886]
P51170	SCNNG_HUMAN	Amiloride-sensitive sodium channel subunit gamma (Epithelial Na(+) channel subunit gamma) (ENaCG) (Gamma-ENaC) (Gamma-NaCH) (Nonvoltage-gated sodium channel 1 subunit gamma) (SCNEG)	SCNN1G		CHEMBL1628484;		DB00594;DB00384;		PF00858;	IPR004724;IPR001873;IPR020903;	excretion [GO:0007588]; ion transmembrane transport [GO:0034220]; multicellular organismal water homeostasis [GO:0050891]; response to stimulus [GO:0050896]; sensory perception of taste [GO:0050909]; sodium ion homeostasis [GO:0055078]; sodium ion transmembrane transport [GO:0035725]; sodium ion transport [GO:0006814]	ion channel activity [GO:0005216]; ligand-gated sodium channel activity [GO:0015280]; sodium channel activity [GO:0005272]; WW domain binding [GO:0050699]	apical plasma membrane [GO:0016324]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; sodium channel complex [GO:0034706]
Q9BYC2	SCOT2_HUMAN	Succinyl-CoA:3-ketoacid coenzyme A transferase 2, mitochondrial (EC 2.8.3.5) (3-oxoacid CoA-transferase 2A) (Testis-specific succinyl-CoA:3-oxoacid CoA-transferase) (SCOT-t)	OXCT2 FKSG25				DB00139;	PATHWAY: Ketone metabolism; succinyl-CoA degradation; acetoacetyl-CoA from succinyl-CoA: step 1/1.	PF01144;	IPR012792;IPR012791;IPR014388;IPR004165;IPR004164;IPR004163;	ketone body catabolic process [GO:0046952]	3-oxoacid CoA-transferase activity [GO:0008260]	mitochondrion [GO:0005739]; motile cilium [GO:0031514]
P55809	SCOT_HUMAN	Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial (EC 2.8.3.5) (3-oxoacid CoA-transferase 1) (Somatic-type succinyl-CoA:3-oxoacid CoA-transferase) (SCOT-s)	OXCT1 OXCT SCOT	3DLX;			DB00139;	PATHWAY: Ketone metabolism; succinyl-CoA degradation; acetoacetyl-CoA from succinyl-CoA: step 1/1.	PF01144;	IPR012792;IPR012791;IPR014388;IPR004165;IPR004164;IPR004163;	adipose tissue development [GO:0060612]; brain development [GO:0007420]; cellular ketone body metabolic process [GO:0046950]; heart development [GO:0007507]; ketone body catabolic process [GO:0046952]; ketone catabolic process [GO:0042182]; positive regulation of insulin secretion involved in cellular response to glucose stimulus [GO:0035774]; response to activity [GO:0014823]; response to drug [GO:0042493]; response to ethanol [GO:0045471]; response to hormone [GO:0009725]; response to nutrient [GO:0007584]; response to starvation [GO:0042594]	3-oxoacid CoA-transferase activity [GO:0008260]; protein homodimerization activity [GO:0042803]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
Q8WTV0	SCRB1_HUMAN	Scavenger receptor class B member 1 (SRB1) (CD36 and LIMPII analogous 1) (CLA-1) (CD36 antigen-like 1) (Collagen type I receptor, thrombospondin receptor-like 1) (SR-BI) (CD antigen CD36)	SCARB1 CD36L1 CLA1		CHEMBL1914272;	Q8WTV0;	DB00144;		PF01130;	IPR005428;IPR002159;	adhesion of symbiont to host [GO:0044406]; androgen biosynthetic process [GO:0006702]; blood vessel endothelial cell migration [GO:0043534]; cholesterol catabolic process [GO:0006707]; cholesterol efflux [GO:0033344]; cholesterol homeostasis [GO:0042632]; cholesterol import [GO:0070508]; detection of lipopolysaccharide [GO:0032497]; endothelial cell proliferation [GO:0001935]; high-density lipoprotein particle clearance [GO:0034384]; high-density lipoprotein particle remodeling [GO:0034375]; intestinal absorption [GO:0050892]; lipopolysaccharide transport [GO:0015920]; lipoprotein metabolic process [GO:0042157]; low-density lipoprotein particle clearance [GO:0034383]; phospholipid transport [GO:0015914]; positive regulation of cholesterol storage [GO:0010886]; positive regulation of endothelial cell migration [GO:0010595]; positive regulation of nitric-oxide synthase activity [GO:0051000]; positive regulation of triglyceride biosynthetic process [GO:0010867]; receptor-mediated endocytosis [GO:0006898]; recognition of apoptotic cell [GO:0043654]; regulation of phagocytosis [GO:0050764]; regulation of phosphatidylcholine catabolic process [GO:0010899]; reverse cholesterol transport [GO:0043691]; triglyceride homeostasis [GO:0070328]; vitamin transmembrane transport [GO:0035461]; wound healing [GO:0042060]	1-phosphatidylinositol binding [GO:0005545]; apolipoprotein A-I binding [GO:0034186]; apolipoprotein binding [GO:0034185]; high-density lipoprotein particle binding [GO:0008035]; high-density lipoprotein particle receptor activity [GO:0070506]; lipopolysaccharide binding [GO:0001530]; lipopolysaccharide receptor activity [GO:0001875]; low-density lipoprotein particle binding [GO:0030169]; phosphatidylserine binding [GO:0001786]; transporter activity [GO:0005215]; virus receptor activity [GO:0001618]	caveola [GO:0005901]; cell surface [GO:0009986]; endocytic vesicle membrane [GO:0030666]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; intracellular membrane-bounded organelle [GO:0043231]; lysosomal membrane [GO:0005765]; microvillus membrane [GO:0031528]; plasma membrane [GO:0005886]
P02775	SCYB7_HUMAN	Platelet basic protein (PBP) (C-X-C motif chemokine 7) (Leukocyte-derived growth factor) (LDGF) (Macrophage-derived growth factor) (MDGF) (Small-inducible cytokine B7) [Cleaved into: Connective tissue-activating peptide III (CTAP-III) (LA-PF4) (Low-affinity platelet factor IV); TC-2; Connective tissue-activating peptide III(1-81) (CTAP-III(1-81)); Beta-thromboglobulin (Beta-TG); Neutrophil-activating peptide 2(74) (NAP-2(74)); Neutrophil-activating peptide 2(73) (NAP-2(73)); Neutrophil-activating peptide 2 (NAP-2); TC-1; Neutrophil-activating peptide 2(1-66) (NAP-2(1-66)); Neutrophil-activating peptide 2(1-63) (NAP-2(1-63))]	PPBP CTAP3 CXCL7 SCYB7 TGB1 THBGB1	1F9P;1NAP;1TVX;					PF00048;	IPR001089;IPR018048;IPR001811;IPR027223;	chemokine-mediated signaling pathway [GO:0070098]; defense response to bacterium [GO:0042742]; glucose transport [GO:0015758]; G-protein coupled receptor signaling pathway [GO:0007186]; immune response [GO:0006955]; inflammatory response [GO:0006954]; leukocyte migration involved in inflammatory response [GO:0002523]; neutrophil chemotaxis [GO:0030593]; neutrophil degranulation [GO:0043312]; platelet degranulation [GO:0002576]; positive regulation of cell division [GO:0051781]; positive regulation of leukocyte chemotaxis [GO:0002690]; regulation of cell proliferation [GO:0042127]; response to lipopolysaccharide [GO:0032496]	chemokine activity [GO:0008009]; CXCR chemokine receptor binding [GO:0045236]; glucose transmembrane transporter activity [GO:0005355]	extracellular region [GO:0005576]; extracellular space [GO:0005615]; platelet alpha granule lumen [GO:0031093]
P02778	SCYBA_HUMAN	C-X-C motif chemokine 10 (10 kDa interferon gamma-induced protein) (Gamma-IP10) (IP-10) (Small-inducible cytokine B10) [Cleaved into: CXCL10(1-73)]	CXCL10 INP10 SCYB10	1LV9;1O7Y;1O7Z;1O80;					PF00048;	IPR001089;IPR018048;IPR027220;IPR001811;	blood circulation [GO:0008015]; cell-cell signaling [GO:0007267]; cell surface receptor signaling pathway [GO:0007166]; cellular response to heat [GO:0034605]; cellular response to lipopolysaccharide [GO:0071222]; chemokine-mediated signaling pathway [GO:0070098]; chemotaxis [GO:0006935]; defense response to virus [GO:0051607]; endothelial cell activation [GO:0042118]; G-protein coupled receptor signaling pathway [GO:0007186]; immune response [GO:0006955]; inflammatory response [GO:0006954]; muscle organ development [GO:0007517]; negative regulation of angiogenesis [GO:0016525]; negative regulation of myoblast differentiation [GO:0045662]; negative regulation of myoblast fusion [GO:1901740]; positive regulation of cAMP-mediated signaling [GO:0043950]; positive regulation of cAMP metabolic process [GO:0030816]; positive regulation of cell proliferation [GO:0008284]; positive regulation of monocyte chemotaxis [GO:0090026]; positive regulation of release of sequestered calcium ion into cytosol [GO:0051281]; positive regulation of T cell migration [GO:2000406]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; regulation of cell proliferation [GO:0042127]; regulation of endothelial tube morphogenesis [GO:1901509]; regulation of T cell chemotaxis [GO:0010819]; response to auditory stimulus [GO:0010996]; response to cold [GO:0009409]; response to gamma radiation [GO:0010332]; response to vitamin D [GO:0033280]; signal transduction [GO:0007165]; T cell chemotaxis [GO:0010818]	cAMP-dependent protein kinase regulator activity [GO:0008603]; chemokine activity [GO:0008009]; CXCR3 chemokine receptor binding [GO:0048248]; heparin binding [GO:0008201]; receptor binding [GO:0005102]	external side of plasma membrane [GO:0009897]; extracellular region [GO:0005576]; extracellular space [GO:0005615]
P48061	SDF1_HUMAN	Stromal cell-derived factor 1 (SDF-1) (hSDF-1) (C-X-C motif chemokine 12) (Intercrine reduced in hepatomas) (IRH) (hIRH) (Pre-B cell growth-stimulating factor) (PBSF) [Cleaved into: SDF-1-beta(3-72); SDF-1-alpha(3-67)]	CXCL12 SDF1 SDF1A SDF1B	1A15;1QG7;1SDF;1VMC;2J7Z;2K01;2K03;2K04;2K05;2KEC;2KED;2KEE;2KOL;2N55;2NWG;2SDF;3GV3;3HP3;4LMQ;4UAI;	CHEMBL3286074;	P48061;	DB06822;		PF00048;	IPR001811;	adult locomotory behavior [GO:0008344]; animal organ regeneration [GO:0031100]; axon guidance [GO:0007411]; blood circulation [GO:0008015]; cell adhesion [GO:0007155]; cell chemotaxis [GO:0060326]; cellular calcium ion homeostasis [GO:0006874]; chemokine-mediated signaling pathway [GO:0070098]; chemotaxis [GO:0006935]; G-protein coupled receptor signaling pathway [GO:0007186]; immune response [GO:0006955]; induction of positive chemotaxis [GO:0050930]; inflammatory response [GO:0006954]; negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage [GO:1902230]; negative regulation of leukocyte apoptotic process [GO:2000107]; negative regulation of leukocyte tethering or rolling [GO:1903237]; neuron migration [GO:0001764]; positive regulation of axon extension involved in axon guidance [GO:0048842]; positive regulation of calcium ion import [GO:0090280]; positive regulation of cell adhesion [GO:0045785]; positive regulation of dopamine secretion [GO:0033603]; positive regulation of endothelial cell proliferation [GO:0001938]; positive regulation of monocyte chemotaxis [GO:0090026]; positive regulation of T cell migration [GO:2000406]; regulation of actin polymerization or depolymerization [GO:0008064]; response to heat [GO:0009408]; response to hypoxia [GO:0001666]; response to mechanical stimulus [GO:0009612]; response to peptide hormone [GO:0043434]; response to radiation [GO:0009314]; response to virus [GO:0009615]; signal transduction [GO:0007165]; telencephalon cell migration [GO:0022029]	chemoattractant activity [GO:0042056]; chemokine activity [GO:0008009]; chemokine receptor binding [GO:0042379]; CXCR chemokine receptor binding [GO:0045236]; receptor binding [GO:0005102]	external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]
P20132	SDHL_HUMAN	L-serine dehydratase/L-threonine deaminase (SDH) (EC 4.3.1.17) (L-serine deaminase) (L-threonine dehydratase) (TDH) (EC 4.3.1.19)	SDS SDH	1P5J;4H27;			DB00133;	PATHWAY: Carbohydrate biosynthesis; gluconeogenesis.	PF00291;	IPR000634;IPR001926;	gluconeogenesis [GO:0006094]; L-serine catabolic process [GO:0006565]; pyruvate biosynthetic process [GO:0042866]	L-serine ammonia-lyase activity [GO:0003941]; L-threonine ammonia-lyase activity [GO:0004794]; protein homodimerization activity [GO:0042803]; pyridoxal phosphate binding [GO:0030170]	cytoplasm [GO:0005737]; mitochondrion [GO:0005739]
O95810	SDPR_HUMAN	Serum deprivation-response protein (Cavin-2) (PS-p68) (Phosphatidylserine-binding protein)	SDPR						PF15237;	IPR026752;IPR033298;		phosphatidylserine binding [GO:0001786]; phospholipid binding [GO:0005543]; protein kinase C binding [GO:0005080]	caveola [GO:0005901]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; membrane raft [GO:0045121]
Q96GA7	SDSL_HUMAN	Serine dehydratase-like (L-serine deaminase) (L-serine dehydratase/L-threonine deaminase) (L-threonine dehydratase) (TDH) (EC 4.3.1.19) (Serine dehydratase 2) (SDH 2) (EC 4.3.1.17)	SDSL	2RKB;					PF00291;	IPR000634;IPR001926;	cellular amino acid metabolic process [GO:0006520]	L-serine ammonia-lyase activity [GO:0003941]; L-threonine ammonia-lyase activity [GO:0004794]; pyridoxal phosphate binding [GO:0030170]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; mitochondrion [GO:0005739]
O43175	SERA_HUMAN	D-3-phosphoglycerate dehydrogenase (3-PGDH) (EC 1.1.1.95)	PHGDH PGDH3	2G76;	CHEMBL2311243;			PATHWAY: Amino-acid biosynthesis; L-serine biosynthesis; L-serine from 3-phospho-D-glycerate: step 1/3.	PF00389;PF02826;	IPR029009;IPR006139;IPR029753;IPR029752;IPR006140;IPR016040;IPR006236;	brain development [GO:0007420]; G1 to G0 transition [GO:0070314]; gamma-aminobutyric acid metabolic process [GO:0009448]; glial cell development [GO:0021782]; glutamine metabolic process [GO:0006541]; glycine metabolic process [GO:0006544]; L-serine biosynthetic process [GO:0006564]; neural tube development [GO:0021915]; neuron projection development [GO:0031175]; regulation of gene expression [GO:0010468]; serine family amino acid biosynthetic process [GO:0009070]; spinal cord development [GO:0021510]; taurine metabolic process [GO:0019530]; threonine metabolic process [GO:0006566]	electron carrier activity [GO:0009055]; NAD binding [GO:0051287]; phosphoglycerate dehydrogenase activity [GO:0004617]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; myelin sheath [GO:0043209]
Q9Y617	Q5T7G6_HUMAN,SERC_HUMAN	Phosphoserine aminotransferase (EC 2.6.1.52) (Phosphohydroxythreonine aminotransferase) (PSAT)	PSAT1 PSA	3E77;				PATHWAY: Amino-acid biosynthesis; L-serine biosynthesis; L-serine from 3-phospho-D-glycerate: step 2/3.; PATHWAY: Cofactor biosynthesis; pyridoxine 5'-phosphate biosynthesis; pyridoxine 5'-phosphate from D-erythrose 4-phosphate: step 3/5.	PF00266;	IPR000192;IPR020578;IPR022278;IPR015424;IPR015421;IPR015422;	L-serine biosynthetic process [GO:0006564]; pyridoxine biosynthetic process [GO:0008615]	O-phospho-L-serine:2-oxoglutarate aminotransferase activity [GO:0004648]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
Q8WTS6	SETD7_HUMAN	Histone-lysine N-methyltransferase SETD7 (EC 2.1.1.43) (Histone H3-K4 methyltransferase SETD7) (H3-K4-HMTase SETD7) (Lysine N-methyltransferase 7) (SET domain-containing protein 7) (SET7/9)	SETD7 KIAA1717 KMT7 SET7 SET9	1H3I;1MT6;1MUF;1N6A;1N6C;1O9S;1XQH;2F69;3CBM;3CBO;3CBP;3M53;3M54;3M55;3M56;3M57;3M58;3M59;3M5A;3OS5;3VUZ;3VV0;4E47;4J7F;4J7I;4J83;4J8O;4JDS;4JLG;5AYF;5EG2;	CHEMBL5523;	Q8WTS6;			PF02493;PF00856;	IPR017155;IPR003409;IPR001214;	cellular response to DNA damage stimulus [GO:0006974]; chromatin organization [GO:0006325]; heterochromatin organization [GO:0070828]; peptidyl-lysine dimethylation [GO:0018027]; peptidyl-lysine monomethylation [GO:0018026]; positive regulation of transcription, DNA-templated [GO:0045893]; regulation of histone H3-K9 methylation [GO:0051570]; response to ethanol [GO:0045471]; transcription, DNA-templated [GO:0006351]	chromatin binding [GO:0003682]; histone-lysine N-methyltransferase activity [GO:0018024]; p53 binding [GO:0002039]; protein-lysine N-methyltransferase activity [GO:0016279]	chromosome [GO:0005694]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]
P35247	SFTPD_HUMAN	Pulmonary surfactant-associated protein D (PSP-D) (SP-D) (Collectin-7) (Lung surfactant protein D)	SFTPD COLEC7 PSPD SFTP4	1B08;1M7L;1PW9;1PWB;2GGU;2GGX;2ORJ;2ORK;2OS9;2RIA;2RIB;2RIC;2RID;2RIE;3DBZ;3G81;3G83;3G84;3IKN;3IKP;3IKQ;3IKR;4E52;4M17;4M18;	CHEMBL2176857;				PF01391;PF00059;PF09006;	IPR001304;IPR016186;IPR018378;IPR016187;IPR008160;IPR015097;	cellular protein metabolic process [GO:0044267]; defense response to bacterium [GO:0042742]; innate immune response [GO:0045087]; lung alveolus development [GO:0048286]; macrophage chemotaxis [GO:0048246]; negative regulation of interleukin-2 biosynthetic process [GO:0045085]; negative regulation of T cell proliferation [GO:0042130]; positive regulation of phagocytosis [GO:0050766]; reactive oxygen species metabolic process [GO:0072593]; receptor-mediated endocytosis [GO:0006898]; regulation of cytokine production [GO:0001817]; regulation of immune response [GO:0050776]; respiratory gaseous exchange [GO:0007585]; surfactant homeostasis [GO:0043129]	carbohydrate binding [GO:0030246]	clathrin-coated endocytic vesicle [GO:0045334]; collagen trimer [GO:0005581]; endocytic vesicle [GO:0030139]; endoplasmic reticulum membrane [GO:0005789]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; lamellar body [GO:0042599]; lysosome [GO:0005764]; proteinaceous extracellular matrix [GO:0005578]
O95470	SGPL1_HUMAN	Sphingosine-1-phosphate lyase 1 (S1PL) (SP-lyase 1) (SPL 1) (hSPL) (EC 4.1.2.27) (Sphingosine-1-phosphate aldolase)	SGPL1 KIAA1252	4Q6R;	CHEMBL3286061;	O95470;		PATHWAY: Lipid metabolism; sphingolipid metabolism. {ECO:0000269|PubMed:11018465, ECO:0000269|PubMed:24809814}.	PF00282;	IPR002129;IPR015424;IPR015421;	androgen metabolic process [GO:0008209]; apoptotic signaling pathway [GO:0097190]; ceramide metabolic process [GO:0006672]; estrogen metabolic process [GO:0008210]; face morphogenesis [GO:0060325]; fatty acid metabolic process [GO:0006631]; fibroblast migration [GO:0010761]; hemopoiesis [GO:0030097]; kidney development [GO:0001822]; Leydig cell differentiation [GO:0033327]; luteinization [GO:0001553]; palate development [GO:0060021]; platelet-derived growth factor receptor signaling pathway [GO:0048008]; post-embryonic development [GO:0009791]; regulation of multicellular organism growth [GO:0040014]; skeletal system morphogenesis [GO:0048705]; spermatogenesis [GO:0007283]; sphingolipid biosynthetic process [GO:0030148]; sphingolipid catabolic process [GO:0030149]; vasculogenesis [GO:0001570]	carboxy-lyase activity [GO:0016831]; pyridoxal phosphate binding [GO:0030170]; sphinganine-1-phosphate aldolase activity [GO:0008117]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; integral component of endoplasmic reticulum membrane [GO:0030176]
P04278	SHBG_HUMAN	Sex hormone-binding globulin (SHBG) (Sex steroid-binding protein) (SBP) (Testis-specific androgen-binding protein) (ABP) (Testosterone-estradiol-binding globulin) (TeBG) (Testosterone-estrogen-binding globulin)	SHBG	1D2S;1F5F;1KDK;1KDM;1LHN;1LHO;1LHU;1LHV;1LHW;	CHEMBL3305;	P04278;	DB01406;DB00858;DB00783;DB04574;DB01185;DB00741;DB06710;DB00648;DB00717;DB06412;DB00421;DB00624;DB05275;		PF00054;	IPR013320;IPR001791;		androgen binding [GO:0005497]; steroid binding [GO:0005496]	extracellular exosome [GO:0070062]; extracellular region [GO:0005576]
Q9Y286	SIGL7_HUMAN	Sialic acid-binding Ig-like lectin 7 (Siglec-7) (Adhesion inhibitory receptor molecule 1) (AIRM-1) (CDw328) (D-siglec) (QA79 membrane protein) (p75) (CD antigen CD328)	SIGLEC7 AIRM1	1NKO;1O7S;1O7V;2DF3;2G5R;2HRL;					PF13895;PF07686;	IPR007110;IPR013783;IPR003599;IPR003598;IPR013106;	cell adhesion [GO:0007155]; regulation of immune response [GO:0050776]	carbohydrate binding [GO:0030246]; receptor activity [GO:0004872]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
Q9NXA8	SIRT5_HUMAN	NAD-dependent protein deacylase sirtuin-5, mitochondrial (EC 3.5.1.-) (Regulatory protein SIR2 homolog 5) (SIR2-like protein 5)	SIRT5 SIR2L5	2B4Y;2NYR;3RIG;3RIY;4F4U;4F56;4G1C;4HDA;5BWL;	CHEMBL2163183;	Q9NXA8;	DB02701;DB04786;		PF02146;	IPR029035;IPR003000;IPR026591;IPR027546;IPR026590;	chromatin silencing [GO:0006342]; negative regulation of cardiac muscle cell apoptotic process [GO:0010667]; negative regulation of reactive oxygen species metabolic process [GO:2000378]; peptidyl-lysine demalonylation [GO:0036047]; peptidyl-lysine desuccinylation [GO:0036049]; protein ADP-ribosylation [GO:0006471]; protein deacetylation [GO:0006476]; protein deglutarylation [GO:0061698]; protein demalonylation [GO:0036046]; protein desuccinylation [GO:0036048]; regulation of ketone biosynthetic process [GO:0010566]; response to nutrient levels [GO:0031667]	NAD+ ADP-ribosyltransferase activity [GO:0003950]; NAD+ binding [GO:0070403]; protein-glutaryllysine deglutarylase activity [GO:0061697]; protein-malonyllysine demalonylase activity [GO:0036054]; protein-succinyllysine desuccinylase activity [GO:0036055]; zinc ion binding [GO:0008270]	cytosol [GO:0005829]; mitochondrial inner membrane [GO:0005743]; mitochondrial intermembrane space [GO:0005758]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]
P19634	SL9A1_HUMAN	Sodium/hydrogen exchanger 1 (APNH) (Na(+)/H(+) antiporter, amiloride-sensitive) (Na(+)/H(+) exchanger 1) (NHE-1) (Solute carrier family 9 member 1)	SLC9A1 APNH1 NHE1	1Y4E;2BEC;2E30;2HTG;2KBV;2L0E;2MDF;2YGG;	CHEMBL2781;	P19634;	DB00594;		PF00999;PF16644;	IPR006153;IPR018422;IPR001970;IPR004709;IPR032103;	cardiac muscle cell contraction [GO:0086003]; cardiac muscle cell differentiation [GO:0055007]; cell growth [GO:0016049]; cell migration [GO:0016477]; cellular response to acidic pH [GO:0071468]; cellular response to antibiotic [GO:0071236]; cellular response to electrical stimulus [GO:0071257]; cellular response to epinephrine stimulus [GO:0071872]; cellular response to hypoxia [GO:0071456]; cellular response to insulin stimulus [GO:0032869]; cellular response to mechanical stimulus [GO:0071260]; cellular sodium ion homeostasis [GO:0006883]; hyaluronan catabolic process [GO:0030214]; hydrogen ion transmembrane transport [GO:1902600]; ion transport [GO:0006811]; maintenance of cell polarity [GO:0030011]; negative regulation of apoptotic process [GO:0043066]; neuron death [GO:0070997]; positive regulation of action potential [GO:0045760]; positive regulation of apoptotic process [GO:0043065]; positive regulation of calcineurin-NFAT signaling cascade [GO:0070886]; positive regulation of calcium:sodium antiporter activity [GO:1903281]; positive regulation of cardiac muscle hypertrophy [GO:0010613]; positive regulation of cell growth [GO:0030307]; positive regulation of mitochondrial membrane permeability [GO:0035794]; positive regulation of NFAT protein import into nucleus [GO:0051533]; positive regulation of the force of heart contraction [GO:0098735]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; potassium ion transmembrane transport [GO:0071805]; protein oligomerization [GO:0051259]; regulation of cardiac muscle cell membrane potential [GO:0086036]; regulation of cardiac muscle contraction by calcium ion signaling [GO:0010882]; regulation of focal adhesion assembly [GO:0051893]; regulation of intracellular pH [GO:0051453]; regulation of pH [GO:0006885]; regulation of sensory perception of pain [GO:0051930]; regulation of stress fiber assembly [GO:0051492]; regulation of the force of heart contraction by cardiac conduction [GO:0086092]; response to acidic pH [GO:0010447]; response to drug [GO:0042493]; response to muscle stretch [GO:0035994]; sodium ion export [GO:0071436]; sodium ion import across plasma membrane [GO:0098719]	calcium-dependent protein binding [GO:0048306]; phosphatidylinositol-4,5-bisphosphate binding [GO:0005546]; potassium:proton antiporter activity [GO:0015386]; protein binding, bridging [GO:0030674]; protein complex scaffold [GO:0032947]; protein phosphatase 2B binding [GO:0030346]; sodium:proton antiporter activity [GO:0015385]; sodium:proton antiporter activity involved in regulation of cardiac muscle cell membrane potential [GO:0086040]; solute:proton antiporter activity [GO:0015299]	apical plasma membrane [GO:0016324]; basolateral plasma membrane [GO:0016323]; cation-transporting ATPase complex [GO:0090533]; cell surface [GO:0009986]; cytoplasm [GO:0005737]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; extracellular exosome [GO:0070062]; focal adhesion [GO:0005925]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; intercalated disc [GO:0014704]; lamellipodium [GO:0030027]; membrane raft [GO:0045121]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; T-tubule [GO:0030315]
Q07837	SLC31_HUMAN	Neutral and basic amino acid transport protein rBAT (NBAT) (D2h) (Solute carrier family 3 member 1) (b(0,+)-type amino acid transport protein)	SLC3A1 RBAT				DB00138;		PF00128;	IPR015902;IPR006047;IPR013781;IPR017853;	amino acid transport [GO:0006865]; basic amino acid transport [GO:0015802]; carbohydrate metabolic process [GO:0005975]; cellular amino acid metabolic process [GO:0006520]; L-cystine transport [GO:0015811]	amino acid transmembrane transporter activity [GO:0015171]; basic amino acid transmembrane transporter activity [GO:0015174]; catalytic activity [GO:0003824]; L-cystine transmembrane transporter activity [GO:0015184]	brush border membrane [GO:0031526]; extracellular exosome [GO:0070062]; integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; mitochondrial inner membrane [GO:0005743]; plasma membrane [GO:0005886]; vacuolar membrane [GO:0005774]
Q9NWM0	SMOX_HUMAN	Spermine oxidase (EC 1.5.3.16) (Polyamine oxidase 1) (PAO-1) (PAOh1)	SMOX C20orf16 SMO UNQ3039/PRO9854		CHEMBL2176769;		DB00127;	PATHWAY: Amine and polyamine degradation; spermine degradation.	PF01593;	IPR002937;IPR023753;	polyamine biosynthetic process [GO:0006596]; polyamine catabolic process [GO:0006598]; spermine catabolic process [GO:0046208]	N1-acetylspermine:oxygen oxidoreductase (N1-acetylspermidine-forming) activity [GO:0052895]; norspermine:oxygen oxidoreductase activity [GO:0052894]; polyamine oxidase activity [GO:0046592]; spermine:oxygen oxidoreductase (spermidine-forming) activity [GO:0052901]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleus [GO:0005634]
Q8NHU3	SMS2_HUMAN	Phosphatidylcholine:ceramide cholinephosphotransferase 2 (EC 2.7.8.27) (Sphingomyelin synthase 2)	SGMS2 SMS2		CHEMBL3112379;	Q8NHU3;			PF14360;	IPR025749;	ceramide biosynthetic process [GO:0046513]; sphingolipid biosynthetic process [GO:0030148]; sphingomyelin biosynthetic process [GO:0006686]	ceramide cholinephosphotransferase activity [GO:0047493]; kinase activity [GO:0016301]; sphingomyelin synthase activity [GO:0033188]	Golgi apparatus [GO:0005794]; integral component of endoplasmic reticulum membrane [GO:0030176]; integral component of Golgi membrane [GO:0030173]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P61278	SMS_HUMAN	Somatostatin (Growth hormone release-inhibiting factor) [Cleaved into: Somatostatin-28; Somatostatin-14]	SST	1P2W;2MI1;	CHEMBL1795130;	P61278;	DB00847;		PF03002;	IPR004250;IPR018142;	cell-cell signaling [GO:0007267]; cell surface receptor signaling pathway [GO:0007166]; chemical synaptic transmission [GO:0007268]; digestion [GO:0007586]; G-protein coupled receptor signaling pathway [GO:0007186]; hormone-mediated apoptotic signaling pathway [GO:0008628]; hyperosmotic response [GO:0006972]; negative regulation of cell proliferation [GO:0008285]; regulation of cell migration [GO:0030334]; response to acidic pH [GO:0010447]; response to amino acid [GO:0043200]; response to drug [GO:0042493]; response to heat [GO:0009408]; response to nutrient [GO:0007584]; response to steroid hormone [GO:0048545]	hormone activity [GO:0005179]	extracellular region [GO:0005576]; extracellular space [GO:0005615]; neuronal cell body [GO:0043025]
P09012	SNRPA_HUMAN	U1 small nuclear ribonucleoprotein A (U1 snRNP A) (U1-A) (U1A)	SNRPA	1AUD;1DRZ;1DZ5;1FHT;1M5K;1M5O;1M5P;1M5V;1NU4;1OIA;1SJ3;1SJ4;1SJF;1U6B;1URN;1VBX;1VBY;1VBZ;1VC0;1VC5;1VC6;1ZZN;2A3J;2NZ4;2OIH;2OJ3;2U1A;3BO2;3BO3;3BO4;3CUL;3CUN;3EGZ;3G8S;3G8T;3G96;3G9C;3HHN;3IIN;3IRW;3IWN;3K0J;3L3C;3MUM;3MUR;3MUT;3MUV;3MXH;3P49;3PGW;3R1H;3R1L;3UCU;3UCZ;3UD3;3UD4;3UTR;4C4W;4PR6;4PRF;4W90;4W92;4YB1;5DDO;5DDP;5DDQ;5DDR;5FJ4;					PF00076;	IPR012677;IPR000504;IPR024888;	mRNA splicing, via spliceosome [GO:0000398]; regulation of mRNA polyadenylation [GO:1900363]	nucleotide binding [GO:0000166]; poly(A) RNA binding [GO:0044822]; RNA binding [GO:0003723]; snRNA stem-loop binding [GO:0035614]; U1 snRNA binding [GO:0030619]; U1 snRNP binding [GO:1990446]	cytoplasm [GO:0005737]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; spliceosomal complex [GO:0005681]; U1 snRNP [GO:0005685]
Q9Y6L6	SO1B1_HUMAN	Solute carrier organic anion transporter family member 1B1 (Liver-specific organic anion transporter 1) (LST-1) (OATP-C) (Sodium-independent organic anion-transporting polypeptide 2) (OATP-2) (Solute carrier family 21 member 6)	SLCO1B1 LST1 OATP1B1 OATP2 OATPC SLC21A6		CHEMBL1697668;	Q9Y6L6;	DB06151;DB06403;DB00345;DB01076;DB06626;DB01053;DB01393;DB06772;DB00520;DB02659;DB01211;DB05239;DB00286;DB00091;DB08912;DB09102;DB00509;DB00390;DB00917;DB06210;DB09272;DB00783;DB00655;DB00973;DB00950;DB01095;DB08884;DB01241;DB09054;DB00224;DB00762;DB00583;DB00451;DB00279;DB01583;DB00227;DB00563;DB00688;DB00220;DB00275;DB01092;DB00213;DB06589;DB00859;DB01132;DB08860;DB00175;DB00908;DB00912;DB01045;DB08864;DB00503;DB00412;DB01098;DB09292;DB01232;DB11362;DB06290;DB00641;DB00877;DB00669;DB00177;DB00661;		PF07648;PF03137;	IPR002350;IPR020846;IPR004156;	bile acid and bile salt transport [GO:0015721]; bile acid metabolic process [GO:0008206]; organic anion transport [GO:0015711]; sodium-independent organic anion transport [GO:0043252]	bile acid transmembrane transporter activity [GO:0015125]; sodium-independent organic anion transmembrane transporter activity [GO:0015347]; thyroid hormone transmembrane transporter activity [GO:0015349]	basolateral plasma membrane [GO:0016323]; integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]
O94956	SO2B1_HUMAN	Solute carrier organic anion transporter family member 2B1 (Organic anion transporter B) (OATP-B) (Organic anion transporter polypeptide-related protein 2) (OATP-RP2) (OATPRP2) (Solute carrier family 21 member 9)	SLCO2B1 KIAA0880 OATP2B1 OATPB SLC21A9		CHEMBL1743124;	O94956;	DB03166;DB00770;DB01076;DB03793;DB01053;DB00286;DB00390;DB00917;DB01049;DB00783;DB00655;DB00950;DB01095;DB01016;DB01050;DB01088;DB04398;DB00654;DB00471;DB00627;DB08860;DB00175;DB01045;DB01098;DB00936;DB01124;		PF03137;	IPR002350;IPR020846;IPR004156;	bile acid and bile salt transport [GO:0015721]; sodium-independent organic anion transport [GO:0043252]	bile acid transmembrane transporter activity [GO:0015125]; organic anion transmembrane transporter activity [GO:0008514]; sodium-independent organic anion transmembrane transporter activity [GO:0015347]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P35610	SOAT1_HUMAN	Sterol O-acyltransferase 1 (EC 2.3.1.26) (Acyl-coenzyme A:cholesterol acyltransferase 1) (ACAT-1) (Cholesterol acyltransferase 1)	SOAT1 ACACT ACACT1 ACAT ACAT1 SOAT STAT		CHEMBL2782;	P35610;	DB00973;DB01094;		PF03062;	IPR004299;IPR014371;IPR030687;	cholesterol efflux [GO:0033344]; cholesterol esterification [GO:0034435]; cholesterol homeostasis [GO:0042632]; cholesterol metabolic process [GO:0008203]; cholesterol storage [GO:0010878]; macrophage derived foam cell differentiation [GO:0010742]; positive regulation of amyloid precursor protein biosynthetic process [GO:0042986]; very-low-density lipoprotein particle assembly [GO:0034379]	cholesterol binding [GO:0015485]; cholesterol O-acyltransferase activity [GO:0034736]; fatty-acyl-CoA binding [GO:0000062]; sterol O-acyltransferase activity [GO:0004772]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; membrane [GO:0016020]
Q9P0Z9	SOX_HUMAN	Peroxisomal sarcosine oxidase (PSO) (EC 1.5.3.1) (EC 1.5.3.7) (L-pipecolate oxidase) (L-pipecolic acid oxidase)	PIPOX LPIPOX PSO		CHEMBL2254;	Q9P0Z9;	DB00145;		PF01266;	IPR006076;IPR023753;IPR006281;	L-lysine catabolic process to acetyl-CoA via L-pipecolate [GO:0033514]; lysine catabolic process [GO:0006554]; oxidation-reduction process [GO:0055114]; tetrahydrofolate metabolic process [GO:0046653]	L-pipecolate oxidase activity [GO:0050031]; receptor binding [GO:0005102]; sarcosine oxidase activity [GO:0008115]	peroxisomal matrix [GO:0005782]; peroxisome [GO:0005777]
P36952	SPB5_HUMAN	Serpin B5 (Maspin) (Peptidase inhibitor 5) (PI-5)	SERPINB5 PI5	1WZ9;1XQG;1XQJ;1XU8;					PF00079;	IPR000240;IPR023795;IPR023796;IPR000215;	extracellular matrix organization [GO:0030198]; morphogenesis of an epithelium [GO:0002009]; movement of cell or subcellular component [GO:0006928]; prostate gland morphogenesis [GO:0060512]; regulation of epithelial cell proliferation [GO:0050678]	serine-type endopeptidase inhibitor activity [GO:0004867]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]
Q9HD40	SPCS_HUMAN	O-phosphoseryl-tRNA(Sec) selenium transferase (EC 2.9.1.2) (Liver-pancreas antigen) (LP) (SLA-p35) (SLA/LP autoantigen) (Selenocysteine synthase) (Sec synthase) (Selenocysteinyl-tRNA(Sec) synthase) (Sep-tRNA:Sec-tRNA synthase) (SepSecS) (Soluble liver antigen) (SLA) (UGA suppressor tRNA-associated protein) (tRNA(Ser/Sec)-associated antigenic protein)	SEPSECS TRNP48	3HL2;4ZDL;4ZDO;4ZDP;				PATHWAY: Aminoacyl-tRNA biosynthesis; selenocysteinyl-tRNA(Sec) biosynthesis; selenocysteinyl-tRNA(Sec) from L-seryl-tRNA(Sec) (archaeal/eukaryal route): step 2/2. {ECO:0000269|PubMed:17142313}.	PF05889;	IPR019793;IPR015424;IPR015421;IPR019872;IPR008829;	selenocysteine incorporation [GO:0001514]; selenocysteine metabolic process [GO:0016259]; selenocysteinyl-tRNA(Sec) biosynthetic process [GO:0097056]	phosphoseryl-selenocysteinyl-tRNA selenium transferase activity [GO:0098621]; tRNA binding [GO:0000049]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleus [GO:0005634]
P19623	SPEE_HUMAN	Spermidine synthase (SPDSY) (EC 2.5.1.16) (Putrescine aminopropyltransferase)	SRM SPS1 SRML1	2O05;2O06;2O07;2O0L;3RW9;	CHEMBL4232;	P19623;	DB00118;	PATHWAY: Amine and polyamine biosynthesis; spermidine biosynthesis; spermidine from putrescine: step 1/1.		IPR030374;IPR030373;IPR029063;IPR001045;IPR030668;	polyamine metabolic process [GO:0006595]; spermidine biosynthetic process [GO:0008295]	protein homodimerization activity [GO:0042803]; spermidine synthase activity [GO:0004766]	cytosol [GO:0005829]
P35270	SPRE_HUMAN	Sepiapterin reductase (SPR) (EC 1.1.1.153)	SPR	1Z6Z;4HWK;4J7U;4J7X;4XWY;4Z3K;					PF00106;	IPR016040;IPR002347;IPR006393;	nitric oxide biosynthetic process [GO:0006809]; oxidation-reduction process [GO:0055114]; regulation of nitric-oxide synthase activity [GO:0050999]; tetrahydrobiopterin biosynthetic process [GO:0006729]	aldo-keto reductase (NADP) activity [GO:0004033]; NADP binding [GO:0050661]; sepiapterin reductase activity [GO:0004757]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleoplasm [GO:0005654]
P52788	SPSY_HUMAN	Spermine synthase (SPMSY) (EC 2.5.1.22) (Spermidine aminopropyltransferase)	SMS	3C6K;3C6M;	CHEMBL4934;	P52788;	DB00127;	PATHWAY: Amine and polyamine biosynthesis; spermine biosynthesis; spermine from spermidine: step 1/1.		IPR030374;IPR030373;IPR029063;IPR015576;	methionine metabolic process [GO:0006555]; polyamine metabolic process [GO:0006595]; spermine biosynthetic process [GO:0006597]	spermine synthase activity [GO:0016768]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P21549	SPYA_HUMAN	Serine--pyruvate aminotransferase (SPT) (EC 2.6.1.51) (Alanine--glyoxylate aminotransferase) (AGT) (EC 2.6.1.44)	AGXT AGT1 SPAT	1H0C;1J04;2YOB;3R9A;4CBR;4CBS;4I8A;4KXK;4KYO;			DB00145;DB00160;DB00133;		PF00266;	IPR000192;IPR020578;IPR015424;IPR015421;IPR015422;IPR024169;	glycine biosynthetic process, by transamination of glyoxylate [GO:0019265]; glyoxylate catabolic process [GO:0009436]; glyoxylate metabolic process [GO:0046487]; L-alanine catabolic process [GO:0042853]; L-cysteine catabolic process [GO:0019448]; Notch signaling pathway [GO:0007219]; oxalic acid secretion [GO:0046724]; proteasomal protein catabolic process [GO:0010498]; pyruvate biosynthetic process [GO:0042866]; response to cAMP [GO:0051591]; response to glucocorticoid [GO:0051384]	alanine-glyoxylate transaminase activity [GO:0008453]; amino acid binding [GO:0016597]; protein homodimerization activity [GO:0042803]; protein self-association [GO:0043621]; pyridoxal phosphate binding [GO:0030170]; receptor binding [GO:0005102]; serine-pyruvate transaminase activity [GO:0004760]; transaminase activity [GO:0008483]	mitochondrial matrix [GO:0005759]; peroxisomal matrix [GO:0005782]; peroxisome [GO:0005777]
P12931	SRC_HUMAN	Proto-oncogene tyrosine-protein kinase Src (EC 2.7.10.2) (Proto-oncogene c-Src) (pp60c-src) (p60-Src)	SRC SRC1	1A07;1A08;1A09;1A1A;1A1B;1A1C;1A1E;1FMK;1HCS;1HCT;1KSW;1O41;1O42;1O43;1O44;1O45;1O46;1O47;1O48;1O49;1O4A;1O4B;1O4C;1O4D;1O4E;1O4F;1O4G;1O4H;1O4I;1O4J;1O4K;1O4L;1O4M;1O4N;1O4O;1O4P;1O4Q;1O4R;1SHD;1Y57;1YI6;1YOJ;1YOL;1YOM;2BDF;2BDJ;2H8H;2SRC;3VRO;3ZMP;3ZMQ;4F59;4F5A;4F5B;4HXJ;4K11;4MXO;4MXX;4MXY;4MXZ;	CHEMBL267;	P12931;	DB06616;DB01254;DB09079;DB08901;		PF07714;PF00017;PF00018;	IPR011009;IPR000719;IPR017441;IPR001245;IPR000980;IPR001452;IPR008266;IPR020635;	activation of protein kinase B activity [GO:0032148]; adherens junction organization [GO:0034332]; angiotensin-activated signaling pathway involved in heart process [GO:0086098]; bone resorption [GO:0045453]; branching involved in mammary gland duct morphogenesis [GO:0060444]; cell cycle [GO:0007049]; cell proliferation [GO:0008283]; cellular response to fatty acid [GO:0071398]; cellular response to fluid shear stress [GO:0071498]; cellular response to hypoxia [GO:0071456]; cellular response to insulin stimulus [GO:0032869]; cellular response to lipopolysaccharide [GO:0071222]; cellular response to peptide hormone stimulus [GO:0071375]; cellular response to platelet-derived growth factor stimulus [GO:0036120]; cellular response to progesterone stimulus [GO:0071393]; cellular response to reactive oxygen species [GO:0034614]; central nervous system development [GO:0007417]; ephrin receptor signaling pathway [GO:0048013]; epidermal growth factor receptor signaling pathway [GO:0007173]; ERBB2 signaling pathway [GO:0038128]; Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096]; forebrain development [GO:0030900]; innate immune response [GO:0045087]; integrin-mediated signaling pathway [GO:0007229]; intracellular estrogen receptor signaling pathway [GO:0030520]; intracellular signal transduction [GO:0035556]; leukocyte migration [GO:0050900]; negative regulation of anoikis [GO:2000811]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154]; negative regulation of extrinsic apoptotic signaling pathway [GO:2001237]; negative regulation of focal adhesion assembly [GO:0051895]; negative regulation of intrinsic apoptotic signaling pathway [GO:2001243]; negative regulation of mitochondrial depolarization [GO:0051902]; negative regulation of protein homooligomerization [GO:0032463]; negative regulation of telomerase activity [GO:0051974]; negative regulation of telomere maintenance via telomerase [GO:0032211]; negative regulation of transcription, DNA-templated [GO:0045892]; neurotrophin TRK receptor signaling pathway [GO:0048011]; oogenesis [GO:0048477]; osteoclast development [GO:0036035]; peptidyl-serine phosphorylation [GO:0018105]; peptidyl-tyrosine autophosphorylation [GO:0038083]; peptidyl-tyrosine phosphorylation [GO:0018108]; platelet activation [GO:0030168]; platelet-derived growth factor receptor signaling pathway [GO:0048008]; positive regulation of apoptotic process [GO:0043065]; positive regulation of canonical Wnt signaling pathway [GO:0090263]; positive regulation of cyclin-dependent protein serine/threonine kinase activity [GO:0045737]; positive regulation of cytokine secretion [GO:0050715]; positive regulation of DNA biosynthetic process [GO:2000573]; positive regulation of epithelial cell migration [GO:0010634]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of glucose metabolic process [GO:0010907]; positive regulation of insulin receptor signaling pathway [GO:0046628]; positive regulation of integrin activation [GO:0033625]; positive regulation of lamellipodium morphogenesis [GO:2000394]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of phosphatidylinositol 3-kinase activity [GO:0043552]; positive regulation of platelet-derived growth factor receptor signaling pathway [GO:0010641]; positive regulation of podosome assembly [GO:0071803]; positive regulation of protein autophosphorylation [GO:0031954]; positive regulation of protein kinase B signaling [GO:0051897]; positive regulation of protein localization to nucleus [GO:1900182]; positive regulation of protein processing [GO:0010954]; positive regulation of protein serine/threonine kinase activity [GO:0071902]; positive regulation of small GTPase mediated signal transduction [GO:0051057]; positive regulation of smooth muscle cell migration [GO:0014911]; positive regulation of transcription, DNA-templated [GO:0045893]; progesterone receptor signaling pathway [GO:0050847]; protein autophosphorylation [GO:0046777]; protein destabilization [GO:0031648]; regulation of bone resorption [GO:0045124]; regulation of caveolin-mediated endocytosis [GO:2001286]; regulation of cell-cell adhesion [GO:0022407]; regulation of cell cycle [GO:0051726]; regulation of cell projection assembly [GO:0060491]; regulation of cell proliferation [GO:0042127]; regulation of early endosome to late endosome transport [GO:2000641]; regulation of epithelial cell migration [GO:0010632]; regulation of intracellular estrogen receptor signaling pathway [GO:0033146]; regulation of podosome assembly [GO:0071801]; regulation of protein binding [GO:0043393]; regulation of vascular permeability [GO:0043114]; response to acidic pH [GO:0010447]; response to drug [GO:0042493]; response to electrical stimulus [GO:0051602]; response to hydrogen peroxide [GO:0042542]; response to interleukin-1 [GO:0070555]; response to mechanical stimulus [GO:0009612]; response to mineralocorticoid [GO:0051385]; response to nutrient levels [GO:0031667]; response to virus [GO:0009615]; signal complex assembly [GO:0007172]; signal transduction [GO:0007165]; single organismal cell-cell adhesion [GO:0016337]; stimulatory C-type lectin receptor signaling pathway [GO:0002223]; stress fiber assembly [GO:0043149]; substrate adhesion-dependent cell spreading [GO:0034446]; T cell costimulation [GO:0031295]; transcytosis [GO:0045056]; transforming growth factor beta receptor signaling pathway [GO:0007179]; uterus development [GO:0060065]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]	ATP binding [GO:0005524]; cadherin binding involved in cell-cell adhesion [GO:0098641]; enzyme binding [GO:0019899]; ephrin receptor binding [GO:0046875]; growth factor receptor binding [GO:0070851]; heme binding [GO:0020037]; hormone receptor binding [GO:0051427]; integrin binding [GO:0005178]; ion channel binding [GO:0044325]; kinase activity [GO:0016301]; kinase binding [GO:0019900]; non-membrane spanning protein tyrosine kinase activity [GO:0004715]; phosphoprotein binding [GO:0051219]; protein kinase activity [GO:0004672]; protein tyrosine kinase activity [GO:0004713]; receptor binding [GO:0005102]; scaffold protein binding [GO:0097110]; SH2 domain binding [GO:0042169]; SH3/SH2 adaptor activity [GO:0005070]	actin filament [GO:0005884]; caveola [GO:0005901]; cell-cell adherens junction [GO:0005913]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extrinsic component of cytoplasmic side of plasma membrane [GO:0031234]; late endosome [GO:0005770]; lysosome [GO:0005764]; mitochondrial inner membrane [GO:0005743]; mitochondrion [GO:0005739]; neuron projection [GO:0043005]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; postsynaptic density [GO:0014069]; ruffle membrane [GO:0032587]
Q9GZT4	SRR_HUMAN	Serine racemase (EC 5.1.1.18) (D-serine ammonia-lyase) (D-serine dehydratase) (EC 4.3.1.18) (L-serine ammonia-lyase) (L-serine dehydratase) (EC 4.3.1.17)	SRR	3L6B;3L6R;	CHEMBL4460;	Q9GZT4;	DB00133;		PF00291;	IPR000634;IPR001926;	aging [GO:0007568]; brain development [GO:0007420]; D-serine biosynthetic process [GO:0070179]; D-serine metabolic process [GO:0070178]; L-serine metabolic process [GO:0006563]; protein homotetramerization [GO:0051289]; pyruvate biosynthetic process [GO:0042866]; response to drug [GO:0042493]; response to lipopolysaccharide [GO:0032496]; response to morphine [GO:0043278]; serine family amino acid metabolic process [GO:0009069]	ATP binding [GO:0005524]; calcium ion binding [GO:0005509]; D-serine ammonia-lyase activity [GO:0008721]; glycine binding [GO:0016594]; L-serine ammonia-lyase activity [GO:0003941]; magnesium ion binding [GO:0000287]; PDZ domain binding [GO:0030165]; protein homodimerization activity [GO:0042803]; pyridoxal phosphate binding [GO:0030170]; serine racemase activity [GO:0030378]; threonine racemase activity [GO:0018114]	apical part of cell [GO:0045177]; cytoplasm [GO:0005737]; neuronal cell body [GO:0043025]; plasma membrane [GO:0005886]
P51649	SSDH_HUMAN	Succinate-semialdehyde dehydrogenase, mitochondrial (EC 1.2.1.24) (Aldehyde dehydrogenase family 5 member A1) (NAD(+)-dependent succinic semialdehyde dehydrogenase)	ALDH5A1 SSADH	2W8N;2W8O;2W8P;2W8Q;2W8R;	CHEMBL1911;	P51649;	DB00534;DB00139;DB00313;	PATHWAY: Amino-acid degradation; 4-aminobutanoate degradation.	PF00171;	IPR016161;IPR016163;IPR016160;IPR029510;IPR016162;IPR015590;IPR010102;	acetate metabolic process [GO:0006083]; central nervous system development [GO:0007417]; galactosylceramide metabolic process [GO:0006681]; gamma-aminobutyric acid catabolic process [GO:0009450]; glucose metabolic process [GO:0006006]; glucosylceramide metabolic process [GO:0006678]; glutamate metabolic process [GO:0006536]; glutamine metabolic process [GO:0006541]; glutathione metabolic process [GO:0006749]; glycerophospholipid metabolic process [GO:0006650]; neurotransmitter catabolic process [GO:0042135]; post-embryonic development [GO:0009791]; protein homotetramerization [GO:0051289]; respiratory electron transport chain [GO:0022904]; short-chain fatty acid metabolic process [GO:0046459]; succinate metabolic process [GO:0006105]	aldehyde dehydrogenase (NAD) activity [GO:0004029]; protein homodimerization activity [GO:0042803]; succinate-semialdehyde dehydrogenase (NAD+) activity [GO:0004777]; succinate-semialdehyde dehydrogenase [NAD(P)+] activity [GO:0009013]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
P30872	SSR1_HUMAN	Somatostatin receptor type 1 (SS-1-R) (SS1-R) (SS1R) (SRIF-2)	SSTR1		CHEMBL1917;	P30872;	DB00104;DB06663;		PF00001;	IPR000276;IPR017452;IPR000586;IPR001116;	cell-cell signaling [GO:0007267]; cell surface receptor signaling pathway [GO:0007166]; cellular response to estradiol stimulus [GO:0071392]; cerebellum development [GO:0021549]; chemical synaptic transmission [GO:0007268]; digestion [GO:0007586]; forebrain development [GO:0030900]; glutamate receptor signaling pathway [GO:0007215]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; negative regulation of cell proliferation [GO:0008285]; response to nutrient [GO:0007584]; response to starvation [GO:0042594]; spermatogenesis [GO:0007283]	neuropeptide binding [GO:0042923]; somatostatin receptor activity [GO:0004994]	cytoplasm [GO:0005737]; integral component of plasma membrane [GO:0005887]; neuron projection [GO:0043005]; plasma membrane [GO:0005886]
P35346	SSR5_HUMAN	Somatostatin receptor type 5 (SS-5-R) (SS5-R) (SS5R)	SSTR5		CHEMBL1792;	P35346;	DB06791;DB00104;DB06663;DB04894;		PF00001;	IPR000276;IPR017452;IPR000586;IPR001184;	cellular response to glucocorticoid stimulus [GO:0071385]; chemical synaptic transmission [GO:0007268]; glucose homeostasis [GO:0042593]; G-protein coupled receptor signaling pathway [GO:0007186]; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger [GO:0007187]; negative regulation of cell proliferation [GO:0008285]; positive regulation of cytokinesis [GO:0032467]; regulation of insulin secretion [GO:0050796]	neuropeptide binding [GO:0042923]; somatostatin receptor activity [GO:0004994]	integral component of plasma membrane [GO:0005887]; neuron projection [GO:0043005]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
Q9Y5Y6	ST14_HUMAN	Suppressor of tumorigenicity 14 protein (EC 3.4.21.109) (Matriptase) (Membrane-type serine protease 1) (MT-SP1) (Prostamin) (Serine protease 14) (Serine protease TADG-15) (Tumor-associated differentially-expressed gene 15 protein)	ST14 PRSS14 SNC19 TADG15	1EAW;1EAX;2FMV;2GV6;2GV7;3BN9;3NCL;3NPS;3P8F;3P8G;3SO3;4IS5;4ISL;4ISN;4ISO;4JYT;4JZ1;4JZI;4O97;4O9V;	CHEMBL3018;	Q9Y5Y6;	DB00013;		PF00431;PF00057;PF01390;PF00089;	IPR000859;IPR023415;IPR002172;IPR009003;IPR017051;IPR000082;IPR001254;IPR018114;IPR033116;	epithelial cell morphogenesis involved in placental branching [GO:0060672]; keratinocyte differentiation [GO:0030216]; neural tube closure [GO:0001843]; proteolysis [GO:0006508]	serine-type endopeptidase activity [GO:0004252]; serine-type peptidase activity [GO:0008236]	basolateral plasma membrane [GO:0016323]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; extrinsic component of plasma membrane [GO:0019897]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P50225	ST1A1_HUMAN	Sulfotransferase 1A1 (ST1A1) (EC 2.8.2.1) (Aryl sulfotransferase 1) (HAST1/HAST2) (Phenol sulfotransferase 1) (Phenol-sulfating phenol sulfotransferase 1) (P-PST 1) (ST1A3) (Thermostable phenol sulfotransferase) (Ts-PST)	SULT1A1 STP STP1 OK/SW-cl.88	1LS6;1Z28;2D06;3QVU;3QVV;3U3J;3U3K;3U3M;3U3O;3U3R;4GRA;	CHEMBL1743291;	P50225;	DB00316;DB00675;		PF00685;	IPR027417;IPR000863;	3'-phosphoadenosine 5'-phosphosulfate metabolic process [GO:0050427]; amine metabolic process [GO:0009308]; catecholamine metabolic process [GO:0006584]; estrogen metabolic process [GO:0008210]; flavonoid metabolic process [GO:0009812]; steroid metabolic process [GO:0008202]; sulfation [GO:0051923]; xenobiotic metabolic process [GO:0006805]	aryl sulfotransferase activity [GO:0004062]; flavonol 3-sulfotransferase activity [GO:0047894]; steroid sulfotransferase activity [GO:0050294]; sulfotransferase activity [GO:0008146]	cytosol [GO:0005829]
O43704	ST1B1_HUMAN	Sulfotransferase family cytosolic 1B member 1 (ST1B1) (Sulfotransferase 1B1) (EC 2.8.2.-) (Sulfotransferase 1B2) (ST1B2) (Thyroid hormone sulfotransferase)	SULT1B1 ST1B2 SULT1B2	2Z5F;3CKL;	CHEMBL1743294;				PF00685;	IPR027417;IPR000863;IPR033289;	3'-phosphoadenosine 5'-phosphosulfate metabolic process [GO:0050427]; cellular biogenic amine metabolic process [GO:0006576]; epithelial cell differentiation [GO:0030855]; flavonoid metabolic process [GO:0009812]; phenol-containing compound metabolic process [GO:0018958]; steroid metabolic process [GO:0008202]; sulfation [GO:0051923]; thyroid hormone metabolic process [GO:0042403]; xenobiotic metabolic process [GO:0006805]	aryl sulfotransferase activity [GO:0004062]; sulfotransferase activity [GO:0008146]	cytosol [GO:0005829]
P49888	ST1E1_HUMAN	Estrogen sulfotransferase (EC 2.8.2.4) (EST-1) (Sulfotransferase 1E1) (ST1E1) (Sulfotransferase, estrogen-preferring)	SULT1E1 STE	1G3M;1HY3;4JVL;4JVM;4JVN;	CHEMBL2346;	P49888;	DB00316;DB01176;		PF00685;	IPR027417;IPR000863;	3'-phosphoadenosine 5'-phosphosulfate metabolic process [GO:0050427]; estrogen metabolic process [GO:0008210]; positive regulation of fat cell differentiation [GO:0045600]; steroid metabolic process [GO:0008202]; sulfation [GO:0051923]	aryl sulfotransferase activity [GO:0004062]; estrone sulfotransferase activity [GO:0004304]; flavonol 3-sulfotransferase activity [GO:0047894]; steroid binding [GO:0005496]; steroid sulfotransferase activity [GO:0050294]; sulfotransferase activity [GO:0008146]	cytosol [GO:0005829]
Q06520	ST2A1_HUMAN	Bile salt sulfotransferase (EC 2.8.2.14) (Dehydroepiandrosterone sulfotransferase) (DHEA-ST) (Hydroxysteroid Sulfotransferase) (HST) (ST2) (ST2A3) (Sulfotransferase 2A1) (ST2A1)	SULT2A1 HST STD	1EFH;1J99;1OV4;2QP3;2QP4;3F3Y;4IFB;	CHEMBL2077;		DB05812;DB00316;		PF00685;	IPR027417;IPR000863;	3'-phosphoadenosine 5'-phosphosulfate metabolic process [GO:0050427]; bile acid catabolic process [GO:0030573]; digestion [GO:0007586]; steroid metabolic process [GO:0008202]; sulfation [GO:0051923]	aryl sulfotransferase activity [GO:0004062]; bile-salt sulfotransferase activity [GO:0047704]; estrone sulfotransferase activity [GO:0004304]; steroid sulfotransferase activity [GO:0050294]; sulfotransferase activity [GO:0008146]	cytoplasm [GO:0005737]; cytosol [GO:0005829]
O00204	ST2B1_HUMAN	Sulfotransferase family cytosolic 2B member 1 (ST2B1) (Sulfotransferase 2B1) (EC 2.8.2.2) (Alcohol sulfotransferase) (Hydroxysteroid sulfotransferase 2)	SULT2B1 HSST2	1Q1Q;1Q1Z;1Q20;1Q22;	CHEMBL1743297;				PF00685;	IPR027417;IPR000863;	3'-phosphoadenosine 5'-phosphosulfate metabolic process [GO:0050427]; steroid metabolic process [GO:0008202]; sulfate assimilation [GO:0000103]	alcohol sulfotransferase activity [GO:0004027]; steroid sulfotransferase activity [GO:0050294]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; extracellular exosome [GO:0070062]; intracellular membrane-bounded organelle [GO:0043231]; nucleus [GO:0005634]
P51692	STA5B_HUMAN	Signal transducer and activator of transcription 5B	STAT5B		CHEMBL5817;	P51692;	DB01254;		PF00017;PF01017;PF02864;PF02865;	IPR011992;IPR008967;IPR000980;IPR001217;IPR013800;IPR015988;IPR013801;IPR012345;IPR013799;	2-oxoglutarate metabolic process [GO:0006103]; allantoin metabolic process [GO:0000255]; cellular response to epidermal growth factor stimulus [GO:0071364]; cellular response to growth factor stimulus [GO:0071363]; cellular response to hormone stimulus [GO:0032870]; citrate metabolic process [GO:0006101]; creatine metabolic process [GO:0006600]; creatinine metabolic process [GO:0046449]; development of secondary female sexual characteristics [GO:0046543]; development of secondary male sexual characteristics [GO:0046544]; fatty acid metabolic process [GO:0006631]; female pregnancy [GO:0007565]; isoleucine metabolic process [GO:0006549]; JAK-STAT cascade [GO:0007259]; JAK-STAT cascade involved in growth hormone signaling pathway [GO:0060397]; lactation [GO:0007595]; lipid storage [GO:0019915]; luteinization [GO:0001553]; mast cell migration [GO:0097531]; natural killer cell differentiation [GO:0001779]; negative regulation of apoptotic process [GO:0043066]; negative regulation of erythrocyte differentiation [GO:0045647]; oxaloacetate metabolic process [GO:0006107]; Peyer's patch development [GO:0048541]; positive regulation of activated T cell proliferation [GO:0042104]; positive regulation of B cell differentiation [GO:0045579]; positive regulation of erythrocyte differentiation [GO:0045648]; positive regulation of gamma-delta T cell differentiation [GO:0045588]; positive regulation of inflammatory response [GO:0050729]; positive regulation of interleukin-2 biosynthetic process [GO:0045086]; positive regulation of mitotic cell cycle [GO:0045931]; positive regulation of multicellular organism growth [GO:0040018]; positive regulation of natural killer cell differentiation [GO:0032825]; positive regulation of natural killer cell mediated cytotoxicity [GO:0045954]; positive regulation of natural killer cell proliferation [GO:0032819]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; progesterone metabolic process [GO:0042448]; prolactin signaling pathway [GO:0038161]; regulation of epithelial cell differentiation [GO:0030856]; regulation of multicellular organism growth [GO:0040014]; regulation of steroid metabolic process [GO:0019218]; regulation of transcription from RNA polymerase II promoter [GO:0006357]; response to estradiol [GO:0032355]; response to interleukin-15 [GO:0070672]; response to interleukin-2 [GO:0070669]; response to interleukin-4 [GO:0070670]; succinate metabolic process [GO:0006105]; taurine metabolic process [GO:0019530]; T cell differentiation in thymus [GO:0033077]; T cell homeostasis [GO:0043029]; valine metabolic process [GO:0006573]	chromatin binding [GO:0003682]; glucocorticoid receptor binding [GO:0035259]; protein dimerization activity [GO:0046983]; protein tyrosine kinase activity [GO:0004713]; RNA polymerase II core promoter sequence-specific DNA binding [GO:0000979]; signal transducer activity [GO:0004871]; transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding [GO:0001077]; transcription factor activity, sequence-specific DNA binding [GO:0003700]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P42224	STAT1_HUMAN	Signal transducer and activator of transcription 1-alpha/beta (Transcription factor ISGF-3 components p91/p84)	STAT1	1BF5;1YVL;2KA6;3WWT;	CHEMBL6101;	P42224;			PF00017;PF12162;PF01017;PF02864;PF02865;	IPR011992;IPR008967;IPR000980;IPR001217;IPR022752;IPR013800;IPR015988;IPR013801;IPR012345;IPR013799;	apoptotic process [GO:0006915]; blood circulation [GO:0008015]; cellular response to insulin stimulus [GO:0032869]; cellular response to interferon-beta [GO:0035458]; cellular response to organic cyclic compound [GO:0071407]; defense response to virus [GO:0051607]; interferon-gamma-mediated signaling pathway [GO:0060333]; JAK-STAT cascade [GO:0007259]; macrophage derived foam cell differentiation [GO:0010742]; metanephric mesenchymal cell differentiation [GO:0072162]; metanephric mesenchymal cell proliferation involved in metanephros development [GO:0072136]; negative regulation by virus of viral protein levels in host cell [GO:0046725]; negative regulation of angiogenesis [GO:0016525]; negative regulation of endothelial cell proliferation [GO:0001937]; negative regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043124]; negative regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis [GO:0003340]; negative regulation of metanephric nephron tubule epithelial cell differentiation [GO:0072308]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; positive regulation of mesenchymal cell proliferation [GO:0002053]; positive regulation of smooth muscle cell proliferation [GO:0048661]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; regulation of apoptotic process [GO:0042981]; regulation of interferon-gamma-mediated signaling pathway [GO:0060334]; regulation of type I interferon-mediated signaling pathway [GO:0060338]; renal tubule development [GO:0061326]; response to cAMP [GO:0051591]; response to cytokine [GO:0034097]; response to drug [GO:0042493]; response to hydrogen peroxide [GO:0042542]; response to interferon-beta [GO:0035456]; response to mechanical stimulus [GO:0009612]; response to nutrient [GO:0007584]; response to peptide hormone [GO:0043434]; transcription, DNA-templated [GO:0006351]; tumor necrosis factor-mediated signaling pathway [GO:0033209]; type I interferon signaling pathway [GO:0060337]	cadherin binding involved in cell-cell adhesion [GO:0098641]; double-stranded DNA binding [GO:0003690]; enzyme binding [GO:0019899]; nuclear hormone receptor binding [GO:0035257]; protein homodimerization activity [GO:0042803]; RNA polymerase II core promoter proximal region sequence-specific DNA binding [GO:0000978]; RNA polymerase II core promoter sequence-specific DNA binding [GO:0000979]; signal transducer activity [GO:0004871]; transcription factor activity, RNA polymerase II core promoter sequence-specific [GO:0000983]; transcription factor activity, sequence-specific DNA binding [GO:0003700]; tumor necrosis factor receptor binding [GO:0005164]	axon [GO:0030424]; cell-cell adherens junction [GO:0005913]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; dendrite [GO:0030425]; nuclear chromatin [GO:0000790]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]
Q13285	STF1_HUMAN	Steroidogenic factor 1 (SF-1) (STF-1) (hSF-1) (Adrenal 4-binding protein) (Fushi tarazu factor homolog 1) (Nuclear receptor subfamily 5 group A member 1) (Steroid hormone receptor Ad4BP)	NR5A1 AD4BP FTZF1 SF1	1YOW;1ZDT;4QJR;4QK4;	CHEMBL4666;	Q13285;			PF00104;PF00105;	IPR016355;IPR000536;IPR001723;IPR001628;IPR013088;	adrenal gland development [GO:0030325]; cell-cell signaling [GO:0007267]; cell differentiation [GO:0030154]; hormone-mediated signaling pathway [GO:0009755]; hormone metabolic process [GO:0042445]; luteinization [GO:0001553]; maintenance of protein location in nucleus [GO:0051457]; male gonad development [GO:0008584]; multicellular organism aging [GO:0010259]; negative regulation of female gonad development [GO:2000195]; positive regulation of male gonad development [GO:2000020]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; primary sex determination [GO:0007538]; regulation of steroid biosynthetic process [GO:0050810]; tissue development [GO:0009888]; transcription initiation from RNA polymerase II promoter [GO:0006367]	chromatin binding [GO:0003682]; DNA binding [GO:0003677]; enzyme binding [GO:0019899]; phospholipid binding [GO:0005543]; RNA polymerase II distal enhancer sequence-specific DNA binding [GO:0000980]; RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding [GO:0004879]; steroid hormone receptor activity [GO:0003707]; transcription coactivator activity [GO:0003713]; transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding [GO:0003705]; transcription regulatory region sequence-specific DNA binding [GO:0000976]; zinc ion binding [GO:0008270]	nucleoplasm [GO:0005654]; nucleus [GO:0005634]; RNA polymerase II transcription factor complex [GO:0090575]
O14965	STK6_HUMAN	Aurora kinase A (EC 2.7.11.1) (Aurora 2) (Aurora/IPL1-related kinase 1) (ARK-1) (Aurora-related kinase 1) (hARK1) (Breast tumor-amplified kinase) (Serine/threonine-protein kinase 15) (Serine/threonine-protein kinase 6) (Serine/threonine-protein kinase aurora-A)	AURKA AIK AIRK1 ARK1 AURA AYK1 BTAK IAK1 STK15 STK6	1MQ4;1MUO;1OL5;1OL6;1OL7;2BMC;2C6D;2C6E;2DWB;2J4Z;2J50;2NP8;2W1C;2W1D;2W1E;2W1F;2W1G;2WQE;2WTV;2WTW;2X6D;2X6E;2X81;2XNE;2XNG;2XRU;3COH;3E5A;3EFW;3FDN;3H0Y;3H0Z;3H10;3HA6;3K5U;3LAU;3M11;3MYG;3NRM;3O50;3O51;3P9J;3QBN;3R21;3R22;3UNZ;3UO4;3UO5;3UO6;3UOD;3UOH;3UOJ;3UOK;3UOL;3UP2;3UP7;3VAP;3W10;3W16;3W18;3W2C;4B0G;4BN1;4BYI;4BYJ;4C3P;4C3R;4CEG;4DEA;4DEB;4DED;4DEE;4DHF;4J8M;4J8N;4JAI;4JAJ;4JBO;4JBP;4JBQ;4O0S;4O0U;4O0W;4PRJ;4UTD;4UYN;4UZD;4UZH;4ZS0;4ZTQ;4ZTR;4ZTS;5AAD;5AAE;5AAF;5AAG;5DN3;5DNR;5DOS;5DPV;5DR2;5DR6;5DR9;5DRD;5DT0;5DT3;5DT4;5EW9;5L8J;5L8K;5L8L;	CHEMBL4722;	O14965;			PF00069;	IPR030616;IPR030611;IPR011009;IPR000719;IPR017441;IPR008271;	anaphase-promoting complex-dependent catabolic process [GO:0031145]; anterior/posterior axis specification [GO:0009948]; cell division [GO:0051301]; centrosome localization [GO:0051642]; DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest [GO:0006977]; G2/M transition of mitotic cell cycle [GO:0000086]; meiotic spindle organization [GO:0000212]; mitotic centrosome separation [GO:0007100]; mitotic nuclear division [GO:0007067]; mitotic spindle organization [GO:0007052]; negative regulation of apoptotic process [GO:0043066]; negative regulation of protein binding [GO:0032091]; neuron projection extension [GO:1990138]; positive regulation of mitotic nuclear division [GO:0045840]; positive regulation of oocyte maturation [GO:1900195]; positive regulation of proteasomal ubiquitin-dependent protein catabolic process [GO:0032436]; protein autophosphorylation [GO:0046777]; protein localization to centrosome [GO:0071539]; protein phosphorylation [GO:0006468]; protein ubiquitination involved in ubiquitin-dependent protein catabolic process [GO:0042787]; regulation of centrosome cycle [GO:0046605]; regulation of cytokinesis [GO:0032465]; regulation of protein stability [GO:0031647]; regulation of signal transduction by p53 class mediator [GO:1901796]; spindle assembly involved in female meiosis I [GO:0007057]; spindle organization [GO:0007051]	ATP binding [GO:0005524]; histone serine kinase activity [GO:0035174]; protein kinase activity [GO:0004672]; protein kinase binding [GO:0019901]; protein serine/threonine/tyrosine kinase activity [GO:0004712]; protein serine/threonine kinase activity [GO:0004674]	axon hillock [GO:0043203]; centriole [GO:0005814]; centrosome [GO:0005813]; chromosome passenger complex [GO:0032133]; cilium [GO:0005929]; condensed nuclear chromosome, centromeric region [GO:0000780]; cytosol [GO:0005829]; germinal vesicle [GO:0042585]; meiotic spindle [GO:0072687]; microtubule [GO:0005874]; microtubule cytoskeleton [GO:0015630]; midbody [GO:0030496]; mitotic spindle [GO:0072686]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; pronucleus [GO:0045120]; spindle [GO:0005819]; spindle midzone [GO:0051233]; spindle pole centrosome [GO:0031616]
P08842	STS_HUMAN	Steryl-sulfatase (EC 3.1.6.2) (Arylsulfatase C) (ASC) (Steroid sulfatase) (Steryl-sulfate sulfohydrolase)	STS ARSC1	1P49;	CHEMBL3559;	P08842;	DB06713;		PF00884;	IPR017849;IPR017850;IPR024607;IPR000917;	epidermis development [GO:0008544]; female pregnancy [GO:0007565]; glycosphingolipid metabolic process [GO:0006687]; post-translational protein modification [GO:0043687]; steroid catabolic process [GO:0006706]	metal ion binding [GO:0046872]; steryl-sulfatase activity [GO:0004773]; sulfuric ester hydrolase activity [GO:0008484]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum lumen [GO:0005788]; endoplasmic reticulum membrane [GO:0005789]; endosome [GO:0005768]; Golgi apparatus [GO:0005794]; integral component of membrane [GO:0016021]; intracellular membrane-bounded organelle [GO:0043231]; lysosome [GO:0005764]; membrane [GO:0016020]; plasma membrane [GO:0005886]
P53597	SUCA_HUMAN	Succinate--CoA ligase [ADP/GDP-forming] subunit alpha, mitochondrial (EC 6.2.1.4) (EC 6.2.1.5) (Succinyl-CoA synthetase subunit alpha) (SCS-alpha)	SUCLG1				DB00139;	PATHWAY: Carbohydrate metabolism; tricarboxylic acid cycle.	PF02629;PF00549;	IPR017440;IPR003781;IPR005810;IPR005811;IPR016040;IPR016102;	nucleoside triphosphate biosynthetic process [GO:0009142]; succinate metabolic process [GO:0006105]; succinyl-CoA metabolic process [GO:0006104]; tricarboxylic acid cycle [GO:0006099]	cofactor binding [GO:0048037]; GTP binding [GO:0005525]; poly(A) RNA binding [GO:0044822]; succinate-CoA ligase (ADP-forming) activity [GO:0004775]; succinate-CoA ligase (GDP-forming) activity [GO:0004776]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; plasma membrane [GO:0005886]
Q9P2R7	Q5T9Q6_HUMAN,SUCB1_HUMAN	Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial (EC 6.2.1.5) (ATP-specific succinyl-CoA synthetase subunit beta) (Renal carcinoma antigen NY-REN-39) (Succinyl-CoA synthetase beta-A chain) (SCS-betaA)	SUCLA2				DB00139;	PATHWAY: Carbohydrate metabolism; tricarboxylic acid cycle; succinate from succinyl-CoA (ligase route): step 1/1. {ECO:0000305|PubMed:15877282}.	PF08442;PF00549;	IPR011761;IPR013650;IPR013815;IPR013816;IPR005811;IPR017866;IPR005809;IPR016102;	succinate metabolic process [GO:0006105]; succinyl-CoA metabolic process [GO:0006104]; succinyl-CoA pathway [GO:0006781]; tricarboxylic acid cycle [GO:0006099]	ATP binding [GO:0005524]; metal ion binding [GO:0046872]; succinate-CoA ligase (ADP-forming) activity [GO:0004775]	extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; myelin sheath [GO:0043209]
Q96I99	SUCB2_HUMAN	Succinate--CoA ligase [GDP-forming] subunit beta, mitochondrial (EC 6.2.1.4) (GTP-specific succinyl-CoA synthetase subunit beta) (Succinyl-CoA synthetase beta-G chain) (SCS-betaG)	SUCLG2				DB00139;	PATHWAY: Carbohydrate metabolism; tricarboxylic acid cycle.	PF08442;PF00549;	IPR013650;IPR013815;IPR013816;IPR005811;IPR017866;IPR005809;IPR016102;	succinate metabolic process [GO:0006105]; succinyl-CoA metabolic process [GO:0006104]; tricarboxylic acid cycle [GO:0006099]	ATP binding [GO:0005524]; GDP binding [GO:0019003]; GTP binding [GO:0005525]; succinate-CoA ligase (GDP-forming) activity [GO:0004776]	microtubule organizing center [GO:0005815]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; succinate-CoA ligase complex (GDP-forming) [GO:0045244]
Q9BXA5	SUCR1_HUMAN	Succinate receptor 1 (G-protein coupled receptor 91) (P2Y purinoceptor 1-like)	SUCNR1 GPR91		CHEMBL2150838;	Q9BXA5;	DB00139;		PF00001;	IPR000276;IPR017452;		G-protein coupled receptor activity [GO:0004930]	extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]
P14410	SUIS_HUMAN	Sucrase-isomaltase, intestinal [Cleaved into: Sucrase (EC 3.2.1.48); Isomaltase (EC 3.2.1.10)]	SI	3LPO;3LPP;	CHEMBL2748;	P14410;	DB00284;DB00747;		PF01055;PF16863;PF00088;	IPR031727;IPR011013;IPR000322;IPR030458;IPR030459;IPR017853;IPR017957;IPR000519;	carbohydrate metabolic process [GO:0005975]; polysaccharide digestion [GO:0044245]	alpha-1,4-glucosidase activity [GO:0004558]; carbohydrate binding [GO:0030246]; oligo-1,6-glucosidase activity [GO:0004574]; sucrose alpha-glucosidase activity [GO:0004575]	apical plasma membrane [GO:0016324]; brush border [GO:0005903]; extracellular exosome [GO:0070062]; Golgi apparatus [GO:0005794]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]
Q8NBJ7	SUMF2_HUMAN	Sulfatase-modifying factor 2 (C-alpha-formylglycine-generating enzyme 2)	SUMF2 PSEC0171 UNQ1968/PRO4500	1Y4J;					PF03781;	IPR016187;IPR005532;	post-translational protein modification [GO:0043687]	metal ion binding [GO:0046872]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum lumen [GO:0005788]
P51687	SUOX_HUMAN	Sulfite oxidase, mitochondrial (EC 1.8.3.1)	SUOX	1MJ4;				PATHWAY: Energy metabolism; sulfur metabolism.	PF00173;PF03404;PF00174;	IPR001199;IPR018506;IPR014756;IPR005066;IPR008335;IPR000572;IPR022407;	nitrate assimilation [GO:0042128]; sulfide oxidation, using sulfide:quinone oxidoreductase [GO:0070221]	heme binding [GO:0020037]; molybdenum ion binding [GO:0030151]; molybdopterin cofactor binding [GO:0043546]; sulfite oxidase activity [GO:0008482]	mitochondrial intermembrane space [GO:0005758]; mitochondrial matrix [GO:0005759]
Q7L0J3	SV2A_HUMAN	Synaptic vesicle glycoprotein 2A	SV2A KIAA0736 PSEC0174	4V11;	CHEMBL1998;		DB01202;		PF07690;PF13599;PF00083;	IPR001646;IPR011701;IPR020846;IPR005828;IPR005829;IPR022308;	cellular calcium ion homeostasis [GO:0006874]; neurotransmitter uptake [GO:0001504]	protein kinase binding [GO:0019901]; receptor activity [GO:0004872]; transmembrane transporter activity [GO:0022857]	cell-cell junction [GO:0005911]; cytoplasm [GO:0005737]; endoplasmic reticulum [GO:0005783]; integral component of membrane [GO:0016021]; neuromuscular junction [GO:0031594]; neuron projection [GO:0043005]; plasma membrane [GO:0005886]; presynaptic active zone [GO:0048786]; synaptic vesicle [GO:0008021]; synaptic vesicle membrane [GO:0030672]; terminal bouton [GO:0043195]
P49588	SYAC_HUMAN	Alanine--tRNA ligase, cytoplasmic (EC 6.1.1.7) (Alanyl-tRNA synthetase) (AlaRS) (Renal carcinoma antigen NY-REN-42)	AARS	4XEM;4XEO;	CHEMBL3574;	P49588;	DB00160;		PF02272;PF01411;PF07973;	IPR002318;IPR018162;IPR018165;IPR018164;IPR023033;IPR003156;IPR018163;IPR009000;IPR012947;	alanyl-tRNA aminoacylation [GO:0006419]; cerebellar Purkinje cell layer development [GO:0021680]; endoplasmic reticulum unfolded protein response [GO:0030968]; hair follicle development [GO:0001942]; negative regulation of neuron apoptotic process [GO:0043524]; neuromuscular process controlling balance [GO:0050885]; protein folding [GO:0006457]; response to amino acid [GO:0043200]; tRNA aminoacylation for protein translation [GO:0006418]; tRNA modification [GO:0006400]; tRNA processing [GO:0008033]	alanine-tRNA ligase activity [GO:0004813]; amino acid binding [GO:0016597]; aminoacyl-tRNA editing activity [GO:0002161]; ATP binding [GO:0005524]; tRNA binding [GO:0000049]; zinc ion binding [GO:0008270]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]
Q5JTZ9	SYAM_HUMAN	Alanine--tRNA ligase, mitochondrial (EC 6.1.1.7) (Alanyl-tRNA synthetase) (AlaRS)	AARS2 AARSL KIAA1270				DB00160;		PF01411;PF07973;	IPR002318;IPR018162;IPR018165;IPR018164;IPR023033;IPR018163;IPR009000;IPR012947;	mitochondrial alanyl-tRNA aminoacylation [GO:0070143]; mitochondrial respiratory chain complex assembly [GO:0033108]; tRNA modification [GO:0006400]	alanine-tRNA ligase activity [GO:0004813]; amino acid binding [GO:0016597]; ATP binding [GO:0005524]; tRNA binding [GO:0000049]; zinc ion binding [GO:0008270]	mitochondrion [GO:0005739]
P49589	SYCC_HUMAN	Cysteine--tRNA ligase, cytoplasmic (EC 6.1.1.16) (Cysteinyl-tRNA synthetase) (CysRS)	CARS				DB00151;		PF01406;	IPR015803;IPR024909;IPR014729;IPR032678;IPR009080;	cysteinyl-tRNA aminoacylation [GO:0006423]; tRNA aminoacylation for protein translation [GO:0006418]	ATP binding [GO:0005524]; cysteine-tRNA ligase activity [GO:0004817]; metal ion binding [GO:0046872]; protein homodimerization activity [GO:0042803]; tRNA binding [GO:0000049]	cytoplasm [GO:0005737]; cytosol [GO:0005829]
Q9HA77	SYCM_HUMAN	Probable cysteine--tRNA ligase, mitochondrial (EC 6.1.1.16) (Cysteinyl-tRNA synthetase) (CysRS)	CARS2 OK/SW-cl.10				DB00151;		PF01406;	IPR015803;IPR024909;IPR014729;IPR032678;IPR009080;	cysteinyl-tRNA aminoacylation [GO:0006423]	ATP binding [GO:0005524]; cysteine-tRNA ligase activity [GO:0004817]; metal ion binding [GO:0046872]	cytoplasm [GO:0005737]; mitochondrial matrix [GO:0005759]
P14868	SYDC_HUMAN	Aspartate--tRNA ligase, cytoplasmic (EC 6.1.1.12) (Aspartyl-tRNA synthetase) (AspRS) (Cell proliferation-inducing gene 40 protein)	DARS PIG40	4J15;			DB00128;		PF00152;PF01336;	IPR004364;IPR018150;IPR006195;IPR004523;IPR002312;IPR012340;IPR004365;	aspartyl-tRNA aminoacylation [GO:0006422]; protein complex assembly [GO:0006461]; translation [GO:0006412]; tRNA aminoacylation for protein translation [GO:0006418]	aminoacylase activity [GO:0004046]; aspartate-tRNA ligase activity [GO:0004815]; ATP binding [GO:0005524]; poly(A) RNA binding [GO:0044822]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]
Q6PI48	SYDM_HUMAN	Aspartate--tRNA ligase, mitochondrial (EC 6.1.1.12) (Aspartyl-tRNA synthetase) (AspRS)	DARS2	4AH6;			DB00128;		PF02938;PF00152;PF01336;	IPR004364;IPR018150;IPR006195;IPR004524;IPR002312;IPR004115;IPR029351;IPR012340;IPR004365;	mitochondrial asparaginyl-tRNA aminoacylation [GO:0070145]; tRNA aminoacylation [GO:0043039]; tRNA aminoacylation for protein translation [GO:0006418]	aspartate-tRNA(Asn) ligase activity [GO:0050560]; aspartate-tRNA ligase activity [GO:0004815]; ATP binding [GO:0005524]; protein homodimerization activity [GO:0042803]; tRNA binding [GO:0000049]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]
Q5JPH6	SYEM_HUMAN	Probable glutamate--tRNA ligase, mitochondrial (EC 6.1.1.17) (Glutamyl-tRNA synthetase) (GluRS)	EARS2 KIAA1970						PF00749;	IPR008925;IPR020751;IPR001412;IPR004527;IPR000924;IPR020061;IPR020058;IPR014729;	glutamyl-tRNA aminoacylation [GO:0006424]; tRNA aminoacylation for mitochondrial protein translation [GO:0070127]	ATP binding [GO:0005524]; glutamate-tRNA(Gln) ligase activity [GO:0050561]; glutamate-tRNA ligase activity [GO:0004818]; RNA binding [GO:0003723]; tRNA binding [GO:0000049]; zinc ion binding [GO:0008270]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
P07814	SYEP_HUMAN	Bifunctional glutamate/proline--tRNA ligase (Bifunctional aminoacyl-tRNA synthetase) (Cell proliferation-inducing gene 32 protein) (Glutamatyl-prolyl-tRNA synthetase) [Includes: Glutamate--tRNA ligase (EC 6.1.1.17) (Glutamyl-tRNA synthetase) (GluRS); Proline--tRNA ligase (EC 6.1.1.15) (Prolyl-tRNA synthetase)]	EPRS GLNS PARS QARS QPRS PIG32	1FYJ;4HVC;4K86;4K87;4K88;5A1N;5A34;5A5H;5BMU;	CHEMBL3873;	P07814;	DB00172;		PF00043;PF03129;PF09180;PF00749;PF03950;PF00587;PF00458;	IPR002314;IPR001412;IPR006195;IPR004154;IPR004526;IPR000924;IPR020061;IPR020058;IPR020059;IPR010987;IPR004046;IPR004499;IPR016061;IPR017449;IPR033721;IPR020056;IPR011035;IPR014729;IPR009068;IPR000738;	cellular response to interferon-gamma [GO:0071346]; glutamyl-tRNA aminoacylation [GO:0006424]; negative regulation of translation [GO:0017148]; prolyl-tRNA aminoacylation [GO:0006433]; protein complex assembly [GO:0006461]; tRNA aminoacylation for protein translation [GO:0006418]	ATP binding [GO:0005524]; glutamate-tRNA ligase activity [GO:0004818]; GTPase binding [GO:0051020]; proline-tRNA ligase activity [GO:0004827]; RNA stem-loop binding [GO:0035613]	aminoacyl-tRNA synthetase multienzyme complex [GO:0017101]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; GAIT complex [GO:0097452]; intracellular ribonucleoprotein complex [GO:0030529]; membrane [GO:0016020]
Q9Y285	SYFA_HUMAN	Phenylalanine--tRNA ligase alpha subunit (EC 6.1.1.20) (CML33) (Phenylalanyl-tRNA synthetase alpha subunit) (PheRS)	FARSA FARS FARSL FARSLA	3L4G;			DB00120;		PF01409;	IPR006195;IPR004529;IPR002319;IPR011991;	phenylalanyl-tRNA aminoacylation [GO:0006432]; protein heterotetramerization [GO:0051290]; tRNA aminoacylation for protein translation [GO:0006418]	ATP binding [GO:0005524]; phenylalanine-tRNA ligase activity [GO:0004826]; poly(A) RNA binding [GO:0044822]; tRNA binding [GO:0000049]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; membrane [GO:0016020]; phenylalanine-tRNA ligase complex [GO:0009328]
Q9NSD9	SYFB_HUMAN	Phenylalanine--tRNA ligase beta subunit (EC 6.1.1.20) (Phenylalanyl-tRNA synthetase beta subunit) (PheRS)	FARSB FARSLB FRSB HSPC173	3L4G;			DB00120;		PF03483;PF03484;	IPR005146;IPR009061;IPR004531;IPR020825;IPR005147;	phenylalanyl-tRNA aminoacylation [GO:0006432]; protein heterotetramerization [GO:0051290]; translation [GO:0006412]; tRNA aminoacylation for protein translation [GO:0006418]	ATP binding [GO:0005524]; magnesium ion binding [GO:0000287]; phenylalanine-tRNA ligase activity [GO:0004826]; RNA binding [GO:0003723]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; membrane [GO:0016020]; phenylalanine-tRNA ligase complex [GO:0009328]
O95363	SYFM_HUMAN	Phenylalanine--tRNA ligase, mitochondrial (EC 6.1.1.20) (Phenylalanyl-tRNA synthetase) (PheRS)	FARS2 FARS1 HSPC320	3CMQ;3HFV;3TEG;3TUP;	CHEMBL2511;	O95363;	DB00120;		PF03147;PF01409;	IPR006195;IPR004530;IPR002319;IPR005121;	phenylalanyl-tRNA aminoacylation [GO:0006432]; tRNA aminoacylation for protein translation [GO:0006418]; tRNA processing [GO:0008033]	ATP binding [GO:0005524]; magnesium ion binding [GO:0000287]; phenylalanine-tRNA ligase activity [GO:0004826]; tRNA binding [GO:0000049]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
P41250	SYG_HUMAN	Glycine--tRNA ligase (EC 3.6.1.17) (EC 6.1.1.14) (Diadenosine tetraphosphate synthetase) (AP-4-A synthetase) (Glycyl-tRNA synthetase) (GlyRS)	GARS	2PME;2PMF;2Q5H;2Q5I;2ZT5;2ZT6;2ZT7;2ZT8;2ZXF;4KQE;4KR2;4KR3;4QEI;5E6M;			DB00145;		PF03129;PF00587;PF00458;	IPR002314;IPR006195;IPR004154;IPR027031;IPR033731;IPR009068;IPR002315;IPR000738;	diadenosine tetraphosphate biosynthetic process [GO:0015966]; glycyl-tRNA aminoacylation [GO:0006426]; tRNA aminoacylation for protein translation [GO:0006418]	ATP binding [GO:0005524]; bis(5'-nucleosyl)-tetraphosphatase (asymmetrical) activity [GO:0004081]; glycine-tRNA ligase activity [GO:0004820]; protein dimerization activity [GO:0046983]	axon [GO:0030424]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]; nucleoplasm [GO:0005654]; secretory granule [GO:0030141]
P12081	SYH_HUMAN	Histidine--tRNA ligase, cytoplasmic (EC 6.1.1.21) (Histidyl-tRNA synthetase) (HisRS)	HARS HRS	1X59;2LW7;4G84;4G85;4PHC;4X5O;	CHEMBL4002;	P12081;	DB00117;		PF03129;PF00458;	IPR006195;IPR004154;IPR015807;IPR004516;IPR033656;IPR009068;IPR000738;	histidyl-tRNA aminoacylation [GO:0006427]; mitochondrial translation [GO:0032543]; translation [GO:0006412]; tRNA aminoacylation for protein translation [GO:0006418]	ATP binding [GO:0005524]; histidine-tRNA ligase activity [GO:0004821]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrion [GO:0005739]
P41252	SYIC_HUMAN	Isoleucine--tRNA ligase, cytoplasmic (EC 6.1.1.5) (Isoleucyl-tRNA synthetase) (IRS) (IleRS)	IARS		CHEMBL3235;	P41252;	DB00167;		PF08264;PF00133;	IPR001412;IPR002300;IPR033709;IPR002301;IPR023586;IPR013155;IPR014729;IPR009080;IPR009008;	isoleucyl-tRNA aminoacylation [GO:0006428]; osteoblast differentiation [GO:0001649]; tRNA aminoacylation for protein translation [GO:0006418]	aminoacyl-tRNA editing activity [GO:0002161]; ATP binding [GO:0005524]; GTPase binding [GO:0051020]; isoleucine-tRNA ligase activity [GO:0004822]; tRNA binding [GO:0000049]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; nucleoplasm [GO:0005654]
Q9NSE4	SYIM_HUMAN	Isoleucine--tRNA ligase, mitochondrial (EC 6.1.1.5) (Isoleucyl-tRNA synthetase) (IleRS)	IARS2				DB00167;		PF08264;PF00133;PF06827;	IPR001412;IPR002300;IPR033708;IPR002301;IPR023585;IPR013155;IPR014729;IPR009080;IPR009008;IPR010663;	isoleucyl-tRNA aminoacylation [GO:0006428]; tRNA aminoacylation for protein translation [GO:0006418]	aminoacyl-tRNA editing activity [GO:0002161]; ATP binding [GO:0005524]; isoleucine-tRNA ligase activity [GO:0004822]; tRNA binding [GO:0000049]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
Q15046	SYK_HUMAN	Lysine--tRNA ligase (EC 6.1.1.6) (Lysyl-tRNA synthetase) (LysRS)	KARS KIAA0070	3BJU;4DPG;4YCU;4YCW;	CHEMBL5575;	Q15046;	DB00123;		PF00152;PF01336;	IPR004364;IPR018150;IPR006195;IPR002313;IPR018149;IPR012340;IPR004365;	diadenosine tetraphosphate biosynthetic process [GO:0015966]; lysyl-tRNA aminoacylation [GO:0006430]; tRNA aminoacylation for protein translation [GO:0006418]; tRNA processing [GO:0008033]; viral process [GO:0016032]	amino acid binding [GO:0016597]; ATP binding [GO:0005524]; lysine-tRNA ligase activity [GO:0004824]; metal ion binding [GO:0046872]; tRNA binding [GO:0000049]	aminoacyl-tRNA synthetase multienzyme complex [GO:0017101]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular region [GO:0005576]; microtubule cytoskeleton [GO:0015630]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
Q9P2J5	SYLC_HUMAN	Leucine--tRNA ligase, cytoplasmic (EC 6.1.1.4) (Leucyl-tRNA synthetase) (LeuRS)	LARS KIAA1352	2WFD;	CHEMBL3258;	Q9P2J5;	DB00149;		PF08264;PF00133;	IPR001412;IPR002300;IPR004493;IPR013155;IPR014729;IPR009080;IPR009008;	leucyl-tRNA aminoacylation [GO:0006429]; tRNA aminoacylation for protein translation [GO:0006418]	aminoacyl-tRNA editing activity [GO:0002161]; ATP binding [GO:0005524]; leucine-tRNA ligase activity [GO:0004823]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleus [GO:0005634]
Q15031	SYLM_HUMAN	Probable leucine--tRNA ligase, mitochondrial (EC 6.1.1.4) (Leucyl-tRNA synthetase) (LeuRS)	LARS2 KIAA0028				DB00149;		PF08264;PF00133;	IPR001412;IPR002300;IPR002302;IPR013155;IPR014729;IPR009080;IPR009008;	leucyl-tRNA aminoacylation [GO:0006429]; tRNA aminoacylation for protein translation [GO:0006418]	aminoacyl-tRNA editing activity [GO:0002161]; ATP binding [GO:0005524]; leucine-tRNA ligase activity [GO:0004823]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
Q96GW9	SYMM_HUMAN	Methionine--tRNA ligase, mitochondrial (EC 6.1.1.10) (Methionyl-tRNA synthetase 2) (Mitochondrial methionyl-tRNA synthetase) (MtMetRS)	MARS2				DB00134;		PF09334;	IPR014758;IPR015413;IPR014729;IPR009080;	methionyl-tRNA aminoacylation [GO:0006431]; tRNA aminoacylation for protein translation [GO:0006418]	ATP binding [GO:0005524]; methionine-tRNA ligase activity [GO:0004825]	mitochondrial matrix [GO:0005759]
P56192	SYM_HUMAN	Methionine--tRNA ligase, cytoplasmic (EC 6.1.1.10) (Methionyl-tRNA synthetase) (MetRS)	MARS	2DJV;4BL7;4BVX;4BVY;	CHEMBL2870;	P56192;	DB00134;		PF00043;PF09334;PF00458;	IPR001412;IPR010987;IPR004046;IPR023458;IPR014758;IPR015413;IPR029038;IPR014729;IPR009068;IPR009080;IPR000738;	methionyl-tRNA aminoacylation [GO:0006431]; tRNA aminoacylation for protein translation [GO:0006418]	ATP binding [GO:0005524]; methionine-tRNA ligase activity [GO:0004825]; tRNA binding [GO:0000049]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]
O43776	SYNC_HUMAN	Asparagine--tRNA ligase, cytoplasmic (EC 6.1.1.22) (Asparaginyl-tRNA synthetase) (AsnRS)	NARS	4ZYA;			DB00174;		PF00152;PF01336;	IPR004364;IPR018150;IPR006195;IPR004522;IPR002312;IPR012340;IPR004365;	asparaginyl-tRNA aminoacylation [GO:0006421]; tRNA aminoacylation for protein translation [GO:0006418]	asparagine-tRNA ligase activity [GO:0004816]; ATP binding [GO:0005524]; nucleic acid binding [GO:0003676]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrion [GO:0005739]
Q96I59	SYNM_HUMAN	Probable asparagine--tRNA ligase, mitochondrial (EC 6.1.1.22) (Asparaginyl-tRNA synthetase) (AsnRS)	NARS2				DB00174;		PF00152;PF01336;	IPR004364;IPR018150;IPR006195;IPR004522;IPR002312;IPR012340;IPR004365;	asparaginyl-tRNA aminoacylation [GO:0006421]	asparagine-tRNA ligase activity [GO:0004816]; ATP binding [GO:0005524]; nucleic acid binding [GO:0003676]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
Q7L3T8	SYPM_HUMAN	Probable proline--tRNA ligase, mitochondrial (EC 6.1.1.15) (Prolyl-tRNA synthetase) (ProRS)	PARS2				DB00172;		PF03129;PF00587;	IPR002314;IPR006195;IPR004154;IPR002316;IPR004500;IPR033730;	prolyl-tRNA aminoacylation [GO:0006433]	ATP binding [GO:0005524]; proline-tRNA ligase activity [GO:0004827]; RNA binding [GO:0003723]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
P47897	SYQ_HUMAN	Glutamine--tRNA ligase (EC 6.1.1.18) (Glutaminyl-tRNA synthetase) (GlnRS)	QARS	4R3Z;4YE6;4YE8;4YE9;	CHEMBL3054;	P47897;	DB00130;		PF00749;PF03950;PF04558;PF04557;	IPR001412;IPR004514;IPR007638;IPR007639;IPR000924;IPR020061;IPR020058;IPR020059;IPR020056;IPR011035;IPR014729;	brain development [GO:0007420]; glutaminyl-tRNA aminoacylation [GO:0006425]; tRNA aminoacylation for protein translation [GO:0006418]	ATP binding [GO:0005524]; glutamine-tRNA ligase activity [GO:0004819]; RNA binding [GO:0003723]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
P49591	SYS_HUMAN	Serine--tRNA ligase, cytoplasmic (EC 6.1.1.11) (Seryl-tRNA synthetase) (SerRS) (Seryl-tRNA(Ser/Sec) synthetase)	SARS SERS	3VBB;4L87;4RQE;4RQF;			DB00133;	PATHWAY: Aminoacyl-tRNA biosynthesis; selenocysteinyl-tRNA(Sec) biosynthesis; L-seryl-tRNA(Sec) from L-serine and tRNA(Sec): step 1/1.	PF02403;PF00587;	IPR002314;IPR006195;IPR002317;IPR015866;IPR033729;IPR010978;	selenocysteine metabolic process [GO:0016259]; selenocysteinyl-tRNA(Sec) biosynthetic process [GO:0097056]; seryl-tRNA aminoacylation [GO:0006434]; translation [GO:0006412]; tRNA aminoacylation for protein translation [GO:0006418]; tRNA processing [GO:0008033]	ATP binding [GO:0005524]; RNA binding [GO:0003723]; selenocysteine-tRNA ligase activity [GO:0098619]; serine-tRNA ligase activity [GO:0004828]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
P26639	SYTC_HUMAN	Threonine--tRNA ligase, cytoplasmic (EC 6.1.1.3) (Threonyl-tRNA synthetase) (ThrRS)	TARS	1WWT;4HWT;4P3N;4TTV;	CHEMBL3391;	P26639;	DB00156;		PF03129;PF02824;PF00587;PF07973;	IPR002314;IPR006195;IPR004154;IPR012675;IPR004095;IPR012676;IPR002320;IPR018163;IPR033728;IPR012947;	threonyl-tRNA aminoacylation [GO:0006435]; translation [GO:0006412]; tRNA aminoacylation for protein translation [GO:0006418]	ATP binding [GO:0005524]; protein homodimerization activity [GO:0042803]; RNA binding [GO:0003723]; threonine-tRNA ligase activity [GO:0004829]	actin cytoskeleton [GO:0015629]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]
Q9BW92	SYTM_HUMAN	Threonine--tRNA ligase, mitochondrial (EC 6.1.1.3) (Threonyl-tRNA synthetase) (ThrRS) (Threonyl-tRNA synthetase-like 1)	TARS2 TARSL1		CHEMBL3351186;		DB00156;		PF03129;PF02824;PF00587;PF07973;	IPR002314;IPR006195;IPR004154;IPR012675;IPR004095;IPR012676;IPR002320;IPR018163;IPR033728;IPR012947;	mitochondrial threonyl-tRNA aminoacylation [GO:0070159]	ATP binding [GO:0005524]; RNA binding [GO:0003723]; threonine-tRNA ligase activity [GO:0004829]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
P37840	SYUA_HUMAN	Alpha-synuclein (Non-A beta component of AD amyloid) (Non-A4 component of amyloid precursor) (NACP)	SNCA NACP PARK1	1XQ8;2JN5;2KKW;2M55;2N0A;2X6M;3Q25;3Q26;3Q27;3Q28;3Q29;4BXL;4R0U;4R0W;4RIK;4RIL;4ZNN;5CRW;	CHEMBL6152;	P37840;			PF01387;	IPR001058;IPR002460;	activation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0006919]; adult locomotory behavior [GO:0008344]; aging [GO:0007568]; behavioral response to cocaine [GO:0048148]; cellular protein metabolic process [GO:0044267]; cellular response to copper ion [GO:0071280]; cellular response to epinephrine stimulus [GO:0071872]; cellular response to fibroblast growth factor stimulus [GO:0044344]; cellular response to oxidative stress [GO:0034599]; dopamine biosynthetic process [GO:0042416]; dopamine uptake involved in synaptic transmission [GO:0051583]; excitatory postsynaptic potential [GO:0060079]; extracellular fibril organization [GO:0043206]; fatty acid metabolic process [GO:0006631]; long-term synaptic potentiation [GO:0060291]; microglial cell activation [GO:0001774]; mitochondrial ATP synthesis coupled electron transport [GO:0042775]; mitochondrial membrane organization [GO:0007006]; negative regulation of apoptotic process [GO:0043066]; negative regulation of chaperone-mediated autophagy [GO:1904715]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154]; negative regulation of dopamine metabolic process [GO:0045963]; negative regulation of dopamine uptake involved in synaptic transmission [GO:0051585]; negative regulation of exocytosis [GO:0045920]; negative regulation of histone acetylation [GO:0035067]; negative regulation of microtubule polymerization [GO:0031115]; negative regulation of mitochondrial electron transport, NADH to ubiquinone [GO:1902957]; negative regulation of monooxygenase activity [GO:0032769]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of neuron death [GO:1901215]; negative regulation of norepinephrine uptake [GO:0051622]; negative regulation of platelet-derived growth factor receptor signaling pathway [GO:0010642]; negative regulation of protein phosphorylation [GO:0001933]; negative regulation of serotonin uptake [GO:0051612]; negative regulation of thrombin receptor signaling pathway [GO:0070495]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; negative regulation of transporter activity [GO:0032410]; neutral lipid metabolic process [GO:0006638]; oxidation-reduction process [GO:0055114]; phospholipid metabolic process [GO:0006644]; positive regulation of apoptotic process [GO:0043065]; positive regulation of endocytosis [GO:0045807]; positive regulation of glutathione peroxidase activity [GO:1903284]; positive regulation of hydrogen peroxide catabolic process [GO:1903285]; positive regulation of inositol phosphate biosynthetic process [GO:0060732]; positive regulation of neurotransmitter secretion [GO:0001956]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of protein serine/threonine kinase activity [GO:0071902]; positive regulation of receptor recycling [GO:0001921]; positive regulation of release of sequestered calcium ion into cytosol [GO:0051281]; protein destabilization [GO:0031648]; receptor internalization [GO:0031623]; regulation of acyl-CoA biosynthetic process [GO:0050812]; regulation of dopamine secretion [GO:0014059]; regulation of glutamate secretion [GO:0014048]; regulation of locomotion [GO:0040012]; regulation of long-term neuronal synaptic plasticity [GO:0048169]; regulation of macrophage activation [GO:0043030]; regulation of phospholipase activity [GO:0010517]; regulation of reactive oxygen species biosynthetic process [GO:1903426]; regulation of synaptic vesicle recycling [GO:1903421]; response to drug [GO:0042493]; response to interferon-gamma [GO:0034341]; response to interleukin-1 [GO:0070555]; response to iron(II) ion [GO:0010040]; response to lipopolysaccharide [GO:0032496]; response to magnesium ion [GO:0032026]; synapse organization [GO:0050808]; synaptic vesicle endocytosis [GO:0048488]	alpha-tubulin binding [GO:0043014]; calcium ion binding [GO:0005509]; copper ion binding [GO:0005507]; cysteine-type endopeptidase inhibitor activity involved in apoptotic process [GO:0043027]; dynein binding [GO:0045502]; ferrous iron binding [GO:0008198]; histone binding [GO:0042393]; Hsp70 protein binding [GO:0030544]; identical protein binding [GO:0042802]; kinesin binding [GO:0019894]; magnesium ion binding [GO:0000287]; oxidoreductase activity [GO:0016491]; phospholipid binding [GO:0005543]; phosphoprotein binding [GO:0051219]; tau protein binding [GO:0048156]; transcription regulatory region DNA binding [GO:0044212]; zinc ion binding [GO:0008270]	actin cytoskeleton [GO:0015629]; axon [GO:0030424]; cell cortex [GO:0005938]; cell junction [GO:0030054]; cytoplasm [GO:0005737]; cytoplasmic vesicle membrane [GO:0030659]; cytosol [GO:0005829]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; fibril [GO:0043205]; Golgi apparatus [GO:0005794]; growth cone [GO:0030426]; inclusion body [GO:0016234]; lysosome [GO:0005764]; membrane [GO:0016020]; mitochondrion [GO:0005739]; nuclear outer membrane [GO:0005640]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; postsynapse [GO:0098794]; ribosome [GO:0005840]; rough endoplasmic reticulum [GO:0005791]; synaptic vesicle [GO:0008021]; terminal bouton [GO:0043195]
P26640	SYV_HUMAN	Valine--tRNA ligase (EC 6.1.1.9) (Protein G7a) (Valyl-tRNA synthetase) (ValRS)	VARS G7A VARS2		CHEMBL2612;	P26640;	DB00161;		PF08264;PF00043;PF00133;	IPR001412;IPR002300;IPR033705;IPR010987;IPR004046;IPR013155;IPR014729;IPR009080;IPR009008;IPR002303;	tRNA aminoacylation for protein translation [GO:0006418]; valyl-tRNA aminoacylation [GO:0006438]	aminoacyl-tRNA editing activity [GO:0002161]; ATP binding [GO:0005524]; valine-tRNA ligase activity [GO:0004832]	cytosol [GO:0005829]; mitochondrion [GO:0005739]
Q9UGM6	SYWM_HUMAN	Tryptophan--tRNA ligase, mitochondrial (EC 6.1.1.2) ((Mt)TrpRS) (Tryptophanyl-tRNA synthetase) (TrpRS)	WARS2				DB00150;		PF00579;	IPR001412;IPR002305;IPR014729;IPR002306;IPR024109;	tRNA aminoacylation for protein translation [GO:0006418]; tryptophanyl-tRNA aminoacylation [GO:0006436]; vasculogenesis [GO:0001570]	ATP binding [GO:0005524]; tryptophan-tRNA ligase activity [GO:0004830]	mitochondrial matrix [GO:0005759]
P23381	SYW_HUMAN	Tryptophan--tRNA ligase, cytoplasmic (EC 6.1.1.2) (Interferon-induced protein 53) (IFP53) (Tryptophanyl-tRNA synthetase) (TrpRS) (hWRS) [Cleaved into: T1-TrpRS; T2-TrpRS]	WARS IFI53 WRS	1O5T;1R6T;1R6U;1ULH;2AKE;2AZX;2DR2;2QUH;2QUI;2QUJ;2QUK;			DB00150;		PF00579;PF00458;	IPR001412;IPR002305;IPR014729;IPR009068;IPR002306;IPR000738;	angiogenesis [GO:0001525]; negative regulation of cell proliferation [GO:0008285]; regulation of angiogenesis [GO:0045765]; translation [GO:0006412]; tRNA aminoacylation for protein translation [GO:0006418]; tryptophanyl-tRNA aminoacylation [GO:0006436]	ATP binding [GO:0005524]; tryptophan-tRNA ligase activity [GO:0004830]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleus [GO:0005634]
P54577	SYYC_HUMAN	Tyrosine--tRNA ligase, cytoplasmic (EC 6.1.1.1) (Tyrosyl-tRNA synthetase) (TyrRS) [Cleaved into: Tyrosine--tRNA ligase, cytoplasmic, N-terminally processed]	YARS	1N3L;1NTG;1Q11;4Q93;4QBT;	CHEMBL3179;	P54577;	DB00135;		PF00579;PF01588;	IPR002305;IPR012340;IPR014729;IPR002547;IPR002307;	apoptotic process [GO:0006915]; tRNA aminoacylation for protein translation [GO:0006418]; tyrosyl-tRNA aminoacylation [GO:0006437]; valyl-tRNA aminoacylation [GO:0006438]	ATP binding [GO:0005524]; interleukin-8 receptor binding [GO:0005153]; poly(A) RNA binding [GO:0044822]; signal transducer activity [GO:0004871]; tRNA binding [GO:0000049]; tyrosine-tRNA ligase activity [GO:0004831]; valine-tRNA ligase activity [GO:0004832]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular space [GO:0005615]; nucleus [GO:0005634]
Q9Y2Z4	SYYM_HUMAN	Tyrosine--tRNA ligase, mitochondrial (EC 6.1.1.1) (Tyrosyl-tRNA synthetase) (TyrRS)	YARS2 CGI-04	2PID;3ZXI;			DB00135;		PF00579;	IPR001412;IPR002305;IPR014729;IPR002942;IPR002307;IPR024088;	mitochondrial tyrosyl-tRNA aminoacylation [GO:0070184]; translation [GO:0006412]; tRNA aminoacylation [GO:0043039]; tRNA aminoacylation for protein translation [GO:0006418]	ATP binding [GO:0005524]; poly(A) RNA binding [GO:0044822]; protein homodimerization activity [GO:0042803]; tRNA binding [GO:0000049]; tyrosine binding [GO:0072545]; tyrosine-tRNA ligase activity [GO:0004831]	cytosol [GO:0005829]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
P21731	TA2R_HUMAN	Thromboxane A2 receptor (TXA2-R) (Prostanoid TP receptor)	TBXA2R	1LBN;	CHEMBL2069;	P21731;	DB01207;		PF00001;	IPR000276;IPR017452;IPR008365;IPR001105;	adenylate cyclase-activating G-protein coupled receptor signaling pathway [GO:0007189]; cellular response to lipopolysaccharide [GO:0071222]; G-protein coupled receptor signaling pathway [GO:0007186]; inflammatory response [GO:0006954]; positive regulation of angiogenesis [GO:0045766]; positive regulation of blood coagulation [GO:0030194]; positive regulation of blood pressure [GO:0045777]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of smooth muscle contraction [GO:0045987]; positive regulation of vasoconstriction [GO:0045907]; response to drug [GO:0042493]; response to ethanol [GO:0045471]; response to nutrient [GO:0007584]; response to testosterone [GO:0033574]; second-messenger-mediated signaling [GO:0019932]	guanyl-nucleotide exchange factor activity [GO:0005085]; thromboxane A2 receptor activity [GO:0004961]	acrosomal vesicle [GO:0001669]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
Q96RJ0	TAAR1_HUMAN	Trace amine-associated receptor 1 (TaR-1) (Trace amine receptor 1)	TAAR1 TA1 TAR1 TRAR1		CHEMBL5857;	Q96RJ0;	DB00182;DB01576;DB01577;DB06714;		PF00001;	IPR000276;IPR017452;IPR009133;IPR009132;	cAMP biosynthetic process [GO:0006171]; G-protein coupled receptor signaling pathway [GO:0007186]	G-protein coupled receptor activity [GO:0004930]; trace-amine receptor activity [GO:0001594]	integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]
Q03518	TAP1_HUMAN	Antigen peptide transporter 1 (APT1) (ATP-binding cassette sub-family B member 2) (Peptide supply factor 1) (Peptide transporter PSF1) (PSF-1) (Peptide transporter TAP1) (Peptide transporter involved in antigen processing 1) (Really interesting new gene 4 protein)	TAP1 ABCB2 PSF1 RING4 Y3	1JJ7;			DB01259;		PF00664;PF00005;	IPR003593;IPR011527;IPR013305;IPR003439;IPR017871;IPR027417;IPR013306;	adaptive immune response [GO:0002250]; antigen processing and presentation of endogenous peptide antigen via MHC class I [GO:0019885]; antigen processing and presentation of endogenous peptide antigen via MHC class Ib via ER pathway, TAP-dependent [GO:0002489]; antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-dependent [GO:0002485]; antigen processing and presentation of exogenous protein antigen via MHC class Ib, TAP-dependent [GO:0002481]; antigen processing and presentation of peptide antigen via MHC class I [GO:0002474]; cytosol to ER transport [GO:0046967]; defense response [GO:0006952]; intracellular transport of viral protein in host cell [GO:0019060]; peptide transport [GO:0015833]; positive regulation of antigen processing and presentation of peptide antigen via MHC class I [GO:0002591]; transmembrane transport [GO:0055085]	ADP binding [GO:0043531]; ATPase activity, coupled to transmembrane movement of substances [GO:0042626]; ATP binding [GO:0005524]; MHC class Ib protein binding [GO:0023029]; peptide antigen binding [GO:0042605]; peptide antigen-transporting ATPase activity [GO:0015433]; peptide transporter activity [GO:0015197]; protein homodimerization activity [GO:0042803]; TAP1 binding [GO:0046978]; TAP2 binding [GO:0046979]	endoplasmic reticulum membrane [GO:0005789]; host cell [GO:0043657]; integral component of endoplasmic reticulum membrane [GO:0030176]; integral component of membrane [GO:0016021]; membrane [GO:0016020]; mitochondrion [GO:0005739]; TAP complex [GO:0042825]
P68366	TBA1_HUMAN	Tubulin alpha-4A chain (Alpha-tubulin 1) (Testis-specific alpha-tubulin) (Tubulin H2-alpha) (Tubulin alpha-1 chain)	TUBA4A TUBA1		CHEMBL2095182;		DB06772;DB01179;DB00541;		PF00091;PF03953;	IPR002452;IPR008280;IPR000217;IPR018316;IPR023123;IPR017975;IPR003008;	G2/M transition of mitotic cell cycle [GO:0000086]; microtubule-based process [GO:0007017]; platelet degranulation [GO:0002576]	GTPase activity [GO:0003924]; GTP binding [GO:0005525]; structural constituent of cytoskeleton [GO:0005200]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; microtubule [GO:0005874]
Q13748	TBA2_HUMAN	Tubulin alpha-3C/D chain (Alpha-tubulin 2) (Alpha-tubulin 3C/D) (Tubulin alpha-2 chain) [Cleaved into: Detyrosinated tubulin alpha-3C/D chain]	TUBA3C TUBA2; TUBA3D		CHEMBL2095182;				PF00091;PF03953;	IPR002452;IPR008280;IPR000217;IPR018316;IPR023123;IPR017975;IPR003008;	microtubule-based process [GO:0007017]	GTPase activity [GO:0003924]; GTP binding [GO:0005525]; structural constituent of cytoskeleton [GO:0005200]	cytoplasm [GO:0005737]; microtubule [GO:0005874]; nucleus [GO:0005634]
Q71U36	TBA3_HUMAN	Tubulin alpha-1A chain (Alpha-tubulin 3) (Tubulin B-alpha-1) (Tubulin alpha-3 chain) [Cleaved into: Detyrosinated tubulin alpha-1A chain]	TUBA1A TUBA3	5JCO;	CHEMBL2095182;		DB00518;DB00643;DB00570;		PF00091;PF03953;	IPR002452;IPR008280;IPR000217;IPR018316;IPR023123;IPR017975;IPR003008;	cell division [GO:0051301]; cytoskeleton-dependent intracellular transport [GO:0030705]; G2/M transition of mitotic cell cycle [GO:0000086]; microtubule-based process [GO:0007017]	GTPase activity [GO:0003924]; GTP binding [GO:0005525]; structural constituent of cytoskeleton [GO:0005200]; structural molecule activity [GO:0005198]	cytoplasmic microtubule [GO:0005881]; cytoplasmic ribonucleoprotein granule [GO:0036464]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; microtubule [GO:0005874]; myelin sheath [GO:0043209]; nucleus [GO:0005634]; recycling endosome [GO:0055037]
Q9BQE3	TBA6_HUMAN	Tubulin alpha-1C chain (Alpha-tubulin 6) (Tubulin alpha-6 chain) [Cleaved into: Detyrosinated tubulin alpha-1C chain]	TUBA1C TUBA6		CHEMBL2095182;				PF00091;PF03953;	IPR002452;IPR008280;IPR000217;IPR018316;IPR023123;IPR017975;IPR003008;	cell division [GO:0051301]; cytoskeleton-dependent intracellular transport [GO:0030705]; microtubule-based process [GO:0007017]	GTPase activity [GO:0003924]; GTP binding [GO:0005525]; structural constituent of cytoskeleton [GO:0005200]; structural molecule activity [GO:0005198]	cytoplasm [GO:0005737]; microtubule [GO:0005874]; nucleus [GO:0005634]; vesicle [GO:0031982]
Q9NY65	TBA8_HUMAN	Tubulin alpha-8 chain (Alpha-tubulin 8) (Tubulin alpha chain-like 2)	TUBA8 TUBAL2						PF00091;PF03953;	IPR002452;IPR008280;IPR000217;IPR018316;IPR023123;IPR017975;IPR003008;	microtubule-based process [GO:0007017]	GTPase activity [GO:0003924]; GTP binding [GO:0005525]; structural constituent of cytoskeleton [GO:0005200]	cytoplasm [GO:0005737]; microtubule [GO:0005874]
P68363	TBAK_HUMAN	Tubulin alpha-1B chain (Alpha-tubulin ubiquitous) (Tubulin K-alpha-1) (Tubulin alpha-ubiquitous chain) [Cleaved into: Detyrosinated tubulin alpha-1B chain]	TUBA1B	2E4H;5IJ0;5IJ9;	CHEMBL2095182;				PF00091;PF03953;	IPR002452;IPR008280;IPR000217;IPR018316;IPR023123;IPR017975;IPR003008;	cell division [GO:0051301]; cellular response to interleukin-4 [GO:0071353]; cytoskeleton-dependent intracellular transport [GO:0030705]; microtubule-based process [GO:0007017]; microtubule cytoskeleton organization [GO:0000226]	double-stranded RNA binding [GO:0003725]; GTPase activity [GO:0003924]; GTP binding [GO:0005525]; structural constituent of cytoskeleton [GO:0005200]; structural molecule activity [GO:0005198]; ubiquitin protein ligase binding [GO:0031625]	cytoplasmic microtubule [GO:0005881]; extracellular exosome [GO:0070062]; microtubule [GO:0005874]; myelin sheath [GO:0043209]
Q9H4B7	TBB1_HUMAN	Tubulin beta-1 chain	TUBB1		CHEMBL1915;	Q9H4B7;	DB06772;DB01394;DB01248;DB01229;DB00309;		PF00091;PF03953;	IPR013838;IPR002453;IPR008280;IPR000217;IPR018316;IPR023123;IPR017975;IPR003008;	spindle assembly [GO:0051225]	GTPase activity [GO:0003924]; GTP binding [GO:0005525]; structural constituent of cytoskeleton [GO:0005200]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; microtubule [GO:0005874]
P68371	TBB2C_HUMAN,TBB2_HUMAN	Tubulin beta-4B chain (Tubulin beta-2 chain) (Tubulin beta-2C chain)	TUBB4B TUBB2C		CHEMBL1848;		DB00518;DB00643;		PF00091;PF03953;	IPR013838;IPR002453;IPR008280;IPR000217;IPR018316;IPR023123;IPR017975;IPR003008;	G2/M transition of mitotic cell cycle [GO:0000086]; microtubule-based process [GO:0007017]; movement of cell or subcellular component [GO:0006928]; natural killer cell mediated cytotoxicity [GO:0042267]	double-stranded RNA binding [GO:0003725]; GTPase activity [GO:0003924]; GTP binding [GO:0005525]; MHC class I protein binding [GO:0042288]; structural constituent of cytoskeleton [GO:0005200]; unfolded protein binding [GO:0051082]	cytoskeleton [GO:0005856]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular matrix [GO:0031012]; extracellular vesicle [GO:1903561]; microtubule [GO:0005874]; myelin sheath [GO:0043209]; nucleus [GO:0005634]
P07437	TBB2_HUMAN	Tubulin beta chain (Tubulin beta-5 chain)	TUBB TUBB5 OK/SW-cl.56	3QNZ;3QO0;	CHEMBL5444;		DB01394;DB01179;DB00570;DB00541;DB00361;		PF00091;PF03953;	IPR013838;IPR002453;IPR008280;IPR000217;IPR018316;IPR023123;IPR017975;IPR003008;	cell division [GO:0051301]; cellular process [GO:0009987]; cytoskeleton-dependent intracellular transport [GO:0030705]; G2/M transition of mitotic cell cycle [GO:0000086]; microtubule-based process [GO:0007017]; movement of cell or subcellular component [GO:0006928]; natural killer cell mediated cytotoxicity [GO:0042267]; spindle assembly [GO:0051225]	GTPase activity [GO:0003924]; GTP binding [GO:0005525]; MHC class I protein binding [GO:0042288]; structural constituent of cytoskeleton [GO:0005200]; structural molecule activity [GO:0005198]; ubiquitin protein ligase binding [GO:0031625]	cell body [GO:0044297]; cytoplasmic ribonucleoprotein granule [GO:0036464]; cytoskeleton [GO:0005856]; extracellular exosome [GO:0070062]; extracellular matrix [GO:0031012]; extracellular region [GO:0005576]; microtubule [GO:0005874]; nuclear envelope lumen [GO:0005641]; nucleus [GO:0005634]; protein complex [GO:0043234]
Q99867	TBB4Q_HUMAN	Deleted.
P78353	TBB4Q_HUMAN	Deleted.
Q13509	TBB3_HUMAN,TBB4_HUMAN	Tubulin beta-3 chain (Tubulin beta-4 chain) (Tubulin beta-III)	TUBB3 TUBB4	5IJ0;5IJ9;5JCO;	CHEMBL2597;		DB04845;		PF00091;PF03953;	IPR013838;IPR002453;IPR008280;IPR000217;IPR018316;IPR023123;IPR017975;IPR003008;	axon guidance [GO:0007411]; microtubule-based process [GO:0007017]; mitotic nuclear division [GO:0007067]	GTPase activity [GO:0003924]; GTP binding [GO:0005525]; peptide binding [GO:0042277]; structural constituent of cytoskeleton [GO:0005200]	axon [GO:0030424]; cell periphery [GO:0071944]; cytoplasm [GO:0005737]; dendrite [GO:0030425]; extracellular exosome [GO:0070062]; microtubule [GO:0005874]; neuronal cell body [GO:0043025]; nucleus [GO:0005634]
P04350	TBB4_HUMAN	Tubulin beta-4A chain (Tubulin 5 beta) (Tubulin beta-4 chain)	TUBB4A TUBB4 TUBB5		CHEMBL2095182;				PF00091;PF03953;	IPR013838;IPR002453;IPR008280;IPR000217;IPR018316;IPR023123;IPR017975;IPR003008;	G2/M transition of mitotic cell cycle [GO:0000086]; microtubule-based process [GO:0007017]	GTPase activity [GO:0003924]; GTP binding [GO:0005525]; structural constituent of cytoskeleton [GO:0005200]	cilium [GO:0005929]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; internode region of axon [GO:0033269]; microtubule [GO:0005874]; myelin sheath [GO:0043209]; neuronal cell body [GO:0043025]; nucleus [GO:0005634]
O75347	TBCA_HUMAN	Tubulin-specific chaperone A (TCP1-chaperonin cofactor A) (Tubulin-folding cofactor A) (CFA)	TBCA	1H7C;					PF02970;	IPR004226;	post-chaperonin tubulin folding pathway [GO:0007023]; protein folding [GO:0006457]; tubulin complex assembly [GO:0007021]	chaperone binding [GO:0051087]; poly(A) RNA binding [GO:0044822]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; microtubule [GO:0005874]; microtubule cytoskeleton [GO:0015630]; nucleolus [GO:0005730]
P20061	TCO1_HUMAN	Transcobalamin-1 (TC-1) (Haptocorrin) (HC) (Protein R) (Transcobalamin I) (TC I) (TCI)	TCN1 TC1	2CKV;4KKI;4KKJ;			DB00115;DB00200;		PF01122;PF14478;	IPR002157;IPR027954;	cobalamin metabolic process [GO:0009235]; cobalamin transport [GO:0015889]; cobalt ion transport [GO:0006824]	cobalamin binding [GO:0031419]	extracellular region [GO:0005576]; extracellular space [GO:0005615]
P20062	TCO2_HUMAN	Transcobalamin-2 (TC-2) (Transcobalamin II) (TC II) (TCII)	TCN2 TC2	2BB5;4ZRP;4ZRQ;			DB00115;DB00200;		PF01122;PF14478;	IPR002157;IPR027954;IPR008930;	cobalamin metabolic process [GO:0009235]; cobalamin transport [GO:0015889]; cobalt ion transport [GO:0006824]	cobalamin binding [GO:0031419]; metal ion binding [GO:0046872]	endosome [GO:0005768]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; lysosomal lumen [GO:0043202]
P37173	TGFR2_HUMAN	TGF-beta receptor type-2 (TGFR-2) (EC 2.7.11.30) (TGF-beta type II receptor) (Transforming growth factor-beta receptor type II) (TGF-beta receptor type II) (TbetaR-II)	TGFBR2	1KTZ;1M9Z;1PLO;2PJY;3KFD;4P7U;4XJJ;5E8V;5E8Y;5E91;5E92;	CHEMBL4267;	P37173;			PF08917;PF07714;	IPR011009;IPR000719;IPR017441;IPR001245;IPR008271;IPR000333;IPR017194;IPR015013;	activation of protein kinase activity [GO:0032147]; aging [GO:0007568]; animal organ regeneration [GO:0031100]; apoptotic process [GO:0006915]; atrioventricular valve morphogenesis [GO:0003181]; blood vessel development [GO:0001568]; brain development [GO:0007420]; bronchus morphogenesis [GO:0060434]; cardiac left ventricle morphogenesis [GO:0003214]; common-partner SMAD protein phosphorylation [GO:0007182]; digestive tract development [GO:0048565]; embryo implantation [GO:0007566]; embryonic cranial skeleton morphogenesis [GO:0048701]; embryonic hemopoiesis [GO:0035162]; endocardial cushion fusion [GO:0003274]; gastrulation [GO:0007369]; growth plate cartilage chondrocyte growth [GO:0003430]; heart development [GO:0007507]; heart looping [GO:0001947]; in utero embryonic development [GO:0001701]; lens development in camera-type eye [GO:0002088]; lens fiber cell apoptotic process [GO:1990086]; lung lobe morphogenesis [GO:0060463]; mammary gland morphogenesis [GO:0060443]; membranous septum morphogenesis [GO:0003149]; myeloid dendritic cell differentiation [GO:0043011]; negative regulation of cardiac muscle cell proliferation [GO:0060044]; negative regulation of transforming growth factor beta receptor signaling pathway [GO:0030512]; Notch signaling pathway [GO:0007219]; outflow tract morphogenesis [GO:0003151]; outflow tract septum morphogenesis [GO:0003148]; palate development [GO:0060021]; pathway-restricted SMAD protein phosphorylation [GO:0060389]; patterning of blood vessels [GO:0001569]; peptidyl-serine phosphorylation [GO:0018105]; peptidyl-threonine phosphorylation [GO:0018107]; positive regulation of angiogenesis [GO:0045766]; positive regulation of B cell tolerance induction [GO:0002663]; positive regulation of cell proliferation [GO:0008284]; positive regulation of epithelial cell migration [GO:0010634]; positive regulation of epithelial to mesenchymal transition [GO:0010718]; positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation [GO:1905007]; positive regulation of mesenchymal cell proliferation [GO:0002053]; positive regulation of NK T cell differentiation [GO:0051138]; positive regulation of reactive oxygen species metabolic process [GO:2000379]; positive regulation of skeletal muscle tissue regeneration [GO:0043415]; positive regulation of smooth muscle cell proliferation [GO:0048661]; positive regulation of T cell tolerance induction [GO:0002666]; positive regulation of tolerance induction to self antigen [GO:0002651]; protein phosphorylation [GO:0006468]; receptor-mediated endocytosis [GO:0006898]; regulation of cell proliferation [GO:0042127]; regulation of gene expression [GO:0010468]; response to cholesterol [GO:0070723]; response to drug [GO:0042493]; response to estrogen [GO:0043627]; response to glucose [GO:0009749]; response to hypoxia [GO:0001666]; response to mechanical stimulus [GO:0009612]; response to nutrient [GO:0007584]; response to steroid hormone [GO:0048545]; smoothened signaling pathway [GO:0007224]; trachea formation [GO:0060440]; transforming growth factor beta receptor signaling pathway [GO:0007179]; tricuspid valve morphogenesis [GO:0003186]; vasculogenesis [GO:0001570]; ventricular septum morphogenesis [GO:0060412]; wound healing [GO:0042060]	ATP binding [GO:0005524]; glycosaminoglycan binding [GO:0005539]; metal ion binding [GO:0046872]; receptor signaling protein serine/threonine kinase activity [GO:0004702]; SMAD binding [GO:0046332]; transforming growth factor beta-activated receptor activity [GO:0005024]; transforming growth factor beta binding [GO:0050431]; transforming growth factor beta receptor activity, type II [GO:0005026]; transmembrane receptor protein serine/threonine kinase activity [GO:0004675]; type III transforming growth factor beta receptor binding [GO:0034714]; type I transforming growth factor beta receptor binding [GO:0034713]	caveola [GO:0005901]; cytosol [GO:0005829]; external side of plasma membrane [GO:0009897]; integral component of membrane [GO:0016021]; membrane raft [GO:0045121]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]; transforming growth factor beta receptor homodimeric complex [GO:0070022]
P22735	TGM1_HUMAN	Protein-glutamine gamma-glutamyltransferase K (EC 2.3.2.13) (Epidermal TGase) (Transglutaminase K) (TG(K)) (TGK) (TGase K) (Transglutaminase-1) (TGase-1)	TGM1 KTG	2XZZ;	CHEMBL2810;	P22735;	DB00130;		PF00927;PF01841;PF00868;	IPR023608;IPR013783;IPR014756;IPR002931;IPR013808;IPR008958;IPR001102;	cell envelope organization [GO:0043163]; cellular protein modification process [GO:0006464]; keratinization [GO:0031424]; keratinocyte differentiation [GO:0030216]; peptide cross-linking [GO:0018149]; positive regulation of cell cycle [GO:0045787]; positive regulation of keratinocyte proliferation [GO:0010838]	metal ion binding [GO:0046872]; protein-glutamine gamma-glutamyltransferase activity [GO:0003810]	cornified envelope [GO:0001533]; extracellular exosome [GO:0070062]; intrinsic component of membrane [GO:0031224]
P21980	TGM2_HUMAN	Protein-glutamine gamma-glutamyltransferase 2 (EC 2.3.2.13) (Tissue transglutaminase) (Transglutaminase C) (TG(C)) (TGC) (TGase C) (Transglutaminase H) (TGase H) (Transglutaminase-2) (TGase-2)	TGM2	1FAU;1KV3;2Q3Z;3LY6;3S3J;3S3P;3S3S;4PYG;	CHEMBL2730;	P21980;	DB00130;		PF00927;PF01841;PF00868;	IPR023608;IPR013783;IPR014756;IPR002931;IPR013808;IPR008958;IPR001102;	apoptotic cell clearance [GO:0043277]; blood vessel remodeling [GO:0001974]; branching involved in salivary gland morphogenesis [GO:0060445]; isopeptide cross-linking via N6-(L-isoglutamyl)-L-lysine [GO:0018153]; negative regulation of endoplasmic reticulum calcium ion concentration [GO:0032471]; positive regulation of apoptotic process [GO:0043065]; positive regulation of cell adhesion [GO:0045785]; positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway [GO:0051482]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of inflammatory response [GO:0050729]; positive regulation of mitochondrial calcium ion concentration [GO:0051561]; positive regulation of smooth muscle cell proliferation [GO:0048661]; protein homooligomerization [GO:0051260]; salivary gland cavitation [GO:0060662]	GTP binding [GO:0005525]; metal ion binding [GO:0046872]; protein-glutamine gamma-glutamyltransferase activity [GO:0003810]	cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; extracellular exosome [GO:0070062]; extracellular matrix [GO:0031012]; focal adhesion [GO:0005925]; intrinsic component of plasma membrane [GO:0031226]; mitochondrion [GO:0005739]
O95932	TGM3L_HUMAN	Protein-glutamine gamma-glutamyltransferase 6 (EC 2.3.2.13) (Transglutaminase Y) (TGY) (TGase Y) (Transglutaminase-3-like) (TGase-3-like) (Transglutaminase-6) (TG6) (TGase-6)	TGM6 TGM3L		CHEMBL2079852;	O95932;	DB00130;		PF00927;PF01841;PF00868;	IPR023608;IPR013783;IPR014756;IPR002931;IPR013808;IPR008958;IPR001102;	peptide cross-linking [GO:0018149]	metal ion binding [GO:0046872]; protein-glutamine gamma-glutamyltransferase activity [GO:0003810]	cytoplasm [GO:0005737]
Q08188	TGM3_HUMAN	Protein-glutamine gamma-glutamyltransferase E (EC 2.3.2.13) (Transglutaminase E) (TG(E)) (TGE) (TGase E) (Transglutaminase-3) (TGase-3) [Cleaved into: Protein-glutamine gamma-glutamyltransferase E 50 kDa catalytic chain; Protein-glutamine gamma-glutamyltransferase E 27 kDa non-catalytic chain]	TGM3	1L9M;1L9N;1NUD;1NUF;1NUG;	CHEMBL3363;	Q08188;	DB00130;		PF00927;PF01841;PF00868;	IPR023608;IPR013783;IPR014756;IPR002931;IPR013808;IPR008958;IPR001102;	cell envelope organization [GO:0043163]; cellular protein modification process [GO:0006464]; hair follicle morphogenesis [GO:0031069]; keratinization [GO:0031424]; keratinocyte differentiation [GO:0030216]; peptide cross-linking [GO:0018149]; protein tetramerization [GO:0051262]	calcium ion binding [GO:0005509]; catalytic activity [GO:0003824]; protein-glutamine gamma-glutamyltransferase activity [GO:0003810]; transferase activity, transferring acyl groups [GO:0016746]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; extrinsic component of cytoplasmic side of plasma membrane [GO:0031234]
P49221	TGM4_HUMAN	Protein-glutamine gamma-glutamyltransferase 4 (EC 2.3.2.13) (Fibrinoligase) (Prostate transglutaminase) (Prostate-specific transglutaminase) (Transglutaminase P) (TG(P)) (TGP) (TGase P) (Transglutaminase-4) (TGase-4)	TGM4				DB00130;		PF00927;PF01841;PF00868;	IPR023608;IPR013783;IPR014756;IPR002931;IPR013808;IPR008958;IPR001102;	peptide cross-linking [GO:0018149]	metal ion binding [GO:0046872]; protein-glutamine gamma-glutamyltransferase activity [GO:0003810]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; extracellular matrix [GO:0031012]; Golgi apparatus [GO:0005794]
O43548	TGM5_HUMAN	Protein-glutamine gamma-glutamyltransferase 5 (EC 2.3.2.13) (Transglutaminase X) (TG(X)) (TGX) (TGase X) (Transglutaminase-5) (TGase-5)	TGM5 TGMX				DB00130;		PF00927;PF01841;PF00868;	IPR023608;IPR013783;IPR014756;IPR002931;IPR013808;IPR008958;IPR001102;	cellular protein modification process [GO:0006464]; epidermis development [GO:0008544]; peptide cross-linking [GO:0018149]	metal ion binding [GO:0046872]; protein-glutamine gamma-glutamyltransferase activity [GO:0003810]	cytoplasm [GO:0005737]
Q96PF1	TGM7_HUMAN	Protein-glutamine gamma-glutamyltransferase Z (Transglutaminase Z) (TG(Z)) (TGZ) (TGase Z) (EC 2.3.2.13) (Transglutaminase-7) (TGase-7)	TGM7				DB00130;		PF00927;PF01841;PF00868;	IPR023608;IPR013783;IPR014756;IPR002931;IPR013808;IPR008958;IPR001102;	peptide cross-linking [GO:0018149]	metal ion binding [GO:0046872]; protein-glutamine gamma-glutamyltransferase activity [GO:0003810]
P24557	O14987_HUMAN,THAS_HUMAN	Thromboxane-A synthase (TXA synthase) (TXS) (EC 5.3.99.5) (Cytochrome P450 5A1)	TBXAS1 CYP5 CYP5A1		CHEMBL1835;	P24557;	DB01207;DB00795;		PF00067;	IPR001128;IPR017972;IPR002401;	cyclooxygenase pathway [GO:0019371]; icosanoid metabolic process [GO:0006690]	12-hydroxyheptadecatrienoic acid synthase activity [GO:0036134]; heme binding [GO:0020037]; iron ion binding [GO:0005506]; monooxygenase activity [GO:0004497]; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen [GO:0016705]; thromboxane-A synthase activity [GO:0004796]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]
P10827	THA_HUMAN	Thyroid hormone receptor alpha (Nuclear receptor subfamily 1 group A member 1) (V-erbA-related protein 7) (EAR-7) (c-erbA-1) (c-erbA-alpha)	THRA EAR7 ERBA1 NR1A1 THRA1 THRA2	1NAV;2H77;2H79;3HZF;3ILZ;3JZB;4LNW;4LNX;	CHEMBL1860;	P10827;	DB00509;DB00451;DB00279;DB01583;		PF00104;PF00105;	IPR000536;IPR001723;IPR001728;IPR001628;IPR013088;	cartilage condensation [GO:0001502]; cytoplasmic sequestering of transcription factor [GO:0042994]; erythrocyte differentiation [GO:0030218]; female courtship behavior [GO:0008050]; hormone-mediated signaling pathway [GO:0009755]; learning or memory [GO:0007611]; negative regulation of DNA-templated transcription, initiation [GO:2000143]; negative regulation of RNA polymerase II transcriptional preinitiation complex assembly [GO:0017055]; negative regulation of transcription, DNA-templated [GO:0045892]; ossification [GO:0001503]; positive regulation of female receptivity [GO:0045925]; positive regulation of myotube differentiation [GO:0010831]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; regulation of heart contraction [GO:0008016]; regulation of lipid catabolic process [GO:0050994]; regulation of myeloid cell apoptotic process [GO:0033032]; regulation of thyroid hormone mediated signaling pathway [GO:0002155]; regulation of transcription from RNA polymerase II promoter [GO:0006357]; response to cold [GO:0009409]; thyroid gland development [GO:0030878]; transcription from RNA polymerase II promoter [GO:0006366]; transcription initiation from RNA polymerase II promoter [GO:0006367]; Type I pneumocyte differentiation [GO:0060509]	chromatin DNA binding [GO:0031490]; protein domain specific binding [GO:0019904]; steroid hormone receptor activity [GO:0003707]; steroid receptor RNA activator RNA binding [GO:0002153]; TBP-class protein binding [GO:0017025]; thyroid hormone binding [GO:0070324]; thyroid hormone receptor activity [GO:0004887]; transcription factor activity, sequence-specific DNA binding [GO:0003700]; transcription factor binding [GO:0008134]; transcription regulatory region DNA binding [GO:0044212]; transcription regulatory region sequence-specific DNA binding [GO:0000976]; zinc ion binding [GO:0008270]	cytosol [GO:0005829]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P10828	THB1_HUMAN,THB2_HUMAN	Thyroid hormone receptor beta (Nuclear receptor subfamily 1 group A member 2) (c-erbA-2) (c-erbA-beta)	THRB ERBA2 NR1A2 THR1	1BSX;1N46;1NAX;1NQ0;1NQ1;1NQ2;1NUO;1Q4X;1R6G;1XZX;1Y0X;2J4A;2NLL;2PIN;3D57;3GWS;3IMY;3JZC;4ZO1;	CHEMBL1947;	P10828;	DB00509;DB00451;DB00279;DB01583;		PF00104;PF00105;	IPR000536;IPR001723;IPR001728;IPR001628;IPR013088;	animal organ morphogenesis [GO:0009887]; female courtship behavior [GO:0008050]; negative regulation of female receptivity [GO:0007621]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; regulation of heart contraction [GO:0008016]; sensory perception of sound [GO:0007605]; transcription, DNA-templated [GO:0006351]; transcription initiation from RNA polymerase II promoter [GO:0006367]; Type I pneumocyte differentiation [GO:0060509]	chromatin DNA binding [GO:0031490]; DNA binding [GO:0003677]; enzyme binding [GO:0019899]; sequence-specific DNA binding [GO:0043565]; steroid hormone receptor activity [GO:0003707]; thyroid hormone binding [GO:0070324]; thyroid hormone receptor activity [GO:0004887]; transcription corepressor activity [GO:0003714]; transcription factor activity, sequence-specific DNA binding [GO:0003700]; zinc ion binding [GO:0008270]	extracellular exosome [GO:0070062]; nuclear chromatin [GO:0000790]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P05543	THBG_HUMAN	Thyroxine-binding globulin (Serpin A7) (T4-binding globulin)	SERPINA7 TBG	2CEO;2RIV;2RIW;2XN3;2XN5;2XN6;2XN7;4X30;4YIA;	CHEMBL3843;		DB00451;DB00279;DB01583;		PF00079;	IPR023795;IPR023796;IPR000215;	thyroid hormone transport [GO:0070327]	serine-type endopeptidase inhibitor activity [GO:0004867]	extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]
Q8IV48	THEX1_HUMAN	3'-5' exoribonuclease 1 (EC 3.1.-.-) (3'-5' exonuclease ERI1) (Eri-1 homolog) (Histone mRNA 3'-end-specific exoribonuclease) (Histone mRNA 3'-exonuclease 1) (Protein 3'hExo) (HEXO)	ERI1 3'EXO THEX1	1W0H;1ZBH;1ZBU;4L8R;4QOZ;					PF00929;PF02037;	IPR013520;IPR012337;IPR003034;	exonucleolytic trimming to generate mature 3'-end of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) [GO:0000467]; gene silencing by RNA [GO:0031047]; rRNA 3'-end processing [GO:0031125]	3'-5' exonuclease activity [GO:0008408]; histone pre-mRNA stem-loop binding [GO:0071207]; metal ion binding [GO:0046872]; ribosome binding [GO:0043022]; rRNA binding [GO:0019843]	cytoplasm [GO:0005737]; histone pre-mRNA 3'end processing complex [GO:0071204]; nucleolus [GO:0005730]; nucleus [GO:0005634]
Q9BWD1	THIC_HUMAN	Acetyl-CoA acetyltransferase, cytosolic (EC 2.3.1.9) (Acetyl-CoA transferase-like protein) (Cytosolic acetoacetyl-CoA thiolase)	ACAT2 ACTL	1WL4;1WL5;					PF02803;PF00108;	IPR002155;IPR016039;IPR020610;IPR020617;IPR020613;IPR020616;	fatty acid beta-oxidation [GO:0006635]; lipid metabolic process [GO:0006629]	acetyl-CoA C-acetyltransferase activity [GO:0003985]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; mitochondrion [GO:0005739]; nucleolus [GO:0005730]; nucleus [GO:0005634]
P24752	THIL_HUMAN	Acetyl-CoA acetyltransferase, mitochondrial (EC 2.3.1.9) (Acetoacetyl-CoA thiolase) (T2)	ACAT1 ACAT MAT	2F2S;2IB7;2IB8;2IB9;2IBU;2IBW;2IBY;	CHEMBL2616;	P24752;	DB00795;		PF02803;PF00108;	IPR002155;IPR016039;IPR020615;IPR020610;IPR020617;IPR020613;IPR020616;	acetyl-CoA biosynthetic process [GO:0006085]; acetyl-CoA catabolic process [GO:0046356]; adipose tissue development [GO:0060612]; brain development [GO:0007420]; branched-chain amino acid catabolic process [GO:0009083]; coenzyme A biosynthetic process [GO:0015937]; coenzyme A metabolic process [GO:0015936]; fatty acid beta-oxidation [GO:0006635]; isoleucine catabolic process [GO:0006550]; ketone body biosynthetic process [GO:0046951]; ketone body catabolic process [GO:0046952]; ketone body metabolic process [GO:1902224]; liver development [GO:0001889]; metanephric proximal convoluted tubule development [GO:0072229]; propionyl-CoA biosynthetic process [GO:1902860]; protein homooligomerization [GO:0051260]; response to hormone [GO:0009725]; response to organic cyclic compound [GO:0014070]; response to starvation [GO:0042594]	acetyl-CoA C-acetyltransferase activity [GO:0003985]; carbon-carbon lyase activity [GO:0016830]; coenzyme binding [GO:0050662]; ligase activity, forming carbon-carbon bonds [GO:0016885]; metal ion binding [GO:0046872]	extracellular exosome [GO:0070062]; mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
Q8IYQ7	THNSL_HUMAN	Threonine synthase-like 1 (TSH1)	THNSL1				DB00156;		PF00291;PF01202;PF14821;	IPR027417;IPR031322;IPR000623;IPR029144;IPR004450;IPR001926;		pyridoxal phosphate binding [GO:0030170]	cytoplasm [GO:0005737]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P00734	THRB_HUMAN	Prothrombin (EC 3.4.21.5) (Coagulation factor II) [Cleaved into: Activation peptide fragment 1; Activation peptide fragment 2; Thrombin light chain; Thrombin heavy chain]	F2	1A2C;1A3B;1A3E;1A46;1A4W;1A5G;1A61;1ABI;1ABJ;1AD8;1AE8;1AFE;1AHT;1AI8;1AIX;1AWF;1AWH;1AY6;1B5G;1B7X;1BA8;1BB0;1BCU;1BHX;1BMM;1BMN;1BTH;1C1U;1C1V;1C1W;1C4U;1C4V;1C4Y;1C5L;1C5N;1C5O;1CA8;1D3D;1D3P;1D3Q;1D3T;1D4P;1D6W;1D9I;1DE7;1DIT;1DM4;1DOJ;1DWB;1DWC;1DWD;1DWE;1DX5;1E0F;1EB1;1EOJ;1EOL;1FPC;1FPH;1G30;1G32;1G37;1GHV;1GHW;1GHX;1GHY;1GJ4;1GJ5;1H8D;1H8I;1HAG;1HAH;1HAI;1HAO;1HAP;1HBT;1HDT;1HGT;1HLT;1HUT;1HXE;1HXF;1IHS;1IHT;1JMO;1JOU;1JWT;1K21;1K22;1KTS;1KTT;1LHC;1LHD;1LHE;1LHF;1LHG;1MH0;1MU6;1MU8;1MUE;1NM6;1NO9;1NRN;1NRO;1NRP;1NRQ;1NRR;1NRS;1NT1;1NU7;1NU9;1NY2;1NZQ;1O0D;1O2G;1O5G;1OOK;1OYT;1P8V;1PPB;1QBV;1QHR;1QJ1;1QJ6;1QJ7;1QUR;1RD3;1RIW;1SB1;1SFQ;1SG8;1SGI;1SHH;1SL3;1SR5;1T4U;1T4V;1TA2;1TA6;1TB6;1TBZ;1THP;1THR;1THS;1TMB;1TMT;1TMU;1TOM;1TQ0;1TQ7;1TWX;1UMA;1UVS;1VR1;1VZQ;1W7G;1WAY;1WBG;1XM1;1XMN;1YPE;1YPG;1YPJ;1YPK;1YPL;1YPM;1Z71;1Z8I;1Z8J;1ZGI;1ZGV;1ZRB;2A0Q;2A2X;2A45;2AFQ;2ANK;2ANM;2B5T;2BDY;2BVR;2BVS;2BVX;2BXT;2BXU;2C8W;2C8X;2C8Y;2C8Z;2C90;2C93;2CF8;2CF9;2CN0;2FEQ;2FES;2GDE;2GP9;2H9T;2HGT;2HNT;2HPP;2HPQ;2HWL;2JH0;2JH5;2JH6;2OD3;2PGB;2PGQ;2PKS;2PW8;2R2M;2THF;2UUF;2UUJ;2UUK;2V3H;2V3O;2ZC9;2ZDA;2ZDV;2ZF0;2ZFF;2ZFP;2ZFQ;2ZFR;2ZG0;2ZGB;2ZGX;2ZHE;2ZHF;2ZHQ;2ZHW;2ZI2;2ZIQ;2ZNK;2ZO3;3B23;3B9F;3BEF;3BEI;3BF6;3BIU;3BIV;3BV9;3C1K;3C27;3D49;3DA9;3DD2;3DHK;3DT0;3DUX;3E6P;3EE0;3EGK;3EQ0;3F68;3GIC;3GIS;3HAT;3HKJ;3HTC;3JZ1;3JZ2;3K65;3LDX;3LU9;3NXP;3P17;3P6Z;3P70;3PMH;3PO1;3QDZ;3QGN;3QLP;3QTO;3QTV;3QWC;3QX5;3R3G;3RLW;3RLY;3RM0;3RM2;3RML;3RMM;3RMN;3RMO;3S7H;3S7K;3SHA;3SHC;3SI3;3SI4;3SQE;3SQH;3SV2;3T5F;3TU7;3U69;3U8O;3U8R;3U8T;3U98;3U9A;3UTU;3UWJ;3VXE;3VXF;4AX9;4AYV;4AYY;4AZ2;4BAH;4BAK;4BAM;4BAN;4BAO;4BAQ;4BOH;4CH2;4CH8;4DIH;4DII;4DT7;4DY7;4E05;4E06;4E7R;4H6S;4H6T;4HFP;4HTC;4HZH;4I7Y;4LOY;4LXB;4LZ1;4LZ4;4MLF;4N3L;4NZE;4NZQ;4O03;4RKJ;4RKO;4RN6;4THN;4UD9;4UDW;4UE7;4UEH;4UFD;4UFE;4UFF;4UFG;4YES;5A2M;5AF9;5AFY;5AFZ;5AHG;5CMX;5E8E;5EDK;5EDM;5GDS;5JDU;5LUY;7KME;8KME;	CHEMBL204;	P00734;	DB00025;DB00278;DB05777;DB00006;DB00100;DB06695;DB00055;DB00001;DB00170;DB01123;DB04786;DB04898;		PF00594;PF00051;PF09396;PF00089;	IPR017857;IPR000294;IPR000001;IPR013806;IPR018056;IPR009003;IPR001314;IPR003966;IPR018992;IPR001254;IPR018114;IPR033116;	acute-phase response [GO:0006953]; blood coagulation [GO:0007596]; blood coagulation, intrinsic pathway [GO:0007597]; cell surface receptor signaling pathway [GO:0007166]; cellular protein metabolic process [GO:0044267]; ER to Golgi vesicle-mediated transport [GO:0006888]; fibrinolysis [GO:0042730]; leukocyte migration [GO:0050900]; multicellular organism development [GO:0007275]; negative regulation of astrocyte differentiation [GO:0048712]; negative regulation of fibrinolysis [GO:0051918]; negative regulation of platelet activation [GO:0010544]; negative regulation of proteolysis [GO:0045861]; peptidyl-glutamic acid carboxylation [GO:0017187]; platelet activation [GO:0030168]; positive regulation of blood coagulation [GO:0030194]; positive regulation of cell growth [GO:0030307]; positive regulation of cell proliferation [GO:0008284]; positive regulation of collagen biosynthetic process [GO:0032967]; positive regulation of lipid kinase activity [GO:0090218]; positive regulation of phosphatidylinositol 3-kinase signaling [GO:0014068]; positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway [GO:1900738]; positive regulation of protein localization to nucleus [GO:1900182]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of reactive oxygen species metabolic process [GO:2000379]; positive regulation of release of sequestered calcium ion into cytosol [GO:0051281]; proteolysis [GO:0006508]; regulation of blood coagulation [GO:0030193]; regulation of cell shape [GO:0008360]; regulation of cytosolic calcium ion concentration [GO:0051480]; regulation of gene expression [GO:0010468]; response to wounding [GO:0009611]; signal peptide processing [GO:0006465]	calcium ion binding [GO:0005509]; growth factor activity [GO:0008083]; receptor binding [GO:0005102]; serine-type endopeptidase activity [GO:0004252]; thrombospondin receptor activity [GO:0070053]	blood microparticle [GO:0072562]; endoplasmic reticulum lumen [GO:0005788]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; Golgi lumen [GO:0005796]; plasma membrane [GO:0005886]
P49788	TIG1_HUMAN	Retinoic acid receptor responder protein 1 (Phorbol ester-induced gene 1 protein) (PERG-1) (RAR-responsive protein TIG1) (Tazarotene-induced gene 1 protein)	RARRES1 PEIG1 TIG1				DB00755;		PF06907;	IPR009684;IPR027261;	negative regulation of cell proliferation [GO:0008285]		extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]
P20366	TKN1_HUMAN	Protachykinin-1 (PPT) [Cleaved into: Substance P; Neurokinin A (NKA) (Neuromedin L) (Substance K); Neuropeptide K (NPK); Neuropeptide gamma; C-terminal-flanking peptide]	TAC1 NKA NKNA TAC2	2B19;2KS9;2KSA;2KSB;4HOM;						IPR013055;IPR008215;IPR008216;	antibacterial humoral response [GO:0019731]; antifungal humoral response [GO:0019732]; associative learning [GO:0008306]; cell-cell signaling [GO:0007267]; cellular response to nerve growth factor stimulus [GO:1990090]; chemical synaptic transmission [GO:0007268]; defense response to Gram-negative bacterium [GO:0050829]; defense response to Gram-positive bacterium [GO:0050830]; detection of abiotic stimulus [GO:0009582]; inflammatory response [GO:0006954]; innate immune response [GO:0045087]; insemination [GO:0007320]; long-term memory [GO:0007616]; negative regulation of heart rate [GO:0010459]; neuropeptide signaling pathway [GO:0007218]; positive regulation of action potential [GO:0045760]; positive regulation of acute inflammatory response [GO:0002675]; positive regulation of corticosterone secretion [GO:2000854]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of epithelial cell migration [GO:0010634]; positive regulation of lymphocyte proliferation [GO:0050671]; positive regulation of ossification [GO:0045778]; positive regulation of renal sodium excretion [GO:0035815]; positive regulation of saliva secretion [GO:0046878]; positive regulation of stress fiber assembly [GO:0051496]; positive regulation of synaptic transmission, cholinergic [GO:0032224]; positive regulation of synaptic transmission, GABAergic [GO:0032230]; regulation of blood pressure [GO:0008217]; response to hormone [GO:0009725]; response to lipopolysaccharide [GO:0032496]; response to morphine [GO:0043278]; response to pain [GO:0048265]; response to yeast [GO:0001878]; sensory perception of pain [GO:0019233]; tachykinin receptor signaling pathway [GO:0007217]	receptor binding [GO:0005102]	axon [GO:0030424]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; neuronal cell body [GO:0043025]; plasma membrane [GO:0005886]
Q9NYK1	TLR7_HUMAN	Toll-like receptor 7	TLR7 UNQ248/PRO285		CHEMBL5936;	Q9NYK1;	DB01611;DB00724;		PF13306;PF13855;PF01582;	IPR000483;IPR032675;IPR001611;IPR003591;IPR026906;IPR000157;IPR026880;	cellular response to mechanical stimulus [GO:0071260]; defense response to virus [GO:0051607]; I-kappaB phosphorylation [GO:0007252]; inflammatory response [GO:0006954]; innate immune response [GO:0045087]; microglial cell activation [GO:0001774]; MyD88-dependent toll-like receptor signaling pathway [GO:0002755]; positive regulation of chemokine production [GO:0032722]; positive regulation of inflammatory response [GO:0050729]; positive regulation of interferon-alpha biosynthetic process [GO:0045356]; positive regulation of interferon-beta biosynthetic process [GO:0045359]; positive regulation of interferon-gamma biosynthetic process [GO:0045078]; positive regulation of interleukin-6 production [GO:0032755]; positive regulation of interleukin-8 biosynthetic process [GO:0045416]; positive regulation of interleukin-8 production [GO:0032757]; positive regulation of NF-kappaB import into nucleus [GO:0042346]; regulation of protein phosphorylation [GO:0001932]; toll-like receptor 7 signaling pathway [GO:0034154]; toll-like receptor 9 signaling pathway [GO:0034162]; toll-like receptor signaling pathway [GO:0002224]	double-stranded RNA binding [GO:0003725]; drug binding [GO:0008144]; receptor activity [GO:0004872]; single-stranded RNA binding [GO:0003727]; siRNA binding [GO:0035197]; transmembrane signaling receptor activity [GO:0004888]	cytoplasm [GO:0005737]; early phagosome [GO:0032009]; endolysosome membrane [GO:0036020]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; endosome [GO:0005768]; endosome membrane [GO:0010008]; Golgi membrane [GO:0000139]; integral component of plasma membrane [GO:0005887]; lysosome [GO:0005764]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]
Q9NR96	TLR9_HUMAN	Toll-like receptor 9 (CD antigen CD289)	TLR9 UNQ5798/PRO19605		CHEMBL5804;	Q9NR96;	DB00608;DB01611;		PF13516;PF13855;PF01582;	IPR032675;IPR001611;IPR003591;IPR000157;IPR027181;	defense response to bacterium [GO:0042742]; defense response to Gram-negative bacterium [GO:0050829]; I-kappaB phosphorylation [GO:0007252]; inflammatory response [GO:0006954]; innate immune response [GO:0045087]; maintenance of gastrointestinal epithelium [GO:0030277]; MyD88-dependent toll-like receptor signaling pathway [GO:0002755]; negative regulation of calcium-transporting ATPase activity [GO:1901895]; negative regulation of interleukin-6 production [GO:0032715]; negative regulation of interleukin-8 production [GO:0032717]; negative regulation of NF-kappaB transcription factor activity [GO:0032088]; negative regulation of toll-like receptor signaling pathway [GO:0034122]; positive regulation of chemokine production [GO:0032722]; positive regulation of gene expression [GO:0010628]; positive regulation of granulocyte macrophage colony-stimulating factor production [GO:0032725]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of inflammatory response [GO:0050729]; positive regulation of interferon-alpha biosynthetic process [GO:0045356]; positive regulation of interferon-beta biosynthetic process [GO:0045359]; positive regulation of interferon-beta production [GO:0032728]; positive regulation of interferon-gamma biosynthetic process [GO:0045078]; positive regulation of interleukin-10 production [GO:0032733]; positive regulation of interleukin-12 production [GO:0032735]; positive regulation of interleukin-18 production [GO:0032741]; positive regulation of interleukin-6 production [GO:0032755]; positive regulation of interleukin-8 production [GO:0032757]; positive regulation of JNK cascade [GO:0046330]; positive regulation of JUN kinase activity [GO:0043507]; positive regulation of NF-kappaB import into nucleus [GO:0042346]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of nitric-oxide synthase biosynthetic process [GO:0051770]; positive regulation of toll-like receptor signaling pathway [GO:0034123]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of tumor necrosis factor production [GO:0032760]; regulation of cytokine secretion [GO:0050707]; response to molecule of bacterial origin [GO:0002237]; toll-like receptor 9 signaling pathway [GO:0034162]; toll-like receptor signaling pathway [GO:0002224]; tumor necrosis factor production [GO:0032640]	1-phosphatidylinositol-3-kinase activity [GO:0016303]; interleukin-1 receptor binding [GO:0005149]; siRNA binding [GO:0035197]; transmembrane signaling receptor activity [GO:0004888]	apical plasma membrane [GO:0016324]; basolateral plasma membrane [GO:0016323]; cytoplasm [GO:0005737]; early phagosome [GO:0032009]; endolysosome membrane [GO:0036020]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; endosome [GO:0005768]; endosome membrane [GO:0010008]; extracellular region [GO:0005576]; Golgi membrane [GO:0000139]; integral component of membrane [GO:0016021]; lysosome [GO:0005764]; plasma membrane [GO:0005886]
Q9NVH6	TMLH_HUMAN	Trimethyllysine dioxygenase, mitochondrial (EC 1.14.11.8) (Epsilon-trimethyllysine 2-oxoglutarate dioxygenase) (Epsilon-trimethyllysine hydroxylase) (TML hydroxylase) (TML-alpha-ketoglutarate dioxygenase) (TML dioxygenase) (TMLD)	TMLHE TMLH				DB00139;DB00126;	PATHWAY: Amine and polyamine biosynthesis; carnitine biosynthesis.	PF06155;PF02668;	IPR010376;IPR003819;IPR012776;	carnitine biosynthetic process [GO:0045329]; negative regulation of oxidoreductase activity [GO:0051354]	iron ion binding [GO:0005506]; L-ascorbic acid binding [GO:0031418]; oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen [GO:0016702]; trimethyllysine dioxygenase activity [GO:0050353]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]
Q9Y275	TN13B_HUMAN	Tumor necrosis factor ligand superfamily member 13B (B lymphocyte stimulator) (BLyS) (B-cell-activating factor) (BAFF) (Dendritic cell-derived TNF-like molecule) (TNF- and APOL-related leukocyte expressed ligand 1) (TALL-1) (CD antigen CD257) [Cleaved into: Tumor necrosis factor ligand superfamily member 13b, membrane form; Tumor necrosis factor ligand superfamily member 13b, soluble form]	TNFSF13B BAFF BLYS TALL1 TNFSF20 ZTNF4 UNQ401/PRO738	1JH5;1KD7;1KXG;1OQD;1OQE;1OSG;3V56;4V46;4ZCH;	CHEMBL2364158;		DB08879;		PF00229;	IPR006052;IPR008983;	B cell costimulation [GO:0031296]; B cell homeostasis [GO:0001782]; cell proliferation [GO:0008283]; immune response [GO:0006955]; immunoglobulin secretion [GO:0048305]; positive regulation of B cell proliferation [GO:0030890]; positive regulation of cell proliferation [GO:0008284]; positive regulation of germinal center formation [GO:0002636]; positive regulation of T cell proliferation [GO:0042102]; signal transduction [GO:0007165]; T cell costimulation [GO:0031295]; tumor necrosis factor-mediated signaling pathway [GO:0033209]	receptor binding [GO:0005102]	cytoplasm [GO:0005737]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; integral component of membrane [GO:0016021]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]
P01375	TNFA_HUMAN	Tumor necrosis factor (Cachectin) (TNF-alpha) (Tumor necrosis factor ligand superfamily member 2) (TNF-a) [Cleaved into: Tumor necrosis factor, membrane form (N-terminal fragment) (NTF); Intracellular domain 1 (ICD1); Intracellular domain 2 (ICD2); C-domain 1; C-domain 2; Tumor necrosis factor, soluble form]	TNF TNFA TNFSF2	1A8M;1TNF;2AZ5;2E7A;2TUN;2ZJC;2ZPX;3ALQ;3IT8;3L9J;3WD5;4G3Y;4TSV;4TWT;5TSW;	CHEMBL1825;	P01375;	DB00051;DB01427;DB05676;DB08904;DB00608;DB01407;DB00668;DB00005;DB01296;DB06674;DB00065;DB02325;DB08910;DB01411;DB00852;DB01041;		PF00229;	IPR006053;IPR002959;IPR021184;IPR006052;IPR008983;	activation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0006919]; activation of MAPK activity [GO:0000187]; activation of MAPKKK activity [GO:0000185]; cellular response to amino acid stimulus [GO:0071230]; cellular response to nicotine [GO:0071316]; cellular response to organic cyclic compound [GO:0071407]; chronic inflammatory response to antigenic stimulus [GO:0002439]; cortical actin cytoskeleton organization [GO:0030866]; death-inducing signaling complex assembly [GO:0071550]; defense response to Gram-positive bacterium [GO:0050830]; embryonic digestive tract development [GO:0048566]; epithelial cell proliferation involved in salivary gland morphogenesis [GO:0060664]; establishment of protein localization to plasma membrane [GO:0090002]; extracellular matrix organization [GO:0030198]; extrinsic apoptotic signaling pathway [GO:0097191]; extrinsic apoptotic signaling pathway via death domain receptors [GO:0008625]; glucose metabolic process [GO:0006006]; humoral immune response [GO:0006959]; I-kappaB kinase/NF-kappaB signaling [GO:0007249]; inflammatory response [GO:0006954]; intrinsic apoptotic signaling pathway in response to DNA damage [GO:0008630]; JNK cascade [GO:0007254]; leukocyte tethering or rolling [GO:0050901]; lipopolysaccharide-mediated signaling pathway [GO:0031663]; MAPK cascade [GO:0000165]; necroptotic signaling pathway [GO:0097527]; negative regulation of alkaline phosphatase activity [GO:0010693]; negative regulation of bicellular tight junction assembly [GO:1903347]; negative regulation of branching involved in lung morphogenesis [GO:0061048]; negative regulation of cytokine secretion involved in immune response [GO:0002740]; negative regulation of extrinsic apoptotic signaling pathway in absence of ligand [GO:2001240]; negative regulation of fat cell differentiation [GO:0045599]; negative regulation of gene expression [GO:0010629]; negative regulation of glucose import [GO:0046325]; negative regulation of growth of symbiont in host [GO:0044130]; negative regulation of interleukin-6 production [GO:0032715]; negative regulation of lipid catabolic process [GO:0050995]; negative regulation of lipid storage [GO:0010888]; negative regulation of myoblast differentiation [GO:0045662]; negative regulation of myosin-light-chain-phosphatase activity [GO:0035509]; negative regulation of osteoblast differentiation [GO:0045668]; negative regulation of protein complex disassembly [GO:0043242]; negative regulation of transcription, DNA-templated [GO:0045892]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; negative regulation of viral genome replication [GO:0045071]; osteoclast differentiation [GO:0030316]; positive regulation of apoptotic process [GO:0043065]; positive regulation of blood microparticle formation [GO:2000334]; positive regulation of calcidiol 1-monooxygenase activity [GO:0060559]; positive regulation of cell adhesion [GO:0045785]; positive regulation of ceramide biosynthetic process [GO:2000304]; positive regulation of chemokine (C-X-C motif) ligand 2 production [GO:2000343]; positive regulation of chemokine biosynthetic process [GO:0045080]; positive regulation of chemokine production [GO:0032722]; positive regulation of chronic inflammatory response to antigenic stimulus [GO:0002876]; positive regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043280]; positive regulation of cytokine production [GO:0001819]; positive regulation of cytokine secretion [GO:0050715]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of fever generation [GO:0031622]; positive regulation of gene expression [GO:0010628]; positive regulation of hair follicle development [GO:0051798]; positive regulation of heterotypic cell-cell adhesion [GO:0034116]; positive regulation of humoral immune response mediated by circulating immunoglobulin [GO:0002925]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of interferon-gamma production [GO:0032729]; positive regulation of interleukin-6 production [GO:0032755]; positive regulation of interleukin-8 biosynthetic process [GO:0045416]; positive regulation of interleukin-8 production [GO:0032757]; positive regulation of JUN kinase activity [GO:0043507]; positive regulation of leukocyte adhesion to arterial endothelial cell [GO:1904999]; positive regulation of leukocyte adhesion to vascular endothelial cell [GO:1904996]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of membrane protein ectodomain proteolysis [GO:0051044]; positive regulation of mononuclear cell migration [GO:0071677]; positive regulation of NFAT protein import into nucleus [GO:0051533]; positive regulation of NF-kappaB import into nucleus [GO:0042346]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of NIK/NF-kappaB signaling [GO:1901224]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; positive regulation of osteoclast differentiation [GO:0045672]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of phagocytosis [GO:0050766]; positive regulation of podosome assembly [GO:0071803]; positive regulation of programmed cell death [GO:0043068]; positive regulation of protein complex assembly [GO:0031334]; positive regulation of protein complex disassembly [GO:0043243]; positive regulation of protein kinase activity [GO:0045860]; positive regulation of protein kinase B signaling [GO:0051897]; positive regulation of protein localization to cell surface [GO:2000010]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of protein transport [GO:0051222]; positive regulation of sequence-specific DNA binding transcription factor activity [GO:0051091]; positive regulation of smooth muscle cell proliferation [GO:0048661]; positive regulation of superoxide dismutase activity [GO:1901671]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of translational initiation by iron [GO:0045994]; positive regulation of vitamin D biosynthetic process [GO:0060557]; protein import into nucleus, translocation [GO:0000060]; protein kinase B signaling [GO:0043491]; receptor biosynthetic process [GO:0032800]; regulation of branching involved in salivary gland morphogenesis [GO:0060693]; regulation of establishment of endothelial barrier [GO:1903140]; regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043122]; regulation of immunoglobulin secretion [GO:0051023]; regulation of insulin secretion [GO:0050796]; regulation of tumor necrosis factor-mediated signaling pathway [GO:0010803]; response to glucocorticoid [GO:0051384]; response to salt stress [GO:0009651]; response to virus [GO:0009615]; sequestering of triglyceride [GO:0030730]; tumor necrosis factor-mediated signaling pathway [GO:0033209]	cytokine activity [GO:0005125]; identical protein binding [GO:0042802]; protease binding [GO:0002020]; transcription regulatory region DNA binding [GO:0044212]; tumor necrosis factor receptor binding [GO:0005164]	cell surface [GO:0009986]; external side of plasma membrane [GO:0009897]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; integral component of plasma membrane [GO:0005887]; membrane raft [GO:0045121]; phagocytic cup [GO:0001891]; plasma membrane [GO:0005886]; recycling endosome [GO:0055037]
Q06643	TNFC_HUMAN	Lymphotoxin-beta (LT-beta) (Tumor necrosis factor C) (TNF-C) (Tumor necrosis factor ligand superfamily member 3)	LTB TNFC TNFSF3	4MXW;					PF00229;	IPR006053;IPR002961;IPR021184;IPR006052;IPR008983;	cell-cell signaling [GO:0007267]; gene expression [GO:0010467]; immune response [GO:0006955]; lymph node development [GO:0048535]; positive regulation of interleukin-12 biosynthetic process [GO:0045084]; signal transduction [GO:0007165]; skin development [GO:0043588]; tumor necrosis factor-mediated signaling pathway [GO:0033209]	receptor binding [GO:0005102]	extracellular space [GO:0005615]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]
P63316	TNNC1_HUMAN	Troponin C, slow skeletal and cardiac muscles (TN-C)	TNNC1 TNNC	1AP4;1IH0;1J1D;1J1E;1LXF;1MXL;1OZS;1SPY;1WRK;1WRL;2JT0;2JT3;2JT8;2JTZ;2JXL;2KDH;2KFX;2KGB;2KRD;2L1R;2L98;2MKP;2MLE;2MLF;2MZP;2N79;2N7L;3RV5;3SD6;3SWB;4GJE;4GJF;4GJG;4Y99;	CHEMBL2095202;		DB01244;DB01375;DB01023;DB00922;DB00831;		PF13499;PF13833;	IPR011992;IPR018247;IPR002048;	cardiac muscle contraction [GO:0060048]; diaphragm contraction [GO:0002086]; muscle filament sliding [GO:0030049]; regulation of ATPase activity [GO:0043462]; regulation of muscle contraction [GO:0006937]; regulation of muscle filament sliding speed [GO:0032972]; response to metal ion [GO:0010038]; skeletal muscle contraction [GO:0003009]; transition between fast and slow fiber [GO:0014883]; ventricular cardiac muscle tissue morphogenesis [GO:0055010]	actin filament binding [GO:0051015]; calcium-dependent protein binding [GO:0048306]; calcium ion binding [GO:0005509]; protein homodimerization activity [GO:0042803]; troponin I binding [GO:0031013]; troponin T binding [GO:0031014]	actin cytoskeleton [GO:0015629]; cytosol [GO:0005829]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; troponin complex [GO:0005861]
P19438	TNR1A_HUMAN	Tumor necrosis factor receptor superfamily member 1A (Tumor necrosis factor receptor 1) (TNF-R1) (Tumor necrosis factor receptor type I) (TNF-RI) (TNFR-I) (p55) (p60) (CD antigen CD120a) [Cleaved into: Tumor necrosis factor receptor superfamily member 1A, membrane form; Tumor necrosis factor-binding protein 1 (TBPI)]	TNFRSF1A TNFAR TNFR1	1EXT;1FT4;1ICH;1NCF;1TNR;	CHEMBL3378;	P19438;			PF00531;PF00020;	IPR011029;IPR000488;IPR001368;IPR020419;	cellular response to mechanical stimulus [GO:0071260]; cytokine-mediated signaling pathway [GO:0019221]; death-inducing signaling complex assembly [GO:0071550]; defense response to bacterium [GO:0042742]; establishment of protein localization to plasma membrane [GO:0090002]; extrinsic apoptotic signaling pathway via death domain receptors [GO:0008625]; I-kappaB kinase/NF-kappaB signaling [GO:0007249]; immune response [GO:0006955]; inflammatory response [GO:0006954]; intrinsic apoptotic signaling pathway in response to DNA damage [GO:0008630]; negative regulation of inflammatory response [GO:0050728]; positive regulation of ceramide biosynthetic process [GO:2000304]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of inflammatory response [GO:0050729]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of tyrosine phosphorylation of Stat1 protein [GO:0042511]; prostaglandin metabolic process [GO:0006693]; regulation of apoptotic process [GO:0042981]; regulation of cell proliferation [GO:0042127]; regulation of establishment of endothelial barrier [GO:1903140]; regulation of tumor necrosis factor-mediated signaling pathway [GO:0010803]; response to lipopolysaccharide [GO:0032496]; tumor necrosis factor-mediated signaling pathway [GO:0033209]; viral process [GO:0016032]	tumor necrosis factor-activated receptor activity [GO:0005031]; tumor necrosis factor binding [GO:0043120]	cell surface [GO:0009986]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; Golgi membrane [GO:0000139]; integral component of plasma membrane [GO:0005887]; membrane raft [GO:0045121]; mitochondrion [GO:0005739]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]
P25942	TNR5_HUMAN	Tumor necrosis factor receptor superfamily member 5 (B-cell surface antigen CD40) (Bp50) (CD40L receptor) (CDw40) (CD antigen CD40)	CD40 TNFRSF5	1CDF;1CZZ;1D00;1FLL;1LB6;3QD6;5DMI;5DMJ;5IHL;	CHEMBL1250358;	P25942;			PF00020;	IPR001368;IPR020435;	apoptotic signaling pathway [GO:0097190]; B cell proliferation [GO:0042100]; cellular calcium ion homeostasis [GO:0006874]; cellular response to lipopolysaccharide [GO:0071222]; cellular response to mechanical stimulus [GO:0071260]; defense response to protozoan [GO:0042832]; defense response to virus [GO:0051607]; immune response [GO:0006955]; immune response-regulating cell surface receptor signaling pathway [GO:0002768]; inflammatory response [GO:0006954]; multicellular organism development [GO:0007275]; platelet activation [GO:0030168]; positive regulation of B cell proliferation [GO:0030890]; positive regulation of endothelial cell apoptotic process [GO:2000353]; positive regulation of GTPase activity [GO:0043547]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of interleukin-12 production [GO:0032735]; positive regulation of isotype switching to IgG isotypes [GO:0048304]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of protein kinase C signaling [GO:0090037]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of tyrosine phosphorylation of Stat1 protein [GO:0042511]; protein complex assembly [GO:0006461]; protein kinase B signaling [GO:0043491]; regulation of cell proliferation [GO:0042127]; regulation of immune response [GO:0050776]; regulation of immunoglobulin secretion [GO:0051023]; response to lipopolysaccharide [GO:0032496]; tumor necrosis factor-mediated signaling pathway [GO:0033209]	antigen binding [GO:0003823]; enzyme binding [GO:0019899]; receptor activity [GO:0004872]; signal transducer activity [GO:0004871]; tumor necrosis factor-activated receptor activity [GO:0005031]; ubiquitin protein ligase binding [GO:0031625]	CD40 receptor complex [GO:0035631]; cell surface [GO:0009986]; cytoplasm [GO:0005737]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; integral component of plasma membrane [GO:0005887]; intracellular membrane-bounded organelle [GO:0043231]; plasma membrane [GO:0005886]
Q969P6	TOP1M_HUMAN	DNA topoisomerase I, mitochondrial (TOP1mt) (EC 5.99.1.2)	TOP1MT		CHEMBL2362989;		DB00762;DB01030;		PF14370;PF01028;PF02919;	IPR011010;IPR013034;IPR001631;IPR018521;IPR025834;IPR014711;IPR014727;IPR013500;IPR008336;IPR013030;IPR013499;	DNA replication [GO:0006260]; DNA topological change [GO:0006265]	DNA binding [GO:0003677]; DNA topoisomerase type I activity [GO:0003917]	chromosome [GO:0005694]; mitochondrial nucleoid [GO:0042645]; mitochondrion [GO:0005739]; nucleus [GO:0005634]
P11387	TOP1_HUMAN	DNA topoisomerase 1 (EC 5.99.1.2) (DNA topoisomerase I)	TOP1	1A31;1A35;1A36;1EJ9;1K4S;1K4T;1LPQ;1NH3;1R49;1RR8;1RRJ;1SC7;1SEU;1T8I;1TL8;	CHEMBL1781;	P11387;	DB00762;DB04967;DB05630;DB01030;		PF14370;PF01028;PF02919;	IPR011010;IPR013034;IPR001631;IPR018521;IPR025834;IPR014711;IPR014727;IPR013500;IPR008336;IPR013030;IPR013499;	chromatin remodeling [GO:0006338]; chromosome segregation [GO:0007059]; circadian regulation of gene expression [GO:0032922]; circadian rhythm [GO:0007623]; DNA replication [GO:0006260]; DNA topological change [GO:0006265]; embryonic cleavage [GO:0040016]; phosphorylation [GO:0016310]; programmed cell death [GO:0012501]; protein sumoylation [GO:0016925]; response to drug [GO:0042493]; viral process [GO:0016032]	chromatin binding [GO:0003682]; core promoter sequence-specific DNA binding [GO:0001046]; DNA binding [GO:0003677]; DNA topoisomerase type I activity [GO:0003917]; poly(A) RNA binding [GO:0044822]	cytoplasmic mRNA processing body [GO:0000932]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; perikaryon [GO:0043204]; replication fork protection complex [GO:0031298]
P11388	TOP2A_HUMAN	DNA topoisomerase 2-alpha (EC 5.99.1.3) (DNA topoisomerase II, alpha isozyme)	TOP2A TOP2	1LWZ;1ZXM;1ZXN;4FM9;4R1F;	CHEMBL1806;	P11388;	DB00276;DB00537;DB00970;DB00694;DB00380;DB00997;DB00467;DB00445;DB00773;DB09047;DB04576;DB01177;DB01137;DB00978;DB04967;DB01204;DB00218;DB01059;DB01165;DB00487;DB01179;DB01208;DB00444;DB00685;DB00385;		PF00204;PF00521;PF08070;PF02518;PF01751;PF16898;	IPR024946;IPR012542;IPR003594;IPR020568;IPR014721;IPR028466;IPR001241;IPR013760;IPR002205;IPR013758;IPR013757;IPR013506;IPR013759;IPR018522;IPR031660;IPR006171;	apoptotic chromosome condensation [GO:0030263]; cellular response to DNA damage stimulus [GO:0006974]; chromosome segregation [GO:0007059]; DNA ligation [GO:0006266]; DNA topological change [GO:0006265]; DNA unwinding involved in DNA replication [GO:0006268]; embryonic cleavage [GO:0040016]; hematopoietic progenitor cell differentiation [GO:0002244]; mitotic DNA integrity checkpoint [GO:0044774]; mitotic recombination [GO:0006312]; positive regulation of apoptotic process [GO:0043065]; positive regulation of single stranded viral RNA replication via double stranded DNA intermediate [GO:0045870]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of viral genome replication [GO:0045070]; protein sumoylation [GO:0016925]; regulation of circadian rhythm [GO:0042752]; resolution of meiotic recombination intermediates [GO:0000712]; rhythmic process [GO:0048511]; sister chromatid segregation [GO:0000819]	ATP binding [GO:0005524]; chromatin binding [GO:0003682]; DNA binding [GO:0003677]; DNA binding, bending [GO:0008301]; DNA-dependent ATPase activity [GO:0008094]; DNA topoisomerase type II (ATP-hydrolyzing) activity [GO:0003918]; drug binding [GO:0008144]; enzyme binding [GO:0019899]; histone deacetylase binding [GO:0042826]; magnesium ion binding [GO:0000287]; poly(A) RNA binding [GO:0044822]; protein C-terminus binding [GO:0008022]; protein heterodimerization activity [GO:0046982]; protein homodimerization activity [GO:0042803]; protein kinase C binding [GO:0005080]; ubiquitin binding [GO:0043130]	condensed chromosome [GO:0000793]; cytoplasm [GO:0005737]; DNA topoisomerase complex (ATP-hydrolyzing) [GO:0009330]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; protein complex [GO:0043234]
P00750	TPA_HUMAN	Tissue-type plasminogen activator (t-PA) (t-plasminogen activator) (tPA) (EC 3.4.21.68) (Alteplase) (Reteplase) [Cleaved into: Tissue-type plasminogen activator chain A; Tissue-type plasminogen activator chain B]	PLAT	1A5H;1BDA;1PK2;1PML;1RTF;1TPG;1TPK;1TPM;1TPN;5BRR;	CHEMBL1873;	P00750;	DB00513;DB01050;DB01088;DB00013;		PF00008;PF00039;PF00051;PF00089;	IPR013032;IPR000742;IPR000083;IPR000001;IPR013806;IPR018056;IPR009003;IPR001314;IPR026280;IPR001254;IPR018114;IPR033116;	blood coagulation [GO:0007596]; cellular protein modification process [GO:0006464]; fibrinolysis [GO:0042730]; negative regulation of proteolysis [GO:0045861]; plasminogen activation [GO:0031639]; platelet-derived growth factor receptor signaling pathway [GO:0048008]; proteolysis [GO:0006508]; response to hypoxia [GO:0001666]; smooth muscle cell migration [GO:0014909]	glycoprotein binding [GO:0001948]; phosphoprotein binding [GO:0051219]; receptor binding [GO:0005102]; serine-type endopeptidase activity [GO:0004252]	apical part of cell [GO:0045177]; cell surface [GO:0009986]; cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; secretory granule [GO:0030141]
P17752	TPH1_HUMAN	Tryptophan 5-hydroxylase 1 (EC 1.14.16.4) (Tryptophan 5-monooxygenase 1)	TPH1 TPH TPRH TRPH	1IN9;1MLW;3HF6;3HF8;3HFB;5J6D;	CHEMBL5689;	P17752;	DB00150;DB00360;	PATHWAY: Aromatic compound metabolism; serotonin biosynthesis; serotonin from L-tryptophan: step 1/2.	PF00351;	IPR002912;IPR001273;IPR018301;IPR019774;IPR005963;IPR019773;	aromatic amino acid family metabolic process [GO:0009072]; bone remodeling [GO:0046849]; circadian rhythm [GO:0007623]; indolalkylamine biosynthetic process [GO:0046219]; mammary gland alveolus development [GO:0060749]; negative regulation of ossification [GO:0030279]; positive regulation of fat cell differentiation [GO:0045600]; response to immobilization stress [GO:0035902]; serotonin biosynthetic process [GO:0042427]	amino acid binding [GO:0016597]; iron ion binding [GO:0005506]; tryptophan 5-monooxygenase activity [GO:0004510]	cytosol [GO:0005829]; neuron projection [GO:0043005]
Q8IWU9	TPH2_HUMAN	Tryptophan 5-hydroxylase 2 (EC 1.14.16.4) (Neuronal tryptophan hydroxylase) (Tryptophan 5-monooxygenase 2)	TPH2 NTPH	4V06;	CHEMBL5433;	Q8IWU9;	DB00150;	PATHWAY: Aromatic compound metabolism; serotonin biosynthesis; serotonin from L-tryptophan: step 1/2.	PF00351;	IPR002912;IPR001273;IPR018301;IPR019774;IPR005963;IPR019773;	aromatic amino acid family metabolic process [GO:0009072]; cellular response to lithium ion [GO:0071285]; circadian rhythm [GO:0007623]; indolalkylamine biosynthetic process [GO:0046219]; response to activity [GO:0014823]; response to calcium ion [GO:0051592]; response to estrogen [GO:0043627]; response to glucocorticoid [GO:0051384]; response to nutrient levels [GO:0031667]; serotonin biosynthetic process [GO:0042427]	amino acid binding [GO:0016597]; iron ion binding [GO:0005506]; tryptophan 5-monooxygenase activity [GO:0004510]	cytosol [GO:0005829]; neuron projection [GO:0043005]
Q9H3S4	TPK1_HUMAN	Thiamin pyrophosphokinase 1 (hTPK1) (EC 2.7.6.2) (Placental protein 20) (PP20) (Thiamine pyrophosphokinase 1)	TPK1	1OLY;3S4Y;	CHEMBL6155;		DB00152;	PATHWAY: Cofactor biosynthesis; thiamine diphosphate biosynthesis; thiamine diphosphate from thiamine: step 1/1.	PF04265;PF04263;	IPR006282;IPR016966;IPR007373;IPR007371;	thiamine-containing compound metabolic process [GO:0042723]; thiamine diphosphate biosynthetic process [GO:0009229]; thiamine metabolic process [GO:0006772]	ATP binding [GO:0005524]; kinase activity [GO:0016301]; thiamine binding [GO:0030975]; thiamine diphosphokinase activity [GO:0004788]	cytosol [GO:0005829]
O43617	TPPC3_HUMAN	Trafficking protein particle complex subunit 3 (BET3 homolog)	TRAPPC3 BET3 CDABP0066	1SZ7;2C0J;2CFH;3KXC;					PF04051;	IPR016721;IPR024096;IPR007194;	COPII vesicle coating [GO:0048208]		cytoplasm [GO:0005737]; cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; Golgi apparatus [GO:0005794]; Golgi membrane [GO:0000139]; TRAPP complex [GO:0030008]
O14717	TRDMT_HUMAN	tRNA (cytosine(38)-C(5))-methyltransferase (EC 2.1.1.204) (DNA (cytosine-5)-methyltransferase-like protein 2) (Dnmt2) (DNA methyltransferase homolog HsaIIP) (DNA MTase homolog HsaIIP) (M.HsaIIP) (PuMet)	TRDMT1 DNMT2	1G55;			DB00738;		PF00145;	IPR001525;IPR031303;IPR029063;	response to amphetamine [GO:0001975]; tRNA methylation [GO:0030488]; tRNA modification [GO:0006400]	DNA (cytosine-5-)-methyltransferase activity [GO:0003886]; RNA binding [GO:0003723]; tRNA (cytosine-5-)-methyltransferase activity [GO:0016428]; tRNA methyltransferase activity [GO:0008175]	cytoplasm [GO:0005737]; nucleoplasm [GO:0005654]
Q9NP99	TREM1_HUMAN	Triggering receptor expressed on myeloid cells 1 (TREM-1) (Triggering receptor expressed on monocytes 1) (CD antigen CD354)	TREM1	1Q8M;1SMO;	CHEMBL1697674;				PF07686;	IPR007110;IPR013783;IPR003599;IPR013106;	chemokine metabolic process [GO:0050755]; cytokine secretion involved in immune response [GO:0002374]; humoral immune response [GO:0006959]; innate immune response [GO:0045087]; intracellular signal transduction [GO:0035556]; leukocyte migration [GO:0050900]; neutrophil chemotaxis [GO:0030593]; neutrophil extravasation [GO:0072672]; neutrophil mediated killing of gram-negative bacterium [GO:0070945]; regulation of immune response [GO:0050776]	receptor activity [GO:0004872]; scaffold protein binding [GO:0097110]	extracellular region [GO:0005576]; integral component of membrane [GO:0016021]; intracellular [GO:0005622]; plasma membrane [GO:0005886]
P02787	TRFE_HUMAN	Serotransferrin (Transferrin) (Beta-1 metal-binding globulin) (Siderophilin)	TF PRO1400	1A8E;1A8F;1B3E;1BP5;1BTJ;1D3K;1D4N;1DTG;1FQE;1FQF;1JQF;1N7W;1N7X;1N84;1OQG;1OQH;1RYO;1SUV;2HAU;2HAV;2O7U;2O84;3FGS;3QYT;3S9L;3S9M;3S9N;3SKP;3V83;3V89;3V8X;3VE1;4H0W;4X1B;4X1D;5DYH;	CHEMBL4865;		DB01370;DB01294;DB05260;DB00893;		PF00405;	IPR030685;IPR016357;IPR001156;IPR018195;	cellular iron ion homeostasis [GO:0006879]; cellular response to iron ion [GO:0071281]; ferrous iron import into cell [GO:0097460]; iron ion homeostasis [GO:0055072]; platelet degranulation [GO:0002576]; positive regulation of receptor-mediated endocytosis [GO:0048260]; regulation of protein stability [GO:0031647]; retina homeostasis [GO:0001895]; transferrin transport [GO:0033572]	ferric iron binding [GO:0008199]; ferric iron transmembrane transporter activity [GO:0015091]; ferrous iron binding [GO:0008198]; transferrin receptor binding [GO:1990459]	apical plasma membrane [GO:0016324]; basal part of cell [GO:0045178]; basal plasma membrane [GO:0009925]; blood microparticle [GO:0072562]; cell surface [GO:0009986]; clathrin-coated pit [GO:0005905]; cytoplasmic, membrane-bounded vesicle [GO:0016023]; early endosome [GO:0005769]; endocytic vesicle [GO:0030139]; endosome membrane [GO:0010008]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; extrinsic component of external side of plasma membrane [GO:0031232]; HFE-transferrin receptor complex [GO:1990712]; late endosome [GO:0005770]; perinuclear region of cytoplasm [GO:0048471]; recycling endosome [GO:0055037]; secretory granule lumen [GO:0034774]; vesicle [GO:0031982]
P02788	TRFL_HUMAN	Lactotransferrin (Lactoferrin) (EC 3.4.21.-) (Growth-inhibiting protein 12) (Talalactoferrin) [Cleaved into: Lactoferricin-H (Lfcin-H); Kaliocin-1; Lactoferroxin-A; Lactoferroxin-B; Lactoferroxin-C]	LTF GIG12 LF	1B0L;1BKA;1CB6;1DSN;1EH3;1FCK;1H43;1H44;1H45;1HSE;1L5T;1LCF;1LCT;1LFG;1LFH;1LFI;1LGB;1N76;1SQY;1U62;1VFD;1VFE;1XV4;1XV7;1Z6V;1Z6W;2BJJ;2DP4;2GMC;2GMD;2HD4;2PMS;			DB04743;DB08439;		PF00405;	IPR030684;IPR016357;IPR001156;IPR018195;	antibacterial humoral response [GO:0019731]; antifungal humoral response [GO:0019732]; bone morphogenesis [GO:0060349]; cell redox homeostasis [GO:0045454]; cellular protein metabolic process [GO:0044267]; humoral immune response [GO:0006959]; innate immune response in mucosa [GO:0002227]; ion transport [GO:0006811]; iron assimilation by chelation and transport [GO:0033214]; negative regulation by host of viral process [GO:0044793]; negative regulation of apoptotic process [GO:0043066]; negative regulation of ATPase activity [GO:0032780]; negative regulation of lipopolysaccharide-mediated signaling pathway [GO:0031665]; negative regulation of osteoclast development [GO:2001205]; negative regulation of single-species biofilm formation in or on host organism [GO:1900229]; negative regulation of tumor necrosis factor (ligand) superfamily member 11 production [GO:2000308]; negative regulation of viral genome replication [GO:0045071]; negative regulation of viral process [GO:0048525]; ossification [GO:0001503]; positive regulation of bone mineralization involved in bone maturation [GO:1900159]; positive regulation of chondrocyte proliferation [GO:1902732]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of osteoblast differentiation [GO:0045669]; positive regulation of osteoblast proliferation [GO:0033690]; positive regulation of protein serine/threonine kinase activity [GO:0071902]; positive regulation of toll-like receptor 4 signaling pathway [GO:0034145]; regulation of cytokine production [GO:0001817]; regulation of tumor necrosis factor production [GO:0032680]; retina homeostasis [GO:0001895]; transcription, DNA-templated [GO:0006351]	DNA binding [GO:0003677]; heparin binding [GO:0008201]; iron ion binding [GO:0005506]; protein serine/threonine kinase activator activity [GO:0043539]; serine-type endopeptidase activity [GO:0004252]	cell surface [GO:0009986]; cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; nucleus [GO:0005634]; phagocytic vesicle lumen [GO:0097013]; protein complex [GO:0043234]; secretory granule [GO:0030141]; specific granule [GO:0042581]
O60858	TRI13_HUMAN	E3 ubiquitin-protein ligase TRIM13 (EC 6.3.2.-) (B-cell chronic lymphocytic leukemia tumor suppressor Leu5) (Leukemia-associated protein 5) (Putative tumor suppressor RFP2) (RING finger protein 77) (Ret finger protein 2) (Tripartite motif-containing protein 13)	TRIM13 LEU5 RFP2 RNF77					PATHWAY: Protein modification; protein ubiquitination.	PF00643;PF13445;	IPR027370;IPR000315;IPR001841;IPR013083;IPR017907;	anatomical structure morphogenesis [GO:0009653]; ER-associated ubiquitin-dependent protein catabolic process [GO:0030433]; innate immune response [GO:0045087]; negative regulation of viral release from host cell [GO:1902187]; negative regulation of viral transcription [GO:0032897]; positive regulation of cell death [GO:0010942]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of macroautophagy [GO:0016239]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; proteasome-mediated ubiquitin-dependent protein catabolic process [GO:0043161]; protein autoubiquitination [GO:0051865]; response to gamma radiation [GO:0010332]	ligase activity [GO:0016874]; signal transducer activity [GO:0004871]; ubiquitin-protein transferase activity [GO:0004842]; zinc ion binding [GO:0008270]	cytoplasm [GO:0005737]; endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; perinuclear endoplasmic reticulum [GO:0097038]
O75762	TRPA1_HUMAN	Transient receptor potential cation channel subfamily A member 1 (Ankyrin-like with transmembrane domains protein 1) (Transformation-sensitive protein p120)	TRPA1 ANKTM1	3J9P;	CHEMBL6007;	O75762;	DB00825;		PF12796;PF00520;	IPR002110;IPR020683;IPR005821;	calcium ion transmembrane transport [GO:0070588]; cell surface receptor signaling pathway [GO:0007166]; detection of chemical stimulus involved in sensory perception of pain [GO:0050968]; detection of mechanical stimulus involved in sensory perception of pain [GO:0050966]; ion transport [GO:0006811]; protein homotetramerization [GO:0051289]; response to cold [GO:0009409]; response to drug [GO:0042493]; response to hydrogen peroxide [GO:0042542]; response to organic cyclic compound [GO:0014070]; response to organic substance [GO:0010033]; response to pain [GO:0048265]; sensory perception of pain [GO:0019233]; thermoception [GO:0050955]	calcium channel activity [GO:0005262]; calcium-release channel activity [GO:0015278]; channel activity [GO:0015267]; temperature-gated cation channel activity [GO:0097604]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; stereocilium bundle [GO:0032421]
Q7Z2W7	TRPM8_HUMAN	Transient receptor potential cation channel subfamily M member 8 (Long transient receptor potential channel 6) (LTrpC-6) (LTrpC6) (Transient receptor potential p8) (Trp-p8)	TRPM8 LTRPC6 TRPP8		CHEMBL1075319;	Q7Z2W7;	DB00825;		PF00520;	IPR005821;IPR029603;	calcium ion transmembrane transport [GO:0070588]; cellular calcium ion homeostasis [GO:0006874]; detection of temperature stimulus [GO:0016048]; protein homotetramerization [GO:0051289]; protein homotrimerization [GO:0070207]; response to cold [GO:0009409]; thermoception [GO:0050955]	calcium channel activity [GO:0005262]	endoplasmic reticulum membrane [GO:0005789]; external side of plasma membrane [GO:0009897]; integral component of membrane [GO:0016021]; membrane raft [GO:0045121]; plasma membrane [GO:0005886]
Q8NER1	TRPV1_HUMAN	Transient receptor potential cation channel subfamily V member 1 (TrpV1) (Capsaicin receptor) (Osm-9-like TRP channel 1) (OTRPC1) (Vanilloid receptor 1)	TRPV1 VR1		CHEMBL4794;	Q8NER1;	DB00132;DB00168;DB06774;DB00159;		PF12796;PF00520;	IPR002110;IPR020683;IPR005821;IPR004729;IPR008347;IPR024863;	behavioral response to pain [GO:0048266]; calcium ion import into cell [GO:1990035]; calcium ion transmembrane transport [GO:0070588]; cell surface receptor signaling pathway [GO:0007166]; cellular response to acidic pH [GO:0071468]; cellular response to alkaloid [GO:0071312]; cellular response to ATP [GO:0071318]; cellular response to heat [GO:0034605]; cellular response to nerve growth factor stimulus [GO:1990090]; cellular response to temperature stimulus [GO:0071502]; cellular response to tumor necrosis factor [GO:0071356]; chemosensory behavior [GO:0007635]; detection of chemical stimulus involved in sensory perception of pain [GO:0050968]; detection of temperature stimulus involved in sensory perception of pain [GO:0050965]; detection of temperature stimulus involved in thermoception [GO:0050960]; diet induced thermogenesis [GO:0002024]; fever generation [GO:0001660]; glutamate secretion [GO:0014047]; lipid metabolic process [GO:0006629]; microglial cell activation [GO:0001774]; negative regulation of establishment of blood-brain barrier [GO:0090212]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; peptide secretion [GO:0002790]; positive regulation of apoptotic process [GO:0043065]; positive regulation of gastric acid secretion [GO:0060454]; positive regulation of nitric oxide biosynthetic process [GO:0045429]; protein homotetramerization [GO:0051289]; response to capsazepine [GO:1901594]; response to peptide hormone [GO:0043434]; sensory perception of mechanical stimulus [GO:0050954]; smooth muscle contraction involved in micturition [GO:0060083]; thermoception [GO:0050955]; transport [GO:0006810]	ATP binding [GO:0005524]; calcium channel activity [GO:0005262]; calcium-release channel activity [GO:0015278]; chloride channel regulator activity [GO:0017081]; excitatory extracellular ligand-gated ion channel activity [GO:0005231]; extracellular ligand-gated ion channel activity [GO:0005230]; metal ion binding [GO:0046872]; phosphatidylinositol binding [GO:0035091]; phosphoprotein binding [GO:0051219]; temperature-gated ion channel activity [GO:0097603]; transmembrane signaling receptor activity [GO:0004888]	cell junction [GO:0030054]; cytosol [GO:0005829]; dendrite [GO:0030425]; dendritic spine membrane [GO:0032591]; external side of plasma membrane [GO:0009897]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; intrinsic component of plasma membrane [GO:0031226]; neuronal cell body [GO:0043025]; plasma membrane [GO:0005886]; postsynaptic membrane [GO:0045211]
Q8NET8	TRPV3_HUMAN	Transient receptor potential cation channel subfamily V member 3 (TrpV3) (Vanilloid receptor-like 3) (VRL-3)	TRPV3		CHEMBL5522;	Q8NET8;	DB00825;		PF12796;PF00520;	IPR002110;IPR020683;IPR005821;IPR008347;IPR024866;	calcium ion transmembrane transport [GO:0070588]; negative regulation of hair cycle [GO:0042636]; positive regulation of calcium ion import [GO:0090280]; response to heat [GO:0009408]	calcium channel activity [GO:0005262]	integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]
Q16881	TRXR1_HUMAN	Thioredoxin reductase 1, cytoplasmic (TR) (EC 1.8.1.9) (Gene associated with retinoic and interferon-induced mortality 12 protein) (GRIM-12) (Gene associated with retinoic and IFN-induced mortality 12 protein) (KM-102-derived reductase-like factor) (Thioredoxin reductase TR1)	TXNRD1 GRIM12 KDRF	1W1C;2CFY;2J3N;2ZZ0;2ZZB;2ZZC;3QFA;3QFB;	CHEMBL1927;	Q16881;	DB01169;DB03147;		PF00462;PF07992;PF02852;	IPR023753;IPR016156;IPR002109;IPR004099;IPR012999;IPR012336;IPR006338;	cell proliferation [GO:0008283]; cell redox homeostasis [GO:0045454]; mesoderm formation [GO:0001707]; nucleobase-containing small molecule interconversion [GO:0015949]; response to reactive oxygen species [GO:0000302]; selenium compound metabolic process [GO:0001887]; signal transduction [GO:0007165]	electron carrier activity [GO:0009055]; flavin adenine dinucleotide binding [GO:0050660]; methylseleninic acid reductase activity [GO:0098626]; methylselenol reductase activity [GO:0098625]; protein disulfide oxidoreductase activity [GO:0015035]; thioredoxin-disulfide reductase activity [GO:0004791]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrion [GO:0005739]; nucleus [GO:0005634]
P07477	TRY1_HUMAN	Trypsin-1 (EC 3.4.21.4) (Beta-trypsin) (Cationic trypsinogen) (Serine protease 1) (Trypsin I) [Cleaved into: Alpha-trypsin chain 1; Alpha-trypsin chain 2]	PRSS1 TRP1 TRY1 TRYP1	1FXY;1TRN;2RA3;4WWY;4WXV;	CHEMBL209;	P07477;	DB06692;		PF00089;	IPR009003;IPR001314;IPR001254;IPR018114;IPR033116;	cobalamin metabolic process [GO:0009235]; digestion [GO:0007586]; extracellular matrix disassembly [GO:0022617]	metal ion binding [GO:0046872]; serine-type endopeptidase activity [GO:0004252]; serine-type peptidase activity [GO:0008236]	blood microparticle [GO:0072562]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]
P35030	TRY3_HUMAN	Trypsin-3 (EC 3.4.21.4) (Brain trypsinogen) (Mesotrypsinogen) (Serine protease 3) (Serine protease 4) (Trypsin III) (Trypsin IV)	PRSS3 PRSS4 TRY3 TRY4	1H4W;2R9P;3L33;3L3T;3P92;3P95;4DG4;4U30;4U32;5C67;	CHEMBL4551;	P35030;			PF00089;	IPR009003;IPR001314;IPR001254;IPR018114;	cobalamin metabolic process [GO:0009235]; digestion [GO:0007586]; endothelial cell migration [GO:0043542]; proteolysis [GO:0006508]; zymogen activation [GO:0031638]	calcium ion binding [GO:0005509]; serine-type endopeptidase activity [GO:0004252]; serine-type peptidase activity [GO:0008236]	extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]
P20231	TRYB2_HUMAN	Tryptase beta-2 (Tryptase-2) (EC 3.4.21.59) (Tryptase II)	TPSB2 TPS2	1A0L;1AAO;2BM2;2FPZ;2FS8;2FS9;2FWW;2FXR;2GDD;2ZA5;3V7T;		P20231;			PF00089;	IPR009003;IPR001314;IPR001254;IPR018114;IPR033116;		serine-type endopeptidase activity [GO:0004252]; serine-type peptidase activity [GO:0008236]	extracellular region [GO:0005576]
Q8TE23	TS1R2_HUMAN	Taste receptor type 1 member 2 (G-protein coupled receptor 71) (Sweet taste receptor T1R2)	TAS1R2 GPR71 T1R2 TR2				DB00168;		PF00003;PF01094;PF07562;	IPR001828;IPR000337;IPR011500;IPR017978;IPR017979;IPR028082;	detection of chemical stimulus involved in sensory perception of sweet taste [GO:0001582]; G-protein coupled receptor signaling pathway [GO:0007186]; positive regulation of cytokinesis [GO:0032467]; sensory perception of sweet taste [GO:0050916]	G-protein coupled receptor activity [GO:0004930]; protein heterodimerization activity [GO:0046982]; taste receptor activity [GO:0008527]	integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]; sweet taste receptor complex [GO:1903767]
Q7RTX0	TS1R3_HUMAN	Taste receptor type 1 member 3 (Sweet taste receptor T1R3)	TAS1R3 T1R3 TR3						PF00003;PF01094;PF07562;	IPR001828;IPR000337;IPR011500;IPR017978;IPR017979;IPR028082;	detection of chemical stimulus involved in sensory perception of sweet taste [GO:0001582]; G-protein coupled receptor signaling pathway [GO:0007186]; sensory perception of sweet taste [GO:0050916]; sensory perception of umami taste [GO:0050917]	G-protein coupled receptor activity [GO:0004930]; protein heterodimerization activity [GO:0046982]; taste receptor activity [GO:0008527]	integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]; sweet taste receptor complex [GO:1903767]
P07996	TSP1_HUMAN	Thrombospondin-1	THBS1 TSP TSP1	1LSL;1UX6;1Z78;1ZA4;2ERF;2ES3;2OUH;2OUJ;3R6B;5FOE;					PF00090;PF02412;PF05735;PF00093;	IPR013320;IPR001881;IPR013032;IPR000742;IPR001791;IPR028499;IPR003367;IPR017897;IPR008859;IPR000884;IPR028974;IPR001007;	activation of MAPK activity [GO:0000187]; behavioral response to pain [GO:0048266]; cell adhesion [GO:0007155]; cell cycle arrest [GO:0007050]; cell migration [GO:0016477]; cellular response to growth factor stimulus [GO:0071363]; cellular response to heat [GO:0034605]; cellular response to tumor necrosis factor [GO:0071356]; chronic inflammatory response [GO:0002544]; engulfment of apoptotic cell [GO:0043652]; extracellular matrix organization [GO:0030198]; immune response [GO:0006955]; inflammatory response [GO:0006954]; negative regulation of angiogenesis [GO:0016525]; negative regulation of antigen processing and presentation of peptide or polysaccharide antigen via MHC class II [GO:0002581]; negative regulation of apoptotic process [GO:0043066]; negative regulation of blood vessel endothelial cell migration [GO:0043537]; negative regulation of cell-matrix adhesion [GO:0001953]; negative regulation of cGMP-mediated signaling [GO:0010754]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154]; negative regulation of dendritic cell antigen processing and presentation [GO:0002605]; negative regulation of endothelial cell chemotaxis [GO:2001027]; negative regulation of endothelial cell migration [GO:0010596]; negative regulation of endothelial cell proliferation [GO:0001937]; negative regulation of extrinsic apoptotic signaling pathway [GO:2001237]; negative regulation of fibrinolysis [GO:0051918]; negative regulation of fibroblast growth factor receptor signaling pathway [GO:0040037]; negative regulation of focal adhesion assembly [GO:0051895]; negative regulation of interleukin-12 production [GO:0032695]; negative regulation of nitric oxide mediated signal transduction [GO:0010751]; negative regulation of plasma membrane long-chain fatty acid transport [GO:0010748]; negative regulation of plasminogen activation [GO:0010757]; peptide cross-linking [GO:0018149]; platelet degranulation [GO:0002576]; positive regulation of angiogenesis [GO:0045766]; positive regulation of blood coagulation [GO:0030194]; positive regulation of blood vessel endothelial cell migration [GO:0043536]; positive regulation of cell migration [GO:0030335]; positive regulation of cell proliferation [GO:0008284]; positive regulation of chemotaxis [GO:0050921]; positive regulation of endothelial cell apoptotic process [GO:2000353]; positive regulation of endothelial cell migration [GO:0010595]; positive regulation of extrinsic apoptotic signaling pathway via death domain receptors [GO:1902043]; positive regulation of fibroblast migration [GO:0010763]; positive regulation of macrophage activation [GO:0043032]; positive regulation of macrophage chemotaxis [GO:0010759]; positive regulation of phosphorylation [GO:0042327]; positive regulation of protein kinase B signaling [GO:0051897]; positive regulation of reactive oxygen species metabolic process [GO:2000379]; positive regulation of smooth muscle cell proliferation [GO:0048661]; positive regulation of transforming growth factor beta1 production [GO:0032914]; positive regulation of transforming growth factor beta receptor signaling pathway [GO:0030511]; positive regulation of translation [GO:0045727]; positive regulation of tumor necrosis factor biosynthetic process [GO:0042535]; protein O-linked fucosylation [GO:0036066]; regulation of cGMP metabolic process [GO:0030823]; response to calcium ion [GO:0051592]; response to drug [GO:0042493]; response to endoplasmic reticulum stress [GO:0034976]; response to glucose [GO:0009749]; response to hypoxia [GO:0001666]; response to magnesium ion [GO:0032026]; response to mechanical stimulus [GO:0009612]; response to progesterone [GO:0032570]; response to testosterone [GO:0033574]; response to unfolded protein [GO:0006986]; sprouting angiogenesis [GO:0002040]	calcium ion binding [GO:0005509]; collagen V binding [GO:0070052]; fibrinogen binding [GO:0070051]; fibroblast growth factor binding [GO:0017134]; fibronectin binding [GO:0001968]; glycoprotein binding [GO:0001948]; heparin binding [GO:0008201]; identical protein binding [GO:0042802]; integrin binding [GO:0005178]; laminin binding [GO:0043236]; low-density lipoprotein particle binding [GO:0030169]; phosphatidylserine binding [GO:0001786]; proteoglycan binding [GO:0043394]; transforming growth factor beta binding [GO:0050431]	cell surface [GO:0009986]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum lumen [GO:0005788]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; extracellular matrix [GO:0031012]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; fibrinogen complex [GO:0005577]; platelet alpha granule [GO:0031091]; platelet alpha granule lumen [GO:0031093]; sarcoplasmic reticulum [GO:0016529]; secretory granule [GO:0030141]
P02766	TTHY_HUMAN	Transthyretin (ATTR) (Prealbumin) (TBPA)	TTR PALB	1BM7;1BMZ;1BZ8;1BZD;1BZE;1DVQ;1DVS;1DVT;1DVU;1DVX;1DVY;1DVZ;1E3F;1E4H;1E5A;1ETA;1ETB;1F41;1F64;1F86;1FH2;1FHN;1G1O;1GKO;1ICT;1III;1IIK;1IJN;1QAB;1QWH;1RLB;1SOK;1SOQ;1THA;1THC;1TLM;1TSH;1TT6;1TTA;1TTB;1TTC;1TTR;1TYR;1TZ8;1U21;1X7S;1X7T;1Y1D;1Z7J;1ZCR;1ZD6;2B14;2B15;2B16;2B77;2B9A;2F7I;2F8I;2FBR;2FLM;2G3X;2G3Z;2G4E;2G4G;2G5U;2G9K;2GAB;2H4E;2M5N;2NOY;2PAB;2QEL;2QGB;2QGC;2QGD;2QGE;2ROX;2ROY;2TRH;2TRY;2WQA;3A4D;3A4E;3A4F;3B56;3BSZ;3BT0;3CBR;3CFM;3CFN;3CFQ;3CFT;3CN0;3CN1;3CN2;3CN3;3CN4;3CXF;3D2T;3D7P;3DGD;3DID;3DJR;3DJS;3DJT;3DJZ;3DK0;3DK2;3DO4;3ESN;3ESO;3ESP;3FC8;3FCB;3GLZ;3GPS;3GRB;3GRG;3GS0;3GS4;3GS7;3HJ0;3I9A;3I9I;3I9P;3IMR;3IMS;3IMT;3IMU;3IMV;3IMW;3IPB;3IPE;3KGS;3KGT;3KGU;3M1O;3NEE;3NEO;3NES;3NEX;3NG5;3OZK;3OZL;3P3R;3P3S;3P3T;3P3U;3SSG;3TCT;3TFB;3U2I;3U2J;3W3B;4ABQ;4ABU;4ABV;4ABW;4AC2;4AC4;4ACT;4ANK;4D7B;4DER;4DES;4DET;4DEU;4DEW;4FI6;4FI7;4FI8;4HIQ;4HIS;4HJS;4HJT;4HJU;4I85;4I87;4I89;4IIZ;4IK6;4IK7;4IKI;4IKJ;4IKK;4IKL;4KY2;4L1S;4L1T;4MAS;4MRB;4MRC;4N85;4N86;4N87;4PM1;4PME;4PMF;4PVL;4PVM;4PVN;4PWE;4PWF;4PWG;4PWH;4PWI;4PWJ;4PWK;4QRF;4QXV;4QYA;4TKW;4TL4;4TL5;4TLK;4TLS;4TLT;4TLU;4TM9;4TNE;4TNF;4TNG;4TQ8;4TQH;4TQI;4TQP;4WNJ;4WNS;4WO0;4Y9B;4Y9C;4Y9E;4Y9F;4Y9G;4YDM;4YDN;5A6I;5AKS;5AKT;5AKV;5AL0;5AL8;5AYT;5BOJ;5CLX;5CLY;5CLZ;5CM1;5CN3;5CNH;5CR1;5DEJ;5DWP;5E23;5E4A;5E4O;5EN3;5EZP;5HJG;5IHH;5K1J;5K1N;5TTR;	CHEMBL3194;	P02766;	DB00586;DB00255;DB00861;DB01093;DB00451;DB00279;DB01583;		PF00576;	IPR023418;IPR000895;IPR023416;IPR023419;	cellular protein metabolic process [GO:0044267]; extracellular matrix organization [GO:0030198]; retinoid metabolic process [GO:0001523]; retinol metabolic process [GO:0042572]; transport [GO:0006810]	identical protein binding [GO:0042802]; thyroid hormone binding [GO:0070324]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; protein complex [GO:0043234]
P49638	TTPA_HUMAN	Alpha-tocopherol transfer protein (Alpha-TTP)	TTPA TPP1	1OIP;1OIZ;1R5L;			DB00163;		PF00650;PF03765;	IPR001071;IPR001251;IPR011074;	embryonic placenta development [GO:0001892]; intermembrane transport [GO:0046909]; intracellular pH reduction [GO:0051452]; lipid metabolic process [GO:0006629]; negative regulation of cell death [GO:0060548]; negative regulation of establishment of blood-brain barrier [GO:0090212]; response to nutrient [GO:0007584]; response to pH [GO:0009268]; response to toxic substance [GO:0009636]; transport [GO:0006810]; vitamin E metabolic process [GO:0042360]; vitamin transport [GO:0051180]	phosphatidylinositol-3,4-bisphosphate binding [GO:0043325]; phosphatidylinositol-4,5-bisphosphate binding [GO:0005546]; transporter activity [GO:0005215]; vitamin E binding [GO:0008431]	cytosol [GO:0005829]; late endosome [GO:0005770]
O95881	TXD12_HUMAN	Thioredoxin domain-containing protein 12 (EC 1.8.4.2) (Endoplasmic reticulum resident protein 18) (ER protein 18) (ERp18) (Endoplasmic reticulum resident protein 19) (ER protein 19) (ERp19) (Thioredoxin-like protein p19) (hTLP19)	TXNDC12 TLP19 UNQ713/PRO1376	1SEN;2K8V;			DB00143;			IPR012336;IPR017937;IPR013766;	cell differentiation [GO:0030154]; cell redox homeostasis [GO:0045454]; negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway [GO:1902236]	peptide disulfide oxidoreductase activity [GO:0015037]; protein-disulfide reductase (glutathione) activity [GO:0019153]	endoplasmic reticulum lumen [GO:0005788]
P07101	TY3H_HUMAN	Tyrosine 3-monooxygenase (EC 1.14.16.2) (Tyrosine 3-hydroxylase) (TH)	TH TYH	2XSN;4J6S;	CHEMBL1969;	P07101;	DB00120;DB00135;DB00765;DB00360;	PATHWAY: Catecholamine biosynthesis; dopamine biosynthesis; dopamine from L-tyrosine: step 1/2.	PF00351;PF12549;	IPR001273;IPR018301;IPR019774;IPR005962;IPR019773;IPR021164;	aminergic neurotransmitter loading into synaptic vesicle [GO:0015842]; anatomical structure morphogenesis [GO:0009653]; animal organ morphogenesis [GO:0009887]; catecholamine biosynthetic process [GO:0042423]; cellular response to drug [GO:0035690]; cellular response to glucose stimulus [GO:0071333]; cellular response to growth factor stimulus [GO:0071363]; cellular response to manganese ion [GO:0071287]; cellular response to nicotine [GO:0071316]; cerebral cortex development [GO:0021987]; circadian sleep/wake cycle [GO:0042745]; dopamine biosynthetic process [GO:0042416]; dopamine biosynthetic process from tyrosine [GO:0006585]; eating behavior [GO:0042755]; embryonic camera-type eye morphogenesis [GO:0048596]; epinephrine biosynthetic process [GO:0042418]; eye photoreceptor cell development [GO:0042462]; fatty acid metabolic process [GO:0006631]; glycoside metabolic process [GO:0016137]; heart development [GO:0007507]; heart morphogenesis [GO:0003007]; isoquinoline alkaloid metabolic process [GO:0033076]; learning [GO:0007612]; locomotory behavior [GO:0007626]; mating behavior [GO:0007617]; memory [GO:0007613]; multicellular organism aging [GO:0010259]; neurotransmitter biosynthetic process [GO:0042136]; norepinephrine biosynthetic process [GO:0042421]; phthalate metabolic process [GO:0018963]; phytoalexin metabolic process [GO:0052314]; pigmentation [GO:0043473]; regulation of heart contraction [GO:0008016]; response to activity [GO:0014823]; response to amphetamine [GO:0001975]; response to corticosterone [GO:0051412]; response to electrical stimulus [GO:0051602]; response to estradiol [GO:0032355]; response to ethanol [GO:0045471]; response to ether [GO:0045472]; response to herbicide [GO:0009635]; response to hypoxia [GO:0001666]; response to immobilization stress [GO:0035902]; response to isolation stress [GO:0035900]; response to light stimulus [GO:0009416]; response to lipopolysaccharide [GO:0032496]; response to nutrient levels [GO:0031667]; response to peptide hormone [GO:0043434]; response to pyrethroid [GO:0046684]; response to salt stress [GO:0009651]; response to water deprivation [GO:0009414]; response to zinc ion [GO:0010043]; sensory perception of sound [GO:0007605]; social behavior [GO:0035176]; sphingolipid metabolic process [GO:0006665]; synaptic transmission, dopaminergic [GO:0001963]; terpene metabolic process [GO:0042214]; visual perception [GO:0007601]	amino acid binding [GO:0016597]; dopamine binding [GO:0035240]; enzyme binding [GO:0019899]; ferric iron binding [GO:0008199]; ferrous iron binding [GO:0008198]; oxygen binding [GO:0019825]; tetrahydrobiopterin binding [GO:0034617]; tyrosine 3-monooxygenase activity [GO:0004511]	cytoplasm [GO:0005737]; cytoplasmic side of plasma membrane [GO:0009898]; cytoplasmic vesicle [GO:0031410]; cytosol [GO:0005829]; dendrite [GO:0030425]; melanosome membrane [GO:0033162]; mitochondrion [GO:0005739]; neuron projection [GO:0043005]; nucleus [GO:0005634]; perikaryon [GO:0043204]; smooth endoplasmic reticulum [GO:0005790]; synaptic vesicle [GO:0008021]; terminal bouton [GO:0043195]
P19971	TYPH_HUMAN	Thymidine phosphorylase (TP) (EC 2.4.2.4) (Gliostatin) (Platelet-derived endothelial cell growth factor) (PD-ECGF) (TdRPase)	TYMP ECGF1	1UOU;2J0F;2WK5;2WK6;	CHEMBL3106;	P19971;	DB01101;DB00369;DB00322;DB00544;DB00432;	PATHWAY: Pyrimidine metabolism; dTMP biosynthesis via salvage pathway; dTMP from thymine: step 1/2.	PF02885;PF00591;PF07831;	IPR000312;IPR017459;IPR013102;IPR018090;IPR017872;IPR000053;	angiogenesis [GO:0001525]; cell differentiation [GO:0030154]; chemotaxis [GO:0006935]; pyrimidine nucleobase metabolic process [GO:0006206]; pyrimidine nucleoside catabolic process [GO:0046135]; pyrimidine nucleoside salvage [GO:0043097]	phosphorylase activity [GO:0004645]; pyrimidine-nucleoside phosphorylase activity [GO:0016154]; thymidine phosphorylase activity [GO:0009032]; transferase activity, transferring pentosyl groups [GO:0016763]	cytosol [GO:0005829]
Q06418	TYRO3_HUMAN	Tyrosine-protein kinase receptor TYRO3 (EC 2.7.10.1) (Tyrosine-protein kinase BYK) (Tyrosine-protein kinase DTK) (Tyrosine-protein kinase RSE) (Tyrosine-protein kinase SKY) (Tyrosine-protein kinase TIF)	TYRO3 BYK DTK RSE SKY TIF	1RHF;	CHEMBL5314;	Q06418;			PF00041;PF07679;PF07714;	IPR003961;IPR007110;IPR013783;IPR013098;IPR003599;IPR003598;IPR011009;IPR000719;IPR017441;IPR001245;IPR008266;IPR020635;	apoptotic cell clearance [GO:0043277]; cell adhesion [GO:0007155]; forebrain cell migration [GO:0021885]; natural killer cell differentiation [GO:0001779]; negative regulation of inflammatory response [GO:0050728]; negative regulation of innate immune response [GO:0045824]; negative regulation of lymphocyte activation [GO:0051250]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of toll-like receptor signaling pathway [GO:0034122]; neuron cellular homeostasis [GO:0070050]; ovulation cycle [GO:0042698]; phosphatidylinositol 3-kinase signaling [GO:0014065]; platelet activation [GO:0030168]; platelet aggregation [GO:0070527]; protein autophosphorylation [GO:0046777]; protein kinase B signaling [GO:0043491]; secretion by cell [GO:0032940]; signal transduction [GO:0007165]; spermatogenesis [GO:0007283]; substrate adhesion-dependent cell spreading [GO:0034446]; vagina development [GO:0060068]	ATP binding [GO:0005524]; phosphatidylinositol 3-kinase binding [GO:0043548]; protein tyrosine kinase activity [GO:0004713]; receptor signaling protein tyrosine kinase activity [GO:0004716]; transmembrane receptor protein tyrosine kinase activity [GO:0004714]; virus receptor activity [GO:0001618]	endoplasmic reticulum membrane [GO:0005789]; integral component of plasma membrane [GO:0005887]; nuclear envelope [GO:0005635]; nucleus [GO:0005634]
P14679	TYRO_HUMAN	Tyrosinase (EC 1.14.18.1) (LB24-AB) (Monophenol monooxygenase) (SK29-AB) (Tumor rejection antigen AB)	TYR		CHEMBL1973;	P14679;	DB00548;DB01055;DB00600;		PF00264;	IPR002227;IPR008922;	cell proliferation [GO:0008283]; eye pigment biosynthetic process [GO:0006726]; melanin biosynthetic process [GO:0042438]; melanin biosynthetic process from tyrosine [GO:0006583]; response to cAMP [GO:0051591]; response to UV [GO:0009411]; response to vitamin D [GO:0033280]; thymus development [GO:0048538]; visual perception [GO:0007601]	copper ion binding [GO:0005507]; monooxygenase activity [GO:0004497]; monophenol monooxygenase activity [GO:0004503]; protein heterodimerization activity [GO:0046982]; protein homodimerization activity [GO:0042803]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; Golgi-associated vesicle [GO:0005798]; integral component of membrane [GO:0016021]; lysosome [GO:0005764]; melanosome [GO:0042470]; melanosome membrane [GO:0033162]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]
P04818	TYSY_HUMAN	Thymidylate synthase (TS) (TSase) (EC 2.1.1.45)	TYMS TS OK/SW-cl.29	1HVY;1HW3;1HW4;1HZW;1I00;1JU6;1JUJ;1YPV;2ONB;2RD8;2RDA;3EAW;3EBU;3ED7;3EDW;3EF9;3EGY;3EHI;3EJL;3GG5;3GH0;3GH2;3H9K;3HB8;3N5E;3N5G;3OB7;4E28;4FGT;4G2O;4G6W;4GD7;4GYH;4H1I;4JEF;4KPW;4O1U;4O1X;4UP1;5HS3;	CHEMBL1952;	P04818;	DB01101;DB00322;DB00544;DB00441;DB00650;DB00563;DB00642;DB06813;DB00293;DB00432;DB00440;	PATHWAY: Pyrimidine metabolism; dTTP biosynthesis.	PF00303;	IPR023451;IPR000398;IPR020940;	aging [GO:0007568]; cartilage development [GO:0051216]; cell growth [GO:0016049]; cell proliferation [GO:0008283]; circadian rhythm [GO:0007623]; deoxyribonucleoside monophosphate biosynthetic process [GO:0009157]; developmental growth [GO:0048589]; DNA biosynthetic process [GO:0071897]; dTMP biosynthetic process [GO:0006231]; dTTP biosynthetic process [GO:0006235]; dUMP metabolic process [GO:0046078]; G1/S transition of mitotic cell cycle [GO:0000082]; immortalization of host cell by virus [GO:0019088]; intestinal epithelial cell maturation [GO:0060574]; liver regeneration [GO:0097421]; nucleobase-containing compound metabolic process [GO:0006139]; pyrimidine nucleoside biosynthetic process [GO:0046134]; regulation of transcription involved in G1/S transition of mitotic cell cycle [GO:0000083]; regulation of translation [GO:0006417]; response to cytokine [GO:0034097]; response to drug [GO:0042493]; response to ethanol [GO:0045471]; response to folic acid [GO:0051593]; response to glucocorticoid [GO:0051384]; response to organophosphorus [GO:0046683]; response to progesterone [GO:0032570]; response to toxic substance [GO:0009636]; response to vitamin A [GO:0033189]; tetrahydrofolate interconversion [GO:0035999]; uracil metabolic process [GO:0019860]	cofactor binding [GO:0048037]; drug binding [GO:0008144]; folic acid binding [GO:0005542]; mRNA binding [GO:0003729]; nucleotide binding [GO:0000166]; thymidylate synthase activity [GO:0004799]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
Q16222	UAP1_HUMAN	UDP-N-acetylhexosamine pyrophosphorylase (Antigen X) (AGX) (Sperm-associated antigen 2) [Includes: UDP-N-acetylgalactosamine pyrophosphorylase (EC 2.7.7.83) (AGX-1); UDP-N-acetylglucosamine pyrophosphorylase (EC 2.7.7.23) (AGX-2)]	UAP1 SPAG2	1JV1;1JV3;1JVD;1JVG;				PATHWAY: Nucleotide-sugar biosynthesis; UDP-N-acetyl-alpha-D-glucosamine biosynthesis; UDP-N-acetyl-alpha-D-glucosamine from N-acetyl-alpha-D-glucosamine 1-phosphate: step 1/1.	PF01704;	IPR029044;IPR002618;	UDP-N-acetylglucosamine biosynthetic process [GO:0006048]	carbohydrate binding [GO:0030246]; UDP-N-acetylglucosamine diphosphorylase activity [GO:0003977]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleoplasm [GO:0005654]; plasma membrane [GO:0005886]
Q9BZX2	UCK2_HUMAN	Uridine-cytidine kinase 2 (UCK 2) (EC 2.7.1.48) (Cytidine monophosphokinase 2) (Testis-specific protein TSA903) (Uridine monophosphokinase 2)	UCK2 UMPK	1UDW;1UEI;1UEJ;1UFQ;1UJ2;1XRJ;	CHEMBL2469;			PATHWAY: Pyrimidine metabolism; CTP biosynthesis via salvage pathway; CTP from cytidine: step 1/3.; PATHWAY: Pyrimidine metabolism; UMP biosynthesis via salvage pathway; UMP from uridine: step 1/1.	PF00485;	IPR027417;IPR006083;IPR029925;IPR000764;	CMP salvage [GO:0006238]; CTP salvage [GO:0044211]; pyrimidine nucleobase metabolic process [GO:0006206]; pyrimidine nucleoside salvage [GO:0043097]; UMP salvage [GO:0044206]	ATP binding [GO:0005524]; nucleoside kinase activity [GO:0019206]; uridine kinase activity [GO:0004849]	cytosol [GO:0005829]
Q9BY64	UDB28_HUMAN	UDP-glucuronosyltransferase 2B28 (UDPGT 2B28) (EC 2.4.1.17)	UGT2B28		CHEMBL6189;				PF00201;	IPR002213;	flavonoid biosynthetic process [GO:0009813]; flavonoid glucuronidation [GO:0052696]; metabolic process [GO:0008152]; xenobiotic metabolic process [GO:0006805]	glucuronosyltransferase activity [GO:0015020]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; organelle membrane [GO:0031090]
O60701	UGDH_HUMAN	UDP-glucose 6-dehydrogenase (UDP-Glc dehydrogenase) (UDP-GlcDH) (UDPGDH) (EC 1.1.1.22)	UGDH	2Q3E;2QG4;3ITK;3KHU;3PRJ;3PTZ;3TDK;3TF5;4EDF;4QEJ;4RJT;				PATHWAY: Nucleotide-sugar biosynthesis; UDP-alpha-D-glucuronate biosynthesis; UDP-alpha-D-glucuronate from UDP-alpha-D-glucose: step 1/1.	PF00984;PF03720;PF03721;	IPR008927;IPR016040;IPR017476;IPR014027;IPR014026;IPR001732;IPR028356;	carbohydrate metabolic process [GO:0005975]; gastrulation with mouth forming second [GO:0001702]; glycosaminoglycan biosynthetic process [GO:0006024]; UDP-glucose metabolic process [GO:0006011]; UDP-glucuronate biosynthetic process [GO:0006065]	electron carrier activity [GO:0009055]; NAD binding [GO:0051287]; UDP-glucose 6-dehydrogenase activity [GO:0003979]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P52758	UK114_HUMAN	Ribonuclease UK114 (EC 3.1.-.-) (14.5 kDa translational inhibitor protein) (p14.5) (Heat-responsive protein 12) (UK114 antigen homolog)	HRSP12 PSP	1ONI;			DB03793;		PF01042;	IPR013813;IPR006056;IPR019897;IPR006175;	brain development [GO:0007420]; G1 to G0 transition [GO:0070314]; kidney development [GO:0001822]; lung development [GO:0030324]; negative regulation of epithelial cell proliferation [GO:0050680]; negative regulation of translation [GO:0017148]; regulation of translational termination [GO:0006449]; response to lipid [GO:0033993]; response to salt [GO:1902074]	endoribonuclease activity, producing 3'-phosphomonoesters [GO:0016892]; long-chain fatty acid binding [GO:0036041]; platinum binding [GO:1904012]; poly(A) RNA binding [GO:0044822]; transition metal ion binding [GO:0046914]; xenon atom binding [GO:1904013]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; peroxisome [GO:0005777]
Q13564	ABP1_HUMAN,ULA1_HUMAN	NEDD8-activating enzyme E1 regulatory subunit (Amyloid beta precursor protein-binding protein 1, 59 kDa) (APP-BP1) (Amyloid protein-binding protein 1) (Proto-oncogene protein 1)	NAE1 APPBP1 HPP1	1R4M;1R4N;1TT5;1YOV;2NVU;3DBH;3DBL;3DBR;3GZN;	CHEMBL2016431;	Q13564;	DB00171;	PATHWAY: Protein modification; protein neddylation.	PF00899;	IPR030667;IPR016040;IPR000594;	mitotic DNA replication checkpoint [GO:0033314]; neuron apoptotic process [GO:0051402]; protein neddylation [GO:0045116]; regulation of apoptotic process [GO:0042981]; regulation of neuron apoptotic process [GO:0043523]; signal transduction [GO:0007165]	NEDD8 activating enzyme activity [GO:0019781]; protein heterodimerization activity [GO:0046982]; ubiquitin protein ligase binding [GO:0031625]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
P31930	UQCR1_HUMAN	Cytochrome b-c1 complex subunit 1, mitochondrial (Complex III subunit 1) (Core protein I) (Ubiquinol-cytochrome-c reductase complex core protein 1)	UQCRC1						PF00675;PF05193;	IPR011249;IPR011237;IPR011765;IPR007863;	aerobic respiration [GO:0009060]; mitochondrial electron transport, ubiquinol to cytochrome c [GO:0006122]; oxidation-reduction process [GO:0055114]; oxidative phosphorylation [GO:0006119]; protein processing [GO:0016485]; response to activity [GO:0014823]; response to alkaloid [GO:0043279]	metalloendopeptidase activity [GO:0004222]; ubiquinol-cytochrome-c reductase activity [GO:0008121]; ubiquitin protein ligase binding [GO:0031625]; zinc ion binding [GO:0008270]	mitochondrial inner membrane [GO:0005743]; mitochondrial respiratory chain [GO:0005746]; mitochondrial respiratory chain complex III [GO:0005750]; mitochondrion [GO:0005739]; myelin sheath [GO:0043209]
P00749	UROK_HUMAN	Urokinase-type plasminogen activator (U-plasminogen activator) (uPA) (EC 3.4.21.73) [Cleaved into: Urokinase-type plasminogen activator long chain A; Urokinase-type plasminogen activator short chain A; Urokinase-type plasminogen activator chain B]	PLAU	1C5W;1C5X;1C5Y;1C5Z;1EJN;1F5K;1F5L;1F92;1FV9;1GI7;1GI8;1GI9;1GJ7;1GJ8;1GJ9;1GJA;1GJB;1GJC;1GJD;1KDU;1LMW;1O3P;1O5A;1O5B;1O5C;1OWD;1OWE;1OWH;1OWI;1OWJ;1OWK;1SC8;1SQA;1SQO;1SQT;1U6Q;1URK;1VJ9;1VJA;1W0Z;1W10;1W11;1W12;1W13;1W14;2FD6;2I9A;2I9B;2NWN;2O8T;2O8U;2O8W;2R2W;2VIN;2VIO;2VIP;2VIQ;2VIV;2VIW;2VNT;3BT1;3BT2;3IG6;3KGP;3KHV;3KID;3M61;3MHW;3MWI;3OX7;3OY5;3OY6;3PB1;3QN7;3U73;4DVA;4DW2;4FU7;4FU8;4FU9;4FUB;4FUC;4FUD;4FUE;4FUF;4FUG;4FUH;4FUI;4FUJ;4GLY;4H42;4JK5;4JK6;4JNI;4JNL;4K24;4MNV;4MNW;4MNX;4MNY;4OS1;4OS2;4OS4;4OS5;4OS6;4OS7;4X0W;4X1N;4X1P;4X1Q;4X1R;4X1S;4XSK;4ZHL;4ZHM;4ZKN;4ZKO;4ZKR;4ZKS;5HGG;	CHEMBL3286;	P00749;	DB00594;DB00013;		PF00051;PF00089;	IPR013032;IPR000742;IPR000001;IPR013806;IPR018056;IPR009003;IPR001314;IPR001254;IPR018114;IPR033116;	blood coagulation [GO:0007596]; chemotaxis [GO:0006935]; fibrinolysis [GO:0042730]; positive regulation of cell migration [GO:0030335]; proteolysis [GO:0006508]; regulation of cell adhesion mediated by integrin [GO:0033628]; regulation of cell proliferation [GO:0042127]; regulation of receptor activity [GO:0010469]; regulation of smooth muscle cell-matrix adhesion [GO:2000097]; regulation of smooth muscle cell migration [GO:0014910]; regulation of wound healing [GO:0061041]; response to hypoxia [GO:0001666]; signal transduction [GO:0007165]; smooth muscle cell migration [GO:0014909]	serine-type endopeptidase activity [GO:0004252]	cell surface [GO:0009986]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; focal adhesion [GO:0005925]; plasma membrane [GO:0005886]
P37288	V1AR_HUMAN	Vasopressin V1a receptor (V1aR) (AVPR V1a) (Antidiuretic hormone receptor 1a) (Vascular/hepatic-type arginine vasopressin receptor)	AVPR1A AVPR1	1YTV;	CHEMBL1889;	P37288;	DB00872;DB00035;DB00093;DB02638;DB06212;DB00067;		PF00001;PF08983;	IPR015076;IPR000276;IPR017452;IPR001817;IPR001224;	activation of phospholipase C activity [GO:0007202]; blood circulation [GO:0008015]; calcium-mediated signaling [GO:0019722]; cellular response to hormone stimulus [GO:0032870]; cellular response to water deprivation [GO:0042631]; generation of precursor metabolites and energy [GO:0006091]; G-protein coupled receptor signaling pathway [GO:0007186]; grooming behavior [GO:0007625]; maternal aggressive behavior [GO:0002125]; maternal behavior [GO:0042711]; myotube differentiation [GO:0014902]; negative regulation of female receptivity [GO:0007621]; negative regulation of transmission of nerve impulse [GO:0051970]; penile erection [GO:0043084]; positive regulation of cell growth [GO:0030307]; positive regulation of cell proliferation [GO:0008284]; positive regulation of cellular pH reduction [GO:0032849]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of glutamate secretion [GO:0014049]; positive regulation of heart rate [GO:0010460]; positive regulation of prostaglandin biosynthetic process [GO:0031394]; positive regulation of renal sodium excretion [GO:0035815]; positive regulation of systemic arterial blood pressure [GO:0003084]; positive regulation of vasoconstriction [GO:0045907]; regulation of systemic arterial blood pressure by vasopressin [GO:0001992]; response to corticosterone [GO:0051412]; response to peptide [GO:1901652]; social behavior [GO:0035176]; sperm ejaculation [GO:0042713]; telencephalon development [GO:0021537]	peptide binding [GO:0042277]; peptide hormone binding [GO:0017046]; protein kinase C binding [GO:0005080]; vasopressin receptor activity [GO:0005000]	cytoplasmic vesicle [GO:0031410]; endosome [GO:0005768]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P47901	V1BR_HUMAN	Vasopressin V1b receptor (V1bR) (AVPR V1b) (AVPR V3) (Antidiuretic hormone receptor 1b) (Vasopressin V3 receptor)	AVPR1B AVPR3 VPR3		CHEMBL1921;	P47901;	DB00035;DB02638;DB00067;		PF00001;PF08983;	IPR015076;IPR000276;IPR017452;IPR001817;IPR000628;	activation of phospholipase C activity [GO:0007202]; cellular response to hormone stimulus [GO:0032870]; G-protein coupled receptor signaling pathway [GO:0007186]; positive regulation of cytosolic calcium ion concentration [GO:0007204]; positive regulation of vasoconstriction [GO:0045907]; regulation of systemic arterial blood pressure by vasopressin [GO:0001992]; response to peptide [GO:1901652]	peptide binding [GO:0042277]; protein kinase C binding [GO:0005080]; vasopressin receptor activity [GO:0005000]	endosome [GO:0005768]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P30518	V2R_HUMAN	Vasopressin V2 receptor (V2R) (AVPR V2) (Antidiuretic hormone receptor) (Renal-type arginine vasopressin receptor)	AVPR2 ADHR DIR DIR3 V2R	4JQI;	CHEMBL1790;	P30518;	DB00872;DB00035;DB02638;DB06212;DB00067;		PF00001;	IPR000276;IPR017452;IPR001817;IPR000161;	activation of adenylate cyclase activity [GO:0007190]; adenylate cyclase-modulating G-protein coupled receptor signaling pathway [GO:0007188]; cellular response to hormone stimulus [GO:0032870]; excretion [GO:0007588]; hemostasis [GO:0007599]; I-kappaB kinase/NF-kappaB signaling [GO:0007249]; interferon-gamma production [GO:0032609]; negative regulation of renal sodium excretion [GO:0035814]; negative regulation of urine volume [GO:0035811]; positive regulation of cell proliferation [GO:0008284]; positive regulation of gene expression [GO:0010628]; positive regulation of protein ubiquitination [GO:0031398]; positive regulation of systemic arterial blood pressure [GO:0003084]; positive regulation of vasoconstriction [GO:0045907]; regulation of systemic arterial blood pressure by vasopressin [GO:0001992]; renal water homeostasis [GO:0003091]; response to cytokine [GO:0034097]; response to peptide [GO:1901652]; telencephalon development [GO:0021537]	peptide binding [GO:0042277]; vasopressin receptor activity [GO:0005000]	endoplasmic reticulum [GO:0005783]; endosome [GO:0005768]; Golgi apparatus [GO:0005794]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]
P19320	VCAM1_HUMAN	Vascular cell adhesion protein 1 (V-CAM 1) (VCAM-1) (INCAM-100) (CD antigen CD106)	VCAM1 L1CAM	1IJ9;1VCA;1VSC;	CHEMBL3735;	P19320;	DB01136;DB00898;		PF05790;PF07679;PF00047;	IPR003987;IPR007110;IPR013783;IPR008424;IPR013098;IPR003599;IPR003598;IPR013106;IPR013151;IPR003989;	acute inflammatory response [GO:0002526]; aging [GO:0007568]; amine metabolic process [GO:0009308]; B cell differentiation [GO:0030183]; calcium-mediated signaling using intracellular calcium source [GO:0035584]; cell adhesion [GO:0007155]; cell chemotaxis [GO:0060326]; cell-matrix adhesion [GO:0007160]; cellular response to tumor necrosis factor [GO:0071356]; cellular response to vascular endothelial growth factor stimulus [GO:0035924]; chronic inflammatory response [GO:0002544]; extracellular matrix organization [GO:0030198]; heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules [GO:0007157]; interferon-gamma-mediated signaling pathway [GO:0060333]; leukocyte cell-cell adhesion [GO:0007159]; leukocyte tethering or rolling [GO:0050901]; membrane to membrane docking [GO:0022614]; positive regulation of T cell proliferation [GO:0042102]; regulation of immune response [GO:0050776]; response to ethanol [GO:0045471]; response to hypoxia [GO:0001666]; response to ionizing radiation [GO:0010212]; response to lipopolysaccharide [GO:0032496]; response to nicotine [GO:0035094]; response to nutrient [GO:0007584]; response to zinc ion [GO:0010043]; viral process [GO:0016032]	cell adhesion molecule binding [GO:0050839]; integrin binding [GO:0005178]; primary amine oxidase activity [GO:0008131]	alpha9-beta1 integrin-vascular cell adhesion molecule-1 complex [GO:0071065]; apical part of cell [GO:0045177]; cell surface [GO:0009986]; early endosome [GO:0005769]; endoplasmic reticulum [GO:0005783]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; filopodium [GO:0030175]; Golgi apparatus [GO:0005794]; integral component of membrane [GO:0016021]; microvillus [GO:0005902]; plasma membrane [GO:0005886]; podosome [GO:0002102]; sarcolemma [GO:0042383]
P21796	VDAC1_HUMAN	Voltage-dependent anion-selective channel protein 1 (VDAC-1) (hVDAC1) (Outer mitochondrial membrane protein porin 1) (Plasmalemmal porin) (Porin 31HL) (Porin 31HM)	VDAC1 VDAC	2JK4;2K4T;5JDP;			DB01375;		PF01459;	IPR023614;IPR001925;IPR027246;IPR030270;	anion transport [GO:0006820]; apoptotic process [GO:0006915]; behavioral fear response [GO:0001662]; epithelial cell differentiation [GO:0030855]; learning [GO:0007612]; macroautophagy [GO:0016236]; mitochondrial calcium ion transport [GO:0006851]; negative regulation of reactive oxygen species metabolic process [GO:2000378]; neuron-neuron synaptic transmission [GO:0007270]; regulation of mitophagy [GO:1903146]; viral process [GO:0016032]	ion channel binding [GO:0044325]; porin activity [GO:0015288]; protein kinase binding [GO:0019901]; voltage-gated anion channel activity [GO:0008308]	extracellular exosome [GO:0070062]; membrane [GO:0016020]; membrane raft [GO:0045121]; mitochondrial inner membrane [GO:0005743]; mitochondrial nucleoid [GO:0042645]; mitochondrial outer membrane [GO:0005741]; mitochondrion [GO:0005739]; myelin sheath [GO:0043209]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; pore complex [GO:0046930]; synaptic vesicle [GO:0008021]
P45880	VDAC2_HUMAN	Voltage-dependent anion-selective channel protein 2 (VDAC-2) (hVDAC2) (Outer mitochondrial membrane protein porin 2)	VDAC2		CHEMBL6190;	P45880;	DB01375;		PF01459;	IPR023614;IPR001925;IPR027246;IPR030277;	anion transport [GO:0006820]; negative regulation of intrinsic apoptotic signaling pathway [GO:2001243]; negative regulation of protein polymerization [GO:0032272]	nucleotide binding [GO:0000166]; porin activity [GO:0015288]; voltage-gated anion channel activity [GO:0008308]	extracellular exosome [GO:0070062]; membrane raft [GO:0045121]; mitochondrial inner membrane [GO:0005743]; mitochondrial nucleoid [GO:0042645]; mitochondrial outer membrane [GO:0005741]; mitochondrion [GO:0005739]; myelin sheath [GO:0043209]; nucleus [GO:0005634]; pore complex [GO:0046930]; synaptic vesicle [GO:0008021]
Q9Y277	VDAC3_HUMAN	Voltage-dependent anion-selective channel protein 3 (VDAC-3) (hVDAC3) (Outer mitochondrial membrane protein porin 3)	VDAC3				DB01375;		PF01459;	IPR023614;IPR001925;IPR027246;IPR030271;	adenine transport [GO:0015853]; regulation of cilium assembly [GO:1902017]	nucleotide binding [GO:0000166]; porin activity [GO:0015288]; voltage-gated anion channel activity [GO:0008308]	extracellular exosome [GO:0070062]; mitochondrial outer membrane [GO:0005741]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; pore complex [GO:0046930]
P11473	VDR_HUMAN	Vitamin D3 receptor (VDR) (1,25-dihydroxyvitamin D3 receptor) (Nuclear receptor subfamily 1 group I member 1)	VDR NR1I1	1DB1;1IE8;1IE9;1KB2;1KB4;1KB6;1S0Z;1S19;1TXI;1YNW;2HAM;2HAR;2HAS;2HB7;2HB8;3A2I;3A2J;3A3Z;3A40;3A78;3AUQ;3AUR;3AX8;3AZ1;3AZ2;3AZ3;3B0T;3CS4;3CS6;3KPZ;3M7R;3OGT;3P8X;3TKC;3VHW;3W0A;3W0C;3W0Y;3WGP;3WWR;3X31;3X36;4G2I;4ITE;4ITF;4PA2;	CHEMBL1977;	P11473;	DB01436;DB00146;DB02300;DB00136;DB00169;DB01070;DB06410;DB00153;DB00910;		PF00104;PF00105;	IPR000536;IPR001723;IPR000324;IPR001628;IPR013088;	bile acid signaling pathway [GO:0038183]; calcium ion transport [GO:0006816]; cell morphogenesis [GO:0000902]; cellular calcium ion homeostasis [GO:0006874]; decidualization [GO:0046697]; intestinal absorption [GO:0050892]; lactation [GO:0007595]; mammary gland branching involved in pregnancy [GO:0060745]; negative regulation of cell proliferation [GO:0008285]; negative regulation of keratinocyte proliferation [GO:0010839]; negative regulation of transcription, DNA-templated [GO:0045892]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; positive regulation of apoptotic process involved in mammary gland involution [GO:0060058]; positive regulation of gene expression [GO:0010628]; positive regulation of keratinocyte differentiation [GO:0045618]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of vitamin D 24-hydroxylase activity [GO:0010980]; regulation of calcidiol 1-monooxygenase activity [GO:0060558]; signal transduction [GO:0007165]; skeletal system development [GO:0001501]; transcription initiation from RNA polymerase II promoter [GO:0006367]; vitamin D receptor signaling pathway [GO:0070561]	calcitriol binding [GO:1902098]; calcitriol receptor activity [GO:0008434]; DNA binding [GO:0003677]; lithocholic acid binding [GO:1902121]; lithocholic acid receptor activity [GO:0038186]; retinoid X receptor binding [GO:0046965]; sequence-specific DNA binding [GO:0043565]; steroid hormone receptor activity [GO:0003707]; zinc ion binding [GO:0008270]	nucleoplasm [GO:0005654]; nucleus [GO:0005634]; receptor complex [GO:0043235]; RNA polymerase II transcription factor complex [GO:0090575]
P15692	VEGFA_HUMAN	Vascular endothelial growth factor A (VEGF-A) (Vascular permeability factor) (VPF)	VEGFA VEGF	1BJ1;1CZ8;1FLT;1KAT;1KMX;1MJV;1MKG;1MKK;1QTY;1TZH;1TZI;1VGH;1VPF;1VPP;2FJG;2FJH;2QR0;2VGH;2VPF;3BDY;3P9W;3QTK;3S1B;3S1K;3V2A;4DEQ;4GLN;4GLS;4KZN;4QAF;4WPB;4ZFF;5DN2;5FV1;5FV2;5HHC;5HHD;	CHEMBL1783;	P15692;	DB08885;DB00112;DB01136;DB06779;DB01120;DB01017;DB01270;DB03754;DB05294;		PF00341;PF14554;	IPR029034;IPR023581;IPR000072;IPR027928;	activation of protein kinase activity [GO:0032147]; angiogenesis [GO:0001525]; artery morphogenesis [GO:0048844]; basophil chemotaxis [GO:0002575]; branching morphogenesis of an epithelial tube [GO:0048754]; camera-type eye morphogenesis [GO:0048593]; cardiac muscle fiber development [GO:0048739]; cardiac vascular smooth muscle cell development [GO:0060948]; cell maturation [GO:0048469]; cell migration involved in sprouting angiogenesis [GO:0002042]; cellular response to hypoxia [GO:0071456]; cellular response to vascular endothelial growth factor stimulus [GO:0035924]; commissural neuron axon guidance [GO:0071679]; coronary artery morphogenesis [GO:0060982]; coronary vein morphogenesis [GO:0003169]; dopaminergic neuron differentiation [GO:0071542]; endothelial cell chemotaxis [GO:0035767]; epithelial cell differentiation [GO:0030855]; eye photoreceptor cell development [GO:0042462]; growth [GO:0040007]; heart morphogenesis [GO:0003007]; induction of positive chemotaxis [GO:0050930]; in utero embryonic development [GO:0001701]; kidney development [GO:0001822]; lactation [GO:0007595]; lung development [GO:0030324]; lymph vessel morphogenesis [GO:0036303]; macrophage differentiation [GO:0030225]; mammary gland alveolus development [GO:0060749]; mesoderm development [GO:0007498]; monocyte differentiation [GO:0030224]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154]; negative regulation of transcription from RNA polymerase II promoter [GO:0000122]; nervous system development [GO:0007399]; outflow tract morphogenesis [GO:0003151]; ovarian follicle development [GO:0001541]; patterning of blood vessels [GO:0001569]; platelet degranulation [GO:0002576]; positive chemotaxis [GO:0050918]; positive regulation of angiogenesis [GO:0045766]; positive regulation of axon extension involved in axon guidance [GO:0048842]; positive regulation of blood vessel endothelial cell migration [GO:0043536]; positive regulation of branching involved in ureteric bud morphogenesis [GO:0090190]; positive regulation of cell adhesion [GO:0045785]; positive regulation of cell division [GO:0051781]; positive regulation of cell migration [GO:0030335]; positive regulation of cell migration involved in sprouting angiogenesis [GO:0090050]; positive regulation of cell proliferation [GO:0008284]; positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway [GO:0038091]; positive regulation of cellular component movement [GO:0051272]; positive regulation of CREB transcription factor activity [GO:0032793]; positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway [GO:0038033]; positive regulation of endothelial cell migration [GO:0010595]; positive regulation of endothelial cell proliferation [GO:0001938]; positive regulation of epithelial cell proliferation [GO:0050679]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of focal adhesion assembly [GO:0051894]; positive regulation of gene expression [GO:0010628]; positive regulation of histone deacetylase activity [GO:1901727]; positive regulation of leukocyte migration [GO:0002687]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of mast cell chemotaxis [GO:0060754]; positive regulation of mesenchymal cell proliferation [GO:0002053]; positive regulation of neuroblast proliferation [GO:0002052]; positive regulation of p38MAPK cascade [GO:1900745]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of peptidyl-tyrosine autophosphorylation [GO:1900086]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of positive chemotaxis [GO:0050927]; positive regulation of protein autophosphorylation [GO:0031954]; positive regulation of protein complex assembly [GO:0031334]; positive regulation of protein kinase C signaling [GO:0090037]; positive regulation of protein kinase D signaling [GO:1903572]; positive regulation of protein localization to early endosome [GO:1902966]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of receptor internalization [GO:0002092]; positive regulation of retinal ganglion cell axon guidance [GO:1902336]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; positive regulation of transcription from RNA polymerase II promoter in response to hypoxia [GO:0061419]; positive regulation of vascular endothelial growth factor receptor signaling pathway [GO:0030949]; positive regulation of vascular permeability [GO:0043117]; post-embryonic camera-type eye development [GO:0031077]; primitive erythrocyte differentiation [GO:0060319]; regulation of cell shape [GO:0008360]; regulation of cGMP metabolic process [GO:0030823]; regulation of retinal ganglion cell axon guidance [GO:0090259]; regulation of transcription from RNA polymerase II promoter [GO:0006357]; regulation of transcription from RNA polymerase II promoter in response to hypoxia [GO:0061418]; response to hypoxia [GO:0001666]; surfactant homeostasis [GO:0043129]; tube formation [GO:0035148]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]; vascular endothelial growth factor signaling pathway [GO:0038084]; vasculogenesis [GO:0001570]; VEGF-activated neuropilin signaling pathway [GO:0038190]	chemoattractant activity [GO:0042056]; cytokine activity [GO:0005125]; extracellular matrix binding [GO:0050840]; fibronectin binding [GO:0001968]; growth factor activity [GO:0008083]; heparin binding [GO:0008201]; identical protein binding [GO:0042802]; neuropilin binding [GO:0038191]; platelet-derived growth factor receptor binding [GO:0005161]; protein heterodimerization activity [GO:0046982]; protein homodimerization activity [GO:0042803]; receptor agonist activity [GO:0048018]; vascular endothelial growth factor receptor 1 binding [GO:0043183]; vascular endothelial growth factor receptor 2 binding [GO:0043184]; vascular endothelial growth factor receptor binding [GO:0005172]	cell surface [GO:0009986]; cytoplasm [GO:0005737]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; membrane [GO:0016020]; platelet alpha granule lumen [GO:0031093]; proteinaceous extracellular matrix [GO:0005578]; secretory granule [GO:0030141]
P17948	VGFR1_HUMAN	Vascular endothelial growth factor receptor 1 (VEGFR-1) (EC 2.7.10.1) (Fms-like tyrosine kinase 1) (FLT-1) (Tyrosine-protein kinase FRT) (Tyrosine-protein kinase receptor FLT) (FLT) (Vascular permeability factor receptor)	FLT1 FLT FRT VEGFR1	1FLT;1QSV;1QSZ;1QTY;1RV6;2XAC;3HNG;4CKV;4CL7;5EX3;	CHEMBL1868;	P17948;	DB06626;DB09078;DB09079;DB06589;DB08896;DB00398;DB01268;		PF07679;PF00047;PF07714;	IPR007110;IPR013783;IPR013098;IPR003599;IPR003598;IPR013106;IPR013151;IPR011009;IPR000719;IPR017441;IPR001245;IPR008266;IPR020635;IPR001824;IPR009135;	angiogenesis [GO:0001525]; blood vessel morphogenesis [GO:0048514]; cell differentiation [GO:0030154]; cell migration [GO:0016477]; cellular response to vascular endothelial growth factor stimulus [GO:0035924]; embryonic morphogenesis [GO:0048598]; monocyte chemotaxis [GO:0002548]; peptidyl-tyrosine phosphorylation [GO:0018108]; positive regulation of angiogenesis [GO:0045766]; positive regulation of cell migration [GO:0030335]; positive regulation of cell proliferation [GO:0008284]; positive regulation of MAPK cascade [GO:0043410]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of phosphatidylinositol 3-kinase activity [GO:0043552]; positive regulation of phosphatidylinositol 3-kinase signaling [GO:0014068]; positive regulation of phospholipase C activity [GO:0010863]; positive regulation of vascular endothelial growth factor receptor signaling pathway [GO:0030949]; protein autophosphorylation [GO:0046777]; transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169]; vascular endothelial growth factor receptor-1 signaling pathway [GO:0036323]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]	ATP binding [GO:0005524]; growth factor binding [GO:0019838]; placental growth factor-activated receptor activity [GO:0036332]; transmembrane receptor protein tyrosine kinase activity [GO:0004714]; vascular endothelial growth factor-activated receptor activity [GO:0005021]; VEGF-A-activated receptor activity [GO:0036326]; VEGF-B-activated receptor activity [GO:0036327]	endosome [GO:0005768]; extracellular space [GO:0005615]; focal adhesion [GO:0005925]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]
P35968	VGFR2_HUMAN	Vascular endothelial growth factor receptor 2 (VEGFR-2) (EC 2.7.10.1) (Fetal liver kinase 1) (FLK-1) (Kinase insert domain receptor) (KDR) (Protein-tyrosine kinase receptor flk-1) (CD antigen CD309)	KDR FLK1 VEGFR2	1VR2;1Y6A;1Y6B;1YWN;2M59;2MET;2MEU;2OH4;2P2H;2P2I;2QU5;2QU6;2RL5;2X1W;2X1X;2XIR;3B8Q;3B8R;3BE2;3C7Q;3CJF;3CJG;3CP9;3CPB;3CPC;3DTW;3EFL;3EWH;3KVQ;3S35;3S36;3S37;3U6J;3V2A;3V6B;3VHE;3VHK;3VID;3VNT;3VO3;3WZD;3WZE;4AG8;4AGC;4AGD;4ASD;4ASE;5EW3;	CHEMBL279;	P35968;	DB06626;DB08875;DB09078;DB09079;DB06589;DB08901;DB05578;DB08896;DB00398;DB01268;		PF07679;PF00047;PF07714;	IPR007110;IPR013783;IPR013098;IPR003599;IPR003598;IPR013151;IPR011009;IPR000719;IPR017441;IPR001245;IPR008266;IPR020635;IPR001824;IPR009136;	angiogenesis [GO:0001525]; calcium-mediated signaling using intracellular calcium source [GO:0035584]; cell migration involved in sprouting angiogenesis [GO:0002042]; cellular response to vascular endothelial growth factor stimulus [GO:0035924]; embryonic hemopoiesis [GO:0035162]; endothelium development [GO:0003158]; extracellular matrix organization [GO:0030198]; negative regulation of apoptotic process [GO:0043066]; negative regulation of endothelial cell apoptotic process [GO:2000352]; peptidyl-tyrosine autophosphorylation [GO:0038083]; peptidyl-tyrosine phosphorylation [GO:0018108]; positive regulation of angiogenesis [GO:0045766]; positive regulation of cell migration [GO:0030335]; positive regulation of cell proliferation [GO:0008284]; positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway [GO:0038033]; positive regulation of endothelial cell migration [GO:0010595]; positive regulation of endothelial cell proliferation [GO:0001938]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of focal adhesion assembly [GO:0051894]; positive regulation of macroautophagy [GO:0016239]; positive regulation of MAPK cascade [GO:0043410]; positive regulation of mitochondrial depolarization [GO:0051901]; positive regulation of mitochondrial fission [GO:0090141]; positive regulation of nitric-oxide synthase biosynthetic process [GO:0051770]; positive regulation of phosphatidylinositol 3-kinase signaling [GO:0014068]; positive regulation of positive chemotaxis [GO:0050927]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of vasculogenesis [GO:2001214]; protein autophosphorylation [GO:0046777]; regulation of cell shape [GO:0008360]; transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]; vasculogenesis [GO:0001570]; viral process [GO:0016032]	ATP binding [GO:0005524]; growth factor binding [GO:0019838]; Hsp90 protein binding [GO:0051879]; integrin binding [GO:0005178]; protein tyrosine kinase activity [GO:0004713]; receptor signaling protein tyrosine kinase activity [GO:0004716]; transmembrane receptor protein tyrosine kinase activity [GO:0004714]; vascular endothelial growth factor-activated receptor activity [GO:0005021]; vascular endothelial growth factor binding [GO:0038085]	cell junction [GO:0030054]; cytoplasmic, membrane-bounded vesicle [GO:0016023]; early endosome [GO:0005769]; endoplasmic reticulum [GO:0005783]; endosome [GO:0005768]; extracellular region [GO:0005576]; Golgi apparatus [GO:0005794]; integral component of plasma membrane [GO:0005887]; membrane raft [GO:0045121]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; sorting endosome [GO:0097443]
P35916	VGFR3_HUMAN	Vascular endothelial growth factor receptor 3 (VEGFR-3) (EC 2.7.10.1) (Fms-like tyrosine kinase 4) (FLT-4) (Tyrosine-protein kinase receptor FLT4)	FLT4 VEGFR3	4BSJ;4BSK;	CHEMBL1955;	P35916;	DB06626;DB09078;DB09079;DB06589;DB08896;DB00398;DB01268;		PF07679;PF07714;	IPR007110;IPR013783;IPR013098;IPR003599;IPR003598;IPR011009;IPR000719;IPR017441;IPR001245;IPR008266;IPR020635;IPR001824;IPR009137;	blood vessel morphogenesis [GO:0048514]; cellular response to vascular endothelial growth factor stimulus [GO:0035924]; lung alveolus development [GO:0048286]; lymphangiogenesis [GO:0001946]; lymph vessel development [GO:0001945]; negative regulation of apoptotic process [GO:0043066]; peptidyl-tyrosine phosphorylation [GO:0018108]; positive regulation of cell proliferation [GO:0008284]; positive regulation of endothelial cell migration [GO:0010595]; positive regulation of endothelial cell proliferation [GO:0001938]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of JNK cascade [GO:0046330]; positive regulation of MAPK cascade [GO:0043410]; positive regulation of protein kinase C signaling [GO:0090037]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of vascular endothelial growth factor production [GO:0010575]; protein autophosphorylation [GO:0046777]; regulation of blood vessel remodeling [GO:0060312]; respiratory system process [GO:0003016]; sprouting angiogenesis [GO:0002040]; transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]; vasculature development [GO:0001944]	ATP binding [GO:0005524]; growth factor binding [GO:0019838]; protein phosphatase binding [GO:0019903]; transmembrane receptor protein tyrosine kinase activity [GO:0004714]; vascular endothelial growth factor-activated receptor activity [GO:0005021]	cytoplasm [GO:0005737]; extracellular region [GO:0005576]; integral component of plasma membrane [GO:0005887]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]
Q9H598	VIAAT_HUMAN	Vesicular inhibitory amino acid transporter (GABA and glycine transporter) (Solute carrier family 32 member 1) (Vesicular GABA transporter) (hVIAAT)	SLC32A1 VGAT VIAAT				DB00145;		PF01490;	IPR013057;	aging [GO:0007568]; amino acid transmembrane transport [GO:0003333]; hippocampus development [GO:0021766]; ion transport [GO:0006811]; neurotransmitter secretion [GO:0007269]	amino acid transmembrane transporter activity [GO:0015171]; gamma-aminobutyric acid:proton symporter activity [GO:0015495]; glycine transmembrane transporter activity [GO:0015187]; vesicular hydrogen:amino acid antiporter activity [GO:0005276]	cell tip [GO:0051286]; clathrin-sculpted gamma-aminobutyric acid transport vesicle membrane [GO:0061202]; cone cell pedicle [GO:0044316]; dendrite [GO:0030425]; dendrite terminus [GO:0044292]; inhibitory synapse [GO:0060077]; integral component of membrane [GO:0016021]; neuron projection [GO:0043005]; neuron projection terminus [GO:0044306]; plasma membrane [GO:0005886]; presynaptic active zone [GO:0048786]; synaptic vesicle membrane [GO:0030672]
P38435	VKGC_HUMAN	Vitamin K-dependent gamma-carboxylase (EC 4.1.1.90) (Gamma-glutamyl carboxylase) (Peptidyl-glutamate 4-carboxylase) (Vitamin K gamma glutamyl carboxylase)	GGCX GC		CHEMBL2012;		DB01125;DB00100;DB00036;DB00055;DB00170;DB01022;		PF05090;	IPR011020;IPR014710;IPR011051;IPR007782;	blood coagulation [GO:0007596]; cellular protein modification process [GO:0006464]; peptidyl-glutamic acid carboxylation [GO:0017187]	gamma-glutamyl carboxylase activity [GO:0008488]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; membrane [GO:0016020]
Q9BQB6	VKOR1_HUMAN	Vitamin K epoxide reductase complex subunit 1 (EC 1.17.4.4) (Vitamin K1 2,3-epoxide reductase subunit 1)	VKORC1 VKOR MSTP134 MSTP576 UNQ308/PRO351		CHEMBL1930;	Q9BQB6;	DB01418;DB00266;DB00170;DB00498;DB00946;DB00682;		PF07884;	IPR012932;	blood coagulation [GO:0007596]; bone development [GO:0060348]; drug metabolic process [GO:0017144]; peptidyl-glutamic acid carboxylation [GO:0017187]; vitamin K metabolic process [GO:0042373]	quinone binding [GO:0048038]; vitamin-K-epoxide reductase (warfarin-sensitive) activity [GO:0047057]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]
Q8N0U8	VKORL_HUMAN	Vitamin K epoxide reductase complex subunit 1-like protein 1 (VKORC1-like protein 1) (EC 1.17.4.4)	VKORC1L1				DB00170;		PF07884;	IPR012932;	cellular response to oxidative stress [GO:0034599]; peptidyl-glutamic acid carboxylation [GO:0017187]; vitamin K metabolic process [GO:0042373]	quinone binding [GO:0048038]; vitamin-K-epoxide reductase (warfarin-sensitive) activity [GO:0047057]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]
Q05940	VMAT2_HUMAN	Synaptic vesicular amine transporter (Monoamine transporter) (Solute carrier family 18 member 2) (Vesicular amine transporter 2) (VAT2)	SLC18A2 SVMT VMAT2		CHEMBL1893;	Q05940;	DB00182;DB00865;DB01089;DB01576;DB01363;DB01364;DB06706;DB01577;DB00368;DB06714;DB00206;DB04844;		PF07690;	IPR011701;IPR020846;	aminergic neurotransmitter loading into synaptic vesicle [GO:0015842]; chemical synaptic transmission [GO:0007268]; dopamine transport [GO:0015872]; locomotory behavior [GO:0007626]; monoamine transport [GO:0015844]; negative regulation of reactive oxygen species biosynthetic process [GO:1903427]; neurotransmitter loading into synaptic vesicle [GO:0098700]; neurotransmitter secretion [GO:0007269]; post-embryonic development [GO:0009791]; response to amphetamine [GO:0001975]; response to toxic substance [GO:0009636]; sequestering of neurotransmitter [GO:0042137]	monoamine transmembrane transporter activity [GO:0008504]; serotonin transmembrane transporter activity [GO:0015222]	clathrin-sculpted monoamine transport vesicle membrane [GO:0070083]; integral component of plasma membrane [GO:0005887]; membrane [GO:0016020]; plasma membrane [GO:0005886]; synaptic vesicle [GO:0008021]; synaptic vesicle membrane [GO:0030672]; terminal bouton [GO:0043195]
P02774	VTDB_HUMAN	Vitamin D-binding protein (DBP) (VDB) (Gc protein-derived macrophage activating factor) (Gc-MAF) (GcMAF) (Gc-globulin) (Group-specific component) (Gc) (Vitamin D-binding protein-macrophage activating factor) (DBP-maf)	GC	1J78;1J7E;1KW2;1KXP;1LOT;1MA9;	CHEMBL2259;	P02774;	DB01436;DB00169;DB04224;		PF00273;PF09164;	IPR000264;IPR020858;IPR020857;IPR014760;IPR000213;IPR015247;	vitamin D metabolic process [GO:0042359]; vitamin transport [GO:0051180]	actin binding [GO:0003779]; calcidiol binding [GO:1902118]; vitamin D binding [GO:0005499]; vitamin transporter activity [GO:0051183]	blood microparticle [GO:0072562]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; lysosomal lumen [GO:0043202]
P42768	WASP_HUMAN	Wiskott-Aldrich syndrome protein (WASp)	WAS IMD2	1CEE;1EJ5;1T84;2A3Z;2K42;2OT0;					PF00786;PF00568;PF02205;	IPR000095;IPR011993;IPR027641;IPR011026;IPR000697;IPR003124;	actin filament-based movement [GO:0030048]; actin filament polymerization [GO:0030041]; actin polymerization or depolymerization [GO:0008154]; blood coagulation [GO:0007596]; defense response [GO:0006952]; endosomal transport [GO:0016197]; epidermis development [GO:0008544]; Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096]; immune response [GO:0006955]; negative regulation of cell motility [GO:2000146]; positive regulation of Arp2/3 complex-mediated actin nucleation [GO:2000601]; protein complex assembly [GO:0006461]; regulation of T cell antigen processing and presentation [GO:0002625]; T cell activation [GO:0042110]; T cell receptor signaling pathway [GO:0050852]	GTPase regulator activity [GO:0030695]; phospholipase binding [GO:0043274]; protein kinase binding [GO:0019901]; SH3 domain binding [GO:0017124]	actin cytoskeleton [GO:0015629]; cell-cell junction [GO:0005911]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; vesicle membrane [GO:0012506]
P30291	WEE1_HUMAN	Wee1-like protein kinase (WEE1hu) (EC 2.7.10.2) (Wee1A kinase)	WEE1	1X8B;2IN6;2IO6;2Z2W;3BI6;3BIZ;3CQE;3CR0;	CHEMBL5491;	P30291;			PF00069;	IPR011009;IPR000719;IPR017441;IPR008271;IPR017164;	cell division [GO:0051301]; establishment of cell polarity [GO:0030010]; G2/M transition of mitotic cell cycle [GO:0000086]; microtubule cytoskeleton organization [GO:0000226]; mitotic nuclear division [GO:0007067]; neuron projection morphogenesis [GO:0048812]; regulation of cell cycle [GO:0051726]	ATP binding [GO:0005524]; kinase activity [GO:0016301]; magnesium ion binding [GO:0000287]; non-membrane spanning protein tyrosine kinase activity [GO:0004715]; protein tyrosine kinase activity [GO:0004713]	cytoplasm [GO:0005737]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
Q9UPY5	XCT_HUMAN	Cystine/glutamate transporter (Amino acid transport system xc-) (Calcium channel blocker resistance protein CCBR1) (Solute carrier family 7 member 11) (xCT)	SLC7A11		CHEMBL1075149;	Q9UPY5;	DB06151;DB00138;DB00740;DB01098;DB00795;DB08834;		PF13520;	IPR002293;IPR004760;	amino acid transport [GO:0006865]; brain development [GO:0007420]; lens fiber cell differentiation [GO:0070306]; leukocyte migration [GO:0050900]; platelet aggregation [GO:0070527]; response to nicotine [GO:0035094]; response to oxidative stress [GO:0006979]; response to toxic substance [GO:0009636]	cystine:glutamate antiporter activity [GO:0015327]	cell surface [GO:0009986]; cytoskeleton [GO:0005856]; integral component of membrane [GO:0016021]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; rough endoplasmic reticulum [GO:0005791]
P47989	XDH_HUMAN	Xanthine dehydrogenase/oxidase [Includes: Xanthine dehydrogenase (XD) (EC 1.17.1.4); Xanthine oxidase (XO) (EC 1.17.3.2) (Xanthine oxidoreductase) (XOR)]	XDH XDHA	2CKJ;2E1Q;	CHEMBL1929;	P47989;	DB00041;DB00437;DB00993;DB00958;DB01136;DB00856;DB00515;DB00694;DB00746;DB00997;DB04854;DB03147;DB00583;DB00170;DB01033;DB00336;DB01168;DB00339;DB00127;DB00831;		PF01315;PF02738;PF03450;PF00941;PF00111;PF01799;	IPR002888;IPR001041;IPR006058;IPR000674;IPR016208;IPR008274;IPR012675;IPR005107;IPR016169;IPR016166;IPR016167;IPR002346;IPR022407;IPR014307;	activation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0006919]; lactation [GO:0007595]; negative regulation of endothelial cell differentiation [GO:0045602]; negative regulation of endothelial cell proliferation [GO:0001937]; negative regulation of gene expression [GO:0010629]; negative regulation of protein kinase B signaling [GO:0051898]; negative regulation of protein phosphorylation [GO:0001933]; negative regulation of vascular endothelial growth factor signaling pathway [GO:1900747]; negative regulation of vasculogenesis [GO:2001213]; positive regulation of p38MAPK cascade [GO:1900745]; positive regulation of reactive oxygen species metabolic process [GO:2000379]; purine nucleotide catabolic process [GO:0006195]; xanthine catabolic process [GO:0009115]	2 iron, 2 sulfur cluster binding [GO:0051537]; electron carrier activity [GO:0009055]; flavin adenine dinucleotide binding [GO:0050660]; iron ion binding [GO:0005506]; molybdopterin cofactor binding [GO:0043546]; oxidoreductase activity, acting on CH-OH group of donors [GO:0016614]; oxidoreductase activity, acting on the aldehyde or oxo group of donors [GO:0016903]; protein homodimerization activity [GO:0042803]; xanthine dehydrogenase activity [GO:0004854]; xanthine oxidase activity [GO:0004855]	cytosol [GO:0005829]; extracellular space [GO:0005615]; peroxisome [GO:0005777]; sarcoplasmic reticulum [GO:0016529]
Q13426	XRCC4_HUMAN	DNA repair protein XRCC4 (X-ray repair cross-complementing protein 4)	XRCC4	1FU1;1IK9;3II6;3MUD;3Q4F;3RWR;3SR2;3W03;4XA4;5CHX;5CJ0;5CJ4;5E50;					PF06632;	IPR010585;IPR014751;IPR009089;	cellular response to lithium ion [GO:0071285]; DNA ligation involved in DNA repair [GO:0051103]; DNA recombination [GO:0006310]; double-strand break repair [GO:0006302]; double-strand break repair via nonhomologous end joining [GO:0006303]; establishment of integrated proviral latency [GO:0075713]; positive regulation of ligase activity [GO:0051351]; protein sumoylation [GO:0016925]; response to X-ray [GO:0010165]	protein C-terminus binding [GO:0008022]	cell junction [GO:0030054]; centrosome [GO:0005813]; cytosol [GO:0005829]; DNA-dependent protein kinase-DNA ligase 4 complex [GO:0005958]; DNA ligase IV complex [GO:0032807]; nonhomologous end joining complex [GO:0070419]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]
P07947	YES_HUMAN	Tyrosine-protein kinase Yes (EC 2.7.10.2) (Proto-oncogene c-Yes) (p61-Yes)	YES1 YES	2HDA;	CHEMBL2073;	P07947;	DB01254;		PF07714;PF00017;PF00018;	IPR028459;IPR011009;IPR000719;IPR017441;IPR001245;IPR000980;IPR001452;IPR008266;IPR020635;	cell differentiation [GO:0030154]; cellular protein modification process [GO:0006464]; cellular response to platelet-derived growth factor stimulus [GO:0036120]; cellular response to retinoic acid [GO:0071300]; cellular response to transforming growth factor beta stimulus [GO:0071560]; ephrin receptor signaling pathway [GO:0048013]; Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096]; glucose transport [GO:0015758]; innate immune response [GO:0045087]; leukocyte migration [GO:0050900]; peptidyl-tyrosine autophosphorylation [GO:0038083]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; positive regulation of transcription from RNA polymerase II promoter [GO:0045944]; regulation of cell proliferation [GO:0042127]; regulation of vascular permeability [GO:0043114]; T cell costimulation [GO:0031295]; transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169]	ATP binding [GO:0005524]; enzyme binding [GO:0019899]; ion channel binding [GO:0044325]; non-membrane spanning protein tyrosine kinase activity [GO:0004715]; protein tyrosine kinase activity [GO:0004713]; receptor binding [GO:0005102]	actin filament [GO:0005884]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extrinsic component of cytoplasmic side of plasma membrane [GO:0031234]; focal adhesion [GO:0005925]; Golgi apparatus [GO:0005794]; microtubule organizing center [GO:0005815]; plasma membrane [GO:0005886]
P25311	ZA2G_HUMAN	Zinc-alpha-2-glycoprotein (Zn-alpha-2-GP) (Zn-alpha-2-glycoprotein)	AZGP1 ZAG ZNGP1	1T7V;1T7W;1T7X;1T7Y;1T7Z;1T80;1ZAG;3ES6;					PF07654;PF00129;	IPR007110;IPR013783;IPR003006;IPR003597;IPR011161;IPR011162;IPR001039;	antigen processing and presentation [GO:0019882]; cell adhesion [GO:0007155]; detection of chemical stimulus involved in sensory perception of bitter taste [GO:0001580]; negative regulation of cell proliferation [GO:0008285]; retina homeostasis [GO:0001895]; transmembrane transport [GO:0055085]	antigen binding [GO:0003823]; glycoprotein binding [GO:0001948]; protein transmembrane transporter activity [GO:0008320]; ribonuclease activity [GO:0004540]	extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; nucleus [GO:0005634]; plasma membrane [GO:0005886]
P43403	ZAP70_HUMAN	Tyrosine-protein kinase ZAP-70 (EC 2.7.10.2) (70 kDa zeta-chain associated protein) (Syk-related tyrosine kinase)	ZAP70 SRK	1FBV;1M61;1U59;2CBL;2OQ1;2OZO;2Y1N;3ZNI;4A4B;4A4C;4K2R;4XZ0;4XZ1;	CHEMBL2803;	P43403;			PF07714;PF00017;	IPR011009;IPR023420;IPR000719;IPR017441;IPR001245;IPR000980;IPR008266;IPR020635;IPR012234;	adaptive immune response [GO:0002250]; B cell activation [GO:0042113]; B cell receptor signaling pathway [GO:0050853]; beta selection [GO:0043366]; immune response [GO:0006955]; inflammatory response [GO:0006954]; innate immune response [GO:0045087]; intracellular signal transduction [GO:0035556]; macrophage activation involved in immune response [GO:0002281]; negative thymic T cell selection [GO:0045060]; neutrophil activation involved in immune response [GO:0002283]; peptidyl-tyrosine autophosphorylation [GO:0038083]; peptidyl-tyrosine phosphorylation [GO:0018108]; positive regulation of alpha-beta T cell differentiation [GO:0046638]; positive regulation of alpha-beta T cell proliferation [GO:0046641]; positive regulation of B cell differentiation [GO:0045579]; positive regulation of calcium-mediated signaling [GO:0050850]; positive regulation of cell adhesion mediated by integrin [GO:0033630]; positive regulation of mast cell degranulation [GO:0043306]; positive regulation of T cell differentiation [GO:0045582]; positive thymic T cell selection [GO:0045059]; protein phosphorylation [GO:0006468]; regulation of platelet aggregation [GO:0090330]; T cell activation [GO:0042110]; T cell aggregation [GO:0070489]; T cell differentiation [GO:0030217]; T cell migration [GO:0072678]; T cell receptor signaling pathway [GO:0050852]; transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169]	ATP binding [GO:0005524]; non-membrane spanning protein tyrosine kinase activity [GO:0004715]; protein tyrosine kinase activity [GO:0004713]; receptor binding [GO:0005102]	cell-cell junction [GO:0005911]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extrinsic component of cytoplasmic side of plasma membrane [GO:0031234]; immunological synapse [GO:0001772]; plasma membrane [GO:0005886]; T cell receptor complex [GO:0042101]
P08048	ZFY_HUMAN	Zinc finger Y-chromosomal protein	ZFY	1KLR;1KLS;1XRZ;5ZNF;7ZNF;					PF00096;PF04704;	IPR006794;IPR007087;IPR015880;IPR013087;	multicellular organism development [GO:0007275]; regulation of transcription, DNA-templated [GO:0006355]; transcription, DNA-templated [GO:0006351]	metal ion binding [GO:0046872]; RNA polymerase II regulatory region sequence-specific DNA binding [GO:0000977]; transcription factor activity, sequence-specific DNA binding [GO:0003700]	nucleus [GO:0005634]